% Encoding: UTF-8

@InCollection{Altman1998a,
  author    = {Altman, D. G.},
  title     = {Categorizing continuous variables},
  pages     = {563--567},
  volume    = {1},
  crossref  = {ZZ:EOB},
  owner     = {PaulD},
  timestamp = {2011.06.19},
}

@InCollection{Auvinen1997,
  author    = {Auvinen, Anssi and Karjalainen, Sakari},
  booktitle = {Social Inequalities and Cancer},
  title     = {Possible Explanations for Social Class Differences in Cancer Patient Survival},
  editor    = {Kogevinas, M. and Pearce, N. and Susser, M. and Boffetta, P.},
  pages     = {377--397},
  publisher = {Lyon: International Agency for Research on Cancer},
  series    = {IARC Scientific Publications No. 138},
  crossref  = {ZZ:Kogevinas97},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1997},
}

@InCollection{Gail1998,
  author    = {Gail, M. H.},
  title     = {Dose-response},
  pages     = {1211},
  volume    = {2},
  crossref  = {ZZ:EOB},
  owner     = {PaulD},
  timestamp = {2011.06.19},
}

@InCollection{Inskip2005,
  author    = {Inskip, H.},
  title     = {Standardisation methods},
  pages     = {1-13},
  crossref  = {ZZ:EOB},
  file      = {Inskip2005.pdf:pdf\\Inskip2005.pdf:PDF;Inskip2005.pdf:Inskip2005.pdf:PDF},
  owner     = {PaulD},
  timestamp = {2013.07.11},
}

@InCollection{Jensen1991a,
  author    = {Jensen, O. M. and Storm, H. H.},
  booktitle = {Cancer Registration: Principles and Methods},
  title     = {Purposes and Uses of Cancer Registration},
  chapter   = {3},
  editor    = {Jensen, O. M. and Parkin, D. M. and MacLennan, R. and Muir, C. S. and Skeet, R. G.},
  pages     = {7-21},
  publisher = {Lyon: International Agency for Research on Cancer},
  series    = {IARC Scientific Publications No. 95},
  crossref  = {ZZ:Jensen91},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1991},
}

@InCollection{MacLennan1991,
  author    = {MacLennan, R.},
  booktitle = {Cancer Registration: Principles and Methods},
  title     = {Items of Patient Information which may be Collected by Registries},
  chapter   = {6},
  editor    = {Jensen, O. M. and Parkin, D. M. and MacLennan, R. and Muir, C. S. and Skeet, R. G.},
  pages     = {43-63},
  publisher = {Lyon: International Agency for Research on Cancer},
  series    = {IARC Scientific Publications No. 95},
  crossref  = {ZZ:Jensen91},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1991},
}

@InCollection{Parkin1991,
  author    = {Parkin, D. M. and Hakulinen, T.},
  booktitle = {Cancer Registration: Principles and Methods},
  title     = {Analysis of Survival},
  chapter   = {3},
  editor    = {Jensen, O. M. and Parkin, D. M. and MacLennan, R. and Muir, C. S. and Skeet, R. G.},
  pages     = {7-21},
  publisher = {Lyon: International Agency for Research on Cancer},
  series    = {IARC Scientific Publications No. 95},
  crossref  = {ZZ:Jensen91},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1991},
}

@InCollection{Preston1998a,
  author     = {Preston, D.},
  title      = {Excess Relative Risk},
  pages      = {1425},
  translator = {an},
  volume     = {2},
  crossref   = {ZZ:EOB},
  owner      = {PaulD},
  timestamp  = {2011.06.19},
}

@InCollection{Preston1998b,
  author    = {Preston, D.},
  title     = {Excess Risk},
  pages     = {1425--1426},
  volume    = {2},
  crossref  = {ZZ:EOB},
  owner     = {PaulD},
  timestamp = {2011.06.19},
}

@InCollection{Pukkala1992,
  author    = {Pukkala, E.},
  booktitle = {Geographical \& Environmental Epidemiology: {M}ethods for Small-Area Studies},
  title     = {Use of Record Linkage in Small-Area Studies},
  editor    = {Elliott, P. and Cuzick, J. and English, D. and Stern, R.},
  pages     = {125-131},
  publisher = {Oxford: Oxford University Press},
  crossref  = {ZZ:Elliott92},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1992},
}

@InCollection{Saxen1982,
  author    = {Sax{\'e}n, E.},
  title     = {Trends: facts or fallacy},
  pages     = {5-16},
  crossref  = {ZZ:Magnus82},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1982},
}

@InCollection{Signorello2002,
  author    = {Signorello, L. B. and Adami, H-O.},
  title     = {Prostate Cancer},
  chapter   = {18},
  pages     = {400-28},
  crossref  = {ZZ:Adami02},
  owner     = {PaulD},
  timestamp = {2011.06.19},
}

@InCollection{Tsiatis1998,
  author    = {Tsiatis, A. A.},
  title     = {Competing Risks},
  pages     = {824-834},
  volume    = {1},
  crossref  = {ZZ:EOB},
  owner     = {PaulD},
  timestamp = {2011.06.19},
}

@InCollection{Veath1998,
  author    = {V{\ae}th, M.},
  title     = {Excess Mortality},
  pages     = {1423--1425},
  volume    = {2},
  crossref  = {ZZ:EOB},
  owner     = {PaulD},
  timestamp = {2011.06.19},
}

@InCollection{Young1991,
  author    = {Young, J. L.},
  booktitle = {Cancer Registration: Principles and Methods},
  title     = {The Hospital-based Cancer Registry},
  chapter   = {13},
  editor    = {Jensen, O. M. and Parkin, D. M. and MacLennan, R. and Muir, C. S. and Skeet, R. G.},
  pages     = {177-184},
  publisher = {Lyon: International Agency for Research on Cancer},
  series    = {IARC Scientific Publications No. 95},
  crossref  = {ZZ:Jensen91},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1991},
}

@Book{Parkin1985,
  title     = {The Role of the Registry in Cancer Control},
  editor    = {Parkin, D. M. and Wagner, G. and Muir, C. S.},
  publisher = {Lyon: International Agency for Research on Cancer},
  series    = {IARC Scientific Publications No. 66},
  booktitle = {The Role of the Registry in Cancer Control},
  crossref  = {ZZ:Parkin85},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1985},
}

@Book{Jensen1991,
  title     = {Cancer Registration: Principles and Methods},
  editor    = {Jensen, O. M. and Parkin, D. M. and MacLennan, R. and Muir, C. S. and Skeet, R. G.},
  publisher = {Lyon: International Agency for Research on Cancer},
  series    = {IARC Scientific Publications No. 95},
  booktitle = {Cancer Registration: Principles and Methods},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1991},
}

@InCollection{Berrino1995a,
  author    = {Berrino, F. and Est{\`e}ve, J. and Coleman, M. P.},
  booktitle = {Survival of Cancer Patients in {E}urope: The {EUROCARE} Study},
  title     = {Basic Issues in Estimating and Comparing the Survival of Cancer Patients},
  chapter   = {1},
  editor    = {F Berrino and M Sant and A Verdecchia and R Capocaccia and T Hakulinen and J Est{\`e}ve},
  pages     = {1--14},
  publisher = {Lyon: International Agency for Research on Cancer},
  series    = {IARC Scientific Publications No. 132},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@InCollection{Coebergh1995,
  author    = {Coebergh, J. W. W.},
  booktitle = {Survival of Cancer Patients in {E}urope: The {EUROCARE} Study},
  title     = {Summary and Discussion of Results},
  chapter   = {18},
  editor    = {F Berrino and M Sant and A Verdecchia and R Capocaccia and T Hakulinen and J Est{\`e}ve},
  pages     = {444--463},
  publisher = {Lyon: International Agency for Research on Cancer},
  series    = {IARC Scientific Publications No. 132},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@InCollection{Hakulinen1995,
  author    = {Timo Hakulinen},
  booktitle = {Survival of Cancer Patients in {E}urope: The {EUROCARE} Study},
  title     = {Health Care System, Cancer Registration and Follow-up of Cancer Patients in {F}inland},
  editor    = {F Berrino and M Sant and A Verdecchia and R Capocaccia and T Hakulinen and J Est{\`e}ve},
  pages     = {53-54},
  publisher = {Lyon: International Agency for Research on Cancer},
  series    = {IARC Scientific Publications No. 132},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@InCollection{Sant1995,
  author    = {Sant, M. and Gatta, G},
  booktitle = {Survival of Cancer Patients in {E}urope: The {EUROCARE} Study},
  title     = {The {EUROCARE} Database},
  chapter   = {2},
  editor    = {F Berrino and M Sant and A Verdecchia and R Capocaccia and T Hakulinen and J Est{\`e}ve},
  pages     = {15-31},
  publisher = {Lyon: International Agency for Research on Cancer},
  series    = {IARC Scientific Publications No. 132},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@InCollection{Storm1995,
  author    = {Storm, H. H.},
  booktitle = {Survival of Cancer Patients in {E}urope: The {EUROCARE} Study},
  title     = {Health Care System, Cancer Registration and Follow-up of Cancer Patients in {D}enmark},
  chapter   = {5},
  editor    = {F Berrino and M Sant and A Verdecchia and R Capocaccia and T Hakulinen and J Est{\`e}ve},
  pages     = {48-50},
  publisher = {Lyon: International Agency for Research on Cancer},
  series    = {IARC Scientific Publications No. 132},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@InCollection{Verdecchia1995,
  author    = {Verdecchia, A. and Capocaccia, R. and Hakulinen, T.},
  booktitle = {Survival of Cancer Patients in {E}urope: The {EUROCARE} Study},
  title     = {Methods of data analysis},
  chapter   = {3},
  editor    = {F Berrino and M Sant and A Verdecchia and R Capocaccia and T Hakulinen and J Est{\`e}ve},
  pages     = {32-37},
  publisher = {Lyon: International Agency for Research on Cancer},
  series    = {IARC Scientific Publications No. 132},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@Book{Berrino1995,
  title     = {Survival of Cancer Patients in {E}urope: The {EUROCARE} Study},
  editor    = {F Berrino and M Sant and A Verdecchia and R Capocaccia and T Hakulinen and J Est{\`e}ve},
  publisher = {Lyon: International Agency for Research on Cancer},
  series    = {IARC Scientific Publications No. 132},
  booktitle = {Survival of Cancer Patients in {E}urope: The {EUROCARE} Study},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@Book{Fin:HFA86,
  author    = {Sosiaali- ja terveysministeri{\"o}},
  title     = {Terveytt{\"a} kaikille vuoteen 2000. Suomen terveyspolitiikan pitk{\"a}n aikav{\"a}lin tavoite- ja toimintaohjelma},
  publisher = {Helsinki: Sosiaali- ja terveysministeri{\"o}},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1986},
}

@Electronic{SCBdatabase,
  author    = {Statistiska centralbyr\r{a}n ({S}tatistics {S}weden)},
  title     = {Statistical database},
  url       = {http://www.statistikdatabasen.scb.se/pxweb/en/ssd/},
  owner     = {hanbow},
  timestamp = {2016.08.18},
}

@Manual{SCB2003,
  author       = {Statistiska centralbyr{\aa}n (Statistics {S}weden)},
  title        = {Multi-generation register 2002: A description of contents and quality},
  note         = {\tt http://www.scb.se/Statistik/BE/OV9999/2003M00/BE96ST0305.1.pdf},
  organization = {Statistiska centralbyr{\aa}n},
  owner        = {PaulD},
  timestamp    = {2011.06.19},
  year         = {2003},
}

@Book{Aalen2008a,
  author    = {O Aalen and O Borgan and H.K Gjessing},
  title     = {Survival and Event History Analysis},
  publisher = {Springer},
  address   = {New York},
  owner     = {sanelo},
  timestamp = {2013.09.16},
  year      = {2008},
}

@Article{Aalen1978,
  author    = {Aalen, O.O. and Johansen S.},
  title     = {An empirial transition matrix for nonhomogeneous Markov chains based on censored observations},
  pages     = {141-150},
  volume    = {5},
  journal   = {Scandinavian Journal of Statistics},
  owner     = {pl4},
  timestamp = {2015.07.07},
  year      = {1978},
}

@Article{Aalen1994,
  author      = {O. O. Aalen},
  title       = {Effects of frailty in survival analysis.},
  number      = {3},
  pages       = {227--243},
  volume      = {3},
  abstract    = {Unobserved individual heterogeneity, also called frailty, is a major
	concern in the application of survival analysis. Hazard rates do
	not give direct information on the change over time in the individual
	risk, but are strongly influenced by selection effects operating
	in the population. The individuals surviving up to a certain time
	will on average be less frail than the original population. Models
	are reviewed that account for this phenomenon, and some medical examples
	are discussed. It is emphasized that the frailty phenomenon may be
	modelled in many different ways, and a stochastic process approach
	is discussed as an alternative to the common proportional frailty
	model.},
  institution = {University of Oslo, Norway.},
  journal     = {Stat Methods Med Res},
  owner       = {pl4},
  pmid        = {7820293},
  timestamp   = {2008.12.16},
  year        = {1994},
}

@Book{Aalen2008,
  author    = {Aalen, O. O. and Borgan, O. and Gjessing H.},
  title     = {Event History Analysis: A Process Point of View},
  publisher = {Springer},
  file      = {Aalen2008.pdf:pdf\\Aalen2008.pdf:PDF;Aalen2008.pdf:Aalen2008.pdf:PDF},
  owner     = {pl4},
  timestamp = {2013.06.10},
  year      = {2008},
}

@Article{Aalen2014,
  author      = {Aalen, Odd O. and Valberg, Morten and Grotmol, Tom and Tretli, Steinar},
  title       = {Understanding variation in disease risk: the elusive concept of frailty.},
  doi         = {10.1093/ije/dyu192},
  language    = {eng},
  url         = {http://dx.doi.org/10.1093/ije/dyu192},
  abstract    = {The concept of frailty plays a major role in the statistical field
	of survival analysis. Frailty variation refers to differences in
	risk between individuals which go beyond known or measured risk factors.
	In other words, frailty variation is unobserved heterogeneity. Although
	understanding frailty is of interest in its own right, the literature
	on survival analysis has demonstrated that existence of frailty variation
	can lead to surprising artefacts in statistical estimation that are
	important to examine. We present literature that demonstrates the
	presence and significance of frailty variation between individuals.
	We discuss the practical content of frailty variation, and show the
	link between frailty and biological concepts like (epi)genetics and
	heterogeneity in disease risk. There are numerous suggestions in
	the literature that a good deal of this variation may be due to randomness,
	in addition to genetic and/or environmental factors. Heterogeneity
	often manifests itself as clustering of cases in families more than
	would be expected by chance. We emphasize that apparently moderate
	familial relative risks can only be explained by strong underlying
	variation in disease risk between families and individuals. Finally,
	we highlight the potential impact of frailty variation in the interpretation
	of standard epidemiological measures such as hazard and incidence
	rates.},
  file        = {Aalen2014.pdf:Aalen2014.pdf:PDF},
  institution = {Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway and Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway.},
  journal     = {Int J Epidemiol},
  medline-pst = {aheadofprint},
  month       = {Dec},
  owner       = {pl4},
  pii         = {dyu192},
  pmid        = {25501685},
  timestamp   = {2015.01.30},
  year        = {2014},
}

@Article{Abdel_Rahman2009,
  author      = {M. Abdel-Rahman and D. Stockton and B. Rachet and T. Hakulinen and M. P. Coleman},
  title       = {What if cancer survival in {B}ritain were the same as in {E}urope: how many deaths are avoidable?},
  doi         = {10.1038/sj.bjc.6605401},
  pages       = {S115--S124},
  volume      = {101 Suppl 2},
  abstract    = {OBJECTIVE: To estimate the number of deaths among cancer patients
	diagnosed in Great Britain that would be avoidable within 5 years
	of diagnosis if the mean (or highest) survival in Europe for patients
	diagnosed during 1985-1989, 1990-1994 and 1995-1999 were achieved.
	DESIGN: Five-year relative survival for cancers in Great Britain
	compared with that from other countries in the EUROCARE-2, -3 and
	-4 studies. Calculation of excess deaths (those more than expected
	from mortality in the general population) that would be avoidable
	among cancer patients in Britain if relative survival were the same
	as in Europe. SETTING: Great Britain (England, Wales, Scotland) and
	13 other European countries. SUBJECTS: 2.8 million adults diagnosed
	in Britain with 1 of 39 cancers during 1985-1989 (followed up to
	1994), 1990-1994 (followed up to 1999) and 1995-1999 (followed up
	to 2003). MAIN OUTCOME MEASURE: Annual number of avoidable deaths
	within 5 years of diagnosis. Percentage of the excess (cancer-related)
	deaths among cancer patients that would be avoidable. RESULTS: Compared
	with the mean European 5-year relative survival, the largest numbers
	of avoidable deaths for patients diagnosed during 1985-1989 were
	for cancers of the breast (about 18\% of the excess mortality from
	this cancer, 7541 deaths), prostate (14\%, 4285), colon (9\%, 4090),
	stomach (8\%, 3483) and lung (2\%, 3548). For 1990-1994, the largest
	numbers of avoidable deaths were for cancers of the prostate (20\%,
	7335), breast (15\%, 6165), colon (9\%, 4376), stomach (9\%, 3672),
	lung (2\%, 3735) and kidney (22\%, 2644). For 1995-1999, most of
	the avoidable deaths were for cancers of the prostate (17\%, 5758),
	breast (15\%, 5475), lung (3\%, 4923), colon (10\%, 4295), stomach
	(9\%, 3137) and kidney (21\%, 2686).Overall, some 6600-7500 premature
	deaths would have been avoided each year among cancer patients diagnosed
	in Britain during 1985-1999 if the mean survival in Europe had been
	achieved. This represents 6-7\% of cancer-related mortality. Compared
	with the highest European survival, avoidable premature mortality
	among cancer patients fell from about 12 800 deaths a year (12.2\%
	of cancer-related mortality) to about 11 400 deaths a year (10.6\%)
	over the same period.A large component of the avoidable mortality
	is due to prostate cancer: excluding this cancer from comparison
	with the European mean survival reduces the annual number of avoidable
	deaths by 1000-1500, and the percentage of excess mortality by up
	to 1\%. Compared with the highest survival, the annual number of
	avoidable deaths would be 1500-2000 fewer, and 1-2\% lower as a percentage
	of excess mortality, but the overall trend in avoidable premature
	mortality among cancer patients would be similar, falling from 11.4\%
	(1985-1989) to 10.3\% (1990-1994) and 9.7\% for those diagnosed during
	1995-1999.For several cancers, survival in Britain was slightly higher
	than the mean survival in Europe; this represented some 110-180 premature
	deaths avoided each year during the period 1985-2003. CONCLUSIONS:
	Avoidable premature mortality among cancer patients diagnosed in
	Britain during 1985-1999 has represented 6-7\% of cancer-related
	mortality compared with the mean survival in Europe. Compared with
	the highest levels of survival in Europe, the reduction from 12.2\%
	to 10.6\% of cancer-related mortality reflects small but steady progress
	over the period 1985-2003.},
  file        = {Abdel_Rahman2009.pdf:pdf\\Abdel_Rahman2009.pdf:PDF},
  institution = {Cancer Research UK Cancer Survival Group, Non-Communicable Disease Epidemiology Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, UK.},
  journal     = {British Journal of Cancer},
  owner       = {pl4},
  pii         = {6605401},
  pmid        = {19956155},
  timestamp   = {2010.03.19},
  year        = {2009},
}

@Article{Abrahamowicz2007,
  author      = {Michal Abrahamowicz and Todd A MacKenzie},
  title       = {Joint estimation of time-dependent and non-linear effects of continuous covariates on survival.},
  doi         = {10.1002/sim.2519},
  number      = {2},
  pages       = {392--408},
  volume      = {26},
  abstract    = {In order to yield more flexible models, the Cox regression model,
	lambda(t;x) = lambda(0)(t)exp(betax), has been generalized using
	different non-parametric model estimation techniques. One generalization
	is the relaxation of log-linearity in x, lambda(t;x) = lambda(0)(t)exp[r(x)].
	Another is the relaxation of the proportional hazards assumption,
	lambda(t;x) = lambda(0)(t)exp[beta(t)x]. These generalizations are
	typically considered independently of each other. We propose the
	product model, lambda(t;x) = lambda(0)(t)exp[beta(t)r(x)] which allows
	for joint estimation of both effects, and investigate its properties.
	The functions describing the time-dependent beta(t) and non-linear
	r(x) effects are modelled simultaneously using regression splines
	and estimated by maximum partial likelihood. Likelihood ratio tests
	are proposed to compare alternative models. Simulations indicate
	that both the recovery of the shapes of the two functions and the
	size of the tests are reasonably accurate provided they are based
	on the correct model. By contrast, type I error rates may be highly
	inflated, and the estimates considerably biased, if the model is
	misspecified. Applications in cancer epidemiology illustrate how
	the product model may yield new insights about the role of prognostic
	factors.},
  file        = {Abrahamowicz2007.pdf:Abrahamowicz2007.pdf:PDF;Abrahamowicz2007.pdf:pdf\\Abrahamowicz2007.pdf:PDF},
  institution = {Department of Epidemiology and Biostatistics, McGill University, Montreal, Que., Canada H3A 1A2. michal@epimgh.mcgill.ca},
  journal     = {Statistics in Medicine},
  month       = jan,
  owner       = {pl4},
  pmid        = {16479552},
  timestamp   = {2009.02.12},
  year        = {2007},
}

@Article{Abrahamowicz1996,
  author    = {Abrahamowicz, M. and MacKenzie, T. and Esdaile J.M.},
  title     = {Time-dependent hazard ratio: modeling and hypothesis testing with application in lupus nephritis},
  pages     = {1432--1439},
  volume    = {91},
  file      = {Abrahamowicz1996.pdf:pdf\\Abrahamowicz1996.pdf:PDF;Abrahamowicz1996.pdf:Abrahamowicz1996.pdf:PDF},
  journal   = {Journal of the American Statistical Association},
  owner     = {pl4},
  timestamp = {2009.02.12},
  year      = {1996},
}

@Article{Abrams2005,
  author      = {Keith R Abrams and Clare L Gillies and Paul C Lambert},
  title       = {Meta-analysis of heterogeneously reported trials assessing change from baseline.},
  doi         = {10.1002/sim.2423},
  number      = {24},
  pages       = {3823--3844},
  volume      = {24},
  abstract    = {This paper considers the quantitative synthesis of published comparative
	study results when the outcome measures used in the individual studies
	and the way in which they are reported varies between studies. Whilst
	the former difficulty may be overcome, at least to a limited extent,
	by the use of standardized effects, the latter is often more problematic.
	Two potential solutions to this problem are; sensitivity analyses
	and a fully Bayesian approach, in which pertinent external information
	is included. Both approaches are illustrated using the results of
	two systematic reviews and meta-analyses which consider the difference
	in mean change in systolic blood pressure and the difference in physical
	functioning between an intervention and control group. The two examples
	illustrate that by adopting a fully Bayesian approach, as opposed
	to undertaking sensitivity analyses assuming fixed values for unknown
	parameters, the overall intervention effect can be estimated with
	greater uncertainty, but that assessing the sensitivity of results
	to choice of prior distributions in such analyses is crucial.},
  file        = {:pdf\\abrams2005.pdf:PDF},
  institution = {Centre for Biostatistics and Genetic Epidemiology, Department of Health Sciences, University of Leicester, UK. keith.abrams@le.ac.uk},
  journal     = {Statistics in Medicine},
  month       = dec,
  owner       = {pl4},
  pmid        = {16320285},
  timestamp   = {2008.10.15},
  year        = {2005},
}

@Article{Adami1989,
  author    = {Adami, H. and Hakulinen, T. and Ewertz, M. and Tretli, S. and Holmberg, L. and Karjalainen, S.},
  title     = {The Survival Pattern in Male Breast Cancer. {A}n Analysis of 1429 Patients from the {N}ordic Countries},
  pages     = {1177--1182},
  volume    = {64},
  journal   = {Cancer},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1989},
}

@Article{Adami1996,
  author      = {H. O. Adami},
  title       = {Sweden: A paradise for Epidemiologists?},
  number      = {9001},
  pages       = {588--589},
  volume      = {347},
  file        = {Adami1996.pdf:pdf\\Adami1996.pdf:PDF},
  institution = {Nordic School of Public Health, Goteborg.},
  journal     = {Lancet},
  month       = mar,
  owner       = {pl4},
  pmid        = {8596324},
  timestamp   = {2011.05.23},
  year        = {1996},
}

@Article{Adami1986,
  author      = {Adami, H. O. and Malker, B. and Holmberg, L. and Persson, I. and Stone, B.},
  title       = {The relation between survival and age at diagnosis in breast cancer.},
  doi         = {10.1056/NEJM198608283150906},
  language    = {eng},
  number      = {9},
  pages       = {559--563},
  url         = {http://dx.doi.org/10.1056/NEJM198608283150906},
  volume      = {315},
  abstract    = {We analyzed the relation between age at diagnosis and relative survival
	(ratio of observed to expected survival) in 57,068 women in Sweden
	in whom breast cancer was diagnosed in 1960 to 1978 (about 98 percent
	of all cases). Women who were 45 to 49 years old had the best prognosis,
	with a relative survival exceeding that of the youngest patients
	(less than 30 years) by 7.6 to 12.9 percent at different periods
	of observation. Relative survival declined markedly after the age
	of 49--particularly in women aged 50 to 59--and the oldest women
	(greater than 75) had the worst rate. The difference in relative
	survival between those older than 75 and those 45 to 49 increased
	from 8.6 percent at 2 years to 12.2, 20.3, and 27.5 percent after
	5, 10, and 15 years of follow-up, respectively. The long-term annual
	mortality rate due to breast cancer approached 1 to 2 percent at
	the premenopausal ages but exceeded 5 percent throughout the period
	of observation in the oldest age group. An understanding of the biologic
	basis for the complex relation between age and prognosis might provide
	a better understanding of the natural history of breast cancer in
	women.},
  file        = {Adami1986.pdf:pdf\\Adami1986.pdf:PDF},
  journal     = {N Engl J Med},
  keywords    = {Adult; Age Factors; Aged; Breast Neoplasms, diagnosis/mortality; Female; Follow-Up Studies; Humans; Menopause; Middle Aged; Prognosis; Registries; Sweden},
  medline-pst = {ppublish},
  month       = {Aug},
  owner       = {PaulD},
  pmid        = {3736639},
  timestamp   = {2013.03.06},
  year        = {1986},
}

@Article{Adolfsson1998,
  author    = {Adolfsson, J. and Helgason, A. R. and Dickman, P. and Steineck, G.},
  title     = {Urinary and Bowel Symptoms in Men With and Without Prostate Cancer: Results from an Observational Study in the {S}tockholm Area},
  pages     = {11--16},
  volume    = {33},
  journal   = {European Urology},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1998},
}

@InCollection{Akaike1973,
  author    = {H. Akaike},
  booktitle = {Second International Symposium on Information Theory},
  title     = {Information theory as an extension of the maximum likelihood principle},
  editor    = {B. N. Petrov and F. Csaki},
  pages     = {267--281},
  publisher = {Akademiai Kiado},
  address   = {Budapest},
  journal   = {Annals of the Institute of Statistical Mathematics},
  timestamp = {2005.11.01},
  year      = {1973},
}

@Article{Alakomi2007,
  author      = {Hanna-Leena Alakomi and Riitta Puupponen-Pimi\"{a} and Anna-Marja Aura and Ilkka M Helander and Liisa Nohynek and Kirsi-Marja Oksman-Caldentey and Maria Saarela},
  title       = {Weakening of salmonella with selected microbial metabolites of berry-derived phenolic compounds and organic acids.},
  doi         = {10.1021/jf070190y},
  number      = {10},
  pages       = {3905--3912},
  volume      = {55},
  abstract    = {Gram-negative bacteria are important food spoilage and pathogenic
	bacteria. Their unique outer membrane (OM) provides them with a hydrophilic
	surface structure, which makes them inherently resistant to many
	antimicrobial agents, thus hindering their control. However, with
	permeabilizers, compounds that disintegrate and weaken the OM, Gram-negative
	cells can be sensitized to several external agents. Although antimicrobial
	activity of plant-derived phenolic compounds has been widely reported,
	their mechanisms of action have not yet been well demonstrated. The
	aim of our study was to elucidate the role of selected colonic microbial
	metabolites of berry-derived phenolic compounds in the weakening
	of the Gram-negative OM. The effect of the agents on the OM permeability
	of Salmonella was studied utilizing a fluorescence probe uptake assay,
	sensitization to hydrophobic antibiotics, and lipopolysaccharide
	(LPS) release. Our results show that 3,4-dihydroxyphenylacetic acid,
	3-hydroxyphenylacetic acid, 3-(3,4-dihydroxyphenyl)propionic acid
	(3,4-diHPP), 3-(4-hydroxyphenyl)propionic acid, 3-phenylpropionic
	acid, and 3-(3-hydroxyphenyl)propionic acid efficiently destabilized
	the OM of Salmonella enterica subsp. enterica serovar Typhimurium
	and S. enterica subsp. enterica serovar Infantis as indicated by
	an increase in the uptake of the fluorescent probe 1-N-phenylnaphthylamine
	(NPN). The OM-destabilizing activity of the compounds was partially
	abolished by MgCl2 addition, indicating that part of their activity
	is based on removal of OM-stabilizing divalent cations. Furthermore,
	3,4-dihydroxyphenylacetic acid, 3-hydroxyphenylacetic acid, and 3,4-diHPP
	increased the susceptibility of S. enterica subsp. enterica serovar
	Typhimurium strains for novobiocin. In addition, organic acids present
	in berries, such as malic acid, sorbic acid, and benzoic acid, were
	shown to be efficient permeabilizers of Salmonella as shown by an
	increase in the NPN uptake assay and by LPS release.},
  institution = {VTT Technical Research Centre of Finland, P.O. Box 1000, FI-02044 Espoo, Finland. Hanna-Leena.Alakomi@vtt.fi},
  journal     = {J Agric Food Chem},
  month       = may,
  owner       = {pl4},
  pmid        = {17439151},
  timestamp   = {2011.05.26},
  year        = {2007},
}

@Article{Aleman2007,
  author      = {Berthe M P Aleman and Alexandra W van den Belt-Dusebout and Marie L De Bruin and Mars B van 't Veer and Margreet H A Baaijens and Jan Paul de Boer and Augustinus A M Hart and Willem J Klokman and Marianne A Kuenen and Gabey M Ouwens and Harry Bartelink and Flora E van Leeuwen},
  title       = {Late cardiotoxicity after treatment for {H}odgkin lymphoma.},
  doi         = {10.1182/blood-2006-07-034405},
  number      = {5},
  pages       = {1878--1886},
  volume      = {109},
  abstract    = {We assessed cardiovascular disease (CVD) incidence in 1474 survivors
	of Hodgkin lymphoma (HL) younger than 41 years at treatment (1965-1995).
	Multivariable Cox regression and competing risk analyses were used
	to quantify treatment effects on CVD risk. After a median follow-up
	of 18.7 years, risks of myocardial infarction (MI) and congestive
	heart failure (CHF) were strongly increased compared with the general
	population (standardized incidence ratios [SIRs] = 3.6 and 4.9, respectively),
	resulting in 35.7 excess cases of MI and 25.6 excess cases of CHF
	per 10 000 patients/year. SIRs of all CVDs combined remained increased
	for at least 25 years and were more strongly elevated in younger
	patients. Mediastinal radiotherapy significantly increased the risks
	of MI, angina pectoris, CHF, and valvular disorders (2- to 7-fold).
	Anthracyclines significantly added to the elevated risks of CHF and
	valvular disorders from mediastinal RT (hazard ratios [HRs] were
	2.81 and 2.10, respectively). The 25-year cumulative incidence of
	CHF after mediastinal radiotherapy and anthracyclines in competing
	risk analyses was 7.9\%. In conclusion, risks of several CVDs are
	3- to 5-fold increased in survivors of HL compared with the general
	population, even after prolonged follow-up, leading to increasing
	absolute excess risks over time. Anthracyclines further increase
	the elevated risks of CHF and valvular disorders from mediastinal
	radiotherapy.},
  institution = {Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.},
  journal     = {Blood},
  month       = mar,
  owner       = {PaulD},
  pii         = {blood-2006-07-034405},
  pmid        = {17119114},
  timestamp   = {2008.12.30},
  year        = {2007},
}

@Article{Aleman2007a,
  author      = {Aleman, Berthe M P. and {van Leeuwen}, Flora E.},
  title       = {Are we improving the long-term burden of {H}odgkin's lymphoma patients with modern treatment?},
  doi         = {10.1016/j.hoc.2007.07.005},
  language    = {eng},
  number      = {5},
  pages       = {961--975},
  url         = {http://dx.doi.org/10.1016/j.hoc.2007.07.005},
  volume      = {21},
  abstract    = {The cure rate of patients who have Hodgkin's lymphoma (HL) amounts
	to 80\% or more because of risk-adapted treatment using modern chemotherapy
	and radiotherapy schedules. In this article we describe important
	late effects after treatment of HL and how we expect the long-term
	burden of patients who have HL to change applying modern treatments.
	Because treatment always has side effects to some extent, awareness
	of possible late effects after treatment remains important for patients
	and treating physicians.},
  institution = {Department of Radiotherapy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. b.aleman@nki.nl},
  journal     = {Hematol Oncol Clin North Am},
  keywords    = {Antineoplastic Combined Chemotherapy Protocols, adverse effects/therapeutic use; Cardiovascular Diseases; Follow-Up Studies; Hodgkin Disease, complications/therapy; Humans; Lymphatic Irradiation, adverse effects; Neoplasms, Second Primary; Quality of Life; Risk Factors; Survival Analysis; Survivors},
  medline-pst = {ppublish},
  month       = {Oct},
  owner       = {sanelo},
  pii         = {S0889-8588(07)00090-1},
  pmid        = {17908631},
  timestamp   = {2013.08.07},
  year        = {2007},
}

@Article{Alexander1986,
  author    = {Alexander, H. M. and Balding, D. J. and Dobson, A. J. and Gibberd, R. W. and Loyd, D. M.},
  title     = {Risk Factors and Heart Disease Mortality: {A} Regional Perspective},
  pages     = {20--22},
  volume    = {144},
  journal   = {Medical Journal of Australia},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1986},
}

@Article{Allemani2013,
  author      = {Allemani, Claudia and Sant, Milena and Weir, Hannah K. and Richardson, Lisa C. and Baili, Paolo and Storm, Hans and Siesling, Sabine and Torrella-Ramos, Ana and Voogd, Adri C. and Aareleid, Tiiu and Ardanaz, Eva and Berrino, Franco and Bielska-Lasota, Magdalena and Bolick, Susan and Cirilli, Claudia and Colonna, Marc and Contiero, Paolo and Cress, Rosemary and Crocetti, Emanuele and Fulton, John P. and Grosclaude, Pascale and Hakulinen, Timo and Izarzugaza, M Isabel and Malmstrom, Per and Peignaux, Karin and Primic-Zakelj, Maja and Rachtan, Jadwiga and {Safaei Diba}, Chakameh and Sanchez, Maria-Jose and Schymura, Maria J. and Shen, Tiefu and Traina, Adele and Tryggvadottir, Laufey and Tumino, Rosario and Velten, Michel and Vercelli, Marina and Wolf, Holly J. and Woronoff, Anne-Sophie and Wu, Xiaocheng and Coleman, Michel P.},
  title       = {Breast cancer survival in the {US} and {E}urope: a {CONCORD} high-resolution study.},
  doi         = {10.1002/ijc.27725},
  language    = {eng},
  number      = {5},
  pages       = {1170--1181},
  url         = {http://dx.doi.org/10.1002/ijc.27725},
  volume      = {132},
  abstract    = {Breast cancer survival is reportedly higher in the US than in Europe.
	The first worldwide study (CONCORD) found wide international differences
	in age-standardized survival. The aim of this study is to explain
	these survival differences. Population-based data on stage at diagnosis,
	diagnostic procedures, treatment and follow-up were collected for
	about 20,000 women diagnosed with breast cancer aged 15-99 years
	during 1996-98 in 7 US states and 12 European countries. Age-standardized
	net survival and the excess hazard of death up to 5 years after diagnosis
	were estimated by jurisdiction (registry, country, European region),
	age and stage with flexible parametric models. Breast cancers were
	generally less advanced in the US than in Europe. Stage also varied
	less between US states than between European jurisdictions. Early,
	node-negative tumors were more frequent in the US (39\%) than in
	Europe (32\%), while locally advanced tumors were twice as frequent
	in Europe (8\%), and metastatic tumors of similar frequency (5-6\%).
	Net survival in Northern, Western and Southern Europe (81-84\%) was
	similar to that in the US (84\%), but lower in Eastern Europe (69\%).
	For the first 3 years after diagnosis the mean excess hazard was
	higher in Eastern Europe than elsewhere: the difference was most
	marked for women aged 70-99 years, and mainly confined to women with
	locally advanced or metastatic tumors. Differences in breast cancer
	survival between Europe and the US in the late 1990s were mainly
	explained by lower survival in Eastern Europe, where low healthcare
	expenditure may have constrained the quality of treatment.},
  file        = {Allemani2013.pdf:pdf\\Allemani2013.pdf:PDF},
  institution = {Cancer Research UK Cancer Survival Group, Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom. claudia.allemani@lshtm.ac.uk},
  journal     = {International Journal of Cancer},
  keywords    = {Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms, mortality; Europe, epidemiology; Female; Follow-Up Studies; Humans; Middle Aged; Registries; United States, epidemiology; Young Adult},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {pl4},
  pmid        = {22815141},
  timestamp   = {2013.11.01},
  year        = {2013},
}

@Article{Allemani2014,
  author      = {Allemani, Claudia and Weir, Hannah K. and Carreira, Helena and Harewood, Rhea and Spika, Devon and Wang, Xiao-Si and Bannon, Finian and Ahn, Jane V. and Johnson, Christopher J. and Bonaventure, Audrey and Marcos-Gragera, Rafael and Stiller, Charles and {Azevedo E Silva}, Gulnar and Chen, Wan-Qing and Ogunbiyi, Olufemi J. and Rachet, Bernard and Soeberg, Matthew J. and You, Hui and Matsuda, Tomohiro and Bielska-Lasota, Magdalena and Storm, Hans and Tucker, Thomas C. and Coleman, Michel P. and , the C. O. N. C. O. R. D Working Group},
  title       = {Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries ({CONCORD-2}).},
  language    = {eng},
  url         = {http://dx.doi.org/10.1016/S0140-6736(14)62038-9},
  file        = {Allemani2014.pdf:pdf\\Allemani2014.pdf:PDF;Allemani2014.pdf:Allemani2014.pdf:PDF},
  institution = {Tropical Medicine, London, UK. Electronic address: concord@lshtm.ac.uk.},
  journal     = {Lancet},
  medline-pst = {aheadofprint},
  month       = {Nov},
  owner       = {pl4},
  pmid        = {25467588},
  timestamp   = {2016.03.10},
  year        = {2014},
}

@Article{Allignol2011,
  author      = {Allignol, Arthur and Schumacher, Martin and Wanner, Christoph and Drechsler, Christiane and Beyersmann, Jan},
  title       = {Understanding competing risks: a simulation point of view.},
  doi         = {10.1186/1471-2288-11-86},
  language    = {eng},
  pages       = {86},
  volume      = {11},
  abstract    = {Competing risks methodology allows for an event-specific analysis
	of the single components of composite time-to-event endpoints. A
	key feature of competing risks is that there are as many hazards
	as there are competing risks. This is not always well accounted for
	in the applied literature.We advocate a simulation point of view
	for understanding competing risks. The hazards are envisaged as momentary
	event forces. They jointly determine the event time. Their relative
	magnitude determines the event type. 'Empirical simulations' using
	data from a recent study on cardiovascular events in diabetes patients
	illustrate subsequent interpretation. The method avoids concerns
	on identifiability and plausibility known from the latent failure
	time approach.The 'empirical simulations' served as a proof of concept.
	Additionally manipulating baseline hazards and treatment effects
	illustrated both scenarios that require greater care for interpretation
	and how the simulation point of view aids the interpretation. The
	simulation algorithm applied to real data also provides for a general
	tool for study planning.There are as many hazards as there are competing
	risks. All of them should be analysed. This includes estimation of
	baseline hazards. Study planning must equally account for these aspects.},
  file        = {Allignol2011.pdf:pdf\\Allignol2011.pdf:PDF},
  institution = {Freiburg Center for Data Analysis and Modeling, University of Freiburg, Germany. arthur.allignol@fdm.uni-freiburg.de},
  journal     = {BMC Med Res Methodol},
  medline-pst = {epublish},
  owner       = {pl4},
  pii         = {1471-2288-11-86},
  pmid        = {21639902},
  timestamp   = {2012.02.06},
  year        = {2011},
}

@Manual{Allison1996,
  author       = {Allison, Paul D.},
  title        = {Survival Analysis Using the SAS System: A Practical Guide},
  organization = {Cary, NC: SAS Institute Inc.},
  owner        = {PaulD},
  timestamp    = {2011.06.19},
  year         = {1996},
}

@Article{altman2009b,
  author    = {D. G. Altman},
  title     = {Prognostic models: a methodological framework and review of models for breast cancer.},
  pages     = {235-Â“243},
  volume    = {27},
  file      = {altman2009b.pdf:altman2009b.pdf:PDF},
  journal   = {Cancer Investigation},
  owner     = {BettyS},
  timestamp = {2016.11.28},
  year      = {2009},
}

@Article{Altman1998,
  author      = {D. G. Altman},
  title       = {Confidence intervals for the number needed to treat.},
  number      = {7168},
  pages       = {1309--1312},
  volume      = {317},
  institution = {Imperial Cancer Research Fund Medical Statistics Group, Centre for Statistics in Medicine, Institute of Health Sciences, Oxford OX3 7LF. d.altman@icrf.icnet.uk},
  journal     = {BMJ},
  month       = nov,
  owner       = {pl4},
  pmid        = {9804726},
  timestamp   = {2009.07.07},
  year        = {1998},
}

@Book{Altman1991,
  author    = {Altman, D. G.},
  title     = {Practical Statistics for Medical Research},
  publisher = {London: Chapman and Hall},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1991},
}

@Article{Altman1999,
  author      = {D. G. Altman and P. K. Andersen},
  title       = {Calculating the number needed to treat for trials where the outcome is time to an event.},
  number      = {7223},
  pages       = {1492--1495},
  volume      = {319},
  file        = {Altman1999.pdf:pdf\\Altman1999.pdf:PDF;Altman1999.pdf:Altman1999.pdf:PDF},
  institution = {Imperial Cancer Research Group Medical Statistics Group, Centre for Statistics in Medicine, Institute of Health Sciences, Headington, Oxford OX3 7LF. d.altman@icrf.icnet.uk},
  journal     = {BMJ},
  month       = dec,
  owner       = {pl4},
  pmid        = {10582940},
  timestamp   = {2010.04.12},
  year        = {1999},
}

@Article{Altman1998b,
  author    = {Altman, D. G. and Bland, J. M.},
  title     = {Time to event (survival) data},
  pages     = {468--469},
  volume    = {317},
  journal   = {British Medical Journal},
  owner     = {PaulD},
  timestamp = {2011.06.27},
  year      = {1998},
}

@Article{Altman1994,
  author    = {Altman, D. G. and Lausen, B. and Sauerbrei, W. and Schumacher, M.},
  title     = {Dangers of using "optimal" cutpoints in the evaluation of prognostic factors},
  pages     = {829--35},
  volume    = {86},
  journal   = {Journal of the National Cancer Institute},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1994},
}

@Article{AltRoy00,
  author    = {D. G. Altman and P. Royston},
  title     = {What do we mean by validating a prognostic model?},
  pages     = {453--473},
  volume    = {19},
  file      = {AltRoy00.pdf:AltRoy00.pdf:PDF;AltRoy00.pdf:pdf\\AltRoy00.pdf:PDF},
  journal   = {Statistics in Medicine},
  owner     = {pl4},
  timestamp = {2010.03.08},
  year      = {2000},
}

@Article{Altman1995,
  author      = {D. G. Altman and B. L. De Stavola and S. B. Love and K. A. Stepniewska},
  title       = {Review of survival analyses published in cancer journals.},
  number      = {2},
  pages       = {511--518},
  volume      = {72},
  abstract    = {Survival analysis has found widespread applications in medicine in
	the last 10-15 years. However, there has been no published review
	of the use and presentation of survival analyses. We have carried
	out a systematic review of the research papers published between
	October and December 1991 in five clinical oncology journals. A total
	of 132 papers were reviewed. We looked at several aspects of study
	design, data handling, analysis and presentation of the results.
	We found that almost half of the papers did not give any summary
	of length of follow-up; that in 62\% of papers at least one end point
	was not clearly defined; and that both logrank and multivariate analyses
	were frequently reported at most only as P-values [63/84 (75\%) and
	22/47 (47\%) respectively]. Furthermore, although many studies were
	small, uncertainty of the estimates was rarely indicated [in 13/84
	(15\%) logrank and 16/47 (34\%) multivariate results]. The procedure
	for categorisation of continuous variables in logrank analyses was
	explained in only 8/49 (16\%) papers. The quality of graphs was felt
	to be poor in 43/117 (37\%) papers which included at least one survival
	curve. To address some of the presentational inadequacies found in
	this review we include new suggested guidelines for the presentation
	of survival analyses in medical journals. These would complement
	the statistical guidelines recommended by several clinical oncology
	journals.},
  file        = {altman1995.pdf:altman1995.pdf:PDF},
  institution = {Medical Statistics Laboratory, Imperial Cancer Research Fund, London, UK.},
  journal     = {British Journal of Cancer},
  month       = aug,
  owner       = {pl4},
  pmid        = {7640241},
  timestamp   = {2008.11.18},
  year        = {1995},
}

@Article{altman2009,
  author    = {D. G. Altman and Y. Vergouwe and P. Royston and K. G. M. Moons},
  title     = {Prognosis and prognostic research: validating a prognostic model.},
  volume    = {338},
  journal   = {BMJ},
  owner     = {BettyS},
  timestamp = {2016.11.28},
  year      = {2009},
}

@Article{Ambler2001,
  author    = {Ambler, G. and Royston, P.},
  title     = {Fractional polynomial model selection procedures: investigation of type I error rate},
  number    = {1},
  pages     = {89--108},
  volume    = {69},
  file      = {Ambler2001.pdf:Ambler2001.pdf:PDF;Ambler2001.pdf:pdf\\Ambler2001.pdf:PDF},
  journal   = {Journal of Statistical Computation and Simulation},
  owner     = {pl4},
  timestamp = {2008.12.03},
  year      = {2001},
}

@Article{Ambrogi2008,
  author      = {F. Ambrogi and E. Biganzoli and P. Boracchi},
  title       = {Estimates of clinically useful measures in competing risks survival analysis.},
  doi         = {10.1002/sim.3455},
  number      = {30},
  pages       = {6407--6425},
  volume      = {27},
  abstract    = {Competing risks occur frequently in follow-up clinical studies. To
	assess treatment or covariate effects, measures of clinical impact
	based on crude cumulative incidence should be considered, such as
	relative risks or the absolute risk reduction. In this work, transformation
	models through suitable link functions provide a straightforward
	approach to obtain point and interval estimates of such measures.
	An extension of the Klein and Andersen proposal, based on pseudo-values,
	is considered. Non-additive effects were tested by interactions between
	baseline (spline function on time) and covariates. The methods are
	applied to the evaluation of the impact of axillary lymph node nanometastases
	on metastatic relapse of breast cancer patients. Further, a literature
	data set on prostate cancer was used for illustration.},
  file        = {Ambrogi2008.pdf:Ambrogi2008.pdf:PDF;Ambrogi2008.pdf:pdf\\Ambrogi2008.pdf:PDF},
  institution = {Istituto di Statistica Medica e Biometria},
  journal     = {Statistics in Medicine},
  month       = dec,
  owner       = {pl4},
  pmid        = {18937229},
  timestamp   = {2010.07.05},
  year        = {2008},
}

@Book{ACS2015,
  author    = {{American Cancer Society}},
  title     = {Global Cancer Facts and Figures},
  edition   = {3},
  publisher = {Atlanta: American Cancer Society},
  file      = {ACS2015.pdf:pdf\\ACS2015.pdf:PDF;ACS2015.pdf:ACS2015.pdf:PDF},
  owner     = {PaulD},
  timestamp = {2015.03.02},
  year      = {2015},
}

@Article{Amery1985,
  author    = {A. Amery and W. Birkenh\"{a}ger and P. Brixko and C. Bulpitt and D. Clement and M. Deruyttere and A. De Schaepdryver and C. Dollery and R. Fagard and F. Forette},
  title     = {Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial.},
  number    = {8442},
  pages     = {1349--1354},
  volume    = {1},
  abstract  = {A double-blind randomised placebo-controlled trial of antihypertensive
	treatment was conducted in patients over the age of 60. Entry criteria
	included both a sitting diastolic blood pressure on placebo treatment
	in the range 90-119 mm Hg and a systolic pressure in the range 160-239
	mm Hg. 840 patients were randomised either to active treatment (hydrochlorothiazide
	+ triamterene) or to matching placebo. If the blood pressure remained
	raised, methyldopa was added to the active regimen and matching placebo
	in the placebo group. An overall intention-to-treat analysis, combining
	the double-blind part of the trial and all subsequent follow-up,
	revealed a non-significant change in total mortality rate (-9\%,
	p = 0.41) but a significant reduction in cardiovascular mortality
	rate (-27\%, p = 0.037). The latter was due to a reduction in cardiac
	mortality (-38\%, p = 0.036) and a non-significant decrease in cerebrovascular
	mortality (-32\%, p = 0.16). In the double-blind part of the trial,
	total mortality rate was not significantly reduced (-26\%, p = 0.077).
	Cardiovascular mortality was reduced in the actively treated group
	(-38\%, p = 0.023), owing to a reduction in cardiac deaths (-47\%,
	p = 0.048) and a non-significant decrease in cerebrovascular mortality
	(-43\%, p = 0.15). Deaths from myocardial infarction were reduced
	(-60\%, p = 0.043). Study-terminating morbid cardiovascular events
	were significantly reduced by active treatment (-60\%, p = 0.0064).
	Non-terminating cerebrovascular events were reduced (-52\%, p = 0.026),
	but the non-terminating cardiac events were not (+3\%, p = 0.98).
	In the patients randomised to active treatment there were 29 fewer
	cardiovascular events and 14 fewer cardiovascular deaths per 1000
	patient years during the double-blind part of the trial.},
  journal   = {Lancet},
  month     = jun,
  owner     = {pl4},
  pmid      = {2861311},
  timestamp = {2008.11.18},
  year      = {1985},
}

@Article{Ananth1999,
  author    = {Ananth, Cande V. and Preisser, John S.},
  title     = {Bivariate logistic regression: {M}odelling the association of small for gestational age births in twin gestations},
  pages     = {2011--2023},
  volume    = {18},
  journal   = {Statistics in Medicine},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1999},
}

@Article{Andersen2002,
  author    = {Andersen, Elisabeth Wreford and Andersen, Per Kragh},
  title     = {Adjustment for misclassification in studies of familial aggregation of disease using routine register data},
  pages     = {3595--3607},
  volume    = {21},
  journal   = {Statistics in Medicine},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2002},
}

@Article{Andersen1982,
  author    = {P.K. Andersen and R.D. Gill},
  title     = {Cox's regression model for counting processes: A large sample study.},
  pages     = {1100--1120},
  volume    = {10},
  file      = {Andersen1982.pdf:Andersen1982.pdf:PDF;Andersen1982.pdf:pdf\\Andersen1982.pdf:PDF},
  journal   = {Annals of Statistics},
  owner     = {pl4},
  timestamp = {2010.01.07},
  year      = {1982},
}

@Article{Andersen2013,
  author       = {Andersen, P. K.},
  journal      = {Staististics in Medicine},
  title        = {Decomposition of number of life years lost according to causes of death.},
  doi          = {10.1002/sim.5903},
  language     = {eng},
  pages        = {5278-85},
  url          = {http://dx.doi.org/10.1002/sim.5903},
  volume       = {32},
  abstract     = {We study the competing risks model and show that the cause j cumulative
	incidence function integrated from 0 to ? has a natural interpretation
	as the expected number of life years lost due to cause j before time
	?. This is analogous to the ?-restricted mean lifetime, which is
	the survival function integrated from 0 to ?. It is discussed how
	the number of years lost may be related to subject-specific explanatory
	variables in a regression model based on pseudo-observations, and
	the method is exemplified using data from a bone marrow transplantation
	study. Finally, inclusion of standard mortality rates is discussed.},
  file         = {Andersen2013.pdf:pdf\\Andersen2013.pdf:PDF;Andersen2013.pdf:Andersen2013.pdf:PDF},
  institution  = {Department of Biostatistics, University of Copenhagen, {\AA}Â˜. Farimagsgade 5, PB2099, DK-1014 Copenhagen K, Denmark.},
  journal      = {Statistics in Medicine},
  medline-pst  = {aheadofprint},
  month        = {Jul},
  owner        = {PaulD},
  pmid         = {23839860},
  timestamp    = {2013.07.11},
  year         = {2013},
}

@Article{Andersen1991,
  author    = {Andersen, P. K.},
  title     = {Survival Analysis 1982-1991: The Second Decade of the Proportional Hazards Regression Model},
  pages     = {1931--1941},
  volume    = {10},
  journal   = {Statistics in Medicine},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1991},
}

@Article{Andersen2002a,
  author      = {Per Kragh Andersen and Steen Z Abildstrom and Susanne Rosth{\o}j},
  title       = {Competing risks as a multi-state model.},
  number      = {2},
  pages       = {203--215},
  volume      = {11},
  abstract    = {This paper deals with the competing risks model as a special case
	of a multi-state model. The properties of the model are reviewed
	and contrasted to the so-called latent failure time approach. The
	relation between the competing risks model and right-censoring is
	discussed and regression analysis of the cumulative incidence function
	briefly reviewed. Two real data examples are presented and a guide
	to the practitioner is given.},
  file        = {Andersen2002a.pdf:Andersen2002a.pdf:PDF;Andersen2002a.pdf:pdf\\Andersen2002a.pdf:PDF},
  institution = {Department of Biostatistics, University of Copenhagen, Denmark and Danish Epidemiology Science Centre, Copenhagen, Denmark. pka@biostat.ku.dk},
  journal     = {Stat Methods Med Res},
  month       = apr,
  owner       = {pl4},
  pmid        = {12040697},
  timestamp   = {2010.07.09},
  year        = {2002},
}

@Book{Andersen1996,
  author               = {Andersen, P. K. and Borgan, O. and Gill, R. D. and Keiding, N.},
  title                = {Statistical Models Based on Counting Processes (Springer Series in Statistics)},
  edition              = {Corrected},
  isbn                 = {0387945199},
  publisher            = {Springer},
  url                  = {http://www.worldcat.org/isbn/0387945199},
  abstract             = {Modern survival analysis and more general event history analysis may
	be effectively handled in the mathematical framework of counting
	processes, stochastic integration, martingale central limit theory
	and product integration. This book presents this theory, which has
	been the subject of an intense research activity during the past
	one-and-a- half decades. The exposition of the theory is integrated
	with careful presentation of many practical examples, almost exclusively
	from the authors' own experience, with detailed numerical and graphical
	illustrations. Statistical Models Based on Counting Processes may
	be viewed as a research monograph for mathematical statisticians
	and biostatisticians, although almost all methods are given in concrete
	detail to be used in practice by other mathematically oriented researchers
	studying event histories (demographers, econometricians, epidemiologists,
	actuarial mathematicians, reliabilty engineers and biologists). Much
	of the material has so far only been available in the journal literature
	(if at all), and so a wide variety of researchers will find this
	an invaluable survey of the subject. "This book is a masterful account
	of the counting process approach...is certain to be the standard
	reference for the area, and should be on the bookshelf of anyone
	interested in event-history analysis." --International Statistical
	Institute Short Book Reviews "...this impressive reference, which
	contains a a wealth of powerful mathematics, practical examples,
	and analytic insights, as well as a complete integration of historical
	developments and recent advances in event history analysis." --Journal
	of the American Statistical Association},
  citeulike-article-id = {5281024},
  citeulike-linkout-0  = {http://www.amazon.ca/exec/obidos/redirect?tag=citeulike09-20\&amp;path=ASIN/0387945199},
  citeulike-linkout-1  = {http://www.amazon.de/exec/obidos/redirect?tag=citeulike01-21\&amp;path=ASIN/0387945199},
  citeulike-linkout-2  = {http://www.amazon.fr/exec/obidos/redirect?tag=citeulike06-21\&amp;path=ASIN/0387945199},
  citeulike-linkout-3  = {http://www.amazon.jp/exec/obidos/ASIN/0387945199},
  citeulike-linkout-4  = {http://www.amazon.co.uk/exec/obidos/ASIN/0387945199/citeulike00-21},
  citeulike-linkout-5  = {http://www.amazon.com/exec/obidos/redirect?tag=citeulike07-20\&path=ASIN/0387945199},
  citeulike-linkout-6  = {http://www.worldcat.org/isbn/0387945199},
  citeulike-linkout-7  = {http://books.google.com/books?vid=ISBN0387945199},
  citeulike-linkout-8  = {http://www.amazon.com/gp/search?keywords=0387945199\&index=books\&linkCode=qs},
  citeulike-linkout-9  = {http://www.librarything.com/isbn/0387945199},
  day                  = {20},
  file                 = {:Andersen1996.pdf:PDF},
  howpublished         = {Paperback},
  month                = dec,
  owner                = {pl4},
  posted-at            = {2009-07-27 13:14:59},
  timestamp            = {2010.07.13},
  year                 = {1996},
}

@Article{Andersen2012,
  author    = {Andersen, P. K. and Geskus, R. B. and {de Witte}, T. and Putter, H.},
  title     = {Competing risks in epidemiology: possibilities and pitfalls},
  pages     = {861-70},
  volume    = {41},
  file      = {:Andersen2012.pdf:PDF},
  journal   = {Int J Epidemiol},
  owner     = {PaulD},
  timestamp = {2012.01.17},
  year      = {2012},
}

@Article{Andersen2012a,
  author      = {Andersen, P. K. and Keiding, N.},
  title       = {Interpretability and importance of functionals in competing risks and multistate models.},
  doi         = {10.1002/sim.4385},
  language    = {eng},
  number      = {11-12},
  pages       = {1074--1088},
  url         = {http://dx.doi.org/10.1002/sim.4385},
  volume      = {31},
  abstract    = {The basic parameters in both survival analysis and more general multistate
	models, including the competing risks model and the illness-death
	model, are the transition hazards. It is often necessary to supplement
	the analysis of such models with other model parameters, which are
	all functionals of the transition hazards. Unfortunately, not all
	such functionals are equally meaningful in practical contexts, even
	though they may be mathematically well defined. We have found it
	useful to check whether the functionals satisfy three simple principles,
	which may be used as criteria for practical interpretability.},
  file        = {Andersen2012a.pdf:pdf\\Andersen2012a.pdf:PDF;Andersen2012a.pdf:Andersen2012a.pdf:PDF},
  institution = {Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark. p.k.andersen@biostat.ku.dk},
  journal     = {Stat Med},
  keywords    = {Cause of Death; Data Interpretation, Statistical; Humans; Markov Chains; Models, Statistical; Risk; Survival Analysis},
  medline-pst = {ppublish},
  month       = {May},
  owner       = {pl4},
  pmid        = {22081496},
  timestamp   = {2015.02.04},
  year        = {2012},
}

@Article{Andersen2002b,
  author      = {Andersen, Per Kragh and Keiding, Niels},
  title       = {Multi-state models for event history analysis.},
  language    = {eng},
  number      = {2},
  pages       = {91--115},
  volume      = {11},
  abstract    = {An introduction to event history analysis via multi-state models in
	given. Examples include the two-state model for survival analysis,
	the competing risks and illness-death models, and models for bone
	marrow transplantation. Statistical model specification via transition
	intensities and likelihood inference is introduced. Consequences
	of observational patterns are discussed, and a real example concerning
	mortality and bleeding episodes in a liver cirrhosis trial is discussed.},
  file        = {Andersen2002b.pdf:pdf\\Andersen2002b.pdf:PDF},
  institution = {Department of Biostatistics, University of Copenhagen, Danish Epidemiology Science Centre, Copenhagen, Denmark. pka@biostat.ku.dk},
  journal     = {Stat Methods Med Res},
  keywords    = {Biometry; Bone Marrow Transplantation, adverse effects/statistics /&/ numerical data; Cohort Studies; Death; Humans; Life Change Events; Likelihood Functions; Markov Chains; Models, Biological; Proportional Hazards Models; Regression Analysis; Risk; Software; Survival Analysis},
  medline-pst = {ppublish},
  month       = {Apr},
  owner       = {sanelo},
  pmid        = {12040698},
  timestamp   = {2013.08.02},
  year        = {2002},
}

@Article{Andersen2010,
  author      = {Per Kragh Andersen and Maja Pohar Perme},
  title       = {Pseudo-observations in survival analysis.},
  doi         = {10.1177/0962280209105020},
  number      = {1},
  pages       = {71--99},
  volume      = {19},
  abstract    = {We review recent work on the application of pseudo-observations in
	survival and event history analysis. This includes regression models
	for parameters like the survival function in a single point, the
	restricted mean survival time and transition or state occupation
	probabilities in multi-state models, e.g. the competing risks cumulative
	incidence function. Graphical and numerical methods for assessing
	goodness-of-fit for hazard regression models and for the Fine-Gray
	model in competing risks studies based on pseudo-observations are
	also reviewed. Sensitivity to covariate-dependent censoring is studied.
	The methods are illustrated using a data set from bone marrow transplantation.},
  file        = {Andersen2010.pdf:Andersen2010.pdf:PDF;Andersen2010.pdf:pdf\\Andersen2010.pdf:PDF},
  institution = {Department of Biostatistics, University of Copenhagen, Copenhagen K, Denmark. P.K.Andersen@biostat.ku.dk},
  journal     = {Stat Methods Med Res},
  month       = feb,
  owner       = {pl4},
  pii         = {0962280209105020},
  pmid        = {19654170},
  timestamp   = {2010.07.09},
  year        = {2010},
}

@Article{Andersen1989,
  author      = {P. K. Andersen and M. Vaeth},
  title       = {Simple parametric and nonparametric models for excess and relative mortality.},
  number      = {2},
  pages       = {523--535},
  volume      = {45},
  abstract    = {This paper studies two classes of hazard-rate-based models for the
	mortality in a group of individuals taking normal life expectancy
	into account. In a multiplicative hazard model, the estimate for
	the relative mortality generalises the standardised mortality ratio,
	and the adequacy of a model with constant relative mortality can
	be tested using a type of total time on test statistic. In an additive
	hazard model, continuous-time generalisations of a "corrected" survival
	curve and a "normal" survival curve are obtained, and the adequacy
	of a model with constant excess mortality can again be tested using
	a type of total time on test statistic. A model including both the
	multiplicative hazard model and the additive hazard model is briefly
	considered. The use of the models is illustrated on a set of data
	concerning survival after operation for malignant melanoma.},
  file        = {Andersen1989.pdf:Andersen1989.pdf:PDF;Andersen1989.pdf:pdf\\Andersen1989.pdf:PDF},
  institution = {Statistical Research Unit, University of Copenhagen, Denmark.},
  journal     = {Biometrics},
  month       = jun,
  owner       = {pl4},
  pmid        = {2765636},
  timestamp   = {2008.10.15},
  year        = {1989},
}

@InProceedings{Anderson-Cook97,
  author    = {Anderson-Cook, C. M. and Thornton, Tim and Robles, Randy},
  booktitle = {ASA Proceedings of the Section on Statistics in Sports},
  title     = {Measuring Hockey Powerplay and Penalty Killing Efficiency: {A} New Approach},
  pages     = {11--14},
  publisher = {American Statistical Association (Alexandria, VA)},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1997},
}

@Article{Andersson2009,
  author      = {Andersson, Anne and N{\"a}slund, Ulf and Tavelin, Bj{\"o}rn and Enblad, Gunilla and Gustavsson, Anita and Malmer, Beatrice},
  title       = {Long-term risk of cardiovascular disease in {H}odgkin lymphoma survivors--retrospective cohort analyses and a concept for prospective intervention.},
  doi         = {10.1002/ijc.24147},
  language    = {eng},
  number      = {8},
  pages       = {1914--1917},
  url         = {http://dx.doi.org/10.1002/ijc.24147},
  volume      = {124},
  abstract    = {Previous studies have shown increased cardiovascular mortality as
	late side effects in Hodgkin lymphoma (HL) patients. This study identifies
	stratifying risk factors for surveillance and defines concepts for
	a clinical feasible and noninvasive prospective protocol for intervention
	of cardiovascular side effects. HL patients diagnosed between 1965
	and 1995 (n = 6.946) and their first-degree relatives (FDR) were
	identified through the Swedish Cancer Registry and the Swedish Multigeneration
	Registry. For the HL and FDR cohort, in-patient care for cardiovascular
	disease (CVD) was registered through the Hospital Discharge Registry,
	Sweden. Standard incidence ratios of developing CVD for the HL cohort
	were calculated. A markedly increased risk for in-patient care of
	CVD was observed in HL patients with HL diagnosed at age 40 years
	or younger and with more than 10 years follow-up. In the HL survivors,
	a family history of congestive heart failure (CHF) and coronary artery
	disease (CAD) increased the risk for these diseases. The Swedish
	Hodgkin Intervention and Prevention study started in 2007. In the
	pilot feasibility study for prospective intervention (47 patients),
	about 25\% of the cases had side effects and laboratory abnormalities.
	These patients were referred to a cardiologist or general practitioner.
	In the prospective cohort, a positive family history for CHF or CAD
	could be a stratifying risk factor when setting up a surveillance
	model. The prospective on-going study presents an intervention model
	that screens and treats for comorbidity factors. This article also
	presents an overview of the study concept.},
  institution = {Department of Radiation Sciences, Oncology, Ume{\aa} University, Ume{\aa}, Sweden. anne.andersson@onkologi.umu.se},
  journal     = {Int J Cancer},
  keywords    = {Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases, complications/therapy; Child; Child, Preschool; Cohort Studies; Comorbidity; Female; Follow-Up Studies; Hodgkin Disease, complications/therapy; Humans; Male; Middle Aged; Prospective Studies; Retrospective Studies; Risk},
  medline-pst = {ppublish},
  month       = {Apr},
  owner       = {sanelo},
  pmid        = {19165857},
  timestamp   = {2013.08.07},
  year        = {2009},
}

@PhdThesis{Andersson:phdthesis:2013,
  author    = {Therese Andersson},
  title     = {Quantifying cancer patient survival: extensions and applications of cure models and life expectancy estimation},
  type      = {PhD Thesis},
  url       = {http://publications.ki.se/xmlui/handle/10616/41668},
  file      = {:pdf\\Thesis_Therese_Andersson.pdf:PDF},
  groups    = {PhD Thesis},
  owner     = {PaulD},
  school    = {Karolinska Institutet},
  timestamp = {2013.10.23},
  year      = {2013},
}

@Article{Andersson2013,
  author    = {Andersson, T. M-L. and Dickman, P. W. and Eloranta, S. and Lambe, M. and Lambert, P. C.},
  title     = {Estimating the loss in expectation of life due to cancer using flexible parametric survival models},
  doi       = {10.1002/sim.5943},
  pages     = {5286-5300},
  volume    = {32},
  file      = {Andersson2013.pdf:pdf\\Andersson2013.pdf:PDF},
  groups    = {Study 1. Extrapolation, ec_phd},
  journal   = {Statistics in Medicine},
  owner     = {pl4},
  timestamp = {2013.02.05},
  year      = {2013},
}

@Article{Andersson2011,
  author      = {T. M-L. Andersson and P. W. Dickman and S. Eloranta and P. C. Lambert},
  title       = {Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models.},
  doi         = {10.1186/1471-2288-11-96},
  language    = {eng},
  number      = {1},
  pages       = {96},
  volume      = {11},
  abstract    = {ABSTRACT: BACKGROUND: When the mortality among a cancer patient group
	returns to the same level as in the general population, that is,
	the patients no longer experience excess mortality, the patients
	still alive are considered "statistically cured". Cure models can
	be used to estimate the cure proportion as well as the survival function
	of the "uncured". One limitation of parametric cure models is that
	the functional form of the survival of the "uncured" has to be specified.
	It can sometimes be hard to find a survival function flexible enough
	to fit the observed data, for example, when there is high excess
	hazard within a few months from diagnosis, which is common among
	older age groups. This has led to the exclusion of older age groups
	in population-based cancer studies using cure models. METHODS: Here
	we have extended the flexible parametric survival model to incorporate
	cure as a special case to estimate the cure proportion and the survival
	of the "uncured". Flexible parametric survival models use splines
	to model the underlying hazard function, and therefore no parametric
	distribution has to be specified. RESULTS: We have compared the fit
	from standard cure models to our flexible cure model, using data
	on colon cancer patients in Finland. This new method gives similar
	results to a standard cure model, when it is reliable, and better
	fit when the standard cure model gives biased estimates. CONCLUSIONS:
	Cure models within the framework of flexible parametric models enables
	cure modelling when standard models give biased estimates. These
	flexible cure models enable inclusion of older age groups and can
	give stage-specific estimates, which is not always possible from
	parametric cure models.},
  file        = {Andersson2011.pdf:Andersson2011.pdf:PDF},
  journal     = {BMC Medical Research Methodology},
  keywords    = {Cure models; theory},
  medline-pst = {aheadofprint},
  owner       = {PaulD},
  pii         = {1471-2288-11-96},
  pmid        = {21696598},
  timestamp   = {2011.07.03},
  year        = {2011},
}

@Article{Andersson2015,
  author      = {Andersson, T. M-L. and Dickman, P. W. and Eloranta, S. and Sj{\"{o}}vall, A. and Lambe, M. and Lambert, P. C.},
  title       = {The loss in expectation of life after colon cancer: a population-based study.},
  doi         = {10.1186/s12885-015-1427-2},
  language    = {eng},
  number      = {1},
  pages       = {412},
  url         = {http://dx.doi.org/10.1186/s12885-015-1427-2},
  volume      = {15},
  abstract    = {To demonstrate how assessment of life expectancy and loss in expectation
	of life can be used to address a wide range of research questions
	of public health interest pertaining to the prognosis of cancer patients.We
	identified 135,092 cases of colon adenocarcinoma diagnosed during
	1961-2011 from the population-based Swedish Cancer Register. Flexible
	parametric survival models for relative survival were used to estimate
	the life expectancy and the loss in expectation of life.The loss
	in expectation of life for males aged 55 at diagnosis was 13.5ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years
	(95ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â \% CI 13.2-13.8) in 1965 and 12.8 (12.4-13.3) in 2005. For males
	aged 85 the corresponding figures were 3.21 (3.15-3.28) and 2.10
	(2.04-2.17). The pattern was similar for females, but slightly greater
	loss in expectation of life. The loss in expectation of life is reduced
	given survival up to a certain time point post diagnosis. Among patients
	diagnosed in 2011, 945 life years could potentially be saved if the
	colon cancer survival among males could be brought to the same level
	as for females.Assessment of loss in expectation of life facilitates
	the understanding of the impact of cancer, both on individual and
	population level. Clear improvements in survival among colon cancer
	patients have led to a gain in life expectancy, partly due to a general
	increase in survival from all causes.},
  file        = {Andersson2015.pdf:Andersson2015.pdf:PDF},
  institution = {Department of Health Sciences, University of Leicester, Leicester, UK. pl4@leicester.ac.uk.},
  journal     = {BMC Cancer},
  medline-pst = {epublish},
  owner       = {pl4},
  pii         = {10.1186/s12885-015-1427-2},
  pmid        = {25982368},
  timestamp   = {2015.05.28},
  year        = {2015},
}

@Article{Andersson2014,
  author      = {Andersson, T. M-L. and Eriksson, H. and Hansson, J. and M{\aa}nsson-Brahme, E. and Dickman, P. W. and Eloranta, S. and Lambe, M. and Lambert, P. C.},
  title       = {Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: a population-based study.},
  doi         = {10.1016/j.canep.2013.12.006},
  language    = {eng},
  number      = {1},
  pages       = {93--99},
  url         = {http://dx.doi.org/10.1016/j.canep.2013.12.006},
  volume      = {38},
  abstract    = {A large proportion of patients with cutaneous malignant melanoma (CMM)
	do not experience excess mortality due to their disease. This group
	of patients is referred to as the cure proportion. Few studies have
	examined the possibility of cure for CMM. The aim of this study was
	to estimate the cure proportion of patients with CMM in a Swedish
	population.We undertook a population-based study of 5850 CMM patients
	in two Swedish health care regions during 1996-2005. We used flexible
	parametric cure models to estimate cure proportions and median survival
	times (MSTs) of uncured by stage, sex, age and anatomical site.Disease
	stage at diagnosis was the most important factor for the probability
	of cure, with a cure proportion of approximately 1.0 for stage IA.
	While the probability of cure decreased with older age, the influence
	of age was smaller on the MST of uncured. Differences in prognosis
	between males and females were mainly attributed to differences in
	cure as opposed to differences in MST of uncured.This population-based
	study showed approximately 100\% cure among stage IA disease. Almost
	50\% of patients had stage IA disease and the high cure proportion
	for this large patient group is reassuring.},
  file        = {Andersson2014.pdf:pdf\\Andersson2014.pdf:PDF;Andersson2014.pdf:Andersson2014.pdf:PDF},
  institution = {Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; University of Leicester, Department of Health Sciences, Leicester, UK.},
  journal     = {Cancer Epidemiology},
  medline-pst = {ppublish},
  month       = {Feb},
  owner       = {PaulD},
  pii         = {S1877-7821(13)00192-6},
  pmid        = {24447700},
  timestamp   = {2014.04.28},
  year        = {2014},
}

@Article{Andersson2012,
  author    = {T. M-L. Andersson and P. C. Lambert},
  title     = {Fitting and modeling cure in population-based cancer studies within the framework of flexible parametric survival models},
  number    = {4},
  pages     = {623-628},
  volume    = {12},
  file      = {Andersson2012.pdf:pdf\\Andersson2012.pdf:PDF;Andersson2012.pdf:Andersson2012.pdf:PDF},
  journal   = {The Stata Journal},
  keywords  = {Cure models; theory},
  owner     = {pl4},
  timestamp = {2012.03.31},
  year      = {2012},
}

@Article{Andersson2010,
  author      = {T. M-L. Andersson and P. C. Lambert and A. R. Derolf and S. Y. Kristinsson and S. Eloranta and O. Landgren and M. Bj\"{o}rkholm and P. W. Dickman},
  title       = {Temporal trends in the proportion cured among adults diagnosed with acute myeloid leukaemia in {S}weden 1973-2001, a population-based study.},
  doi         = {10.1111/j.1365-2141.2009.08026.x},
  pages       = {918--924},
  volume      = {148},
  abstract    = {Large age-dependant differences in temporal trends in 1- and 5-year
	relative survival have been observed in patients with acute myeloid
	leukaemia (AML) in Sweden. This investigation used an alternative
	approach to studying patient survival that simultaneously estimated
	the proportion of patients cured from their cancer and the survival
	of the 'uncured'. We conducted a population-based study including
	6439 AML patients aged 19-80 years in Sweden between 1973 and 2001.
	Mixture cure models were estimated, with age at diagnosis categorised
	(19-40, 41-60, 61-70 and 71-80) and year of diagnosis modelled using
	splines. In 1975 the cure proportion was </=6\% in all age groups
	and the median survival time for 'uncured' patients was <0.5 years.
	In 2000 the cure proportion was 68\% (95\% confidence interval 56-77\%)
	in the youngest group, and 32\% (25-39\%), 8\% (3-21\%), and 4\%
	(2-8\%) in the other groups, respectively. The median survival times
	for 'uncured' were 0.74 (0.43-1.26), 0.71 (0.53-0.97), 0.69 (0.51-0.95)
	and 0.37 (0.31-0.44) years, respectively. A dramatic improvement
	in the cure proportion was seen in younger patients, whereas improvement
	in older ages was mainly within the survival of the 'uncured'. This
	novel approach of analysing survival data could be a valuable tool
	for physicians, patients, health care planners and health economists.},
  file        = {Andersson2010.pdf:Andersson2010.pdf:PDF;Andersson2010.pdf:pdf\\Andersson2010.pdf:PDF},
  institution = {Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.},
  journal     = {Br J Haematol},
  keywords    = {Cure models; Application},
  month       = dec,
  owner       = {pl4},
  pii         = {BJH8026},
  pmid        = {19995394},
  timestamp   = {2010.04.05},
  year        = {2010},
}

@Conference{Andersson2012a,
  author       = {Andersson, T. M-L. and Lambert, P. C and Eriksson, H and M{\aa}nsson-Brahme, E and Hansson, J and Dickman, P. W. and Eloranta, S and Lambe, M},
  title        = {Estimating the cure proportion of malignant melanoma, a population-based study in 2 regions of {S}weden},
  note         = {Conference abstract},
  organization = {The {A}nnual meeting of the {A}ssociation of the {N}ordic {C}ancer {R}egistries},
  address      = {Oslo, Norway},
  month        = {Aug},
  owner        = {sanelo},
  timestamp    = {2013.10.11},
  year         = {2012},
}

@Article{Andrae2012,
  author      = {Andrae, B. and Andersson, T. M-L. and Lambert, P. C. and Kemetli, L. and Silfverdal, L. and Strander, B. and Ryd, W. and Dillner, J. and T\"{o}rnberg, S. and Spar\'{e}n, P.},
  title       = {Screening and cervical cancer cure: population based cohort study.},
  doi         = {10.1136/bmj.e900},
  language    = {eng},
  pages       = {e900},
  volume      = {344},
  abstract    = {To determine whether detection of invasive cervical cancer by screening
	results in better prognosis or merely increases the lead time until
	death.Nationwide population based cohort study.Sweden.All 1230 women
	with cervical cancer diagnosed during 1999-2001 in Sweden prospectively
	followed up for an average of 8.5 years.Cure proportions and five
	year relative survival ratios, stratified by screening history, mode
	of detection, age, histopathological type, and FIGO (International
	Federation of Gynecology and Obstetrics) stage.In the screening ages,
	the cure proportion for women with screen detected invasive cancer
	was 92\% (95\% confidence interval 75\% to 98\%) and for symptomatic
	women was 66\% (62\% to 70\%), a statistically significant difference
	in cure of 26\% (16\% to 36\%). Among symptomatic women, the cure
	proportion was significantly higher for those who had been screened
	according to recommendations (interval cancers) than among those
	overdue for screening: difference in cure 14\% (95\% confidence interval
	6\% to 23\%). Cure proportions were similar for all histopathological
	types except small cell carcinomas and were closely related to FIGO
	stage. A significantly higher cure proportion for screen detected
	cancers remained after adjustment for stage at diagnosis (difference
	15\%, 7\% to 22\%).Screening is associated with improved cure of
	cervical cancer. Confounding cannot be ruled out, but the effect
	was not attributable to lead time bias and was larger than what is
	reflected by down-staging. Evaluations of screening programmes should
	consider the assessment of cure proportions.},
  file        = {Andrae2012.pdf:Andrae2012.pdf:PDF},
  institution = {Centre for Research and Development, Uppsala University/County Council of G\"{a}vleborg S-80188 G\"{a}vle, Sweden.},
  journal     = {BMJ},
  medline-pst = {epublish},
  owner       = {pl4},
  pmid        = {22381677},
  timestamp   = {2012.03.31},
  year        = {2012},
}

@Article{Andrinopoulou2012,
  author      = {Andrinopoulou, Eleni-Rosalina and Rizopoulos, Dimitris and Jin, Ruyun and Bogers, Ad J J C. and Lesaffre, Emmanuel and Takkenberg, Johanna J M.},
  title       = {An introduction to mixed models and joint modeling: analysis of valve function over time.},
  doi         = {10.1016/j.athoracsur.2012.02.049},
  language    = {eng},
  number      = {6},
  pages       = {1765--1772},
  volume      = {93},
  abstract    = {An important target of many clinical studies is to identify biomarkers,
	including risk scores, with strong prognostic capabilities. While
	biomarker evaluations are commonly utilized to predict the progress
	of the disease at single time points, appropriate statistical tools
	to assess the prognostic value of serial biomarker evaluation are
	rarely used. The goal of this paper is to demonstrate flexible and
	appropriate statistical methodology to assess the predictive capability
	of serial echocardiographic measurements of allograft aortic valve
	function. Moreover, the concept of joint modeling of longitudinal
	and survival data to optimally utilize the relationship between repeated
	valve function measurements and time-to-death or time-to-reoperation,
	is introduced and illustrated. Optimal and suboptimal methods are
	illustrated using a prospective cohort of patients who survived aortic
	valve or root replacement with an allograft valve and who were followed
	clinically and echocardiographically over time.},
  file        = {Andrinopoulou2012.pdf:Andrinopoulou2012.pdf:PDF},
  institution = {Department of Biostatistics, Erasmus MC, Rotterdam, The Netherlands; Department of Cardiothoracic Surgery, Erasmus MC, Rotterdam, The Netherlands.},
  journal     = {Ann Thorac Surg},
  medline-pst = {ppublish},
  month       = jun,
  owner       = {pl4},
  pii         = {S0003-4975(12)00409-2},
  pmid        = {22632482},
  timestamp   = {2012.06.16},
  year        = {2012},
}

@Article{De_angelis1999,
  author      = {R. {De Angelis} and R. Capocaccia and T. Hakulinen and B. Soderman and A. Verdecchia},
  title       = {Mixture models for cancer survival analysis: application to population-based data with covariates.},
  number      = {4},
  pages       = {441--454},
  volume      = {18},
  abstract    = {The interest in estimating the probability of cure has been increasing
	in cancer survival analysis as the curability of many cancer diseases
	is becoming a reality. Mixture survival models provide a way of modelling
	time to death when cure is possible, simultaneously estimating death
	hazard of fatal cases and the proportion of cured case. In this paper
	we propose an application of a parametric mixture model to relative
	survival rates of colon cancer patients from the Finnish population-based
	cancer registry, and including major survival determinants as explicative
	covariates. Disentangling survival into two different components
	greatly facilitates the analysis and the interpretation of the role
	of prognostic factors on survival patterns. For example, age plays
	a different role in determining, from one side, the probability of
	cure, and, from the other side, the life expectancy of fatal cases.
	The results support the hypothesis that observed survival trends
	are really due to a real prognostic gain for more recently diagnosed
	patients.},
  file        = {De_angelis1999.pdf:De_angelis1999.pdf:PDF;De_angelis1999.pdf:pdf\\De_angelis1999.pdf:PDF},
  institution = {Istituto Superiore di Sanita, Laboratory of Epidemiology and Biostatistics, Roma, Italy.},
  journal     = {Statistics in Medicine},
  keywords    = {Cure models},
  month       = feb,
  owner       = {pl4},
  pii         = {3.0.CO;2-M},
  pmid        = {10070685},
  timestamp   = {2008.12.05},
  year        = {1999},
}

@Article{Angell-Andersen2004,
  author      = {E. Angell-Andersen and S. Tretli and M. P. Coleman and F. Langmark and T. Grotmol},
  title       = {Colorectal cancer survival trends in Norway 1958-1997.},
  doi         = {10.1016/j.ejca.2003.09.034},
  number      = {5},
  pages       = {734--742},
  volume      = {40},
  abstract    = {The purpose of this study was to examine the pattern of survival for
	colorectal adenocarcinoma (CRC), and to investigate the prognostic
	factors for the disease. In the analysis, 50993 cases of CRC aged
	40-84 years, diagnosed between 1958 and 1997 in Norway, were included.
	Esteve's relative survival method was used, together with a time
	trend analysis, conducted by least-squares linear regression. Cox
	proportional hazards regression analysis was used to examine cause-specific
	mortality. Five-year relative CRC survival has increased by an estimated
	3\% per 5-year diagnostic period. In 1958-1962, relative survival
	was about 40\% for both males and females, and increased to 56 and
	60\%, respectively, in 1993-1997. Rectal cancer had a higher cause-specific
	mortality (RR 1.26, 95\% CI 1.22-1.30) than proximal colon (reference)
	and distal colon (RR 0.97, 95\% CI 0.93-1.00 cancers), while females
	had a lower cause-specific mortality than males (RR 0.88, 95\% CI
	0.86-0.90). The increase in the relative survival rate in Norway
	is probably due to improved treatments and advanced diagnostics.
	Norway has a higher CRC survival rate than the EUROCARE average.},
  file        = {Angell-Andersen2004.pdf:Angell-Andersen2004.pdf:PDF;Angell-Andersen2004.pdf:pdf\\Angell-Andersen2004.pdf:PDF},
  institution = {Cancer Registry of Norway, Institute of Population-based Cancer Research, Montebello, N-0310 Oslo, Norway. elisabeth.andersen@kreftregisteret.no},
  journal     = {European Journal of Cancer},
  month       = mar,
  owner       = {pl4},
  pii         = {S0959804903009225},
  pmid        = {15010075},
  timestamp   = {2008.10.15},
  year        = {2004},
}

@Article{Antunes2016,
  author    = {Antunes, L. and Mendon\c{c}a, D. and Bento, M.J. and Rachet, B.},
  title     = {No inequalities in survival from colorectal cancer by education and socioeconomic deprivation - a population-based study in the North Region of Portugal, 2000-2002},
  pages     = {608},
  volume    = {16},
  file      = {Antunes2016.pdf:Antunes2016.pdf:PDF;Antunes2016.pdf:pdf\\Antunes2016.pdf:PDF},
  journal   = {BMC Cancer},
  owner     = {hanbow},
  timestamp = {2016.09.06},
  year      = {2016},
}

@Article{Aparicio2001,
  author      = {Aparicio, T. and Ducreux, M. and Baudin, E. and Sabourin, J. C. and {De Baere}, T. and Mitry, E. and Schlumberger, M. and Rougier, P.},
  title       = {Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.},
  language    = {eng},
  number      = {8},
  pages       = {1014--1019},
  volume      = {37},
  abstract    = {A few studies have suggested an antitumour activity of somatostatin
	analogues in neuroendocrine tumours (NET). The aim of this study
	was to evaluate the antitumour efficacy of somatostatin analogues
	in patients with documented progressive tumours. 35 consecutive patients
	with documented tumour progression were treated with somatostatin
	analogues. Patients were classified into two groups. In Group 1,
	tumours were progressing rapidly (an increase of 50\% or more in
	the lesion surface area in 3 months) and in Group 2, tumours were
	progressing more slowly (an increase of less than 50\% in the lesion
	surface area in 3 months but greater than 25\% in 6 months). Treatment
	consisted of subcutaneous (s.c.) octreotide, 100 microg thrice daily
	for 17 patients, intramuscular lanreotide, 30 mg/every 14 days for
	11 patients and for 7 patients both somatostatin analogues were used
	successively during the follow-up. Primary tumour sites were the
	small intestine (n=12), pancreas (n=13), lungs (n=5), and other sites
	(n=5). 18 patients had the carcinoid syndrome with flushing and/or
	diarrhoea. The median duration of treatment was 7 months. Treatment
	was discontinued in 3 patients due to side-effects. One patient (3\%)
	achieved a partial response and the disease was stabilised in 20
	patients (57\%) for a median duration of 11 months (6-48 months).
	Stabilisation of patients in Group 1 was significantly less frequent
	at 6 months than that of patients in Group 2 (4/12 and 13/17 respectively,
	P<0.02). Somatostatin analogue treatment resulted in one partial
	response (3\%) and 20 cases of stabilisation (57\%) in 35 patients
	with progressive NET. A slow tumour growth rate before treatment
	is predictive of a good response to somatostatin analogues which
	could be considered an option for first-line treatment.},
  institution = {Service de Gastroentologie, Institut Gustave Roussy, 94805, Villejuif, France.},
  journal     = {Eur J Cancer},
  keywords    = {Adult; Aged; Antineoplastic Agents, Hormonal, therapeutic use; Disease Progression; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors, drug therapy; Octreotide, therapeutic use; Peptides, Cyclic, therapeutic use; Somatostatin, analogs /&/ derivatives/therapeutic use; Treatment Outcome},
  medline-pst = {ppublish},
  month       = {May},
  owner       = {pl4},
  pii         = {S0959804901000739},
  pmid        = {11334727},
  timestamp   = {2013.05.29},
  year        = {2001},
}

@Article{Ar1991,
  author      = {Ar, A. and Girard, H. and Rodeau, J. L.},
  title       = {Oxygen uptake and chorioallantoic blood flow changes during acute hypoxia and hyperoxia in the 16 day chicken embryo.},
  language    = {eng},
  number      = {3},
  pages       = {295--312},
  volume      = {83},
  abstract    = {Oxygen consumption rate (MO2) of hen eggs was measured on incubation
	day 16 (37.8 degrees C, 55\% humidity) during acute exposure (90
	min) to ambient hyperoxia (FI02 = 0.42) or hypoxia (FIO2 = 0.105).
	During the last part of these exposures, an H2 washout method was
	used to estimate relative changes in chorioallantoic membrane (CAM)
	blood flow, taking as an index the net change in the H2 washout rate
	constant between any experimental condition and the circulation arrested
	egg. Doubling normoxic FIO2 increased MO2 to an asymptotic value
	which was 4\% above the normal (P less than 0.05; MO2 in normoxia
	= 890 mumols/h) even after correcting for the normoxic increase in
	MO2 with time during development (delta MO2/delta t = 21.5 mumols/h2;
	P less than 0.001). Halving FIO2 reduced MO2 calculated in the same
	way to 388 mumols/h. The estimate of the CAM blood flow, relative
	to normoxia, was 1.12 in hyperoxia (not significant, P = 0.05) and
	0.68 in hypoxia (P less than 0.001). The limited changes in CAM blood
	flow and MO2 during hyperoxia indicate that they are both already
	close to their maximal values in normoxia. During acute hypoxia the
	16 day embryo behaves as an oxygen-conformer; however, the small
	relative decrease in MO2 per unit of the flow index observed during
	hyperoxia suggests that the embryo can regulate its CAM blood flow
	to a small extent. The survival of the embryo and its recovery from
	hypoxia without a detectable O2 repayment suggest small if any anaerobic
	regulatory pathways and indicate a true metabolic depression.},
  institution = {Laboratoire d'Etude des Relations Physiologiques, CNRS, l'Universitas Louis Pasteur, Strasbourg, France.},
  journal     = {Respir Physiol},
  keywords    = {Allantois, blood supply/metabolism; Animals; Anoxia; Chick Embryo; Chorion, blood supply/metabolism; Hydrogen, metabolism; Kinetics; Oxygen Consumption; Statistics as Topic},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {pl4},
  pmid        = {2052758},
  timestamp   = {2013.05.29},
  year        = {1991},
}

@Article{Aranda81,
  author    = {F. J. Aranda-Ordaz},
  title     = {On two families of transformations to additivity for binary response data},
  pages     = {357--363},
  volume    = {68},
  file      = {Aranda81.pdf:Aranda81.pdf:PDF;Aranda81.pdf:pdf\\Aranda81.pdf:PDF},
  journal   = {Biometrika},
  timestamp = {2005.11.01},
  year      = {1981},
}

@Article{Armstrong1995,
  author      = {B. G. Armstrong},
  title       = {Comparing standardized mortality ratios.},
  language    = {eng},
  number      = {1},
  pages       = {60--64},
  volume      = {5},
  abstract    = {It is well known that the ratio of two standardized mortality ratios
	(SMRs) is not in general an unbiased estimate of the underlying within-stratum
	ratio of rates of one subcohort relative to another. It is also established,
	although less well known, that a sufficient condition for unbiasedness
	is that the underlying stratum-specific rates in each of the two
	subcohorts be proportional to the reference population. Further,
	the ratio of SMRs is more precise than the wholly internal (Poisson
	regression) estimate of rate ratio. In data that are compatible with
	the proportionality assumption, use of the ratio of SMRs thus buys
	precision at the cost of increased vulnerability to bias. To further
	elucidate choice between methods, we derive expressions for the asymptotic
	precision of each. These show that improved precision of ratio of
	SMRs depends on the extent to which the distribution of expected
	deaths over strata is different in the two cohorts, or equivalently,
	on the variance over strata of the proportion of expected deaths
	falling in the first cohort. The results are illustrated by hypothetic
	examples.},
  file        = {Armstrong1995.pdf:Armstrong1995.pdf:PDF},
  institution = {School of Occupational Health, McGill University, Montreal, Quebec, Canada.},
  journal     = {Ann Epidemiol},
  medline-pst = {ppublish},
  month       = jan,
  owner       = {PaulD},
  pii         = {104727979400032O},
  pmid        = {7728286},
  timestamp   = {2010.06.11},
  year        = {1995},
}

@Article{Armstrong1992,
  author    = {Armstrong, B. K.},
  title     = {The Role of the Cancer Registry in Cancer Control},
  pages     = {569--579},
  volume    = {3},
  file      = {Armstrong1992.pdf:pdf\\Armstrong1992.pdf:PDF;Armstrong1992.pdf:Armstrong1992.pdf:PDF},
  journal   = {Cancer Cause Control},
  owner     = {PaulD},
  timestamp = {2016.01.08},
  year      = {1992},
}

@Article{Armstrong1984,
  author    = {Armstrong, B. K.},
  title     = {Survival of Patients with Cancer (Editorial)},
  pages     = {698--699},
  volume    = {141},
  journal   = {Medical Journal of Australia},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1984},
}

@Article{Arndt2004,
  author    = {V. Arndt and M. Talb\"{a}ck and O. Gefeller and T. Hakulinen and H. Brenner},
  title     = {Modification of SAS macros for a more efficient analysis of relative survival rates.},
  doi       = {10.1016/j.ejca.2003.12.013},
  number    = {5},
  pages     = {778--779},
  volume    = {40},
  file      = {Arndt2004.pdf:Arndt2004.pdf:PDF;Arndt2004.pdf:pdf\\Arndt2004.pdf:PDF},
  journal   = {European Journal of Cancer},
  month     = mar,
  owner     = {pl4},
  pii       = {S0959804904000073},
  pmid      = {15010081},
  timestamp = {2008.12.02},
  year      = {2004},
}

@Article{Askling2001,
  author    = {J Askling and PW Dickman and P Karl\'{e}n and O Brostr\"{o}m and A Lapidus and R L\"{o}fberg and A Ekbom},
  title     = {Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study.},
  number    = {9252},
  pages     = {262--6},
  volume    = {357},
  abstract  = {BACKGROUND: Inflammatory bowel disease (IBD) and colorectal cancer
	might share a common cause and, therefore, relatives of patients
	with IBD could be at increased risk of this malignant disease. We
	aimed to assess cancer rates among first-degree relatives of patients
	with IBD to try to determine whether an association between the two
	diseases exists. METHODS: In a population-based study, we identified
	114,102 first-degree relatives by registry linkage and followed them
	up for cancer occurrence. We used standardised incidence ratio (SIR)
	of cancer as relative risk. FINDINGS: 560 colorectal cancers were
	identified among relatives. First-degree relatives of patients with
	Crohn's disease or ulcerative colitis were not at increased risk
	of cancer (SIR 0.90, 95\% CI 0.82-0.97). The relative risk was 0.96
	(0.87-1.06, n=379) for colon cancer and 0.78 (0.68-0.91, 181) for
	rectal cancer. The SIRs were not affected by age, relation to patient,
	or type or extent of IBD in the patient. Relatives of patients with
	both IBD and colorectal cancer had an 80\% increased risk of colorectal
	cancer. INTERPRETATION: Our results do not endorse a common cause
	of IBD and colorectal cancer. The slightly decreased relative risk
	for colorectal cancer among relatives could indicate the proportion
	of all colorectal cancer cases attributable to IBD.},
  journal   = {Lancet},
  month     = jan,
  owner     = {PaulD},
  pii       = {S0140673600036126},
  timestamp = {2011.06.19},
  year      = {2001},
}

@Article{Askling2001a,
  author    = {J Askling and PW Dickman and P Karl\'{e}n and O Brostr\"{o}m and A Lapidus and R L\"{o}fberg and A Ekbom},
  title     = {Family history as a risk factor for colorectal cancer in inflammatory bowel disease.},
  number    = {6},
  pages     = {1356--62},
  volume    = {120},
  abstract  = {BACKGROUND & AIMS: Familial colorectal cancer (CRC) is a risk factor
	for CRC in healthy individuals and, as indicated by case-control
	studies, possibly in ulcerative colitis. Little is known about the
	cancer risk in familial inflammatory bowel disease (IBD). We assessed
	the significance of familial CRC, or IBD, on the risk for CRC in
	patients with IBD. METHODS: Population-based cohort study of 19,876
	individuals with ulcerative colitis or Crohn's disease born between
	1941 and 1995. Registry-based follow-up and assessment of familial
	CRC, and IBD. Risk of CRC assessed as incidence proportion ("absolute
	risk," IP) and relative risk (RR). RESULTS: Familial CRC was associated
	with a more than 2-fold risk of CRC (adjusted RR = 2.5, 95\% confidence
	interval 1.4-4.4) and an increase in the IP of CRC at 54 years of
	age from 3.8\% to 6.9\%. Patients with a first-degree relative diagnosed
	with CRC before 50 years of age had a higher RR (9.2, 95\% confidence
	interval 3.7-23) and the highest IP (29\%). No association with familial
	IBD was observed. CONCLUSIONS: Information on family history of CRC
	may be a simple way to identify individuals with IBD at elevated
	risk of developing CRC.},
  journal   = {Gastroenterology},
  month     = may,
  owner     = {PaulD},
  pii       = {S0016508501665193},
  timestamp = {2011.06.19},
  year      = {2001},
}

@Article{Aubard2002,
  author      = {Aubard, Y. and Genet, D. and Eyraud, J. L. and Clavere, P. and Tubiana-Mathieu, N. and Philippe, H. J.},
  title       = {Impact of screening on breast cancer detection. Retrospective comparative study of two periods ten years apart.},
  language    = {eng},
  number      = {1},
  pages       = {37--41},
  volume      = {23},
  abstract    = {The aim of this study was to evaluate changes in the mode of discovery
	of breast cancer in the last 15 years. We compared two periods separated
	by a 10-year interval, during which a mass mammographic screening
	programme was established in our department.We made a retrospective
	comparison of the records of female patients with breast cancer diagnosed
	in our hospital over the period 1986-1989 (first period) and 1997-1999
	(second period). The mass screening programme for breast cancer began
	in 1995.We collected 372 patients in the first period and 341 in
	the second. We found a significant change in the mode of the discovery
	of breast cancer between the two periods: 80.2\% versus 51.9\%, respectively,
	of the cases of breast cancer were discovered by breast self-examination,
	10.2\% versus 13.7\% were discovered by a physician, and 4.8\% versus
	29.1\% were discovered by routine mammography as part of an individual
	or mass screening programme. The mean size of the tumours decreased
	significantly (2.6 cm versus 2.3 cm: p = 0.019), and the number of
	tumours with initial metastases or lymph node involvement decreased,
	almost attaining the level of significance (p = 0.06). It is difficult
	to compare the survival and disease-free survival curves because
	of the short follow-up in the second period (median follow-up = 10
	months). However, a marked difference appears to be developing (p
	< 0.0001): patients diagnosed by mammography are showing better survival
	and disease-free survival compared with the others.We observed that
	more widespread use of mammography screening for breast cancer led
	to smaller tumours being discovered during the second period, with
	less lymph node involvement and less initial metastasis. Breast cancer
	screening is one of the most intensively evaluated health care practices
	with eight completed randomized trials yet its net benefit has remained
	controversial. It has been shown that, at least for patients aged
	50 to 70, properly organized mass screening for breast cancer led
	to a reduction in mortality rate. However, individual breast self-exam,
	physician and mammographic screening can interfere with assessment
	of mass screening programmes in terms of individual benefit. In addition,
	introducing a mass screening programme may induce opportunistic screening
	in non-invited age groups and influence health behaviour in the target
	and non target populations. A retrospective study was performed to
	evaluate the mode of discovery, the diagnostic presentation, and
	prognostic factors in breast cancer in a French department before
	and after initiation of a mass-screening programme (MSP).},
  institution = {CHU Dupuytren, Limoges, France.},
  journal     = {Eur J Gynaecol Oncol},
  keywords    = {Adult; Age Distribution; Aged; Breast Neoplasms, epidemiology/prevention /&/ control; Disease-Free Survival; Female; France, epidemiology; Humans; Incidence; Mammography, methods/statistics /&/ numerical data; Mass Screening, organization /&/ administration; Middle Aged; Probability; Program Development; Program Evaluation; Risk Factors; Survival Analysis; Time Factors},
  medline-pst = {ppublish},
  owner       = {pl4},
  pmid        = {11876389},
  timestamp   = {2013.05.29},
  year        = {2002},
}

@Article{Augustsson1999,
  author    = {Augustsson, K. and Skog, K. and J{\"a}gerstad, M. and Dickman, P. W. and Steineck, G.},
  title     = {Dietary heterocyclic amines and cancer of the colon, rectum, bladder, and kidney: a population-based study},
  pages     = {703--707},
  volume    = {353},
  journal   = {Lancet},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1999},
}

@Article{Auvinen1992,
  author    = {Auvinen, A.},
  title     = {Social Class and Colon Cancer Survival in {F}inland},
  pages     = {402--409},
  volume    = {70},
  journal   = {Cancer},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1992},
}

@Article{Auvinen1995,
  author    = {Auvinen, Anssi and Karjalainen, Sakari and Pukkala, Eero},
  title     = {Social Class and Cancer Patient Survival in {F}inland},
  pages     = {1089--1102},
  volume    = {142},
  journal   = {American Journal of Epidemiology},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@Article{Ayadi2001,
  author      = {Ayadi, A. and Zheng, H. and Sobieszczuk, P. and Buchwalter, G. and Moerman, P. and Alitalo, K. and Wasylyk, B.},
  title       = {Net-targeted mutant mice develop a vascular phenotype and up-regulate egr-1.},
  doi         = {10.1093/emboj/20.18.5139},
  language    = {eng},
  number      = {18},
  pages       = {5139--5152},
  url         = {http://dx.doi.org/10.1093/emboj/20.18.5139},
  volume      = {20},
  abstract    = {The ternary complex factors (TCFs) Net, Elk-1 and Sap-1 regulate immediate
	early genes through serum response elements (SREs) in vitro, but,
	surprisingly, their in vivo roles are unknown. Net is a repressor
	that is expressed in sites of vasculogenesis during mouse development.
	We have made gene-targeted mice that express a hypomorphic mutant
	of Net, Net delta, which lacks the Ets DNA-binding domain. Strikingly,
	homozygous mutant mice develop a vascular defect and up-regulate
	an immediate early gene implicated in vascular disease, egr-1. They
	die after birth due to respiratory failure, resulting from the accumulation
	of chyle in the thoracic cage (chylothorax). The mice have dilated
	lymphatic vessels (lymphangiectasis) as early as E16.5. Interestingly,
	they express more egr-1 in heart and pulmonary arteries at E18.5.
	Net negatively regulates the egr-1 promoter and binds specifically
	to SRE-5. Egr-1 has been associated with pathologies involving vascular
	stenosis (e.g. atherosclerosis), and here egr-1 dysfunction could
	possibly be associated with obstructions that ultimately affect the
	lymphatics. These results show that Net is involved in vascular biology
	and egr-1 regulation in vivo.},
  institution = {CNRS/INSERM/ULP, 1 Rue Laurent Fries, BP 163, 67404 Illkirch cedex, France.},
  journal     = {EMBO J},
  keywords    = {Animals; Basic Helix-Loop-Helix Transcription Factors; Chylothorax, etiology/metabolism/pathology; DNA-Binding Proteins, biosynthesis/genetics; Dilatation, Pathologic, metabolism/pathology; Drosophila Proteins; Early Growth Response Protein 1; Endothelium, embryology/metabolism; Gene Targeting; Heart, embryology; Immediate-Early Proteins; Lung, blood supply/embryology/metabolism; Lymphatic System, embryology/metabolism/pathology; Mice; Mice, Mutant Strains; Myocardium, metabolism; Phenotype; Promoter Regions, Genetic; RNA, Messenger, biosynthesis; Repressor Proteins, genetics/physiology; Survival Analysis; Transcription Factors, biosynthesis/genetics; Up-Regulation; Vascular Diseases, etiology},
  medline-pst = {ppublish},
  month       = {Sep},
  owner       = {pl4},
  pmid        = {11566878},
  timestamp   = {2013.05.29},
  year        = {2001},
}

@Article{Bohmer1912,
  author    = {B\"{o}hmer, P. E.},
  title     = {Theorie der unabh\"{a}ngigen {W}ahrscheinlichkeiten},
  pages     = {327--343},
  volume    = {2},
  journal   = {Rapports, M{\'e}moires et Proc\`{e}s-verbaux de Septi{\`e}me Congr{\`e}s International d'Actuaires, Amsterdam},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1912},
}

@Article{Baade2004,
  author    = {P. D. Baade and M. D. Coory and J. F. Aitken},
  title     = {International trends in prostate-cancer mortality: the decrease is continuing and spreading.},
  doi       = {10.1023/B:CACO.0000024212.66334.26},
  pages     = {237--41},
  volume    = {15},
  abstract  = {OBJECTIVE: To measure recent changes in prostate-cancer mortality
	across 24 developed countries. METHODS: Mortality data for men aged
	50-79 years were obtained from the World Health Organisation mortality
	database and we assessed trends in age-standardised mortality rates
	using joinpoint regression models. RESULTS: Significant reductions
	in prostate-cancer mortality were observed in United Kingdom, United
	States, Austria, Canada, Italy, France, Germany, Australia and Spain,
	and downward trends were also observable in the Netherlands, Ireland
	and {S}weden. CONCLUSIONS: Mortality declines for prostate cancer
	are now evident in 12 out of the 24 developed countries considered
	in this analysis. Increases in PSA screening and better treatment
	of early-stage disease, possibly acting in combination, remain plausible
	hypotheses.},
  journal   = {Cancer Causes Control},
  owner     = {PaulD},
  pii       = {5265642},
  timestamp = {2011.06.19},
  year      = {2004},
}

@Article{Baade2016,
  author      = {Baade, Peter D and Dasgupta, Paramita and Dickman, Paul W and Cramb, Susanna and Williamson, John D and Condon, John R and Garvey, Gail},
  title       = {Quantifying the changes in survival inequality for Indigenous people diagnosed with cancer in {Q}ueensland, {A}ustralia.},
  doi         = {10.1016/j.canep.2016.05.002},
  language    = {eng},
  pages       = {1--8},
  url         = {http://dx.doi.org/10.1016/j.canep.2016.05.002},
  volume      = {43},
  abstract    = {The survival inequality faced by Indigenous Australians after a cancer
	diagnosis is well documented; what is less understood is whether
	this inequality has changed over time and what this means in terms
	of the impact a cancer diagnosis has on Indigenous people. Survival
	information for all patients identified as either Indigenous (n=3168)
	or non-Indigenous (n=211,615) and diagnosed in Queensland between
	1997 and 2012 were obtained from the Queensland Cancer Registry,
	with mortality followed up to 31st December, 2013. Flexible parametric
	survival models were used to quantify changes in the cause-specific
	survival inequalities and the number of lives that might be saved
	if these inequalities were removed. Among Indigenous cancer patients,
	the 5-year cause-specific survival (adjusted by age, sex and broad
	cancer type) increased from 52.9\% in 1997-2006 to 58.6\% in 2007-2012,
	while it improved from 61.0\% to 64.9\% among non-Indigenous patients.
	This meant that the adjusted 5-year comparative survival ratio (Indigenous:
	non-Indigenous) increased from 0.87 [0.83-0.88] to 0.89 [0.87-0.93],
	with similar improvements in the 1-year comparative survival. Using
	a simulated cohort corresponding to the number and age-distribution
	of Indigenous people diagnosed with cancer in Queensland each year
	(n=300), based on the 1997-2006 cohort mortality rates, 35 of the
	170 deaths due to cancer (21\%) expected within five years of diagnosis
	were due to the Indigenous: non-Indigenous survival inequality. This
	percentage was similar when applying 2007-2012 cohort mortality rates
	(19\%; 27 out of 140 deaths). Indigenous people diagnosed with cancer
	still face a poorer survival outlook than their non-Indigenous counterparts,
	particularly in the first year after diagnosis. The improving survival
	outcomes among both Indigenous and non-Indigenous cancer patients,
	and the decreasing absolute impact of the Indigenous survival disadvantage,
	should provide increased motivation to continue and enhance current
	strategies to further reduce the impact of the survival inequalities
	faced by Indigenous people diagnosed with cancer.},
  institution = {Menzies School of Health Research, Charles Darwin University, 147 Wharf Street, Spring Hill, QLD 4004, Australia.},
  journal     = {Cancer Epidemiol},
  medline-pst = {aheadofprint},
  month       = {May},
  owner       = {PaulD},
  pii         = {S1877-7821(16)30057-1},
  pmid        = {27186865},
  timestamp   = {2016.06.08},
  year        = {2016},
}

@Article{Baade2011,
  author      = {Baade, Peter D. and Youlden, Danny R. and Chambers, Suzanne K.},
  title       = {When do {I} know {I} am cured? {U}sing conditional estimates to provide better information about cancer survival prospects.},
  language    = {eng},
  number      = {2},
  pages       = {73--77},
  volume      = {194},
  abstract    = {To report the latest conditional survival estimates for patients with
	cancer in Queensland, Australia.Descriptive study of state-wide population-based
	data from the Queensland Cancer Registry on patients aged 15-89 years
	who were diagnosed with invasive cancer between 1982 and 2007.Conditional
	5-year relative survival for the 13 most common types of invasive
	cancer, and all cancers combined.The prognosis for patients with
	cancer generally improves with each additional year that they survive.
	A significant excess in mortality compared with the general population
	ceases to occur within 10 years after diagnosis for survivors of
	stomach, colorectal, cervical and thyroid cancer and melanoma, with
	these groups having a conditional 5-year relative survival of at
	least 95\% after 10 years. For the remaining cancers we studied (pancreatic,
	lung, breast, prostate, kidney, and bladder cancer, non-Hodgkin lymphoma,
	and leukaemia), conditional 5-year relative survival estimates (at
	10 years after diagnosis) ranged from 82\% to 94\%, suggesting that
	patients in these cohorts continue to have poorer survival compared
	with the age-matched general population.Estimates of conditional
	survival have the potential to provide useful information for cancer
	clinicians, patients and their carers as they are confronted by personal
	and surveillance-related decisions. This knowledge may be effective
	in building realistic hope and helping people manage uncertainty
	about the future. We suggest that measures of conditional survival
	be incorporated into routine statistical reporting in Australia.},
  institution = {Viertel Centre for Research in Cancer Control, Cancer Council Queensland, Brisbane, QLD, Australia. peterbaade@cancerqld.org.au},
  journal     = {Med J Aust},
  keywords    = {Breast Neoplasms, mortality; Colorectal Neoplasms, surgery; Female; Humans; Kidney Neoplasms, mortality; Leukemia, mortality; Lung Neoplasms, mortality; Male; Melanoma, mortality; Neoplasms, diagnosis/mortality; Pancreatic Neoplasms, mortality; Probability; Prognosis; Prostatic Neoplasms, mortality; Quality of Life; Queensland, epidemiology; Stomach Neoplasms, mortality; Survival Analysis; Thyroid Neoplasms, mortality; Urinary Bladder Neoplasms, mortality; Uterine Cervical Neoplasms, mortality},
  medline-pst = {ppublish},
  month       = {Jan},
  owner       = {sanelo},
  pii         = {baa10523_fm},
  pmid        = {21241220},
  timestamp   = {2013.08.12},
  year        = {2011},
}

@Article{Bahmanyar2007,
  author    = {Shahram Bahmanyar and Weimin Ye and Paul W Dickman and Olof Nyr\'{e}n},
  title     = {Long-Term Risk of Gastric Cancer by Subsite in Operated and Unoperated Patients Hospitalized for Peptic Ulcer.},
  doi       = {10.1111/j.1572-0241.2007.01161.x},
  abstract  = {OBJECTIVE: We aimed to investigate whether the elevated risk of gastric
	cancer among patients with gastric ulcer (GU) and the enigmatic low
	risk among patients with duodenal ulcer (DU) pertain to both cardia
	and noncardia cancer. We also studied the risks among operated patients
	while taking the disparate baseline risks into consideration. METHODS:
	Retrospective cohorts of 59,550 and 79,412 unoperated patients with
	DU and GU, respectively, plus 12,840 patients with partial gastric
	resection and 8,105 with vagotomy, recorded in the Swedish Inpatient
	Register since 1970, were followed from the first hospitalization
	(date of operation for the surgery cohort) until occurrence of any
	cancer, death, emigration, definitive surgery, or December 31, 2003.
	Standardized incidence ratios (SIRs) with 95\% confidence intervals
	(CIs) expressed relative risk (RR), compared to the age-, sex-, and
	calendar period-matched Swedish population. Cox regression produced
	adjusted RR estimates among operated patients, relative to unoperated
	ones with the same ulcer type. RESULTS: While unoperated DU patients
	had a halved risk of noncardia cancer (SIR = 0.5, 95\% CI 0.4-0.7),
	their risk of cardia cancer was slightly above expectation (SIR =
	1.2, 95\% CI 0.8-1.7). Unoperated GU patients had doubled risks for
	both cancers (SIR = 2.1, 95\% CI 2.0-2.4 and SIR = 1.9, 95\% CI 1.4-2.3,
	respectively). DU patients who underwent gastric resection had a
	60\% risk elevation (RR = 1.6, 95\% CI 1.0-2.5) compared to unoperated
	ones. Vagotomy was associated with a greater risk in the first 10
	yr, but this excess disappeared with further follow-up. Resected
	GU patients had a 40\% risk reduction relative to their unoperated
	peers (RR = 0.6, 95\% CI 0.5-0.8). This reduction persisted well
	beyond the first postoperative decade. CONCLUSION: The DU-related
	protection against gastric cancer does not seem to pertain to cardia
	cancer. With gastric resection, risks are shifted toward normality,
	regardless of underlying ulcer type.},
  journal   = {Am J Gastroenterol},
  month     = mar,
  owner     = {PaulD},
  pii       = {AJG1161},
  pmid      = {17355418},
  timestamp = {2007.04.04},
  year      = {2007},
}

@Article{Bailar1997,
  author    = {J. C. Bailar and H. L. Gornik},
  title     = {{C}ancer undefeated.},
  number    = {22},
  pages     = {1569--1574},
  volume    = {336},
  abstract  = {BACKGROUND: Despite decades of basic and clinical research and trials
	of promising new therapies, cancer remains a major cause of morbidity
	and mortality. We assessed overall progress against cancer in the
	United States from 1970 through 1994 by analyzing changes in age-adjusted
	mortality rates. METHODS: We obtained from the National Center for
	Health Statistics data on all deaths from cancer and from cancer
	at specific sites, as well as on deaths due to cancer according to
	age, race, and sex, for the years 1970 through 1994. We computed
	age-specific mortality rates and adjusted them to the age distribution
	of the U.S. population in 1990. RESULTS: Age-adjusted mortality due
	to cancer in 1994 (200.9 per 100,000 population) was 6.0 percent
	higher than the rate in 1970 (189.6 per 100,000). After decades of
	steady increases, the age-adjusted mortality due to all malignant
	neoplasms plateaued, then decreased by 1.0 percent from 1991 to 1994.
	The decline in mortality due to cancer was greatest among black males
	and among persons under 55 years of age. Mortality among white males
	55 or older has also declined recently. These trends reflect a combination
	of changes in death rates from specific types of cancer, with important
	declines due to reduced cigarette smoking and improved screening
	and a mixture of increases and decreases in the incidence of types
	of cancer not closely related to tobacco use. CONCLUSIONS: The war
	against cancer is far from over. Observed changes in mortality due
	to cancer primarily reflect changing incidence or early detection.
	The effect of new treatments for cancer on mortality has been largely
	disappointing. The most promising approach to the control of cancer
	is a national commitment to prevention, with a concomitant rebalancing
	of the focus and funding of research.},
  journal   = {N Engl J Med},
  month     = may,
  owner     = {PaulD},
  pmid      = {9304056},
  timestamp = {2006.03.31},
  year      = {1997},
}

@Article{Baili2008,
  author      = {Paolo Baili and Andrea Micheli and Roberta De Angelis and Hannah K Weir and Silvia Francisci and Mariano Santaquilani and Timo Hakulinen and Manuela Quaresmas and Michel P Coleman and C. O. N. C. O. R. D. Working Group},
  title       = {Life tables for world-wide comparison of relative survival for cancer ({CONCORD} study).},
  number      = {5},
  pages       = {658--668},
  volume      = {94},
  abstract    = {BACKGROUND: The CONCORD study compares population-based relative survival
	from cancer using data from cancer registries in five continents.
	To estimate relative survival, general mortality life tables are
	required. Available statistics are incomplete, so various approaches
	are used to construct complete life tables. This article outlines
	how the life tables were constructed for CONCORD; it compares life
	expectancy at birth between 101 populations covered by cancer registries
	in 31 countries and compares the impact of two approaches to the
	deployment of life tables in relative survival analysis. METHODS:
	The CONCORD approach, using specific mathematical methods, produced
	complete (single-year-of-age) life tables by sex, cancer registry
	area, calendar year (1990-1999) and race (only in the USA). In order
	to study the impact of different approaches, we compared relative
	survival in the USA using the US national life table, centered on
	the relevant census years, and the CONCORD approach. We estimated
	relative survival in each American participating cancer registry
	for patients diagnosed with breast (women), colorectal or prostate
	cancer during 1990-1994 and followed up to 1999. RESULTS: Average
	life expectancy at birth during 1990-1999 varied in CONCORD cancer
	registry areas from 64 to 78 years in males and from 71 to 84 years
	in females. It increased during the 1990s more in men than in women.
	In the USA, it was lower in blacks than in whites. Relative survival
	in American populations was lower with the CONCORD approach, which
	incorporates trends and geographic variation in background mortality,
	than with the USA census life tables. CONCLUSIONS: International
	variation in background mortality by geographic area, calendar time,
	race, age and sex is wide. We suggest that in international comparisons
	of cancer relative survival, complete life tables that are specific
	for cancer registry area, calendar year and race should be used.},
  file        = {Baili2008.pdf:Baili2008.pdf:PDF;Baili2008.pdf:pdf\\Baili2008.pdf:PDF},
  institution = {Descriptive Epidemiology and Health Planning Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. lifetable@istitutotumori.mi.it},
  journal     = {Tumori},
  owner       = {pl4},
  pmid        = {19112937},
  timestamp   = {2009.11.05},
  year        = {2008},
}

@Article{Baili2005,
  author    = {Baili, P. and Micheli, A. and Montanari, A. and Capocaccia, R.},
  title     = {Comparison of four methods for estimating complete life tables from abridged life tables by using mortality data supplied to {EUROCARE}-3},
  pages     = {183-98},
  volume    = {12},
  file      = {Baili2005.pdf:pdf\\Baili2005.pdf:PDF;Baili2005.pdf:Baili2005.pdf:PDF},
  journal   = {Math Popul Stud},
  owner     = {hanbow},
  timestamp = {2016.09.06},
  year      = {2005},
}

@Article{Baker2003,
  author      = {Richard Baker and James Falconer Smith and Paul C Lambert},
  title       = {Randomised controlled trial of the effectiveness of feedback in improving test ordering in general practice.},
  number      = {4},
  pages       = {219--223},
  volume      = {21},
  abstract    = {OBJECTIVE: To assess the effectiveness of feedback on the number of
	pathology tests ordered by general practices. DESIGN: Randomised
	controlled trial. SETTING: General practices in two primary care
	groups in Leicestershire, UK. SUBJECTS: 58 general practitioners
	in 17 practices received guidelines then feedback at 3-month intervals
	for 1 year about the numbers of thyroid function, rheumatoid factor
	tests and urine cultures they ordered, and 38 general practitioners
	in 16 practices received guidelines then feedback about lipid and
	plasma viscosity tests. MAIN OUTCOME MEASURES: Numbers of tests requested
	per thousand patients registered with each practice. RESULTS; There
	were no changes in the numbers of tests per thousand requested in
	either of the study groups for any of the tests. CONCLUSIONS: Feedback
	did not have an influence on test ordering by general practitioners
	in this study. More intensive strategies may be required to change
	the use of laboratory tests.},
  file        = {baker2003.pdf:baker2003.pdf:PDF},
  institution = {Clinical Governance Research and Development Unit, Department of General Practice and Primary Health Care, University of Leicester, Leicester General Hospital, UK. rb14@le.ac.uk},
  journal     = {Scand J Prim Health Care},
  month       = dec,
  owner       = {pl4},
  pmid        = {14695072},
  timestamp   = {2008.10.15},
  year        = {2003},
}

@Book{Baker1978,
  author    = {Baker, R. J. and Nelder, J. A.},
  title     = {The {GLIM} System Release 3 Manual},
  publisher = {Numerical Algorithms Group},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1978},
}

@Article{Bakoyannis2012,
  author      = {Bakoyannis, Giorgos and Touloumi, Giota},
  title       = {Practical methods for competing risks data: a review.},
  doi         = {10.1177/0962280210394479},
  language    = {eng},
  number      = {3},
  pages       = {257--272},
  url         = {http://dx.doi.org/10.1177/0962280210394479},
  volume      = {21},
  abstract    = {Competing risks data arise naturally in medical research, when subjects
	under study are at risk of more than one mutually exclusive event
	such as death from different causes. The competing risks framework
	also includes settings where different possible events are not mutually
	exclusive but the interest lies on the first occurring event. For
	example, in HIV studies where seropositive subjects are receiving
	highly active antiretroviral therapy (HAART), treatment interruption
	and switching to a new HAART regimen act as competing risks for the
	first major change in HAART. This article introduces competing risks
	data and critically reviews the widely used statistical methods for
	estimation and modelling of the basic (estimable) quantities of interest.
	We discuss the increasingly popular Fine and Gray model for subdistribution
	hazard of interest, which can be readily fitted using standard software
	under the assumption of administrative censoring. We present a simulation
	study, which explores the robustness of inference for the subdistribution
	hazard to the assumption of administrative censoring. This shows
	a range of scenarios within which the strictly incorrect assumption
	of administrative censoring has a relatively small effect on parameter
	estimates and confidence interval coverage. The methods are illustrated
	using data from HIV-1 seropositive patients from the collaborative
	multicentre study CASCADE (Concerted Action on SeroConversion to
	AIDS and Death in Europe).},
  institution = {Department of Hygiene, Epidemiology and Medical Statistics, Athens University Medical School, Athens, Greece.},
  journal     = {Stat Methods Med Res},
  keywords    = {Antiretroviral Therapy, Highly Active; HIV Infections, drug therapy; Humans; Models, Theoretical; Risk Assessment},
  medline-pst = {ppublish},
  month       = {Jun},
  owner       = {sanelo},
  pii         = {0962280210394479},
  pmid        = {21216803},
  timestamp   = {2013.07.30},
  year        = {2012},
}

@Article{Bantis2012,
  author    = {L.E. Bantis and J.V. Tsimikas and S.D. Georgiou},
  title     = {Survival estimation through the cumulative hazard function with montone natural cubic splines},
  pages     = {364--396},
  volume    = {18},
  file      = {Bantis2012.pdf:Bantis2012.pdf:PDF},
  journal   = {Lifetime Data Analysis},
  owner     = {pl4},
  timestamp = {2012.06.16},
  year      = {2012},
}

@Article{Barillier1993,
  author      = {Barillier, A. and Garnier, J.},
  title       = {Influence of temperature and substrate concentration on bacterial growth yield in Seine River water batch cultures.},
  language    = {eng},
  number      = {5},
  pages       = {1678--1682},
  volume      = {59},
  abstract    = {The growth of natural bacterial assemblages was monitored in 3-liter
	reactors under various temperature and substrate concentration conditions.
	The oxygen concentration was continuously monitored, and subsamples
	were taken at short time intervals to determine bacterial number
	and biomass. The rate of bacterial mortality was also determined.
	Bacterial growth yield was calculated as the ratio of net production
	(increase in biomass corrected for mortality) to gross production
	(net production plus oxygen consumption expressed in carbon units).
	Averaging 33\%, the growth yield did not show any trend with temperatures
	in the range of 8 to 25 degrees C but increased with the concentration
	of dissolved organic carbon in the range of 2 to 12 mg of C.liter-1.},
  institution = {CEMAGREF, Paris, France.},
  journal     = {Appl Environ Microbiol},
  keywords    = {Bacteria, growth /&/ development/isolation /&/ purification/metabolism; Bacteriological Techniques; Carbon, metabolism; Culture Media; Evaluation Studies as Topic; France; Fresh Water; Oxygen; Temperature; Water Microbiology},
  medline-pst = {ppublish},
  month       = {May},
  owner       = {pl4},
  pmid        = {8517757},
  timestamp   = {2013.05.29},
  year        = {1993},
}

@Article{Barlow2009,
  author      = {Barlow, Lotti and Westergren, Kerstin and Holmberg, Lars and Talb\"{a}ck, Mats},
  title       = {The completeness of the {S}wedish {C}ancer {R}egister: a sample survey for year 1998.},
  doi         = {10.1080/02841860802247664},
  language    = {eng},
  number      = {1},
  pages       = {27--33},
  volume      = {48},
  abstract    = {The Swedish Cancer Register (SCR) is used extensively for monitoring
	cancer incidence and survival and for research purposes. Completeness
	and reliability of cancer registration are thus of great importance
	for all types of use of the cancer register. The aim of the study
	was to estimate the overall coverage of malignant cancer cases in
	1998 and to reveal possible reasons behind non-reporting.We selected
	all malignant cancer cases in the Hospital Discharge Register (HDR)
	from 1998 and compared these records to those reported to the SCR.
	There were 43,761 discharges for 42,010 individuals of whom 3,429
	individuals were not recorded in the SCR. From these 3 429 records
	we randomly selected 202 patients for review of their medical records
	to determine whether they should have been registered on the SCR
	as incident cases in 1998.About half of the 202 cases (93 malignant
	and 8 benign) should have been reported, which translates into an
	additional 1 579 malignant cases (95\% CI 1 349-1 808), or 3.7\%
	of the cases reported in 1998. The crude incidence rate for males
	and females combined would increase from 493 per 100,000 to 511 (95\%
	CI 508-514) if these cases were taken into account.The overall completeness
	of the SCR is high and comparable to other high quality registers
	in Northern Europe. For most uses in epidemiological or public health
	surveillance, the underreporting will be without major impact. However,
	for specific research questions our findings have implications, as
	the degree of underreporting is site specific, increases with age,
	and does not seem to be random, as diagnoses without histology or
	cytology verification are overrepresented. An annual comparison of
	the SCR against the HDR could point to hospitals, geographic areas
	or specific diagnoses where organizational and administrative changes
	should be introduced to improve reporting.},
  file        = {Barlow2009.pdf:Barlow2009.pdf:PDF;Barlow2009.pdf:pdf\\Barlow2009.pdf:PDF},
  institution = {Centre for Epidemiology, The National Board of Health and Welfare, Stockholm, Sweden.},
  journal     = {Acta Oncologica},
  medline-pst = {ppublish},
  owner       = {paulD},
  pii         = {902131375},
  pmid        = {18767000},
  timestamp   = {2011.10.05},
  year        = {2009},
}

@Article{Barros2003,
  author      = {A J D Barros and V N Hirakata},
  title       = {Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio.},
  doi         = {10.1186/1471-2288-3-21},
  language    = {eng},
  pages       = {21},
  volume      = {3},
  abstract    = {BACKGROUND: Cross-sectional studies with binary outcomes analyzed
	by logistic regression are frequent in the epidemiological literature.
	However, the odds ratio can importantly overestimate the prevalence
	ratio, the measure of choice in these studies. Also, controlling
	for confounding is not equivalent for the two measures. In this paper
	we explore alternatives for modeling data of such studies with techniques
	that directly estimate the prevalence ratio. METHODS: We compared
	Cox regression with constant time at risk, Poisson regression and
	log-binomial regression against the standard Mantel-Haenszel estimators.
	Models with robust variance estimators in Cox and Poisson regressions
	and variance corrected by the scale parameter in Poisson regression
	were also evaluated. RESULTS: Three outcomes, from a cross-sectional
	study carried out in Pelotas, Brazil, with different levels of prevalence
	were explored: weight-for-age deficit (4\%), asthma (31\%) and mother
	in a paid job (52\%). Unadjusted Cox/Poisson regression and Poisson
	regression with scale parameter adjusted by deviance performed worst
	in terms of interval estimates. Poisson regression with scale parameter
	adjusted by chi2 showed variable performance depending on the outcome
	prevalence. Cox/Poisson regression with robust variance, and log-binomial
	regression performed equally well when the model was correctly specified.
	CONCLUSIONS: Cox or Poisson regression with robust variance and log-binomial
	regression provide correct estimates and are a better alternative
	for the analysis of cross-sectional studies with binary outcomes
	than logistic regression, since the prevalence ratio is more interpretable
	and easier to communicate to non-specialists than the odds ratio.
	However, precautions are needed to avoid estimation problems in specific
	situations.},
  file        = {Barros2003.pdf:Barros2003.pdf:PDF;Barros2003.pdf:pdf\\Barros2003.pdf:PDF},
  institution = {Universidade Federal de Pelotas, Brazil. abarros@epidemio-ufpel.org.br},
  journal     = {BMC Med Res Methodol},
  medline-pst = {epublish},
  month       = oct,
  owner       = {pl4},
  pii         = {1471-2288-3-21},
  pmid        = {14567763},
  timestamp   = {2010.06.01},
  year        = {2003},
}

@Article{Bartlett2016,
  author      = {Bartlett, Jonathan W and Taylor, Jeremy M G},
  title       = {Missing covariates in competing risks analysis.},
  doi         = {10.1093/biostatistics/kxw019},
  language    = {eng},
  url         = {http://dx.doi.org/10.1093/biostatistics/kxw019},
  abstract    = {Studies often follow individuals until they fail from one of a number
	of competing failure types. One approach to analyzing such competing
	risks data involves modeling the cause-specific hazards as functions
	of baseline covariates. A common issue that arises in this context
	is missing values in covariates. In this setting, we first establish
	conditions under which complete case analysis (CCA) is valid. We
	then consider application of multiple imputation to handle missing
	covariate values, and extend the recently proposed substantive model
	compatible version of fully conditional specification (SMC-FCS) imputation
	to the competing risks setting. Through simulations and an illustrative
	data analysis, we compare CCA, SMC-FCS, and a recent proposal for
	imputing missing covariates in the competing risks setting.},
  file        = {Bartlett2016.pdf:pdf\\Bartlett2016.pdf:PDF},
  institution = {Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA.},
  journal     = {Biostatistics},
  medline-pst = {aheadofprint},
  month       = {May},
  pii         = {kxw019},
  pmid        = {27179002},
  year        = {2016},
}

@Article{Bashir2001,
  author      = {Bashir, S. A. and Est\`{e}ve, J.},
  title       = {Projecting cancer incidence and mortality using {Bayes}ian age-period-cohort models.},
  language    = {eng},
  number      = {3},
  pages       = {287--296},
  volume      = {6},
  abstract    = {We present a practical application of an age-period-cohort model in
	a Bayesian frame-work for making cancer-burden projections.Second
	degree autoregressive smoothing was used on the age, period and cohort
	effects for estimating future incidence and mortality.We are able
	to demonstrate the feasibility, flexibility and strengths of this
	approach. Compared with previously used methods, it performed better
	for providing point estimates when past trends continued into the
	future. However, the extremely wide credible intervals need careful
	interpretation.Part of the uncertainty is attributable to the possible
	inadequacy of the model and not necessarily relevant in the prediction
	of what would happen if the present trends continue into the future.},
  file        = {Bashir2001.pdf:Bashir2001.pdf:PDF},
  institution = {Service de Biostatistique, Centre Hospitalier Lyon Sud, Pierre-Benite, France.},
  journal     = {J Epidemiol Biostat},
  medline-pst = {ppublish},
  owner       = {pl4},
  pmid        = {11437093},
  timestamp   = {2012.09.10},
  year        = {2001},
}

@Article{Bassett1986,
  author    = {Bassett, M. T. and Krieger, N.},
  title     = {Social Class and Black-White Differences in Breast Cancer Survival},
  pages     = {1400--1403},
  volume    = {76},
  journal   = {American Journal of Public Health},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1986},
}

@Article{Baumgarten1989,
  author    = {Baumgarten, M. and Seliske, P. and Goldberg, M. S.},
  title     = {Warning Regarding the Use of {GLIM} Macros for the Estimation of Risk Ratios},
  pages     = {1065},
  volume    = {130},
  journal   = {American Journal of Epidemiology},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1989},
}

@Article{Baxi2010,
  author      = {Baxi, Shrujal S. and Matasar, Matthew J.},
  title       = {State-of-the-art issues in {H}odgkin's lymphoma survivorship.},
  doi         = {10.1007/s11912-010-0123-2},
  language    = {eng},
  number      = {6},
  pages       = {366--373},
  url         = {http://dx.doi.org/10.1007/s11912-010-0123-2},
  volume      = {12},
  abstract    = {The prognosis of Hodgkin's lymphoma (HL) has markedly improved as
	management strategies evolved. In the modern era, less than 15\%
	of patients with early-stage, non-bulky HL will relapse, and less
	than one third of those with advanced disease will relapse. As therapy
	for HL intensified, and as disease-related outcomes improved, the
	impact of the late effects of therapy has become increasingly important.
	There is a growing body of literature describing the late morbidity
	experienced by survivors of HL, including risks of second primary
	malignancy, cardiac disease, pulmonary disease, and endocrine dysfunction.
	Additionally, the impact of disease and treatment on psychosocial
	function and quality of life has been a subject of investigation,
	with survivors often suffering from impairment. An understanding
	of these risks and the management implications inherent to them is
	central to the care of survivors of HL.},
  institution = {Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.},
  journal     = {Curr Oncol Rep},
  keywords    = {Antineoplastic Agents, administration /&/ dosage; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases, etiology; Combined Modality Therapy; Endocrine System Diseases, etiology; Female; Hodgkin Disease, complications/mortality/pathology/psychology/therapy; Humans; Lung Diseases, etiology; Male; Morbidity; Neoplasm Staging; Neoplasms, Second Primary, mortality; Prognosis; Quality of Life; Survival Rate},
  medline-pst = {ppublish},
  month       = {Nov},
  owner       = {sanelo},
  pmid        = {20734173},
  timestamp   = {2013.08.07},
  year        = {2010},
}

@Article{Beck1982,
  author      = {Beck, J. R. and Kassirer, J. P. and Pauker, S. G.},
  title       = {A convenient approximation of life expectancy (the "{DEALE}"). {I}. Validation of the method.},
  language    = {eng},
  number      = {6},
  pages       = {883--888},
  volume      = {73},
  abstract    = {The physician developing a treatment plan for a particular patient
	often needs to know the life expectancy associated with the outcomes
	of therapeutic choices. Currently available methods for estimating
	life expectancy are cumbersome and of limited clinical use. We describe
	a simple approximation of life expectancy (the "DEALE") that is based
	on the assumption that survival follows a simple declining exponential
	function. In this approach, the reciprocal of the age-, sex-, and
	race-adjusted life expectancy is used to estimate the mortality rate
	of a healthy person. The life expectancy of a person who also has
	one or more diseases is obtained by adding disease-specific mortalities
	to the age-, sex-, and race-adjusted mortality rate and taking the
	reciprocal of that sum. In this paper we show that this approximation
	estimates life expectancy accurately for the great majority of clinical
	problems.},
  journal     = {American Jorunal of Medicine},
  keywords    = {Adult; Age Factors; Aged; Continental Population Groups; Female; Humans; Life Expectancy; Male; Middle Aged; Sex Factors; Statistics as Topic},
  medline-pst = {ppublish},
  month       = {Dec},
  owner       = {theand},
  pmid        = {7148881},
  timestamp   = {2012.09.18},
  year        = {1982},
}

@Article{Begg2002,
  author    = {Colin B Begg and Deborah Schrag},
  title     = {Attribution of deaths following cancer treatment.},
  number    = {14},
  pages     = {1044--1045},
  volume    = {94},
  file      = {begg2002.pdf:begg2002.pdf:PDF},
  journal   = {J Natl Cancer Inst},
  month     = jul,
  owner     = {pl4},
  pmid      = {12122090},
  timestamp = {2008.10.15},
  year      = {2002},
}

@Article{Beham2006,
  author      = {A. Beham and M. Rentsch and K. P\"{u}llmann and L. Mantouvalou and H. Spatz and H. J. Schlitt and A. Obed},
  title       = {Survival benefit in patients after palliative resection vs non-resection colon cancer surgery.},
  number      = {41},
  pages       = {6634--6638},
  volume      = {12},
  abstract    = {AIM: To evaluate survival in patients undergoing palliative resection
	versus non-resection surgery for primary colorectal cancer in a retrospective
	analysis. METHODS: Demographics, TNM status, operating details and
	survival were reviewed for 67 patients undergoing surgery for incurable
	colorectal cancer. Palliative resection of the primary tumor was
	performed in 46 cases in contrast to 21 patients with non-resection
	of the primary tumor and bypass surgery. Risk factors for postoperative
	mortality and poor survival were analyzed with univariate and multivariate
	analyses. RESULTS: The two groups were comparable in terms of age,
	gender, preoperative presence of ileus and tumor stage. Multivariate
	analysis showed that median survival was significantly higher in
	patients with palliative resection surgery (544 vs 233 d). Differentiation
	of the tumor and tumor size were additional independent factors that
	were associated with a significantly poorer survival rate. CONCLUSION:
	Palliative resection surgery for primary colorectal cancer is associated
	with a higher median survival rate. Also, the presence of liver metastasis
	and tumor size are associated with poor survival. Therefore, resection
	of the primary tumor should be considered in patients with non-curable
	colon cancer.},
  file        = {Beham2006.pdf:Beham2006.pdf:PDF;Beham2006.pdf:pdf\\Beham2006.pdf:PDF},
  institution = {Department of Surgery, The University of Regensburg, Franz-Josef-Strauss Allee 11, 93053 Regensburg, Germany. alexander.beham@klinik.uni-regensburg.de},
  journal     = {World J Gastroenterol},
  month       = nov,
  owner       = {pl4},
  pmid        = {17075976},
  timestamp   = {2008.10.15},
  year        = {2006},
}

@Article{Behr1992,
  author      = {Behr, P. and Kupferberg, A. and Leray, C. and Schellenbaum, L. and Urban, P. F. and Vincendon, G. and Mersel, M.},
  title       = {Effect of dibutyryl cyclic AMP and isoproterenol on 7 beta-hydroxycholesterol cytotoxicity and esterification in spontaneous transformed cell lines derived from astrocyte primary cultures.},
  language    = {eng},
  number      = {2},
  pages       = {151--154},
  volume      = {313},
  abstract    = {Incubation of spontaneous transformed cells derived from astrocyte
	primary cultures with 30 microM 7 beta-hydroxycholesterol (7 beta-OH-CH)
	which is lethal to the cells or with 150 microM isoproterenol reduces
	the intracellular level of cAMP (4- and 2-fold respectively). Treatment
	of the cultures with 0.5 mM dibutyryl (db)-cAMP and 7 beta-OH-CH
	increases 3-fold the intracellular level of cAMP and both, db-cAMP
	and isoproterenol, raise the lethal effect of 7 beta-OH-CH and its
	esterification on C-3-OH by naturally occurring fatty acids (metabolite).
	Kinetic studies of net steryl-3-esters hydrolysis revealed that db-cAMP
	and isoproterenol lower that of cholesteryl-3-esters (2-fold) whereas
	the opposite is found for the metabolite. These data demonstrate
	that (i) high cAMP intracellular levels modulate differently the
	net hydrolysis of cholesteryl-3-esters and metabolite, (ii) isoproterenol
	acts otherwise than cAMP on 7 beta-OH-CH esterification, (iii) the
	cytotoxicity of 7 beta-OH-CH is linked to its own esterification.
	The accumulation of metabolite subsequent to db-cAMP or isoproterenol
	treatment as a result of acyl-CoA:cholesterol acyl transferase activation
	is discussed.},
  institution = {Laboratoire de Neurobiologie Moleculaire des Interactions Cellulaires, Centre de Neurochimie du CNRS, Strasbourg, France.},
  journal     = {FEBS Lett},
  keywords    = {Animals; Astrocytes, metabolism; Bucladesine, pharmacology; Cell Line, Transformed; Cell Survival, drug effects; Cholesterol Esters, metabolism; Cyclic AMP, analysis; Hydroxycholesterols, metabolism/pharmacology; Isoproterenol, pharmacology; Rats},
  medline-pst = {ppublish},
  month       = {Nov},
  owner       = {pl4},
  pii         = {0014-5793(92)81433-M},
  pmid        = {1330703},
  timestamp   = {2013.05.29},
  year        = {1992},
}

@Article{Bejan-Angoulvant2008,
  author      = {Theodora Bejan-Angoulvant and Anne-Marie Bouvier and Nadine Bossard and Aurelien Belot and Val\'{e}rie Jooste and Guy Launoy and Laurent Remontet},
  title       = {Hazard regression model and cure rate model in colon cancer relative survival trends: are they telling the same story?},
  doi         = {10.1007/s10654-008-9226-6},
  number      = {4},
  pages       = {251--259},
  volume      = {23},
  abstract    = {Hazard regression models and cure rate models can be advantageously
	used in cancer relative survival analysis. We explored the advantages
	and limits of these two models in colon cancer and focused on the
	prognostic impact of the year of diagnosis on survival according
	to the TNM stage at diagnosis. The analysis concerned 9,998 patients
	from three French registries. In the hazard regression model, the
	baseline excess death hazard and the time-dependent effects of covariates
	were modelled using regression splines. The cure rate model estimated
	the proportion of 'cured' patients and the excess death hazard in
	'non-cured' patients. The effects of year of diagnosis on these parameters
	were estimated for each TNM cancer stage. With the hazard regression
	model, the excess death hazard decreased significantly with more
	recent years of diagnoses (hazard ratio, HR 0.97 in stage III and
	0.98 in stage IV, P < 0.001). In these advanced stages, this favourable
	effect was limited to the first years of follow-up. With the cure
	rate model, recent years of diagnoses were significantly associated
	with longer survivals in 'non-cured' patients with advanced stages
	(HR 0.95 in stage III and 0.97 in stage IV, P < 0.001) but had no
	significant effect on cure (odds ratio, OR 0.99 in stages III and
	IV, P > 0.5). The two models were complementary and concordant in
	estimating colon cancer survival and the effects of covariates. They
	provided two different points of view of the same phenomenon: recent
	years of diagnosis had a favourable effect on survival, but not on
	cure.},
  file        = {Bejan-Angoulvant2008.pdf:Bejan-Angoulvant2008.pdf:PDF;Bejan-Angoulvant2008.pdf:pdf\\Bejan-Angoulvant2008.pdf:PDF},
  institution = {Hospices Civils de Lyon, Service de Biostatistiques, Centre Hospitalier Lyon Sud, Pierre-B\'{e}nite, France. theodora.bejan-angoulvant@chu-lyon.fr},
  journal     = {European Journal of Epidemiology},
  keywords    = {Cure models; theory},
  owner       = {pl4},
  pmid        = {18264781},
  timestamp   = {2009.01.07},
  year        = {2008},
}

@Article{Bell1995,
  author    = {Bell, C. M. J. and Lawrence, G. and Pheby, D. F. H. and Smith, J. and Coleman, M. P.},
  title     = {The Role of Cancer Registries},
  pages     = {143--144},
  volume    = {7},
  journal   = {Clinical Oncology},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@Article{Bell1999,
  author      = {S. C. Bell and A. W. Halligan and A. Martin and J. Ashmore and A. H. Shennan and P. C. Lambert and D. J. Taylor},
  title       = {The role of observer error in antenatal dipstick proteinuria analysis.},
  number      = {11},
  pages       = {1177--1180},
  volume      = {106},
  abstract    = {OBJECTIVE: To determine the role of inter-observer error and the influence
	of training upon dipstick urine analysis. DESIGN: A two phase observational
	and training study. METHODS: Five standard solutions of serum albumin
	were used to test the accuracy of midwives and nursing auxiliaries
	involved in dipstick urine analysis at a maternity hospital. The
	standard solutions were chosen such that they should have resulted
	in negative (n = 2) and positive (n = 3) dipstick test results, respectively.
	SETTING: A teaching maternity hospital and academic department of
	obstetrics and gynaecology. PARTICIPANTS: Twenty midwives, 20 nursing
	auxiliaries and nine laboratory technicians. RESULTS: For the two
	nonproteinuric solutions, a higher false positive rate was observed
	for nursing auxiliaries (40\% and 55\%), compared with midwives (5\%
	and 30\%) (P = 0.020 and P = 0.20, respectively). Before training,
	laboratory technicians recorded high false positive rates (67\% and
	89\%), but after training these were reduced to 0\% and 22\% (P =
	0.25 and P = 0.023, respectively). Both nursing auxiliaries and midwives
	recorded false negative rates of between 10\% and 45\% for the three
	proteinuric solutions. CONCLUSIONS: Observer error may be reduced
	by assigning midwives to urine dipstick analysis or by the implementation
	of directed training. Classification of pre-eclampsia or other hypertensive
	diseases of pregnancy on the basis of the presence and degree of
	proteinuria should be confirmed with a 24-hour quantitative protein
	collection.},
  file        = {Bell1999.pdf:Bell1999.pdf:PDF;Bell1999.pdf:pdf\\Bell1999.pdf:PDF},
  institution = {Department of Obstetrics and Gynaecology, University of Leicester, UK.},
  journal     = {Br J Obstet Gynaecol},
  month       = nov,
  owner       = {pl4},
  pmid        = {10549963},
  timestamp   = {2008.10.15},
  year        = {1999},
}

@Article{Bellavia2014a,
  author      = {Bellavia, Andrea and {\AA}Â…kerstedt, Torbj{\"o}rn and Bottai, Matteo and Wolk, Alicja and Orsini, Nicola},
  title       = {Sleep duration and survival percentiles across categories of physical activity.},
  doi         = {10.1093/aje/kwt280},
  language    = {eng},
  number      = {4},
  pages       = {484--491},
  url         = {http://dx.doi.org/10.1093/aje/kwt280},
  volume      = {179},
  abstract    = {The association between long sleep duration and death is not fully
	understood. Long sleep is associated with low physical activity,
	which is a strong predictor of death. Our aim was to investigate
	the association between sleep duration and death across categories
	of total physical activity in a large prospective cohort of Swedish
	men and women. We followed a population-based cohort of 70,973 participants
	(37,846 men and 33,127 women), aged 45-83 years, from January 1998
	to December 2012. Sleep duration and physical activity levels were
	assessed through a questionnaire. We evaluated the association of
	interest in terms of mortality rates by estimating hazard ratios
	with Cox regression and in terms of survival by evaluating 15th survival
	percentile differences with Laplace regression. During 15 years of
	follow-up, we recorded 14,575 deaths (8,436 men and 6,139 women).
	We observed a significant interaction between sleep duration and
	physical activity in predicting death (P < 0.001). Long sleep duration
	(>8 hours) was associated with increased mortality risk (hazard ratio
	= 1.24; 95\% confidence interval: 1.11, 1.39) and shorter survival
	(15th percentile difference = -20 months; 95\% confidence interval:
	-30, -11) among only those with low physical activity. The association
	between long sleep duration and death might be partly explained by
	comorbidity with low physical activity.},
  file        = {Bellavia2014a.pdf:Bellavia2014a.pdf:PDF},
  journal     = {Am J Epidemiol},
  keywords    = {Aged; Aged, 80 and over; Cardiovascular Diseases, mortality; Cohort Studies; Exercise, physiology; Female; Humans; Male; Middle Aged; Mortality; Multivariate Analysis; Neoplasms, mortality; Questionnaires; Regression Analysis; Risk; Sleep, physiology; Sweden, epidemiology},
  medline-pst = {ppublish},
  month       = {Feb},
  owner       = {pl4},
  pii         = {kwt280},
  pmid        = {24264294},
  timestamp   = {2014.06.02},
  year        = {2014},
}

@Article{Bender2005,
  author      = {Ralf Bender and Thomas Augustin and Maria Blettner},
  title       = {Generating survival times to simulate Cox proportional hazards models.},
  doi         = {10.1002/sim.2059},
  number      = {11},
  pages       = {1713--1723},
  volume      = {24},
  abstract    = {Simulation studies present an important statistical tool to investigate
	the performance, properties and adequacy of statistical models in
	pre-specified situations. One of the most important statistical models
	in medical research is the proportional hazards model of Cox. In
	this paper, techniques to generate survival times for simulation
	studies regarding Cox proportional hazards models are presented.
	A general formula describing the relation between the hazard and
	the corresponding survival time of the Cox model is derived, which
	is useful in simulation studies. It is shown how the exponential,
	the Weibull and the Gompertz distribution can be applied to generate
	appropriate survival times for simulation studies. Additionally,
	the general relation between hazard and survival time can be used
	to develop own distributions for special situations and to handle
	flexibly parameterized proportional hazards models. The use of distributions
	other than the exponential distribution is indispensable to investigate
	the characteristics of the Cox proportional hazards model, especially
	in non-standard situations, where the partial likelihood depends
	on the baseline hazard. A simulation study investigating the effect
	of measurement errors in the German Uranium Miners Cohort Study is
	considered to illustrate the proposed simulation techniques and to
	emphasize the importance of a careful modelling of the baseline hazard
	in Cox models.},
  file        = {Bender2005.pdf:Bender2005.pdf:PDF;Bender2005.pdf:pdf\\Bender2005.pdf:PDF},
  institution = {Institute for Quality and Efficiency in Health Care, Cologne, Germany. Ralf.Bender@iqwig.de},
  journal     = {Statistics in Medicine},
  month       = jun,
  owner       = {pl4},
  pmid        = {15724232},
  timestamp   = {2008.10.15},
  year        = {2005},
}

@Article{Bender2002,
  author      = {Bender, Ralf and Blettner, Maria},
  title       = {Calculating the "number needed to be exposed" with adjustment for confounding variables in epidemiological studies.},
  language    = {eng},
  number      = {5},
  pages       = {525--530},
  volume      = {55},
  abstract    = {The number needed to treat (NNT) is a popular summary statistic to
	describe the absolute effect of a new treatment compared with a standard
	treatment or control concerning the risk of an adverse event. The
	NNT concept can be applied whenever the risk of an adverse event
	is compared between two groups; for the comparison of exposed with
	unexposed subjects in epidemiological studies, we propose the term
	"number needed to be exposed" (NNE). Whereas in randomized clinical
	trials NNT can be calculated on the basis of a simple 2 x 2 table,
	in epidemiological studies methods to adjust for confounders are
	required in most applications. We derive a method based upon multiple
	logistic regression analysis to perform point and interval estimation
	of NNE with adjustment for confounding variables. The adjusted NNE
	can be calculated from the adjusted odds ratio (OR) and the unexposed
	event rate (UER) estimated by means of an appropriate multiple logistic
	regression model. As UER is dependent on the confounders, the adjusted
	NNEs also vary with the values of the confounding variables. Two
	methods are proposed to take the dependence of NNE on the values
	of the confounders into account. The adjusted number needed to be
	exposed can be a useful complement to the commonly presented results
	in epidemiological studies, such as ORs and attributable risks.},
  institution = {Department of Epidemiology and Medical Statistics, School of Public Health, University of Bielefeld, PO Box 100131, D-33501 Bielefeld, Germany. Ralf.Bender@uni-bielefeld.de},
  journal     = {J Clin Epidemiol},
  keywords    = {Clinical Trials as Topic, statistics /&/ numerical data; Confidence Intervals; Confounding Factors (Epidemiology); Epidemiologic Methods; Humans; Patient Selection; Sample Size},
  medline-pst = {ppublish},
  month       = {May},
  owner       = {pl4},
  pii         = {S0895435601005108},
  pmid        = {12007557},
  timestamp   = {2013.03.24},
  year        = {2002},
}

@Article{Benhamiche1998,
  author      = {Benhamiche, A. M. and Faivre, J. and Tazi, M. A. and Darsouni, R. and Villing, A. L. and Couillault, C.},
  title       = {[Superficial cancer of the stomach: evolution of their characteristics over a 20 year period in one population].},
  language    = {fre},
  number      = {1},
  pages       = {13--18},
  volume      = {22},
  abstract    = {The aim of this study was to analyse the incidence, treatment and
	prognosis of early gastric cancer in a population-based series and
	to draw a picture of time trends.Over a 20-year period (1976-1995),
	80 early gastric cancers were diagnosed in the Cote d'Or area (493,000
	residents). Incidence rates were calculated by sex, age groups and
	5-year periods. Prognostic factors were determined using the Kaplan-Meier
	method and the Cox model.Age-standardized incidence rates were 0.8/100,000
	in men and 0.3/100,000 in women. Incidence increased slightly over
	time (NS) and their proportion among gastric cancers increased from
	3.4\% (1976-1980) to 7.9\% (1991-1995) (P < 0.01). Among these cancers,
	25 were intramucosal (31.3\%), 55 were submucosal (68.8\%) and 8
	had lymph node metastases (10.0\%). Overall 21 patients (24.1\%)
	had already been treated for a peptic ulcer. The 5-year crude survival
	rate was 63.1\% and the corresponding net survival rate was 86.3\%.
	Lymph node metastases, location, sex and cancer extension and age
	were independent prognostic factors.Though it is on the increase,
	the proportion of early gastric cancers remains low among gastric
	cancers. This study confirms the importance of performing a gastroscopy
	with biopsy upon each bout of ulcer and that the prognosis is lower
	than suggested by hospital based series.},
  institution = {Registre des Cancers Digestifs.},
  journal     = {Gastroenterol Clin Biol},
  keywords    = {Aged; Aged, 80 and over; Cross-Sectional Studies; Female; France, epidemiology; Humans; Incidence; Male; Middle Aged; Neoplasm Invasiveness; Precancerous Conditions, pathology; Prognosis; Stomach Neoplasms, epidemiology/pathology/therapy},
  medline-pst = {ppublish},
  month       = {Jan},
  owner       = {pl4},
  pii         = {MDOI-GCB-02-1998-22-1-0399-8320-101019-ART79},
  pmid        = {9762160},
  timestamp   = {2013.05.29},
  year        = {1998},
}

@Article{Benichou1990a,
  author      = {Benichou, J. and Gail, M. H.},
  title       = {Estimates of absolute cause-specific risk in cohort studies.},
  language    = {eng},
  number      = {3},
  pages       = {813--826},
  volume      = {46},
  abstract    = {In this paper we study methods for estimating the absolute risk of
	an event c1 in a time interval [t1, t2], given that the individual
	is at risk at t1 and given the presence of competing risks. We discuss
	some advantages of absolute risk for measuring the prognosis of an
	individual patient and some difficulties of interpretation for comparing
	two treatment groups. We also discuss the importance of the concept
	of absolute risk in evaluating public health measures to prevent
	disease. Variance calculations permit one to gauge the relative importance
	of random and systematic errors in estimating absolute risk. Efficiency
	calculations were also performed to determine how much precision
	is lost in estimating absolute risk with a nonparametric approach
	or with a flexible piecewise exponential model rather than a simple
	exponential model, and other calculations indicate the extent of
	bias that arises with the simple exponential model when that model
	is invalid. Such calculations suggest that the more flexible models
	will be useful in practice. Simulations confirm that asymptotic methods
	yield reliable variance estimates and confidence interval coverages
	in samples of practical size.},
  file        = {Benichou1990a.pdf:Benichou1990a.pdf:PDF},
  institution = {National Cancer Institute, Bethesda, Maryland 20892.},
  journal     = {Biometrics},
  keywords    = {Biometry; Clinical Trials as Topic, statistics /&/ numerical data; Cohort Studies; Humans; Models, Statistical; Proportional Hazards Models; Risk},
  medline-pst = {ppublish},
  owner       = {pl4},
  pmid        = {2242416},
  timestamp   = {2015.02.02},
  year        = {1990},
}

@Article{Bennaceur-Griscelli1999,
  author      = {Bennaceur-Griscelli, A. and Tourino, C. and Izac, B. and Vainchenker, W. and Coulombel, L.},
  title       = {Murine stromal cells counteract the loss of long-term culture-initiating cell potential induced by cytokines in CD34(+)CD38(low/neg) human bone marrow cells.},
  language    = {eng},
  number      = {2},
  pages       = {529--538},
  volume      = {94},
  abstract    = {Evidence has been provided recently that shows that high concentrations
	of cytokines can fulfill functions previously attributed to stromal
	cells, such as promote the survival of, and led to a net increase
	in human primitive progenitors initiating long-term cultures in vitro
	(LTC-IC) or engrafting NOD-SCID (nonobese diabetic severe-combined
	immunodeficient) recipients in vivo. These data prompted us to re-evaluate
	whether stromal cells will further alter the properties of primitive
	progenitor cells exposed to cytokines. Single CD34(+)CD38(low) and
	CD38(neg) cells were incubated 10 days in serum-containing or serum-free
	medium in the presence or in the absence of murine marrow-derived
	stromal cells (MS-5). Recombinant human cytokines stem cell factor
	(SCF), pegylated-megakaryocyte growth and differentiation factor
	(PEG-MGDF), FLT3-L, Interleukin (IL)-3, IL-6, and granulocyte-macrophage
	colony-stimulating factor (GM-CSF) were systematically added at various
	concentrations (10 to 300 ng/mL). Cell proliferation and LTC-IC potential
	were evaluated in each clone after 10 days. A striking and consistent
	observation was the retention of a high LTC-IC potential in clones
	exposed to cytokines in the presence of stromal feeders, whereas
	clones exposed to cytokines alone in the absence of stromal feeders
	rapidly lost their LTC-IC potential as they proliferated. This was
	reflected both by the higher proportion of wells containing LTC-IC
	and by the high numbers of CFC produced after 5 weeks in clones grown
	with MS-5 during the first 10 days. We further showed by analyzing
	multiple replicates of a single clone at day 10 that MS-5 cells promoted
	a net increase in the LTC-IC compartment through self-renewal divisions.
	Interestingly, these primitive LTC-IC were equally distributed among
	small and large clones, as counted at day 10, indicating that active
	proliferation and loss of LTC-IC potential could be dissociated.
	These observations show that, in primitive cells, stromal cells counteract
	differentiation events triggered by cytokines and promoted self-renewal
	divisions. Furthermore, the almost identical distribution of the
	size of the clones with or without MS-5 suggests that proliferation
	and function of human primitive cells may be independently regulated
	by external signals, and that the former is primarily under the control
	of cytokines.},
  institution = {INSERM U 362, Institut Gustave Roussy, Villejuif, France.},
  journal     = {Blood},
  keywords    = {ADP-ribosyl Cyclase; Animals; Antigens, CD; Antigens, CD34, analysis; Antigens, CD38; Antigens, Differentiation, analysis; Bone Marrow Cells, physiology; Cell Division, drug effects; Cells, Cultured; Coculture Techniques; Colony-Forming Units Assay; Culture Media, Serum-Free, pharmacology; Cytokines, pharmacology; Granulocyte-Macrophage Colony-Stimulating Factor, pharmacology; Hematopoietic Stem Cells, cytology/drug effects; Humans; Interleukin-3, pharmacology; Interleukin-6, pharmacology; Membrane Glycoproteins; Membrane Proteins, pharmacology; Mice; NAD+ Nucleosidase, analysis; Polyethylene Glycols, pharmacology; Recombinant Proteins, pharmacology; Stem Cell Factor, pharmacology; Stromal Cells, physiology; Thrombopoietin, pharmacology},
  medline-pst = {ppublish},
  month       = {Jul},
  owner       = {pl4},
  pmid        = {10397720},
  timestamp   = {2013.05.29},
  year        = {1999},
}

@Article{Bennett1983,
  author    = {D. Bennett},
  title     = {Analysis of survival data by the proportional odds model},
  pages     = {273--277},
  volume    = {2},
  journal   = {Statistics in Medicine},
  owner     = {pl4},
  timestamp = {2009.08.07},
  year      = {1983},
}

@Article{Beral2002,
  author    = {Beral, V. and Banks, E. and Reeves, G.},
  title     = {Evidence from randomised trials on the long-term effects of hormone replacement therapy},
  pages     = {942--4},
  volume    = {360},
  journal   = {Lancet},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2002},
}

@Article{Beral2010,
  author      = {Valerie Beral and Richard Peto},
  title       = {{UK} cancer survival statistics.},
  language    = {eng},
  pages       = {c4112},
  volume      = {341},
  file        = {Beral2010.pdf:Beral2010.pdf:PDF;Beral2010.pdf:pdf\\Beral2010.pdf:PDF},
  journal     = {BMJ},
  medline-pst = {epublish},
  owner       = {PaulD},
  pmid        = {20702551},
  timestamp   = {2011.06.27},
  year        = {2010},
}

@Article{Berg1977,
  author    = {Berg, J. W. and Ross, R. and Latourette, H. B.},
  title     = {Economic Status and Survival of Cancer Patients},
  pages     = {467--477},
  volume    = {39},
  journal   = {Cancer},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1977},
}

@Article{Berger2003,
  author      = {Ursula Berger and Juliane Sch\"{a}fer and Kurt Ulm},
  title       = {Dynamic Cox modelling based on fractional polynomials: time-variations in gastric cancer prognosis.},
  doi         = {10.1002/sim.1411},
  number      = {7},
  pages       = {1163--1180},
  volume      = {22},
  abstract    = {The most popular model used for survival analysis is the proportional
	hazards regression model proposed by Cox. This is mainly due to its
	exceptional simplicity. Nevertheless the fundamental assumption of
	the Cox model is the proportionality of the hazards. For many applications,
	however, this assumption is doubtful. Proposals to extend the Cox
	model for non-proportional hazards to allow for dynamic effect structures
	usually either depend on prespecifications or require non-standard
	estimation techniques and are thus not favoured in application. Moreover,
	tests to verify the dynamic effect structures are not straightforward
	or lack omnibus power. In this paper we propose a flexible method
	for modelling dynamic effects in survival data within the Cox framework.
	The method is based on fractional polynomials as introduced by Royston
	and Altman. This allows for a transformation of the dynamic predictor
	which leads back to the conventional Cox model and hence fitting
	is straightforward using standard estimation techniques. In addition,
	it offers the possibility of easily verifying the existence of time-variation.
	We describe a model selection algorithm which selects time-varying
	effects only when evidence is given in the data. We illustrate the
	properties of the approach in a simulation study and compare it with
	other methods. In a survival study of gastric cancer patients, we
	apply the approach to analyse dynamic structures in the effects of
	prognostic factors.},
  file        = {Berger2003.pdf:Berger2003.pdf:PDF;Berger2003.pdf:pdf\\Berger2003.pdf:PDF},
  institution = {Medical Research Council, Social and Public Health Science Unit, University of Glasgow, 4 Lillybank Gardens, Scotland, UK. Ursula@msoc.mrc.gla.ac.uk},
  journal     = {Statistics in Medicine},
  month       = apr,
  owner       = {pl4},
  pmid        = {12652560},
  timestamp   = {2008.10.15},
  year        = {2003},
}

@Article{Bergfeldt2000,
  author    = {Bergfeldt, K. and Silfversward, C. and Einhorn, S. and Hall, P.},
  title     = {Overestimated risk of second primary malignancies in ovarian cancer patients},
  pages     = {100--105},
  volume    = {36},
  journal   = {European Journal of Cancer},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2000},
}

@Article{Berglund2011,
  author      = {Berglund, Anders and Garmo, Hans and Tishelman, Carol and Holmberg, Lars and Stattin, P{\"a}r and Lambe, Mats},
  title       = {Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in {PCB}a{S}e {S}weden.},
  doi         = {10.1016/j.juro.2010.10.061},
  language    = {eng},
  number      = {3},
  pages       = {833--839},
  url         = {http://dx.doi.org/10.1016/j.juro.2010.10.061},
  volume      = {185},
  abstract    = {We examined associations among comorbidity, treatment decisions and
	mortality in patients with prostate cancer.A total of 77,536 men
	diagnosed with prostate cancer between 1997 and 2006 were identified
	in PCBaSe Sweden from the National Prostate Cancer Register of Sweden.
	Logistic, Cox and competing risk regression were used to assess associations
	among Charlson comorbidity index, treatment and mortality. The Charlson
	comorbidity index was categorized into no (0), mild (1) and severe
	comorbidity (2+).In men with low risk prostate cancer 5,975 of the
	13,245 (45.1\%) patients without comorbidity underwent radical prostatectomy
	compared to 256 of the 1,399 (18.9\%) men with severe comorbidity.
	Following adjustment for age and period of diagnosis, radical prostatectomy
	was less likely to be offered to men with severe comorbidity (OR
	0.48, 95\% CI 0.41-0.55). In men with high risk prostate cancer,
	radiotherapy was more common (range 7.7\% to 21.3\%) than radical
	prostatectomy (range 3.0\% to 11.2\%) regardless of comorbidity burden.
	All cause and competing cause but not prostate cancer specific mortality
	were increased in men with severe comorbidity (all cause HR 1.99,
	95\% CI 1.93-2.05; competing cause sHR 2.66, 95\% CI 2.56-2.78; prostate
	cancer specific sHR 0.98, 95\% CI 0.93-1.03). The cumulative probability
	of prostate cancer death given no death from competing causes was
	significantly higher in men with severe comorbidity in all risk groups
	(p<0.01).Comorbidity affects treatment choices, and is associated
	with all cause, competing cause and conditional prostate cancer specific
	mortality. An increased conditional prostate cancer specific mortality
	in men with severe comorbidity may reflect less aggressive treatment,
	impaired tumor defense, lifestyle factors and poor general health
	behavior.},
  institution = {Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. anders.berglund@ki.se},
  journal     = {J Urol},
  keywords    = {Aged; Aged, 80 and over; Cohort Studies; Humans; Male; Prostatic Neoplasms, complications/mortality/therapy; Risk Factors; Severity of Illness Index; Sweden},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {sanelo},
  pii         = {S0022-5347(10)04962-1},
  pmid        = {21239002},
  timestamp   = {2013.09.17},
  year        = {2011},
}

@Article{Bergmark1999,
  author    = {K Bergmark and E Avall-Lundqvist and PW Dickman and L Henningsohn and G Steineck},
  title     = {Vaginal changes and sexuality in women with a history of cervical cancer.},
  number    = {18},
  pages     = {1383--9},
  volume    = {340},
  abstract  = {BACKGROUND: In women with cervical cancer, treatment causes changes
	in vaginal anatomy and function. The effect of these changes on sexual
	function and the extent, if any, to which they distress women are
	not known. METHODS: In 1996 and 1997, we attempted to contact 332
	women with a history of early-stage cervical cancer (age range, 26
	to 80 years) who had been treated in 1991 and 1992 at the seven departments
	of gynecological oncology in {S}weden and 489 women without a history
	of cancer (controls) to ask them to answer an anonymous questionnaire
	about vaginal changes and sexual function. RESULTS: We received completed
	questionnaires from 256 of the women with a history of cervical cancer
	and 350 of the controls. A total of 167 of 247 women with a history
	of cancer (68 percent) and 236 of 330 controls (72 percent) reported
	that they had regular vaginal intercourse. Twenty-six percent of
	the women who had cancer and 11 percent of the controls reported
	insufficient vaginal lubrication for sexual intercourse, 26 percent
	of the women who had cancer and 3 percent of the controls reported
	a short vagina, and 23 percent of the women who had cancer and 4
	percent of the controls reported an insufficiently elastic vagina.
	Twenty-six percent of the women who had cancer reported moderate
	or much distress due to vaginal changes, as compared with 8 percent
	of the women in the control group. Dyspareunia was also more common
	among the women who had cervical cancer. The frequency of orgasms
	and orgasmic pleasure was similar in the two groups. Among the women
	who had cervical cancer, the type of treatment received had little
	if any effect on the prevalence of specific vaginal changes. CONCLUSIONS:
	Women who have been treated for cervical cancer have persistent vaginal
	changes that compromise sexual activity and result in considerable
	distress.},
  journal   = {N Engl J Med},
  month     = may,
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1999},
}

@Article{Bergmark2006,
  author    = {K. Bergmark and E. Avall-Lundqvist and P. W. Dickman and L. Henningsohn and G. Steineck},
  title     = {Lymphedema and bladder-emptying difficulties after radical hysterectomy for early cervical cancer and among population controls.},
  doi       = {10.1111/j.1525-1438.2006.00601.x},
  pages     = {1130--1139},
  volume    = {16},
  abstract  = {The aim of the study was to acquire knowledge that can be used to
	refine radical hysterectomy to improve quality-of-life outcome. Data
	were collected in 1996-1997 by means of an anonymous postal questionnaire
	in a follow-up study of two cohorts (patients and population controls).
	We attempted to enroll all 332 patients with stage IB-IIA cervical
	cancer registered in 1991-1992 at the seven departments of gynecological
	oncology in {S}weden and 489 population controls. Ninety three (37\%)
	of the 256 women with a history of cervical cancer who answered the
	questionnaire (77\%) were treated with surgery alone. Three-hundred
	fifty population controls answered the questionnaire (72\%). Women
	treated with radical hysterectomy, as compared with controls, had
	an 8-fold increase in symptoms indicating lymphedema (25\% reported
	distress due to lymphedema), a nearly 9-fold increase in difficult
	emptying of the bladder, and a 22-fold increase in the need to strain
	to initiate bladder evacuation. Ninety percent of the patients were
	not willing to trade off survival for freedom from symptoms. Avoiding
	to induce long-term lymphedema or bladder-emptying difficulties would
	probably improve quality of life after radical hysterectomy (to cure
	cervical cancer). Few women want to compromise survival to avoid
	long-term symptoms.},
  journal   = {Int J Gynecol Cancer},
  owner     = {PaulD},
  pii       = {IJG601},
  pmid      = {16803496},
  timestamp = {2006.10.04},
  year      = {2006},
}

@Article{Bergmark2002,
  author    = {Karin Bergmark and Elisabeth Avall-Lundqvist and Paul W Dickman and Lars Henningsohn and Gunnar Steineck},
  title     = {Patient-rating of distressful symptoms after treatment for early cervical cancer.},
  number    = {5},
  pages     = {443--50},
  volume    = {81},
  abstract  = {BACKGROUND: More refined information on sources of symptom-induced
	distress in a patient population can improve the quality of pretreatment
	information, make follow-up visits more efficient and guide research
	priorities in the efforts to modify treatments. METHODS: In a population-based
	epidemiological study covering all of {S}weden, data were collected
	1996-97 by means of an anonymous postal questionnaire. We attempted
	to enroll all 332 patients with stage IB-IIA cervical cancer registered
	in 1991-92 at the seven departments of gynecological oncology in
	{S}weden. RESULTS: A total of 256 cases (77\%) completed the questionnaire.
	After surgery, alone or in combination with intracavitary radiotherapy,
	several symptoms related to sexual dysfunction are the primary sources
	of symptom-induced distress (reduced orgasm frequency: much distress
	23\% (surgery alone) and 23\% (intracavitary radiotherapy and surgery),
	respectively, overall intercourse dysfunction: much distress 17\%
	and 20\%, respectively, followed by lymphedema (much distress 14\%
	and 14\%, respectively). Dyspareunia (much distress 24\%) and defecation
	urgency (much distress 22\%) are two leading causes of distress after
	surgery and external radiotherapy. After treatment with radiotherapy
	alone, loose stool and dyspareunia were the two most distressful
	symptoms (much distress 19\% each). When a symptom occurs, fecal
	leakage and reduced orgasm frequency are the two most distressful
	ones (measured as much distress, 38\% each). CONCLUSIONS: The observed
	symptoms are distressful and should, if one focuses on patient satisfaction,
	be given priority.},
  journal   = {Acta Obstet Gynecol Scand},
  month     = may,
  owner     = {PaulD},
  pii       = {aog810512},
  timestamp = {2011.06.19},
  year      = {2002},
}

@Article{Bergmark2005,
  author    = {Karin Bergmark and Elisabeth Avall-Lundqvist and Paul W Dickman and Gunnar Steineck and Lars Henningsohn},
  title     = {Synergy between sexual abuse and cervical cancer in causing sexual dysfunction.},
  doi       = {10.1080/00926230591006476},
  pages     = {361--383},
  volume    = {31},
  abstract  = {Experiencing a sexual abuse creates a life-long traumatic memory.
	The life-long effect of such abuse on sexuality, well-being, the
	risk of contracting cervical cancer, or problems after treatment
	for cervical cancer is not known. A population-based follow-up study
	in 1996-97 that used an anonymous postal questionnaire for data collection,
	256 women with stage IB-IIA cervical cancer registered in 1991-92
	in {S}weden, and 350 women without cervical cancer frequency matched
	for age and region of residence, provided information. Among the
	women with a history of cervical cancer and the control women, 46
	(18\%) and 50 (15\%), respectively, reported a history of sexual
	abuse. The follow-up was 1-70 years after the sexual abuse. The relative
	risk (with 95\% confidence interval) of decreased well-being was
	2.4 (1.1-5.2) among controls and 2.7 (1.1-6.4) among former cervical
	cancer patients. A history of both sexual abuse and cervical cancer
	gave a relative risk of 30.0 (7.0-129.0) for superficial dyspareunia.
	Sexual abuse increased the risk of sexual problems after treatment.
	The sexually abused cervical cancer patients were generally less
	willing than other patients to trade off possible maximal survival
	and forgo parts of the treatment. A history of sexual abuse and cervical
	cancer are both independent risk factors for sexual dysfunction and
	decreased well-being, and there may be a large synergy when both
	factors are combined. Diagnosis and treatment of cervical cancer
	may be improved by recognition of a sexual abuse history.},
  journal   = {J Sex Marital Ther},
  owner     = {PaulD},
  pii       = {N50W4W4V838W4462},
  pmid      = {16176913},
  timestamp = {2006.10.04},
  year      = {2005},
}

@InCollection{Berkson1942,
  author    = {Berkson, J.},
  booktitle = {Carcinoma and other malignant lesions of the stomach},
  title     = {The calculation of survival rates.},
  editor    = {Walters, W. and Gray, H.K. and Priestly, J.T.},
  pages     = {467--484},
  publisher = {Philadelphia: Sanders},
  file      = {Berkson1942.pdf:pdf\\Berkson1942.pdf:PDF;Berkson1942.pdf:Berkson1942.pdf:PDF},
  owner     = {PaulD},
  timestamp = {2013.06.24},
  year      = {1942},
}

@Article{Berkson1952,
  author    = {J. Berkson and R.P. Gage},
  title     = {Survival curve for cancer patients following treatment},
  pages     = {501--515},
  volume    = {47},
  file      = {Berkson1952.pdf:Berkson1952.pdf:PDF;Berkson1952.pdf:pdf\\Berkson1952.pdf:PDF},
  journal   = {Journal of the American Statistical Association},
  owner     = {pl4},
  timestamp = {2008.10.15},
  year      = {1952},
}

@Article{Berkson1950,
  author    = {Berkson, J. and Gage, R. P.},
  title     = {Calculation of Survival Rates for Cancer},
  pages     = {270--286},
  volume    = {25},
  journal   = {Proceedings of Staff Meetings of the Mayo Clinic},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1950},
}

@Article{Berlin2002,
  author      = {Jesse A Berlin and Jill Santanna and Christopher H Schmid and Lynda A Szczech and Harold I Feldman and Anti-Lymphocyte Antibody Induction Therapy Study Group},
  title       = {Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head.},
  number      = {3},
  pages       = {371--387},
  volume      = {21},
  abstract    = {When performing a meta-analysis, interest often centres on finding
	explanations for heterogeneity in the data, rather than on producing
	a single summary estimate. Such exploratory analyses are frequently
	undertaken with published, study-level data, using techniques of
	meta-analytic regression. Our goal was to explore a real-world example
	for which both published, group-level and individual patient-level
	data were available, and to compare the substantive conclusions reached
	by both methods. We studied the benefits of anti-lymphocyte antibody
	induction therapy among renal transplant patients in five randomized
	trials, focusing on whether there are subgroups of patients in whom
	therapy might prove particularly beneficial. Allograft failure within
	5 years was the endpoint studied. We used a variety of analytic approaches
	to the group-level data, including weighted least-squares regression
	(N=5 studies), logistic regression (N=628, the total number of subjects),
	and a hierarchical Bayesian approach. We fit logistic regression
	models to the patient-level data. In the patient-level analysis,
	we found that treatment was significantly more effective among patients
	with elevated (20 per cent or more) panel reactive antibodies (PRA)
	than among patients without elevated PRA. These patients comprise
	a small (about 15 per cent of patients) subgroup of patients that
	benefited from therapy. The group-level analyses failed to detect
	this interaction. We recommend using individual patient data, when
	feasible, to study patient characteristics, in order to avoid the
	potential for ecological bias introduced by group-level analyses.},
  file        = {berlin2002.pdf:berlin2002.pdf:PDF},
  institution = {University of Pennsylvania School of Medicine, Department of Biostatistics and Epidemiology and Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA 19104-6021, USA. jberlin@cceb.upenn.edu},
  journal     = {Statistics in Medicine},
  month       = feb,
  owner       = {pl4},
  pmid        = {11813224},
  timestamp   = {2008.11.18},
  year        = {2002},
}

@Article{Berrino2003,
  author    = {F. Berrino},
  title     = {The {EUROCARE} Study: strengths, limitations and perspectives of population-based, comparative survival studies.},
  pages     = {v9--13},
  volume    = {14 Suppl 5},
  file      = {Berrino2003.pdf:Berrino2003.pdf:PDF;Berrino2003.pdf:pdf\\Berrino2003.pdf:PDF},
  journal   = {Ann Oncol},
  owner     = {pl4},
  pmid      = {14684497},
  timestamp = {2008.10.15},
  year      = {2003},
}

@Article{Berrino2007,
  author      = {F. Berrino and R. De Angelis and M. Sant and S. Rosso and M. Bielska-Lasota and M. B. Lasota and J. W. Coebergh and M. Santaquilani and {EUROCARE Working Group}},
  title       = {Survival for eight major cancers and all cancers combined for {E}uropean adults diagnosed in 1995-99: results of the {EUROCARE}-4 study.},
  number      = {9},
  pages       = {773--783},
  volume      = {8},
  abstract    = {BACKGROUND: EUROCARE is the largest population-based cooperative study
	on survival of patients with cancer. The EUROCARE project aims to
	regularly monitor, analyse, and explain survival trends and between-country
	differences in survival. This report (EUROCARE-4) presents survival
	data for eight selected cancer sites and for all cancers combined,
	diagnosed in adult (aged >/=15 years) Europeans in 1995-99 and followed
	up until the end of 2003. METHODS: We analysed data from 83 cancer
	registries in 23 European countries on 2 699 086 adult cancer cases
	that were diagnosed in 1995-99 and followed up to December, 2003.
	We calculated country-specific and mean-weighted age-adjusted 5-year
	relative survival for eight major cancers. Additionally, case-mix-adjusted
	5-year survival for all cancers combined was calculated by countries
	ranked by total national expenditure on health (TNEH). Changes to
	survival were analysed relative to cases diagnosed in 1990-94. FINDINGS:
	Mean age-adjusted 5-year relative survival for colorectal (53.8\%
	[95\% CI 53.3-54.1]), lung (12.3\% [12.1-12.5]), breast (78.9\% [78.6-79.2]),
	prostate (75.7\% [75.2-76.2]), and ovarian (36.3\% [35.7-37.0]) cancer
	was highest in Nordic countries (except Denmark) and central Europe,
	intermediate in southern Europe, lower in the UK and Ireland, and
	worst in eastern Europe. Survival for melanoma (81.6\% [81.0-82.3]),
	cancer of the testis (94.2\% [93.4-95.0]), and Hodgkin's disease
	(80.0\% [79.0-81.0]) varied little with geography. All-cancer survival
	correlated with TNEH for most countries. Denmark and UK had lower
	all-cancer survival than countries with similar TNEH; Finland had
	high all-cancer survival, but moderate TNEH. Survival increased and
	intercountry survival differences narrowed between the data for 1990-94
	and 1995-99 for, notably, Hodgkin's disease (range 66.1-82.9 [IQR
	72.2-78.6] vs 74.0-83.9 [78.6-81.9]), colorectal (29.4-56.7 [45.8-54.1]
	vs 38.8-59.7 [50.7-57.5]), and breast (61.7-82.7 [72.3-78.3] vs 69.3-87.6
	[76.6-82.7]) sites. INTERPRETATION: Increases in survival and decreases
	in geographic differences over time, which are mainly due to improvements
	in health-care services in countries with poor survival, might indicate
	better cancer care. Wealthy countries with high TNEH generally had
	good cancer outcomes, but those with conspicuously worse outcomes
	than those with similar TNEH might not be allocating health resources
	efficiently.},
  file        = {Berrino2007.pdf:Berrino2007.pdf:PDF;Berrino2007.pdf:pdf\\Berrino2007.pdf:PDF},
  institution = {Department of Preventive and Predictive Medicine, Fondazione Istituto Nazionale dei Tumori, Milan, Italy.},
  journal     = {Lancet Oncology},
  month       = sep,
  owner       = {pl4},
  pmid        = {17714991},
  timestamp   = {2010.03.18},
  year        = {2007},
}

@Article{Berrino2001,
  author      = {F. Berrino and G. Gatta and M. Sant and R. Capocaccia},
  title       = {The {EUROCARE} study of survival of cancer patients in Europe: aims, current status, strengths and weaknesses.},
  number      = {6},
  pages       = {673--677},
  volume      = {37},
  file        = {Berrino2001.pdf:Berrino2001.pdf:PDF;Berrino2001.pdf:pdf\\Berrino2001.pdf:PDF},
  institution = {Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.},
  journal     = {European Journal of Cancer},
  month       = apr,
  owner       = {pl4},
  pii         = {S0959-8049(01)00008-9},
  pmid        = {11311640},
  timestamp   = {2008.10.15},
  year        = {2001},
}

@Article{Berrino1997,
  author    = {Berrino, F. and Micheli, A. and Sant, M. and Capocaccia, R},
  title     = {Interpreting Survival Differences and Trends},
  pages     = {9--16},
  volume    = {83},
  journal   = {Tumori},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1997},
}

@Article{Berry1983,
  author    = {Berry, G.},
  title     = {The Analysis of Mortality by the Subject-Years Method},
  pages     = {173--184},
  volume    = {39},
  journal   = {Biometrics},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1983},
}

@Article{Berry2010,
  author      = {Berry, Sarah D. and Ngo, Long and Samelson, Elizabeth J. and Kiel, Douglas P.},
  title       = {Competing risk of death: an important consideration in studies of older adults.},
  doi         = {10.1111/j.1532-5415.2010.02767.x},
  language    = {eng},
  number      = {4},
  pages       = {783--787},
  url         = {http://dx.doi.org/10.1111/j.1532-5415.2010.02767.x},
  volume      = {58},
  abstract    = {Clinical studies often face the difficult problem of how to account
	for participants who die without experiencing the study outcome of
	interest. In a geriatric population with considerable comorbidities,
	the competing risk of death is especially high. Traditional approaches
	to describe risk of disease include Kaplan-Meier survival analysis
	and Cox proportional hazards regression, but these methods can overestimate
	risk of disease by failing to account for the competing risk of death.
	This report discusses traditional survival analysis and competing
	risk analysis as used to estimate risk of disease in geriatric studies.
	Furthermore, it illustrates a competing risk approach to estimate
	risk of second hip fracture in the Framingham Osteoporosis Study
	and compares the results with traditional survival analysis. In this
	example, survival analysis overestimated the 5-year risk of second
	hip fracture by 37\% and the 10-year risk by 75\% compared with competing
	risk estimates. In studies of older individuals in which a substantial
	number of participants die during a long follow-up, the cumulative
	incidence competing risk estimate and competing risk regression should
	be used to determine incidence and effect estimates. Use of a competing
	risk approach is critical to accurately determining disease risk
	for elderly individuals and therefore best inform clinical decision-making.},
  institution = {Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts 02131, USA. sarahberry@hrca.harvard.edu},
  journal     = {J Am Geriatr Soc},
  keywords    = {Aged; Analysis of Variance; Bias (Epidemiology); Biomedical Research, organization /&/ administration; Cause of Death; Comorbidity; Geriatric Assessment, methods; Geriatrics; Hip Fractures, epidemiology/etiology; Humans; Incidence; Kaplan-Meier Estimate; Life Expectancy; Longitudinal Studies; Osteoporosis, complications; Proportional Hazards Models; Recurrence; Risk Assessment, methods},
  medline-pst = {ppublish},
  month       = {Apr},
  owner       = {sanelo},
  pii         = {JGS2767},
  pmid        = {20345862},
  timestamp   = {2013.07.30},
  year        = {2010},
}

@Article{Betensky2001a,
  author    = {Betensky, R. A. and Hudson, J. I. and Jones, C. A. and Hu, F. and Wang , B. and Chen, C. and Xu, X.},
  title     = {A computationally simple test of homogeneity of odds ratios for twin data},
  pages     = {228--38},
  volume    = {20},
  journal   = {Genet Epidemiol},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2001},
}

@Article{Betensky2001b,
  author    = {Betensky, Rebecca A. and Williams, Paige L. and Lederman, Howard M.},
  title     = {A comparison of models for clustered binary outcomes: {A}nalysis of a designed immunology experiment},
  number    = {1},
  pages     = {43--61},
  volume    = {50},
  journal   = {Applied Statistics},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2001},
}

@Article{Beutler2002,
  author    = {Beutler, E. and Felitti, V. J. and Koziol, J. A. and Ho, N. J. and Gelbart, T.},
  title     = {Penetrance of {845G$\rightarrow$A (C282Y) {HF}E} hereditary haemochromatosis mutation in the {USA}},
  pages     = {211--8},
  volume    = {359},
  journal   = {Lancet},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2002},
}

@Book{Beyersmann2012,
  author    = {J. Beyersmann and A. Allignol and M. Schumacher},
  title     = {Competing Risks and Multistate Models with R},
  publisher = {Springer},
  file      = {Beyersmann2012.pdf:Beyersmann2012.pdf:PDF},
  owner     = {pl4},
  timestamp = {2014.05.28},
  year      = {2012},
}

@Article{Beyersmann2007,
  author      = {Jan Beyersmann and Markus Dettenkofer and Hartmut Bertz and Martin Schumacher},
  title       = {A competing risks analysis of bloodstream infection after stem-cell transplantation using subdistribution hazards and cause-specific hazards.},
  doi         = {10.1002/sim.3006},
  number      = {30},
  pages       = {5360--5369},
  volume      = {26},
  abstract    = {After peripheral blood stem-cell transplantation, patients treated
	for severe haematologic diseases enter a critical phase (neutropenia).
	Analysis of bloodstream infection during neutropenia has to account
	for competing risks. Separate Cox analyses of all cause-specific
	hazards are the standard technique of choice, but are hard to interpret
	when the overall effects of covariates on the cumulative incidence
	function (CIF) are of interest. Proportional subdistribution hazards
	modelling of the subdistribution of the CIF is establishing itself
	as an interpretation-friendly alternative. We apply both methods
	and discuss their relative merits.},
  file        = {Beyersmann2007.pdf:Beyersmann2007.pdf:PDF;Beyersmann2007.pdf:pdf\\Beyersmann2007.pdf:PDF},
  institution = {Freiburg Centre for Data Analysis and Modelling, University of Freiburg, Eckerstrasse 1, 79104 Freiburg, Germany. beyersmann@fdm.uni-freiburg.de},
  journal     = {Statistics in Medicine},
  month       = dec,
  owner       = {pl4},
  pmid        = {17634974},
  timestamp   = {2009.10.17},
  year        = {2007},
}

@Article{Beyersmann2009,
  author      = {Beyersmann, Jan and Latouche, Aur\'{e}lien and Buchholz, Anika and Schumacher, Martin},
  title       = {Simulating competing risks data in survival analysis.},
  doi         = {10.1002/sim.3516},
  language    = {eng},
  number      = {6},
  pages       = {956--971},
  volume      = {28},
  abstract    = {Competing risks analysis considers time-to-first-event ('survival
	time') and the event type ('cause'), possibly subject to right-censoring.
	The cause-, i.e. event-specific hazards, completely determine the
	competing risk process, but simulation studies often fall back on
	the much criticized latent failure time model. Cause-specific hazard-driven
	simulation appears to be the exception; if done, usually only constant
	hazards are considered, which will be unrealistic in many medical
	situations. We explain simulating competing risks data based on possibly
	time-dependent cause-specific hazards. The simulation design is as
	easy as any other, relies on identifiable quantities only and adds
	to our understanding of the competing risks process. In addition,
	it immediately generalizes to more complex multistate models. We
	apply the proposed simulation design to computing the least false
	parameter of a misspecified proportional subdistribution hazard model,
	which is a research question of independent interest in competing
	risks. The simulation specifications have been motivated by data
	on infectious complications in stem-cell transplanted patients, where
	results from cause-specific hazards analyses were difficult to interpret
	in terms of cumulative event probabilities. The simulation illustrates
	that results from a misspecified proportional subdistribution hazard
	analysis can be interpreted as a time-averaged effect on the cumulative
	event probability scale.},
  file        = {Beyersmann2009.pdf:Beyersmann2009.pdf:PDF},
  institution = {Freiburg Centre for Data Analysis and Modelling, University of Freiburg, Eckerstrasse 1, 79104 Freiburg, Germany. jan.beyersmann@fdm.uni-freiburg.de},
  journal     = {Stat Med},
  medline-pst = {ppublish},
  owner       = {pl4},
  pmid        = {19125387},
  timestamp   = {2012.02.03},
  year        = {2009},
}

@Article{Bhaskaran2014,
  author      = {Bhaskaran, Krishnan and Douglas, Ian and Forbes, Harriet and dos-Santos-Silva, Isabel and Leon, David A. and Smeeth, Liam},
  title       = {Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5$\cdot$24 million UK adults.},
  doi         = {10.1016/S0140-6736(14)60892-8},
  language    = {eng},
  number      = {9945},
  pages       = {755--765},
  url         = {http://dx.doi.org/10.1016/S0140-6736(14)60892-8},
  volume      = {384},
  abstract    = {High body-mass index (BMI) predisposes to several site-specific cancers,
	but a large-scale systematic and detailed characterisation of patterns
	of risk across all common cancers adjusted for potential confounders
	has not previously been undertaken. We aimed to investigate the links
	between BMI and the most common site-specific cancers.With primary
	care data from individuals in the Clinical Practice Research Datalink
	with BMI data, we fitted Cox models to investigate associations between
	BMI and 22 of the most common cancers, adjusting for potential confounders.
	We fitted linear then non-linear (spline) models; investigated effect
	modification by sex, menopausal status, smoking, and age; and calculated
	population effects.5ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·24 million individuals were included; 166,955
	developed cancers of interest. BMI was associated with 17 of 22 cancers,
	but effects varied substantially by site. Each 5 kg/m(2) increase
	in BMI was roughly linearly associated with cancers of the uterus
	(hazard ratio [HR] 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·62, 99\% CI 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·56-1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·69; p<0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·0001), gallbladder
	(1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·31, 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·12-1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·52; p<0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·0001), kidney (1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·25, 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·17-1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·33; p<0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·0001),
	cervix (1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·10, 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·03-1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·17; p=0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·00035), thyroid (1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·09, 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·00-1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·19; p=0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·0088),
	and leukaemia (1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·09, 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·05-1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·13; p?0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·0001). BMI was positively associated
	with liver (1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·19, 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·12-1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·27), colon (1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·10, 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·07-1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·13), ovarian (1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·09,
	1.04-1.14), and postmenopausal breast cancers (1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·05, 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·03-1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·07) overall
	(all p<0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·0001), but these effects varied by underlying BMI or individual-level
	characteristics. We estimated inverse associations with prostate
	and premenopausal breast cancer risk, both overall (prostate 0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·98,
	0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·95-1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·00; premenopausal breast cancer 0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·89, 0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·86-0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·92) and in never-smokers
	(prostate 0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·96, 0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·93-0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·99; premenopausal breast cancer 0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·89, 0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·85-0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·94).
	By contrast, for lung and oral cavity cancer, we observed no association
	in never smokers (lung 0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·99, 0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·93-1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·05; oral cavity 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·07, 0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·91-1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·26):
	inverse associations overall were driven by current smokers and ex-smokers,
	probably because of residual confounding by smoking amount. Assuming
	causality, 41\% of uterine and 10\% or more of gallbladder, kidney,
	liver, and colon cancers could be attributable to excess weight.
	We estimated that a 1 kg/m(2) population-wide increase in BMI would
	result in 3790 additional annual UK patients developing one of the
	ten cancers positively associated with BMI.BMI is associated with
	cancer risk, with substantial population-level effects. The heterogeneity
	in the effects suggests that different mechanisms are associated
	with different cancer sites and different patient subgroups.National
	Institute for Health Research, Wellcome Trust, and Medical Research
	Council.},
  file        = {Bhaskaran2014.pdf:Bhaskaran2014.pdf:PDF},
  institution = {Department of Non-Communicable Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, UK; Farr Institute of Health Informatics Research, London, UK.},
  journal     = {Lancet},
  keywords    = {Adult; Body Mass Index; Cohort Studies; Female; Great Britain, epidemiology; Humans; Male; Middle Aged; Neoplasms, epidemiology; Proportional Hazards Models; Risk},
  medline-pst = {ppublish},
  month       = {Aug},
  owner       = {pl4},
  pii         = {S0140-6736(14)60892-8},
  pmid        = {25129328},
  timestamp   = {2015.01.01},
  year        = {2014},
}

@Article{Bhaskaran2008,
  author    = {K. Bhaskaran and O. Hamouda and M. Sannes and F. Boufassa and A. M. Johnson and P. C. Lambert and K. Porter and {{CASCADE} Collaboration}},
  title     = {Changes in the risk of death after {HIV} seroconversion compared with mortality in the general population.},
  doi       = {10.1001/jama.300.1.51},
  number    = {1},
  pages     = {51--59},
  volume    = {300},
  file      = {bhaskaran2008.pdf:bhaskaran2008.pdf:PDF},
  journal   = {JAMA},
  month     = jul,
  owner     = {pl4},
  pii       = {300/1/51},
  pmid      = {18594040},
  timestamp = {2008.10.15},
  year      = {2008},
}

@Article{Bhaskaran2013,
  author      = {Bhaskaran, K. and Rachet, B. and Evans, S. and Smeeth, L.},
  title       = {Beta-blockers and prostate cancer survival--interpretation of competing risks models.},
  doi         = {10.1016/j.eururo.2013.07.004},
  language    = {eng},
  number      = {4},
  pages       = {e86--e87},
  url         = {http://dx.doi.org/10.1016/j.eururo.2013.07.004},
  volume      = {64},
  file        = {Bhaskaran2013.pdf:Bhaskaran2013.pdf:PDF;Bhaskaran2013.pdf:pdf\\Bhaskaran2013.pdf:PDF},
  journal     = {Eur Urol},
  medline-pst = {ppublish},
  month       = {Oct},
  owner       = {PaulD},
  pii         = {S0302-2838(13)00719-7},
  pmid        = {23895794},
  timestamp   = {2014.06.17},
  year        = {2013},
}

@Article{Billingham2002,
  author      = {L. J. Billingham and K. R. Abrams},
  title       = {Simultaneous analysis of quality of life and survival data.},
  number      = {1},
  pages       = {25--48},
  volume      = {11},
  abstract    = {In many phase III clinical trials, particularly in the field of cancer,
	the comparison of treatments is based on both length of survival
	and quality of life. Subjects are followed over time until death
	and during this period, quality of life is assessed on a number of
	occasions. Simultaneous analysis of these two outcomes supplements
	the comparison of treatments in terms of each outcome independently
	with an assessment of the net effect. In addition, it provides a
	means of accounting for the informative dropout due to death of patients
	within the time frame of the quality of life study. The methods also
	have the potential to be extended to allow for informative dropout
	from the quality of life study prior to death. There are a number
	of broad approaches for the simultaneous analysis of quality of life
	and survival data. The most widely used approach in clinical research
	is quality-adjusted survival analysis, where treatments are compared
	in terms of a composite measure of quality and quantity of life.
	The paper reviews the different techniques for quality-adjusted survival
	analysis, illustrating the methodology by application to data from
	a phase III clinical trial in pancreatic cancer. In addition, alternative
	approaches using multistate survival analysis and joint modelling
	methods are also discussed.},
  file        = {Billingham2002.pdf:Billingham2002.pdf:PDF;Billingham2002a.pdf:Billingham2002a.pdf:PDF;Billingham2002.pdf:pdf\\Billingham2002.pdf:PDF},
  institution = {Cancer Research Campaign Trials Unit, Institute for Cancer Studies, Medical School, University of Birmingham, Birmingham B15 2TT, UK.},
  journal     = {Statistical Methods in Medical Research},
  month       = feb,
  owner       = {pl4},
  pmid        = {11923992},
  timestamp   = {2008.10.15},
  year        = {2002},
}

@Article{Billingham2002a,
  author      = {L. J. Billingham and S. Bathers and A. Burton and S. Bryan and M. H. Cullen},
  title       = {Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer.},
  number      = {2},
  pages       = {219--225},
  volume      = {37},
  abstract    = {In a recently published randomised trial of chemotherapy versus palliative
	care in advanced non-small cell lung cancer (the MIC2 trial), chemotherapy
	was shown to prolong survival without compromising quality of life.
	The study presented here examines patterns of care and their associated
	costs within a representative subgroup of patients from the MIC2
	trial. The study consisted of 116 patients from the South Birmingham
	Health Authority area. The total health service cost for each patient
	from entry to trial to death or last follow-up was calculated by
	combining the resources used with their associated unit costs. The
	mean cost for patients with complete data on the chemotherapy arm
	was 6999 pounds sterling (standard deviation (S.D.) 4194 pounds sterling)
	compared to 4076 pounds sterling (S.D. 3078 pounds sterling) for
	those with complete data on the palliative care arm. Non-parametric
	bootstrapping gave a difference between treatment arms in mean cost
	of 2924 pounds sterling(95\% CI 1234 pounds sterling - 4323 pounds
	sterling). With a difference in mean survival of 2.4 months, this
	translates to an incremental cost-effectiveness ratio of 14,620 pounds
	sterling per life year gained. Chemotherapy was found to be more
	costly than standard palliative care, mainly due to the increased
	number of hospital in-patient days.},
  file        = {Billingham2002a.pdf:Billingham2002a.pdf:PDF;Billingham2002a.pdf:pdf\\Billingham2002a.pdf:PDF},
  institution = {Cancer Research UK Trials Unit, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. l.j.billingham@bham.ac.uk},
  journal     = {Lung Cancer},
  month       = aug,
  owner       = {pl4},
  pii         = {S0169500202000429},
  pmid        = {12140146},
  timestamp   = {2008.10.15},
  year        = {2002},
}

@Article{Birgisson2005,
  author      = {H. Birgisson and M. Talb\"{a}ck and U. Gunnarsson and L. P{\aa}hlman and B. Glimelius},
  title       = {Improved survival in cancer of the colon and rectum in Sweden.},
  doi         = {10.1016/j.ejso.2005.05.002},
  number      = {8},
  pages       = {845--853},
  volume      = {31},
  abstract    = {AIMS: To analyse time-trends in survival of patients with colon and
	rectal cancer in Sweden. PATIENTS AND METHODS: Data including all
	patients diagnosed with adenocarcinoma of the colon and rectum between
	1960 and 1999, from the Swedish Cancer Registry, were analysed. The
	observed and relative survival rates were calculated according to
	the Hakulinen cohort method. RESULTS: Five-year relative survival
	rate for cancer of the colon improved significantly from 39.6\% in
	1960--1964 to 57.2\% in 1995--1999 and for rectal cancer from 36.1
	to 57.6\%, respectively. Corresponding observed survival improved
	from 31.2 to 44.3\% for colon cancer and from 28.4 to 45.4\% for
	rectal cancer. The largest improvement of survival were seen during
	the later part of the period observed. CONCLUSION: The survival of
	patients with colon and rectal cancer in Sweden continues to improve,
	especially in rectal cancer, which now has a 5-year observed and
	relative survival rate comparable to that for colon cancer. The survival
	improvement in rectal cancer is probably a result of the implementation
	of total mesorectal excision and pre-operative radiotherapy.},
  file        = {Birgisson2005.pdf:Birgisson2005.pdf:PDF;Birgisson2005.pdf:pdf\\Birgisson2005.pdf:PDF},
  institution = {Department of Surgery, Akademiska Sjukhuset, S-75185 Uppsala, Sweden. helgi.birgisson@akademiska.se},
  journal     = {Eur J Surg Oncol},
  month       = oct,
  owner       = {pl4},
  pii         = {S0748-7983(05)00138-1},
  pmid        = {15979269},
  timestamp   = {2008.10.15},
  year        = {2005},
}

@Article{Bjorge1995,
  author    = {Bjorge, T. and Gunbjorud, A. B. and Haugen, O. A. and Skare, G. B. and Trope, C. and Thoresen, S. O.},
  title     = {Mass Screening for Cervical Cancer in {N}orway: Evaluation of the Pilot Project},
  pages     = {477--484},
  volume    = {6},
  journal   = {Cancer Causes \& Control},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@Article{Bjorge1993,
  author    = {Bjorge, T. and Thoresen, S. O. and Skare, G. B.},
  title     = {Incidence, Survival and Mortality in Cervical Cancer in {N}orway, 1956-1990},
  pages     = {2291--2297},
  volume    = {29A},
  journal   = {European Journal of Cancer},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1993},
}

@InCollection{Black1998,
  author    = {Black, R. J. and Sankaranarayanan, R. and Parkin, D. M.},
  booktitle = {Cancer Survival in Developing Countries},
  title     = {Interpretation of population-based cancer survival data},
  editor    = {Sankaranarayanan, R. and Black, R. J. and Parkin, D. M.},
  pages     = {13--17},
  publisher = {Lyon: International Agency for Research on Cancer},
  series    = {IARC Scientific Publications No. 145},
  url       = {http://apps.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan=1&codcol=73&codcch=145},
  owner     = {PaulD},
  timestamp = {2011.06.24},
  year      = {1998},
}

@Article{Blackstone1986,
  author    = {Blackstone, EH and Naftel, DC and Turner, ME},
  title     = {The decomposition of time-varying hazard into phases, each incorporating a separate stream of concomitant information},
  pages     = {615--624},
  volume    = {81},
  file      = {Blackstone1986.pdf:Blackstone1986.pdf:PDF;Blackstone1986.pdf:pdf\\Blackstone1986.pdf:PDF},
  journal   = {Journal of the American Statistical Association},
  owner     = {pl4},
  timestamp = {2008.10.15},
  year      = {1986},
}

@Article{Blakely2012,
  author      = {Blakely, Tony and Soeberg, Matthew and Carter, Kristie and Costilla, Roy and Atkinson, June and Sarfati, Diana},
  title       = {Bias in relative survival methods when using incorrect life-tables: lung and bladder cancer by smoking status and ethnicity in {N}ew {Z}ealand.},
  doi         = {10.1002/ijc.27531},
  language    = {eng},
  number      = {6},
  pages       = {E974--E982},
  url         = {http://dx.doi.org/10.1002/ijc.27531},
  volume      = {131},
  abstract    = {Relative survival and excess mortality approaches are commonly used
	to estimate and compare net survival from cancer. These approaches
	are based on the assumption that the underlying (non-cancer) mortality
	rate of cancer patients is the same as that of the general population.
	This assumption is likely to be violated particularly in the context
	of smoking-related cancers. The magnitude of this bias has not been
	estimated. The objective of this article is to estimate the bias
	in relative survival ratios (RSRs) and excess mortality rate ratios
	(EMRRs) from using total population compared to correct subpopulation
	specific life-tables. Analyses were conducted on 1996-2001 linked
	census-cancer data (including smoking status) for people with lung
	and bladder cancer, using sex-specific (standard practice), sex-
	and ethnic-specific, sex- and smoking-specific and sex-, ethnic-
	and smoking-specific life-tables. Five-year RSRs using sex-specific
	life-tables, compared to fully stratified life-tables, were underestimated
	by 10-25\% for current smoking and Maori populations. For example,
	the current smoker male bladder cancer RSR was 0.700 for sex-specific
	life-tables, compared to 0.838 for fully stratified life-tables.
	Similarly, EMRRs comparing current to never smokers and Maori to
	non-Maori were overestimated using sex-specific life-tables only:
	modestly only for lung cancer, but markedly for bladder cancer. For
	example, the EMRR comparing current to never smokers with bladder
	cancer in a fully adjusted regression model was 1.475 when using
	sex-specific life-tables only, but reduced to 1.098 when using fully
	stratified life-tables. Substantial bias can occur when estimating
	relative cancer survival across subpopulations if non-matching life-tables
	are used.},
  file        = {Blakely2012.pdf:Blakely2012.pdf:PDF;Blakely2012.pdf:pdf\\Blakely2012.pdf:PDF},
  institution = {Department of Public Health, University of Otago, Wellington, New Zealand. tony.blakely@otago.ac.nz},
  journal     = {Int J Cancer},
  keywords    = {Adult; Aged; Aged, 80 and over; Bias (Epidemiology); Female; Humans; Life Tables; Lung Neoplasms, ethnology/mortality; Male; Middle Aged; New Zealand, epidemiology; Smoking, adverse effects; Urinary Bladder Neoplasms, ethnology/mortality},
  medline-pst = {ppublish},
  month       = {Sep},
  owner       = {sanelo},
  pmid        = {22419246},
  timestamp   = {2013.10.04},
  year        = {2012},
}

@Book{Blaxter1990,
  author    = {Blaxter, M.},
  title     = {Health and Lifestyles},
  publisher = {Routledge, Great Britain},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1990},
}

@Article{Boag1949,
  author    = {Boag, J.},
  title     = {Maximum likelihood estimates of the proportion of patients cured by cancer therapy},
  pages     = {15--44},
  volume    = {11},
  file      = {Boag1949.pdf:Boag1949.pdf:PDF;Boag1949.pdf:pdf\\Boag1949.pdf:PDF},
  journal   = {J R Stat Soc Ser B Stat Methodol},
  owner     = {pl4},
  timestamp = {2008.10.15},
  year      = {1949},
}

@Article{Boggon2013a,
  author      = {Boggon, Rachael and {van Staa}, Tjeerd P. and Chapman, Michael and Gallagher, Arlene M. and Hammad, Tarek A. and Richards, Mike A.},
  title       = {Cancer recording and mortality in the General Practice Research Database and linked cancer registries.},
  doi         = {10.1002/pds.3374},
  language    = {eng},
  number      = {2},
  pages       = {168--175},
  url         = {http://dx.doi.org/10.1002/pds.3374},
  volume      = {22},
  abstract    = {Large electronic datasets are increasingly being used to evaluate
	healthcare delivery. The aim of this study was to compare information
	held by cancer registries with that of the General Practice Research
	Database (GPRD).A convenience sample of 101?020 patients aged 40+
	years drawn from GPRD formed the primary data source. This cohort
	was derived from a larger sample originally established for a cohort
	study of diabetes. GPRD records were linked with those from cancer
	registries in the National Cancer Data Repository (NCDR). Concordance
	between the two datasets was then evaluated. For cases recorded only
	on one dataset, validation was sought from other datasets (Hospital
	Episode Statistics and death registration) and by detailed analysis
	of a subset of GPRD records.A total of 5797 cancers (excluding non-melanomatous
	skin cancer) were recorded on GPRD. Of these cases, 4830 were also
	recorded on NCDR (concordance rate of 83.3\%). Of the 976 cases recorded
	on GPRD but not on NCDR, 528 were present also in the hospital records
	or death certificates. Of the 341 cases recorded on NCDR but not
	on GPRD, 307 were recorded in these other two datasets. Rates of
	concordance varied by cancer type. Cancer registries recorded larger
	numbers of patients with lung, colorectal, and pancreatic cancers,
	whereas GPRD recorded more haematological cancers and melanomas.
	As expected, GPRD recorded significantly more non-melanomatous skin
	cancer. Concordance decreased with increasing age.Although concordance
	levels were reasonably high, the findings from this study can be
	used to direct efforts for better recording in both datasets.},
  institution = {Clinical Practice Research Datalink, Medicines and Healthcare Products Regulatory Agency, London, UK.},
  journal     = {Pharmacoepidemiol Drug Saf},
  keywords    = {Adult; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual, standards/trends; Female; General Practice, standards/trends; Humans; Male; Middle Aged; Neoplasms, diagnosis/mortality; Registries, standards; Survival Rate, trends},
  medline-pst = {ppublish},
  month       = {Feb},
  owner       = {pl4},
  pmid        = {23239282},
  timestamp   = {2015.12.06},
  year        = {2013},
}

@Article{Bolard2002,
  author      = {P. Bolard and C. Quantin and M. Abrahamowicz and J. Esteve and R. Giorgi and H. Chadha-Boreham and C. Binquet and J. Faivre},
  title       = {Assessing time-by-covariate interactions in relative survival models using restrictive cubic spline functions.},
  number      = {3},
  pages       = {113--122},
  volume      = {7},
  abstract    = {BACKGROUND: The Cox model is widely used in the evaluation of prognostic
	factors in clinical research. However, in population-based studies,
	which assess long-term survival of unselected populations, relative-survival
	models are often considered more appropriate. In both approaches,
	the validity of proportional hazards hypothesis should be evaluated.
	METHODS: We propose a new method in which restricted cubic spline
	functions are employed to model time-by-covariate interactions in
	relative survival analyses. The method allows investigation of the
	shape of possible dependence of the covariate effect on time without
	having to specify a particular functional form. Restricted cubic
	spline functions allow graphing of such time-by-covariate interactions,
	to test formally the proportional hazards assumption, and also to
	test the linearity of the time-by-covariate interaction. RESULTS:
	Application of our new method to assess mortality in colon cancer
	provides strong evidence against the proportional hazards hypothesis,
	which is rejected for all prognostic factors. The results corroborate
	previous analyses of similar data-sets, suggesting the importance
	of both modelling of non-proportional hazards and relative survival
	approach. We also demonstrate the advantages of using restricted
	cubic spline functions for modelling non-proportional hazards in
	relative-survival analysis. The results provide new insights in the
	estimated impact of older age and of period of diagnosis. DISCUSSION:
	Using restricted cubic splines in a relative survival model allows
	the representation of both simple and complex patterns of changes
	in relative risks over time, with a single parsimonious model without
	a priori assumptions about the functional form of these changes.},
  file        = {Bolard2002.pdf:Bolard2002.pdf:PDF;Bolard2002.pdf:pdf\\Bolard2002.pdf:PDF},
  groups      = {Excess mortality model},
  institution = {Department of Medical Information, Centre Hospitalier de Chalon, Chalon sur Sa{\AA}ÂƒÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â´ne, France.},
  journal     = {J Cancer Epidemiol Prev},
  owner       = {pl4},
  pmid        = {12665210},
  timestamp   = {2008.12.16},
  year        = {2002},
}

@Article{Bolard2001,
  author      = {P. Bolard and C. Quantin and J. Esteve and J. Faivre and M. Abrahamowicz},
  title       = {Modelling time-dependent hazard ratios in relative survival: application to colon cancer.},
  number      = {10},
  pages       = {986--996},
  volume      = {54},
  abstract    = {The Cox model is widely used in the evaluation of prognostic factors
	in clinical research. In population-based studies, however, which
	assess long-term survival of unselected populations, relative survival
	models are often considered more appropriate. In both approaches,
	the validity of proportional hazard hypothesis should be evaluated.
	To explore the validity of the proportional hazard assumption in
	a population-based study of colon cancer, to propose non-proportional
	hazard relative survival models and to evaluate their utility. The
	use of a piecewise proportional hazard relative survival model in
	colon cancer has shown that the effects of most clinical prognostic
	factors such as age, period of diagnosis and stage are non-proportional.
	The non-proportional hazard relative survival models developed in
	this article have been found to be efficient tools for better understanding
	the time-dependent aspect of prognostic factors.},
  file        = {bolard2001.pdf:bolard2001.pdf:PDF},
  institution = {Registre Bourguignon des Tumeurs Digestives (Burgundy Registry of Digestive Tumors), Facult\'{e} de M\'{e}decine, 7 Bd Jeanne d'Arc 21033, Dijon Cedex, France.},
  journal     = {Journal of Clinical Epidemiology},
  month       = oct,
  owner       = {pl4},
  pii         = {S0895-4356(01)00363-8},
  pmid        = {11576809},
  timestamp   = {2008.12.16},
  year        = {2001},
}

@InCollection{Bolund2008,
  author    = {Bolund, C.},
  booktitle = {Onkologi},
  title     = {Etik i sjukv{\aa}rden},
  editor    = {Ringborg, U. and Dalianis, T. and Henriksson, R.},
  pages     = {608-620},
  publisher = {Liber},
  owner     = {sanelo},
  timestamp = {2013.10.16},
  year      = {2008},
}

@InCollection{Bolund2008a,
  author    = {Bolund, C. and Brandberg, Y.},
  booktitle = {Onkologi},
  title     = {Psykosocial onkologi},
  editor    = {Ringborg, U and Dalianis, T. and Henriksson, R.},
  pages     = {586-597},
  publisher = {Liber},
  owner     = {sanelo},
  timestamp = {2013.10.16},
  year      = {2008},
}

@Book{Bonett1992b,
  author    = {Bonett, A. and Dickman, P. and Roder, D. and Hakulinen, T. and Gibberd, R.},
  title     = {Survival of Cancer Patients in {South Australia} During 1977-1990},
  publisher = {Adelaide: Lutheran Publishing House},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1992},
}

@Article{Boos2003,
  author    = {D.D. Boos},
  title     = {Introduction to the bootstrap world},
  pages     = {168--174},
  volume    = {18},
  file      = {Boos2003.pdf:Boos2003.pdf:PDF;Boos2003.pdf:pdf\\Boos2003.pdf:PDF},
  journal   = {Statistical Science},
  owner     = {pl4},
  timestamp = {2009.12.03},
  year      = {2003},
}

@Article{Borgan2000,
  author      = {Borgan, O. and Langholz, B. and Samuelsen, S. O. and Goldstein, L. and Pogoda, J.},
  title       = {Exposure stratified case-cohort designs.},
  language    = {eng},
  number      = {1},
  pages       = {39--58},
  volume      = {6},
  abstract    = {A variant of the case-cohort design is proposed for the situation
	in which a correlate of the exposure (or prognostic factor) of interest
	is available for all cohort members, and exposure information is
	to be collected for a case-cohort sample. The cohort is stratified
	according to the correlate, and the subcohort is selected by stratified
	random sampling. A number of possible methods for the analysis of
	such exposure stratified case-cohort samples are presented, some
	of their statistical properties developed, and approximate relative
	efficiency and optimal allocation to the strata discussed. The methods
	are compared to each other, and to randomly sampled case-cohort studies,
	in a limited computer simulation study. We found that all of the
	proposed analysis methods performed well and were more efficient
	than a randomly sampled case-cohort study.},
  file        = {Borgan2000.pdf:Borgan2000.pdf:PDF},
  institution = {Department of Mathematics, University of Oslo, Norway. borgan@math.uio.no},
  journal     = {Lifetime Data Anal},
  keywords    = {Biometry; Case-Control Studies; Cohort Studies; Humans; Likelihood Functions; Proportional Hazards Models; Research Design; Sampling Studies; Survival Analysis},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {pl4},
  pmid        = {10763560},
  timestamp   = {2013.03.21},
  year        = {2000},
}

@Article{Borgan2003,
  author    = {Borgan, O. and Samuelsen, S. O.},
  title     = {A review of cohort samping designs for Cox's regression model: Potentials in epidemiology},
  pages     = {239--248},
  volume    = {13},
  file      = {Borgan2003.pdf:Borgan2003.pdf:PDF},
  journal   = {Norsk Epidemiologic Perspectives \& Innovations},
  timestamp = {2005.11.01},
  year      = {2003},
}

@Article{Bossard2007,
  author      = {Bossard, N. and Velten, M. and Remontet, L. and Belot, A. and Maarouf, N. and Bouvier, A. M. and Guizard, A. V. and Tretarre, B. and Launoy, G. and Colonna, M. and Danzon, A. and Molinie, F. and Troussard, X. and Bourdon-Raverdy, N. and Carli, P. M. and Jaffr{\'{e}}, A. and Bessaguet, C. and Sauleau, E. and Schvartz, C. and Arveux, P. and Maynadi{\'{e}}, M. and Grosclaude, P. and Est{\`{e}}ve, J. and Faivre, J.},
  title       = {Survival of cancer patients in France: a population-based study from The Association of the French Cancer Registries (FRANCIM).},
  doi         = {10.1016/j.ejca.2006.07.021},
  language    = {eng},
  number      = {1},
  pages       = {149--160},
  url         = {http://dx.doi.org/10.1016/j.ejca.2006.07.021},
  volume      = {43},
  abstract    = {We present the main results of the first population-based cancers
	survival study gathering all French registry data. Survival data
	on 205,562 cancer cases diagnosed between 01/01/1989 and 31/12/1997
	were analysed. Relative survival was estimated using an excess rate
	model. The evolution of the excess mortality rate over the follow-up
	period was graphed. The analysis emphasised the effect of age at
	diagnosis and its variation with time after diagnosis. For breast
	and prostate cancers, the age-standardised five-year relative survivals
	were 84\% and 77\%, respectively. The corresponding results in men
	and women were 56\% versus 58\% for colorectal cancer and 12\% versus
	16\% for lung cancer. For some cancer sites, the excess mortality
	rate decreased to low values by five years after diagnosis. For most
	cancer sites, age at diagnosis was a negative prognostic factor but
	this effect was often limited to the first year after diagnosis.},
  institution = {Hospices Civils de Lyon, Service de Biostatistique, Lyon, F-69003, France. nadine.bossard@chu-lyon.fr},
  journal     = {Eur J Cancer},
  keywords    = {Adolescent; Adult; Aged; Aged, 80 and over; Child; Epidemiologic Methods; Female; France, epidemiology; Humans; Male; Middle Aged; Neoplasms, mortality; Registries, statistics /&/ numerical data},
  medline-pst = {ppublish},
  month       = {Jan},
  owner       = {pl4},
  pii         = {S0959-8049(06)00817-3},
  pmid        = {17084622},
  timestamp   = {2015.04.29},
  year        = {2007},
}

@Article{Bottai2010,
  author      = {Bottai, Matteo and Cai, Bo and McKeown, Robert E.},
  title       = {Logistic quantile regression for bounded outcomes.},
  doi         = {10.1002/sim.3781},
  language    = {eng},
  number      = {2},
  pages       = {309--317},
  url         = {http://dx.doi.org/10.1002/sim.3781},
  volume      = {29},
  abstract    = {When research interest lies in continuous outcome variables that take
	on values within a known range (e.g. a visual analog scale for pain
	within 0 and 100 mm), the traditional statistical methods, such as
	least-squares regression, mixed-effects models, and even classic
	nonparametric methods such as the Wilcoxon's test, may prove inadequate.
	Frequency distributions of bounded outcomes are often unimodal, U-shaped,
	and J-shaped. To the best of our knowledge, in the biomedical and
	epidemiological literature bounded outcomes have seldom been analyzed
	by appropriate methods that, for one, correctly constrain inference
	to lie within the feasible range of values. In many respects, continuous
	bounded outcomes can be likened to probabilities or propensities.
	Yet, what has long been heeded when modeling the probability of binary
	outcomes with the widespread use of logistic and probit regression,
	so far appears to have been overlooked with continuous bounded outcomes
	with consequences at times disastrous. Logistic quantile regression
	constitutes an effective method to fill this gap.},
  file        = {Bottai2010.pdf:Bottai2010.pdf:PDF},
  institution = {Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, 800 Sumter Street, Columbia, SC 29208, USA. mbottai@mailbox.sc.edu},
  journal     = {Stat Med},
  keywords    = {Adolescent; Algorithms; Confidence Intervals; Depression, diagnosis/epidemiology; Epidemiologic Research Design; Family Relations; Female; Humans; Linear Models; Logistic Models; Male; Psychiatric Status Rating Scales; Sex Factors; South Carolina, epidemiology; Statistical Distributions; Statistics, Nonparametric},
  medline-pst = {ppublish},
  month       = {Jan},
  owner       = {pl4},
  pmid        = {19941281},
  timestamp   = {2014.06.02},
  year        = {2010},
}

@Article{Bottai2010a,
  author      = {Bottai, Matteo and Zhang, Jiajia},
  title       = {Laplace regression with censored data.},
  doi         = {10.1002/bimj.200900310},
  language    = {eng},
  number      = {4},
  pages       = {487--503},
  url         = {http://dx.doi.org/10.1002/bimj.200900310},
  volume      = {52},
  abstract    = {We consider a regression model where the error term is assumed to
	follow a type of asymmetric Laplace distribution. We explore its
	use in the estimation of conditional quantiles of a continuous outcome
	variable given a set of covariates in the presence of random censoring.
	Censoring may depend on covariates. Estimation of the regression
	coefficients is carried out by maximizing a non-differentiable likelihood
	function. In the scenarios considered in a simulation study, the
	Laplace estimator showed correct coverage and shorter computation
	time than the alternative methods considered, some of which occasionally
	failed to converge. We illustrate the use of Laplace regression with
	an application to survival time in patients with small cell lung
	cancer.},
  file        = {Bottai2010a.pdf:Bottai2010a.pdf:PDF},
  institution = {Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, SC, USA.},
  journal     = {Biom J},
  keywords    = {Analysis of Variance; Antineoplastic Agents, therapeutic use; Clinical Trials as Topic; Humans; Likelihood Functions; Lung Neoplasms, drug therapy; Probability; Regression Analysis; Small Cell Lung Carcinoma, drug therapy; Survival Analysis},
  medline-pst = {ppublish},
  month       = {Aug},
  owner       = {pl4},
  pmid        = {20680972},
  timestamp   = {2014.06.02},
  year        = {2010},
}

@Article{Bottai2013,
  author    = {M. BotM. Bottai and N. Orsini},
  title     = {A command for {L}aplace regression},
  pages     = {302-314},
  volume    = {13},
  file      = {Bottai2013.pdf:Bottai2013.pdf:PDF},
  journal   = {The Stata Journal},
  owner     = {pl4},
  timestamp = {2014.06.02},
  year      = {2013},
}

@Article{Bouhafs2002,
  author      = {Bouhafs, A. and Fassi-Fehri, H. and Ranchin, B. and Cochat, P. and Martin, X.},
  title       = {[Surgical aspects of kidney transplantation in children (study of 148 cases)].},
  language    = {fre},
  number      = {5},
  pages       = {301--309},
  volume      = {36},
  abstract    = {Kidney transplantation is the best treatment for end-stage renal disease.
	This procedure is by now routinely used and permits children survival
	and rehabilitation. We describe the surgical complications of kidney
	graft in our paediatric experience.From April 1987 to August 2000,
	175 kidney transplantation were proceeded in the department of urology
	and transplantation in Edouard Herriot Hospital (Lyon). Twenty-nine
	kidneys (17\%) were from living related donors and 146 (83\%) were
	from cadaveric donors. We evaluated 148 kidney transplantation (132
	patients) in 79 male and 53 female children. Mean age was ten years
	(range: seven months to 18 years). Twelve allografts were from living
	related donors and 136 cadaveric donors.Twelve patients died of various
	medical complications. One patient was lost of sight. Surgical complications
	were postoperative bleeding, lymphocele, urologic and digestive troubles.
	The rest of our patients had uneventful evolution.A general commitment
	is the only way to promote organ donation and enable patients with
	terminal renal failure to have access to renal transplantation.},
  institution = {Service d'urologie et de la transplantation, hospital Edouard-Herriot, place d'Arsonval, 69437 Lyon, France. samiraothmani@iam.net.ma},
  journal     = {Ann Urol (Paris)},
  keywords    = {Adolescent; Child; Child, Preschool; Female; Humans; Infant; Kidney Failure, Chronic, surgery; Kidney Transplantation; Living Donors; Male; Postoperative Complications; Prognosis; Treatment Outcome},
  medline-pst = {ppublish},
  month       = {Oct},
  owner       = {pl4},
  pmid        = {12481620},
  timestamp   = {2013.05.29},
  year        = {2002},
}

@Article{Bower2016a,
  author    = {Bower, H. and Andersson, T. M. L. and Bjorkholm, M. and Dickman, P. W. and Lambert, P. C. and Derolf, A. R.},
  title     = {Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life},
  doi       = {10.1038/bcj.2016.3},
  pages     = {e390},
  volume    = {6},
  file      = {Bower2016a.pdf:pdf\\Bower2016a.pdf:PDF;Bower2016a.pdf:Bower2016a.pdf:PDF},
  journal   = {Blood Cancer Journal},
  owner     = {hanbow},
  pmid      = {26849011},
  timestamp = {2016.02.29},
  year      = {2016},
}

@Article{Bower2016b,
  author     = {Bower, H. and Bj\"{o}rkholm, M. and Dickman, P. W. and H\"{o}glund, M. and Lambert, P. C. and Andersson, T. M-L.},
  title      = {Life expectancy of chronic myeloid leukemia patients is approaching the life expectancy of the general population},
  doi        = {10.1200/JCO.2015.66.2866},
  pages      = {2851-2857},
  url        = {http://jco.ascopubs.org/content/early/2016/06/15/JCO.2015.66.2866},
  volume     = {34},
  file       = {Bower2016b.pdf:pdf\\Bower2016b.pdf:PDF;Bower2016b.pdf:Bower2016b.pdf:PDF},
  groups     = {CML, Study 2. Quality of Life},
  journal    = {Journal of Clinical Oncology},
  owner      = {hanbow},
  pmid       = {27325849},
  readstatus = {read},
  timestamp  = {2016.06.21},
  year       = {2016},
}

@Article{Bower2019a,
  author    = {Bower, H. and Crowther, M.J. and Rutherford, M. J. and Andersson, T M L. and Clements, M. and Liu, X.R. and Dickman, P.W. and Lambert, P. C.},
  title     = {Capturing simple and complex time-dependent effects using flexible parametric survival models:},
  doi       = {https://doi.org/10.1080/03610918.2019.1634201},
  file      = {:Bower2019a.pdf:PDF},
  journal   = {Communications in Statistics - Simulation and Computation},
  owner     = {pl4},
  timestamp = {2015.10.25},
  year      = {2019},
}

@Article{Brandberg1998,
  author    = {Yvonne Brandberg},
  title     = {Quality of Life in Clinical Trials: Assessment and Utility with Special Reference to {rHuEPO}},
  pages     = {S8-S12},
  volume    = {15 (Suppl. 1)},
  journal   = {Medical Oncology},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1998},
}

@Article{Bratt2010,
  author      = {Bratt, Ola and Berglund, Anders and Adolfsson, Jan and Johansson, Jan-Erik and T{\"o}rnblom, Magnus and Stattin, P{\"a}r and {for the Steering Committee of the Swedish National Prostate Cancer Register}},
  title       = {Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the {N}ational {P}rostate {C}ancer {R}egister of {S}weden.},
  doi         = {10.3109/00365599.2010.498793},
  language    = {eng},
  number      = {6},
  pages       = {384--390},
  url         = {http://dx.doi.org/10.3109/00365599.2010.498793},
  volume      = {44},
  abstract    = {To investigate the effects of prostate-specific antigen (PSA) testing
	of men without clinical signs of prostate cancer on the incidence
	of prostate cancer in Sweden.Information on the cause of diagnosis,
	tumour characteristics and primary treatment for patients diagnosed
	with prostate cancer between January 1999 and December 2007 was extracted
	from the National Prostate Cancer Register of Sweden. This register
	includes data for 95\% of Swedish prostate cancer cases.The total
	age-standardized annual incidence of prostate cancer per 100,000
	men increased from 187 in 1999 to 233 in 2004, but decreased thereafter
	to 196 in 2007. The incidence of asymptomatic cases also peaked in
	2004 (at 62 per 100,000 men), but varied six-fold between different
	counties in that year (16-98 per 100,000 men). Asymptomatic cases
	(n = 17,143) constituted 15\% of all new cases in 2000 and 30\% in
	2007. Almost as many cases were diagnosed in stage T1c in men with
	symptoms, usually from the lower urinary tract. Together these two
	groups constituted 29\% of all new cases in 2000 and 52\% in 2007.
	It was estimated that at least one-third of all Swedish men aged
	50-75 years had a PSA test between 2000 and 2007.Even though screening
	for prostate cancer is not recommended in Sweden, PSA testing of
	men without clinical signs of prostate cancer is common. The effects
	on the Swedish incidence of prostate cancer were similar to those
	reported from the USA.},
  institution = {Department of Urology, Helsingborg Hospital, Lund University, Sweden. ola.bratt@skane.se},
  journal     = {Scand J Urol Nephrol},
  keywords    = {Age Distribution; Aged; Aged, 80 and over; Humans; Incidence; Male; Mass Screening; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen, blood; Prostatic Neoplasms, diagnosis/epidemiology; Registries; Sweden, epidemiology},
  medline-pst = {ppublish},
  month       = {Dec},
  owner       = {sanelo},
  pmid        = {20624113},
  timestamp   = {2013.07.31},
  year        = {2010},
}

@Article{Bratt2008,
  author      = {Bratt, Ola and Damber, Jan-Erik and K{\"a}rvinge, Christina and Malm, Torbj{\"o}rn and Hensj{\"o}, Lars-Olof and Hyttsten, Ellen},
  title       = {[The National Board of Health and Welfare's guidelines for prostatic cancer care. PSA test screening--only for well-informed men].},
  language    = {swe},
  number      = {8},
  pages       = {524--528},
  volume      = {105},
  institution = {Urologiska kliniken, Universitetssjukhuset i Lund. ola.bratt@skane.se},
  journal     = {Lakartidningen},
  keywords    = {Humans; Male; Mass Screening; Patient Education as Topic; Practice Guidelines as Topic; Prostate-Specific Antigen, blood; Prostatic Neoplasms, blood/diagnosis/therapy; Sensitivity and Specificity; Sweden; Tumor Markers, Biological, blood},
  medline-pst = {ppublish},
  owner       = {sanelo},
  pmid        = {18363292},
  timestamp   = {2013.07.31},
  year        = {2008},
}

@Article{Braveman2005,
  author    = {Braveman, P. A. and Cubbin, C. and Egerter, S. and Chideya, S. and Marchi, K. S. and Metzler, M. and Posner, S.},
  title     = {Socioeconomic status in health research: one size does not fit all},
  pages     = {2879-88},
  volume    = {22},
  file      = {Braveman2005.pdf:Braveman2005.pdf:PDF;Braveman2005.pdf:pdf\\Braveman2005.pdf:PDF},
  journal   = {Jama},
  owner     = {hanbow},
  timestamp = {2016.05.19},
  year      = {2005},
}

@Article{Bray2006,
  author      = {Bray, F. and M{\o}ller, B.},
  title       = {Predicting the future burden of cancer},
  doi         = {10.1038/nrc1781},
  language    = {eng},
  number      = {1},
  pages       = {63--74},
  volume      = {6},
  abstract    = {As observations in the past do not necessarily hold into the future,
	predicting future cancer occurrence is fraught with uncertainty.
	Nevertheless, predictions can aid health planners in allocating resources
	and allow scientists to explore the consequence of interventions
	aimed at reducing the impact of cancer. Simple statistical models
	have been refined over the past few decades and often provide reasonable
	predictions when applied to recent trends. Intrinsic to their interpretation,
	however, is an understanding of the forces that drive time trends.
	We explain how and why cancer predictions are made, with examples
	to illustrate the concepts in practice.},
  file        = {Bray2006.pdf:Bray2006.pdf:PDF},
  institution = {Cancer Registry of Norway, Institute of Population-based Research, Montebello, Oslo, 0310, Norway. freddie.bray@kreftregisteret.no},
  journal     = {Nat Rev Cancer},
  medline-pst = {ppublish},
  month       = jan,
  owner       = {pl4},
  pii         = {nrc1781},
  pmid        = {16372017},
  timestamp   = {2012.09.10},
  year        = {2006},
}

@Article{Bray2009,
  author      = {Bray, Freddie and Parkin, D Max},
  title       = {Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness.},
  doi         = {10.1016/j.ejca.2008.11.032},
  language    = {eng},
  number      = {5},
  pages       = {747--755},
  url         = {http://dx.doi.org/10.1016/j.ejca.2008.11.032},
  volume      = {45},
  abstract    = {The value of the modern cancer registry and its ability to carry out
	cancer control activities rely heavily on the underlying quality
	of its data and the quality control procedures in place. This two-part
	review provides an update of the practical aspects and techniques
	for addressing data quality at the cancer registry. This first installment
	of the review examines the factors influencing three of the four
	key aspects, namely, the comparability, validity and timeliness of
	cancer registry data. Comparability of cancer data may be established
	through a comprehensive review of the registration routines in place.
	Validity is examined via numerical indices of that permit comparisons
	with other registries, or, within a registry, over time, or with
	respect to specified subsets of cases. There are no international
	guidelines for timeliness at present, although specific standards
	for the abstraction and reporting of registry have been set out by
	certain organisations.},
  file        = {Bray2009.pdf:Bray2009.pdf:PDF;Bray2009.pdf:pdf\\Bray2009.pdf:PDF},
  institution = {Department of Clinical and Registry-Based Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Montebello, Oslo, Norway. freddie.bray@kreftregisteret.no},
  journal     = {Eur J Cancer},
  keywords    = {Death Certificates; Humans; Incidence; Incidental Findings; Mass Screening; Neoplasms, Multiple Primary, epidemiology; Neoplasms, classification/diagnosis/epidemiology; Quality Control; Registries, standards; Reproducibility of Results; Research Design, standards},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {pl4},
  pii         = {S0959-8049(08)00920-9},
  pmid        = {19117750},
  timestamp   = {2015.12.06},
  year        = {2009},
}

@Article{Bredart2002,
  author      = {Bredart, Anne and Bottomley, Andrew},
  title       = {Treatment satisfaction as an outcome measure in cancer clinical treatment trials.},
  doi         = {10.1586/14737167.2.6.597},
  language    = {eng},
  number      = {6},
  pages       = {597--606},
  url         = {http://dx.doi.org/10.1586/14737167.2.6.597},
  volume      = {2},
  abstract    = {For many years, medical research has focused on 'hard' end-points,
	such as survival or time to progression, when evaluating research
	in cancer clinical trials. However, over recent years more recognition
	has been given to 'softer' end-points, such as quality of life and
	treatment satisfaction. In many respects, research into treatment
	satisfaction is in its early stages of development, but we are already
	beginning to understand that patients' treatment satisfaction can
	provide great insights into the management of cancer patients. In
	our review, we discuss the specific conceptual and methodological
	issues we face when assessing treatment satisfaction in cancer clinical
	trials and critically review earlier studies of cancer treatment
	satisfaction.},
  institution = {Institut Curie, Psycho-Oncology Unit, 26, rue d'Ulm, F - 75231 Paris Cedex 05 France. anne.bredart@curie.net},
  journal     = {Expert Rev Pharmacoecon Outcomes Res},
  medline-pst = {ppublish},
  month       = {Dec},
  owner       = {pl4},
  pmid        = {19807484},
  timestamp   = {2013.05.29},
  year        = {2002},
}

@Article{Brenner2002f,
  author      = {Hermann Brenner},
  title       = {Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis.},
  doi         = {10.1016/S0140-6736(02)11199-8},
  number      = {9340},
  pages       = {1131--1135},
  volume      = {360},
  abstract    = {BACKGROUND: Long-term survival rates for many types of cancer have
	substantially improved in past decades because of advances in early
	detection and treatment. However, much of this improvement is only
	seen many years later with traditional cohort-based methods of survival
	analysis. I aimed to assess achievements in cancer patients' survival
	by an alternative method of survival analysis,known as period analysis,
	which provides more up-to-date estimates of long-term survival rates
	than do conventional methods. METHODS: The 1973-98 database of the
	Surveillance, Epidemiology, and End Results (SEER) programme of the
	US National Cancer Institute was analysed by period analysis. FINDINGS:
	Estimates of 5-year, 10-year, 15-year, and 20-year relative survival
	rates for all types of cancer were 63\%, 57\%, 53\%, and 51\%, respectively,
	by period analysis. These estimates were 1\%, 7\%, 11\%, and 11\%
	higher, respectively, than corresponding estimates by cohort-based
	survival analysis. By period analysis, 20-year relative survival
	rates were close to 90\% for thyroid and testis cancer, exceeded
	80\% for melanomas and prostate cancer, were about 80\% for endometrial
	cancer, and almost 70\% for bladder cancer and Hodgkin's disease.
	A 20-year relative survival rate of 65\% was estimated for breast
	cancer, of 60\% for cervical cancer, and of about 50\% for colorectal,
	ovarian, and renal cancer. INTERPRETATION: Timely detection of improvements
	in long-term survival rates might help to prevent clinicians and
	their patients from undue discouragement or depression by outdated
	and often overly pessimistic survival expectations. It also adds
	to the value of cancer surveillance as a basis for appropriate public-health
	decisions.},
  file        = {Brenner2002f.pdf:Brenner2002f.pdf:PDF;Brenner2002f.pdf:pdf\\Brenner2002f.pdf:PDF},
  institution = {Department of Epidemiology, German Centre for Research on Ageing, Bergheimer Str 20, 69115, Heidelberg, Germany. brenner@dzfa.uni-heidelberg.de},
  journal     = {Lancet},
  month       = oct,
  owner       = {pl4},
  pii         = {S0140-6736(02)11199-8},
  pmid        = {12387961},
  timestamp   = {2008.12.02},
  year        = {2002},
}

@Article{Brenner2005e,
  author      = {Hermann Brenner and Volker Arndt},
  title       = {Further enhanced monitoring of cancer patient survival by stage-adjusted period analysis.},
  doi         = {10.1158/1055-9965.EPI-05-0103},
  number      = {8},
  pages       = {1917--1921},
  volume      = {14},
  abstract    = {Monitoring progress in cancer patient survival is an important task
	of population-based cancer registration. Period analysis has been
	shown to provide more up-to-date estimates of cancer patient survival
	than traditional methods of survival analysis. However, even period
	estimates may disclose recent improvements in long-term survival
	with some delay as they are still partly based on the survival experience
	of patients diagnosed years ago. If these patients had a less favorable
	stage distribution than the patients diagnosed in a more recent calendar
	period (e.g., due to progress in early detection), period estimates
	may underestimate long-term survival for patients diagnosed in that
	period. This particular source of potential underestimation can be
	overcome by adjustment of the stage distribution of all patients
	included in period analysis to the stage distribution of the patients
	diagnosed in the period of interest. The principle, application,
	and use of stage adjustment of period survival estimates are illustrated
	with 5- and 10-year relative survival estimates of patients diagnosed
	with breast cancer and followed with respect to survival in the United
	States between 1973 and 2001, using data of the Surveillance, Epidemiology,
	and End Results Program of the National Cancer Institute. We show
	that stage adjustment may often further enhance the benefits of period
	analysis for deriving up-to-date cancer survival estimates.},
  file        = {brenner2005e.pdf:brenner2005e.pdf:PDF},
  institution = {Department of Epidemiology, German Centre for Research on Ageing, Bergheimer Strasse 20, D-69115 Heidelberg, Germany. brenner@dzfa.uni-heidelberg.de},
  journal     = {Cancer Epidemiol Biomarkers Prev},
  month       = aug,
  owner       = {pl4},
  pii         = {14/8/1917},
  pmid        = {16103437},
  timestamp   = {2008.12.02},
  year        = {2005},
}

@Article{Brenner2005f,
  author      = {Hermann Brenner and Volker Arndt},
  title       = {Period analysis of cancer patient survival in datasets from which the month of diagnosis has been removed.},
  doi         = {10.1016/j.ejca.2004.11.018},
  number      = {3},
  pages       = {438--444},
  volume      = {41},
  abstract    = {Up-to-date monitoring of long-term survival is an important task of
	population-based cancer registries. Period analysis, a new method
	of survival analysis introduced a few years ago, has been shown to
	be particularly useful for that purpose. The "classical" period analysis
	uses a life-table approach which requires both the year and month
	of diagnosis for implementation in pertinent software programs. However,
	an increasing number of cancer registries remove the month of diagnosis
	from their datasets, mainly to ensure the highest possible protection
	against re-identification of patients. In this paper, we present
	modifications of period analysis that allow the application of this
	technique, while almost completely preserving its advantages, in
	datasets without the month of diagnosis. The modified techniques
	are illustrated and evaluated using examples from the Surveillance,
	Epidemiology, and End Results (SEER) programme of the United States
	(US) National Cancer Institute (NCI), which also has removed month
	of diagnosis from its most recently released public use database.},
  file        = {Brenner2005f.pdf:Brenner2005f.pdf:PDF;Brenner2005f.pdf:pdf\\Brenner2005f.pdf:PDF},
  institution = {Department of Epidemiology, German Centre for Research on Ageing, Bergheimer Strasse 20, D-69115 Heidelberg, Germany. Brenner@dzfa.uni-heidelberg.de},
  journal     = {European Journal of Cancer},
  month       = feb,
  owner       = {pl4},
  pii         = {S0959-8049(04)00978-5},
  pmid        = {15691645},
  timestamp   = {2008.12.02},
  year        = {2005},
}

@Article{Brenner2005g,
  author      = {Hermann Brenner and Volker Arndt},
  title       = {Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis.},
  doi         = {10.1200/JCO.2005.11.148},
  number      = {3},
  pages       = {441--447},
  volume      = {23},
  abstract    = {PURPOSE: In the era of widespread prostate specific antigen (PSA)
	screening, a large proportion of older men have to live with a diagnosis
	of prostate cancer. In this study, we applied a new method for up-to-date
	analysis of long-term survival to evaluate if and to what extent
	these patients still have any excess mortality compared to the general
	population. METHODS: Five- and 10-year absolute and relative survival
	rates for the year 2000 were derived from the 1973 to 2000 database
	of the Surveillance, Epidemiology and End Results Program using the
	recently introduced period analysis methodology. RESULTS: Overall,
	5- and 10-year relative survival rates were approximately 99\% and
	95\%; that is, excess mortality compared with the general population
	was as low as 1\% and 5\% within 5 and 10 years following diagnosis,
	respectively. Two-thirds of patients were diagnosed with well or
	moderately differentiated localized/regional prostate cancer, and
	among these patients, 5- and 10-year relative survival rates were
	above 100\% (indicating the lack of any excess mortality) at all
	ages. CONCLUSION: While the value of PSA screening for lowering mortality
	due to prostate cancer remains to be shown by randomized clinical
	trials, the majority of patients diagnosed with prostate cancer in
	the PSA screening era do not have excess mortality compared to the
	general population under current patterns of medical care. This information
	may be important for both clinical management of, and for patients'
	coping with, the disease.},
  file        = {Brenner2005g.pdf:Brenner2005g.pdf:PDF;Brenner2005g.pdf:pdf\\Brenner2005g.pdf:PDF},
  institution = {Department of Epidemiology, German Centre for Research on Ageing, Bergheimer Strasse 20, D-69115 Heidelberg, Germany. brenner@dzfa.uni-heidelberg.de},
  journal     = {Journal of Clinical Oncology},
  month       = jan,
  owner       = {pl4},
  pii         = {JCO.2005.11.148},
  pmid        = {15572727},
  timestamp   = {2008.12.02},
  year        = {2005},
}

@Article{Brenner2004c,
  author      = {Hermann Brenner and Volker Arndt},
  title       = {Recent increase in cancer survival according to age: higher survival in all age groups, but widening age gradient.},
  doi         = {10.1007/s10552-004-1484-3},
  number      = {9},
  pages       = {903--910},
  volume      = {15},
  abstract    = {A major increase in long-term survival of cancer patients in the 1990s
	has recently been demonstrated. It is unclear, however, to what extent
	this increase has been shared by cancer patients at various ages.
	Using the 1973-2000 data base of the Surveillance, Epidemiology,
	and End Results programme, recent increase in 10-year relative survival
	of cancer patients in the US was assessed for 4 major age groups
	and 15 major cancer sites by comparing results of a period analysis
	for the 1996-2000 period with results of a cohort analysis for patients
	diagnosed in 1986-1990. Period estimates of 10-year relative survival
	for all forms of cancer combined in 1996-2000 were 66.1\%, 58.8\%,
	56.3\% and 47.1\% for age groups 15-54, 55-64, 65-74 and > or = 75
	years, respectively. They were 7.4\%, 10.4\%, 7.8\% and 3.0\% units
	higher than the respective 1986-1990 cohort estimates for these age
	groups. The increase in 10-year relative survival strongly varied
	by cancer site, but it was generally less pronounced in older than
	in younger patients. We conclude that long-term survival expectations
	of cancer patients have increased in all age groups in the 1990s.
	However, for most common forms of cancer, the age gradient in survival
	has either persisted or widened.},
  file        = {Brenner2004c.pdf:Brenner2004c.pdf:PDF;Brenner2004c.pdf:pdf\\Brenner2004c.pdf:PDF},
  institution = {Department of Epidemiology, German Centre for Research on Ageing, Bergheimer Strasse 20, Heidelberg, D-69115, Germany. brenner@dzfa.uni-heidelberg.de},
  journal     = {Cancer Causes Control},
  month       = nov,
  owner       = {pl4},
  pii         = {5381484},
  pmid        = {15577292},
  timestamp   = {2008.12.02},
  year        = {2004},
}

@Article{Brenner2004,
  author      = {Hermann Brenner and Volker Arndt and Olaf Gefeller and Timo Hakulinen},
  title       = {An alternative approach to age adjustment of cancer survival rates.},
  doi         = {10.1016/j.ejca.2004.07.007},
  number      = {15},
  pages       = {2317--2322},
  volume      = {40},
  abstract    = {The measures of cancer prognosis most commonly reported by cancer
	registries are 5- or 10-year absolute or relative survival rates.
	Because cancer survival rates often vary by the age of cancer patients,
	and because the age structure of cancer patients often varies between
	populations, age adjustment is crucial for comparative analyses of
	cancer survival rates. However, traditional age adjustment often
	breaks down for long-term survival rates, particularly for sparse
	data, and it may provide inconsistent results for relative survival
	rates, even if age adjustment is made to the study population's own
	age distribution. In this manuscript, we propose an alternative approach
	to age adjustment of both absolute and relative survival rates to
	overcome both the practical and conceptual problems inherent in traditional
	age adjustment. We outline the computational realisation of this
	approach, and we give an empirical illustration of its application
	using data from the nationwide Finnish Cancer Registry.},
  file        = {Brenner2004.pdf:pdf\\Brenner2004.pdf:PDF},
  institution = {Department of Epidemiology, German Centre for Research on Ageing, Bergheimer Strasse 20, D-69115 Heidelberg, Germany. brenner@dzfa.uni-heidelberg.de},
  journal     = {Eur J Cancer},
  month       = oct,
  owner       = {pl4},
  pii         = {S0959-8049(04)00567-2},
  pmid        = {15454258},
  timestamp   = {2008.12.02},
  year        = {2004},
}

@Article{Brenner1997,
  author      = {H. Brenner and O. Gefeller},
  title       = {Deriving more up-to-date estimates of long-term patient survival.},
  number      = {2},
  pages       = {211--216},
  volume      = {50},
  abstract    = {Statistics reflective of patient survival should be as up-to-date
	as possible. We illustrate that traditional methods for analysing
	survival have important limitations with regard to up-to-dateness
	of long-term cumulative survival estimates. We propose an alternative
	approach, denoted "period analysis," that may be used to overcome
	or at least substantially reduce these limitations. The conceptual
	background and the computational realization of the new method are
	outlined and its application is illustrated by an analysis of long-term
	survival of patients with testicular cancer in Saarland, Germany.},
  file        = {Brenner1997.pdf:Brenner1997.pdf:PDF;Brenner1997.pdf:pdf\\Brenner1997.pdf:PDF},
  institution = {Department of Epidemiology, University of Ulm, Germany.},
  journal     = {Journal of Clinical Epidemiology},
  owner       = {pl4},
  pii         = {S0895-4356(97)00280-1},
  pmid        = {9120515},
  timestamp   = {2008.12.02},
  year        = {1997},
}

@Article{Brenner1996,
  author    = {Brenner, H. and Gefeller, O.},
  title     = {An alternative approach to monitoring cancer patient survival},
  pages     = {2004--2010},
  volume    = {78},
  journal   = {Cancer},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1996},
}

@Article{Brenner2004a,
  author      = {H. Brenner and O. Gefeller and T. Hakulinen},
  title       = {Period analysis for 'up-to-date' cancer survival data: theory, empirical evaluation, computational realisation and applications.},
  number      = {3},
  pages       = {326--335},
  volume      = {40},
  abstract    = {Long-term survival rates are the most commonly used outcome measures
	for patients with cancer. However, traditional long-term survival
	statistics, which are derived by cohort-based types of analysis,
	essentially reflect the survival expectations of patients diagnosed
	many years ago. They are therefore often severely outdated at the
	time they become available. A couple of years ago, a new method of
	survival analysis, denoted period analysis, has been introduced to
	derive more 'up-to-date' estimates of long-term survival rates. We
	give a comprehensive review of the new methodology, its statistical
	background, empirical evaluation, computational realisation and applications.
	We conclude that period analysis is a powerful tool to provide more
	'up-to-date' cancer survival rates. More widespread use by cancer
	registries should help to increase the use of cancer survival statistics
	for patients, clinicians, and public health authorities.},
  file        = {brenner2004a.pdf:brenner2004a.pdf:PDF},
  institution = {Department of Epidemiology, German Centre for Research on Ageing, Bergheimer Str 20, D-69115, Heidelberg, Germany. brenner@dzfa.uni-heidelberg.de},
  journal     = {European Journal of Cancer},
  month       = feb,
  owner       = {pl4},
  pii         = {S0959804903009237},
  pmid        = {14746849},
  timestamp   = {2008.12.02},
  year        = {2004},
}

@Article{Brenner2002,
  author      = {H. Brenner and O. Gefeller and T. Hakulinen},
  title       = {A computer program for period analysis of cancer patient survival.},
  number      = {5},
  pages       = {690--695},
  volume      = {38},
  abstract    = {Monitoring of long-term survival rates, which is now routinely performed
	by many cancer registries throughout the world, should be as up-to-date
	as possible. A few years ago, a new method of survival analysis,
	denoted period analysis, has been proposed which provides more up-to-date
	estimates of long-term survival rates than traditional survival analysis
	by exclusively reflecting the survival experience of patients within
	a recent calendar period. However, application of this method has
	so far been hindered by the lack of pertinent computer programs.
	In this paper, we present a simple and easy-to-use computer program
	(SAS macro) that enables one to carry out period analysis (as well
	as conventional analysis) of both absolute and relative survival
	rates with the type of data commonly available in population-based
	cancer registries. We illustrate application of the program with
	examples from the nationwide Finnish Cancer Registry.},
  file        = {Brenner2002.pdf:Brenner2002.pdf:PDF;Brenner2002.pdf:pdf\\Brenner2002.pdf:PDF},
  institution = {Department of Epidemiology, German Centre for Research on Ageing, Bergheimer Strasse 20, D-69115 Heidelberg, Germany. brenner@dzfa.uni-heidelberg.de},
  journal     = {European Journal of Cancer},
  month       = mar,
  owner       = {pl4},
  pii         = {S0959804902000035},
  pmid        = {11916552},
  timestamp   = {2008.12.02},
  year        = {2002},
}

@Article{Brenner2001a,
  author      = {H. Brenner and O. Gefeller and C. Stegmaier and H. Ziegler},
  title       = {More up-to-date monitoring of long-term survival rates by cancer registries: an empirical example.},
  number      = {3},
  pages       = {248--252},
  volume      = {40},
  abstract    = {A few years ago, a new method of survival analysis, denoted period
	analysis, has been developed to derive more up-to-date estimates
	of long-term survival rates of cancer patients, but this method has
	rarely been applied so far. Using empirical examples from the Saarland
	Cancer Registry, we illustrate how seriously traditional long-term
	survival estimates may lag behind survival expectations of newly
	diagnosed cancer patients in the case of recent improvement in prognosis,
	and to what extent this problem may be reduced by period analysis
	of survival. We conclude that period analysis should be more widely
	used for deriving more up-to-date long-term survival estimates.},
  institution = {Dept. of Epidemiology, German Centre for Research on Ageing, Heidelberg. brenner@dzfa.uni-heidelberg.de},
  journal     = {Methods Inf Med},
  month       = jul,
  owner       = {pl4},
  pmid        = {11501640},
  timestamp   = {2008.12.02},
  year        = {2001},
}

@Article{Brenner2007c,
  author      = {Hermann Brenner and Adam Gondos and Volker Arndt},
  title       = {Recent major progress in long-term cancer patient survival disclosed by modeled period analysis.},
  doi         = {10.1200/JCO.2007.11.3431},
  number      = {22},
  pages       = {3274--3280},
  volume      = {25},
  abstract    = {PURPOSE: To disclose most recent trends in long-term cancer patient
	survival. METHODS: We estimated trends in 5- and 10-year relative
	survival of cancer patients in the United States in 1998 to 2003
	from the 1973 to 2003 database of the Surveillance, Epidemiology,
	and End Results Program using recently introduced period-analysis
	modeling techniques that provide the most up-to-date and precise
	survival estimates. RESULTS: Statistically significant and partly
	very substantial improvement in 5- and 10-year relative survival
	in the 1998 to 2003 period was seen for 14 of 24 of the assessed
	common forms of cancer, including breast and colorectal cancer. For
	example, by 2003, 5-year relative survival exceeded 90\% for patients
	with breast cancer and reached levels of about two thirds for patients
	with colorectal cancer and kidney cancer and patients with non-Hodgkin's
	lymphoma. Unfortunately, 5-year relative survival remained essentially
	unchanged at approximately 16\% for lung cancer patients, and, despite
	statistically significant improvement, as low as 7\% for pancreatic
	cancer patients. Overall, improvement was most pronounced for patients
	with regional tumor spread and somewhat less so for patients with
	localized tumors, whereas hardly any improvement was achieved for
	patients with distant tumor spread. CONCLUSION: Our analysis discloses
	further major improvement in prognosis for most, but not all forms
	of cancer in recent years. The largest contribution to this improvement
	comes from improved prognosis of patients with regional tumor spread.},
  file        = {Brenner2007c.pdf:Brenner2007c.pdf:PDF;Brenner2007c.pdf:pdf\\Brenner2007c.pdf:PDF},
  institution = {Aging Research, German Cancer Research Center, Bergheimer Str 20, D-69115 Heidelberg, Germany. h.brenner@dkfz-heidelberg.de},
  journal     = {Journal of Clinical Oncology},
  month       = aug,
  owner       = {pl4},
  pii         = {25/22/3274},
  pmid        = {17664474},
  timestamp   = {2008.12.02},
  year        = {2007},
}

@Article{Brenner2008a,
  author      = {Hermann Brenner and Adam Gondos and Dianne Pulte},
  title       = {Ongoing improvement in long-term survival of patients with {H}odgkin disease at all ages and recent catch-up of older patients.},
  doi         = {10.1182/blood-2007-10-115493},
  number      = {6},
  pages       = {2977--2983},
  volume      = {111},
  abstract    = {Since the breakthroughs in combination chemotherapy of patients with
	Hodgkin disease (HD) starting in the 1960s, prognosis of patients
	has been rising steadily. Trends in long-term survival of patients
	with HD on the population level should therefore be monitored in
	an as timely as possible manner. We assessed trends in age specific
	5- and 10-year relative survival of patients with HD in the United
	States from 1980-1984 to 2000-2004 from the 1973-2004 database of
	the Surveillance, Epidemiology, and End Results (SEER) Program. Period
	analysis was used to disclose recent developments with minimum delay.
	Overall, 5-year relative survival steadily increased from 73.5\%
	to 85.2\% (+11.7 percentage units), and 10-year relative survival
	increased from 62.1\% to 80.1\% (+18.0 percentage units) between
	1980-1984 and 2000-2004, according to period analysis. The increase
	was particularly pronounced for patients aged 45 to 59 years and
	60 years and older (increases in 10-year relative survival by 24.8
	and 23.3 percentage points, respectively). Nevertheless, a strong
	age gradient persisted, with 10-year relative survival of 92.7\%,
	88.7\%, 84.9\%, 76.2\%, and 44.9\% in patients aged 15 to 24 years,
	25 to 34 years, 35 to 44 years, 45 to 54 years, and 60 years and
	older, respectively, in 2000-2004. Our period analysis discloses
	ongoing, major improvement in long-term survival of patients with
	HD in recent years, particularly among older patients.},
  institution = {Aging Research, German Cancer Research Center, Heidelberg, Germany. h.brenner@dkfz-heidelberg.de},
  journal     = {Blood},
  month       = mar,
  owner       = {PaulD},
  pii         = {blood-2007-10-115493},
  pmid        = {18096762},
  timestamp   = {2008.12.30},
  year        = {2008},
}

@Article{Brenner2009,
  author      = {Hermann Brenner and Timo Hakulinen},
  title       = {Up-to-date cancer survival: period analysis and beyond.},
  doi         = {10.1002/ijc.24021},
  language    = {eng},
  number      = {6},
  pages       = {1384--1390},
  volume      = {124},
  abstract    = {Since its introduction in 1996, period analysis has been shown to
	be useful for deriving more up-to-date cancer survival estimates,
	and the method is now increasingly used for that purpose in national
	and international cancer survival studies. However, period analysis,
	like other commonly employed methods, is just a special case from
	a broad class of design options in the analysis of cancer survival
	data. Here, we explore a broader range of design options, including
	2 model-based approaches, for deriving up-to-date estimates of 5-
	and 10-year relative survival for patients diagnosed in the most
	recent 5-year interval for which data are available. The performance
	of the various designs is evaluated empirically for 20 common forms
	of cancer using more than 50-year long time series of data from the
	Finnish Cancer Registry. Period analysis as well as the 2 model-based
	approaches, one using a "cohort-type model" and another using a "period-type
	model", all performed better than traditional cohort or complete
	analysis. Compared with "standard period analysis", the cohort-type
	model further increased up-to-dateness of survival estimates, whereas
	the period-type model increased their precision. While our analysis
	confirms advantages of period analysis over traditional methods in
	terms of up-to-dateness of cancer survival data, further improvements
	are possible by flexible use of model-based approaches.},
  institution = {Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany. h.brenner@dkfz-heidelberg.de},
  journal     = {Int J Cancer},
  medline-pst = {ppublish},
  month       = mar,
  owner       = {PaulD},
  pmid        = {19058217},
  timestamp   = {2010.04.05},
  year        = {2009},
}

@Article{Brenner2009a,
  author      = {Brenner, H. and Hakulinen, T.},
  title       = {Implications of incomplete registration of deaths on long-term survival estimates from population-based cancer registries.},
  doi         = {10.1002/ijc.24344},
  language    = {eng},
  number      = {2},
  pages       = {432--437},
  url         = {http://dx.doi.org/10.1002/ijc.24344},
  volume      = {125},
  abstract    = {International comparison of population-based cancer survival is a
	key component of monitoring progress against cancer. Its validity
	depends to an unknown degree on completeness of ascertainment of
	deaths in the cancer registries involved which may vary according
	to legal and administrative circumstances. The aim of this study
	was to assess the impact of incomplete registration of deaths through
	various mechanisms on the validity of long-term absolute and relative
	survival estimates. For that purpose, we simulated underascertainment
	of deaths through linkage failure of registry data with death certificates
	with probabilities between 0.1 and 5\%, and underascertainment of
	deaths by unregistered annual emigration with probabilities between
	0.05 and 2\%, using data from the Finnish Cancer Registry. The expected
	impact on estimates of 5-, 10- and 15-year absolute and relative
	survival was assessed. We demonstrate that even modest levels of
	under-registration of deaths may lead to severe overestimation of
	long-term survival estimates, ranging from 0 to 31 percent units
	in the scenarios assessed. In general, relative survival is much
	more affected than absolute survival, and potential problems are
	much larger for relative survival estimates in older compared with
	younger patients. Potential overestimation strongly increases with
	length of follow-up, and this increase is particularly pronounced
	for under-registration of deaths because of unrecorded emigration.
	Every effort should be made in cancer registry based survival analyses
	to ascertain deaths with close to 100\% completeness. When such completeness
	cannot be achieved, long-term relative survival estimates and their
	comparison across populations must be interpreted with much caution.},
  file        = {Brenner2009a.pdf:Brenner2009a.pdf:PDF},
  institution = {Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany. h.brenner@dkfz-heidelberg.de},
  journal     = {International Journal of Cancer},
  medline-pst = {ppublish},
  month       = {Jul},
  owner       = {localuser},
  pmid        = {19422045},
  timestamp   = {2013.05.31},
  year        = {2009},
}

@Article{Brenner2008,
  author      = {Hermann Brenner and Timo Hakulinen},
  title       = {Period versus cohort modeling of up-to-date cancer survival.},
  doi         = {10.1002/ijc.23087},
  number      = {4},
  pages       = {898--904},
  volume      = {122},
  abstract    = {Recently, 2 modeling strategies have been proposed and shown to be
	useful to increase precision of up-to-date cancer survival estimates
	and to predict cancer patient survival: modeled period analysis and
	modeled cohort analysis. We aimed to compare the performance of both
	types of modeling for providing up-to-date and precise cancer survival
	estimates. Data from the nationwide Finnish Cancer Registry were
	used to assess how well both approaches would have been able to predict
	5-year relative survival of concurrently diagnosed patients if they
	had been applied for that purpose throughout the past decades. Analyses
	were carried out for 20 common forms of cancer. For each cancer,
	5-year relative survival was modeled with either approach for each
	single calendar year from 1962 to 1997. Mean differences and mean
	squared differences from 5-year relative survival later observed
	for patients diagnosed in the 5-year period around those calendar
	years were calculated. Survival estimates obtained by period modeling
	had much lower standard errors than those obtained by cohort modeling.
	Furthermore, for a clear majority of cancers, period modeling on
	average also provided better prediction of 5-year relative survival
	than cohort modeling. We conclude that, although both modeling strategies
	have their merits and specific indications, period modeling of survival
	has distinct advantages for up-to-date and precise estimation of
	cancer survival in population-based cancer survival studies.},
  file        = {Brenner2008.pdf:Brenner2008.pdf:PDF;Brenner2008.pdf:pdf\\Brenner2008.pdf:PDF},
  institution = {Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Bergheimer Strasse 20, Heidelberg, Germany. h.brenner@dkfz-heidelberg.de},
  journal     = {International Journal of Cancer},
  month       = feb,
  owner       = {pl4},
  pmid        = {17957801},
  timestamp   = {2008.12.02},
  year        = {2008},
}

@Article{Brenner2007,
  author      = {Hermann Brenner and Timo Hakulinen},
  title       = {Maximizing the benefits of model-based period analysis of cancer patient survival.},
  doi         = {10.1158/1055-9965.EPI-06-1046},
  number      = {8},
  pages       = {1675--1681},
  volume      = {16},
  abstract    = {Period analysis has been shown to provide more up-to-date estimates
	of cancer survival than traditional methods of survival analysis.
	There is, however, a tradeoff between up-to-dateness and precision
	of period survival estimates: increasing up-to-dateness by restricting
	the analysis to a relatively short period, such as the most recent
	calendar year, goes along with loss of precision. Recently, a model-based
	approach was proposed, in which more precise period survival estimates
	for the most recent year can be obtained through modeling of survival
	trends within a recent 5-year period. We assess possibilities to
	extend the time window used for modeling to come up with even more
	precise, but equally accurate and up-to-date estimates of prognosis.
	Empirical evaluation using data from the Finnish Cancer Registry
	shows that extension of the time window to about 10 years provides,
	in most cases, as accurate results as using a 5-year time window
	(whereas further extension may lead to considerably less accurate
	results in some cases). Using 10-year time windows for modeling,
	SEs of survival estimates can be approximately halved compared with
	conventional period survival estimates for the most recent calendar
	year. Furthermore, we present a modification of the modeling approach,
	which allows extension to 10-year time windows to be achieved without
	the need to include additional cohorts of patients diagnosed longer
	time ago and which provides similarly accurate survival estimates
	at comparable levels of precision in most cases. Our analyses indicate
	opportunities to further maximize benefits of model-based period
	analysis of cancer survival.},
  file        = {Brenner2007.pdf:Brenner2007.pdf:PDF;Brenner2007.pdf:pdf\\Brenner2007.pdf:PDF},
  institution = {Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Bergheimer Strasse 20, D-69115 Heidelberg, Germany. h.brenner@dkfz-heidelberg.de},
  journal     = {Cancer Epidemiol Biomarkers Prev},
  month       = aug,
  owner       = {pl4},
  pii         = {16/8/1675},
  pmid        = {17684145},
  timestamp   = {2008.12.02},
  year        = {2007},
}

@Article{Brenner2007a,
  author      = {Hermann Brenner and Timo Hakulinen},
  title       = {Patients with previous cancer should not be excluded in international comparative cancer survival studies.},
  doi         = {10.1002/ijc.22932},
  number      = {10},
  pages       = {2274--2278},
  volume      = {121},
  abstract    = {In international comparisons or time trend analyses of cancer survival,
	it is common practice to restrict analyses to patients with a first
	cancer, i.e., to exclude patients with previous cancer diagnoses.
	However, the proportion of cancer patients with known previous cancer
	depends on the time cancer registries have been running, which results
	in varying proportions of excluded patients across registries. If
	prognosis of patients with second cancers differs from prognosis
	of patients with first cancers, varying exclusions may bias survival
	comparisons. We empirically evaluate the dependence of proportions
	of patients recorded as having a first cancer on time since initiation
	of cancer registration and the impact of excluding patients with
	known previous cancer on cancer survival estimates using the data
	of the nationwide Finnish Cancer Registry. Among 20 common cancer
	sites investigated, the proportion of "first cancers" varied between
	97.4 and 99.7\% in 1953-1957, the first 5-years of cancer registration,
	and decreased continuously to levels between 83.9 and 92.7\% in 1993-1997.
	Excluding patients with a previous cancer diagnosis had little impact
	on estimates of survival of cancer patients diagnosed in 1953-1957,
	but increased 5-year relative survival estimates among patients diagnosed
	in 1993-1997 for each of the 20 cancers. The extent of the increase
	varied by cancer site and age. The increase ranged up to 2.9\% points
	for crude and up to 1.7\% points for age adjusted 5-year relative
	survival. These results caution against exclusion of patients with
	previous cancer diagnosis in comparative analyses of cancer survival.},
  file        = {Brenner2007a.pdf:Brenner2007a.pdf:PDF;Brenner2007a.pdf:pdf\\Brenner2007a.pdf:PDF},
  institution = {Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Bergheimer Strasse 20, D-69115 Heidelberg, Germany. h.brenner@dkfz-heidelberg.de},
  journal     = {International Journal of Cancer},
  month       = nov,
  owner       = {pl4},
  pmid        = {17594692},
  timestamp   = {2008.12.02},
  year        = {2007},
}

@Article{Brenner2007b,
  author      = {Hermann Brenner and Timo Hakulinen},
  title       = {Model based hybrid analysis of cancer patient survival.},
  doi         = {10.1016/j.ejca.2007.01.015},
  number      = {5},
  pages       = {921--927},
  volume      = {43},
  abstract    = {In many cancer registries, registration of new cases is somewhat less
	up-to-date than mortality follow-up. In such situations, hybrid analysis,
	a combination of cohort and period analysis, rather than 'pure' period
	analysis has been proposed to derive up-to-date survival estimates.
	We evaluate application and adaptation of a modelling strategy that
	has recently been introduced to enhance precision of period survival
	estimates, to 'hybrid type of data'. Using data from the Finnish
	Cancer Registry, we show that modelling again strongly increases
	precision of survival estimates. Furthermore, special models adapted
	to the hybrid type of data are shown to provide even more precise
	and, in a clear majority of cases, also more valid predictions of
	survival of recently diagnosed patients than models ignoring the
	hybrid type of data. Finally, we show that model-based estimation
	of and testing for recent trends may give different answers if period
	rather than hybrid modelling is used for hybrid type of registry
	data. We conclude that modelling is useful for both hybrid and period
	analyses of cancer survival, but the different data structure needs
	to be taken into account in the set-up of models.},
  file        = {Brenner2007b.pdf:Brenner2007b.pdf:PDF;Brenner2007b.pdf:pdf\\Brenner2007b.pdf:PDF},
  institution = {Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Bergheimer Strasse 20, D-69115 Heidelberg, Germany. h.brenner@dkfz-heidelberg.de},
  journal     = {European Journal of Cancer},
  month       = mar,
  owner       = {pl4},
  pii         = {S0959-8049(07)00040-8},
  pmid        = {17329096},
  timestamp   = {2008.12.02},
  year        = {2007},
}

@Article{Brenner2006,
  author      = {Hermann Brenner and Timo Hakulinen},
  title       = {Up-to-date estimates of cancer patient survival even with common latency in cancer registration.},
  doi         = {10.1158/1055-9965.EPI-06-0167},
  number      = {9},
  pages       = {1727--1732},
  volume      = {15},
  abstract    = {In an era of ongoing improvement in cancer patient survival, available
	long-term survival figures from cancer registries are often outdated
	and too pessimistic for two reasons: first, delay in availability
	of cancer registry data, typically in the order of a few years, and,
	second, application of cohort-based methods of survival analysis,
	which provide survival estimates for patients diagnosed many years
	ago. We developed a model-based period analysis approach aimed to
	overcome both problems. We provide extensive empirical evaluation
	of our approach by comparing its performance with that of previously
	available methods for monitoring of 5- and 10-year relative survival,
	with the use of data from the nationwide Finnish Cancer Registry
	of 490,279 patients ages >/=15 years and diagnosed with one of 20
	common forms of cancer between 1953 and 1997. We show that, in most
	cases, the model-based approach predicts 5- and 10-year relative
	survival expectations of newly diagnosed patients quite closely and
	much better than any of the previously available methods, including
	standard period analysis. We conclude that the model-based approach
	may enable deriving up-to-date cancer survival rates even with the
	common latency in availability of cancer registry data.},
  file        = {Brenner2006.pdf:Brenner2006.pdf:PDF;Brenner2006.pdf:pdf\\Brenner2006.pdf:PDF},
  institution = {Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Bergheimer Strasse 20, D-69115 Heidelberg, Germany. h.brenner@dkfz-heidelberg.de},
  journal     = {Cancer Epidemiol Biomarkers Prev},
  month       = sep,
  owner       = {pl4},
  pii         = {15/9/1727},
  pmid        = {16985036},
  timestamp   = {2008.12.02},
  year        = {2006},
}

@Article{Brenner2006a,
  author      = {Hermann Brenner and Timo Hakulinen},
  title       = {Up-to-date and precise estimates of cancer patient survival: model-based period analysis.},
  doi         = {10.1093/aje/kwj243},
  number      = {7},
  pages       = {689--696},
  volume      = {164},
  abstract    = {Monitoring of progress in cancer patient survival by cancer registries
	should be as up-to-date as possible. Period analysis has been shown
	to provide more up-to-date survival estimates than do traditional
	methods of survival analysis. However, there is a trade-off between
	up-to-dateness and the precision of period estimates, in that increasing
	the up-to-dateness of survival estimates by restricting the analysis
	to a relatively short, recent time period, such as the most recent
	calendar year for which cancer registry data are available, goes
	along with a loss of precision. The authors propose a model-based
	approach to maximize the up-to-dateness of period estimates at minimal
	loss of precision. The approach is illustrated for monitoring of
	5-year relative survival of patients diagnosed with one of 20 common
	forms of cancer in Finland between 1953 and 2002 by use of data from
	the nationwide Finnish Cancer Registry. It is shown that the model-based
	approach provides survival estimates that are as up-to-date as the
	most up-to-date conventional period estimates and at the same time
	much more precise than the latter. The modeling approach may further
	enhance the use of period analysis for deriving up-to-date cancer
	survival rates.},
  file        = {Brenner2006a.pdf:Brenner2006a.pdf:PDF;Brenner2006a.pdf:pdf\\Brenner2006a.pdf:PDF},
  institution = {Department of Epidemiology, German Centre for Research on Ageing, Heidelberg, Germany. h.brenner@dkfz-heidelberg.de},
  journal     = {American Journal of Epidemiology},
  month       = oct,
  owner       = {pl4},
  pii         = {kwj243},
  pmid        = {16840519},
  timestamp   = {2008.12.02},
  year        = {2006},
}

@Article{Brenner2006b,
  author      = {Hermann Brenner and Timo Hakulinen},
  title       = {Period estimates of cancer patient survival are more up-to-date than complete estimates even at comparable levels of precision.},
  doi         = {10.1016/j.jclinepi.2005.10.012},
  number      = {6},
  pages       = {570--575},
  volume      = {59},
  abstract    = {BACKGROUND AND OBJECTIVE: Period analysis provides more up-to-date
	estimates of cancer patient survival than traditional methods, but
	there is a trade-off between up-to-dateness and precision. Our objective
	was to compare the performance of period and complete analysis in
	terms of up-to-dateness and precision of survival estimates. STUDY
	DESIGN AND SETTING: Five-year relative survival data actually observed
	for patients diagnosed with 1 of 20 common forms of cancer in Finland
	in 36 overlapping 5-year periods between 1958-1962 and 1993-1997
	were compared with period estimates and various variants of complete
	estimates of 5-year relative survival potentially available during
	these periods. RESULTS: At comparable levels of up-to-dateness, survival
	estimates from period analysis were more precise than survival estimates
	from complete analysis. At comparable levels of precision, period
	analysis provided more up-to-date survival estimates than did complete
	analysis. CONCLUSION: These results further encourage more widespread
	use of period analysis as a standard tool for up-to-date monitoring
	of cancer patient survival by population-based cancer registries.},
  file        = {Brenner2006b.pdf:Brenner2006b.pdf:PDF;Brenner2006b.pdf:pdf\\Brenner2006b.pdf:PDF},
  institution = {Department of Epidemiology, German Center for Research on Aging, Bergheimer Strasse 20, D-69115 Heidelberg, Germany. h.brenner@dkfz-heidelberg.de},
  journal     = {Journal of Clinical Epidemiology},
  month       = jun,
  owner       = {pl4},
  pii         = {S0895-4356(05)00430-0},
  pmid        = {16713519},
  timestamp   = {2008.12.02},
  year        = {2006},
}

@Article{Brenner2005,
  author      = {H. Brenner and T. Hakulinen},
  title       = {Age adjustment of cancer survival rates: methods, point estimates and standard errors.},
  doi         = {10.1038/sj.bjc.6602704},
  number      = {3},
  pages       = {372--375},
  volume      = {93},
  abstract    = {We empirically evaluated the performance of a new method for age adjustment
	of cancer survival compared to traditional age adjustment using data
	from the Finnish Cancer Registry. We find that both methods provide
	almost identical results for absolute survival but the new method
	generally provides more meaningful estimates of relative survival
	with often a smaller standard error.},
  file        = {Brenner2005.pdf:Brenner2005.pdf:PDF;Brenner2005.pdf:pdf\\Brenner2005.pdf:PDF},
  institution = {Department of Epidemiology, German Centre for Research on Ageing, Bergheimer Strasse 20, D-69115 Heidelberg, Germany. Brenner@dzfa.uni-heidelberg.de},
  journal     = {British Journal of Cancer},
  month       = aug,
  owner       = {pl4},
  pii         = {6602704},
  pmid        = {16052220},
  timestamp   = {2008.12.02},
  year        = {2005},
}

@Article{Brenner2005a,
  author      = {Hermann Brenner and Timo Hakulinen},
  title       = {Reduction in selective under-ascertainment bias in population-based estimates of cancer patient survival by age adjustment.},
  doi         = {10.1016/j.ejca.2005.03.029},
  number      = {12},
  pages       = {1788--1793},
  volume      = {41},
  abstract    = {Selective under-ascertainment of cancer patients by cancer registries
	may bias population-based estimates of cancer patient survival. As
	prognosis is strongly age related for many forms of cancer, age adjustment
	of cancer survival rates, which is primarily used to enhance the
	validity of comparative analyses between cancer populations, might
	also effectively reduce this type of bias. We empirically assessed
	this potential "side-effect" of age adjustment using data from the
	Finnish Cancer Registry. Analyses of five-year absolute and relative
	survival for patients diagnosed in 1990-1994, and age adjustment
	to the age structure of patients diagnosed in 1985-1989, were used
	as examples. Various patterns of selective under-ascertainment were
	simulated, and the bias in crude and age adjusted five-year survival
	rates was compared. Age adjusted estimates were less biased in most
	scenarios, which may be an additional argument for application of
	age adjustment in the analysis and reporting of population-based
	cancer survival rates.},
  file        = {Brenner2005a.pdf:Brenner2005a.pdf:PDF;Brenner2005a.pdf:pdf\\Brenner2005a.pdf:PDF},
  institution = {Department of Epidemiology, German Centre for Research on Ageing, Bergheimer Strasse 20, D-69115 Heidelberg, Germany. brenner@dzfa.uni-heidelberg.de},
  journal     = {European Journal of Cancer},
  month       = aug,
  owner       = {pl4},
  pii         = {S0959-8049(05)00432-6},
  pmid        = {16043349},
  timestamp   = {2008.12.02},
  year        = {2005},
}

@Article{Brenner2005b,
  author      = {Hermann Brenner and Timo Hakulinen},
  title       = {Substantial overestimation of standard errors of relative survival rates of cancer patients.},
  doi         = {10.1093/aje/kwi099},
  number      = {8},
  pages       = {781--786},
  volume      = {161},
  abstract    = {Relative survival rates are among the most commonly reported outcome
	measures of cancer patients. They are calculated as ratios of observed
	survival rates and the expected survival rates in the absence of
	cancer. Standard errors of relative survival rates are commonly calculated
	by dividing the standard error for absolute survival rates by the
	expected survival, without taking possible random variation of the
	latter into account. The aim of this study was to empirically assess
	the validity of these commonly reported standard errors. Using data
	from the nationwide Finnish Cancer Registry, the authors calculated
	5- and 10-year absolute, expected, and relative survival rates for
	patients with 25 common forms of cancer in Finland in 1989. The authors
	used bootstrap analysis to empirically assess the random error of
	absolute and relative survival rates and then compared the results
	with conventionally derived estimates of standard errors. The conventional
	and bootstrap standard errors were closely similar for all estimates
	of absolute survival. By contrast, the conventional estimates of
	standard errors of 5- and 10-year relative survival exceeded the
	bootstrap estimates by up to 17\% and 32\%, respectively. The authors
	conclude that conventional derivation may substantially overestimate
	standard errors for relative survival.},
  file        = {Brenner2005b.pdf:Brenner2005b.pdf:PDF;Brenner2005b.pdf:pdf\\Brenner2005b.pdf:PDF},
  institution = {German Centre for Research on Ageing, Heidelberg, Germany. brenner@dzfa.uni-heidelberg.de},
  journal     = {Am J Epidemiol},
  month       = apr,
  owner       = {pl4},
  pii         = {161/8/781},
  pmid        = {15800271},
  timestamp   = {2008.12.02},
  year        = {2005},
}

@Article{Brenner2005c,
  author    = {Hermann Brenner and Timo Hakulinen},
  title     = {Long-term survival and cure of patients diagnosed with breast cancer before age 50 years.},
  doi       = {10.1200/JCO.2005.05.127},
  number    = {7},
  pages     = {1585; author reply 1586},
  volume    = {23},
  file      = {Brenner2005c.pdf:Brenner2005c.pdf:PDF;Brenner2005c.pdf:pdf\\Brenner2005c.pdf:PDF},
  journal   = {Journal of Clinical Oncology},
  month     = mar,
  owner     = {pl4},
  pii       = {23/7/1585},
  pmid      = {15735137},
  timestamp = {2008.12.02},
  year      = {2005},
}

@Article{Brenner2005d,
  author      = {H. Brenner and T. Hakulinen},
  title       = {Population-based monitoring of cancer patient survival in situations with imperfect completeness of cancer registration.},
  doi         = {10.1038/sj.bjc.6602323},
  number      = {3},
  pages       = {576--579},
  volume      = {92},
  abstract    = {Selective underascertainment of cases may bias estimates of cancer
	patient survival. We show that the magnitude of potential bias strongly
	depends on the time periods affected by underascertainment and on
	the type of survival analysis (cohort analysis vs period analysis).
	We outline strategies on how to minimise or overcome potential biases.},
  file        = {Brenner2005d.pdf:Brenner2005d.pdf:PDF;Brenner2005d.pdf:pdf\\Brenner2005d.pdf:PDF},
  institution = {Department of Epidemiology, German Centre for Research on Ageing, Bergheimer Strasse 20, D-69115 Heidelberg, Germany. Brenner@dzfa.uni-heidelberg.de},
  journal     = {British Journal of Cancer},
  month       = feb,
  owner       = {pl4},
  pii         = {6602323},
  pmid        = {15655546},
  timestamp   = {2008.12.02},
  year        = {2005},
}

@Article{Brenner2004b,
  author      = {Hermann Brenner and Timo Hakulinen},
  title       = {Are patients diagnosed with breast cancer before age 50 years ever cured?},
  doi         = {10.1200/JCO.2004.04.067},
  number      = {3},
  pages       = {432--438},
  volume      = {22},
  abstract    = {PURPOSE: Breast cancer diagnosed before the age of 50 years has become
	a common disease in many developed countries. Although average remaining
	life expectancy in the affected age groups is usually several decades,
	data regarding survival perspectives beyond 10 to 20 years after
	diagnosis are sparse. The aim of this study was to assess long-term
	survival in a large population-based sample of patients diagnosed
	with breast cancer before age 50 years. PATIENTS AND METHODS: Relative
	survival within up to 40 years after diagnosis was assessed for cohorts
	of women diagnosed with breast cancer before age 50 years and notified
	to the nationwide Finnish Cancer Registry within various time intervals
	since 1953. In addition, up-to-date estimates of 40-year relative
	survival were obtained by exclusively looking at the survival experience
	of breast cancer patients in recent years (1993 to 1999) using period
	analysis, a new method of survival analysis. RESULTS: Prognosis of
	patients diagnosed with breast cancer before age 50 years has considerably
	improved during the past decades. According to the latest estimates
	from period analysis, cumulative 40-year relative survival is now
	approximately 43\% for all cancers combined, 57\% for localized cancers,
	and 24\% for cancers with regional tumor spread. Nevertheless, patients
	diagnosed with breast cancer before age 50 years continue to have
	increased mortality throughout at least four decades after diagnosis.
	This applies even if breast cancer is diagnosed in a localized stage
	and in the absence of a second primary breast cancer. CONCLUSION:
	Despite major improvement in prognosis over time, breast cancer occurring
	among patients who are younger than 50 years remains a chronic disease
	that affects prognosis for decades.},
  file        = {Brenner2004b.pdf:Brenner2004b.pdf:PDF;Brenner2004b.pdf:pdf\\Brenner2004b.pdf:PDF},
  institution = {Department of Epidemiology, German Centre for Research on Aging, Bergheimer Strasse 20, D-69115 Heidelberg, Germany. Brenner@dzfa-uni-heidelberg.de},
  journal     = {Journal of Clinical Oncology},
  month       = feb,
  owner       = {pl4},
  pii         = {JCO.2004.04.067},
  pmid        = {14691121},
  timestamp   = {2008.12.02},
  year        = {2004},
}

@Article{Brenner2003,
  author      = {Hermann Brenner and Timo Hakulinen},
  title       = {On crude and age-adjusted relative survival rates.},
  number      = {12},
  pages       = {1185--1191},
  volume      = {56},
  abstract    = {Relative survival rates, such as 5- or 10-year relative survival rates,
	which quantify "net survival" of cancer patients, are the most commonly
	reported measures of cancer outcome by cancer registries. Because
	relative survival rates vary with age for many forms of cancer, and
	because the age distribution of cancer patients varies between different
	populations or within one population over time, age adjustment of
	relative survival rates is often employed in international comparisons
	or in time series analyses of cancer patient survival. In this article,
	we show that derivation of crude and of age-adjusted relative survival
	rates in the traditional way is conceptually inconsistent, and that
	this inconsistency has important practical implications. We show
	ways to overcome this inconsistency in the derivation and interpretation
	of crude and age-adjusted relative survival rates.},
  file        = {Brenner2003.pdf:Brenner2003.pdf:PDF;Brenner2003.pdf:pdf\\Brenner2003.pdf:PDF},
  institution = {Department of Epidemiology, German Centre for Research on Ageing, Bergheimer Strasse 20, D-69115, Heidelberg, Germany. brenner@dzfa.uni-heidelberg.de},
  journal     = {Journal of Clinical Epidemiology},
  month       = dec,
  owner       = {pl4},
  pii         = {S0895435603002099},
  pmid        = {14680669},
  timestamp   = {2008.12.02},
  year        = {2003},
}

@Article{Brenner2002a,
  author    = {Hermann Brenner and Timo Hakulinen},
  title     = {Very-long-term survival rates of patients with cancer.},
  number    = {21},
  pages     = {4405--4409},
  volume    = {20},
  file      = {Brenner2002a.pdf:Brenner2002a.pdf:PDF;Brenner2002a.pdf:pdf\\Brenner2002a.pdf:PDF},
  journal   = {Journal of Clinical Oncology},
  month     = nov,
  owner     = {pl4},
  pmid      = {12409346},
  timestamp = {2008.12.02},
  year      = {2002},
}

@Article{Brenner2002b,
  author      = {Hermann Brenner and Timo Hakulinen},
  title       = {Advanced detection of time trends in long-term cancer patient survival: experience from 50 years of cancer registration in Finland.},
  number      = {6},
  pages       = {566--577},
  volume      = {156},
  abstract    = {Timely monitoring of trends in long-term patient survival is an important
	task of cancer registries. Recently, a new method, denoted period
	analysis, has been proposed to enhance up-to-date monitoring of survival.
	The authors assessed the use of period analysis for advanced detection
	of time trends in long-term cancer patient survival based on data
	from the nationwide Finnish Cancer Registry by comparing estimates
	of 10-, 15-, and 20-year relative survival rates obtained by period
	analysis and by traditional (cohort) analysis of survival at various
	points of time between 1953 and 1997. Time trends are graphically
	displayed for the 15 most common forms of cancer. Long-term survival
	rates strongly improved over time for most forms of cancer. The slope
	and shape of trend curves obtained by period analysis are very similar
	to those obtained by traditional survival analysis. However, detection
	of progress in 10-, 15-, and 20-year survival rates of newly diagnosed
	patients could have been advanced by 5-10 years, 10-15 years, and
	15-20 years, respectively, with the use of period analysis rather
	than traditional cohort survival analysis. The authors conclude that
	period analysis should be routinely used to advance detection of
	progress in long-term cancer patient survival.},
  file        = {Brenner2002b.pdf:Brenner2002b.pdf:PDF;Brenner2002b.pdf:pdf\\Brenner2002b.pdf:PDF},
  institution = {Department of Epidemiology, German Centre for Research on Ageing, Heidelberg, Germany. brenner@dzfa.uni-heidelberg.de},
  journal     = {American Journal of Epidemiology},
  month       = sep,
  owner       = {pl4},
  pmid        = {12226004},
  timestamp   = {2008.12.02},
  year        = {2002},
}

@Article{Brenner2002c,
  author      = {Hermann Brenner and Timo Hakulinen},
  title       = {Up-to-date long-term survival curves of patients with cancer by period analysis.},
  number      = {3},
  pages       = {826--832},
  volume      = {20},
  abstract    = {PURPOSE: Provision of up-to-date long-term survival curves is an important
	task of cancer registries. Traditionally, survival curves have been
	derived for cohorts of patients diagnosed many years ago. Using data
	of the Finnish Cancer Registry, we provide an empirical assessment
	of the use of a new method of survival analysis, denoted period analysis,
	for deriving more up-to-date survival curves. PATIENTS AND METHODS:
	We calculated 10-year relative survival curves actually observed
	for patients diagnosed with one of the 15 most common forms of cancer
	in 1983 to 1987, and we compared them with the most up-to-date 10-year
	relative survival curves that might have been obtained in 1983 to
	1987 using either traditional (cohort-wise) or period analysis. We
	also give the most recent 10-year survival curves obtained by period
	analysis for the 1993 to 1997 period. RESULTS: For all forms of cancer,
	period analysis of the 1983 to 1987 data yielded survival curves
	that were very close to the survival curves later observed for patients
	who were newly diagnosed in that period (median and maximum difference
	of 10-year relative survival estimates: 0.9 and 5.7 percent units,
	respectively). By contrast, the survival curves obtained by traditional
	(cohort-wise) survival analysis in 1983 to 1987 would have been much
	lower for most forms of cancer (median and maximum difference: 5.8
	and 18.4 percent units, respectively). The 10-year survival curves
	for the 1993 to 1997 period are substantially more favorable than
	previously available, traditionally derived survival curves for most
	forms of cancer. CONCLUSION: Period analysis is a useful tool for
	deriving up-to-date long-term survival curves of patients with cancer.},
  file        = {Brenner2002c.pdf:Brenner2002c.pdf:PDF;Brenner2002c.pdf:pdf\\Brenner2002c.pdf:PDF},
  institution = {Department of Epidemiology, German Centre for Research on Ageing, Heidelberg, Germany. brenner@dzfa.uni-heidelberg.de},
  journal     = {Journal of Clinical Oncology},
  month       = feb,
  owner       = {pl4},
  pmid        = {11821467},
  timestamp   = {2008.12.02},
  year        = {2002},
}

@Article{Brenner2001,
  author      = {H. Brenner and T. Hakulinen},
  title       = {Long-term cancer patient survival achieved by the end of the 20th century: most up-to-date estimates from the nationwide Finnish cancer registry.},
  doi         = {10.1054/bjoc.2001.1905},
  number      = {3},
  pages       = {367--371},
  volume      = {85},
  abstract    = {A new method of survival analysis, denoted period analysis, has recently
	been developed, which has been shown to provide more up-to-date estimates
	of long-term survival rates than traditional methods of survival
	analysis. We applied period analysis to data from the nationwide
	Finnish cancer registry to provide up-to-date estimates of 5-, 10-,
	15- and 20-year relative survival rates (RSR) achieved by the end
	of the 20th century. For most forms of cancer, period estimates of
	long-term survival are much higher than corresponding traditional
	survival estimates which suggests that for these cancers there has
	been ongoing major progress in survival rates in recent years which
	so far has remained undisclosed by traditional methods of survival
	analysis. For example, period analysis reveals that 10 year RSR have
	come close to (or even exceed) 80\% for cancer of the corpus uteri
	and melanoma, 75\% for breast cancer, 70\% for bladder cancer, 65\%
	for cancer of the cervix uteri, and 55\% for cancer of the colon
	and prostate. Period analysis further reveals that 20 year RSR have
	now come close to (or even exceed) 75\% for endometrial cancer and
	melanoma, 60\% for breast cancer and cervical cancer, 55\% for colon
	cancer and bladder cancer, and 40\%-50\% for cancer of the rectum,
	the ovaries, kidneys and nervous system.},
  file        = {Brenner2001.pdf:Brenner2001.pdf:PDF;Brenner2001.pdf:pdf\\Brenner2001.pdf:PDF},
  institution = {Department of Epidemiology, German Centre for Research on Ageing, Bergheimer Str. 20, Heidelberg, D-69115, Germany.},
  journal     = {British Journal of Cancer},
  month       = aug,
  owner       = {pl4},
  pii         = {S0007092001919056},
  pmid        = {11487267},
  timestamp   = {2008.12.02},
  year        = {2001},
}

@Article{Brenner2002d,
  author    = {Hermann Brenner and Timo Hakulinen and Olaf Gefeller},
  title     = {Computational realization of period analysis for monitoring cancer patient survival.},
  doi       = {10.1097/01.EDE.0000023225.86063.72},
  number    = {5},
  pages     = {611--612},
  volume    = {13},
  journal   = {Epidemiology},
  month     = sep,
  owner     = {pl4},
  pii       = {00001648-200209000-00031},
  pmid      = {12192239},
  timestamp = {2008.12.02},
  year      = {2002},
}

@Article{Brenner1991,
  author    = {Brenner, H. and Mielck, A. and Klein, R. and Ziegler, H.},
  title     = {The role of socioeconomic factors in the survival of patients with colorectal cancer in {S}aarland/{G}ermany},
  pages     = {807--815},
  volume    = {44},
  journal   = {Journal of Clinical Epidemiology},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1991},
}

@Article{Brenner2004d,
  author      = {Hermann Brenner and Bernard Rachet},
  title       = {Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases.},
  doi         = {10.1016/j.ejca.2004.07.022},
  number      = {16},
  pages       = {2494--2501},
  volume      = {40},
  abstract    = {Up-to-date monitoring of long-term survival is an important task of
	population-based and clinical cancer registries. A few years ago,
	a new method of survival analysis, denoted period analysis, was introduced
	to provide more up-to-date estimates of long-term survival. However,
	a prototypical period analysis may not be applicable in situations
	with delayed recording of incident cases. We introduce herein a hybrid
	type of analysis that combines elements of both traditional and period
	analyses which may still be feasible in such settings. The performance
	of the hybrid type of analysis compared with other design options
	is empirically evaluated and illustrated for children diagnosed with
	cancer in the United States. The empirical evaluation indicates that
	hybrid analysis may be useful to derive more up-to-date estimates
	of long-term survival compared with traditional design options if
	there is a strong improvement of survival over time, even in situations
	with a substantial delay in recording of incident cases.},
  file        = {Brenner2004d.pdf:Brenner2004d.pdf:PDF;Brenner2004d.pdf:pdf\\Brenner2004d.pdf:PDF},
  institution = {Department of Epidemiology, German Centre for Research on Ageing, Bergheimer Strasse 20, D-69115 Heidelberg, Germany. brenner@dzfa.uni-heidelberg.de},
  journal     = {European Journal of Cancer},
  month       = nov,
  owner       = {pl4},
  pii         = {S0959-8049(04)00608-2},
  pmid        = {15519525},
  timestamp   = {2008.12.02},
  year        = {2004},
}

@Article{Brenner2002e,
  author      = {Hermann Brenner and Bengt S\"{o}derman and Timo Hakulinen},
  title       = {Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370,000 cancer patients in {F}inland.},
  number      = {2},
  pages       = {456--462},
  volume      = {31},
  abstract    = {BACKGROUND: Providing up-to-date estimates of cancer patient survival
	rates is an important task of cancer registries. A few years ago,
	a new method of survival analysis, denoted period analysis, was proposed
	to enhance the recency of long-term survival estimates. The aim of
	this paper is to provide a comprehensive empirical evaluation of
	the use of this method. METHODS: Using data from the nationwide Finnish
	Cancer Registry, we compare 5-year and 10-year relative survival
	rates of 371 849 patients diagnosed with one of the 16 most common
	forms of cancer in Finland at various time intervals between 1953
	and 1992 with the most up-to-date estimates of 5-year or 10-year
	relative survival that might have been obtained in those time intervals
	by traditional methods of survival analysis and by period analysis
	of survival. RESULTS: Survival rates strongly increased over time
	for most forms of cancer. For these cancers, traditional estimates
	of 5- and 10-year survival rates would have severely lagged behind
	the survival rates later observed for newly diagnosed patients, and
	period analysis would consistently have provided much more up-to-date
	estimates of survival rates. CONCLUSIONS: We conclude that period
	analysis should be implemented as a standard tool for providing up-to-date
	estimates of long-term survival rates by cancer registries.},
  file        = {Brenner2002e.pdf:Brenner2002e.pdf:PDF;Brenner2002e.pdf:pdf\\Brenner2002e.pdf:PDF},
  institution = {Department of Epidemiology, German Centre for Research on Ageing, Heidelberg, Germany. brenner@dzfa.uni-heidelberg.de},
  journal     = {International Journal of Epidemiology},
  month       = apr,
  owner       = {pl4},
  pmid        = {11980816},
  timestamp   = {2008.12.02},
  year        = {2002},
}

@Article{Brenner2003a,
  author      = {H. Brenner and C. Spix},
  title       = {Combining cohort and period methods for retrospective time trend analyses of long-term cancer patient survival rates.},
  doi         = {10.1038/sj.bjc.6601295},
  number      = {7},
  pages       = {1260--1265},
  volume      = {89},
  abstract    = {Assessing trends in long-term cancer patient survival is an essential
	component of monitoring progress against cancer by cancer registries.
	Traditional assessment of long-term survival ('cohort analysis')
	is very useful to disclose trends in long-term survival rates of
	patients diagnosed many years ago, but it does not allow the disclosure
	of recent trends in long-term survival rates. The latter can be achieved
	by an alternative method of survival analysis ('period analysis'),
	which has been proposed a few years ago. On the other hand, unlike
	cohort analysis, period analysis does not provide estimates of long-term
	survival rates for patients diagnosed in the early years after initiation
	of cancer registration. In this paper, a method of retrospective
	analysis of time trends in long-term survival rates is introduced,
	which combines the advantages of both cohort and period analysis
	('mixed analysis'). This method thereby allows for a comprehensive
	monitoring of trends in long-term survival over an extended time
	span from the earliest to the most recent years of cancer registration.
	The use of the method is illustrated for retrospective time trend
	analyses of long-term survival of cancer patients in the United States
	with the 1973-1999 database of the Surveillance, Epidemiology, and
	End Results Program of the National Cancer Institute.},
  file        = {Brenner2003a.pdf:Brenner2003a.pdf:PDF;Brenner2003a.pdf:pdf\\Brenner2003a.pdf:PDF},
  institution = {Department of Epidemiology, German Centre for Research on Ageing, Bergheimer Str 20, D-69115 Heidelberg, Germany. brenner@dzfa.uni-heidelberg.de},
  journal     = {British Journal of Cancer},
  month       = oct,
  owner       = {pl4},
  pii         = {6601295},
  pmid        = {14520457},
  timestamp   = {2008.12.02},
  year        = {2003},
}

@Article{Brenner2007d,
  author      = {Hermann Brenner and Eva Steliarova-Foucher and Volker Arndt},
  title       = {Up-to-date monitoring of childhood cancer long-term survival in Europe: methodology and application to all forms of cancer combined.},
  doi         = {10.1093/annonc/mdm186},
  number      = {9},
  pages       = {1561--1568},
  volume      = {18},
  abstract    = {BACKGROUND: The Automated Childhood Cancer Information System (ACCIS)
	provides a unique database for monitoring and comparing long-term
	prognosis of children with cancer in Europe. The 'period' method
	has been shown particularly useful for that purpose. PATIENTS AND
	METHODS: The ACCIS database was used for comparative analyses of
	up-to-date long-term survival in four regions and 19 countries of
	Europe by period analysis. Overall, follow-up data on 49,503 children
	diagnosed between 1985 and the end of the 1990s were included. Period
	estimates of 10-year survival were derived for the 1995-99 period
	and compared with estimates obtained by cohort and complete analysis.
	In this article, the methodology is described and the approach is
	illustrated for all forms of childhood cancer combined. RESULTS:
	Long-term childhood cancer survival achieved in Europe by the end
	of the twentieth century is much higher than previous estimates indicated.
	The overall period estimate of 10-year survival was 71\% for all
	countries combined, but it varied between 45\% for Estonian children
	and 79\% for Swedish and Finnish children with cancer. CONCLUSION:
	Period analysis is the method of choice to monitor population-based
	survival. Despite major improvement during the past decades, tremendous
	variation in childhood cancer survival between European countries
	has persisted.},
  file        = {Brenner2007d.pdf:Brenner2007d.pdf:PDF;Brenner2007d.pdf:pdf\\Brenner2007d.pdf:PDF},
  institution = {Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany. h.brenner@dkfz-heidelberg.de},
  journal     = {Ann Oncol},
  month       = sep,
  owner       = {pl4},
  pii         = {mdm186},
  pmid        = {17660498},
  timestamp   = {2008.12.02},
  year        = {2007},
}

@Article{Breslow1977,
  author    = {N. Breslow and C. W. Chan and G. Dhom and R. A. Drury and L. M. Franks and B. Gellei and Y. S. Lee and S. Lundberg and B. Sparke and N. H. Sternby and H. Tulinius},
  title     = {Latent carcinoma of prostate at autopsy in seven areas. {T}he {I}nternational {A}gency for {R}esearch on {C}ancer, {L}yons, {F}rance.},
  number    = {5},
  pages     = {680--8},
  url       = {http://www.iarc.fr/en/publications/pdfs-online/stat/sp32/},
  volume    = {20},
  abstract  = {A world-wide comparative study of the frequency and characteristics
	of latent carcinoma of the prostate was undertaken in seven areas,
	using standardized methods and "blind" microscopic evaluation in
	order to reduce selection and observer bias. The morphological features
	of 350 latent carcinomas found in 1,327 prostates were examined.
	Two Chinese populations, from Hong Kong and Singapore, showed a low
	frequency of latent carcinoma in comparison with western Europeans
	in {S}weden and the Federal Republic of Germany and negroes from
	Jamaica; an intermediate position was found for Israelis and black
	Ugandans. The frequency of small latent carcinomas was about 12\%
	in all the areas investigated and did not vary with age. Rates for
	larger latent carcinomas increased sharply with age ans showed an
	area-to-area variation resembling that of clinical carcinoma of prostate.
	The small carcinomas were almost exclusively situated in the outer
	half of the prostate and latent carcinomas of all sizes were evenly
	distributed between the anterior and posterior halves of the prostate
	and the right and left sides of the outer prostatic shell. Certain
	disagreements in diagnosis were noted when the sections from each
	area were evaluated independently by a different pathologist. Most
	of these disagreements were resolved by re-reading the sections;
	their occurrence had no significant effect on the geographical comparisons.},
  journal   = {Int J Cancer},
  month     = nov,
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1977},
}

@Book{Breslow1987,
  author    = {Breslow, N. E. and Day, N. E.},
  title     = {Statistical Methods in Cancer Research: {V}olume II - {T}he Design and Analysis of Cohort Studies},
  publisher = {Lyon: IARC},
  series    = {IARC Scientific Publications No. 82},
  url       = {http://www.iarc.fr/en/publications/pdfs-online/stat/sp82/},
  file      = {Breslow1987.pdf:Breslow1987.pdf:PDF},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1987},
}

@Book{Breslow1980,
  author    = {Breslow, N. E. and Day, N. E.},
  title     = {Statistical Methods in Cancer Research: {V}olume I - {T}he analysis of Case-Control Studies},
  publisher = {Lyon: IARC},
  series    = {IARC Scientific Publications No. 32},
  url       = {http://www.iarc.fr/en/publications/pdfs-online/stat/sp32/},
  file      = {Breslow1980.pdf:Breslow1980.pdf:PDF},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1980},
}

@Article{Breslow1983,
  author    = {Breslow, N. E. and Lubin, J. H. and Langholz, B.},
  title     = {Multiplicative Models and Cohort Analysis},
  volume    = {78},
  journal   = {Journal of the American Statistical Association},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1983},
}

@Book{Briggs1968,
  author    = {Briggs, W. and Bryan, G. H. and Walker, G.},
  title     = {The Tutorial Algebra},
  publisher = {London: University Tutorial Press},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1968},
}

@Article{Brillinger1986,
  author    = {Brillinger, D. R.},
  title     = {The Natural Variability of Vital Rates and Associated Statistics},
  pages     = {693--734},
  volume    = {42},
  file      = {Brillinger1986.pdf:pdf\\Brillinger1986.pdf:PDF;Brillinger1986.pdf:Brillinger1986.pdf:PDF},
  journal   = {Biometrics},
  owner     = {PaulD},
  timestamp = {2015.09.23},
  year      = {1986},
}

@Article{Brooke1998,
  author      = {A. M. Brooke and P. C. Lambert and P. R. Burton and C. Clarke and D. K. Luyt and H. Simpson},
  title       = {Recurrent cough: natural history and significance in infancy and early childhood.},
  number      = {4},
  pages       = {256--261},
  volume      = {26},
  abstract    = {We investigated the outcome for a sample of children in whom recurrent
	cough was reported in the preschool years to determine 1) whether
	they shared the characteristics attributed to cough variant asthma,
	and 2) the proportion who developed classical wheezy asthma at follow-up
	during the early school years. A cohort of children identified as
	having recurrent cough in the preschool period was reassessed during
	the early school years. Previously identified asymptomatic preschool
	children who remained symptom-free provided a comparison group with
	respect to current respiratory symptoms, lung function, bronchial
	reactivity to inhaled methacholine, atopic status, peak flow variability,
	and recorded night cough. The response rate was modest, with 41\%
	attending the follow-up study; information on current symptoms was
	available from a further 16\%. Ascertainment of current symptoms
	showed that 70 of 125 (56.0\% [95\% CI 47.3-64.5\%]) were symptom-free
	at follow-up, 46 (36.8\% [28.7-45.5\%]) continued to have recurrent
	cough in the absence of colds, and 9 (7.2\% [3.6-12.8\%]) reported
	recent attacks of wheeze. When comparing the 46 children whose recurrent
	cough persisted from the preschool period through to follow-up with
	subjects from the asymptomatic comparison group, the former had significantly
	more night cough (50.0\% vs. 16.8\%; P< 0.01), were more likely to
	be treated (10.9\% vs. 1.7\%; P=0.01), or were diagnosed (26.1\%
	vs. 5.7\%; P < 0.001) as asthmatic. They also showed greater bronchial
	reactivity than their asymptomatic counterparts (1.23 mg/ml vs. 3.35
	mg/ml; P=0.002). Atopic status and other indices of lung function
	were similar between groups. We conclude that there are a group of
	children with long-term recurrent cough who display features consistent
	with a diagnosis of cough variant asthma, but at 2-4 years of follow-up,
	few progress to develop asthma characterized by wheeze.},
  file        = {Brooke1998.pdf:Brooke1998.pdf:PDF;Brooke1998.pdf:pdf\\Brooke1998.pdf:PDF},
  institution = {Department of Child Health, University of Leicester, UK.},
  journal     = {Pediatr Pulmonol},
  month       = oct,
  owner       = {pl4},
  pii         = {3.0.CO;2-O},
  pmid        = {9811075},
  timestamp   = {2008.10.15},
  year        = {1998},
}

@Article{Brooke1996,
  author      = {A. M. Brooke and P. C. Lambert and P. R. Burton and C. Clarke and D. K. Luyt and H. Simpson},
  title       = {Night cough in a population-based sample of children: characteristics, relation to symptoms and associations with measures of asthma severity.},
  number      = {1},
  pages       = {65--71},
  volume      = {9},
  abstract    = {Nocturnal cough in asthma is a common but poorly understood phenomenon.
	The aims of this study were to determine the relationship between
	recorded night cough, reported night cough and current wheeze in
	a population-based sample of children previously identified as wheezy,
	and to examine the relationship of nocturnal cough to current symptoms,
	markers of asthma severity and environmental exposure. Children were
	reassessed in the early school years by measuring current symptoms,
	ventilatory function, bronchial reactivity, peak flow variability,
	respiratory symptom diaries and home monitoring of overnight cough,
	transcutaneous arterial oxygen saturation, room temperature and humidity.
	Night studies were performed on 59 asymptomatic children and 41 children
	with current wheeze. Cough occurred more frequently in current wheezers
	compared to asymptomatic children (16 out of 41 (39\%) vs 11 out
	of 59 (19\%)), and more cough episodes were recorded (median 3.5
	vs 2.0). Night cough was not associated with bronchial reactivity,
	peak flow variability, degree of morning dip, mean overnight arterial
	oxygen saturation, ventilatory function, maternal smoking or treatment
	of asthma. However, it was associated with lower overnight air temperature.
	Although night cough is more common in current wheezers, there is
	poor agreement between recorded and reported night cough. Objective
	tests of asthma severity are of little use in predicting its presence
	in this age group. The sleeping environment deserves further study.},
  file        = {Brooke1996.pdf:Brooke1996.pdf:PDF;Brooke1996.pdf:pdf\\Brooke1996.pdf:PDF},
  institution = {Dept. of Child Health, University of Leicester, UK.},
  journal     = {Eur Respir J},
  month       = jan,
  owner       = {pl4},
  pmid        = {8834336},
  timestamp   = {2008.10.15},
  year        = {1996},
}

@Article{Brooke1995,
  author      = {A. M. Brooke and P. C. Lambert and P. R. Burton and C. Clarke and D. K. Luyt and H. Simpson},
  title       = {The natural history of respiratory symptoms in preschool children.},
  number      = {6 Pt 1},
  pages       = {1872--1878},
  volume      = {152},
  abstract    = {We studied the natural history of preschool respiratory symptoms in
	a population-based sample of children followed during the early school
	years. Current symptoms, ventilatory function, bronchial responsiveness
	to methacholine (BR), atopic status, and peak expiratory flow variability
	(PEFV) were assessed. Among those initially asymptomatic (210 subjects),
	83.3\% remained symptom-free, 6.7\% started to wheeze, and 10\% developed
	recurrent cough. Nearly half (46.9\%) of the initial wheezing group
	(145 subjects) became symptom-free, 37.9\% continued to wheeze, and
	15.2\% reported recurrent cough. Over half (56.0\%) of the cough
	group (127 subjects) became symptom-free, 7.2\% developed wheeze,
	and 36.8\% reported continuing cough. Preschool wheezers showed the
	greatest BR (geometric mean 1.91 mg/ml) and the highest atopic prevalence
	(AP) (43.6\%) when compared with the preschool asymptomatic group
	(BR: 3.39 mg/ml; AP: 23.8\%) and the cough group (BR: 2.62 mg/ml;
	AP: 26.7\%) (p = 0.0001 and p = 0.006 respectively). Children whose
	wheeze had persisted from the preschool period exhibited the poorest
	ventilatory function, the highest BR, a high AP, and high PEFV. The
	study shows that fewer than half of preschool wheezy children continued
	to wheeze in the early school years but those with persistent wheeze
	display many of the clinical characteristics consistent with a diagnosis
	of asthma.},
  institution = {Department of Child Health, University of Leicester, England.},
  journal     = {Am J Respir Crit Care Med},
  month       = dec,
  owner       = {pl4},
  pmid        = {8520749},
  timestamp   = {2008.10.15},
  year        = {1995},
}

@Article{Brookmeyer1986,
  author    = {Brookmeyer, R. and Liang, K. Y. and Linet, M.},
  title     = {Matched Case-Control Designs and Overmatched Analysis},
  pages     = {693--701},
  volume    = {124},
  journal   = {American Journal of Epidemiology},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1986},
}

@Article{Brown1983,
  author    = {C. C. Brown},
  title     = {The statistical comparison of relative survival rates.},
  number    = {4},
  pages     = {941--948},
  volume    = {39},
  abstract  = {A statistical procedure for comparing the survival of two or more
	groups of patients adjusted for normal mortality expectation, i.e.
	for calculating relative survival, is proposed. The method is shown
	to correspond to some commonly used procedures for comparing unadjusted
	survival; it provides an improvement over these procedures in many
	situations, even when the normal mortality expectations for the patient
	groups are the same. An example of its use is given.},
  file      = {Brown1983.pdf:Brown1983.pdf:PDF;Brown1983.pdf:pdf\\Brown1983.pdf:PDF},
  journal   = {Biometrics},
  month     = dec,
  owner     = {pl4},
  pmid      = {6671129},
  timestamp = {2008.12.16},
  year      = {1983},
}

@Article{Brown2001,
  author      = {Brown, M. L. and Lipscomb, J. and Snyder, C.},
  title       = {The burden of illness of cancer: economic cost and quality of life.},
  doi         = {10.1146/annurev.publhealth.22.1.91},
  language    = {eng},
  pages       = {91--113},
  url         = {http://dx.doi.org/10.1146/annurev.publhealth.22.1.91},
  volume      = {22},
  abstract    = {Cancer is a major public health issue and represents a significant
	burden of disease. In this chapter, we analyze the main measures
	of burden of disease as relate to cancer. Specifically, we review
	incidence and mortality, years of life lost from cancer, and cancer
	prevalence. We also discuss the economic burden of cancer, including
	cost of illness, phase-specific and long-term costs, and indirect
	costs. We then examine the impact of cancer on health-related quality
	of life as measured in global terms (disability-adjusted life years
	and quality-adjusted life years) and using evaluation-oriented applications
	of health-related quality of life scales. Throughout, we note the
	relative strengths and weaknesses of the various approaches to measuring
	the burden of cancer as well as the methodologic challenges that
	persist in burden-of-illness research. We conclude with a discussion
	of the research agenda to improve our understanding of the burden
	of cancer and of illness more generally.},
  file        = {Brown2001.pdf:Brown2001.pdf:PDF;Brown2001.pdf:pdf\\Brown2001.pdf:PDF},
  institution = {Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland 20892, USA. mb53o@nih.gov},
  journal     = {Annu Rev Public Health},
  keywords    = {Cost of Illness; Health Care Costs; Health Planning; Humans; Medical Record Linkage; Neoplasms, economics/epidemiology/mortality; Quality of Life; SEER Program, statistics /&/ numerical data; United States, epidemiology},
  medline-pst = {ppublish},
  owner       = {theand},
  pii         = {22/1/91},
  pmid        = {11274513},
  timestamp   = {2012.09.14},
  year        = {2001},
}

@Article{Brunaud2001,
  author      = {Brunaud, L. and Antunes, L. and Collinet-Adler, S. and Marchal, F. and Ayav, A. and Bresler, L. and Boissel, P.},
  title       = {Acute mesenteric venous thrombosis: case for nonoperative management.},
  doi         = {10.1067/mva.2001.117331},
  language    = {eng},
  number      = {4},
  pages       = {673--679},
  url         = {http://dx.doi.org/10.1067/mva.2001.117331},
  volume      = {34},
  abstract    = {Initial treatment in the management of acute mesenteric vein thrombosis
	(MVT) is controversial. Some authors have proposed a surgical approach,
	whereas others have advocated medical therapy (anticoagulation).
	In this study, we analyzed and compared the results obtained with
	surgical and medical treatment to determine the best initial management
	for this disease.We retrospectively reviewed the records of patients
	treated for MVT in a secondary care surgical department from January
	1987 to December 1999. Before January 1995, our departmental policy
	was to perform surgery in patients with suspected MVT. Since January
	1995, we have preferred a medical approach when achievable. Each
	patient in this study was assessed for diagnosis, initial management
	(laparotomy or anticoagulation), morbidity, mortality, duration of
	hospitalization, the need for secondary operation, portal hypertension,
	and survival rates.Twenty-six patients were treated, 14 before January
	1995 (group 1) and 12 since January 1995 (group 2). Morbidity, mortality,
	secondary operation, portal hypertension, and 2-year survival rates
	were 34.6\%, 19.2\%, 15.3\%, 19.2\%, and 76.9\%, respectively. No
	statistical difference was observed between the two groups. The mean
	duration of hospitalization was 51.6 days in group 1 and 23.2 days
	in group 2 (P < .05). Among the 12 patients treated by means of laparotomy
	with bowel resection, 10 patients (83\%) had mucosal necrosis without
	transmural necrosis at pathologic study.Nonoperative management for
	acute MVT is feasible when the initial diagnosis with a computed
	tomography scan is certain and when the bowel infarction has not
	led to transmural necrosis and bowel perforation. The morbidity,
	mortality, and survival rates are similar in cases of surgical and
	nonoperative management. The length of hospital stay is shorter when
	patients are treated with a nonoperative approach. A nonoperative
	approach, when indicated, avoids the resection of macroscopically
	infarcted small bowel (without transmural necrosis) in cases that
	are potentially reversible with anticoagulation alone.},
  institution = {Department of Visceral and Endocrine Surgery, University Hospital NANCY Brabois, Vandoeuvre les Nancy, France. lbrunaud@planete.net},
  journal     = {J Vasc Surg},
  keywords    = {Acute Disease; Aged; Anticoagulants, therapeutic use; Causality; Comorbidity; Female; Humans; Hypertension, Portal, etiology; Laparotomy, standards; Length of Stay, statistics /&/ numerical data; Male; Mesenteric Vascular Occlusion, complications/diagnosis/drug therapy/mortality/surgery; Mesenteric Veins; Middle Aged; Morbidity; Patient Selection; Proportional Hazards Models; Reoperation, statistics /&/ numerical data; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Venous Thrombosis, complications/diagnosis/drug therapy/mortality/surgery},
  medline-pst = {ppublish},
  month       = {Oct},
  owner       = {pl4},
  pii         = {S0741-5214(01)87279-7},
  pmid        = {11668323},
  timestamp   = {2013.05.29},
  year        = {2001},
}

@Article{Brunaud2002,
  author      = {Brunaud, L. and Cormier, L. and Ayav, A. and Klein, M. and Roumier, X. and Zarnegar, R. and Bresler, L. and Boissel, P.},
  title       = {[Does the size of pheochromocytoma influence the results of its laparoscopic excision?].},
  language    = {fre},
  number      = {5},
  pages       = {362--369},
  volume      = {127},
  abstract    = {The tumor size is considered as a limitation for laparoscopic adrenalectomy.
	The aim of this study was to assess diagnostic characteristics, hemodynamic
	modifications, and outcome of intraperitoneal laparoscopic adrenalectomy
	according to the size of pheochromocytoma.Retrospective study from
	January 1997 to December 2000. Results were evaluated according to
	the size of pathologic study (< or > or = 5 cm).Forty two patients
	underwent laparoscopic adrenalectomy during this period. Among them,
	11 (26\%) were operated on for adrenal pheochromocytoma (6 patients
	< 5 cm and 5 patients > or = 5 cm). Preoperative systolic hypertension
	was 138 mmHg and 178 mmHg respectively (p = 0.01). Urinary metanephrine/normetanephrine
	rate was 1.259 and 0.268 respectively (p = 0.08). Capsular tumor
	effraction rate was 27\%. Tumor size was 37\% larger than that estimated
	by CT scan (24\% versus 52\%). Mean hospital stay was 10 days and
	8 days respectively. Morbidity and mortality were 18\% and 0\%. All
	these criteria were not statistically significant among the two groups
	of patients.Pheochromocytoma size > or = 5 cm do not modify outcome
	of patients but is responsible for preferential noradrenaline secretion
	and stronger hemodynamic modifications. Tumor fragmentation rate
	and CT scan size underestimation seem important in this group of
	patients. These characteristics have to be integrated to improve
	laparoscopic adrenalectomy outcome of patients with pheochromocytoma
	> or = 5 cm.},
  institution = {CHU Nancy-Brabois, 54511 Vandoeuvre les Nancy, France. lbrunaud@planete.net},
  journal     = {Ann Chir},
  keywords    = {Adrenal Gland Neoplasms, pathology/surgery; Adult; Female; Hemodynamics; Humans; Laparoscopy; Length of Stay; Male; Middle Aged; Neoplasm Staging; Patient Selection; Pheochromocytoma, pathology/surgery; Retrospective Studies; Risk Factors; Treatment Outcome},
  medline-pst = {ppublish},
  month       = {May},
  owner       = {pl4},
  pmid        = {12094419},
  timestamp   = {2013.05.29},
  year        = {2002},
}

@Article{Buckley1984,
  author    = {J.D. Buckley},
  title     = {Additive and multiplicative models for relative survival rates},
  pages     = {515--62},
  volume    = {40},
  file      = {Buckley1984.pdf:Buckley1984.pdf:PDF;Buckley1984.pdf:pdf\\Buckley1984.pdf:PDF},
  groups    = {Excess mortality model},
  journal   = {Biometrics},
  owner     = {pl4},
  timestamp = {2008.12.16},
  year      = {1984},
}

@Article{Bull1997,
  author    = {Bull, K. and Spiegelhalter, D. J.},
  title     = {Tutorials in Biostatistics: {S}urvival Analysis in Observational Studies},
  pages     = {1041--1074},
  volume    = {16},
  journal   = {Statistics in Medicine},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1997},
}

@Article{Buntrock2007,
  author      = {Buntrock, Stefan and Hopfgarten, Thomas and Adolfsson, Jan and Onel{\"o}v, Erik and Steineck, Gunnar},
  title       = {The Internet and prostate cancer patients: searching for and finding information.},
  doi         = {10.1080/00365590701303827},
  language    = {eng},
  number      = {5},
  pages       = {367--374},
  url         = {http://dx.doi.org/10.1080/00365590701303827},
  volume      = {41},
  abstract    = {To define the characteristics of prostate cancer patients who use
	the Internet.In October 2002, 511 prostate cancer patients from Stockholm-Gotland
	County completed a postal questionnaire consisting of 146 questions
	regarding use of the Internet, demographic factors, level of information
	about the disease and its treatment, quality of life and trade-off
	possibilities.The response rate was 86.5\% (n=511) and the mean age
	of the respondents was 71 years. A total of 210 men (41.1\%) had
	access to the Internet. Eighty-two men (16.4\%) had looked for information
	on prostate cancer, either by themselves or with the aid of others.
	Among men aged 50-60 years, 39\% were Internet users, compared to
	8\% among men aged 75-80 years; the figures for university graduates
	versus those who had only attended elementary school were 33\% and
	3\%, respectively. Fifty of the 82 men (61\%) who searched for information
	regarded themselves as being satisfactorily informed by online information.Of
	the men in this cohort, 16\% searched the Internet for information
	regarding their prostate cancer. Young and well-educated men utilized
	the Internet more frequently than others, but they did not find information
	more often than older and less well-educated men. It is possible
	that the Internet promotes social inequality in obtaining healthcare
	in favor of well-educated, highly paid individuals.},
  file        = {Buntrock2007.pdf:Buntrock2007.pdf:PDF;Buntrock2007.pdf:pdf\\Buntrock2007.pdf:PDF},
  institution = {Division of Clinical Cancer Epidemiology, Karolinska Institute, Stockholm, Sweden.},
  journal     = {Scand J Urol Nephrol},
  keywords    = {Access to Information; Aged; Aged, 80 and over; Delivery of Health Care; Demography; Humans; Information Storage and Retrieval; Information Systems; Internet, utilization; Male; Middle Aged; Prostatic Neoplasms, pathology},
  medline-pst = {ppublish},
  owner       = {sanelo},
  pii         = {778575121},
  pmid        = {17853004},
  timestamp   = {2013.10.17},
  year        = {2007},
}

@Article{Burnet2005,
  author      = {Burnet, N. G. and Jefferies, S. J. and Benson, R. J. and Hunt, D. P. and Treasure, F. P.},
  title       = {Years of life lost ({YLL}) from cancer is an important measure of population burden -- and should be considered when allocating research funds.},
  doi         = {10.1038/sj.bjc.6602321},
  language    = {eng},
  number      = {2},
  pages       = {241--245},
  url         = {http://dx.doi.org/10.1038/sj.bjc.6602321},
  volume      = {92},
  abstract    = {Recently, cancer mortality has been compared to research spending
	by the National Cancer Research Institute (NCRI), whose research
	budget is approximately pound sterling 250 million. The analysis
	shows a mis-match between mortality and research spending. As well
	as crude mortality rates, other measures of cancer burden should
	be considered because they contribute additional information. 'Years
	of life lost' (YLL) summed over each individual dying after a diagnosis
	of cancer represents a population-based mortality indicator of the
	impact of that disease on society. Years of life lost divided by
	the number of deaths for each cancer site produces an additional
	statistic, the average years of life lost (AYLL), which is a measure
	of the burden of cancer to the individual patient. For 17 cancer
	sites where data are available, four tumour sites have a rather large
	difference in mortality, comparing YLL to crude mortality. Years
	of life lost shows the population burden from cancers of the ovary,
	cervix, and CNS to be rather larger than suggested by crude mortality,
	despite screening programmes for cervix cancer. Using YLL, the underprovision
	of funding for lung cancer research is similar to that reported using
	percentage mortality. Breast cancer and leukaemia receive a relatively
	higher research spend than the population burden of these cancers,
	and the spending on leukaemia is quite extreme. Prostate cancer has
	a low per cent YLL but attracts a moderate amount of research spending.
	The use of AYLL as an indicator of individual cancer burden considerably
	changes the ranking of the mortality from different tumours. The
	mean AYLL is 12.5 years. Prostate cancer has the lowest AYLL, only
	6.1 years; brain tumour patients have the highest, at just over 20
	years. Comparing AYLL to research spending suggests four 'Cinderella'
	cancer sites with high individual cancer burden but low research
	spending: CNS tumours, cervix and kidney cancers, and melanoma. Breast
	cancer and leukaemia have roughly average AYLL but a considerable
	excess of research spending. YLL emphasises the discrepancy between
	research spending and mortality, and may be helpful for decisions
	concerning research support. Average years of life lost measures
	the burden to individual patients and may be helpful where individuals'
	needs are relevant, such as palliative care. As well as crude mortality,
	more subtle and comprehensive calculations of mortality statistics
	would be useful in debates on research funding and public health
	issues.},
  file        = {Burnet2005.pdf:Burnet2005.pdf:PDF;Burnet2005.pdf:pdf\\Burnet2005.pdf:PDF},
  institution = {Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK. ngb21@cam.ac.uk},
  journal     = {Br J Cancer},
  keywords    = {Biomedical Research, economics; Humans; Life Expectancy; Neoplasms, mortality; Research Support as Topic, economics},
  medline-pst = {ppublish},
  month       = {Jan},
  owner       = {theand},
  pii         = {6602321},
  pmid        = {15655548},
  timestamp   = {2012.09.14},
  year        = {2005},
}

@Article{Burnham2004,
  author    = {K. P. Burnham},
  title     = {Multimodel inference: understanding {AI}C and BIC in model selection},
  pages     = {261--304},
  volume    = {33},
  file      = {Burnham2004.pdf:Burnham2004.pdf:PDF;Burnham2004.pdf:pdf\\Burnham2004.pdf:PDF},
  journal   = {Sociological Methods and Research},
  owner     = {pl4},
  timestamp = {2009.05.07},
  year      = {2004},
}

@Book{Burnham2002,
  author    = {Burnham, K. P. and Anderson, D. R.},
  title     = {Model selection and multimodel inference: a practical information-theoretic approach},
  publisher = {Springer},
  owner     = {hanbow},
  timestamp = {2015.05.12},
  year      = {2002},
}

@Article{Burton2004,
  author    = {Burton, A. and Altman, D. G.},
  title     = {Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines},
  pages     = {4-8},
  volume    = {91},
  journal   = {British Journal of Cancer},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2004},
}

@Article{Burton2006,
  author      = {Andrea Burton and Douglas G Altman and Patrick Royston and Roger L Holder},
  title       = {The design of simulation studies in medical statistics.},
  doi         = {10.1002/sim.2673},
  number      = {24},
  pages       = {4279--4292},
  volume      = {25},
  abstract    = {Simulation studies use computer intensive procedures to assess the
	performance of a variety of statistical methods in relation to a
	known truth. Such evaluation cannot be achieved with studies of real
	data alone. Designing high-quality simulations that reflect the complex
	situations seen in practice, such as in prognostic factors studies,
	is not a simple process. Unfortunately, very few published simulation
	studies provide sufficient details to allow readers to understand
	fully all the processes required to design a simulation study. When
	planning a simulation study, it is recommended that a detailed protocol
	be produced, giving full details of how the study will be performed,
	analysed and reported. This paper details the important considerations
	necessary when designing any simulation study, including defining
	specific objectives of the study, determining the procedures for
	generating the data sets and the number of simulations to perform.
	A checklist highlighting the important considerations when designing
	a simulation study is provided. A small review of the literature
	identifies the current practices within published simulation studies.},
  file        = {Burton2006.pdf:pdf\\Burton2006.pdf:PDF},
  institution = {Cancer Research UK/NHS Centre for Statistics in Medicine, Oxford, UK. andrea.burton@cancer.org.uk},
  journal     = {Statistics in Medicine},
  month       = dec,
  owner       = {pl4},
  pmid        = {16947139},
  timestamp   = {2009.12.03},
  year        = {2006},
}

@Article{Burton2005,
  author      = {Paul R Burton and Katrina J Scurrah and Martin D Tobin and Lyle J Palmer},
  title       = {Covariance components models for longitudinal family data.},
  doi         = {10.1093/ije/dyi069},
  number      = {5},
  pages       = {1063--77; discussion1077--9},
  volume      = {34},
  abstract    = {A longitudinal family study is an epidemiological design that involves
	repeated measurements over time in a sample that includes families.
	Such studies, that may also include relative pairs and unrelated
	individuals, allow closer investigation of not only the factors that
	cause a disease to arise, but also the genetic and environmental
	determinants that modulate the subsequent progression of that disease.
	Knowledge of such determinants may pay high dividends in terms of
	prognostic assessment and in the development of new treatments that
	may be tailored to the prognostic profile of individual patients.
	Unfortunately longitudinal family studies are difficult to analyse.
	They conflate the complex within-family correlation structure of
	a cross-sectional family study with the correlation over time that
	is intrinsic to longitudinal repeated measures. Here we describe
	an approach to analysis that is relatively straightforward to implement,
	yet is flexible in its application. It represents a natural extension
	of a Gibbs-sampling-based approach to the analysis of cross-sectional
	family studies that we have described previously. The approach can
	be applied to pedigrees of arbitrary complexity. It is applicable
	to continuous traits, repeated binary disease states, and repeated
	counts or rates with a Poisson distribution. It not only supports
	the analysis of observed determinants, including measured genotypes,
	but also allows decomposition of the correlation structure, thereby
	permitting conclusions to be drawn about the effect of unobserved
	genes and environment on key features of disease progression, and
	hence to estimate the heritability of these features. We demonstrate
	the efficacy of our methods using a range of simulated data analyses,
	and illustrate its practical application to longitudinal blood pressure
	data measured in families from the Framingham Heart Study.},
  file        = {Burton2005.pdf:Burton2005.pdf:PDF;Burton2005.pdf:pdf\\Burton2005.pdf:PDF},
  institution = {Biostatistics and Genetic Epidemiology, Department of Health Sciences, Institute of Genetics, University of Leicester, UK. paul.genepi@ntlworld.com},
  journal     = {International Journal of Epidemiology},
  month       = oct,
  owner       = {pl4},
  pii         = {dyi069},
  pmid        = {15831561},
  timestamp   = {2010.07.15},
  year        = {2005},
}

@Article{Bwakura-Dangarembizi2014,
  author      = {Bwakura-Dangarembizi, Mutsawashe and Kendall, Lindsay and Bakeera-Kitaka, Sabrina and Nahirya-Ntege, Patricia and Keishanyu, Rosette and Nathoo, Kusum and Spyer, Moira J. and Kekitiinwa, Adeodata and Lutaakome, Joseph and Mhute, Tawanda and Kasirye, Philip and Munderi, Paula and Musiime, Victor and Gibb, Diana M. and Walker, A Sarah and Prendergast, Andrew J. and , Antiretroviral Research for Watoto (A. R. R. O. W) Trial Team},
  title       = {{A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.}},
  language    = {eng},
  number      = {1},
  pages       = {41--53},
  volume      = {370},
  abstract    = {Co-trimoxazole (fixed-dose trimethoprim-sulfamethoxazole) prophylaxis
	administered before antiretroviral therapy (ART) reduces morbidity
	in children infected with the human immunodeficiency virus (HIV).
	We investigated whether children and adolescents receiving long-term
	ART in sub-Saharan Africa could discontinue co-trimoxazole.We conducted
	a randomized, noninferiority trial of stopping versus continuing
	daily open-label co-trimoxazole in children and adolescents in Uganda
	and Zimbabwe. Eligible participants were older than 3 years of age,
	had been receiving ART for more than 96 weeks, were using insecticide-treated
	bed nets (in malaria-endemic areas), and had not had Pneumocystis
	jirovecii pneumonia. Coprimary end points were hospitalization or
	death and adverse events of grade 3 or 4.A total of 758 participants
	were randomly assigned to stop or continue co-trimoxazole (382 and
	376 participants, respectively), after receiving ART for a median
	of 2.1 years (interquartile range, 1.8 to 2.3). The median age was
	7.9 years (interquartile range, 4.6 to 11.1), and the median CD4
	T-cell percentage was 33\% (interquartile range, 26 to 39). Participants
	who stopped co-trimoxazole had higher rates of hospitalization or
	death than those who continued (72 participants [19\%] vs. 48 [13\%];
	hazard ratio, 1.64; 95\% confidence interval [CI], 1.14 to 2.37;
	P?=?0.007; noninferiority not shown). There was no evidence of variation
	across ages (P=0.93 for interaction). A total of 2 participants in
	the prophylaxis-stopped group (1\%) died, as did 3 in the prophylaxis-continued
	group (1\%). Most hospitalizations in the prophylaxis-stopped group
	were for malaria (49 events, vs. 21 in the prophylaxis-continued
	group) or infections other than malaria (53 vs. 25), particularly
	pneumonia, sepsis, and meningitis. Rates of adverse events of grade
	3 or 4 were similar in the two groups (hazard ratio, 1.20; 95\% CI,
	0.83 to 1.72; P=0.33), but more grade 4 adverse events occurred in
	the prophylaxis-stopped group (hazard ratio, 2.04; 95\% CI, 0.99
	to 4.22; P=0.05), with anemia accounting for the largest number of
	events (12, vs. 2 with continued prophylaxis).Continuing co-trimoxazole
	prophylaxis after 96 weeks of ART was beneficial, as compared with
	stopping prophylaxis, with fewer hospitalizations for both malaria
	and infection not related to malaria. (Funded by the United Kingdom
	Medical Research Council and others; ARROW Current Controlled Trials
	number, ISRCTN24791884.).},
  institution = {From the University of Zimbabwe, College of Health Sciences, Harare (M.B.-D., K.N., T.M.); the Medical Research Council Clinical Trials Unit at University College London (L.K., M.J.S., D.M.G., A.S.W., A.J.P.) and Centre for Paediatrics, Blizard Institute, Queen Mary, University of London (A.J.P.), London; and the Paediatric Infectious Diseases Clinic of Baylor-Uganda, Mulago Hospital (S.B.-K., A.K., P.K.), and Joint Clinical Research Center (R.K., V.M.), Kampala, and the Medical Research Council and Uganda Virus Research Institute, Uganda Research Unit on AIDS, Entebbe (P.N.-N., J.L., P.M.) - all in Uganda.},
  journal     = {N Engl J Med},
  keywords    = {Adolescent; Anti-Infective Agents, adverse effects/therapeutic use; Anti-Retroviral Agents, therapeutic use; CD4 Lymphocyte Count; Child; Child, Preschool; Female; Follow-Up Studies; HIV Infections, complications/drug therapy/mortality; Hospitalization, statistics /&/ numerical data; Humans; Kaplan-Meier Estimate; Malaria, complications/prevention /&/ control; Male; Trimethoprim-Sulfamethoxazole Combination, adverse effects/therapeutic use; Uganda; Withholding Treatment; Zimbabwe},
  medline-pst = {ppublish},
  month       = {Jan},
  owner       = {Michael},
  pmid        = {24382064},
  timestamp   = {2014.03.26},
  year        = {2014},
}

@InCollection{Byar1982,
  author    = {Byar, David P.},
  booktitle = {Statistics in Medical Research},
  title     = {Analysis of survival data: {C}ox and {W}eibull models with covariates},
  chapter   = {12},
  editor    = {Mike, V. and Stanley, K. E.},
  pages     = {365--401},
  publisher = {New York: John Wiley},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1982},
}

@Article{Cain1992,
  author    = {Cain, K. and Diehr, P.},
  title     = {Testing the Null Hypothesis in Small Area Analysis},
  pages     = {267--293},
  volume    = {27},
  journal   = {HSR: Health Services Research},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1992},
}

@Article{Calvet1992,
  author      = {Calvet, M. C. and Calvet, J. and Teilhac, J. R. and Drian, M. J.},
  title       = {Networks formed by dorsal root ganglion neurites within spinal cord explants: a computer-aided analysis of HRP intracellularly labeled neurons.},
  language    = {eng},
  number      = {1-2},
  pages       = {1--10},
  volume      = {584},
  abstract    = {Dorsal root ganglion (DRG) neurons from rat embryos were explanted
	either alone or with the attached spinal cord (SC). Neuritic processes
	were mapped out histologically using an intracellular iontophoretic
	HRP method. Computer reconstructions and morphometric parameters
	allowed a comparative quantitative analysis of the DRG neurons and
	of their neuritic processes in both models. The first model, strongly
	dependent on nerve growth factor (NGF) for its survival, developed
	large multidirectional processes. The second model showed a bipolar
	distribution of its neuritic processes, the central one entering
	predominantly the dorsolateral part of the cord explant and ramifying
	both homo- and heterolaterally. The quantitative data revealed a
	significant decrease in the overall size of the neuritic networks
	of the second model (with attached SC). A discriminant analysis permitted
	the recognition of these two populations of DRG neurons. The role
	of the spinal cord explant, and more precisely the target cells of
	the dorsal horn, was considered to be a prominent factor in the development
	of the DRG neuritic networks.},
  institution = {INSERM U 336, Montpellier, France.},
  journal     = {Brain Res},
  keywords    = {Animals; Cells, Cultured; Female; Fetal Tissue Transplantation, physiology; Ganglia, Spinal, cytology; Histocytochemistry; Horseradish Peroxidase; Image Processing, Computer-Assisted; Iontophoresis; Nerve Net, physiology; Neurites, physiology; Neurons, physiology; Pregnancy; Rats; Spinal Cord, cytology},
  medline-pst = {ppublish},
  month       = {Jul},
  owner       = {pl4},
  pii         = {0006-8993(92)90871-6},
  pmid        = {1515930},
  timestamp   = {2013.05.29},
  year        = {1992},
}

@Article{Campbell1985,
  author    = {M. J. Campbell},
  title     = {Multiplicative and additive models with external controls in a cohort study of cancer mortality.},
  number    = {3},
  pages     = {353--360},
  volume    = {4},
  abstract  = {The use of additive and multiplicative hazard models is examined for
	a cohort study of 2696 women followed up for 12 years. The multiplicative
	model implied that women with a haemoglobin level less than 12 g/dl
	were at higher risk from cancer, and the additive model showed that
	this risk was confined to women after the menopause. Despite difficulties
	in fitting and in interpretation, additive model can be useful in
	the analysis of cohort studies.},
  file      = {Campbell1985.pdf:Campbell1985.pdf:PDF;Campbell1985.pdf:pdf\\Campbell1985.pdf:PDF},
  journal   = {Statistics in Medicine},
  owner     = {pl4},
  pmid      = {4059721},
  timestamp = {2008.12.16},
  year      = {1985},
}

@Article{Campos-Filho90,
  author    = {Campos-Filho, N. and Franco, E. L.F.},
  title     = {Microcomputer-Assisted Multivariate Survival Data Analysis Using {C}ox's Proportional Hazards Regression Model},
  pages     = {81--87},
  volume    = {31},
  journal   = {Computer Programs in Biomedicine},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1990},
}

@Booklet{IncisiveHealth2014,
  author    = {Incisive Health for Cancer Research UK},
  date      = {2014},
  title     = {Saving lives, averting costs: An analysis of the financial implications of achieving earlier diagnosis of colorectal, lung and ovarian cancer.},
  file      = {IncisiveHealth2014.pdf:pdf\\IncisiveHealth2014.pdf:PDF},
  owner     = {BettyS},
  timestamp = {2016.12.09},
}

@Manual{Cantor2003,
  author       = {Alan Cantor},
  title        = {SAS Survival Analysis Techniques for Medical Research},
  edition      = {Second},
  organization = {BBU Press},
  owner        = {PaulD},
  timestamp    = {2011.06.19},
  year         = {2003},
}

@Manual{Cantor1997,
  author       = {Alan Cantor},
  title        = {Extending SAS Survival Analysis Techniques for Medical Research},
  organization = {Cary, NC: SAS Institute Inc.},
  owner        = {PaulD},
  timestamp    = {2011.06.19},
  year         = {1998},
}

@Article{Capocaccia1997a,
  author      = {R. Capocaccia and R. De Angelis},
  title       = {Estimating the completeness of prevalence based on cancer registry data.},
  number      = {4},
  pages       = {425--440},
  volume      = {16},
  abstract    = {Prevalence data provided by cancer registries are generally biased,
	since the patients that were diagnosed before the starting of the
	registry's activity cannot be included in the statistics. The relevance
	of this incompleteness bias is estimated in this paper. Incidence
	and relative survival are modelled as parametric functions describing
	a wide class of cancer diseases. Prevalence estimates are then computed
	considering different hypotheses on disease reversibility. The ratio
	between the prevalence observed by the registry and the total estimated
	prevalence is used as an index of completeness. An analytical evaluation
	of this ratio, as a function of the parameters characterizing the
	observational process and the biological behaviour of the disease,
	is given.},
  file        = {Capocaccia1997a.pdf:Capocaccia1997a.pdf:PDF;Capocaccia1997a.pdf:pdf\\Capocaccia1997a.pdf:PDF},
  institution = {Laboratory of Epidemiology and Biostatistics, Istituto Superiore di Sanit\'{a}, Roma, Italy.},
  journal     = {Stat Med},
  month       = feb,
  owner       = {pl4},
  pii         = {3.0.CO;2-Z},
  pmid        = {9044530},
  timestamp   = {2009.08.12},
  year        = {1997},
}

@Article{Carey1993,
  author    = {Carey, Vincent and Zeger, Scott L. and Diggle, Peter},
  title     = {Modelling multivariate binary data with alternating logistic regressions},
  pages     = {517--526},
  volume    = {80},
  journal   = {Biometrika},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1993},
}

@Article{Carlsson2000,
  author      = {Carlsson, M.},
  title       = {Cancer patients seeking information from sources outside the health care system.},
  language    = {eng},
  number      = {6},
  pages       = {453--457},
  volume      = {8},
  abstract    = {Most of the information patients receive about cancer and its treatment
	is probably provided by staff in health care, but if patients do
	not get sufficient information there is a risk that they might rely
	on nonmedical sources to satisfy their need. The aim of this study
	was to survey the degree to which patients seek information from
	sources outside the health care system. All adult cancer patients
	visiting or being admitted to the Oncology Department on 1 day were
	asked to complete a questionnaire. In the course of that day, 192
	adult patients visited the Oncology Department, and the response
	rate was 74\%. The patients had used an active information-seeking
	strategy, i.e., had sought information from the following sources,
	only to a limited degree: the Internet (6\%) medical books (37\%),
	narratives (32\%) and telephone helplines (10\%). A more passive
	information-seeking strategy was more common; the patients obtained
	information from television and radio (82\%), newspapers (86\%),
	other patients (46\%) and friends (55\%). There was a significant
	correlation between educational level and information-seeking from
	the Internet, medical books and telephone helplines. Persons with
	a higher level of formal education had used these sources more than
	people with less education (P<0.05). Younger patients (<60 years)
	and those with a higher level of formal education had greater access
	to the Internet (P<0.0001) and read about cancer in the papers to
	a greater degree than older ones (P<0.05). Younger patients (P<0.05)
	and women (P<0.01) had used narratives to a greater degree than older
	patients and men. The main finding of this study was that the patients
	actively sought information about cancer only to a limited degree,
	but the majority of patients take an interest when cancer issues
	are presented in newspapers and magazines, or on radio and television.},
  institution = {Department of Public Health and Caring Sciences, Uppsala, Sweden.},
  journal     = {Support Care Cancer},
  keywords    = {Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Female; Humans; Information Services; Male; Medical Oncology, education; Middle Aged; Neoplasms, psychology; Patient Education as Topic, methods; Questionnaires},
  medline-pst = {ppublish},
  month       = {Nov},
  owner       = {sanelo},
  pmid        = {11094989},
  timestamp   = {2013.08.01},
  year        = {2000},
}

@Article{Carlsson2009,
  author      = {Carlsson, M. E.},
  title       = {Cancer patients seeking information from sources outside the health care system: change over a decade.},
  doi         = {10.1016/j.ejon.2009.03.005},
  language    = {eng},
  number      = {4},
  pages       = {304--305},
  url         = {http://dx.doi.org/10.1016/j.ejon.2009.03.005},
  volume      = {13},
  institution = {Department of Public Health and Caring Sciences, D{\"o}belnsgatan 2, Uppsala SE-752 37, Sweden. maria.carlsson@pubcare.uu.se},
  journal     = {Eur J Oncol Nurs},
  keywords    = {Adult; Aged; Aged, 80 and over; Books; Chi-Square Distribution; Female; Friends; Hotlines; Humans; Information Dissemination, methods; Internet, utilization; Male; Mass Media; Middle Aged; Neoplasms, prevention /&/ control/psychology; Nursing Methodology Research; Patient Acceptance of Health Care, psychology/statistics /&/ numerical data; Patient Education as Topic, methods/trends; Questionnaires; Sweden},
  medline-pst = {ppublish},
  month       = {Sep},
  owner       = {sanelo},
  pii         = {S1462-3889(09)00045-3},
  pmid        = {19362053},
  timestamp   = {2013.08.01},
  year        = {2009},
}

@Article{Carlsson2013,
  author      = {Carlsson, Sigrid and Sandin, Fredrik and Fall, Katja and Lambe, Mats and Adolfsson, Jan and Stattin, P{\"a}r and Bill-Axelson, Anna},
  title       = {Risk of suicide in men with low-risk prostate cancer.},
  doi         = {10.1016/j.ejca.2012.12.018},
  language    = {eng},
  number      = {7},
  pages       = {1588--1599},
  url         = {http://dx.doi.org/10.1016/j.ejca.2012.12.018},
  volume      = {49},
  abstract    = {Risk of suicide is increased among men with prostate cancer. We investigated
	this association among men with low-risk cancer, usually detected
	by prostate specific antigen (PSA)-testing.Relative risk (RR) of
	suicide was calculated by use of Poisson regression analysis within
	the Prostate Cancer data Base Sweden (PCBaSe) 2.0, a nation-wide,
	population-based database, comparing 105,736 men diagnosed with prostate
	cancer between 1997-2009 to 528,658 matched prostate cancer-free
	men.During the first 6 months after diagnosis, there were 38 suicides
	among men with prostate cancer; incidence rate 0.73 per 1000 person-years
	(PY) and 30 suicides in the comparison cohort; 0.11 per 1000 PY,
	corresponding to a RR of suicide of 6.5 (95\% confidence interval
	(CI) 4.0-10). Risk was highest among men with distant metastases,
	incidence rate 1.25 per 1000 PY, RR 10 (95\% CI 5.1-21) but risk
	was also increased for men with low-risk tumours, incidence rate
	difference 0.45 per 1000 PY and RR 5.2 (95\% CI 2.3-12) and across
	categories of socioeconomic status and comorbidity. Eighteen months
	after diagnosis, risk of suicide had decreased to 0.27 per 1000 PY,
	RR 1.0 (95\% CI 0.68-1.5) for low-risk prostate cancer but remained
	increased among men with metastases, 0.57 per 1000 PY, RR 1.8 (95\%
	CI 1.1-2.9).Although the increase in absolute risk of suicide was
	modest, our findings reflect the severe psychological stress that
	prostate cancer patients may experience after diagnosis. The increased
	risk of suicide observed in men with prostate cancer, including low-risk,
	calls for increased awareness.},
  institution = {Department of Surgery, Urology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. carlssos@mskcc.org},
  journal     = {Eur J Cancer},
  keywords    = {Aged; Aged, 80 and over; Cohort Studies; Comorbidity; Confidence Intervals; Databases, Factual, statistics /&/ numerical data; Humans; Incidence; Male; Middle Aged; Neoplasm Staging; Poisson Distribution; Prostate-Specific Antigen, analysis; Prostatic Neoplasms, diagnosis/epidemiology; Regression Analysis; Risk Assessment, statistics /&/ numerical data/trends; Risk Factors; Socioeconomic Factors; Suicide, statistics /&/ numerical data/trends; Sweden, epidemiology; Time Factors},
  medline-pst = {ppublish},
  month       = {May},
  owner       = {sanelo},
  pii         = {S0959-8049(12)01014-3},
  pmid        = {23337463},
  timestamp   = {2013.08.05},
  year        = {2013},
}

@Article{Caro2004,
  author      = {Caro, J Jaime and Ishak, Khajak J. and Migliaccio-Walle, Kristen},
  title       = {Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis.},
  doi         = {10.1111/j.1524-4733.2004.75013.x},
  language    = {eng},
  number      = {5},
  pages       = {627--635},
  url         = {http://dx.doi.org/10.1111/j.1524-4733.2004.75013.x},
  volume      = {7},
  abstract    = {Economic evaluations typically require estimates of survival beyond
	the limited follow-up in clinical trials. The objective of this study
	was to demonstrate a data-driven approach to deriving these estimates.To
	provide survival estimates for analyses of the CAPRIE trial, data
	were obtained from Saskatchewan on more than 50,000 patients like
	those in the trial: diagnosed with peripheral arterial disease (PAD),
	myocardial infarction, or ischemic stroke between 1985 and 1995;
	follow-up to December 31, 2000. Mean survival was estimated by integrating
	the full survival curve derived by applying hazard functions over
	time. Cox proportional hazards analyses were carried out in each
	of four periods defined to ensure proportionality.Adjusting for mean
	age in CAPRIE, mean survival ranged from 12.1 years after index stroke
	to 13.6 years after diagnosis of PAD. Comorbidities reduced mean
	survival by 1 to 2 years. Subsequent events had a marked detrimental
	effect, decreasing life-expectancy by 50\% or more, and disease in
	multiple vascular beds led to survival of less than 5 years.These
	analyses demonstrate the analytic methods required to accurately
	estimate survival. The trial ages were much lower than in the observational
	study. Thus, the estimates are optimistic for the general population.Accurate
	valuation of interventions depends on valid survival estimates. These
	analyses confirm that survival is significantly reduced in patients
	with atherothrombotic disease, particularly with additional comorbidities.},
  institution = {Caro Research Institute, Concord, MA 01742, USA. jcaro@caroresearch.com},
  journal     = {Value Health},
  keywords    = {Aged; Aspirin, therapeutic use; Cardiovascular Diseases, drug therapy/mortality; Cost of Illness; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Life Expectancy; Male; Middle Aged; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Ticlopidine, analogs /&/ derivatives/therapeutic use},
  medline-pst = {ppublish},
  owner       = {theand},
  pii         = {S1098-3015(10)60226-4},
  pmid        = {15367257},
  timestamp   = {2012.09.18},
  year        = {2004},
}

@Article{Carpenter2000,
  author      = {J. Carpenter and J. Bithell},
  title       = {Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians.},
  number      = {9},
  pages       = {1141--1164},
  volume      = {19},
  abstract    = {Since the early 1980s, a bewildering array of methods for constructing
	bootstrap confidence intervals have been proposed. In this article,
	we address the following questions. First, when should bootstrap
	confidence intervals be used. Secondly, which method should be chosen,
	and thirdly, how should it be implemented. In order to do this, we
	review the common algorithms for resampling and methods for constructing
	bootstrap confidence intervals, together with some less well known
	ones, highlighting their strengths and weaknesses. We then present
	a simulation study, a flow chart for choosing an appropriate method
	and a survival analysis example.},
  file        = {Carpenter2000.pdf:Carpenter2000.pdf:PDF;Carpenter2000.pdf:pdf\\Carpenter2000.pdf:PDF},
  institution = {Medical Statistics Unit, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, U.K.},
  journal     = {Statistics in Medicine},
  month       = may,
  owner       = {pl4},
  pii         = {3.0.CO;2-F},
  pmid        = {10797513},
  timestamp   = {2009.11.27},
  year        = {2000},
}

@Book{Carpenter2007,
  author    = {J.R. Carpenter and M.G. Kenward},
  title     = {Missing data in randomised controlled trials -- a practical guide},
  publisher = {NCCRM},
  owner     = {pl4},
  timestamp = {2009.12.08},
  year      = {2007},
}

@Book{Carpenter2013,
  author    = {Carpenter, James R. and Kenward, Michael G.},
  title     = {Multiple imputation and its application},
  publisher = {Chichester: John Wiley \& Sons},
  owner     = {PaulD},
  timestamp = {2015.10.06},
  year      = {2013},
}

@Article{Carre2001,
  author      = {Carre, D. and Coton, T. and Delpy, R. and Guisset, M. and Debonne, J. M.},
  title       = {[Acute infectious diarrhea: current treatment and perspectives].},
  language    = {fre},
  number      = {6},
  pages       = {521--528},
  volume      = {61},
  abstract    = {Acute infectious diarrhea is a worldwide public health problem. In
	developing countries it remains a major cause infant mortality despite
	therapeutic progress, especially with regard to the efficacy of oral
	rehydration, during the last two decades. Mortality in industrialized
	countries is much lower and generally stable. In most cases, acute
	diarrhea is a self-limiting illness that resolves with or without
	symptomatic treatment in a few days. In view of the high frequency
	and generally benign course of diarrheal diseases, management must
	emphasize a cost-effective approach with selective use of available
	diagnostic methods. The initial approach should be based on the patient's
	history, physical examination, and risk factors to identify infections
	that require more specific measures. The purpose of this report is
	to review currently available drug therapies and to describe treatment
	guidelines for adolescents and adults with uncompromised immune systems.
	Early rehydration is still the mainstay of treatment. Use of "etiological"
	treatment using antimicrobial or antiparasitic agents depends on
	the severity of disease and risk factors.},
  journal     = {Med Trop (Mars)},
  keywords    = {Acute Disease; Adolescent; Adult; Aged; Anti-Bacterial Agents, therapeutic use; Antidiarrheals, therapeutic use; Developing Countries; Diarrhea, epidemiology/pathology/therapy; Female; Fluid Therapy; Humans; Male; Medical History Taking; Middle Aged; Physical Examination; Prognosis; Public Health; Risk Factors},
  medline-pst = {ppublish},
  owner       = {pl4},
  pmid        = {11980405},
  timestamp   = {2013.05.29},
  year        = {2001},
}

@Book{Carstairs1991,
  author    = {Carstairs, Vera and Morris, Russell},
  title     = {Deprivation and health in Scotland},
  publisher = {Aberdeen University Press},
  owner     = {hanbow},
  timestamp = {2015.07.22},
  year      = {1991},
}

@Article{Carstensen2007,
  author      = {B. Carstensen},
  title       = {Age-period-cohort models for the Lexis diagram.},
  doi         = {10.1002/sim.2764},
  number      = {15},
  pages       = {3018--3045},
  volume      = {26},
  abstract    = {Analysis of rates from disease registers are often reported inadequately
	because of too coarse tabulation of data and because of confusion
	about the mechanics of the age-period-cohort model used for analysis.
	Rates should be considered as observations in a Lexis diagram, and
	tabulation a necessary reduction of data, which should be as small
	as possible, and age, period and cohort should be treated as continuous
	variables. Reporting should include the absolute level of the rates
	as part of the age-effects. This paper gives a guide to analysis
	of rates from a Lexis diagram by the age-period-cohort model. Three
	aspects are considered separately: (1) tabulation of cases and person-years;
	(2) modelling of age, period and cohort effects; and (3) parametrization
	and reporting of the estimated effects. It is argued that most of
	the confusion in the literature comes from failure to make a clear
	distinction between these three aspects. A set of recommendations
	for the practitioner is given and a package for R that implements
	the recommendations is introduced.},
  file        = {Carstensen2007.pdf:Carstensen2007.pdf:PDF;Carstensen2007.pdf:pdf\\Carstensen2007.pdf:PDF},
  institution = {Steno Diabetes Center, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark. bxc@steno.dk},
  journal     = {Statistics in Medicine},
  month       = jul,
  owner       = {pl4},
  pmid        = {17177166},
  timestamp   = {2008.11.21},
  year        = {2007},
}

@TechReport{Carstensen2005,
  author      = {Carstensen, Bendix},
  institution = {Steno Diabetes Center, Denmark},
  title       = {Demography and epidemiology: Practical use of the {L}exis diagram in the computer age, or: Who needs the {C}ox-model anyway?},
  url         = {http://biostat.ku.dk/reports/2006/rr-06-2.pdf/},
  owner       = {sanelo},
  timestamp   = {2013.07.30},
  year        = {2005},
}

@Misc{Carstensen:lexis,
  author    = {Carstensen, Bendix},
  title     = {Lexis macro for splitting person-time in SAS},
  note      = {\url{http://www.biostat.ku.dk/~bxc/Lexis/}},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2004},
}

@Article{Carstensen1996,
  author    = {Carstensen, B.},
  title     = {Regression models for interval censored survival data: {A}pplication to {HIV} infection in {D}anish homosexual men},
  pages     = {2177--2189},
  volume    = {15},
  journal   = {Statistics in Medicine},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1996},
}

@Article{Cayla1994,
  author    = {Cayla, J. A. and Artazcoz, L. and Iglesias, B. and Jansa, J. M. and Plasencia, A.},
  title     = {Epidemiology of {AIDS} in {B}arcelona (1981-1991) {(II)}. {A} Study of Mortality and Survival},
  note      = {(in Spanish)},
  pages     = {129--135},
  volume    = {102},
  journal   = {Medicina Clinica},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1994},
}

@Other{mskcc2016,
  author    = {Memorial Sloan Kettering Cancer Center},
  owner     = {BettyS},
  timestamp = {2016.12.09},
  url       = {https://www.mskcc.org/cancer-care/types/colon/prediction-tools},
  year      = {Accessed December 2016},
}

@Article{Chan1996,
  author    = {Chan, L. Y. and Dickman, P. W. and Gibberd, R. W.},
  title     = {A Statistic for Detecting Differences Between {P}oisson Means and its Application to Measuring Systematic Regional Variation in Mortality},
  note      = {(submitted)},
  journal   = {Journal of the American Statistical Association},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1996},
}

@TechReport{Chan1992,
  author      = {Chan, L. Y. and Gibberd, R. W.},
  institution = {{NSW} Health Services Research Group},
  title       = {A New Variability Index for Measuring Systematic Regional Variation},
  address     = {University of Newcastle, Australia},
  owner       = {PaulD},
  timestamp   = {2011.06.19},
  year        = {1992},
}

@Article{Chandre2000,
  author      = {Chandre, F. and Darriet, F. and Duchon, S. and Finot, L. and Manguin, S. and Carnevale, P. and Guillet, P.},
  title       = {Modifications of pyrethroid effects associated with kdr mutation in Anopheles gambiae.},
  language    = {eng},
  number      = {1},
  pages       = {81--88},
  volume      = {14},
  abstract    = {Effects of knockdown resistance (kdr) were investigated in three pyrethroid-resistant
	(RR) strains of the Afrotropical mosquito Anopheles gambiae Giles
	(Diptera: Culicidae): Kou from Burkina Faso, Tola and Yao from Cote
	d'Ivoire; compared with a standard susceptible (SS) strain from Kisumu,
	Kenya. The kdr factor was incompletely recessive, conferring 43-fold
	resistance ratio at LD50 level and 29-fold at LD95 level, as determined
	by topical application tests with Kou strain. When adult mosquitoes
	were exposed to 0.25\% permethrin-impregnated papers, the 50\% and
	95\% knockdown times (KdT) were 23 and 42 min for SS females, compared
	with 40 and 62 min for RS (F1 Kou x Kisumu) females. On 1\% permethrin
	the KdT50 and KdT95 were 11 and 21 min for SS compared with 18 and
	33 min for RS females. Following 1 h exposure to permethrin (0.25\%
	or 1\%), no significant knockdown of Kou RR females occurred within
	24 h. Permethrin irritancy to An. gambiae was assessed by comparing
	'time to first take-off' (TO) for females. The standard TO50 and
	TO95 values for Kisumu SS on untreated paper were 58 and 1044 s,
	respectively, vs. 3.7 and 16.5 s on 1\% permethrin. For Kou RR females
	the comparable values were 27.3 s for TO50 and 294 s for TO95, with
	intermediate RS values of 10.1 s for TO50 and 71.9 s for TO95. Thus,
	TO values for RS were 2.7-4.4 times more than for SS, and those for
	RR were 7-18 times longer than for SS. Experiments with pyrethroid-impregnated
	nets were designed to induce hungry female mosquitoes to pass through
	holes cut in the netting. Laboratory 'tunnel tests' used a bait guinea-pig
	to attract mosquitoes through circular holes (5 x 1 cm) in a net
	screen. With untreated netting, 75-83\% of laboratory-reared females
	passed through the holes overnight, 63-69\% blood-fed successfully
	and 9-17\% died, with no significant differences between SS and RR
	genotypes. When the netting was treated with permethrin 250mg ai/m2
	the proportions that passed through the holes overnight were only
	10\% of SS vs. 40-46\% of RR (Tola & Kou); mortality rates were 100\%
	of SS compared with 59-82\% of RR; bloodmeals were obtained by 9\%
	of Kou RR and 17\% of Tola RR, but none of the Kisumu SS females.
	When the net was treated with deltamethrin 25 mg ai/m2 the proportions
	of An. gambiae that went through the holes and blood-fed successfully
	were 3.9\% of Kisumu SS and 3.5\% of Yaokoffikro field population
	(94\% R). Mortality rates were 97\% of Kisumu SS vs. 47\% of Yaokoffikro
	R. Evidently this deltamethrin treatment was sufficient to kill nearly
	all SS and half of the Yaokoffikro R An. gambiae population despite
	its high kdr frequency. Experimental huts at Yaokoffikro were used
	for overnight evaluation of bednets against An. gambiae females.
	The huts were sealed to prevent egress of mosquitoes released at
	20.00 hours and collected at 05.00 hours. Each net was perforated
	with 225 square holes (2 x 2 cm). A man slept under the net as bait.
	With untreated nets, only 4-6\% of mosquitoes died overnight and
	bloodmeals were taken by 17\% of SS vs. 29\% of Yaokoffikro R (P<0.05).
	Nets treated with permethrin 500 mg/m2 caused mortality rates of
	95\% Kisumu SS and 45\% Yao R (P<0.001) and blood-feeding rates were
	reduced to 1.3\% of SS vs. 8.1\% of Yao R (P<0.05). Nets treated
	with deltamethrin 25 mg/m2 caused mortality rates of 91\% Kisumu
	SS and 54\% Yao R (P<0.001) and reduced blood-feeding rates to zero
	for SS vs. 2.5\% for Yao R (P>0.05). (ABSTRACT TRUNCATED)},
  institution = {Development (IRD formerly ORSTOM), Montpellier, France. chandre@ipr.ird.ci},
  journal     = {Med Vet Entomol},
  keywords    = {Animals; Anopheles; Bedding and Linens; Female; Insecticide Resistance, genetics; Insecticides; Lethal Dose 50; Male; Mosquito Control; Permethrin; Pyrethrins; World Health Organization},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {pl4},
  pmid        = {10759316},
  timestamp   = {2013.05.29},
  year        = {2000},
}

@Article{Chandre1999,
  author      = {Chandre, F. and Darriet, F. and Manguin, S. and Brengues, C. and Carnevale, P. and Guillet, P.},
  title       = {Pyrethroid cross resistance spectrum among populations of Anopheles gambiae s.s. from CoteÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â d'Ivoire.},
  language    = {eng},
  number      = {1},
  pages       = {53--59},
  volume      = {15},
  abstract    = {Field samples of Anopheles gambiae s.s. from Cote d'Ivoire were tested
	with 5 pyrethroids (cyfluthrin, lambda-cyhalothrin, alpha-cypermethrin,
	deltamethrin, permethrin), 1 pseudo-pyrethroid (etofenprox), and
	an organochlorine (DDT). With the use of World Health Organization
	diagnostic tests, 5 out of 6 samples were found cross-resistant to
	these insecticides. A strong decrease in knockdown effect and mortality
	was also observed when testing deltamethrin-impregnated nettings.
	With a polymerase chain reaction amplification of specific alleles
	diagnostic test, resistance was found associated with the presence
	of a kdr mutation. The strong correlation between kdr allelic frequency
	and resistance to DDT or etofenprox indicated that kdr was the main
	resistance factor for these 2 insecticides. On the contrary, a lower
	correlation was observed between kdr frequency and resistance to
	4 of the 5 pyrethroids tested, suggesting that another mechanism
	was also involved, likely a metabolic detoxification. These results
	point out the necessity to monitor pyrethroid resistance and the
	presence of kdr before implementation of any impregnated bed-net
	programs for malaria control.},
  institution = {ORSTOM, Laboratoire de Lutte contre les Insectes Nuisibles, Montpellier, France.},
  journal     = {J Am Mosq Control Assoc},
  keywords    = {Alleles; Animals; Anopheles, genetics; Cote d'Ivoire; Gene Frequency; Insecticide Resistance; Mosquito Control, methods; Nitriles; Pyrethrins},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {pl4},
  pmid        = {10342269},
  timestamp   = {2013.05.29},
  year        = {1999},
}

@Article{Chantereau1992,
  author      = {Chantereau, M. J. and Faivre, J. and Boutron, M. C. and Piard, F. and Arveux, P. and Bedenne, L. and Hillon, P.},
  title       = {Epidemiology, management, and prognosis of malignant large bowel polyps within a defined population.},
  language    = {eng},
  number      = {2},
  pages       = {259--263},
  volume      = {33},
  abstract    = {The population based registry of digestive tract tumours established
	for the department of Cote d'Or, France (population 480,000) was
	used to study the epidemiology and management of malignant large
	bowel polyps. In a 10 year period (1976-85), 146 cases were recorded
	in the area. Age standardised incidence rates were 2.7 per 100,000
	for men and 1.4 per 100,000 for women. Although incidence rates increased
	significantly during the study period, large bowel cancer diagnosed
	as a malignant polyp remained relatively rare (6.2\% of all registered
	large bowel cancers). Two malignant polyps (1.4\%) were less than
	1 cm in diameter, 34 (23.3\%) were more than 30 mm. Sixty patients
	were treated by endoscopic polypectomy, four by contact radiotherapy,
	21 by surgical local excision, 58 by colectomy (10 preceded by polypectomy),
	and three by colotomy. Operative mortality was 8.2\% after intra-abdominal
	surgery, 4.8\% after local surgical excision, and 0\% after polypectomy
	(p less than 0.05). All deaths occurred in patients over 65 years.
	The five year cumulative recurrence rates were 8.9\% after surgical
	excision and 11.3\% after endoscopic polypectomy (NS). The corresponding
	five year net survival rates were 86.1\% and 95.9\%. Endoscopic excision
	alone can be considered a sufficient treatment for adenomas with
	malignant change unless there is evidence of incomplete resection
	or a high risk of lymph node metastases.},
  journal     = {Gut},
  keywords    = {Aged; Colorectal Neoplasms, epidemiology/pathology/surgery; Female; France, epidemiology; Humans; Incidence; Intestinal Polyps, epidemiology/pathology/surgery; Male; Middle Aged; Prognosis; Survival Rate},
  medline-pst = {ppublish},
  month       = {Feb},
  owner       = {pl4},
  pmid        = {1541423},
  timestamp   = {2013.05.29},
  year        = {1992},
}

@Article{Chappell2012,
  author      = {Chappell, Rick},
  title       = {Competing risk analyses: how are they different and why should you care?},
  doi         = {10.1158/1078-0432.CCR-12-0455},
  language    = {eng},
  number      = {8},
  pages       = {2127--2129},
  url         = {http://dx.doi.org/10.1158/1078-0432.CCR-12-0455},
  volume      = {18},
  abstract    = {Competing risks are events in which at least one precludes the observation
	of the other, such as toxicity and death. This commentary discusses
	and distinguishes between the two common types of competing risk
	analyses, the Kaplan-Meier and cumulative incidence curves.},
  file        = {Chappell2012.pdf:Chappell2012.pdf:PDF;Chappell2012.pdf:pdf\\Chappell2012.pdf:PDF},
  institution = {Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792, USA. chappell@stat.wisc.edu},
  journal     = {Clin Cancer Res},
  keywords    = {Data Interpretation, Statistical; Humans; Male; Neoplasms, therapy; Proportional Hazards Models; Prostatic Neoplasms, therapy},
  medline-pst = {ppublish},
  month       = {Apr},
  owner       = {PaulD},
  pii         = {1078-0432.CCR-12-0455},
  pmid        = {22427347},
  timestamp   = {2014.10.13},
  year        = {2012},
}

@Article{Charlson1987,
  author      = {Charlson, M. E. and Pompei, P. and Ales, K. L. and MacKenzie, C. R.},
  title       = {A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.},
  language    = {eng},
  number      = {5},
  pages       = {373--383},
  volume      = {40},
  abstract    = {The objective of this study was to develop a prospectively applicable
	method for classifying comorbid conditions which might alter the
	risk of mortality for use in longitudinal studies. A weighted index
	that takes into account the number and the seriousness of comorbid
	disease was developed in a cohort of 559 medical patients. The 1-yr
	mortality rates for the different scores were: "0", 12\% (181); "1-2",
	26\% (225); "3-4", 52\% (71); and "greater than or equal to 5", 85\%
	(82). The index was tested for its ability to predict risk of death
	from comorbid disease in the second cohort of 685 patients during
	a 10-yr follow-up. The percent of patients who died of comorbid disease
	for the different scores were: "0", 8\% (588); "1", 25\% (54); "2",
	48\% (25); "greater than or equal to 3", 59\% (18). With each increased
	level of the comorbidity index, there were stepwise increases in
	the cumulative mortality attributable to comorbid disease (log rank
	chi 2 = 165; p less than 0.0001). In this longer follow-up, age was
	also a predictor of mortality (p less than 0.001). The new index
	performed similarly to a previous system devised by Kaplan and Feinstein.
	The method of classifying comorbidity provides a simple, readily
	applicable and valid method of estimating risk of death from comorbid
	disease for use in longitudinal studies. Further work in larger populations
	is still required to refine the approach because the number of patients
	with any given condition in this study was relatively small.},
  journal     = {J Chronic Dis},
  keywords    = {Actuarial Analysis; Age Factors; Breast Neoplasms, epidemiology; Epidemiologic Methods; Female; Follow-Up Studies; Humans; Longitudinal Studies; Morbidity; New York City; Prognosis; Prospective Studies; Risk},
  medline-pst = {ppublish},
  owner       = {sanelo},
  pmid        = {3558716},
  timestamp   = {2013.09.19},
  year        = {1987},
}

@Article{Chaturvedi2008,
  author    = {Chaturvedi, A.K. and Mbulaiteye, S. M. and Engels, E. A.},
  title     = {Underestimation of Relative Risks by Standardized Incidence Ratios for {AIDS}-Related Cancers},
  pages     = {230-234},
  volume    = {18},
  file      = {Chaturvedi2008.pdf:Chaturvedi2008.pdf:PDF;Chaturvedi2008.pdf:pdf\\Chaturvedi2008.pdf:PDF},
  journal   = {Annals of Epidemiology},
  owner     = {hanbow},
  timestamp = {2016.10.13},
  year      = {2008},
}

@Article{Cheung2003,
  author      = {Yin Bun Cheung and Fei Gao and Kei Siong Khoo},
  title       = {Age at diagnosis and the choice of survival analysis methods in cancer epidemiology.},
  number      = {1},
  pages       = {38--43},
  volume      = {56},
  abstract    = {A young age at diagnosis of cancer is often seen as an indicator of
	the aggressiveness of the tumor. However, empirical studies have
	shown conflicting results on the association between age at diagnosis
	and survival. There are two choices of time scale for a Cox regression
	model: time since diagnosis, and age. The regression analysis of
	relative survival rates is an alternative to the Cox model. Using
	breast cancer data from a population-based cancer registry, we illustrate
	the features of Cox models using the two time scales and compare
	them with the relative survival approach. Using a Cox model with
	time since diagnosis as the time scale, a younger age at diagnosis
	is associated with a lower mortality; using age as the time scale
	gives the opposite result. The relative survival approach agrees
	with the Cox model with age as the time scale. We maintain that a
	careful clarification of research purpose and a careful choice of
	methods are necessary.},
  file        = {Cheung2003.pdf:Cheung2003.pdf:PDF;Cheung2003.pdf:pdf\\Cheung2003.pdf:PDF},
  institution = {Epidemiological Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore. ctecyb@nccs.com.sg},
  journal     = {Journal of Clinical Epidemiology},
  month       = jan,
  owner       = {pl4},
  pii         = {S089543560200536X},
  pmid        = {12589868},
  timestamp   = {2009.04.16},
  year        = {2003},
}

@Book{Chiang1968,
  author    = {Chiang, C. L.},
  title     = {Introduction to Stochastic Processes in Biostatistics},
  publisher = {New York: John Wiley and Sons},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1968},
}

@Article{Chirikos1985,
  author    = {Chirikos, T. N. and Horner, R. D.},
  title     = {Economic Status and Survivorship in Digestive System Cancers},
  pages     = {210--217},
  volume    = {56},
  journal   = {Cancer},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1985},
}

@Article{Chirikos1984,
  author    = {Chirikos, T. N. and Reiches, N. A. and Moeschberger, M. L.},
  title     = {Economic Differentials in Cancer Survival: A Multivariate Analysis},
  pages     = {183--193},
  volume    = {37},
  journal   = {Journal of Chronic Diseases},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1984},
}

@Article{Cho2013,
  author      = {Cho, Hyunsoon and Klabunde, Carrie N. and Yabroff, K Robin and Wang, Zhuoqiao and Meekins, Angela and Lansdorp-Vogelaar, Iris and Mariotto, Angela B.},
  title       = {Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies.},
  doi         = {10.7326/0003-4819-159-10-201311190-00005},
  language    = {eng},
  number      = {10},
  pages       = {667--676},
  url         = {http://dx.doi.org/10.7326/0003-4819-159-10-201311190-00005},
  volume      = {159},
  abstract    = {Many guidelines recommend considering health status and life expectancy
	when making cancer screening decisions for elderly persons.To estimate
	life expectancy for elderly persons without a history of cancer,
	taking into account comorbid conditions.Population-based cohort study.A
	5\% sample of Medicare beneficiaries in selected geographic areas,
	including their claims and vital status information.Medicare beneficiaries
	aged 66 years or older between 1992 and 2005 without a history of
	cancer (n = 407 749).Medicare claims were used to identify comorbid
	conditions included in the Charlson index. Survival probabilities
	were estimated by comorbidity group (no, low/medium, and high) and
	for the 3 most prevalent conditions (diabetes, chronic obstructive
	pulmonary disease, and congestive heart failure) by using the Cox
	proportional hazards model. Comorbidity-adjusted life expectancy
	was calculated based on comparisons of survival models with U.S.
	life tables. Survival probabilities from the U.S. life tables providing
	the most similar survival experience to the cohort of interest were
	used.Persons with higher levels of comorbidity had shorter life expectancies,
	whereas those with no comorbid conditions, including very elderly
	persons, had favorable life expectancies relative to an average person
	of the same chronological age. The estimated life expectancy at age
	75 years was approximately 3 years longer for persons with no comorbid
	conditions and approximately 3 years shorter for those with high
	comorbidity relative to the average U.S. population.The cohort was
	limited to Medicare fee-for-service beneficiaries aged 66 years or
	older living in selected geographic areas. Data from the Surveillance,
	Epidemiology, and End Results cancer registry and Medicare claims
	lack information on functional status and severity of comorbidity,
	which might influence life expectancy in elderly persons.Life expectancy
	varies considerably by comorbidity status in elderly persons. Comorbidity-adjusted
	life expectancy may help physicians tailor recommendations for stopping
	or continuing cancer screening for individual patients.},
  file        = {Cho2013.pdf:Cho2013.pdf:PDF;Cho2013.pdf:pdf\\Cho2013.pdf:PDF},
  journal     = {Ann Intern Med},
  keywords    = {Aged; Aged, 80 and over; Comorbidity; Early Detection of Cancer; Female; Health Status; Humans; Life Expectancy; Life Tables; Male; Mass Screening; Medicare; United States},
  medline-pst = {ppublish},
  month       = {Nov},
  owner       = {PaulD},
  pii         = {1770670},
  pmid        = {24247672},
  timestamp   = {2014.12.01},
  year        = {2013},
}

@Article{Cho2013a,
  author      = {Cho, Hyunsoon and Mariotto, Angela B. and Mann, Bhupinder S. and Klabunde, Carrie N. and Feuer, Eric J.},
  title       = {Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence.},
  doi         = {10.1093/aje/kws580},
  language    = {eng},
  number      = {3},
  pages       = {339--349},
  url         = {http://dx.doi.org/10.1093/aje/kws580},
  volume      = {178},
  abstract    = {With advances in prevention, screening, and treatment, cancer patients
	are living longer; hence, non-cancer-related health status will likely
	play a larger role in determining their life expectancy. In this
	study, we present a novel method for characterizing non-cancer--related
	health status of cancer patients using population-based cancer registry
	data. We assessed non-cancer-related health status in the context
	of survival from other causes of death and prevalence of comorbidities.
	Data from the Surveillance, Epidemiology, and End Results program
	(2000-2006) were used to analyze cancer patients' survival probabilities
	by cause of death. Other-cause survival was estimated using a left-truncated
	survival method with the hazard of death due to other causes characterized
	as a function of age. Surveillance, Epidemiology, and End Results
	data linked to Medicare claims (1992-2005) were used to quantify
	comorbidity prevalence. Relative to the US population, survival from
	a non-cancer-related death was higher for patients diagnosed with
	early stage breast and prostate cancer but lower for lung cancer
	patients at all stages. Lung cancer patients had worse comorbidity
	status than did other cancer patients. The present study represents
	the first attempt to evaluate the non-cancer-related health status
	of US cancer patients by cancer site (breast, prostate, colorectal,
	and lung) and stage. The findings provide insight into non-cancer-related
	health issues among cancer patients and their risk of dying from
	other causes.},
  file        = {Cho2013a.pdf:Cho2013a.pdf:PDF;Cho2013a.pdf:pdf\\Cho2013a.pdf:PDF},
  institution = {Data Modeling Branch, Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, 9609 Medical Center Drive, Room 4E568, Bethesda, MD 20892, USA. choh3@mail.nih.gov},
  journal     = {Am J Epidemiol},
  keywords    = {Age Factors; Aged; Aged, 80 and over; Breast Neoplasms, epidemiology/mortality/pathology; Cause of Death; Colorectal Neoplasms, epidemiology/mortality/pathology; Comorbidity; Diabetes Mellitus, epidemiology; Female; Follow-Up Studies; Health Status; Humans; Life Expectancy; Life Tables; Lung Neoplasms, epidemiology/mortality/pathology; Male; Medicare, statistics /&/ numerical data; Middle Aged; Multiple Organ Failure, epidemiology; Neoplasm Staging; Paralysis, epidemiology; Prevalence; Prostatic Neoplasms, epidemiology/mortality/pathology; SEER Program, statistics /&/ numerical data; Survival Rate; United States, epidemiology; Vascular Diseases, epidemiology},
  medline-pst = {ppublish},
  month       = {Aug},
  owner       = {PaulD},
  pii         = {kws580},
  pmid        = {23825168},
  timestamp   = {2014.12.01},
  year        = {2013},
}

@Article{Cho2014,
  author      = {Cho, Hyunsoon and Mariotto, Angela B. and Schwartz, Lisa M. and Luo, Jun and Woloshin, Steven},
  title       = {When do changes in cancer survival mean progress? {T}he insight from population incidence and mortality.},
  doi         = {10.1093/jncimonographs/lgu014},
  language    = {eng},
  number      = {49},
  pages       = {187--197},
  url         = {http://dx.doi.org/10.1093/jncimonographs/lgu014},
  volume      = {2014},
  abstract    = {It is often assumed that increases in cancer survival reflect true
	progress against cancer. This is true when these increases are accompanied
	by decreased burden of disease: Fewer people being diagnosed or dying
	from cancer (ie, decreased incidence and mortality). But increased
	survival can also occur even when incidence is increasing and mortality
	is unchanged.To use trends in cancer burden-incidence and mortality-to
	illustrate when changes in survival reflect true progress.Using data
	from 1975 to 2010 collected by the Surveillance, Epidemiology, and
	End Results Program (incidence, survival) and the National Center
	for Health Statistics (mortality), we analyzed US trends in five-year
	relative survival, age-adjusted incidence, and mortality for selected
	cancers to identify patterns that do and do not reflect progress.Among
	the nine common cancers examined, survival increased in seven, and
	changed little or not at all for two. In some cases, increased survival
	was accompanied by decreased burden of disease, reflecting true progress.
	For example, from 1975 to 2010, five-year survival for colon cancer
	patients improved (from 48\% to 68\%) while cancer burden fell: Fewer
	cases (incidence decreased from 60 to 41 per 100000) and fewer deaths
	(mortality decreased from 28 to 16 per 100000), a pattern explained
	by both increased early detection (with removal of cancer precursors)
	and more effective treatment. In other cases, however, increased
	survival did not reflect true progress. In melanoma, kidney, and
	thyroid cancer, five-year survival increased but incidence increased
	with no change in mortality. This pattern suggests overdiagnosis
	from increased early detection, an increase in cancer burden.Changes
	in survival must be interpreted in the context of incidence and mortality.
	Increased survival only represents progress when accompanied by a
	reduction in incidence, mortality, or ideally both.},
  file        = {Cho2014.pdf:pdf\\Cho2014.pdf:PDF;Cho2014.pdf:Cho2014.pdf:PDF},
  institution = {Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD (HC, ABM); Division of Cancer Registration and Surveillance, National Cancer Center, Goyang-si Gyeonggi-do, Korea (HC); Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH, Geisel School of Medicine at Dartmouth, Hanover NH, Veterans Affairs Outcomes Group, Department of Veterans Affairs Medical Center, White River Junction, VT (LMS, SW); Information Management Services, Inc., Calverton, MD (JL).},
  journal     = {J Natl Cancer Inst Monogr},
  medline-pst = {ppublish},
  month       = {Nov},
  owner       = {PaulD},
  pii         = {lgu014},
  pmid        = {25417232},
  timestamp   = {2014.12.01},
  year        = {2014},
}

@Article{Chocron2000,
  author      = {Chocron, S. and Etievent, J. P. and Viel, J. F. and Dussaucy, A. and Clement, F. and Kaili, D. and Yan, Y.},
  title       = {Preoperative quality of life as a predictive factor of 3-year survival after open heart operations.},
  language    = {eng},
  number      = {3},
  pages       = {722--727},
  volume      = {69},
  abstract    = {The aim of this prospective study was twofold: to determine the evolution
	of quality of life in heart surgery patients through the first 3
	postoperative years using the Nottingham Health Profile questionnaire
	and to determine whether preoperative quality of life influences
	3-year survival.From January to July 1994, 215 patients underwent
	elective open heart operation in our department. Patients filled
	in the Nottingham Health Profile questionnaire five times: preoperatively,
	postoperatively at month 3, and at each anniversary of their operation
	for 3 years. The evolution of quality of life scores through time
	were compared using analysis of covariance with repeated measures.
	Analysis of 3-year survival prognostic factors was achieved using
	the Cox proportional hazards model.Quality of life scores varied
	through time, but not significantly. Multivariate analysis showed
	two independent risk factors to influence 3-year survival: dyspnea
	class (III-IV versus I-II, relative risk = 2.80, 95\% confidence
	interval = 1.2 to 6.5) and the energy section of the Nottingham Health
	Profile questionnaire (relative risk = 1.02 by unit, 95\% confidence
	interval = 1.01 to 1.03).Our study shows quality of life scores to
	be stable for the first 3 years after operation and the preoperative
	energy score to be predictive of 3-year survival.},
  journal     = {Ann Thorac Surg},
  keywords    = {Aged; Cardiac Surgical Procedures, mortality; Female; Humans; Male; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Time Factors},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {pl4},
  pii         = {S0003-4975(99)01329-6},
  pmid        = {10750750},
  timestamp   = {2013.05.29},
  year        = {2000},
}

@Article{Chowdhury2013,
  author      = {Chowdhury, Simon and Robinson, David and Cahill, Declan and Rodriguez-Vida, Alejo and Holmberg, Lars and M{\o}ller, Henrik},
  title       = {Causes of death in men with prostate cancer: an analysis of 50,000 men from the {Thames Cancer Registry}.},
  doi         = {10.1111/bju.12212},
  language    = {eng},
  number      = {2},
  pages       = {182--189},
  url         = {http://dx.doi.org/10.1111/bju.12212},
  volume      = {112},
  abstract    = {To investigate causes of death in a UK cohort of patients with prostate
	cancer.We examined causes of death in a UK cohort of 50,066 men with
	prostate cancer diagnosed between 1997 and 2006 reported to the Thames
	Cancer Registry (TCR) and followed-up to the end of 2007. The underlying
	cause of death was taken from the death certificate. Uptake of PSA
	screening was low in the UK during the period studied. We examined
	the relationship between cause of death and patient characteristics
	at diagnosis including age, cancer stage, and treatment (lesss than
	6 months of diagnosis).In all, 20,181 deaths occurred during the
	period; 49.8\% recorded as being due to prostate cancer, 17ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·8\% to
	cardiovascular disease, 11ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·6\% to other cancers, and 20ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·7\% to other
	causes. Irrespective of age, cancer stage, or treatment less than
	6 months of diagnosis, prostate cancer was an important cause of
	death ranging from 31ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·6\% to 74ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·3\% of all deaths in different subgroups.For
	men with prostate cancer diagnosed in a setting where uptake of PSA
	screening is low, our findings challenge the belief that prostate
	cancer is not an important cause of death.},
  file        = {Chowdhury2013.pdf:Chowdhury2013.pdf:PDF;Chowdhury2013.pdf:pdf\\Chowdhury2013.pdf:PDF},
  institution = {Department of Medical Oncology, Guy's Hospital, King's College London, London, UK. Simon.Chowdhury@gstt.nhs.uk},
  journal     = {BJU Int},
  keywords    = {Aged; Cause of Death; Great Britain; Humans; Male; Middle Aged; Prostatic Neoplasms, mortality; Registries},
  medline-pst = {ppublish},
  month       = {Jul},
  owner       = {PaulD},
  pmid        = {23795786},
  timestamp   = {2014.06.20},
  year        = {2013},
}

@Article{Chu2008,
  author      = {Po-Ching Chu and Jung-Der Wang and Jing-Shiang Hwang and Yu-Yin Chang},
  title       = {Estimation of life expectancy and the expected years of life lost in patients with major cancers: extrapolation of survival curves under high-censored rates.},
  doi         = {10.1111/j.1524-4733.2008.00350.x},
  number      = {7},
  pages       = {1102--1109},
  volume      = {11},
  abstract    = {OBJECTIVES: There exists a lack of extrapolation methods for long-term
	survival analysis when censored rates are high (25-50\%). This study
	aimed at estimating life expectancy (LE) after the diagnosis of cancer
	and the expected years of life lost (EYLL) using a newly developed
	semiparametric method. METHODS: Patients (n = 425,294) diagnosed
	with 17 different types of major cancer were enrolled. All of the
	patients were registered with the Taiwan Cancer Registry between
	1990 and 2001; their survivals were followed through the end of 2004.
	The survival function for an age- and sex-matched reference population
	was generated using the Monte Carlo method from the life table of
	the general population. Lifetime survival of the cancer patients
	(up to 50 years) were obtained using linear extrapolation of a logit-transformed
	curve of the survival ratio between the cancer and reference populations.
	The estimates were compared with the results from the extrapolation
	of fitted Weibull models. RESULTS: The 15-year survival, LE, and
	EYLL for 17 different types of cancer were determined, of which the
	LE of breast, cervical, ovarian, and skin cancers exceeded 15 years;
	nasopharyneal, leukemia, bladder, kidney, and colorectal cancers
	exceeded 10 years. Validity tests indicated that the relative biases
	of the extrapolated estimates were usually <5\% under high censoring
	rates. CONCLUSIONS: The newly developed method is feasible and relatively
	accurate to project LE and EYLL, which could also be merged with
	data pertaining to quality of life, for a more detailed outcome assessment
	in the future.},
  file        = {:pdf/Chu2008.pdf:PDF},
  institution = {Institute of Occupational Medicine and Industrial Hygiene, College of Public Health, National Taiwan University, Taiwan.},
  journal     = {Value Health},
  month       = dec,
  owner       = {pl4},
  pii         = {VHE350},
  pmid        = {18489497},
  timestamp   = {2010.01.04},
  year        = {2008},
}

@Article{Clark2001,
  author    = {T. G. Clark and M. E. Stewart and D. G. Altman H. Gabra and J. F. Smyth},
  title     = {A prognostic model for ovarian cancer},
  pages     = {944-952},
  volume    = {85},
  file      = {Clark2001.pdf:Clark2001.pdf:PDF;Clark2001.pdf:pdf\\Clark2001.pdf:PDF},
  journal   = {British Journal of Cancer},
  owner     = {pl4},
  timestamp = {2009.11.04},
  year      = {2001},
}

@Book{Clayton1993,
  author    = {Clayton, D. and Hills, M.},
  title     = {Statistical Models in Epidemiology},
  publisher = {Oxford: Oxford University Press},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1993},
}

@Article{Clayton1987,
  author    = {D. Clayton and E. Schifflers},
  title     = {Models for temporal variation in cancer rates. II: Age-period-cohort models.},
  number    = {4},
  pages     = {469--481},
  volume    = {6},
  abstract  = {Our first paper reviewed methods for modelling variation in cancer
	incidence and mortality rates in terms of either period effects or
	cohort effects in the general multiplicative risk model. There we
	drew attention to the difficulty of attributing regular trends to
	either period or cohort influences. In this paper we turn to the
	more realistic problem in which neither period nor cohort effects
	alone lead to an adequate description of the data. We describe the
	age-period-cohort model and show how its ambiguities surrounding
	regular trends 'intensify'. We recommend methods for presenting the
	results of analyses based upon this model which minimize the serious
	risk of misleading implications and critically review previous suggestions.
	The discussion is illustrated by an analysis of breast cancer mortality
	in Japan with special reference to the phenomenon of 'Clemmesen's
	hook'.},
  file      = {Clayton1987.pdf:Clayton1987.pdf:PDF},
  journal   = {Statistics in Medicine},
  month     = jun,
  owner     = {pl4},
  pmid      = {3629048},
  timestamp = {2009.11.04},
  year      = {1987},
}

@Article{Clayton1987b,
  author      = {Clayton, D. and Schifflers, E.},
  title       = {Models for temporal variation in cancer rates. I: Age-period and age-cohort models.},
  language    = {eng},
  number      = {4},
  pages       = {449--467},
  volume      = {6},
  abstract    = {A main concern of descriptive epidemiologists is the presentation
	and interpretation of temporal variations in cancer rates. In its
	simplest form, this problem is that of the analysis of a set of rates
	arranged in a two-way table by age group and calendar period. We
	review the modern approach to the analysis of such data which justifies
	traditional methods of age standardization in terms of the multiplicative
	risk model. We discuss the use of this model when the temporal variations
	are due to purely secular (period) influences and when they are attributable
	to generational (cohort) influences. Finally we demonstrate the serious
	difficulties which attend the interpretation of regular trends. The
	methods described are illustrated by examples for incidence rates
	of bladder cancer in Birmingham, U.K., mortality from bladder cancer
	in Italy, and mortality from lung cancer in Belgium.},
  file        = {Clayton1987b.pdf:Clayton1987b.pdf:PDF},
  journal     = {Statistics in Medicine},
  medline-pst = {ppublish},
  month       = jun,
  owner       = {pl4},
  pmid        = {3629047},
  timestamp   = {2012.09.10},
  year        = {1987},
}

@Manual{Clements2016,
  author  = {Clements, M.},
  title   = {Rstpm2: Generalized Survival Models. R package.},
  url     = {http://CRAN.R-project.org/package=rstpm2},
  urldate = {July 2016},
  year    = {2016},
}

@Article{Clements2005,
  author      = {Clements, Mark S. and Armstrong, Bruce K. and Moolgavkar, Suresh H.},
  title       = {Lung cancer rate predictions using generalized additive models.},
  doi         = {10.1093/biostatistics/kxi028},
  language    = {eng},
  number      = {4},
  pages       = {576--589},
  volume      = {6},
  abstract    = {Predictions of lung cancer incidence and mortality are necessary for
	planning public health programs and clinical services. It is proposed
	that generalized additive models (GAMs) are practical for cancer
	rate prediction. Smooth equivalents for classical age-period, age-cohort,
	and age-period-cohort models are available using one-dimensional
	smoothing splines. We also propose using two-dimensional smoothing
	splines for age and period. Variance estimation can be based on the
	bootstrap. To assess predictive performance, we compared the models
	with a Bayesian age-period-cohort model. Model comparison used cross-validation
	and measures of predictive performance for recent predictions. The
	models were applied to data from the World Health Organization Mortality
	Database for females in five countries. Model choice between the
	age-period-cohort models and the two-dimensional models was equivocal
	with respect to cross-validation, while the two-dimensional GAMs
	had very good predictive performance. The Bayesian model performed
	poorly due to imprecise predictions and the assumption of linearity
	outside of observed data. In summary, the two-dimensional GAM performed
	well. The GAMs make the important prediction that female lung cancer
	rates in these countries will be stable or begin to decline in the
	future.},
  file        = {Clements2005.pdf:Clements2005.pdf:PDF},
  institution = {National Centre for Epidemiology and Population Health, The Australian National University, Canberra, ACT 0200, Australia. Mark.Clements@anu.edu.au},
  journal     = {Biostatistics},
  medline-pst = {ppublish},
  month       = oct,
  owner       = {pl4},
  pii         = {kxi028},
  pmid        = {15860544},
  timestamp   = {2012.02.06},
  year        = {2005},
}

@Article{Clerc-Urmes2014,
  author    = {I. Clerc-Urm{\AA}Â¨s and M. Grzebyk and G. H{\AA}Â©delin},
  title     = {Net survival estimation with stns},
  pages     = {87-102},
  volume    = {14},
  file      = {Clerc-Urmes2014.pdf:Clerc-Urmes2014.pdf:PDF},
  journal   = {The Stata Journal},
  owner     = {CarolineW},
  timestamp = {2014.04.28},
  year      = {2014},
}

@Book{Cleves2004,
  author    = {Cleves, M. A. and Gould, W. W. and Gutierrez, R. G.},
  title     = {An Introduction to Survival Analysis Using Stata},
  edition   = {Revised},
  publisher = {Stata Press},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2004},
}

@Book{Cleves2008,
  author    = {Cleves, M. A. and Gould, W. W. and Gutierrez, R. G. and Marchenko, Y.},
  title     = {An Introduction to Survival Analysis Using Stata},
  edition   = {2nd},
  publisher = {Stata Press},
  owner     = {PaulD},
  timestamp = {2008.11.09},
  year      = {2008},
}

@Book{Cleves2010,
  author    = {M. Cleves and R. G. Gutierrez and W. W. Gould and Y. Marchenko},
  title     = {An Introduction to Survival Analysis Using Stata},
  edition   = {3rd},
  publisher = {Stata Press},
  address   = {College Station, Texas},
  owner     = {pl4},
  timestamp = {2011.01.17},
  year      = {2010},
}

@Other{mayoclinic2016,
  author    = {Mayo Clinic},
  owner     = {BettyS},
  timestamp = {2016.12.09},
  url       = {http://www.mayoclinic.org/medical-professionals/cancer-prediction-tools/colon-cancer},
  year      = {Accessed December 2016},
}

@Book{Cochran1977,
  author    = {Cochran, W. G.},
  title     = {Sampling Techniques},
  edition   = {3rd},
  publisher = {New York: John Wiley},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1977},
}

@Article{Cochran1936,
  author    = {Cochran, W. G.},
  title     = {The $\chi^2$ Distribution for the Binomial and {P}oisson Series, with Small Expectations},
  pages     = {207--217},
  volume    = {1},
  journal   = {Annals of Eugenics},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1936},
}

@Article{Cohart1955a,
  author    = {Cohart, E. M.},
  title     = {Socioeconomic Distribution of Cancer of the Female Sex Organs in {N}ew {H}aven},
  pages     = {34--41},
  volume    = {8},
  journal   = {Cancer},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1955},
}

@Article{Cohart1955b,
  author    = {Cohart, E. M.},
  title     = {Socioeconomic Distribution of Cancer of the Lung in {N}ew {H}aven},
  pages     = {1126--1129},
  volume    = {8},
  journal   = {Cancer},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1955},
}

@Article{Cohart1955c,
  author    = {Cohart, E. M.},
  title     = {Socioeconomic Distribution of Cancer of the Gastrointestinal Tract in {N}ew {H}aven},
  pages     = {379--388},
  volume    = {8},
  journal   = {Cancer},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1955},
}

@Article{Cohen1983,
  author    = {Cohen, Jacob},
  title     = {The cost of dichotomisation},
  pages     = {249--253},
  volume    = {7},
  journal   = {Applied Psychological Measurement},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1983},
}

@Article{Cole2004,
  author      = {S.R. Cole and M.A. Hern\'{a}n},
  title       = {Adjusted survival curves with inverse probability weights.},
  doi         = {10.1016/j.cmpb.2003.10.004},
  number      = {1},
  pages       = {45--49},
  volume      = {75},
  abstract    = {Kaplan-Meier survival curves and the associated nonparametric log
	rank test statistic are methods of choice for unadjusted survival
	analyses, while the semiparametric Cox proportional hazards regression
	model is used ubiquitously as a method for covariate adjustment.
	The Cox model extends naturally to include covariates, but there
	is no generally accepted method to graphically depict adjusted survival
	curves. The authors describe a method and provide a simple worked
	example using inverse probability weights (IPW) to create adjusted
	survival curves. When the weights are non-parametrically estimated,
	this method is equivalent to direct standardization of the survival
	curves to the combined study population.},
  file        = {Cole2004.pdf:Cole2004.pdf:PDF;Cole2004.pdf:pdf\\Cole2004.pdf:PDF},
  institution = {Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe Street E-7014, Baltimore, MD 21205, USA. scole@jhu.edu},
  journal     = {Comput Methods Programs Biomed},
  owner       = {pl4},
  pii         = {S0169260703001378},
  pmid        = {15158046},
  timestamp   = {2009.01.14},
  year        = {2004},
}

@Article{Coleman2014,
  author      = {Coleman, Michel P.},
  title       = {Cancer survival: global surveillance will stimulate health policy and improve equity.},
  doi         = {10.1016/S0140-6736(13)62225-4},
  language    = {eng},
  number      = {9916},
  pages       = {564--573},
  url         = {http://dx.doi.org/10.1016/S0140-6736(13)62225-4},
  volume      = {383},
  abstract    = {Millions of people will continue to be diagnosed with cancer every
	year for the foreseeable future. These patients all need access to
	optimum health care. Population-based cancer survival is a key measure
	of the overall effectiveness of health systems in management of cancer.
	Survival varies very widely around the world. Global surveillance
	of cancer survival is needed, because unless these avoidable inequalities
	are measured, and reported on regularly, nothing will be done explicitly
	to reduce them.},
  file        = {Coleman2014.pdf:Coleman2014.pdf:PDF;Coleman2014.pdf:pdf\\Coleman2014.pdf:PDF},
  institution = {Tropical Medicine, London, UK. Electronic address: michel.coleman@lshtm.ac.uk.},
  journal     = {Lancet},
  keywords    = {Adult; Aged; Cost of Illness; Health Planning, organization /&/ administration; Health Policy; Health Services Accessibility, organization /&/ administration/standards; Healthcare Disparities; Humans; International Cooperation; Middle Aged; Mortality, Premature; Neoplasms, mortality/prevention /&/ control; Public Health Surveillance; Survival Analysis; World Health},
  medline-pst = {ppublish},
  month       = {Feb},
  owner       = {PaulD},
  pii         = {S0140-6736(13)62225-4},
  pmid        = {24351320},
  timestamp   = {2014.10.15},
  year        = {2014},
}

@Article{Coleman2015,
  author      = {Coleman, Michel P. and Allemani, Claudia},
  title       = {Cancer: the elephant in the room.},
  doi         = {10.1016/S0140-6736(15)60571-2},
  language    = {eng},
  number      = {9973},
  pages       = {1047--1048},
  url         = {http://dx.doi.org/10.1016/S0140-6736(15)60571-2},
  volume      = {385},
  institution = {Cancer Research UK Cancer Survival Group, Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.},
  journal     = {Lancet},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {PaulD},
  pii         = {S0140-6736(15)60571-2},
  pmid        = {25797546},
  timestamp   = {2015.03.24},
  year        = {2015},
}

@Book{Coleman1999,
  author    = {Coleman, M. P. and Babb, P. and Damiecki, P. and Grosclaude, P. and Honjo, S. and Jones, J. and Knerer, G. and Pitard, A. and Quinn, M. and Sloggett, A. and De Stavola, B.},
  title     = {Cancer Survival Trends in {E}ngland and {W}ales, 1971--1995: Deprivation and {NHS} Region},
  number    = {61},
  publisher = {London: The Stationery Office},
  series    = {Studies in Medical and Population Subjects},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1999},
}

@Article{Coleman2003,
  author      = {Coleman, Michel P. and Evans, Barry G. and Barrett, Geraldine},
  title       = {Confidentiality and the public interest in medical research--will we ever get it right?},
  language    = {eng},
  number      = {3},
  pages       = {219--228},
  url         = {http://www.clinmed.rcpjournal.org/content/3/3/219},
  volume      = {3},
  file        = {Coleman2003.pdf:pdf\\Coleman2003.pdf:PDF;Coleman2003.pdf:Coleman2003.pdf:PDF},
  institution = {London School of Hygiene and Tropical Medicine. michel.coleman@lshtm.ac.uk},
  journal     = {Clin Med},
  keywords    = {Access to Information; Biomedical Research, legislation /&/ jurisprudence; Confidentiality; Ethics, Medical; Great Britain; Humans; Liability, Legal; Medical Records, legislation /&/ jurisprudence; Public Opinion},
  medline-pst = {ppublish},
  owner       = {PaulD},
  pmid        = {12848254},
  timestamp   = {2015.03.24},
  year        = {2003},
}

@Article{Coleman2011,
  author      = {M. P. Coleman and D. Forman and H. Bryant and J. Butler and B. Rachet and C. Maringe and U. Nur and E. Tracey and M. Coory and J. Hatcher and C. E. McGahan and D. Turner and L. Marrett and M. Gjerstorff and T. B. Johannesen and J. Adolfsson and M. Lambe and G. Lawrence and D. Meechan and E. J. Morris and R. Middleton and J. Steward and M. A. Richards and {the ICBP Module 1 Working Group}},
  title       = {Cancer survival in {A}ustralia, {C}anada, {D}enmark, {N}orway, {S}weden, and the {UK}, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data.},
  pages       = {127--138},
  volume      = {377},
  abstract    = {BACKGROUND: Cancer survival is a key measure of the effectiveness
	of health-care systems. Persistent regional and international differences
	in survival represent many avoidable deaths. Differences in survival
	have prompted or guided cancer control strategies. This is the first
	study in a programme to investigate international survival disparities,
	with the aim of informing health policy to raise standards and reduce
	inequalities in survival. METHODS: Data from population-based cancer
	registries in 12 jurisdictions in six countries were provided for
	XX million adults diagnosed with primary colorectal, lung, breast
	(women), or ovarian cancer during 1995-2007, with follow-up to Dec
	31, 2007. Data quality control and analyses were done centrally with
	a common protocol, overseen by external experts. We estimated 1-year
	and 5-year relative survival, constructing 252 complete life tables
	to control for background mortality by age, sex, and calendar year.
	We report age-specific and age-standardised relative survival at
	1 and 5 years, and 5-year survival conditional on survival to the
	first anniversary of diagnosis. We also examined incidence and mortality
	trends during 1985-2005. FINDINGS: Relative survival improved during
	1995-2007 for all four cancers in all jurisdictions. Survival was
	persistently higher in Australia, Canada, and Sweden, intermediate
	in Norway, and lower in Denmark, England, Northern Ireland, and Wales,
	particularly in the first year after diagnosis and for patients aged
	65 years and older. International differences narrowed at all ages
	for breast cancer, from about 9\% to 5\% at 1 year and from about
	14\% to 8\% at 5 years, but less or not at all for the other cancers.
	For colorectal cancer, the international range narrowed only for
	patients aged 65 years and older, by 2-6\% at 1 year and by 2-3\%
	at 5 years. INTERPRETATION: Up-to-date survival trends show increases
	but persistent differences between countries. Trends in cancer incidence
	and mortality are broadly consistent with these trends in survival.
	Data quality and changes in classification are not likely explanations.
	The patterns are consistent with later diagnosis or differences in
	treatment, particularly in Denmark and the UK, and in patients aged
	65 years and older. FUNDING: Department of Health, England; and Cancer
	Research UK.},
  file        = {Coleman2011.pdf:pdf\\Coleman2011.pdf:PDF},
  institution = {Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK.},
  journal     = {Lancet},
  month       = dec,
  owner       = {pl4},
  pmid        = {21183212},
  timestamp   = {2011.01.07},
  year        = {2011},
}

@Article{Coleman2008a,
  author      = {Michel P Coleman and Manuela Quaresma and Franco Berrino and Jean-Michel Lutz and Roberta De Angelis and Riccardo Capocaccia and Paolo Baili and Bernard Rachet and Gemma Gatta and Timo Hakulinen and Andrea Micheli and Milena Sant and Hannah K Weir and J. Mark Elwood and Hideaki Tsukuma and Sergio Koifman and Gulnar Azevedo E Silva and Silvia Francisci and Mariano Santaquilani and Arduino Verdecchia and Hans H Storm and John L Young and {CONCORD Working Group}},
  title       = {Cancer survival in five continents: a worldwide population-based study ({CONCORD}).},
  number      = {8},
  pages       = {730--756},
  volume      = {9},
  abstract    = {BACKGROUND: Cancer survival varies widely between countries. The CONCORD
	study provides survival estimates for 1.9 million adults (aged 15-99
	years) diagnosed with a first, primary, invasive cancer of the breast
	(women), colon, rectum, or prostate during 1990-94 and followed up
	to 1999, by use of individual tumour records from 101 population-based
	cancer registries in 31 countries on five continents. This is, to
	our knowledge, the first worldwide analysis of cancer survival, with
	standard quality-control procedures and identical analytic methods
	for all datasets. METHODS: To compensate for wide international differences
	in general population (background) mortality by age, sex, country,
	region, calendar period, and (in the USA) ethnic origin, we estimated
	relative survival, the ratio of survival noted in the patients with
	cancer, and the survival that would have been expected had they been
	subject only to the background mortality rates. 2800 life tables
	were constructed. Survival estimates were also adjusted for differences
	in the age structure of populations of patients with cancer. FINDINGS:
	Global variation in cancer survival was very wide. 5-year relative
	survival for breast, colorectal, and prostate cancer was generally
	higher in North America, Australia, Japan, and northern, western,
	and southern Europe, and lower in Algeria, Brazil, and eastern Europe.
	CONCORD has provided the first opportunity to estimate cancer survival
	in 11 states in USA covered by the National Program of Cancer Registries
	(NPCR), and the study covers 42\% of the US population, four-fold
	more than previously available. Cancer survival in black men and
	women was systematically and substantially lower than in white men
	and women in all 16 states and six metropolitan areas included. Relative
	survival for all ethnicities combined was 2-4\% lower in states covered
	by NPCR than in areas covered by the Surveillance Epidemiology and
	End Results (SEER) Program. Age-standardised relative survival by
	use of the appropriate race-specific and state-specific life tables
	was up to 2\% lower for breast cancer and up to 5\% lower for prostate
	cancer than with the census-derived national life tables used by
	the SEER Program. These differences in population coverage and analytical
	method have both contributed to the survival deficit noted between
	Europe and the USA, from which only SEER data have been available
	until now. INTERPRETATION: Until now, direct comparisons of cancer
	survival between high-income and low-income countries have not generally
	been available. The information provided here might therefore be
	a useful stimulus for change. The findings should eventually facilitate
	joint assessment of international trends in incidence, survival,
	and mortality as indicators of cancer control.},
  file        = {Coleman2008a.pdf:pdf\\Coleman2008a.pdf:PDF},
  institution = {Cancer Research UK Cancer Survival Group, Non-Communicable Disease Epidemiology Unit, London School of Hygiene and Tropical Medicine, London, UK. michel.coleman@lshtm.ac.uk},
  journal     = {Lancet Oncol},
  month       = {Aug},
  owner       = {PaulD},
  pmid        = {18639491},
  timestamp   = {2008.08.22},
  year        = {2008},
}

@Article{Coleman2011a,
  author      = {Coleman, Michel P. and Rachet, Bernard and Woods, Laura and Berrino, Franco and Butler, John and Capocaccia, Riccardo and Dickman, Paul W. and Gavin, Anna and Giorgi, Roch and Hamilton, Willie and Lambert, Paul C. and Peake, Michael D. and Perme, Maja Pohar and Stare, Janez and Vedstedt, Peter},
  title       = {Rebuttal to editorial saying cancer survival statistics are misleading.},
  doi         = {10.1136/bmj.d4214},
  language    = {eng},
  pages       = {d4214},
  volume      = {343},
  file        = {Coleman2011a.pdf:Coleman2011a.pdf:PDF;Coleman2011a.pdf:pdf\\Coleman2011a.pdf:PDF},
  journal     = {BMJ},
  medline-pst = {epublish},
  owner       = {PaulD},
  pmid        = {21729985},
  timestamp   = {2013.01.17},
  year        = {2011},
}

@Article{Coleman2004,
  author      = {M. P. Coleman and B. Rachet and L. M. Woods and E. Mitry and M. Riga and N. Cooper and M. J. Quinn and H. Brenner and J. Est\`{e}ve},
  title       = {Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001.},
  doi         = {10.1038/sj.bjc.6601696},
  number      = {7},
  pages       = {1367--1373},
  url         = {http://dx.doi.org/10.1038/sj.bjc.6601696},
  volume      = {90},
  abstract    = {We examined national trends and socioeconomic inequalities in cancer
	survival in England and Wales during the 1990s, using population-based
	data on 2.2 million patients who were diagnosed with one of the 20
	most common cancers between 1986 and 1999 and followed up to 2001.
	Patients were assigned to one of five deprivation categories (from
	'affluent' to 'deprived') using characteristics of their electoral
	ward of residence at diagnosis. We estimated relative survival up
	to 5 years after diagnosis, adjusting separately in each deprivation
	category for background mortality by age, sex and calendar period.
	We estimated trends in survival and in the difference in survival
	between deprivation categories ('deprivation gap') over the periods
	1986-90, 1991-95 and 1996-99. We used period analysis to examine
	likely survival rates in the near future. Survival improved for most
	cancers in both sexes during the 1990s, and appears likely to continue
	improving for most cancers in the near future. The deprivation gap
	in survival between rich and poor was wider for patients diagnosed
	in the late 1990s than in the late 1980s. Increases in cancer survival
	in England and Wales during the 1990s are shown to be significantly
	associated with a widening deprivation gap in survival.},
  file        = {Coleman2004.pdf:Coleman2004.pdf:PDF;Coleman2004.pdf:pdf\\Coleman2004.pdf:PDF},
  institution = {Cancer and Public Health Unit, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. michel.coleman@lshtm.ac.uk},
  journal     = {British Journal of Cancer},
  month       = {Apr},
  owner       = {pl4},
  pii         = {6601696},
  pmid        = {15054456},
  timestamp   = {2008.12.02},
  year        = {2004},
}

@Article{MRC99,
  author    = {Medical Research Council Renal Cancer Collaborators},
  title     = {Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial},
  pages     = {14--17},
  volume    = {353},
  file      = {MRC99.pdf:pdf\\MRC99.pdf:PDF;MRC99.pdf:MRC99.pdf:PDF},
  journal   = {Lancet},
  timestamp = {2005.11.01},
  year      = {1999},
}

@Book{Collett1994,
  author    = {Collett, D.},
  title     = {Modelling Survival Data in Medical Research},
  publisher = {London: Chapman {\&} Hall},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1994},
}

@Article{Cologne2012,
  author      = {Cologne, John and Preston, Dale L. and Imai, Kazue and Misumi, Munechika and Yoshida, Kengo and Hayashi, Tomonori and Nakachi, Kei},
  title       = {Conventional case-cohort design and analysis for studies of interaction.},
  doi         = {10.1093/ije/dys102},
  language    = {eng},
  number      = {4},
  pages       = {1174--1186},
  url         = {http://dx.doi.org/10.1093/ije/dys102},
  volume      = {41},
  abstract    = {The case-cohort study design has received significant methodological
	attention in the statistical and epidemiological literature but has
	not been used as widely as other cohort-based sampling designs, such
	as the nested case-control design. Despite its efficiency and practicality
	for a wide range of epidemiological study purposes, researchers may
	not yet be aware of the fact that the design can be analysed using
	standard software with only minor adjustments. Furthermore, although
	the large number of options for design and analysis of case-cohort
	studies may be daunting, they can be reduced to a few simple recommendations.We
	review conventional methods for the design and analysis of case-cohort
	studies and describe empirical comparisons based on a study of radiation,
	gene polymorphisms and cancer in the Japanese atomic bomb survivor
	cohort.Stratified, as opposed to simple, random subcohort selection
	is recommended, especially for studies of gene-environment interaction,
	which are notorious for lacking statistical power. Methods based
	on the score-unbiased exact pseudo-likelihood (or its analogue with
	stratified case-cohort data) are recommended for use in conjunction
	with the asymptotic variance estimator.We present an example of how
	to implement case-cohort analysis methods using SPSS, a popular statistical
	package that lacks some of the features necessary to directly adapt
	and implement published methods based on other software platforms.
	We also illustrate case-control analysis using Epicure, which provides
	greater risk-modelling flexibility than other software. Our conclusions
	and recommendations should help investigators to better understand
	and apply the case-cohort design in epidemiological research.},
  file        = {Cologne2012.pdf:pdf\\Cologne2012.pdf:PDF;Cologne2012.pdf:Cologne2012.pdf:PDF},
  institution = {Department of Statistics, Radiation Effects Research Foundation, Hiroshima, Japan. jcologne@rerf.jp},
  journal     = {International Journal of Epidemiology},
  keywords    = {Case-Control Studies; Epidemiologic Methods; Humans; Japan, epidemiology; Lung Neoplasms, epidemiology; Models, Statistical; Neoplasms, Radiation-Induced, epidemiology; Nuclear Warfare; Polymorphism, Genetic, radiation effects; Radiation Injuries, epidemiology; Receptor, Epidermal Growth Factor, genetics; Research Design},
  medline-pst = {ppublish},
  month       = {Aug},
  owner       = {pl4},
  pii         = {dys102},
  pmid        = {22815332},
  timestamp   = {2013.07.05},
  year        = {2012},
}

@Article{Colonna2002,
  author      = {Colonna, M. and Grosclaude, P. and Launoy, G. and Arveux, P. and Buemi, A. and Raverdy, N. and Schaffer, P. and Tretarre, B. and Exbrayat, C. and Faivre, J.},
  title       = {[Estimate of regional prevalence of colorectal cancer in France].},
  language    = {fre},
  number      = {3},
  pages       = {243--251},
  volume      = {50},
  abstract    = {Colorectal cancer prevalence is an important determinant of the health
	demand that completes information provided by cancer incidence. Current
	estimations established from data for the years 1985 and 1995 can
	be used to establish a precise description of changing healthcare
	needs for colorectal cancer.Prevalence estimates method were based
	on incidence data computed on the regional scale by the FRANCIM network
	and mortality data provided by INSERM. We used the relationship that
	exists between the net risk of cancer, the net risk of dying of the
	given cancer and the age-specific prevalence of cancer.In 1995, the
	prevalence of patients who had a diagnosis of colorectal cancer amounted
	to 200 000 persons. The estimated number of prevalent cases was never
	lower than 3500 in any region and in 7 regions this number was higher
	than 10 000. From 1985 to 1995, there has been an increase of 35\%
	in the prevalence rates.The evaluation of the number of persons who
	have had a diagnosis of colorectal cancer provides knowledge for
	health care planning. Such information on the regional scale is very
	useful for the health organisation (SROS). This geographical level
	induces difficulties not encountered at the national level.},
  journal     = {Rev Epidemiol Sante Publique},
  keywords    = {Colorectal Neoplasms, epidemiology; Female; France, epidemiology; Humans; Male; Prevalence},
  medline-pst = {ppublish},
  month       = {Jun},
  owner       = {pl4},
  pii         = {MDOI-RESP-06-2002-50-3-0396-7620-101019-ART2},
  pmid        = {12122341},
  timestamp   = {2013.05.29},
  year        = {2002},
}

@Book{Colton1974,
  author    = {Colton, T.},
  title     = {Statistics in Medicine},
  publisher = {Boston: Little, Brown},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1974},
}

@Article{Colzani2011,
  author      = {Colzani, Edoardo and Liljegren, Annelie and Johansson, Anna L V. and Adolfsson, Jan and Hellborg, Henrik and Hall, Per F L. and Czene, Kamila},
  title       = {Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics.},
  doi         = {10.1200/JCO.2010.32.6462},
  language    = {eng},
  number      = {30},
  pages       = {4014--4021},
  url         = {http://dx.doi.org/10.1200/JCO.2010.32.6462},
  volume      = {29},
  abstract    = {The proportion of women living with a diagnosis of breast cancer in
	developed countries is increasing. Because breast cancer-specific
	deaths decrease with time since diagnosis, it is important to assess
	the burden of other causes of death in women diagnosed with breast
	cancer.Different causes of death within 10 years from diagnosis were
	assessed in 12,850 women younger than 75 years of age with stage
	1 to 3 breast cancer diagnosed in Stockholm and Gotland regions 1990
	to 2006. Flexible parametric survival models were used to estimate
	hazard ratios over time since diagnosis by tumor characteristics
	and age at diagnosis.The proportion of deaths attributed to breast
	cancer ranged from 95.0\% among women younger than age 45 years at
	diagnosis to 44.5\% among women age 65 to 74 years. The proportions
	of circulatory system-specific deaths and deaths resulting from other
	causes increased with older age at diagnosis. Patients with one to
	three positive lymph nodes were more likely to die as a result of
	breast cancer during the first 10 years of follow-up compared with
	women without positive lymph nodes. Women with estrogen receptor
	(ER) -positive tumors had the same risk of dying as a result of breast
	cancer 5 years after diagnosis compared with women with ER-negative
	tumors.Lymph node negativity is an important long-term predictor
	of more favorable prognosis. The nature of the relationship between
	ER status and risk of dying as a result of breast cancer after 5
	years of follow-up requires further investigation. Circulatory system
	diseases are an important cause of death, especially in women diagnosed
	with breast cancer at an older age.},
  file        = {Colzani2011.pdf:Colzani2011.pdf:PDF;Colzani2011.pdf:pdf\\Colzani2011.pdf:PDF},
  institution = {Department of Medical Epidemiology and Biostatistics (MEB), Karolinska Institutet, Stockholm, Sweden. edoardo.colzani@ki.se},
  journal     = {J Clin Oncol},
  medline-pst = {ppublish},
  month       = {Oct},
  owner       = {pl4},
  pii         = {JCO.2010.32.6462},
  pmid        = {21911717},
  timestamp   = {2012.04.13},
  year        = {2011},
}

@Book{Congdon2006,
  author    = {P. Congdon},
  title     = {Bayesian Statistical Modelling},
  publisher = {Wiley},
  address   = {London},
  owner     = {pl4},
  timestamp = {2010.07.15},
  year      = {2006},
}

@Article{Connor1972,
  author    = {Connor, R. J.},
  title     = {Grouping for testing trends in categorical data},
  pages     = {601-604},
  volume    = {67},
  journal   = {Journal of the American Statistical Association},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1972},
}

@Article{Cook1995,
  author      = {R. J. Cook and D. L. Sackett},
  title       = {The number needed to treat: a clinically useful measure of treatment effect.},
  number      = {6977},
  pages       = {452--454},
  volume      = {310},
  abstract    = {The relative benefit of an active treatment over a control is usually
	expressed as the relative risk, the relative risk reduction, or the
	odds ratio. These measures are used extensively in both clinical
	and epidemiological investigations. For clinical decision making,
	however, it is more meaningful to use the measure "number needed
	to treat." This measure is calculated on the inverse of the absolute
	risk reduction. It has the advantage that it conveys both statistical
	and clinical significance to the doctor. Furthermore, it can be used
	to extrapolate published findings to a patient at an arbitrary specified
	baseline risk when the relative risk reduction associated with treatment
	is constant for all levels of risk.},
  institution = {Department of Statistics and Actuarial Science, University of Waterloo, Canada.},
  journal     = {BMJ},
  month       = {Feb},
  owner       = {pl4},
  pmid        = {7873954},
  timestamp   = {2010.11.04},
  year        = {1995},
}

@Article{Cooper2007,
  author      = {Nicola J Cooper and Paul C Lambert and Keith R Abrams and Alexander J Sutton},
  title       = {Predicting costs over time using {B}ayesian {M}arkov chain {M}onte {C}arlo methods: an application to early inflammatory polyarthritis.},
  doi         = {10.1002/hec.1141},
  number      = {1},
  pages       = {37--56},
  url         = {http://dx.doi.org/10.1002/hec.1141},
  volume      = {16},
  abstract    = {This article focuses on the modelling and prediction of costs due
	to disease accrued over time, to inform the planning of future services
	and budgets. It is well documented that the modelling of cost data
	is often problematic due to the distribution of such data; for example,
	strongly right skewed with a significant percentage of zero-cost
	observations. An additional problem associated with modelling costs
	over time is that cost observations measured on the same individual
	at different time points will usually be correlated. In this study
	we compare the performance of four different multilevel/hierarchical
	models (which allow for both the within-subject and between-subject
	variability) for analysing healthcare costs in a cohort of individuals
	with early inflammatory polyarthritis (IP) who were followed-up annually
	over a 5-year time period from 1990/1991. The hierarchical models
	fitted included linear regression models and two-part models with
	log-transformed costs, and two-part model with gamma regression and
	a log link. The cohort was split into a learning sample, to fit the
	different models, and a test sample to assess the predictive ability
	of these models. To obtain predicted costs on the original cost scale
	(rather than the log-cost scale) two different retransformation factors
	were applied. All analyses were carried out using Bayesian Markov
	chain Monte Carlo (MCMC) simulation methods.},
  file        = {cooper2007.pdf:cooper2007.pdf:PDF},
  institution = {Centre for Biostatistics and Genetic Epidemiology, Department of Health Sciences, University of Leicester, UK. njc21@le.ac.uk},
  journal     = {Health Economics},
  month       = {Jan},
  owner       = {pl4},
  pmid        = {16981192},
  timestamp   = {2008.10.15},
  year        = {2007},
}

@Article{Corazziari2004,
  author      = {Isabella Corazziari and Mike Quinn and Riccardo Capocaccia},
  title       = {Standard cancer patient population for age standardising survival ratios.},
  doi         = {10.1016/j.ejca.2004.07.002},
  number      = {15},
  pages       = {2307--2316},
  url         = {http://dx.doi.org/10.1016/j.ejca.2004.07.002},
  volume      = {40},
  abstract    = {Standard adult cancer patients populations are derived in this paper
	as a tool for the calculation of age-standardised cancer survival
	figures. Previously used standards in survival analysis have been
	site- and/or study-specific. Here, multivariate methods have been
	used to define the smallest possible number of general standard cancer
	patient populations which are simple to use and provide standardised
	survival values close to the raw ones for the largest possible number
	of cancer sites. The analysis was based on data for over 1.1 million
	cancer patients included in the EUROCARE-2 study. The proposed standard
	populations consist of three age distributions, appropriate for cancers
	with incidence patterns: (1) increasing with age - the vast majority
	of cancers; (2) broadly constant with age and (3) mainly affecting
	young adults. The three standard distributions are presented by both
	broad and five-year age classes. The latter can be used to determine
	which of the three standards would be used for sites not included
	in the cluster analysis because their survival is generally calculated
	in unusual age groups. Overall, standard 1 is appropriate for over
	91\% of cases, standard 2 for just over 7\%, and standard 3 for less
	than 2\%. The proposed standards were tested on European (EUROCARE-2
	and EUROCARE-3) and US (Surveillance, Epidemiology and End Results
	Program, SEER) relative survival data. There was very good correspondence
	between the raw (population weighted) and age-standardised survival
	figures.},
  file        = {Corazziari2004.pdf:Corazziari2004.pdf:PDF},
  institution = {Centre of Epidemiology, National Institute of Health, viale Regina Elena 299, 00161 Rome, Italy.},
  journal     = {Eur J Cancer},
  month       = {Oct},
  owner       = {PaulD},
  pii         = {S0959-8049(04)00528-3},
  pmid        = {15454257},
  timestamp   = {2008.08.22},
  year        = {2004},
}

@Article{Corbel2002,
  author      = {Corbel, V. and Darriet, F. and Chandre, F. and Hougard, J. M.},
  title       = {Insecticide mixtures for mosquito net impregnation against malaria vectors.},
  language    = {eng},
  number      = {3},
  pages       = {255--259},
  volume      = {9},
  abstract    = {Insecticides belonging to the pyrethroid family are the only compounds
	currently available for the treatment of mosquito nets. Unfortunately,
	some malaria vector species have developed resistance to pyrethroids
	and the lack of alternative chemical categories is a great concern.
	One strategy for resistance management would be to treat mosquito
	nets with a mixture associating two insecticides having different
	modes of action. This study presents the results obtained with insecticide
	mixtures containing several proportions of bifenthrin (a pyrethroid
	insecticide) and carbosulfan (a carbamate insecticide). The mixtures
	were sprayed on mosquito net samples and their efficacy were tested
	against a susceptible strain of Anopheles gambiae, the major malaria
	vector in Africa. A significant synergism was observed with a mixture
	containing 25 mg/m2 of bifenthrin (half the recommended dosage for
	treated nets) and 6.25 mg/m2 of carbosulfan (about 2\% of the recommended
	dosage). The observed mortality was significantly more than expected
	in the absence of any interaction (80\% vs 41\%) and the knock-down
	effect was maintained, providing an effective barrier against susceptible
	mosquitoes.},
  institution = {IRD, 911, avenue Agropolis, BP 64501, 34394 Montpellier, France.},
  journal     = {Parasite},
  keywords    = {Animals; Anopheles; Bedding and Linens; Carbamates; Dose-Response Relationship, Drug; Drug Synergism; Insecticide Resistance; Insecticides; Mosquito Control, methods; Pyrethrins},
  medline-pst = {ppublish},
  month       = {Sep},
  owner       = {pl4},
  pmid        = {12375369},
  timestamp   = {2013.05.29},
  year        = {2002},
}

@Article{Corbiere2009,
  author    = {Fabien Corbiere and Daniel Commenges and Jeremy M. G. Taylor and Pierre Joly},
  title     = {A penalized likelihood approach for mixture cure models},
  pages     = {510-524},
  volume    = {28},
  journal   = {Stat Med},
  owner     = {theand},
  timestamp = {2010.09.29},
  year      = {2009},
}

@Article{Corbineau2001,
  author      = {Corbineau, H. and Lelong, B. and Langanay, T. and Verhoye, J. P. and Leguerrier, A.},
  title       = {Echocardiographic assessment and preliminary clinical results after aortic valve replacement with the Medtronic Mosaic bioprosthesis.},
  language    = {eng},
  number      = {2},
  pages       = {171--176},
  volume      = {10},
  abstract    = {The study aim was to examine prospectively the clinical performance
	and durability of the Medtronic Mosaic bioprosthesis, a stented porcine
	aortic valve that combines improvements in tissue preservation, notably
	net zero differential pressure fixation of the leaflets, with antimineralization
	treatment using 2-amino-oleic acid (AOA).A total of 158 Mosaic valves
	was implanted; 152 in patients aged over 70 years, and six in patients
	aged <70 years with contraindications to anticoagulant therapy. Mean
	age was 73.7 years. All valves were implanted in the supraannular
	position. Thirty-two patients (20\%) required concomitant procedures,
	including coronary revascularization, ascending aorta replacement
	and/or mitral annuloplasty. Postoperative anticoagulation (heparin)
	was prescribed for ten days, followed by antiplatelet therapy. No
	long-term oral anticoagulants were prescribed, except in some patients
	with atrial fibrillation. The follow up included routine clinical
	and blood work-up, and echocardiography at six months and one year
	after surgery.There were seven early (0-30 days) and five late deaths
	(>30 days). One death was caused by a hemorrhagic stroke at three
	months in a patient without anticoagulant or antiplatelet therapy.
	No thromboembolic complications or structural valve deterioration
	were observed during follow up. At two years, freedom from endocarditis
	and reoperation was each 99.6\%. NYHA class was excellent, with 98\%
	of patients in class I or II at one year. Patient survival was 92\%
	at two years. Hemodynamically, the valve was performing well, with
	mean systolic gradients of 13.6, 13.2, 12.6 and 9.6 mmHg for the
	21, 23, 25 and 27 mm valves, respectively. There was no evidence
	of structural valve deterioration.Long-term evaluations are mandatory
	to confirm the durability of any new bioprosthetic valve. Satisfactory
	early clinical and hemodynamic results with the new Mosaic bioprosthesis
	warrant its continued implantation in the aortic position for patients
	over the age of 70 years.},
  institution = {Department of Cardiovascular and Thoracic Surgery, University Hospital Center, Rennes, France.},
  journal     = {J Heart Valve Dis},
  keywords    = {Aged; Aged, 80 and over; Aortic Valve, physiopathology/transplantation/ultrasonography; Equipment Failure Analysis; Female; Heart Valve Diseases, physiopathology/surgery/ultrasonography; Heart Valve Prosthesis; Hemodynamics, physiology; Humans; Male; Middle Aged; Prospective Studies; Time Factors},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {pl4},
  pmid        = {11297203},
  timestamp   = {2013.05.29},
  year        = {2001},
}

@Article{Corder1993,
  author    = {Corder, E. H. and Saunders, A. M. and Strittmatter, W. J. and Schmechel, D. E. and Gaskell, P. C. and Small, G. W. and Roses, A. D. and Haines, J. L. and Pericak-Vance, M. A.},
  title     = {Gene dose of apolipoprotein $E$ type 4 allele and the risk of {A}lzheimer's disease in late onset families},
  pages     = {828-9},
  volume    = {261},
  journal   = {Science},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1993},
}

@Article{Cortese2008,
  author      = {Cortese, Giuliana and Scheike, Thomas H.},
  title       = {Dynamic regression hazards models for relative survival.},
  doi         = {10.1002/sim.3242},
  language    = {eng},
  number      = {18},
  pages       = {3563--3584},
  url         = {http://dx.doi.org/10.1002/sim.3242},
  volume      = {27},
  abstract    = {A natural way of modelling relative survival through regression analysis
	is to assume an additive form between the expected population hazard
	and the excess hazard due to the presence of an additional cause
	of mortality. Within this context, the existing approaches in the
	parametric, semiparametric and non-parametric setting are compared
	and discussed. We study the additive excess hazards models, where
	the excess hazard is on additive form. This makes it possible to
	assess the importance of time-varying effects for regression models
	in the relative survival framework. We show how recent developments
	can be used to make inferential statements about the non-parametric
	version of the model. This makes it possible to test the key hypothesis
	that an excess risk effect is time varying in contrast to being constant
	over time. In case some covariate effects are constant, we show how
	the semiparametric additive risk model can be considered in the excess
	risk setting, providing a better and more useful summary of the data.
	Estimators have explicit form and inference based on a resampling
	scheme is presented for both the non-parametric and semiparametric
	models. We also describe a new suggestion for goodness of fit of
	relative survival models, which consists on statistical and graphical
	tests based on cumulative martingale residuals. This is illustrated
	on the semiparametric model with proportional excess hazards. We
	analyze data from the TRACE study using different approaches and
	show the need for more flexible models in relative survival.},
  file        = {Cortese2008.pdf:Cortese2008.pdf:PDF;Cortese2008.pdf:pdf\\Cortese2008.pdf:PDF},
  groups      = {Excess mortality model},
  institution = {Department of Statistical Sciences, University of Padova, Via Cesare Battisti 241/243, 35121 Padova, Italy. gcortese@stat.unipd.it},
  journal     = {Stat Med},
  keywords    = {Algorithms; Biomedical Research, statistics /&/ numerical data; Cohort Studies; Denmark; Female; Humans; Male; Myocardial Infarction, mortality; Proportional Hazards Models; Survival Analysis},
  medline-pst = {ppublish},
  month       = {Aug},
  owner       = {sanelo},
  pmid        = {18338318},
  timestamp   = {2013.09.16},
  year        = {2008},
}

@Article{Coviello2015,
  author    = {E. Coviello and P. W. Dickman and K. Sepp\"{a} and A. Pokhrel},
  title     = {Estimating net survival using a life table approach},
  number    = {1},
  pages     = {173-185},
  url       = {http://www.stata-journal.com/article.html?article=st0375},
  volume    = {15},
  file      = {Coviello2015.pdf:Coviello2015.pdf:PDF;Coviello2015.pdf:pdf\\Coviello2015.pdf:PDF},
  journal   = {The Stata Journal},
  owner     = {PaulD},
  timestamp = {2015.09.23},
  year      = {2015},
}

@Article{Coviello2004,
  author    = {V. Coviello and M. Boggess},
  title     = {Cumulative incidence estimation in the presence of competing risks},
  pages     = {103-112},
  volume    = {4},
  file      = {Coviello2004.pdf:Coviello2004.pdf:PDF;Coviello2004.pdf:pdf\\Coviello2004.pdf:PDF},
  journal   = {The Stata Journal},
  owner     = {pl4},
  timestamp = {2010.07.05},
  year      = {2004},
}

@Article{Cox2008,
  author      = {Christopher Cox},
  title       = {The generalized {F} distribution: an umbrella for parametric survival analysis.},
  doi         = {10.1002/sim.3292},
  number      = {21},
  pages       = {4301--4312},
  url         = {http://dx.doi.org/10.1002/sim.3292},
  volume      = {27},
  abstract    = {In a recent tutorial my colleagues and I advocated the generalized
	gamma (GG) distribution as a platform for parametric survival analysis.
	The GG family includes all four of the common types of hazard functions,
	making it particularly useful for estimating individual hazard functions
	as well as both relative hazards and relative times. In addition,
	the GG includes most of the commonly used parametric survival distributions.
	Survival analysis based on the GG distribution is practical since
	regression models are available in commonly used statistical packages.
	It is well known that the GG is contained in an even larger family,
	the generalized F (GF) distribution, which also includes the log
	logistic. The GF thus provides additional flexibility for parametric
	modeling. In this paper we discuss the GF family from this perspective.
	We provide a characterization of the hazard functions of the GF,
	showing that, except for the GG, the available hazard functions are
	limited to decreasing and arc-shaped hazards and, in particular,
	that the hazard function can be decreasing but not monotone. We also
	discuss fitting the GF with an alternative parameterization using
	standard statistical software and refine a description of the hazard
	functions for death after a diagnosis of clinical AIDS in four different
	eras of HIV therapy.},
  file        = {cox2008.pdf:cox2008.pdf:PDF},
  institution = {Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Room E7642, Baltimore, MD 21205, USA. ccox@jhsph.edu},
  journal     = {Statistics in Medicine},
  month       = {Sep},
  owner       = {pl4},
  pmid        = {18407568},
  timestamp   = {2008.10.14},
  year        = {2008},
}

@Article{Cox1972,
  author    = {D. R. Cox},
  title     = {Regression models and life-tables (with discussion)},
  pages     = {187--220},
  volume    = {34},
  file      = {:cox1972.pdf:PDF},
  journal   = {JRSSB},
  timestamp = {2005.11.01},
  year      = {1972},
}

@Article{Cox1959,
  author    = {Cox, D. R.},
  title     = {The Analysis of Exponentially Distributed Life-Times with Two Types of Failure},
  issn      = {00359246},
  language  = {English},
  number    = {2},
  pages     = {411-421},
  url       = {http://www.jstor.org/stable/2983812},
  volume    = {21},
  abstract  = {A number of alternative probability models are considered for the
	interpretation of failure data when there are two or more types of
	failure. Some of the statistical techniques that can be used for
	such data are illustrated on an example discussed recently by Mendenhall
	and Hader.},
  journal   = {Journal of the Royal Statistical Society. Series B (Methodological)},
  owner     = {PaulD},
  timestamp = {2015.03.25},
  year      = {1959},
}

@Article{Cox1957,
  author    = {D. R. Cox},
  title     = {Note on grouping},
  pages     = {543--547},
  volume    = {52},
  file      = {Cox1957.pdf:Cox1957.pdf:PDF;Cox1957.pdf:pdf\\Cox1957.pdf:PDF},
  journal   = {Journal of the American Statistical Association},
  owner     = {pl4},
  timestamp = {2010.03.08},
  year      = {1957},
}

@Book{Cox2000,
  author    = {Cox, D. R. and Reid, N.},
  title     = {The theory of the design of experiments},
  publisher = {Boca Raton: Chapman \& Hall/CRC},
  series    = {Monographs on statistics and applied probability, 86},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2000},
}

@Article{Cronin2000,
  author      = {K. A. Cronin and E. J. Feuer},
  title       = {Cumulative cause-specific mortality for cancer patients in the presence of other causes: a crude analogue of relative survival.},
  number      = {13},
  pages       = {1729--1740},
  volume      = {19},
  abstract    = {A common population-based cancer progress measure for net survival
	(survival in the absence of other causes) of cancer patients is relative
	survival. Relative survival is defined as the ratio of a population
	of observed survivors in a cohort of cancer patients to the proportion
	of expected survivors in a comparable set of cancer-free individuals
	in the general public, thus giving a measure of excess mortality
	due to cancer. Relative survival was originally designed to address
	the question of whether or not there is evidence that patients have
	been cured. It has proven to be a useful survival measure in several
	areas, including the evaluation of cancer control efforts and the
	application of cure models. However, it is not representative of
	the actual survival patterns observed in a cohort of cancer patients.
	This paper suggests a measure for cumulative crude (in the presence
	of other causes) cause-specific probability of death for a population
	diagnosed with cancer. The measure does not use cause of death information
	which can be unreliable for population cancer registries. Point estimates
	and variances are derived for crude cause-specific probability of
	death using relative survival instead of cause of death information.
	Examples are given for men diagnosed with localized prostate cancer
	over the age of 70 and women diagnosed with regional breast cancer
	using Surveillance, Epidemiology and End Results (SEER) Program data.
	The examples emphasize the differences in crude and net mortality
	measures and suggest areas where a crude measure is more informative.
	Estimates of this type are especially important for older patients
	as new screening modalities detect cancers earlier and choice of
	treatment or even 'watchful waiting' become viable options. Published
	in 2000 by John Wiley & Sons, Ltd.},
  file        = {:pdf\\cronin2000.pdf:PDF},
  institution = {Applied Research Branch, National Cancer Institute, EPN 4103, 6130 Executive Boulevard, Bethesda, MD 20892, USA. cronink@dcpcepn.nci.nih.gov},
  journal     = {Statistics in Medicine},
  keywords    = {Cure models},
  owner       = {pl4},
  pii         = {3.0.CO;2-9},
  pmid        = {10861774},
  timestamp   = {2008.10.29},
  year        = {2000},
}

@Article{Crowther2013a,
  author    = {Crowther, M. J. and Abrams, K. R. and Lambert, P. C.},
  title     = {Joint modelling of longitudinal and survival data},
  pages     = {165-184},
  volume    = {13},
  file      = {Crowther2013a.pdf:pdf\\Crowther2013a.pdf:PDF},
  journal   = {The Stata Journal},
  owner     = {pl4},
  timestamp = {2013.03.21},
  year      = {2013},
}

@Article{Crowther2012,
  author      = {Crowther, M. J. and Abrams, K. R. and Lambert, P. C.},
  title       = {Flexible parametric joint modelling of longitudinal and survival data.},
  doi         = {10.1002/sim.5644},
  language    = {eng},
  number      = {30},
  pages       = {4456--4471},
  url         = {http://dx.doi.org/10.1002/sim.5644},
  volume      = {31},
  abstract    = {The joint modelling of longitudinal and survival data is a highly
	active area of biostatistical research. The submodel for the longitudinal
	biomarker usually takes the form of a linear mixed effects model.
	We describe a flexible parametric approach for the survival submodel
	that models the log baseline cumulative hazard using restricted cubic
	splines. This approach overcomes limitations of standard parametric
	choices for the survival submodel, which can lack the flexibility
	to effectively capture the shape of the underlying hazard function.
	Numerical integration techniques, such as Gauss-Hermite quadrature,
	are usually required to evaluate both the cumulative hazard and the
	overall joint likelihood; however, by using a flexible parametric
	model, the cumulative hazard has an analytically tractable form,
	providing considerable computational benefits. We conduct an extensive
	simulation study to assess the proposed model, comparing it with
	a B-spline formulation, illustrating insensitivity of parameter estimates
	to the baseline cumulative hazard function specification. Furthermore,
	we compare non-adaptive and fully adaptive quadrature, showing the
	superiority of adaptive quadrature in evaluating the joint likelihood.
	We also describe a useful technique to simulate survival times from
	complex baseline hazard functions and illustrate the methods using
	an example data set investigating the association between longitudinal
	prothrombin index and survival of patients with liver cirrhosis,
	showing greater flexibility and improved stability with fewer parameters
	under the proposed model compared with the B-spline approach. We
	provide user-friendly Stata software.},
  file        = {Crowther2012.pdf:Crowther2012.pdf:PDF},
  institution = {Department of Health Sciences, University of Leicester, Adrian Building, University Road, Leicester, LE1 7RH, UK. michael.crowther@le.ac.uk},
  journal     = {Statistics in Medicine},
  medline-pst = {ppublish},
  month       = {Dec},
  owner       = {pl4},
  pmid        = {23037571},
  timestamp   = {2013.03.05},
  year        = {2012},
}

@Article{Crowther2016a,
  author    = {Crowther, M. J. and Lambert, P C},
  title     = {Parametric multi-state survival models: flexible modelling allowing transition-specific distributions with application to estimating clinically useful measures of effect differences},
  doi       = {10.1002/sim.7448},
  pages     = {4719-4742},
  volume    = {36},
  file      = {:Crowther2016a.pdf:PDF},
  journal   = {Statistics in Medicine},
  owner     = {miccro},
  pmid      = {28872690},
  timestamp = {2016.04.27},
  year      = {2017},
}

@Article{Crowther2014,
  author      = {Crowther, M.J. and Lambert, P.C.},
  title       = {A general framework for parametric survival analysis.},
  doi         = {10.1002/sim.6300},
  language    = {eng},
  number      = {30},
  pages       = {5280--5297},
  url         = {http://dx.doi.org/10.1002/sim.6300},
  volume      = {33},
  abstract    = {Parametric survival models are being increasingly used as an alternative
	to the Cox model in biomedical research. Through direct modelling
	of the baseline hazard function, we can gain greater understanding
	of the risk profile of patients over time, obtaining absolute measures
	of risk. Commonly used parametric survival models, such as the Weibull,
	make restrictive assumptions of the baseline hazard function, such
	as monotonicity, which is often violated in clinical datasets. In
	this article, we extend the general framework of parametric survival
	models proposed by Crowther and Lambert (Journal of Statistical Software
	53:12, 2013), to incorporate relative survival, and robust and cluster
	robust standard errors. We describe the general framework through
	three applications to clinical datasets, in particular, illustrating
	the use of restricted cubic splines, modelled on the log hazard scale,
	to provide a highly flexible survival modelling framework. Through
	the use of restricted cubic splines, we can derive the cumulative
	hazard function analytically beyond the boundary knots, resulting
	in a combined analytic/numerical approach, which substantially improves
	the estimation process compared with only using numerical integration.
	User-friendly Stata software is provided, which significantly extends
	parametric survival models available in standard software.},
  file        = {Crowther2014.pdf:Crowther2014.pdf:PDF;Crowther2014.pdf:pdf\\Crowther2014.pdf:PDF},
  institution = {Department of Health Sciences, University of Leicester, Adrian Building, University Road, Leicester, LE1 7RH, U.K.},
  journal     = {Statistics in Medicine},
  medline-pst = {ppublish},
  owner       = {pl4},
  pmid        = {25220693},
  timestamp   = {2015.02.16},
  year        = {2014},
}

@Article{Crowther2013,
  author    = {M. J. Crowther and P. C. Lambert},
  title     = {stgenreg: A Stata Package for General Parametric Survival Analysis},
  doi       = {10.18637/jss.v053.i12},
  pages     = {1-17},
  volume    = {53},
  file      = {Crowther2013.pdf:pdf\\Crowther2013.pdf:PDF},
  journal   = {Journal of Statistical Software},
  owner     = {pl4},
  timestamp = {2013.03.05},
  year      = {2013},
}

@Article{Crowther2013c,
  author      = {Crowther, M.J. and Lambert, P.C.},
  title       = {Simulating biologically plausible complex survival data},
  doi         = {10.1002/sim.5823},
  language    = {eng},
  pages       = {4118--4134},
  url         = {http://dx.doi.org/10.1002/sim.5823},
  volume      = {32},
  abstract    = {Simulation studies are conducted to assess the performance of current
	and novel statistical models in pre-defined scenarios. It is often
	desirable that chosen simulation scenarios accurately reflect a biologically
	plausible underlying distribution. This is particularly important
	in the framework of survival analysis, where simulated distributions
	are chosen for both the event time and the censoring time. This paper
	develops methods for using complex distributions when generating
	survival times to assess methods in practice. We describe a general
	algorithm involving numerical integration and root-finding techniques
	to generate survival times from a variety of complex parametric distributions,
	incorporating any combination of time-dependent effects, time-varying
	covariates, delayed entry, random effects and covariates measured
	with error. User-friendly Stata software is provided.},
  file        = {Crowther2013c.pdf:pdf\\Crowther2013c.pdf:PDF},
  institution = {University of Leicester, Department of Health Sciences, Adrian Building, University Road, Leicester LE1 7RH, U.K.},
  journal     = {Statistics in Medicine},
  medline-pst = {aheadofprint},
  owner       = {pl4},
  pmid        = {23613458},
  timestamp   = {2014.01.02},
  year        = {2013},
}

@Article{Crowther2012b,
  author    = {Crowther, M. J. and Lambert, P. C.},
  title     = {Simulating complex survival data},
  pages     = {674-687},
  volume    = {12},
  file      = {Crowther2012b.pdf:pdf\\Crowther2012b.pdf:PDF},
  journal   = {The Stata Journal},
  owner     = {pl4},
  timestamp = {2013.03.21},
  year      = {2012},
}

@Article{Crowther2013b,
  author      = {Crowther, M. J. and Lambert, P. C. and Abrams, K. R.},
  title       = {Adjusting for measurement error in baseline prognostic biomarkers included in a time-to-event analysis: a joint modelling approach.},
  doi         = {10.1186/1471-2288-13-146},
  language    = {eng},
  pages       = {146},
  url         = {http://dx.doi.org/10.1186/1471-2288-13-146},
  volume      = {13},
  abstract    = {Methodological development of joint models of longitudinal and survival
	data has been rapid in recent years; however, their full potential
	in applied settings are yet to be fully explored. We describe a novel
	use of a specific association structure, linking the two component
	models through the subject specific intercept, and thus extend joint
	models to account for measurement error in a biomarker, even when
	only the baseline value of the biomarker is of interest. This is
	a common occurrence in registry data sources, where often repeated
	measurements exist but are simply ignored.The proposed specification
	is evaluated through simulation and applied to data from the General
	Practice Research Database, investigating the association between
	baseline Systolic Blood Pressure (SBP) and the time-to-stroke in
	a cohort of obese patients with type 2 diabetes mellitus.By directly
	modelling the longitudinal component we reduce bias in the hazard
	ratio for the effect of baseline SBP on the time-to-stroke, showing
	the large potential to improve on previous prognostic models which
	use only observed baseline biomarker values.The joint modelling of
	longitudinal and survival data is a valid approach to account for
	measurement error in the analysis of a repeatedly measured biomarker
	and a time-to-event. User friendly Stata software is provided.},
  file        = {Crowther2013b.pdf:pdf\\Crowther2013b.pdf:PDF},
  institution = {University of Leicester, Department of Health Sciences, Adrian Building, University Road, Leicester LE1 7RH, UK. michael.crowther@le.ac.uk.},
  journal     = {BMC Medical Research Methodology},
  medline-pst = {epublish},
  owner       = {pl4},
  pii         = {1471-2288-13-146},
  pmid        = {24289257},
  timestamp   = {2014.01.02},
  year        = {2013},
}

@Article{Crowther2014b,
  author      = {Crowther, Michael J. and Look, Maxime P. and Riley, Richard D.},
  title       = {Multilevel mixed effects parametric survival models using adaptive Gauss-Hermite quadrature with application to recurrent events and individual participant data meta-analysis.},
  doi         = {10.1002/sim.6191},
  language    = {eng},
  number      = {22},
  pages       = {3844--3858},
  url         = {http://dx.doi.org/10.1002/sim.6191},
  volume      = {33},
  abstract    = {Multilevel mixed effects survival models are used in the analysis
	of clustered survival data, such as repeated events, multicenter
	clinical trials, and individual participant data (IPD) meta-analyses,
	to investigate heterogeneity in baseline risk and covariate effects.
	In this paper, we extend parametric frailty models including the
	exponential, Weibull and Gompertz proportional hazards (PH) models
	and the log logistic, log normal, and generalized gamma accelerated
	failure time models to allow any number of normally distributed random
	effects. Furthermore, we extend the flexible parametric survival
	model of Royston and Parmar, modeled on the log-cumulative hazard
	scale using restricted cubic splines, to include random effects while
	also allowing for non-PH (time-dependent effects). Maximum likelihood
	is used to estimate the models utilizing adaptive or nonadaptive
	Gauss-Hermite quadrature. The methods are evaluated through simulation
	studies representing clinically plausible scenarios of a multicenter
	trial and IPD meta-analysis, showing good performance of the estimation
	method. The flexible parametric mixed effects model is illustrated
	using a dataset of patients with kidney disease and repeated times
	to infection and an IPD meta-analysis of prognostic factor studies
	in patients with breast cancer. User-friendly Stata software is provided
	to implement the methods.},
  file        = {Crowther2014b.pdf:Crowther2014b.pdf:PDF;Crowther2014b.pdf:pdf\\Crowther2014b.pdf:PDF},
  institution = {University of Leicester, Department of Health Sciences, Adrian Building, University Road, Leicester LE1 7RH, U.K.},
  journal     = {Stat Med},
  medline-pst = {ppublish},
  month       = {Sep},
  owner       = {pl4},
  pmid        = {24789760},
  timestamp   = {2014.11.27},
  year        = {2014},
}

@Article{Cupples1995,
  author    = {L. A. Cupples and D. R. Gagnon and R. Ramaswamy and R. B. D'Agostino},
  title     = {Age-adjusted survival curves with application in the {F}ramingham Study},
  pages     = {1731-1744},
  volume    = {14},
  file      = {Cupples1995.pdf:pdf\\Cupples1995.pdf:PDF;Cupples1995.pdf:Cupples1995.pdf:PDF},
  journal   = {Statistics in Medicine},
  owner     = {pl4},
  timestamp = {2016.02.17},
  year      = {1995},
}

@Article{Curtis1993,
  author    = {Curtis, J. R. and Patrick, D. L.},
  title     = {Race and Survival Time With {AIDS}: {A} Synthesis of the Literature},
  pages     = {1425-1428},
  volume    = {83},
  journal   = {American Journal of Public Health},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1993},
}

@Article{Cutler1963,
  author    = {Cutler, S. J. and Axtell, L. M.},
  title     = {Partitioning of a Patient Population with Respect to Different Mortality Patterns},
  pages     = {701-712},
  volume    = {58},
  file      = {Cutler1963.pdf:pdf\\Cutler1963.pdf:PDF;Cutler1963.pdf:Cutler1963.pdf:PDF},
  journal   = {Journal of the American Statistical Association},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1963},
}

@Article{Cutler1958,
  author    = {S. J. Cutler And F. Ederer},
  title     = {{M}aximum utilization of the life table method in analyzing survival.},
  number    = {6},
  pages     = {699--712},
  volume    = {8},
  journal   = {J Chronic Dis},
  owner     = {PaulD},
  pmid      = {13598782},
  timestamp = {2006.04.25},
  year      = {1958},
}

@Article{Cvancarova2013,
  author    = {Cvancarova, Milada and Aagnes, Bjarte and FossÃ¥, Sophie D. and Lambert, Paul C and MÃ¸ller, BjÃ¸rn and Bray, Freddie},
  title     = {Proportion cured models applied to 23 cancer sites in Norway},
  doi       = {10.1002/ijc.27802},
  issn      = {1097-0215},
  number    = {7},
  pages     = {1700â€“1710},
  url       = {http://dx.doi.org/10.1002/ijc.27802},
  volume    = {132},
  journal   = {International Journal of Cancer},
  month     = dec,
  publisher = {Wiley},
  year      = {2012},
}

@Article{Daling2002,
  author    = {Janet R Daling and Kathleen E Malone and David R Doody and Lynda F Voigt and Leslie Bernstein and Ralph J Coates and Polly A Marchbanks and Sandra A Norman and Linda K Weiss and Giske Ursin and Jesse A Berlin and Ronald T Burkman and Dennis Deapen and Suzanne G Folger and Jill A McDonald and Michael S Simon and Brian L Strom and Phyllis A Wingo and Robert Spirtas},
  title     = {Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma.},
  doi       = {10.1002/cncr.10984},
  number    = {12},
  pages     = {2455-64},
  url       = {http://dx.doi.org/10.1002/cncr.10984},
  volume    = {95},
  abstract  = {BACKGROUND: The incidence of invasive lobular carcinoma has been increasing
	among postmenopausal women in some parts of the United States. Part
	of this may be due to changes in classification over time. However,
	the use of combined (estrogen and progestin) hormone replacement
	therapy (CHRT) also has increased during the last decade and may
	account in part for the increase in invasive lobular breast carcinoma.
	METHODS: A large, multicenter case-control study of Caucasian and
	African-American women who were diagnosed at age < 65 years with
	their first invasive breast tumor from July 1, 1994 through April
	30, 1998 was conducted. In-person interviews were conducted with
	1749 postmenopausal patients, and their responses were compared with
	the responses of 1953 postmenopausal control women identified through
	random-digit dialing who met the study criteria of being postmenopausal
	at the time of diagnosis. Polytomous logistic regression was used
	to calculate the odds ratio (OR) as an estimate of the relative risk
	and to compute the 95\% confidence interval (95\%CI) associated with
	the use of various regimens of hormone replacement therapy (HRT)
	among women diagnosed with ductal breast carcinoma, lobular (or mixed
	lobular and ductal) breast carcinoma, and a grouping of other histologic
	types of breast carcinoma. RESULTS: Ever use of unopposed estrogen
	therapy (ERT) was not associated with an increase in the risk of
	any histologic type of breast carcinoma. The risk of invasive lobular
	breast carcinoma and the risk of breast carcinoma of the grouping
	of other histologies increased among women currently using CHRT (OR,
	2.2; 95\%CI, 1.4-3.3; and OR, 1.9; 95\%CI, 1.0-3.4, respectively).
	The risk increase was greater for the mixed lobular-ductal type than
	for the pure lobular type of breast carcinoma, although the difference
	was not statistically significant. There was some indication that
	>or= 5 years of continuous CHRT (>or= 25 days per month of progestin)
	was associated with a higher risk of lobular breast carcinoma (OR,
	2.5; 95\%CI, 1.4-4.3) compared with sequential CHRT (< 25 days per
	month of progestin; OR, 1.5; 95\%CI, 0.8-2.6). Current use of continuous
	CHRT was only moderately associated with risk of ductal breast carcinoma.
	CONCLUSIONS: Postmenopausal women who take CHRT appear to be at an
	increased risk of lobular breast carcinoma. Data from this study
	suggest that neither ERT use nor CHRT substantially increase the
	risk of ductal breast carcinoma among women age < 65 years.},
  journal   = {Cancer},
  month     = {Dec},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2002},
}

@Article{dane:lock:1995,
  author    = {Danehy, Timothy J. and Lock, Robin H.},
  title     = {{CHODR} -- {U}sing Statistics to Predict College Hockey},
  pages     = {10--14},
  volume    = {13},
  journal   = {Stats. The Magazine for Students of Statistics},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@Article{Danieli2012,
  author      = {Danieli, Coraline and Remontet, Laurent and Bossard, Nadine and Roche, Laurent and Belot, Aur\'{e}lien},
  title       = {Estimating net survival: the importance of allowing for informative censoring.},
  doi         = {10.1002/sim.4464},
  language    = {eng},
  number      = {8},
  pages       = {775--786},
  url         = {http://dx.doi.org/10.1002/sim.4464},
  volume      = {31},
  abstract    = {Net survival, the one that would be observed if cancer were the only
	cause of death, is the most appropriate indicator to compare cancer
	mortality between areas or countries. Several parametric and non-parametric
	methods have been developed to estimate net survival, particularly
	when the cause of death is unknown. These methods are based either
	on the relative survival ratio or on the additive excess hazard model,
	the latter using the general population mortality hazard to estimate
	the excess mortality hazard (the hazard related to net survival).
	The present work used simulations to compare estimator abilities
	to estimate net survival in different settings such as the presence/absence
	of an age effect on the excess mortality hazard or on the potential
	time of follow-up, knowing that this covariate has an effect on the
	general population mortality hazard too. It showed that when age
	affected the excess mortality hazard, most estimators, including
	specific survival, were biased. Only two estimators were appropriate
	to estimate net survival. The first is based on a multivariable excess
	hazard model that includes age as covariate. The second is non-parametric
	and is based on the inverse probability weighting. These estimators
	take differently into account the informative censoring induced by
	the expected mortality process. The former offers great flexibility
	whereas the latter requires neither the assumption of a specific
	distribution nor a model-building strategy. Because of its simplicity
	and availability in commonly used software, the nonparametric estimator
	should be considered by cancer registries for population-based studies.},
  file        = {Danieli2012.pdf:pdf\\Danieli2012.pdf:PDF},
  institution = {Hospices Civils de Lyon, Service de Biostatistique, F-69003, Lyon, France. coraline.danieli@chu-lyon.fr},
  journal     = {Stat Med},
  medline-pst = {ppublish},
  month       = {Apr},
  owner       = {pl4},
  pmid        = {22281942},
  timestamp   = {2012.05.10},
  year        = {2012},
}

@Article{Darby2003,
  author      = {Darby, Sarah and McGale, Paul and Peto, Richard and Granath, Fredrik and Hall, Per and Ekbom, Anders},
  title       = {Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90 000 {S}wedish women.},
  language    = {eng},
  number      = {7383},
  pages       = {256--257},
  volume      = {326},
  institution = {Clinical Trial Service Unit and Epidemiological Studies Unit, Radcliffe Infirmary, Oxford OX2 6HE. sarah.darby@ctsu.ox.ac.uk},
  journal     = {BMJ},
  keywords    = {Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms, mortality/radiotherapy; Cardiovascular Diseases, mortality; Cohort Studies; Female; Humans; Middle Aged; Survival Rate; Sweden, epidemiology},
  medline-pst = {ppublish},
  month       = {Feb},
  owner       = {sanelo},
  pmid        = {12560277},
  timestamp   = {2013.08.02},
  year        = {2003},
}

@Article{Darby2013,
  author      = {Darby, Sarah C. and Ewertz, Marianne and McGale, Paul and Bennet, Anna M. and Blom-Goldman, Ulla and Br{\AA}Â¸nnum, Dorthe and Correa, Candace and Cutter, David and Gagliardi, Giovanna and Gigante, Bruna and Jensen, Maj-Britt and Nisbet, Andrew and Peto, Richard and Rahimi, Kazem and Taylor, Carolyn and Hall, Per},
  title       = {Risk of ischemic heart disease in women after radiotherapy for breast cancer.},
  doi         = {10.1056/NEJMoa1209825},
  language    = {eng},
  number      = {11},
  pages       = {987--998},
  url         = {http://dx.doi.org/10.1056/NEJMoa1209825},
  volume      = {368},
  abstract    = {Radiotherapy for breast cancer often involves some incidental exposure
	of the heart to ionizing radiation. The effect of this exposure on
	the subsequent risk of ischemic heart disease is uncertain.We conducted
	a population-based case-control study of major coronary events (i.e.,
	myocardial infarction, coronary revascularization, or death from
	ischemic heart disease) in 2168 women who underwent radiotherapy
	for breast cancer between 1958 and 2001 in Sweden and Denmark; the
	study included 963 women with major coronary events and 1205 controls.
	Individual patient information was obtained from hospital records.
	For each woman, the mean radiation doses to the whole heart and to
	the left anterior descending coronary artery were estimated from
	her radiotherapy chart.The overall average of the mean doses to the
	whole heart was 4.9 Gy (range, 0.03 to 27.72). Rates of major coronary
	events increased linearly with the mean dose to the heart by 7.4\%
	per gray (95\% confidence interval, 2.9 to 14.5; P<0.001), with no
	apparent threshold. The increase started within the first 5 years
	after radiotherapy and continued into the third decade after radiotherapy.
	The proportional increase in the rate of major coronary events per
	gray was similar in women with and women without cardiac risk factors
	at the time of radiotherapy.Exposure of the heart to ionizing radiation
	during radiotherapy for breast cancer increases the subsequent rate
	of ischemic heart disease. The increase is proportional to the mean
	dose to the heart, begins within a few years after exposure, and
	continues for at least 20 years. Women with preexisting cardiac risk
	factors have greater absolute increases in risk from radiotherapy
	than other women. (Funded by Cancer Research UK and others.).},
  institution = {Clinical Trial Service Unit, University of Oxford, Oxford, United Kingdom. sarah.darby@ctsu.ox.ac.uk},
  journal     = {N Engl J Med},
  keywords    = {Adult; Aged; Breast Neoplasms, complications/drug therapy/radiotherapy/surgery; Case-Control Studies; Chemotherapy, Adjuvant; Female; Heart, radiation effects; Humans; Mastectomy; Middle Aged; Myocardial Ischemia, etiology/mortality; Radiation Injuries, etiology/mortality; Radiotherapy Dosage; Radiotherapy, Adjuvant, adverse effects; Risk; Risk Factors},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {sanelo},
  pmid        = {23484825},
  timestamp   = {2013.10.10},
  year        = {2013},
}

@Article{Darby2005,
  author      = {Darby, Sarah C. and McGale, Paul and Taylor, Carolyn W. and Peto, Richard},
  title       = {Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in {US} {SEER} cancer registries.},
  doi         = {10.1016/S1470-2045(05)70251-5},
  language    = {eng},
  number      = {8},
  pages       = {557--565},
  url         = {http://dx.doi.org/10.1016/S1470-2045(05)70251-5},
  volume      = {6},
  abstract    = {Radiotherapy for early breast cancer can decrease breast cancer mortality
	but increase other mortality, mainly from heart disease and lung
	cancer. The mean cardiac dose from irradiation of a left-sided breast
	cancer can be two or three times that for a right-sided breast cancer.
	The mean ipsilateral (ie, on the same side as the breast cancer)
	lung dose can also be two or three times the mean contralateral lung
	dose. Particularly during the 1970s, when typical heart and lung
	exposures were greater than now, the laterality of an irradiated
	breast cancer could measurably affect cardiac mortality and mortality
	from cancer of the right or the left lung decades later. This study
	aimed to assess the hazards in the general US population from routine
	cancer-registry and death-certificate data.We analysed data for 308
	861 US women with early breast cancer of known laterality (left-sided
	or right-sided) who were registered in the US Surveillance Epidemiology
	and End Results (SEER) cancer registries during 1973-2001 and followed
	prospectively for cause-specific mortality until Jan 1, 2002.115
	165 (37\%) received radiotherapy. Among those who did not, tumour
	laterality was of little relevance to subsequent mortality. For women
	diagnosed during 1973-82 and irradiated, the cardiac mortality ratio
	(left versus right tumour laterality) was 1.20 (95\% CI 1.04-1.38)
	less than 10 years afterwards, 1.42 (1.11-1.82) 10-14 years afterwards,
	and 1.58 (1.29-1.95) after 15 years or more (trend: 2p=0.03). For
	women diagnosed during 1983-92 and irradiated, the cardiac mortality
	ratio was 1.04 (0.91-1.18) less than 10 years afterwards and 1.27
	(0.99-1.63) 10 or more years afterwards. For women diagnosed during
	1993-2001 and irradiated the cardiac mortality ratio was 0.96 (0.82-1.12),
	with none yet followed for 10 years. Among women irradiated for breast
	cancer who subsequently developed an ipsilateral or contralateral
	lung cancer, the lung cancer mortality ratio (ipsilateral versus
	contralateral) for women diagnosed during 1973-82 and irradiated
	was 1.17 (0.62-2.19), 2.00 (1.00-4.00), and 2.71 (1.65-4.48), respectively,
	less than 10 years, 10-14 years, and 15 or more years afterwards
	(trend: 2p=0.04). For women irradiated after 1982 there is, as yet,
	little information on lung cancer risks more than 10 years afterwards.US
	breast cancer radiotherapy regimens of the 1970s and early 1980s
	appreciably increased mortality from heart disease and lung cancer
	10-20 years afterwards with, as yet, little direct evidence on the
	hazards after more than 20 years. Since the early 1980s, improvements
	in radiotherapy planning should have reduced such risks, but the
	long-term hazards in the general populations of various countries
	still need to be monitored directly.},
  institution = {Clinical Trial Service Unit, University of Oxford, Oxford, UK. sarah.darby@ctsu.ox.ac.uk},
  journal     = {Lancet Oncol},
  keywords    = {Adult; Aged; Breast Neoplasms, radiotherapy; Female; Follow-Up Studies; Functional Laterality; Heart Diseases, etiology/mortality; Humans; Lung Neoplasms, etiology/mortality; Middle Aged; Radiation Injuries, mortality; SEER Program, statistics /&/ numerical data},
  medline-pst = {ppublish},
  month       = {Aug},
  owner       = {sanelo},
  pii         = {S1470-2045(05)70251-5},
  pmid        = {16054566},
  timestamp   = {2013.08.02},
  year        = {2005},
}

@Article{Darriet2000,
  author      = {Darriet, F. and N'guessan, R. and Carnevale, P.},
  title       = {[Evaluation in test huts of the protective effects of untreated mosquito nets against Anopheles gambiae s.s. bites].},
  language    = {fre},
  number      = {6},
  pages       = {413--417},
  volume      = {10},
  institution = {Laboratoire de lutte contre les insectes nuisibles (LIN/IRD), 911, avenue Agropolis, BP 5045, 34032 Montpellier Cedex 1, France.},
  journal     = {Sante},
  keywords    = {Animals; Anopheles, physiology; Bedding and Linens, standards; Feeding Behavior; Housing; Humans; Insect Bites and Stings, prevention /&/ control; Mosquito Control, instrumentation},
  medline-pst = {ppublish},
  owner       = {pl4},
  pmid        = {11226938},
  timestamp   = {2013.05.29},
  year        = {2000},
}

@Article{Daskivich2013,
  author      = {Daskivich, Timothy J. and Fan, Kang-Hsien and Koyama, Tatsuki and Albertsen, Peter C. and Goodman, Michael and Hamilton, Ann S. and Hoffman, Richard M. and Stanford, Janet L. and Stroup, Antoinette M. and Litwin, Mark S. and Penson, David F.},
  title       = {Effect of age, tumor risk, and comorbidity on competing risks for survival in a {U}.{S}. population-based cohort of men with prostate cancer.},
  doi         = {10.7326/0003-4819-158-10-201305210-00005},
  language    = {eng},
  number      = {10},
  pages       = {709--717},
  url         = {http://dx.doi.org/10.7326/0003-4819-158-10-201305210-00005},
  volume      = {158},
  abstract    = {Accurate estimation of life expectancy is essential to offering appropriate
	care to men with early-stage prostate cancer, but mortality risks
	associated with comorbidity are poorly defined.To determine the effect
	of age, comorbidity, and tumor risk on other-cause and prostate cancer-specific
	mortality in men with early-stage disease.Prospective cohort study.A
	nationally representative, population-based cohort.3183 men with
	nonmetastatic prostate cancer at diagnosis.Baseline self-reported
	comorbidity (scored as a count of 12 major comorbid conditions),
	tumor characteristics, initial treatment, and overall and disease-specific
	mortality through 14 years of follow-up. Survival analyses that accounted
	for competing risks were performed.Fourteen-year cumulative other-cause
	mortality rates were 24\%, 33\%, 46\%, and 57\% for men with 0, 1,
	2, and 3 or more comorbid conditions, respectively. For men diagnosed
	at age 65 years, subhazard ratios for other-cause mortality among
	those with 1, 2, or 3 or more comorbid conditions (vs. none) were
	1.2 (95\% CI, 1.0 to 1.4), 1.7 (CI, 1.4 to 2.0), and 2.4 (CI, 2.0
	to 2.8), respectively. Among men with 3 or more comorbid conditions,
	10-year other-cause mortality rates were 26\%, 40\%, and 71\% for
	those aged 60 years or younger, 61 to 74 years, and 75 years or older
	at diagnosis, respectively. Prostate cancer-specific mortality was
	minimal in patients with low-risk (3\%) and intermediate-risk (7\%)
	disease but appreciable in those with high-risk disease (18\%) and
	did not vary by number of comorbid conditions (10\% to 11\% in all
	groups).Comorbid conditions were self-reported.Older men with multiple
	major comorbid conditions are at high risk for other-cause mortality
	within 10 years of diagnosis and should consider this information
	when deciding between conservative management and aggressive treatment
	for low- or intermediate-risk prostate cancer.National Cancer Institute.},
  institution = {University of California, Los Angeles, Los Angeles, CA 90024, USA.},
  journal     = {Ann Intern Med},
  keywords    = {Age Factors; Aged; Cause of Death; Comorbidity; Humans; Incidence; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prospective Studies; Prostatic Neoplasms, mortality/pathology; Risk Factors},
  medline-pst = {ppublish},
  month       = {May},
  owner       = {sanelo},
  pii         = {1688109},
  pmid        = {23689764},
  timestamp   = {2013.09.17},
  year        = {2013},
}

@Article{Day1985,
  author    = {Day, N. E.},
  title     = {The Assessment of Lead Time and Length Bias in the Evaluation of Screening Programmes},
  pages     = {51-58},
  volume    = {7},
  journal   = {Maturitas},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1985},
}

@Article{Dayal1987,
  author    = {Dayal, H. H. and Polissar, L. and Dahlberg, S.},
  title     = {Race, Socioeconomic Status, and Other Prognostic Factors for Survival from Colo-Rectal Cancer},
  pages     = {857-864},
  volume    = {40},
  journal   = {Journal of Chronic Diseases},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1987},
}

@Article{Dayal1985,
  author    = {Dayal, H. H. and Polissar, L. and Dahlberg, S.},
  title     = {Race, Socioeconomic Status, and Other Prognostic Factors for Survival from Prostate Cancer},
  pages     = {2208-2216},
  volume    = {49},
  journal   = {Journal of the National Cancer Institute},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1985},
}

@Article{Dayal1982,
  author    = {Dayal, H. H. and Power, R. N. and Chiu, C.},
  title     = {Race and Socio-Economic Status in Survival from Breast Cancer},
  pages     = {675-683},
  volume    = {35},
  journal   = {Journal of Chronic Diseases},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1982},
}

@Article{DeAngelis2014,
  author      = {{De Angelis}, Roberta and Sant, Milena and Coleman, Michel P. and Francisci, Silvia and Baili, Paolo and Pierannunzio, Daniela and Trama, Annalisa and Visser, Otto and Brenner, Hermann and Ardanaz, Eva and Bielska-Lasota, Magdalena and Engholm, Gerda and Nennecke, Alice and Siesling, Sabine and Berrino, Franco and Capocaccia, Riccardo and , E. U. R. O. C. A. R. E-5 Working Group},
  title       = {Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study.},
  doi         = {10.1016/S1470-2045(13)70546-1},
  language    = {eng},
  number      = {1},
  pages       = {23--34},
  url         = {http://dx.doi.org/10.1016/S1470-2045(13)70546-1},
  volume      = {15},
  abstract    = {Cancer survival is a key measure of the effectiveness of health-care
	systems. EUROCARE-the largest cooperative study of population-based
	cancer survival in Europe-has shown persistent differences between
	countries for cancer survival, although in general, cancer survival
	is improving. Major changes in cancer diagnosis, treatment, and rehabilitation
	occurred in the early 2000s. EUROCARE-5 assesses their effect on
	cancer survival in 29 European countries.In this retrospective observational
	study, we analysed data from 107 cancer registries for more than
	10 million patients with cancer diagnosed up to 2007 and followed
	up to 2008. Uniform quality control procedures were applied to all
	datasets. For patients diagnosed 2000-07, we calculated 5-year relative
	survival for 46 cancers weighted by age and country. We also calculated
	country-specific and age-specific survival for ten common cancers,
	together with survival differences between time periods (for 1999-2001,
	2002-04, and 2005-07).5-year relative survival generally increased
	steadily over time for all European regions. The largest increases
	from 1999-2001 to 2005-07 were for prostate cancer (73.4\% [95\%
	CI 72.9-73.9] vs 81.7\% [81.3-82.1]), non-Hodgkin lymphoma (53.8\%
	[53.3-54.4] vs 60.4\% [60.0-60.9]), and rectal cancer (52.1\% [51.6-52.6]
	vs 57.6\% [57.1-58.1]). Survival in eastern Europe was generally
	low and below the European mean, particularly for cancers with good
	or intermediate prognosis. Survival was highest for northern, central,
	and southern Europe. Survival in the UK and Ireland was intermediate
	for rectal cancer, breast cancer, prostate cancer, skin melanoma,
	and non-Hodgkin lymphoma, but low for kidney, stomach, ovarian, colon,
	and lung cancers. Survival for lung cancer in the UK and Ireland
	was much lower than for other regions for all periods, although results
	for lung cancer in some regions (central and eastern Europe) might
	be affected by overestimation. Survival usually decreased with age,
	although to different degrees depending on region and cancer type.The
	major advances in cancer management that occurred up to 2007 seem
	to have resulted in improved survival in Europe. Likely explanations
	of differences in survival between countries include: differences
	in stage at diagnosis and accessibility to good care, different diagnostic
	intensity and screening approaches, and differences in cancer biology.
	Variations in socioeconomic, lifestyle, and general health between
	populations might also have a role. Further studies are needed to
	fully interpret these findings and how to remedy disparities.Italian
	Ministry of Health, European Commission, Compagnia di San Paolo Foundation,
	Cariplo Foundation.},
  file        = {DeAngelis2014.pdf:pdf\\DeAngelis2014.pdf:PDF;DeAngelis2014.pdf:DeAngelis2014.pdf:PDF},
  institution = {Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanit{\AA}Â , Rome, Italy.},
  journal     = {Lancet Oncol},
  keywords    = {Adolescent; Adult; Age Factors; Aged; Europe; Female; Humans; Male; Middle Aged; Neoplasms, mortality; Retrospective Studies; Time Factors},
  medline-pst = {ppublish},
  month       = {Jan},
  owner       = {PaulD},
  pii         = {S1470-2045(13)70546-1},
  pmid        = {24314615},
  timestamp   = {2014.03.13},
  year        = {2014},
}

@Book{deBoer2001,
  author    = {C. {de B}oer},
  title     = {A practical guide to splines},
  edition   = {Revised},
  publisher = {Springer},
  address   = {New York},
  timestamp = {2005.11.01},
  year      = {2001},
}

@Article{Dekker2008,
  author      = {Friedo W Dekker and Ren\'{e}e de Mutsert and Paul C van Dijk and Carmine Zoccali and Kitty J Jager},
  title       = {Survival analysis: time-dependent effects and time-varying risk factors.},
  doi         = {10.1038/ki.2008.328},
  number      = {8},
  pages       = {994--997},
  url         = {http://dx.doi.org/10.1038/ki.2008.328},
  volume      = {74},
  abstract    = {In traditional Kaplan-Meier or Cox regression analysis, usually a
	risk factor measured at baseline is related to mortality thereafter.
	During follow-up, however, things may change: either the effect of
	a fixed baseline risk factor may vary over time, resulting in a weakening
	or strengthening of associations over time, or the risk factor itself
	may vary over time. In this paper, short-term versus long-term effects
	(so-called time-dependent effects) of a fixed baseline risk factor
	are addressed. An example is presented showing that underweight is
	a strong risk factor for mortality in dialysis patients, especially
	in the short run. In contrast, overweight is a risk factor for mortality,
	which is stronger in the long run than in the short run. In addition,
	the analysis of how time-varying risk factors (so-called time-dependent
	risk factors) are related to mortality is demonstrated by paying
	attention to the pitfall of adjusting for sequelae. The proper analysis
	of effects over time should be driven by a clear research question.
	Both kinds of research questions, that is those of time-dependent
	effects as well those of time-dependent risk factors, can be analyzed
	with time-dependent Cox regression analysis. It will be shown that
	using time-dependent risk factors usually implies focusing on short-term
	effects only.},
  institution = {Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands. f.w.dekker@lumc.nl},
  journal     = {Kidney International},
  month       = {Oct},
  owner       = {pl4},
  pii         = {ki2008328},
  pmid        = {18633346},
  timestamp   = {2009.02.11},
  year        = {2008},
}

@Article{Demetrius1989,
  author      = {Demetrius, L.},
  title       = {Growth rate, population entropy, and perturbation theory.},
  language    = {eng},
  number      = {2},
  pages       = {159--180},
  volume      = {93},
  abstract    = {This paper is concerned with the connection between two classes of
	population variables: measures of population growth rate--the Malthusian
	parameter, the net reproduction rate, the gross reproduction rate,
	and the mean life expectancy; and measures of demographic heterogeneity--population
	entropy. It is shown that the entropy functions predict the response
	of the growth rate parameters to perturbations in the age-specific
	fecundity and mortality schedule. These results are invoked to introduce
	the notion of environmental intensity. The intensity function, expressed
	in terms of the entropy parameters, is applied to give a comparative
	study of the effect of environmental factors on the dynamics of Swedish
	and French populations.},
  journal     = {Math Biosci},
  keywords    = {Age Factors; Female; Fertility; France; Humans; Male; Mathematics; Models, Statistical; Mortality; Population Dynamics; Sweden},
  medline-pst = {ppublish},
  month       = {Apr},
  owner       = {pl4},
  pii         = {0025-5564(89)90021-7},
  pmid        = {2520027},
  timestamp   = {2013.05.29},
  year        = {1989},
}

@Article{Deming1953,
  author    = {Deming, W.E.},
  title     = {On the distinction between enumerative and analytic surveys},
  number    = {262},
  pages     = {244--255},
  url       = {http://www.tandfonline.com/doi/abs/10.1080/01621459.1953.10483470},
  volume    = {48},
  file      = {Deming1953.pdf:pdf\\Deming1953.pdf:PDF;Deming1953.pdf:Deming1953.pdf:PDF},
  groups    = {Superpopulation},
  journal   = {Journal of the American Statistical Association},
  owner     = {PaulD},
  publisher = {Taylor \& Francis},
  timestamp = {2013.01.24},
  year      = {1953},
}

@Article{Deming1941,
  author    = {Deming, W.E. and Stephan, F.F.},
  title     = {On the interpretation of censuses as samples},
  number    = {213},
  pages     = {45--49},
  url       = {http://www.tandfonline.com/doi/abs/10.1080/01621459.1941.10502070},
  volume    = {36},
  file      = {Deming1941.pdf:pdf\\Deming1941.pdf:PDF;Deming1941.pdf:Deming1941.pdf:PDF},
  groups    = {Superpopulation},
  journal   = {Journal of the American Statistical Association},
  owner     = {PaulD},
  publisher = {Taylor \& Francis},
  timestamp = {2013.01.24},
  year      = {1941},
}

@Article{Demiris2011,
  author      = {Demiris, Nikolaos and Lunn, David and Sharples, Linda D.},
  title       = {Survival extrapolation using the poly-Weibull model.},
  doi         = {10.1177/0962280211419645},
  language    = {eng},
  url         = {http://dx.doi.org/10.1177/0962280211419645},
  abstract    = {Recent studies of (cost-) effectiveness in cardiothoracic transplantation
	have required estimation of mean survival over the lifetime of the
	recipients. In order to calculate mean survival, the complete survivor
	curve is required but is often not fully observed, so that survival
	extrapolation is necessary. After transplantation, the hazard function
	is bathtub-shaped, reflecting latent competing risks which operate
	additively in overlapping time periods. The poly-Weibull distribution
	is a flexible parametric model that may be used to extrapolate survival
	and has a natural competing risks interpretation. In addition, treatment
	effects and subgroups can be modelled separately for each component
	of risk. We describe the model and develop inference procedures using
	freely available software. The methods are applied to two problems
	from cardiothoracic transplantation.},
  institution = {Agricultural University of Athens, Athens, Greece.},
  journal     = {Stat Methods Med Res},
  medline-pst = {aheadofprint},
  month       = {Nov},
  owner       = {theand},
  pii         = {0962280211419645},
  pmid        = {21937472},
  timestamp   = {2012.09.18},
  year        = {2011},
}

@Article{Demiris2006,
  author      = {Demiris, N. and Sharples, L. D.},
  title       = {Bayesian evidence synthesis to extrapolate survival estimates in cost-effectiveness studies.},
  doi         = {10.1002/sim.2366},
  language    = {eng},
  number      = {11},
  pages       = {1960--1975},
  url         = {http://dx.doi.org/10.1002/sim.2366},
  volume      = {25},
  abstract    = {This paper is concerned with survival extrapolation that represents
	an integral part of cost-effectiveness analysis. In the absence of
	long-term survival estimates from randomized clinical trials or meta-analysis
	we show how age-sex matched U.K. population data can additionally
	be used to estimate survival patterns. We adopt a Bayesian approach
	and we synthesize evidence from different sources such as patient
	registries, U.K. population statistics and meta-analyses. We also
	present methodology for Bayesian analysis of the additive hazards
	model and we show how to apply the techniques using freely available
	software. The methods are illustrated using data from a cohort of
	cardiac arrhythmia patients.},
  institution = {MRC Biostatistics Unit, Institute of Public Health, University Forvie site, Robinson Way, Cambridge CB2 2SR, UK. nikolaos.demiris@mrc-bsu.cam.ac.uk},
  journal     = {Stat Med},
  keywords    = {Aged; Cohort Studies; Defibrillators, Implantable, economics/standards; Female; Great Britain; Humans; Male; Middle Aged; Models, Economic; Proportional Hazards Models; Software; Survival Analysis; Ventricular Fibrillation, therapy},
  medline-pst = {ppublish},
  month       = {Jun},
  owner       = {theand},
  pmid        = {16220511},
  timestamp   = {2012.09.18},
  year        = {2006},
}

@Article{Dent1983,
  author    = {Dent, O. F. and Chapuis, P. H. and Goulston, K. J.},
  title     = {Relationship of Survival to Stage of the Tumour and Duration of Symptoms in Colorectal Cancer},
  pages     = {274-275},
  volume    = {1},
  journal   = {Medical Journal of Australia},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1983},
}

@Article{Derolf2009,
  author      = {Derolf, {\AA}sa Rangert and Kristinsson, Sigurdur Yngvi and Andersson, Therese M-L. and Landgren, Ola and Dickman, Paul W. and Bj{\o}rkholm, Magnus},
  title       = {Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in {S}weden between 1973 and 2005.},
  doi         = {10.1182/blood-2008-09-179341},
  language    = {eng},
  number      = {16},
  pages       = {3666--3672},
  url         = {http://dx.doi.org/10.1182/blood-2008-09-179341},
  volume      = {113},
  abstract    = {We evaluated survival patterns for all registered acute myeloid leukemia
	(AML) patients diagnosed in Sweden in 1973 to 2005 (N = 9729; median
	age, 69 years). Patients were categorized into 6 age groups and 4
	calendar periods (1973-1980, 1981-1988, 1989-1996, and 1997-2005).
	Relative survival ratios were computed as measures of patient survival.
	One-year survival improved over time in all age groups, whereas 5-
	and 10-year survival improved in all age groups, except for patients
	80+ years. The 5-year relative survival ratios in the last calendar
	period were 0.65, 0.58, 0.36, 0.15, 0.05, and 0.01 for the age groups
	0 to 18, 19 to 40, 41 to 60, 61 to 70, 71 to 80, and 80+ years, respectively.
	Intensified chemotherapy, a continuous improvement in supportive
	care, and allogeneic stem cell transplantation are probably the most
	important factors contributing to this finding. In contrast, there
	was no improvement in survival in AML patients with a prior diagnosis
	of a myelodysplastic syndrome during 1993 to 2005 (n = 219). In conclusion,
	AML survival has improved during the last decades. However, the majority
	of AML patients die of their disease and age remains an important
	predictor of prognosis. New effective agents with a more favorable
	toxicity profile are needed to improve survival, particularly in
	the elderly.},
  institution = {Division of Hematology, Department of Medicine, Karolinska University Hospital, Solna and Karolinska Institutet, Stockholm, Sweden. asa.derolf@karolinska.se},
  journal     = {Blood},
  medline-pst = {ppublish},
  month       = {Apr},
  owner       = {Paul},
  pii         = {blood-2008-09-179341},
  pmid        = {19020306},
  timestamp   = {2012.06.07},
  year        = {2009},
}

@Article{Desbiens2007,
  author      = {Desbiens, Norman A.},
  title       = {The reporting of statistics in medical educational studies: an observational study.},
  doi         = {10.1186/1471-2288-7-35},
  language    = {eng},
  pages       = {35},
  url         = {http://dx.doi.org/10.1186/1471-2288-7-35},
  volume      = {7},
  abstract    = {There is confusion in the medical literature as to whether statistics
	should be reported in survey studies that query an entire population,
	as is often done in educational studies. Our objective was to determine
	how often statistical tests have been reported in such articles in
	two prominent journals that publish these types of studies.For this
	observational study, we used electronic searching to identify all
	survey studies published in Academic Medicine and the Journal of
	General Internal Medicine in which an entire population was studied.
	We tallied whether inferential statistics were used and whether p-values
	were reported.Eighty-four articles were found: 62 in Academic Medicine
	and 22 in the Journal of General Internal Medicine. Overall, 38 (45\%)
	of the articles reported or stated that they calculated statistics:
	35\% in Academic Medicine and 73\% in the Journal of General Internal
	Medicine.Educational enumeration surveys frequently report statistical
	tests. Until a better case can be made for doing so, a simple rule
	can be proffered to researchers. When studying an entire population
	(e.g., all program directors, all deans, and all medical schools)
	for factual information, do not perform statistical tests. Reporting
	percentages is sufficient and proper.},
  groups      = {Superpopulation},
  institution = {Department of Medicine, University of Tennessee College of Medicine, Chattanooga, TN, USA. nadesbiens@gmail.com},
  journal     = {BMC Med Res Methodol},
  keywords    = {Bibliometrics; Data Interpretation, Statistical; Education, Medical, statistics /&/ numerical data; Humans; Internal Medicine; Internet; Periodicals as Topic, statistics /&/ numerical data; Program Evaluation, statistics /&/ numerical data},
  medline-pst = {epublish},
  owner       = {PaulD},
  pii         = {1471-2288-7-35},
  pmid        = {17659082},
  timestamp   = {2013.03.07},
  year        = {2007},
}

@Article{Desjeux2001,
  author      = {Desjeux, G. and Lemardeley, P. and Colin, C. and Pascal, B. and Labar{\AA}Â§ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â±ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¥, J.},
  title       = {[Cost-benefit ratio of tick-borne encephalitis vaccination of French troops based in Kosovo].},
  language    = {fre},
  number      = {3},
  pages       = {249--257},
  volume      = {49},
  abstract    = {French military troops based in Kosovo are exposed to Tick-Borne Encephalitis
	(TBE) biorisk. An efficacious vaccine is available to prevent this
	disease, burdened by high morbidity and mortality. The epidemiologic
	features of TBE in Kosovo are unprecise. To help the French Department
	of Defense to make a decision about immunization against TBE, we
	performed a cost-benefit analysis.By a Bayes'analysis decision, we
	have estimated the net benefits for a three-injection vaccine program
	versus absence of vaccination, for all French military troops based
	in Kosovo. Time expectancy was 4 years. Through the review of several
	medical reports, we have estimated the useful parameters for this
	study: morbidity incidence rate, mortality rate, sequelae rate, efficacy
	vaccine and side effects. We have chosen as initial hypothesis a
	sero-conversion rate of 1,080 per 100,000 men-by-year. Human life
	was valorized in francs, by calculating the allowance paid by Department
	of Defense to the family in case of death or for sequelae.Net benefits
	arised to 2.17 millions of francs. The vaccine program cost was 25.0
	millions of francs. 140 cases of encephalitis viruses were saved
	by vaccination. Nevertheless a sensibility analysis has shown that
	results are well reliable with TBE incidence rate.The break even
	point being close to the incidence rate of the initial assumption,
	the decision to vaccine all French military troops depends at the
	same time on a better knowledge of the incidence of the disease in
	Kosovo, but also of the number of potentially avoided cases of tick-borne
	encephalitis and of the programs of vaccination concerning this disease
	of the other countries forming the United Nations Organization forces.},
  journal     = {Rev Epidemiol Sante Publique},
  keywords    = {Bayes Theorem; Cost of Illness; Cost-Benefit Analysis; Decision Trees; Encephalitis, Tick-Borne, economics/epidemiology/prevention /&/ control; France, ethnology; Humans; Incidence; Military Personnel, statistics /&/ numerical data; Morbidity; Program Evaluation; Risk Factors; Seasons; Sensitivity and Specificity; Seroepidemiologic Studies; Time Factors; Vaccination, economics/standards; Yugoslavia, epidemiology},
  medline-pst = {ppublish},
  month       = {Jun},
  owner       = {pl4},
  pii         = {MDOI-RESP-06-2001-49-3-0398-7620-101019-ART5},
  pmid        = {11427828},
  timestamp   = {2013.05.29},
  year        = {2001},
}

@Article{Devesa1995a,
  author      = {Devesa, S. S. and Donaldson, J. and Fears, T.},
  title       = {Graphical presentation of trends in rates.},
  language    = {eng},
  number      = {4},
  pages       = {300--304},
  volume      = {141},
  abstract    = {A variety of graphical approaches have been used to visually portray
	and analyze temporal trends, especially annual rates of change, in
	disease rates. In reviewing their own work, the authors have found
	that they could improve on their graphical presentations by choosing
	an arithmetic or logarithmic scale according to the research question
	being addressed, by selecting scaling ratios of the axes that allow
	one to detect specific rates of change, and by using uniform scaling
	ratios to facilitate comparisons across graphs. Different presentations
	of the same data can result in different impressions. The authors
	used rates over a 40-year period to illustrate the concepts involved
	and to investigate the portrayal of various rates of change. These
	principles extend to the plotting of odds ratios or relative risks,
	where the choice of an arithmetic rather than a logarithmic axis
	also can result in a misleading plot. The authors conclude that a
	graph should be designed and studied with care, clearly reflect the
	truth, convey information, and make a point without overemphasizing.
	For the particular problem addressed here, displaying temporal trends
	in disease rates, they see advantages in justifiable uniformity.
	Attention to plotting techniques in the epidemiologic and medical
	literature should be encouraged.},
  file        = {Devesa1995a.pdf:Devesa1995a.pdf:PDF},
  institution = {Biostatistics Branch, Epidemiology and Biostatistics Program, National Cancer Institute, Bethesda, MD 20892-7368.},
  journal     = {American Journal of Epidemiology},
  medline-pst = {ppublish},
  month       = {Feb},
  owner       = {pl4},
  pmid        = {7840107},
  timestamp   = {2012.09.10},
  year        = {1995},
}

@Article{Wreede2011,
  author    = {L.C. {de Wreede} and M. Fiocco and H. Putter},
  title     = {mstate: An {R} package for the analysis of competing risks and multi-state models},
  volume    = {38},
  file      = {Wreede2011.pdf:Wreede2011.pdf:PDF},
  journal   = {Journal of Statistical Software},
  owner     = {pl4},
  timestamp = {2012.02.08},
  year      = {2011},
}

@Article{Dimatteo2001,
  author    = {I. Di{M}atteo and C. R. Genovese and R. E. Kass},
  title     = {Bayesian curve-fitting with free-knot splines},
  pages     = {1055-1071},
  volume    = {88},
  file      = {Dimatteo2001.pdf:Dimatteo2001.pdf:PDF;Dimatteo2001.pdf:pdf\\Dimatteo2001.pdf:PDF},
  journal   = {Biometrika},
  owner     = {pl4},
  timestamp = {2009.10.27},
  year      = {2001},
}

@Misc{presentation_pauld_20130124_leicester_superpopulation,
  author    = {Paul W Dickman},
  title     = {Should we present measures of uncertainty when we have enumerated the entire population?},
  file      = {presentation_pauld_20130124_leicester_superpopulation.pdf:pdf\\presentation_pauld_20130124_leicester_superpopulation.pdf:PDF;presentation_pauld_20130124_leicester_superpopulation.pdf:presentation_pauld_20130124_leicester_superpopulation.pdf:PDF},
  groups    = {Presentation},
  keywords  = {Presentation},
  owner     = {PaulD},
  timestamp = {2013.01.25},
}

@Misc{presentation_pauld_20130306_su_cansurv_overview,
  author    = {Paul W Dickman},
  title     = {An overview and some recent advances in statistical methods for population-based cancer survival analysis},
  file      = {presentation_pauld_20130306_su_cansurv_overview.pdf:presentation_pauld_20130306_su_cansurv_overview.pdf:PDF;presentation_pauld_20130306_su_cansurv_overview.pdf:pdf\\presentation_pauld_20130306_su_cansurv_overview.pdf:PDF},
  groups    = {Presentation},
  keywords  = {Presentation},
  owner     = {PaulD},
  timestamp = {2013.01.25},
}

@PhdThesis{Dickman:phdthesis:1997,
  author    = {Paul W. Dickman},
  title     = {Estimating regional variation in cancer patient survival},
  type      = {PhD Thesis},
  url       = {http://publications.ki.se/xmlui/handle/10616/41668},
  file      = {:pdf\\Thesis_Paul_Dickman.pdf:PDF},
  groups    = {PhD Thesis},
  owner     = {PaulD},
  school    = {University of Newcastle},
  timestamp = {2013.10.23},
  year      = {1997},
}

@Article{Dickman2006,
  author      = {P. W. Dickman and H-O. Adami},
  title       = {Interpreting trends in cancer patient survival.},
  doi         = {10.1111/j.1365-2796.2006.01677.x},
  number      = {2},
  pages       = {103--117},
  url         = {http://dx.doi.org/10.1111/j.1365-2796.2006.01677.x},
  volume      = {260},
  abstract    = {Data on cancer patient survival are an invaluable tool in the evaluation
	of therapeutic progress against cancer as well as other lethal diseases.
	As with all quantitative information routinely used in evidence-based
	clinical management--including diagnostic tests, prognostic markers
	and comparisons of therapeutic interventions--data on patient survival
	require evaluation based on an understanding of the underlying statistical
	methodology, methods of data collection and classification, and,
	most notably, clinical and biologic insight. This article contains
	an introduction to the methods used for estimating cancer patient
	survival, including cause-specific survival, relative survival and
	period analysis. The methods, and their interpretation, are illustrated
	through presentation of trends in incidence, mortality and patient
	survival for a range of different cancers. Our aim was to lay out
	the strengths and limitations of survival analysis as a tool in the
	evaluation of progress in the diagnosis and treatment of cancer.},
  file        = {Dickman2006.pdf:Dickman2006.pdf:PDF;Dickman2006.pdf:pdf\\Dickman2006.pdf:PDF},
  institution = {Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, and Department of Epidemiology, Harvard University, Boston, MA, USA. paul.dickman@ki.se},
  journal     = {Journal of Internal Medicine},
  owner       = {pl4},
  pii         = {JIM1677},
  pmid        = {16882274},
  timestamp   = {2008.10.15},
  year        = {2006},
}

@Article{Dickman2004a,
  author      = {Paul W Dickman and Jan Adolfsson and Kent {\AA}str\"{o}m and Gunnar Steineck},
  title       = {Hip fractures in men with prostate cancer treated with orchiectomy.},
  number      = {6 Pt 1},
  pages       = {2208--2212},
  volume      = {172},
  abstract    = {PURPOSE: Androgen deprivation therapy increases the risk of osteoporosis
	related fractures. This issue is of increasing importance in men
	with prostate cancer as increasingly more undergo androgen deprivation
	therapy and therapy is administered sooner following diagnosis. Data
	directly addressing the long-term fracture risk in men diagnosed
	with prostate cancer are limited. MATERIALS AND METHODS: Using population
	based registries in Sweden we studied the incidence of hip fractures
	in 17,731 men diagnosed with prostate cancer from 1964 to 1996 who
	were treated with bilateral orchiectomy within 6 months of diagnosis.
	The fracture incidence was compared to the incidence in 43,230 men
	diagnosed with prostate cancer but not treated with orchiectomy and
	in 362,354 of similar age who were randomly selected from the general
	population. RESULTS: Men treated with orchiectomy were at increased
	risk for hip fracture. The estimated relative risk comparing men
	who underwent orchiectomy to population controls was 2.11 (95\% CI
	1.94 to 2.29) for femoral neck fractures and 2.16 (95\% CI 1.97 to
	2.36) for intertrochanter fractures. An increased risk of hip fracture
	was observed as early as 6 months after orchiectomy and the relative
	risk remained fairly constant up to 15 years following orchiectomy.
	CONCLUSIONS: Hip fracture risk increases almost immediately following
	orchiectomy and the excess risk persists for at least 15 years. This
	side effect should be considered when assessing the merits of androgen
	deprivation therapy, particularly in symptom-free men diagnosed with
	localized prostate cancer. Measures to prevent osteoporosis should
	be considered in men undergoing androgen deprivation therapy.},
  file        = {dickman2004a.pdf:dickman2004a.pdf:PDF},
  institution = {Department of Oncology, Karolinska Institutet, Stockholm, Sweden. paul.dickman@mep.ki.se},
  journal     = {Journal of Urology},
  month       = {Dec},
  owner       = {pl4},
  pii         = {00005392-200412010-00022},
  pmid        = {15538233},
  timestamp   = {2009.02.26},
  year        = {2004},
}

@Article{Dickman1998,
  author      = {P. W. Dickman and A. Auvinen and E. T. Voutilainen and T. Hakulinen},
  title       = {Measuring social class differences in cancer patient survival: is it necessary to control for social class differences in general population mortality? {A} {F}innish population-based study.},
  number      = {11},
  pages       = {727--734},
  volume      = {52},
  abstract    = {STUDY OBJECTIVES: Estimation of cancer patient survival by social
	class has been performed using observed, corrected (cause specific),
	and relative (with expected survival based on the national population)
	survival rates. Each of these measures are potentially biased and
	the optimal method is to calculate relative survival rates using
	social class specific death rates to estimate expected survival.
	This study determined the degree to which the choice of survival
	measure affects the estimation of social class differences in cancer
	patient survival. SETTING AND PARTICIPANTS: All Finnish residents
	diagnosed with at least one of 10 common malignant neoplasms during
	the period 1977-1985 were identified from the Finnish Cancer Registry
	and followed up for deaths to the end of 1992. DESIGN: Survival rates
	were calculated by site, sex, and age at 5, 10, and 15 years subsequent
	to diagnosis for each of three measures of survival; relative survival,
	corrected (cause specific) survival, and relative survival adjusted
	for social class differences in general mortality. Regression models
	were fitted to each set of rates for the first five years of follow
	up. MAIN RESULTS: The degree of variation in relative survival resulting
	from social class decreased, although did not disappear, after controlling
	for social class differences in general mortality. The results obtained
	using corrected survival were close to those obtained using relative
	survival with a social class correction. The differences between
	the three measures were largest when the proportion of deaths from
	other causes was large, for example, in cancers with high survival,
	among older patients, and for longer follow up times. CONCLUSIONS:
	Although each of the three measures gave comparable results, it is
	recommended that relative survival rates are used with expected survival
	adjusted for social class when studying social class variation in
	cancer patient survival. If this is not an available option, it is
	recommended that corrected survival rates are used. Relative survival
	rates without the social class correction overestimate social class
	differences and should be used with caution.},
  file        = {Dickman1998.pdf:Dickman1998.pdf:PDF;Dickman1998.pdf:pdf\\Dickman1998.pdf:PDF},
  institution = {Department of Cancer Epidemiology, Karolinska Institute, Stockholm, Sweden.},
  journal     = {J Epidemiol Community Health},
  month       = {Nov},
  owner       = {pl4},
  pmid        = {10396505},
  timestamp   = {2008.10.15},
  year        = {1998},
}

@Article{Dickman2015,
  author    = {P. W. Dickman and E. Coviello},
  title     = {Estimating and modelling relative survival},
  number    = {1},
  pages     = {186-215},
  url       = {http://www.stata-journal.com/article.html?article=st0376},
  volume    = {15},
  file      = {Dickman2015.pdf:pdf\\Dickman2015.pdf:PDF;Dickman2015.pdf:Dickman2015.pdf:PDF},
  journal   = {The Stata Journal},
  owner     = {pl4},
  timestamp = {2015.09.23},
  year      = {2015},
}

@Manual{strs,
  author    = {P. W. Dickman and E. Coviello and M. Hills},
  title     = {Estimating and modelling relative survival using Stata},
  note      = {\texttt{http://pauldickman.com/rsmodel/stata_colon/}},
  url       = {http://pauldickman.com/rsmodel/stata_colon/},
  timestamp = {2005.11.01},
  year      = {2012},
}

@Article{Dickman1997,
  author      = {P. W. Dickman and R. W. Gibberd and T. Hakulinen},
  title       = {Estimating potential savings in cancer deaths by eliminating regional and social class variation in cancer survival in the {N}ordic countries.},
  number      = {3},
  pages       = {289--298},
  volume      = {51},
  abstract    = {STUDY OBJECTIVES: To examine equity in the health care system with
	regard to cancer patient care by estimating the level of systematic
	regional variation in cancer survival in the Nordic countries. Specifically,
	those cancer sites which exhibit high levels of systematic regional
	variation in survival and hence inequity were identified. Estimating
	the reduction in cancer deaths which could be achieved by eliminating
	this variation so that everyone receives effective care will provide
	a readily interpretable measure of the amount of systematic regional
	variation. A comprehensive analysis of regional variation in survival
	has not previously been conducted so appropriate statistical methodology
	must be developed. SETTING AND PARTICIPANTS: All those aged 0-90
	years who had been diagnosed with at least one of 12 common malignant
	neoplasms between 1977 and 1992 in Denmark, Finland, Norway, and
	Sweden. DESIGN: A separate analysis was conducted for each country.
	Regression models for the relative survival ratio were used to estimate
	the relative risk of excess mortality attributable to cancer in each
	region after correcting for age and sex. An estimate of the amount
	of systematic regional variation in survival was obtained by subtracting
	the estimated expected random variation from the observed regional
	variation. An estimate was then made of the potential reduction in
	the number of cancer deaths for 2008-12 if regional variation in
	survival were eliminated so that everyone received the same level
	of effective care. MAIN RESULTS: Between 2008 and 2012, an estimated
	2.5\% of deaths from cancers in the 12 sites studied could be prevented
	by eliminating regional variation in survival. The percentage of
	potentially avoidable deaths did not depend on country or sex but
	it did depend on cancer site. There was no relationship between the
	level of regional variation in a given country and the level of survival.
	The cancer sites for which the greatest percentage savings could
	be achieved were melanoma (11\%) and cervix uteri (6\%). The sites
	for which the highest number of deaths could be prevented were prostate,
	colon, melanoma, and breast. CONCLUSIONS: This methodology showed
	a small amount of systematic regional variation in cancer survival
	in the Nordic countries. The cancer sites with high levels of regional
	variation identified are potential targets for cancer control programmes.},
  file        = {Dickman1997.pdf:Dickman1997.pdf:PDF;Dickman1997.pdf:pdf\\Dickman1997.pdf:PDF},
  institution = {Department of Cancer Epidemiology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden.},
  journal     = {J Epidemiol Community Health},
  month       = {Jun},
  owner       = {pl4},
  pmid        = {9229059},
  timestamp   = {2008.10.15},
  year        = {1997},
}

@Article{Dickman1997d,
  author    = {Dickman, P. W. and Hakulinen, T.},
  title     = {The Accuracy of Index Dates and Calculation of Survival Time from Cancer Registry Data},
  pages     = {87-94},
  volume    = {2},
  journal   = {Journal of Epidemiology and Biostatistics},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1997},
}

@Article{Dickman1997c,
  author    = {Dickman, P. W. and Hakulinen, T.},
  title     = {Adjusting for Region of Residence in Relative Survival Analysis},
  pages     = {213-218},
  volume    = {1},
  journal   = {Journal of Epidemiology and Biostatistics},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1996},
}

@Article{Dickman1999,
  author      = {P. W. Dickman and T. Hakulinen and T. Luostarinen and E. Pukkala and R. Sankila and B. S\"{o}derman and L. Teppo},
  title       = {Survival of cancer patients in Finland 1955-1994.},
  pages       = {1--103},
  volume      = {38 Suppl 12},
  abstract    = {INTRODUCTION: The study of survival of cancer patients is essential
	for monitoring the effectiveness of cancer control. The previous
	monograph describing cancer patient survival in Finland was published
	by the Finnish Cancer Registry in 1981 and covered patients diagnosed
	in 1953-1974. This new supplement assesses cancer patient survival
	up to the year 1995. MATERIAL AND METHODS: The study includes over
	560000 tumours registered at the Finnish Cancer Registry with a date
	of diagnosis between 1955 and 1994. Patients were followed up to
	the end of 1995. Trends in relative survival rates are studied over
	four 10-year diagnostic periods from 1955 to 1994. In addition, detailed
	results are presented for patients diagnosed during 1985-1994, including
	relative survival rates tabulated by stage, sex, and age. Additional
	sections describe differences in cancer patient survival according
	to social class and region of residence and a comparison of cancer
	patient survival in Finland to other European countries. RESULTS:
	Patient survival improved over time for almost all anatomical sites.
	The main exception is in cancer of the cervix uteri, where patient
	survival has decreased slightly from 1965-1974 to 1985-1994 due to
	the selective prevention of less aggressive tumours through cytologic
	screening. Very few differences in patient survival are observed
	between males and females. A substantial improvement in survival
	can be seen for childhood cancers. CONCLUSION: The increasing survival
	rates reflect improvements that have taken place in various areas
	of cancer control, from health education and early diagnosis to treatment
	and aftercare. This study provides valuable reference information
	for both clinicians and health administrators, as well as a baseline
	for more detailed studies of patient survival for individual anatomical
	sites.},
  file        = {Dickman1999.pdf:Dickman1999.pdf:PDF;Dickman1999.pdf:pdf\\Dickman1999.pdf:PDF},
  institution = {Finnish Cancer Registry, Helsinki.},
  journal     = {Acta Oncol},
  owner       = {pl4},
  pmid        = {10225326},
  timestamp   = {2008.10.15},
  year        = {1999},
}

@Article{Dickman2003,
  author    = {Paul W Dickman and Lars-Erik Holm and G\"{o}ran Lundell and John D Boice and Per Hall},
  title     = {Thyroid cancer risk after thyroid examination with 131{I}: a population-based cohort study in {S}weden.},
  doi       = {10.1002/ijc.11258},
  number    = {4},
  pages     = {580-7},
  url       = {http://dx.doi.org/10.1002/ijc.11258},
  volume    = {106},
  abstract  = {Ionizing radiation is the only established cause of thyroid cancer,
	though the effect of diagnostic administration of (131)I on thyroid
	cancer risk appears minimal. The annual number of thyroid examinations
	using radioiodine is currently 5 per 1,000 individuals worldwide,
	so this issue is of public health importance. Our objective was to
	evaluate the excess risk of thyroid cancer following a range of known
	doses of (131)I administered for diagnostic purposes. We conducted
	a nationwide, population-based cohort study in {S}weden including
	all 36,792 individuals who received (131)I for diagnostic purposes
	during 1952-1969 and were alive and free of thyroid cancer 2 years
	after exposure. Accrual of person-time at risk commenced 2 years
	after the first (131)I administration. Follow-up for cancer was to
	the end of 1998. Standardized incidence ratios (SIRs) were calculated
	as the ratio between the observed and expected numbers of thyroid
	cancers. Estimates were stratified by previous exposure to external
	radiation therapy to the neck, reason for thyroid examination, (131)I
	dose, sex, age at exposure and time since exposure. Thyroid cancers
	(n = 129) were diagnosed during 886,618 person-years at risk. Excess
	thyroid cancers were observed only among the 1,767 patients who reported
	previous external radiation therapy to the neck [SIR = 9.8, 95\%
	confidence interval (CI) 6.3-14.6] and among those originally referred
	due to suspicion of a thyroid tumor (SIR = 3.5, 95\% CI 2.7-4.4 for
	11,015 patients without previous external radiation therapy). The
	24,010 patients without previous exposure to external radiation therapy
	to the neck who were referred for a reason other than suspicion of
	a thyroid tumor received an estimated dose to the thyroid of 0.94
	Gy. Among these patients, 36 thyroid cancers were observed compared
	to 39.5 expected (SIR = 0.91, 95\% CI 0.64-1.26). We found no evidence
	that administration of (131)I for diagnostic purposes increases risk
	of thyroid cancer. However, our study included few patients under
	age 20, so the results apply primarily to exposure among adults.
	Our data suggest that protraction of dose may result in a lower risk
	than brief X-ray exposure of the same total dose.},
  journal   = {Int J Cancer},
  month     = {Sep},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2003},
}

@Article{Dickman2013,
  author      = {Dickman, Paul W. and Lambert, Paul C. and Coviello, Enzo and Rutherford, Mark J.},
  title       = {Estimating net survival in population-based cancer studies.},
  doi         = {10.1002/ijc.28041},
  language    = {eng},
  number      = {2},
  pages       = {519-21},
  url         = {http://dx.doi.org/10.1002/ijc.28041},
  volume      = {133},
  file        = {Dickman2013.pdf:pdf\\Dickman2013.pdf:PDF;Dickman2013.pdf:Dickman2013.pdf:PDF},
  institution = {Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. paul.dickman@ki.se.},
  journal     = {International Journal of Cancer},
  owner       = {pl4},
  pmid        = {23338817},
  timestamp   = {2013.02.05},
  year        = {2013},
}

@Article{Dickman2004,
  author      = {P. W. Dickman and A. Sloggett and M. Hills and T. Hakulinen},
  title       = {Regression models for relative survival.},
  doi         = {10.1002/sim.1597},
  number      = {1},
  pages       = {51--64},
  url         = {http://dx.doi.org/10.1002/sim.1597},
  volume      = {23},
  abstract    = {Four approaches to estimating a regression model for relative survival
	using the method of maximum likelihood are described and compared.
	The underlying model is an additive hazards model where the total
	hazard is written as the sum of the known baseline hazard and the
	excess hazard associated with a diagnosis of cancer. The excess hazards
	are assumed to be constant within pre-specified bands of follow-up.
	The likelihood can be maximized directly or in the framework of generalized
	linear models. Minor differences exist due to, for example, the way
	the data are presented (individual, aggregated or grouped), and in
	some assumptions (e.g. distributional assumptions). The four approaches
	are applied to two real data sets and produce very similar estimates
	even when the assumption of proportional excess hazards is violated.
	The choice of approach to use in practice can, therefore, be guided
	by ease of use and availability of software. We recommend using a
	generalized linear model with a Poisson error structure based on
	collapsed data using exact survival times. The model can be estimated
	in any software package that estimates GLMs with user-defined link
	functions (including SAS, Stata, S-plus, and R) and utilizes the
	theory of generalized linear models for assessing goodness-of-fit
	and studying regression diagnostics.},
  file        = {dickman2004.pdf:dickman2004.pdf:PDF},
  groups      = {Excess mortality model},
  institution = {Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden. paul.dickman@mep.ki.se},
  journal     = {Stat Med},
  month       = {Jan},
  owner       = {pl4},
  pmid        = {14695639},
  timestamp   = {2008.10.15},
  year        = {2004},
}

@Article{Diehr1990,
  author    = {Diehr, P. and Cain, K. and Connell, F. and Volinn, E.},
  title     = {What Is Too Much Variation? {T}he Null Hypothesis in Small-Area Analysis},
  pages     = {741-771},
  volume    = {24},
  journal   = {HSR: Health Services Research},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1990},
}

@Article{Diehr1992,
  author    = {Diehr, P. and Cain, K. and Kreuter, W. and Rosenkranz, S.},
  title     = {Can Small-Area Analysis Detect Variation in Surgery Rates? {T}he Power of Small-Area Variation Analysis},
  pages     = {484-501},
  volume    = {30},
  journal   = {Medical Care},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1992},
}

@Article{Dieras2001,
  author      = {Dieras, V. and Beuzeboc, P. and Laurence, V. and Pierga, J. Y. and Pouillart, P.},
  title       = {Interaction between Herceptin and taxanes.},
  doi         = {55401},
  language    = {eng},
  pages       = {43--49},
  url         = {http://dx.doi.org/55401},
  volume      = {61 Suppl 2},
  abstract    = {The taxanes and Herceptin have been shown to possess significant clinical
	activity in metastatic breast cancer. Preclinical testing of taxane/Herceptin
	combinations demonstrated additive and synergistic interactions with
	paclitaxel and docetaxel, respectively. In a pivotal clinical trial,
	combination of paclitaxel (3-weekly) and Herceptin was associated
	with an increased response rate compared with paclitaxel monotherapy
	(41\% vs. 17\%; p = 0.001). The combination therapy also significantly
	improved time to disease progression (6.9 vs. 2.7 months; p < 0.05).
	In a phase II study of weekly paclitaxel plus Herceptin in patients
	with normal or increased tumor HER2 levels, a response was observed
	in 60\% of patients and the regimen was well tolerated. Responses
	were more frequent in patients with HER2-overexpressing tumors (83\%
	vs. 45\%). Preliminary results from a phase II study of Herceptin
	plus docetaxel in patients with HER2-overexpressing tumors indicate
	significant activity, with a response observed in 7 (44\%) of 16
	evaluable patients. The preliminary results of a trial of weekly
	docetaxel and Herceptin demonstrate a response rate of 54\% in 13
	evaluable patients. Additional European trials of Hercep- tin/taxane
	combinations as first- and second-line and adjuvant therapy are ongoing.
	The results of the studies to date indicate that regimens combining
	Herceptin with 3-weekly and weekly taxane are effective and well
	tolerated.},
  institution = {Department of Medical Oncology, Institut Curie, Service de Medecine Oncologique, Paris, France. veronique.dieras@curie.net},
  journal     = {Oncology},
  keywords    = {Adult; Aged; Animals; Antibodies, Monoclonal, Humanized; Antibodies, administration /&/ dosage/adverse effects/pharmacology; Antineoplastic Agents, Phytogenic, administration /&/ dosage/pharmacology; Antineoplastic Agents, administration /&/ dosage/adverse effects/pharmacology; Antineoplastic Combined Chemotherapy Protocols, adverse effects/therapeutic use; Breast Neoplasms, chemistry/drug therapy/mortality/pathology; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Heart Diseases, chemically induced; Humans; Mice; Mice, Nude; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins, analysis; Nervous System Diseases, chemically induced; Neutropenia, chemically induced; Paclitaxel, administration /&/ dosage/adverse effects/analogs /&/ derivatives/pharmacology; Palliative Care; Randomized Controlled Trials as Topic; Receptor, erbB-2, analysis; Receptor, erbB-3, analysis; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Tumor Markers, Biological, analysis; Xenograft Model Antitumor Assays},
  medline-pst = {ppublish},
  owner       = {pl4},
  pii         = {55401},
  pmid        = {11694787},
  timestamp   = {2013.05.29},
  year        = {2001},
}

@Article{Dieras2002,
  author      = {Dieras, V. and Bougnoux, P. and Petit, T. and Chollet, P. and Beuzeboc, P. and Borel, C. and Husseini, F. and Goupil, A. and Kerbrat, P. and Misset, J. L. and Bensmaine, M. A. and Tabah-Fisch, I. and Pouillart, P.},
  title       = {Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients.},
  language    = {eng},
  number      = {2},
  pages       = {258--266},
  volume      = {13},
  journal     = {Ann Oncol},
  keywords    = {Adult; Aged; Antineoplastic Combined Chemotherapy Protocols, therapeutic use; CA-125 Antigen, analysis; Carboplatin, administration /&/ dosage; Cisplatin, administration /&/ dosage; Female; Humans; Middle Aged; Organoplatinum Compounds, adverse effects/therapeutic use; Ovarian Neoplasms, drug therapy; Paclitaxel, administration /&/ dosage},
  medline-pst = {ppublish},
  month       = {Feb},
  owner       = {pl4},
  pmid        = {11886003},
  timestamp   = {2013.05.29},
  year        = {2002},
}

@Article{Dignam2008,
  author      = {Dignam, James J. and Kocherginsky, Maria N.},
  title       = {Choice and interpretation of statistical tests used when competing risks are present.},
  doi         = {10.1200/JCO.2007.12.9866},
  language    = {eng},
  number      = {24},
  pages       = {4027--4034},
  url         = {http://dx.doi.org/10.1200/JCO.2007.12.9866},
  volume      = {26},
  abstract    = {In clinical cancer research, competing risks are frequently encountered.
	For example, individuals undergoing treatment for surgically resectable
	disease may experience recurrence near the removed tumor, metastatic
	recurrence at other sites, occurrence of second primary cancer, or
	death resulting from noncancer causes before any of these events.
	Two quantities, the cause-specific hazard function and the cumulative
	incidence function, are commonly used to summarize outcomes by event
	type. Tests for event-specific differences between treatment groups
	may thus be based on comparison of (a) cause-specific hazards via
	a log-rank or related test, or (b) the cumulative incidence functions
	via one of several available tests. Inferential results for tests
	based on these different metrics can differ considerably for the
	same cause-specific end point. Depending on the questions of principal
	interest, one or both metrics may be appropriate to consider. We
	present simulation study results and discuss examples from cancer
	clinical trials to illustrate these points and provide guidance for
	analysis when competing risks are present.},
  file        = {Dignam2008.pdf:Dignam2008.pdf:PDF},
  institution = {Department of Health Studies, The University of Chicago, Chicago, IL 60637, USA. jdignam@health.bsd.uchicago.edu},
  journal     = {J Clin Oncol},
  medline-pst = {ppublish},
  month       = {Aug},
  owner       = {pl4},
  pii         = {26/24/4027},
  pmid        = {18711194},
  timestamp   = {2012.02.06},
  year        = {2008},
}

@Article{Dignam2012,
  author    = {Dignam, J. J. and Zhang, Q. and Kocherginsky, M.},
  title     = {The Use and Interpretation of Competing Risks Regression Models},
  doi       = {10.1158/1078-0432.CCR-11-2097},
  number    = {8},
  pages     = {2301-2308},
  volume    = {18},
  file      = {:Dignam2012.pdf:PDF},
  journal   = {Clin Cancer Res},
  month     = {Apr},
  publisher = {American Association for Cancer Research},
  timestamp = {2005.11.01},
  year      = {2012},
}

@Book{Dobson1990,
  author    = {Dobson, A. J.},
  title     = {An Introduction to Generalized Linear Modelling},
  publisher = {London: Chapman and Hall},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1990},
}

@Article{Domart-Coulon2000,
  author      = {Domart-Coulon, I. and Auzoux-Bordenave, S. and Doumenc, D. and Khalanski, M.},
  title       = {Cytotoxicity assessment of antibiofouling compounds and by-products in marine bivalve cell cultures.},
  language    = {eng},
  number      = {3},
  pages       = {245--251},
  volume      = {14},
  abstract    = {Short-term primary cell cultures were derived from adult marine bivalve
	tissues: the heart of oyster Crassostrea gigas and the gill of clam
	Ruditapes decussatus. These cultures were used as experimental in
	vitro models to assess the acute cytotoxicity of an organic molluscicide,
	Mexel-432, used in antibiofouling treatments in industrial cooling
	water systems. A microplate cell viability assay, based on the enzymatic
	reduction of tetrazolium dye (MTT) in living bivalve cells, was adapted
	to test the cytotoxicity of this compound: in both in vitro models,
	toxicity thresholds of Mexel-432 were compared to those determined
	in vivo with classic acute toxicity tests. The clam gill cell model
	was also used to assess the cytotoxicity of by-products of chlorination,
	a major strategy of biofouling control in the marine environment.
	The applications and limits of these new in vitro models for monitoring
	aquatic pollutants were discussed, in reference with the standardized
	Microtox test.},
  institution = {URA CNRS 699 Biologie des Invertebres Marins, Museum National d'Histoire Naturelle, 57 rue Cuvier, 75005 Paris, France. coulon@dc.net},
  journal     = {Toxicol In Vitro},
  keywords    = {Animals; Bivalvia; Cell Survival, drug effects; Cells, Cultured; Dose-Response Relationship, Drug; Molluscacides, toxicity; Ostreidae; Water Pollutants, Chemical, toxicity},
  medline-pst = {ppublish},
  month       = {Jun},
  owner       = {pl4},
  pii         = {S0887-2333(00)00011-4},
  pmid        = {10806375},
  timestamp   = {2013.05.29},
  year        = {2000},
}

@Article{Doornaert2003,
  author      = {Doornaert, Blandine and Leblond, Valerie and Galiacy, Stephane and Gras, Gabriel and Planus, Emmanuelle and Laurent, Valerie and Isabey, Daniel and Lafuma, Chantal},
  title       = {Negative impact of DEP exposure on human airway epithelial cell adhesion, stiffness, and repair.},
  doi         = {10.1152/ajplung.00039.2002},
  language    = {eng},
  number      = {1},
  pages       = {L119--L132},
  url         = {http://dx.doi.org/10.1152/ajplung.00039.2002},
  volume      = {284},
  abstract    = {Epidemiological and experimental studies suggest that diesel exhaust
	particles (DEPs) may be associated with increased respiratory mortality
	and morbidity. Several recent studies have also shown that DEPs increase
	the production of inflammatory cytokines by human bronchial epithelium
	(HBE) cells in vitro. The present study investigates the effects
	of DEPs on the interaction of l-HBE cells (16HBE14o-) with the cell
	and matrix microenvironment based on evaluation of integrin-type
	cell/matrix ligand expression, cytoskeleton (CSK) stiffness, and
	matrix remodeling via matrix metalloproteinase (MMP)-1, MMP-2, and
	MMP-9 expression. The results showed that DEP exposure induced: 1)
	a net dose-dependent decrease in CSK stiffness through actin fibers,
	2) a concomitant specific reduction of both alpha(3)- and beta(1)-integrin
	subunits extensively expressed on the HBE cell surface, 3) a decrease
	in the level of CD44, which is a major HBE cell-cell and HBE cell-matrix
	adhesion molecule; and 4) an isolated decrease in MMP-1 expression
	without any change in tissue inhibitor of matrix metalloproteinase
	(TIMP)-1 or TIMP-2 tissue inhibitors. Restrictive modulation of cell-matrix
	interaction, cell-cell connection, CSK stiffness, and fibrillary
	collagen remodeling results in a decreased wound closure capacity
	and an increased deadhesion capacity. In conclusion, on the basis
	of these results, we can propose that, in addition to their ability
	to increase the production of inflammatory cytokines, DEPs could
	also alter the links between actin CSK and the extracellular matrix,
	suggesting that they might facilitate HBE cell detachment in vivo.},
  journal     = {Am J Physiol Lung Cell Mol Physiol},
  keywords    = {Actins, physiology; Antigens, CD29, metabolism; Antigens, CD44, metabolism; Bronchi, drug effects/physiology; Cell Adhesion, drug effects; Cell Line; Cell Membrane, physiology; Cytoskeleton, drug effects/physiology; Dose-Response Relationship, Drug; Elasticity; Epithelial Cells, drug effects/physiology; Humans; Integrin alpha1, metabolism; Matrix Metalloproteinase 1, metabolism; Phagocytosis; Protein Isoforms, metabolism; Respiratory Mucosa, drug effects/physiology; Vehicle Emissions, adverse effects; Wound Healing, drug effects},
  medline-pst = {ppublish},
  month       = {Jan},
  owner       = {pl4},
  pii         = {284/1/L119},
  pmid        = {12471014},
  timestamp   = {2013.05.29},
  year        = {2003},
}

@Article{Downing2015,
  author          = {Downing, Amy and Morris, Eva J A and Richards, Mike and Corner, Jessica and Wright, Penny and Sebag-Montefiore, David and Finan, Paul and Kind, Paul and Wood, Charlotte and Lawton, Sarah and Feltbower, Richard and Wagland, Richard and Vernon, Sally and Thomas, James and Glaser, Adam W},
  title           = {Health-related quality of life after colorectal cancer in England: a patient-reported outcomes study of individuals 12 to 36 months after diagnosis.},
  doi             = {10.1200/JCO.2014.56.6539},
  issn            = {1527-7755},
  issue           = {6},
  pages           = {616--624},
  volume          = {33},
  abstract        = {This population-level study was conducted to define the health-related
	quality of life (HRQL) of individuals living with and beyond colorectal
	cancer (CRC) and to identify factors associated with poor health
	outcomes. All individuals diagnosed with CRC in England in 2010 and
	2011 who were alive 12 to 36 months after diagnosis were sent a questionnaire.
	This included questions related to treatment, disease status, other
	long-term conditions (LTCs), generic HRQL (EuroQol-5D), and cancer-specific
	outcomes (Functional Assessment of Cancer Therapy and Social Difficulties
	Inventory items). The response rate was 63.3% (21,802 of 34,467 patients).
	One or more generic health problems were reported by 65% of respondents,
	with 10% of patients reporting problems in all five domains. The
	reporting of problems was higher than in the general population and
	was most marked in those age less than 55 years. Certain subgroups
	reported a higher number of problems, notably those with one or more
	other LTCs, those with active or recurrent disease, those with a
	stoma, and those at the extremes of the age range (< 55 and > 85
	years). Of respondents without a stoma, 16.3% reported no bowel control.
	Reversal of a stoma resulted in fewer severe bowel problems but more
	moderate problems than those who had never had a stoma. A quarter
	of rectal cancer respondents (25.1%) reported difficulties with sexual
	matters (compared with 11.2% of colon cancer respondents). This study
	demonstrates the success of a national patient-reported outcomes
	survey. The results have the potential to support system-wide improvement
	in health outcomes through the identification of particular challenges
	faced by individuals after treatment for CRC.},
  citation-subset = {IM},
  completed       = {2015-04-14},
  country         = {United States},
  created         = {2015-2-20},
  issn-linking    = {0732-183X},
  journal         = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  keywords        = {Age Factors; Aged; Aged, 80 and over; Colorectal Neoplasms, epidemiology, physiopathology, psychology; England, epidemiology; Female; Humans; Male; Middle Aged; Quality of Life; Self Report; Surveys and Questionnaires},
  month           = {Feb},
  nlm-id          = {8309333},
  owner           = {NLM},
  pii             = {JCO.2014.56.6539},
  pmid            = {25559806},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2016-11-22},
  timestamp       = {2016.11.28},
  year            = {2015},
}

@Article{Doz2002,
  author      = {Doz, F. and Neuenschwander, S. and Bouffet, E. and Gentet, J. C. and Schneider, P. and Kalifa, C. and Mechinaud, F. and Chastagner, P. and {De Lumley}, L. and Sariban, E. and Plantaz, D. and Mosseri, V. and Bours, D. and Alapetite, C. and Zucker, J. M.},
  title       = {Carboplatin before and during radiation therapy for the treatment of malignant brain stem tumours: a study by the Soci{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚ÂµÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â© Fran{\AA}Â¦ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â©se d'Oncologie P{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â£ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â©atrique.},
  language    = {eng},
  number      = {6},
  pages       = {815--819},
  volume      = {38},
  abstract    = {Childhood malignant brain stem tumours have a very poor prognosis
	with a median survival of 9 months despite radiotherapy. No chemotherapy
	has improved survival. However, carboplatin has been reported to
	have activity in glial tumours as well as antitumour synergy with
	radiation. Our aims were to test the response rate of these tumours
	to carboplatin alone and to evaluate the efficacy on survival of
	carboplatin alone followed by concurrent carboplatin and radiotherapy.
	Patients younger than 16 years with typical clinical and radiological
	presentation of infiltrating brain stem tumour, as well as histologically-documented
	cases in the atypical forms, were eligible. Two courses of carboplatin
	(1050 mg/m2 over 3 days) were administered initially. This treatment
	was followed by a chemoradiotherapy phase including five weekly carboplatin
	courses (200 mg/m2) and conventional radiotherapy. 38 eligible patients
	were included. No tumour response was observed after the initial
	phase. This schedule of first-line carboplatin followed by concurrent
	carboplatin and radiotherapy did not improve survival.},
  journal     = {Eur J Cancer},
  keywords    = {Adolescent; Antineoplastic Agents, therapeutic use; Brain Stem Neoplasms, drug therapy/radiotherapy; Carboplatin, therapeutic use; Child; Child, Preschool; Combined Modality Therapy, methods; Female; Humans; Male; Survival Analysis},
  medline-pst = {ppublish},
  month       = {Apr},
  owner       = {pl4},
  pii         = {S0959804902000291},
  pmid        = {11937316},
  timestamp   = {2013.05.29},
  year        = {2002},
}

@Misc{Duhigg2012,
  author       = {Charles Duhigg},
  title        = {How Companies Learn Your Secrets},
  howpublished = {New York Times},
  url          = {http://www.nytimes.com/2012/02/19/magazine/shopping-habits.html?pagewanted=all&_r=0},
  file         = {Duhigg2012.pdf:pdf\\Duhigg2012.pdf:PDF;Duhigg2012.pdf:Duhigg2012.pdf:PDF},
  owner        = {PaulD},
  timestamp    = {2014.10.10},
  year         = {2012},
}

@Article{Durand-Zaleski1996,
  author      = {Durand-Zaleski, I. and Bastuji-Garin, S. and Zaleski, S. and Weil, B. and Rostoker, G.},
  title       = {A cost analysis of the prevention of end-stage renal disease: immunoglobulin therapy for IgA nephropathy.},
  language    = {eng},
  number      = {4},
  pages       = {326--334},
  volume      = {16},
  abstract    = {A cost analysis was used to evaluate three possible immunoglobulin
	(IgG) treatment protocols for end-stage renal disease due to IgA
	nephropathy. The perspective chosen for the cost analysis was that
	of the health-care delivery system. The baseline strategy was the
	absence of IgG treatment, and alternative strategies corresponded
	to three protocols presently on trial: all three included a high
	initial dose of intravenous IgG. Protocol 1 followed with intramuscular
	IgG injections only, protocol 2 with intramuscular plus intravenous
	injections, and protocol 3 with intravenous injections only. The
	costs of treatment included the costs of immunoglobulins, outpatient
	hospital costs, and the costs of tests; the saving (costs averted)
	resulted from kidney dialysis averted. The bottom line for the health-care
	system is a net savings of $233,000, $213,000, or $83,000, depending
	on the protocol chosen. The computation of costs did not value physical
	and psychological health benefits. Thus, any subjective benefit,
	such as improved comfort, or objective benefit, such as longer life
	expectancy, would be an improvement over the results presented here.},
  journal     = {Med Decis Making},
  keywords    = {Adult; Cost-Benefit Analysis; Glomerular Filtration Rate; Glomerulonephritis, IGA, economics/therapy; Health Care Costs; Humans; Immunization, Passive, economics; Immunoglobulin G, administration /&/ dosage/economics; Immunoglobulins, Intravenous, economics/therapeutic use; Injections, Intramuscular, economics; Kidney Failure, Chronic, prevention /&/ control; Male; Models, Econometric; Renal Dialysis, economics; Survival Analysis},
  medline-pst = {ppublish},
  owner       = {pl4},
  pmid        = {8912294},
  timestamp   = {2013.05.29},
  year        = {1996},
}

@Article{Durand-Zaleski1997,
  author      = {Durand-Zaleski, I. and Delaunay, L. and Langeron, O. and Belda, E. and Astier, A. and Brun-Buisson, C.},
  title       = {Infection risk and cost-effectiveness of commercial bags or glass bottles for total parenteral nutrition.},
  language    = {eng},
  number      = {3},
  pages       = {183--188},
  volume      = {18},
  abstract    = {To determine whether the greater daily expense of administering total
	parenteral nutrition (TPN) via plastic bags changed once daily, compared
	to glass bottles changed thrice daily, could be offset by savings
	from a reduction in nosocomial infections.The costs and potential
	benefits of commercially available TPN bags and TPN in glass containers
	were compared. Costs were computed from the viewpoint of the hospital,
	first in a general model and then for two specific examples, Crohn's
	disease and intensive-care unit (ICU) patients. The extra cost of
	using bags was $20 per day. The total cost of nosocomial bacteremia
	was estimated at $6,000. The monetary benefits of using TPN bags
	were $6,000XT, where XT was the percentage of nosocomial infections
	averted. We also considered that reduction in intravenous (IV)-line
	manipulation could reduce bacteremia-related mortality and computed
	a cost-per-life-saved ratio.Modeling showed that TPN in bags could
	yield a net benefit when the absolute reduction in the daily risk
	of nosocomial bacteremia reached the threshold value of 0.3\%. Such
	a reduction could not be attained in patients with Crohn's disease,
	and corresponded to a 50\% to 60\% reduction of infection rates in
	ICU patients. Varying the risk of mortality attributable to IV-line-related
	infection from 1\% to 13\% resulted in a cost effectiveness of using
	TPN bags ranging from $90,000 to $7,000 per life saved in ICU, assuming
	a two-thirds reduction in IV-line infections, and from $180,000 to
	$14,000 if the infection rate was reduced by one third.The baseline
	cost-minimization analysis concluded that the extra cost of TPN bags
	was not justified by the extra savings. The cost-effectiveness analysis,
	however, found that the cost per life saved fell within the accepted
	range of public health interventions, provided a large fraction of
	infections are averted using TPN bags.},
  journal     = {Infect Control Hosp Epidemiol},
  keywords    = {Cost-Benefit Analysis; Cross Infection, economics/prevention /&/ control; Drug Packaging, economics; Equipment and Supplies, Hospital, economics/standards; France; Glass; Hospital Costs; Humans; Length of Stay, economics; Parenteral Nutrition, Total, economics/instrumentation; Risk Factors; Value of Life},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {pl4},
  pmid        = {9090546},
  timestamp   = {2013.05.29},
  year        = {1997},
}

@Article{Durrleman1989,
  author      = {S. Durrleman and R. Simon},
  title       = {Flexible regression models with cubic splines.},
  number      = {5},
  pages       = {551--561},
  volume      = {8},
  abstract    = {We describe the use of cubic splines in regression models to represent
	the relationship between the response variable and a vector of covariates.
	This simple method can help prevent the problems that result from
	inappropriate linearity assumptions. We compare restricted cubic
	spline regression to non-parametric procedures for characterizing
	the relationship between age and survival in the Stanford Heart Transplant
	data. We also provide an illustrative example in cancer therapeutics.},
  file        = {Durrleman1989.pdf:pdf\\Durrleman1989.pdf:PDF;Durrleman1989.pdf:Durrleman1989.pdf:PDF},
  institution = {Biometric Research Branch, NCI, Bethesda, MD 20892.},
  journal     = {Statistics in Medicine},
  month       = {May},
  owner       = {pl4},
  pmid        = {2657958},
  timestamp   = {2008.11.20},
  year        = {1989},
}

@Article{Dyba1995,
  author    = {Dyba, T. and Hakulinen, T.},
  title     = {Confidence and Prediction Intervals for Disease Incidence Using {GLIM}},
  pages     = {27-32},
  volume    = {25},
  journal   = {{GLIM} Newsletter},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@Article{Dyba1994,
  author    = {Dyba, T. and Hakulinen, T.},
  title     = {Confidence Intervals for Model-based cumulative Relative Survival Rates Using {GLIM}},
  pages     = {29-35},
  volume    = {23},
  journal   = {{GLIM} Newsletter},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1994},
}

@Article{Dziak2012,
  author    = {Dziak, J. J. and Coffman, D. L. and Lanza, S. T. and Li, R.},
  title     = {Sensitivity and specificity of information criteria},
  file      = {Dziak2012.pdf:Dziak2012.pdf:PDF;Dziak2012.pdf:pdf\\Dziak2012.pdf:PDF},
  journal   = {The Methodology Center and Department of Statistics, Penn State, The Pennsylvania State University},
  owner     = {hanbow},
  timestamp = {2015.05.11},
  year      = {2012},
}

@Book{WHO1986,
  author    = {World Health Organisation Regional Office for {E}urope},
  title     = {Targets for Health for All: Targets in Support of the {E}uropean Regional Strategy for Health for All},
  publisher = {Copenhagen: World Health Organisation Regional Office for {E}urope},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1986},
}

@Article{Eaker2006,
  author    = {Sonja Eaker and Paul W Dickman and Leif Bergkvist and Lars Holmberg},
  title     = {Differences in Management of Older Women Influence Breast Cancer Survival: Results from a Population-Based Database in {S}weden.},
  doi       = {10.1371/journal.pmed.0030025},
  pages     = {e25},
  url       = {http://dx.doi.org/10.1371/journal.pmed.0030025},
  volume    = {3},
  abstract  = {BACKGROUND: Several reports have shown that less aggressive patterns
	of diagnostic activity and care are provided to elderly breast carcinoma
	patients. We sought to investigate whether differences in the management
	of older women with breast cancer are associated with survival. METHODS
	AND FINDINGS: In an observational study using a population-based
	clinical breast cancer register of one health-care region in {S}weden,
	we identified 9,059 women aged 50-84 y diagnosed with primary breast
	cancer between 1992 and 2002. The 5-y relative survival ratio was
	estimated for patients classified by age group, diagnostic activity,
	tumor characteristics, and treatment. The 5-y relative survival for
	breast cancer patients was lower (up to 13\%) in women 70-84 y of
	age compared to women aged 50-69 y, and the difference was most pronounced
	in stage IIB-III and in the unstaged. Significant differences in
	disease management were found, as older women had larger tumors,
	had fewer nodes examined, and did not receive treatment by radiotherapy
	or by chemotherapy as often as the younger women. Adjustment for
	diagnostic activity, tumor characteristics, and treatment diminished
	the relative excess mortality in stages III and in the unstaged,
	whereas the excess mortality was only marginally affected in stage
	IIB. CONCLUSIONS: Less diagnostic activity, less aggressive treatment,
	and later diagnosis in older women are associated with poorer survival.
	The large differences in treatment of older women are difficult to
	explain by co-morbidity alone.},
  journal   = {PLoS Med},
  owner     = {PaulD},
  pii       = {05-PLME-RA-0247R1},
  pmid      = {16409108},
  timestamp = {2006.10.04},
  year      = {2006},
}

@Article{Eaker2005,
  author    = {Sonja Eaker and Paul W Dickman and Vivan Hellstr\"{o}m and Matthew M Zack and Johan Ahlgren and Lars Holmberg},
  title     = {Regional differences in breast cancer survival despite common guidelines.},
  doi       = {10.1158/1055-9965.EPI-05-0317},
  pages     = {2914--2918},
  url       = {http://dx.doi.org/10.1158/1055-9965.EPI-05-0317},
  volume    = {14},
  abstract  = {PURPOSE: Despite a uniform regional breast cancer care program, breast
	cancer survival differs within regions. We therefore examined breast
	cancer survival in relation to differences in diagnostic activity,
	tumor characteristics, and treatment in seven Swedish counties within
	a single health care region. METHODS: We conducted a population-based
	observational study using a clinical breast cancer register in one
	Swedish health care region. Eligible women (n = 7,656) ages 40 to
	69 years diagnosed with primary breast cancer between 1992 and 2002
	were followed up until 2003. The 7-year relative survival ratio was
	used to estimate breast cancer survival. Excess mortality was modeled
	using Poisson regression to study differences in survival between
	counties. RESULTS: The 7-year relative survival for breast cancer
	patients was significantly lower (up to 7\% in absolute risk difference)
	in one county (county A) compared with the others. This difference
	existed only among women diagnosed before 1998, ages 50 to 59 years,
	and was strongest among stage II breast cancer patients. Adjustment
	for amount of diagnostic activity eliminated the survival differences
	among the counties. The amount of diagnostic activity was also lower
	in county A during the same time period. After county A, during 1997-1998,
	began to adhere strictly to the regional breast cancer care program,
	neither any survival differences nor diagnostic activity differences
	were observed. INTERPRETATIONS: Markers of diagnostic activity explained
	survival differences within our region, and the underlying mechanisms
	may be several. Low diagnostic activity may entail later diagnosis
	or inadequate characterization of the tumor and thereby missed treatment
	opportunities. Strengthening of multidisciplinary management of breast
	cancer can improve survival.},
  journal   = {Cancer Epidemiol Biomarkers Prev},
  owner     = {PaulD},
  pii       = {14/12/2914},
  pmid      = {16365009},
  timestamp = {2006.10.04},
  year      = {2005},
}

@Article{Eaker2011,
  author      = {S. Eaker and A. Wigertz and P. C. Lambert and L. Bergkvist and J. Ahlgren and M. Lambe and {Uppsala/\"{O}rebro Breast Cancer Group}},
  title       = {Breast cancer, sickness absence, income and marital status. {A} study on life situation 1 year prior diagnosis compared to 3 and 5 years after diagnosis.},
  doi         = {10.1371/journal.pone.0018040},
  number      = {3},
  pages       = {e18040},
  volume      = {6},
  abstract    = {Improved cancer survival poses important questions about future life
	conditions of the survivor. We examined the possible influence of
	a breast cancer diagnosis on subsequent working and marital status,
	sickness absence and income.We conducted a matched cohort study including
	4,761 women 40-59 years of age and registered with primary breast
	cancer in a Swedish population-based clinical register during 1993-2003,
	and 2,3805 women without breast cancer. Information on socioeconomic
	standing was obtained from a social database 1 year prior and 3 and
	5 years following the diagnosis. In Conditional Poisson Regression
	models, risk ratios (RRs) and 95\% confidence intervals (CIs) were
	estimated to assess the impact of a breast cancer diagnosis.Three
	years after diagnosis, women who had had breast cancer more often
	had received sickness benefits (RR = 1.49, 95\% CI 1.40-1.58) or
	disability pension (RR = 1.47, 95\% CI 1.37-1.58) than had women
	without breast cancer. We found no effect on income (RR = 0.99),
	welfare payments (RR = 0.98), or marital status (RR = 1.02). A higher
	use of sickness benefits and disability pension was evident in all
	stages of the disease, although the difference in use of sickness
	benefits decreased after 5 years, whereas the difference in disability
	pension increased. For woman with early stage breast cancer, the
	sickness absence was higher following diagnosis among those with
	low education, who had undergone mastectomy, and had received chemo-
	or hormonal therapy. Neither tumour size nor presence of lymph nodes
	metastasis was associated with sickness absence after adjustment
	for treatment.Even in early stage breast cancer, a diagnosis negatively
	influences working capacity both 3 and 5 years after diagnosis, and
	it seems that the type of treatment received had the largest impact.
	A greater focus needs to be put on rehabilitation of breast cancer
	patients, work-place adaptations and research on long-term sequelae
	of treatment.},
  institution = {Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. sonja.eaker@surgsci.uu.se},
  journal     = {PLoS One},
  owner       = {pl4},
  pmid        = {21479209},
  timestamp   = {2011.06.20},
  year        = {2011},
}

@Article{Ederer1961,
  author    = {F. Ederer and L.M. Axtell and S.J. Cutler},
  title     = {The relative survival rate: A statistical methodology},
  pages     = {101-121},
  volume    = {6},
  file      = {Ederer1961.pdf:Ederer1961.pdf:PDF;Ederer1961.pdf:pdf\\Ederer1961.pdf:PDF},
  journal   = {National Cancer Institute Monograph},
  owner     = {pl4},
  timestamp = {2009.10.13},
  year      = {1961},
}

@TechReport{Ederer1959,
  author      = {F. Ederer and H. Heise},
  institution = {National Cancer Institute, Bethesda, MD},
  title       = {Instructions to {IBM} 650 programmers in processing survival computations. Methodological note No. 10, End Results Evaluation Section},
  owner       = {pl4},
  timestamp   = {2009.10.13},
  year        = {1959},
}

@Article{Ederer1959b,
  author       = {Ederer, F. and Heise, H.},
  title        = {The effect of eliminating deaths from cancer on general population survival rates},
  howpublished = {Methodological note No. 11, End Results Evaluation Section, National Cancer Institute, Bethesda MD},
  owner        = {PaulD},
  timestamp    = {2011.06.19},
  year         = {1959},
}

@Article{Edwards2014,
  author      = {Edwards, Brenda K. and Noone, Anne-Michelle and Mariotto, Angela B. and Simard, Edgar P. and Boscoe, Francis P. and Henley, S Jane and Jemal, Ahmedin and Cho, Hyunsoon and Anderson, Robert N. and Kohler, Betsy A. and Eheman, Christie R. and Ward, Elizabeth M.},
  title       = {Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer.},
  doi         = {10.1002/cncr.28509},
  language    = {eng},
  number      = {9},
  pages       = {1290--1314},
  url         = {http://dx.doi.org/10.1002/cncr.28509},
  volume      = {120},
  abstract    = {The American Cancer Society (ACS), the Centers for Disease Control
	and Prevention (CDC), the National Cancer Institute (NCI), and the
	North American Association of Central Cancer Registries (NAACCR)
	collaborate annually to provide updates on cancer incidence and death
	rates and trends in these outcomes for the United States. This year's
	report includes the prevalence of comorbidity at the time of first
	cancer diagnosis among patients with lung, colorectal, breast, or
	prostate cancer and survival among cancer patients based on comorbidity
	level.Data on cancer incidence were obtained from the NCI, the CDC,
	and the NAACCR; and data on mortality were obtained from the CDC.
	Long-term (1975/1992-2010) and short-term (2001-2010) trends in age-adjusted
	incidence and death rates for all cancers combined and for the leading
	cancers among men and women were examined by joinpoint analysis.
	Through linkage with Medicare claims, the prevalence of comorbidity
	among cancer patients who were diagnosed between 1992 through 2005
	residing in 11 Surveillance, Epidemiology, and End Results (SEER)
	areas were estimated and compared with the prevalence in a 5\% random
	sample of cancer-free Medicare beneficiaries. Among cancer patients,
	survival and the probabilities of dying of their cancer and of other
	causes by comorbidity level, age, and stage were calculated.Death
	rates continued to decline for all cancers combined for men and women
	of all major racial and ethnic groups and for most major cancer sites;
	rates for both sexes combined decreased by 1.5\% per year from 2001
	through 2010. Overall incidence rates decreased in men and stabilized
	in women. The prevalence of comorbidity was similar among cancer-free
	Medicare beneficiaries (31.8\%), breast cancer patients (32.2\%),
	and prostate cancer patients (30.5\%); highest among lung cancer
	patients (52.9\%); and intermediate among colorectal cancer patients
	(40.7\%). Among all cancer patients and especially for patients diagnosed
	with local and regional disease, age and comorbidity level were important
	influences on the probability of dying of other causes and, consequently,
	on overall survival. For patients diagnosed with distant disease,
	the probability of dying of cancer was much higher than the probability
	of dying of other causes, and age and comorbidity had a smaller effect
	on overall survival.Cancer death rates in the United States continue
	to decline. Estimates of survival that include the probability of
	dying of cancer and other causes stratified by comorbidity level,
	age, and stage can provide important information to facilitate treatment
	decisions.},
  institution = {Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.},
  journal     = {Cancer},
  keywords    = {Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Breast Neoplasms, epidemiology/mortality; Child; Child, Preschool; Colorectal Neoplasms, epidemiology/mortality; Comorbidity, trends; Female; Humans; Incidence; Infant; Infant, Newborn; Lung Neoplasms, epidemiology/mortality; Male; Middle Aged; Neoplasms, epidemiology/mortality; Prevalence; Prostatic Neoplasms, epidemiology/mortality; SEER Program; Survival Analysis; Survival Rate, trends; United States, epidemiology; Young Adult},
  medline-pst = {ppublish},
  month       = {May},
  owner       = {PaulD},
  pmid        = {24343171},
  timestamp   = {2014.12.01},
  year        = {2014},
}

@Book{Efron1993,
  author    = {Efron, B. and Tibshirani, R.J.},
  title     = {An introduction to the bootstrap},
  publisher = {Chapman and Hall},
  owner     = {pl4},
  timestamp = {2009.02.12},
  year      = {1993},
}

@Article{Eide2008,
  author      = {Eide, Geir E.},
  title       = {Attributable fractions for partitioning risk and evaluating disease prevention: a practical guide.},
  doi         = {10.1111/j.1752-699X.2008.00091.x},
  language    = {eng},
  pages       = {92--103},
  url         = {http://dx.doi.org/10.1111/j.1752-699X.2008.00091.x},
  volume      = {2 Suppl 1},
  abstract    = {The attributable fraction (AF) is used for quantifying the fraction
	of diseased ascribable to one or more exposures. The methodology
	and software for its estimation has undergone a considerable development
	during the last decades.To introduce methods for: (i) apportioning
	excess risk to multiple exposures, groups of exposures and subpopulations;
	(ii) graphical description; and (iii) survival data.Adjusted, sequential
	and average AFs are reasonable measures obtainable with standard
	software. The latter two both sum up to the combined AF for a set
	of exposures. The average AFs are independent of the exposures' ordering.
	For an ordered, preventive strategy, scaled sample space cubes illustrate
	the effects on the risk of disease from stepwise exposure removal.
	Pie charts illustrate the portions of the total risk ascribed to
	different exposures or risk-profiles. Attributable hazard fraction,
	AF before time t, and AF within study incorporate time to disease
	and interventions.The practice of crude calculations of AFs in epidemiology
	should be abandoned. Further development of methods for AFs with
	survival data and possibly linking it to causal modelling is of interest.},
  file        = {Eide2008.pdf:pdf\\Eide2008.pdf:PDF;Eide2008.pdf:Eide2008.pdf:PDF},
  institution = {Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway. Geir.Egil.Eide@Haukeland.No},
  journal     = {Clin Respir J},
  keywords    = {Humans; Lung Diseases, epidemiology/prevention /&/ control; Models, Statistical; Risk Assessment; Risk Factors},
  medline-pst = {ppublish},
  month       = {Oct},
  owner       = {PaulD},
  pii         = {CRJ091},
  pmid        = {20298357},
  timestamp   = {2015.03.25},
  year        = {2008},
}

@Article{Ejerblad2004,
  author    = {Elisabeth Ejerblad and C Michael Fored and Per Lindblad and Jon Fryzek and Paul W Dickman and Carl-Gustaf Elinder and Joseph K McLaughlin and Olof Nyr\'{e}n},
  title     = {Association between smoking and chronic renal failure in a nationwide population-based case-control study.},
  doi       = {10.1097/01.ASN.0000135048.35659.10},
  number    = {8},
  pages     = {2178-85},
  url       = {http://dx.doi.org/10.1097/01.ASN.0000135048.35659.10},
  volume    = {15},
  abstract  = {For determining whether smoking is associated with an increased risk
	for chronic renal failure (CRF) overall and by type of renal disease,
	smoking data were analyzed from a nationwide population-based case-control
	study. Eligible as cases were native 18- to 74-yr-old Swedes whose
	serum creatinine for the first time and permanently exceeded 3.4
	mg/dl (men) or 2.8 mg/dl (women). A total of 926 cases (78\% of all
	eligible) and 998 control subjects (75\% of 1330 randomly selected
	subjects from the source population), frequency matched to the cases
	by gender and age within 10 yr, were included. A face-to-face interview
	and a self-administered questionnaire provided information about
	smoking habits and other lifestyle factors. Logistic regression models
	estimated odds ratios (OR) as measures of relative risk for disease-specific
	types of CRF among smokers compared with never-smokers. Despite a
	modest and nonsignificant overall association, the risk increased
	with high daily doses (OR among smokers of >20 cigarettes/d, 1.51;
	95\% confidence interval [CI], 1.06 to 2.15), long duration (OR among
	smokers for >40 yr, 1.45; 95\% CI, 1.00 to 2.09), and a high cumulative
	dose (OR among smokers with >30 pack-years, 1.52; 95\% CI, 1.08 to
	2.14). Smoking increased risk most strongly for CRF classified as
	nephrosclerosis (OR among smokers with >20 pack-years, 2.2; 95\%
	CI, 1.3 to 3.8), but significant positive associations were also
	noted with glomerulonephritis. This study thus suggests that heavy
	cigarette smoking increases the risk of CRF for both men and women,
	at least CRF classified as nephrosclerosis and glomerulonephritis.},
  journal   = {J Am Soc Nephrol},
  month     = {Aug},
  owner     = {PaulD},
  pii       = {15/8/2178},
  timestamp = {2011.06.19},
  year      = {2004},
}

@Article{Ekman2006,
  author    = {Alexandra Ekman and Paul W Dickman and Asa Klint and Elisabete Weiderpass and Jan-Eric Litton},
  title     = {Feasibility of using web-based questionnaires in large population-based epidemiological studies.},
  doi       = {10.1007/s10654-005-6030-4},
  pages     = {103--111},
  url       = {http://dx.doi.org/10.1007/s10654-005-6030-4},
  volume    = {21},
  abstract  = {To date, few large web-based epidemiological studies have been performed
	in a population-based setting. {S}weden has optimal prerequisites
	for web-based studies with more than 80\% of the general population
	having access to the Internet. Our aim was to investigate (I) response
	rates in an epidemiological study using primarily the web as a tool
	for data collection and (II) whether socio-demographic patterns vary
	between responders to a web and a paper questionnaire. In 2003, we
	invited 47,859 women to complete a web questionnaire. Two reminders
	were sent to non-responders; in the first a random sample received
	a paper questionnaire and in the second the majority received a paper
	questionnaire. All other non-responders received web questionnaires.
	Differences in response rates between responders to web and paper
	questionnaires with regard to socio-demographic and other variables
	were analyzed, and estimates of the bias introduced by these differences
	were estimated. In total, 41\% of the women responded to the web
	questionnaire and 31\% to the paper questionnaire (overall response
	rate 72\%). The web-, paper- and non-responders respectively did
	not differ significantly in age, physical activity levels, and body
	mass index. Women answering web or paper questionnaires had a higher
	level of education and income and a lower level of smoking than non-responders.
	The bias associated with collecting information using web questionnaires
	was not greater than that caused by paper questionnaires. We conclude
	that web-based questionnaires are a feasible tool for data collection
	in large population based epidemiological studies in {S}weden.},
  journal   = {Eur J Epidemiol},
  owner     = {PaulD},
  pmid      = {16518678},
  timestamp = {2006.10.04},
  year      = {2006},
}

@Article{ElandtJohnson1975,
  author    = {E. C. Elandt-Johnson},
  title     = {Definition of rates: Some remarks on their use and misuse},
  pages     = {267--271},
  volume    = {102},
  file      = {ElandtJohnson1975.pdf:ElandtJohnson1975.pdf:PDF;ElandtJohnson1975.pdf:pdf\\ElandtJohnson1975.pdf:PDF},
  journal   = {American Journal of Epidemiology},
  owner     = {pl4},
  timestamp = {2009.11.09},
  year      = {1975},
}

@Article{Ellis2014a,
  author      = {Ellis, L. and Coleman, M. P. and Rachet, B.},
  title       = {The impact of life tables adjusted for smoking on the socio-economic difference in net survival for laryngeal and lung cancer.},
  doi         = {10.1038/bjc.2014.217},
  language    = {eng},
  number      = {1},
  pages       = {195--202},
  url         = {http://dx.doi.org/10.1038/bjc.2014.217},
  volume      = {111},
  abstract    = {Net survival is a key measure in cancer control, but estimates for
	cancers that are strongly associated with smoking may be biased.
	General population life tables represent background mortality in
	net survival, but may not adequately reflect the higher mortality
	experienced by smokers.Life tables adjusted for smoking were developed,
	and their impact on net survival and inequalities in net survival
	for laryngeal and lung cancers was examined.The 5-year net survival
	estimated with smoking-adjusted life tables was consistently higher
	than the survival estimated with unadjusted life tables: 7\% higher
	for laryngeal cancer and 1.5\% higher for lung cancer. The impact
	of using smoking-adjusted life tables was more pronounced in affluent
	patients; the deprivation gap in 5-year net survival for laryngeal
	cancer widened by 3\%, from 11\% to 14\%.Using smoking-adjusted life
	tables to estimate net survival has only a small impact on the deprivation
	gap in survival, even when inequalities are substantial. Adjusting
	for the higher, smoking-related background mortality did increase
	the estimates of net survival for all deprivation groups, and may
	be more important when measuring the public health impact of differences
	or changes in survival, such as avoidable deaths or crude probabilities
	of death.},
  file        = {Ellis2014a.pdf:pdf\\Ellis2014a.pdf:PDF;Ellis2014a.pdf:Ellis2014a.pdf:PDF},
  institution = {Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.},
  journal     = {Br J Cancer},
  keywords    = {Adult; Aged; Aged, 80 and over; England, epidemiology; Female; Humans; Laryngeal Neoplasms, economics/mortality; Life Tables; Lung Neoplasms, economics/mortality; Male; Middle Aged; Smoking, adverse effects/economics/mortality; Social Class; Survival Analysis},
  medline-pst = {ppublish},
  month       = {Jul},
  owner       = {PaulD},
  pii         = {bjc2014217},
  pmid        = {24853177},
  timestamp   = {2015.03.24},
  year        = {2014},
}

@Article{Ellis2012,
  author      = {Ellis, Libby and Coleman, Michel P. and Rachet, Bernard},
  title       = {How many deaths would be avoidable if socioeconomic inequalities in cancer survival in {E}ngland were eliminated? A national population-based study, 1996-2006.},
  doi         = {10.1016/j.ejca.2011.10.008},
  language    = {eng},
  number      = {2},
  pages       = {270--278},
  url         = {http://dx.doi.org/10.1016/j.ejca.2011.10.008},
  volume      = {48},
  abstract    = {Inequalities in survival between rich and poor have been reported
	for most adult cancers in England. This study aims to quantify the
	public health impact of these inequalities by estimating the number
	of cancer-related deaths that would be avoidable if all patients
	were to have the same cancer survival as the most affluent patients.National
	Cancer Registry data for all adults diagnosed with one of 21 common
	cancers in England were used to estimate relative survival. We estimated
	the number of excess (cancer-related) deaths that would be avoidable
	within three years after diagnosis if relative survival for patients
	in all deprivation groups was as high as the most affluent group.For
	patients diagnosed during 2004-2006, 7122 of the 64,940 excess deaths
	a year (11\%) would have been avoidable if three-year survival for
	all patients had been as high as in the most affluent group. The
	annual number of avoidable deaths fell from 8435 (13\%) a year for
	patients diagnosed during 1996-2000. Over 60\% of the total number
	of avoidable deaths occurred within six months after diagnosis and
	approximately 70\% occurred in the two most deprived groups.The downward
	trend in the annual number of avoidable deaths reflects more an improvement
	in survival in England overall, rather than a narrowing of the deficit
	in cancer survival between poor and rich. The lack of any substantial
	change in the percentage of avoidable excess deaths highlights the
	persistent nature of the deficit in survival between affluent and
	deprived groups.},
  file        = {Ellis2012.pdf:Ellis2012.pdf:PDF;Ellis2012.pdf:pdf\\Ellis2012.pdf:PDF},
  institution = {Department of Non-Communicable Disease Epidemiology, Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK. libby.ellis@lshtm.ac.uk},
  journal     = {Eur J Cancer},
  keywords    = {England, epidemiology; Epidemiologic Studies; Humans; Neoplasms, mortality; Poverty; Registries; Social Class; Survival Analysis},
  medline-pst = {ppublish},
  owner       = {pl4},
  pii         = {S0959-8049(11)00795-7},
  pmid        = {22093945},
  timestamp   = {2013.06.11},
  year        = {2012},
}

@Article{Ellis2014,
  author      = {Ellis, Libby and Woods, Laura M. and Est{\`{e}}ve, Jacques and Eloranta, Sandra and Coleman, Michel P. and Rachet, Bernard},
  title       = {Cancer incidence, survival and mortality: explaining the concepts.},
  doi         = {10.1002/ijc.28990},
  language    = {eng},
  number      = {8},
  pages       = {1774--1782},
  url         = {http://dx.doi.org/10.1002/ijc.28990},
  volume      = {135},
  abstract    = {Cancer incidence, survival and mortality are essential population-based
	indicators for public health and cancer control. Confusion and misunderstanding
	still surround the estimation and interpretation of these indicators.
	Recurring controversies over the use and misuse of population-based
	cancer statistics in health policy suggests the need for further
	clarification. In our article, we describe the concepts that underlie
	the measures of incidence, survival and mortality, and illustrate
	the synergy between these measures of the cancer burden. We demonstrate
	the relationships between trends in incidence, survival and mortality,
	using real data for cancers of the lung and breast from England and
	Sweden. Finally, we discuss the importance of using all three measures
	in combination when interpreting overall progress in cancer control,
	and we offer some recommendations for their use.},
  file        = {Ellis2014.pdf:pdf\\Ellis2014.pdf:PDF;Ellis2014.pdf:Ellis2014.pdf:PDF},
  institution = {Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, United Kingdom.},
  journal     = {Int J Cancer},
  keywords    = {Aged; Breast Neoplasms, mortality/therapy; England, epidemiology; Female; Humans; Incidence; Lung Neoplasms, mortality/therapy; Male; Middle Aged; Sweden, epidemiology},
  medline-pst = {ppublish},
  month       = {Oct},
  owner       = {PaulD},
  pmid        = {24945976},
  timestamp   = {2015.03.24},
  year        = {2014},
}

@PhdThesis{Eloranta:phdthesis:2013,
  author    = {Sandra Eloranta},
  title     = {Development and Application of Statistical Methods for Population-Based Cancer Patient Survival},
  type      = {PhD Thesis},
  file      = {:pdf\\Thesis_Sandra_Eloranta.pdf:PDF},
  groups    = {PhD Thesis},
  owner     = {PaulD},
  school    = {Karolinska Institutet},
  timestamp = {2013.10.23},
  year      = {2013},
}

@Article{Eloranta2013,
  author      = {Eloranta, S. and Adolfsson, J. and Lambert, P.C. and Stattin, P. and Akre, O. and Andersson, T.M-L. and Dickman, P.W.},
  title       = {How can we make cancer survival statistics more useful for patients and clinicians: An illustration using localized prostate cancer in {S}weden.},
  doi         = {10.1007/s10552-012-0141-5},
  language    = {eng},
  pages       = {505--515},
  url         = {http://dx.doi.org/10.1007/s10552-012-0141-5},
  volume      = {24},
  abstract    = {PURPOSE: Studies of cancer patient survival typically report relative
	survival or cause-specific survival using data from patients diagnosed
	many years in the past. From a risk-communication perspective, such
	measures are suboptimal for several reasons; their interpretation
	is not transparent for non-specialists, competing causes of death
	are ignored and the estimates are unsuitable to predict the outcome
	of newly diagnosed patients. In this paper, we discuss the relative
	merits of recently developed alternatives to traditionally reported
	measures of cancer patient survival. METHODS: In a relative survival
	framework, using a period approach, we estimated probabilities of
	death in the presence of competing risks. To illustrate the methods,
	we present estimates of survival among 23,353 initially untreated,
	or hormonally treated men with intermediate- or high-risk localized
	prostate cancer using Swedish population-based data. RESULTS: Among
	all groups of newly diagnosed patients, the probability of dying
	from prostate cancer, accounting for competing risks, was lower compared
	to the corresponding estimates where competing risks were ignored.
	Accounting for competing deaths was particularly important for patients
	aged more than 70 years at diagnosis in order to avoid overestimating
	the risk of dying from prostate cancer. CONCLUSIONS: We argue that
	period estimates of survival, accounting for competing risks, provide
	the tools to communicate the actual risk that cancer patients, diagnosed
	today, face to die from their disease. Such measures should offer
	a more useful basis for risk communication between patients and clinicians
	and we advocate their use as means to answer prognostic questions.},
  file        = {Eloranta2013.pdf:pdf\\Eloranta2013.pdf:PDF;Eloranta2013.pdf:Eloranta2013.pdf:PDF},
  institution = {Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Box 281, 171 77, Stockholm, Sweden, sandra.eloranta@ki.se.},
  journal     = {Cancer Causes Control},
  medline-pst = {aheadofprint},
  owner       = {PaulD},
  pmid        = {23296456},
  timestamp   = {2013.01.15},
  year        = {2013},
}

@Misc{presentation_sandra_20130313_forsakringskassan,
  author    = {Sandra Eloranta and Paul W Dickman},
  title     = {Borde vi m{\"a}ta statistisk os{\"a}kerhet vid totalunders{\"o}kningar?},
  file      = {presentation_sandra_20130313_forsakringskassan.pdf:presentation_sandra_20130313_forsakringskassan.pdf:PDF;presentation_sandra_20130313_forsakringskassan.pdf:pdf\\presentation_sandra_20130313_forsakringskassan.pdf:PDF},
  groups    = {Presentation},
  keywords  = {Presentation},
  owner     = {PaulD},
  timestamp = {2013.09.18},
}

@Article{Eloranta2014,
  author      = {Eloranta, S. and Lambert, P. C. and Andersson, T. M-L. and Bj{\"{o}}rkholm, M. and Dickman, P. W.},
  title       = {The application of cure models in the presence of competing risks: a tool for improved risk communication in population-based cancer patient survival.},
  doi         = {10.1097/EDE.0000000000000130},
  language    = {eng},
  number      = {5},
  pages       = {742--748},
  url         = {http://dx.doi.org/10.1097/EDE.0000000000000130},
  volume      = {25},
  abstract    = {Quantifying cancer patient survival from the perspective of cure is
	clinically relevant. However, most cure models estimate cure assuming
	no competing causes of death. We use a relative survival framework
	to demonstrate how flexible parametric cure models can be used in
	combination with competing-risks theory to incorporate noncancer
	deaths. Under a model that incorporates statistical cure, we present
	the probabilities that cancer patients (1) have died from their cancer,
	(2) have died from other causes, (3) will eventually die from their
	cancer, or (4) will eventually die from other causes, all as a function
	of time since diagnosis. We further demonstrate how conditional probabilities
	can be used to update the prognosis among survivors (eg, at 1 or
	5 years after diagnosis) by summarizing the proportion of patients
	who will not die from their cancer. The proposed method is applied
	to Swedish population-based data for persons diagnosed with melanoma,
	colon cancer, or acute myeloid leukemia between 1973 and 2007.},
  file        = {Eloranta2014.pdf:Eloranta2014.pdf:PDF},
  institution = {From the aDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; bDepartment of Health Sciences, University of Leicester, Leicester, UK; and cDepartment of Medicine, Division of Hematology, Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden.},
  journal     = {Epidemiology},
  medline-pst = {ppublish},
  owner       = {pl4},
  pmid        = {25036430},
  timestamp   = {2015.04.14},
  year        = {2014},
}

@Article{Eloranta2012,
  author    = {S. Eloranta and P. C. Lambert and T. M-L. Andersson and K. Czene and P. Hall and M. Bj\"{o}rkholm and P. W. Dickman},
  title     = {Partitioning of excess mortality in population-based cancer patient survival studies using flexible parametric survival models},
  doi       = {10.1186/1471-2288-12-86},
  pages     = {86},
  volume    = {12},
  file      = {Eloranta2012.pdf:Eloranta2012.pdf:PDF;Eloranta2012.pdf:pdf\\Eloranta2012.pdf:PDF},
  journal   = {BMC Medical Research Methodology},
  owner     = {pl4},
  pmid      = {22726307},
  timestamp = {2012.03.31},
  year      = {2012},
}

@Article{Eloranta2010,
  author      = {S. Eloranta and P. C. Lambert and N. Cavalli-Bj{{\"o}}rkman and T. M-L Andersson and B. Glimelius and P. W. Dickman},
  title       = {Does socioeconomic status influence the prospect of cure from colon cancer--a population-based study in {S}weden 1965-2000.},
  doi         = {10.1016/j.ejca.2010.05.028},
  language    = {eng},
  number      = {16},
  pages       = {2965--2972},
  volume      = {46},
  abstract    = {AIM OF STUDY: Differences in the survival of colon cancer patients
	by socioeconomic status have been demonstrated in several populations,
	but the underlying reasons for the differences are not well understood.
	By simultaneously estimating the proportion of patients cured from
	colon cancer and the survival times of the 'uncured' we hope to increase
	understanding of how socioeconomic status affects survival following
	a diagnosis of colon cancer. METHODS: We conducted a population-based
	cohort study of 58,873 patients diagnosed with colon cancer in Sweden
	1965-2000. Socioeconomic status was classified based on occupation.
	We fitted mixture cure models and Poisson regression models adjusted
	for age, sex and calendar period. RESULTS: We observed higher excess
	mortality, lower proportion cured and shorter survival times among
	the uncured in patients from lower socioeconomic groups compared
	to the highest socioeconomic group. There was no evidence that the
	gap between the socioeconomic groups reduced over time. Farmers had
	the lowest odds of cure (odds ratio (OR) 0.85, 95\% confidence interval
	(CI) 0.75-0.95) compared to higher non-manual workers followed by
	self-employed (0.91, 0.81-1.03), manual workers (0.93, 0.85-1.03)
	and lower non-manual workers (0.98, 0.89-1.08). CONCLUSION: Patients
	from lower socioeconomic groups in Sweden experience worse survival
	following a diagnosis of colon cancer. Differences exist in both
	the cure proportion and the survival time of the uncured, suggesting
	that socioeconomic differences cannot be attributed solely to lead
	time bias.Although this study has furthered our understanding of
	socioeconomic differences in survival, more detailed studies are
	required in order to identify, and subsequently remove, the underlying
	reasons for the differences.},
  file        = {Eloranta2010.pdf:Eloranta2010.pdf:PDF;Eloranta2010.pdf:pdf\\Eloranta2010.pdf:PDF},
  institution = {Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Box 281, S-171 77 Stockholm, Sweden. Sandra.eloranta@ki.se},
  journal     = {European Journal of Cancer},
  keywords    = {Cure models; Application},
  medline-pst = {ppublish},
  month       = nov,
  owner       = {PaulD},
  pii         = {S0959-8049(10)00452-1},
  pmid        = {20580545},
  timestamp   = {2010.11.30},
  year        = {2010},
}

@Article{Eloranta2013a,
  author      = {Eloranta, S. and Lambert, P. C. and Sj{\"o}berg, J. and Andersson, T. M-L. and Bj{\"o}rkholm, M. and Dickman, P. W.},
  title       = {Temporal trends in mortality from diseases of the circulatory system after treatment for {H}odgkin lymphoma: a population-based cohort study in {S}weden (1973 to 2006)},
  doi         = {10.1200/JCO.2012.45.2714},
  language    = {eng},
  number      = {11},
  pages       = {1435--1441},
  url         = {http://dx.doi.org/10.1200/JCO.2012.45.2714},
  volume      = {31},
  abstract    = {Hodgkin lymphoma (HL) survival in Sweden has improved dramatically
	over the last 40 years, but little is known about the extent to which
	efforts aimed at reducing long-term treatment-related mortality have
	contributed to the improved prognosis.We used population-based data
	from Sweden to estimate the contribution of treatment-related mortality
	caused by diseases of the circulatory system (DCS) to temporal trends
	in excess HL mortality among 5,462 patients diagnosed at ages 19
	to 80 between 1973 and 2006. Flexible parametric survival models
	were used to estimate excess mortality. In addition, we used recent
	advances in statistical methodology to estimate excess mortality
	in the presence of competing causes of death.Excess DCS mortality
	within 20 years after diagnosis has decreased continually since the
	mid-1980s and is expected to further decrease among patients diagnosed
	in the modern era. Age at diagnosis and sex were important predictors
	for excess DCS mortality, with advanced age and male sex being associated
	with higher excess DCS mortality. However, when accounting for competing
	causes of death, we found that excess DCS mortality constitutes a
	relatively small proportion of the overall mortality among patients
	with HL in Sweden.Excess DCS mortality is no longer a common source
	of mortality among Swedish patients with HL. The main causes of death
	among long-term survivors today are causes other than HL, although
	other (non-DCS) excess mortality also persists for as long as 20
	years after diagnosis, particularly among older patients.},
  file        = {Eloranta2013a.pdf:pdf\\Eloranta2013a.pdf:PDF},
  institution = {Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Box 281, SE-171 77 Stockholm, Sweden. Sandra.eloranta@ki.se},
  journal     = {Journal of Clinical Oncology},
  keywords    = {Adult; Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases, complications/mortality/therapy; Cause of Death; Cohort Studies; Female; Hodgkin Disease, complications/mortality/therapy; Humans; Male; Middle Aged; Mortality, trends; Population Surveillance, methods; Registries, statistics /&/ numerical data; Risk Assessment, methods/statistics /&/ numerical data; Risk Factors; Sex Factors; Survivors, statistics /&/ numerical data; Sweden; Young Adult},
  medline-pst = {ppublish},
  owner       = {theand},
  pii         = {JCO.2012.45.2714},
  pmid        = {23439756},
  timestamp   = {2013.10.07},
  year        = {2013},
}

@Article{Emiliano2014,
  author    = {Emiliano, P. C. and Vivanco, M. J. F. and de Menezes, F. S.},
  title     = {Information criteria: How do they behave in different models?},
  doi       = {http://dx.doi.org/10.1016/j.csda.2013.07.032},
  issn      = {0167-9473},
  number    = {0},
  pages     = {141 - 153},
  url       = {http://www.sciencedirect.com/science/article/pii/S0167947313002776},
  volume    = {69},
  abstract  = {Abstract The choice of the best model is crucial in modeling data,
	and parsimony is one of the principles that must guide this choice.
	Despite their broad use in model selection, the foundations of the
	Akaike information criterion (AIC), the corrected Akaike criterion
	(AICc) and the Bayesian information criterion (BIC) are, in general,
	poorly understood. The AIC, \{AICc\} and \{BIC\} penalize the likelihoods
	in order to select the simplest model. These criteria are based upon
	concepts of information and entropy, which are explained in this
	work, by focusing on a statistical approach. The three criteria are
	compared through Monte Carlo simulations, and the applications of
	these criteria are investigated in the selection of normal models,
	the selection of biological growth models and selection of time series
	models. For the simulation with normal models, all three criteria
	exhibited poor performance for a small sample size N = 100 (particularly,
	when the variances are slightly different). For biological growth
	model simulations with a very small sample size N = 13 the \{AIC\}
	and \{AICc\} showed better performance in comparison to the BIC.
	The simulation based on time series models produced results similar
	to the normal model simulations. For these simulations, the \{BIC\}
	exhibited superior performance, in some cases, in comparison to the
	other two information criteria (AIC and AICc) for a small sample
	size N = 100 , but in other cases, the \{BIC\} performed poorly,
	as did the \{AIC\} and AICc.},
  file      = {Emiliano2014.pdf:pdf\\Emiliano2014.pdf:PDF;Emiliano2014.pdf:Emiliano2014.pdf:PDF},
  journal   = {Computational Statistics \& Data Analysis},
  keywords  = {Akaike information criterion (AIC)},
  owner     = {hanbow},
  timestamp = {2015.05.11},
  year      = {2014},
}

@Article{Engeland1998a,
  author    = {A Engeland and T Haldorsen and PW Dickman and T Hakulinen and TR M\"{o}ller and HH Storm and H Tulinius},
  title     = {Relative survival of cancer patients--a comparison between {D}enmark and the other {N}ordic countries.},
  number    = {1},
  pages     = {49-59},
  volume    = {37},
  abstract  = {The results of a Nordic collaborative project revealed that Danish
	cancer patients had a poorer prognosis than patients in the other
	Nordic countries for some major cancer sites. The present study was
	undertaken to further explore the differences in survival between
	Denmark and the other Nordic countries. All cancer cases diagnosed
	in the Nordic countries during 1958 to 1991/92 were included in the
	analysis. Relative survival and excess mortality were calculated
	for intervals in the first five years after diagnosis. Since the
	1950s, the prognosis of cancer patients has improved in all the countries,
	but more moderately in Denmark. For cancers of the stomach, colon,
	rectum, breast (female), and prostate, the Danish patients had a
	markedly lower relative survival than the patients in the other countries.
	They also had the lowest proportion of localized tumours. It appears
	that Danish cancer patients are diagnosed at a later stage of disease
	than patients in the other Nordic countries.},
  journal   = {Acta Oncol},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1998},
}

@Article{Engeland1993,
  author    = {Engeland, A. and Haldorsen, T. and Tretli, S. and Hakulinen, T. and H{\"o}rte, L. G. and Luostarinen, T. and Magnus, K. and Schou, G. and Sigvaldason, H. and Tulinius, H. and Storm, H. H. and Vaittinen, P.},
  title     = {Prediction of Cancer Incidence in the {N}ordic Countries Up to the Years 2000 and 2010. {A} Collaborative Study of the Five {N}ordic Cancer Registries},
  volume    = {101 (Suppl. 38)},
  groups    = {Cancer registry reports},
  journal   = {APMIS},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1993},
}

@Article{Engeland1995a,
  author    = {Engeland, A. and Haldorsen, T. and Tretli, S. and Hakulinen, T. and H{\"o}rte, L. G. and Luostarinen, T. and Schou, G. and Sigvaldason, H. and Storm, H. H. and Tulinius, H. and Vaittinen, P.},
  title     = {Prediction of Cancer Mortality in the {N}ordic Countries Up to the Years 2000 and 2010. {A} Collaborative Study of the Five {N}ordic Cancer Registries},
  pages     = {1-163},
  volume    = {103 (Suppl. 49)},
  groups    = {Cancer registry reports},
  journal   = {APMIS},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@TechReport{Engeland1995b,
  author      = {Engeland, A. and Haldorsen, T. and Tretli, S. and Hakulinen, T. and H{\"o}rte, L. G. and Luostarinen, T. and Schou, G. and Sigvaldason, H. and Storm, H. H. and Tulinius, H. and Vaittinen, P.},
  institution = {The Cancer Registry of {N}orway},
  title       = {Prediction of Cancer Mortality in the {N}ordic Countries Up to the Years 2000 and 2010, on the Basis of Relative Survival Analysis},
  number      = {no. 1},
  groups      = {Cancer registry reports},
  owner       = {PaulD},
  timestamp   = {2011.06.19},
  year        = {1995},
}

@Article{Enstrom1977,
  author    = {Enstrom, J. E. and Austin, D. F.},
  title     = {Interpreting Cancer Survival Rates},
  pages     = {847-851},
  volume    = {195},
  file      = {Enstrom1977.pdf:Enstrom1977.pdf:PDF},
  journal   = {Science},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1977},
}

@Article{Epstein2012,
  author      = {Epstein, Mara M. and Edgren, Gustaf and Rider, Jennifer R. and Mucci, Lorelei A. and Adami, Hans-Olov},
  title       = {Temporal trends in cause of death among {S}wedish and {US} men with prostate cancer.},
  doi         = {10.1093/jnci/djs299},
  language    = {eng},
  number      = {17},
  pages       = {1335--1342},
  url         = {http://dx.doi.org/10.1093/jnci/djs299},
  volume      = {104},
  abstract    = {A growing proportion of men diagnosed with localized prostate cancer
	detected through prostate-specific antigen testing are dying from
	causes other than prostate cancer. Temporal trends in specific causes
	of death among prostate cancer patients have not been well described.We
	analyzed causes of death among all incident prostate cancer cases
	recorded in the nationwide Swedish Cancer Registry (1961-2008; n
	= 210 112) and in the US Surveillance, Epidemiology, and End Results
	Program (1973-2008; n = 490 341). We calculated the cumulative incidence
	of death due to seven selected causes that accounted for more than
	80\% of the reported deaths (including ischemic heart disease and
	non-prostate cancer) and analyzed mortality trends by calendar year
	and age at diagnosis and length of follow-up.During follow-up through
	2008, prostate cancer accounted for 52\% of all reported deaths in
	Sweden and 30\% of reported deaths in the United States among men
	with prostate cancer; however, only 35\% of Swedish men and 16\%
	of US men diagnosed with prostate cancer died from this disease.
	In both populations, the cumulative incidence of prostate cancer-specific
	death declined during follow-up, while the cumulative incidences
	of death from ischemic heart disease and non-prostate cancer remained
	constant. The 5-year cumulative incidence of death from prostate
	cancer among all men was 29\% in Sweden and 11\% in the United States.In
	Sweden and the United States, men diagnosed with prostate cancer
	are less likely to die from prostate cancer than from another cause.
	Because many of these other causes of death are preventable through
	changes in lifestyle, interventions that target lifestyle factors
	should be integrated into prostate cancer management.},
  institution = {Department of Epidemiology, Harvard School of Public Health, 677 Huntington Ave, 9th floor, Boston, MA 02115, USA. mameyer@hsph.harvard.edu},
  journal     = {J Natl Cancer Inst},
  keywords    = {Aged; Aged, 80 and over; Cause of Death, trends; Humans; Male; Middle Aged; Mortality, trends; Population Surveillance; Prostate-Specific Antigen, blood; Prostatic Neoplasms, diagnosis/immunology/mortality; Registries; Risk Factors; Risk Reduction Behavior; SEER Program; Sweden, epidemiology; Time Factors; Tumor Markers, Biological, blood; United States, epidemiology},
  medline-pst = {ppublish},
  month       = {Sep},
  owner       = {sanelo},
  pii         = {djs299},
  pmid        = {22835388},
  timestamp   = {2013.09.17},
  year        = {2012},
}

@Article{Esmail1995,
  author      = {A. Esmail and P. C. Lambert and D. R. Jones and E. A. Mitchell},
  title       = {Prevalence of risk factors for sudden infant death syndrome in south east {E}ngland before the 1991 national '{B}ack to {S}leep' health education campaign.},
  journal     = {J Public Health Med},
  year        = {1995},
  volume      = {17},
  number      = {3},
  month       = {Sep},
  pages       = {282--289},
  file        = {Esmail1995.pdf:Esmail1995.pdf:PDF;Esmail1995.pdf:pdf\\Esmail1995.pdf:PDF},
  institution = {Department of Public Health Sciences, St George's Hospital Medical School, Crammer Terrace, London.},
  owner       = {pl4},
  pmid        = {8527180},
  timestamp   = {2008.10.15},
}

@Book{Esteve1994,
  author    = {Est{\`e}ve, J. and Benhamou, E. and Raymond, L.},
  title     = {Statistical Methods in Cancer Research Volume {IV}: Descriptive Epidemiology},
  publisher = {Lyon: International Agency for Research on Cancer},
  series    = {IARC Scientific Publications No. 128},
  url       = {http://www.iarc.fr/en/publications/pdfs-online/stat/sp128/},
  file      = {Esteve1994.pdf:Esteve1994.pdf:PDF},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1994},
}

@Article{Esteve1990,
  author      = {J. Est\`{e}ve and E. Benhamou and M. Croasdale and L. Raymond},
  title       = {Relative survival and the estimation of net survival: elements for further discussion.},
  number      = {5},
  pages       = {529--538},
  volume      = {9},
  abstract    = {The methods of calculation of survival corrected for independent cause
	of death are discussed, and a maximum likelihood method is proposed
	and illustrated by survival of colon cancer patients in Geneva. The
	methods which are at present favoured for doing such calculations
	are subject to various biases when estimating net survival if the
	populations are heterogeneous for life expectancy. The proposed maximum
	likelihood approach would eliminate these biases by enabling relevant
	adjustment for covariates which influence survival. The routine use
	of such methods would permit better comparison of survival within
	and between populations.},
  file        = {Esteve1990.pdf:pdf\\Esteve1990.pdf:PDF},
  groups      = {Excess mortality model},
  institution = {International Agency for Research on Cancer, Lyon, France.},
  journal     = {Statistics in Medicine},
  month       = {May},
  owner       = {pl4},
  pmid        = {2349404},
  timestamp   = {2008.12.16},
  year        = {1990},
}

@Book{Eylenbosch1991,
  author    = {Eylenbosch, W. J.},
  title     = {Primary Prevention and Cancer},
  note      = {Recent results in cancer research; 122},
  publisher = {Berlin: Springer-Verlag},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1991},
}

@Book{Finland1989,
  author    = {Central Statistical Office of {F}inland},
  title     = {Classification of Socio-Economic Status},
  note      = {(in Finnish)},
  publisher = {Helsinki: Central Statistical Office of Finland},
  series    = {Handbook no. 17},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1989},
}

@Book{Finland1974,
  author    = {Central Statistical Office of {F}inland},
  title     = {Population census 1970},
  publisher = {Helsinki: Central Statistical Office of Finland},
  volume    = {9. Occupation and Social Position},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1974},
}

@Article{Faes2007,
  author      = {Christel Faes and Marc Aerts and Helena Geys and Geert Molenberghs},
  title       = {Model averaging using fractional polynomials to estimate a safe level of exposure.},
  doi         = {10.1111/j.1539-6924.2006.00863.x},
  number      = {1},
  pages       = {111--123},
  url         = {http://dx.doi.org/10.1111/j.1539-6924.2006.00863.x},
  volume      = {27},
  abstract    = {Quantitative risk assessment involves the determination of a safe
	level of exposure. Recent techniques use the estimated dose-response
	curve to estimate such a safe dose level. Although such methods have
	attractive features, a low-dose extrapolation is highly dependent
	on the model choice. Fractional polynomials, basically being a set
	of (generalized) linear models, are a nice extension of classical
	polynomials, providing the necessary flexibility to estimate the
	dose-response curve. Typically, one selects the best-fitting model
	in this set of polynomials and proceeds as if no model selection
	were carried out. We show that model averaging using a set of fractional
	polynomials reduces bias and has better precision in estimating a
	safe level of exposure (say, the benchmark dose), as compared to
	an estimator from the selected best model. To estimate a lower limit
	of this benchmark dose, an approximation of the variance of the model-averaged
	estimator, as proposed by Burnham and Anderson, can be used. However,
	this is a conservative method, often resulting in unrealistically
	low safe doses. Therefore, a bootstrap-based method to more accurately
	estimate the variance of the model averaged parameter is proposed.},
  file        = {Faes2007.pdf:pdf\\Faes2007.pdf:PDF;Faes2007.pdf:Faes2007.pdf:PDF},
  institution = {Center for Statistics, Hasselt University, Diepenbeek, Belgium. christel.faes@uhasselt.be},
  journal     = {Risk Analysis},
  month       = {Feb},
  owner       = {pl4},
  pii         = {RISK863},
  pmid        = {17362404},
  timestamp   = {2009.10.27},
  year        = {2007},
}

@Article{Fagerlin2011,
  author      = {Fagerlin, Angela and Zikmund-Fisher, Brian J. and Ubel, Peter A.},
  title       = {Helping patients decide: ten steps to better risk communication.},
  doi         = {10.1093/jnci/djr318},
  language    = {eng},
  number      = {19},
  pages       = {1436--1443},
  url         = {http://dx.doi.org/10.1093/jnci/djr318},
  volume      = {103},
  abstract    = {With increasing frequency, patients are being asked to make complex
	decisions about cancer screening, prevention, and treatment. These
	decisions are fraught with emotion and cognitive difficulty simultaneously.
	Many Americans have low numeracy skills making the cognitive demands
	even greater whenever, as is often the case, patients are presented
	with risk statistics and asked to make comparisons between the risks
	and benefits of multiple options and to make informed medical decisions.
	In this commentary, we highlight 10 methods that have been empirically
	shown to improve patients' understanding of risk and benefit information
	and/or their decision making. The methods range from presenting absolute
	risks using frequencies (rather than presenting relative risks) to
	using a risk format that clarifies how treatment changes risks from
	preexisting baseline levels to using plain language. We then provide
	recommendations for how health-care providers and health educators
	can best to communicate this complex medical information to patients,
	including using plain language, pictographs, and absolute risks instead
	of relative risks.},
  institution = {Center for Bioethics and Social Sciences in Medicine, 300 North Ingalls St, Rm 7C27, Ann Arbor, MI 48109-5429, USA. fagerlin@umich.edu},
  journal     = {J Natl Cancer Inst},
  keywords    = {Choice Behavior; Cognition; Communication; Comprehension; Decision Making; Emotions; Evidence-Based Medicine; Health Literacy; Humans; Neoplasms, prevention /&/ control/therapy; Odds Ratio; Probability; Risk Assessment, methods; Risk Factors; Time Factors; Truth Disclosure; Uncertainty; United States},
  medline-pst = {ppublish},
  month       = {Oct},
  owner       = {sanelo},
  pii         = {djr318},
  pmid        = {21931068},
  timestamp   = {2013.10.08},
  year        = {2011},
}

@Article{Falcaro2015,
  author      = {Falcaro, Milena and Nur, Ula and Rachet, Bernard and Carpenter, James R.},
  title       = {Estimating excess hazard ratios and net survival when covariate data are missing: strategies for multiple imputation.},
  doi         = {10.1097/EDE.0000000000000283},
  language    = {eng},
  number      = {3},
  pages       = {421--428},
  url         = {http://dx.doi.org/10.1097/EDE.0000000000000283},
  volume      = {26},
  abstract    = {Net survival is the survival probability we would observe if the disease
	under study were the only cause of death. When estimated from routinely
	collected population-based cancer registry data, this indicator is
	a key metric for cancer control. Unfortunately, such data typically
	contain a non-negligible proportion of missing values on important
	prognostic factors (eg, tumor stage).We carried out an empirical
	study to compare the performance of complete records analysis and
	several multiple imputation strategies when net survival is estimated
	via a flexible parametric proportional hazards model that includes
	stage, a partially observed categorical covariate. Starting from
	fully observed cancer registry data, we induced missingness on stage
	under three scenarios. For each of these scenarios, we simulated
	100 incomplete datasets and evaluated the performance of the different
	strategies.Ordinal logistic models are not suitable for the imputation
	of tumor stage. Complete records analysis may lead to grossly misleading
	estimates of net survival, even when the missing data mechanism is
	conditionally independent of survival time given the covariates and
	the bias on the excess hazard ratios estimates is negligible.As key
	covariates are unlikely missing completely at random, studies estimating
	net survival should not use complete records. When the missingness
	can be inferred from available data, appropriate multiple imputation
	should be performed. In the context of flexible parametric proportional
	hazards models with a partially observed stage covariate, a multinomial
	logistic imputation model for stage should be used and should include
	the Nelson-Aalen cumulative hazard estimate and the event indicator.},
  file        = {Falcaro2015.pdf:Falcaro2015.pdf:PDF},
  institution = {From the aUniversity College London, London, United Kingdom; bLondon School of Hygiene and Tropical Medicine, London, United Kingdom; and cMRC Clinical Trials Unit, London, United Kingdom.},
  journal     = {Epidemiology},
  medline-pst = {ppublish},
  month       = {May},
  owner       = {pl4},
  pmid        = {25774607},
  timestamp   = {2015.06.01},
  year        = {2015},
}

@Article{Fall2008,
  author      = {Fall, Katja and Str{{\"o}}mberg, Fredrik and Rosell, Johan and Andr{\AA}Â¨n, Ove and Varenhorst, Eberhard and {South-East Region Prostate Cancer Group}},
  title       = {Reliability of death certificates in prostate cancer patients.},
  doi         = {10.1080/00365590802078583},
  language    = {eng},
  number      = {4},
  pages       = {352--357},
  url         = {http://dx.doi.org/10.1080/00365590802078583},
  volume      = {42},
  abstract    = {To evaluate the reliability of cause-of-death diagnoses among prostate
	cancer patients.Information from death certificates obtained from
	the Swedish Death Register was compared with systematically reviewed
	medical records from the population-based Swedish Regional Prostate
	Cancer Register, South-East Region. In total, 5675 patients were
	included who had been diagnosed with prostate cancer between 1987
	and 1999 and who had died before 1 January 2003.The proportion of
	prostate cancer cases classified as having died from prostate cancer
	was 3\% higher in the official death certificates than in the reviewed
	records [0.03, 95\% confidence interval (CI) 0.02 to 0.04]. Overall
	agreement between the official cause of death and the reviewed data
	was 86\% (95\% CI 85 to 87\%). A higher accuracy was observed among
	men with localized disease (88\%, 95\% CI 87 to 89\%), aged 60 years
	or younger at death (96\%, 95\% CI 93 to 100\%), or who had undergone
	curative treatment (91\%, 95\% CI 88 to 95\%). This study indicates
	a relatively high reliability of official cause-of-death statistics
	of prostate cancer patients in Sweden.Mortality data obtained from
	death certificates may be useful in the evaluation of large-scale
	prostate cancer intervention programmes, especially among younger
	patients with localized disease.},
  file        = {Fall2008.pdf:pdf\\Fall2008.pdf:PDF},
  institution = {Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. katja.Fall@ki.se},
  journal     = {Scand J Urol Nephrol},
  medline-pst = {ppublish},
  owner       = {theand},
  pii         = {792973169},
  pmid        = {18609293},
  timestamp   = {2013.02.12},
  year        = {2008},
}

@Article{Fang2012,
  author      = {Fang, Fang and Fall, Katja and Mittleman, Murray A. and Spar{\AA}Â©n, P{\"a}r and Ye, Weimin and Adami, Hans-Olov and Valdimarsd{\AA}Â³ttir, Unnur},
  title       = {Suicide and cardiovascular death after a cancer diagnosis.},
  doi         = {10.1056/NEJMoa1110307},
  language    = {eng},
  number      = {14},
  pages       = {1310--1318},
  url         = {http://dx.doi.org/10.1056/NEJMoa1110307},
  volume      = {366},
  abstract    = {Receiving a diagnosis of cancer is a traumatic experience that may
	trigger immediate adverse health consequences beyond the effects
	of the disease or treatment.Using Poisson and negative binomial regression
	models, we conducted a historical cohort study involving 6,073,240
	Swedes to examine the associations between a cancer diagnosis and
	the immediate risk of suicide or death from cardiovascular causes
	from 1991 through 2006. To adjust for unmeasured confounders, we
	also performed a nested, self-matched case-crossover analysis among
	all patients with cancer who died from suicide or cardiovascular
	diseases in the cohort.As compared with cancer-free persons, the
	relative risk of suicide among patients receiving a cancer diagnosis
	was 12.6 (95\% confidence interval [CI], 8.6 to 17.8) during the
	first week (29 patients; incidence rate, 2.50 per 1000 person-years)
	and 3.1 (95\% CI, 2.7 to 3.5) during the first year (260 patients;
	incidence rate, 0.60 per 1000 person-years). The relative risk of
	cardiovascular death after diagnosis was 5.6 (95\% CI, 5.2 to 5.9)
	during the first week (1318 patients; incidence rate, 116.80 per
	1000 person-years) and 3.3 (95\% CI, 3.1 to 3.4) during the first
	4 weeks (2641 patients; incidence rate, 65.81 per 1000 person-years).
	The risk elevations decreased rapidly during the first year after
	diagnosis. Increased risk was particularly prominent for cancers
	with a poor prognosis. The case-crossover analysis largely confirmed
	results from the main analysis.In this large cohort study, patients
	who had recently received a cancer diagnosis had increased risks
	of both suicide and death from cardiovascular causes, as compared
	with cancer-free persons. (Funded by the Swedish Council for Working
	Life and Social Research and others.).},
  institution = {Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. fang.fang@ki.se},
  journal     = {N Engl J Med},
  keywords    = {Cardiovascular Diseases, complications/mortality; Cohort Studies; Female; Humans; Incidence; Male; Neoplasms, complications/psychology; Poisson Distribution; Regression Analysis; Risk; Suicide, statistics /&/ numerical data; Sweden, epidemiology},
  medline-pst = {ppublish},
  month       = {Apr},
  owner       = {sanelo},
  pmid        = {22475594},
  timestamp   = {2013.08.01},
  year        = {2012},
}

@Article{Farrington1996,
  author    = {Farrington, C. P.},
  title     = {Interval censored survival data: {A} generalized linear modelling approach},
  pages     = {283-292},
  volume    = {15},
  journal   = {Statistics in Medicine},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1996},
}

@Article{Farrow1995,
  author    = {Farrow, D. C. and Hunt, W. C. and Samet, J. M.},
  title     = {Biased Comparisons of Lung Cancer Survival Across Geographic Areas: Effects of Stage Bias},
  pages     = {558-560},
  volume    = {6},
  journal   = {Epidemiology},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@Article{Farrow1996,
  author    = {Farrow, D. C. and Samet, J. M. and Hunt, W. C.},
  title     = {Regional Variation in Survival Following the Diagnosis of Cancer},
  pages     = {843-847},
  volume    = {49},
  journal   = {Journal of Clinical Epidemiology},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1996},
}

@Article{Feinstein1985,
  author    = {Feinstein, A. R. and Sosin, D. M. and Wells, C. K.},
  title     = {The {W}ill {R}ogers Phenomenon: Stage Migration and New Diagnostic Techniques as a Source of Misleading Statistics for Survival in Cancer},
  pages     = {1604-1608},
  volume    = {312},
  journal   = {New England Journal of Medicine},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1985},
}

@Article{Feinstein1993,
  author    = {Feinstein, J. S.},
  title     = {The Relationship Between Socioeconomic Status and Health: A Review of the Literature},
  pages     = {279-322},
  volume    = {71},
  journal   = {Millbank Quarterly},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1993},
}

@Article{Feiveson2002,
  author    = {A.H. Feiveson},
  title     = {Power by simulation},
  pages     = {107-124},
  volume    = {2},
  file      = {Feiveson2002.pdf:pdf\\Feiveson2002.pdf:PDF;Feiveson2002.pdf:Feiveson2002.pdf:PDF},
  journal   = {The Stata Journal},
  owner     = {pl4},
  timestamp = {2009.12.03},
  year      = {2002},
}

@Article{Feldman2014,
  author      = {Feldman, Adina L. and Johansson, Anna L V. and Lambert, Paul C. and Sieurin, Johanna and Yang, Fei and Pedersen, Nancy L. and Wirdefeldt, Karin},
  title       = {Familial Coaggregation of Alzheimer's Disease and Parkinson's Disease: Systematic Review and Meta-Analysis.},
  doi         = {10.1159/000355452},
  language    = {eng},
  number      = {2},
  pages       = {69--80},
  url         = {http://dx.doi.org/10.1159/000355452},
  volume      = {42},
  abstract    = {Background: Familial aggregation has been shown for Alzheimer's disease
	(AD) and Parkinson's disease (PD) separately, and it has been hypothesized
	that these diseases also coaggregate in families. Methods: The authors
	investigated familial coaggregation of AD and PD by conducting a
	systematic review and meta-analysis. PubMed was searched for relevant
	studies published through the end of October 2012. Three independent
	investigators screened publications and extracted data. Relative
	risk estimates of AD risk associated with family history of PD or
	parkinsonism, or PD risk associated with family history of AD or
	dementia, were summarized into metaestimates using random effects
	models. Heterogeneity and publication bias were tested using Higgins'
	and Egger's tests, respectively. Results: We included 16 studies
	in the review, with 14 included in any meta-analysis. AD risk associated
	with family history of PD yielded a summary hazard ratio of 1.18
	(95\% CI: 1.00-1.39) based on 5 reconstructed cohort studies and
	a summary odds ratio (OR) of 1.40 (95\% CI: 0.92-2.12) based on 7
	case-control studies. PD risk associated with family history of AD
	yielded a summary OR of 0.75 (95\% CI: 0.49-1.16) based on 3 studies.
	There was no significant heterogeneity among studies, nor significant
	publication bias. Conclusions: There may be familial coaggregation
	of AD and PD, although the association was modest and only apparent
	when studying AD risk associated with family history of PD.},
  file        = {Feldman2014.pdf:pdf\\Feldman2014.pdf:PDF},
  institution = {Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.},
  journal     = {Neuroepidemiology},
  medline-pst = {aheadofprint},
  month       = {Nov},
  owner       = {pl4},
  pii         = {000355452},
  pmid        = {24296900},
  timestamp   = {2014.01.06},
  year        = {2014},
}

@Article{Ferret2002,
  author      = {Ferret, Pierre-Jacques and Soum, Emmanuelle and Negre, Olivier and Fradelizi, Didier},
  title       = {Auto-protective redox buffering systems in stimulated macrophages.},
  language    = {eng},
  pages       = {3},
  volume      = {3},
  abstract    = {Macrophages, upon encounter with micro-organisms or stimulated by
	cytokines, produce various effector molecules aimed at destroying
	the foreign agents and protecting the organism. Reactive oxygen species
	(ROS) and reactive nitrogen species (RNS) are front line molecules
	exerting strong cytotoxic activities against micro-organisms and
	many cells, including macrophages themselves. Using cells of the
	murine macrophage cell line (RAW 264.7) stimulated in vitro with
	lipopolysaccharide (LPS) and/or interferon (IFN-gamma), which induce
	strong endogenous NO production, we examined by which mechanisms
	a fraction of activated macrophages protect themselves from nitrosative
	stress and manage to escape destruction?We observed that survivors
	(10-50\% depending on the experiments) had acquired a resistant phenotype
	being capable to survive when further exposed in vitro to an apoptosis
	inducing dose of the NO donor compound DETA-NO. These cells expressed
	an increased steady-state levels of Mn SOD, CuZn SOD and catalase
	mRNA (130-200\%), together with an increased activity of the corresponding
	enzymes. Intracellular concentration of glutathione was also increased
	(x 3.5 fold at 6 hours, still maintained x 5.2 fold at 48 hours).
	Neither mRNA for glutathione peroxydase, gamma-glutamylcysteine synthase
	and glutathione reductase, nor thioredoxine and thioredoxine reductase,
	were significantly modified. Additional experiments in which RAW
	264.7 cells were stimulated with LPS and/or IFN-gamma in the presence
	of relatively specific inhibitors of both Mn and Cu/Zn SOD, aminotriazol
	(ATZ) catalase inhibitor and buthionine sulfoximine (BSO) glutathione
	inhibitor, showed that inhibiting LPS-induced up-regulation of intracellular
	redox buffering systems also prevented acquisition of the resistant
	phenotype.Our data suggest a direct causal relationship between survival
	of a fraction of macrophages and a up-regulation of key sets of auto-protective
	intracellular redox buffering systems, occurring simultaneously with
	modulation of expression of apoptotic molecules of the Bcl2-Bcl-XL/Bax-Bad
	family.},
  journal     = {BMC Immunol},
  keywords    = {Animals; Buffers; Cell Line; Interferon-alpha, metabolism; Lipopolysaccharides, pharmacology; Macrophage Activation; Macrophages, drug effects/metabolism; Mice; Nitric Oxide, metabolism; Oxidation-Reduction; Reactive Oxygen Species, metabolism},
  medline-pst = {epublish},
  month       = {Mar},
  owner       = {pl4},
  pmid        = {11914132},
  timestamp   = {2013.05.29},
  year        = {2002},
}

@Article{Ferriere1992,
  author      = {Ferri{\AA}Â§ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â±ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¥, R. and Clobert, J.},
  title       = {Evolutionarily stable age at first reproduction in a density-dependent model.},
  language    = {eng},
  number      = {2},
  pages       = {253--267},
  volume      = {157},
  abstract    = {We develop a new model of life history evolution to investigate the
	evolution of age at first reproduction. Density dependence is taken
	into account. For a given "species", age of maturity, offspring survival,
	immature survival, adult survival, fecundity, immature age-classes
	entering in competition with adults and immature competitive ability
	are traits adjustable by natural selection, and constitute a particular
	strategy. On the contrary, the type of intraspecific competition
	(scramble or contest), strength of competition and inherent net reproductive
	rate Ro(inh) are fixed (specific) characteristics. As a consequence
	of fixing Ro(inh), the evolution of any trait will affect trade-offs
	between others. Evolutionarily stable strategies are determined numerically
	by using the mathematical concept of Lyapunov exponents. Altogether,
	we consider 960 different hypothetical "species" (i.e. different
	combinations of fixed traits). Corresponding ESSs are analyzed with
	respect to their age at first reproduction, adult survival and immature
	competitive ability components. They appear to be gathered in three
	groups. One is intuitive and characterized by a reduction of immature
	competitive ability and a correlation of age of maturity with adult
	survival; populations reach mainly equilibria. The two other groups
	respectively include "species" with low age of maturity but high
	adult survival, and "species" close to semelparity with delayed maturity;
	immature competitive ability may not be minimized, and populations
	possibly exhibit complex dynamics. In conclusion, the hypothesis
	that the evolution of a demographic parameter modifies trade-offs
	between others turns out to have important consequences. We argue
	that life history theory cannot ignore the source and mode-of-operation
	of density dependence and must regard potential short-term instability
	as essential.},
  journal     = {J Theor Biol},
  keywords    = {Animals; Biological Evolution; Computer Simulation; Models, Biological; Sexual Maturation, physiology},
  medline-pst = {ppublish},
  month       = {Jul},
  owner       = {pl4},
  pmid        = {1434675},
  timestamp   = {2013.05.29},
  year        = {1992},
}

@Article{Feuer2012,
  author      = {Feuer, Eric J. and Lee, Minjung and Mariotto, Angela B. and Cronin, Kathy A. and Scoppa, Steve and Penson, David F. and Hachey, Mark and Cynkin, Laurie and Carter, Ginger A. and Campbell, David and Percy-Laurry, Antoinette and Zou, Zhaohui and Schrag, Deborah and Hankey, Benjamin F.},
  title       = {The {C}ancer {S}urvival {Q}uery {S}ystem: making survival estimates from the {S}urveillance, {E}pidemiology, and {E}nd {R}esults program more timely and relevant for recently diagnosed patients.},
  doi         = {10.1002/cncr.27615},
  language    = {eng},
  number      = {22},
  pages       = {5652--5662},
  url         = {http://dx.doi.org/10.1002/cncr.27615},
  volume      = {118},
  abstract    = {Population-based cancer registries that include patient follow-up
	generally provide information regarding net survival (ie, survival
	associated with the risk of dying of cancer in the absence of competing
	risks). However, registry data also can be used to calculate survival
	from cancer in the presence of competing risks, which is more clinically
	relevant.Statistical methods were developed to predict the risk of
	death from cancer and other causes, as well as natural life expectancy
	if the patient did not have cancer based on a profile of prognostic
	factors including characteristics of the cancer, demographic factors,
	and comorbid conditions. The Surveillance, Epidemiology, and End
	Results (SEER) Program database was used to calculate the risk of
	dying of cancer. Because the risks of dying of cancer versus other
	causes are assumed to be independent conditional on the prognostic
	factors, a wide variety of independent data sources can be used to
	calculate the risk of death from other causes. Herein, the risk of
	death from other causes was estimated using SEER and Medicare claims
	data, and was matched to the closest fitting portion of the US life
	table to obtain a "health status-adjusted age."A nomogram was developed
	for prostate cancer as part of a Web-based Cancer Survival Query
	System that is targeted for use by physicians and patients to obtain
	information on a patient's prognosis. More nomograms currently are
	being developed.Nomograms of this type can be used as one tool to
	assist cancer physicians and their patients to better understand
	their prognosis and to weigh alternative treatment and palliative
	strategies.},
  institution = {Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA.},
  journal     = {Cancer},
  keywords    = {Breast Neoplasms, diagnosis/epidemiology/mortality; Data Interpretation, Statistical; Female; Humans; Life Expectancy; Male; Nomograms; Prognosis; Prostatic Neoplasms, diagnosis/epidemiology/mortality; Registries; Risk; Risk Factors; SEER Program; Survival Rate},
  medline-pst = {ppublish},
  month       = {Nov},
  owner       = {sanelo},
  pmid        = {22569947},
  timestamp   = {2013.09.16},
  year        = {2012},
}

@Article{Feuer2014,
  author      = {Feuer, Eric J. and Rabin, Borsika A. and Zou, Zhaohui and Wang, Zhuoqiao and Xiong, Xiaoqin and Ellis, Jennifer L. and Steiner, John F. and Cynkin, Laurie and Nekhlyudov, Larissa and Bayliss, Elizabeth and Hankey, Benjamin F.},
  title       = {The Surveillance, Epidemiology, and End Results Cancer Survival Calculator SEER*CSC: Validation in a Managed Care Setting.},
  doi         = {10.1093/jncimonographs/lgu021},
  language    = {eng},
  number      = {49},
  pages       = {265--274},
  url         = {http://dx.doi.org/10.1093/jncimonographs/lgu021},
  volume      = {2014},
  abstract    = {Nomograms for prostate and colorectal cancer are included in the Surveillance,
	Epidemiology, and End Results (SEER) Cancer Survival Calculator,
	under development by the National Cancer Institute. They are based
	on the National Cancer Institute's SEER data, coupled with Medicare
	data, to estimate the probabilities of surviving or dying from cancer
	or from other causes based on a set of patient and tumor characteristics.
	The nomograms provide estimates of survival that are specific to
	the characteristics of the tumor, age, race, gender, and the overall
	health of a patient. These nomograms have been internally validated
	using the SEER data. In this paper, we externally validate the nomograms
	using data from Kaiser Permanente Colorado.The SEER Cancer Survival
	Calculator was externally validated using time-dependent area under
	the Receiver Operating Characteristic curve statistics and calibration
	plots for retrospective cohorts of 1102 prostate cancer and 990 colorectal
	cancer patients from Kaiser Permanente Colorado.The time-dependent
	area under the Receiver Operating Characteristic curve statistics
	were computed for one, three, five, seven, and 10 year(s) postdiagnosis
	for prostate and colorectal cancer and ranged from 0.77 to 0.89 for
	death from cancer and from 0.72 to 0.81 for death from other causes.
	The calibration plots indicated a very good fit of the model for
	death from cancer for colorectal cancer and for the higher risk group
	for prostate cancer. For the lower risk groups for prostate cancer
	(<10\% chance of dying of prostate cancer in 10 years), the model
	predicted slightly worse prognosis than observed. Except for the
	lowest risk group for colorectal cancer, the models for death from
	other causes for both prostate and colorectal cancer predicted slightly
	worse prognosis than observed.The results of the external validation
	indicated that the colorectal and prostate cancer nomograms are reliable
	tools for physicians and patients to use to obtain information on
	prognosis and assist in establishing priorities for both treatment
	of the cancer and other conditions, particularly when a patient is
	elderly and/or has significant comorbidities. The slightly better
	than predicted risk of death from other causes in a health maintenance
	organization (HMO) setting may be due to an overall healthier population
	and the integrated management of disease relative to the overall
	population (as represented by SEER).},
  file        = {Feuer2014.pdf:pdf\\Feuer2014.pdf:PDF;Feuer2014.pdf:Feuer2014.pdf:PDF},
  institution = {Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD (EJF, LC); Cancer Research Network Cancer Communication Research Center (BAR); and Institute for Health Research (JLE, JFS), Kaiser Permanente Colorado, Denver, CO; Information Management Services, Inc., Calverton, MD (ZZ, ZW, XX); Department of Family Medicine, University of Colorado School of Medicine, Denver, CO (EB); Department of Population Medicine, Harvard Medical School, Boston, MA (LN); CANSTAT, Plano, TX (BFH). bhankey0411@aol.com.},
  journal     = {J Natl Cancer Inst Monogr},
  medline-pst = {ppublish},
  month       = {Nov},
  owner       = {PaulD},
  pii         = {lgu021},
  pmid        = {25417240},
  timestamp   = {2014.12.05},
  year        = {2014},
}

@Article{Fine2001,
  author      = {Fine, J. P.},
  title       = {Regression modeling of competing crude failure probabilities.},
  doi         = {10.1093/biostatistics/2.1.85},
  language    = {eng},
  number      = {1},
  pages       = {85--97},
  url         = {http://dx.doi.org/10.1093/biostatistics/2.1.85},
  volume      = {2},
  abstract    = {In a randomized trial of tamoxifen therapy for breast cancer, women
	can experience tumor recurrence or die from competing causes. One
	goal of analysis is to describe the effect of tamoxifen on the probabilities
	of recurrence or death from other causes. To this end, we propose
	a semi-parametric transformation model for the crude failure probabilities
	of a competing risk, conditional on covariates. The model is developed
	as an extension of the standard approach to survival data with independent
	right censoring. Estimation of the regression coefficients is achieved
	with a rank-based least squares criterion. Simulations show that
	the procedure works well with practical sample sizes. A separate
	estimating function is developed for the baseline parameter. Prediction
	of covariate-adjusted failure probabilities is considered. The methodology
	is motivated and illustrated with data from the tamoxifen trial.},
  file        = {Fine2001.pdf:pdf\\Fine2001.pdf:PDF;Fine2001.pdf:Fine2001.pdf:PDF},
  institution = {Medical Informatics, University of Wisconsin, Madison, WI 53706, USA. fine@biostat.wisc.edu},
  journal     = {Biostatistics},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {pl4},
  pii         = {2/1/85},
  pmid        = {12933558},
  timestamp   = {2015.02.04},
  year        = {2001},
}

@Article{Fine1999a,
  author    = {Fine, J. P.},
  title     = {Analysing competing risks data with transformation models},
  pages     = {817-830},
  volume    = {61},
  file      = {Fine1999a.pdf:pdf\\Fine1999a.pdf:PDF;Fine1999a.pdf:Fine1999a.pdf:PDF},
  journal   = {Journal of the Royal Statistical Society (B)},
  owner     = {pl4},
  timestamp = {2013.08.29},
  year      = {1999},
}

@Article{Fine1999,
  author    = {J. P. Fine and R. J. Gray},
  title     = {A proportional hazards model for the subdistribution of a competing risk},
  pages     = {496-509.},
  volume    = {446},
  file      = {Fine1999.pdf:Fine1999.pdf:PDF;Fine1999.pdf:pdf\\Fine1999.pdf:PDF},
  journal   = {Journal of the American Statistical Association},
  owner     = {pl4},
  timestamp = {2010.04.06},
  year      = {1999},
}

@Article{Fink2012,
  author      = {Fink, Aliza K. and German, Robert R. and Heron, Melonie and Stewart, Sherri L. and Johnson, Christopher J. and Finch, Jack L. and Yin, Daixin and Schaeffer, Philip E. and , Accuracy of Cancer Mortality Working Group},
  title       = {Impact of using multiple causes of death codes to compute site-specific, death certificate-based cancer mortality statistics in the {United States}},
  doi         = {10.1016/j.canep.2011.07.004},
  language    = {eng},
  number      = {1},
  pages       = {22--28},
  url         = {http://dx.doi.org/10.1016/j.canep.2011.07.004},
  volume      = {36},
  abstract    = {Cancer mortality statistics, an important indicator for monitoring
	cancer burden, are traditionally restricted to instances when cancer
	is determined to be the underlying cause of death (UCD) based on
	information recorded on standard certificates of death. This study's
	objective was to determine the impact of using multiple causes of
	death codes to compute site-specific cancer mortality statistics.The
	state cancer registries of California, Colorado and Idaho provided
	linked cancer registry and death certificate data for individuals
	who died between 2002 and 2004, had at least one cancer listed on
	their death certificate and were diagnosed with cancer between 1993
	and 2004. These linked data were used to calculate the site-specific
	proportion of cancers not selected as the UCD (non-UCD) among all
	cancer-related deaths (any mention on the death certificate). In
	addition, the retrospective concordance between the death certificate
	and the population-based cancer registry, measured as confirmations
	rates, was calculated for deaths with cancer as the UCD, as a non-UCD,
	and for any mention.Overall, non-UCD deaths comprised 9.5 percent
	of total deaths; 11 of the 79 cancer sites had proportions greater
	than 3 standard deviations from 9.5 percent. The confirmation rates
	for UCD and for any mention did not differ significantly for any
	of the cancer sites. CONCLUSION AND IMPACT: The site-specific variation
	in proportions and rates suggests that for a few cancer sites, death
	rates might be computed for both UCD and any mention of the cancer
	site on the death certificate. Nevertheless, this study provides
	evidence that, in general, restricting to UCD deaths will not under
	report cancer mortality statistics.},
  institution = {ICF International Inc., Bethesda, MD 20814, USA. afink@icfi.com},
  journal     = {Cancer Epidemiol},
  keywords    = {Cause of Death; Death Certificates; Humans; Neoplasms, epidemiology/mortality; Registries; Retrospective Studies; Survival Rate; United States, epidemiology},
  medline-pst = {ppublish},
  month       = {Feb},
  owner       = {PaulD},
  pii         = {S1877-7821(11)00117-2},
  pmid        = {21907006},
  timestamp   = {2013.09.18},
  year        = {2012},
}

@Article{Fisher1999,
  author    = {Fisher, L. D. and Lin, D. Y.},
  title     = {Time-dependent covariates in the Cox proportional-hazards regression model},
  pages     = {145-57},
  volume    = {20},
  journal   = {Annu Rev Public Health},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1999},
}

@Article{Flanders1990,
  author    = {WD Flanders and IM Longini},
  title     = {Estimating benefits of screening from observational cohort studies.},
  number    = {8},
  pages     = {969-80},
  volume    = {9},
  abstract  = {Analysis and interpretation of observational studies of screening
	effectiveness is difficult because several biases threaten validity,
	including the structural healthy screenee bias, length bias, and
	effects of lead time. Although methods for the analysis of observational
	studies of screening effectiveness have been proposed, most have
	limitations such as incomplete control of length bias, or a heavy
	reliance on distributional assumptions. In this report we present
	a method for the analysis of observational cohort studies of screening
	effectiveness. Although developed independently and formulated specifically
	for estimating benefits of screening, our approach is implied by
	a more general approach developed previously by Robins. Our approach,
	in contrast to other available methods, avoids the healthy screenee
	bias, and length and lead time bias, and allows an empirical approach
	to analysis that need not depend highly on distributional assumptions.
	We illustrate application of the approach with analysis of published
	data from a study of breast cancer screening.},
  journal   = {Stat Med},
  month     = {Aug},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1990},
}

@Book{Fleiss1973,
  author    = {Fleiss, J. L.},
  title     = {Statistical methods for rates and proportions},
  publisher = {New York: Wiley},
  owner     = {PaulD},
  timestamp = {2008.08.22},
  year      = {1973},
}

@Article{Fored2001,
  author    = {CM Fored and E Ejerblad and P Lindblad and JP Fryzek and PW Dickman and LB Signorello and L Lipworth and CG Elinder and WJ Blot and JK McLaughlin and MM Zack and O Nyr\'{e}n},
  title     = {Acetaminophen, aspirin, and chronic renal failure.},
  doi       = {10.1056/NEJMoa010323},
  number    = {25},
  pages     = {1801-8},
  url       = {http://dx.doi.org/10.1056/NEJMoa010323},
  volume    = {345},
  abstract  = {BACKGROUND: Several epidemiologic studies have demonstrated an association
	between heavy consumption of nonnarcotic analgesics and the occurrence
	of chronic renal failure, but it is unclear which is the cause and
	which is the effect METHODS: In a nationwide, population-based, case-control
	study of early-stage chronic renal failure in {S}weden, face-to-face
	interviews were conducted with 926 patients with newly diagnosed
	renal failure and 998 control subjects, of whom 918 and 980, respectively,
	had complete data. We used logistic-regression models to estimate
	the relative risks of disease-specific types of chronic renal failure
	associated with the use of various analgesics RESULTS: Aspirin and
	acetaminophen were used regularly by 37 percent and 25 percent, respectively,
	of the patients with renal failure and by 19 percent and 12 percent,
	respectively, of the controls. Regular use of either drug in the
	absence of the other was associated with an increase by a factor
	of 2.5 in the risk of chronic renal failure from any cause. The relative
	risks rose with increasing cumulative lifetime doses, rose more consistently
	with acetaminophen use than with aspirin use, and were increased
	for most disease-specific types of chronic renal failure. When we
	disregarded the recent use of analgesics, which could have occurred
	in response to antecedents of renal disease, the associations were
	only slightly attenuated CONCLUSIONS: Our results are consistent
	with the existence of exacerbating effects of acetaminophen and aspirin
	on chronic renal failure. However, we cannot rule out the possibility
	of bias due to the triggering of analgesic consumption by predisposing
	conditions.},
  journal   = {N Engl J Med},
  month     = {Dec},
  owner     = {PaulD},
  pii       = {345/25/1801},
  timestamp = {2011.06.19},
  year      = {2001},
}

@Article{Forsea2016,
  author       = {Ana-Maria Forsea},
  journal      = {ecancer},
  title        = {Cancer registries in {E}urope -- going forward is the only option},
  doi          = {10.3332/ecancer.2016.641},
  issue        = {10},
  pages        = {641},
  owner        = {PaulD},
  timestamp    = {2016.06.08},
  year         = {2016},
}

@Book{Fox1982,
  author    = {Fox, A. J.},
  title     = {Longitudinal Study: Socio-Demographic Mortality Differentials 1971--1975},
  publisher = {London: Office of Population Censuses and Surveys},
  series    = {LS no. 1},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1982},
}

@Article{Fox1985,
  author    = {Fox, A. J. and Goldblatt, P. O. and Jones, D. R.},
  title     = {Social Class Mortality Differentials: Artefact, Selection or Life Circumstances?},
  pages     = {1-8},
  volume    = {39},
  journal   = {Journal of Epidemiology and Community Health},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1985},
}

@Article{Fox1984,
  author    = {Fox, A. J. and Jones, D. R. and Goldblatt, P. O.},
  title     = {Approaches to Studying the Effect of Socio-economic Circumstances on Geographic Differences in Mortality in {E}ngland and {W}ales},
  pages     = {309-314},
  volume    = {40},
  file      = {:/Users/yitche/survbib/pdf/Bullement2019.pdf:PDF},
  journal   = {British Medical Bulletin},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1984},
}

@Article{Francois2001,
  author      = {Fran{\AA}Â¦ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â®ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â©s, J. and Parrou, J. L.},
  title       = {Reserve carbohydrates metabolism in the yeast Saccharomyces cerevisiae.},
  language    = {eng},
  number      = {1},
  pages       = {125--145},
  volume      = {25},
  abstract    = {Glycogen and trehalose are the two glucose stores of yeast cells.
	The large variations in the cell content of these two compounds in
	response to different environmental changes indicate that their metabolism
	is controlled by complex regulatory systems. In this review we present
	information on the regulation of the activity of the enzymes implicated
	in the pathways of synthesis and degradation of glycogen and trehalose
	as well as on the transcriptional control of the genes encoding them.
	cAMP and the protein kinases Snf1 and Pho85 appear as major actors
	in this regulation. From a metabolic point of view, glucose-6-phosphate
	seems the major effector in the net synthesis of glycogen and trehalose.
	We discuss also the implication of the recently elucidated TOR-dependent
	nutrient signalling pathway in the control of the yeast glucose stores
	and its integration in growth and cell division. The unexpected roles
	of glycogen and trehalose found in the control of glycolytic flux,
	stress responses and energy stores for the budding process, demonstrate
	that their presence confers survival and reproductive advantages
	to the cell. The findings discussed provide for the first time a
	teleonomic value for the presence of two different glucose stores
	in the yeast cell.},
  institution = {Centre de Bioingenierie Gilbert Durand, UMR-CNRS 5504, UMR-INRA 792, D{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¯ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¡rtement de G{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â­ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â©e Biochimique et Alimentaire, Institut National des Sciences Appliqu{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¤ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â³, 135 Avenue de Rangeuil, 31077 Toulouse Cedex 04, France. fran_jm@insa-tlse.fr},
  journal     = {FEMS Microbiol Rev},
  keywords    = {Bacterial Proteins, genetics/metabolism; Gene Expression Regulation, Fungal; Glycogen, genetics/metabolism; Saccharomyces cerevisiae, genetics/growth /&/ development/metabolism; Signal Transduction; Trehalose, genetics/metabolism},
  medline-pst = {ppublish},
  month       = {Jan},
  owner       = {pl4},
  pii         = {S0168-6445(00)00059-0},
  pmid        = {11152943},
  timestamp   = {2013.05.29},
  year        = {2001},
}

@Article{Francisci2009,
  author      = {Francisci, Silvia and Capocaccia, Riccardo and Grande, Enrico and Santaquilani, Mariano and Simonetti, Arianna and Allemani, Claudia and Gatta, Gemma and Sant, Milena and Zigon, Giulia and Bray, Freddie and Janssen-Heijnen, Maryska and , E. U. R. O. C. A. R. E Working Group},
  title       = {The cure of cancer: a European perspective.},
  doi         = {10.1016/j.ejca.2008.11.034},
  language    = {eng},
  number      = {6},
  pages       = {1067--1079},
  url         = {http://dx.doi.org/10.1016/j.ejca.2008.11.034},
  volume      = {45},
  abstract    = {Cancer survival analyses based on cancer registry data do not provide
	direct information on the main aim of cancer treatment, the cure
	of the patient. In fact, classic survival indicators do not distinguish
	between patients who are cured, and patients who will die of their
	disease and in whom prolongation of survival is the main objective
	of treatment. In this study, we applied parametric cure models to
	the cancer incidence and follow-up data provided by 49 EUROCARE-4
	(European Cancer Registry-based study, fourth edition) cancer registries,
	with the aims of providing additional insights into the survival
	of European cancer patients diagnosed from 1988 to 1999, and of investigating
	between-population differences. Between-country estimates the proportion
	of cured patients varied from about 4-13\% for lung cancer, from
	9\% to 30\% for stomach cancer, from 25\% to 49\% for colon and rectum
	cancer, and from 55\% to 73\% for breast cancer. For all cancers
	combined, estimates varied between 21\% and 47\% in men, and 38\%
	and 59\% in women and were influenced by the distribution of cases
	by cancer site. Countries with high proportions of cured and long
	fatal case survival times for all cancers combined were characterised
	by generally favourable case mix. For the European pool of cases
	both the proportion of cured and the survival time of fatal cases
	were associated with age, and increased from the early to the latest
	diagnosis period. The increases over time in the proportions of Europeans
	estimated cured of lung, stomach and colon and rectum cancers are
	noteworthy and suggest genuine progress in cancer control. The proportion
	of cured of all cancers combined is a useful general indicator of
	cancer control as it reflects progress in diagnosis and treatment,
	as well as success in the prevention of rapidly fatal cancers.},
  institution = {Cancer Epidemiology Unit, National Center for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanit{\AA}Â , Rome, Italy. silvia.francisci@iss.it},
  journal     = {Eur J Cancer},
  keywords    = {Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Europe, epidemiology; Female; Humans; Male; Middle Aged; Neoplasms, mortality/therapy; Prognosis; Survival Analysis; Young Adult},
  medline-pst = {ppublish},
  month       = {Apr},
  owner       = {theand},
  pii         = {S0959-8049(08)00918-0},
  pmid        = {19131242},
  timestamp   = {2013.09.14},
  year        = {2009},
}

@Article{Friberg1997,
  author      = {Friberg, S.},
  title       = {5-year cure rate: yet another myth.},
  language    = {eng},
  number      = {2},
  pages       = {73--75},
  volume      = {65},
  journal     = {J Surg Oncol},
  keywords    = {Humans; Models, Statistical; Neoplasms, mortality; Prognosis; Survival Rate},
  medline-pst = {ppublish},
  month       = {Jun},
  owner       = {sanelo},
  pii         = {3.0.CO;2-K},
  pmid        = {9209516},
  timestamp   = {2013.08.01},
  year        = {1997},
}

@Article{Gail1975,
  author      = {Gail, M.},
  title       = {A review and critique of some models used in competing risk analysis.},
  language    = {eng},
  number      = {1},
  pages       = {209--222},
  volume      = {31},
  abstract    = {We have introduced a notation which allows one to define competing
	risk models easily and to examine underlying assumptions. We have
	treated the actuarial model for competing risk in detail, comparing
	it with other models and giving useful variance formulae both for
	the case when times of death are available and for the case when
	they are not. The generality of these methods is illustrated by an
	example treating two dependent competing risks.},
  journal     = {Biometrics},
  keywords    = {Analysis of Variance; Humans; Life Expectancy; Mathematics; Models, Theoretical; Mortality},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {PaulD},
  pmid        = {1164533},
  timestamp   = {2015.03.24},
  year        = {1975},
}

@InCollection{Gail1982,
  author    = {Gail, M. H.},
  booktitle = {Encyclopedia of Statistical Sciences},
  title     = {Competing Risks},
  editor    = {Kotz, S. and Johnson, N. L.},
  pages     = {75-81},
  publisher = {John Wiley \& Sons: New York},
  volume    = {2},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1982},
}

@Article{Gail2008,
  author      = {Gail, Mitchell H.},
  title       = {Estimation and interpretation of models of absolute risk from epidemiologic data, including family-based studies.},
  doi         = {10.1007/s10985-007-9070-0},
  language    = {eng},
  number      = {1},
  pages       = {18--36},
  url         = {http://dx.doi.org/10.1007/s10985-007-9070-0},
  volume      = {14},
  abstract    = {Absolute risk is the chance that a person with given risk factors
	and free of the disease of interest at age a will be diagnosed with
	that disease in the interval (a, a + tau]. Absolute risk is sometimes
	called cumulative incidence. Absolute risk is a "crude" risk because
	it is reduced by the chance that the person will die of competing
	causes of death before developing the disease of interest. Cohort
	studies admit flexibility in modeling absolute risk, either by allowing
	covariates to affect the cause-specific relative hazards or to affect
	the absolute risk itself. An advantage of cause-specific relative
	risk models is that various data sources can be used to fit the required
	components. For example, case-control data can be used to estimate
	relative risk and attributable risk, and these can be combined with
	registry data on age-specific composite hazard rates for the disease
	of interest and with national data on competing hazards of mortality
	to estimate absolute risk. Family-based designs, such as the kin-cohort
	design and collections of pedigrees with multiple affected individuals
	can be used to estimate the genotype-specific hazard of disease.
	Such analyses must be adjusted for ascertainment, and failure to
	take into account residual familial risk, such as might be induced
	by unmeasured genetic variants or by unmeasured behavioral or environmental
	exposures that are correlated within families, can lead to overestimates
	of mutation-specific absolute risk in the general population.},
  institution = {Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, EPS 8032, Bethesda, MD 20892-7244, USA. gailm@mail.nih.gov},
  journal     = {Lifetime Data Anal},
  keywords    = {Biometry; Epidemiologic Measurements; Family; Humans; Likelihood Functions; Models, Statistical; Risk Assessment, statistics /&/ numerical data},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {sanelo},
  pmid        = {18058231},
  timestamp   = {2013.08.01},
  year        = {2008},
}

@Article{Galloway1994,
  author      = {Galloway, P. R.},
  title       = {A reconstruction of the population of north Italy from 1650 to 1881 using annual inverse projection with comparisons to England, France, and Sweden.},
  language    = {eng},
  number      = {3},
  pages       = {223--274},
  volume      = {10},
  abstract    = {"North Italy annual population and vital rates are reconstructed from
	1650 to 1881 using series of vital event indices from many rural
	parishes and cities. Inverse projection is applied to the reconstructed
	series of vital events and population to generate annual age distribution,
	gross reproduction rate, net reproduction rate, life expectancy at
	birth, and infant mortality rate. The results are compared with official
	sources and detailed demographic rates produced by annual inverse
	projection using data from England, France, and Sweden. Over the
	long term, North Italy is generally characterized by stagnant and
	relatively high mortality. Fertility and nuptiality are relatively
	high at the beginning and at the end of the period." (SUMMARY IN
	FRE)},
  journal     = {Eur J Popul},
  keywords    = {Demography; Developed Countries; England; Europe; Family; Family Characteristics; Fertility; France; Great Britain; Italy; Marriage; Mortality; Population; Population Characteristics; Population Dynamics; Retrospective Studies; Scandinavia; Social Sciences; Sweden; Vital Statistics},
  medline-pst = {ppublish},
  owner       = {pl4},
  pmid        = {12288311},
  timestamp   = {2013.05.29},
  year        = {1994},
}

@Article{Gamel2001,
  author      = {J. W. Gamel and R. L. Vogel},
  title       = {Non-parametric comparison of relative versus cause-specific survival in Surveillance, Epidemiology and End Results ({SEER}) programme breast cancer patients.},
  number      = {5},
  pages       = {339--352},
  volume      = {10},
  abstract    = {Cancer-related mortality can be measured by two dissimilar methods:
	cause-specific survival (based on mortality attributed to a specific
	cause), and relative survival (based on mortality relative to a matched
	cohort). We used both methods to determine actuarial survival in
	a population of 119,502 breast cancer patients from the Surveillance,
	Epidemiology and End Results (SEER) programme data set, with 20 years
	of follow-up. The population was divided into four strata by patient
	age and tumour stage. In all strata, there was only minimal deviation
	between the two survival methods. Of particular interest was the
	cause-specific treatment of patients recorded as dead of unknown
	cause, i.e. those deaths that could not be attributed with certainty
	to either 'breast cancer' or to 'other causes'. Findings suggest
	that the most reliable results may be obtained by apportioning these
	deaths between 'dead of cause' and 'withdrawn at the time of death'.
	This apportionment is based on the relative number of deaths attributed
	to 'breast cancer' versus 'other causes'.},
  file        = {Gamel2001.pdf:pdf\\Gamel2001.pdf:PDF},
  institution = {Veterans Administration Medical Center and University of Louisville School of Medicine, Louisville, Kentucky, USA. jgamel@louisville.edu},
  journal     = {Statistical Methods in Medical Research},
  month       = {Oct},
  owner       = {pl4},
  pmid        = {11697226},
  timestamp   = {2008.12.16},
  year        = {2001},
}

@Article{Gamel2000,
  author    = {Gamel, J. W. and Weller, E. A. and Wesley, M. N. and Feuer, E. J.},
  title     = {Parametric cure models of relative and cause-specific survival for grouped survival times},
  pages     = {99-110},
  volume    = {61},
  journal   = {Computer Methods and Programs in Biomedicine},
  keywords  = {Cure models; theory},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2000},
}

@Article{Gatta2000,
  author      = {G. Gatta and R. Capocaccia and M. P. Coleman and L. A. Gloeckler Ries and T. Hakulinen and A. Micheli and M. Sant and A. Verdecchia and F. Berrino},
  title       = {Toward a comparison of survival in {A}merican and {E}uropean cancer patients.},
  language    = {eng},
  number      = {4},
  pages       = {893--900},
  volume      = {89},
  abstract    = {BACKGROUND: Only recently have extensive population-based cancer survival
	data become available in Europe, providing an opportunity to compare
	survival in Europe and the United States. METHODS: The authors considered
	12 cancers: lung, breast, stomach, colon, rectum, melanoma, cervix
	uteri, corpus uteri, ovary, prostate, Hodgkin disease, and non-Hodgkin
	lymphoma. The authors analyzed 738,076 European and 282,398 U.S.
	patients, whose disease was diagnosed in 1985-1989, obtained from
	41 EUROCARE cancer registries in 17 countries and 9 U.S. SEER registries.
	Relative survival was estimated to correct for competing causes of
	mortality. RESULTS: Europeans had significantly lower survival rates
	than U.S. patients for most cancers. Differences in 5-year relative
	survival rates were higher for prostate (56\% vs. 81\%), skin melanoma
	(76\% vs. 86\%), colon (47\% vs. 60\%), rectum (43\% vs. 57\%), breast
	(73\% vs. 82\%), and corpus uteri (73\% vs. 83\%). Survival declined
	with increasing age at diagnosis for most cancers in both the U.S.
	and Europe but was more marked in Europe. CONCLUSIONS: Survival for
	most major cancers was worse in Europe than the U.S. especially for
	older patients. Differences in data collection, analysis, and quality
	apparently had only marginal influences on survival rate differences.
	Further research is required to clarify the reasons for the survival
	rate differences.},
  file        = {Gatta2000.pdf:Gatta2000.pdf:PDF;Gatta2000.pdf:pdf\\Gatta2000.pdf:PDF},
  institution = {Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.},
  journal     = {Cancer},
  medline-pst = {ppublish},
  month       = {Aug},
  owner       = {pl4},
  pii         = {3.0.CO;2-9},
  pmid        = {10951355},
  timestamp   = {2010.05.19},
  year        = {2000},
}

@Article{Gauderman2002,
  author    = {Gauderman, W. J.},
  title     = {Sample size requirements for matched case-control studies of gene-environment interaction},
  pages     = {35-50},
  volume    = {21},
  journal   = {Statistics in Medicine},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2002},
}

@Article{Gelber1993,
  author      = {Gelber, R. D. and Goldhirsch, A. and Cole, B. F.},
  title       = {Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. International Breast Cancer Study Group.},
  language    = {eng},
  number      = {6},
  pages       = {485--499},
  volume      = {14},
  abstract    = {Using parametric models, a procedure for projecting survival estimates
	beyond the follow-up limits of a clinical trial is developed. The
	methodology consists of fitting an appropriate parametric model to
	the tail of a survival curve and using the estimated model in conjunction
	with the Kaplan-Meier product-limit estimate to produce a composite
	survival-function estimator. This estimator is especially useful
	whenever a parametric model is more easily fit to the tail rather
	than to the entire survival curve. Probability plots are used to
	evaluate different parametric models as well as to determine appropriate
	values for the cut points that define the survival-function tail.
	The bootstrap method provides estimates of variation in the projected
	survival curve. The resulting projected survival estimates allow
	one to make inferences on long-term treatment effects in clinical
	trials. As a motivating application, we project survival curves to
	estimate long-term treatment effects on quality-of-life-adjusted
	survival. This represents an extension of a statistical procedure
	called Q-TWiST (Quality-adjusted Time Without Symptoms of disease
	and Toxicity of treatment), which evaluates treatments in terms of
	both quantity and quality of life. In a standard Q-TWiST analysis,
	the average time spent in each of a number of health states, which
	differ in quality of life, is estimated from clinical trial data.
	The health states are weighted according to the quality of life experienced,
	and the results are combined to produce an estimate of quality-adjusted
	survival. Such estimates, however, are restricted to the follow-up
	limit of the data. The way in which the extrapolation methodology
	provides longer range estimates of Q-TWiST is described. To illustrate
	the techniques, we apply the methodology to data from the International
	Breast Cancer Study Group Trial V, which compares long-duration adjuvant
	chemotherapy versus short-duration chemotherapy in the treatment
	of node-positive breast cancer. Five-year median follow-up data are
	used to predict 10-year results in terms of mean survival and mean
	Q-TWiST. The results indicate that patients continue to benefit greatly
	from the long-duration chemotherapy between 5 and 10 years following
	treatment.},
  institution = {on, Massachusetts 02115.},
  journal     = {Control Clin Trials},
  keywords    = {Antineoplastic Agents, therapeutic use; Breast Neoplasms, drug therapy/mortality; Chemotherapy, Adjuvant; Clinical Trials as Topic, statistics /&/ numerical data; Female; Humans; Models, Statistical; Outcome Assessment (Health Care); Quality of Life; Survival Analysis; Treatment Outcome},
  medline-pst = {ppublish},
  month       = {Dec},
  owner       = {theand},
  pmid        = {8119064},
  timestamp   = {2012.09.18},
  year        = {1993},
}

@Electronic{Gelman2011,
  author       = {Andrew Gelman},
  title        = {How do you interpret standard errors from a regression fit to the entire population?},
  url          = {http://andrewgelman.com/2011/10/25/how-do-you-interpret-standard-errors-from-a-regression-fit-to-the-entire-population/},
  groups       = {Superpopulation},
  howpublished = {Blog},
  month        = {Oct},
  owner        = {PaulD},
  timestamp    = {2013.03.07},
  year         = {2011},
}

@Electronic{Gelman2009,
  author       = {Andrew Gelman},
  title        = {How does statistical analysis differ when analyzing the entire population rather than a sample?},
  url          = {http://andrewgelman.com/2009/07/03/how_does_statis/},
  groups       = {Superpopulation},
  howpublished = {Blog},
  month        = {July},
  owner        = {PaulD},
  timestamp    = {2013.03.07},
  year         = {2009},
}

@Article{Genell2010,
  author    = {Genell, A. and Nemes, S. and Steineck, G. and Dickman, P. W.},
  title     = {A simulation study comparing Bayesian Model Averaging and Stepwise Regression.},
  journal   = {BMC Medical Research Methodology},
  owner     = {PaulD},
  timestamp = {2010.11.30},
  year      = {2010 (in press)},
}

@Article{Gerds2012,
  author      = {Gerds, Thomas A. and Scheike, Thomas H. and Andersen, Per K.},
  title       = {Absolute risk regression for competing risks: interpretation, link functions, and prediction.},
  doi         = {10.1002/sim.5459},
  language    = {eng},
  number      = {29},
  pages       = {3921--3930},
  url         = {http://dx.doi.org/10.1002/sim.5459},
  volume      = {31},
  abstract    = {In survival analysis with competing risks, the transformation model
	allows different functions between the outcome and explanatory variables.
	However, the model's prediction accuracy and the interpretation of
	parameters may be sensitive to the choice of link function. We review
	the practical implications of different link functions for regression
	of the absolute risk (or cumulative incidence) of an event. Specifically,
	we consider models in which the regression coefficients ? have the
	following interpretation: The probability of dying from cause D during
	the next t years changes with a factor exp(?) for a one unit change
	of the corresponding predictor variable, given fixed values for the
	other predictor variables. The models have a direct interpretation
	for the predictive ability of the risk factors. We propose some tools
	to justify the models in comparison with traditional approaches that
	combine a series of cause-specific Cox regression models or use the
	Fine-Gray model. We illustrate the methods with the use of bone marrow
	transplant data.},
  file        = {Gerds2012.pdf:Gerds2012.pdf:PDF},
  institution = {Department of Biostatistics, University of Copenhagen, Denmark. tag@biostat.ku.dk},
  journal     = {Stat Med},
  keywords    = {Bone Marrow Transplantation, mortality; Humans; Leukemia, mortality/surgery; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment, methods; Risk Factors; Survival Analysis},
  medline-pst = {ppublish},
  month       = {Dec},
  owner       = {pl4},
  pmid        = {22865706},
  timestamp   = {2015.02.04},
  year        = {2012},
}

@Article{German2011,
  author      = {German, Robert R. and Fink, Aliza K. and Heron, Melonie and Stewart, Sherri L. and Johnson, Chris J. and Finch, Jack L. and Yin, Daixin and , Accuracy of Cancer Mortality Study Group},
  title       = {The accuracy of cancer mortality statistics based on death certificates in the {United States}},
  doi         = {10.1016/j.canep.2010.09.005},
  language    = {eng},
  number      = {2},
  pages       = {126--131},
  url         = {http://dx.doi.org/10.1016/j.canep.2010.09.005},
  volume      = {35},
  abstract    = {One measure of the accuracy of cancer mortality statistics is the
	concordance between cancer defined as the underlying cause of death
	from death certificates and cancer diagnoses recorded in central,
	population-based cancer registries. Previous studies of such concordance
	are outdated.To characterize the accuracy of cancer mortality statistics
	from the concordance between cancer cause of death and primary cancer
	site at diagnosis.Central cancer registry records from California,
	Colorado, and Idaho in the U.S. were linked with state vital statistics
	data and evaluated by demographic and tumor information across 79
	site categories. A retrospective arm (confirmation rate per 100 deaths)
	compared death certificate data from 2002 to 2004 with cancer registry
	diagnoses from 1993 to 2004, while a prospective arm (detection rate
	per 100 deaths) compared cancer registry diagnoses from 1993 to 1995
	with death certificate data from 1993 to 2004 by International Statistical
	Classification of Diseases and Related Health Problems (ICD) version
	used to code deaths.With n=265,863 deaths where cancer was recorded
	as the underlying cause based on the death certificate, the overall
	confirmation rate for ICD-10 was 82.8\% (95\% confidence interval
	[CI], 82.6-83.0\%), the overall detection rate for ICD-10 was 81.0\%
	(95\% CI, 80.4-81.6\%), and the overall detection rate for ICD-9
	was 85.0\% (95\% CI, 84.8-85.2\%). These rates varied across primary
	sites, where some rates were <50\%, some were 95\% or greater, and
	notable differences between confirmation and detection rates were
	observed.Important unique information on the quality of cancer mortality
	data obtained from death certificates is provided. In addition, information
	is provided for future studies of the concordance of primary cancer
	site between population-based cancer registry data and data from
	death certificates, particularly underlying causes of death coded
	in ICD-10.},
  file        = {German2011.pdf:pdf\\German2011.pdf:PDF;German2011.pdf:German2011.pdf:PDF},
  institution = {Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Atlanta, GA 30341, USA.},
  journal     = {Cancer Epidemiol},
  keywords    = {Adult; Aged; Aged, 80 and over; Death Certificates; Female; Humans; Male; Middle Aged; Neoplasms, mortality; SEER Program; United States, epidemiology; Young Adult},
  medline-pst = {ppublish},
  month       = {Apr},
  owner       = {PaulD},
  pii         = {S1877-7821(10)00165-7},
  pmid        = {20952269},
  timestamp   = {2013.09.18},
  year        = {2011},
}

@Book{Geskus2016,
  author    = {Geskus, R. B.},
  title     = {Data analysis with competing risks and intermediate states},
  publisher = {Chapman and Hall},
  owner     = {pl4},
  timestamp = {2016.03.07},
  year      = {2016},
}

@Article{Geskus2011,
  author      = {Geskus, Ronald B.},
  title       = {Cause-specific cumulative incidence estimation and the {F}ine and {G}ray model under both left truncation and right censoring.},
  doi         = {10.1111/j.1541-0420.2010.01420.x},
  language    = {eng},
  number      = {1},
  pages       = {39--49},
  url         = {http://dx.doi.org/10.1111/j.1541-0420.2010.01420.x},
  volume      = {67},
  abstract    = {Summary The standard estimator for the cause-specific cumulative incidence
	function in a competing risks setting with left truncated and/or
	right censored data can be written in two alternative forms. One
	is a weighted empirical cumulative distribution function and the
	other a product-limit estimator. This equivalence suggests an alternative
	view of the analysis of time-to-event data with left truncation and
	right censoring: individuals who are still at risk or experienced
	an earlier competing event receive weights from the censoring and
	truncation mechanisms. As a consequence, inference on the cumulative
	scale can be performed using weighted versions of standard procedures.
	This holds for estimation of the cause-specific cumulative incidence
	function as well as for estimation of the regression parameters in
	the Fine and Gray proportional subdistribution hazards model. We
	show that, with the appropriate filtration, a martingale property
	holds that allows deriving asymptotic results for the proportional
	subdistribution hazards model in the same way as for the standard
	Cox proportional hazards model. Estimation of the cause-specific
	cumulative incidence function and regression on the subdistribution
	hazard can be performed using standard software for survival analysis
	if the software allows for inclusion of time-dependent weights. We
	show the implementation in the R statistical package. The proportional
	subdistribution hazards model is used to investigate the effect of
	calendar period as a deterministic external time varying covariate,
	which can be seen as a special case of left truncation, on AIDS related
	and non-AIDS related cumulative mortality.},
  file        = {Geskus2011.pdf:Geskus2011.pdf:PDF},
  institution = {Academic Medical Center, Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands. statistics@inter.nl.net},
  journal     = {Biometrics},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {pl4},
  pii         = {BIOM1420},
  pmid        = {20377575},
  timestamp   = {2012.01.17},
  year        = {2011},
}

@Article{Ghali2001,
  author    = {W. A. Ghali and H. Quan and R. Brant and G. van Melle and C. M. Norris and P. D. Faris and P. D. Galbraith and M. L. Knudtson and {APPROACH Investigators}},
  title     = {Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models.},
  number    = {12},
  pages     = {1494--1497},
  volume    = {286},
  file      = {Ghali2001.pdf:Ghali2001.pdf:PDF;Ghali2001.pdf:pdf\\Ghali2001.pdf:PDF},
  journal   = {JAMA},
  month     = {Sep},
  owner     = {pl4},
  pmid      = {11572743},
  timestamp = {2009.01.14},
  year      = {2001},
}

@Article{Gibberd1990,
  author    = {Gibberd, R. W. and Hardes, G. and Lam, P.},
  title     = {Using {DRG}s to Determine the Variability in Hospital Admission Rates and Length of Stay in {NSW}},
  pages     = {193-195},
  volume    = {1},
  journal   = {System Science in Health Care},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1990},
}

@Article{Gigerenzer2012,
  author      = {Gigerenzer, G. and Galesic, M.},
  title       = {Why do single event probabilities confuse patients?},
  language    = {eng},
  pages       = {e245},
  volume      = {344},
  institution = {Centre for Adaptive Behaviour and Cognition, Max Planck Institute for Human Development, Berlin. gigerenzer@mpib-berlin.mpg.de},
  journal     = {BMJ},
  keywords    = {Communication; Humans; Probability; Professional-Patient Relations; Risk},
  medline-pst = {epublish},
  owner       = {sanelo},
  pmid        = {22236599},
  timestamp   = {2013.10.17},
  year        = {2012},
}

@Article{Gill2011,
  author          = {Gill, Sharlene and Loprinzi, Charles and Kennecke, Hagen and Grothey, Axel and Nelson, Garth and Woods, Ryan and Speers, Caroline and Alberts, Steven R and Bardia, Aditya and O'Connell, Michael J and Sargent, Daniel J},
  title           = {Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online.},
  doi             = {10.1002/cncr.26003},
  issn            = {1097-0142},
  issue           = {18},
  pages           = {4155--4165},
  volume          = {117},
  abstract        = {Numeracy and Adjuvant! are 2 web-based calculators that are used widely
	to estimate the prognosis and potential benefit of adjuvant 5-fluorouracil
	(5-FU)-based therapy for patients with stage II and III colon cancer.
	In this study, the authors compared the predicted survival estimates
	from these models with the actual observed estimates in independent
	datasets that were derived from a population cohort and from clinical
	trials. The population cohort was derived from the British Columbia
	Colorectal Cancer Outcomes Unit database, which identified referred
	patients with stage II and III colon cancer from 1995 to 1996 and
	from 1999 to 2003. Patients who were enrolled in North Central Cancer
	Trials Group (NCCTG) trials NCCTG 94651 and NCCTG 914653 were included
	in the trials dataset. Patient and disease data were used to predict
	5-year relapse-free and overall survival using both tools. In the
	population-based dataset (N = 2033), Adjuvant! offered more reliable
	predictions of prognosis for patients who underwent surgery alone,
	but it had reliability similar to that of Numeracy for predicting
	the prognosis for patients who received adjuvant 5-FU. Both models
	tended to overestimate survival for patients with stage II disease
	who received 5-FU. In the trials dataset of patients who underwent
	and received 5-FU (N = 1729), Numeracy and Adjuvant! demonstrated
	similar performance and improved correctness. This independent validation
	analysis demonstrated that both Numeracy and Adjuvant! had similar
	predictive performance and acceptable reliability for patients with
	stage III disease. Survival outcomes of patients with stage II colon
	cancer who received adjuvant 5-FU were slightly lower than estimated
	by either model.},
  chemicals       = {Fluorouracil},
  citation-subset = {AIM, IM},
  completed       = {2011-10-31},
  country         = {United States},
  created         = {2011-09-07},
  issn-linking    = {0008-543X},
  journal         = {Cancer},
  keywords        = {Aged; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms, drug therapy, mortality, pathology; Disease-Free Survival; Female; Fluorouracil, therapeutic use; Humans; Internet; Male; Middle Aged; Models, Statistical; Neoplasm Staging; Population Surveillance; Prognosis},
  mid             = {NIHMS268661},
  month           = {Sep},
  nlm             = {PMC3111760},
  nlm-id          = {0374236},
  owner           = {NLM},
  pmc             = {PMC3111760},
  pmid            = {21365628},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2016-11-22},
  timestamp       = {2016.12.09},
  year            = {2011},
}

@Article{Gillies2007,
  author      = {Clare L Gillies and Keith R Abrams and Paul C Lambert and Nicola J Cooper and Alex J Sutton and Ron T Hsu and Kamlesh Khunti},
  title       = {Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis.},
  doi         = {10.1136/bmj.39063.689375.55},
  number      = {7588},
  pages       = {299},
  url         = {http://dx.doi.org/10.1136/bmj.39063.689375.55},
  volume      = {334},
  abstract    = {OBJECTIVE: To quantify the effectiveness of pharmacological and lifestyle
	interventions to prevent or delay type 2 diabetes in people with
	impaired glucose tolerance. DATA SOURCES: Medline, Embase, and the
	Cochrane library searched up to July 2006. Expert opinions sought
	and reference lists of identified studies and any relevant published
	reviews checked. STUDY SELECTION: Randomised controlled trials that
	evaluated interventions to delay or prevent type 2 diabetes in individuals
	with impaired glucose tolerance. RESULTS: 21 trials met the inclusion
	criteria, of which 17, with 8084 participants with impaired glucose
	tolerance, reported results in enough detail for inclusion in the
	meta-analyses. From the meta-analyses the pooled hazard ratios were
	0.51 (95\% confidence interval 0.44 to 0.60) for lifestyle interventions
	v standard advice, 0.70 (0.62 to 0.79) for oral diabetes drugs v
	control, 0.44 (0.28 to 0.69) for orlistat v control, and 0.32 (0.03
	to 3.07) for the herbal remedy jiangtang bushen recipe v standard
	diabetes advice. These correspond to numbers needed to treat for
	benefit (NNTB) and harm (NNTH) of 6.4 for lifestyle (95\% credible
	interval, NNTB 5.0 to NNTB 8.4), 10.8 for oral diabetes drugs (NNTB
	8.1 to NNTB 15.0), 5.4 for orlistat (NNTB 4.1 to NNTB 7.6), and 4.0
	for jiangtang bushen (NNTH 16.9 to NNTB 24.8). CONCLUSIONS: Lifestyle
	and pharmacological interventions reduce the rate of progression
	to type 2 diabetes in people with impaired glucose tolerance. Lifestyle
	interventions seem to be at least as effective as drug treatment.},
  file        = {gillies2007.pdf:gillies2007.pdf:PDF},
  institution = {Centre for Biostatistics and Genetic Epidemiology, Department of Health Sciences, University of Leicester, Leicester LE1 7RH. clg13@le.ac.uk},
  journal     = {BMJ},
  month       = {Feb},
  owner       = {pl4},
  pii         = {bmj.39063.689375.55},
  pmid        = {17237299},
  timestamp   = {2008.10.15},
  year        = {2007},
}

@Article{Gillies2008,
  author      = {Clare L Gillies and Paul C Lambert and Keith R Abrams and Alex J Sutton and Nicola J Cooper and Ron T Hsu and Melanie J Davies and Kamlesh Khunti},
  title       = {Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis.},
  doi         = {10.1136/bmj.39545.585289.25},
  number      = {7654},
  pages       = {1180--1185},
  url         = {http://dx.doi.org/10.1136/bmj.39545.585289.25},
  volume      = {336},
  abstract    = {OBJECTIVE: To compare four potential screening strategies, and subsequent
	interventions, for the prevention and treatment of type 2 diabetes:
	(a) screening for type 2 diabetes to enable early detection and treatment,
	(b) screening for type 2 diabetes and impaired glucose tolerance,
	intervening with lifestyle interventions in those with a diagnosis
	of impaired glucose tolerance to delay or prevent diabetes, (c) as
	for (b) but with pharmacological interventions, and (d) no screening.
	DESIGN: Cost effectiveness analysis based on development and evaluation
	of probabilistic, comprehensive economic decision analytic model,
	from screening to death. SETTING: A hypothetical population, aged
	45 at time of screening, with above average risk of diabetes. DATA
	SOURCES: Published clinical trials and epidemiological studies retrieved
	from electronic bibliographic databases; supplementary data obtained
	from the Department of Health statistics for England and Wales, the
	screening those at risk (STAR) study, and the Leicester division
	of the ADDITION study. METHODS: A hybrid decision tree/Markov model
	was developed to simulate the long term effects of each screening
	strategy, in terms of both clinical and cost effectiveness outcomes.
	The base case model assumed a 50 year time horizon with discounting
	of both costs and benefits at 3.5\%. Sensitivity analyses were carried
	out to investigate assumptions of the model and to identify which
	model inputs had most impact on the results. RESULTS: Estimated costs
	for each quality adjusted life year (QALY) gained (discounted at
	3.5\% a year for both costs and benefits) were pound14,150 (euro17
	560; $27,860) for screening for type 2 diabetes, pound6242 for screening
	for diabetes and impaired glucose tolerance followed by lifestyle
	interventions, and pound7023 for screening for diabetes and impaired
	glucose tolerance followed by pharmacological interventions, all
	compared with no screening. At a willingness-to-pay threshold of
	pound20,000 the probability of the intervention being cost effective
	was 49\%, 93\%, and 85\% for each of the active screening strategies
	respectively. CONCLUSIONS: Screening for type 2 diabetes and impaired
	glucose tolerance, with appropriate intervention for those with impaired
	glucose tolerance, in an above average risk population aged 45, seems
	to be cost effective. The cost effectiveness of a policy of screening
	for diabetes alone, which offered no intervention to those with impaired
	glucose tolerance, is still uncertain.},
  file        = {gillies2008.pdf:gillies2008.pdf:PDF},
  institution = {Centre for Biostatistics and Genetic Epidemiology, Department of Health Sciences, University of Leicester, Leicester LE1 7RH. clg13@le.ac.uk},
  journal     = {BMJ},
  month       = {May},
  owner       = {pl4},
  pii         = {bmj.39545.585289.25},
  pmid        = {18426840},
  timestamp   = {2008.10.15},
  year        = {2008},
}

@Article{Giorgi2016,
  author       = {Giorgi, R and CENSUR working survival group},
  title        = {Challenges in the estimation of Net SURvival: The CENSUR working survival group.},
  doi          = {10.1016/j.respe.2016.05.005},
  issn         = {0398-7620},
  issue        = {5},
  pages        = {367--371},
  volume       = {64},
  abstract     = {Net survival, the survival probability that would be observed, in
	a hypothetical world, where the cancer of interest would be the only
	possible cause of death, is a key indicator in population-based cancer
	studies. Accounting for mortality due to other causes, it allows
	cross-country comparisons or trends analysis and provides a useful
	indicator for public health decision-making. The objective of this
	study was to show how the creation and formalization of a network
	comprising established research teams, which already had substantial
	and complementary experience in both cancer survival analysis and
	methodological development, make it possible to meet challenges and
	thus provide more adequate tools, to improve the quality and the
	comparability of cancer survival data, and to promote methodological
	transfers in areas of emerging interest. The Challenges in the Estimation
	of Net SURvival (CENSUR) working survival group is composed of international
	researchers highly skilled in biostatistics, methodology, and epidemiology,
	from different research organizations in France, the United Kingdom,
	Italy, Slovenia, and Canada, and involved in French (FRANCIM) and
	European (EUROCARE) cancer registry networks. The expected advantages
	are an interdisciplinary, international, synergistic network capable
	of addressing problems in public health, for decision-makers at different
	levels; tools for those in charge of net survival analyses; a common
	methodology that makes unbiased cross-national comparisons of cancer
	survival feasible; transfer of methods for net survival estimations
	to other specific applications (clinical research, occupational epidemiology);
	and dissemination of results during an international training course.
	The formalization of the international CENSUR working survival group
	was motivated by a need felt by scientists conducting population-based
	cancer research to discuss, develop, and monitor implementation of
	a common methodology to analyze net survival in order to provide
	useful information for cancer control and cancer policy. A "team
	science" approach is necessary to address new challenges concerning
	the estimation of net survival.},
  country      = {France},
  created      = {2016-10-29},
  file         = {:pdf\\Giorgi2016.pdf:PDF},
  issn-linking = {0398-7620},
  journal      = {Revue d'epidemiologie et de sante publique},
  keywords     = {Analyse de survie; Cancer; Estimateur de Pohar-Perme; Excess hazard model; Life tables; Mod{\AA}Â¨le statistique; Mod{\AA}Â¨le {\AA}Â  taux en exc{\AA}Â¨s; Net survival; Pohar-Perme estimator; Statistical model; Survie nette; Survival analysis; Table de mortalit{\AA}Â©},
  month        = oct,
  nlm-id       = {7608039},
  owner        = {NLM},
  pii          = {S0398-7620(16)30680-0},
  pmid         = {27793412},
  pubmodel     = {Print-Electronic},
  pubstatus    = {ppublish},
  revised      = {2016-12-19},
  year         = {2016},
}

@Article{Giorgi2003,
  author      = {R. Giorgi and M. Abrahamowicz and C. Quantin and P. Bolard and J. Esteve and J. Gouvernet and J. Faivre},
  title       = {A relative survival regression model using {B}-spline functions to model non-proportional hazards.},
  doi         = {10.1002/sim.1484},
  number      = {17},
  pages       = {2767--2784},
  url         = {http://dx.doi.org/10.1002/sim.1484},
  volume      = {22},
  abstract    = {Relative survival, a method for assessing prognostic factors for disease-specific
	mortality in unselected populations, is frequently used in population-based
	studies. However, most relative survival models assume that the effects
	of covariates on disease-specific mortality conform with the proportional
	hazards hypothesis, which may not hold in some long-term studies.
	To accommodate variation over time of a predictor's effect on disease-specific
	mortality, we developed a new relative survival regression model
	using B-splines to model the hazard ratio as a flexible function
	of time, without having to specify a particular functional form.
	Our method also allows for testing the hypotheses of hazards proportionality
	and no association on disease-specific hazard. Accuracy of estimation
	and inference were evaluated in simulations. The method is illustrated
	by an analysis of a population-based study of colon cancer.},
  file        = {Giorgi2003.pdf:Giorgi2003.pdf:PDF;Giorgi2003.pdf:pdf\\Giorgi2003.pdf:PDF},
  groups      = {Excess mortality model},
  institution = {LERTIM, Facult\'{e} de M\'{e}decine, Universit\'{e} de la M\'{e}diterran\'{e}e, 27 Bd Jean Moulin 13385 Marseille Cedex, France.},
  journal     = {Stat Med},
  month       = {Sep},
  owner       = {pl4},
  pmid        = {12939785},
  timestamp   = {2008.12.16},
  year        = {2003},
}

@Article{Giorgi2008,
  author      = {Roch Giorgi and Aur\'{e}lien Belot and Jean Gaudart and Guy Launoy and and the French Network of Cancer Registries FRANCIM},
  title       = {The performance of multiple imputation for missing covariate data within the context of regression relative survival analysis.},
  number      = {30},
  pages       = {6310--6331},
  volume      = {27},
  abstract    = {Relative survival assesses the effects of prognostic factors on disease-specific
	mortality when the cause of death is uncertain or unavailable. It
	provides an estimate of patients' survival, allowing for the effects
	of other independent causes of death. Regression-based relative survival
	models are commonly used in population-based studies to model the
	effects of some prognostic factors and to estimate net survival.
	Most often, studies focus on routinely collected prognostic factors
	for which the proportion of missing values is usually low (around
	5 per cent). However, in some cases, additional factors are collected
	with a greater proportion of missingness. In the present article,
	we systematically assess the performance of multiple imputation in
	regression analysis of relative survival through a series of simulation
	experiments. According to the assumptions concerning the missingness
	mechanism (completely at random, at random, and not at random) and
	the missingness pattern (monotone, non-monotone), several strategies
	were considered and compared: all cases analysis, complete cases
	analysis, missing data indicator analysis, and multiple imputation
	by chained equations (MICE) analysis. We showed that MICE performs
	well in estimating the hazard ratios and the baseline hazard function
	when the missing mechanism is missing at random (MAR) conditionally
	on the vital status. In the situations where the missing mechanism
	was not MAR conditionally on vital status, complete case behaves
	consistently. As illustration, we used data of the French Cancer
	Registries on relative survival of patients with colorectal cancer.
	Copyright (c) 2008 John Wiley & Sons, Ltd.},
  file        = {Giorgi2008.pdf:Giorgi2008.pdf:PDF;Giorgi2008.pdf:pdf\\Giorgi2008.pdf:PDF},
  institution = {Laboratoire d'Enseignement et de Recherche sur le Traitement de l'Information M\'{e}dicale, EA 3283, Facult\'{e} de M\'{e}decine, Universit\'{e} de la M\'{e}diterran\'{e}e, Marseille, France.},
  journal     = {Statistics in Medicine},
  month       = {Dec},
  owner       = {pl4},
  pmid        = {19021241},
  timestamp   = {2008.12.16},
  year        = {2008},
}

@Article{Giorgi2005,
  author      = {Roch Giorgi and Joanny Gouvernet},
  title       = {Analysis of time-dependent covariates in a regressive relative survival model.},
  doi         = {10.1002/sim.2400},
  number      = {24},
  pages       = {3863--3870},
  url         = {http://dx.doi.org/10.1002/sim.2400},
  volume      = {24},
  abstract    = {Relative survival is a method for assessing prognostic factors for
	disease-specific mortality. However, most relative survival models
	assume that the effect of covariate on disease-specific mortality
	is fixed-in-time, which may not hold in some studies and requires
	adapted modelling. We propose an extension of the Esteve et al. regressive
	relative survival model that uses the counting process approach to
	accommodate time-dependent effect of a predictor's on disease-specific
	mortality. This approach had shown its robustness, and the properties
	of the counting process give a simple and attractive computational
	solution to model time-dependent covariates. Our approach is illustrated
	with the data from the Stanford Heart Transplant Study and with data
	from a hospital-based study on invasive breast cancer. Advantages
	of modelling time-dependent covariates in relative survival analysis
	are discussed.},
  file        = {Giorgi2005.pdf:Giorgi2005.pdf:PDF;Giorgi2005.pdf:pdf\\Giorgi2005.pdf:PDF},
  institution = {LERTIM, Facult\'{e} de M\'{e}decine, Universit\'{e} de la M\'{e}diterran\'{e}e, 27 Bd Jean Moulin, 13385 Marseille Cedex, France. roch.giorgi@ap-hm.fr},
  journal     = {Statistics in Medicine},
  month       = {Dec},
  owner       = {pl4},
  pmid        = {16320266},
  timestamp   = {2008.12.16},
  year        = {2005},
}

@Article{Giorgi2005a,
  author      = {Roch Giorgi and Julie Payan and Joanny Gouvernet},
  title       = {RSURV: a function to perform relative survival analysis with S-PLUS or R.},
  doi         = {10.1016/j.cmpb.2005.01.001},
  number      = {2},
  pages       = {175--178},
  url         = {http://dx.doi.org/10.1016/j.cmpb.2005.01.001},
  volume      = {78},
  abstract    = {Relative survival is a method used to estimate net survival using
	the expected mortality in the general population. This method is
	frequently used in cancer registries, more particularly with the
	Esteve et al. regressive proportional hazards model. Recently, extensions
	of this model have been developed to account for time-dependent covariate
	and for time-dependent hazards using B-spline functions. We propose
	a function, RSurv, to take into account these extensions. Written
	in the R/S language this function has the same structure of the standard
	Cox function coxph of R and S-PLUS software with the goal to homogenise
	survival functions and to take advantages of the power of R and S-PLUS
	software. We also propose a function, plot.RSurv, for plotting relative
	survival curves and time-dependent hazards ratio. The usage of these
	functions is exemplified by a study of a breast cancer hospital-based
	data set.},
  file        = {Giorgi2005a.pdf:Giorgi2005a.pdf:PDF;Giorgi2005a.pdf:pdf\\Giorgi2005a.pdf:PDF},
  institution = {LERTIM, Facult\'{e} de M\'{e}decine, Universit\'{e} de la M\'{e}diterran\'{e}e, 27 Bd Jean Moulin 13385, Marseille Cedex, France. roch.giorgi@ap-hm.fr},
  journal     = {Comput Methods Programs Biomed},
  month       = {May},
  owner       = {pl4},
  pii         = {S0169-2607(05)00015-5},
  pmid        = {15848272},
  timestamp   = {2008.12.16},
  year        = {2005},
}

@Article{Glimelius1996,
  author      = {Glimelius, B. and Enblad, G. and Kalkner, M. and Gustavsson, A. and Jakobsson, M. and Branehog, I. and Lenner, P. and Bjorkholm, M.},
  title       = {Treatment of {H}odgkin's disease: the {S}wedish {N}ational {C}are {P}rogramme experience.},
  doi         = {10.3109/10428199609067582},
  language    = {eng},
  number      = {1-2},
  pages       = {71--78},
  url         = {http://dx.doi.org/10.3109/10428199609067582},
  volume      = {21},
  abstract    = {Since 1985 a Swedish National Care Programme has provided tailored
	principles for the diagnosis, staging, treatment and follow-up of
	patients with Hodgkin's disease (HD). This report gives the rationale
	behind the recommendations and presents treatment results for 648
	patients diagnosed between 1985 and 1989 after a median follow-up
	of 70 months. Two hundred and twenty-nine (35\%) patients were over
	60 years of age. Treatment results for patients below 60 years of
	age in early and intermediate stages were favourable, provided the
	recommendations were followed. In advanced stages, the outcome was
	inferior in patients with CS IIB bulky disease and stage IVB. The
	prognosis of elderly patients remains poor, although it is too early
	to evaluate any impact of revisions made in 1989. The tailored principles,
	which usually entail less staging and/or treatment than is generally
	the case in the early and intermediate stages, produced favourable
	results when applied to an unselected group of patients with HD.
	Only minor changes were made in the recommendations during the 1994
	revision.},
  institution = {Department of Oncology, Akademiska Hospital, Uppsala, Sweden.},
  journal     = {Leuk Lymphoma},
  keywords    = {Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols, therapeutic use; Bleomycin, administration /&/ dosage; Combined Modality Therapy; Dacarbazine, administration /&/ dosage; Doxorubicin, administration /&/ dosage; Female; Hodgkin Disease, drug therapy/pathology/radiotherapy; Humans; Male; Mechlorethamine, administration /&/ dosage; Middle Aged; Neoplasm Staging; Prednisone, administration /&/ dosage; Procarbazine, administration /&/ dosage; Sweden; Vinblastine, administration /&/ dosage; Vincristine, administration /&/ dosage},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {sanelo},
  pmid        = {8907272},
  timestamp   = {2013.08.07},
  year        = {1996},
}

@Article{Glynn1994,
  author    = {Glynn, R. J. and Rosner, B.},
  title     = {Comparison of alternative regression models for paired binary data},
  pages     = {1023--36},
  volume    = {13},
  journal   = {Statistics in Medicine},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1994},
}

@Article{Goeman2004,
  author    = {J.J. Goeman and S. Le Cessie and R.J. Baatenburg de Jong and S.A. van de Geer},
  title     = {Predicting survival using disease history: a model combining relative survival and frailty},
  pages     = {21-34},
  volume    = {58},
  file      = {Goeman2004.pdf:Goeman2004.pdf:PDF;Goeman2004.pdf:pdf\\Goeman2004.pdf:PDF},
  journal   = {Statistica Neerlandica},
  owner     = {pl4},
  timestamp = {2008.12.16},
  year      = {2004},
}

@Article{Goldacre1993,
  author    = {Goldacre, M. J.},
  title     = {Cause-Specific Mortality: Understanding Uncertain Tips of the Disease Iceberg},
  pages     = {491-496},
  volume    = {47},
  journal   = {Journal of Epidemiology and Community Health},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1993},
}

@Article{Goldstein1996,
  author    = {Harvey Goldstein and David J. Spiegelhalter},
  title     = {League Tables and Their Limitations: Statistical Issues in Comparisons of Institutional Performance},
  pages     = {385-409},
  volume    = {159},
  journal   = {Journal of the Royal Statistical Society (A)},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1996},
}

@Article{Gondos2008,
  author      = {A. Gondos and F. Bray and D. H. Brewster and J. W W Coebergh and T. Hakulinen and M. L G Janssen-Heijnen and J. Kurtinaitis and H. Brenner and E. U. N. I. C. E. Survival Working Group},
  title       = {Recent trends in cancer survival across Europe between 2000 and 2004: a model-based period analysis from 12 cancer registries.},
  doi         = {10.1016/j.ejca.2008.03.010},
  number      = {10},
  pages       = {1463--1475},
  url         = {http://dx.doi.org/10.1016/j.ejca.2008.03.010},
  volume      = {44},
  abstract    = {BACKGROUND: Monitoring population-based cancer survival is an essential
	component in the evaluation of cancer control, but subject to an
	inherent delay in the reporting of the most recent survival estimates
	with traditional techniques of analysis. METHODS: We examined survival
	trends between the years 2000 and 2004 for 20 common cancers based
	on follow-up data from 12 cancer registries from diverse areas of
	Europe using model-based period analysis techniques. RESULTS: Between
	2000 and 2004, marked rises were seen in 5-year relative survival
	amongst patients with prostate, breast and colorectal cancer, which
	were statistically significant in 10, 8 and 7 of the 12 participating
	cancer registries, respectively. For cancer sites amenable to effective
	early detection and treatment, major geographical differences in
	patient prognosis still persisted, with a lower survival generally
	observed in Eastern European countries. CONCLUSION: Model-based period
	analysis enables the timely monitoring of recent trends in population-based
	cancer survival. For colorectal and breast cancers, the identified
	rises in survival are probably (at least partly) explained by the
	improvements in clinical care and the management of the disease.
	Nevertheless, persisting geographic differences do point to the potential
	for a further reduction in the burden of cancer throughout Europe,
	towards which improvements in diverse areas of care, including secondary
	prevention, access to advances in treatment as well as subspecialisation
	and regionalisation of oncologic care may all contribute.},
  file        = {Gondos2008.pdf:Gondos2008.pdf:PDF;Gondos2008.pdf:pdf\\Gondos2008.pdf:PDF},
  institution = {Division of Clinical Epidemiology and Ageing Research, German Cancer Research Center, Bergheimer Strasse 20, 69115 Heidelberg, Germany. a.gondos@dkfz.de},
  journal     = {European Journal of Cancer},
  month       = {Jul},
  owner       = {pl4},
  pii         = {S0959-8049(08)00244-X},
  pmid        = {18455387},
  timestamp   = {2008.12.02},
  year        = {2008},
}

@Article{Gondos2009,
  author      = {Gondos, Adam and Holleczek, Bernd and Janssen-Heijnen, Maryska and Brewster, David H. and Bray, Freddie and Rosso, Stefano and Hakulinen, Timo and Brenner, Hermann and , {E. U. N. I. C. E Survival Working Group}},
  title       = {Model-based projections for deriving up-to-date cancer survival estimates: an international evaluation.},
  doi         = {10.1002/ijc.24614},
  language    = {eng},
  number      = {11},
  pages       = {2666--2672},
  url         = {http://dx.doi.org/10.1002/ijc.24614},
  volume      = {125},
  abstract    = {Model-based projections were shown to be useful for deriving most
	up-to-date population-based cancer survival estimates. However, the
	performance of these projections, which can be derived by various
	approaches, has only been evaluated in very few cancer patient populations.
	Using incidence and follow-up data for 22 common cancers from 9 long-standing
	population-based cancer registries from diverse parts of Europe,
	we compared the performance of model-based period and cohort analysis
	for predicting 5-year relative survival of patients diagnosed in
	1996-2000 against standard survival analysis approaches (cohort,
	complete and period analysis). Overall, model-based predictions provided
	a best estimate of the later observed actual survival in 135 of 198
	occasions, compared to 25, 18 and 33 occasions for cohort, complete
	and period analysis, respectively. Projections based on cohort and
	period type modeling performed essentially equally well on average,
	and their performance was better for more common cancers, in registries
	with larger population bases, and for cancers subjected to continuous
	clinical progress and/or ongoing screening efforts. Projections from
	model-based analysis may contribute to improved timeliness of monitoring
	of concurrent trends in population-based cancer survival in cancer
	registries operating in different populations and socioeconomic environments.},
  institution = {Division of Clinical Epidemiology and Ageing Research, German Cancer Research Center, Heidelberg, Germany. a.gondos@dkfz.de},
  journal     = {Int J Cancer},
  keywords    = {Cohort Studies; Europe, epidemiology; Humans; International Agencies; Models, Statistical; Neoplasms, mortality; Prognosis; Registries; Risk Factors; Survival Rate; Time Factors},
  medline-pst = {ppublish},
  month       = {Dec},
  owner       = {sanelo},
  pmid        = {19672858},
  timestamp   = {2013.08.01},
  year        = {2009},
}

@Article{Gooley1999,
  author      = {Gooley, T. A. and Leisenring, W. and Crowley, J. and Storer, B. E.},
  title       = {Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.},
  language    = {eng},
  number      = {6},
  pages       = {695--706},
  volume      = {18},
  abstract    = {A topic that has received attention in both the statistical and medical
	literature is the estimation of the probability of failure for endpoints
	that are subject to competing risks. Despite this, it is not uncommon
	to see the complement of the Kaplan-Meier estimate used in this setting
	and interpreted as the probability of failure. If one desires an
	estimate that can be interpreted in this way, however, the cumulative
	incidence estimate is the appropriate tool to use in such situations.
	We believe the more commonly seen representations of the Kaplan-Meier
	estimate and the cumulative incidence estimate do not lend themselves
	to easy explanation and understanding of this interpretation. We
	present, therefore, a representation of each estimate in a manner
	not ordinarily seen, each representation utilizing the concept of
	censored observations being 'redistributed to the right.' We feel
	these allow a more intuitive understanding of each estimate and therefore
	an appreciation of why the Kaplan-Meier method is inappropriate for
	estimation purposes in the presence of competing risks, while the
	cumulative incidence estimate is appropriate.},
  file        = {Gooley1999.pdf:Gooley1999.pdf:PDF;Gooley1999.pdf:pdf\\Gooley1999.pdf:PDF},
  institution = {Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA 98109-1024, USA. tgooley@fhcrc.org},
  journal     = {Stat Med},
  keywords    = {Confounding Factors (Epidemiology); Humans; Probability; Risk Adjustment, methods; Statistics, Nonparametric},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {PaulD},
  pii         = {3.0.CO;2-O},
  pmid        = {10204198},
  timestamp   = {2015.03.24},
  year        = {1999},
}

@Article{Gordon1992,
  author    = {Gordon, N. H. and Crowe, J. P. and Brumberg, D. J. and Berger, N. A.},
  title     = {Socioeconomic Factors and Race in Breast Cancer Recurrence and Survival},
  pages     = {609-618},
  volume    = {135},
  journal   = {American Journal of Epidemiology},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1992},
}

@Book{Gore1993,
  author    = {Gore, A. and Ratcliffe, M.},
  title     = {{PowerBook}: The Digital Nomads Guide},
  publisher = {Random House Electronic Publishing},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1993},
}

@Book{Gould2010,
  author    = {Gould, W. Pitblado, J. and Poi, B.},
  title     = {Maximum Likelihood Estimation with Stata},
  edition   = {Fourth},
  publisher = {Stata Press},
  owner     = {hanbow},
  timestamp = {2015.07.03},
  year      = {2010},
}

@Article{Gouskova2014,
  author    = {Gouskova, N.A. and Kundu, S. and Imrey, P.B. and Fine, J.P.},
  title     = {Number needed to treat for time-to-event data with competing risks},
  pages     = {181-192},
  volume    = {33},
  file      = {Gouskova2014.pdf:Gouskova2014.pdf:PDF},
  journal   = {Statistics in Medicine},
  owner     = {pl4},
  timestamp = {2016.09.26},
  year      = {2014},
}

@Article{Graffeo2012,
  author    = {Graffeo, N. and Jooste, V. and Giorgi, R.},
  title     = {The impact of additional life-table variables on excess mortality},
  pages     = {4219-30},
  volume    = {31},
  journal   = {Statistics in Medicine},
  owner     = {hanbow},
  timestamp = {2016.08.23},
  year      = {2012},
}

@Article{GramThern94,
  author    = {P. M. Grambsch and T. M. Therneau},
  title     = {Proportional hazards tests and diagnostics based on weighted residuals},
  pages     = {515--526},
  volume    = {81},
  file      = {GramThern94.pdf:pdf\\GramThern94.pdf:PDF;GramThern94.pdf:GramThern94.pdf:PDF},
  journal   = {Biometrika},
  timestamp = {2005.11.01},
  year      = {1994},
}

@Article{Gran2015,
  author      = {Gran, Jon Michael and Lie, Stein Atle and {{\~{A}}}{\textasciitilde}yeflaten, Irene and Borgan, {{\~{A}}}{\textasciitilde}rnulf and Aalen, Odd O},
  title       = {Causal inference in multi-state models-sickness absence and work for 1145 participants after work rehabilitation.},
  doi         = {10.1186/s12889-015-2408-8},
  language    = {eng},
  pages       = {1082},
  url         = {http://dx.doi.org/10.1186/s12889-015-2408-8},
  volume      = {15},
  abstract    = {Multi-state models, as an extension of traditional models in survival
	analysis, have proved to be a flexible framework for analysing the
	transitions between various states of sickness absence and work over
	time. In this paper we study a cohort of work rehabilitation participants
	and analyse their subsequent sickness absence using Norwegian registry
	data on sickness benefits. Our aim is to study how detailed individual
	covariate information from questionnaires explain differences in
	sickness absence and work, and to use methods from causal inference
	to assess the effect of interventions to reduce sickness absence.
	Examples of the latter are to evaluate the use of partial versus
	full time sick leave and to estimate the effect of a cooperation
	agreement on a more inclusive working life.Covariate adjusted transition
	intensities are estimated using Cox proportional hazards and Aalen
	additive hazards models, while the effect of interventions are assessed
	using methods of inverse probability weighting and G-computation.Results
	from covariate adjusted analyses show great differences in sickness
	absence and work for patients with assumed high risk and low risk
	covariate characteristics, for example based on age, type of work,
	income, health score and type of diagnosis. Causal analyses show
	small effects of partial versus full time sick leave and a positive
	effect of having a cooperation agreement, with about 5 percent points
	higher probability of returning to work.Detailed covariate information
	is important for explaining transitions between different states
	of sickness absence and work, also for patient specific cohorts.
	Methods for causal inference can provide the needed tools for going
	from covariate specific estimates to population average effects in
	multi-state models, and identify causal parameters with a straightforward
	interpretation based on interventions.},
  file        = {Gran2015.pdf:pdf\\Gran2015.pdf:PDF},
  institution = {Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway. o.o.aalen@medisin.uio.no.},
  journal     = {BMC Public Health},
  keywords    = {Absenteeism; Adult; Employment, statistics /&/ numerical data; Female; Humans; Male; Middle Aged; Models, Biological; Occupational Medicine; Registries; Rehabilitation; Return to Work, statistics /&/ numerical data; Risk Factors; Sick Leave, statistics /&/ numerical data; Survival Analysis; Work},
  medline-pst = {epublish},
  pii         = {10.1186/s12889-015-2408-8},
  pmc         = {PMC4619267},
  pmid        = {26498223},
  year        = {2015},
}

@Article{Graubard2002,
  author    = {Graubard, B.I. and Korn, E.L.},
  title     = {Inference for superpopulation parameters using sample surveys},
  number    = {1},
  pages     = {73--96},
  url       = {http://projecteuclid.org/euclid.ss/1023798999},
  volume    = {17},
  file      = {Graubard2002.pdf:Graubard2002.pdf:PDF;Graubard2002.pdf:pdf\\Graubard2002.pdf:PDF},
  groups    = {Superpopulation},
  journal   = {Statistical Science},
  owner     = {PaulD},
  publisher = {Institute of Mathematical Statistics},
  timestamp = {2013.01.24},
  year      = {2002},
}

@Article{Gray1988,
  author    = {R.J. Gray},
  title     = {A class of K-sample tests for comparing the cumulative incidence of a competing risk},
  pages     = {1141-1154},
  volume    = {16},
  file      = {Gray1988.pdf:pdf\\Gray1988.pdf:PDF;Gray1988.pdf:Gray1988.pdf:PDF},
  journal   = {The Annals of Statistics},
  owner     = {pl4},
  timestamp = {2013.08.08},
  year      = {1988},
}

@Article{Greenland1995,
  author    = {S. Greenland},
  title     = {Avoiding power loss associated with categorization and ordinal scores in dose-response and trend analysis},
  number    = {4},
  pages     = {450-4},
  volume    = {6},
  journal   = {Epidemiology},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@Article{Greenland1995a,
  author    = {S. Greenland},
  title     = {Dose-response and trend analysis in epidemiology: alternatives to categorical analysis},
  number    = {4},
  pages     = {356-65},
  volume    = {6},
  journal   = {Epidemiology},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@Article{Greenland1995c,
  author    = {S Greenland and WD Finkle},
  title     = {A critical look at methods for handling missing covariates in epidemiologic regression analyses.},
  number    = {12},
  pages     = {1255-64},
  volume    = {142},
  abstract  = {Epidemiologic studies often encounter missing covariate values. While
	simple methods such as stratification on missing-data status, conditional-mean
	imputation, and complete-subject analysis are commonly employed for
	handling this problem, several studies have shown that these methods
	can be biased under reasonable circumstances. The authors review
	these results in the context of logistic regression and present simulation
	experiments showing the limitations of the methods. The method based
	on missing-data indicators can exhibit severe bias even when the
	data are missing completely at random, and regression (conditional-mean)
	imputation can be inordinately sensitive to model misspecification.
	Even complete-subject analysis can outperform these methods. More
	sophisticated methods, such as maximum likelihood, multiple imputation,
	and weighted estimating equations, have been given extensive attention
	in the statistics literature. While these methods are superior to
	simple methods, they are not commonly used in epidemiology, no doubt
	due to their complexity and the lack of packaged software to apply
	these methods. The authors contrast the results of multiple imputation
	to simple methods in the analysis of a case-control study of endometrial
	cancer, and they find a meaningful difference in results for age
	at menarche. In general, the authors recommend that epidemiologists
	avoid using the missing-indicator method and use more sophisticated
	methods whenever a large proportion of data are missing.},
  journal   = {Am J Epidemiol},
  month     = {Dec},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@Article{Greenland1999,
  author    = {S. Greenland and K. B. Michels and J. M. Robins and C. Poole and W. C. Willett},
  title     = {Presenting statistical uncertainty in trends and dose-response relations},
  number    = {12},
  pages     = {1077-86},
  volume    = {149},
  journal   = {American Journal of Epidemiology},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1999},
}

@Article{Greenland1995b,
  author    = {S. Greenland and C. Poole},
  title     = {Interpretation and analysis of differential exposure variability and zero-exposure categories for continuous exposures},
  pages     = {326-328},
  volume    = {6},
  journal   = {Epidemiology},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@Article{Greenwald1996,
  author    = {Greenwald, H. P. and Borgatta, E. F. and McCorkle, R. and Polissar, N. L.},
  title     = {Explaining Reduced Cancer Survival Among the Disadvantaged},
  pages     = {215-238},
  volume    = {74},
  journal   = {Milbank Quarterly},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1996},
}

@Article{Greenwald1994,
  author    = {Greenwald, H. P. and Polissar, N. L. and Borgatta, E. F. and McCorkle, R.},
  title     = {Detecting Survival Effects of Socioeconomic Status: Problems in the Use of Aggregate Measures},
  pages     = {903-909},
  volume    = {47},
  journal   = {Journal of Clinical Epidemiology},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1994},
}

@Book{Greenwood1926,
  author    = {Greenwood, M.},
  title     = {The Errors of Sampling of the Survivorship Table},
  publisher = {London: Her Majesty's Stationery Office},
  series    = {Reports on Public Health and Medical Subjects},
  volume    = {33},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1926},
}

@Manual{Scotland1996,
  author       = {Clinical Outcomes Working Group},
  title        = {Clinical Outcome Indicators: Section B, Cancer Survival by Health Board},
  organization = {Information and Statistics Division, National Health Service in {S}cotland},
  owner        = {PaulD},
  timestamp    = {2011.06.19},
  year         = {1996},
}

@Article{Grunfeld2002,
  author      = {E. A. Grunfeld and A. J. Ramirez and M. S. Hunter and M. A. Richards},
  title       = {Women's knowledge and beliefs regarding breast cancer.},
  doi         = {10.1038/sj.bjc.6600260},
  number      = {9},
  pages       = {1373--1378},
  url         = {http://dx.doi.org/10.1038/sj.bjc.6600260},
  volume      = {86},
  abstract    = {Approximately 20-30\% of women delay for 12 weeks or more from self-discovery
	of a breast symptom to presentation to a health care provider, and
	such delay intervals are associated with poorer survival. Understanding
	the factors that influence patient delay is important for the development
	of an effective, targeted health intervention programme to shorten
	patient delay. The aim of the study was to elicit knowledge and beliefs
	about breast cancer among a sample of the general female population,
	and examine age and socio-economic variations in responses. Participants
	were randomly selected through the Postal Address File, and data
	were collected through the Office of National Statistics. Geographically
	distributed throughout the UK, 996 women participated in a short
	structured interview to elicit their knowledge of breast cancer risk,
	breast cancer symptoms, and their perceptions of the management and
	outcomes associated with breast cancer. Women had limited knowledge
	of their relative risk of developing breast cancer, of associated
	risk factors and of the diversity of potential breast cancer-related
	symptoms. Older women were particularly poor at identifying symptoms
	of breast cancer, risk factors associated with breast cancer and
	their personal risk of developing the disease. Poorer knowledge of
	symptoms and risks among older women may help to explain the strong
	association between older age and delay in help-seeking. If these
	findings are confirmed they suggest that any intervention programme
	should target older women in particular, given that advancing age
	is a risk factor for both developing breast cancer and for subsequent
	delayed presentation.},
  file        = {Grunfeld2002.pdf:Grunfeld2002.pdf:PDF;Grunfeld2002.pdf:pdf\\Grunfeld2002.pdf:PDF},
  institution = {Psychology Unit, Guy's, King's and St Thomas' Medical School, Guy's Campus, London SE1 9RT, UK. beth.grunfeld@kcl.ac.uk},
  journal     = {British Journal of Cancer},
  month       = {May},
  owner       = {pl4},
  pmid        = {11986766},
  timestamp   = {2010.03.23},
  year        = {2002},
}

@Article{Grynberg1996,
  author      = {Grynberg, A. and Ziegler, D. and Rupp, H.},
  title       = {Sympathoadrenergic overactivity and lipid metabolism.},
  language    = {eng},
  pages       = {223--230},
  volume      = {10 Suppl 1},
  abstract    = {Epidemiological studies have identified high heart rates as a risk
	factor for coronary heart disease mortality, and heart rate was found
	to correlate with the severity of coronary atherosclerosis. Heart
	rate was positively correlated with serum concentrations of total
	cholesterol, triglycerides, and non-HDL cholesterol. Since heart
	rate responds sensitively to sympathoadrenergic activity, it was
	hypothesized that catecholamines play a crucial role in the unfavorable
	lipid alterations. In addition to influences on circulating lipids,
	the question arose whether catecholamines have more specific effects
	on molecular species of structural lipids. Of particular importance
	is the question of the involvement of catecholamines in the recently
	suggested correlation between arachidonic acid and stroke mortality.
	It is therefore attempted to delineate the possible effects of catecholamines
	on the fatty acid composition of the phospholipids of heart muscle
	and vasculature. This was achieved in rats by either catecholamine
	injection or by swimming, a condition known to be associated with
	marked sympatho-adrenergic stimulation. In swimming rats, linoleic
	acid was decreased by up to 40\% in heart phospholipids, whereas
	stearic acid and arachidonic acid were increased. Similarly, chronic
	norepinephrine treatment in rats resulted in a net decrease in linoleic
	acid and an increase in arachidonic acid and docosahexaenoic acid,
	which was particularly pronounced when rats were fed an n-3 polyunsaturated
	fatty acid (PUFA)-rich oil diet. Thus, catecholamines do affect the
	PUFA composition of heart membranes, mainly through an increase in
	arachidonic acid content. To further define the action of catecholamines
	on structural lipids, isolated rat ventricular myocytes in culture
	were subjected four times to 30 minutes of isoproterenol (10(-6)
	M) stimulation over 48 hours. No changes in membrane lipid parameters
	were observed, although the beating rate was increased by 30\% during
	the stimulation. When the cell membranes were enriched in n-3 PUFAs
	(in association with a decrease in arachidonic acid), the positive
	chronotropic effect elicited by isoproterenol was raised to + 50\%,
	indicating the modulation of adrenergic function by membrane PUFAs.
	However, isoproterenol treatment again had no effect on the phospholipid
	fatty acid composition. Thus, the effect of catecholamines on membrane
	lipids observed in intact organism appears to be indirect and to
	involve most probably organs such as the liver and adipose tissue.
	Catecholamines are expected to induce a lipolysis-linked quantitative
	and qualitative alteration in circulating fatty acids, which in turn
	alter the heart membrane composition, similar to the composition
	changes elicited by diet lipid alterations. Since there is increasing
	evidence that such fatty acid changes affect the activity of membrane
	proteins, the possibility emerges that this mechanism may contribute
	to the catecholamine-linked cardiovascular mortality.},
  institution = {INRA, Unit{\AA}Â§ÃƒÂƒÃ‚Â…ÃƒÂ‚Ã‚Â¸ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¤e Nutrition Lipidique, Dijon, France.},
  journal     = {Cardiovasc Drugs Ther},
  keywords    = {Animals; Catecholamines, metabolism/pharmacology; Cell Membrane, metabolism; Cells, Cultured; Culture Media; Fatty Acids, metabolism/pharmacology; Heart Ventricles, cytology/ultrastructure; Heart, drug effects/innervation; Membrane Lipids, metabolism; Myocardium, metabolism/ultrastructure; Rats; Receptors, Adrenergic, physiology; Sympathetic Nervous System, physiology},
  medline-pst = {ppublish},
  month       = {Jun},
  owner       = {pl4},
  pmid        = {8827944},
  timestamp   = {2013.05.29},
  year        = {1996},
}

@Article{Grytli2014,
  author      = {Grytli, Helene Hartvedt and Fagerland, Morten Wang and Foss{\aa}, Sophie D. and Task{\'{e}}n, Kristin Austlid},
  title       = {Association between use of $\beta$-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.},
  doi         = {10.1016/j.eururo.2013.01.007},
  language    = {eng},
  number      = {3},
  pages       = {635--641},
  url         = {http://dx.doi.org/10.1016/j.eururo.2013.01.007},
  volume      = {65},
  abstract    = {We recently reported reduced prostate cancer (PCa)-specific mortality
	for beta-blocker users among patients receiving androgen-deprivation
	therapy in a health survey cohort including 655 PCa patients. Information
	on clinical characteristics was limited.To assess the association
	between beta-blockers and PCa-specific mortality in a cohort of 3561
	prostate cancer patients with high-risk or metastatic disease, and
	to address potential confounding from the use of statins or acetylsalicylic
	acid (ASA).Clinical information from all men reported to the Cancer
	Registry of Norway with a PCa diagnosis between 2004 and 2009 (n=24
	571) was coupled with information on filled prescriptions between
	2004 and 2011 from the Norwegian Prescription Database. Exclusion
	criteria were low- or intermediate-risk disease; planned radiotherapy
	or radical prostatectomy; initiation of beta-blocker, ASA, or statin
	use after diagnosis where applicable; missing information on baseline
	Gleason score, prostate-specific antigen level, T stage or performance
	status; and missing follow-up.Cox proportional hazards modelling
	and competing risk regression modelling were used to analyse the
	effects of beta-blocker use on all-cause and PCa-specific mortality,
	respectively. Differences between beta-blocker users and nonusers
	regarding baseline clinical characteristics were assessed by the
	Wilcoxon-Mann-Whitney U test, Pearson chi-square test, and Student
	t test.Median follow-up was 39 mo. beta-blocker use was associated
	with reduced PCa mortality (adjusted subhazard ratio: 0.79; 95\%
	confidence interval [CI], 0.68-0.91; p value: 0.001). The observed
	reduction in PCa mortality was independent of the use of statins
	or ASA. We observed no association with all-cause mortality (adjusted
	hazard ratio: 0.92; 95\% CI, 0.83-1.02). The main limitations of
	the study were the observational study design and short follow-up.beta-blocker
	use was associated with reduced PCa-specific mortality in patients
	with high-risk or metastatic disease at the time of diagnosis. Our
	findings need validation from further observational studies.},
  file        = {Grytli2014.pdf:Grytli2014.pdf:PDF;Grytli2014.pdf:pdf\\Grytli2014.pdf:PDF},
  institution = {Department of Tumor Biology, Institute of Cancer Research, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Electronic address: k.a.tasken@medisin.uio.no.},
  journal     = {Eur Urol},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {PaulD},
  pii         = {S0302-2838(13)00010-9},
  pmid        = {23351721},
  timestamp   = {2014.06.17},
  year        = {2014},
}

@Book{Gu2013,
  author    = {Gu, C.},
  title     = {Smoothing Spline ANOVA Models},
  edition   = {2nd},
  publisher = {Springer},
  owner     = {hanbow},
  timestamp = {2015.05.11},
  year      = {2013},
}

@Article{Gu2004,
  author    = {Gu, C.},
  title     = {Model diagnostics for smoothing spline ANOVA models},
  doi       = {10.2307/3316020},
  issn      = {{0319-5724}},
  number    = {4},
  pages     = {347-358},
  volume    = {32},
  file      = {Gu2004.pdf:Gu2004.pdf:PDF;Gu2004.pdf:pdf\\Gu2004.pdf:PDF},
  journal   = {Canadian Journal of Statistics- Revue Canadienne de Statistique},
  month     = {DEC},
  owner     = {hanbow},
  timestamp = {2015.01.20},
  unique-id = {{ISI:000226504300002}},
  year      = {2004},
}

@Article{Gueyffier1995,
  author      = {F. Gueyffier and F. Boutitie and J. P. Boissel and J. Coope and J. Cutler and T. Ekbom and R. Fagard and L. Friedman and H. M. Perry and S. Pocock},
  title       = {INDANA: a meta-analysis on individual patient data in hypertension. Protocol and preliminary results.},
  number      = {4},
  pages       = {353--362},
  volume      = {50},
  abstract    = {The overall effect of antihypertensive drug treatment has been well
	documented. The proportion of patients who benefit varies according
	to their baseline cardiovascular risk, and is small for the majority
	of people treated. Some investigators propose limiting the treatment
	target population to patients at high cardiovascular risk, but several
	assumptions must be made to justify this procedure. The INDANA project
	is a meta-analysis based on individual patient data, and thus offers
	the opportunity to check the validity of these assumptions. Its main
	objective is to identify responders (and non-responders) in the drug
	treatment of hypertension. The rationale and methods for such an
	approach are presented here, with the solution for some technical
	problems. The conclusion of the data collection has shown that the
	project is feasible. The results of the main analysis should be available
	in 1996, and should contribute to the selection of responders and
	to the individualization of the treatment of hypertension.},
  institution = {Service de Pharmacologie Clinique, Lyon, France.},
  journal     = {Therapie},
  owner       = {pl4},
  pmid        = {7482389},
  timestamp   = {2008.11.18},
  year        = {1995},
}

@Article{Gupta1976,
  author      = {Gupta, R. B.},
  title       = {A hypothetical study of populations under constant mortality and fertility.},
  language    = {eng},
  number      = {1},
  pages       = {62--81},
  volume      = {18},
  abstract    = {28 countries with different characteristics have been selected in
	order to observe the amount of time it takes for these different
	countries to reach stable age distributions. The individual populations
	by sex and age were projected for 150 years in 5-year intervals with
	the present constant mortality and fertility schedules by component
	method. Observations have been made by considering the following
	characteristics of population when it has acquired stability: age
	distribution; the rate of growth, birthrate, and mortality rate;
	the population change; the intrinsic rate of growth, birthrate and
	mortality rate; and approximate time taken to stabilize the population.
	The initial age distribution has a significant part in the amount
	of time it takes for a population to acquire stability, and its intrinsic
	rate of growth is mostly dependent upon the existing age distribution
	of that population. The time taken for a country's population to
	become stable depends upon the age distribution, fertility and mortality
	schedules at the beginning. It has been observed that countries having
	a higher intrinsic rate of growth take comparatively less time in
	acquiring stability than the countries having a lower intrinsic rate
	of growth. The mortality and fertility schedules of a country is
	another important phenomenon. The populations of the different countries
	at the point of stability were growing according to their rates of
	growth. No specific trend of population growth could be found among
	the groups of countries. Time taken for stabilizing the population
	is completely based upon age distributions, fertility and mortality
	schedules a particular country was having at the beginning. The range
	of time taken for different countries to acquire stability generally
	ranged from 100 to 135 years. Among the different countries the relationship
	for the time it takes to acquire stability has not been established.
	This is a hypothetical approach in order to obtain some idea as to
	how a population with different characteristics acts in the long
	run when some of its characteristics are assumed to be constant.},
  journal     = {Artha Vijnana},
  keywords    = {Africa; Age Factors; Asia; Asia, Southeastern; Asia, Western; Australia; Austria; Birth Rate; Bulgaria; Central America; Chile; Costa Rica; Demography; Europe; Europe, Eastern; Far East; Fertility; France; Germany, East; Germany, West; Great Britain; Greece; Hungary; India; Indonesia; Israel; Japan; Korea; Latin America; Luxembourg; Models, Theoretical; Mortality; Pacific Islands; Pakistan; Philippines; Population; Population Characteristics; Population Dynamics; Population Growth; Research; Romania; Singapore; South Africa; South America; Sri Lanka; Statistics as Topic; Switzerland; Taiwan},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {pl4},
  pmid        = {12277045},
  timestamp   = {2013.05.29},
  year        = {1976},
}

@Article{Gutierrez2002,
  author    = {R. G. Gutierrez},
  title     = {Parametric frailty and shared frailty survival models},
  pages     = {22-44},
  volume    = {2},
  file      = {Gutierrez2002.pdf:Gutierrez2002.pdf:PDF;Gutierrez2002.pdf:pdf\\Gutierrez2002.pdf:PDF},
  journal   = {The Stata Journal},
  owner     = {pl4},
  timestamp = {2010.07.14},
  year      = {2002},
}

@Manual{Hedelin1997,
  author       = {H{\'e}delin, G.},
  title        = {{RELSURV 2.0} a program for relative survival analysis},
  organization = {Department of Epidemiology and Public Health, Faculty of Medicine, Louis Pasteur University, Strasbourg, France},
  owner        = {PaulD},
  timestamp    = {2011.06.19},
  year         = {1997},
}

@Article{Haemaelaeinen2007,
  author      = {P\"{a}ivi H\"{a}m\"{a}l\"{a}inen and Jukka Takala and Kaija Leena Saarela},
  title       = {Global estimates of fatal work-related diseases.},
  doi         = {10.1002/ajim.20411},
  number      = {1},
  pages       = {28--41},
  url         = {http://dx.doi.org/10.1002/ajim.20411},
  volume      = {50},
  abstract    = {Work-related mortality is a relatively new concept which aims to widen
	occupational health and safety; to take into account not only recognized
	fatal occupational accidents and diseases but also other work-related
	deaths. Few countries in the world have a register for work-related
	diseases.Estimates are calculated using baseline world mortality
	scenarios of all diseases for the year 2000 and attributable fractions
	made for work-related diseases in Finland, as adjusted.It is estimated
	that about 2 million work-related deaths take place annually. Men
	suffer two thirds of those deaths. The biggest groups of work-related
	diseases are cancers, circulatory diseases and communicable diseases.Information
	about work-related diseases is needed for prevention, as people in
	developed countries are working longer, and the age of retirement
	is being raised in many countries. As a result, workers are being
	exposed to different kinds of substances and working conditions for
	a longer time. In developing countries, work exposures may already
	start in infancy. Due to industrialization, workers in developing
	countries are facing new conditions with a lack of relevant knowledge
	and skills. With the help of information, nations can direct resources
	and skills for appropriate purposes such as regulatory measures on
	health and safety at work.},
  institution = {Tampere University of Technology, Institute of Occupational Safety Engineering, Tampere, Finland.},
  journal     = {Am J Ind Med},
  month       = {Jan},
  owner       = {pl4},
  pmid        = {17154410},
  timestamp   = {2011.05.26},
  year        = {2007},
}

@Article{Haberman1990,
  author    = {Haberman, S. and Renshaw, A. E.},
  title     = {Generalised Linear Models and Excess Mortality from Peptic Ulcers},
  pages     = {21-32},
  volume    = {9},
  journal   = {Insurance: Mathematics and Economics},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1990},
}

@Article{Hagel2009,
  author      = {Hagel, E. and Garmo, H. and Bill-Axelson, A. and Bratt, O. and Johansson, J.-E. and Adolfsson, J. and Lambe, M. and Stattin, P.},
  title       = {{PCBaSe} {S}weden: a register-based resource for prostate cancer research.},
  doi         = {10.3109/00365590903024577},
  language    = {eng},
  number      = {5},
  pages       = {342--349},
  url         = {http://dx.doi.org/10.3109/00365590903024577},
  volume      = {43},
  abstract    = {Objective. To construct a database for clinical epidemiological prostate
	cancer research based on linkages between the National Prostate Cancer
	Register (NPCR) of Sweden, a population-based, nationwide quality
	database, and other nationwide registries. Material and methods.
	By use of the individually unique Swedish Personal Identity Number,
	the NPCR was linked to the Swedish Cancer Registry, the Cause of
	Death Register, the Prescribed Drug Register, the National Patient
	Register and the Acute Myocardial Infarction Register, all held at
	the Centre for Epidemiology at the National Board of Health and Welfare,
	and the Register of the Total Population, the Longitudinal Integration
	Database for Health Insurance and Labor Market Studies and the Multi-Generation
	Register, held at Statistics Sweden, and to the Swedish Hernia Register.
	Results. Record linkages between the NPCR and the Swedish Cancer
	Registry, the Cause of Death Register and the Register of the Total
	Population generated a database, named PCBaSe Sweden, including 80
	079 prostate cancer cases, diagnosed between 1 January 1996 and 31
	December 2006. Record linkage between PCBaSe Sweden and the Prescribed
	Drug Register generated 59 721 unique matches and linkage to the
	Acute Myocardial Infarction Register resulted in 11 459 matches.
	Conclusion. PCBaSe Sweden is a newly created and unique database
	with over 80 000 cases of prostate cancer with comprehensive data
	on inpatient and outpatient care, patterns of use of prescribed drugs
	and socioeconomic and familial factors. Many topics in clinical prostate
	cancer epidemiology can be investigated. using PCBaSe Sweden.},
  institution = {Department of Surgical and Perioperative Sciences, Urology and Andrology, Ume{\aa} University, Ume{\aa}, Sweden.},
  journal     = {Scand J Urol Nephrol},
  medline-pst = {ppublish},
  owner       = {pl4},
  pii         = {10.3109/00365590903024577},
  pmid        = {19921977},
  timestamp   = {2012.04.13},
  year        = {2009},
}

@Book{Haight1967,
  author    = {Haight, F. A.},
  title     = {Handbook of the {P}oisson Distribution - Publications in Operations Research},
  publisher = {New York: John Wiley},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1967},
}

@InCollection{Hakama1991,
  author    = {Hakama, M.},
  booktitle = {Cancer screening : a report of the workshop to update conclusions on screening for cancer of sites previously considered and to evaluate some new sites, held at {S}elwyn {C}ollege, {C}ambridge, {UK}, {A}pril 2-5, 1990},
  title     = {Screening for Breast Cancer in Finland},
  editor    = {Miller, A. B.},
  pages     = {18-22},
  publisher = {New York : Cambridge University Press [on behalf of the International Union against Cancer]},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1991},
}

@Article{Hakama1993,
  author    = {Hakama, M.},
  title     = {Potential Contribution of Screening to Cancer Mortality Reduction},
  pages     = {513-520},
  volume    = {17},
  journal   = {Cancer Detection \& Prevention},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1993},
}

@Article{Hakama1977,
  author    = {M. Hakama and T. Hakulinen},
  title     = {Estimating the expectation of life in cancer survival studies with incomplete follow-up information.},
  number    = {9},
  pages     = {585--597},
  volume    = {30},
  file      = {Hakama1977.pdf:Hakama1977.pdf:PDF;Hakama1977.pdf:pdf\\Hakama1977.pdf:PDF},
  journal   = {Journal of Chronic Diseases},
  month     = {Sep},
  owner     = {pl4},
  pmid      = {903390},
  timestamp = {2008.12.16},
  year      = {1977},
}

@Article{Hakama1997,
  author    = {Hakama, M. and Hristova, L.},
  title     = {Effect of screening in the {N}ordic cancer control up to the year 2017},
  pages     = {119-128},
  volume    = {36},
  journal   = {Acta Oncologica},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1997},
}

@Article{Hakama1975,
  author    = {Hakama, M. and Joutsenlahti, U. and Virtanen, A. and R{\"a}s{\"a}nen-Virtanen, U.},
  title     = {Mass Screening for Cervical Cancer in {F}inland 1963--71},
  pages     = {101-111},
  volume    = {7},
  journal   = {Annals of Clinical Research},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1975},
}

@Article{Hakama1989,
  author    = {Hakama, M. and Karjalainen, S. and Hakulinen, T.},
  title     = {Outcome-Based Equity in the Treatment of Colon Cancer Patients in {F}inland},
  pages     = {619-630},
  volume    = {5},
  journal   = {International Journal of Technology Assessment in Health Care},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1989},
}

@Unpublished{Hakulinen1988b,
  author    = {Timo Hakulinen},
  title     = {On the National Cancer Statistics Clearing House in {A}ustralia},
  note      = {(Unpublished research report)},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1988},
}

@Article{Hakulinen1986a,
  author    = {Hakulinen, T.},
  title     = {On Competing Risks of Removal},
  pages     = {39-49},
  volume    = {23},
  journal   = {Journal of Social Medicine},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1986},
}

@Article{Hakulinen1983,
  author    = {Hakulinen, T.},
  title     = {A Comparison of Nationwide Cancer Survival Statistics in {F}inland and {N}orway},
  pages     = {35-46},
  volume    = {36},
  journal   = {World Health Statistics Quarterly},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1983},
}

@Article{Hakulinen1982,
  author    = {T. Hakulinen},
  title     = {Cancer survival corrected for heterogeneity in patient withdrawal.},
  number    = {4},
  pages     = {933--942},
  volume    = {38},
  abstract  = {Survival from cancer over a certain time period is often measured
	by the 'relative survival rate'. This is the ratio of the observed
	survival rate in the group of patients to the survival rate expected
	in a group of people in the general population, who are similar to
	the patients with respect to all of the possible factors affecting
	survival at the beginning of the period, except for the disease under
	study. When patterns of patient withdrawal differ for a number of
	subgroups of patients with equal relative survival rates, the current
	method of derivation of the relative survival rate is biased. A method
	based on the concept of an 'expected life table' is proposed for
	removal of the bias. Examples based on material from the Finnish
	Cancer Registry suggest that the practical performance of the proposed
	method is better than that of other alternatives, even when the relative
	survival rates in the subgroups are not equal.},
  file      = {Hakulinen1982.pdf:pdf\\Hakulinen1982.pdf:PDF},
  journal   = {Biometrics},
  month     = {Dec},
  owner     = {pl4},
  pmid      = {7168796},
  timestamp = {2008.12.16},
  year      = {1982},
}

@Article{Hakulinen1977b,
  author    = {Hakulinen, T.},
  title     = {On Competing Risks of Death},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1977},
}

@Article{Hakulinen1977c,
  author    = {Hakulinen, T.},
  title     = {On Long-Term Relative Survival Rates},
  pages     = {431-443},
  volume    = {30},
  journal   = {Journal of Chronic Diseases},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1977},
}

@Article{Hakulinen1985,
  author    = {Hakulinen, T. and Abeywickrama, K.},
  title     = {A Computer Program Package for Relative Survival Analysis},
  pages     = {197-207},
  volume    = {19},
  journal   = {Computer Programs in Biomedicine},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1985},
}

@Book{Hakulinen1988a,
  author    = {Hakulinen, T. and Gibberd, R. and Abeywickrama, K. and S{\"o}derman, B.},
  title     = {A Computer Program Package for Cancer Survival Studies},
  publisher = {Helsinki: Finnish Cancer Registry},
  series    = {Cancer Society of Finland Publication No. 39},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1988},
}

@Article{Hakulinen1981,
  author    = {Hakulinen, T. and Pukkala, E. and Hakama, M. and Lehtonen, M. and Sax{\'e}n, E. and Teppo, L.},
  title     = {Survival of Cancer Patients in {F}inland in 1953--1974},
  pages     = {1-101},
  volume    = {13 (Suppl. 31)},
  journal   = {Annals of Clinical Research},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1981},
}

@Article{Hakulinen1977a,
  author    = {Hakulinen, T. and Rahiala, M.},
  title     = {An example on the risk dependence and additivity of intensities in the theory of competing risks},
  pages     = {557-559},
  volume    = {33},
  file      = {Hakulinen1977a.pdf:Hakulinen1977a.pdf:PDF;Hakulinen1977a.pdf:pdf\\Hakulinen1977a.pdf:PDF},
  journal   = {Biometrics},
  owner     = {pl4},
  timestamp = {2009.02.12},
  year      = {1977},
}

@Article{Hakulinen2011,
  author      = {T. Hakulinen and K. Sepp\"{a} and P. C. Lambert},
  title       = {Choosing the relative survival method for cancer survival estimation.},
  doi         = {10.1016/j.ejca.2011.03.011},
  language    = {eng},
  number      = {14},
  pages       = {2202-2210},
  url         = {http://dx.doi.org/10.1016/j.ejca.2011.03.011},
  volume      = {47},
  abstract    = {BACKGROUND: The methods on how to calculate cumulative relative survival
	have been ambiguous and have given differences in empirical results.
	METHODS: The gold standard for the cumulative relative survival ratio
	is the weighted average of age-specific cumulative relative survival
	ratios, with weights proportional to numbers of patients at diagnosis.
	Mathematics and representative empirical materials from the population-based
	Finnish Cancer Registry were studied for the different relative survival
	methods and compared with the gold standard. RESULTS: The theoretical
	and empirical results show a good agreement between the method suggested
	in 1959 by Ederer and Heise (the so-called Ederer II method) and
	the gold standard. This result is in part due the fact that as follow-up
	time increases the conditional (annual) relative survival ratios
	become increasingly more independent of age. Moreover, the dependence
	between the excess mortality due to cancer and the baseline general
	mortality does not introduce an important enough selection in practice
	to cause a notable bias. CONCLUSION: The use of the method by Ederer
	and Heise, multiplication of the annual relative survival ratios,
	instead of direct standardisation, should be considered in future
	applications. This would be particularly important for the long-term
	follow-up when age-specific relative survival is not available in
	the oldest age categories.},
  file        = {Hakulinen2011.pdf:pdf\\Hakulinen2011.pdf:PDF},
  institution = {Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Pieni Roobertinkatu 9, FI-00130 Helsinki, Finland.},
  journal     = {European Journal of Cancer},
  medline-pst = {aheadofprint},
  owner       = {PaulD},
  pii         = {S0959-8049(11)00173-0},
  pmid        = {21549589},
  timestamp   = {2011.06.09},
  year        = {2011},
}

@Article{Hakulinen1987a,
  author    = {T. Hakulinen and L. Tenkanen},
  title     = {Regression analyses of relative survival rates},
  pages     = {309-317},
  volume    = {36},
  file      = {Hakulinen1987a.pdf:Hakulinen1987a.pdf:PDF;Hakulinen1987a.pdf:pdf\\Hakulinen1987a.pdf:PDF},
  groups    = {Excess mortality model},
  journal   = {Applied Statistics},
  owner     = {pl4},
  timestamp = {2008.10.28},
  year      = {1987},
}

@Article{Hakulinen1987b,
  author    = {Hakulinen, T. and Tenkanen, L. and Abeywickrama, K. and P{\"a}iv{\"a}rinta, L.},
  title     = {Testing Equality of Relative Survival Patterns Based on Aggregated Data},
  pages     = {313-325},
  volume    = {43},
  journal   = {Biometrics},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1987},
}

@Article{Hakulinen1987,
  author    = {T. Hakulinen and L. Tenkanen and K. Abeywickrama and L. Paivarinta},
  title     = {Testing equality of relative survival patterns based on aggregated data},
  pages     = {313-325},
  volume    = {43},
  file      = {Hakulinen1987.pdf:Hakulinen1987.pdf:PDF;Hakulinen1987a.pdf:Hakulinen1987a.pdf:PDF;Hakulinen1987.pdf:pdf\\Hakulinen1987.pdf:PDF},
  journal   = {Biometrics},
  owner     = {pl4},
  timestamp = {2008.10.28},
  year      = {1987},
}

@Article{Hakulinen1986,
  author    = {Hakulinen, T. and Teppo, L. and Sax{\'e}n, E.},
  title     = {Do the Predictions for Cancer Incidence Come True? {E}xperience from {F}inland},
  pages     = {12},
  volume    = {57},
  journal   = {Cancer},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1986},
}

@Article{Halbig2000,
  author      = {Halbig, P. and Hodjati, M. H. and Mazloumi-Gavgani, A. S. and Mohite, H. and Davies, C. R.},
  title       = {Further evidence that deltamethrin-impregnated collars protect domestic dogs from sandfly bites.},
  language    = {eng},
  number      = {2},
  pages       = {223--226},
  volume      = {14},
  abstract    = {In many foci of zoonotic visceral leishmaniasis (ZVL), domestic dogs
	are important reservoir hosts of the causative Leishmania parasites
	transmitted by phlebotomine sandflies (Diptera: Psychodidae). We
	tested the protective value of impregnated dog collars (20 g plastic
	containing deltamethrin 800 mg ai) against Phlebotomus papatasi (Scopoli)
	sandflies in Iran. For each assay, the dog was sedated and caged
	in a net with 70-100 wild-caught sandflies overnight (23.30-06.30
	hours). Dogs wearing the collars were bitten by approximately 80\%
	fewer sandflies than before collars were fitted, i.e. 51\% vs. 11\%
	of hungry female flies exposed. Sandfly mortality rates following
	20 h exposure to dogs with collars (18\%) or without collars (17\%)
	were not significantly different. Effects of collars were tested
	when dogs had been wearing them for 8 days. A previous trial against
	the sandfly P. perniciosus Newstead in France, using smaller dogs,
	showed that effects of such collars were not fully realized until
	they had been worn for 2 weeks or more; they remained effective for
	at least 8 months and killed significant proportions of the sandflies
	exposed. Present results with P. papatasi, confirming that this simple
	device provides effective protection against sandflies, are considered
	sufficiently encouraging to justify a community-wide field trial
	of deltamethrin-impregnated dog collars against ZVL vector sandflies
	in Iran.},
  institution = {Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, UK.},
  journal     = {Med Vet Entomol},
  keywords    = {Administration, Topical; Animals; Bites and Stings, prevention /&/ control/veterinary; Dog Diseases, prevention /&/ control; Dogs; Drug Delivery Systems, veterinary; Ectoparasitic Infestations, prevention /&/ control/veterinary; Female; Insecticides, administration /&/ dosage; Iran; Male; Nitriles; Psychodidae; Pyrethrins, administration /&/ dosage},
  medline-pst = {ppublish},
  month       = {Jun},
  owner       = {pl4},
  pmid        = {10872869},
  timestamp   = {2013.05.29},
  year        = {2000},
}

@Article{Halligan1996,
  author    = {A. Halligan and P. C. Lambert and E. O'Brien and A. Shennan},
  title     = {Characteristics of a reversed circadian blood pressure rhythm in pregnant women with hypertension.},
  number    = {2},
  pages     = {135},
  volume    = {10},
  file      = {halligan1996a.pdf:halligan1996a.pdf:PDF},
  journal   = {J Hum Hypertens},
  month     = {Feb},
  owner     = {pl4},
  pmid      = {8867569},
  timestamp = {2008.10.15},
  year      = {1996},
}

@Article{Halligan1996a,
  author      = {A. Halligan and A. Shennan and P. C. Lambert and M. de Swiet and D. J. Taylor},
  title       = {Diurnal blood pressure difference in the assessment of preeclampsia.},
  doi         = {10.1016/0029-7844(95)00379-7},
  number      = {2},
  pages       = {205--208},
  url         = {http://dx.doi.org/10.1016/0029-7844(95)00379-7},
  volume      = {87},
  abstract    = {OBJECTIVE: To evaluate diurnal variation in blood pressure (BP) in
	normal gravidas and those with preeclampsia, using ambulatory BP
	monitoring. METHODS: A cross-sectional comparative observational
	study was performed in three teaching hospital maternity units. Twenty-four
	normotensive and 24 preeclamptic women who were similar in age, weight,
	and mean duration of gestation (35 weeks) were studied. Diurnal variation
	and BP measurement were assessed using ambulatory BP monitors validated
	for use in pregnancy and for which normal reference ranges for pregnancy
	have been derived. RESULTS: At night, the BP fall was less in preeclamptic
	women than in normotensive women. The day-night BP difference decreased
	as average BP rose (diastolic gradient = -0.54 [95\% confidence interval
	(CI) -0.77 to -0.31], systolic gradient = -0.36 [95\% CI -0.58 to
	-0.14], where gradient denotes a unit increase in BP leading to an
	increase or decrease in the day-night difference). CONCLUSION: The
	decrease in day-night BP difference observed in preeclampsia is inversely
	related to average BP. This blunting of the day-night BP difference
	may be a useful adjunctive measure of disease severity in preeclampsia.},
  file        = {halligan1996a.pdf:halligan1996a.pdf:PDF},
  institution = {Department of Obstetrics and Gynaecology, University of Leicester, United Kingdom.},
  journal     = {Obstet Gynecol},
  month       = {Feb},
  owner       = {pl4},
  pii         = {0029-7844(95)00379-7},
  pmid        = {8559524},
  timestamp   = {2008.10.15},
  year        = {1996},
}

@Article{Halligan1997,
  author      = {A. W. Halligan and A. Shennan and P. C. Lambert and S. C. Bell and D. J. Taylor and M. de Swiet},
  title       = {Automated blood pressure measurement as a predictor of proteinuric pre-eclampsia.},
  number      = {5},
  pages       = {559--562},
  volume      = {104},
  abstract    = {OBJECTIVES: To investigate the relation between antenatal clinic,
	obstetric day unit and 24-hour ambulatory blood pressure measurements
	and 24-hour proteinuria levels in hypertensive pregnancies. DESIGN:
	An observational study. PARTICIPANTS: Forty-eight women presenting
	with new hypertension after 20 weeks of gestation. RESULTS: The closest
	relation was found between ambulatory blood pressure measurements
	and 24-hour proteinuria levels. No significant relation was found
	between the conventional diastolic blood pressure threshold of 90
	mmHg and 24-hour proteinuria levels. CONCLUSIONS: Ambulatory blood
	pressure measurement gives better information about disease status
	in pre-eclampsia as assessed by proteinuria than does conventional
	sphygmomanometry.},
  file        = {Halligan1997.pdf:Halligan1997.pdf:PDF;Halligan1997.pdf:pdf\\Halligan1997.pdf:PDF},
  institution = {University of Leicester, UK.},
  journal     = {Br J Obstet Gynaecol},
  month       = {May},
  owner       = {pl4},
  pmid        = {9166197},
  timestamp   = {2008.10.15},
  year        = {1997},
}

@Article{Hallman2006,
  author      = {Mikko Hallman and Outi Peltoniemi and Timo Saarela},
  title       = {Early neonatal hydrocortisone: study rather than treat.},
  doi         = {10.1542/peds.2006-2250},
  number      = {6},
  pages       = {2540--2542},
  url         = {http://dx.doi.org/10.1542/peds.2006-2250},
  volume      = {118},
  institution = {Department of Pediatrics, University of Oulu, PO Box 5000, University of Oulu, FIN-90014 Oulu, Finland. mikko.hallman@oulu.fi},
  journal     = {Pediatrics},
  month       = {Dec},
  owner       = {pl4},
  pii         = {118/6/2540},
  pmid        = {17142539},
  timestamp   = {2011.05.26},
  year        = {2006},
}

@Article{Halmin2008,
  author    = {Halmin, M. and Bellocco, R. and Lagerlund, M. and Karlsson, P. and Tejler, G. and Lambe, M.},
  title     = {Long-term inequalities in breast cancer survival - a ten year follow-up study of patients managed within a {N}ational {H}ealth {C}are {S}ystem ({S}weden)},
  pages     = {216-224},
  volume    = {47},
  file      = {Halmin2008.pdf:pdf\\Halmin2008.pdf:PDF;Halmin2008.pdf:Halmin2008.pdf:PDF},
  journal   = {Acta Oncologica},
  owner     = {hanbow},
  timestamp = {2016.09.13},
  year      = {2008},
}

@Article{Halpern1991,
  author    = {Halpern, D. F. and Coren, S.},
  title     = {Handedness and life span},
  pages     = {998},
  volume    = {324},
  journal   = {New England Journal of Medicine},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1991},
}

@Article{Hanahan2000,
  author      = {Hanahan, D. and Weinberg, R. A.},
  title       = {The hallmarks of cancer.},
  language    = {eng},
  number      = {1},
  pages       = {57--70},
  volume      = {100},
  institution = {Department of Biochemistry, Hormone Research Institute, University of California at San Francisco, 94143, USA.},
  journal     = {Cell},
  keywords    = {Animals; Apoptosis; Cell Transformation, Neoplastic; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Experimental, blood supply/genetics/pathology; Neoplasms, blood supply/etiology/genetics/pathology; Neovascularization, Pathologic},
  medline-pst = {ppublish},
  month       = {Jan},
  owner       = {sanelo},
  pii         = {S0092-8674(00)81683-9},
  pmid        = {10647931},
  timestamp   = {2013.08.01},
  year        = {2000},
}

@Article{Hankey1999,
  author      = {Hankey, B. F. and Feuer, E. J. and Clegg, L. X. and Hayes, R. B. and Legler, J. M. and Prorok, P. C. and Ries, L. A. and Merrill, R. M. and Kaplan, R. S.},
  title       = {Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.},
  language    = {eng},
  number      = {12},
  pages       = {1017--1024},
  volume      = {91},
  abstract    = {The prostate-specific antigen test was approved by the U.S. Food and
	Drug Administration in 1986 to monitor the disease status in patients
	with prostate cancer and, in 1994, to aid in prostate cancer detection.
	However, after 1986, the test was performed on many men who had not
	been previously diagnosed with prostate cancer, apparently resulting
	in the diagnosis of a substantial number of early tumors. Our purpose
	is to provide insight into the effect of screening on prostate cancer
	rates. Detailed data are presented for whites because the size of
	the population allows for calculating statistically reliable rates;
	however, similar overall trends are seen for African-Americans and
	other races.Prostate cancer incidence data from the National Cancer
	Institute's Surveillance, Epidemiology, and End Results Program and
	mortality data from the National Center for Health Statistics were
	analyzed.The following findings are consistent with a screening effect:
	1) the recent decrease since 1991 in the incidence of distant stage
	disease, after not having been perturbed by screening; 2) the decline
	in the incidence of earlier stage disease beginning the following
	year (i.e., 1992); 3) the recent increases and decreases in prostate
	cancer incidence and mortality by age that appear to indicate a calendar
	period effect; and 4) trends in the incidence of distant stage disease
	by tumor grade and trends in the survival of patients with distant
	stage disease by calendar year that provide suggestive evidence of
	the tendency of screening to detect slower growing tumors.The decline
	in the incidence of distant stage disease holds the promise that
	testing for prostate-specific antigen may lead to a sustained decline
	in prostate cancer mortality. However, population data are complex,
	and it is difficult to confidently attribute relatively small changes
	in mortality to any one cause.},
  institution = {Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD 20892, USA. bh43a@nih.gov},
  journal     = {J Natl Cancer Inst},
  keywords    = {African Americans, statistics /&/ numerical data; Age Distribution; Aged; Aged, 80 and over; European Continental Ancestry Group, statistics /&/ numerical data; Humans; Incidence; Male; Mass Screening, methods; Middle Aged; Mortality, trends; Neoplasm Staging; Population Surveillance; Prostate-Specific Antigen, blood; Prostatic Neoplasms, epidemiology/ethnology/immunology/mortality/pathology; SEER Program; Survival Rate; United States, epidemiology},
  medline-pst = {ppublish},
  month       = {Jun},
  owner       = {sanelo},
  pmid        = {10379964},
  timestamp   = {2013.07.31},
  year        = {1999},
}

@Article{Hannoun1976,
  author      = {Hannoun, C.},
  title       = {[The concept of risk in influenza (author's transl)].},
  language    = {fre},
  number      = {3-4},
  pages       = {241--251},
  volume      = {24},
  abstract    = {The evaluation of morbidity risk is difficult in influenza because
	of a lack of accurate quantitative information and of a high variability
	of the virus. The level of specific herd immunity towards epidemic
	strains is an important factor of prevision. As far as mortality
	is concerned, there is a net and regular increase of risk up from
	the age of 45. In addition to elderly, other high risk categories
	are known such as patients suffering of a number of organic deficiences
	or chronical conditions, pregnant women and children. The best evaluation
	of efficacy of vaccines is the study of incidence reduction in a
	vaccinated group in comparison to unvaccinated controls. Present
	vaccines are really efficient to reduce the risk of getting the disease,
	except in the case of an antigenic shift, which means the activity
	of a new antigenic component. These advantages are to be weighted
	to the small risk of vaccine reactions, which are not frequent and
	usually benign. Several vaccination strategies can be used. In France,
	it has been decided to recommand vaccine to priority groups: people
	over 65 and deficient patients. This policy is eqlivalent in many
	western countries (West Europe, USA); it is not efficient in preventing
	or delaying epidemics.},
  journal     = {Rev Epidemiol Sante Publique},
  keywords    = {Aged; Child; Female; France; Humans; Immunity; Influenza Vaccines, adverse effects; Influenza, Human, epidemiology/immunology; Middle Aged; Orthomyxoviridae; Pregnancy; Risk},
  medline-pst = {ppublish},
  owner       = {pl4},
  pmid        = {1005853},
  timestamp   = {2013.05.29},
  year        = {1976},
}

@Book{Hansen1953,
  author    = {Hansen, M. H. and Hurwitz, W. N. and Madow, W. G.},
  title     = {Sample Survey Methods and Theory},
  pages     = {107},
  publisher = {New York: John Wiley},
  volume    = {2},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1953},
}

@Book{Harrell2001,
  author    = {F. E. Harrell},
  title     = {Regression modeling strategies with application to linear models, logistic regression and survival analysis},
  publisher = {Springer},
  owner     = {pl4},
  timestamp = {2009.08.07},
  year      = {2001},
}

@Article{Harrell1984,
  author    = {Harrell, F. E. and Lee, K. L. and Califf, R. M. and Pryor, D. B. and Rosati, R. A.},
  title     = {Regression Modelling Strategies for Improved Prognostic Prediction},
  pages     = {143-152},
  volume    = {3},
  journal   = {Statistics in Medicine},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1984},
}

@Book{Harris1991,
  author    = {Harris, E. K. and Albert, A.},
  title     = {Survivorship Analysis for Clinical Studies},
  publisher = {New York: Marcel Dekker},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1991},
}

@Article{Harrison2008,
  author      = {Kathleen McDavid Harrison and Qiang Ling and Ruiguang Song and H. Irene Hall},
  title       = {County-level socioeconomic status and survival after {HIV} diagnosis, {United States}.},
  doi         = {10.1016/j.annepidem.2008.09.003},
  language    = {eng},
  number      = {12},
  pages       = {919--927},
  url         = {http://dx.doi.org/10.1016/j.annepidem.2008.09.003},
  volume      = {18},
  abstract    = {PURPOSE: To estimate relative survival (RS) after human immunodeficiency
	virus (HIV) diagnosis, by race/ethnicity and county-level socioeconomic
	status (SES). METHODS: We estimated 5-year RS by age, race/ethnicity,
	transmission category, sex, diagnosis year, CD4 count, and by county-level
	SES variables from the U.S. Census. Data, from the national HIV/AIDS
	Reporting System, were for HIV-infected persons ages > or =13 years
	(diagnosis during 1996-2003 and follow-up through 2005). We calculated
	RS proportions by using a maximum likelihood algorithm and modeled
	the relative risk of excess death (RR) using generalized linear models,
	with poverty as a random effect. RESULTS: For men, RS was worse in
	counties with larger proportions of people living below the 2000
	U.S. poverty level (87.7\% for poverty of > or =20\% vs. 90.1\% for
	poverty of <5.0\%) and where unemployment was greater (87.8\% where
	unemployment > 7.1\% vs. 90.5\% where unemployment < 4.0\%). The
	effects of county-level SES on RS of women were similar. In multilevel
	multivariate models, RR for men and women within 5 years after an
	HIV diagnosis was significantly worse in counties where 10.0-19.9\%
	(compared with <5.0\%) lived below the poverty level (RR = 1.3 [95\%
	CI 1.2-1.5] and RR = 1.8 [95\% CI 1.4-2.2], respectively). CONCLUSIONS:
	RS was worse in lower SES areas. To help address the impact of county-level
	SES, resources for HIV testing, care, and proven economic interventions
	should be directed to areas with concentrations of economically disadvantaged
	people.},
  institution = {Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. KMcDavid@cdc.gov},
  journal     = {Ann Epidemiol},
  medline-pst = {ppublish},
  month       = {Dec},
  owner       = {PaulD},
  pii         = {S1047-2797(08)00295-0},
  pmid        = {19041591},
  timestamp   = {2009.08.28},
  year        = {2008},
}

@Article{Hartman2007,
  author      = {Mikael Hartman and Kamila Czene and Marie Reilly and Jan Adolfsson and Jonas Bergh and Hans-Olov Adami and Paul W Dickman and Per Hall},
  title       = {Incidence and prognosis of synchronous and metachronous bilateral breast cancer.},
  doi         = {10.1200/JCO.2006.10.5056},
  number      = {27},
  pages       = {4210--4216},
  url         = {http://dx.doi.org/10.1200/JCO.2006.10.5056},
  volume      = {25},
  abstract    = {PURPOSE: Because the incidence of breast cancer is increasing and
	prognosis is improving, a growing number of women are at risk of
	developing bilateral disease. Little is known, however, about incidence
	trends and prognostic features of bilateral breast cancer. PATIENTS
	AND METHODS: Among 123,757 women with a primary breast cancer diagnosed
	in Sweden from 1970 to 2000, a total of 6,550 developed bilateral
	breast cancer. We separated synchronous (diagnosed within 3 months
	after a first breast cancer) and metachronous bilateral cancer, and
	analyzed incidence and mortality rates of breast cancer using Poisson
	regression models. RESULTS: The incidence of synchronous breast cancer
	increased by age and by 40\% during the 1970s, whereas the incidence
	of metachronous cancer decreased by age and by approximately 30\%
	since the early 1980s, most likely due to increasing use of adjuvant
	therapy. Women who developed bilateral cancer within 5 years and
	at age younger than 50 years were 3.9 times (95\% CI, 3.5 to 4.5)
	more likely to die as a result of breast cancer than women with unilateral
	cancer. Women with a bilateral cancer diagnosed more than 10 years
	after the first cancer had a prognosis similar to that of a unilateral
	breast cancer. Adjuvant chemotherapy of primary cancer is a predictor
	of poor survival after diagnosis of early metachronous cancers. CONCLUSION:
	We found profound differences in the incidence trends and prognostic
	outlook between synchronous and metachronous bilateral breast cancer
	diagnosed at different ages. Adjuvant chemotherapy therapy has a
	dual effect on metachronous cancer: it reduces the risk, while at
	the same time it seems to worsen the prognosis.},
  file        = {Hartman2007.pdf:Hartman2007.pdf:PDF;Hartman2007.pdf:pdf\\Hartman2007.pdf:PDF},
  institution = {Department of Medical Epidemiology and Biostatistics, Stockholm S\"{o}der Hospital and Oncologic Center, Clintec, Stockholm, Sweden. Mikael.Hartman@ki.se},
  journal     = {Journal of Clinical Oncology},
  month       = {Sep},
  owner       = {pl4},
  pii         = {25/27/4210},
  pmid        = {17878475},
  timestamp   = {2009.04.03},
  year        = {2007},
}

@Article{Harvei1996,
  author    = {Harvei, S. and Tretli, S. and Langmark, F.},
  title     = {Quality of Prostate Cancer Data in the {C}ancer {R}egistry of {N}orway},
  pages     = {104-110},
  volume    = {32A},
  journal   = {European Journal of Cancer},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1996},
}

@Article{Hastie1993,
  author    = {T. J. Hastie and R. J. Tibshirani},
  title     = {Varying-coefficient models (with discussion)},
  pages     = {757--796},
  volume    = {55},
  journal   = {Journal of the Royal Statistical Society (Series B)},
  owner     = {pl4},
  timestamp = {2011.01.13},
  year      = {1993},
}

@Article{He2016,
  author  = {P. He and F. Erikson and T.H. Schieke and M.-J. Zhang},
  title   = {A proportional hazards regression model for the subdistribution with covariates-adjusted censoring weight for competing risks data},
  doi     = {10.1111/sjos.12167},
  pages   = {103ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Â“122},
  volume  = {43},
  file    = {He2016.pdf:pdf\\He2016.pdf:PDF},
  journal = {Scandinavian Journal of Statistics},
  year    = {2016},
}

@Article{HealeyBird2008,
  author      = {Brian R J {Healey Bird} and Sandra M Swain},
  title       = {Cardiac toxicity in breast cancer survivors: review of potential cardiac problems.},
  doi         = {10.1158/1078-0432.CCR-07-1033},
  language    = {eng},
  number      = {1},
  pages       = {14--24},
  url         = {http://dx.doi.org/10.1158/1078-0432.CCR-07-1033},
  volume      = {14},
  abstract    = {As breast cancer survival is increased by the diagnosis of earlier-stage
	disease and treatments improve, the side effects of cancer treatments,
	such as cardiotoxicity, remain clinically important. Although physicians
	have known for 30 years that anthracyclines cause acute and chronic
	cardiotoxicity, the cardiotoxic effects of radiation therapy, hormonal
	therapy (including tamoxifen and the aromatase inhibitors), and chemotherapy
	with taxanes and trastuzumab treatment have emerged more recently.
	This review examines the cardiac toxicity of adjuvant therapy, monitoring
	for early changes and existing guidelines for monitoring cardiac
	function in patients with breast cancer.},
  file        = {HealeyBird2008.pdf:HealeyBird2008.pdf:PDF;HealeyBird2008.pdf:pdf\\HealeyBird2008.pdf:PDF},
  institution = {Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, MD, USA.},
  journal     = {Clin Cancer Res},
  medline-pst = {ppublish},
  month       = {Jan},
  owner       = {PaulD},
  pii         = {14/1/14},
  pmid        = {18172247},
  timestamp   = {2011.06.27},
  year        = {2008},
}

@TechReport{SCR2000,
  author      = {The National Board of Health and Welfare, Centre for Epidemiology},
  institution = {The National Board of Health and Welfare},
  title       = {Cancer Incidence in {S}weden 2000},
  note        = {URL: \url{http://www.sos.se/fulltext/42/2002-42-5/2002-42-5.pdf } [accessed June 11, 2004]},
  type        = {Article 2002-42-5},
  groups      = {Cancer registry reports},
  owner       = {PaulD},
  timestamp   = {2011.06.19},
  year        = {2002},
}

@Article{Heinaevaara2006,
  author      = {Sirpa Hein\"{a}vaara and Timo Hakulinen},
  title       = {Predicting the lung cancer burden: Accounting for selection of the patients with respect to general population mortality.},
  doi         = {10.1002/sim.2443},
  number      = {17},
  pages       = {2967--2980},
  url         = {http://dx.doi.org/10.1002/sim.2443},
  volume      = {25},
  abstract    = {Incidence, survival, prevalence and mortality are the elements of
	the cancer burden. The cancer burden is thus contributed by the same
	individuals from the diagnosis of cancer (incidence) until possible
	death from cancer (mortality). It would therefore be natural that
	predictions of future cancer burden, those needed by health administration,
	for example, could be based on individual data. This paper presents
	a new model for estimating future cancer burden, a model where individuals
	are followed from birth to death with or without a diagnosis of cancer.
	The model can formally be expressed as a summation of log-likelihoods
	of getting cancer and of surviving the cancer and other causes of
	death until death or censoring. The new model is illustrated with
	data of Finnish males with or without a diagnosis of lung cancer
	in calendar period 1987-1997. Incidence is modelled with a general
	age-cohort model with a drift and survival from cancer with a parametric
	mixture model. In a model for survival from other causes of death,
	selection of patients with respect to general population mortality
	is accounted for. Future cancer burden is illustrated with short-term
	predictions of prevalence and mortality.},
  file        = {Heinaevaara2006.pdf:Heinaevaara2006.pdf:PDF;Heinaevaara2006.pdf:pdf\\Heinaevaara2006.pdf:PDF},
  institution = {Finnish Cancer Registry, Liisankatu 21 B, 00170 Helsinki, Finland. sirpa.heinavaara@cancer.fi},
  journal     = {Statistics in Medicine},
  month       = {Sep},
  owner       = {pl4},
  pmid        = {16345061},
  timestamp   = {2009.10.13},
  year        = {2006},
}

@Article{Heinavaara2002c,
  author    = {Sirpa Hein\"{a}vaara and Risto Sankila and Hans Storm and Fr{\o}ydis Langmark and Timo Hakulinen},
  title     = {Relative survival of patients with prostate cancer as a first or subsequent tumor--a {N}ordic collaborative study.},
  number    = {9},
  pages     = {797-806},
  volume    = {13},
  abstract  = {OBJECTIVE: To present a new model for estimating relative survival
	of patients with two primary cancers, to study whether survival from
	cancer is similar between a first and subsequent tumor, and to provide
	an illustration of prognoses for patients with cancer as a subsequent
	tumor. METHODS: Data on Danish, Finnish, and Norwegian patients with
	a first and subsequent prostate cancer, after a first primary colorectal
	cancer, were analyzed with a new model. RESULTS: Survival from first
	and subsequent prostate cancer was similar within each country. Survival
	from subsequent prostate cancer was not affected by the time interval
	between the first colorectal and subsequent prostate cancer. CONCLUSIONS:
	The survival from subsequent cancer should be adjusted for the underlying
	first primary cancer. The overall relative survival of patients with
	two primary cancers will be worse than those with a respective single
	cancer only. However, with a proper adjustment the subsequent cancer
	itself is not more fatal than a similar cancer as the only tumor
	of the patient.},
  journal   = {Cancer Causes Control},
  month     = {Nov},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2002},
}

@Article{Heinaevaara2002,
  author      = {S. Hein\"{a}vaara and L. Teppo and T. Hakulinen},
  title       = {Cancer-specific survival of patients with multiple cancers: {a}n application to patients with multiple breast cancers.},
  doi         = {10.1002/sim.1247},
  number      = {21},
  pages       = {3183--3195},
  url         = {http://dx.doi.org/10.1002/sim.1247},
  volume      = {21},
  abstract    = {In the analysis of cause-specific survival, the causes of death must
	be known. For single-cancer patients with a known cause of death,
	the estimation of the cause-specific survival rate is straightforward.
	For multiple-cancer patients with two primary cancers, however, the
	analysis of cause-specific survival rates is more complex, particularly
	if the cancers are of the same primary site. In these situations,
	a concept of cancer-specific survival may also be distinguished from
	cause-specific survival. Cancer-specific survival rates are studied
	here by introducing two models, the primary one where the death from
	cancer is attributed to one of the cancers, and an alternative where
	such an attribution is not necessary. The models are illustrated
	using data on patients with multiple breast cancers. The model-based
	survival rates are compared with each other and with the corresponding
	relative survival rates based on analogous modelling of relative
	survival. The results show that for the subsequent breast cancer,
	the cancer-specific survival rates based on the alternative, where
	the distinction between the cancers as a cause of death was not necessary,
	tended to be higher than those based on that distinction. It is thus
	possible that the subsequent cancer was too often coded as a cause
	of death, particularly when being localized at diagnosis.},
  file        = {Heinaevaara2002.pdf:Heinaevaara2002.pdf:PDF;Heinaevaara2002.pdf:pdf\\Heinaevaara2002.pdf:PDF},
  institution = {Finnish Cancer Registry, Liisankatu 21 B, 00170 Helsinki, Finland. sirpa.heinavaara@cancer.fi},
  journal     = {Statistics in Medicine},
  month       = {Nov},
  owner       = {pl4},
  pmid        = {12375298},
  timestamp   = {2008.12.16},
  year        = {2002},
}

@Article{Heisterkamp1993,
  author    = {Heisterkamp, S. H. and Doornbos, G. and Gankema, M.},
  title     = {Disease Mapping Using Empirical {B}ayes and {B}ayes Methods on Mortality Statistics in the {N}etherlands},
  pages     = {1895-1913},
  volume    = {12},
  journal   = {Statistics in Medicine},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1993},
}

@Article{Helander1989,
  author      = {I. M. Helander and M. Vaara and S. Sukupolvi and M. Rhen and S. Saarela and U. Z\"{a}hringer and P. H. M\"{a}kel\"{a}},
  title       = {rfaP mutants of Salmonella typhimurium.},
  number      = {3},
  pages       = {541--546},
  volume      = {185},
  abstract    = {Salmonella typhimurium rfaP mutants were isolated and characterised
	with respect to their sensitivity towards hydrophobic antibiotics
	and detergents, and their lipopolysaccharides were chemically analysed.
	The rfaP mutants were selected after diethylsulfate mutagenesis or
	as spontaneous mutants. The mutation in two independent mutants SH7770
	(line LT2) and SH8551 (line TML) was mapped by cotransduction with
	cysE to the rfa locus. The mutants were sensitive to hydrophobic
	antibiotics (clindamycin, erythromycin and novobiocin) and detergents
	(benzalkoniumchloride and sodium dodecyl sulfate). Analysis of their
	lipopolysaccharides by chemical methods and by sodium dodecyl sulfate/polyacrylamide
	gel electrophoresis revealed that their saccharide portion was, to
	a large extent, of chemotype Rc with small proportions of material
	containing a more complete core oligosaccharide and O-specific chains.
	Only 2.5 mol phosphate/mol lipopolysaccharide was found whereas the
	phosphate content of the lipopolysaccharide of a galE mutant strain
	was 4.8 mol. Thus the rfaP mutant lipopolysaccharides lacked more
	than two phosphate residues. Assessment of the location of phosphate
	groups in rfaP lipopolysaccharides revealed the presence of at least
	2 mol phosphate in lipid A, indicating that the core oligosaccharide
	was almost devoid of phosphate. The chemical, physiological and genetic
	data obtained for these mutants are in full agreement with those
	reported earlier for rfaP mutants of Salmonella minnesota.},
  institution = {Molecular Biology Unit, National Public Health Institute, Helsinki, Finland.},
  journal     = {Eur J Biochem},
  month       = {Nov},
  owner       = {pl4},
  pmid        = {2686988},
  timestamp   = {2011.05.26},
  year        = {1989},
}

@Article{Helgason2001,
  author    = {AR Helgason and PW Dickman and J Adolfsson and G Steineck},
  title     = {Emotional isolation: prevalence and the effect on well-being among 50-80-year-old prostate cancer patients.},
  number    = {2},
  pages     = {97-101},
  volume    = {35},
  abstract  = {OBJECTIVE: To investigate to what extent prostate cancer patients
	confide their emotional concerns, and whether having no one to confide
	in affects well-being. MATERIAL AND METHODS: A population-based study
	using epidemiological methods. A questionnaire was mailed to all
	431 living prostate cancer patients aged 50-80 at the time of selection,
	diagnosed 1.5-2 years previously in Stockholm County, and 435 randomly
	selected men in the same age group. The questionnaire was completed
	anonymously. The main outcome measures included questions assessing
	the extent to which the men could share emotionally taxing feelings
	with their partner or others and questions assessing well-being.
	RESULTS: The questionnaire was returned by 79\% of the patients and
	by 73\% of the randomly selected men. Approximately one in five patients
	had no one to confide in. Of patients living with a partner, only
	one in 10 confided in someone other than their partner. Three out
	of 10 patients living in a relationship could not confide in their
	partner. Men having no one to confide in were less content with their
	life and reported poorer psychological and overall well-being compared
	with other men. The prostate cancer patients were not more likely
	to have someone to confide in than men in general. CONCLUSIONS: The
	results indicate that a lack of emotional support may be a problem
	for many prostate cancer patients and that the traditional psychosocial
	support offered to most cancer patients in {S}weden may not reach
	male patients. There may be a need for a gender-adapted approach
	to emotional support.},
  journal   = {Scand J Urol Nephrol},
  month     = {Apr},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2001},
}

@Article{Helgason1996a,
  author    = {Helgason, A. R. and Adolfsson, J. and Dickman, P. and Arver, S. and Fredrikson, M. and G{\"o}thberg, M. and Steineck, G.},
  title     = {Sexual Desire, Erection, Orgasm and Ejaculatory Functions and Their Importance to Elderly {S}wedish Men: {A} Population-based Study},
  pages     = {285-291},
  volume    = {25},
  journal   = {Age and Aging},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1996},
}

@Article{Helgason1997a,
  author    = {Helgason, A. R. and Adolfsson, J. and Dickman, P. and Arver, S. and Fredrikson, M. and Steineck, G.},
  title     = {Factors Associated With Waning Sexual Function Among Elderly Men and Prostate Cancer Patients},
  pages     = {155--159},
  volume    = {158},
  journal   = {The Journal of Urology},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1997},
}

@Article{Helgason1996b,
  author    = {Helgason, A. R. and Adolfsson, J. and Dickman, P. and Fredrikson, M. and Arver, S. and Steineck, G.},
  title     = {Waning Sexual Function -- the Most Important Disease-Specific Distress for Patients with Prostate Cancer},
  pages     = {1417--1421},
  volume    = {73},
  journal   = {British Journal of Cancer},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1996},
}

@Article{Helgason1997c,
  author    = {Helgason, A. R. and Adolfsson, J. and Dickman, P. and Fredrikson, M. and Steineck, G.},
  title     = {Distress due to Unwanted Side-Effects of Prostate Cancer Treatment is Related to Impaired Well-Being (Quality of Life)},
  pages     = {128--133},
  volume    = {1},
  journal   = {Prostate Cancer and Prostatic Disease},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1997},
}

@Article{Helgason1997b,
  author    = {Helgason, A. R. and Arver, S. and Adolfsson, J. and Dickman, P. and Granath, F. and Steineck, G.},
  title     = {`Potency' - the validation of information from a self-administered questionnaire using objective measurements of night-time erections and test-retest reliability},
  pages     = {135--141},
  volume    = {81},
  journal   = {British Journal of Urology},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1998},
}

@Article{Hellmich1998,
  author      = {M. Hellmich and K. R. Abrams and D. R. Jones and P. C. Lambert},
  title       = {A {B}ayesian approach to a general regression model for ROC curves.},
  number      = {4},
  pages       = {436--443},
  volume      = {18},
  abstract    = {A fully Bayesian approach to a general nonlinear ordinal regression
	model for ROC-curve analysis is presented. Samples from the marginal
	posterior distributions of the model parameters are obtained by a
	Markov-chain Monte Carlo (MCMC) technique--Gibbs sampling. These
	samples facilitate the calculation of point estimates and credible
	regions as well as inferences for the associated areas under the
	ROC curves. The analysis of an example using freely available software
	shows that the use of noninformative vague prior distributions for
	all model parameters yields posterior summary statistics very similar
	to the conventional maximum-likelihood estimates. Clinically important
	advantages of this Bayesian approach are: the possible inclusion
	of prior knowledge and beliefs into the ROC analysis (via the prior
	distributions), the possible calculation of the posterior predictive
	distribution of a future patient outcome, and the potential to address
	questions such as: "What is the probability that a certain diagnostic
	test is better in one setting than in another?"},
  file        = {Hellmich1998.pdf:Hellmich1998.pdf:PDF;Hellmich1998.pdf:pdf\\Hellmich1998.pdf:PDF},
  institution = {Department of Epidemiology and Public Health, University of Leicester, UK.},
  journal     = {Medical Decision Making},
  owner       = {pl4},
  pmid        = {10372587},
  timestamp   = {2008.10.15},
  year        = {1998},
}

@Article{Helminen2006,
  author      = {M. Helminen and E. Saarela and J. Salmela},
  title       = {Characterisation of patients treated at the Red Cross field hospital in Kashmir during the first three weeks of operation.},
  doi         = {10.1136/emj.2006.036012},
  number      = {8},
  pages       = {654--656},
  url         = {http://dx.doi.org/10.1136/emj.2006.036012},
  volume      = {23},
  abstract    = {To evaluate the characteristics of patients treated at a field hospital
	in the first month after a major earthquake.Age, sex, diagnosis,
	and operations performed on patients admitted to the field hospital
	of the International Committee of the Red Cross in Pakistani Kashmir
	between 21 October and 10 November 2005 were recorded and the data
	analysed.During the three week period of this study, 316 patients
	were treated at the hospital; 246 were women and children (77.9\%).
	Two thirds were hospitalised, over 90\% because of the need for surgery
	or surgical consultation. Altogether 345 operations were performed
	on 157 patients. The majority of patients had infected wounds with
	or without fractures.Most patients need medical evaluation in consequence
	of earthquake-related trauma even weeks after the catastrophe, especially
	in areas difficult of access.},
  institution = {Pediatric Research Centre, Tampere University Hospital, Tampere, Finland. merja.helminen@pshp.fi},
  journal     = {Emerg Med J},
  month       = {Aug},
  owner       = {pl4},
  pii         = {23/8/654},
  pmid        = {16858109},
  timestamp   = {2011.05.26},
  year        = {2006},
}

@Article{Henningsohn2001,
  author    = {L Henningsohn and H Wijkstr\"{o}m and PW Dickman and K Bergmark and G Steineck},
  title     = {Distressful symptoms after radical cystectomy with urinary diversion for urinary bladder cancer: a {S}wedish population-based study.},
  number    = {2},
  pages     = {151-62},
  volume    = {40},
  abstract  = {OBJECTIVE: To study the excess prevalence of distressful symptoms
	after radical surgery for urinary bladder cancer. METHODS: We included
	all patients who underwent cystectomy due to bladder cancer before
	1996 in Stockholm County. A control group was randomly selected from
	the general population. Information was collected by means of an
	anonymous postal questionnaire. RESULTS: Completed questionnaires
	were returned by 310 (71\%) controls and 251 (85\%) cystectomized
	individuals. A 5-fold (reservoir) and 9-fold (conduit) increase in
	defecation urgency and a 4-fold (reservoir) and 6-fold (conduit)
	increase in faecal leakage were reported in individuals operated
	on. Urinary tract infection was increased 3-fold in cystectomized
	individuals compared with controls, during the previous year 26\%
	of the patients reported a symptomatic infection. The perception
	of a reduced physical attractiveness due to disease was more than
	5-fold increased in the men operated on compared to the controls.
	The majority, 135 out of 201 (67\%), reported that they would have
	refused alternative bladder-sparing procedures if they decreased
	the prospects of survival by even as little as 1\%. CONCLUSIONS:
	The patient's situation after cystectomy is considerably impaired
	due to changed bowel and sexual function, urinary tract infections
	and a sense of decreased attractiveness. However, most patients are
	in spite of this unwilling to compromise survival.},
  journal   = {Eur Urol},
  month     = {Aug},
  owner     = {PaulD},
  pii       = {eur40151},
  timestamp = {2011.06.19},
  year      = {2001},
}

@Article{Henningsohn2002,
  author    = {Lars Henningsohn and Hans Wijkstr\"{o}m and Paul W Dickman and Karin Bergmark and Gunnar Steineck},
  title     = {Distressful symptoms after radical radiotherapy for urinary bladder cancer.},
  number    = {2},
  pages     = {215-25},
  volume    = {62},
  abstract  = {BACKGROUND: Radical radiotherapy for muscle-invasive urinary bladder
	cancer can sterilize the tumour with preserved organ function. Here
	we studied symptoms, symptom distress and trade-off among long-term
	survivors and compared figures to those of population controls and
	patients who had undergone cystectomy. MATERIALS AND METHODS: We
	identified 71 patients who had had urinary bladder cancer treated
	with radical radiotherapy before 1995. For comparison, 325 patients
	treated with radical cystectomy and urostomy, continent or non-continent,
	during the same period and 460 individuals randomly selected from
	the general population were included. Information was collected by
	means of an anonymously answered postal questionnaire to avoid investigator-related
	bias. RESULTS: Answers were obtained from 58 (82\%) radiated patients,
	251 (85\%) cystectomized patients and 310 (71\%) population controls.
	Of the radiated patients, 74\% reported little or no distress from
	symptoms from the urinary tract, 38\% had had intercourse the previous
	month and 57\% (men) reported they had ejaculated. Among the cystectomized
	patients, 13\% had had intercourse and 0\% (men) had ejaculated.
	Moderate or much distress from symptoms from the gastrointestinal
	tract was reported by 32\% of the radiated patients, 24\% of the
	cystectomized patients and 9\% of the population controls. After
	radical radiotherapy, 46\% of the patients were willing to accept
	some risk of decreased survival to become symptom-free. CONCLUSIONS:
	About 3/4 of these long-term survivors after radical radiotherapy
	for bladder cancer had a functioning urinary bladder with little
	or no distress from the urinary tract. The prevalence of sexual dysfunction
	was lower than after cystectomy and the prevalence of distress from
	the gastrointestinal tract was comparable.},
  journal   = {Radiother Oncol},
  month     = {Feb},
  owner     = {PaulD},
  pii       = {S0167814001004558},
  timestamp = {2011.06.19},
  year      = {2002},
}

@Article{Henson1995,
  author    = {Donald Earl Henson and Lynn A. Ries},
  title     = {The Relative Survival Rate},
  pages     = {1687-1688},
  volume    = {76},
  journal   = {Cancer},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@Article{Herget2014,
  author      = {Herget, G. W. and Neuburger, M. and B{\"{o}}hm, J. and Siepe, M. and Oberst, M. and S{\"{u}}dkamp, N. P.},
  title       = {[Reno-pulmo-aortal Fibromuscular Dysplasia Causing Angiorrhexis and Mimicking Pheochromocytoma?/?Paraganglioma - Case Report].},
  doi         = {10.1055/s-0031-1283794},
  language    = {ger},
  pages       = {e79--e82},
  url         = {http://dx.doi.org/10.1055/s-0031-1283794},
  volume      = {139 Suppl 2},
  institution = {Universit{\"a}tsklinikum Freiburg, Department Orthop{\"a}die und Traumatologie, Freiburg i.?Br., Deutschland.},
  journal     = {Zentralbl Chir},
  medline-pst = {ppublish},
  month       = {Dec},
  owner       = {pl4},
  pmid        = {22065338},
  timestamp   = {2015.01.30},
  year        = {2014},
}

@Article{Hernan2004,
  author      = {Hern{\'{a}}n, Miguel A. and Hern{\'{a}}ndez-D{\'{i}}az, Sonia and Robins, James M.},
  title       = {A structural approach to selection bias},
  language    = {eng},
  number      = {5},
  pages       = {615--625},
  volume      = {15},
  abstract    = {The term "selection bias" encompasses various biases in epidemiology.
	We describe examples of selection bias in case-control studies (eg,
	inappropriate selection of controls) and cohort studies (eg, informative
	censoring). We argue that the causal structure underlying the bias
	in each example is essentially the same: conditioning on a common
	effect of 2 variables, one of which is either exposure or a cause
	of exposure and the other is either the outcome or a cause of the
	outcome. This structure is shared by other biases (eg, adjustment
	for variables affected by prior exposure). A structural classification
	of bias distinguishes between biases resulting from conditioning
	on common effects ("selection bias") and those resulting from the
	existence of common causes of exposure and outcome ("confounding").
	This classification also leads to a unified approach to adjust for
	selection bias.},
  institution = {Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA. miguel_hernan@post.harvard.edu},
  journal     = {Epidemiology},
  keywords    = {Case-Control Studies; Disease, etiology; Environmental Exposure, adverse effects; Epidemiologic Methods; Epidemiologic Research Design; Evaluation Studies as Topic; Humans; Longitudinal Studies; Models, Theoretical; Research; Research Subjects; Risk Factors; Selection Bias},
  medline-pst = {ppublish},
  month       = {Sep},
  owner       = {PaulD},
  pii         = {00001648-200409000-00020},
  pmid        = {15308962},
  timestamp   = {2016.02.17},
  year        = {2004},
}

@Article{Hernan2010,
  author      = {Miguel A Hern\'{a}n},
  title       = {The hazards of hazard ratios.},
  doi         = {10.1097/EDE.0b013e3181c1ea43},
  language    = {eng},
  number      = {1},
  pages       = {13--15},
  url         = {http://dx.doi.org/10.1097/EDE.0b013e3181c1ea43},
  volume      = {21},
  file        = {Hernan2010.pdf:pdf\\Hernan2010.pdf:PDF;Hernan2010.pdf:Hernan2010.pdf:PDF},
  institution = {Department of Epidemiology, Harvard School of Public Health, and the Harvard-MIT Division of Health Sciences and Technology, Boston, MA 02115, USA. miguel_hernan@post.harvard.edu},
  journal     = {Epidemiology},
  medline-pst = {ppublish},
  month       = {Jan},
  owner       = {PaulD},
  pii         = {00001648-201001000-00004},
  pmid        = {20010207},
  timestamp   = {2010.06.02},
  year        = {2010},
}

@Article{Hernan2008,
  author      = {M. A. Hern\'{a}n and A. Alonso and R. Logan and F. Grodstein and K. B. Michels and W. C. Willett and J. E. Manson and J. M. Robins},
  title       = {Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease.},
  doi         = {10.1097/EDE.0b013e3181875e61},
  language    = {eng},
  number      = {6},
  pages       = {766--779},
  url         = {http://dx.doi.org/10.1097/EDE.0b013e3181875e61},
  volume      = {19},
  abstract    = {BACKGROUND: The Women's Health Initiative randomized trial found greater
	coronary heart disease (CHD) risk in women assigned to estrogen/progestin
	therapy than in those assigned to placebo. Observational studies
	had previously suggested reduced CHD risk in hormone users. METHODS:
	Using data from the observational Nurses' Health Study, we emulated
	the design and intention-to-treat (ITT) analysis of the randomized
	trial. The observational study was conceptualized as a sequence of
	"trials," in which eligible women were classified as initiators or
	noninitiators of estrogen/progestin therapy. RESULTS: The ITT hazard
	ratios (HRs) (95\% confidence intervals) of CHD for initiators versus
	noninitiators were 1.42 (0.92-2.20) for the first 2 years, and 0.96
	(0.78-1.18) for the entire follow-up. The ITT HRs were 0.84 (0.61-1.14)
	in women within 10 years of menopause, and 1.12 (0.84-1.48) in the
	others (P value for interaction = 0.08). These ITT estimates are
	similar to those from the Women's Health Initiative. Because the
	ITT approach causes severe treatment misclassification, we also estimated
	adherence-adjusted effects by inverse probability weighting. The
	HRs were 1.61 (0.97-2.66) for the first 2 years, and 0.98 (0.66-1.49)
	for the entire follow-up. The HRs were 0.54 (0.19-1.51) in women
	within 10 years after menopause, and 1.20 (0.78-1.84) in others (P
	value for interaction = 0.01). We also present comparisons between
	these estimates and previously reported Nurses' Health Study estimates.
	CONCLUSIONS: Our findings suggest that the discrepancies between
	the Women's Health Initiative and Nurses' Health Study ITT estimates
	could be largely explained by differences in the distribution of
	time since menopause and length of follow-up.},
  file        = {Hernan2008.pdf:pdf\\Hernan2008.pdf:PDF;Hernan2008.pdf:Hernan2008.pdf:PDF},
  institution = {Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. miguel_hernan@post.harvard.edu},
  journal     = {Epidemiology},
  medline-pst = {ppublish},
  month       = {Nov},
  owner       = {pl4},
  pii         = {00001648-200811000-00002},
  pmid        = {18854702},
  timestamp   = {2010.06.01},
  year        = {2008},
}

@Article{Herndon1995,
  author    = {Herndon, James E. and Harrell, Frank E.},
  title     = {The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariables},
  doi       = {10.1002/sim.4780141906},
  issn      = {1097-0258},
  number    = {19},
  pages     = {2119--2129},
  url       = {http://dx.doi.org/10.1002/sim.4780141906},
  volume    = {14},
  abstract  = {We incorporate a cubic spline function where the tails are linearly
	constrained, as the baseline hazard, into the proportional hazards
	model. We show estimation of covariable coefficients and survival
	probabilities with this model to be as efficient statistically as
	with the Cox proportional hazards model when covariables are fixed.
	Examples show that the inclusion of time-dependent covariables defined
	as step functions into the restricted cubic spline proportional hazards
	model reduces computation time by a factor of 213 over the Cox model.
	Advantages of the spline model also include flexibility of the hazard,
	smooth survival curves, and confidence limits for the survival and
	hazard estimates when there are time-dependent covariables present.},
  file      = {Herndon1995.pdf:pdf\\Herndon1995.pdf:PDF;Herndon1995.pdf:Herndon1995.pdf:PDF},
  journal   = {Statistics in Medicine},
  owner     = {PaulD},
  publisher = {Wiley Subscription Services, Inc., A Wiley Company},
  timestamp = {2012.11.12},
  year      = {1995},
}

@Article{Hess1995,
  author    = {Kenneth R. Hess},
  title     = {Graphical Methods for Assessing Vioations of the Proportional Hazards Assumption in {C}ox Regression},
  pages     = {1707-1723},
  volume    = {14},
  journal   = {Statistics in Medicine},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@Article{Heuer1997,
  author      = {Heuer, C.},
  title       = {Modeling of time trends and interactions in vital rates using restricted regression splines.},
  language    = {eng},
  number      = {1},
  pages       = {161--177},
  volume      = {53},
  abstract    = {For the analysis of time trends in incidence and mortality rates,
	the age-period-cohort (apc) model has became a widely accepted method.
	The considered data are arranged in a two-way table by age group
	and calendar period, which are mostly subdivided into 5- or 10-year
	intervals. The disadvantage of this approach is the loss of information
	by data aggregation and the problems of estimating interactions in
	the two-way layout without replications. In this article we show
	how splines can be useful when yearly data, i.e., 1-year age groups
	and 1-year periods, are given. The estimated spline curves are still
	smooth and represent yearly changes in the time trends. Further,
	it is straightforward to include interaction terms by the tensor
	product of the spline functions. If the data are given in a nonrectangular
	table, e.g., 5-year age groups and 1-year periods, the period and
	cohort variables can be parameterized by splines, while the age variable
	is parameterized as fixed effect levels, which leads to a semiparametric
	apc model. An important methodological issue in developing the nonparametric
	and semiparametric models is stability of the estimated spline curve
	at the boundaries. Here cubic regression splines will be used, which
	are constrained to be linear in the tails. Another point of importance
	is the nonidentifiability problem due to the linear dependency of
	the three time variables. This will be handled by decomposing the
	basis of each spline by orthogonal projection into constant, linear,
	and nonlinear terms, as suggested by Holford (1983, Biometrics 39,
	311-324) for the traditional apc model. The advantage of using splines
	for yearly data compared to the traditional approach for aggregated
	data is the more accurate curve estimation for the nonlinear trend
	changes and the simple way of modeling interactions between the time
	variables. The method will be demonstrated with hypothetical data
	as well as with cancer mortality data.},
  file        = {Heuer1997.pdf:Heuer1997.pdf:PDF},
  institution = {Department of Biometry, University of Heidelberg, Germany.},
  journal     = {Biometrics},
  medline-pst = {ppublish},
  month       = {Mar},
  owner       = {pl4},
  pmid        = {9147590},
  timestamp   = {2012.09.10},
  year        = {1997},
}

@Article{Hills2014,
  author    = {Hills, M. and Rachet, B. and Falcaro, M.},
  title     = {strel2: A command for estimating excess hazard and relative survival in large population-based studies},
  pages     = {176-190},
  volume    = {14},
  file      = {Hills2014.pdf:Hills2014.pdf:PDF;Hills2014.pdf:pdf\\Hills2014.pdf:PDF},
  journal   = {The Stata Journal},
  owner     = {hanbow},
  timestamp = {2014.04.28},
  year      = {2014},
}

@PhdThesis{Hinchliffe:phdthesis:2013,
  author    = {Sally Rose Hinchliffe},
  title     = {Advancing and appraising competing risks methodology for better communication of survival statistics},
  type      = {PhD Thesis},
  url       = {http://hdl.handle.net/2381/28176},
  file      = {:pdf\\Thesis_Sally_Hinchliffe.pdf:PDF},
  groups    = {PhD Thesis},
  owner     = {PaulD},
  school    = {University of Leicester},
  timestamp = {2013.10.23},
  year      = {2013},
}

@Article{Hinchliffe2013b,
  author      = {Hinchliffe, S.R. and Abrams, K.R. and Lambert, P.C.},
  title       = {The impact of under and over-recording of cancer on death certificates in a competing risks analysis: a simulation study.},
  doi         = {10.1016/j.canep.2012.08.012},
  language    = {eng},
  number      = {1},
  pages       = {11--19},
  url         = {http://dx.doi.org/10.1016/j.canep.2012.08.012},
  volume      = {37},
  abstract    = {With linked register and cause of death data becoming more accessible
	than ever, competing risks methodology is being increasingly used
	as a way of obtaining "real world" probabilities of death broken
	down by specific causes. It is important, in terms of the validity
	of these studies, to have accurate cause of death information. However,
	it is well documented that cause of death information taken from
	death certificates is often lacking in accuracy and completeness.We
	assess through use of a simulation study the effect of under and
	over-recording of cancer on death certificates in a competing risks
	analysis consisting of three competing causes of death: cancer, heart
	disease and other causes. Using realistic levels of misclassification,
	we consider 24 scenarios and examine the bias in the cause-specific
	hazard ratios and the cumulative incidence function.The bias in the
	cumulative incidence function was highest in the oldest age group
	reaching values as high as 2.6 percentage units for the "good" cancer
	prognosis scenario and 9.7 percentage units for the "poor" prognosis
	scenario.The bias resulting from the chosen levels of misclassification
	in this study accentuate concerns that unreliable cause of death
	information may be providing misleading results. The results of this
	simulation study convey an important message to applied epidemiological
	researchers.},
  file        = {Hinchliffe2013b.pdf:Hinchliffe2013b.pdf:PDF},
  institution = {d Genetic Epidemiology, Department of Health Sciences, 2nd Floor Adrian Building, University Road, University of Leicester, Leicester LE1 7RH, UK. srh20@leicester.ac.uk},
  journal     = {Cancer Epidemiology},
  medline-pst = {ppublish},
  owner       = {pl4},
  pii         = {S1877-7821(12)00128-2},
  pmid        = {22999870},
  timestamp   = {2013.03.05},
  year        = {2013},
}

@Article{Hinchliffe2012,
  author      = {Hinchliffe, Sally R. and Dickman, Paul W. and Lambert, Paul C.},
  title       = {Adjusting for the proportion of cancer deaths in the general population when using relative survival: A sensitivity analysis.},
  doi         = {10.1016/j.canep.2011.09.007},
  language    = {eng},
  number      = {2},
  pages       = {148--152},
  url         = {http://dx.doi.org/10.1016/j.canep.2011.09.007},
  volume      = {36},
  abstract    = {Background: Relative survival is an extensively used method in population
	based cancer studies as it provides a measure of survival without
	the need for accurate cause of death information. It gives an estimate
	for the probability of dying from cancer in the absence of other
	causes by estimating the excess mortality in the study population
	when compared to an external group. The external group is usually
	the general population within a country or state and mortality estimates
	are taken from national life tables that are broken down by age,
	sex, calendar year and, where applicable, race/ethnicity. One potential
	bias when using relative survival that is most often overlooked occurs
	when there are a high proportion of deaths due to a specific cancer
	in the external group. Methods: This paper uses data from the Finnish
	Cancer Registry to illustrate, through the use of a simple sensitivity
	analysis, the impact that specific cancer deaths in the population
	mortality figures can have on the estimate of relative survival.
	Results: We found that when examining specific diseases such as breast
	cancer and colon cancer, the proportion of deaths due to these specific
	cancers in the general population is so small in comparison to the
	total mortality that they make little difference to the relative
	survival estimates. However, prostate cancer proved to be an exception
	to this. For all cancer sites combined the sensitivity analysis illustrates
	a major limitation for this type of analysis, particularly with the
	older age groups. Conclusion: We recommend that, with a classification
	of diseases as wide as all cancer sites, relative survival should
	not be used without appropriate adjustment.},
  file        = {Hinchliffe2012.pdf:Hinchliffe2012.pdf:PDF;Hinchliffe2012a.pdf:Hinchliffe2012a.pdf:PDF;Hinchliffe2012.pdf:pdf\\Hinchliffe2012.pdf:PDF;Hinchliffe2012a.pdf:pdf\\Hinchliffe2012a.pdf:PDF},
  institution = {Department of Health Sciences, Centre for Biostatistics and Genetic Epidemiology, University of Leicester, Leicester, UK.},
  journal     = {Cancer Epidemiology},
  medline-pst = {ppublish},
  month       = {Apr},
  owner       = {pl4},
  pii         = {S1877-7821(11)00148-2},
  pmid        = {22000329},
  timestamp   = {2012.04.08},
  year        = {2012},
}

@Article{Hinchliffe2013,
  author    = {Hinchliffe, S. R. and Lambert, P. C.},
  title     = {Flexible parametric modelling of cause-specific hazards to estimate cumulative incidence functions},
  doi       = {10.1186/1471-2288-13-13},
  pages     = {13},
  volume    = {13},
  file      = {Hinchliffe2013.pdf:Hinchliffe2013.pdf:PDF;Hinchliffe2013.pdf:pdf\\Hinchliffe2013.pdf:PDF},
  journal   = {BMC Medical Research Methodology},
  owner     = {pl4},
  timestamp = {2013.02.08},
  year      = {2013},
}

@Article{Hinchliffe2013d,
  author    = {Hinchliffe, S. R. and Lambert, P. C.},
  title     = {Extending the flexible parametric survival model for competing risks},
  pages     = {344-355},
  volume    = {13},
  file      = {Hinchliffe2013d.pdf:pdf\\Hinchliffe2013d.pdf:PDF;Hinchliffe2013d.pdf:Hinchliffe2013d.pdf:PDF},
  journal   = {The Stata Journal},
  owner     = {pl4},
  timestamp = {2013.03.21},
  year      = {2013},
}

@Article{Hinchliffe2012a,
  author    = {Hinchliffe, S. R. and Rutherford, M. J. and Crowther, M. J. and Nelson, C. P. and Lambert, P. C.},
  title     = {Should relative survival be used with lung cancer data?},
  doi       = {10.1038/bjc.2012.182},
  pages     = {1854-1859},
  volume    = {106},
  file      = {Hinchliffe2012a.pdf:pdf\\Hinchliffe2012a.pdf:PDF},
  journal   = {British Journal of Cancer},
  owner     = {pl4},
  timestamp = {2012.04.08},
  year      = {2012},
}

@Article{Hinchliffe2013e,
  author    = {Hinchliffe, S. R. and Scott, D. A. and Lambert, P. C.},
  title     = {Flexible parametric illness-death models},
  pages     = {759-775},
  volume    = {13},
  file      = {Hinchliffe2013c.pdf:pdf\\Hinchliffe2013c.pdf:PDF},
  journal   = {The Stata Journal},
  owner     = {pl4},
  timestamp = {2013.03.21},
  year      = {2013},
}

@Article{Hinchliffe2013a,
  author      = {Hinchliffe, S. R. and Seaton, S. E. and Lambert, P. C. and Draper, E. S. and Field, D. J. and Manktelow, B. N.},
  title       = {Modelling time to death or discharge in neonatal care: an application of competing risks.},
  doi         = {10.1111/ppe.12053},
  language    = {eng},
  number      = {4},
  pages       = {426--433},
  url         = {http://dx.doi.org/10.1111/ppe.12053},
  volume      = {27},
  abstract    = {Understanding length of stay for babies in neonatal care is vital
	for planning services and for counselling parents. While previous
	work has focused on the length of stay of babies who survive to discharge,
	when investigating resource use within neonatal care, it is important
	to also incorporate information on those babies who die while in
	care. We present an analysis using competing risks methodology which
	allows the simultaneous modelling of babies who die in neonatal care
	and those who survive to discharge.Data were obtained on 2723 babies
	born at 24-28 weeks gestational age in 2006-10 and admitted to neonatal
	care. Death and discharge alive are two mutually exclusive events
	and can be treated as competing risks. A flexible parametric modelling
	approach was used to analyse these two competing events and obtain
	estimates of the absolute probabilities of death or discharge.The
	absolute probabilities of death or discharge are presented in graphical
	form showing the cause-specific cumulative incidence over time by
	gender, gestational age and birthweight. The discharge of babies
	alive generally occurred over a longer time period for babies of
	lower gestational age and smaller birthweight than for bigger babies.This
	study has presented a useful statistical method for modelling the
	length of stay where there are significant rates of in-unit mortality.
	In health care systems that are increasingly focusing on costs and
	resource planning, it is essential to consider not only length of
	stay of survivors but also for those patients who die before discharge.},
  file        = {Hinchliffe2013a.pdf:Hinchliffe2013a.pdf:PDF},
  institution = {Department of Health Sciences, University of Leicester, Leicester, UK.},
  journal     = {Paediatr Perinat Epidemiol},
  keywords    = {Birth Weight, physiology; England; Female; Gestational Age; Humans; Infant Mortality; Infant, Newborn; Intensive Care, Neonatal, statistics /&/ numerical data; Length of Stay; Male; Models, Theoretical; Patient Discharge, statistics /&/ numerical data; Risk Factors; Time Factors},
  medline-pst = {ppublish},
  month       = {Jul},
  owner       = {pl4},
  pmid        = {23772944},
  timestamp   = {2014.06.05},
  year        = {2013},
}

@Article{Hjort1992,
  author    = {Hjort, N.L.},
  title     = {On inference in parametric survival data models},
  pages     = {355--387},
  volume    = {60},
  journal   = {International Statistical Review},
  owner     = {pl4},
  timestamp = {2008.11.04},
  year      = {1992},
}

@Article{Hoel1993,
  author    = {Hoel, D. G. and Ron, E. and Carter, R. and Mabuchi, K.},
  title     = {Influence of death certificate errors on cancer mortality trends},
  pages     = {1063-1068},
  volume    = {85},
  journal   = {Journal of the National Cancer Institute},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1993},
}

@Article{Hoem1987,
  author    = {Hoem, J. M.},
  title     = {Statistical Analysis of a Multiplicative Model and its Application to the Standardization of Vital Rates: A Review},
  pages     = {119-152},
  volume    = {55},
  journal   = {International Statistical Review},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1987},
}

@Article{Hoeting1999,
  author    = {J. A . Hoeting and D. Madigan and A. E. Raftery and C. T. Volinsky},
  title     = {Bayesian model averaging: a tutorial},
  pages     = {382-401},
  file      = {Hoeting1999.pdf:pdf\\Hoeting1999.pdf:PDF;Hoeting1999.pdf:Hoeting1999.pdf:PDF},
  journal   = {Statistical science},
  owner     = {hanbow},
  timestamp = {2015.05.12},
  year      = {1999},
}

@Article{Hofer1999,
  author    = {SO Hofer and G Molema and RA Hermens and HJ Wanebo and JS Reichner and HJ Hoekstra},
  title     = {The effect of surgical wounding on tumour development.},
  number    = {3},
  pages     = {231-43},
  volume    = {25},
  abstract  = {For more than a century, a role for wound healing in the outgrowth
	of tumours has been implied based on observations in both experimental
	and clinical studies. Wound healing can be divided into stages of
	inflammatory, proliferative, repair and remodelling processes. Through
	proper regulation of activation of epithelial, endothelial and inflammatory
	cells, platelets and fibroblasts, and the production of growth factors,
	wounds heal and the various cell types resume their normal function.
	In tumour growth, similar processes of cell activation and growth
	factor production are observed. These processes are, however, differently
	regulated leading to ongoing cellular activation. In recent years,
	growth factors such as EGF, TGF-alpha and TGF-beta, bFGF, IGF I and
	II, and PDGF have been identified to play a role in the different
	stages of wound healing. In addition, some of these factors have
	now been identified as also being involved in the outgrowth of tumours.
	In this review, cell types involved in wound healing and tumour growth,
	as well as the growth factors and cytokines they produce and the
	role of the extracellular matrix, extensively present in both conditions,
	are being discussed. A better understanding of the time interval
	during which the sequelae of events in wound healing occur in relation
	to the time interval of tumour recurrence may be the basis for defining
	new therapeutic strategies that can interfere with tumour outgrowth
	without affecting wound healing processes. These new therapeutic
	approaches may be of importance especially after surgery or other
	invasive (diagnostic) procedures in cancer patients.},
  journal   = {Eur J Surg Oncol},
  month     = {Jun},
  owner     = {PaulD},
  pii       = {S0748798398906345},
  timestamp = {2011.06.19},
  year      = {1999},
}

@Article{Hofer1998,
  author    = {SO Hofer and D Shrayer and JS Reichner and HJ Hoekstra and HJ Wanebo},
  title     = {Wound-induced tumor progression: a probable role in recurrence after tumor resection.},
  number    = {4},
  pages     = {383-9},
  volume    = {133},
  abstract  = {OBJECTIVE: To determine the effect of several wound factors on melanoma
	growth in a mouse model. DESIGN: Cohort analytic study. SETTING:
	Animal research facility of Roger Williams Medical Center, Providence,
	RI. STUDY GROUP: Seventeen groups of 5 C57BL/6 mice each. INTERVENTIONS:
	A surgical wound was created in 1 hind limb, after which different
	concentrations of B16F10 melanoma cells were injected in adjacent
	subcutaneous tissue. The nonwounded hind limb in the same mouse served
	as a control. In this fashion, a critical tumor cell dose was determined
	that showed tumor growth in the wounded but not the control hind
	limb. Tumor growth in control hind limbs then was compared with that
	in the "artificially wounded" hind limbs, which were co-injected
	with mouse wound fluid or growth factors. Early (day 1) and late
	(day 10) wound fluids and tumor growth factor beta (TGF-beta), basic
	fibroblast growth factor (bFGF), both combined, and interleukin 6
	(IL-6) were used. MAIN OUTCOME MEASURE: Wound factors increase tumor
	growth, indicating potentiation of tumor recurrence at a surgical
	wound. RESULTS: The critical tumor cell dose was 10(3) cells. All
	growth factors and both wound fluids showed increased tumor growth
	over time except IL-6. Hind limbs injected with early wound fluid
	showed increased tumor growth over time when compared with those
	injected with late wound fluid (P<.001), TGF-beta (P<.001), bFGF
	(P<.001), and IL-6 (P<.001). Combined TGF-beta and bFGF co-injection
	resulted in increased tumor growth compared with TGF-beta (P<.001)
	and bFGF (P<.001), but did not differ significantly from early wound
	fluid (P<.07). CONCLUSIONS: The healing wound and its mediators in
	wound fluid or purified growth factors significantly enhanced tumor
	growth. Combining TGF-beta and bFGF increased tumor growth to a level
	closer to wound fluid. The inflammatory response provoked by wound
	healing mediators may be an important mechanism in tumor growth after
	ablative surgery.},
  journal   = {Arch Surg},
  month     = {Apr},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1998},
}

@Article{Hogg1994,
  author    = {Hogg, R. S. and Strathdee, S. A. and Craib, K. J. and O'Shaughnessy, M. V. and Montaner, J. S. and Schechter, M. T.},
  title     = {Lower Socioeconomic Status and Shorter Survival Following {HIV} Infection},
  pages     = {1120-1124},
  volume    = {344},
  journal   = {Lancet},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1994},
}

@Article{Holcomb2001,
  author      = {W. L. Holcomb and T. Chaiworapongsa and D. A. Luke and K. D. Burgdorf},
  title       = {An odd measure of risk: use and misuse of the odds ratio.},
  language    = {eng},
  number      = {4},
  pages       = {685--688},
  volume      = {98},
  abstract    = {OBJECTIVE: To determine how often the odds ratio, as used in clinical
	research of obstetrics and gynecology, differs substantially from
	the risk ratio estimate and to assess whether the difference in these
	measures leads to misinterpretation of research results. METHODS:
	Articles from 1998 through 1999 in Obstetrics & Gynecology and the
	American Journal of Obstetrics and Gynecology were searched for the
	term "odds ratio." The key odds ratio in each article was identified,
	and, when possible, an estimated risk ratio was calculated. The odds
	ratios and the estimated risk ratios were compared quantitatively
	and graphically. RESULTS: Of 151 studies using odds ratios, 107 were
	suitable to estimate a risk ratio. The difference between the odds
	ratio and the estimated risk ratio was greater than 20\% in 47 (44\%)
	of these articles. An odds ratio appears to magnify an effect compared
	with a risk ratio. In 39 (26\%) articles the odds ratio was interpreted
	as a risk ratio without explicit justification. CONCLUSION: The odds
	ratio is frequently used, and often misinterpreted, in the current
	literature of obstetrics and gynecology.},
  file        = {Holcomb2001.pdf:Holcomb2001.pdf:PDF;Holcomb2001.pdf:pdf\\Holcomb2001.pdf:PDF},
  institution = {Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Women's Health, St. Louis University School of Medicine, and School of Public Health, St. Louis University, St. Louis, Missouri, USA. holcombw@slucare1.sluh.edu},
  journal     = {Obstet Gynecol},
  medline-pst = {ppublish},
  month       = {Oct},
  owner       = {pl4},
  pii         = {S0029784401014880},
  pmid        = {11576589},
  timestamp   = {2010.06.01},
  year        = {2001},
}

@Article{Holford1983,
  author    = {Holford, T.R.},
  title     = {The estimation of age, period and cohort effects for vital rates},
  pages     = {311--324},
  url       = {http://www.jstor.org/stable/10.2307/2531004},
  file      = {Holford1983.pdf:Holford1983.pdf:PDF},
  journal   = {Biometrics},
  owner     = {Paul},
  timestamp = {2012.12.30},
  year      = {1983},
}

@Article{Holford1991,
  author      = {Holford, T. R.},
  title       = {Understanding the effects of age, period, and cohort on incidence and mortality rates.lan},
  doi         = {10.1146/annurev.pu.12.050191.002233},
  language    = {eng},
  pages       = {425--457},
  url         = {http://dx.doi.org/10.1146/annurev.pu.12.050191.002233},
  volume      = {12},
  abstract    = {Time trends for population-based disease rates often are summarized
	by using direct adjustment by period of diagnosis or death. Similarly,
	the effect of age often is presented graphically as age-specific
	rates for a given period of diagnosis. These approaches may be necessary
	if there is an absence of long-term data, as they provide a natural
	way for annually updating information when monitoring trends, or
	they may be a convenient way of summarizing a large amount of data
	(7, 10, 11, 39, 45). However, these summaries only can adjust for
	the effect of age in a given period; they implicitly ignore the cohort
	effect. The effect of cohort is an important factor in understanding
	time trends for many diseases. Thus, it is not advisable to use data
	analytic strategies that routinely ignore it. Another alternative
	to modeling is to give a graphical presentation of the age-specific
	rates themselves. As I noted in the introduction, some of the first
	analyses to identify the effect of cohort on diseases, such as tuberculosis
	and lung cancer, relied entirely on a graphical analysis. Although
	graphs certainly are an important part of the interpretation of time
	trends, it would be a mistake to limit your analysis to impressions
	of points on a graph. For example, such a perusal would not give
	an objective indication of the statistical significance of a particular
	pattern. Regression analysis forces us to recognize a fundamental
	problem with interpreting time trends in disease rates--a problem
	that you should remember, even when trying to understand a graphical
	display of time trends in age-specific rates.The article is concerned
	with the effects of age, period, and cohort on disease incidence
	and with mortality from that disease. The emphasis is on the interpretation
	of results from fitting regression models to data that include age,
	birth cohort, and period or year of diagnosis. Some examples are
	presented using U.S. data for lung cancer.},
  file        = {Holford1991.pdf:Holford1991.pdf:PDF},
  institution = {Yale University Medical School, New Haven, CT 06510.},
  journal     = {Annu Rev Public Health},
  medline-pst = {ppublish},
  owner       = {pl4},
  pmid        = {2049144},
  timestamp   = {2012.09.10},
  year        = {1991},
}

@Article{Hollander2006,
  author      = {N. Holl\"{a}nder and N. H. Augustin and W. Sauerbrei},
  title       = {Investigation on the improvement of prediction by bootstrap model averaging.},
  number      = {1},
  pages       = {44--50},
  volume      = {45},
  abstract    = {OBJECTIVES: We illustrate a recently proposed two-step bootstrap model
	averaging (bootstrap MA) approach to cope with model selection uncertainty.
	The predictive performance is investigated in an example and in a
	simulation study. Results are compared to those derived from other
	model selection methods. METHODS: In the framework of the linear
	regression model we use the two-step bootstrap MA, which consists
	of a screening step to eliminate covariates thought to have no influence
	on the response, and a model-averaging step. We also apply the full
	model, variable selection using backward elimination based on Akaike's
	Information Criterion (AIC), the Bayes Information Criterion (BIC)
	and the bagging approach. The predictive performance is measured
	by the mean squared error (MSE) and the coverage of confidence intervals
	for the true response. RESULTS: We obtained similar results for all
	approaches in the example. In the simulation the MSE was reduced
	by all approaches in comparison to the full model. The smallest values
	are obtained for bootstrap MA. Only the bootstrap MA and the full
	model correctly estimated the nominal coverage. The backward elimination
	procedures led to substantial underestimation and bagging to an overestimation
	of the true coverage. The screening step of bootstrap MA eliminates
	most of the unimportant factors. CONCLUSION: The new bootstrap MA
	approach shows promising results for predictive performance. It increases
	practical usefulness by eliminating unimportant factors in the screening
	step.},
  institution = {Institut f\"{u}r Medizinische Biometrie und Medizinische Informatik, Stefan-Meier-Strasse 26, 79104 Freiburg, Germany. norbert.hollaender@novartis.com},
  journal     = {Methods Inf Med},
  owner       = {pl4},
  pii         = {06010044},
  pmid        = {16482369},
  timestamp   = {2008.12.05},
  year        = {2006},
}

@Article{Holmberg2012,
  author      = {Holmberg, L. and Robinson, D. and Sandin, F. and Bray, F. and Linklater, K. M. and Klint, A. and Lambert, P. C. and Adolfsson, J. and Hamdy, F. C. and Catto, J. and M{\o}ller, H.},
  title       = {A comparison of prostate cancer survival in {E}ngland, {N}orway and {S}weden: a population-based study.},
  doi         = {10.1016/j.canep.2011.08.001},
  language    = {eng},
  number      = {1},
  pages       = {e7--12},
  url         = {http://dx.doi.org/10.1016/j.canep.2011.08.001},
  volume      = {36},
  abstract    = {The objective of the study was to compare patterns of survival 2001-2004
	in prostate cancer patients from England, Norway and Sweden in relation
	to age and period of follow-up.Excess mortality in men with prostate
	cancer was estimated using nation-wide cancer register data using
	a period approach for relative survival. 179,112 men in England,
	23,192 in Norway and 59,697 in Sweden were included.In all age groups,
	England had the lowest survival, particularly so among men aged 80+.
	Overall age-standardised five-year survival was 76.4\%, 80.3\% and
	83.0\% for England, Norway and Sweden, respectively. The majority
	of the excess deaths in England were confined to the first year of
	follow-up.The results indicate that a small but important group of
	older patients present at a late stage and succumb early to their
	cancers, possibly in combination with severe comorbidity, and this
	situation is more common in England than in Norway or Sweden.},
  file        = {Holmberg2012.pdf:Holmberg2012.pdf:PDF},
  institution = {King's College London, Medical School, Division of Cancer Studies, Section of Cancer Epidemiology, SE1 9RT London, UK. lars.holmberg@kcl.ac.uk},
  journal     = {Cancer Epidemiology},
  medline-pst = {ppublish},
  month       = {Feb},
  owner       = {pl4},
  pii         = {S1877-7821(11)00122-6},
  pmid        = {21907655},
  timestamp   = {2012.04.08},
  year        = {2012},
}

@Article{Holmberg2010,
  author      = {Holmberg, L. and Sandin, F. and Bray, F. and Richards, M. and Spicer, J. and Lambe, M. and Klint, A. and Peake, M. and Strand, T.-E. and Linklater, K. and Robinson, D. and M{\o}ller, H.},
  title       = {National comparisons of lung cancer survival in {E}ngland, {N}orway and {S}weden 2001-2004: differences occur early in follow-up.},
  doi         = {10.1136/thx.2009.124222},
  language    = {eng},
  number      = {5},
  pages       = {436--441},
  url         = {http://dx.doi.org/10.1136/thx.2009.124222},
  volume      = {65},
  abstract    = {BACKGROUND Countries with a similar expenditure on healthcare within
	Europe exhibit differences in lung cancer survival. Survival in lung
	cancer was studied in 2001-2004 in England, Norway and Sweden. METHODS
	Nationwide cancer registries in England, Norway and Sweden were used
	to identify 250 828 patients with lung cancer from England, 18 386
	from Norway and 24 886 from Sweden diagnosed between 1996 and 2004,
	after exclusion of patients registered through death certificate
	only or with missing, zero or negative survival times. 5-Year relative
	survival was calculated by application of the period approach. The
	excess mortality between the countries was compared using a Poisson
	regression model. RESULTS In all subcategories of age, sex and follow-up
	period, the 5-year survival was lower in England than in Norway and
	Sweden. The age-standardised survival estimates were 6.5\%, 9.3\%
	and 11.3\% for men and 8.4\%, 13.5\% and 15.9\% for women in the
	respective countries in 2001-2004. The difference in excess risk
	of dying between the countries was predominantly confined to the
	first year of follow-up. The relative excess risk ratio during the
	first 3 months of follow-up comparing England with Norway 2001-2004
	varied between 1.23 and 1.46, depending on sex and age, and between
	1.56 and 1.91 comparing England with Sweden. CONCLUSION Access to
	healthcare and population awareness are likely to be major reasons
	for the differences, but it cannot be excluded that diagnostic and
	therapeutic activity play a role. Future improvements in lung cancer
	management may be seen early in follow-up.},
  file        = {Holmberg2010.pdf:pdf\\Holmberg2010.pdf:PDF;Holmberg2010.pdf:Holmberg2010.pdf:PDF},
  institution = {Division of Cancer Studies, King's College London, School of Medicine, Research Oncology, 3rd Floor Bermondsey Wing, Guy's Hospital, London SE1 9RT, UK. lars.holmberg@kcl.ac.uk},
  journal     = {Thorax},
  medline-pst = {ppublish},
  owner       = {pl4},
  pii         = {65/5/436},
  pmid        = {20435867},
  timestamp   = {2013.06.24},
  year        = {2010},
}

@Article{Horm1989,
  author      = {J. W. Horm and E. J. Sondik},
  title       = {Person-years of life lost due to cancer in the United States, 1970 and 1984.},
  number      = {11},
  pages       = {1490--1493},
  volume      = {79},
  abstract    = {The number of deaths due to cancer in the United States reached an
	all-time high of 453,450 deaths in 1984 and, due to the dynamics
	of population growth, will continue to increase if the risk of dying
	from cancer does not change. Between 1970 and 1984, the total Person-Years
	of Life Lost (PYLL), the sum of the difference between the actual
	age at death and the expected remaining lifetime for each person
	who died of cancer, increased for most cancer sites as well as for
	all sites combined. In 1984, 6,881,281 person-years of life were
	lost due to cancer deaths, up from 5,303,668 in 1970. The exceptions
	are those cancers for which there has been major progress in either
	prevention or treatment; e.g., stomach and cervix uteri (prevention)
	and testicular, Hodgkin's disease, leukemia, and childhood cancers
	(treatment). The Average Years of Life Lost (AYLL) per person dying
	from cancer in 1984 was generally less than in 1970. Overall, each
	person who died from cancer in 1984 died 15.2 years earlier than
	his/her life expectancy. The greatest loss was for those who died
	of childhood cancers (66.9 years earlier), followed by testicular
	cancer (35.8 years earlier). The least loss relative to the expectation
	of life was for those who died of prostate cancer. The 25,400 men
	who died from prostate cancer in 1984 died an average of nine years
	earlier than otherwise expected.},
  file        = {Horm1989.pdf:pdf\\Horm1989.pdf:PDF;Horm1989.pdf:Horm1989.pdf:PDF},
  institution = {Division of Cancer Prevention and Control, National Cancer Institute, Bethesda, MD 20892.},
  journal     = {Am J Public Health},
  month       = {Nov},
  owner       = {pl4},
  pmid        = {2817158},
  timestamp   = {2009.03.26},
  year        = {1989},
}

@Book{Hosmer2008,
  author    = {D.W. Hosmer and S. Lemeshow and S. May},
  title     = {Applied Survival Analysis: Regression Modeling of Time to Event Data, Second Edition},
  publisher = {Wiley},
  owner     = {pl4},
  timestamp = {2009.11.04},
  year      = {2008},
}

@Article{vanHouw00,
  author    = {H. C. van Houwelingen},
  title     = {Validation, calibration, revision and combination of prognostic survival models},
  pages     = {3401--3415},
  volume    = {19},
  file      = {vanHouw00.pdf:vanHouw00.pdf:PDF;vanHouw00.pdf:pdf\\vanHouw00.pdf:PDF},
  journal   = {Statistics in Medicine},
  owner     = {pl4},
  timestamp = {2010.03.08},
  year      = {2000},
}

@Article{Howlader2014,
  author      = {Howlader, Nadia and Mariotto, Angela B. and Woloshin, Steven and Schwartz, Lisa M.},
  title       = {Providing clinicians and patients with actual prognosis: cancer in the context of competing causes of death.},
  doi         = {10.1093/jncimonographs/lgu022},
  language    = {eng},
  number      = {49},
  pages       = {255--264},
  url         = {http://dx.doi.org/10.1093/jncimonographs/lgu022},
  volume      = {2014},
  abstract    = {To isolate progress against cancer from changes in competing causes
	of death, population cancer registries have traditionally reported
	cancer prognosis (net measures). But clinicians and cancer patients
	generally want to understand actual prognosis (crude measures): the
	chance of surviving, dying from the specific cancer and from competing
	causes of death in a given time period.To compare cancer and actual
	prognosis in the United States for four leading cancers-lung, breast,
	prostate, and colon-by age, comorbidity, and cancer stage and to
	provide templates to help patients, clinicians, and researchers understand
	actual prognosis.Using population-based registry data from the Surveillance,
	Epidemiology, and End Results (SEER) Program, we calculated cancer
	prognosis (relative survival) and actual prognosis (five-year overall
	survival and the "crude" probability of dying from cancer and competing
	causes) for three important prognostic determinants (age, comorbidity
	[Charlson-score from 2012 SEER-Medicare linkage dataset] and cancer
	stage at diagnosis).For younger, healthier, and earlier stage cancer
	patients, cancer and actual prognosis estimates were quite similar.
	For older and sicker patients, these prognosis estimates differed
	substantially. For example, the five-year overall survival for an
	85-year-old patient with colorectal cancer is 54\% (cancer prognosis)
	versus 22\% (actual prognosis)-the difference reflecting the patient's
	substantial chance of dying from competing causes. The corresponding
	five-year chances of dying from the patient's cancer are 46\% versus
	37\%. Although age and comorbidity lowered actual prognosis, stage
	at diagnosis was the most powerful factor: The five-year chance of
	colon cancer death was 10\% for localized stage and 83\% for distant
	stage.Both cancer and actual prognosis measures are important. Cancer
	registries should routinely report both cancer and actual prognosis
	to help clinicians and researchers understand the difference between
	these measures and what question they can and cannot answer. We encourage
	them to use formats like the ones presented in this paper to communicate
	them clearly.},
  file        = {Howlader2014.pdf:Howlader2014.pdf:PDF;Howlader2014.pdf:pdf\\Howlader2014.pdf:PDF},
  institution = {Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD (NH, AM); Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH, Department of Veterans Affairs Medical Center, Veterans Affairs Outcomes Group, White River Junction, VT (SW, LMS).},
  journal     = {J Natl Cancer Inst Monogr},
  medline-pst = {ppublish},
  month       = {Nov},
  owner       = {PaulD},
  pii         = {lgu022},
  pmid        = {25417239},
  timestamp   = {2014.12.05},
  year        = {2014},
}

@Article{Howlader2010,
  author      = {Howlader, Nadia and Ries, Lynn A G. and Mariotto, Angela B. and Reichman, Marsha E. and Ruhl, Jennifer and Cronin, Kathleen A.},
  title       = {Improved estimates of cancer-specific survival rates from population-based data.},
  doi         = {10.1093/jnci/djq366},
  language    = {eng},
  number      = {20},
  pages       = {1584--1598},
  url         = {http://dx.doi.org/10.1093/jnci/djq366},
  volume      = {102},
  abstract    = {Accurate estimates of cancer survival are important for assessing
	optimal patient care and prognosis. Evaluation of these estimates
	via relative survival (a ratio of observed and expected survival
	rates) requires a population life table that is matched to the cancer
	population by age, sex, race and/or ethnicity, socioeconomic status,
	and ideally risk factors for the cancer under examination. Because
	life tables for all subgroups in a study may be unavailable, we investigated
	whether cause-specific survival could be used as an alternative for
	relative survival.We used data from the Surveillance, Epidemiology,
	and End Results Program for 2,330,905 cancer patients from January
	1, 1992, through December 31, 2004. We defined cancer-specific deaths
	according to the following variables: cause of death, only one tumor
	or the first of multiple tumors, site of the original cancer diagnosis,
	and comorbidities. Estimates of relative survival and cause-specific
	survival that were derived by use of an actuarial method were compared.Among
	breast cancer patients who were white, black, or of Asian or Pacific
	Islander descent and who were older than 65 years, estimates of 5-year
	relative survival (107.5\%, 106.6\%, and 103.0\%, respectively) were
	higher than estimates of 5-year cause-specific survival (98.6\%,
	95\% confidence interval [CI] = 98.4\% to 98.8\%; 97.4\%, 95\% CI
	= 96.2\% to 98.2\%; and 99.2\%, 95\% CI = 98.4\%, 99.6\%, respectively).
	Relative survival methods likely underestimated rates for cancers
	of the oral cavity and pharynx (eg, for white cancer patients aged
	{\AA}Â¢ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Â°ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¥65 years, relative survival = 54.2\%, 95\% CI = 53.1\% to 55.3\%,
	and cause-specific survival = 60.1\%, 95\% CI = 59.1\% to 60.9\%)
	and the lung and bronchus (eg, for black cancer patients aged {\AA}Â¢ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Â°ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¥65
	years, relative survival = 10.5\%, 95\% CI = 9.9\% to 11.2\%, and
	cause-specific survival = 11.9\%, 95\% CI = 11.2 \% to 12.6\%), largely
	because of mismatches between the population with these diseases
	and the population used to derive the life table. Socioeconomic differences
	between groups with low and high status in relative survival estimates
	appeared to be inflated (eg, corpus and uterus socioeconomic status
	gradient was 13.3\% by relative survival methods and 8.8\% by cause-specific
	survival methods).Although accuracy of the cause of death on a death
	certificate can be problematic for cause-specific survival estimates,
	cause-specific survival methods may be an alternative to relative
	survival methods when suitable life tables are not available.},
  file        = {Howlader2010.pdf:Howlader2010.pdf:PDF;Howlader2010.pdf:pdf\\Howlader2010.pdf:PDF},
  institution = {Data Analysis and Interpretation Branch, Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, 6116 Executive Blvd, Ste 504, Bethesda, MD 20892-8315, USA. howladern@mail.nih.gov},
  journal     = {J Natl Cancer Inst},
  medline-pst = {ppublish},
  month       = {Oct},
  owner       = {Paul},
  pii         = {djq366},
  pmid        = {20937991},
  timestamp   = {2012.05.14},
  year        = {2010},
}

@Article{Hristova1997,
  author    = {Hristova, L. and Hakama, M.},
  title     = {Effect of Screening for Cancer in the {N}ordic Countries on Deaths, Costs and Quality of Life up to the Year 2017},
  pages     = {1-60},
  volume    = {36 (Suppl. 9)},
  journal   = {Acta Oncologica},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1997},
}

@Article{Hsieh2002,
  author    = {Hsieh, Hsin-Ju and Chen, Tony Hsiu-Hsi and Chang, Shu-Hui},
  title     = {Assessing chronic disease progression using non-homogeneous exponential regression Markov models: an illustration using a selective breast cancer screening in Taiwan},
  number    = {22},
  pages     = {3369--3382},
  volume    = {21},
  journal   = {Statistics in medicine},
  owner     = {miccro},
  publisher = {Wiley Online Library},
  timestamp = {2015.10.28},
  year      = {2002},
}

@Article{Hsu2003,
  author      = {Ronald T Hsu and Paul C Lambert and Mary Dixon-Woods and Jennifer J Kurinczuk},
  title       = {Effect of {NHS} walk-in centre on local primary healthcare services: before and after observational study.},
  doi         = {10.1136/bmj.326.7388.530},
  number      = {7388},
  pages       = {530},
  url         = {http://dx.doi.org/10.1136/bmj.326.7388.530},
  volume      = {326},
  abstract    = {OBJECTIVE: To assess the effect of an NHS walk-in centre on local
	primary and emergency healthcare services. DESIGN: Before and after
	observational study. SETTING: Loughborough, which had an NHS walk-in
	centre, and Market Harborough, the control town. PARTICIPANTS: 12
	general practices. MAIN OUTCOME MEASURES: Mean daily rate of emergency
	general practitioner consultations, mean number of half days to the
	sixth bookable routine appointment, and attendance rates at out of
	hours services, minor injuries units, and accident and emergency
	departments. RESULTS: The change between the before and after study
	periods was not significantly different in the two towns for daily
	rate of emergency general practice consultations (mean difference
	-0.02/1000 population, 95\% confidence interval -0.75 to 0.71), the
	time to the sixth bookable routine appointment (-0.24 half-days,
	-1.85 to 1.37), and daily rate of attendances at out of hours services
	(0.07/1000 population, -0.06 to 0.19). However, attendance at the
	local minor injuries unit was significantly higher in Loughborough
	than Market Harborough (rate ratio 1.22, 1.12 to 1.33). Non-ambulance
	attendances at accident and emergency departments fell less in Loughborough
	than Market Harborough (rate ratio 1.17, 1.03 to 1.33). CONCLUSIONS:
	The NHS walk-in centre did not greatly affect the workload of local
	general practitioners. However, the workload of the local minor injuries
	unit increased significantly, probably because it was in the same
	building as the walk-in centre.},
  file        = {hsu2003.pdf:hsu2003.pdf:PDF},
  institution = {Department of Epidemiology and Public Health, University of Leicester, Leicester LE1 6TP. rth4@leicester.ac.uk},
  journal     = {BMJ},
  month       = {Mar},
  owner       = {pl4},
  pii         = {326/7388/530},
  pmid        = {12623913},
  timestamp   = {2008.10.15},
  year        = {2003},
}

@Electronic{England_lifetables,
  author       = {http://www.statistics.gov.uk/downloads/theme_population/Interim_Life/ILTUK0608Reg.xls},
  howpublished = {(last accessed 22/2/2011)},
  owner        = {pl4},
  timestamp    = {2010.03.19},
}

@Article{Hu2002,
  author      = {G. Hu and B. Modrek and H. M F Riise Stensland and J. Saarela and P. Pajukanta and V. Kustanovich and L. Peltonen and S. F. Nelson and C. Lee},
  title       = {Efficient discovery of single-nucleotide polymorphisms in coding regions of human genes.},
  doi         = {10.1038/sj.tpj.6500109},
  number      = {4},
  pages       = {236--242},
  url         = {http://dx.doi.org/10.1038/sj.tpj.6500109},
  volume      = {2},
  abstract    = {Single nucleotide polymorphisms in protein coding regions (cSNPs)
	are of great interest for their effects on phenotype and potential
	for mapping disease genes. We have identified 5,400 novel exonic
	SNPs from alignments of public EST data to the draft human genome
	sequence, and approximately 12,000 more novel exonic SNPs from EST
	cluster alignments. We found 82\% of the genomic-aligned SNPs and
	63\% of the EST-only SNPs to be detectably polymorphic in 20 Finnish
	DNA samples. 37\% of the SNPs mapped to known protein coding regions,
	yielding 6,500 distinct, novel cSNPs from the two datasets. These
	data reveal selection against mutations that alter protein structure,
	and distinct classes of genes under strongly positive vs. negative
	pressure from natural selection for amino acid replacement (detected
	by K(A)/K(S)ratio). We have searched these cSNPs for compatibility
	with the amino acid profile at each site and structural impact on
	protein core stability.},
  institution = {Department of Chemistry and Biochemistry, University of California, Los Angeles, CA, USA.},
  journal     = {Pharmacogenomics J},
  owner       = {pl4},
  pmid        = {12196912},
  timestamp   = {2011.05.26},
  year        = {2002},
}

@Article{Huberman1999,
  author    = {M Huberman and B Langholz},
  title     = {Application of the missing-indicator method in matched case-control studies with incomplete data.},
  number    = {12},
  pages     = {1340-5},
  volume    = {150},
  abstract  = {A common practice in matched case-control studies with incomplete
	data is to perform two analyses in parallel: a matched analysis of
	the complete pairs and an unmatched analysis of all subjects carried
	out after breaking the matching in the complete pairs. The missing-indicator
	method, which has the advantage of making use of the data in the
	incomplete pairs while still preserving the matching in the complete
	pairs, is recommended as an alternative method of analysis. It is
	shown here that its estimate of the odds ratio is a compromise between
	the odds ratios estimated by a matched analysis of the complete pairs
	and an unmatched analysis of the incomplete pairs. The method is
	illustrated using data from a matched case-control study of the risk
	of childhood leukemia from exposure to residential electric and magnetic
	fields.},
  journal   = {Am J Epidemiol},
  month     = {Dec},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1999},
}

@Article{Huschitt2014,
  author      = {Huschitt, S. and Strau{\ss}, P. and Plaksin, A. and Siech, M.},
  title       = {[Video-Assisted Transanal Endoscopic Microsurgery of Rectal Tumours - V-TEM].},
  doi         = {10.1055/s-0032-1315101},
  language    = {ger},
  pages       = {e49--e54},
  url         = {http://dx.doi.org/10.1055/s-0032-1315101},
  volume      = {139 Suppl 2},
  abstract    = {Transanal endoscopic microsurgery (TEM) has become increasingly established
	as the method of choice for the local resection of endoscopically
	unresectable rectal adenomas and early-stage, low-risk rectal carcinomas.
	Multiple studies have shown that the single port-technique TEM results
	in significantly less trauma with comparable overall treatment outcome
	as compared to conventional radical surgical techniques. However,
	TEM is not widely used due to high initial set-up costs, the need
	for highly complex equipment and demanding surgical skill requirements.To
	mitigate these challenges we have successfully developed a video-assisted
	TEM (V-TEM) method, which resulted in approximately 50?\% lower initial
	set-up costs through the introduction of simplified original TEM
	surgical equipment. Between October 2003 and September 2011 we have
	completed 103 resections using the V-TEM method.The observed rates
	of complications and local recurrences are comparable to reported
	rates.We were able to mitigate the challenges of TEM through the
	establishment of the technically less demanding V-TEM method, which
	resulted in approximately 50?\% lower initial set-up costs while
	maintaining overall treatment outcomes.},
  institution = {Klinik f{\AA}Â¼r Allgemein-, Thorax- und Gef{\"a}{\AA}ÂŸchirurgie, Ostalb-Klinikum Aalen, Aalen, Deutschland.},
  journal     = {Zentralbl Chir},
  medline-pst = {ppublish},
  month       = {Dec},
  owner       = {pl4},
  pmid        = {23468401},
  timestamp   = {2015.01.30},
  year        = {2014},
}

@Article{Hussain2008,
  author    = {Hussain, S. K. and Altieri, A. and Sundquist, J. and Hemminki, K.},
  title     = {Influence of education level on breast cancer risk and survival in {S}weden between 1990 and 2004},
  pages     = {165-169},
  volume    = {122},
  file      = {Hussain2008.pdf:pdf\\Hussain2008.pdf:PDF;Hussain2008.pdf:Hussain2008.pdf:PDF},
  journal   = {International Journal of Cancer},
  owner     = {hanbow},
  timestamp = {2016.09.13},
  year      = {2008},
}

@Article{Hwang1999,
  author      = {Hwang, J. S. and Wang, J. D.},
  title       = {Monte Carlo estimation of extrapolation of quality-adjusted survival for follow-up studies.},
  language    = {eng},
  number      = {13},
  pages       = {1627--1640},
  volume      = {18},
  abstract    = {The expected quality-adjusted survival (QAS) for an index population
	with a specific disease can be estimated by summing the product of
	the survival function and the mean quality of life function of the
	population. In many follow-up studies with heavy censoring, the expected
	QAS may not be well estimated due to the lack of data beyond the
	close of follow-up. In this paper, we first created a reference population
	from the life tables of the general population according to the Monte
	Carlo method. Secondly, we fitted a simple linear regression line
	to the logit of the ratio of quality-adjusted survival functions
	for the index and reference populations up to the end of follow-up.
	Finally, combining information on the reference population with the
	fitted line, we predicted the expected quality-adjusted survival
	curve beyond the follow-up period for the index population. Simulation
	studies have shown that the simple Monte Carlo estimation procedure
	is a potential approach for estimating expected QAS and the survival
	function beyond the follow-up with a certain degree of accuracy.},
  file        = {:pdf/Hwang_1999.pdf:PDF},
  institution = {Institute of Statistical Science, Academia Sinica, Taipei 115, Taiwan. jshwang@stat.sinica.edu.tw},
  journal     = {Statistics in Medicine},
  keywords    = {Computer Simulation; Female; Follow-Up Studies; Humans; Life Tables; Linear Models; Male; Middle Aged; Monte Carlo Method; Proportional Hazards Models; Quality-Adjusted Life Years; Survival Analysis; Survival Rate; Taiwan, epidemiology},
  medline-pst = {ppublish},
  month       = {Jul},
  owner       = {theand},
  pii         = {3.0.CO;2-D},
  pmid        = {10407234},
  timestamp   = {2012.09.17},
  year        = {1999},
}

@Article{Iachina2002,
  author    = {Iachina, M. and Jorgensen, B. and Christensen, K. and Iachine, I.},
  title     = {Analysis of functional abilities for elderly {D}anish twins using {GEE} models},
  pages     = {289-93},
  volume    = {5},
  journal   = {Twin Res},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2002},
}

@Article{Iacobelli2013,
  author      = {Iacobelli, S. and Carstensen, B.},
  title       = {Multiple time scales in multi-state models.},
  doi         = {10.1002/sim.5976},
  language    = {eng},
  number      = {30},
  pages       = {5315--5327},
  url         = {http://dx.doi.org/10.1002/sim.5976},
  volume      = {32},
  abstract    = {In multi-state models, it has been the tradition to model all transition
	intensities on one time scale, usually the time since entry into
	the study ('clock-forward' approach). The effect of time since an
	intermediate event has been accommodated either by changing the time
	scale to time since entry to the new state ('clock-back' approach)
	or by including the time at entry to the new state as a covariate.
	In this paper, we argue that the choice of time scale for the various
	transitions in a multi-state model should be dealt with as an empirical
	question, as also the question of whether a single time scale is
	sufficient. We illustrate that these questions are best addressed
	by using parametric models for the transition rates, as opposed to
	the traditional Cox-model-based approaches. Specific advantages are
	that dependence of failure rates on multiple time scales can be made
	explicit and described in informative graphical displays. Using a
	single common time scale for all transitions greatly facilitates
	computations of probabilities of being in a particular state at a
	given time, because the machinery from the theory of Markov chains
	can be applied. However, a realistic model for transition rates is
	preferable, especially when the focus is not on prediction of final
	outcomes from start but on the analysis of instantaneous risk or
	on dynamic prediction. We illustrate the various approaches using
	a data set from stem cell transplant in leukemia and provide supplementary
	online material in R.},
  file        = {Iacobelli2013.pdf:Iacobelli2013.pdf:PDF},
  institution = {Centro Interdipartimentale di Biostatistica e Bioinformatica, Universit{\AA}Â  Tor Vergata, Rome, Italy; Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation, Leiden, the Netherlands.},
  journal     = {Statistics in Medicine},
  keywords    = {Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, therapy; Markov Chains; Mesenchymal Stem Cell Transplantation, standards; Models, Statistical; Recurrence; Time Factors},
  medline-pst = {ppublish},
  month       = {Dec},
  owner       = {pl4},
  pmid        = {24027131},
  timestamp   = {2015.04.19},
  year        = {2013},
}

@Article{Ibrahim2010,
  author      = {Ibrahim, J.G. and Chu, H. and Chen, L.M.},
  title       = {Basic concepts and methods for joint models of longitudinal and survival data.},
  doi         = {10.1200/JCO.2009.25.0654},
  language    = {eng},
  number      = {16},
  pages       = {2796--2801},
  url         = {http://dx.doi.org/10.1200/JCO.2009.25.0654},
  volume      = {28},
  abstract    = {Joint models for longitudinal and survival data are particularly relevant
	to many cancer clinical trials and observational studies in which
	longitudinal biomarkers (eg, circulating tumor cells, immune response
	to a vaccine, and quality-of-life measurements) may be highly associated
	with time to event, such as relapse-free survival or overall survival.
	In this article, we give an introductory overview on joint modeling
	and present a general discussion of a broad range of issues that
	arise in the design and analysis of clinical trials using joint models.
	To demonstrate our points throughout, we present an analysis from
	the Eastern Cooperative Oncology Group trial E1193, as well as examine
	some operating characteristics of joint models through simulation
	studies.},
  file        = {Ibrahim2010.pdf:pdf\\Ibrahim2010.pdf:PDF;Ibrahim2010.pdf:Ibrahim2010.pdf:PDF},
  institution = {Department of Biostatistics, University of North Carolina, Chapel Hill, NC 27599, USA. ibrahim@bios.unc.edu},
  journal     = {Journal of Clinical Oncology},
  medline-pst = {ppublish},
  month       = {Jun},
  owner       = {pl4},
  pii         = {JCO.2009.25.0654},
  pmid        = {20439643},
  timestamp   = {2012.04.13},
  year        = {2010},
}

@Article{Ishiguro1997,
  author    = {Ishiguro, M. and Sakamoto, Y. and Kitagawa, G.},
  title     = {Bootstrapping log likelihood and EIC, an extention of AIC},
  pages     = {411-434},
  volume    = {49},
  file      = {Ishiguro1997.pdf:pdf\\Ishiguro1997.pdf:PDF;Ishiguro1997.pdf:Ishiguro1997.pdf:PDF},
  journal   = {Annals of the Institute of Statistical Mathematics},
  owner     = {hanbow},
  timestamp = {2015.05.26},
  year      = {1997},
}

@Article{Ito2012,
  author      = {Ito, Yuri and Nakayama, Tomio and Tsukuma, Hideaki and Miyashiro, Isao and Ioka, Akiko and Sugimoto, Tomoyuki and Rachet, Bernard},
  title       = {Role of age and tumour stage in the temporal pattern of 'cure' from stomach cancer: A population-based study in {O}saka, {J}apan.},
  doi         = {10.1016/j.canep.2011.12.008},
  language    = {eng},
  number      = {2},
  pages       = {128--132},
  url         = {http://dx.doi.org/10.1016/j.canep.2011.12.008},
  volume      = {36},
  abstract    = {Objectives: To evaluate progress in stomach cancer care in Japan since
	1975. Design: Population-based study of data extracted from the Osaka
	Cancer Registry. Setting: Population-based cancer registry in the
	area of Osaka Prefecture. Participants: All 66,032 cases diagnosed
	with a stomach cancer in Osaka Prefecture, Japan between 1975 and
	2000 and registered in the Osaka Cancer Registry. Main outcome measures:
	'Cure' fraction and median survival time for 'uncured' patients were
	estimated with multivariable mixture 'cure' model. The role played
	by age and stage at diagnosis on the changes in 'cure' parameters
	between 1975 and 2000 was evaluated. Missing stage was handled by
	multiple imputation approach. Results: More than 50\% of the patients
	diagnosed with a stomach cancer in 1996-2000 were estimated 'cured'
	from their cancer, corresponding to a 20\% increase since 1975-1980.
	Median survival time for 'uncured' patients however remained unchanged
	at about 8 months. 'Cure' fraction was over 85\% for localised tumours
	and 30\% for regional tumours, but stayed as low as 2.5\% for distant
	metastatic cancers. Improvement was underestimated by about 10\%
	because of ageing of cancer patients. Changes in stage distribution
	explained up to 40\% of the increase in 'cure' fraction among men
	and up to 13\% in women. Overdiagnosis was unlikely to play any role
	in these patterns. Conclusions: 'Cure' fraction from stomach cancer
	dramatically increased in Osaka, Japan since 1975, partly because
	of earlier stage at diagnosis, but mostly due to improvement in treatment
	of stomach cancer patients. This study, based on a leading country
	in term of stomach cancer management, provides insightful results
	for other countries in which 'cure' fraction is usually much lower.},
  institution = {Center for Cancer Control and Statistics, Osaka Medical Centre for Cancer and Cardiovascular Diseases, Osaka, Japan.},
  journal     = {Cancer Epidemiol},
  medline-pst = {ppublish},
  month       = {Apr},
  owner       = {pl4},
  pii         = {S1877-7821(11)00202-5},
  pmid        = {22300953},
  timestamp   = {2012.03.31},
  year        = {2012},
}

@Article{Jaegerstad2005,
  author    = {Margaretha J\"{a}gerstad and Kerstin Skog},
  title     = {Genotoxicity of heat-processed foods.},
  doi       = {10.1016/j.mrfmmm.2005.01.030},
  pages     = {156--172},
  url       = {http://dx.doi.org/10.1016/j.mrfmmm.2005.01.030},
  volume    = {574},
  abstract  = {Gene-environment interactions include exposure to genotoxic compounds
	from our diet and it is no doubt, that humans are regularly exposed
	to e.g. food toxicants, not least from cooked foods. This paper reviews
	briefly four classes of cooked food toxicants, e.g. acrylamide, heterocyclic
	amines, nitrosamines and polyaromatic hydrocarbons. Many of these
	compounds have been recognised for decades also as environmental
	pollutants. In addition cigarette smokers and some occupational workers
	are exposed to them. Their occurrence, formation, metabolic activation,
	genotoxicity and human cancer risk are briefly presented along with
	figures on estimated exposure. Several lines of evidence indicate
	that cooking conditions and dietary habits can contribute to human
	cancer risk through the ingestion of genotoxic compounds from heat-processed
	foods. Such compounds cause different types of DNA damage: nucleotide
	alterations and gross chromosomal aberrations. Most genotoxic compounds
	begin their action at the DNA level by forming carcinogen-DNA adducts,
	which result from the covalent binding of a carcinogen or part of
	a carcinogen to a nucleotide. The genotoxic and carcinogenic potential
	of these cooked food toxicants have been evaluated regularly by the
	International Agency for Research on Cancer (IARC), which has come
	to the conclusion that several of these food-borne toxicants present
	in cooked foods are possibly (2A) or probably (2B) carcinogenic to
	humans, based on both high-dose, long-term animal studies and in
	vitro and in vivo genotoxicity tests. Yet, there is insufficient
	scientific evidence that these genotoxic compounds really cause human
	cancer, and no limits have been set for their presence in cooked
	foods. However, the competent authorities in most Western countries
	recommend minimising their occurrence, therefore this aspect is also
	included in this review.},
  journal   = {Mutat Res},
  owner     = {PaulD},
  pii       = {S0027-5107(05)00097-7},
  pmid      = {15914214},
  timestamp = {2005.11.17},
  year      = {2005},
}

@Article{Jackson2011,
  author    = {Jackson, Christopher H},
  title     = {Multi-state models for panel data: the msm package for R},
  number    = {8},
  pages     = {1--29},
  volume    = {38},
  journal   = {Journal of Statistical Software},
  owner     = {miccro},
  timestamp = {2015.10.27},
  year      = {2011},
}

@Article{Jahnukainen2007,
  author      = {Timo Jahnukainen and Marja Ala-Houhala and Ville Saarela and Matti Nuutinen},
  title       = {[Not Available].},
  number      = {1},
  pages       = {73--80},
  volume      = {123},
  institution = {TYKS:n lastenklinikka, Turku. timo.jahnukainen@tyks.fi},
  journal     = {Duodecim},
  owner       = {pl4},
  pmid        = {17328296},
  timestamp   = {2011.05.26},
  year        = {2007},
}

@Article{Jalonen2002,
  author      = {Tuula O Jalonen and Kati Pulkkinen and Maritta Ukkonen and Marika Saarela and Irina Elovaara},
  title       = {Differential intracellular expression of CCR5 and chemokines in multiple sclerosis subtypes.},
  doi         = {10.1007/s004150200067},
  number      = {5},
  pages       = {576--583},
  url         = {http://dx.doi.org/10.1007/s004150200067},
  volume      = {249},
  abstract    = {Chemokines are small chemoattractant cytokines which participate in
	the migration of immune cells into the CNS and contribute to the
	T cell-mediated pathogenesis of multiple sclerosis (MS). The expression
	of chemokines and their receptors in freshly isolated mononuclear
	cells from peripheral blood (PBMC) was studied in relation to MS
	subtype, disease duration and progression in a total of 57 patients
	with MS (22 relapsing remitting, RRMS; 21 secondary progressive,
	SPMS; 14 primary progressive, PPMS) and 17 healthy controls. The
	RNA expression of CCR5 in PBMC was analysed by reverse transcription
	polymerase chain reaction (RT-PCR) using specific oligonucleotide
	primers. The PBMC levels of CCR5-ligands MIP-1 alpha/beta and RANTES,
	and chemokines MCP-1, IL-8, lymphotactin, IP-10 and I-309 were analysed
	by ribonuclease protection assay (RPA). Significantly increased intracellular
	CCR5 RNA expression intensity was detected in PPMS when compared
	with SPMS ( p=0.009), RRMS ( p=0.013), and controls ( p=0.023). However,
	the surface expression of CCR5 on CD4(+) cells from PBMC, analysed
	by flow cytometry, appeared to be similar in all MS subtypes and
	controls. The CCR5-ligands RANTES and MIP-1b were expressed constitutively
	in all patients and controls. Interleukin-8 was found in all MS subtypes
	and controls, but IP-10 was detected only in RRMS and SPMS, and lymphotactin
	occasionally in other subtypes but PPMS. MCP-1, MIP-1a or I-309 were
	not expressed in any of the groups studied. A correlation was found
	between the RNA levels of RANTES and CCR5 in PPMS ( r=0.735). Differential
	profile in the expression of CCR5 and chemokines between PPMS and
	other MS subtypes may contribute to differences in the pathogenesis
	of MS and thus can be of importance in the development of new treatments
	for MS.},
  institution = {Medical School, University of Tampere.},
  journal     = {J Neurol},
  month       = {May},
  owner       = {pl4},
  pmid        = {12021948},
  timestamp   = {2011.05.26},
  year        = {2002},
}

@Article{Janes2007,
  author      = {Rita Janes and P\"{a}ivi Vieira and Mika Saarela and Kirsi Aaltonen and Tuomo Alanko and Sanna Siitonen and Marja-Liisa Karjalainen-Lindsberg},
  title       = {[Not Available].},
  number      = {4},
  pages       = {413--418},
  volume      = {123},
  file        = {:Janes2010.pdf:PDF},
  institution = {HYKS:n sy\"{o}p\"{a}tautien klinikka, HUS. rita.janes@hus.fi},
  journal     = {Duodecim},
  owner       = {pl4},
  pmid        = {17405706},
  timestamp   = {2011.05.26},
  year        = {2007},
}

@Article{Jann2007,
  author    = {B. Jann},
  title     = {Making regression tables simplified},
  pages     = {227-224},
  volume    = {7},
  file      = {Jann2007.pdf:Jann2007.pdf:PDF;Jann2007.pdf:pdf\\Jann2007.pdf:PDF},
  journal   = {The Stata Journal},
  owner     = {pl4},
  timestamp = {2008.11.21},
  year      = {2007},
}

@Article{Jansen2013,
  author      = {Jansen, L. and Hakulinen, T. and Brenner, H.},
  title       = {Study populations for period analyses of cancer survival.},
  doi         = {10.1038/bjc.2013.14},
  language    = {eng},
  number      = {3},
  pages       = {699--707},
  url         = {http://dx.doi.org/10.1038/bjc.2013.14},
  volume      = {108},
  abstract    = {Period analysis is increasingly used to compute long-term cancer survival,
	as it provides better prediction of survival of newly diagnosed patients
	than traditional cohort analysis. However, the patient population
	to which period survival estimates best pertain to and which should
	be described in a study is less obvious.Using Finnish Cancer Registry
	data on 23 common cancer sites, age-standardized period estimates
	of 5-, 10-, 15-, and 20-year relative survival were computed for
	each 2-, 5-, and 10-year calendar period in 1954-2003 and compared
	with survival estimates for two cohorts by means of mean, mean absolute
	and mean squared differences: a full cohort of all patients potentially
	contributing some data to the survival analysis and a restricted
	cohort of patients diagnosed in the period of interest.In most computations,
	survival estimates for the full cohorts were on average closer to
	the period estimates for the majority of cancer sites. For 10-year
	survival, results were less obvious with respect to the mean difference.
	However, mean squared and mean absolute differences were smaller
	for the majority of cancers when using the full cohort.Our results
	suggest that the full cohort should be described in reports of period
	survival analysis.},
  file        = {Jansen2013.pdf:Jansen2013.pdf:PDF;Jansen2013.pdf:pdf\\Jansen2013.pdf:PDF},
  institution = {Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Im Neuenheimer Feld 581, Heidelberg 69120, Germany. l.jansen@dkfz.de},
  journal     = {Br J Cancer},
  keywords    = {Age Factors; Cohort Studies; Female; Finland, epidemiology; Follow-Up Studies; Humans; Male; Neoplasms, epidemiology/mortality; Prognosis; Registries; Survival Rate; Time Factors},
  medline-pst = {ppublish},
  month       = {Feb},
  owner       = {PaulD},
  pii         = {bjc201314},
  pmid        = {23361050},
  timestamp   = {2015.03.23},
  year        = {2013},
}

@Article{Jansen2012,
  author      = {Jansen, L. and Hakulinen, T. and Brenner, H.},
  title       = {Standard errors of non-standardised and age-standardised relative survival of cancer patients.},
  doi         = {10.1038/bjc.2011.560},
  language    = {eng},
  number      = {3},
  pages       = {569--574},
  url         = {http://dx.doi.org/10.1038/bjc.2011.560},
  volume      = {106},
  abstract    = {Relative survival estimates cancer survival in the absence of other
	causes of death. Previous work has shown that standard errors of
	non-standardised relative survival may be substantially overestimated
	by the conventionally used method. However, evidence was restricted
	to non-standardised relative survival estimates using Hakulinen's
	method. Here, we provide a more comprehensive evaluation of the accuracy
	of standard errors including age-standardised survival and estimation
	by the Ederer II method.Five- and ten-year non-standardised and age-standardised
	relative survival was estimated for patients diagnosed with 25 common
	forms of cancer in Finland in 1989-1993, using data from the nationwide
	Finnish Cancer Registry. Standard errors of mutually comparable non-standardised
	and age-standardised relative survival were computed by the conventionally
	used method and compared with bootstrap standard errors.When using
	Hakulinen's method, standard errors of non-standardised relative
	survival were overestimated by up to 28\%. In contrast, standard
	errors of age-standardised relative survival were accurately estimated.
	When using the Ederer II method, deviations of the standard errors
	of non-standardised and age-standardised relative survival were generally
	small to negligible.In most cases, overestimations of standard errors
	are effectively overcome by age standardisation and by using Ederer
	II rather than Hakulinen's method.},
  file        = {Jansen2012.pdf:Jansen2012.pdf:PDF;Jansen2012.pdf:pdf\\Jansen2012.pdf:PDF},
  institution = {Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), POB 10 19 49, Heidelberg D-69009, Germany.},
  journal     = {Br J Cancer},
  keywords    = {Adolescent; Adult; Age Factors; Aged; Data Interpretation, Statistical; Female; Finland, epidemiology; Humans; Male; Middle Aged; Neoplasms, mortality; Registries; Survival Analysis; Young Adult; ology)},
  medline-pst = {ppublish},
  month       = {Jan},
  owner       = {PaulD},
  pii         = {bjc2011560},
  pmid        = {22173672},
  timestamp   = {2015.03.23},
  year        = {2012},
}

@Article{Janssen-Heijnen01,
  author    = {M. L. Janssen-Heijnen and J. W. Coebergh and P. J. Klinkhamer and R. M. Schipper and T. A. Splinter and W. J. Mooi},
  title     = {Is there a common etiology for the rising incidence of and decreasing survival with adenocarcinoma of the lung?},
  number    = {2},
  pages     = {256-8},
  volume    = {12},
  abstract  = {We studied possible explanations for the deteriorating survival for
	adenocarcinoma of the lung between 1975 and 1994 in relation with
	trends in incidence. The proportion of adenocarcinoma among men has
	been increasing since 1975 and for those born after 1920, while survival
	has decreased since 1975 and for those born since 1930. Among women,
	both the proportion of adenocarcinoma and survival have remained
	more or less constant. The rising incidence and the decreasing survival
	may both be related to changes in tobacco use, the increased use
	of low-tar filter cigarettes since the 1960s being the most likely
	candidate.},
  journal   = {Epidemiology},
  month     = {Mar},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2001},
}

@Article{Jansson2005a,
  author    = {Catarina Jansson and Anna L V Johansson and Ingvar A Bergdahl and Paul W Dickman and Nils Plato and Johanna Adami and Paolo Boffetta and Jesper Lagergren},
  title     = {Occupational exposures and risk of esophageal and gastric cardia cancers among male {S}wedish construction workers.},
  doi       = {10.1007/s10552-005-1723-2},
  number    = {6},
  pages     = {755--764},
  url       = {http://dx.doi.org/10.1007/s10552-005-1723-2},
  volume    = {16},
  abstract  = {OBJECTIVE: The rising incidence and the strong male predominance among
	patients with esophageal and gastric cardia adenocarcinoma remain
	unexplained. We hypothesized that occupational airborne exposures
	in a traditional male dominated industry might contribute to these
	observations. METHODS: A prospective, large cohort study of Swedish
	construction workers was linked to the Swedish population-based registers
	of Cancer, Causes of Death and Total Population. 260,052 men were
	followed from 1971 through 2000. Industrial hygienists assessed specific
	exposures for 200 job titles, and occupational airborne exposures
	were analyzed separately and combined. Incidence rate ratios (IRR),
	with 95\% confidence intervals (CI), were estimated in multivariable
	Cox regression models adjusted for attained age, calendar period,
	smoking status and body mass. RESULTS: We found positive associations
	between high exposure to asbestos (IRR 4.5 [95\% CI 1.4-14.3]) and
	cement dust (IRR 3.8 [95\% CI 1.5-9.6]) and risk of esophageal adenocarcinoma.
	Associations were seen between high exposure to asphalt fumes (IRR
	2.3 [95\% CI 1.0-5.3]) and wood dust (IRR 4.8 [95\% CI 1.2-19.4])
	and risk of cardia adenocarcinoma. No consistent associations regarding
	esophageal squamous-cell carcinoma were found. CONCLUSIONS: Exposure
	to asbestos and cement dust may be risk factors for esophageal adenocarcinoma,
	and exposure to asphalt fumes and wood dust may increase the risk
	of cardia adenocarcinoma. However, these associations cannot explain
	the major sex differences or the increasing incidence trends of these
	tumors.},
  journal   = {Cancer Causes Control},
  month     = {Aug},
  owner     = {PaulD},
  pmid      = {16049815},
  timestamp = {2006.10.04},
  year      = {2005},
}

@Article{Jansson2004,
  author    = {Catarina Jansson and Anna L V Johansson and Kerstin Jeding and Paul W Dickman and Olof Nyr\'{e}n and Jesper Lagergren},
  title     = {Psychosocial working conditions and the risk of esophageal and gastric cardia cancers.},
  number    = {7},
  pages     = {631-41},
  volume    = {19},
  abstract  = {BACKGROUND: For reasons yet unknown, the incidence of esophageal and
	gastric cardia adenocarcinoma is increasing rapidly and moderately,
	respectively. These tumors occur predominantly among males. We hypothesized
	that stressful psychosocial working conditions might be involved
	in the etiology of these cancers. OBJECTIVE: To study if job strain,
	work pace satisfaction and coping are linked to the risk of esophageal
	or cardia cancers. METHODS: A nationwide Swedish population-based
	case-control study including 189 and 262 esophageal and cardia adenocarcinoma
	cases, respectively, 167 esophageal squamous-cell carcinoma cases,
	and 820 controls. All study subjects were interviewed. The relative
	risk was estimated using odds ratios, with 95\% confidence intervals,
	adjusted for potential confounders. RESULTS: We found no statistically
	significant associations between two different measures of job strain
	and the three cancer types, except between one job strain measure
	and risk of cardia adenocarcinoma (OR: 2.2; 95\% CI: 1.0-4.8). There
	was a moderately strong association between having a covert coping
	style, compared to an overt, and risk of both esophageal (OR: 1.8;
	95\% CI: 1.2-2.8) and cardia adenocarcinoma (OR: 1.5; 95\% CI: 1.0-2.3).
	Among subjects reporting low work pace satisfaction we found an almost
	4-fold increased risk of esophageal squamous-cell carcinoma (OR:
	3.8; 95\% CI: 1.3-11.0), and a nearly 3-fold increased risk of esophageal
	adenocarcinoma (OR: 2.8; 95\% CI: 1.1-7.0). CONCLUSIONS: Work-related
	stress does not seem to be of importance in the etiology of adenocarcinoma
	of the esophagus or the gastric cardia. However, the interaction
	of a stressful work environment and the individual's responses to
	it may be associated with a moderately increased risk of these cancer
	types.},
  journal   = {Eur J Epidemiol},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2004},
}

@Article{Jansson2003,
  author    = {M. Jansson and M. Gatz and S. Berg and B. Johansson and B. Malmberg and G. E. McClearn and M. Schalling and N. L. Pedersen},
  title     = {Association between depressed mood in the elderly and a {5-HTR2A} gene variant},
  note      = {(in press)},
  pages     = {00--00},
  url       = {http://www3.interscience.wiley.com/cgi-bin/abstract/104082544/},
  volume    = {00},
  journal   = {American Journal of Medical Genetics Part {B}: Neuropsychiatric Genetics},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2003},
}

@Article{Jansson2005,
  author    = {M{\aa}rten Jansson and Shane McCarthy and Patrick F Sullivan and Paul Dickman and Bj\"{o}rn Andersson and Lars Oreland and Martin Schalling and Nancy L Pedersen},
  title     = {{MAOA} haplotypes associated with thrombocyte-{MAO} activity.},
  doi       = {10.1186/1471-2156-6-46},
  pages     = {46},
  url       = {http://dx.doi.org/10.1186/1471-2156-6-46},
  volume    = {6},
  abstract  = {BACKGROUND: The aim was to ascertain whether thrombocyte MAO (trbc-MAO)
	activity and depressed state are genetically associated with the
	MAO locus on chromosome X (Xp11.3 - 11.4). We performed novel sequencing
	of the MAO locus and validated genetic variants found in public databases
	prior to constructing haplotypes of the MAO locus in a Swedish sample
	(N = 573 individuals). RESULTS: Our results reveal a profound SNP
	desert in the MAOB gene. Both the MAOA and MAOB genes segregate as
	two distinct LD blocks. We found a significant association between
	two MAOA gene haplotypes and reduced trbc-MAO activity, but no association
	with depressed state. CONCLUSION: The MAO locus seems to have an
	effect on trbc-MAO activity in the study population. The findings
	suggest incomplete X-chromosome inactivation at this locus. It is
	plausible that a gene-dosage effect can provide some insight into
	the greater prevalence of depressed state in females than males.},
  journal   = {BMC Genet},
  owner     = {PaulD},
  pii       = {1471-2156-6-46},
  pmid      = {16174289},
  timestamp = {2006.10.04},
  year      = {2005},
}

@Article{Jatoi2011,
  author      = {Ismail Jatoi and William F Anderson and Jong-Hyeon Jeong and Carol K Redmond},
  title       = {Breast cancer adjuvant therapy: time to consider its time-dependent effects.},
  doi         = {10.1200/JCO.2010.32.3550},
  language    = {eng},
  number      = {17},
  pages       = {2301--2304},
  url         = {http://dx.doi.org/10.1200/JCO.2010.32.3550},
  volume      = {29},
  file        = {Jatoi2011.pdf:pdf\\Jatoi2011.pdf:PDF;Jatoi2011.pdf:Jatoi2011.pdf:PDF},
  journal     = {J Clin Oncol},
  medline-pst = {ppublish},
  month       = {Jun},
  owner       = {PaulD},
  pii         = {JCO.2010.32.3550},
  pmid        = {21555693},
  timestamp   = {2011.06.21},
  year        = {2011},
}

@Article{Jauniaux2002,
  author      = {Jauniaux, T. and Petitjean, D. and Brenez, C. and Borrens, M. and Brosens, L. and Haelters, J. and Tavernier, T. and Coignoul, F.},
  title       = {Post-mortem findings and causes of death of harbour porpoises (Phocoena phocoena) stranded from 1990 to 2000 along the coastlines of Belgium and Northern France.},
  doi         = {10.1053/jcpa.2001.0547},
  language    = {eng},
  number      = {4},
  pages       = {243--253},
  url         = {http://dx.doi.org/10.1053/jcpa.2001.0547},
  volume      = {126},
  abstract    = {Between the years 1990 and 2000, an attempt was made to determine
	the causes of death of 55 harbour porpoises stranded along the Belgian
	and northern French coasts. From 1990 to 1996, only five carcasses
	were collected as against seven in 1997, eight in 1998, 27 in 1999
	and eight in 2000. The sex ratio was normal and most of the animals
	were juvenile. The most common findings were emaciation, severe parasitosis
	and pneumonia. A few cases of fishing net entanglement were observed.
	The main microscopical lesions were acute pneumonia, massive lung
	oedema, enteritis, hepatitis and gastritis. Encephalitis was observed
	in six cases. No evidence of morbillivirus infection was detected.
	Pneumonia was associated with bacteria or parasites, or both. The
	causes of death and the lesions were similar to those previously
	reported in other countries bordering the North Sea. The cause of
	the increased numbers of carcasses in 1999 was unclear but did not
	include viral epizootics or net entanglement. A temporary increase
	in the porpoise population in the southern North Sea may have been
	responsible.},
  institution = {Department of Pathology, Veterinary College, Li{\AA}Â§ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¦ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¥, B43, 4000, Belgium},
  journal     = {J Comp Pathol},
  keywords    = {Animals; Animals, Newborn; Autopsy, veterinary; Bacterial Infections, mortality/pathology/veterinary; Belgium, epidemiology; Cause of Death; Female; France, epidemiology; Male; Parasitic Diseases, Animal, mortality/pathology; Porpoises; Virus Diseases, mortality/pathology/veterinary},
  medline-pst = {ppublish},
  month       = {May},
  owner       = {pl4},
  pii         = {S002199750190547X},
  pmid        = {12056772},
  timestamp   = {2013.05.29},
  year        = {2002},
}

@ARTICLE{Jeffreys2005,
  author = {Jeffreys, M. and Stevanovic, V. and Tobias, M. and Lewis, C. and
	Ellison-Loschmann, L. and Pearce, N. and Blakely, T.},
  title = {Ethnic inequalities in cancer survival in {N}ew {Z}ealand: linkage
	study},
  journal = {American Journal of Public Health},
  year = {2005},
  volume = {95},
  pages = {834-7},
  file = {Jeffreys2005.pdf:Jeffreys2005.pdf:PDF;Jeffreys2005.pdf:pdf\\Jeffreys2005.pdf:PDF},
  owner = {hanbow},
  timestamp = {2016.05.19}
}

@ARTICLE{Jemal2011,
  author = {Jemal, Ahmedin and Bray, Freddie and Center, Melissa M. and Ferlay,
	Jacques and Ward, Elizabeth and Forman, David},
  title = {Global cancer statistics.},
  journal = {CA Cancer J Clin},
  year = {2011},
  volume = {61},
  pages = {69--90},
  number = {2},
  abstract = {The global burden of cancer continues to increase largely because
	of the aging and growth of the world population alongside an increasing
	adoption of cancer-causing behaviors, particularly smoking, in economically
	developing countries. Based on the GLOBOCAN 2008 estimates, about
	12.7 million cancer cases and 7.6 million cancer deaths are estimated
	to have occurred in 2008; of these, 56\% of the cases and 64\% of
	the deaths occurred in the economically developing world. Breast
	cancer is the most frequently diagnosed cancer and the leading cause
	of cancer death among females, accounting for 23\% of the total cancer
	cases and 14\% of the cancer deaths. Lung cancer is the leading cancer
	site in males, comprising 17\% of the total new cancer cases and
	23\% of the total cancer deaths. Breast cancer is now also the leading
	cause of cancer death among females in economically developing countries,
	a shift from the previous decade during which the most common cause
	of cancer death was cervical cancer. Further, the mortality burden
	for lung cancer among females in developing countries is as high
	as the burden for cervical cancer, with each accounting for 11\%
	of the total female cancer deaths. Although overall cancer incidence
	rates in the developing world are half those seen in the developed
	world in both sexes, the overall cancer mortality rates are generally
	similar. Cancer survival tends to be poorer in developing countries,
	most likely because of a combination of a late stage at diagnosis
	and limited access to timely and standard treatment. A substantial
	proportion of the worldwide burden of cancer could be prevented through
	the application of existing cancer control knowledge and by implementing
	programs for tobacco control, vaccination (for liver and cervical
	cancers), and early detection and treatment, as well as public health
	campaigns promoting physical activity and a healthier dietary intake.
	Clinicians, public health professionals, and policy makers can play
	an active role in accelerating the application of such interventions
	globally.},
  doi = {10.3322/caac.20107},
  institution = {Surveillance Research, American Cancer Society, Atlanta, GA, USA.
	ahmedin.jemal@cancer.org},
  keywords = {Humans; Internationality; Neoplasms, epidemiology},
  language = {eng},
  medline-pst = {ppublish},
  owner = {theand},
  pii = {caac.20107},
  pmid = {21296855},
  timestamp = {2013.08.05},
  url = {http://dx.doi.org/10.3322/caac.20107}
}

@ARTICLE{Jenny2002,
  author = {Jenny, Jean-Yves and Boeri, Cyril},
  title = {Accuracy of implantation of a unicompartmental total knee arthroplasty
	with 2 different instrumentations: a case-controlled comparative
	study.},
  journal = {J Arthroplasty},
  year = {2002},
  volume = {17},
  pages = {1016--1020},
  number = {8},
  month = {Dec},
  abstract = {The accuracy of implantation is an accepted prognostic factor for
	the long-term survival of unicompartmental total knee arthroplasties
	(UKAs). We adapted the conventional instruments for tricompartmental
	total knee arthroplasty implantation, with intramedullary femoral
	and extramedullary tibial guiding rods, to a UKA implantation. A
	total of 52 patients in whom a UKA was implanted with this instrumentation
	were matched (using age, sex, body mass index, preoperative coronal
	mechanical femorotibial angle, and severity of preoperative degenerative
	changes according to Ahlback) with 52 patients operated with the
	alternative instruments. Accuracy of implant placement measured by
	radiography was improved significantly by the new instrumentation,
	but there was no difference in the survival rate or the clinical
	outcome after 5 years in both groups. No complication related to
	the new instrumentation occurred. Longer follow-up is required to
	determine the advantages and disadvantages of both techniques.},
  doi = {10.1054/arth.2002.34524},
  institution = {Center for Trauma and Orthopedic Surgery, Strasbourg, France. jean-yves.jenny@evc.net},
  keywords = {Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee, instrumentation;
	Case-Control Studies; Female; Follow-Up Studies; Humans; Male; Middle
	Aged; Treatment Outcome},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {S0883540302002577},
  pmid = {12478512},
  timestamp = {2013.05.29},
  url = {http://dx.doi.org/10.1054/arth.2002.34524}
}

@ARTICLE{Jeong2007,
  author = {Jong-Hyeon Jeong and Jason P Fine},
  title = {Parametric regression on cumulative incidence function.},
  journal = {Biostatistics},
  year = {2007},
  volume = {8},
  pages = {184--196},
  number = {2},
  month = {Apr},
  abstract = {We propose parametric regression analysis of cumulative incidence
	function with competing risks data. A simple form of Gompertz distribution
	is used for the improper baseline subdistribution of the event of
	interest. Maximum likelihood inferences on regression parameters
	and associated cumulative incidence function are developed for parametric
	models, including a flexible generalized odds rate model. Estimation
	of the long-term proportion of patients with cause-specific events
	is straightforward in the parametric setting. Simple goodness-of-fit
	tests are discussed for evaluating a fixed odds rate assumption.
	The parametric regression methods are compared with an existing semiparametric
	regression analysis on a breast cancer data set where the cumulative
	incidence of recurrence is of interest. The results demonstrate that
	the likelihood-based parametric analyses for the cumulative incidence
	function are a practically useful alternative to the semiparametric
	analyses.},
  doi = {10.1093/biostatistics/kxj040},
  file = {Jeong2007.pdf:Jeong2007.pdf:PDF;Jeong2007.pdf:pdf\\Jeong2007.pdf:PDF},
  institution = {Department of Biostatistics, University of Pittsburgh, Pittsburgh,
	PA 15261, USA. jeong@nsabp.pitt.edu},
  owner = {pl4},
  pii = {kxj040},
  pmid = {16636138},
  timestamp = {2009.09.28},
  url = {http://dx.doi.org/10.1093/biostatistics/kxj040}
}

@ARTICLE{Jeong2006,
  author = {Jong-Hyeon Jeong and Jason P Fine},
  title = {Direct parametric inference for the cumulative incidence function},
  journal = {Applied Statistics},
  year = {2006},
  volume = {55},
  pages = {187-200},
  file = {Jeong2006.pdf:Jeong2006.pdf:PDF;Jeong2006.pdf:pdf\\Jeong2006.pdf:PDF},
  owner = {pl4},
  timestamp = {2009.09.28}
}

@ARTICLE{Ji2012,
  author = {Ji, Jianguang and Sundquist, Kristina and Sundquist, Jan and Hemminki,
	Kari},
  title = {Comparability of cancer identification among Death Registry, Cancer
	Registry and Hospital Discharge Registry.},
  journal = {Int J Cancer},
  year = {2012},
  volume = {131},
  pages = {2085--2093},
  number = {9},
  month = {Nov},
  abstract = {Registry-based cancer incidence and mortality data are widely used
	for etiologic research, cancer control and health care monitoring
	and planning. The complete coverage of all cases is the key criteria
	of data quality but it is difficult to assess because the alternative
	sources of data may be flawed. The aim of our study was to examine,
	at a nationwide level, the completeness of the Swedish Cancer Registry
	(CR) regarding persons who died of cancer, based on the Cause of
	Death Registry (DR), and using the Hospital Discharge Registry (HDR)
	as an additional source of data. Individuals who died of cancer from
	years 1999 through 2008 recorded in DR were linked to CR and HDR.
	A total of 190,692 individuals were identified from DR with cancer
	as the underlying cause of death; the mean identification rate of
	concordant cancer in CR was 79.8\%, depending on tumor site and age
	at death. Breast, bladder and prostate cancers showed the highest
	rate of identification, whereas bone, liver and pancreatic cancers
	showed the lowest rate of identification. CR had no records on 10.6\%
	of cancer cases recorded in DR. Similarly, the identification rate
	in HDR was 84.5\% for concordant cancer and with 9.6\% of cases missing.
	Neither source reported cancers for 3.4\% of cancer cases recorded
	in DR. In conclusion, some 10\% of cancer deaths had no cancer records
	in CR or in HDR, and 3.4\% were missing in both sources. The identification
	rate depended on tumor site, age at death and, to some extent, death
	outside hospital.},
  doi = {10.1002/ijc.27462},
  file = {Ji2012.pdf:pdf\\Ji2012.pdf:PDF},
  institution = {Department of Medicine, Center for Primary Health Care Research,
	Lund University, Sweden. Jianguang.ji@med.lu.se},
  keywords = {Female; Humans; Male; Neoplasms, epidemiology/mortality; Patient Discharge;
	Registries; Survival Rate; Sweden, epidemiology},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pmid = {22307919},
  timestamp = {2013.12.17},
  url = {http://dx.doi.org/10.1002/ijc.27462}
}

@ARTICLE{Johansson2009,
  author = {Anna Johansson and Paul Dickman and Michael Kramer and Sven Cnattingius},
  title = {Maternal Smoking and Infant Mortality: Does Quitting Smoking Reduce
	the Risk of Infant Death?},
  journal = {Epidemiology},
  year = {2009},
  month = {Mar},
  abstract = {BACKGROUND:: Maternal smoking has repeatedly been associated with
	increased infant mortality rates. No study has investigated whether
	smoking cessation influences the risk of infant death. This study
	estimates infant mortality after the second pregnancy in relation
	to smoking behavior in both the first and the second pregnancy. METHODS::
	We used the Swedish Medical Birth Register to identify women who
	delivered their first and second singleton infants during 1983-2002.
	Maternal smoking during the 2 pregnancies was categorized into (1)
	never smoker, (2) quitter, (3) starter, and (4) persistent smoker.
	In the second pregnancy, 555,046 live births (of at least 22 completed
	gestational weeks) were followed for infant death within 1 year.
	Cox regression was used to estimate hazard ratios (HRs) with 95\%
	confidence intervals (CIs). RESULTS:: Compared with infants born
	to never smokers, the HR (95\% CI) of infant mortality in the second
	pregnancy was 2.0 (1.7-2.4) among infants born to persistently heavy
	smokers, whereas among women who stopped smoking in the second pregnancy,
	the HRs were 1.4 (1.0-2.0) among those who had been heavy smokers
	in the first pregnancy, and 1.0 (0.8-1.2) among those who had been
	light smokers. The association of smoking during pregnancy with infant
	mortality was modified by infant's age, and was strongest at 4-15
	weeks after birth. The smoking effect on neonatal mortality, but
	not postneonatal mortality, was mediated by gestational age. CONCLUSIONS::
	Smoking cessation reduced the risk of infant death. The smoking-related
	risk of neonatal mortality appears to be mediated by smoking effects
	on gestational age, a factor that only partly explains the association
	between smoking and postneonatal mortality.},
  doi = {10.1097/EDE.0b013e31819dcc6a},
  file = {Johansson2009.pdf:Johansson2009.pdf:PDF;Johansson2009.pdf:pdf\\Johansson2009.pdf:PDF},
  institution = {From the aDepartment of Medical Epidemiology and Biostatistics, Karolinska
	Institutet, Stockholm, Sweden; and bDepartments of Pediatrics and
	of Epidemiology and Biostatistics, McGill University Faculty of Medicine,
	Montreal, Canada.},
  owner = {pl4},
  pmid = {19289964},
  timestamp = {2009.04.28},
  url = {http://dx.doi.org/10.1097/EDE.0b013e31819dcc6a}
}

@ARTICLE{Johansson2015,
  author = {Johansson, Anna L V. and Andersson, Therese M-L. and Hsieh, Chung-Cheng
	and Cnattingius, Sven and Dickman, Paul W. and Lambe, Mats},
  title = {Family history and risk of pregnancy-associated breast cancer (PABC).},
  journal = {Breast Cancer Res Treat},
  year = {2015},
  volume = {151},
  pages = {209--217},
  number = {1},
  month = {May},
  abstract = {The risk of breast cancer is at least two-fold increased in young
	women with a family history of breast cancer. Pregnancy has a dual
	effect on breast cancer risk; a short-term increase followed by a
	long-term protection. We investigated if the risk of breast cancer
	during and within 10ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years following pregnancy is affected by a family
	history of breast cancer. We followed a cohort of women aged 15-44ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years
	between 1963 and 2009 identified in Swedish population-based registers.
	Family history was defined as having a mother or sister with breast
	cancer. We estimated incidence rate ratios of breast cancer during
	pregnancy and time intervals up to 10ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years post-delivery, with a
	focus on pregnancy-associated breast cancer (PABC), defined as breast
	cancer during pregnancy or within 2ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years post-delivery. In 3,452,506
	women, there were 15,548 cases of breast cancer (1208 were PABC).
	Compared to nulliparous women, the risk of breast cancer was decreased
	during pregnancy, similar during first year and increased during
	second year post-delivery. The pattern was similar in women with
	or without family history of breast cancer. A peak in risk was observed
	5-6ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years following the first birth regardless of family history.
	After a second birth, this peak was only present in women with a
	family history. Our results indicate that women with a family history
	of breast cancer do not have a different breast cancer risk during
	and within 10ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years following pregnancy compared to women without
	a family history.},
  doi = {10.1007/s10549-015-3369-4},
  institution = {Department of Medical Epidemiology and Biostatistics, Karolinska
	Institutet, P.O. Box 281, SE-17177, Stockholm, Sweden, anna.johansson@ki.se.},
  keywords = {Adolescent; Adult; Breast Neoplasms, epidemiology/pathology; Female;
	Humans; Pregnancy; Pregnancy Complications, Neoplastic, epidemiology/pathology;
	Risk Factors},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pmid = {25893584},
  timestamp = {2016.06.14},
  url = {http://dx.doi.org/10.1007/s10549-015-3369-4}
}

@ARTICLE{Johansson2011,
  author = {Johansson, Anna L V. and Andersson, Therese M-L. and Hsieh, Chung-Cheng
	and Cnattingius, Sven and Lambe, Mats},
  title = {Increased mortality in women with breast cancer detected during pregnancy
	and different periods postpartum.},
  journal = {Cancer Epidemiol Biomarkers Prev},
  year = {2011},
  volume = {20},
  pages = {1865--1872},
  number = {9},
  month = {Sep},
  abstract = {Because of a continued trend toward postponed childbearing, the incidence
	of pregnancy-associated breast cancer (PABC) is likely to increase.
	This study investigated the mortality in women with PABC in relation
	to when the tumor was detected (during pregnancy, different postpartum
	periods) and by time since diagnosis, compared with women with non-PABC.A
	population-based cohort study of 15,721 Swedish women diagnosed with
	breast cancer between ages 15 to 44 years, of whom 1,110 (7\%) had
	a PABC (diagnosed during or within two years after pregnancy). Information
	on outcome and potential confounders was obtained from population-based
	health registers. Mortality rates and HRs with 95\% CIs were estimated.Women
	with PABC had higher mortality compared with women with non-PABC
	diagnosed at the same age and calendar period. Among women with PABC,
	46\% died within 15 years after diagnosis, whereas 34\% died among
	non-PABC patients. The mortality in both groups peaked at around
	two years after diagnosis, with the highest peak occurring in women
	diagnosed 4 to 6 months after delivery (HR = 3.8, 95\% CI: 2.4-5.9).
	An increased mortality among women with PABC remained until 10 years
	after diagnosis.Women with PABC had a poorer prognosis compared with
	women with breast cancer and no recent birth. The mortality increase
	was most pronounced in the subgroup of women diagnosed shortly after
	delivery.An increased awareness among clinicians may help reduce
	the mortality in women with PABC, for example, by avoiding undue
	delays in diagnosis and treatment.},
  doi = {10.1158/1055-9965.EPI-11-0515},
  file = {Johansson2011.pdf:Johansson2011.pdf:PDF},
  institution = {Department of Medical Epidemiology and Biostatistics, University
	of Massachusetts Medical School, Worcester, Massachusetts, USA. anna.johansson@ki.se},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {1055-9965.EPI-11-0515},
  pmid = {21750168},
  timestamp = {2012.04.08},
  url = {http://dx.doi.org/10.1158/1055-9965.EPI-11-0515}
}

@ARTICLE{Johansson2004,
  author = {Jan-Erik Johansson and Ove Andr\'{e}n and Swen-Olof Andersson and
	Paul W Dickman and Lars Holmberg and Anders Magnuson and Hans-Olov
	Adami},
  title = {Natural history of early, localized prostate cancer.},
  journal = {JAMA},
  year = {2004},
  volume = {291},
  pages = {2713-9},
  number = {22},
  month = {Jun},
  abstract = {CONTEXT: Among men with early prostate cancer, the natural history
	without initial therapy determines the potential for survival benefit
	following radical local treatment. However, little is known about
	disease progression and mortality beyond 10 to 15 years of watchful
	waiting. OBJECTIVE: To examine the long-term natural history of untreated,
	early stage prostatic cancer. DESIGN: Population-based, cohort study
	with a mean observation period of 21 years. SETTING: Regionally well-defined
	catchment area in central {S}weden (recruitment March 1977 through
	February 1984). PATIENTS: A consecutive sample of 223 patients (98\%
	of all eligible) with early-stage (T0-T2 NX M0 classification), initially
	untreated prostatic cancer. Patients with tumor progression were
	hormonally treated (either by orchiectomy or estrogens) if they had
	symptoms. MAIN OUTCOME MEASURES: Progression-free, cause-specific,
	and overall survival. RESULTS: After complete follow-up, 39 (17\%)
	of all patients experienced generalized disease. Most cancers had
	an indolent course during the first 10 to 15 years. However, further
	follow-up from 15 (when 49 patients were still alive) to 20 years
	revealed a substantial decrease in cumulative progression-free survival
	(from 45.0\% to 36.0\%), survival without metastases (from 76.9\%
	to 51.2\%), and prostate cancer-specific survival (from 78.7\% to
	54.4\%). The prostate cancer mortality rate increased from 15 per
	1000 person-years (95\% confidence interval, 10-21) during the first
	15 years to 44 per 1000 person-years (95\% confidence interval, 22-88)
	beyond 15 years of follow-up (P =.01). CONCLUSION: Although most
	prostate cancers diagnosed at an early stage have an indolent course,
	local tumor progression and aggressive metastatic disease may develop
	in the long term. These findings would support early radical treatment,
	notably among patients with an estimated life expectancy exceeding
	15 years.},
  doi = {10.1001/jama.291.22.2713},
  owner = {PaulD},
  pii = {291/22/2713},
  timestamp = {2011.06.19},
  url = {http://dx.doi.org/10.1001/jama.291.22.2713}
}

@ARTICLE{Johansson2000,
  author = {Johansson, L. A. and Westerling, R.},
  title = {Comparing {S}wedish hospital discharge records with death certificates:
	implications for mortality statistics.},
  journal = {Int J Epidemiol},
  year = {2000},
  volume = {29},
  pages = {495--502},
  number = {3},
  month = {Jun},
  abstract = {The quality of mortality statistics is of crucial importance to epidemiological
	research. Traditional editing techniques used by statistical offices
	capture only obvious errors in death certification. In this study
	we match Swedish hospital discharge data to death certificates and
	discuss the implications for mortality statistics.Swedish death certificates
	for 1995 were linked to the national hospital discharge register.
	The resulting database comprised 69 818 individuals (75\% of all
	deaths), 39 872 (43\%) of whom died in hospital. The diagnostic statements
	were compared at Basic Tabulation List level.The last main diagnosis
	and the underlying cause of death agreed in 46\% of cases. Agreement
	decreased rapidly after discharge. For hospital deaths, the main
	diagnosis was reported on 83\% of the certificates, but only on 46\%
	of certificates for non-hospital deaths. Malignant neoplasms and
	other dramatic conditions showed the best agreement and were often
	reported as underlying causes. Conditions that might follow from
	some other disease were often reported as contributory causes, while
	symptomatic and some chronic conditions were often omitted. In 13\%
	of cases, an ill-defined main condition was replaced by a more specific
	cause of death.There is no apparent reason to question the death
	certificate if the main diagnosis and underlying cause agree, or
	if the main diagnosis is a probable complication of the stated underlying
	cause. However, cases in which the main diagnosis cannot be considered
	a complication of the reported underlying cause should be investigated,
	and assessments made of the feasibility and cost-effectiveness of
	routinely linking hospital records to death certificates.},
  institution = {Statistics Sweden. Department of Public Health and Caring Sciences,
	Unit of Social Medicine, Uppsala University, Sweden.},
  keywords = {Adolescent; Adult; Aged; Aged, 80 and over; Cause of Death; Child;
	Child, Preschool; Databases, Factual; Death Certificates; Female;
	Humans; Infant; Infant, Newborn; Male; Medical Record Linkage; Middle
	Aged; Mortality, trends; Patient Discharge, statistics /&/ numerical
	data; Quality Control; Reproducibility of Results; Sweden, epidemiology},
  language = {eng},
  medline-pst = {ppublish},
  owner = {sanelo},
  pmid = {10869322},
  timestamp = {2013.10.10}
}

@ARTICLE{Johnson2012,
  author = {Johnson, Christopher J. and Hahn, Christine G. and Fink, Aliza K.
	and German, Robert R.},
  title = {Variability in cancer death certificate accuracy by characteristics
	of death certifiers.},
  journal = {Am J Forensic Med Pathol},
  year = {2012},
  volume = {33},
  pages = {137--142},
  number = {2},
  month = {Jun},
  abstract = {Death certificates are the source for mortality statistics and are
	used to set public health goals. Accurate death certificates are
	vital in tracking outcomes of cancer. Deaths may be certified by
	physicians or other medical professionals, coroners, or medical examiners.
	Idaho is one of 3 states that participated in a Centers for Disease
	Control and Prevention-funded study to assess the concordance between
	cancer-specific causes of death and primary cancer site among linked
	cancer registry/death certificate data. We investigated variability
	in the accuracy of cancer death certificates by characteristics of
	death certifiers, including certifier type (physician vs coroner),
	physician specialty, years of experience as death certifier, and
	number of deaths certified. This study showed significant differences
	by certifier type/physician specialty in the accuracy of cancer mortality
	measured by death certificates. Nonphysician coroners had lower accuracy
	rates compared with physicians. Although nonphysician coroners certified
	less than 5\% of cancer deaths in Idaho, they were significantly
	less likely to match the primary site from the cancer registry. Results
	from this study may be useful in the future training of death certifiers
	to improve the accuracy of death certificates and cancer mortality
	statistics.},
  doi = {10.1097/PAF.0b013e318219877e},
  file = {Johnson2012.pdf:pdf\\Johnson2012.pdf:PDF;Johnson2012.pdf:Johnson2012.pdf:PDF},
  institution = {Cancer Data Registry of Idaho, Division of Public Health, Boise,
	ID 83702, USA. cjohnson@teamiha.org},
  keywords = {Coroners and Medical Examiners, statistics /&/ numerical data; Death
	Certificates; Female; Humans; Idaho; Linear Models; Male; Medicine,
	statistics /&/ numerical data; Neoplasms, mortality; Physicians,
	statistics /&/ numerical data; Registries},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pmid = {21490500},
  timestamp = {2013.09.18},
  url = {http://dx.doi.org/10.1097/PAF.0b013e318219877e}
}

@ARTICLE{Johnson2013,
  author = {Johnson, Christopher J. and Weir, Hannah K. and Fink, Aliza K. and
	German, Robert R. and Finch, Jack L. and Rycroft, Randi K. and Yin,
	Daixin and , Accuracy of Cancer Mortality Study Group},
  title = {The impact of {National Death Index} linkages on population-based
	cancer survival rates in the {United States}},
  journal = {Cancer Epidemiol},
  year = {2013},
  volume = {37},
  pages = {20--28},
  number = {1},
  month = {Feb},
  abstract = {In order to ensure accurate survival estimates, population-based cancer
	registries must ascertain all, or nearly all, patients diagnosed
	with cancer in their catchment area, and obtain complete follow-up
	information on all deaths that occurred among registered cancer patients.
	In the US, linkage with state death records may not be sufficient
	to ascertain all deaths. Since 1979, all state vital statistics offices
	have reported their death certificate information to the National
	Death Index (NDI).This study was designed to measure the impact of
	linkage with the NDI on population-based relative and cancer cause-specific
	survival rates in the US.Central cancer registry records for patients
	diagnosed 1993-1995 from California, Colorado, and Idaho were linked
	with death certificate information (deaths 1993-2004) from their
	individual state vital statistics offices and with the NDI. Two databases
	were created: one contained incident records with deceased patients
	linked only to state death records and the second database contained
	incident records with deceased patients linked to both state death
	records and the NDI. Survival estimates and 95\% confidence intervals
	from each database were compared by state and primary site category.At
	60 months follow-up, 42.1-48.1\% of incident records linked with
	state death records and an additional 0.7-3.4\% of records linked
	with the NDI. Survival point estimates from the analysis without
	NDI were not contained within the corresponding 95\% CIs from the
	NDI augmented analysis for all sites combined and colorectal, pancreas,
	lung and bronchus, breast, prostate, non-Hodgkin lymphoma, and Kaposi
	sarcoma cases in all 3 states using relative survival methods. Additional
	combinations of state and primary site had significant survival estimate
	differences, which differed by method (relative versus cause-specific
	survival).To ensure accurate population-based cancer survival rates,
	linkage with the National Death Index to ascertain out of state and
	late registered deaths is a necessary process for US central cancer
	registries.},
  doi = {10.1016/j.canep.2012.08.007},
  institution = {Cancer Data Registry of Idaho, Boise, ID 83701, USA. cjohnson@teamiha.org},
  keywords = {Death Certificates; Humans; Neoplasms, mortality; Registries; Survival
	Rate; United States, epidemiology},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pii = {S1877-7821(12)00116-6},
  pmid = {22959341},
  timestamp = {2013.09.18},
  url = {http://dx.doi.org/10.1016/j.canep.2012.08.007}
}

@ARTICLE{Johnson2010,
  author = {Johnson, Christopher J. and Weir, Hannah K. and Yin, Daixin and Niu,
	Xiaoling},
  title = {The impact of patient follow-up on population-based survival rates.},
  journal = {J Registry Manag},
  year = {2010},
  volume = {37},
  pages = {86--103},
  number = {3},
  abstract = {This study was designed to measure the impact of variation in patient
	follow-up on survival statistics.surveillance, epidemiology and end
	results (SEER) data were used to construct four additional datasets.
	These datasets simulated scenarios of complete, incomplete, and no
	follow-up of live patients; and complete and incomplete death ascertainment.
	Sixty-month observed survival proportions were calculated using the
	actual SEER data and the four additional datasets.The 60-month observed
	survival proportion increased from 54.44\% under the original SEER
	dataset to 54.62\% under complete ascertainment of deaths with no
	follow-up among live patients. Under complete death ascertainment,
	randomly imputing loss to follow-up among 20\% of live cases resulted
	in a 1\%-2\% decrease in 60-month observed survival for 71 of the
	102 SEER site categories. With follow-up limited to ascertainment
	of deaths, randomly missing 6\% of deaths resulted in a 1\% or greater
	increase in 60-month observed survival for 99 SEER site categories.This
	study provides evidence to support the importance of complete death
	ascertainment for producing accurate cancer survival statistics,
	and that ascertainment of deaths only should generally be sufficient
	for survival analysis.},
  institution = {Cancer Data Registry of Idaho, 615 N. 7th Street, P.O. Box 1278,
	Boise, IN 83701-1278, USA. cjohnson@teamiha.org},
  keywords = {Follow-Up Studies; Humans; Lost to Follow-Up; Neoplasms, mortality;
	SEER Program; Survival Rate; United States, epidemiology},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pmid = {21462880},
  timestamp = {2013.09.18}
}

@ARTICLE{Jonsson2011,
  author = {Jonsson, H{\aa}kan and Holmstr{\"o}m, Benny and Duffy, Stephen W. and Stattin,
	P{\"a}r},
  title = {Uptake of prostate-specific antigen testing for early prostate cancer
	detection in Sweden.},
  journal = {Int J Cancer},
  year = {2011},
  volume = {129},
  pages = {1881--1888},
  number = {8},
  month = {Oct},
  abstract = {The aim of our study was to estimate uptake of prostate-specific antigen
	(PSA) testing in an entire country, including time trends and geographical
	differences. Data from the Swedish Cancer Register on prostate cancer
	incidence between 1980 and 2007 and published data from the Gothenburg
	branch of the European randomized study of screening for prostate
	cancer (ERSPC), a population-based PSA screening study, were used
	in two models of changes in incidence of prostate cancer as a proxy
	for uptake of PSA testing in all 24 Swedish counties. The estimated
	annual PSA testing, irrespective of previous years' exposure, reached
	a peak of 12\% of all men in 2004 and decreased thereafter to 6\%
	in 2007 and varied from less than 5 to 20\% between counties. Under
	the assumption that men who underwent annual PSA testing were previously
	unexposed to PSA testing, the cumulated uptake of PSA testing in
	men aged 55-69 years in Sweden increased from zero in 1997 to 56\%
	in 2007. Our study shows that it is possible to estimate uptake of
	PSA testing in the population from the prostate cancer incidence
	pattern. There were large geographical variations in uptake of PSA
	testing despite a uniform health care system in Sweden and there
	was a substantial increase in the uptake of PSA testing during the
	study period, despite that there were no national recommendations
	for PSA-based prostate cancer screening.},
  doi = {10.1002/ijc.25846},
  institution = {Department of Radiation Sciences, Oncology, Ume{\aa} University, Ume{\aa},
	Sweden. Hakan.jonsson@oc.umu.se},
  keywords = {Early Detection of Cancer, trends; Humans; Incidence; Male; Prostate-Specific
	Antigen, analysis; Prostatic Neoplasms, diagnosis/epidemiology; Sweden,
	epidemiology},
  language = {eng},
  medline-pst = {ppublish},
  owner = {sanelo},
  pmid = {21154740},
  timestamp = {2013.07.31},
  url = {http://dx.doi.org/10.1002/ijc.25846}
}

@ARTICLE{Joos2014,
  author = {Joo{\ss}, Kevin and Sommer, Johannes and Bunz, Svenja-Catharina and
	Neus{\"{u}}{\ss}, Christian},
  title = {In-line SPE-CE using a fritless bead string design--application for
	the analysis of organic sulfonates including inline SPE-CE-MS for
	APTS-labeled glycans.},
  journal = {Electrophoresis},
  year = {2014},
  volume = {35},
  pages = {1236--1243},
  number = {9},
  month = {May},
  abstract = {Despite many advantages like high separation efficiency CE comprises
	the main limitation of low concentration sensitivity, when compared
	to HPLC. In-line SPE is an efficient way to increase concentration
	sensitivity. Here, a fritless in-line-SPE-CE-MS method was developed
	in order to analyze anions of strong acids. Mixed-mode (weak anion
	exchange and RP) particles were used for enrichment and an acidic
	BGE was applied for separation. Different particle and capillary
	sizes were tested. A novel bead string design with a 100 ?m id column
	filled with particles of 90 ?m followed by a separation capillary
	with 50 ?m id was easy to prepare and showed the best performance
	with respect to separation efficiency and reproducibility. Three
	aromatic sulfonic acids were employed in an in-line SPE-CE-UV approach
	for method development. Method validation was performed with respect
	to reproducibility, robustness, and linearity. Thereafter the method
	was transferred to SPE-CE-MS and applied to the analysis of glycans
	labeled with 8-aminopyrene-1,3,6-trisulfonic acid. Lower limits of
	detection in the low nM range were achieved injecting about 10 ?L
	of sample. This corresponds to an enrichment factor of more than
	800 compared to the corresponding CE-MS method without preconcentration.},
  doi = {10.1002/elps.201300388},
  institution = {Faculty of Chemistry, Aalen University, Aalen, Germany.},
  keywords = {Electrophoresis, Capillary, instrumentation/methods; Limit of Detection;
	Linear Models; Mass Spectrometry, methods; Polysaccharides, analysis/chemistry/isolation
	/&/ purification; Pyrenes, chemistry; Reproducibility of Results;
	Solid Phase Extraction, instrumentation/methods; Sulfonic Acids,
	analysis/chemistry/isolation /&/ purification},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {24170563},
  timestamp = {2015.01.30},
  url = {http://dx.doi.org/10.1002/elps.201300388}
}

@Article{Jooste2013,
  author      = {Jooste, V. and Grosclaude, P. and Remontet, L. and Launoy, G. and Baldi, I. and MolinieÂ F. and Arveux, P. and Bossard, N. and Bouvier, A-M. and Colonna, M. and , {French Network of Cancer Registries (FRANCIM)}},
  title       = {Unbiased estimates of long-term net survival of solid cancers in {F}rance.},
  language    = {eng},
  number      = {10},
  pages       = {2370--2377},
  volume      = {132},
  abstract    = {In cancer studies, net survival (observed if cancer was the only cause
	of death) is a useful indicator but survival estimation at 5 years
	is insufficient for planning healthcare needs. We estimated the net
	survivals at 5 and 10 years in a cohort of 387,961 patients who had
	solid tumors between 1989 and 2004 and were followed-up until January
	1, 2008. The cases were actively followed-up. Net survival was estimated
	with the unbiased Pohar-Perme method. The standardized net survival
	used the international cancer survival standard weights. In men,
	the standardized net survivals ranged from 92\% at 5 years and 89\%
	at 10 years (testis) to 6\% at 5 years and 5\% at 10 years (pancreas).
	In women, it ranged from 91\% at 5 years and 88\% at 10 years (thyroid)
	to 10\% at 5 years and 7\% at 10 years (pancreas). The most frequent
	cancers had the highest net survivals: 84\% at 5 years and 71\% at
	10 years for prostate and 84\% at 5 years and 74\% at 10 years for
	breast cancer. Advanced age was associated with poorer prognosis.
	In most cancers, the net survivals at 5 and 10 years increased over
	periods of diagnosis. Net cancer survival is unaffected by mortalities
	due to other causes. It is the only indicator suitable for comparisons
	between countries or periods of diagnosis within a given country.
	The 10-year net survival confirmed the persistent unfavorable role
	of age in prognosis and the general improvement of cancer management
	over the last decade.},
  file        = {Jooste2013.pdf:pdf\\Jooste2013.pdf:PDF},
  institution = {FRANCIM (French Network of Cancer Registries), Toulouse, France.},
  journal     = {International Journal of Cancer},
  keywords    = {Adult; Age Distribution; Age Factors; Aged; Bias (Epidemiology); Female; France, epidemiology; Humans; Male; Middle Aged; Models, Statistical; Neoplasms, mortality; Prognosis; Registries; Risk Factors; Sex Distribution; Survival Analysis},
  medline-pst = {ppublish},
  month       = {May},
  owner       = {pl4},
  pmid        = {23001495},
  timestamp   = {2013.05.29},
  year        = {2013},
}

@Book{Jorner2008,
  author    = {Jorner, U},
  title     = {Summa Summarum SCBs f{\"o}rsta 150 {\aa}r},
  publisher = {Statistics Sweden (Statistiska Centralbyr{\aa}n)},
  owner     = {sanelo},
  timestamp = {2013.08.01},
  year      = {2008},
}

@Book{Kalbfleisch1980,
  author    = {Kalbfleisch, J. D. and Prentice, R. L.},
  title     = {The Statistical Analysis of Failure Time Data},
  publisher = {New York: John Wiley and Sons},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1980},
}

@ARTICLE{Kandala2015,
  author = {Kandala, N-B. and Connock, M. and Pulikottil-Jacob, R. and Sutcliffe,
	P. and Crowther, M. J. and Grove, A. and Mistry, H. and Clarke, A.},
  title = {Setting benchmark revision rates for total hip replacement: analysis
	of registry evidence.},
  journal = {BMJ},
  year = {2015},
  volume = {350},
  pages = {h756},
  abstract = {To compare 10 year revision rates for frequently used types of primary
	total hip replacement to inform setting of a new benchmark rate in
	England and Wales that will be of international relevance.Retrospective
	cohort study.National Joint Registry.239?000 patient records.Revision
	rates for five frequently used types of total hip replacement that
	differed according to bearing surface and fixation mode, encompassing
	62\% of all primary total hip replacements in the National Joint
	Registry for England and Wales. Revision rates were compared using
	Kaplan-Meier and competing risks analyses, and five and 10 year rates
	were estimated using well fitting parametric models.Estimated revision
	rates at 10 years were 4\% or below for four of the five types of
	total hip replacement investigated. Rates differed little according
	to Kaplan-Meier or competing risks analysis, but differences between
	prosthesis types were more substantial. Cemented prostheses with
	ceramic-on-polyethylene bearing surfaces had the lowest revision
	rates (1.88-2.11\% at 10 years depending on the method used), and
	cementless prostheses with ceramic-on-ceramic bearing surfaces had
	the highest revision rates (3.93-4.33\%). Men were more likely to
	receive revision of total hip replacement than were women, and this
	difference was statistically significant for four of the five prosthesis
	types.Ten year revision rate estimates were all less than 5\%, and
	in some instances considerably less. The results suggest that the
	current revision rate benchmark should be at least halved from 10\%
	to less than 5\% at 10 years. This has implications for benchmarks
	internationally.},
  file = {Kandala2015.pdf:pdf\\Kandala2015.pdf:PDF},
  institution = {Warwick Evidence, Division of Health Sciences, Warwick Medical School,
	University of Warwick, Coventry CV4 7AL, UK Aileen.Clarke@warwick.ac.uk.},
  language = {eng},
  medline-pst = {epublish},
  owner = {pl4},
  pmid = {25752749},
  timestamp = {2015.04.14}
}

@ARTICLE{Kaplan1958,
  author = {Kaplan, E. L. and Meier, P},
  title = {Nonparametric Estimation from Incomplete Observations},
  journal = {Journal of the American Statistical Association},
  year = {1958},
  volume = {53},
  pages = {457-481},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@PhdThesis{Karjalainen1991,
  author    = {Karjalainen, Sakari},
  title     = {Equity and Cancer Patient Survival},
  note      = {Acta Universitatis Tamperensis, ser {A} vol 316},
  groups    = {PhD Thesis},
  owner     = {PaulD},
  school    = {University of Tampere, Finland},
  timestamp = {2011.06.19},
  year      = {1991},
}

@ARTICLE{Karjalainen1990a,
  author = {Sakari Karjalainen},
  title = {Geographical Variation in Cancer Patient Survival in {F}inland: Chance,
	Confounding, or Effect of Treatment},
  journal = {Journal of Epidemiology and Community Health},
  year = {1990},
  volume = {44},
  pages = {210-214},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Karjalainen1988,
  author = {Karjalainen, S. and Hakulinen, T.},
  title = {Survival and Prognostic Factors of Patients with Skin Melanoma: A
	Regression-Model Analysis Based on Nationwide Cancer Registry Data},
  journal = {Cancer},
  year = {1988},
  volume = {62},
  pages = {2274-2280},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Karjalainen1990b,
  author = {Sakari Karjalainen and Eero Pukkala},
  title = {Social Class as a Prognostic Factor in Breast Cancer Survival},
  journal = {Cancer},
  year = {1990},
  volume = {66},
  pages = {819-826},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Karp1994,
  author = {Karp, S. J.},
  title = {Clinical Oncology Information Network},
  journal = {British Medical Journal},
  year = {1994},
  volume = {308},
  pages = {147-148},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Kathirgamatamby1953,
  author = {Kathirgamatamby, N.},
  title = {Note on the {P}oisson Index of Dispersion},
  journal = {Biometrika},
  year = {1953},
  volume = {40},
  pages = {225-228},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Kato1992,
  author = {Kato, I. and Tominaga, S. and Ikari, A.},
  title = {The Role of Socioeconomic Factors in the Survival of Patients with
	Gastrointestinal Cancers},
  journal = {Japanese Journal of Clinical Oncology},
  year = {1992},
  volume = {22},
  pages = {270-277},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Kay1984,
  author = {Kay, R.},
  title = {Goodness of Fit Methods for the Proportional Hazards Regression Model},
  journal = {Rev. Epidemiol. Sante. Pub.},
  year = {1984},
  volume = {32},
  pages = {158-198},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Keiding1995,
  author = {N. Keiding},
  title = {Historical controls and modern survival analysis},
  journal = {Lifetime Data Analysis},
  year = {1995},
  volume = {1},
  pages = {19-25},
  file = {Keiding1995.pdf:Keiding1995.pdf:PDF;Keiding1995.pdf:pdf\\Keiding1995.pdf:PDF},
  owner = {pl4},
  timestamp = {2010.09.03}
}

@ARTICLE{Keiding1991,
  author = {N. Keiding},
  title = {Age-specific incidence and prevalence: A statistical perspective},
  journal = {Journal of the Rotal Statistical Society, Series A},
  year = {1991},
  volume = {154},
  pages = {371-412},
  file = {Keiding1991.pdf:Keiding1991.pdf:PDF;Keiding1991.pdf:pdf\\Keiding1991.pdf:PDF},
  owner = {pl4},
  timestamp = {2010.06.01}
}

@ARTICLE{Keiding1990,
  author = {N. Keiding},
  title = {Statistical inference in the {L}exis diagram},
  journal = {Philosophical Transactions: Physical Sciences and Engineering},
  year = {1990},
  volume = {332},
  pages = {487-509},
  file = {Keiding1990.pdf:Keiding1990.pdf:PDF;Keiding1990.pdf:pdf\\Keiding1990.pdf:PDF},
  owner = {pl4},
  timestamp = {2010.06.01}
}

@ARTICLE{Keiding1987,
  author = {Keiding, N.},
  title = {The Method of Expected Number of Deaths, 1786-1886-1986},
  journal = {International Statistical Review},
  year = {1987},
  volume = {55},
  pages = {5844},
  file = {Keiding1987.pdf:Keiding1987.pdf:PDF;Keiding1987.pdf:pdf\\Keiding1987.pdf:PDF},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Keiding2001,
  author = {Keiding, N and Klein, JP and Horowitz, MM},
  title = {Multi-state models and outcome prediction in bone marrow transplantation.},
  journal = {Stat Med},
  year = {2001},
  volume = {20},
  pages = {1871--1885},
  number = {12},
  month = {Jun},
  abstract = {Multi-state models have proved versatile and useful in the statistical
	analysis of the complicated course of events after bone marrow transplantation.
	Working from data from the International Bone Marrow Transplant Registry,
	we show that summary probability calculations may be useful to explore
	hypothetical scenarios where some transition intensities are set
	by the researcher. A multi-state Markov process model is specified
	with six states: the initial state 0; acute; chronic and both acute
	and chronic graft-versus-host disease A, C and AC; relapse R and
	death in remission D. Transition rates between the states are estimated
	using Nelson-Aalen estimators and Cox regression models and combined
	to transition probability estimators using Aalen-Johansen product
	integration. Besides the estimated transition probabilities to D
	and R we explore hypothetical probabilities obtained by artificially
	changing certain transition intensities, with the general purposes
	of getting summary views of the development for actual patients 'in
	this world' and of exploring the intrinsic information from real
	patients about consequences of various changed conditions.},
  doi = {10.1002/sim.810},
  institution = {Department of Biostatistics, University of Copenhagen, Denmark. n.keiding@biostat.ku.dk},
  keywords = {Bone Marrow Transplantation, immunology; Graft vs Host Disease, etiology;
	Humans; Leukemia, therapy; Markov Chains; Models, Biological; Predictive
	Value of Tests; Proportional Hazards Models; Recurrence; Treatment
	Outcome},
  language = {eng},
  medline-pst = {ppublish},
  pmid = {11406847},
  url = {http://dx.doi.org/10.1002/sim.810}
}

@ARTICLE{Keiding1986,
  author = {Keiding, N. and V{\ae}th, M.},
  title = {Calculating Expected Mortality},
  journal = {Statistics in Medicine},
  year = {1986},
  volume = {5},
  pages = {327-334},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Keirn1985,
  author = {Keirn, W. and Metter, G.},
  title = {Survival of Cancer Patients By Economic Status in a Free Care Setting},
  journal = {Cancer},
  year = {1985},
  volume = {55},
  pages = {1552-1555},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Kellokumpu-Lehtinen2013,
  author = {Kellokumpu-Lehtinen, Pirkko-Liisa and Harmenberg, Ulrika and Joensuu,
	Timo and McDermott, Ray and Hervonen, Petteri and Ginman, Claes and
	Luukkaa, Marjaana and Nyandoto, Paul and Hemminki, Akseli and Nilsson,
	Sten and McCaffrey, John and Asola, Raija and Turpeenniemi-Hujanen,
	Taina and Laestadius, Fredrik and Tasmuth, Tiina and Sandberg, Katinka
	and Keane, Maccon and Lehtinen, Ilari and Luukkaala, Tiina and Joensuu,
	Heikki and , for the P. R. O. S. T. Y study group},
  title = {2-weekly versus 3-weekly docetaxel to treat castration-resistant
	advanced prostate cancer: a randomised, phase 3 trial.},
  journal = {Lancet Oncology},
  year = {2013},
  volume = {14},
  pages = {117--124},
  number = {2},
  month = {Feb},
  abstract = {BACKGROUND: Docetaxel administered every 3 weeks is a standard treatment
	for castration-resistant advanced prostate cancer. We hypothesised
	that 2-weekly administration of docetaxel would be better tolerated
	than 3-weekly docetaxel in patients with castration-resistant advanced
	prostate cancer, and did a prospective, multicentre, randomised,
	phase 3 study to compare efficacy and safety. METHODS: Eligible patients
	had advanced prostate cancer (metastasis, a prostate-specific-antigen
	test result of more than 10{\AA}Â‚ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·0 ng/mL, and WHO performance status
	score of 0-2), had received no chemotherapy (except with estramustine),
	had undergone surgical or chemical castration, and had been referred
	to a treatment centre in Finland, Ireland, or Sweden. Enrolment and
	treatment were done between March 1, 2004, and May 31, 2009. Randomisation
	was done centrally and stratified by centre and WHO performance status
	score of 0-1 vs 2. Patients were assigned 75 mg/m(2) docetaxel intravenously
	on day 1 of a 3-week cycle, or 50 mg/m(2) docetaxel intravenously
	on days 1 and 15 of a 4-week cycle. 10 mg oral prednisolone was administered
	daily to all patients. The primary endpoint was time to treatment
	failure (TTTF). We assessed data in the per-protocol population.
	This study is registered with ClinicalTrials.gov, number NCT00255606.
	FINDINGS: 177 patients were randomly assigned to the 2-weekly docetaxel
	group and 184 to the 3-weekly group. 170 patients in the 2-weekly
	group and 176 in the 3-weekly group were included in the analysis.
	The 2-weekly administration was associated with significantly longer
	TTTF than was 3-weekly administration (5{\AA}Â‚ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·6 months, 95\% CI 5{\AA}Â‚ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·0-6{\AA}Â‚ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·2
	vs 4{\AA}Â‚ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·9 months, 4{\AA}Â‚ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·5-5{\AA}Â‚ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·4; hazard ratio 1{\AA}Â‚ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·3, 95\% CI 1{\AA}Â‚ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·1-1{\AA}Â‚ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·6,
	p=0{\AA}Â‚ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·014). Grade 3-4 adverse events occurred more frequently in the
	3-weekly than in the 2-weekly administration group, including neutropenia
	(93 [53\%] vs 61 [36\%]), leucopenia (51 [29\%] vs 22 [13\%]), and
	febrile neutropenia (25 [14\%] vs six [4\%]). Neutropenic infections
	were reported more frequently in patients who received docetaxel
	every 3 weeks (43 [24\%] vs 11 [6\%], p=0{\AA}Â‚ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·002). INTERPRETATION:
	Administration of docetaxel every 2 weeks seems to be well tolerated
	in patients with castration-resistant advanced prostate cancer and
	could be a useful option when 3-weekly single-dose administration
	is unlikely to be tolerated. FUNDING: Sanofi.},
  file = {Kellokumpu-Lehtinen2013.pdf:Kellokumpu-Lehtinen2013.pdf:PDF},
  institution = {Department of Oncology, Tampere University Hospital, Tampere, Finland.
	Electronic address: Pirkko-Liisa.Kellokumpu-Lehtinen@uta.fi.},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {23294853},
  timestamp = {2013.02.04}
}

@ARTICLE{Kelly2000,
  author = {P. J. Kelly and L. L. Lim},
  title = {Survival analysis for recurrent event data: an application to childhood
	infectious diseases.},
  journal = {Statistics in Medicine},
  year = {2000},
  volume = {19},
  pages = {13--33},
  number = {1},
  month = {Jan},
  file = {Kelly2000.pdf:Kelly2000.pdf:PDF;Kelly2000.pdf:pdf\\Kelly2000.pdf:PDF},
  owner = {pl4},
  pii = {3.0.CO;2-5},
  pmid = {10623910},
  timestamp = {2010.07.14}
}

@ARTICLE{Kerr1998,
  author = {Kerr, G. P. and Kunkler, I. H. and Langlands, A. O. and Rodger, A.},
  title = {({I}n)curability of breast cancer: a 30-year report of a series of
	3933 patients},
  journal = {Breast},
  year = {1998},
  volume = {7},
  pages = {190-194},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Keurentjes2012,
  author = {Keurentjes, J. C. and Fiocco, M. and Schreurs, B. W. and Pijls, B.
	G. and Nouta, K. A. and Nelissen, R G H H.},
  title = {Revision surgery is overestimated in hip replacement.},
  journal = {Bone Joint Res},
  year = {2012},
  volume = {1},
  pages = {258--262},
  number = {10},
  month = {Oct},
  abstract = {The Kaplan-Meier estimation is widely used in orthopedics to calculate
	the probability of revision surgery. Using data from a long-term
	follow-up study, we aimed to assess the amount of bias introduced
	by the Kaplan-Meier estimator in a competing risk setting.We describe
	both the Kaplan-Meier estimator and the competing risk model, and
	explain why the competing risk model is a more appropriate approach
	to estimate the probability of revision surgery when patients die
	in a hip revision surgery cohort. In our study, a total of 62ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â acetabular
	revisions were performed. After a mean of 25 years, no patients were
	lost to follow-up, 13 patients had undergone revision surgery and
	33 patients died of causes unrelated to their hip.The Kaplan-Meier
	estimator overestimates the probability of revision surgery in our
	example by 3\%, 11\%, 28\%, 32\% and 60\% at five, ten, 15, 20 and
	25 years, respectively. As the cumulative incidence of the competing
	event increases over time, as does the amount of bias.Ignoring competing
	risks leads to biased estimations of the probability of revision
	surgery. In order to guide choosing the appropriate statistical analysis
	in future clinical studies, we propose a flowchart.},
  doi = {10.1302/2046-3758.110.2000104},
  file = {Keurentjes2012.pdf:Keurentjes2012.pdf:PDF},
  institution = {Leiden University Medical Center, Department of Orthopaedic Surgery,
	Albinusdreef 2, PO Box 9600, Postzone J-11-S, 2300 RC Leiden, the
	Netherlands.},
  language = {eng},
  medline-pst = {epublish},
  owner = {pl4},
  pii = {2000104},
  pmid = {23610656},
  timestamp = {2014.11.19},
  url = {http://dx.doi.org/10.1302/2046-3758.110.2000104}
}

@ARTICLE{Kieler2003,
  author = {Helle Kieler and Tuttan Zettergren and Hanna Svensson and Paul W
	Dickman and Anders Larsson},
  title = {Assessing urinary albumin excretion in pre-eclamptic women: which
	sample to use?},
  journal = {BJOG},
  year = {2003},
  volume = {110},
  pages = {12-7},
  number = {1},
  month = {Jan},
  abstract = {OBJECTIVE: To evaluate whether the gold standard of 24-hour urine
	collection for measuring albumin excretion in pre-eclamptic women
	could be substituted by shorter collection periods. DESIGN: Prospective
	study. SETTING: Fetal maternity ward, university hospital. PARTICIPANTS:
	Thirty women with pre-eclampsia and a positive urinary test strip
	for protein of at least 2+. METHODS: From each woman, within a 25-hour
	period, three spot, two 12-hour (day and night) and one 24-hour urine
	sample were collected. Urine albumin concentrations in milligrammes
	per litre were analysed by rate nephelometry on a Beckman Array protein
	system. The urinary albumin concentrations in the spot and the 12-hour
	samples were compared with the concentration in the 24-hour urine
	collection. MAIN OUTCOME MEASURES: Urinary albumin concentrations
	in spot and 12-hour samples measured against the standard 24-hour
	albumin excretion. RESULTS: Albumin concentrations in the day and
	night collection fitted closely with the concentrations of the 24-hour
	collection. The median difference between the 24-hour and the day
	collection was -3 mg/L (interquartile range -264 to 116 mg/L). The
	median difference between the 24-hour and the night collection was
	17 mg/L (interquartile range -186 to 210 mg/L). The association of
	urinary albumin concentration in the 24-hour collection and the spot
	samples was much weaker. Of the spot urine samples, the albumin concentration
	in the sample taken on the morning after admission to hospital was
	closest to the 24-hour urinary albumin excretion, with a median difference
	of -62 mg/L (interquartile range -1131 to 285 mg/L). CONCLUSION:
	The gold standard of 24-hour urinary excretion for assessment of
	albuminuria in pre-eclamptic women can be substituted with a 12-hour
	collection. Spot urine samples were inaccurate and are therefore
	not recommended for quantification of albumin excretion.},
  owner = {PaulD},
  pii = {S1470032802014404},
  timestamp = {2011.06.19}
}

@ARTICLE{Killick-Kendrick1997,
  author = {Killick-Kendrick, R. and Killick-Kendrick, M. and Focheux, C. and
	Dereure, J. and Puech, M. P. and Cadiergues, M. C.},
  title = {Protection of dogs from bites of phlebotomine sandflies by deltamethrin
	collars for control of canine leishmaniasis.},
  journal = {Med Vet Entomol},
  year = {1997},
  volume = {11},
  pages = {105--111},
  number = {2},
  month = {Apr},
  abstract = {Dog collars made of PVC plastic impregnated with the pyrethroid insecticide
	deltamethrin at 40 mg/g were investigated for their protective efficacy
	against phlebotomine sandflies. Collared dogs were kept separately
	(two untreated control dogs lived together) in outdoor enclosures,
	each with a kennel, in the C{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚ÂµÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¥nnes, southern France. To measure
	sandfly mortality and anti-feeding effects due to the deltamethrin-impregnated
	collars worn continuously by the dogs for up to 8 months, each dog
	was periodically sedated and exposed for 2h to 150-200 laboratory-reared
	Phlebotomus perniciosus females (plus c. 25 males) inside a net (1.2
	m square, 1.8 m high) indoors. After dogs were removed from the nets,
	allowed to recover and returned to their kennels, any dead sandflies
	were collected from inside the net and counted. Surviving flies were
	kept overnight, then scored according to whether they were still
	alive or dead, unfed or blood-fed. From tests 2, 3, 4, 13, 20, 26
	and 34 weeks after the dogs began wearing collars, the overall numbers
	of blood-fed female sandflies recaptured were 75 from two dogs with
	collars, compared with 1911 from two collarless dogs. Thus, for every
	100 flies which fed on collarless dogs, only 4 fed on collared dogs,
	i.e. the collars protected dogs from 96\% of the bites and this activity
	was maintained for up to 34 weeks. During the same period, the percentage
	of recaptured female sandflies that had fed on collared dogs was
	0-12\% compared to 55-95\% on collarless dogs. Immediately after
	dogs were taken out of the nets, 21-60\% of flies confined with the
	collared dogs were found dead, compared to 0-12\% with the controls.
	It is concluded that, at least in the Mediterranean subregion, this
	insecticidal collar would protect a dog from the majority of sandfly
	bites and retain a killing effect for a complete sandfly season.
	Moreover, it seems likely that the use of collars on all dogs in
	a focus of Leishmania infantum would reduce contact between sandfly
	vectors and canine reservoir hosts sufficiently to diminish the risk
	of infection for humans as well as dogs.},
  institution = {Department of Biology, Imperial College at Silwood Park, Berkshire,
	U.K.},
  keywords = {Animals; Dog Diseases, parasitology/prevention /&/ control; Dogs;
	Female; France; Insect Bites and Stings, prevention /&/ control/veterinary;
	Insecticides; Leishmaniasis, prevention /&/ control/transmission/veterinary;
	Male; Nitriles; Phlebotomus; Pyrethrins},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {9226637},
  timestamp = {2013.05.29}
}

@ARTICLE{Kim2007,
  author = {Kim, Haesook T.},
  title = {Cumulative incidence in competing risks data and competing risks
	regression analysis.},
  journal = {Clin Cancer Res},
  year = {2007},
  volume = {13},
  pages = {559--565},
  number = {2 Pt 1},
  month = {Jan},
  abstract = {Competing risks occur commonly in medical research. For example, both
	treatment-related mortality and disease recurrence are important
	outcomes of interest and well-known competing risks in cancer research.
	In the analysis of competing risks data, methods of standard survival
	analysis such as the Kaplan-Meier method for estimation of cumulative
	incidence, the log-rank test for comparison of cumulative incidence
	curves, and the standard Cox model for the assessment of covariates
	lead to incorrect and biased results. In this article, we discuss
	competing risks data analysis which includes methods to calculate
	the cumulative incidence of an event of interest in the presence
	of competing risks, to compare cumulative incidence curves in the
	presence of competing risks, and to perform competing risks regression
	analysis. A hypothetical numeric example and real data are used to
	compare those three methods in the competing risks data analysis
	to their respective counterparts in the standard survival analysis.
	The source and magnitude of bias from the Kaplan-Meier estimate is
	also detailed.},
  doi = {10.1158/1078-0432.CCR-06-1210},
  file = {Kim2007.pdf:Kim2007.pdf:PDF},
  institution = {Department of Biostatistics and Computational Biology, Dana-Farber
	Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. kim.haesook@jimmy.harvard.edu},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pii = {13/2/559},
  pmid = {17255278},
  timestamp = {2012.11.21},
  url = {http://dx.doi.org/10.1158/1078-0432.CCR-06-1210}
}

@ARTICLE{Kim2012,
  author = {Kim, Michelle M. and Hoffman, Karen E. and Levy, Lawrence B. and
	Frank, Steven J. and Pugh, Thomas J. and Choi, Seungtaek and Nguyen,
	Quynh N. and McGuire, Sean E. and Lee, Andrew K. and Kuban, Deborah
	A.},
  title = {Prostate cancer-specific mortality after definitive radiation therapy:
	who dies of disease?},
  journal = {Eur J Cancer},
  year = {2012},
  volume = {48},
  pages = {1664--1671},
  number = {11},
  month = {Jul},
  abstract = {A competing risks analysis was undertaken to identify subgroups at
	greatest risk of dying from prostate cancer (PC) after definitive
	external beam radiation therapy (RT)ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â±androgen deprivation therapy
	(ADT) in the prostate specific antigen (PSA) era.Outcomes of 2675
	men with localised PC treated with RTÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â±ADT from 1987-2007 were analysed.
	Prostate cancer-specific mortality (PCSM) and non-PCSM rates were
	calculated after stratifying patients according to National Comprehensive
	Cancer Network (NCCN) risk-group, RT dose, use of ADT and age at
	treatment.Only 0.2\% of low-risk men died of PC 10 years after treatment.
	All of these deaths occurred in patients treated with < 72 Gy, and
	only one patient ? 70 years old who received ? 72 Gy died of PC at
	last follow-up. Likewise, none of the patients with intermediate-risk
	disease treated with ? 72 Gy and ADT died of PC at 10 years, and
	the highest 10-year rate of PCSM was seen in men ? 70 years old treated
	with < 72 Gy without ADT (5.1\%). Among high-risk men < 70 years
	old, treatment with RT dose < 72 Gy without ADT yielded similar 10-year
	rates of PCSM (15.2\%) and non-PCSM (18.5\%), whereas men treated
	with ? 72 Gy and ADT were twice as likely to die from other causes
	(16.2\%) than PC (9.4\%). In high-risk men ? 70 years old, dose-escalation
	with ADT reduced 10-year PCSM from 14\% to 4\%, and most deaths were
	due to other causes.Low- and intermediate-risk patients treated with
	definitive RT are unlikely to die of PC. PCSM is higher in men with
	high-risk disease but may be reduced with dose-escalation and ADT,
	although patients are still twice as likely to die of other causes.},
  doi = {10.1016/j.ejca.2012.01.026},
  institution = {Department of Radiation Oncology, The University of Texas MD Anderson
	Cancer Center, 1515 Holcombe Boulevard Unit 97, Houston, TX 77030-4009,
	USA. mmkim@mdanderson.org},
  keywords = {Age Factors; Aged; Androgen Antagonists, therapeutic use; Cause of
	Death; Humans; Male; Prostatic Neoplasms, drug therapy/mortality/radiotherapy;
	Radiotherapy Dosage; Risk Assessment; Survival Rate; United States},
  language = {eng},
  medline-pst = {ppublish},
  owner = {sanelo},
  pii = {S0959-8049(12)00067-6},
  pmid = {22336663},
  timestamp = {2013.09.17},
  url = {http://dx.doi.org/10.1016/j.ejca.2012.01.026}
}

@ARTICLE{Kim2011,
  author = {Kim, Sungduk and Chen, Ming-Hui and Dey, Dipak K.},
  title = {A new threshold regression model for survival data with a cure fraction.},
  journal = {Lifetime Data Anal},
  year = {2011},
  volume = {17},
  pages = {101--122},
  number = {1},
  month = {Jan},
  abstract = {Due to the fact that certain fraction of the population suffering
	a particular type of disease get cured because of advanced medical
	treatment and health care system, we develop a general class of models
	to incorporate a cure fraction by introducing the latent number N
	of metastatic-competent tumor cells or infected cells caused by bacteria
	or viral infection and the latent antibody level R of immune system.
	Various properties of the proposed models are carefully examined
	and a Markov chain Monte Carlo sampling algorithm is developed for
	carrying out Bayesian computation for model fitting and comparison.
	A real data set from a prostate cancer clinical trial is analyzed
	in detail to demonstrate the proposed methodology.},
  doi = {10.1007/s10985-010-9166-9},
  institution = {Division of Epidemiology, Statistics and Prevention Research, Eunice
	Kennedy Shriver National Institute of Child Health and Human Development,
	NIH, Rockville, MD 20852, USA. kims2@mail.nih.gov},
  keywords = {Bayes Theorem; Clinical Trials as Topic; Disease-Free Survival; Humans;
	Male; Markov Chains; Models, Statistical; Monte Carlo Method; Prostatic
	Neoplasms, immunology/mortality/therapy; Regression Analysis; Survival
	Analysis},
  language = {eng},
  medline-pst = {ppublish},
  owner = {theand},
  pmid = {20414804},
  timestamp = {2013.10.01},
  url = {http://dx.doi.org/10.1007/s10985-010-9166-9}
}

@ARTICLE{King2012,
  author = {King, Nicholas B and Harper, Sam and Young, Meredith E},
  title = {Use of relative and absolute effect measures in reporting health
	inequalities: structured review},
  journal = {BMJ},
  year = {2012},
  volume = {345},
  abstract = {Objective To examine the frequency of reporting of absolute and relative
	effect measures in health inequalities research.Design Structured
	review of selected general medical and public health journals.Data
	sources 344 articles published during 2009 in American Journal of
	Epidemiology, American Journal of Public Health, BMJ, Epidemiology,
	International Journal of Epidemiology, JAMA, Journal of Epidemiology
	and Community Health, The Lancet, The New England Journal of Medicine,
	and Social Science and Medicine.Main outcome measures Frequency and
	proportion of studies reporting absolute effect measures, relative
	effect measures, or both in abstract and full text; availability
	of absolute risks in studies reporting only relative effect measures.Results
	40\% (138/344) of articles reported a measure of effect in the abstract;
	among these, 88\% (122/138) reported only a relative measure, 9\%
	(13/138) reported only an absolute measure, and 2\% (3/138) reported
	both. 75\% (258/344) of all articles reported only relative measures
	in the full text; among these, 46\% (119/258) contained no information
	on absolute baseline risks that would facilitate calculation of absolute
	effect measures. 18\% (61/344) of all articles reported only absolute
	measures in the full text, and 7\% (25/344) reported both absolute
	and relative measures. These results were consistent across journals,
	exposures, and outcomes.Conclusions Health inequalities are most
	commonly reported using only relative measures of effect, which may
	influence readers{\textquoteright} judgments of the magnitude, direction,
	significance, and implications of reported health inequalities.},
  doi = {10.1136/bmj.e5774},
  file = {King2012.pdf:pdf\\King2012.pdf:PDF;King2012.pdf:King2012.pdf:PDF},
  isbn = {1756-1833},
  owner = {hanbow},
  publisher = {BMJ Publishing Group Ltd},
  timestamp = {2015.07.09}
}

@ARTICLE{Kippen2007,
  author = {Kippen, Rebecca and Evans, Ann and Gray, Edith},
  title = {Parental preference for sons and daughters in a Western industrial
	setting: evidence and implications.},
  journal = {J Biosoc Sci},
  year = {2007},
  volume = {39},
  pages = {583--597},
  number = {4},
  month = {Jul},
  abstract = {This paper considers whether sex composition of existing children
	in Australian families is an important factor in parity progression.
	Using census data from 1981, 1986, 1991, 1996 and 2001, women are
	linked with their co-resident children, allowing investigation of
	family sex composition and its changing impact over time on the propensity
	to have another child. The study finds that parents are much more
	likely to have a third and fourth birth if existing children are
	all of the same sex, indicating a strong preference for children
	of both sexes. This increased propensity has added around three per
	cent to the fertility of recent cohorts. The paper concludes with
	a discussion of the potential impact of sex-selection technologies
	on fertility. The authors argue that future widespread use of reliable
	sex-selection technologies might act to increase fertility in the
	short term, but would lead to a long-term reduction in fertility.},
  doi = {10.1017/S0021932006001477},
  institution = {Demography and Sociology Program, The Australian National University,
	Canberra, Australia.},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {S0021932006001477},
  pmid = {16959062},
  timestamp = {2012.03.31},
  url = {http://dx.doi.org/10.1017/S0021932006001477}
}

@ARTICLE{Kirmani2001,
  author = {S. N. U. A. Kirmani and R. C. Gupta},
  title = {On the Proportional Odds Model in Survival Analysis},
  journal = {Annals of the Institute of Statistical Mathematics},
  year = {2001},
  volume = {53},
  pages = {203-216},
  file = {Kirmani2001.pdf:Kirmani2001.pdf:PDF;Kirmani2001.pdf:pdf\\Kirmani2001.pdf:PDF},
  owner = {pl4},
  timestamp = {2009.08.07}
}

@Book{Klein2003,
  author    = {J.P. Klein and M. L. Moeschberger},
  title     = {Survival analysis: techniques for censored and truncated data},
  publisher = {Springer (Second edition)},
  file      = {:pdf/klein2003.pdf:PDF},
  owner     = {pl4},
  timestamp = {2009.05.07},
  year      = {2003},
}

@ARTICLE{Klein2005,
  author = {J. P. Klein and P. K. Andersen},
  title = {Regression modeling of competing risks data based on pseudovalues
	of the cumulative incidence function.},
  journal = {Biometrics},
  year = {2005},
  volume = {61},
  pages = {223--229},
  number = {1},
  month = {Mar},
  abstract = {Typically, regression models for competing risks outcomes are based
	on proportional hazards models for the crude hazard rates. These
	estimates often do not agree with impressions drawn from plots of
	cumulative incidence functions for each level of a risk factor. We
	present a technique which models the cumulative incidence functions
	directly. The method is based on the pseudovalues from a jackknife
	statistic constructed from the cumulative incidence curve. These
	pseudovalues are used in a generalized estimating equation to obtain
	estimates of model parameters. We study the properties of this estimator
	and apply the technique to a study of the effect of alternative donors
	on relapse for patients given a bone marrow transplant for leukemia.},
  doi = {10.1111/j.0006-341X.2005.031209.x},
  file = {Klein2005.pdf:Klein2005.pdf:PDF;Klein2005.pdf:pdf\\Klein2005.pdf:PDF},
  institution = {Division of Biostatistics, Medical College of Wisconsin, 9701 Watertown
	Plank Road, Milwaukee, Wisconsin 53226, USA. klein@mcw.edu},
  owner = {pl4},
  pii = {BIOM031209},
  pmid = {15737097},
  timestamp = {2010.07.05},
  url = {http://dx.doi.org/10.1111/j.0006-341X.2005.031209.x}
}

@Book{Kleinbaum1996,
  author    = {David G. Kleinbaum},
  title     = {Survival Analysis: A Self-Learning Text},
  publisher = {Springer},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1996},
}

@ARTICLE{Knize2005,
  author = {Mark G Knize and James S Felton},
  title = {Formation and human risk of carcinogenic heterocyclic amines formed
	from natural precursors in meat.},
  journal = {Nutr Rev},
  year = {2005},
  volume = {63},
  pages = {158--165},
  abstract = {A group of heterocyclic amines that are mutagens and rodent carcinogens
	form when meat is cooked to medium and well-done states. The precursors
	of these compounds are natural meat components: creatinine, amino
	acids, and sugars. Defined model systems of dry-heated precursors
	mimic the amounts and proportions of heterocyclic amines found in
	meat. Results from model systems and cooking experiments suggest
	ways to reduce their formation and, thus, reduce human intake. Human
	cancer epidemiology studies related to the consumption of well-done
	meat products are listed and compared in this review.},
  owner = {PaulD},
  pmid = {15971410},
  timestamp = {2005.11.17}
}

@ARTICLE{Knol2008,
  author = {Mirjam J Knol and Jan P Vandenbroucke and Pippa Scott and Matthias
	Egger},
  title = {What do case-control studies estimate? Survey of methods and assumptions
	in published case-control research.},
  journal = {Am J Epidemiol},
  year = {2008},
  volume = {168},
  pages = {1073--1081},
  number = {9},
  month = {Nov},
  abstract = {To evaluate strategies used to select cases and controls and how reported
	odds ratios are interpreted, the authors examined 150 case-control
	studies published in leading general medicine, epidemiology, and
	clinical specialist journals from 2001 to 2007. Most of the studies
	(125/150; 83\%) were based on incident cases; among these, the source
	population was mostly dynamic (102/125; 82\%). A minority (23/125;
	18\%) sampled from a fixed cohort. Among studies with incident cases,
	105 (84\%) could interpret the odds ratio as a rate ratio. Fifty-seven
	(46\% of 125) required the source population to be stable for such
	interpretation, while the remaining 48 (38\% of 125) did not need
	any assumptions because of matching on time or concurrent sampling.
	Another 17 (14\% of 125) studies with incident cases could interpret
	the odds ratio as a risk ratio, with 16 of them requiring the rare
	disease assumption for this interpretation. The rare disease assumption
	was discussed in 4 studies but was not relevant to any of them. No
	investigators mentioned the need for a stable population. The authors
	conclude that in current case-control research, a stable exposure
	distribution is much more frequently needed to interpret odds ratios
	than the rare disease assumption. At present, investigators conducting
	case-control studies rarely discuss what their odds ratios estimate.},
  doi = {10.1093/aje/kwn217},
  file = {Knol2008.pdf:Knol2008.pdf:PDF;Knol2008.pdf:pdf\\Knol2008.pdf:PDF},
  institution = {Julius Center for Health Sciences and Primary Care, University Medical
	Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, the Netherlands.
	m.j.knol@umcutrecht.nl},
  owner = {pl4},
  pii = {kwn217},
  pmid = {18794220},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1093/aje/kwn217}
}

@Book{Knuth1984,
  author    = {Donald E. Knuth},
  title     = {The {{\TeX}book}},
  publisher = {Addison-Wesley},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1984},
}

@Book{Kogevinas1990,
  author    = {Manolis Kogevinas},
  title     = {Longitudinal Study: Socio-Demographic Differences in Cancer Survival},
  publisher = {London: Office of Population Censuses and Surveys},
  series    = {LS no. 5},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1990},
}

@ARTICLE{Kogevinas1991,
  author = {Kogevinas, M. and Marmot, M. G. and Fox, A. J. and Goldblatt, P.
	O.},
  title = {Socioeconomic Differences in Cancer Survival},
  journal = {Journal of Epidemiology and Community Health},
  year = {1991},
  volume = {45},
  pages = {200-203},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Koivisto2007,
  author = {M. Koivisto and O. M. Peltoniemi and T. Saarela and O. Tammela and
	P. Jouppila and M. Hallman},
  title = {Blood glucose level in preterm infants after antenatal exposure to
	glucocorticoid.},
  journal = {Acta Paediatr},
  year = {2007},
  volume = {96},
  pages = {664--668},
  number = {5},
  month = {May},
  abstract = {To determine the impact of antenatal glucocorticoid on neonatal glucose
	homeostasis.This is a retrospective gestationally paired survey followed
	by a randomized study. On the basis of the interval between last
	antenatal dexamethasone and birth, 228 preterm infants born before
	34 weeks were divided into Short (< 24 h), Intermediate (1-6 days),
	and Long (> or = 7 days) exposure groups and compared their gestationally
	paired controls. After a single course of betamethasone, the parturients
	remaining undelivered for one week were randomized to receive either
	one dose of betamethasone (n = 52) or placebo (n = 53). Glucose values
	were recorded at 11 time points in the first 3 days of life. Hypoglycaemic
	and hyperglycaemic values were counted.There were no overall differences
	in mean glucose levels between the antenatal glucocorticoid and the
	control groups. However, the long exposure time to antenatal glucocorticoid
	was associated with increased risk of hyperglycaemia (OR 4.1; 2.2-7.6).Antenatal
	glucocorticoid administration was associated with subtle disturbances
	of glucose homeostasis in preterm infants. These differences were
	dependent on the length of drug-delivery interval so that long exposition
	time seemed to increase the incidence of hyperglycaemia during the
	first days of life.},
  doi = {10.1111/j.1651-2227.2007.00242.x},
  institution = {Department of Paediatrics, University of Oulu, Oulu, Finland.},
  owner = {pl4},
  pii = {APA242},
  pmid = {17376183},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1111/j.1651-2227.2007.00242.x}
}

@ARTICLE{Koller2012,
  author = {Koller, Michael T. and Raatz, Heike and Steyerberg, Ewout W. and
	Wolbers, Marcel},
  title = {Competing risks and the clinical community: irrelevance or ignorance?},
  journal = {Stat Med},
  year = {2012},
  volume = {31},
  pages = {1089--1097},
  number = {11-12},
  month = {May},
  abstract = {Life expectancy has dramatically increased in industrialized nations
	over the last 200 hundred years. The aging of populations carries
	over to clinical research and leads to an increasing representation
	of elderly and multimorbid individuals in study populations. Clinical
	research in these populations is complicated by the fact that individuals
	are likely to experience several potential disease endpoints that
	prevent some disease-specific endpoint of interest from occurrence.
	Large developments in competing risks methodology have been achieved
	over the last decades, but we assume that recognition of competing
	risks in the clinical community is still marginal. It is the aim
	of this article to address translational aspects of competing risks
	to the clinical community. We describe clinical populations where
	competing risks issues may arise. We then discuss the importance
	of agreement between the competing risks methodology and the study
	aim, in particular the distinction between etiologic and prognostic
	research questions. In a review of 50 clinical studies performed
	in individuals susceptible to competing risks published in high-impact
	clinical journals, we found competing risks issues in 70\% of all
	articles. Better recognition of issues related to competing risks
	and of statistical methods that deal with competing risks in accordance
	with the aim of the study is needed.},
  doi = {10.1002/sim.4384},
  file = {Koller2012.pdf:Koller2012.pdf:PDF},
  institution = {Basel Institute for Clinical Epidemiology and Biostatistics, University
	Hospital Basel, Switzerland. kollerm@uhbs.ch},
  keywords = {Aged; Aged, 80 and over; Aging; Biomedical Research, statistics /&/
	numerical data; Data Interpretation, Statistical; Female; Humans;
	Life Expectancy; Male; Models, Statistical; Risk},
  language = {eng},
  medline-pst = {ppublish},
  owner = {sanelo},
  pmid = {21953401},
  timestamp = {2013.10.11},
  url = {http://dx.doi.org/10.1002/sim.4384}
}

@ARTICLE{Komarek2007,
  author = {Arnost Kom\'{a}rek and Emmanuel Lesaffre and Catherine Legrand},
  title = {Baseline and treatment effect heterogeneity for survival times between
	centers using a random effects accelerated failure time model with
	flexible error distribution.},
  journal = {Statistics in Medicine},
  year = {2007},
  volume = {26},
  pages = {5457--5472},
  number = {30},
  month = {Dec},
  abstract = {Nowadays, most clinical trials are conducted in different centers
	and even in different countries. In most multi-center studies, the
	primary analysis assumes that the treatment effect is constant over
	centers. However, it is also recommended to perform an exploratory
	analysis to highlight possible center by treatment interaction, especially
	when several countries are involved. We propose in this paper an
	exploratory Bayesian approach to quantify this interaction in the
	context of survival data. To this end we used and generalized a random
	effects accelerated failure time model. The generalization consists
	in using a penalized Gaussian mixture as an error distribution on
	top of multivariate random effects that are assumed to follow a normal
	distribution. For computational convenience, the computations are
	based on Markov chain Monte Carlo techniques. The proposed method
	is illustrated on the disease-free survival times of early breast
	cancer patients collected in the EORTC trial 10854.},
  doi = {10.1002/sim.3083},
  file = {Komarek2007.pdf:Komarek2007.pdf:PDF;Komarek2007.pdf:pdf\\Komarek2007.pdf:PDF},
  institution = {Biostatistical Centre, Katholieke Universiteit Leuven, Kapucijnenvoer
	35, 3000 Leuven, Belgium.},
  owner = {pl4},
  pmid = {17910009},
  timestamp = {2008.11.18},
  url = {http://dx.doi.org/10.1002/sim.3083}
}

@ARTICLE{Konishi1996,
  author = {Konishi, S. and Kitagawa, G.},
  title = {Generalised information criteria in model selection},
  journal = {Biometrika},
  year = {1996},
  volume = {83},
  pages = {875-890},
  file = {Konishi1996.pdf:Konishi1996.pdf:PDF;Konishi1996.pdf:pdf\\Konishi1996.pdf:PDF},
  owner = {hanbow},
  timestamp = {2015.05.26}
}

@ARTICLE{Korhonen2005,
  author = {T. Korhonen and S. Saarela},
  title = {Role of adiposity hormones in the mouse during fasting and winter-acclimatization.},
  journal = {Comp Biochem Physiol A Mol Integr Physiol},
  year = {2005},
  volume = {140},
  pages = {217--223},
  number = {2},
  month = {Feb},
  abstract = {The influence of fasting and winter-acclimatization (cold and short-day
	acclimatization) on mouse plasma leptin, ghrelin, growth hormone
	(GH) and melatonin concentrations was determined from blood samples
	taken at mid-day and midnight. A 16-h fast decreased the plasma leptin
	but almost doubled the plasma ghrelin concentrations which contribute
	to energy saving, appetite stimulation and, in the case of leptin,
	to inhibition of reproduction. Winter-acclimatization did not affect
	plasma ghrelin concentrations, whereas leptin decreased to the same
	level as in fasting. The low leptin concentrations possibly enable
	an increased caloric intake for the purpose of thermogenesis. Fasting
	and winter-acclimatization seemed to abolish the diurnal leptin rhythm,
	but had no effect on that of ghrelin. Plasma melatonin concentration
	correlated negatively with ghrelin, suggesting a possible role for
	melatonin in the regulation of ghrelin concentration. SNS-activity
	and insulin appear to be the main regulators of leptin plasma concentration
	in the mouse, rather than melatonin as in some seasonal mammals.
	Interestingly, endogenous ghrelin did not stimulate GH secretion,
	which is a well-documented reaction to exogenous ghrelin injections.},
  doi = {10.1016/j.cbpb.2005.01.006},
  institution = {Department of Biology, University of Oulu, P.O. Box 3000, FIN-90014
	Oulu, Finland. tuula.b.korhonen@oulu.fi},
  owner = {pl4},
  pii = {S1095-6433(05)00007-3},
  pmid = {15748862},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1016/j.cbpb.2005.01.006}
}

@ARTICLE{Korn1998,
  author = {Korn, E.L. and Graubard, B.I.},
  title = {Variance estimation for superpopulation parameters},
  journal = {Statistica Sinica},
  year = {1998},
  volume = {8},
  pages = {1131--1152},
  file = {Korn1998.pdf:Korn1998.pdf:PDF;Korn1998.pdf:pdf\\Korn1998.pdf:PDF},
  groups = {Superpopulation},
  owner = {PaulD},
  timestamp = {2013.01.24}
}

@ARTICLE{Korn1997,
  author = {E. L. Korn and B. I. Graubard and D. Midthune},
  title = {Time-to-event analysis of longitudinal follow-up of a survey: choice
	of the time-scale.},
  journal = {American Journal of Epidemiology},
  year = {1997},
  volume = {145},
  pages = {72--80},
  number = {1},
  month = {Jan},
  abstract = {Following individuals sampled in a large-scale health survey for the
	development of diseases and/or death offers the opportunity to assess
	the prognostic significance of various risk factors. The proportional
	hazards regression model, which allows for the control of covariates,
	is frequently used for the analysis of such data. The authors discuss
	the appropriate time-scale for such regression models, and they recommend
	that age rather than time since the baseline survey (time-on-study)
	be used. Additionally, with age as the time-scale, control for calendar-period
	and/or birth cohort effects can be achieved by stratifying the model
	on birth cohort. Because, as discussed by the authors, many published
	analyses have used regression models with time-on-study as the time-scale,
	it is important to assess the magnitude of the error incurred from
	this type of incorrect modeling. The authors provide simple conditions
	for when incorrect use of time-on-study as the time-scale will nevertheless
	yield approximately unbiased proportional hazards regression coefficients.
	Examples are given using data from the first National Health and
	Nutrition Examination Survey (NHANES I) Epidemiologic Followup Study.
	Additional issues concerning the analysis of longitudinal follow-up
	of survey data are briefly discussed.},
  file = {Korn1997.pdf:Korn1997.pdf:PDF;Korn1997.pdf:pdf\\Korn1997.pdf:PDF},
  institution = {Biometric Research Branch, National Cancer Institute, Bethesda, MD
	20892, USA.},
  owner = {pl4},
  pmid = {8982025},
  timestamp = {2009.04.16}
}

@ARTICLE{Koscielny2001,
  author = {Koscielny, S. and Thames, H. D.},
  title = {Biased methods for estimating local and distant failure rates in
	breast carcinoma and a "commonsense" approach.},
  journal = {Cancer},
  year = {2001},
  volume = {92},
  pages = {2220--2227},
  number = {8},
  month = {Oct},
  abstract = {Several methods are used to estimate risks of local and distant failure
	after treatment of breast carcinoma. The authors' purpose was to
	present a physician-friendly description of the potential bias in
	these methods, and to suggest an improvement.The cumulative incidence
	based on first event (cumulative incidence [CI]) and Kaplan-Meier
	method based on first (KM[1st]) or all (KM[any]) events, are applied
	to a database comprising 2521 women treated for breast carcinoma
	at the same institution and observed for more than 20 years. The
	authors relate these estimates to the region containing all possible
	estimates of failure rate. This region contains the "true" risk (net
	risk, or risk that would be observed in the absence of competing
	risks) of local or distant failure.The CI estimate is the lowest
	possible estimate of the true failure rate. Under certain "commonsense"
	assumptions, the CI estimate is below the lowest possible estimate
	of risk of failure. The KM(1st) estimate is higher than the CI estimate
	and lower than the KM(any) estimate. Under the same commonsense assumptions,
	the KM(1st) method also underestimates the true failure rate.Methods
	based on time to first event such as CI and KM(1st) underestimate
	the true risk. In the design of clinical trials, consideration should
	be given to longer follow-up and the KM(any) method of analyzing
	results because it provides a less biased estimate.},
  institution = {Department of Medical Statistics, Institut Gustave Roussy, Villejuif,
	France. koscieln@igr.fr},
  keywords = {Bias (Epidemiology); Breast Neoplasms, mortality/therapy; Female;
	Humans; Middle Aged; Prognosis; Risk Factors; Survival Analysis;
	Treatment Failure},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {3.0.CO;2-V},
  pmid = {11596041},
  timestamp = {2013.05.29}
}

@Book{Kramer1988,
  author    = {Kramer, M. S.},
  title     = {Clinical Epidemiology and Biostatistics},
  publisher = {Berlin: Springer-Verlag},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1988},
}

@ARTICLE{Kravdal2002,
  author = {{\o}. Kravdal},
  title = {A cancer survival model that takes sociodemographic variations in
	"normal" mortality into account: comparison with other models.},
  journal = {J Epidemiol Community Health},
  year = {2002},
  volume = {56},
  pages = {309--318},
  number = {4},
  month = {Apr},
  abstract = {STUDY OBJECTIVES: Sociodemographic differentials in cancer survival
	have occasionally been studied by using a relative survival approach,
	where all cause mortality among persons with a cancer diagnosis is
	compared with that among similar persons without such a diagnosis
	("normal" mortality). One should ideally take into account that this
	"normal" mortality not only depends on age, sex, and period, but
	also various other sociodemographic variables. However, this has
	very rarely been done. A method that permits such variations to be
	considered is presented here, as an alternative to an existing technique,
	and is compared with a relative survival model where these variations
	are disregarded and two other methods that have often been used.
	DESIGN, SETTING, AND PARTICIPANTS: The focus is on how education
	and marital status affect the survival from 12 common cancer types
	among men and women aged 40-80. Four different types of hazard models
	are estimated, and differences between effects are compared. The
	data are from registers and censuses and cover the entire Norwegian
	population for the years 1960-1991. There are more than 100 000 deaths
	to cancer patients in this material. MAIN RESULTS AND CONCLUSIONS:
	A model for registered cancer mortality among cancer patients gives
	results that for most, but not all, sites are very similar to those
	from a relative survival approach where educational or marital variations
	in "normal" mortality are taken into account. A relative survival
	approach without consideration of these sociodemographic variations
	in "normal" mortality gives more different results, the most extreme
	example being the doubling of the marital differentials in survival
	from prostate cancer. When neither sufficient data on cause of death
	nor on variations in "normal" mortality are available, one may well
	choose the simplest method, which is to model all cause mortality
	among cancer patients. There is little reason to bother with the
	estimation of a relative-survival model that does not allow sociodemographic
	variations in "normal" mortality beyond those related to age, sex,
	and period. Fortunately, both these less data demanding models perform
	well for the most aggressive cancers.},
  file = {Kravdal2002.pdf:Kravdal2002.pdf:PDF;Kravdal2002.pdf:pdf\\Kravdal2002.pdf:PDF},
  institution = {Department of Economics, University of Oslo, PO Box 1095 Blindern,
	N-0317 Oslo, Norway. okravdal@econ.uio.no},
  owner = {pl4},
  pmid = {11896140},
  timestamp = {2008.12.16}
}

@ARTICLE{Kristinsson2009,
  author = {Kristinsson, Sigurdur Y. and Bj\"{o}rkholm, Magnus and Andersson,
	Therese M-L. and Eloranta, Sandra and Dickman, Paul W. and Goldin,
	Lynn R. and Blimark, Cecilie and Mellqvist, Ulf-Henrik and Wahlin,
	Anders and Turesson, Ingemar and Landgren, Ola},
  title = {Patterns of survival and causes of death following a diagnosis of
	monoclonal gammopathy of undetermined significance: a population-based
	study.},
  journal = {Haematologica},
  year = {2009},
  volume = {94},
  pages = {1714--1720},
  number = {12},
  month = {Dec},
  abstract = {There are limited data on survival patterns among patients with monoclonal
	gammopathy of undetermined significance.We compared the survival
	of 4,259 patients with monoclonal gammopathy of undetermined significance,
	collected from hematology outpatient units in Sweden, with the survival
	of the general population by computing relative survival ratios.
	We also compared causes of death in these patients with those in
	16,151 matched controls.One-, 5-, 10-, and 15-year relative survival
	ratios were 0.98 (95\% CI 0.97-0.99), 0.93 (0.91-0.95), 0.82 (0.79-0.84),
	and 0.70 (0.64-0.76), respectively. Younger age at diagnosis of the
	gammopathy was associated with a significantly lower excess mortality
	compared to that in older patients (p<0.001). The excess mortality
	among patients with gammopathy increased with longer follow-up (p<0.0001).
	IgM (versus IgG/A) gammopathy was associated with a superior survival
	(p=0.038). Patients with monoclonal gammopathy of undetermined significance
	had an increased risk of dying from multiple myeloma (hazards ratio
	(HR)=553; 95\% CI 77-3946), Waldenstr\"{o}m's macroglobulinemia (HR=infinity),
	other lymphoproliferative malignancies (6.5; 2.8-15.1), other hematologic
	malignancies (22.9; 8.9-58.7), amyloidosis (HR=infinity), bacterial
	infections (3.4; 1.7-6.7), ischemic heart disease (1.3; 1.1-1.4),
	other heart disorders (1.5; 1.2-1.8), other hematologic conditions
	(6.9; 2.7-18), liver (2.1; 1.1-4.2), and renal diseases (3.2; 2.0-4.9).Our
	finding of decreased life expectancy in patients with monoclonal
	gammopathy of undetermined significance, which was most pronounced
	in the elderly and explained by both malignant transformation and
	non-malignant causes, is of importance in the understanding and clinical
	management of this disease. The underlying mechanisms may be causally
	related to the gammopathy, but may also be explained by underlying
	disease that led to the detection of the hematologic disease. Our
	results are of importance since they give a true estimation of survival
	in patients with monoclonal gammopathy of undetermined significance
	diagnosed in clinical practice.},
  doi = {10.3324/haematol.2009.010066},
  institution = {Department of Medicine, Division of Hematology, Karolinska University
	Hospital Solna and Karolinska Institutet, Stockholm, Sweden. sigurdur.kristinsson@karolins-ka.se},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {haematol.2009.010066},
  pmid = {19608666},
  timestamp = {2012.04.18},
  url = {http://dx.doi.org/10.3324/haematol.2009.010066}
}

@ARTICLE{Kristinsson2009c,
  author = {Kristinsson, Sigurdur Yngvi and Derolf, Asa Rangert and Edgren, Gustaf
	and Dickman, Paul W. and Bj{\AA}Â¯ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¿ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â½olm, Magnus},
  title = {Socioeconomic differences in patient survival are increasing for
	acute myeloid leukemia and multiple myeloma in {S}weden.},
  journal = {J Clin Oncol},
  year = {2009},
  volume = {27},
  pages = {2073--2080},
  number = {12},
  month = {Apr},
  abstract = {An association between socioeconomic status (SES) and survival in
	acute myeloid leukemia (AML) and multiple myeloma (MM) has not been
	established in developed countries. We assessed the impact of SES
	on survival in two large population-based cohorts of AML and MM patients
	diagnosed in Sweden 1973 to 2005.The relative risk of death (all
	cause and cause specific) in relation to SES was estimated using
	Cox's proportional hazards regression. We also conducted analyses
	stratified by calendar periods (1973 to 1979, 1980 to 1989, 1990
	to 1999, and 2000 to 2005).We identified a total of 9,165 and 14,744
	patients with AML and MM, respectively. Overall, higher white-collar
	workers had a lower mortality than other SES groups for both AML
	(P = .005) and MM (P < .005). In AML patients, a consistently higher
	overall mortality was observed in blue-collar workers compared with
	higher white-collar workers in the last three periods (hazard ratio
	[HR], 1.26; 95\% CI, 1.05 to 1.51; HR, 1.23; 95\% CI, 1.05 to 1.45;
	HR, 1.28; 95\% CI, 1.04 to 1.57, respectively). In MM, no difference
	was observed in the first two calendar periods. However, in 1990
	to 1999, self-employed (HR, 1.18; 95\% CI, 1.02 to 1.37), blue-collar
	workers (HR, 1.18; 95\% CI, 1.04 to 1.32), and retired (HR, 1.45;
	95\% CI, 1.16 to 1.80) had a higher mortality compared to higher
	white-collar workers. In 2000 to 2005, blue-collar workers had a
	higher mortality (HR, 1.31; 95\% CI, 1.07 to 1.60) compared with
	higher white-collar workers.SES was significantly associated with
	survival in both AML and MM. Most conspicuously, a lower mortality
	was observed among the highest SES group during more recent calendar
	periods. Differences in management, comorbidity, and lifestyle, are
	likely factors to explain these findings.},
  doi = {10.1200/JCO.2008.18.2006},
  institution = {Division of Hematology, Department of Medicine, Karolinska University
	Hospital Solna, SE-171 76 Stockholm, Sweden. sigurdur.kristinsson@karolinska.se},
  language = {eng},
  medline-pst = {ppublish},
  owner = {Paul},
  pii = {JCO.2008.18.2006},
  pmid = {19289627},
  timestamp = {2012.06.07},
  url = {http://dx.doi.org/10.1200/JCO.2008.18.2006}
}

@ARTICLE{Kristinsson2009a,
  author = {Kristinsson, Sigurdur Y. and Dickman, Paul W. and Wilson, Wyndham
	H. and Caporaso, Neil and Bj{\AA}Â¯ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¿ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â½olm, Magnus and Landgren, Ola},
  title = {Improved survival in chronic lymphocytic leukemia in the past decade:
	a population-based study including 11,179 patients diagnosed between
	1973-2003 in {S}weden},
  journal = {Haematologica},
  year = {2009},
  volume = {94},
  pages = {1259--1265},
  number = {9},
  month = {Sep},
  abstract = {Clinical management of chronic lymphocytic leukemia patients has changed
	considerably over the last years, reflected in an increased use of
	prognostic markers, new therapeutic agents and procedures, and supportive
	care measures. However, to date, clinical trials have not shown a
	survival benefit.Using population-based data from Sweden, we assessed
	variations in survival among all chronic lymphocytic leukemia patients
	(n=11,179) reported from 1973-2003. Relative survival ratios were
	computed as measures of patient survival.Overall we found significantly
	improved (p<0.0001) 5-, 10-, and 20-year relative survival ratio
	for the entire cohort during the study period. Improved 5- and 10-year
	relative survival ratio was found for all age-groups (p<0.0001) and
	both sexes. Compared to females, however, males had a significantly
	inferior survival in all age groups and calendar periods (p<0.0001).
	Younger chronic lymphocytic leukemia patients had a superior survival
	compared to older chronic lymphocytic leukemia patients, in all calendar
	periods (p<0.0001). Five-year relative survival ratio has not improved
	in the youngest chronic lymphocytic leukemia patients since the 1980s;
	however, older patients have had a continuous improvement in 5 year-relative
	survival ratio.The observed improvements are likely due to improved
	therapeutic developments and supportive care. Our findings suggest
	that elderly chronic lymphocytic leukemia patients might benefit
	more from the recently introduced drugs in chronic lymphocytic leukemia.
	Future clinical trials are needed to better define underlying mechanisms
	of observed heterogeneity in chronic lymphocytic leukemia survival
	by age and sex, and evaluate the role of newer chronic lymphocytic
	leukemia therapy in the elderly.},
  doi = {10.3324/haematol.2009.007849},
  institution = {Department of Medicine, Division of Hematology, Karolinska University
	Hospital, Stockholm, Sweden. sigurdur.kristinsson@karolins-ka.se},
  language = {eng},
  medline-pst = {ppublish},
  owner = {Paul},
  pii = {94/9/1259},
  pmid = {19734417},
  timestamp = {2012.06.07},
  url = {http://dx.doi.org/10.3324/haematol.2009.007849}
}

@ARTICLE{Kristinsson2007,
  author = {Kristinsson, Sigurdur Yngvi and Landgren, Ola and Dickman, Paul W.
	and Derolf, Asa Rangert and Bj{\AA}Â¯ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¿ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â½olm, Magnus},
  title = {Patterns of survival in multiple myeloma: a population-based study
	of patients diagnosed in {S}weden from 1973 to 2003.},
  journal = {J Clin Oncol},
  year = {2007},
  volume = {25},
  pages = {1993--1999},
  number = {15},
  month = {May},
  abstract = {To define patterns of survival among all multiple myeloma (MM) patients
	diagnosed in Sweden during a 30-year period.A total of 14,381 MM
	patients (7,643 males; 6,738 females) were diagnosed in Sweden from
	1973 to 2003 (median age, 69.9 years; range 19 to 101 years). Patients
	were categorized into six age categories and four calendar periods
	(1973 to 1979, 1980 to 1986, 1987 to 1993, and 1994 to 2003). We
	computed relative survival ratios (RSRs) as measures of patient survival.One-year
	survival improved (P < .001) over time in all age groups and RSRs
	were 0.73, 0.78, 0.80, and 0.82 for the four calendar periods; however,
	improvement in 5-year (P < .001) and 10-year (P < .001) RSR was restricted
	to patients younger than 70 years and younger than 60 years, respectively.
	For the first time, in analyses restricted to MM patients diagnosed
	at age younger than 60 years, we found a 29\% (P < .001) reduced
	10-year mortality in the last calendar period (1994 to 2003) compared
	with the preceding calendar period (1987 to 1993). Females with MM
	had a 3\% (P = .024) lower excess mortality than males.One-year MM
	survival has increased for all age groups during the last decades;
	5-year and 10-year MM survival has increased in younger patients
	(younger than 60 to 70 years). High-dose melphalan with subsequent
	autologous stem-cell transplantation, thalidomide, and a continuous
	improvement in supportive care measures are probably the most important
	factors contributing to this finding. New effective agents with a
	more favorable toxicity profile are needed to improve survival further,
	particularly in the elderly.},
  doi = {10.1200/JCO.2006.09.0100},
  institution = {Division of Hematology, Department of Medicine, Karolinska Karolinska
	University Hospital and Institutet, Stockholm, Sweden.},
  language = {eng},
  medline-pst = {ppublish},
  owner = {Paul},
  pii = {JCO.2006.09.0100},
  pmid = {17420512},
  timestamp = {2012.06.07},
  url = {http://dx.doi.org/10.1200/JCO.2006.09.0100}
}

@ARTICLE{Kuha2004,
  author = {Kuha, J.},
  title = {{AIC} and {BIC} comparisons of assumptions and performance},
  journal = {Sociological Methods \& Research},
  year = {2004},
  volume = {33},
  pages = {188-229},
  file = {Kuha2004.pdf:Kuha2004.pdf:PDF;Kuha2004.pdf:pdf\\Kuha2004.pdf:PDF},
  owner = {hanbow},
  timestamp = {2015.05.12}
}

@ARTICLE{Kulathinal2007,
  author = {Sangita Kulathinal and Juha Karvanen and Olli Saarela and Kari Kuulasmaa},
  title = {Case-cohort design in practice - experiences from the MORGAM Project.},
  journal = {Epidemiol Perspect Innov},
  year = {2007},
  volume = {4},
  pages = {15},
  abstract = {When carefully planned and analysed, the case-cohort design is a powerful
	choice for follow-up studies with multiple event types of interest.
	While the literature is rich with analysis methods for case-cohort
	data, little is written about the designing of a case-cohort study.
	Our experiences in designing, coordinating and analysing the MORGAM
	case-cohort study are potentially useful for other studies with similar
	characteristics. The motivation for using the case-cohort design
	in the MORGAM genetic study is discussed and issues relevant to its
	planning and analysis are studied. We propose solutions for appending
	the earlier case-cohort selection after an extension of the follow-up
	period and for achieving maximum overlap between earlier designs
	and the case-cohort design. Approaches for statistical analysis are
	studied in a simulation example based on the MORGAM data.},
  doi = {10.1186/1742-5573-4-15},
  file = {Kulathinal2007.pdf:Kulathinal2007.pdf:PDF;Kulathinal2007.pdf:pdf\\Kulathinal2007.pdf:PDF},
  institution = {Indic Society for Education and Development, Tapovan Bridge, Nashik
	422 009, India.},
  owner = {pl4},
  pii = {1742-5573-4-15},
  pmid = {18053196},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1186/1742-5573-4-15}
}

@ARTICLE{Kullback1951,
  author = {Kullback, S. and Leibler, R. A.},
  title = {On Information and Sufficiency},
  journal = {Annals of Mathematical Statistics},
  year = {1951},
  volume = {22},
  pages = {79-86},
  file = {Kullback1951.pdf:Kullback1951.pdf:PDF;Kullback1951.pdf:pdf\\Kullback1951.pdf:PDF},
  owner = {hanbow},
  timestamp = {2015.05.08}
}

@ARTICLE{Kuss2008,
  author = {Kuss, Oliver and Blankenburg, Thomas and Haerting, Johannes},
  title = {A relative survival model for clustered responses.},
  journal = {Biom J},
  year = {2008},
  volume = {50},
  pages = {408--418},
  number = {3},
  month = {Jun},
  abstract = {Relative Survival is the ratio of the overall survival of a group
	of patients to the expected survival for a demographically similar
	group. It is commonly used in disease registries to estimate the
	effect of a particular disease when the true cause of death is not
	reliably known. Regression models for relative survival have been
	described and we extend these models to allow for clustered responses
	by embedding them into the class of Generalized linear mixed models
	(GLMM). The method is motivated and demonstrated by a data set from
	the HALLUCA study, an epidemiological study which investigated provision
	of medical care to lung cancer patients in the region of Halle in
	the eastern part of Germany.},
  doi = {10.1002/bimj.200710426},
  institution = {Institute of Medical Epidemiology, Biostatistics, and Informatics,
	University of Halle-Wittenberg, Magdeburger Str. 8, 06097 Halle Saale,
	Germany. oliver.kuss@medizin.uni-halle.de},
  keywords = {Aged; Cluster Analysis; Female; Humans; Lung Neoplasms, epidemiology/therapy;
	Male; Middle Aged; Models, Statistical; Regression Analysis; Risk
	Factors; Survival Analysis},
  language = {eng},
  medline-pst = {ppublish},
  owner = {miccro},
  pmid = {18435505},
  timestamp = {2015.06.14},
  url = {http://dx.doi.org/10.1002/bimj.200710426}
}

@InBook{Laeaerae2011,
  author    = {L{\"a}{\"a}r{\"a}, E.},
  booktitle = {Methods in Biobanking},
  title     = {Study designs for biobank-based epidemiologic research on chronic diseases},
  chapter   = {6},
  editor    = {Joakim Dillner},
  publisher = {Springer},
  series    = {Methods in molecular biology},
  url       = {http://www.springerlink.com/index/T620772NW2114817.pdf},
  file      = {Laeaerae2011.pdf:Laeaerae2011.pdf:PDF;Laeaerae2011.pdf:pdf\\Laeaerae2011.pdf:PDF},
  owner     = {PaulD},
  timestamp = {2013.01.24},
  year      = {2011},
}

@ARTICLE{Laara1987,
  author = {L{\"a}{\"a}r{\"a}, E. and Day, N. and Hakama, M.},
  title = {Trends in Mortality from Cervical Cancer in the {N}ordic Countries:
	Association with Organised Screening Programmes},
  journal = {Lancet},
  year = {1987},
  volume = {1},
  pages = {1247--1249},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Lagerlund2005,
  author = {Lagerlund, M. and Bellocco, R. and Karlsson, P. and Tejler, G. and
	Lambe, M.},
  title = {Socio-economic factors and breast cancer survival - a population-based
	cohort study ({S}weden)},
  journal = {Cancer Causes and Control},
  year = {2005},
  volume = {16},
  pages = {419-430},
  file = {Lagerlund2005.pdf:Lagerlund2005.pdf:PDF;Lagerlund2005.pdf:pdf\\Lagerlund2005.pdf:PDF},
  owner = {hanbow},
  timestamp = {2016.09.13}
}

@ARTICLE{Lahelma1990,
  author = {Eero Lahelma and Tapani Valkonen},
  title = {Health and Social Inequities in {F}inland and Elsewhere},
  journal = {Social Science \& Medicine},
  year = {1990},
  volume = {31},
  pages = {257-265},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Lahlou2000,
  author = {Lahlou, A. and Lang, P. and Charpentier, B. and Barrou, B. and Glotz,
	D. and Baron, C. and Hiesse, C. and Kreis, H. and Legendre, C. and
	Bedrossian, J. and Mougenot, B. and Sraer, J. D. and Rondeau, E.},
  title = {Hemolytic uremic syndrome. Recurrence after renal transplantation.
	Groupe Coop{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â±ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¡tif de l'Ile-de-France (GCIF).},
  journal = {Medicine (Baltimore)},
  year = {2000},
  volume = {79},
  pages = {90--102},
  number = {2},
  month = {Mar},
  abstract = {Hemolytic uremic syndrome (HUS) is an uncommon cause of end-stage
	renal failure in adults, and few data are available concerning the
	outcome of renal transplantation in these patients. We conducted
	this retrospective multicentric study to appreciate the outcome of
	adult renal transplant recipients whose primary disease was HUS.
	Sixteen patients, transplanted between 1975 and 1995, were included
	in the study. In each case, initial diagnosis of HUS was documented
	by a kidney biopsy. These 16 patients received a total of 25 allografts:
	1 graft for 9 patients, 2 grafts for 5 patients, and 3 grafts for
	2 patients. Nine patients (56\%) developed definite clinical and
	pathologic evidence of recurrence on at least 1 graft. Four additional
	patients (25\%) demonstrated only some clinical or pathologic evidence
	of recurrence which could not be distinguished from acute vascular
	rejection. Three patients had no sign of recurrence of the initial
	disease. The 1-year graft survival rate was 63\% and the 5-year graft
	survival rate was 18.5\%. In the group of patients with proven or
	possible recurrence (n = 13), the 1-year and 5-year graft survival
	rates were 49\% and less than 10\%, respectively. The recurrence
	was an early event, occurring before the end of the first month after
	transplantation in half the cases. The recurrence rate was 92\% in
	non-nephrectomized patients and 50\% in patients with bilateral nephrectomy.
	In the literature, 71 adult patients with primary HUS had received
	a total of 90 kidney grafts. Among them, 54\% had a recurrence on
	their graft, which was diagnosed in 52\% of the kidney transplants.
	It is note-worthy that when data from the literature are pooled with
	our results, the rate of recurrence appears to be significantly lower
	in binephrectomized patients than in patients with their native kidneys
	at the time of transplantation (5 of 14 versus 27 of 35 patients,
	respectively, p = 0.0155). By univariate analysis, no other risk
	factor for recurrence could be identified. Treatment with cyclosporine
	A did not influence the recurrence rate. We conclude that recurrence
	of HUS after renal transplantation is a frequent, early, and severe
	complication, leading rapidly to graft loss. Prospective studies
	are needed to confirm that bilateral nephrectomy prior to transplantation
	decreases the rate of recurrence.},
  institution = {Service de N{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¯ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¨rologie A, H{\AA}Â³ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¯ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â´al Tenon, Paris, France. nila@altavista.net},
  keywords = {Actuarial Analysis; Adult; Age of Onset; Chi-Square Distribution;
	Female; Graft Survival, physiology; Hemolytic-Uremic Syndrome, complications/epidemiology/pathology/surgery;
	Humans; Kidney Failure, Chronic, etiology/surgery; Kidney Transplantation;
	Male; Middle Aged; Recurrence; Retrospective Studies; Risk Factors;
	Statistics, Nonparametric; Time Factors},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {10771707},
  timestamp = {2013.05.29}
}

@ARTICLE{Laird1981,
  author = {N. Laird and D. Olivier},
  title = {Covariance analysis of censored survival data using log-linear analysis
	techniques},
  journal = {Journal of the American Statistical Association},
  year = {1981},
  volume = {76},
  pages = {231-240},
  file = {Laird1981.pdf:Laird1981.pdf:PDF;Laird1981.pdf:pdf\\Laird1981.pdf:PDF},
  owner = {pl4},
  timestamp = {2008.11.18}
}

@ARTICLE{Lambe1994,
  author = {M. Lambe and C. Hsieh and D. Trichopoulos and A. Ekbom and M. Pavia
	and H. O. Adami},
  title = {Transient increase in the risk of breast cancer after giving birth.},
  journal = {New England Journal of Medicine},
  year = {1994},
  volume = {331},
  pages = {5--9},
  number = {1},
  month = {Jul},
  abstract = {BACKGROUND. The effect of pregnancy on the risk of breast cancer is
	not clear. We tested the hypothesis that the risk of breast cancer
	increases transiently after pregnancy but then falls to a level below
	that of age-matched nulliparous women. METHODS. We conducted a case-control
	study of a nationwide cohort in Sweden, using a computerized record
	linkage between the Cancer Registry and the Fertility Registry. The
	study subjects were women born from 1925 through 1960 who were resident
	citizens of Sweden at the time of the 1960 census. A total of 12,666
	patients with breast cancer were compared with 62,121 age-matched
	control subjects. We used conditional logistic regression to estimate
	odds ratios for the development of breast cancer at different ages,
	according to maternal age at first delivery (in uniparous as compared
	with nulliparous women) and age at second delivery (in biparous as
	compared with uniparous women). RESULTS. Uniparous women were at
	higher risk of breast cancer than nulliparous women for up to 15
	years after childbirth and at lower risk thereafter. The excess risk
	was most pronounced among women who were older at the time of their
	first delivery (odds ratio 5 years after delivery among women 35
	years old at first delivery, 1.26; 95 percent confidence interval,
	1.10 to 1.44). Women who had two pregnancies had a less striking
	increase in risk. CONCLUSIONS. Pregnancy has a dual effect on the
	risk of breast cancer: it transiently increases the risk after childbirth
	but reduces the risk in later years. In women with two pregnancies,
	the short-term adverse effect is masked by the long-term protection
	imparted by the first pregnancy. A plausible biologic interpretation
	is that pregnancy increases the short-term risk of breast cancer
	by stimulating the growth of cells that have undergone the early
	stages of malignant transformation but that it confers long-term
	protection by inducing the differentiation of normal mammary stem
	cells that have the potential for neoplastic change.},
  institution = {Department of Social Medicine, University Hospital, Uppsala, Sweden.},
  owner = {pl4},
  pmid = {8202106},
  timestamp = {2009.04.01}
}

@Article{Lambert2016a,
  author    = {P. C. Lambert},
  title     = {The estimation and modelling of cause-specific cumulative incidence functions using time-dependent weights},
  journal   = {The Stata Journal},
  year      = {2017},
  volume    = {17},
  pages     = {181-207},
  url       = {http://www.stata-journal.com/article.html?article=st0471},
  owner     = {pl4},
  timestamp = {2016.01.12},
}

@PhdThesis{Lambert2000,
  author    = {P. C. Lambert},
  title     = {Hierarchical models in medical research},
  type      = {PhD Thesis},
  file      = {Lambert2000.pdf:pdf\\Lambert2000.pdf:PDF},
  groups    = {PhD Thesis},
  owner     = {pl4},
  school    = {University of Leicester},
  timestamp = {2013.10.23},
  year      = {2000},
}

@Article{Lambert2016,
  author    = {Lambert, P. C. and Wilkes, S. R. and Crowther, M.J.},
  title     = {Flexible parametric modelling of the cause-specific cumulative incidence function},
  doi       = {10.1002/sim.7208},
  pages     = {1429-1446},
  volume    = {36},
  file      = {:Lambert2016.pdf:PDF},
  journal   = {Statistics in Medicine},
  owner     = {pl4},
  pmid      = {28008649},
  timestamp = {2016.01.12},
  year      = {2017},
}

@Misc{Cox_40_Paul_Lambert,
  author    = {Paul C Lambert},
  title     = {Parametric Survival Models},
  file      = {Cox_40_Paul_Lambert.pdf:Cox_40_Paul_Lambert.pdf:PDF},
  keywords  = {Presentation},
  owner     = {pl4},
  timestamp = {2013.03.11},
}

@ARTICLE{Lambert2007b,
  author = {P. C. Lambert},
  title = {Modeling of the cure fraction in survival studies},
  journal = {The Stata Journal},
  year = {2007},
  volume = {7},
  pages = {351-375},
  file = {Lambert2007b.pdf:Lambert2007b.pdf:PDF;Lambert2007b.pdf:pdf\\Lambert2007b.pdf:PDF},
  keywords = {Cure models},
  owner = {pl4},
  timestamp = {2008.10.28}
}

@ARTICLE{Lambert2001,
  author = {P. C. Lambert and K. R. Abrams and D. R. Jones and A. W. Halligan
	and A. Shennan},
  title = {Analysis of ambulatory blood pressure monitor data using a hierarchical
	model incorporating restricted cubic splines and heterogeneous within-subject
	variances.},
  journal = {Statistics in Medicine},
  year = {2001},
  volume = {20},
  pages = {3789--3805},
  number = {24},
  month = {Dec},
  abstract = {Hypertensive disorders of pregnancy are associated with significant
	maternal and foetal morbidity. Measurement of blood pressure remains
	the standard way of identifying individuals at risk. There is growing
	interest in the use of ambulatory blood pressure monitors (ABPM),
	which can record an individual's blood pressure many times over a
	24-hour period. From a clinical perspective interest lies in the
	shape of the blood pressure profile over a 24-hour period and any
	differences in the profile between groups. We propose a two-level
	hierarchical linear model incorporating all ABPM data into a single
	model. We contrast a classical approach with a Bayesian approach
	using the results of a study of 206 pregnant women who were asked
	to wear an ABPM for 24 hours after referral to an obstetric day unit
	with high blood pressure. As the main interest lies in the shape
	of the profile, we use restricted cubic splines to model the mean
	profiles. The use of restricted cubic splines provides a flexible
	way to model the mean profiles and to make comparisons between groups.
	From examining the data and the fit of the model it is apparent that
	there were heterogeneous within-subject variances in that some women
	tend to have more variable blood pressure than others. Within the
	Bayesian framework it is relatively easy to incorporate a random
	effect to model the between-subject variation in the within-subject
	variances. Although there is substantial heterogeneity in the within-subject
	variances, allowing for this in the model has surprisingly little
	impact on the estimates of the mean profiles or their confidence/credible
	intervals. We thus demonstrate a powerful method for analysis of
	ABPM data and also demonstrate how heterogeneous within-subject variances
	can be modelled from a Bayesian perspective.},
  file = {Lambert2001.pdf:Lambert2001.pdf:PDF;Lambert2001.pdf:pdf\\Lambert2001.pdf:PDF},
  institution = {Department of Epidemiology and Public Health, University of Leicester,
	22-28 Princess Road West, Leicester LE1 6TP UK.},
  owner = {pl4},
  pii = {10.1002/sim.1172},
  pmid = {11782034},
  timestamp = {2008.10.15}
}

@Article{Lambert2008a,
  author      = {Paul C Lambert and Lucinda J Billingham and Nicola J Cooper and Alex J Sutton and Keith R Abrams},
  title       = {Estimating the cost-effectiveness of an intervention in a clinical trial when partial cost information is available: a {B}ayesian approach.},
  doi         = {10.1002/hec.1243},
  number      = {1},
  pages       = {67--81},
  url         = {http://dx.doi.org/10.1002/hec.1243},
  volume      = {17},
  abstract    = {There is an increasing need to establish whether health-care interventions
	are cost effective as well as clinically effective. It is becoming
	increasingly common for cost studies to be incorporated into clinical
	trials, either on all patients or more usually on a subset of patients.
	Establishing the total cost per patient is complex, as it requires
	information on resource use, which may come from a variety of different
	sources. This complexity may lead to considerable missing data, and
	can result in some patients only having partial cost information.
	In this paper we consider a clinical trial consisting of 351 patients
	with advanced non-small cell lung cancer comparing chemotherapy with
	standard palliative care. A subset of 115 patients was selected for
	the cost sub-study. Total cost was split into four components, for
	which resource use was collected. Complete resource data were available
	on 82 patients. For the remaining patients at least one of the cost
	components was missing. The objective of this paper is to develop
	a Bayesian approach which simultaneously models both the clinical
	effectiveness data and the cost data, by modelling the individual
	components. This also provides estimates of the cost-effectiveness
	in terms of the Incremental Net Monetary Benefit (INMB) and Cost-Effectiveness
	Acceptability Curves (CEAC). We compare a number of different models
	of increasing complexity. The models estimate the interrelationships
	between the four cost components and survival, and thus enable a
	predictive distribution for each missing cost item to be obtained.},
  file        = {lambert2008a.pdf:lambert2008a.pdf:PDF},
  institution = {Centre for Biostatistics and Genetic Epidemiology, Department of Health Sciences, University of Leicester, Leicester, UK. paul.lambert@le.ac.uk},
  journal     = {Health Economics},
  month       = {Jan},
  owner       = {pl4},
  pmid        = {17533622},
  timestamp   = {2008.10.15},
  year        = {2008},
}

@ARTICLE{Lambert2004,
  author = {Paul C Lambert and Paul R Burton and Keith R Abrams and Adrian M
	Brooke},
  title = {The analysis of peak expiratory flow data using a three-level hierarchical
	model.},
  journal = {Statistics in Medicine},
  year = {2004},
  volume = {23},
  pages = {3821--3839},
  number = {24},
  month = {Dec},
  abstract = {Peak expiratory flow (PEF) is a measure commonly used in clinical
	practice and research for respiratory diseases such as asthma. In
	research, PEF is usually recorded in a diary for a 2-week period
	with two or more measurements per day. Interest may lie in whether
	certain groups of individuals tend to have higher or lower PEF. In
	addition the variability of PEF may be of interest as, for example,
	asthmatics tend to have more variable airways. In this paper we develop
	a three-level hierarchical model that can simultaneously model the
	mean level and variability of PEF. The variability is broken down
	into three components, between-subject variability, between-day within-subject
	variability, and within-day within-subject variability. The latter
	two components are of specific clinical interest. We fit both classical
	and Bayesian models. The Bayesian models have the advantage of taking
	the uncertainty in the variance component estimates into account
	when estimating the standard errors of the fixed effects. In addition,
	the Bayesian models provide an intuitive and simple way to investigate
	the within-subject variance components.},
  doi = {10.1002/sim.1951},
  file = {Lambert2004.pdf:Lambert2004.pdf:PDF;Lambert2004.pdf:pdf\\Lambert2004.pdf:PDF},
  institution = {Centre for Biostatistics and Genetic Epidemiology, Department of
	Health Sciences, University of Leicester, 22-28 Princess Road West,
	Leicester LE1 6TP, UK. pl4@leicester.ac.uk},
  owner = {pl4},
  pmid = {15580603},
  timestamp = {2008.10.15},
  url = {http://dx.doi.org/10.1002/sim.1951}
}

@Article{Lambert2010a,
  author    = {P. C. Lambert and P. W. Dickman and C. P. Nelson and P. Royston},
  title     = {Estimating the crude probability of death due to cancer and other causes using relative survival models},
  doi       = {10.1002/sim.3762},
  pages     = {885 - 895},
  volume    = {29},
  file      = {Lambert2010a.pdf:pdf\\Lambert2010a.pdf:PDF},
  journal   = {Statistics in Medicine},
  owner     = {pl4},
  pmid      = {20213719},
  timestamp = {2009.03.25},
  year      = {2010},
}

@ARTICLE{Lambert2007,
  author = {P. C. Lambert and P. W. Dickman and P. {\"{O}}sterlund and T. M-L. Andersson
	and R. Sankila and B. Glimelius},
  title = {Temporal trends in the proportion cured for cancer of the colon and
	rectum: a population-based study using data from the {F}innish Cancer
	Registry.},
  journal = {International Journal of Cancer},
  year = {2007},
  volume = {121},
  pages = {2052--2059},
  number = {9},
  abstract = {Colorectal cancer is the third most common cancer worldwide and the
	second most common cancer in Europe. Cumulative relative survival
	curves for both cancer of the colon and cancer of the rectum generally
	plateau after approximately 6-8 years. When this occurs, "population"
	or "statistical" cure is reached. We analyzed data from the Finnish
	Cancer Registry over a 50-year period using methods that simultaneously
	estimate the proportion of patients cured of disease (the cure fraction)
	and the survival time distribution of the "uncured" group. Our primary
	aim was to investigate temporal trends in the cure fraction and median
	survival of the uncured by age group for both cancer of the colon
	and rectum. For both cancers, the cure fraction has increased dramatically
	over time for all age groups. However, the difference in the cure
	fraction between age groups has reduced over time, particularly for
	cancer of the colon. Median survival in the uncured has also increased
	over time in all age groups but there still remains an inverse relationship
	between age and median survival, with shorter median survival with
	increasing age. The reasons for these impressive increases in patient
	survival are complex, but are highly likely to be strongly related
	to many improvements in cancer care over this same time period.},
  doi = {10.1002/ijc.22948},
  file = {lambert2007.pdf:lambert2007.pdf:PDF},
  institution = {Department of Health Sciences, Centre for Biostatistics and Genetic
	Epidemiology, University of Leicester, Leicester, United Kingdom,
	and Department of Oncology, Helsinki University Central Hospital,
	Finland. paul.lambert@le.ac.uk},
  owner = {pl4},
  pmid = {17640061},
  timestamp = {2008.10.15},
  url = {http://dx.doi.org/10.1002/ijc.22948}
}

@Article{Lambert2015,
  author    = {Lambert, P. C. and Dickman, P. W. and Rutherford, M. J.},
  title     = {Comparison of approaches to estimating age-standardized net survival},
  doi       = {10.1186/s12874-015-0057-3},
  pages     = {64},
  volume    = {15},
  file      = {Lambert2015.pdf:Lambert2015.pdf:PDF;Lambert2015.pdf:pdf\\Lambert2015.pdf:PDF},
  journal   = {BMC Med Res Methodol},
  owner     = {PaulD},
  pmid      = {26275405},
  timestamp = {2014.09.11},
  year      = {2015},
}

@Article{Lambert2010,
  author    = {P. C. Lambert and P. W. Dickman and C. L. Weston and J. R. Thompson},
  title     = {Estimating the cure fraction in population-based cancer studies by using finite mixture models},
  journal   = {Journal of the Royal Statistical Society, Series C},
  year      = {2010},
  volume    = {59},
  pages     = {35-55},
  doi       = {10.1111/j.1467-9876.2009.00677.x},
  file      = {Lambert2010.pdf:Lambert2010.pdf:PDF;Lambert2010.pdf:pdf\\Lambert2010.pdf:PDF},
  keywords  = {Cure models; theory},
  owner     = {pl4},
  timestamp = {2010.02.03},
}

@Article{Lambert2011,
  author      = {P. C. Lambert and L. Holmberg and F. Sandin and F. Bray and K. M. Linklater and A. Purushotham and D. Robinson and H. M{\o}ller},
  title       = {Quantifying differences in breast cancer survival between {E}ngland and {N}orway.},
  journal     = {Cancer Epidemiology},
  year        = {2011},
  volume      = {35},
  pages       = {526-533},
  doi         = {10.1016/j.canep.2011.04.003},
  url         = {http://dx.doi.org/10.1016/j.canep.2011.04.003},
  abstract    = {Background: Survival from breast cancer is lower in the UK than in
	some other European countries. We compared survival in England and
	Norway by age and time from diagnosis. Methods: We included 303,648
	English and 24,919 Norwegian cases of breast cancer diagnosed 1996-2004
	using flexible parametric relative survival models, enabling improved
	quantification of differences in survival. Crude probabilities were
	estimated to partition the probability of death due to all causes
	into that due to cancer and other causes and to estimate the number
	of "avoidable" deaths. Results: England had lower relative survival
	for all ages with the difference increasing with age. Much of the
	difference was due to higher excess mortality in England in the first
	few months after diagnosis. Older patients had a higher proportion
	of deaths due to other causes. At 5 years post diagnosis, a woman
	aged 85 in England had probabilities of 0.35 of dying of cancer and
	0.32 of dying of other causes, whilst in Norway they were 0.26 and
	0.35. By eight years the number of "avoidable" all-cause deaths in
	England was 1020 with the number of "avoidable" breast cancer related
	deaths 1488. Conclusion: Lower breast cancer survival in England
	is mainly due to higher mortality in the first year after diagnosis.
	Crude probabilities aid our understanding of the impact of disease
	on individual patients and help assess different treatment options.},
  file        = {Lambert2011.pdf:Lambert2011.pdf:PDF},
  institution = {Centre for Biostatistics and Genetic Epidemiology, Department of Health Sciences, 2nd Floor Adrian Building, University of Leicester, University Road, Leicester LE1 7RH, United Kingdom; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, PO Box 281, SE-171 77 Stockholm, Sweden.},
  owner       = {pl4},
  pii         = {S1877-7821(11)00067-1},
  pmid        = {21606014},
  timestamp   = {2011.06.20},
}

@ARTICLE{Lambert2009,
  author = {P. C. Lambert and P. Royston},
  title = {Further development of flexible parametric models for survival analysis},
  journal = {The Stata Journal},
  year = {2009},
  volume = {9},
  pages = {265-290},
  file = {Lambert2009.pdf:Lambert2009.pdf:PDF;Lambert2009.pdf:pdf\\Lambert2009.pdf:PDF},
  owner = {pl4},
  timestamp = {2009.03.18}
}

@ARTICLE{Lambert2005,
  author = {P. C. Lambert and L. K. Smith and D. R. Jones and J. L. Botha},
  title = {Additive and multiplicative covariate regression models for relative
	survival incorporating fractional polynomials for time-dependent
	effects.},
  journal = {Statistics in Medicine},
  year = {2005},
  volume = {24},
  pages = {3871--3885},
  number = {24},
  abstract = {Relative survival is used to estimate patient survival excluding causes
	of death not related to the disease of interest. Rather than using
	cause of death information from death certificates, which is often
	poorly recorded, relative survival compares the observed survival
	to that expected in a matched group from the general population.
	Models for relative survival can be expressed on the hazard (mortality)
	rate scale as the sum of two components where the total mortality
	rate is the sum of the underlying baseline mortality rate and the
	excess mortality rate due to the disease of interest. Previous models
	for relative survival have assumed that covariate effects act multiplicatively
	and have thus provided relative effects of differences between groups
	using excess mortality rate ratios. In this paper we consider (i)
	the use of an additive covariate model, which provides estimates
	of the absolute difference in the excess mortality rate; and (ii)
	the use of fractional polynomials in relative survival models for
	the baseline excess mortality rate and time-dependent effects. The
	approaches are illustrated using data on 115 331 female breast cancer
	patients diagnosed between 1 January 1986 and 31 December 1990. The
	use of additive covariate relative survival models can be useful
	in situations when the excess mortality rate is zero or slightly
	less than zero and can provide useful information from a public health
	perspective. The use of fractional polynomials has advantages over
	the usual piecewise estimation by providing smooth estimates of the
	baseline excess mortality rate and time-dependent effects for both
	the multiplicative and additive covariate models. All models presented
	in this paper can be estimated within a generalized linear models
	framework and thus can be implemented using standard software.},
  doi = {10.1002/sim.2399},
  file = {lambert2005.pdf:lambert2005.pdf:PDF;lambert2005a.pdf:lambert2005a.pdf:PDF},
  institution = {Department of Health Sciences, Centre for Biostatistics and Genetic
	Epidemiology, University of Leicester, 22-28 Princess Road West,
	Leicester, LE1 6TP, UK. pl4@le.ac.uk},
  owner = {pl4},
  pmid = {16320260},
  timestamp = {2008.10.15},
  url = {http://dx.doi.org/10.1002/sim.2399}
}

@ARTICLE{Lambert2002,
  author = {P. C. Lambert and A. J. Sutton and K. R. Abrams and D. R. Jones},
  title = {A comparison of summary patient-level covariates in meta-regression
	with individual patient data meta-analysis.},
  journal = {Journal of Clinical Epidemiology},
  year = {2002},
  volume = {55},
  pages = {86--94},
  number = {1},
  abstract = {OBJECTIVES: To compare meta-analysis of summary study level data with
	the equivalent individual patient data (IPD) analysis when interest
	lies in identification of binary patient characteristics related
	to treatment efficacy. DESIGN: A simulation study comparing meta-regression
	with IPD analyses of randomized controlled trials. METHODS: Twenty-seven
	different meta-analysis situations were simulated with 1000 repetitions
	in each case. The following parameters were varied: (1) the treatment
	effect magnitude for different patient risk groups; (2) sample sizes
	of individual studies; and (3) number of studies. The meta-regression
	and IPD results were then compared for each situation. RESULTS: The
	statistical power of meta-regression was dramatically and consistently
	lower than that of IPD analysis, with little agreement between the
	parameter estimates obtained from the two methods. Only in meta-analyses
	of large numbers of large trials, did meta-regression detect differential
	treatment effects between risk groups with any consistency. CONCLUSIONS:
	Meta-analysis of summary data may be adequate when estimating a single
	pooled treatment effect or investigating study level characteristics.
	However, when interest lies in investigating whether patient characteristics
	are related to treatment, IPD analysis will generally be necessary
	to discover any such relationships. In these situations practitioners
	should try to obtain individual-level data.},
  file = {Lambert2002.pdf:Lambert2002.pdf:PDF;Lambert2002.pdf:pdf\\Lambert2002.pdf:PDF},
  institution = {Department of Epidemiology and Public Health, University of Leicester,
	22-28 Princess Road West, LE1 6TP, Leicester, UK. p14@le.ac.uk},
  owner = {pl4},
  pii = {S0895435601004140},
  pmid = {11781126},
  timestamp = {2008.10.15}
}

@ARTICLE{Lambert2008,
  author = {Paul C Lambert and Alex J Sutton and Paul R Burton and Keith R Abrams
	and David R Jones},
  title = {Comments on 'trying to be precise about vagueness' by Stephen Senn,
	Statistics in Medicine 2007; 26:1417-1430.},
  journal = {Statistics in Medicine},
  year = {2008},
  volume = {27},
  pages = {619--22, author reply 622-4},
  number = {4},
  doi = {10.1002/sim.3043},
  file = {lambert2008a.pdf:lambert2008a.pdf:PDF},
  owner = {pl4},
  pmid = {17847156},
  timestamp = {2008.10.15},
  url = {http://dx.doi.org/10.1002/sim.3043}
}

@Article{Lambert2005a,
  author      = {Paul C Lambert and Alex J Sutton and Paul R Burton and Keith R Abrams and David R Jones},
  title       = {How vague is vague? A simulation study of the impact of the use of vague prior distributions in {MCMC} using {WinBUGS}.},
  doi         = {10.1002/sim.2112},
  number      = {15},
  pages       = {2401--2428},
  url         = {http://dx.doi.org/10.1002/sim.2112},
  volume      = {24},
  abstract    = {There has been a recent growth in the use of Bayesian methods in medical
	research. The main reasons for this are the development of computer
	intensive simulation based methods such as Markov chain Monte Carlo
	(MCMC), increases in computing power and the introduction of powerful
	software such as WinBUGS. This has enabled increasingly complex models
	to be fitted. The ability to fit these complex models has led to
	MCMC methods being used as a convenient tool by frequentists, who
	may have no desire to be fully Bayesian.Often researchers want 'the
	data to dominate' when there is no prior information and thus attempt
	to use vague prior distributions. However, with small amounts of
	data the use of vague priors can be problematic. The results are
	potentially sensitive to the choice of prior distribution. In general
	there are fewer problems with location parameters. The main problem
	is with scale parameters. With scale parameters, not only does one
	have to decide the distributional form of the prior distribution,
	but also whether to put the prior distribution on the variance, standard
	deviation or precision.We have conducted a simulation study comparing
	the effects of 13 different prior distributions for the scale parameter
	on simulated random effects meta-analysis data. We varied the number
	of studies (5, 10 and 30) and compared three different between-study
	variances to give nine different simulation scenarios. One thousand
	data sets were generated for each scenario and each data set was
	analysed using the 13 different prior distributions. The frequentist
	properties of bias and coverage were investigated for the between-study
	variance and the effect size.The choice of prior distribution was
	crucial when there were just five studies. There was a large variation
	in the estimates of the between-study variance for the 13 different
	prior distributions. With a large number of studies the choice of
	prior distribution was less important. The effect size estimated
	was not biased, but the precision with which it was estimated varied
	with the choice of prior distribution leading to varying coverage
	intervals and, potentially, to different statistical inferences.
	Again there was less of a problem with a larger number of studies.
	There is a particular problem if the between-study variance is close
	to the boundary at zero, as MCMC results tend to produce upwardly
	biased estimates of the between-study variance, particularly if inferences
	are based on the posterior mean.The choice of 'vague' prior distribution
	can lead to a marked variation in results, particularly in small
	studies. Sensitivity to the choice of prior distribution should always
	be assessed.},
  file        = {lambert2005a.pdf:lambert2005a.pdf:PDF},
  institution = {Centre for Biostatistics and Genetic Epidemiology, Department of Health Sciences, University of Leicester, UK. pl4@le.ac.uk},
  journal     = {Statistics in Medicine},
  owner       = {pl4},
  pmid        = {16015676},
  timestamp   = {2008.10.15},
  year        = {2005},
}

@ARTICLE{Lambert2007a,
  author = {P. C. Lambert and J. R. Thompson and C. L. Weston and P. W. Dickman},
  title = {Estimating and modeling the cure fraction in population-based cancer
	survival analysis.},
  journal = {Biostatistics},
  year = {2007},
  volume = {8},
  pages = {576--594},
  number = {3},
  abstract = {In population-based cancer studies, cure is said to occur when the
	mortality (hazard) rate in the diseased group of individuals returns
	to the same level as that expected in the general population. The
	cure fraction (the proportion of patients cured of disease) is of
	interest to patients and is a useful measure to monitor trends in
	survival of curable disease. There are 2 main types of cure fraction
	model, the mixture cure fraction model and the non-mixture cure fraction
	model, with most previous work concentrating on the mixture cure
	fraction model. In this paper, we extend the parametric non-mixture
	cure fraction model to incorporate background mortality, thus providing
	estimates of the cure fraction in population-based cancer studies.
	We compare the estimates of relative survival and the cure fraction
	between the 2 types of model and also investigate the importance
	of modeling the ancillary parameters in the selected parametric distribution
	for both types of model.},
  doi = {10.1093/biostatistics/kxl030},
  file = {lambert2007a.pdf:lambert2007a.pdf:PDF},
  institution = {Department of Health Sciences, Centre for Biostatistics and Genetic
	Epidemiology, University of Leicester, 22-28 Princess Road West,
	Leicester LE1 6TP, UK. pl4@le.ac.uk},
  keywords = {Cure models; theory},
  owner = {pl4},
  pii = {kxl030},
  pmid = {17021277},
  timestamp = {2008.10.15},
  url = {http://dx.doi.org/10.1093/biostatistics/kxl030}
}

@ARTICLE{Lamont1993,
  author = {Lamont, D. W. and Symonds, R. P. and Brodie, M. M. and Nwabineli,
	N. J. and Gillis, C. R.},
  title = {Age, Socio-Economic Status and Survival from Cancer of Cervix in
	The {W}est of {S}cotland 1980-87},
  journal = {British Journal of Cancer},
  year = {1993},
  volume = {67},
  pages = {351-357},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@Book{Lamport1994,
  author    = {Leslie Lamport},
  title     = {{\LaTeX \rm:} {A} Document Preparation System},
  publisher = {Addison-Wesley},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1994},
}

@ARTICLE{Lancaster1952,
  author = {Lancaster, H. O.},
  title = {Statistical Control of Counting Experiments},
  journal = {Biometrika},
  year = {1952},
  volume = {39},
  pages = {419-422},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Landgren2002,
  author = {Ola Landgren and Johan Askling and Paul W Dickman and Eva Osby and
	Ulla Axdorph and Anders Ekbom and Magnus Bj\"{o}rkholm},
  title = {Parental longevity and survival in elderly patients with {H}odgkin's
	lymphoma.},
  journal = {Haematologica},
  year = {2002},
  volume = {87},
  pages = {595-601},
  number = {6},
  month = {Jun},
  abstract = {BACKGROUND AND OBJECTIVES: In general, elderly patients with Hodgkin's
	lymphoma (HL) have a less favorable prognosis than younger patients.
	Factors such as inadequate therapy often due to decreased tolerance
	to treatment, presence of intercurrent diseases and accumulation
	of certain clinical and biological risk factors contribute to the
	poor outcome. Established predictors of prognosis in HL are less
	appropriate in the elderly population. Consequently, there is a need
	for additional markers to guide treatment decisions and to improve
	prediction of outcome. In the general population, the expected length
	of life of an individual is intimately associated with that of his/her
	parents. In a small cohort of elderly HL patients, we had previously
	observed high familial life-span of two previous generations predicts
	superior survival. The aim of this study was to test the hypothesis
	that parental longevity alone--an easily accessible and non-disease
	associated variable--is also associated with improved outcome using
	an enlarged series of elderly HL patients. DESIGN AND METHODS: One
	hundred and twenty-one patients with HL >60 years at diagnosis were
	included. The median follow-up time was 67 (range 37-175) months.
	Data regarding age at death and reported cause of death were available
	through parish offices for 228 (94\%) parents. The effect of parental
	lifespan on HL survival included the use of Kaplan-Meier curves and
	Cox' proportional hazards regression analysis. RESULTS. Maternal
	as well as paternal lifespan correlated poorly with HL survival,
	both with regard to overall and disease-specific survival. There
	was, however, a tendency towards a decreased risk of dying among
	patients with low maternal lifespan (all-cause mortality: RR=0.7,
	95\% CI 0.5-1.0). INTERPRETATION AND CONCLUSIONS: Parental longevity
	does not predict superior survival in elderly patients with HL.},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@Article{Landgren2008a,
  author      = {Ola Landgren and Lynn R Goldin and Sigurdur Y Kristinsson and Elin A Helgadottir and Jan Samuelsson and Magnus Bj\"{o}rkholm},
  title       = {Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in {S}weden.},
  doi         = {10.1182/blood-2008-03-143602},
  number      = {6},
  pages       = {2199--2204},
  url         = {http://dx.doi.org/10.1182/blood-2008-03-143602},
  volume      = {112},
  abstract    = {Previous small studies have reported familial clustering of myeloproliferative
	neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia
	(ET), and myelofibrosis (MF). We identified 6217 PV, 2838 ET, 1172
	MF, and 812 MPN unclassifiable (NOS) patients diagnosed in {S}weden,
	43 550 controls, and first-degree relatives of cases (n = 24 577)
	and controls (n = 99 542). Using a marginal survival model, we calculated
	relative risks (RRs) and 95\% confidence intervals as measures of
	familial aggregation. Relatives of MPN patients had significantly
	increased risks of PV (RR = 5.7; 3.5-9.1), ET (RR = 7.4; 3.7-14.8),
	and MPN NOS (RR = 7.5; 2.7-20.8). Analyses stratified by type of
	first-degree relative revealed consistently higher risks for siblings,
	compatible with a model of recessive genetic inheritance, which can
	be confirmed only by identifying the susceptibility gene(s). Mean
	age at MPN diagnosis was not different (P = .20) for affected relatives
	of cases (57.5 years) versus controls (60.6 years), and risk of MPN
	by age was not different for parents versus offspring of MPN cases
	(P = .10), providing no support for anticipation. Relatives of MPN
	patients had a borderline increased risk of chronic myeloid leukemia
	(CML; RR = 1.9; 0.9-3.8; P = .09). Our findings of 5- to 7-fold elevated
	risk of MPNs among first-degree relatives of MPN patients support
	the hypothesis that common, strong, shared susceptibility genes predispose
	to PV, ET, MF, and possibly CML.},
  institution = {Human Services, Bethesda, MD 20892-7236, USA. landgreo@mail.nih.gov},
  journal     = {Blood},
  month       = {Sep},
  owner       = {PaulD},
  pii         = {blood-2008-03-143602},
  pmid        = {18451307},
  timestamp   = {2008.12.30},
  year        = {2008},
}

@ARTICLE{lange2011,
  author = {Lange, Theis and Hansen, J{\AA}Â¸rgen},
  title = {Direct and Indirect Effects in a Survival Context},
  journal = {Epidemiology},
  year = {2011},
  volume = {22},
  pages = {575-581},
  number = {4},
  file = {:pdf\\lange2011.pdf:PDF},
  owner = {BettyS},
  timestamp = {2016.12.09}
}

@ARTICLE{Langholz2007,
  author = {B. Langholz},
  title = {Use of Cohort Information in the Design and Analysis of Case-Control
	Studies},
  journal = {Scandinavian Journal of Statistics},
  year = {2007},
  volume = {34},
  pages = {120-136},
  number = {1},
  month = {Mar},
  doi = {10.1111/j.1467-9469.2006.00548.x},
  file = {:Langholz2007.pdf:PDF},
  publisher = {Wiley Blackwell (Blackwell Publishing)},
  timestamp = {2005.11.01}
}

@ARTICLE{Langholz1997,
  author = {B. Langholz and O. Borgan},
  title = {Estimation of absolute risk from nested case-control data.},
  journal = {Biometrics},
  year = {1997},
  volume = {53},
  pages = {767--774},
  number = {2},
  month = {Jun},
  abstract = {Benichou and Gail (1995, Biometrics 51, 182-194) describe methods
	for estimating the absolute risk of developing disease given a set
	of covariate values over a specified time interval from a case-control
	study within a cohort. The methods are most suitable for unmatched
	case-control studies, and are restricted to categorical covariates.
	Expanding on methods for estimating relative mortality from nested
	case-control studies presented in Borgan and Langholz (1993, Biometrics
	49, 593-602), we present methods for estimating absolute risk from
	individually matched nested case-control data. These methods accommodate
	continuous and time-dependent covariate histories, the sampling of
	cases, and various control sampling designs.},
  file = {Langholz1997.pdf:pdf\\Langholz1997.pdf:PDF;Langholz1997.pdf:Langholz1997.pdf:PDF},
  institution = {Department of Preventive Medicine, University of Southern California,
	School of Medicine, Los Angeles 90033, USA.},
  owner = {pl4},
  pmid = {9192463},
  timestamp = {2011.05.25}
}

@ARTICLE{Langholz1994,
  author = {B Langholz and D Clayton},
  title = {Sampling strategies in nested case-control studies.},
  journal = {Environ Health Perspect},
  year = {1994},
  volume = {102 Suppl 8},
  pages = {47-51},
  month = {Nov},
  abstract = {A stratified version of nested case-control sampling which we call
	"countermatching" is presented. This design uses data available for
	all cohort members to obtain a sample for collecting additional information
	in a case-control substudy. Hitherto the only stratified sampling
	design for such studies has involved matching of controls to cases
	with respect to confounding variables. However, in some situations,
	rather than sampling to make controls as similar as possible to cases,
	we might wish to make them as different as possible. This is achieved
	by the counter-matched design. Statistical analysis of counter-matched
	studies is straightforward using existing computer software. We investigate
	the use of the design when a surrogate measure of exposure is available
	for the full cohort, but accurate exposure data is to be collected
	only in a nested case-control study, and when exposure data are available
	for the whole cohort but data concerning important confounders are
	not. Asymptotic relative efficiency calculations indicate that a
	substantial efficiency gain relative to simple random sampling of
	controls can be expected in these situations. We also illustrate
	how the design might be implemented in practice.},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Lantz1991,
  author = {Lantz, I. and Gl{\"a}msta, E. L. and Talb{\"a}ck, L. and Nyberg, F.},
  title = {Hemorphins derived from hemoglobin have an inhibitory action on angiotensin
	converting enzyme activity.},
  journal = {FEBS Lett},
  year = {1991},
  volume = {287},
  pages = {39--41},
  number = {1-2},
  month = {Aug},
  abstract = {The hemorphins are opioid active peptides, which are enzymatically
	released from the beta-chain of hemoglobin. In this paper we report
	an inhibitory effect of these peptides on angiotensin converting
	enzyme (ACE) activity, known to be involved in blood pressure regulation.
	The hemorphins were found to be quite stable in tissue extracts containing
	ACE, and their importance as naturally occurring ACE inhibitors is
	discussed.},
  institution = {Uppsala University, Department of Pharmacology, Sweden.},
  keywords = {Amino Acid Sequence; Angiotensin-Converting Enzyme Inhibitors, pharmacology;
	Blood Pressure, physiology; Chromatography, High Pressure Liquid;
	Edetic Acid, pharmacology; Hemoglobins, isolation /&/ purification/metabolism/pharmacology;
	Humans; Lung, enzymology; Molecular Sequence Data; Peptide Fragments,
	isolation /&/ purification/metabolism/pharmacology; Peptidyl-Dipeptidase
	A, metabolism},
  language = {eng},
  medline-pst = {ppublish},
  owner = {theand},
  pii = {0014-5793(91)80011-Q},
  pmid = {1652464},
  timestamp = {2013.03.14}
}

@ARTICLE{Laprie2001,
  author = {Laprie, C. and Abadie, J. and Amardeilh, M. F. and Net, J. L. and
	Lagadic, M. and Delverdier, M.},
  title = {MIB-1 immunoreactivity correlates with biologic behaviour in canine
	cutaneous melanoma.},
  journal = {Vet Dermatol},
  year = {2001},
  volume = {12},
  pages = {139--147},
  number = {3},
  month = {Jun},
  abstract = {The growth fraction of 68 canine cutaneous melanomas was determined
	by immunostaining with MIB-1, a monoclonal antibody to a Ki-67 epitope
	that recognizes all proliferating cells. Fifty tumours were classified
	histologically as benign and 18 as malignant. The Ki-67 proliferative
	index (percentage of positive cells over 500 neoplastic cells) was
	low (< 15\%) in 55 cases and high (> or = 15\%) in 13 cases. High
	Ki-67 proliferative index and histological malignancy were both associated
	with significantly poorer 2-year survival (P < 0.0001). However,
	the predictive value of the Ki-67 proliferative index (97\%) was
	higher than the predictive value of classical histology (91\%). The
	evaluation of the growth fraction by the Ki-67 proliferative index
	is highly predictive of the biological behaviour of canine cutaneous
	melanoma.},
  institution = {Unit{\AA}Â§ÃƒÂƒÃ‚Â…ÃƒÂ‚Ã‚Â¸ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¤'Anatomie pathologique associ{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â£ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â INRA s{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¢ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Âµrit{\AA}Â§ÃƒÂƒÃ‚Â…ÃƒÂ‚Ã‚Â¸ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¡limentaire,
	Ecole Nationale V{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚ÂµÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â©rinaire de Toulouse, 23 Chemin des Capelles,
	31076 Toulouse, France.},
  keywords = {Animals; Antigens, Nuclear; Dog Diseases, diagnosis/immunology/mortality;
	Dogs; Female; Immunohistochemistry, veterinary; Ki-67 Antigen; Male;
	Melanoma, diagnosis/immunology/veterinary; Nuclear Proteins, diagnostic
	use/immunology; Prognosis; Retrospective Studies; Skin Neoplasms,
	diagnosis/immunology/veterinary; Survival Analysis; Tumor Markers,
	Biological, immunology},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {11420929},
  timestamp = {2013.05.29}
}

@ARTICLE{Larfors2009,
  author = {G. Larfors and P. C. Lambert and M. Lambe and A. Ekbom and S. Cnattingius},
  title = {Placental weight and breast cancer survival in young women.},
  journal = {Cancer Epidemiol Biomarkers Prev},
  year = {2009},
  volume = {18},
  pages = {777--783},
  number = {3},
  month = {Mar},
  abstract = {A growing body of evidence indicates that reproductive history influences
	survival in breast cancer, especially among women diagnosed during
	or shortly after a pregnancy. However, little is known about the
	underlying mechanisms. We hypothesized that increasing placental
	weight, as an indirect marker of exposure to elevated hormone levels
	during pregnancy, would be associated with reduced survival in breast
	cancer. A cohort of 1873 women with at least one pregnancy after
	January 1st, 1973, and a subsequent breast cancer diagnosis before
	the end of 1991 were followed up for death or emigration through
	2006. Information on placental weight and potential confounding factors
	were collected from medical records and from nationwide registers,
	which resulted in data on placental weight in the most recent pregnancy
	before diagnosis for 1,057 cases. For each 100-gram increase in placental
	weight, the adjusted hazard ratio of death was 1.09 [95\% confidence
	interval (CI), 0.99-1.19]. The association was stronger among primiparous
	women (adjusted hazard ratio, 1.26; 95\% CI, 1.09-1.47), and among
	women diagnosed during pregnancy or within 2 years from last birth
	(adjusted hazard ratio, 1.30; 95\% CI, 1.06-1.59). Increasing placental
	weight is associated with reduced breast cancer survival. These findings
	are consistent with the hypothesis that the reduced survival in breast
	cancer among women with a recent childbirth is linked to pregnancy
	hormone exposure. (Cancer Epidemiol Biomarkers Prev 2009;18(3):777-83).},
  doi = {10.1158/1055-9965.EPI-08-0979},
  file = {Larfors2009.pdf:Larfors2009.pdf:PDF;Larfors2009.pdf:pdf\\Larfors2009.pdf:PDF},
  institution = {Department of Medical Epidemiology and Biostatistics, Karolinska
	Institutet, SE-171 77 Stockholm, Sweden. gunnar.larfors@ki.se.},
  owner = {pl4},
  pii = {1055-9965.EPI-08-0979},
  pmid = {19240233},
  timestamp = {2009.03.19},
  url = {http://dx.doi.org/10.1158/1055-9965.EPI-08-0979}
}

@ARTICLE{Larmi1978,
  author = {T. K. Larmi and E. Saarela and S. Tuononen and R. Pokela and P. K\"{a}rk\"{o}l\"{a}
	and L. Nuutinen and M. I. Kairaluoma},
  title = {Effect of initial myocardial anoxia on coronary flow during aortic
	valve replacement.},
  journal = {Scand J Thorac Cardiovasc Surg},
  year = {1978},
  volume = {12},
  pages = {229--233},
  number = {3},
  abstract = {Flow to the right and left coronary arteries was recorded continuously
	during aortic valve replacement using continous constant-pressure
	coronary perfusion at 32 degrees C in 13 patients. The initially
	high coronary flow decreased gradually until a certain level, the
	so-called resting flow level, was reached and stabilized there as
	long as perfusion temperature remained unchanged. At 32 degrees C,
	resting flow was about 50\% of the peak hyperaemic flow. The length
	of preceding anoxia had a significant effect on the duration of reactive
	hyperaemic response. After a short anoxic period, resting flow level
	was reached in about 3 min, after moderate period in 15 min and after
	long anoxia in 35 min, respectively.},
  owner = {pl4},
  pmid = {725563},
  timestamp = {2011.05.26}
}

@ARTICLE{Larsen2009,
  author = {I. K. Larsen and M. Sm{\aa}stuen and T. B. Johannesen and F. Langmark
	and D. M. Parkin and F. Bray and B. M{\o}ller},
  title = {Data quality at the {C}ancer {R}egistry of {N}orway: an overview
	of comparability, completeness, validity and timeliness.},
  journal = {European Journal of Cancer},
  year = {2009},
  volume = {45},
  pages = {1218--1231},
  number = {7},
  month = {May},
  abstract = {AIM: To provide a comprehensive evaluation of the quality of the data
	collected on both solid and non-solid tumours at the Cancer Registry
	of Norway (CRN). METHODS: Established quantitative and semi-quantitative
	methods were used to assess comparability, completeness, accuracy
	and timeliness of data for the period 1953-2005, with special attention
	to the registration period 2001-2005. RESULTS: The CRN coding and
	classification system by and large follows international standards,
	with some further subdivisions of morphology groupings performed
	in-house. The overall completeness was estimated at 98.8\% for the
	registration period 2001-2005. There remains a variable degree of
	under-reporting particularly for haematological malignancies (C90-95)
	and tumours of the central nervous system (C70-72). For the same
	period, 93.8\% of the cases were morphologically verified (site-specific
	range: 60.0-99.8\%). The under-reporting in 2005 due to timely publication
	is estimated at 2.2\% overall, based on the number of cases received
	at the registry during the following year. CONCLUSION: This review
	suggests the routines in place at the CRN yields comparable data
	that can be considered reasonably accurate, close-to-complete and
	timely, thereby justifying our policy of the reporting of annual
	incidence one year after the year of diagnosis.},
  doi = {10.1016/j.ejca.2008.10.037},
  file = {Larsen2009.pdf:Larsen2009.pdf:PDF;Larsen2009.pdf:pdf\\Larsen2009.pdf:PDF},
  institution = {Department of Clinical and Registry-based Research, Cancer Registry
	of Norway, Institute of Population-based Cancer Research, Fridjof
	Nansens vei 19, Postbox 5313, Majorstuen, N-0304 Oslo, Norway. inger.kristin.larsen@kreftregisteret.no},
  owner = {pl4},
  pii = {S0959-8049(08)00869-1},
  pmid = {19091545},
  timestamp = {2010.03.19},
  url = {http://dx.doi.org/10.1016/j.ejca.2008.10.037}
}

@ARTICLE{Larson1985,
  author = {M.G. Larson and G.E. Dinse},
  title = {A mixture model for the regression analysis of competing risks data},
  journal = {Journal of the Royal Statistical Society. Series C (Applied Statistics)},
  year = {1985},
  volume = {34},
  pages = {201-211},
  file = {Larson1985.pdf:Larson1985.pdf:PDF},
  owner = {pl4},
  timestamp = {2012.02.28}
}

@Article{Latimer2014,
  author      = {Latimer, Nicholas R. and Abrams, Keith R. and Lambert, Paul C. and Crowther, Michael J. and Wailoo, Allan J. and Morden, James P. and Akehurst, Ron L. and Campbell, Michael J.},
  title       = {Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations.},
  doi         = {10.1177/0272989X13520192},
  language    = {eng},
  number      = {3},
  pages       = {387--402},
  url         = {http://dx.doi.org/10.1177/0272989X13520192},
  volume      = {34},
  abstract    = {Treatment switching commonly occurs in clinical trials of novel interventions
	in the advanced or metastatic cancer setting. However, methods to
	adjust for switching have been used inconsistently and potentially
	inappropriately in health technology assessments (HTAs).We present
	recommendations on the use of methods to adjust survival estimates
	in the presence of treatment switching in the context of economic
	evaluations.We provide background on the treatment switching issue
	and summarize methods used to adjust for it in HTAs. We discuss the
	assumptions and limitations associated with adjustment methods and
	draw on results of a simulation study to make recommendations on
	their use.We demonstrate that methods used to adjust for treatment
	switching have important limitations and often produce bias in realistic
	scenarios. We present an analysis framework that aims to increase
	the probability that suitable adjustment methods can be identified
	on a case-by-case basis. We recommend that the characteristics of
	clinical trials, and the treatment switching mechanism observed within
	them, should be considered alongside the key assumptions of the adjustment
	methods. Key assumptions include the "no unmeasured confounders"
	assumption associated with the inverse probability of censoring weights
	(IPCW) method and the "common treatment effect" assumption associated
	with the rank preserving structural failure time model (RPSFTM).The
	limitations associated with switching adjustment methods such as
	the RPSFTM and IPCW mean that they are appropriate in different scenarios.
	In some scenarios, both methods may be prone to bias; "2-stage" methods
	should be considered, and intention-to-treat analyses may sometimes
	produce the least bias. The data requirements of adjustment methods
	also have important implications for clinical trialists.},
  file        = {Latimer2014.pdf:Latimer2014.pdf:PDF},
  institution = {School of Health and Related Research, University of Sheffield, Sheffield, UK (NRL, AJW, RLA, MJC).},
  journal     = {Medical Decision Making},
  medline-pst = {ppublish},
  month       = {Apr},
  owner       = {pl4},
  pii         = {0272989X13520192},
  pmid        = {24449433},
  timestamp   = {2014.05.28},
  year        = {2014},
}

@ARTICLE{Latouche2013,
  author = {Latouche, A. and Allignol, A. and Beyersmann, J. and Labopin, M.
	and Fine, J. P.},
  title = {A competing risks analysis should report results on all cause-specific
	hazards and cumulative incidence functions.},
  journal = {J Clin Epidemiol},
  year = {2013},
  volume = {66},
  pages = {648--653},
  number = {6},
  month = {Jun},
  abstract = {Competing risks endpoints are frequently encountered in hematopoietic
	stem cell transplantation where patients are exposed to relapse and
	treatment-related mortality. Both cause-specific hazards and direct
	models for the cumulative incidence functions have been used for
	analyzing such competing risks endpoints. For both approaches, the
	popular models are of a proportional hazards type. Such models have
	been used for studying prognostic factors in acute and chronic leukemias.
	We argue that a complete understanding of the event dynamics requires
	that both hazards and cumulative incidence be analyzed side by side,
	and that this is generally the most rigorous scientific approach
	to analyzing competing risks data. That is, understanding the effects
	of covariates on cause-specific hazards and cumulative incidence
	functions go hand in hand. A case study illustrates our proposal.},
  doi = {10.1016/j.jclinepi.2012.09.017},
  file = {Latouche2013.pdf:Latouche2013.pdf:PDF},
  institution = {Conservatoire National des Arts et M{\AA}Â©tiers, IMATH, 292 Rue Saint
	Martin, Case 441, EA4629 Paris, France. aurelien.latouche@cnam.fr},
  keywords = {Data Interpretation, Statistical; Hematopoietic Stem Cell Transplantation,
	mortality/statistics /&/ numerical data; Humans; Incidence; Models,
	Statistical; Recurrence; Risk Assessment, statistics /&/ numerical
	data; Survival Analysis; Time Factors; Transplantation Conditioning;
	Treatment Failure},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {S0895-4356(12)00348-4},
  pmid = {23415868},
  timestamp = {2014.06.02},
  url = {http://dx.doi.org/10.1016/j.jclinepi.2012.09.017}
}

@ARTICLE{Lau1998,
  author = {J. Lau and J. P. Ioannidis and C. H. Schmid},
  title = {Summing up evidence: one answer is not always enough.},
  journal = {Lancet},
  year = {1998},
  volume = {351},
  pages = {123--127},
  number = {9096},
  month = {Jan},
  abstract = {Are meta-analyses the brave new world, or are the critics of such
	combined analyses right to say that the biases inherent in clinical
	trials make them uncombinable? Negative trials are often unreported,
	and hence can be missed by meta-analysts. And how much heterogeneity
	between trials is acceptable? A recent major criticism is that large
	randomised trials do not always agree with a prior meta-analysis.
	Neither individual trials nor meta-analyses, reporting as they do
	on population effects, tell how to treat the individual patient.
	Here we take a more rounded approach to meta-analyses, arguing that
	their strengths outweigh their weaknesses, although the latter must
	not be brushed aside.},
  doi = {10.1016/S0140-6736(97)08468-7},
  file = {lau1998.pdf:lau1998.pdf:PDF},
  institution = {Division of Clinical Care Research, New England Medical Center Hospitals,
	Boston, MA 02111, USA. joseph.lau@es.nemc.org},
  owner = {pl4},
  pii = {S0140-6736(97)08468-7},
  pmid = {9439507},
  timestamp = {2008.11.18},
  url = {http://dx.doi.org/10.1016/S0140-6736(97)08468-7}
}

@ARTICLE{Laudicella2016a,
  author = {Laudicella, Mauro and Walsh, Brendan and Burns, Elaine and Smith,
	Peter C},
  title = {Cost of care for cancer patients in England: evidence from population-based
	patient-level data.},
  journal = {British journal of cancer},
  year = {2016},
  volume = {114},
  pages = {1286--1292},
  month = {May},
  abstract = {Health systems are facing the challenge of providing care to an increasing
	population of patients with cancer. However, evidence on costs is
	limited due to the lack of large longitudinal databases. We matched
	cost of care data to population-based, patient-level data on cancer
	patients in England. We conducted a retrospective cohort study including
	all patients age 18 and over with a diagnosis of colorectal (275?985
	patients), breast (359?771), prostate (286?426) and lung cancer (283?940)
	in England between 2001 and 2010. Incidence costs, prevalence costs,
	and phase of care costs were estimated separately for patients age
	18-64 and ?65. Costs of care were compared by patients staging, before
	and after diagnosis, and with a comparison population without cancer.
	Incidence costs in the first year of diagnosis are noticeably higher
	in patients age 18-64 than age ?65 across all examined cancers. A
	lower stage diagnosis is associated with larger cost savings for
	colorectal and breast cancer in both age groups. The additional costs
	of care because of the main four cancers amounts to ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â£1.5 billion
	in 2010, namely 3.0% of the total cost of hospital care. Population-based,
	patient-level data can be used to provide new evidence on the cost
	of cancer in England. Early diagnosis and cancer prevention have
	scope for achieving large cost savings for the health system.},
  citation-subset = {IM},
  country = {England},
  created = {2016-05-25},
  doi = {10.1038/bjc.2016.77},
  file = {Laudicella2016a.pdf:pdf\\Laudicella2016a.pdf:PDF},
  issn = {1532-1827},
  issn-linking = {0007-0920},
  issue = {11},
  nlm = {PMC4891510},
  nlm-id = {0370635},
  owner = {NLM},
  pii = {bjc201677},
  pmc = {PMC4891510},
  pmid = {27070711},
  pubmodel = {Print-Electronic},
  pubstatus = {ppublish},
  revised = {2016-06-12},
  timestamp = {2016.12.09}
}

@ARTICLE{Launois1996,
  author = {Launois, R. and Reboul-Marty, J. and Henry, B. and Bonneterre, J.},
  title = {A cost-utility analysis of second-line chemotherapy in metastatic
	breast cancer. Docetaxel versus paclitaxel versus vinorelbine.},
  journal = {Pharmacoeconomics},
  year = {1996},
  volume = {10},
  pages = {504--521},
  number = {5},
  month = {Nov},
  abstract = {The aim of this study was to determine the incremental effectiveness,
	the incremental health-related quality of life (differences in quality-adjusted
	progression-free survival between treatments), the incremental cost
	and the incremental cost-effectiveness and cost-utility ratios, for
	docetaxel, paclitaxel and vinorelbine, when these drugs were used
	as second-line treatment in patients with metastatic breast cancer.
	In the absence of comparative direct evidence of the relative efficacy
	of docetaxel, paclitaxel and vinorelbine in this setting, a model
	was designed to determine the effects of the 3 interventions on health
	outcome and cost. A Markov process model, based on 53 disease states,
	was thus constructed to evaluate the socioeconomics of the 3 treatment
	regimens. The model allows assessments from the start of second-line
	chemotherapy until death. Costs were evaluated from the combined
	view of the healthcare system and the patient. Direct nonmedical
	and indirect costs were excluded. Consumption per episode of care
	was estimated by retrospective analysis of 153 medical reports from
	5 different hospitals. Hospital costs were allocated values from
	the national accounting costs by diagnosis-related group (DRG). The
	content of the health states was based on the multiattribute health
	states classification system (MASH). Preference values were assigned
	by application of a standard reference lottery using 20 oncological
	nurses as proxies for the patients. The health-related quality-of-life
	score was used as a quality adjustment weighting factor to calculate
	quality-adjusted progression-free survival associated with the 3
	different regimens. Docetaxel reduces the time spent in progression,
	decreases the number of complications due to progressive disease
	and thereby provides better quality of life. It provides a benefit
	of 57 disease- and discomfort-free days compared with vinorelbine
	and 22 days compared with paclitaxel. Docetaxel may be thought of
	as self-financing as a result of savings in hospital admissions,
	providing net savings of 6800 French francs (FF; 1993 values) compared
	with expenditure associated with vinorelbine treatment and FF700
	compared with the equivalent figures for paclitaxel.},
  institution = {Universit{\AA}Â§ÃƒÂƒÃ‚Â…ÃƒÂ‚Ã‚Â¸ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¤e Paris, Facult{\AA}Â§ÃƒÂƒÃ‚Â…ÃƒÂ‚Ã‚Â¸ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¤e M{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â£ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¥cine L{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â®ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â®ard de Vinci, D{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¯ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¡rtement
	de Sant{\AA}Â§ÃƒÂƒÃ‚Â…ÃƒÂ‚Ã‚Â¸?ublique et d'Economie de la Sant{\AA}Â§ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚ÂªÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â Bobigny, France.},
  keywords = {Antineoplastic Agents, economics; Breast Neoplasms, drug therapy;
	Cost-Benefit Analysis, economics; Female; Humans; Paclitaxel, analogs
	/&/ derivatives/economics/therapeutic use; Taxoids; Vinblastine,
	analogs /&/ derivatives/economics/therapeutic use},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {10169397},
  timestamp = {2013.05.29}
}

@ARTICLE{Launois1997,
  author = {Launois, R. J. and Reboul-Marty, J. M. and Bonneterre, J.},
  title = {[A medico-economic evaluation of second line chemotherapy in metastatic
	breast cancer: comparison between docetaxel, paclitaxel, and vinorelbine].},
  journal = {Bull Cancer},
  year = {1997},
  volume = {84},
  pages = {709--721},
  number = {7},
  month = {Jul},
  abstract = {Despite health public problems arised by metastatic breast cancer,
	specific studies remain rare, and especially when concerning second
	line chemotherapy. Today, these studies seem essential to allow the
	clinician, facing the choice between different treatments, to make
	the best decision. Two recent treatments, docetaxel and paclitaxel,
	administered every 3 weeks, were compared to the referenced treatment:
	vinorelbine administered every week. The study aims at evaluating
	these 3 therapeutic options on second line treatment of metastatic
	breast cancer. For each of these 3 strategies, our end points were:
	(1) the duration of progression free survival; (2) the quality adjusted
	on progression free survival; (3) the cost including the intrinsic
	cost of chemotherapy as well as the cost of treatment-related and
	disease-related complications, due to toxicity. Savings obtained
	with the treatment by delaying relapse were subtracted from expenditure.
	We used a Markov model to describe the patient's evolution after
	the administration of the compared treatments. The evaluation concerns
	the period from the beginning of second line chemotherapy to death.
	Only direct medical costs were taken into account. Non medical costs
	and indirect costs were excluded. For each clinical state, resources
	utilisation was estimated by a retrospective multicentric analysis
	of 153 medical records of metastatic breast cancer, treated on second
	line. Resources valuation of hospital costs were based on a national
	survey on the cost of medical services per DRGs. Quality of life
	was estimated by a group of nurses in oncology, using the feeling
	thermometer and standard gamble technics. Incremental cost utility
	ratios were calculated. Docetaxel reduces the time spent in progression,
	decreases the number of complications due to progressive disease
	and thereby provides better quality of life. It provides a benefit
	of 57 disease- and discomfort-free days, compared to vinorelbine
	and 22 days compared to paclitaxel. Docetaxel may be thought of as
	a self-financing strategy as a result of savings in hospital admissions,
	providing net saving of French Francs (FF) 6,800 in 1993 prices,
	compared with expenditure associated with vinorelbine treatment and
	FF 700 compared with the equivalent figures for paclitaxel. A sensitivity
	analysis confirms the robustness of those results.},
  institution = {Universit{\AA}Â§ÃƒÂƒÃ‚Â…ÃƒÂ‚Ã‚Â¸ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¤e Paris-Nord, Facult{\AA}Â§ÃƒÂƒÃ‚Â…ÃƒÂ‚Ã‚Â¸ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¤e m{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â£ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¥cine L{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â®ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â®ard-de-Vinci, D{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¯ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¡rtement
	de sant{\AA}Â§ÃƒÂƒÃ‚Â…ÃƒÂ‚Ã‚Â¸ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â°ublique et d'{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¢ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¯nomie de la sant{\AA}Â§ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚ÂªÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â Bobigny, France.},
  keywords = {Aged; Antineoplastic Agents, Phytogenic, economics/therapeutic use;
	Breast Neoplasms, drug therapy/economics/mortality; Cost-Benefit
	Analysis; Drug Administration Schedule; Female; Humans; Neoplasm
	Metastasis; Paclitaxel, administration /&/ dosage/analogs /&/ derivatives;
	Quality of Life; Sensitivity and Specificity; Survival Analysis;
	Taxoids; Treatment Outcome; Vinblastine, administration /&/ dosage/analogs
	/&/ derivatives},
  language = {fre},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {9339197},
  timestamp = {2013.05.29}
}

@ARTICLE{Lavelle2007,
  author = {K. Lavelle and A. Moran and A. Howell and N. Bundred and M. Campbell
	and C. Todd},
  title = {Older women with operable breast cancer are less likely to have surgery.},
  journal = {British Journal of Surgery},
  year = {2007},
  volume = {94},
  pages = {1209--1215},
  number = {10},
  month = {Oct},
  abstract = {BACKGROUND: Older women are less likely to receive standard management
	for breast cancer than younger postmenopausal women. Whether differences
	in general health explain variations in the rates of surgery is not
	known. METHODS: In this prospective cohort study, 76 women aged 65
	years or more attending breast units in Greater Manchester completed
	a survey measuring functional status (Elderly Population Health Status
	Survey's Activity of Daily Living), generic health status (Short
	Form 12) and health-related quality of life (European Organization
	for Research on Treatment of Cancer Quality of Life Questionnaire
	C30). Case-note review assessed co-morbidity (Charlson Index) and
	management. Primary surgery for operable breast cancer was investigated
	using logistic regression. RESULTS: A Charlson Index of 1 or more
	did not predict the use of surgery (P = 0.363). However, for each
	point increase on the 1-4 scale indicating worsening functional status,
	the odds of having surgery decreased by 16 times (odds ratio 0.063).
	The odds of a woman of 80 years or more having surgery decreased
	by a factor of 44 (odds ratio 0.023) compared with women aged 65-79
	years, accounting for co-morbidity, functional status, pretreatment
	stage, social deprivation and type of hospital. CONCLUSION: Older
	women were less likely to have surgery for operable breast cancer
	than younger women, even after accounting for differences in general
	health and co-morbidity.},
  doi = {10.1002/bjs.5834},
  file = {Lavelle2007.pdf:Lavelle2007.pdf:PDF;Lavelle2007.pdf:pdf\\Lavelle2007.pdf:PDF},
  institution = {School of Nursing, Midwifery and Social Work, University of Manchester,
	Withington Hospital, Manchester, UK. katrina.j.lavelle@manchester.ac.uk},
  owner = {pl4},
  pmid = {17590857},
  timestamp = {2010.03.21},
  url = {http://dx.doi.org/10.1002/bjs.5834}
}

@ARTICLE{Lavelle2007a,
  author = {K. Lavelle and C. Todd and A. Moran and A. Howell and N. Bundred
	and M. Campbell},
  title = {Non-standard management of breast cancer increases with age in the
	{UK}: a population based cohort of women > or =65 years.},
  journal = {British Journal of Cancer},
  year = {2007},
  volume = {96},
  pages = {1197--1203},
  number = {8},
  month = {Apr},
  abstract = {Evidence suggests that compared to younger women, older women are
	less likely to receive standard management for breast cancer. Whether
	this disparity persists once differences in tumour characteristics
	have been adjusted for has not been investigated in the UK. A retrospective
	cohort study involving case note review was undertaken, based on
	the North Western Cancer Registry database of women aged > or =65
	years, resident in Greater Manchester with invasive breast cancer
	registered over a 1-year period (n=480). Adjusting for tumour characteristics
	associated with age by logistic regression analyses, older women
	were less likely to receive standard management than younger women
	for all indicators investigated. Compared to women aged 65-69 years,
	women aged > or =80 years with operable (stage 1-3a) breast cancer
	have increased odds of not receiving triple assessment (OR=5.5, 95\%
	confidence interval (CI): 2.1-14.5), not receiving primary surgery
	(OR=43.0, 95\% CI: 9.7-191.3), not undergoing axillary node surgery
	(OR=27.6, 95\% CI: 5.6-135.9) and not undergoing tests for steroid
	receptors (OR=3.0, 95\% CI: 1.7-5.5). Women aged 75-79 years have
	increased odds of not receiving radiotherapy following breast-conserving
	surgery compared to women aged 65-69 years (OR=11.0, 95\% CI: 2.0-61.6).
	These results demonstrate that older women in the UK are less likely
	to receive standard management for breast cancer, compared to younger
	women and this disparity cannot be explained by differences in tumour
	characteristics.},
  doi = {10.1038/sj.bjc.6603709},
  file = {Lavelle2007a.pdf:Lavelle2007a.pdf:PDF;Lavelle2007a.pdf:pdf\\Lavelle2007a.pdf:PDF},
  institution = {School of Nursing, Midwifery and Social Work, The University of Manchester,
	Manchester, UK. katrina.j.lavelle@manchester.ac.uk},
  owner = {pl4},
  pii = {6603709},
  pmid = {17387342},
  timestamp = {2010.03.21},
  url = {http://dx.doi.org/10.1038/sj.bjc.6603709}
}

@Book{Lawless1982,
  author    = {Lawless, J. F.},
  title     = {Statistical Models {\&} Methods for Lifetime Data},
  publisher = {New York: John Wiley and Sons},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1982},
}

@Book{Le1997,
  author    = {Le, C. T.},
  title     = {Applied Survival Analysis},
  publisher = {John Wiley \& Sons},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1997},
}

@Book{Lee1993,
  author    = {Lee, E. T.},
  title     = {Statistical Methods for Survival Data Analysis},
  publisher = {New York: John Wiley and Sons},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1993},
}

@ARTICLE{Lee1997,
  author = {Lee, E. T. and Go, O. T.},
  title = {Survival Analysis in Public Health Research},
  journal = {Annual Reviews in Public Health},
  year = {1997},
  volume = {18},
  pages = {105-134},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Lee2012,
  author = {Lee, Minjung and Cronin, Kathleen A. and Gail, Mitchell H. and Feuer,
	Eric J.},
  title = {Predicting the absolute risk of dying from colorectal cancer and
	from other causes using population-based cancer registry data},
  journal = {Statistics in Medicine},
  year = {2012},
  volume = {31},
  pages = {489-500},
  number = {5},
  month = {Feb},
  doi = {10.1002/sim.4454},
  file = {Lee2012.pdf:Lee2012.pdf:PDF},
  publisher = {Wiley Blackwell (John Wiley \& Sons)},
  timestamp = {2005.11.01}
}

@ARTICLE{Lee2011a,
  author = {Lee, Minjung and Fine, Jason P.},
  title = {Inference for cumulative incidence quantiles via parametric and nonparametric
	approaches.},
  journal = {Statistics in Medicine},
  year = {2011},
  volume = {30},
  pages = {3221--3235},
  number = {27},
  month = {Nov},
  abstract = {In survival analysis, a point estimate and confidence interval for
	median survival time have been frequently used to summarize the survival
	curve. However, such quantile analyses on competing risks data have
	not been widely investigated. In this paper, we propose parametric
	inferences for quantiles from the cumulative incidence function and
	develop parametric confidence intervals for quantiles. In addition,
	we study a simplified method of inference for the nonparametric approach.
	We compare the parametric and nonparametric inferences in empirical
	studies. Simulation studies show that the procedures perform well,
	with parametric analyses yielding smaller mean square error when
	the model is not too badly misspecified. We illustrate the methods
	with data from a breast cancer clinical trial.},
  doi = {10.1002/sim.4349},
  file = {Lee2011a.pdf:Lee2011a.pdf:PDF},
  institution = {Department of Statistics, University of Wisconsin, Madison, WI 53706,
	USA. leem5@mail.nih.gov},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {21898525},
  timestamp = {2012.02.06},
  url = {http://dx.doi.org/10.1002/sim.4349}
}

@ARTICLE{Lee1994,
  author = {Lee, P. N.},
  title = {Comparison of autopsy, clinical and death certificate diagnosis with
	particular reference to lung cancer. {A} review of the published
	data},
  journal = {APMIS},
  year = {1994},
  volume = {102 (Suppl. 45)},
  pages = {1-42},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Lee1992,
  author = {Lee, RD and Carter, LR},
  title = {Modeling and forecasting {U.S.} mortality Rates},
  journal = {J Am Stat Assoc},
  year = {1992},
  volume = {87},
  pages = {659-671},
  number = {412},
  owner = {sanelo},
  timestamp = {2013.08.07}
}

@ARTICLE{Legrand2005,
  author = {Catherine Legrand and Vincent Ducrocq and Paul Janssen and Richard
	Sylvester and Luc Duchateau},
  title = {A Bayesian approach to jointly estimate centre and treatment by centre
	heterogeneity in a proportional hazards model.},
  journal = {Statistics in Medicine},
  year = {2005},
  volume = {24},
  pages = {3789--3804},
  number = {24},
  month = {Dec},
  abstract = {When multicentre clinical trial data are analysed, it has become more
	and more popular to look for possible heterogeneity in outcome between
	centres. However, beyond the investigation of such heterogeneity,
	it is also interesting to consider heterogeneity in treatment effect
	over centres. For time-to-event outcomes, this may be investigated
	by including a random centre effect and a random treatment by centre
	interaction in a Cox proportional hazards model.Assuming independence
	between the random effects, we propose a Bayesian approach to fit
	our proposed model. The parameters of interest are the variance components
	sigma(0) (2) and sigma(1) (2) of these random effects, which can
	be interpreted as a measure of centre and treatment effect over centres
	heterogeneity of the hazard. These variance components are estimated
	from their marginal posterior density after integrating out the fixed
	treatment effect and the random effects. As this integration cannot
	be performed analytically, the marginal posterior density is approximated
	using the Laplace integration technique. Statistical inference is
	then based on the characteristics of the posterior marginal density,
	such as the mode and the standard deviation. We demonstrate the proposed
	technique using data from a pooled database of seven EORTC bladder
	cancer clinical trials. Substantial centre and treatment effect over
	centres heterogeneity in disease-free interval was found.},
  doi = {10.1002/sim.2475},
  file = {Legrand2005.pdf:Legrand2005.pdf:PDF;Legrand2005.pdf:pdf\\Legrand2005.pdf:PDF},
  institution = {European Organisation for Research and Treatment of Cancer, Brussels,
	Belgium. catherine.legrand@eortc.be},
  owner = {pl4},
  pmid = {16320274},
  timestamp = {2008.11.18},
  url = {http://dx.doi.org/10.1002/sim.2475}
}

@ARTICLE{Legro2001,
  author = {RS Legro},
  title = {Polycystic ovary syndrome: the new millenium.},
  journal = {Mol Cell Endocrinol},
  year = {2001},
  volume = {184},
  pages = {87-93},
  number = {1-2},
  month = {Nov},
  abstract = {Our understanding of Polycystic Ovary Syndrome (PCOS) has been hampered
	by varying diagnostic criteria, and ignorance of the etiology of
	the syndrome. PCOS women are uniquely insulin resistant and obesity
	aggravates this underlying predisposition to insulin resistance.
	Diagnostic criteria which focus on hyperandrogenism and/or menstrual
	irregularity are more likely to identify insulin resistant women,
	than such criteria as abnormal gonadotropin secretion or ovarian
	morphology. The lack of a clear etiologic mechanism to the syndrome
	has led to a multitude of symptom-oriented treatments with few therapies
	improving all aspects of the endocrine syndrome of PCOS. Improving
	insulin sensitivity has become established as a baseline treatment
	strategy in PCOS. There are, however, few randomized controlled trials
	of adequate power to provide an evidence based guide to treatment
	in PCOS.},
  owner = {PaulD},
  pii = {S0303720701006402},
  timestamp = {2011.06.19}
}

@InCollection{Leon1989,
  author    = {Leon, D. and Wilkinson, R. G.},
  booktitle = {Health Inequalities in European Countries},
  title     = {Inequalities in Prognosis: Socio-economic Differences in Cancer and Heart Disease Survival},
  editor    = {Fox, J.},
  pages     = {280-300},
  publisher = {Aldershot: Gower},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1989},
}

@ARTICLE{Lesnoff2000,
  author = {Lesnoff, M. and Lancelot1, R. and Tillard, E. and Dohoo, I. R.},
  title = {A steady-state approach of benefit-cost analysis with a periodic
	leslie-matrix model. Presentation and application to the evaluation
	of a sheep-diseases preventive scheme in Kolda, Senegal.},
  journal = {Prev Vet Med},
  year = {2000},
  volume = {46},
  pages = {113--128},
  number = {2},
  month = {Jul},
  abstract = {A seasonal population-dynamics matrix model (periodic Leslie-matrix
	model) was developed to model short production cycles and high seasonal
	variations occurring in demographic rates and offtake patterns for
	small ruminants. The year was split into 24- and 15-day phases. Population-size
	changes were modelled by the recurrence equation x(j+1)=B(j)x(j),
	where j was the 15-day phase, x an age-class population size vector
	and B a fecundity-, mortality-, offtake- and intake-rate matrix.
	Given an initial vector x(1), annual dynamics were described by x(25)=B(24)...B(1)x(1)=Ax(1),
	where A was the annual projection matrix.A steady-state hypothesis
	was used to estimate offtake gains and financial returns from a trial
	of pasteurellosis vaccination and anthelminthic drench in traditionally
	managed sheep flocks in Senegal, from July 1987 to June 1988. Nineteen
	villages and 76 herds were involved in the experiment. Villages were
	randomly allocated to one of the four treatment combinations in a
	factorial design, and subsequent demographic rates and net offtake
	patterns were measured. In the trial, vaccination had a negative
	effect on offtakes among females. No vaccination effect was observed
	for males. A positive effect of deworming was found for both sexes.
	From the trial data, our model calculated that the overall ratio
	of offtakes (i.e. number of animals) for dewormed over undrenched
	sheep was 1.2 (95\% confidence interval: 1.1, 1.4). The deworming
	financial benefit-cost ratio was 3.7 (1.9, 5.4).},
  institution = {Centre de Coop{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â±ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¡tion Internationale en Recherche Agronomique pour
	le D{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚ÂµÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¥loppement, D{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¯ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¡rtement Elevage et M{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â£ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¥cine V{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚ÂµÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â©rinaire (CIRAD-Emvt),
	Campus International de Baillarguet, BP 5035, 34032 Cedex 1, Montpellier,
	France. mathieu.lesnoff@cirad.fr},
  keywords = {Animals; Anthelmintics, economics/therapeutic use; Cost-Benefit Analysis;
	Demography; Models, Theoretical; Pasteurella Infections, economics/prevention
	/&/ control/veterinary; Population Dynamics; Sheep; Sheep Diseases,
	economics/immunology/prevention /&/ control; Vaccination, economics/veterinary},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {S0167587700001392},
  pmid = {10878299},
  timestamp = {2013.05.29}
}

@ARTICLE{LeTreut1997,
  author = {{Le Treut}, Y. P. and Delpero, J. R. and Dousset, B. and Cherqui,
	D. and Segol, P. and Mantion, G. and Hannoun, L. and Benhamou, G.
	and Launois, B. and Boillot, O. and Domergue, J. and Bismuth, H.},
  title = {Results of liver transplantation in the treatment of metastatic neuroendocrine
	tumors. A 31-case French multicentric report.},
  journal = {Ann Surg},
  year = {1997},
  volume = {225},
  pages = {355--364},
  number = {4},
  month = {Apr},
  abstract = {The purpose of this study was to assess the value and timing of orthotopic
	liver transplantation (OLT) in the treatment of metastatic neuroendocrine
	tumors (NET).Liver metastasis from NET seems less invasive than other
	secondary tumors. This observation suggests that OLT may be indicated
	when other therapies become ineffective. However, the potential benefit
	of this highly aggressive procedure is difficult to assess due to
	the scarcity and heterogeneity of NET.A retrospective multicentric
	study was carried out, including all cases of OLT for NET performed
	in France between 1989 and 1994. There were 15 cases of metastatic
	carcinoid tumor and 16 cases of islet cell carcinomas. Hormone-related
	symptoms were present in 16 cases (55\%). Only 5 patients (16\%)
	had no previous surgical or medical therapy before OLT. Median delay
	from diagnosis of liver metastasis and OLT was 19 months (range,
	2 to 120).The primary tumor was removed at the time of OLT in 11
	cases, by upper abdominal exenteration in 7 cases and the Whipple
	resection in 3. Actuarial survival rate after OLT was 59\% at 1 year,
	47\% at 3 years, and 36\% at 5 years. Survival rates were significantly
	higher for metastatic carcinoid tumors (69\% at 5 years) than for
	noncarcinoid apudomas (8\% at 4 years), because of higher tumor-
	and non-tumor-related mortality rates for the latter.OLT can achieve
	control of hormonal symptoms and prolong survival in selected patients
	with liver metastasis of carcinoid tumors. It does not seem indicated
	for other NET.},
  institution = {Department of Surgery, Hopital de La Conception, Marseilles, France.},
  keywords = {Adult; Female; France; Humans; Liver Neoplasms, mortality/secondary/surgery;
	Liver Transplantation, methods; Male; Middle Aged; Neuroendocrine
	Tumors, mortality/secondary/surgery; Postoperative Complications,
	epidemiology; Retrospective Studies; Survival Rate; Time Factors},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {9114793},
  timestamp = {2013.05.29}
}

@ARTICLE{Leung1997,
  author = {Leung, K. M. and Elashoff, R. M. and Afifi, A. A.},
  title = {Censoring Issues in Survival Analysis},
  journal = {Annual Reviews in Public Health},
  year = {1997},
  volume = {18},
  pages = {83-104},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{li2013,
  author = {B.-Q. Li and T. Huang and J. Zhang and N. Zhang and G.-H. Huang and
	L. Liu and Y.-D. Cai},
  title = {An Ensemble Prognostic Model for Colorectal Cancer.},
  journal = {PLoS ONE},
  year = {2013},
  volume = {8},
  file = {li2013.PDF:li2013.PDF:PDF},
  owner = {BettyS},
  timestamp = {2016.11.28}
}

@ARTICLE{Li2001,
  author = {C.S. Li and J.M.G. Taylor and J.P. Sy},
  title = {Identifiability of cure models},
  journal = {Statistics and Probability Letters},
  year = {2001},
  volume = {54},
  pages = {389-395},
  file = {Li2001.pdf:Li2001.pdf:PDF;Li2001.pdf:pdf\\Li2001.pdf:PDF},
  keywords = {Cure models; theory},
  owner = {pl4},
  timestamp = {2009.01.07}
}

@ARTICLE{Li2003,
  author = {Christopher I Li and Benjamin O Anderson and Janet R Daling and Roger
	E Moe},
  title = {Trends in incidence rates of invasive lobular and ductal breast carcinoma.},
  journal = {JAMA},
  year = {2003},
  volume = {289},
  pages = {1421-4},
  number = {11},
  month = {Mar},
  abstract = {CONTEXT: Research has suggested that use of combined estrogen and
	progestin hormone replacement therapy (CHRT) increases breast cancer
	risk and that CHRT use is more strongly associated with the risk
	of invasive lobular breast carcinoma than that of invasive ductal
	carcinoma. Lobular carcinoma is less common than ductal carcinoma
	but can be more difficult to diagnose because of its subtle elusive
	infiltrative pattern. OBJECTIVE: To evaluate trends in invasive lobular
	and ductal carcinoma incidence rates from 1987 through 1999, during
	which time use of CHRT increased in the United States. DESIGN: Descriptive
	epidemiologic study. SETTING: Nine cancer registries that participate
	in the Surveillance, Epidemiology, and End Results (SEER) program
	of the National Cancer Institute and that cover Atlanta, Ga; Detroit,
	Mich; San Francisco-Oakland, Calif; Seattle, Wash; and Connecticut,
	Hawaii, Iowa, New Mexico, and Utah. POPULATION: Women 30 years of
	age and older residing in the areas covered by the 9 SEER registries.
	MAIN OUTCOME MEASURES: Proportional changes in incidence rates of
	invasive lobular and ductal carcinoma among women with no prior history
	of breast cancer. RESULTS: A total of 190 458 women were included
	in this analysis who were identified through the registries as having
	invasive breast cancer; 7682 of the 198 140 potentially eligible
	women (ie, those identified as not having in situ breast cancer)
	were excluded from this analysis because stage of cancer was unknown.
	Invasive breast cancer incidence rates adjusted for age and for SEER
	historic stage increased 1.04-fold (95\% confidence interval [CI],
	1.004-1.07) from 1987-1999 (206.7/100 000 to 214.1/100 000, age-adjusted).
	However, incidence rates of tumors classified as lobular increased
	1.52-fold (95\% CI, 1.42-1.63), and those classified as mixed ductal-lobular
	increased 1.96-fold (95\% CI, 1.80-2.14); rates of these types combined
	increased 1.65-fold (95\% CI, 1.55-1.78) (19.8/100 000 to 33.4/100
	000, age-adjusted). In contrast, ductal carcinoma rates remained
	largely constant (153.8/100 000 to 155.3/100 000, age-adjusted; proportional
	change, 1.03 [95\% CI, 0.99-1.06]). The proportion of breast cancers
	with a lobular component increased from 9.5\% in 1987 to 15.6\% in
	1999. CONCLUSIONS: Ductal carcinoma incidence rates remained essentially
	constant from 1987-1999 while lobular carcinoma rates increased steadily.
	This increase presents a clinical challenge given that lobular carcinoma
	is more difficult to detect than ductal carcinoma by both physical
	examination and mammography.},
  owner = {PaulD},
  pii = {jbr30056},
  timestamp = {2011.06.19}
}

@ARTICLE{Li2016,
  author = {Li, Guowei and Sajobi, Tolulope T and Menon, Bijoy K and Korngut,
	Lawrence and Lowerison, Mark and James, Matthew and Wilton, Stephen
	B and Williamson, Tyler and Gill, Stephanie and Drogos, Lauren L
	and Smith, Eric E and Vohra, Sunita and Hill, Michael D and Thabane,
	Lehana and , 2016 Symposium on Registry-Based Randomized Controlled
	Trials in Calgary},
  title = {Registry-based randomized controlled trials- what are the advantages,
	challenges, and areas for future research?},
  journal = {J Clin Epidemiol},
  year = {2016},
  month = {Aug},
  abstract = {Registry-based randomized controlled trials are defined as pragmatic
	trials that use registries as a platform for case records, data collection,
	randomization, and follow-up. Recently, the application of registry-based
	randomized controlled trials has attracted increasing attention in
	health research to address comparative effectiveness research questions
	in real-world settings, mainly due to their low cost, enhanced generalizability
	of findings, rapid consecutive enrollment, and the potential completeness
	of follow-up for the reference population, when compared with conventional
	randomized effectiveness trials. However several challenges of registry-based
	randomized controlled trials have to be taken into consideration,
	including registry data quality, ethical issues, and methodological
	challenges. In this article, we summarize the advantages, challenges,
	and areas for future research related to registry-based randomized
	controlled trials.},
  file = {Li2016.pdf:Li2016.pdf:PDF;Li2016.pdf:pdf\\Li2016.pdf:PDF},
  institution = {Biostatistics, McMaster University, 1280 Main St W, Hamilton, Ontario
	L8S 4L8, Canada; St. Joseph's Healthcare Hamilton, McMaster University,
	50 Charlton Ave E, Hamilton, Ontario L8N 1Y2, Canada. Electronic
	address: thabanl@mcmaster.ca.},
  language = {eng},
  medline-pst = {aheadofprint},
  owner = {PaulD},
  pmid = {27555082},
  timestamp = {2016.11.02}
}

@ARTICLE{Li2004,
  author = {Xianbin Li and Xiaoyan Song and Ronald H Gray},
  title = {Comparison of the missing-indicator method and conditional logistic
	regression in 1:m matched case-control studies with missing exposure
	values.},
  journal = {Am J Epidemiol},
  year = {2004},
  volume = {159},
  pages = {603-10},
  number = {6},
  month = {Mar},
  abstract = {The missing-indicator method and conditional logistic regression have
	been recommended as alternative approaches for data analysis in matched
	case-control studies with missing exposure values. The authors evaluated
	the performance of the two methods using Monte Carlo simulation.
	Data were generated from a 1:m matched design based on McNemar's
	2 x 2 tables with four scenarios for missing values: completely-at-random,
	case-dependent, exposure-dependent, and case/exposure-dependent.
	In their analysis, the authors used conditional logistic regression
	for complete pairs and the missing-indicator method for all pairs.
	For 1:1 matched studies, given no confounding between exposure and
	disease, the two methods yielded unbiased estimates. Otherwise, conditional
	logistic regression produced unbiased estimates with empirical confidence
	interval coverage similar to nominal coverage under the first three
	missing-value scenarios, whereas the missing-indicator method produced
	slightly more bias and lower confidence interval coverage. An increased
	number of matched controls was associated with slightly more bias
	and lower confidence interval coverage. Under the case/exposure-dependent
	missing-value scenario, neither method performed satisfactorily;
	this indicates the need for more sophisticated statistical methods
	for handling such missing values. Overall, compared with the missing-indicator
	method, conditional logistic regression provided a slight advantage
	in terms of bias and coverage probability, at the cost of slightly
	reduced statistical power and efficiency.},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Liberatos1988,
  author = {Liberatos, P. and Link, B. G. and Kelsey, J. L.},
  title = {The Measurement of Social Class in Epidemiology},
  journal = {Epidemiol Rev},
  year = {1988},
  volume = {10},
  pages = {87-121},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Lin1991,
  author = {Lin, D. Y. and Wei, L. J.},
  title = {Goodness-of-fit tests for the general {C}ox regression model},
  journal = {Statistica Sinica},
  year = {1991},
  volume = {1},
  pages = {1--17},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Lin1989,
  author = {Lin, D. Y. and Wei, L. J.},
  title = {The robust inference for the {C}ox proportional hazards model},
  journal = {Journal of the American Statistical Association},
  year = {1989},
  volume = {84},
  pages = {1074--1078},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Lin1993,
  author = {Lin, D. Y. and Wei, L. J. and Ying, Z.},
  title = {Checking the {C}ox model with cumulative sums of martingale-based
	residuals},
  journal = {Biometrika},
  year = {1993},
  volume = {80},
  pages = {557--572},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Linden1969,
  author = {Linden, G.},
  title = {The influence of Social Class in the Survival of Cancer Patients},
  journal = {American Journal of Public Health and the Nations Health},
  year = {1969},
  volume = {59},
  pages = {267-274},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Lipkus2007,
  author = {Lipkus, Isaac M.},
  title = {Numeric, verbal, and visual formats of conveying health risks: suggested
	best practices and future recommendations.},
  journal = {Med Decis Making},
  year = {2007},
  volume = {27},
  pages = {696--713},
  number = {5},
  abstract = {Perception of health risk can affect medical decisions and health
	behavior change. Yet the concept of risk is a difficult one for the
	public to grasp. Whether perceptions of risk affect decisions and
	behaviors often relies on how messages of risk magnitudes (i.e.,
	likelihood) are conveyed. Based on expert opinion, this article offers,
	when possible, best practices for conveying magnitude of health risks
	using numeric, verbal, and visual formats. This expert opinion is
	based on existing empirical evidence, review of papers and books,
	and consultations with experts in risk communication. This article
	also discusses formats to use pertaining to unique risk communication
	challenges (e.g., conveying small-probability events, interactions).
	Several recommendations are suggested for enhancing precision in
	perception of risk by presenting risk magnitudes numerically and
	visually. Overall, there are little data to suggest best practices
	for verbal communication of risk magnitudes. Across the 3 formats,
	few overall recommendations could be suggested because of 1) lack
	of consistency in testing formats using the same outcomes in the
	domain of interest, 2) lack of critical tests using randomized controlled
	studies pitting formats against one another, and 3) lack of theoretical
	progress detailing and testing mechanisms why one format should be
	more efficacious in a specific context to affect risk magnitudes
	than others. Areas of future research are provided that it is hoped
	will help illuminate future best practices.},
  doi = {10.1177/0272989X07307271},
  institution = {Duke University Medical Center, Durham, North Carolina 27701, USA.
	lipku001@mc.duke.edu},
  keywords = {Communication; Decision Making; Humans; Patient Education as Topic,
	methods; Patient Participation; Practice Guidelines as Topic; Risk
	Assessment; United States},
  language = {eng},
  medline-pst = {ppublish},
  owner = {sanelo},
  pii = {0272989X07307271},
  pmid = {17873259},
  timestamp = {2013.10.08},
  url = {http://dx.doi.org/10.1177/0272989X07307271}
}

@ARTICLE{Lipworth1969,
  author = {Lipworth, L. and Abelin, T. and Connelly, R. R.},
  title = {Socio-economic Factors in the Prognosis of Cancer Patients},
  journal = {Journal of Chronic Diseases},
  year = {1969},
  volume = {23},
  pages = {105-116},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Liu2008,
  author = {Liu, Lei and Huang, Xuelin},
  title = {The use of Gaussian quadrature for estimation in frailty proportional
	hazards models.},
  journal = {Stat Med},
  year = {2008},
  volume = {27},
  pages = {2665--2683},
  number = {14},
  month = {Jun},
  abstract = {In this paper, we propose a novel Gaussian quadrature estimation method
	in various frailty proportional hazards models. We approximate the
	unspecified baseline hazard by a piecewise constant one, resulting
	in a parametric model that can be fitted conveniently by Gaussian
	quadrature tools in standard software such as SAS Proc NLMIXED. We
	first apply our method to simple frailty models for correlated survival
	data (e.g. recurrent or clustered failure times), then to joint frailty
	models for correlated failure times with informative dropout or a
	dependent terminal event such as death. Simulation studies show that
	our method compares favorably with the well-received penalized partial
	likelihood method and the Monte Carlo EM (MCEM) method, for both
	normal and Gamma frailty models. We apply our method to three real
	data examples: (1) the time to blindness of both eyes in a diabetic
	retinopathy study, (2) the joint analysis of recurrent opportunistic
	diseases in the presence of death for HIV-infected patients, and
	(3) the joint modeling of local, distant tumor recurrences and patients
	survival in a soft tissue sarcoma study. The proposed method greatly
	simplifies the implementation of the (joint) frailty models and makes
	them much more accessible to general statistical practitioners.},
  doi = {10.1002/sim.3077},
  institution = {Division of Biostatistics and Epidemiology, Department of Public
	Health Sciences, University of Virginia, Charlottesville, VA 22908-0717,
	USA. liulei@virginia.edu},
  keywords = {Humans; Normal Distribution; Proportional Hazards Models; Survival
	Analysis},
  language = {eng},
  medline-pst = {ppublish},
  owner = {Michael},
  pmid = {17910008},
  timestamp = {2013.05.08},
  url = {http://dx.doi.org/10.1002/sim.3077}
}

@ARTICLE{Liu1998,
  author = {L. Liu and J. G. Wang and L. Gong and G. Liu and J. A. Staessen},
  title = {Comparison of active treatment and placebo in older Chinese patients
	with isolated systolic hypertension. Systolic Hypertension in China
	(Syst-China) Collaborative Group.},
  journal = {J Hypertens},
  year = {1998},
  volume = {16},
  pages = {1823--1829},
  number = {12 Pt 1},
  month = {Dec},
  abstract = {BACKGROUND: Isolated systolic hypertension occurs in around 8\% of
	Chinese people aged 60 years or older. In 1988, the Systolic Hypertension
	in China (Syst-China) Collaborative Group started to investigate
	whether active treatment could reduce the incidence of stroke and
	other cardiovascular complications in older patients with isolated
	systolic hypertension. METHODS: All patients were initially started
	on masked placebo. After stratification for centre, sex and previous
	cardiovascular complications, alternate patients (n=1253) were assigned
	nitrendipine at 10-40 mg daily, with the addition of captopril at
	12.5-50.0 mg daily or hydrochlorothiazide at 12.5-50.0 mg daily,
	or both, if a sufficient blood pressure fall was not obtained. In
	the remaining 1141 control patients, matching placebos were administered
	similarly. RESULTS: At entry, sitting blood pressure averaged 170.5
	mmHg systolic and 86.0 mmHg diastolic, age averaged 66.5 years and
	total serum cholesterol was 5.1 mmol/l. After 2 years of follow-up,
	sitting systolic and diastolic blood pressures had fallen by 10.9
	mmHg and 1.9 mmHg in the placebo group and by 20.0 mmHg and 5.0 mmHg
	in the active treatment group. The intergroup differences were 9.1
	mmHg systolic (95\% confidence interval 7.6-10.7 mmHg ) and 3.2 mmHg
	diastolic (95\% confidence interval 2.4-4.0). Active treatment reduced
	total strokes by 38\% (from 20.8 to 13.0 endpoints per 1000 patient-years,
	P=0.01), all-cause mortality by 39\% (from 28.4 to 17.4 endpoints
	per 1000 patient-years, P=0.003), cardiovascular mortality by 39\%
	(from 15.2 to 9.4 endpoints per 1000 patient-years, P=0.03), stroke
	mortality by 58\% (from 6.9 to 2.9 endpoints per 1000 patient-years,
	P=0.02), and ail fatal and nonfatal cardiovascular endpoints by 37\%
	(from 33.3 to 21.4 endpoints per 1000 patient-years, P=0.004). CONCLUSIONS:
	Antihypertensive treatment prevents stroke and other cardiovascular
	complications in older Chinese patients with isolated systolic hypertension.
	Treatment of 1000 Chinese patients for 5 years could prevent 55 deaths,
	39 strokes or 59 major cardiovascular endpoints.},
  file = {Liu1998.pdf:Liu1998.pdf:PDF;Liu1998.pdf:pdf\\Liu1998.pdf:PDF},
  institution = {Hypertension Division, Cardiovascular Institute and Fuwai Hospital,
	Chinese Academy of Medical Sciences, Beijing, People's Republic of
	China.},
  owner = {pl4},
  pmid = {9869017},
  timestamp = {2008.11.18}
}

@InProceedings{lock:dane:1997,
  author    = {Lock, Robin H. and Danehy, Timothy J.},
  booktitle = {ASA Proceedings of the Section on Statistics in Sports},
  title     = {Using a {P}oisson Model to Rate Teams and Predict Scores in Ice Hockey},
  pages     = {25--30},
  publisher = {American Statistical Association (Alexandria, VA)},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1997},
}

@ARTICLE{Louis1984,
  author = {Louis, T. A.},
  title = {Estimating a Population of Parameter Values Using {B}ayes and Empirical
	{B}ayes Methods},
  journal = {Journal of the American Statistical Association},
  year = {1984},
  volume = {79},
  pages = {393-398},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Lowry1996,
  author = {Lowry, R. and Kann, L. and Collins, J. L. and Kolbe, L. J.},
  title = {The Effect of Socioeconomic Status on Chronic Disease Behaviour Among
	{US} Adolescents},
  journal = {JAMA},
  year = {1996},
  volume = {276},
  pages = {792-797},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Lu2016,
  author = {Lu, Donghao and Andersson, Therese M L and Fall, Katja and Hultman,
	Christina M and Czene, Kamila and Valdimarsdottir, Unnur and Fang,
	Fang},
  title = {Clinical Diagnosis of Mental Disorders Immediately Before and After
	Cancer Diagnosis: A Nationwide Matched Cohort Study in Sweden.},
  journal = {JAMA oncology},
  year = {2016},
  month = {Apr},
  abstract = {Psychiatric comorbidities are common among patients with cancer. However,
	whether or not there is increased risk of mental disorders during
	the diagnostic workup leading to a cancer diagnosis was unknown.
	To examine the relative risks of depression, anxiety, substance abuse,
	somatoform/conversion disorder, and stress reaction/adjustment disorder
	during the periods before and after cancer diagnosis compared with
	individuals without cancer. Nationwide matched cohort study from
	January 1, 2001, to December 31, 2010, in a Swedish population and
	health registers. We estimated the time-varying hazard ratios (HRs)
	of the first clinical diagnosis of the studied mental disorders from
	2 years before cancer diagnosis, through the time of diagnosis, and
	until 10 years after diagnosis, adjusting for age, sex, calendar
	period, and educational level. To assess milder mental conditions
	and symptoms, we further assessed the use of related psychiatric
	medications for patients with cancer diagnosed during 2008-2009.
	The study included 304{\AA}Â¢ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â‚ÃƒÂ‚Ã‚Â¬ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¯118 patients with cancer and 3{\AA}Â¢ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â‚ÃƒÂ‚Ã‚Â¬ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¯041{\AA}Â¢ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â‚ÃƒÂ‚Ã‚Â¬ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¯174
	cancer-free individuals who were randomly selected from the Swedish
	population and individually matched to the patients with cancer on
	year of birth and sex. The median age at diagnosis for the patients
	with cancer was 69 years, and 46.9% of the patients were female.
	The relative rate for all studied mental disorders started to increase
	from 10 months before cancer diagnosis (HR, 1.1; 95% CI, 1.1-1.2),
	peaked during the first week after diagnosis (HR, 6.7; 95% CI, 6.1-7.4),
	and decreased rapidly thereafter but remained elevated 10 years after
	diagnosis (HR, 1.1; 95% CI, 1.1-1.2). The rate elevation was clear
	for all main cancers except nonmelanoma skin cancer and was stronger
	for cancers of poorer prognosis. Compared with cancer-free individuals,
	increased use of psychiatric medications was noted from 1 month before
	cancer diagnosis and peaked around 3 months after diagnosis among
	patients with cancer. Patients diagnosed as having cancer had increased
	risks of several common mental disorders from the year before diagnosis.
	These findings support the existing guidelines of integrating psychological
	management into cancer care and further call for extended vigilance
	for multiple mental disorders starting from the time of the cancer
	diagnostic workup.},
  created = {2016-4-28},
  doi = {10.1001/jamaoncol.2016.0483},
  file = {Lu2016.pdf:Lu2016.pdf:PDF},
  issn = {2374-2445},
  journal-abbreviation = {JAMA Oncol},
  nlm-id = {101652861},
  owner = {NLM},
  pmid = {27124325},
  pubmodel = {Print-Electronic},
  pubstatus = {aheadofprint},
  revised = {2016-4-29},
  status = {Publisher}
}

@ARTICLE{Lu2000,
  author = {Lu, W. and Andrieu, J. M.},
  title = {HIV protease inhibitors restore impaired T-cell proliferative response
	in vivo and in vitro: a viral-suppression-independent mechanism.},
  journal = {Blood},
  year = {2000},
  volume = {96},
  pages = {250--258},
  number = {1},
  month = {Jul},
  abstract = {In 99 adults infected with human immunodeficiency virus type 1 (HIV-1)
	who received highly active antiretroviral therapy (HAART) (including
	2 nucleoside analogues and 1 or 2 protease inhibitors) for 1 year,
	CD4(+) and CD8(+) T cells (including memory and naive subsets) increased
	similarly among patients with sustained plasma viral load decrease,
	transient decrease, or no decrease. A linear correlation was observed
	between the decrease in serum beta(2)-microglobulin concentration
	(an independent surrogate marker of HIV disease) and the increase
	in peripheral blood T-cells (CD4(+) and CD8(+)) counts. In vitro,
	HIV protease inhibitors indinavir and saquinavir (but not nucleoside
	analogues) enhanced the survival of patients' peripheral blood T
	cells at doses that are at least 30-fold lower than those required
	for achieving 90\% viral inhibition in the same cultures. This enhanced
	T-cell survival (which is similar for CD4 and CD8 cells) was associated
	with a restoration of T-cell proliferative response to immune stimuli.
	However, neither TCR/CD3-ligation- nor Fas-ligation-triggered apoptosis
	was affected by either of the 2 protease inhibitors. A reduction
	in apoptosis observed after prolonged culture of patient T cells
	in the presence of the protease inhibitors could result from restored
	T-cell proliferation. These findings explain the discrepancies between
	virologic and immunologic responses that are increasingly reported
	in patients receiving HAART, and may provide insights into the pathogenesis
	of HIV infection.},
  institution = {Laboratory of Molecular Oncology and Virology, Necker Faculty of
	Medicine at Laennec Hospital, Ren{\AA}Â§ÃƒÂƒÃ‚Â…ÃƒÂ‚Ã‚Â¸ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Âžescartes (Paris V) University,
	Paris, France. weilu@intercancer.net},
  keywords = {Adult; Apoptosis; Biological Markers, blood; CD4 Lymphocyte Count;
	CD8-Positive T-Lymphocytes, immunology; Cells, Cultured; Drug Therapy,
	Combination; Female; HIV Protease Inhibitors, therapeutic use; HIV
	Seropositivity, blood/drug therapy/immunology; HIV-1, isolation /&/
	purification; Humans; Lymphocyte Activation, drug effects; Lymphocyte
	Count; Male; T-Lymphocytes, drug effects/immunology; Viral Load;
	beta 2-Microglobulin, blood},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {10891458},
  timestamp = {2013.05.29}
}

@ARTICLE{Ludvigsson2009,
  author = {Jonas F Ludvigsson and Petra Otterblad-Olausson and Birgitta U Pettersson
	and Anders Ekbom},
  title = {The {S}wedish personal identity number: possibilities and pitfalls
	in healthcare and medical research.},
  journal = {Eur J Epidemiol},
  year = {2009},
  volume = {24},
  pages = {659--667},
  number = {11},
  abstract = {Swedish health care and national health registers are dependent on
	the presence of a unique identifier. This paper describes the Swedish
	personal identity number (PIN) and explores ethical issues of its
	use in medical research. A ten-digit-PIN is maintained by the National
	Tax Board for all individuals that have resided in Sweden since 1947.
	Until January 2008, an estimated 75,638 individuals have changed
	PIN. The most common reasons for change of PIN are incorrect recording
	of date of birth or sex among immigrants or newborns. Although uncommon,
	change of sex always leads to change of PIN since the PIN is sex-specific.
	The most common reasons for re-use of PIN (n = 15,887), is when immigrants
	are assigned a PIN that has previously been assigned to someone else.
	This is sometimes necessary since there is a shortage of certain
	PIN combinations referring to dates of birth in the 1950s and 1960s.
	Several ethical issues can be raised pro and con the use of PIN in
	medical research. The Swedish PIN is a useful tool for linkages between
	medical registers and allows for virtually 100\% coverage of the
	Swedish health care system. We suggest that matching of registers
	through PIN and matching of national health registers without the
	explicit approval of the individual patient is to the benefit for
	both the individual patient and for society.},
  doi = {10.1007/s10654-009-9350-y},
  file = {Ludvigsson2009.pdf:Ludvigsson2009.pdf:PDF;Ludvigsson2009.pdf:pdf\\Ludvigsson2009.pdf:PDF},
  institution = {Department of Paediatrics, Orebro University Hospital, Orebro, Sweden,
	jonasludvigsson@yahoo.com.},
  owner = {pl4},
  pmid = {19504049},
  timestamp = {2010.01.04},
  url = {http://dx.doi.org/10.1007/s10654-009-9350-y}
}

@ARTICLE{Lui1990,
  author = {Lui, K. J. and Martinez, B. and Mercy, J.},
  title = {An Application of the Empirical {B}ayes Approach to Directly Adjusted
	Rates: {A} Note on Suicide Mapping in {C}alifornia},
  journal = {Suicide and Life-Threatening Behaviour},
  year = {1990},
  volume = {20},
  pages = {240-253},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Lundgren2006,
  author = {Catharina Ihre Lundgren and Per Hall and Paul W Dickman and Jan Zedenius},
  title = {Clinically significant prognostic factors for differentiated thyroid
	carcinoma: a population-based, nested case-control study.},
  journal = {Cancer},
  year = {2006},
  volume = {106},
  pages = {524--531},
  abstract = {BACKGROUND: Different scoring systems currently are being used to
	stratify patients with differentiated thyroid carcinoma (DTC) into
	risk groups. DTC is usually subdivided into papillary thyroid carcinoma
	(PTC) and follicular thyroid carcinoma (FTC). The objective of the
	current study was to identify those factors that predict long-term
	unfavorable prognosis and to evaluate the predictive accuracy of
	the TNM staging system. METHODS: The authors conducted a nested case-control
	study within the cohort of all patients (n=5123) diagnosed with DTC
	in {S}weden between 1958-1987 who survived at least 1 year after
	diagnosis. One control, matched by age at diagnosis, gender, and
	calendar period, was randomly selected for each case (patients who
	died of DTC). All patients were classified at the time of diagnosis
	according to the TNM staging system. The effect of prognostic factors
	on DTC mortality was evaluated using conditional logistic regression.
	RESULTS: Patients with widely invasive FTC experienced a significantly
	higher mortality compared with PTC patients. The grade of differentiation
	was found to influence mortality significantly. Patients with TNM
	Stage IV disease had a higher mortality rate compared with patients
	with Stage II disease (odds ratio [OR]=9.1; 95\% confidence interval
	[95\% CI], 5.7-14.6). Patients with lymph node metastases experienced
	a higher mortality (OR=2.5; 95\% CI, 1.6-4.1) and patients with distant
	metastasis at the time of diagnosis were found to have a nearly 7-fold
	higher mortality rate (OR=6.6; 95\% CI, 4.1-10.5). Incomplete surgical
	excision was associated with higher mortality, particularly in patients
	with Stage I disease. CONCLUSIONS: In the current study, the following
	were found to be clinically significant prognostic factors for patients
	with DTC: histopathologic subgroup, TNM staging including lymph node
	metastases and distant metastases, and completeness of the surgical
	excision.},
  doi = {10.1002/cncr.21653},
  owner = {PaulD},
  pmid = {16369995},
  timestamp = {2006.10.04},
  url = {http://dx.doi.org/10.1002/cncr.21653}
}

@ARTICLE{Lundgren2003,
  author = {Catharina Ihre Lundgren and Per Hall and Anders Ekbom and Jan Frisell
	and Jan Zedenius and Paul W Dickman},
  title = {Incidence and survival of {S}wedish patients with differentiated
	thyroid cancer.},
  journal = {Int J Cancer},
  year = {2003},
  volume = {106},
  pages = {569-73},
  number = {4},
  month = {Sep},
  abstract = {Papillary (PTC) and follicular (FTC) thyroid cancers are rare disorders
	but are, nevertheless, among the most common cancers in individuals
	below 40 years of age. From the population-based Swedish Cancer Registry
	we identified 3,588 individuals with PTC and 1,966 with FTC during
	1958-87. Histopathology was determined by examining the original
	histopathology reports. The relative survival ratio (RSR) was used
	as the measure of patient survival. Incidence of both PTC and FTC
	was higher among women, especially for PTC and particularly during
	the fertile part of female life. Incidence of PTC increased significantly
	over time, a trend that was not observed for FTC. Five-year relative
	survival appeared to be higher for patients diagnosed with PTC compared
	to FTC, although this difference was almost completely explained
	by the confounding effect of age. Patients with PTC experience lower
	mortality during the period 7-20 years after diagnosis. Excess mortality
	was lower among women, although the magnitude of the difference varied
	with age and histopathology. In contrast to our perceptions based
	on clinical practice, we observed no difference in excess mortality
	between patients diagnosed with PTC and FTC during the years immediately
	after diagnosis (where the majority of deaths occur). Our data suggest
	that there may exist a subgroup of thyroid tumors with superior prognosis
	diagnosed in women during the fertile part of female life. Sex hormones
	may play a role in the etiology of these tumors.},
  doi = {10.1002/ijc.11275},
  owner = {PaulD},
  timestamp = {2011.06.19},
  url = {http://dx.doi.org/10.1002/ijc.11275}
}

@ARTICLE{Lundmark2006,
  author = {Frida Lundmark and Hanne F Harbo and Elisabeth G Celius and Janna
	Saarela and Pameli Datta and Annette Oturai and Cecilia M Lindgren
	and Thomas Masterman and Hugh Salter and Jan Hillert},
  title = {Association analysis of the LAG3 and CD4 genes in multiple sclerosis
	in two independent populations.},
  journal = {J Neuroimmunol},
  year = {2006},
  volume = {180},
  pages = {193--198},
  number = {1-2},
  month = {Nov},
  abstract = {We have investigated the genetic involvement of the CD4 and the LAG3
	genes, two appealing candidates for MS due to their suggested role
	in MS pathology. We genotyped a Swedish case-control material consisting
	of 920 MS patients and 778 controls in an initial study of CD4, three
	SNPs showed a significant association with MS. An independent material
	consisting of 1720 Nordic MS patients and 1416 controls were used
	for confirmation of associated markers in CD4 and to do a confirmative
	study of the LAG3 gene from previous findings. The result, including
	a total of 2640 MS patients and 2194 controls shows no significant
	association with CD4 and LAG3 and MS. We conclude that these genes
	are of minor importance in regard of genetic predisposition to the
	MS.},
  doi = {10.1016/j.jneuroim.2006.08.009},
  institution = {Division of Neurology, Department of Clinical Neuroscience, Karolinska
	Institutet at Karolinska University Hospital, Huddinge, Stockholm,
	Sweden. frida.lundmark@ki.se},
  owner = {pl4},
  pii = {S0165-5728(06)00334-1},
  pmid = {17020785},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1016/j.jneuroim.2006.08.009}
}

@ARTICLE{Lunn2009,
  author = {David Lunn and David Spiegelhalter and Andrew Thomas and Nicky Best},
  title = {The BUGS project: Evolution, critique and future directions.},
  journal = {Statistics in Medicine},
  year = {2009},
  volume = {28},
  pages = {3049--3067},
  number = {25},
  month = {Nov},
  abstract = {BUGS is a software package for Bayesian inference using Gibbs sampling.
	The software has been instrumental in raising awareness of Bayesian
	modelling among both academic and commercial communities internationally,
	and has enjoyed considerable success over its 20-year life span.
	Despite this, the software has a number of shortcomings and a principal
	aim of this paper is to provide a balanced critical appraisal, in
	particular highlighting how various ideas have led to unprecedented
	flexibility while at the same time producing negative side effects.
	We also present a historical overview of the BUGS project and some
	future perspectives.},
  doi = {10.1002/sim.3680},
  file = {Lunn2009.pdf:Lunn2009.pdf:PDF;Lunn2009.pdf:pdf\\Lunn2009.pdf:PDF},
  institution = {Medical Research Council Biostatistics Unit, Institute of Public
	Health, University Forvie Site, Robinson Way, Cambridge CB2 0SR,
	U.K. david.lunn@mrc-bsu.cam.ac.uk},
  owner = {pl4},
  pmid = {19630097},
  timestamp = {2010.07.14},
  url = {http://dx.doi.org/10.1002/sim.3680}
}

@ARTICLE{Lunn1995,
  author = {M. Lunn and D. McNeil},
  title = {Applying {C}ox regression to competing risks.},
  journal = {Biometrics},
  year = {1995},
  volume = {51},
  pages = {524--532},
  number = {2},
  month = {Jun},
  abstract = {Two methods are given for the joint estimation of parameters in models
	for competing risks in survival analysis. In both cases Cox's proportional
	hazards regression model is fitted using a data duplication method.
	In principle either method can be used for any number of different
	failure types, assuming independent risks. Advantages of the augmented
	data approach are that it limits over-parametrisation and it runs
	immediately on existing software. The methods are used to reanalyse
	data from two well-known published studies, providing new insights.},
  file = {Lunn1995.pdf:Lunn1995.pdf:PDF;Lunn1995.pdf:pdf\\Lunn1995.pdf:PDF},
  institution = {St. Hughs College, Oxford, United Kingdom.},
  owner = {pl4},
  pmid = {7662841},
  timestamp = {2010.07.15}
}

@ARTICLE{Luomala2007a,
  author = {M. Luomala and R. Laaksonen and T. Janatuinen and R. Vesalainen and
	P. Nuutila and M. Saarela and K. Mattila and M. Kalij\"{a}rvi and
	T. Solakivi and J. Knuuti and M. Hurme and T. Lehtim\"{a}ki},
  title = {High plasma levels of CD40 are associated with low coenzyme Q and
	vitamin E content of low-density lipoprotein in healthy men.},
  journal = {Scand J Clin Lab Invest},
  year = {2007},
  volume = {67},
  pages = {115--122},
  number = {2},
  abstract = {There is a growing body of evidence to suggest that low-density lipoprotein
	(LDL) cholesterol, inflammation and oxidative stress are pivotal
	in the development of cardiovascular disease, but their interconnections
	are not well known. The objective of this study was to determine
	whether immunological activation, reflected by the plasma levels
	of soluble CD40 (sCD40), interleukin (IL)-1beta, tumor necrosis factor-alpha
	and IL-6 are associated with the antioxidant potential of LDL particles
	or with common lipid, immunological or thrombotic markers in 51 young
	healthy men.We determined the coenzyme Q level from an oxidized LDL
	fraction, obtaining the concentration for ubiquinone, which indicates
	total coenzyme Q levels.The plasma level of sCD40 was negatively
	correlated with LDL ubiquinone (r=-0.45, p=0.001) and E vitamin (r=-0.37,
	p=0.008) and positively correlated with plasma concentration of plasminogen
	activator inhibitor-1 (PAI-1, r=0.52, p=0.002) and caspase-1 (r=0.40,
	p=0.004). No correlation was detected between sCD40 and plasma lipid
	or C-reactive protein concentrations. As sCD40 was strongly correlated
	with the content of LDL ubiquinone and vitamin E, their values were
	compared according to groups formed by sCD40 tertiles. Analysis of
	variance showed that there were significant differences in LDL ubiquinone
	(p<0.0001) and vitamin E (p=0.004) concentrations between sCD40 tertiles.The
	data indicate that increased activation of the CD40 system is related
	to low levels of LDL ubiquinone and vitamin E. This suggests that
	chronic or increased immunological activation may consume the antioxidant
	potential of LDL particles.},
  doi = {10.1080/00365510600979394},
  institution = {Laboratory of Atherosclerosis Genetics, Center for Laboratory Medicine,
	Department of Clinical Chemistry, Tampere University Hospital, Tampere,
	Finland. mari.luomala@uta.fi},
  owner = {pl4},
  pii = {772863342},
  pmid = {17365991},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1080/00365510600979394}
}

@ARTICLE{Luoto1994,
  author = {Luoto, R. and Pekkanen, J. and Uutela, A. and Tuomilehto, J.},
  title = {Cardiovascular Risks and Socioeconomic Status: Differences Between
	Men and Women in {F}inland},
  journal = {Journal of Epidemiology and Community Health},
  year = {1994},
  volume = {48},
  pages = {348-354},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Luxemburger1994,
  author = {Luxemburger, C. and Perea, W. A. and Delmas, G. and Pruja, C. and
	Pecoul, B. and Moren, A.},
  title = {Permethrin-impregnated bed nets for the prevention of malaria in
	schoolchildren on the Thai-Burmese border.},
  journal = {Trans R Soc Trop Med Hyg},
  year = {1994},
  volume = {88},
  pages = {155--159},
  number = {2},
  abstract = {A double-blind controlled trial was undertaken from August 1990 to
	February 1991 among Karen children on the Thai-Burmese border to
	evaluate the effects on malaria incidence and prevalence of permethrin-treated
	bed nets. Three hundred and fifty schoolchildren, aged 4 to 15 years,
	were allocated at random to receive either a permethrin-impregnated
	net or a non-treated net. The incidence of malaria infections, confirmed
	by a blood film, was assessed during 6 months. Three surveys were
	conducted, on admission and 3 and 6 months later, to measure the
	prevalence of infections and spleen rates. Compliance was assessed
	by monthly home visiting. The use of permethrin-treated bed nets
	reduced the number of parasitaemic Plasmodium falciparum infections
	by 38\% and the number of symptomatic episodes by 42\%. The number
	of P. vivax malaria attacks was similar in each group. The prevalence
	of positive blood films in the 2 groups did not change significantly
	during the study. A reduction in spleen rate by 50\% in both groups
	at the end of the study period could not be related to the overall
	use of nets. Compliance was high and no side-effect was reported.
	The long-term effects on morbidity and mortality need to be assessed
	after distribution of permethrin treated bed nets at the village
	level.},
  institution = {M{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â£ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¥cins Sans Fronti{\AA}Â§ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â±ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¥s, Paris, France.},
  keywords = {Adolescent; Child; Child, Preschool; Dose-Response Relationship, Drug;
	Double-Blind Method; Female; Humans; Incidence; Insecticides, adverse
	effects; Malaria, Falciparum, epidemiology/prevention /&/ control;
	Malaria, Vivax, epidemiology/prevention /&/ control; Male; Mosquito
	Control, methods; Myanmar, epidemiology; Patient Compliance; Permethrin;
	Prevalence; Pyrethrins, adverse effects; Thailand, epidemiology},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {8036656},
  timestamp = {2013.05.29}
}

@ARTICLE{Lynge1989,
  author = {Lynge, E. and Madsen, M. and Engholm, G.},
  title = {Effect of Organized Screening on Incidence and Mortality of Cervical
	Cancer in {D}enmark},
  journal = {Cancer Research},
  year = {1989},
  volume = {49},
  pages = {2157-2160},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@Conference{Moller2012,
  author       = {B M{\o}ller and B Aagnes},
  title        = {Conditional survival statistics in standard cancer registry reporting},
  note         = {Conference abstract},
  organization = {The {A}nnual meeting of the {A}ssociation of the {N}ordic {C}ancer {R}egistries},
  address      = {Olso, Norway},
  month        = {Aug},
  owner        = {sanelo},
  timestamp    = {2013.09.17},
  year         = {2012},
}

@ARTICLE{Moeller2009,
  author = {H. M{\o}ller and K. M. Linklater and D. Robinson},
  title = {A visual summary of the {EUROCARE}-4 results: a {UK} perspective},
  journal = {British Journal of Cancer},
  year = {2009},
  volume = {101 Suppl 2},
  pages = {S110--S114},
  month = {Dec},
  abstract = {BACKGROUND: This paper provides a one-page visual summary of the previously
	published relative survival estimates for 42 types of cancers in
	23 countries in Europe. METHODS: The cancer patients in these analyses
	were 15 years or older at the time of their diagnosis in the period
	1995-1999. Follow-up was to the end of 2003 and relative survival
	estimates were computed by the cohort method. RESULTS: The analysis
	of 1-year survival had good discriminatory power and visibly separated
	a group of countries with consistently high survival estimates (Switzerland,
	France, Sweden, Belgium and Italy) and another group of countries
	with lower estimates (Poland, Czech Republic, Ireland, Denmark and
	United Kingdom-Northern Ireland). After the first year, there was
	less variation between the countries. CONCLUSION: To more fully understand
	the UK situation, a rational comparison would select countries with
	data-quality, prosperity and healthcare systems that are similar
	to the United Kingdom. In otherwise comparable populations, a pronounced
	difference in 1-year survival is most likely to be due to variation
	in a strong prognostic factor, which exerts its effect in the short
	term. A likely explanation for the short-term survival deficit in
	the United Kingdom compared with the Nordic countries is a less favourable
	stage distribution in the United Kingdom. However, the present superficial
	analysis does not exclude possible functions for other factors relating
	to the organisation and quality of cancer care services.},
  doi = {10.1038/sj.bjc.6605400},
  file = {Moeller2009.pdf:Moeller2009.pdf:PDF;Moeller2009.pdf:pdf\\Moeller2009.pdf:PDF},
  institution = {Thames Cancer Registry, Kings College London, 42 Weston Street, London,
	UK. henrik.moller@kcl.ac.uk},
  owner = {pl4},
  pii = {6605400},
  pmid = {19956154},
  timestamp = {2010.03.19},
  url = {http://dx.doi.org/10.1038/sj.bjc.6605400}
}

@ARTICLE{Moeller2011,
  author = {H. M{\o}ller and S. Richards and N. Hanchett and S. P. Riaz and M.
	L\"{u}chtenborg and L. Holmberg and D. Robinson},
  title = {Completeness of case ascertainment and survival time error in {E}nglish
	cancer registries: impact on 1-year survival estimates.},
  journal = {Br J Cancer},
  year = {2011},
  abstract = {Background:It has been suggested that cancer registries in England
	are too dependent on processing of information from death certificates,
	and consequently that cancer survival statistics reported for England
	are systematically biased and too low.Methods:We have linked routine
	cancer registration records for colorectal, lung, and breast cancer
	patients with information from the Hospital Episode Statistics (HES)
	database for the period 2001-2007. Based on record linkage with the
	HES database, records missing in the cancer register were identified,
	and dates of diagnosis were revised. The effects of those revisions
	on the estimated survival time and proportion of patients surviving
	for 1 year or more were studied. Cases that were absent in the cancer
	register and present in the HES data with a relevant diagnosis code
	and a relevant surgery code were used to estimate (a) the completeness
	of the cancer register. Differences in survival times calculated
	from the two data sources were used to estimate (b) the possible
	extent of error in the recorded survival time in the cancer register.
	Finally, we combined (a) and (b) to estimate (c) the resulting differences
	in 1-year cumulative survival estimates.Results:Completeness of case
	ascertainment in English cancer registries is high, around 98-99\%.
	Using HES data added 1.9\%, 0.4\% and 2.0\% to the number of colorectal,
	lung, and breast cancer registrations, respectively. Around 5-6\%
	of rapidly fatal cancer registrations had survival time extended
	by more than a month, and almost 3\% of rapidly fatal breast cancer
	records were extended by more than a year. The resulting impact on
	estimates of 1-year survival was small, amounting to 1.0, 0.8, and
	0.4 percentage points for colorectal, lung, and breast cancer, respectively.Interpretation:English
	cancer registration data cannot be dismissed as unfit for the purpose
	of cancer survival analysis. However, investigators should retain
	a critical attitude to data quality and sources of error in international
	cancer survival studies.British Journal of Cancer advance online
	publication, 10 May 2011; doi:10.1038/bjc.2011.168 www.bjcancer.com.},
  doi = {10.1038/bjc.2011.168},
  institution = {King's College London, Thames Cancer Registry, 42 Weston Street,
	London SE1 3QD, UK.},
  language = {eng},
  medline-pst = {aheadofprint},
  owner = {PaulD},
  pii = {bjc2011168},
  pmid = {21559016},
  timestamp = {2011.06.13},
  url = {http://dx.doi.org/10.1038/bjc.2011.168}
}

@ARTICLE{Moeller2010,
  author = {H. M{\o}ller and F. Sandin and F. Bray and A. Klint and K. M. Linklater
	and A. Purushotham and D. Robinson and L. Holmberg},
  title = {Breast cancer survival in {E}ngland, {N}orway and {S}weden: a population-based
	comparison},
  journal = {International Journal of Cancer},
  year = {2010},
  volume = {127},
  pages = {2630-2638},
  file = {Moeller2010.pdf:Moeller2010.pdf:PDF;Moeller2010.pdf:pdf\\Moeller2010.pdf:PDF},
  owner = {pl4},
  timestamp = {2010.03.19}
}

@Article{Moeller2012,
  author      = {M{\o}ller, Henrik and Sandin, Fredrik and Robinson, David and Bray, Freddie and Klint, Sa and Linklater, Karen M. and Lambert, Paul C. and P{\aa}hlman, Lars and Holmberg, Lars and Morris, Eva},
  title       = {Colorectal cancer survival in socioeconomic groups in {E}ngland: variation is mainly in the short term after diagnosis.},
  doi         = {10.1016/j.ejca.2011.05.018},
  language    = {eng},
  number      = {1},
  pages       = {46--53},
  url         = {http://dx.doi.org/10.1016/j.ejca.2011.05.018},
  volume      = {48},
  abstract    = {The objective of this study was to examine differences in cancer survival
	between socioeconomic groups in England, with particular attention
	to survival in the short term of follow-up.Individuals diagnosed
	with colorectal cancer between 1996 and 2004 in England were identified
	from cancer registry records. Five-year cumulative relative survival
	and excess death rates were computed.For colon cancer there was a
	very high excess death rate in the first month of follow-up, and
	the excess death rate was highest in the socioeconomically deprived
	groups. In subsequent periods, excess mortality rates were much lower
	and there was less socioeconomic variation. The pattern of variation
	in excess death rates was generally similar in rectal cancer but
	the socioeconomic difference in death rates persisted several years
	longer. If the excess death rates in the entire colorectal cancer
	patient population were the same as those observed in the most affluent
	socioeconomic quintile, the annual reduction would be 360 deaths
	in colon cancer and 336 deaths in rectal cancer patients. These deaths
	occurred almost entirely in the first month and the first year after
	diagnosis.Recent developments in the national cancer control agenda
	have included an increasing emphasis on outcome measures, with short-term
	cancer survival an operational measure of variation and progress
	in cancer control. In providing clues to the nature of the survival
	differences between socioeconomic groups, the results presented here
	give strong support for this strategy.},
  file        = {Moeller2012.pdf:Moeller2012.pdf:PDF},
  institution = {King's College London, Thames Cancer Registry, 1st Floor Capital House, 42 Weston Street, London SE1 3QD, UK. henrik.moller@kcl.ac.uk},
  journal     = {European Journal of Cancer},
  medline-pst = {ppublish},
  owner       = {pl4},
  pii         = {S0959-8049(11)00351-0},
  pmid        = {21676610},
  timestamp   = {2012.04.08},
  year        = {2012},
}

@ARTICLE{Maekelae2006,
  author = {R. M\"{a}kel\"{a} and P. Dastidar and H. Jokela and O. Jaakkola and
	M. Saarela and R. Punnonen and T. Lehtim\"{a}ki},
  title = {Relation of myeloperoxidase promoter polymorphism and long-term hormone
	replacement therapy to oxidized low-density lipoprotein autoantibodies
	in postmenopausal women.},
  journal = {Scand J Clin Lab Invest},
  year = {2006},
  volume = {66},
  pages = {371--383},
  number = {5},
  abstract = {The myeloperoxidase enzyme (MPO) is a potent precursor of low-density
	lipoprotein (LDL) oxidation in atherosclerotic lesions. The MPO gene
	has a promoter polymorphism, 463G/A, which leads to high (GG) and
	low-expression (AG, AA) genotypes. Hormone replacement therapy (HRT)
	is known to affect MPO activity and LDL oxidation. The purpose of
	this study was to test whether the effect of HRT on the levels of
	oxLDL-ab varies according to MPO genotype.Eighty-seven postmenopausal
	women aged 45-71 years were divided into three groups based on the
	use of HRT. The HRT-EVP group (n = 25) used sequential estradiol
	valerate (EV) plus progestin, the HRT-EV group (n = 32) used EV alone,
	and the control group (n = 30) no HRT. MPO genotypes were determined
	by polymerase chain reaction (PCR) and oxLDL-ab by ELISA.We found
	a significant HRT group by MPO genotype interaction (p = 0.021) in
	plasma oxLDL-ab levels. In subjects with the GG genotype, the oxLDL-ab
	titer increased in the order of 2.13 in controls, 2.53 in the EV
	group and 3.21 in the EVP group (ANOVA for trend p = 0.006).The effects
	of HRT on LDL oxidation can vary according to MPO genotype and the
	concurrent progestin therapy with EV may counteract the more neutral
	effect of EV on LDL oxidation in subjects with the MPO high-expression
	genotype.},
  doi = {10.1080/00365510600727603},
  institution = {Laboratory of Atherosclerosis Genetics, Department of Clinical Chemistry,
	Centre for Laboratory Medicine, Tampere University Hospital, Finland.
	riikka.makela@uta.fi},
  owner = {pl4},
  pii = {V4L4713R03LU3087},
  pmid = {16901848},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1080/00365510600727603}
}

@MastersThesis{MacHarper1992,
  author    = {MacHarper, A. G.},
  title     = {Survival from Cancer and Socio-Economic Status in {South Australia}},
  type      = {o},
  owner     = {PaulD},
  school    = {University of Adelaide},
  timestamp = {2011.06.19},
  year      = {1992},
}

@ARTICLE{Mackenbach1990,
  author = {Mackenbach, J. P. and Bouvier-Colle, M. H. and Jougla, E.},
  title = {`{A}voidable' Mortality and Health Services: A Review of Aggregate
	Data Studies},
  journal = {Journal of Epidemiology and Community Health},
  year = {1990},
  volume = {44},
  pages = {106-111},
  timestamp = {2005.11.01}
}

@ARTICLE{MacLennan1989,
  author = {MacLennan, R.},
  title = {Cancer Prevention in {A}ustralia (Editorial)},
  journal = {Medical Journal of Australia},
  year = {1989},
  volume = {151},
  pages = {490-492},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Maclure1992,
  author = {M. Maclure and S. Greenland},
  title = {Tests for trend and dose response: misinterpretations and alternatives},
  journal = {American Journal of Epidemiology},
  year = {1992},
  volume = {135},
  pages = {96-104},
  number = {1},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Macready2012,
  author = {Macready, Norra},
  title = {Cancer patients connect on the Internet.},
  journal = {J Natl Cancer Inst},
  year = {2012},
  volume = {104},
  pages = {267--268},
  number = {4},
  month = {Feb},
  doi = {10.1093/jnci/djs130},
  file = {:pdf\\MacReady2012.pdf:PDF},
  keywords = {Health Literacy, trends; Humans; Internet; Neoplasms; Patients, psychology;
	Physician-Patient Relations; Self-Help Groups; Social Support},
  language = {eng},
  medline-pst = {ppublish},
  owner = {sanelo},
  pii = {djs130},
  pmid = {22327378},
  timestamp = {2013.10.17},
  url = {http://dx.doi.org/10.1093/jnci/djs130}
}

@ARTICLE{Magnusson1999,
  author = {C Magnusson and JA Baron and N Correia and R Bergstr\"{o}m and HO
	Adami and I Persson},
  title = {Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement
	therapy.},
  journal = {Int J Cancer},
  year = {1999},
  volume = {81},
  pages = {339-44},
  number = {3},
  month = {May},
  abstract = {While use of hormone-replacement therapy (HRT) effectively alleviates
	menopausal symptoms and prevents osteoporosis and possibly cardiovascular
	disease, there is concern of a detrimental impact on breast-cancer
	risk. There is a particular lack of data regarding the effect of
	long-term use of oestrogen-progestin combinations on breast-cancer
	risk. We conducted a large epidemiological study in {S}weden, where
	combined oestrogen-progestin treatment has been predominant, to examine
	the influence of different regimens of menopausal hormone therapy
	on breast-cancer risk. In this population-based case-control study,
	3,345 women aged 50 to 74 years with invasive breast cancer (84\%
	of all eligible) and 3,454 controls of similar age (82\% of all selected)
	were included. Mailed questionnaires and telephone interviews were
	used to collect detailed information on use of hormone replacement
	and on potential confounding factors. Odds ratios (OR) and 95\% confidence
	intervals (CI) were estimated through multiple logistic regression.
	There was a trend of increasing breast-cancer risk with duration
	of oestrogen/oestrogen-progestin use (OR for women treated at least
	10 years, 2.43; 95\% CI, 1.79-3.30, as compared to never-users),
	with statistically significant estimates only for women with BMI<27
	kg/m2. Excess risks were observed to current use and use that ceased
	more than 10 years ago (OR for women treated at least 5 years, OR
	was 2.68, 95\% CI, 2.09-3.42, and OR 2.57, 95\% CI, 1.28-5.15, as
	compared with never-users, respectively). A positive association
	which was noted for use of oestrogen combined with testosterone-derived
	progestins appeared especially pronounced with continuously combined
	regimens. Long-term use of replacement oestrogens with or without
	progestins may substantially increase the incidence of post-menopausal
	breast cancer, particularly among non-obese women.},
  owner = {PaulD},
  pii = {3.0.CO;2-6},
  timestamp = {2011.06.19}
}

@ARTICLE{Makuch1982,
  author = {R.W. Makuch},
  title = {Adjusted survival curve estimation using covariates},
  journal = {Journal of Chronic Diseases},
  year = {1982},
  volume = {35},
  pages = {437-443},
  file = {Makuch1982.pdf:Makuch1982.pdf:PDF;Makuch1982.pdf:pdf\\Makuch1982.pdf:PDF},
  owner = {pl4},
  timestamp = {2010.10.27}
}

@ARTICLE{mallett2010,
  author = {S. Mallett and P. Royston and R. Waters and S. Dutton and D. Altman},
  title = {Reporting performance of prognostic models in cancer: a review},
  journal = {BMC Medicine},
  year = {2010},
  volume = {8},
  number = {1},
  file = {mallett2010.pdf:mallett2010.pdf:PDF},
  owner = {BettyS},
  timestamp = {2016.11.28}
}

@ARTICLE{Mallows1998,
  author = {C. L. Mallows},
  title = {The zeroth problem},
  journal = {American Statistician},
  year = {1998},
  volume = {52},
  pages = {1--9},
  owner = {pl4},
  timestamp = {2011.01.14}
}

@Article{Manca2007,
  author      = {Andrea Manca and Paul C Lambert and Mark Sculpher and Nigel Rice},
  title       = {Cost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical modeling.},
  doi         = {10.1177/0272989X07302132},
  number      = {4},
  pages       = {471--490},
  url         = {http://dx.doi.org/10.1177/0272989X07302132},
  volume      = {27},
  abstract    = {Health care cost-effectiveness analysis (CEA) often uses individual
	patient data (IPD) from multinational randomized controlled trials.
	Although designed to account for between-patient sampling variability
	in the clinical and economic data, standard analytical approaches
	to CEA ignore the presence of between-location variability in the
	study results. This is a restrictive limitation given that countries
	often differ in factors that could affect the results of CEAs, such
	as the availability of health care resources, their unit costs, clinical
	practice, and patient case mix. The authors advocate the use of Bayesian
	bivariate hierarchical modeling to analyze multinational cost-effectiveness
	data. This analytical framework explicitly recognizes that patient-level
	costs and outcomes are nested within countries. Using real-life data,
	the authors illustrate how the proposed methods can be applied to
	obtain (a) more appropriate estimates of overall cost-effectiveness
	and associated measure of sampling uncertainty compared to standard
	CEA and (b) country-specific cost-effectiveness estimates that can
	be used to assess the between-location variability of the study results
	while controlling for differences in country-specific and patient-specific
	characteristics. It is demonstrated that results from standard CEA
	using IPD from multinational trials display a large degree of variability
	across the 17 countries included in the analysis, producing potentially
	misleading results. In contrast, "shrinkage estimates'' obtained
	from the modeling approach proposed here facilitate the appropriate
	quantification of country-specific cost-effectiveness estimates while
	weighting the results based on the level of information available
	within each country. The authors suggest that the methods presented
	here represent a general framework for the analysis of economic data
	collected from different locations.},
  file        = {manca2007.pdf:manca2007.pdf:PDF},
  institution = {Centre for Health Economics, University of York, UK. am126@york.ac.uk},
  journal     = {Medical Decision Making},
  owner       = {pl4},
  pii         = {0272989X07302132},
  pmid        = {17641141},
  timestamp   = {2008.10.15},
  year        = {2007},
}

@ARTICLE{manilich2011,
  author = {E. A. Manilich and R. P. Kiran and T. Radivoyevitch and I. Lavery
	and V. W. Fazio and F. H. Remzi},
  title = {A novel data-driven prognostic model for staging of colorectal cancer.},
  journal = {Journal of the American College of Surgeons},
  year = {2011},
  volume = {213},
  pages = {579ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Â“588},
  file = {manilich2011.pdf:manilich2011.pdf:PDF},
  owner = {BettyS},
  timestamp = {2016.11.28}
}

@ARTICLE{Manson2003,
  author = {Manson, JoAnn E. and Hsia, Judith and Johnson, Karen C. and Rossouw,
	Jacques E. and Assaf, Annlouise R. and Lasser, Norman L. and Trevisan,
	Maurizio and Black, Henry R. and Heckbert, Susan R. and Detrano,
	Robert and Strickland, Ora L. and Wong, Nathan D. and Crouse, John
	R. and Stein, Evan and Cushman, Mary and {Women's Health Initiative
	Investigators}},
  title = {Estrogen plus progestin and the risk of coronary heart disease.},
  journal = {N Engl J Med},
  year = {2003},
  volume = {349},
  pages = {523--534},
  number = {6},
  month = {Aug},
  abstract = {Recent randomized clinical trials have suggested that estrogen plus
	progestin does not confer cardiac protection and may increase the
	risk of coronary heart disease (CHD). In this report, we provide
	the final results with regard to estrogen plus progestin and CHD
	from the Women's Health Initiative (WHI).The WHI included a randomized
	primary-prevention trial of estrogen plus progestin in 16,608 postmenopausal
	women who were 50 to 79 years of age at base line. Participants were
	randomly assigned to receive conjugated equine estrogens (0.625 mg
	per day) plus medroxyprogesterone acetate (2.5 mg per day) or placebo.
	The primary efficacy outcome of the trial was CHD (nonfatal myocardial
	infarction or death due to CHD).After a mean follow-up of 5.2 years
	(planned duration, 8.5 years), the data and safety monitoring board
	recommended terminating the estrogen-plus-progestin trial because
	the overall risks exceeded the benefits. Combined hormone therapy
	was associated with a hazard ratio for CHD of 1.24 (nominal 95 percent
	confidence interval, 1.00 to 1.54; 95 percent confidence interval
	after adjustment for sequential monitoring, 0.97 to 1.60). The elevation
	in risk was most apparent at one year (hazard ratio, 1.81 [95 percent
	confidence interval, 1.09 to 3.01]). Although higher base-line levels
	of low-density lipoprotein cholesterol were associated with an excess
	risk of CHD among women who received hormone therapy, higher base-line
	levels of C-reactive protein, other biomarkers, and other clinical
	characteristics did not significantly modify the treatment-related
	risk of CHD.Estrogen plus progestin does not confer cardiac protection
	and may increase the risk of CHD among generally healthy postmenopausal
	women, especially during the first year after the initiation of hormone
	use. This treatment should not be prescribed for the prevention of
	cardiovascular disease.},
  institution = {and Harvard Medical School, Boston, MA 02215, USA. jmanson@rics.bwh.harvard.edu},
  language = {eng},
  medline-pst = {ppublish},
  owner = {Paul},
  pmid = {12904517},
  timestamp = {2012.06.20}
}

@ARTICLE{Mariotto1999b,
  author = {A. Mariotto and L. G. Dally and A. Micheli and F. Canario and A.
	Verdecchia},
  title = {Cancer prevalence in Italian regions with local cancer registries.},
  journal = {Tumori},
  year = {1999},
  volume = {85},
  pages = {400--407},
  number = {5},
  abstract = {OBJECTIVE: To provide estimates and projections of cancer incidence
	and prevalence for those Italian regions whose population is partially
	covered by a cancer registry (CR) and to determine to what extent
	local CRs can be considered representative of the region, thus improving
	the potential of the information provided by CRs. METHODS: A statistical
	method, MIAMOD (mortality-incidence analysis model), was used to
	estimate regional cancer incidence and prevalence from regional cancer
	mortality data and patient survival data recorded by the cancer registries.
	Estimates of the cancer incidence and prevalence in the various regions
	have thus been obtained for a number of major cancer sitas. A first
	and important step in validating the regional estimates has been
	the comparison of the MIAMOD estimates in the areas covered by the
	cancer registries with empirical incidence and prevalence observed
	by CRs, in order to assess the consistency in data, methods and assumptions.
	Empirical prevalence has been calculated by counting patients with
	a diagnosis of cancer who were alive on the reference date by PREVAL
	method. A correction factor has been applied to include patients
	diagnosed before the period of activity of the registry. RESULTS:
	General consistency was found between empirical and estimated (by
	MIAMOD) incidence and prevalence in the registry areas, which is
	indicative of the quality and the completeness of all data involved
	as well as the appropriateness of model choices. The prevalence of
	all cancers combined for Italian regions with CRs was estimated and
	projected to the year 2000 as ranging between 1,240 per 100,000 in
	Sicilia and 2,781 in Emilia-Romagna for men, while for women these
	figures were 1,765 in Sicilia and 4,019 in Liguria. Comparison of
	cancer prevalence in CR areas with regional estimates shows quite
	good consistency for Piemonte, Liguria and Lombardia, which means
	that the local CRs (of Torino, Genova and Varese, respectively) are
	representative of their respective regions. Prevalence in Emilia-Romagna
	appears to be rather well represented by only one, the Parma CR,
	of the three local CRs. The southern Italian registries of Latina
	and Ragusa recorded a lower cancer prevalence than was actually estimated
	in their respective regions. DISCUSSION: Cancer registries with a
	longer period of activity showed better agreement between empirical
	and estimated figures due to the more precise information provided,
	particularly regarding survival and incidence trends. In conclusion,
	this work shows the potential of the cancer registries not only to
	represent their population with respect to cancer morbidity but also
	as an invaluable tool to extrapolate this information to the larger
	areas they represent.},
  institution = {Superior Institute of Health, Rome, Italy. Verde3@ISS.it},
  owner = {pl4},
  pmid = {10665857},
  timestamp = {2009.10.13}
}

@Article{Mariotto2014,
  author      = {Mariotto, Angela B. and Noone, Anne-Michelle and Howlader, Nadia and Cho, Hyunsoon and Keel, Gretchen E. and Garshell, Jessica and Woloshin, Steven and Schwartz, Lisa M.},
  title       = {Cancer survival: an overview of measures, uses, and interpretation.},
  journal     = {J Natl Cancer Inst Monogr},
  year        = {2014},
  language    = {eng},
  volume      = {2014},
  number      = {49},
  pages       = {145--186},
  doi         = {10.1093/jncimonographs/lgu024},
  url         = {http://dx.doi.org/10.1093/jncimonographs/lgu024},
  abstract    = {Survival statistics are of great interest to patients, clinicians,
	researchers, and policy makers. Although seemingly simple, survival
	can be confusing: there are many different survival measures with
	a plethora of names and statistical methods developed to answer different
	questions. This paper aims to describe and disseminate different
	survival measures and their interpretation in less technical language.
	In addition, we introduce templates to summarize cancer survival
	statistic organized by their specific purpose: research and policy
	versus prognosis and clinical decision making.},
  file        = {Mariotto2014.pdf:pdf/Mariotto2014.pdf:PDF;Mariotto2014.pdf:Mariotto2014.pdf:PDF},
  institution = {Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD (AM, AN, NH, HC); Division of Cancer Registration and Surveillance, National Cancer Center, Goyang-si Gyeonggi-do, Korea (HC); Information Management Services, Inc., Calverton MD (GEK, JG); Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH, Geisel School of Medicine at Dartmouth, Hanover, NH, Department of Veterans Affairs Medical Center, Veterans Affairs Outcomes Group, White River Junction, VT (SW, LMS).},
  medline-pst = {ppublish},
  owner       = {PaulD},
  pii         = {lgu024},
  pmid        = {25417231},
  timestamp   = {2014.12.01},
}

@ARTICLE{Mariotto2013,
  author = {Mariotto, Angela B. and Wang, Zhuoqiao and Klabunde, Carrie N. and
	Cho, Hyunsoon and Das, Barnali and Feuer, Eric J.},
  title = {Life tables adjusted for comorbidity more accurately estimate noncancer
	survival for recently diagnosed cancer patients.},
  journal = {J Clin Epidemiol},
  year = {2013},
  volume = {66},
  pages = {1376--1385},
  number = {12},
  month = {Dec},
  abstract = {To provide cancer patients and clinicians with more accurate estimates
	of a patient's life expectancy with respect to noncancer mortality,
	we estimated comorbidity-adjusted life tables and health-adjusted
	age.Using data from the Surveillance Epidemiology and End Results-Medicare
	database, we estimated comorbidity scores that reflect the health
	status of people who are 66 years of age and older in the year before
	cancer diagnosis. Noncancer survival by comorbidity score was estimated
	for each age, race, and sex. Health-adjusted age was estimated by
	systematically comparing the noncancer survival models with US life
	tables.Comorbidity, cancer status, sex, and race are all important
	predictors of noncancer survival; however, their relative impact
	on noncancer survival decreases as age increases. Survival models
	by comorbidity better predicted noncancer survival than the US life
	tables. The health-adjusted age and national life tables can be consulted
	to provide an approximate estimate of a person's life expectancy,
	for example, the health-adjusted age of a black man aged 75 years
	with no comorbidities is 67 years, giving him a life expectancy of
	13 years.The health-adjusted age and the life tables adjusted by
	age, race, sex, and comorbidity can provide important information
	to facilitate decision making about treatment for cancer and other
	conditions.},
  doi = {10.1016/j.jclinepi.2013.07.002},
  file = {Mariotto2013.pdf:Mariotto2013.pdf:PDF;Mariotto2013.pdf:pdf\\Mariotto2013.pdf:PDF},
  institution = {Division of Cancer Control and Population Sciences, National Cancer
	Institute, 9609 Medical Center Drive, Bethesda, MD 20892, USA. Electronic
	address: mariotta@mail.nih.gov.},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pii = {S0895-4356(13)00266-7},
  pmid = {24035494},
  timestamp = {2014.02.11},
  url = {http://dx.doi.org/10.1016/j.jclinepi.2013.07.002}
}

@ARTICLE{Mariotto2006,
  author = {Angela B Mariotto and Margaret N Wesley and Kathleen A Cronin and
	Karen A Johnson and Eric J Feuer},
  title = {Estimates of long-term survival for newly diagnosed cancer patients:
	a projection approach.},
  journal = {Cancer},
  year = {2006},
  volume = {106},
  pages = {2039--2050},
  number = {9},
  month = {May},
  abstract = {BACKGROUND: Patients with newly diagnosed cancer may request an estimate
	of their prospects for long-term survival. Unfortunately, standard
	estimates of survival may be outdated, because they do not reflect
	recent advances. The authors present a projection method that incorporates
	trends in survival and provides more up-to-date estimates of long-term
	survival for newly diagnosed patients. METHODS: The projection method
	fits a regression model to interval relative survival and includes
	a parameter associated with a trend on diagnosis year. The cumulative
	relative survival rate (CRS) in a target year is calculated by multiplying
	the projected interval survival rates for that year. To investigate
	the predictive ability of the projection approach and to develop
	model-selection rules, data from the Surveillance, Epidemiology,
	and End Results Program and the Connecticut tumor registry were used
	to recreate data that were available at a particular time in the
	past, and those data were used to project survival for specified
	target years. RESULTS: The projection method was better at predicting
	the survival of recently diagnosed patients than current methods,
	especially long-term survival for patients who had disease sites
	with an increasing and stable trend in survival. The authors predicted
	that the 15-year CRS for patients who were diagnosed in 2003 will
	be 61\% for all cancer sites combined, 57\% for colorectal cancer,
	82\% for female breast cancer, 53\% for ovarian cancer, and 97\%
	for prostate cancer. CONCLUSIONS: Although the projection method
	was more speculative than other methods that are aligned more closely
	with current observed data, it offered the possibility of providing
	improved estimates of long-term survival for recently diagnosed patients.
	Caution should be used when applying these methods for cancer sites
	where there has been a dramatic uptake of screening, e.g., prostate
	cancer, for which the projected results may be overly optimistic.},
  doi = {10.1002/cncr.21803},
  file = {Mariotto2006b.pdf:Mariotto2006b.pdf:PDF},
  institution = {Division of Cancer Control and Population Sciences, National Cancer
	Institute, National Institutes of Health, Bethesda, Maryland 20892,
	USA. mariotta@mail.nih.gov},
  owner = {pl4},
  pmid = {16572414},
  timestamp = {2009.10.13},
  url = {http://dx.doi.org/10.1002/cncr.21803}
}

@ARTICLE{Marsh1999,
  author = {GM Marsh and LJ Lucas and AO Youk and LC Schall},
  title = {Mortality patterns among workers exposed to acrylamide: 1994 follow
	up},
  journal = {Occup Environ Med},
  year = {1999},
  volume = {56},
  pages = {181--190},
  number = {3},
  eprint = {http://oem.bmjjournals.com/cgi/reprint/56/3/181.pdf},
  owner = {PaulD},
  timestamp = {2011.06.19},
  url = {http://oem.bmjjournals.com/cgi/content/abstract/56/3/181}
}

@ARTICLE{Marshall2009,
  author = {Marshall, A. and Altman, D. G. and Holder, R. L. and Royston, P.},
  title = {Combining estimates of interest in prognostic modelling studies after
	multiple imputation: current practice and guidelines},
  journal = {BMC Medical Research Methodology},
  year = {2009},
  volume = {9},
  pages = {1-8},
  file = {Marshall2009.pdf:pdf\\Marshall2009.pdf:PDF;Marshall2009.pdf:Marshall2009.pdf:PDF},
  owner = {hanbow},
  timestamp = {2016.08.18}
}

@ARTICLE{Marubini1990,
  author = {E. Marubini and G. Mezzanotte and P. Boracchi and U. Veronesi},
  title = {Long term survival analysis: breast cancer and age at diagnosis.},
  journal = {Statistics in Medicine},
  year = {1990},
  volume = {9},
  pages = {737--748},
  number = {7},
  month = {Jul},
  abstract = {The role of age at surgery of breast cancer patients as a determinant
	of relative survival after making allowance for clinical profile
	was investigated on a case series of 716 women followed for more
	than 20 years in one single institution. Multiplicative and additive
	models for grouped data were adopted to model the standardized mortality
	ratio and the excess death rate respectively. The models were fitted
	by the GLIM system assuming a Poisson error function. We conclude
	that operable breast cancer has a relatively lower impact on total
	mortality in older patients (65 years or more) than in younger ones
	and, moreover, the older patients have a more favourable course.},
  file = {Marubini1990.pdf:Marubini1990.pdf:PDF;Marubini1990.pdf:pdf\\Marubini1990.pdf:PDF},
  institution = {Institute of Medical Statistics and Biometry, University of Milan,
	Italy.},
  owner = {pl4},
  pmid = {2218177},
  timestamp = {2008.12.16}
}

@Book{Marubini1995,
  author    = {Marubini, E. and Valsecchi, M. G. and Emmerson, M.},
  title     = {Analysing Survival Data from Clinical Trials and Observational Studies},
  publisher = {John Wiley \& Sons},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@ARTICLE{Massonnet2002,
  author = {Massonnet, Blandine and Simon, Jean-Christophe and Weisser, Wolfgang
	W.},
  title = {Metapopulation structure of the specialized herbivore Macrosiphoniella
	tanacetaria (Homoptera, Aphididae).},
  journal = {Mol Ecol},
  year = {2002},
  volume = {11},
  pages = {2511--2521},
  number = {12},
  month = {Dec},
  abstract = {We investigated population dynamics, genetic diversity and spatial
	structure in the aphid species Macrosiphoniella tanacetaria, a specialist
	herbivore feeding on tansy, Tanacetum vulgare. Tansy plants (genets)
	consist of many shoots (ramets), and genets are grouped in sites.
	Thus, aphids feeding on tansy can cluster at the level of ramets,
	genets and sites. We studied aphid population dynamics in 1997 and
	2001 and found that within sites: (i). at any time, aphids used only
	a fraction of the available ramets and genets; (ii). at the level
	of ramets, most aphid colonies survived only one week; (iii). at
	the level of genets, mean survival time was less than 4 weeks; and
	(iv). colonization and extinction events occurred throughout the
	season. We sampled aphids in seven sites in the Alsace region, France
	(4-45 km apart) and two sites in Germany in 1999 to study genetic
	structure within and between populations. Genetic analyses using
	nine microsatellite loci showed that: (i). genotypic variability
	was high, (ii). none of the populations was in Hardy-Weinberg equilibrium,
	(iii). heterozygote deficits and linkage disequilibria were frequent,
	and (iv). all populations were genetically differentiated, even at
	a small geographical scale. Renewed sampling of the Alsace sites
	in 2001 showed that three populations had become extinct and significant
	genetic changes had occurred in the remaining four populations. The
	frequencies of extinction and colonization events at several spatial
	scales suggest a hierarchical metapopulation structure for M. tanacetaria.
	Frequent population turnover and drift are likely causes for the
	genetic differentiation of M. tanacetaria populations.},
  institution = {Zoology Institute, University of Basel, Rheinsprung 9, 4051 Basel,
	Switzerland. blandine.massonnet@gmx.net},
  keywords = {Animals; Aphids, genetics/growth /&/ development; Computer Simulation;
	DNA, chemistry/genetics; Female; France; Genetic Variation; Germany;
	Male; Microsatellite Repeats, genetics; Parthenogenesis; Polymerase
	Chain Reaction; Population Dynamics; Statistics, Nonparametric; Tanacetum,
	parasitology},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {1633},
  pmid = {12453236},
  timestamp = {2013.05.29}
}

@ARTICLE{Matsuyama1998,
  author = {Y. Matsuyama and J. Sakamoto and Y. Ohashi},
  title = {A Bayesian hierarchical survival model for the institutional effects
	in a multi-centre cancer clinical trial.},
  journal = {Statistics in Medicine},
  year = {1998},
  volume = {17},
  pages = {1893--1908},
  number = {17},
  month = {Sep},
  abstract = {In randomized clinical trials comparing treatment effects on diseases
	such as cancer, a multi-centre trial is usually conducted to accrue
	the required number of patients in a reasonable period of time. While
	we interpret the average treatment effect, it is necessary to examine
	the homogeneity of the observed treatment effects across institutions,
	that is, treatment-by-institution interaction. If the homogeneity
	is confirmed, the conclusions concerning treatment effects can be
	generalized to a broader patient population. In this paper, a Bayesian
	hierarchical survival model is used to investigate the institutional
	effects on the efficacy of treatment as well as on the baseline risk.
	The marginal posterior distributions are estimated by a Markov chain
	Monte Carlo method, that is, Gibbs sampling, to overcome current
	computational limitations. The robustness of the inferences to the
	distributional assumption for the random effects is also examined.
	We illustrate the methods with analyses of data from a multi-centre
	cancer clinical trial, which investigated the efficacy of immunochemotherapy
	as an adjuvant treatment after curative resection of gastric cancer.
	In this trial there is little difference in the treatment effects
	across institutions and the treatment is shown to be effective, while
	there appears to be substantial variation in the baseline risk across
	institutions. This result indicates that the observed treatment effects
	might be generalized to a broader patient population.},
  file = {Matsuyama1998.pdf:Matsuyama1998.pdf:PDF;Matsuyama1998.pdf:pdf\\Matsuyama1998.pdf:PDF},
  institution = {School of Health Sciences and Nursing, University of Tokyo, Japan.
	matuyama@epistat.m.u-tokyo.ac.jp},
  owner = {pl4},
  pii = {3.0.CO;2-R},
  pmid = {9777685},
  timestamp = {2008.11.18}
}

@ARTICLE{Maukonen2006,
  author = {Johanna Maukonen and Jaana M\"{a}tt\"{o} and Reetta Satokari and
	Hans S\"{o}derlund and Tiina Mattila-Sandholm and Maria Saarela},
  title = {PCR DGGE and RT-PCR DGGE show diversity and short-term temporal stability
	in the Clostridium coccoides-Eubacterium rectale group in the human
	intestinal microbiota.},
  journal = {FEMS Microbiol Ecol},
  year = {2006},
  volume = {58},
  pages = {517--528},
  number = {3},
  month = {Dec},
  abstract = {As the Clostridium coccoides-Eubacterium rectale (Erec; clostridial
	phylogenetic cluster XIVa) group is one of the major groups of the
	human intestinal microbiota, DNA- and RNA-based population analysis
	techniques (denaturing gradient gel electrophoresis; DGGE) were developed
	and applied to assess the diversity and temporal stability (6 months-2
	years) of this faecal clostridial microbiota in 12 healthy adults.
	The stability of the Erec group was compared with the stability of
	the predominant bacterial microbiota, which was also assessed with
	PCR-DGGE. In addition, the Erec group was quantified with a hybridization-based
	method. According to our results, the Erec group was diverse in each
	subject, but interindividual uniqueness was not as clear as that
	of the predominant bacteria. The Erec group was found to be temporally
	as stable as the predominant bacteria. Over 200 clones obtained from
	two samples proved the developed method to be specific. However,
	the amount of bacteria belonging to the Erec group was not related
	to the diversity of that same bacterial group. In conclusion, the
	newly developed DGGE method proved to be a valuable and specific
	tool for the direct assessment of the stability of the Erec group,
	demonstrating diversity in addition to short-term stability in most
	of the subjects studied.},
  doi = {10.1111/j.1574-6941.2006.00179.x},
  institution = {VTT Technical Research Centre of Finland, Espoo, Finland. johanna.maukonen@vtt.fi},
  owner = {pl4},
  pii = {FEM179},
  pmid = {17117993},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1111/j.1574-6941.2006.00179.x}
}

@Book{McClelland1991,
  author    = {McClelland, A.},
  title     = {In Fair Health? {E}quity and the Health Care System},
  publisher = {Melbourne: National Health Strategy},
  series    = {Background Paper No.\ 3},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1991},
}

@Book{Mccullagh1989,
  author    = {McCullagh, P. and Nelder, J. A.},
  title     = {Generalized Linear Models},
  edition   = {2},
  publisher = {London: Chapman and Hall},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1989},
}

@ARTICLE{Mckean2003,
  author = {M. C. Mckean and C. Hewitt and P. C. Lambert and St Myint and M.
	Silverman},
  title = {An adult model of exclusive viral wheeze: inflammation in the upper
	and lower respiratory tracts.},
  journal = {Clin Exp Allergy},
  year = {2003},
  volume = {33},
  pages = {912--920},
  number = {7},
  month = {Jul},
  abstract = {BACKGROUND: We have previously reported an experimental infection
	of young adults with a history of episodic and exclusive viral wheeze
	(EVW) using human coronavirus, in which 16 of 24 with EVW (15 atopic)
	and 11 of 19 healthy controls (seven atopic) developed a symptomatic
	cold with evidence of infection, but only those with EVW developed
	lower respiratory tract symptoms and increased airway responsiveness.
	OBJECTIVE: The aim of this study was to compare the EVW and control
	groups from this study for inflammatory changes occurring in the
	upper and lower respiratory tracts during the experimental infection,
	in particular, to determine whether eosinophil-driven inflammation
	was associated with EVW. METHODS: Nasal lavage and induced sputum
	were collected prior to inoculation (day 0) and 2, 4 and 17 days
	later. Differential cell counts were performed and supernatant was
	assayed for IL-8, IL-5, IFN-gamma, and eosinophilic cationic protein
	(ECP). RESULTS: There was no difference between the two groups in
	any measurement at baseline. In both groups, during colds the volume
	of nasal secretion increased as did leucocyte counts in both upper
	and lower respiratory tracts. A modest increase in nasal neutrophil
	count was seen in both EVW and control groups with symptomatic colds
	on day 2 (median (quartile) difference from baseline 5.4 (0.0, 11.0)
	and 1.8 (-1.1, 2.2)x10(4)/mL of secretions, respectively). The change
	in nasal neutrophil counts in all subjects correlated with nasal
	symptom scores. A significant relative increase in sputum differential
	neutrophil count was seen on day 4 in the EVW group with a cold but
	not in controls (mean difference (95\% confidence interval) 20.4
	(9.6, 31.1)\% and 3.1 (-8.2, 14.5)\%, respectively, P<0.01); however,
	this increase did not correlate with lower respiratory tract symptom
	scores. IL-8 increased in both the upper and lower respiratory tracts
	in both EVW and control subjects with colds, the largest change being
	seen on day 4 in the sputum of those with EVW (mean difference from
	baseline (95\% confidence interval) 2.5 (0.55-4.46) ng/mL). Only
	modest changes were seen in IFN-gamma and no changes were seen in
	IL-5 or ECP. None of the results was influenced by the atopic status
	of the subjects in either group. CONCLUSIONS: EVW wheeze is characterized
	by neutrophilic inflammation in both the upper and lower respiratory
	tracts without eosinophilia (even in atopic subjects). IL-8 is likely
	to be an important chemokine in this process. Symptoms and airway
	responsiveness were correlated with change in neutrophils.},
  file = {Mckean2003.pdf:Mckean2003.pdf:PDF;Mckean2003.pdf:pdf\\Mckean2003.pdf:PDF},
  institution = {Department of Respiratory Paediatrics, Royal Victoria Infirmary,
	Newcastle upon Tyne, UK. Michael.Mckean@nuth.northy.nhs.uk},
  owner = {pl4},
  pii = {1715},
  pmid = {12859447},
  timestamp = {2008.10.15}
}

@ARTICLE{Mckean2001,
  author = {M. C. Mckean and M. Leech and P. C. Lambert and C. Hewitt and S.
	Myint and M. Silverman},
  title = {A model of viral wheeze in nonasthmatic adults: symptoms and physiology.},
  journal = {Eur Respir J},
  year = {2001},
  volume = {18},
  pages = {23--32},
  number = {1},
  month = {Jul},
  abstract = {Episodic wheezing associated with viral infections of the upper respiratory
	tract (URT) is a common problem in young children but also occurs
	in adults. It is hypothesized that an experimental infection with
	human coronavirus (HCoV), the second most prevalent common cold virus,
	would cause lower respiratory tract (LRT) changes in adults with
	a history of viral wheeze. Twenty-four viral wheezers (15 atopic)
	and 19 controls (seven atopic) were inoculated with HCoV 229E and
	monitored for the development of symptoms, changes in airway physiology
	and provocative concentration of methacholine causing a 20\% fall
	in forced expiratory volume in one second (FEV1) (PC20). At baseline,
	viral wheezers were similar to controls in PC20 (mean+/-SD log2PC20:
	5.1+/-1.9 and 5.8+/-1.4 g x L(-1), respectively) but had a lower
	FEV1 than controls (mean+/-SD 85.8+/-11.4 and 95.6+/-13.2\% predicted,
	respectively p < 0.05). Nineteen viral wheezers and 11 controls developed
	colds. Viral wheezers with colds reported significantly more URT
	symptoms than controls (median scores (interquartile range): 24 (10-37)
	and 6 (4-15), respectively p = 0.014). Sixteen viral wheezers and
	no controls reported LRT symptoms (wheeze, chest tightness and shortness
	of breath). The viral wheezers with colds had small (3-4\%) reductions
	in FEV1 and peak expiratory flow on days with LRT symptoms (days
	3-6), but a progressive reduction in PC20 from baseline on days 2,
	4 and 17 after inoculation (by 0.82, 1.35 and 1.82 doubling concentrations,
	respectively). The fall in PC20 affected both atopic and nonatopic
	subjects equally. There were no changes in FEV1 or PC20 in controls.
	An adult model of viral wheeze that is independent of atopy and therefore,
	of classical atopic asthma was established.},
  file = {Mckean2001.pdf:Mckean2001.pdf:PDF;Mckean2001.pdf:pdf\\Mckean2001.pdf:PDF},
  institution = {Dept of Child Health, University of Leicester, UK.},
  owner = {pl4},
  pmid = {11510797},
  timestamp = {2008.10.15}
}

@ARTICLE{McKnight1999,
  author = {B. McKnight and L. S. Cook and N. S. Weiss},
  title = {Logistic regression analysis for more than one characteristic of
	exposure.},
  journal = {Am J Epidemiol},
  year = {1999},
  volume = {149},
  pages = {984--992},
  number = {11},
  month = {Jun},
  abstract = {When more than one characteristic of an exposure is under study, it
	is easy to misinterpret the results of a logistic regression analysis
	that incorporates terms for each characteristic. For example, in
	a study of the risk of endometrial cancer in relation to the duration
	and the recency of use of estrogen replacement therapy (ERT), simultaneously
	including terms for duration and recency of exposure to ERT in a
	logistic model may leave the mistaken impression that it is possible
	to adjust for recency when a given duration of ERT use is compared
	with no use. In this article, the authors show why such an adjusted
	comparison is impossible, and they discuss several pitfalls in the
	interpretation of logistic regression coefficients when two or more
	characteristics of exposure are under study. They also suggest a
	method for avoiding these pitfalls.},
  file = {:pdf\\Mcknight1999.pdf:PDF},
  institution = {Department of Biostatistics, University of Washington, and Fred Hutchinson
	Cancer Research Center, Seattle 98195-7232, USA.},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pmid = {10355373},
  timestamp = {2011.07.17},
  url = {http://aje.oxfordjournals.org/content/149/11/984.long}
}

@ARTICLE{McMurdo2005,
  author = {M. E. T. McMurdo and M. D. Witham and N. D. Gillespie},
  title = {Including older people in clinical research.},
  journal = {BMJ},
  year = {2005},
  volume = {331},
  pages = {1036--1037},
  number = {7524},
  month = {Nov},
  doi = {10.1136/bmj.331.7524.1036},
  file = {McMurdo2005.pdf:McMurdo2005.pdf:PDF;McMurdo2005.pdf:pdf\\McMurdo2005.pdf:PDF},
  owner = {pl4},
  pii = {331/7524/1036},
  pmid = {16269472},
  timestamp = {2010.03.24},
  url = {http://dx.doi.org/10.1136/bmj.331.7524.1036}
}

@ARTICLE{McPherson1981,
  author = {McPherson, K. and Strong, P. M. and Hovind, O. B. and Clifford, P.},
  title = {Regional Variations in the Use of Common Surgical Procedures Within
	and Between {E}ngland and {W}ales, {C}anada and the {U}nited {S}tates
	of {A}merica},
  journal = {Social Science \& Medicine},
  year = {1981},
  volume = {15},
  pages = {273-288},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{McPherson1982,
  author = {McPherson, K. and Wennberg, J. E. and Epstein, A. and Jones, L.},
  title = {Small Area Variations in the use of Common Surgical Procedures: {A}n
	International Comparison of {N}ew {E}ngland, {E}ngland and {N}orway},
  journal = {New England Journal of Medicine},
  year = {1982},
  volume = {307},
  pages = {1310-1314},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Merimsky2000,
  author = {Merimsky, O. and Lepechoux, C. and Terrier, P. and Vanel, D. and
	Delord, J. P. and LeCesne, A.},
  title = {Primary sarcomas of the central nervous system.},
  journal = {Oncology},
  year = {2000},
  volume = {58},
  pages = {210--214},
  number = {3},
  month = {Apr},
  abstract = {The medical files of 14 patients with primary brain and spine sarcomas
	were retrospectively reviewed. Ten patients had primary brain sarcomas
	and 4 primary spinal sarcomas. The tumors probably originated in
	the brain substance or blood vessels, in the meninges or in the inner
	aspect of the skull. The spinal tumors originated in the nerve roots
	of the cauda equina and in the spinal substance or blood vessels.
	The most common type was angiosarcoma. Removal of the brain tumors
	was performed in 95\% of the patients. Radiotherapy was delivered
	to 6 patients with brain sarcomas and to all patients with primary
	spinal sarcomas. Metastatic disease to the lung or pleural effusion
	was evident in 2 patients who underwent total removal of their tumors
	followed by radiation therapy.},
  doi = {12102},
  institution = {Unit of Bone and Soft Tissue Sarcomas, Department of Medicine, Institut
	Gustav Roussy, Villejuif, France. merimsky@zahav.net.il},
  keywords = {Adolescent; Adult; Aged; Brain Neoplasms, etiology/pathology/radiotherapy/surgery/therapy;
	Female; Humans; Male; Medical Records; Middle Aged; Neurilemmoma,
	pathology; Radiotherapy, Adjuvant; Retrospective Studies; Sarcoma,
	etiology/pathology/radiotherapy/surgery/therapy; Spinal Cord Neoplasms,
	etiology/pathology/radiotherapy/surgery/therapy; Survival Analysis;
	Treatment Outcome},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {12102},
  pmid = {10765122},
  timestamp = {2013.05.29},
  url = {http://dx.doi.org/12102}
}

@MastersThesis{Mertsching2013,
  author    = {J. Mertsching},
  title     = {A comparison of different approaches to nonparametric inference for subdistribution. Masters thesis in mathematics.},
  url       = {https://esc.fnwi.uva.nl/thesis/centraal/files/f191267511.pdf},
  owner     = {pl4},
  school    = {University of Amsterdam},
  timestamp = {2016.08.10},
  year      = {2013},
}

@Article{Messori1999,
  author      = {Messori, A. and Trippoli, S.},
  title       = {A new method for expressing survival and life expectancy in lifetime cost-effectiveness studies that evaluate cancer patients (review).},
  language    = {eng},
  number      = {5},
  pages       = {1135--1141},
  volume      = {6},
  abstract    = {The methodology of cost-effectiveness studies that use a lifetime
	perspective is based on the extrapolation to infinity of the survival
	curves. However, the research in this methodological area is at an
	initial phase. Hence, adequate techniques for survival curve extrapolation
	still need to be devised for handling the different clinical settings
	that can be analysed by cost-effectiveness survival studies. After
	a brief overview of the two most commonly used extrapolation methods
	(Markov decision-tree model and Gompertz technique), we describe
	a new method for expressing lifetime survival in cost-effectiveness
	studies that evaluate cancer patients. Our method extrapolates to
	infinity a traditional survival curve by assigning a normal life
	expectancy to patients (or long-term survivors). In this way, the
	value of mean lifetime survival (MLS) for the patient cohort under
	study can be determined using a lifetime perspective. This value
	can be employed in lifetime cost-effectiveness analyses that compare
	different forms of intervention for that disease condition. A separate
	section of our method compares the overall survival pattern of cured
	and not cured patients with that of a reference healthy population
	to assess the impact of the disease on life expectancy. As an example
	of the application of our method, we reanalysed a survival data set
	reported by Spinolo et al in 1992, that refers to patients with acute
	leukaemia who relapsed after their first allogeneic bone marrow transplantation
	and who received a second transplant (n=17, mean age at relapse =
	26 years). The use of our extrapolation method provided the following
	results: MLS for leukaemia patients = 105.9 months per patient or
	8.8 years per patient; MLS for the reference cohort of healthy subjects
	= 583.8 months per patient or 48.6 years per patient. We conclude
	that the extrapolation technique described herein can be useful to
	handle lifetime survival data in cost-effectiveness analysis.},
  institution = {Laboratorio di Farmacoeconomia, c/o Drug Information Centre, Azienda Careggi, 50134 Firenze, Italy.},
  journal     = {Oncology Reports},
  keywords    = {Cost-Benefit Analysis; Humans; Life Expectancy; Methods; Neoplasms, economics/physiopathology; Survival Analysis},
  medline-pst = {ppublish},
  owner       = {theand},
  pmid        = {10425315},
  timestamp   = {2012.09.17},
  year        = {1999},
}

@ARTICLE{Metcalfe2007,
  author = {Metcalfe, Chris and Thompson, Simon G.},
  title = {Wei, Lin and Weissfeld's marginal analysis of multivariate failure
	time data: should it be applied to a recurrent events outcome?},
  journal = {Stat Methods Med Res},
  year = {2007},
  volume = {16},
  pages = {103--122},
  number = {2},
  month = {Apr},
  abstract = {Wei, Lin and Weissfeld (WLW) have applied an elaboration of Cox's
	proportional hazards regression to the analysis of recurrent events
	data. This application is controversial and has attracted criticism
	in a piecemeal fashion over 15 years. A frequently raised concern
	is the method's 'risk set': each individual is considered to be at
	risk of all recurrent events from the start of the observation period.
	The WLW method often gives estimates that exceed those provided by
	alternative approaches. This paper investigates whether the estimates
	are a consequence of biased estimation, or reflect a particular aspect
	of the treatment effect. Simulation studies show that the WLW method
	infringes the proportional hazards assumption when applied to recurrent
	events data, but that the bias this may cause is not behind the distinctive
	effect estimates. Instead, the method's risk set is demonstrated
	to be responsible, leading to discussion of the interpretation of
	the treatment effect being estimated. Analyses of medical data indicate
	that the infringement of the proportional hazards assumption is not
	necessarily greater than that experienced with other applications
	of proportional hazards regression and need not prohibit the application
	of WLW's method to recurrent events data.},
  file = {Metcalfe2007.pdf:Metcalfe2007.pdf:PDF},
  institution = {Department of Social Medicine, University of Bristol, Canynge Hall,
	Bristol, UK. chris.metcalfe@bristol.ac.uk},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {17484295},
  timestamp = {2012.05.08}
}

@ARTICLE{Mettlin1989,
  author = {C Mettlin},
  title = {Trends in years of life lost to cancer: 1970-1985},
  journal = {CA Cancer J Clin},
  year = {1989},
  volume = {39(1)},
  pages = {33-39},
  file = {Mettlin1989.pdf:Mettlin1989.pdf:PDF;Mettlin1989.pdf:pdf\\Mettlin1989.pdf:PDF},
  owner = {theand},
  timestamp = {2012.09.14}
}

@ARTICLE{Meyer2004,
  author = {Meyer, Ralph M. and Ambinder, Richard F. and Stroobants, Sigrid},
  title = {Hodgkin's lymphoma: evolving concepts with implications for practice.},
  journal = {Hematology Am Soc Hematol Educ Program},
  year = {2004},
  pages = {184--202},
  abstract = {Hodgkin's lymphoma is a unique neoplasm of B lymphocytes. Recent data
	provide new understandings of the pathogenesis and options for staging
	and therapy of the disease. Three specific topics are addressed in
	this chapter. In Section I, Dr. Richard Ambinder reviews implications
	of the relationship of Epstein-Barr virus (EBV) and Hodgkin's lymphoma.
	This relation includes varying geographic epidemiologic associations,
	including varying associations with the clinical syndrome of infectious
	mononucleosis. There are plausible mechanisms, including processes
	initiated by viral proteins, by which EBV might lead to tumorigenesis.
	These mechanisms include promotion of genetic instability and alteration
	of normal processes of apoptosis. In addition to an epidemiologic
	association and potential role in pathogenesis, viral antigens may
	pose theoretical targets for anti-cancer therapies, including vaccination.
	In Section II, Dr. Sigrid Stroobants describes the potential role
	of positron emission tomographic (PET) scanning. By assessing differences
	in the metabolic activities of cancer cells, PET scanning may be
	superior to computerized tomographic scanning, which is limited to
	showing structural anatomical abnormalities. In patients with Hodgkin's
	and non-Hodgkin's lymphoma, PET scanning has been tested as an initial
	staging tool, to assess the rate of therapeutic response from a prognostic
	perspective, and to differentiate residual tumor from fibrotic masses
	in patients who have completed therapy. Particularly in assessing
	the nature of a residual mass seen with other post-therapeutic imaging
	modalities, PET scanning may provide unique information; very high
	negative predictive values have been reported. However, before this
	technology can be recommended for incorporation into standard management,
	properly conducted prospective trials are required to better evaluate
	the clinical utility of PET with respect to eventual patient outcomes.
	In Section III, Dr. Ralph Meyer reviews current data regarding the
	management of patients with limited-stage Hodgkin's lymphoma. Over
	the past decade, standard treatment has evolved to consist of combined-modality
	therapy that includes an abbreviated course of chemotherapy and involved-field
	radiation. As this therapy continues to include radiation therapy,
	patients will remain at risk of long-term toxicities that include
	the development of second cancers and cardiovascular events. These
	"late-effects" now account for more deaths than those attributed
	to progressive Hodgkin's lymphoma. Comparative data testing the role
	of chemotherapy alone are now available and demonstrate that omission
	of radiation therapy results in small but statistically significant
	reduction in disease control, but no detectable differences in overall
	survival. Further follow-up will clarify whether chemotherapy alone
	is the preferred treatment option; at present patients should be
	informed of the trade-offs involved in choosing between this option
	and combined modality therapy.},
  doi = {10.1182/asheducation-2004.1.184},
  institution = {Juravinski Cancer Centre and McMaster University, Hamilton ONT, Canada.},
  keywords = {Combined Modality Therapy, adverse effects; Disease-Free Survival;
	Herpesvirus 4, Human, metabolism; Hodgkin Disease, epidemiology/radiography/therapy/virology;
	Humans; Neoplasms, Second Primary, etiology/prevention /&/ control;
	Positron-Emission Tomography; Prognosis; Radiotherapy, adverse effects;
	Viral Proteins, metabolism},
  language = {eng},
  medline-pst = {ppublish},
  owner = {sanelo},
  pii = {2004/1/184},
  pmid = {15561683},
  timestamp = {2013.08.07},
  url = {http://dx.doi.org/10.1182/asheducation-2004.1.184}
}

@ARTICLE{Miladinovic2012,
  author = {Miladinovic, Branko and Kumar, Ambuj and Mhaskar, Rahul and Kim,
	Sehwan and Schonwetter, Ronald and Djulbegovic, Benjamin},
  title = {A flexible alternative to the Cox proportional hazards model for
	assessing the prognostic accuracy of hospice patient survival.},
  journal = {PLoS One},
  year = {2012},
  volume = {7},
  pages = {e47804},
  number = {10},
  abstract = {Prognostic models are often used to estimate the length of patient
	survival. The Cox proportional hazards model has traditionally been
	applied to assess the accuracy of prognostic models. However, it
	may be suboptimal due to the inflexibility to model the baseline
	survival function and when the proportional hazards assumption is
	violated. The aim of this study was to use internal validation to
	compare the predictive power of a flexible Royston-Parmar family
	of survival functions with the Cox proportional hazards model. We
	applied the Palliative Performance Scale on a dataset of 590 hospice
	patients at the time of hospice admission. The retrospective data
	were obtained from the Lifepath Hospice and Palliative Care center
	in Hillsborough County, Florida, USA. The criteria used to evaluate
	and compare the models' predictive performance were the explained
	variation statistic R(2), scaled Brier score, and the discrimination
	slope. The explained variation statistic demonstrated that overall
	the Royston-Parmar family of survival functions provided a better
	fit (R(2)?=0.298; 95\% CI: 0.236-0.358) than the Cox model (R(2)?=0.156;
	95\% CI: 0.111-0.203). The scaled Brier scores and discrimination
	slopes were consistently higher under the Royston-Parmar model. Researchers
	involved in prognosticating patient survival are encouraged to consider
	the Royston-Parmar model as an alternative to Cox.},
  doi = {10.1371/journal.pone.0047804},
  file = {Miladinovic2012.pdf:Miladinovic2012.pdf:PDF},
  institution = {Center for Evidence Based Medicine and Health Outcomes Research,
	University of South Florida, Tampa, Florida, USA. bmiladin@health.usf.edu},
  keywords = {Aged; Aged, 80 and over; Female; Florida; Hospices, statistics /&/
	numerical data; Humans; Kaplan-Meier Estimate; Male; Middle Aged;
	Palliative Care; Prognosis; Proportional Hazards Models; Time Factors},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {PONE-D-12-13593},
  pmid = {23082220},
  timestamp = {2014.03.03},
  url = {http://dx.doi.org/10.1371/journal.pone.0047804}
}

@Article{Minelli2005,
  author      = {Cosetta Minelli and John R Thompson and Keith R Abrams and Paul C Lambert},
  title       = {Bayesian implementation of a genetic model-free approach to the meta-analysis of genetic association studies.},
  doi         = {10.1002/sim.2393},
  number      = {24},
  pages       = {3845--3861},
  url         = {http://dx.doi.org/10.1002/sim.2393},
  volume      = {24},
  abstract    = {A genetic model-free method for the meta-analysis of genetic association
	studies is described that estimates the mode of inheritance from
	the data rather than assuming that it is known. For a bi-allelic
	polymorphism, with G as risk allele and g as wild-type, the genetic
	model depends on the ratio of the two log odds ratios, lambda = log
	OR(Gg)/log OR(GG), where OR(GG) compares GG with gg and OR(Gg) compares
	Gg with gg. Modelling log OR(GG) as a random effect creates a hierarchical
	model that can be implemented within a Bayesian framework.In Bayesian
	modelling, vague prior distributions have to be specified for all
	unknown parameters when no external information is available. When
	the data are sparse even supposedly vague prior distributions may
	have an influence on the posterior estimates. We investigate the
	impact of different vague prior distributions for the between-study
	standard deviation of log OR(GG) and for lambda, by considering three
	published meta-analyses and associated simulations. Our results show
	that depending on the characteristics of the meta-analysis the results
	may indeed be sensitive to the choice of vague prior distribution
	for either parameter.Genetic association studies usually use a case-control
	design that should be analysed by the corresponding retrospective
	likelihood. However, under some circumstances the prospective likelihood
	has been shown to produce identical results and it is usually preferred
	for its simplicity. In our meta-analyses the two likelihoods give
	very similar results.},
  file        = {minelli2005.pdf:minelli2005.pdf:PDF},
  institution = {Centre for Biostatistics and Genetic Epidemiology, Department of Health Sciences, University of Leicester, Leicester, UK. cm109@le.ac.uk},
  journal     = {Statistics in Medicine},
  month       = {Dec},
  owner       = {pl4},
  pmid        = {16320276},
  timestamp   = {2008.10.15},
  year        = {2005},
}

@ARTICLE{Moger2008,
  author = {Tron Anders Moger and Yudi Pawitan and Ornulf Borgan},
  title = {Case-cohort methods for survival data on families from routine registers.},
  journal = {Statistics in Medicine},
  year = {2008},
  volume = {27},
  pages = {1062--1074},
  number = {7},
  month = {Mar},
  abstract = {In the Nordic countries, there exist several registers containing
	information on diseases and risk factors for millions of individuals.
	This information can be linked to families by the use of personal
	identification numbers, and represents a great opportunity for studying
	diseases that show familial aggregation. Due to the size of the registers,
	it is difficult to analyze the data by using traditional methods
	for multivariate survival analysis, such as frailty or copula models.
	Since the size of the cohort is known, case-cohort methods based
	on pseudo-likelihoods are suitable for analyzing the data. We present
	methods for sampling control families both with and without replacement,
	and with or without stratification. The data are stratified according
	to family size and covariate values. Depending on the sampling method,
	results from simulations indicate that one only needs to sample 1-5
	per cent of the control families in order to obtain good efficiency
	compared with a traditional cohort analysis. We also provide an application
	to survival data from the Medical Birth Registry of Norway.},
  doi = {10.1002/sim.3004},
  file = {Moger2008.pdf:pdf\\Moger2008.pdf:PDF;Moger2008.pdf:Moger2008.pdf:PDF},
  institution = {Institute of Basic Medical Sciences, Department of Biostatistics,
	University of Oslo, Blindern, 0317 Oslo, Norway. tronmo@medisin.uio.no},
  owner = {pl4},
  pmid = {17639506},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1002/sim.3004}
}

@ARTICLE{Moine2002,
  author = {Moine, Pierre and Timsit, Jean-Fran{\AA}Â¦ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â®ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â©s and {De Lassence}, Arnaud
	and Troch{\AA}Â§ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚ÂªÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â Gilles and Fosse, Jean-Philippe and Alberti, Corrine
	and Cohen, Yves and , O. U. T. C. O. M. E. R. E. A study group},
  title = {Mortality associated with late-onset pneumonia in the intensive care
	unit: results of a multi-center cohort study.},
  journal = {Intensive Care Med},
  year = {2002},
  volume = {28},
  pages = {154--163},
  number = {2},
  month = {Feb},
  abstract = {To evaluate the attributable mortality associated with late-onset
	nosocomial pneumonia (LOP) while taking into account the severity
	at admission, the evolution of the patients during the first 4 days
	after admission to the ICU and the appropriateness of initial empiric
	antibiotic treatment.Multicenter cohort study with prospective standardization
	of diagnostic interventions when nosocomial pneumonia develops.Medical
	and surgical ICUs of four university-affiliated teaching hospitals.Seven
	hundred sixty-four consecutive patients requiring ICU hospitalization
	for at least 4 days.The clinical and biological data as well as the
	therapeutic data and the outcome were prospectively recorded from
	the day of admission to ICU discharge. Simplified Acute Physiologic
	Score (SAPS II) and Logistic Organ Dysfunction (LOD) score were collected
	and computed within the first 4 calendar days of ICU admission. Variables
	associated with the outcome were selected using a stepwise Cox model.
	The time to acquisition of the first LOP was then introduced in the
	final model as a time-dependent covariate. The analysis was stratified
	by ICU center. Finally, as initial antibiotic therapy could have
	an impact on the increased risk of death induced by LOP, the Cox
	model was applied again introducing LOP immediately adequately treated
	and LOP not immediately adequately treated as two different time-dependent
	covariates.Late-onset pneumonia developed in 89 patients (12\%).
	A McCabe score of more than 1, SAPS II score and increases in SAPS
	between days 1 and 2, days 2 and 3, and days 3 and 4 were significantly
	associated with an increased risk of death. When the time to acquisition
	of the first episode of LOP was introduced into the Cox model, the
	LOP occurrence was associated with increased mortality, even adjusted
	over the selected prognostic parameters and after stratification
	by center (hazard ratio (HR)=1.53, 95\% CI 1.02-2.3, p=0.04). When
	LOP immediately adequately treated and LOP not immediately adequately
	treated were separately introduced into the Cox model, inappropriately
	treated LOP remained significantly associated with an increased risk
	of mortality (HR=1.69, 95\% CI 1.08-2.65, p=0.022), whereas appropriately
	treated LOP did not (HR=1.44, 95\% CI 0.75-2.76, p=0.27).These data
	suggest that, in addition to severity scores, the underlying medical
	conditions and the evolution of severity within the first 4 days
	in ICU, late-onset pneumonia independently contribute to ICU patient
	mortality when empirical antibiotic treatment is not immediately
	appropriate.},
  institution = {D{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¯ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¡rtement d'Anesth{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â²ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â©e R{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â®imation, CHU de Bic{\AA}Â©ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â³ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â²e, 78 rue du G{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¯ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â©ral
	Leclerc, 94275 Le Kremlin Bic{\AA}Â©ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â³ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â²e cedex, France. pierre.moine1@fnac.net},
  keywords = {Aged; Cohort Studies; Cross Infection, epidemiology/microbiology/mortality;
	Female; France, epidemiology; Hospital Mortality; Hospitals, Teaching;
	Humans; Intensive Care Units, statistics /&/ numerical data; Male;
	Middle Aged; Pneumonia, Bacterial, epidemiology/microbiology/mortality;
	Prognosis},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {11907658},
  timestamp = {2013.05.29}
}

@ARTICLE{Mok2009,
  author = {Tony S Mok and Yi-Long Wu and Sumitra Thongprasert and Chih-Hsin
	Yang and Da-Tong Chu and Nagahiro Saijo and Patrapim Sunpaweravong
	and Baohui Han and Benjamin Margono and Yukito Ichinose and Yutaka
	Nishiwaki and Yuichiro Ohe and Jin-Ji Yang and Busyamas Chewaskulyong
	and Haiyi Jiang and Emma L Duffield and Claire L Watkins and Alison
	A Armour and Masahiro Fukuoka},
  title = {Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.},
  journal = {New England Journal of Medicine},
  year = {2009},
  volume = {361},
  pages = {947--957},
  number = {10},
  month = {Sep},
  abstract = {BACKGROUND: Previous, uncontrolled studies have suggested that first-line
	treatment with gefitinib would be efficacious in selected patients
	with non-small-cell lung cancer. METHODS: In this phase 3, open-label
	study, we randomly assigned previously untreated patients in East
	Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers
	or former light smokers to receive gefitinib (250 mg per day) (609
	patients) or carboplatin (at a dose calculated to produce an area
	under the curve of 5 or 6 mg per milliliter per minute) plus paclitaxel
	(200 mg per square meter of body-surface area) (608 patients). The
	primary end point was progression-free survival. RESULTS: The 12-month
	rates of progression-free survival were 24.9\% with gefitinib and
	6.7\% with carboplatin-paclitaxel. The study met its primary objective
	of showing the noninferiority of gefitinib and also showed its superiority,
	as compared with carboplatin-paclitaxel, with respect to progression-free
	survival in the intention-to-treat population (hazard ratio for progression
	or death, 0.74; 95\% confidence interval [CI], 0.65 to 0.85; P<0.001).
	In the subgroup of 261 patients who were positive for the epidermal
	growth factor receptor gene (EGFR) mutation, progression-free survival
	was significantly longer among those who received gefitinib than
	among those who received carboplatin-paclitaxel (hazard ratio for
	progression or death, 0.48; 95\% CI, 0.36 to 0.64; P<0.001), whereas
	in the subgroup of 176 patients who were negative for the mutation,
	progression-free survival was significantly longer among those who
	received carboplatin-paclitaxel (hazard ratio for progression or
	death with gefitinib, 2.85; 95\% CI, 2.05 to 3.98; P<0.001). The
	most common adverse events were rash or acne (in 66.2\% of patients)
	and diarrhea (46.6\%) in the gefitinib group and neurotoxic effects
	(69.9\%), neutropenia (67.1\%), and alopecia (58.4\%) in the carboplatin-paclitaxel
	group. CONCLUSIONS: Gefitinib is superior to carboplatin-paclitaxel
	as an initial treatment for pulmonary adenocarcinoma among nonsmokers
	or former light smokers in East Asia. The presence in the tumor of
	a mutation of the EGFR gene is a strong predictor of a better outcome
	with gefitinib. (ClinicalTrials.gov number, NCT00322452.)},
  doi = {10.1056/NEJMoa0810699},
  file = {Mok2009.pdf:Mok2009.pdf:PDF;Mok2009.pdf:pdf\\Mok2009.pdf:PDF},
  institution = {State Key Laboratory in Oncology in South China, Sir YK Pao Centre
	for Cancer, Department of Clinical Oncology, Chinese University of
	Hong Kong, Hong Kong. tony@clo.cuhk.edu.hk},
  owner = {pl4},
  pii = {NEJMoa0810699},
  pmid = {19692680},
  timestamp = {2010.07.14},
  url = {http://dx.doi.org/10.1056/NEJMoa0810699}
}

@ARTICLE{Monnereau2013,
  author = {Monnereau, A. and Troussard, X. and Belot, A. and Guizard, A-V. and
	Woronoff, A-S. and Bara, S. and Lap{\AA}Â³ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â³ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â±ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¥-Ledoux, B. and Iwaz, J. and
	Tretarre, B. and Maynadi{\AA}Â§ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚ÂªÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â M. and , {French Network of Cancer Registries
	(FRANCIM)}},
  title = {Unbiased estimates of long-term net survival of hematological malignancy
	patients detailed by major subtypes in {F}rance},
  journal = {International Journal of Cancer},
  year = {2013},
  volume = {132},
  pages = {2378--2387},
  number = {10},
  month = {May},
  abstract = {Long-term population-based survival data detailed by cancer subtype
	are important to measure the overall outcomes of malignancy managements.
	We provide net survival estimates at 1, 3, 5 and 10-year postdiagnosis
	on 37,549 hematological malignancy (HM) patients whose ages were
	>15 years, diagnosed between 1989 and 2004 and actively followed
	until 2008 by French population-based cancer registries. These are,
	to our knowledge, the first unbiased estimates of 10-year net survival
	in HMs detailed by subtypes. HMs were classified according to the
	International Classification of Diseases-Oncology 3. Net survival
	was estimated with the unbiased Pohar-Perme method. The results are
	reported by sex and age classes. The changes of these indicators
	by periods of diagnosis were tabulated and the trends of the net
	mortality rates over time since diagnosis graphed. In all, 5- and
	10-year age-standardized net survivals after HMs varied widely from
	81 and 76\% for classical Hodgkin lymphoma (CHL) to 18 and 14\% for
	acute myeloid leukemia (AML). Even in HMs with the most favorable
	prognoses, the net survival decreased between 5- and 10-year postdiagnosis.
	Women had better prognoses than men and age at diagnosis was an unfavorable
	prognostic factor for most HMs. In patients <55 years old, the net
	mortality rate decreased to null values 5-year postdiagnosis in AML
	and 10-year postdiagnosis in CHL, precursor non-HL, chronic myelogenous
	leukemia, diffuse large B-cell lymphoma and follicular lymphoma.
	The prognoses improved for various HMs over the study period. The
	obtained unbiased indicators are important to evaluate national cancer
	plans.},
  file = {Monnereau2013.pdf:pdf\\Monnereau2013.pdf:PDF},
  institution = {Registre des H{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¬ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¯pathies Malignes de la Gironde, Institut Bergoni{\AA}Â§ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Âª?
	Bordeaux, France. A.Monnereau@bordeaux.unicancer.fr},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {23034773},
  timestamp = {2013.05.29}
}

@ARTICLE{Monnet1992,
  author = {Monnet, E. and Boutron, M. C. and Arveux, P. and Milan, C. and Faivre,
	J.},
  title = {Different Multiple Regression Models for Estimating Survival: Use
	in a Population-Based Series of Colorectal Cancers},
  journal = {Journal of Clinical Epidemiology},
  year = {1992},
  volume = {45},
  pages = {267-273},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Montaudon1990,
  author = {Montaudon, D. and Benchekroun, M. N. and Londos-Gagliardi, D. and
	Robert, J.},
  title = {Chromosomal modifications of a rat glioblastoma cell line during
	the acquisition and reversal of doxorubicin resistance.},
  journal = {Anticancer Res},
  year = {1990},
  volume = {10},
  pages = {1667--1675},
  number = {6},
  abstract = {We have studied the cytogenetic alterations occurring during the development
	and reversal of doxorubicin resistance in a clonal line of rat glioblastoma
	cells. We have observed during the acquisition of resistance an increase
	in the modal number of chromosomes, from 42 to 60, and the occurrence,
	in 90\% of the mitoses, or large metacentric markers(s) which were
	infrequent in the sensitive line. This was associated with a net
	increase in total DNA amount per cell, from 5.3 to 8.3 pg. During
	reversal of resistance by 2 years culture without drug of the most
	resistant line, we observed a rapid decrease of the chromosome number
	as well as of the DNA content per cell; however, the large metacentric
	marker(s) were still present in 40\% of the mitoses after 9 months
	of reversal, when the remaining resistance was only 4-fold. In situ
	hybridization of the chromosomes with a probe for the mdr gene revealed
	that the average number of stained chromosomes rose from 7\% in the
	sensitive line to 38\% in the most resistant line; however, only
	9\% of the silver grains were detected on the large metacentric markers.
	We conclude that important chromosome rearrangements occurred during
	the acquisition of resistance to doxorubicin, leading to a random
	distribution of the mdr gene in the genome.},
  institution = {Universit{\AA}Â§ÃƒÂƒÃ‚Â…ÃƒÂ‚Ã‚Â¸ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¤e Bordeaux II, France.},
  keywords = {Animals; Cell Line; Cell Survival, drug effects; Culture Techniques,
	methods; DNA, Neoplasm, analysis/genetics; Doxorubicin, pharmacology;
	Drug Resistance, genetics; Gene Library; Glioma, genetics; Karyotyping;
	Metaphase; Nucleic Acid Hybridization; Rats},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {2285241},
  timestamp = {2013.05.29}
}

@ARTICLE{Montravers1999,
  author = {Montravers, P. and Maulin, L. and Mohler, J. and Carbon, C.},
  title = {Microbiological and inflammatory effects of murine recombinant interleukin-10
	in two models of polymicrobial peritonitis in rats.},
  journal = {Infect Immun},
  year = {1999},
  volume = {67},
  pages = {1579--1584},
  number = {4},
  month = {Apr},
  abstract = {A protective effect of interleukin-10 (IL-10) against the development
	of lethal shock has been demonstrated in various animal models. In
	contrast, the immunosuppressant properties of this mediator have
	been minimally evaluated in low-mortality models of infections. The
	clinical, microbiological, and inflammatory effects of murine recombinant
	IL-10 (mrIL-10) therapy were evaluated in two models of peritonitis
	in rats, which differed in the degree of severity of peritoneal inflammation
	3 days after inoculation of Escherichia coli and Bacteroides fragilis
	with or without Enterococcus faecalis. The severity of the disease
	remained unchanged compared to that in control animals. A dose-related
	decrease in the peritoneal phagocyte count was observed in the treated
	groups compared to the counts in control animals. The subsequent
	experiments were performed exclusively in the mixed gram-positive-gram
	negative model, which exhibits an intense and prolonged inflammatory
	response with similar criteria. The early effects of mrIL-10 (evaluated
	6 h after inoculation), repeated injections of mrIL-10 (four doses
	injected from 0 to 9 h after bacterial challenge), and pretreatment
	(two doses injected 6 and 3 h before inoculation) were evaluated.
	The clinical and microbiological parameters remained unchanged in
	the treated animals. Decreases in the peritoneal phagocyte count
	and the peritoneal concentration of tumor necrosis factor were observed
	following repeated injections of mrIL-10. In summary, our data suggest
	that mrIL-10 does not worsen the manifestations of sepsis. However,
	these results need to be confirmed in clinical practice.},
  institution = {INSERM U. 13, H{\AA}Â³ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¯ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â´al Bichat, 75877 Paris Cedex, France. pmontrav@planete.net},
  keywords = {Animals; Bacteroides fragilis, growth /&/ development/immunology;
	Disease Models, Animal; Enterococcus faecalis, growth /&/ development/immunology;
	Escherichia coli, growth /&/ development/immunology; Injections;
	Interleukin-10, immunology/pharmacokinetics/therapeutic use; Male;
	Mice; Peritonitis, drug therapy/immunology/microbiology; Rats; Rats,
	Sprague-Dawley; Recombinant Fusion Proteins, immunology/pharmacokinetics/therapeutic
	use; Treatment Outcome},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {10084989},
  timestamp = {2013.05.29}
}

@ARTICLE{Mooney1989,
  author = {Mooney, G.},
  title = {The Demand for Effectiveness, Efficiency and Equity of Health Care},
  journal = {Theoretical Medicine},
  year = {1989},
  volume = {10},
  pages = {195-205},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Mooney1987,
  author = {Mooney, G.},
  title = {What Does Equity in Health Mean?},
  journal = {World Health Statistics Quarterly},
  year = {1987},
  volume = {40},
  pages = {296-303},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Mooney1983,
  author = {Mooney, G.},
  title = {Equity in Health Care: Confronting the Confusion},
  journal = {Effective Health Care},
  year = {1983},
  volume = {1},
  pages = {179-185},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Moons2009,
  author = {K.G.J. Moons and D. G. Altman and Y. Vergouwe and P. Royston},
  title = {Prognosis and prognostic research: application and impact of prognostic
	models in clinical practice},
  journal = {BMJ},
  year = {2009},
  volume = {338},
  pages = {1487-1490},
  file = {Moons2009.pdf:Moons2009.pdf:PDF;Moons2009.pdf:pdf\\Moons2009.pdf:PDF},
  owner = {pl4},
  timestamp = {2009.11.04}
}

@ARTICLE{Morfeld2006,
  author = {Morfeld, P. and B\"{u}chte, S. F. and McCunney, R. J. and Claus,
	P.},
  title = {Lung cancer mortality and carbon black exposure: Uncertainties of
	{SMR} analyses in a cohort study at a {G}erman carbon black production
	plant.},
  journal = {Journal of Occupational Health and Environmental Medicine},
  year = {2006},
  volume = {48},
  pages = {1253-1264},
  owner = {hanbow},
  timestamp = {2016.11.21}
}

@ARTICLE{Morfeld2010,
  author = {Morfeld, P. and McCunney, R. J.},
  title = {Bayesian bias adjustments of the lung cancer {SMR} in a cohort of
	{G}erman carbon black production workers},
  journal = {Journal of Occupational Medicine and Toxicology},
  year = {2010},
  volume = {5},
  pages = {23},
  file = {Morfeld2010.pdf:Morfeld2010.pdf:PDF;Morfeld2010.pdf:pdf\\Morfeld2010.pdf:PDF},
  owner = {hanbow},
  timestamp = {2016.10.13}
}

@ARTICLE{Mork1995,
  author = {Mork, J. and Thoresen, S. and Faye-{L}und, H. and Langmark, F. and
	Glattre, E.},
  title = {Head and Neck Cancer in {N}orway},
  journal = {APMIS},
  year = {1995},
  volume = {103},
  pages = {375-82},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Morris2010,
  author = {Morris, E J A. and Forman, D. and Thomas, J. D. and Quirke, P. and
	Taylor, E. F. and Fairley, L. and Cottier, B. and Poston, G.},
  title = {Surgical management and outcomes of colorectal cancer liver metastases.},
  journal = {Br J Surg},
  year = {2010},
  volume = {97},
  pages = {1110--1118},
  number = {7},
  month = {Jul},
  abstract = {This population-based study investigated the frequency of hepatic
	resections for colorectal cancer metastases across England and their
	outcome.Individuals who underwent surgery for colorectal cancer between
	January 1998 and June 2004 within the English National Health Service
	were identified via the National Cancer Data Repository. All episodes
	of care in the 3 years after the initial operation were examined
	to determine the frequency of liver resection. Variations in the
	use of liver resection and survival were assessed.Some 114 155 individuals
	underwent surgery for colorectal cancer over the study period, of
	whom 3116 (2.7 per cent) subsequently had one or more hepatic resections.
	The hepatectomy rate increased from 1.7 per cent in 1998 to 3.8 per
	cent in 2004. There was significant variation in the rate of liver
	resection across cancer networks (range 1.1-4.3 per cent) and hospitals
	(range 0.7-6.8 per cent). The crude 5-year survival rate after liver
	resection was 44.2 (95 per cent confidence interval (c.i.) 42.4 to
	46.1) per cent from the time of hepatectomy and 45.9 (95 per cent
	c.i. 44.1 to 47.7) per cent from the time of colectomy. This was
	comparable to the 5-year survival rate of patients with stage III
	disease (42.2 (95 per cent c.i. 41.7 to 42.7) per cent).The rate
	of resection of liver metastases increased over the study period
	but varied significantly across the country. Patients who underwent
	liver resection had 5-year survival comparable to that of patients
	with stage III colorectal cancer.},
  doi = {10.1002/bjs.7032},
  file = {Morris2010.pdf:pdf\\Morris2010.pdf:PDF},
  institution = {Colorectal Cancer Epidemiology Group, Centre for Epidemiology and
	Biostatistics, University of Leeds, UK. eva.morris@nycris.leedsth.nhs.uk},
  keywords = {Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Hepatectomy,
	mortality; Hospitalization; Humans; Liver Neoplasms, mortality/secondary/surgery;
	Male; Middle Aged; Prospective Studies; Survival Rate; Treatment
	Outcome},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {20632280},
  timestamp = {2013.10.29},
  url = {http://dx.doi.org/10.1002/bjs.7032}
}

@Article{Morris2011,
  author      = {Morris, Eva J A. and Sandin, Fredrik and Lambert, Paul C. and Bray, Freddie and Klint, {\AA}sa and Linklater, Karen and Robinson, David and P{\aa}hlman, Lars and Holmberg, Lars and M{\o}ller, Henrik},
  title       = {A population-based comparison of the survival of patients with colorectal cancer in {E}ngland, {N}orway and {S}weden between 1996 and 2004.},
  doi         = {10.1136/gut.2010.229575},
  language    = {eng},
  number      = {8},
  pages       = {1087--1093},
  url         = {http://dx.doi.org/10.1136/gut.2010.229575},
  volume      = {60},
  abstract    = {To examine differences in the relative survival and excess death rates
	of patients with colorectal cancer in Norway, Sweden and England.All
	individuals diagnosed with colorectal cancer (ICD10 (International
	Classification of Diseases, 10th revision) C18-C20) between 1996
	and 2004 in England, Norway and Sweden were included in this population-based
	study of patients with colorectal cancer. The main outcome measures
	were 5-year cumulative relative period of survival and excess death
	rates stratified by age and period of follow-up.The survival of English
	patients with colorectal cancer was significantly lower than was
	observed in both Norway and Sweden. Five-year age-standardised colon
	cancer relative survival was 51.1\% (95\% CI 50.1\% to 52.0\%) in
	England compared with 57.9\% (95\% CI 55.2\% to 60.5\%) in Norway
	and 59.9\% (95\% CI 57.7\% to 62.0\%) in Sweden. Five-year rectal
	cancer survival was 52.3\% (95\% CI 51.1\% to 53.5\%) in England
	compared with 60.7\% (95\% CI 57.0\% to 64.2\%) and 59.8\% (95\%
	CI 56.9\% to 62.6\%) in Norway and Sweden, respectively. The lower
	survival for colon cancer in England was primarily due to a high
	number of excess deaths among older patients in the first 3 months
	after diagnosis. In patients with rectal cancer, excess deaths remained
	elevated until 2 years of follow-up. If the lower excess death rate
	in Norway applied in the English population, then 890 (13.6\%) and
	654 (16.8\%) of the excess deaths in the colon and rectal cancer
	populations, respectively, could have been prevented at 5 years follow-up.
	Most of these avoidable deaths occurred shortly after diagnosis.There
	was significant variation in survival between the countries, with
	the English population experiencing a poorer outcome, primarily due
	to a relatively higher number of excess deaths in older patients
	in the short term after diagnosis. It seems likely, therefore, that
	in England a greater proportion of the population present with more
	rapidly fatal disease (especially in the older age groups) than in
	Norway or Sweden.},
  file        = {Morris2011.pdf:Morris2011.pdf:PDF},
  institution = {Biostatistics, University of Leeds, NYCRIS, St James's University Hospital, Leeds, UK. eva.morris@nycris.leedsth.nhs.uk},
  journal     = {Gut},
  medline-pst = {ppublish},
  month       = {Aug},
  owner       = {pl4},
  pii         = {gut.2010.229575},
  pmid        = {21303917},
  timestamp   = {2013.02.04},
  year        = {2011},
}

@ARTICLE{Morris2015,
  author = {Morris, M. and Woods, L. M. and Rachet, B.},
  title = {A novel ecological methodology for constructing ethnic-majority life
	tables in the absence of individual ethnicity information},
  journal = {Journal of epidemiology and community health},
  year = {2015},
  volume = {69},
  pages = {361-7},
  file = {Morris2015.pdf:pdf\\Morris2015.pdf:PDF;Morris2015.pdf:Morris2015.pdf:PDF},
  owner = {hanbow},
  timestamp = {2016.05.19}
}

@Article{Mozumder2016,
  author    = {S.I. Mozumder and P.C. Lambert and M.J. Rutherford},
  title     = {Direct likelihood inference on the cause-specific cumulative incidence function: a flexible parametric regression modelling approach},
  journal   = {Statistics in Medicine},
  year      = {2018},
  volume    = {37},
  pages     = {82-97},
  doi       = {10.1002/sim.7498},
  file      = {:Mozumder2016.pdf:PDF},
  owner     = {pl4},
  pmid      = {28971494},
  timestamp = {2016.08.08},
}

@ARTICLE{Mucci2004,
  author = {Lorelei A Mucci and Chung-cheng Hsieh and Paige L Williams and Paul
	W Dickman and Lars Bj\"{o}rkman and Nancy L Pedersen},
  title = {Birth order, sibship size, and housing density in relation to tooth
	loss and periodontal disease: a cohort study among {S}wedish twins.},
  journal = {Am J Epidemiol},
  year = {2004},
  volume = {159},
  pages = {499-506},
  number = {5},
  month = {Mar},
  abstract = {For diseases with an infectious etiology, birth order may dictate
	the age of exposure to childhood infection, while sibship size may
	be a proxy for the probability of exposure. The authors examined
	whether birth order, sibship size, and childhood housing density
	affect risk of tooth loss and periodontal disease. The study included
	28,690 adults aged > or = 42 years who were participating in a 1998-2002
	follow-up of persons listed in the Swedish Twin Registry. Logistic
	regression was used to calculate odds ratios and 95\% confidence
	intervals, with adjustment for age, sex, education, and smoking and
	mutual adjustment for family composition (sibship size and/or birth
	order). Tooth loss and periodontal disease affected 8\% and 19\%
	of the twins, respectively. Each additional sibling increased the
	odds of tooth loss by 10\% (95\% confidence interval (CI): 1.06,
	1.15) and the odds of periodontal disease by 5\% (95\% CI: 1.02,
	1.08). Later birth order was associated with lower odds of periodontal
	disease. Each additional person per room in the childhood home increased
	the odds of tooth loss (odds ratio = 1.28, 95\% CI: 1.03, 1.60) but
	lowered the odds of periodontal disease (odds ratio = 0.65, 95\%
	CI: 0.48, 0.89). These findings are compatible with the hypotheses
	that adult oral diseases are associated with the probability of exposure
	in childhood and that earlier age at exposure lowers risk.},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Mucci2003,
  author = {LA Mucci and PW Dickman and G Steineck and H-O Adami and K Augustsson},
  title = {Dietary acrylamide and cancer of the large bowel, kidney, and bladder:
	absence of an association in a population-based study in {S}weden.},
  journal = {Br J Cancer},
  year = {2003},
  volume = {88},
  pages = {84-9},
  number = {1},
  month = {Jan},
  abstract = {Recently, disturbingly high levels of acrylamide were unexpectedly
	detected in widely consumed food items, notably French fries, potato
	crisps, and bread. Much international public concern arose since
	acrylamide has been classified as a probable carcinogen, although
	based chiefly on laboratory evidence; informative human data are
	largely lacking. We reanalysed a population-based Swedish case-control
	study encompassing cases with cancer of the large bowel (N=591),
	bladder (N=263) and kidney (N=133), and 538 healthy controls, assessing
	dietary acrylamide by linking extensive food frequency data with
	acrylamide levels in certain food items recorded by the Swedish National
	Food Administration. Unconditional logistic regression was used to
	estimate odds ratios, adjusting for potential confounders. We found
	consistently a lack of an excess risk, or any convincing trend, of
	cancer of the bowel, bladder, or kidney in high consumers of 14 different
	food items with a high (range 300-1200 microg kg(-1)) or moderate
	(range 30-299 microg kg(-1)) acrylamide content. Likewise, when we
	analysed quartiles of known dietary acrylamide intake, no association
	was found with cancer of the bladder or kidney. Unexpectedly, an
	inverse trend was found for large bowel cancer (P for trend 0.01)
	with a 40\% reduced risk in the highest compared to lowest quartile.
	We found reassuring evidence that dietary exposure to acrylamide
	in amounts typically ingested by Swedish adults in certain foods
	has no measurable impact on risk of three major types of cancer.
	It should be noted, however, that relation of risk to the acrylamide
	content of all foods could not be studied.},
  doi = {10.1038/sj.bjc.6600726},
  owner = {PaulD},
  pii = {6600726},
  timestamp = {2011.06.19},
  url = {http://dx.doi.org/10.1038/sj.bjc.6600726}
}

@InCollection{Muir1985,
  author    = {Muir, C. S.},
  title     = {The Cancer Registry in Cancer Control: An Overview},
  chapter   = {2},
  editor    = {Parkin, D. M. and Wagner, G. and Muir, C. S.},
  pages     = {13-26},
  publisher = {Lyon: International Agency for Research on Cancer},
  series    = {IARC Scientific Publications No. 66},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1985},
}

@ARTICLE{Muir1977,
  author = {Muir, C. S. and Nectoux, J.},
  title = {Role of the Cancer Registry},
  journal = {National Cancer Institute Monograph},
  year = {1977},
  volume = {47},
  pages = {3-6},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Munro2014,
  author = {Munro, Alastair J.},
  title = {Interpretation of EUROCARE-5.},
  journal = {Lancet Oncol},
  year = {2014},
  volume = {15},
  pages = {2--3},
  number = {1},
  month = {Jan},
  doi = {10.1016/S1470-2045(13)70566-7},
  file = {Munro2014.pdf:pdf\\Munro2014.pdf:PDF;Munro2014.pdf:Munro2014.pdf:PDF},
  institution = {Cancer Research Division, University of Dundee School of Medicine,
	Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK. Electronic
	address: a.j.munro@dundee.ac.uk.},
  keywords = {Female; Humans; Male; Neoplasms, mortality},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pii = {S1470-2045(13)70566-7},
  pmid = {24314614},
  timestamp = {2014.03.13},
  url = {http://dx.doi.org/10.1016/S1470-2045(13)70566-7}
}

@ARTICLE{Murphy1990,
  author = {Murphy, M. and Goldblatt, P. and Thornton-Jones, H. and Silcocks,
	P.},
  title = {Survival Among Women with Cancer of The Uterine Cervix: Influence
	of Marital Status and Social Class},
  journal = {Journal of Epidemiology and Community Health},
  year = {1990},
  volume = {44},
  pages = {293-296},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Mustonen2004,
  author = {Anne-Mari Mustonen and Petteri Nieminen and Juha Asikainen and Seppo
	Saarela and Jussi V K Kukkonen and Heikki Hyv\"{a}rinen},
  title = {Continuous melatonin treatment and fasting in the raccoon dog (Nyctereutes
	procyonoides)--vernal body weight regulation and reproduction.},
  journal = {Zoolog Sci},
  year = {2004},
  volume = {21},
  pages = {163--172},
  number = {2},
  month = {Feb},
  abstract = {The raccoon dog (Nyctereutes procyonoides) is a canid omnivore with
	marked seasonal changes in its body adiposity. The aim of this study
	was to investigate the roles of melatonin, leptin, ghrelin and growth
	hormone (GH) in weight regulation and reproduction of the species.
	Sixteen raccoon dogs were treated with continuous-release melatonin
	implants in Aug 2000 and in Feb 2001 (the MEL group) and 16 animals
	were sham-operated (the SHAM group). Half of the raccoon dogs were
	fasted between Nov 27(th) 2000 and Jan 25(th) 2001. The autumnal
	results have been previously published and this paper reports the
	vernal data. The leptin concentrations of the SHAM females were high
	before the mating season, decreased before estrus, increased during
	gestation and reduced after parturition. The MEL females had higher
	leptin concentrations than the SHAM females in early March, whereas
	the MEL males had lower leptin concentrations than the SHAM males
	in late March. Also the ghrelin and GH concentrations of the SHAM
	females decreased before estrus. Continuous melatonin treatment advanced
	the vernal rise in the ghrelin concentrations and the vernal drop
	and the subsequent rise in the GH concentrations of the females.
	Melatonin also increased their body mass indices from July to Aug
	2001, indicating that it triggers the autumnal accumulation of fat
	in the species.},
  institution = {Department of Biology, University of Joensuu, Finland. ammusto@cc.joensuu.fi},
  owner = {pl4},
  pmid = {14993828},
  timestamp = {2011.05.26}
}

@ARTICLE{Mustonen2006,
  author = {Anne-Mari Mustonen and Matti Puukka and Seppo Saarela and Tommi Paakkonen
	and Jari Aho and Petteri Nieminen},
  title = {Adaptations to fasting in a terrestrial mustelid, the sable (Martes
	zibellina).},
  journal = {Comp Biochem Physiol A Mol Integr Physiol},
  year = {2006},
  volume = {144},
  pages = {444--450},
  number = {4},
  month = {Aug},
  abstract = {The aim of this study was to investigate whether the actively wintering
	Palearctic sable Martes zibellina has evolved physiological adaptations
	to tolerate nutritional scarcity. Sixteen farm-bred male sables were
	divided into a fed control group and an experimental group fasted
	for 4 days. The rate of weight loss in the sable was similar to other
	medium-sized mustelids. Fasting led to hypoglycaemia and to a decreased
	lymphocyte percentage. The sable derived metabolic energy from both
	subcutaneous and intraabdominal white adipose tissues and the relative
	decrease in fat mass was the largest for the retroperitoneal and
	subcutaneous depots. Metabolic energy derived partly from body proteins
	indicated by the increased plasma levels of urea, uric acid and total
	essential amino acids. Triacylglycerols accumulated in the livers
	of the fasted sables and the increased plasma aminotransferase activities
	suggested hepatic dysfunction. The decreased plasma insulin concentrations
	and the elevated cortisol levels probably contributed to stimulated
	lipolysis and protein catabolism. Moreover, fasting increased the
	plasma ghrelin concentrations of the sables and down-regulated the
	thyroid activity.},
  doi = {10.1016/j.cbpa.2006.03.008},
  institution = {Department of Biology, University of Joensuu, P.O. Box 111, FIN-80101,
	Joensuu, Finland. ammusto@cc.joensuu.fi},
  owner = {pl4},
  pii = {S1095-6433(06)00178-4},
  pmid = {16716623},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1016/j.cbpa.2006.03.008}
}

@ARTICLE{Mwalili2005,
  author = {S. M. Mwalili and E. Lesaffre and D. Declerck},
  title = {A Bayesian ordinal logistic regression model to correct for interobserver
	measurement error in a geographical oral health study},
  journal = {Applied Statistics},
  year = {2005},
  volume = {54},
  pages = {77-93},
  file = {Mwalili2005.pdf:Mwalili2005.pdf:PDF;Mwalili2005.pdf:pdf\\Mwalili2005.pdf:PDF},
  owner = {pl4},
  timestamp = {2010.07.15}
}

@ARTICLE{Myasnikova2000,
  author = {E.M. Myasnikova},
  title = {Spline-based estimation of cure rates: an application to the analysis
	of breast cancer data},
  journal = {Mathematical and computer modelling},
  year = {2000},
  volume = {32},
  pages = {217-228},
  owner = {theand},
  timestamp = {2013.10.01}
}

@Book{Norway1996,
  author    = {The Cancer Registry of {N}orway},
  title     = {Cancer in {N}orway 1993},
  publisher = {Oslo: The Cancer Registry of {N}orway},
  groups    = {Cancer registry reports},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1996},
}

@Book{Norway1975b,
  author    = {The Cancer Registry of {N}orway},
  title     = {Survival of Cancer Patients. Cases Diagnosed in {N}orway 1968-1975},
  publisher = {Oslo: The Norwegian Cancer Society},
  groups    = {Cancer registry reports},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1975},
}

@TechReport{SCR2012,
  author      = {{National Board of Health and Welfare}},
  date        = {2012.12.07},
  institution = {The National Board of Health and Welfare (Socialstyrelsen)},
  title       = {Cancer Incidence in {S}weden 2011},
  isrn        = {978-91-7555-003-9},
  number      = {2012-12-19},
  type        = {Official Statistics of {S}weden},
  file        = {SCR2012.pdf:pdf\\SCR2012.pdf:PDF;SCR2012.pdf:SCR2012.pdf:PDF},
  owner       = {PaulD},
  timestamp   = {2016.10.22},
  year        = {2012},
}

@TechReport{RSV19711B,
  author      = {{National Tax Board}},
  institution = {National Tax Board},
  title       = {Population Registration in {S}weden},
  note        = {URL: \url{http://skatteverket.se/broschyrer/711b/711b03.pdf } [accessed June 11, 2004]},
  type        = {Brochure RSV 711B},
  owner       = {PaulD},
  timestamp   = {2011.06.19},
  year        = {2000},
}

@ARTICLE{Nelder1972,
  author = {Nelder, J. A. and Wedderburn, R. W. M.},
  title = {Generalized Linear Models},
  journal = {Journal of the Royal Statistical Society A},
  year = {1972},
  volume = {135},
  pages = {370-384},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Nelson2008a,
  author = {Nelson, Charlotte L. and Sun, Jie L. and Tsiatis, Anastasios A. and
	Mark, Daniel B.},
  title = {Empirical estimation of life expectancy from large clinical trials:
	use of left-truncated, right-censored survival analysis methodology.},
  journal = {Stat Med},
  year = {2008},
  volume = {27},
  pages = {5525--5555},
  number = {26},
  month = {Nov},
  abstract = {In the current era of ever-increasing health care costs, economic
	analyses are an essential component in the comprehensive evaluation
	of new medical interventions. Cost-effectiveness analysis (CEA)--the
	most common form of economic analysis used in medicine--aids policy-makers
	in determining how to allocate finite health care dollars among possible
	alternative therapies. CEA relates the incremental benefits of a
	new technology to its incremental costs in a cost-effectiveness (CE)
	ratio. Although the generally agreed-upon standard of presentation
	for the CE ratio is the lifetime perspective (incremental lifetime
	cost to add one life year), this perspective presents an obvious
	challenge to the statistical analyst. Most large clinical trials
	collect limited follow-up data, and yet their findings form the basis
	of therapeutic recommendations that often extend far beyond the limits
	of the empirical data. Although clinical practice guidelines do not
	yet require explicit modeling to examine the long-term implications
	of their recommendations, health policy analyses routinely rely upon
	such extrapolations. This paper describes methods for using empirical
	patient-level data to extrapolate survival in large clinical trials
	and cohorts beyond a limited follow-up period in which most patients
	remain alive in order to estimate the entire survival distribution
	for a cohort of patients. We accomplish this task through a novel
	combination of models that estimate the hazard rate not only as a
	function of time but also as a function of patient age. Extrapolation
	of survival beyond a limited time frame is made possible by capitalizing
	on the extensive latitude of survival information available across
	the range of ages represented in the data. Variations in approach
	are presented, and issues arising in these analyses are discussed.
	The proposed methodology is developed, applied, and evaluated in
	both a large clinical trial cohort with 5-year follow-up on over
	23,000 patients and a large observational database with long-term
	follow-up on over 4000 patients.},
  doi = {10.1002/sim.3355},
  institution = {Duke Clinical Research Institute, Duke University Medical Center,
	Durham, NC 27715, USA. charlotte.nelson@duke.edu},
  keywords = {Adult; Aged; Aged, 80 and over; Cardiovascular Diseases, economics/epidemiology;
	Cerebrovascular Disorders, economics/epidemiology; Cohort Studies;
	Cost-Benefit Analysis; Female; Health Care Costs; Humans; Life Expectancy;
	Male; Markov Chains; Middle Aged; Models, Statistical; Observation;
	Proportional Hazards Models; Randomized Controlled Trials as Topic,
	methods; Survival Analysis},
  language = {eng},
  medline-pst = {ppublish},
  owner = {theand},
  pmid = {18613251},
  timestamp = {2012.09.18},
  url = {http://dx.doi.org/10.1002/sim.3355}
}

@ARTICLE{Nelson2008,
  author = {C. P. Nelson and P. C. Lambert and I. B. Squire and D. R. Jones},
  title = {Relative survival: what can cardiovascular disease learn from cancer?},
  journal = {European Heart Journal},
  year = {2008},
  volume = {29},
  pages = {941--947},
  number = {7},
  month = {Apr},
  abstract = {AIMS: To illustrate the application of relative survival to observational
	studies in coronary heart disease (CHD) and potential advantages
	compared with all-cause survival methods. Survival after myocardial
	infarction (MI) is generally assessed using all-cause or cause-specific
	methods. Neither method is able to assess the impact of the disease
	or condition of interest in comparison with expected survival in
	a similar population. Relative survival, the ratio of the observed
	and the expected survival rates, is applied routinely in cancer studies
	and may improve on current methods for assessment of survival in
	CHD. METHODS AND RESULTS: Using a cohort of subjects after a first
	recorded acute MI, we discuss the application of relative survival
	in CHD and illustrate a number of the key issues. We compare the
	findings from relative survival with those obtained using Cox proportional
	and non-proportional hazards models in standard all-cause survival.
	Estimated survival rates are higher using relative survival models
	compared with all-cause methods. CONCLUSION: Estimates obtained from
	all-cause mortality fail to disentangle mortality associated with
	the condition of interest from that due to all other causes. Relative
	survival gives an estimate of survival due to the disease of interest
	without the need for cause of death information.},
  doi = {10.1093/eurheartj/ehn079},
  file = {Nelson2008.pdf:pdf\\Nelson2008.pdf:PDF},
  institution = {Centre for Biostatistics and Genetic Epidemiology, Department of
	Health Sciences, University of Leicester, 2nd Floor, Adrian Building,
	University Road, Leicester LE1 7RH, UK. cn46@le.ac.uk},
  owner = {pl4},
  pii = {ehn079},
  pmid = {18326008},
  timestamp = {2008.10.15},
  url = {http://dx.doi.org/10.1093/eurheartj/ehn079}
}

@Article{Nelson2007,
  author      = {C. P. Nelson and P. C. Lambert and I. B. Squire and D. R. Jones},
  title       = {Flexible parametric models for relative survival, with application in coronary heart disease.},
  journal     = {Statistics in Medicine},
  year        = {2007},
  volume      = {26},
  number      = {30},
  pages       = {5486--5498},
  doi         = {10.1002/sim.3064},
  url         = {http://dx.doi.org/10.1002/sim.3064},
  abstract    = {Relative survival is frequently used in population-based studies as
	a method for estimating disease-related mortality without the need
	for information on cause of death. We propose an extension to relative
	survival of a flexible parametric model proposed by Royston and Parmar
	for censored survival data. The model provides smooth estimates of
	the relative survival and excess mortality rates by using restricted
	cubic splines on the log cumulative excess hazard scale. The approach
	has several advantages over some of the more standard relative survival
	models, which adopt a piecewise approach, the main being the ability
	to model time on a continuous scale, the survival and hazard functions
	are obtained analytically and it does not use split-time data.},
  file        = {Nelson2007.pdf:pdf\\Nelson2007.pdf:PDF},
  groups      = {Excess mortality model},
  institution = {>},
  owner       = {pl4},
  pmid        = {17893893},
  timestamp   = {2008.10.15},
}

@ARTICLE{Neuner-Jehle2008,
  author = {Neuner-Jehle, S. and Wegwarth, O. and Steurer, J.},
  title = {[Is one picture worth a thousand words? Risk communication in primary
	care: advantages and shortcomings of different methods].},
  journal = {Praxis (Bern 1994)},
  year = {2008},
  volume = {97},
  pages = {669--676},
  number = {12},
  month = {Jun},
  abstract = {Communication about risk, e.g. cardiovascular risk, is a central task
	of physicians in their daily practice. In this paper we summarize
	the different methods of risk communication published in the literature.
	The different methods and their particular advantages and shortcomings
	are described and some recommendations are formulated. The most significant
	of them are: verbal qualifiers like, your risk for a cardiovascular
	event is moderate, is imprecise and difficult to interpret. Information
	about risk in numerical form is more comprehensible when delivered
	in natural frequencies compared to percentages, pictorial representations
	contribute to a better understanding. Probably not one single mode
	of representation is the most effective way to convey information
	about risk, but a combination of methods.},
  institution = {Institut f{\AA}Â¼r Hausarztmedizin, Universit{\"a}tsspital Z{\AA}Â¼rich. sneuner@bluewin.ch},
  keywords = {Audiovisual Aids; Cardiovascular Diseases, epidemiology/etiology/prevention
	/&/ control; Communication; Computer Graphics; Decision Support Techniques;
	Humans; Patient Education as Topic; Primary Health Care; Risk Assessment},
  language = {ger},
  medline-pst = {ppublish},
  owner = {sanelo},
  pmid = {18661891},
  timestamp = {2013.10.17}
}

@ARTICLE{Neveu1998,
  author = {Neveu, H. and Hafen, T. and Zimmermann, E. and Rumpler, Y.},
  title = {Comparison of the genetic diversity of wild and captive groups of
	Microcebus murinus using the random amplified polymorphic DNA method.},
  journal = {Folia Primatol (Basel)},
  year = {1998},
  volume = {69 Suppl 1},
  pages = {127--135},
  abstract = {Continued survival of most animal species depends on population management
	and active protection. It is generally agreed that, in order to avoid
	extinction of endangered species, ex situ and in situ conservation
	must be developed in tandem. However, even though many recommendations
	have been put forward to promote the survival of captive populations,
	some rapidly become extinct due to loss of genetic diversity (drift
	effect). Genetic markers, such as random amplified polymorphic DNA
	(RAPD) markers, can be applied to rapid testing of many individuals.
	They also permit analysis of very small amounts of DNA, when small
	species such as mouse lemurs (Microcebus) are to be tested. Using
	RAPD markers, we compare genetic diversity in four captive groups
	of Microcebus murinus to that in a sample of 70 wild mouse lemurs.
	Following the principles of Mendelian inheritance, each amplified
	fragment of DNA may be considered as a 'locus' (or an amplifying
	site). The series of bands amplified by a particular primer in any
	individual is referred to as the individual's 'profile'. We tested
	5 primers, or, in the above terms, we studied 98 different 'loci'.
	Results showed that the captive groups had lost genetic information
	with respect to the wild sample. Among the four captive groups, the
	loss of genetic diversity varied according to their number of founders
	and/or the management of their captive reproduction. Our study of
	polymorphism permitted us to establish tools for the genetic management
	of captive breeding, and for the determination of paternity which
	frequently give better results than behavioural studies; and simulation
	of introductions or departures of individuals in one very monomorphic
	group permitted estimation of future increases in its genetic diversity.},
  institution = {Laboratoire de Biologie, Centre de Primatologie, Niederhausbergen,
	France. prima@calva.net},
  keywords = {Amino Acid Sequence; Animals; Animals, Domestic; Animals, Wild; Cheirogaleidae,
	genetics; Conservation of Natural Resources; Extinction, Psychological;
	Genetic Variation; Molecular Sequence Data; Random Amplified Polymorphic
	DNA Technique},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {fpr9a127},
  pmid = {9595690},
  timestamp = {2013.05.29}
}

@ARTICLE{Newby2005,
  author = {P. K. Newby and P. W. Dickman and H-O. Adami and A. Wolk},
  title = {Early anthropometric measures and reproductive factors as predictors
	of body mass index and obesity among older women.},
  journal = {Int J Obes},
  year = {2005},
  volume = {29},
  pages = {1084--1092},
  doi = {10.1038/sj.ijo.0802996},
  owner = {PaulD},
  pii = {0802996},
  pmid = {15925960},
  timestamp = {2006.10.04},
  url = {http://dx.doi.org/10.1038/sj.ijo.0802996}
}

@ARTICLE{Newcombe2006,
  author = {Robert G Newcombe},
  title = {A deficiency of the odds ratio as a measure of effect size.},
  journal = {Stat Med},
  year = {2006},
  volume = {25},
  pages = {4235--4240},
  number = {24},
  month = {Dec},
  abstract = {The odds ratio is probably the most widely used measure of association
	for binary variables. It has many well-recognized advantages and
	disadvantages vis-{\AA}ÂƒÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â -vis the risk ratio. We demonstrate that for
	chained or conditional probabilities, odds ratios can behave paradoxically,
	by failing to show a reinforcement effect that is expressed very
	clearly when risk ratios are used.},
  doi = {10.1002/sim.2683},
  file = {Newcombe2006.pdf:Newcombe2006.pdf:PDF;Newcombe2006.pdf:pdf\\Newcombe2006.pdf:PDF},
  institution = {Wales College of Medicine, Cardiff University, Heath Park, Cardiff
	CF14 4YS, UK. Newcombe@cf.ac.uk},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {16927451},
  timestamp = {2010.06.01},
  url = {http://dx.doi.org/10.1002/sim.2683}
}

@ARTICLE{Ng2002,
  author = {Ng, Andrea K. and Bernardo, M Patricia and Weller, Edie and Backstrand,
	Kendall H. and Silver, Barbara and Marcus, Karen C. and Tarbell,
	Nancy J. and Friedberg, Jonathan and Canellos, George P. and Mauch,
	Peter M.},
  title = {Long-term survival and competing causes of death in patients with
	early-stage {H}odgkin's disease treated at age 50 or younger.},
  journal = {J Clin Oncol},
  year = {2002},
  volume = {20},
  pages = {2101--2108},
  number = {8},
  month = {Apr},
  abstract = {To analyze the long-term survival and the pattern and timing of excess
	mortality in patients with early-stage Hodgkin's disease.Between
	1969 and 1997, 1,080 patients age 50 or younger were treated for
	clinical stage IA to IIB Hodgkin's disease. Overall survival was
	determined, and prognostic factors were assessed. Relative risk and
	absolute excess risk (AR) of mortality were calculated for the entire
	cohort and by prognostic groups (on the basis of B symptoms, mediastinal
	status, and number of sites, modified from the European Organization
	for Research and Treatment of Cancer).The median follow-up was 12
	years. The 15- and 20-year Kaplan-Meier survival estimates were 84\%
	and 78\%, respectively. Cox proportional hazards models showed that
	number of involved sites (P =.006), mediastinal status (P =.02),
	and histology (P =.02) were independent predictors of death from
	all causes. The AR of mortality in patients with a favorable prognosis
	increased over time, whereas for those with an unfavorable prognosis,
	the AR peaked in the first 5 years, predominantly from Hodgkin's
	disease. The relative risk of mortality from all causes, causes other
	than Hodgkin's disease, second tumors, and cardiac disease remained
	significantly elevated more than 20 years after treatment.Patients
	treated for early-stage Hodgkin's disease have a sustained excess
	mortality risk despite good control of the disease. Treatment reduction
	efforts in patients with early-stage, favorable-prognosis disease
	should continue, but for patients with an unfavorable prognosis,
	modified treatment may not be advisable. The excess mortality noted
	beyond two decades underscores the importance of long-term follow-up
	care in patients treated for Hodgkin's disease.},
  institution = {Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber
	Cancer Institute, Boston, MA, USA.},
  keywords = {Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols,
	therapeutic use; Cause of Death; Child; Child, Preschool; Female;
	Hodgkin Disease, mortality/therapy; Humans; Male; Middle Aged; Prognosis;
	Proportional Hazards Models; Radiotherapy, High-Energy; Survival
	Analysis; Survivors},
  language = {eng},
  medline-pst = {ppublish},
  owner = {sanelo},
  pmid = {11956271},
  timestamp = {2013.08.07}
}

@ARTICLE{Nieto1996,
  author = {F. J. Nieto and J. Coresh},
  title = {Adjusting survival curves for confounders: a review and a new method.},
  journal = {American Journal of Epidemiology},
  year = {1996},
  volume = {143},
  pages = {1059--1068},
  number = {10},
  month = {May},
  abstract = {When reporting results from survival analysis, investigators often
	present crude Kaplan-Meier survival curves and adjusted relative
	hazards from the Cox proportional hazards model. Occasionally, the
	investigators will also provide a graphical representation of adjusted
	survival curves based on regression estimates and the average covariate
	values in the study groups. In this paper, the authors review the
	limitations of this approach and examine alternative approaches to
	obtaining adjusted survival curves that have been proposed. Furthermore,
	a new method to obtain multivariate adjusted survival curves is described.
	This method is based on direct adjustment of the observed conditional
	probability of survival at the time of each event. When an unexposed
	group is used as a standard for adjusting an exposed group, the survival
	curve in the exposed group is adjusted to the covariate distribution
	among the unexposed at the time of the event. This method has the
	advantage over the average covariate method of allowing for the possibility
	that the adjusted survival curves differ in shape. The method can
	handle multiple fixed or time-dependent categorical covariates as
	well as left truncated data, and it allows for estimation of confidence
	intervals. The authors have written a macro in SAS language that
	produces the adjusted survival estimates and graphs. This macro is
	available on request and can be downloaded through the World Wide
	Web.},
  file = {Nieto1996.pdf:Nieto1996.pdf:PDF;Nieto1996.pdf:pdf\\Nieto1996.pdf:PDF},
  institution = {Department of Epidemiology, School of Hygiene and Public Health,
	John Hopkins University, Baltimore, MD 21205, USA.},
  owner = {pl4},
  pmid = {8629613},
  timestamp = {2009.01.14}
}

@ARTICLE{Nilssen2014,
  author = {Nilssen, Yngvar and Strand, Trond-Eirik and Wiik, Robert and Bakken,
	Inger Johanne and Yu, Xue Qin and O'Connell, Dianne L. and M{\o}ller,
	Bj{\o}rn},
  title = {Utilizing national patient-register data to control for comorbidity
	in prognostic studies.},
  journal = {Clin Epidemiol},
  year = {2014},
  volume = {6},
  pages = {395--404},
  abstract = {To construct an updated comorbidity index (Patient Register Index
	[PRI]) using national data collections from Norway and compare its
	predictive ability of 1-year mortality with the Charlson Comorbidity
	Index (CCI).Data regarding over 1.11 million patients registered
	in the Norwegian Patient Register in 2010 and 2011 were used to construct
	the PRI. The PRI was evaluated by comparing its model fit and discrimination
	with the CCI.Compared with the CCI, the PRI weights decreased for
	six, increased for four, and were unchanged for seven diseases. When
	the PRI was added to the model including age and sex, the age effects
	were reduced by up to 38\% for patients older than 50 years. All
	measures of model fit improved for the PRI model.Adjustment for comorbidity
	is especially important for patients 50 years of age or older, and
	its effect on 1-year mortality is almost comparable to the age effect.
	The PRI is based on more recent data than the CCI, and is more representative
	of the general population due to its construction.},
  doi = {10.2147/CLEP.S70742},
  file = {Nilssen2014.pdf:Nilssen2014.pdf:PDF;Nilssen2014.pdf:pdf\\Nilssen2014.pdf:PDF},
  institution = {Department of Registration, Cancer Registry of Norway, Oslo, Norway.},
  language = {eng},
  medline-pst = {epublish},
  owner = {PaulD},
  pii = {clep-6-395},
  pmid = {25368532},
  timestamp = {2015.06.22},
  url = {http://dx.doi.org/10.2147/CLEP.S70742}
}

@ARTICLE{Nilsson-Ihrfelt2004,
  author = {Nilsson-Ihrfelt, Elisabeth and Fj{\"a}llskog, Marie-Louise and Blomqvist,
	Carl and Ahlgren, Johan and Edlund, Per and Hansen, J{\"o}rgen and Malmberg,
	Lena and Villman, Kenneth and Andersson, Gerhard},
  title = {Breast cancer on the Internet: the quality of {S}wedish breast cancer
	websites.},
  journal = {Breast},
  year = {2004},
  volume = {13},
  pages = {376--382},
  number = {5},
  month = {Oct},
  abstract = {The aim of this study was to investigate the quality of Swedish-language
	breast cancer information available on the Internet. The questions
	explored were the extent and type of breast cancer information available,
	the coverage and correctness of that information, and whether the
	websites fulfilled the European Commission quality criteria for health-related
	websites. Three search engines were used to find websites containing
	medical information on breast cancer. An oncologist then evaluated
	the 29 relevant sites. Only seven of these were judged suitable for
	breast cancer patients. The coverage and correctness of the medical
	information varied considerably. None of the websites fulfilled the
	European Commission quality criteria. Therefore, considerable effort
	will be required before the Internet can serve as a valuable and
	up-to-date source of information on breast cancer for both professionals
	and laypersons. Our findings broadly match the results of earlier
	studies of English-language websites.},
  doi = {10.1016/j.breast.2004.03.003},
  file = {Nilsson-Ihrfelt2004.pdf:pdf\\Nilsson-Ihrfelt2004.pdf:PDF;Nilsson-Ihrfelt2004.pdf:Nilsson-Ihrfelt2004.pdf:PDF},
  institution = {Department of Psychology, Uppsala University, Box 1225, SE-751 42
	Uppsala, Sweden. elisabeth.nilsson-ihrfelt@psyk.uu.se},
  keywords = {Breast Neoplasms; Female; Humans; Information Dissemination, methods;
	Internet; Quality of Health Care; Sweden},
  language = {eng},
  medline-pst = {ppublish},
  owner = {sanelo},
  pii = {S0960977604000487},
  pmid = {15454192},
  timestamp = {2013.10.17},
  url = {http://dx.doi.org/10.1016/j.breast.2004.03.003}
}

@ARTICLE{Noordzij2013,
  author = {Noordzij, Marlies and Leffondr{\AA}Â©, Karen and {van Stralen}, Karlijn
	J. and Zoccali, Carmine and Dekker, Friedo W. and Jager, Kitty J.},
  title = {When do we need competing risks methods for survival analysis in
	nephrology?},
  journal = {Nephrol Dial Transplant},
  year = {2013},
  volume = {28},
  pages = {2670-2677},
  number = {11},
  month = {Aug},
  abstract = {Survival analyses are commonly applied to study death or other events
	of interest. In such analyses, so-called competing risks may form
	an important problem. A competing risk is an event that either hinders
	the observation of the event of interest or modifies the chance that
	this event occurs. For example, when studying death on dialysis,
	receiving a kidney transplant is an event that competes with the
	event of interest. Conventional methods for survival analysis ignoring
	the competing event(s), such as the Kaplan-Meier method and standard
	Cox proportional hazards regression, may be inappropriate in the
	presence of competing risks, and alternative methods specifically
	designed for analysing competing risks data should then be applied.
	This problem deserves more attention in nephrology research and in
	the current article, we therefore explain the problem of competing
	risks in survival analysis and how using different techniques may
	affect study results.},
  doi = {10.1093/ndt/gft355},
  institution = {ERA-EDTA Registry, Department of Medical Informatics, Academic Medical
	Center, University of Amsterdam, Amsterdam, The Netherlands.},
  language = {eng},
  medline-pst = {aheadofprint},
  owner = {sanelo},
  pii = {gft355},
  pmid = {23975843},
  timestamp = {2013.09.17},
  url = {http://dx.doi.org/10.1093/ndt/gft355}
}

@ARTICLE{Nordenvall2013,
  author = {Nordenvall, Caroline and Nilsson, Per J. and Ye, Weimin and Andersson,
	Therese M-L. and Nyr{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¬ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¬ Olof},
  title = {Tobacco use and cancer survival: a cohort study of 40,230 Swedish
	male construction workers with incident cancer.},
  journal = {Int J Cancer},
  year = {2013},
  volume = {132},
  pages = {155--161},
  number = {1},
  month = {Jan},
  abstract = {On theoretical grounds, nicotine has been implicated as a modifier
	of cancer progression. We investigated possible associations of smoking
	or use of Scandinavian moist snuff (snus) with survival after cancer
	among Swedish male construction workers. Snus use is associated with
	substantial exposure to nicotine but not to the combustion products
	in smoke. Among 336,381 workers with detailed information on tobacco
	use in 1971-1992, we observed 40,230 incident cancers. Complete follow-up
	through 2007 was accomplished through linkage to population and health
	registers. Hazard ratios (HRs) and 95\% confidence intervals (CIs)
	for death from any cause, cancer-specific death and death from other
	causes were derived from Cox proportional hazards regression models
	adjusted for age at diagnosis, body mass index at study entry and
	period of diagnosis. Never users of any tobacco served as reference.
	Increased risks of cancer-specific death were observed both among
	exclusive smokers (HR(all cancer) 1.15, 95\% CI: 1.10-1.21) and never-smoking
	snus users (1.15, 95\% CI: 1.05-1.26). As regards deaths due to other
	causes, exclusive smokers had higher relative risks than exclusive
	snus users (p = 0.03). A history of tobacco use, even exclusive use
	of the seemingly benign snus, is associated with moderately increased
	cancer-specific mortality. Although nicotine might play a role, the
	mechanisms warrant further investigation.},
  doi = {10.1002/ijc.27587},
  institution = {Division of Coloproctology, Center of Surgical Gastroenterology,
	Karolinska University Hospital, Stockholm, Sweden. caroline.nordenvall@
	ki.se},
  language = {eng},
  medline-pst = {ppublish},
  owner = {theand},
  pmid = {22492255},
  timestamp = {2013.01.20},
  url = {http://dx.doi.org/10.1002/ijc.27587}
}

@ARTICLE{Nordstroem2013,
  author = {Nordstr{\"o}m, Tobias and Aly, Markus and Clements, Mark S. and Weibull,
	Caroline E. and Adolfsson, Jan and Gr{\"o}nberg, Henrik},
  title = {Prostate-specific antigen ({PSA}) testing is prevalent and increasing
	in {S}tockholm {C}ounty, {S}weden, Despite no recommendations for
	{PSA} screening: results from a population-based study, 2003-2011.},
  journal = {Eur Urol},
  year = {2013},
  volume = {63},
  pages = {419--425},
  number = {3},
  month = {Mar},
  abstract = {Prostate-specific antigen (PSA) testing has increased in several countries.
	There is incomplete knowledge of PSA testing patterns.Determine the
	prevalence of PSA testing and explore patterns of PSA retesting in
	Stockholm County, Sweden.A population-based study was performed.
	Through registry linkages, we collected population information, data
	on PSA tests, pathology reports, and clinical information. The study
	population comprised males living in Stockholm County in 2011 (n=1034129),
	of which 229 872 had a PSA test during the period 2003-2011.We determined
	limited-duration-point prevalence of PSA testing and performed survival
	analysis on PSA retesting for men aged 40-89 yr.The number of PSA
	tests increased from 54239 in 2003 to 124613 in 2011. During the
	9-yr study period, 46\%, 68\%, and 77\% of men without a prior prostate
	cancer (PCa) diagnosis and aged 50-59 yr, 60-69 yr, and 70-79 yr,
	respectively, had a PSA test. During 2010 and 2011, 25\%, 40\%, and
	46\% of men aged 50-59 yr, 60-69 yr, and 70-79 yr, respectively,
	had a PSA test. The prevalence of PSA testing increased from 2003
	to 2011. The probability of retesting was PSA and age dependent,
	with a 26-mo cumulative incidence of 0.337 (95\% confidence interval,
	0.333-0.341) if the first PSA value was <1 ng/ml. The main limitations
	were (1) that PSA data prior to 2003 were not available and (2) that
	the study cohort was restricted to men who were alive in 2011.Although
	screening for PCa is not recommended in Sweden, PSA testing in Stockholm
	County was high across ages ranging from 40 to 89 yr and increased
	during the period 2003-2011. The probability of PSA retesting was
	high, regardless of the original PSA level. These results contrast
	with current clinical recommendations and raise calls for a change,
	either through structured PCa testing or more detailed guidelines
	on PSA testing.},
  doi = {10.1016/j.eururo.2012.10.001},
  institution = {Department of Clinical Sciences at Danderyds Hospital, Karolinska
	Institutet, Stockholm, Sweden. tobias.nordstrom@ki.se},
  keywords = {Aged; Biopsy, statistics /&/ numerical data/utilization; Humans; Incidence;
	Male; Mass Screening, standards/statistics /&/ numerical data/utilization;
	Middle Aged; Practice Guidelines as Topic; Prevalence; Prostate-Specific
	Antigen, blood; Prostatic Neoplasms, blood/diagnosis/mortality; Risk
	Factors; Sweden, epidemiology},
  language = {eng},
  medline-pst = {ppublish},
  owner = {sanelo},
  pii = {S0302-2838(12)01220-1},
  pmid = {23083803},
  timestamp = {2013.07.31},
  url = {http://dx.doi.org/10.1016/j.eururo.2012.10.001}
}

@ARTICLE{Norman1998,
  author = {P. E. Norman and J. B. Semmens and M. M. Lawrence-Brown and C. D.
	Holman},
  title = {Long term relative survival after surgery for abdominal aortic aneurysm
	in western Australia: population based study.},
  journal = {BMJ},
  year = {1998},
  volume = {317},
  pages = {852--856},
  number = {7162},
  month = {Sep},
  abstract = {OBJECTIVE: To determine the long term relative survival of all patients
	who had surgery for abdominal aortic aneurysm in Western Australia
	during 1985-94. DESIGN: Population based study. SETTING: Western
	Australia. SUBJECTS: All patients who had had surgery for abdominal
	aortic aneurysm in Western Australia during 1985-94. MAIN OUTCOME
	MEASURES: Morbidity and mortality data of patients admitted and surgically
	treated for abdominal aortic aneurysm in Western Australia during
	1985-94. Elective, ruptured, and acute non-ruptured cases were analysed
	separately. Independent analyses for sex and patients aged 80 years
	or more were also undertaken. Postoperative (>30 days) relative survival
	was assessed against age and sex matched controls. RESULTS: Overall,
	1475 (1257 men, 218 women) cases were identified. The crude five
	year survival after elective surgery, including deaths within 30
	days of surgery, was 79\% for both men and women. When compared with
	a matched population the five year relative survival after elective
	surgery was 94.9\% (95\% confidence interval 89.9\% to 99.9\%) for
	men but only 88.0\% (76.3\% to 99.7\%) for women. The five year relative
	survival of those aged 80 years and over was good: 116.6\% (89.1\%
	to 144.0\%) compared with 92.4\% (87.7\% to 97.0\%) for those under
	80 years of age (men and women combined). Cardiovascular disease
	caused 57.8\% of the 341 deaths after 30 days. CONCLUSION: In a condition
	such as abdominal aortic aneurysm, which occurs in elderly patients,
	relative survival is more clinically meaningful than crude survival.
	The five year relative survival in cases of elective and ruptured
	abdominal aortic aneurysm was better in men than in women. This is
	probably because of greater comorbidity in women with abdominal aortic
	aneurysm and this deserves more attention in the future. The long
	term survival outcome in octogenarians supports surgery in selected
	cases.},
  file = {Norman1998.pdf:Norman1998.pdf:PDF;Norman1998.pdf:pdf\\Norman1998.pdf:PDF},
  institution = {University Department of Surgery, Fremantle Hospital, PO Box 480,
	Fremantle, Western Australia 6959, Australia. pnorman@cyllene.uwa.edu.au},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {9748177},
  timestamp = {2010.06.21}
}

@Book{CancerRegistryofNorway2011,
  author    = {Cancer Registry of Norway},
  title     = {Cancer in {N}orway 2009 - Cancer incidence, mortality, survival and prevalence in {N}orway},
  publisher = {Oslo: Cancer Registry of Norway},
  groups    = {Cancer registry reports},
  owner     = {PaulD},
  timestamp = {2011.07.06},
  year      = {2011},
}

@ARTICLE{Nur2010,
  author = {U. Nur and L. G. Shack and B. Rachet and J. R. Carpenter and M. P.
	Coleman},
  title = {Modelling relative survival in the presence of incomplete data: a
	tutorial.},
  journal = {International Journal of Epidemiology},
  year = {2010},
  volume = {39},
  pages = {118--128},
  number = {1},
  month = {Feb},
  abstract = {Missing data frequently create problems in the analysis of population-based
	data sets, such as those collected by cancer registries. Restriction
	of analysis to records with complete data may yield inferences that
	are substantially different from those that would have been obtained
	had no data been missing. 'Naive' methods for handling missing data,
	such as restriction of the analysis to complete records or creation
	of a 'missing' category, have drawbacks that can invalidate the conclusions
	from the analysis. We offer a tutorial on modern methods for handling
	missing data in relative survival analysis.We estimated relative
	survival for 29 563 colorectal cancer patients who were diagnosed
	between 1997 and 2004 and registered in the North West Cancer Intelligence
	Service. The method of multiple imputation (MI) was applied to account
	for the common example of incomplete stage at diagnosis, under the
	missing at random (MAR) assumption. Multivariable regression with
	a generalized linear model and Poisson error structure was then used
	to estimate the excess hazard of death of the colorectal cancer patients,
	over and above the background mortality, adjusting for significant
	predictors of mortality.Incomplete information on stage, morphology
	and grade meant that only 55\% of the data could be included in the
	'complete-case' analysis. All cases could be included after indicator
	method (IM) or MI method. Handling missing data by MI produced a
	significantly lower estimate of the excess mortality for stage, morphology
	and grade, with the largest reductions occurring for late-stage and
	high-grade tumours, when compared with the results of complete-case
	analysis.In complete-case analysis, almost 50\% of the information
	could not be included, and with the IM, all records with missing
	values for stage were combined into a single 'missing' category.
	We show that MI methods greatly improved the results by exploiting
	all the information in the incomplete records. This method also helped
	to ensure efficient inferences about survival were made from the
	multivariate regression analyses.},
  doi = {10.1093/ije/dyp309},
  file = {Nur2010.pdf:Nur2010.pdf:PDF},
  institution = {roup, London School of Hygiene and Tropical Medicine, London, UK.
	ula.nur@lshtm.ac.uk},
  owner = {pl4},
  pii = {dyp309},
  pmid = {19858106},
  timestamp = {2011.06.22},
  url = {http://dx.doi.org/10.1093/ije/dyp309}
}

@ARTICLE{Nyren2014,
  author = {Nyr{\'{e}}n, Olof and Stenbeck, Magnus and Gr{\"{o}}nberg, Henrik},
  title = {The European Parliament proposal for the new EU General Data Protection
	Regulation may severely restrict European epidemiological research.},
  journal = {Eur J Epidemiol},
  year = {2014},
  volume = {29},
  pages = {227--230},
  number = {4},
  month = {Apr},
  doi = {10.1007/s10654-014-9909-0},
  file = {Nyren2014.pdf:pdf\\Nyren2014.pdf:PDF;Nyren2014.pdf:Nyren2014.pdf:PDF},
  institution = {Department of Medical Epidemiology and Biostatistics, Karolinska
	Institutet, 171 77, Stockholm, Sweden, olof.nyren@ki.se.},
  keywords = {Computer Security, legislation /&/ jurisprudence/standards; Confidentiality;
	Epidemiologic Methods; European Union; Humans; Information Management,
	legislation /&/ jurisprudence/standards; International Cooperation;
	Medical Informatics, legislation /&/ jurisprudence/standards; Medical
	Records; Privacy, legislation /&/ jurisprudence},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pmid = {24802287},
  timestamp = {2014.10.10},
  url = {http://dx.doi.org/10.1007/s10654-014-9909-0}
}

@ARTICLE{Obermair2013,
  author = {Obermair, Andreas and Youlden, Danny R. and Baade, Peter D. and Janda,
	Monika},
  title = {The impact of risk-reducing hysterectomy and bilateral salpingo-oophorectomy
	on survival in patients with a history of breast cancer-A population-based
	data linkage study.},
  journal = {International Journal of Cancer},
  year = {2013},
  month = {Oct},
  abstract = {Prophylactic surgery including hysterectomy and bilateral salpingo-oophorectomy
	(BSO) is recommended in breast cancer susceptibility gene (BRCA)-positive
	women, whereas in women from the general population, hysterectomy
	plus BSO may increase the risk of overall mortality. The effect of
	hysterectomy plus BSO on women previously diagnosed with breast cancer
	is unknown. We used data from a population-base data linkage study
	of all women diagnosed with primary breast cancer in Queensland,
	Australia between 1997 and 2008 (n = 21,067). We fitted flexible
	parametric breast cancer-specific and overall survival models with
	95\% confidence intervals (also known as Royston-Parmar models) to
	assess the impact of risk-reducing surgery (removal of uterus, one
	or both ovaries). We also stratified analyses by age 20-49 and 50-79
	years, respectively. Overall, 1,426 women (7\%) underwent risk-reducing
	surgery (13\% of premenopausal women and 3\% of postmenopausal women).
	No women who had risk-reducing surgery compared to 171 who did not
	have risk-reducing surgery developed a gynaecological cancer. Overall,
	3,165 (15\%) women died, including 2,195 (10\%) from breast cancer.
	Hysterectomy plus BSO was associated with significantly reduced risk
	of death overall [adjusted hazard ration (HR), 0.69; 95\% confidence
	interval (CI), 0.53-0.89; p = 0.005]. Risk reduction was greater
	among premenopausal women, whose risk of death halved (HR, 0.45;
	95\% CI, 0.25-0.79; p < 0.006). This was largely driven by reduction
	in breast cancer-specific mortality (HR, 0.43; 95\% CI, 0.24-0.79;
	p < 0.006). This population-based study found that risk-reducing
	surgery halved the mortality risk for premenopausal breast cancer
	patients. Replication of our results in independent cohorts and subsequently
	randomised trials are needed to confirm these findings.},
  doi = {10.1002/ijc.28537},
  institution = {Queensland Centre for Gynaecological Cancer School of Medicine, The
	University of Queensland, Royal Brisbane and Women's Hospital, Brisbane,
	QLD, Australia.},
  language = {eng},
  medline-pst = {aheadofprint},
  owner = {pl4},
  pmid = {24127248},
  timestamp = {2013.11.01},
  url = {http://dx.doi.org/10.1002/ijc.28537}
}

@PhdThesis{Oksanen1998,
  author    = {Oksanen, Hanna},
  title     = {Modelling the Survival of Prostate Cancer Patients},
  note      = {Acta Universitatis Tamperensis, vol 615},
  groups    = {PhD Thesis},
  owner     = {PaulD},
  school    = {University of Tampere, Finland},
  timestamp = {2011.06.19},
  year      = {1998},
}

@ARTICLE{Olschewski1994,
  author = {Olschewski, M. and Schlugen, G. and Schumacher, M. and Altman, D.
	G.},
  title = {Quality of Life Assessment in Clinical Cancer Research},
  journal = {British Journal of Cancer},
  year = {1994},
  volume = {70},
  pages = {1-5},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Olsen2014,
  author = {Olsen, J{\o}rn},
  title = {Data protection and epidemiological research: a new EU regulation
	is in the pipeline.},
  journal = {Int J Epidemiol},
  year = {2014},
  month = {Aug},
  doi = {10.1093/ije/dyu165},
  file = {Olsen2014.pdf:Olsen2014.pdf:PDF;Olsen2014.pdf:pdf\\Olsen2014.pdf:PDF},
  institution = {Department of Public Health-Epidemiology, University of Aarhus, Bartholins
	Alle 2 - Building 1260, DK-8000 Aarhus C, Denmark.},
  language = {eng},
  medline-pst = {aheadofprint},
  owner = {PaulD},
  pii = {dyu165},
  pmid = {25135907},
  timestamp = {2014.10.10},
  url = {http://dx.doi.org/10.1093/ije/dyu165}
}

@ARTICLE{Olson1975,
  author = {Olson, J.},
  title = {Autocorrelation and Visual Map Complexity},
  journal = {Annals of the Association of American Geographers},
  year = {1975},
  volume = {65},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Oommen2003,
  author = {Abraham Oommen and Paul C Lambert and Jonathan Grigg},
  title = {Efficacy of a short course of parent-initiated oral prednisolone
	for viral wheeze in children aged 1-5 years: randomised controlled
	trial.},
  journal = {Lancet},
  year = {2003},
  volume = {362},
  pages = {1433--1438},
  number = {9394},
  month = {Nov},
  abstract = {BACKGROUND: Episodic wheeze triggered by viral colds is common in
	children aged between 1 and 5 years (preschool viral wheeze). Most
	affected children are asymptomatic by age 6 years. Persistence of
	wheeze is associated with above-average systemic eosinophil priming.
	Use of parental-initiated oral prednisolone is recommended at the
	first sign of preschool viral wheeze. However, evidence for this
	treatment strategy is conflicting. We therefore aimed to assess the
	efficacy of a short course of oral prednisolone for preschool viral
	wheeze, with stratification for systemic eosinophil priming. METHODS:
	Children aged 1-5 years admitted to hospital with viral wheeze were
	allocated to either a high-primed or low-primed stratum according
	to amounts of serum eosinophil cationic protein and eosinophil protein
	X, and randomised to parent-initiated prednisolone (20 mg one daily
	for 5 days) or placebo for the next episode. The primary outcomes
	were the 7-day mean daytime and night-time respiratory symptom scores,
	which were analysed by mean differences between treatment groups.
	FINDINGS: 108 children were randomised to placebo and 109 to prednisolone.
	Outcome data were available for 120 (78\%) of 153 children who had
	a further episode of viral wheeze, of whom 51 received prednisolone
	and 69 placebo. Mean daytime (difference in means -0.01 [-0.22 to
	0.20]) and night-time (0.10 [-0.12 to 0.32]) respiratory symptom
	scores and need for hospital admission did not differ between treatment
	groups. Within the high-primed (n=59) and low-primed (n=61) strata
	there was no difference in primary outcome between treatment groups.
	INTERPRETATION: There is no clear benefit of a short course of parent-initiated
	oral prednisolone for viral wheeze in children aged 1-5 years even
	in those with above-average eosinophil priming.},
  doi = {10.1016/S0140-6736(03)14685-5},
  file = {oommen2003.pdf:oommen2003.pdf:PDF},
  institution = {Leicester Children's Asthma Centre, Institute for Lung Health, University
	of Leicester, Leicester, UK.},
  owner = {pl4},
  pii = {S0140-6736(03)14685-5},
  pmid = {14602435},
  timestamp = {2008.10.15},
  url = {http://dx.doi.org/10.1016/S0140-6736(03)14685-5}
}

@Book{WorldHealthOrganisation1999,
  author    = {World Health Organisation},
  title     = {The International Classification of Diseases, Volume 7},
  note      = {(fix this reference)},
  publisher = {World Health Organisation},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1999},
}

@Book{WorldHealthOrganisation1982,
  author    = {World Health Organisation},
  title     = {Plan of Action Implementing the Global Strategy for Health for All},
  publisher = {Geneva: World Health Organisation},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1982},
}

@ARTICLE{Orsini2011,
  author = {N. Orsini and M. Bottai},
  title = {Logistic quantile regression in Stata},
  journal = {The Stata Journal},
  year = {2011},
  volume = {11},
  pages = {327-344},
  file = {Orsini2011.pdf:Orsini2011.pdf:PDF},
  owner = {pl4},
  timestamp = {2014.06.02}
}

@ARTICLE{Orsini2012,
  author = {Orsini, Nicola and Wolk, Alicja and Bottai, Matteo},
  title = {Evaluating percentiles of survival.},
  journal = {Epidemiology},
  year = {2012},
  volume = {23},
  pages = {770--771},
  number = {5},
  month = {Sep},
  doi = {10.1097/EDE.0b013e3182625eff},
  file = {Orsini2012.pdf:Orsini2012.pdf:PDF},
  keywords = {Aged; Cardiovascular Diseases, complications/mortality; Humans; Likelihood
	Functions; Male; Middle Aged; Obesity, complications; Regression
	Analysis; Survival Analysis},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {00001648-201209000-00024},
  pmid = {22872120},
  timestamp = {2014.06.02},
  url = {http://dx.doi.org/10.1097/EDE.0b013e3182625eff}
}

@ARTICLE{Osby2004,
  author = {Eva Osby and Johan Askling and Ola Landgren and Paul W Dickman and
	Anders Ekbom and Magnus Bj\"{o}rkholm},
  title = {Parental longevity and prognosis in elderly patients with aggressive
	non-{H}odgkin's lymphoma.},
  journal = {Acta Oncol},
  year = {2004},
  volume = {43},
  pages = {297-301},
  number = {3},
  abstract = {In general, elderly patients with aggressive non-Hodgkin's lymphoma
	(NHL) have a less favourable prognosis than younger patients. Established
	predictors of prognosis in NHL are less discriminatory in the elderly,
	which is why there is a need for additional markers giving guidance
	on treatment decisions and prediction of outcome. The expected length
	of life of an individual in the general population is intimately
	associated with that of his/her parents. The aim of this study was
	to test the hypothesis that parental longevity is associated with
	improved outcome also among elderly patients with aggressive NHL
	and thus serves as an easily accessible non-disease associated prognostic
	factor. A total of 220 patients ( > 60 years) with aggressive NHL
	with a median age of 71 years (range 60-86) were included. Patients
	were randomized to receive CHOP or CNOP (doxorubicin replaced with
	mitoxantrone) chemotherapy with or without the addition of granulocyte
	colony-stimulating factor. The median follow-up time was 56 (19-89)
	months. Parental data regarding age at death were available through
	parish offices for 425 (97\%) parents. Relative risk (RR) of death
	(disease-specific and all-cause) associated with parental lifespan
	was assessed using Cox proportional hazards regression analyses,
	with adjustment for sex, age, prognostic index, symptoms, and calendar
	period of diagnosis. Maternal lifespan below (versus above) median
	was associated with a borderline significant reduced disease-specific
	(adjusted RR of death from NHL = 1.5; 95\% confidence interval 1.0-2.1)
	and overall survival. The effect of maternal lifespan was somewhat
	more pronounced in patients receiving CHOP than CNOP treatment. Paternal
	lifespan below the median was associated with a borderline significant
	increased disease-specific (adjusted RR of death from NHL = 0.8 [0.5-1.0])
	and overall survival. Combined, maternal, and paternal lifespan had
	little impact on survival. These effects were true also when CHOP
	and CNOP treated patients were analysed separately. Maternal and
	paternal lifespan may predict survival in NHL, but with opposing
	effects. At present parental age appears not to be a clinically useful
	predictor of prognosis in the elderly with aggressive NHL.},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Osmond1985,
  author = {Osmond, C.},
  title = {Using age, period and cohort models to estimate future mortality
	rates.},
  journal = {Int J Epidemiol},
  year = {1985},
  volume = {14},
  pages = {124--129},
  number = {1},
  month = {Mar},
  abstract = {A description of a table of age- and period-specific mortality rates
	may be provided by the use of age, period and cohort models. These
	may be extended to produce estimates of future mortality rates that
	allow for trends related to both birth cohort and period of death.
	Lung cancer mortality rates for women in England and Wales are used
	as an example. The period 1951-70 is used to estimate mortality rates
	for 1971-80 and comparisons are made with the observed values. The
	technique is then used to estimate mortality rates until the year
	2000 based upon 1951-80. The range of conditions for which this method
	is appropriate is discussed.},
  file = {Osmond1985.pdf:Osmond1985.pdf:PDF},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {3988427},
  timestamp = {2012.02.06}
}

@ARTICLE{Ostman2006,
  author = {Pekka Ostman and Sirkku J\"{a}ntti and Kestas Grigoras and Ville
	Saarela and Raimo A Ketola and Sami Franssila and Tapio Kotiaho and
	Risto Kostiainen},
  title = {Capillary liquid chromatography-microchip atmospheric pressure chemical
	ionization-mass spectrometry.},
  journal = {Lab Chip},
  year = {2006},
  volume = {6},
  pages = {948--953},
  number = {7},
  month = {Jul},
  abstract = {A miniaturized nebulizer chip for capillary liquid chromatography-atmospheric
	pressure chemical ionization-mass spectrometry (capillary LC-microchip
	APCI-MS) is presented. The APCI chip consists of two wafers, a silicon
	wafer and a Pyrex glass wafer. The silicon wafer has a DRIE etched
	through-wafer nebulizer gas inlet, an edge capillary insertion channel,
	a stopper, a vaporizer channel and a nozzle. The platinum heater
	electrode and pads for electrical connection were patterned on to
	the Pyrex glass wafer. The two wafers were joined by anodic bonding,
	creating a microchip version of an APCI-source. The sample inlet
	capillary from an LC column is directly connected to the vaporizer
	channel of the APCI chip. The etched nozzle in the microchip forms
	a narrow sample plume, which is ionized by an external corona needle,
	and the formed ions are analyzed by a mass spectrometer. The nebulizer
	chip enables for the first time the use of low flow rate separation
	techniques with APCI-MS. The performance of capillary LC-microchip
	APCI-MS was tested with selected neurosteroids. The capillary LC-microchip
	APCI-MS provides quantitative repeatability and good linearity. The
	limits of detection (LOD) with a signal-to-noise ratio (S/N) of 3
	in MS/MS mode for the selected neurosteroids were 20-1000 fmol (10-500
	nmol l(-1)). LODs (S/N = 3) with commercial macro APCI with the same
	compounds using the same MS were about 10 times higher. Fast heat
	transfer allows the use of the optimized temperature for each compound
	during an LC run. The microchip APCI-source provides a convenient
	and easy method to combine capillary LC to any API-MS equipped with
	an APCI source. The advantages and potentials of the microchip APCI
	also make it a very attractive interface in microfluidic APCI-MS.},
  doi = {10.1039/b601290f},
  institution = {Division of Pharmaceutical Chemistry, Faculty of Pharmacy, P.O. Box
	56, FI-00014, University of Helsinki, Finland. pekka.ostman@helsinki.fi},
  owner = {pl4},
  pmid = {16804601},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1039/b601290f}
}

@ARTICLE{Paahlman2007,
  author = {P{\aa}hlman, L. and Bohe, M. and Cedermark, B. and Dahlberg, M. and
	Lindmark, G. and Sj\"{o}dahl, R. and Ojerskog, B. and Damber, L.
	and Johansson, R.},
  title = {The Swedish rectal cancer registry.},
  journal = {British Journal Surgary},
  year = {2007},
  volume = {94},
  pages = {1285--1292},
  number = {10},
  month = {Oct},
  abstract = {An audit of all patients with rectal cancer in Sweden was launched
	in 1995. This is the first report from the Swedish Rectal Cancer
	Registry (SRCR).Between 1995 and 2003, 13 434 patients treated for
	adenocarcinoma of the rectum were registered with the SRCR; there
	were approximately 1500 new patients annually.Approximately half
	had an anterior resection, a quarter an abdominoperineal resection
	and 15 per cent a Hartmann's procedure. The median 30-day postoperative
	mortality rate was 2.4 per cent and the overall postoperative morbidity
	rate was 35.0 per cent. The 5-year cancer-specific survival rate
	was 62.3 per cent. The 5-year relative survival rate was 70.1 per
	cent after anterior resection, 59.8 per cent after abdominoperineal
	resection and 39.8 per cent after a Hartmann's procedure. The crude
	5-year local recurrence rate was 9.5 per cent overall, 6.1 per cent
	after preoperative radiotherapy and 11.4 per cent after surgery alone.
	For 3868 patients who had a locally curative procedure the local
	recurrence rate was 7.4 per cent overall, 5.9 per cent for those
	who had radiotherapy and 10.2 per cent for those who did not. The
	local recurrence rate was 2.9 per cent (28 of 968) for stage I disease,
	7.9 per cent (112 of 1418) for stage II, 13.9 per cent (188 of 1357)
	for stage III and 8.5 per cent (45 of 532) for stage IV.These good
	population-based results are due, in part, to the nationwide prospective
	quality assurance registration.},
  doi = {10.1002/bjs.5679},
  institution = {Department of Surgery, University Hospital, Uppsala, Sweden.},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {17661309},
  timestamp = {2012.04.13},
  url = {http://dx.doi.org/10.1002/bjs.5679}
}

@TechReport{Page1990,
  author      = {Page, T. and Gibberd, R. W. and Chan, P. and Lam, P.},
  institution = {Hunter Health Statistics Unit},
  title       = {Mortality in {N}ew {S}outh {W}ales 1984-88, Cause Specific Mortality for Area Health Services and Regions},
  address     = {University of Newcastle, Australia},
  owner       = {PaulD},
  timestamp   = {2011.06.19},
  year        = {1990},
}

@ARTICLE{Pajukanta2004,
  author = {P\"{a}ivi Pajukanta and Heidi E Lilja and Janet S Sinsheimer and
	Rita M Cantor and Aldons J Lusis and Massimiliano Gentile and Xiaoqun
	Joyce Duan and Aino Soro-Paavonen and Jussi Naukkarinen and Janna
	Saarela and Markku Laakso and Christian Ehnholm and Marja-Riitta
	Taskinen and Leena Peltonen},
  title = {Familial combined hyperlipidemia is associated with upstream transcription
	factor 1 (USF1).},
  journal = {Nat Genet},
  year = {2004},
  volume = {36},
  pages = {371--376},
  number = {4},
  month = {Apr},
  abstract = {Familial combined hyperlipidemia (FCHL), characterized by elevated
	levels of serum total cholesterol, triglycerides or both, is observed
	in about 20\% of individuals with premature coronary heart disease.
	We previously identified a locus linked to FCHL on 1q21-q23 in Finnish
	families with the disease. This region has also been linked to FCHL
	in families from other populations as well as to type 2 diabetes
	mellitus. These clinical entities have several overlapping phenotypic
	features, raising the possibility that the same gene may underlie
	the obtained linkage results. Here, we show that the human gene encoding
	thioredoxin interacting protein (TXNIP) on 1q, which underlies combined
	hyperlipidemia in mice, is not associated with FCHL. We show that
	FCHL is linked and associated with the gene encoding upstream transcription
	factor 1 (USF1) in 60 extended families with FCHL, including 721
	genotyped individuals (P = 0.00002), especially in males with high
	triglycerides (P = 0.0000009). Expression profiles in fat biopsy
	samples from individuals with FCHL seemed to differ depending on
	their carrier status for the associated USF1 haplotype. USF1 encodes
	a transcription factor known to regulate several genes of glucose
	and lipid metabolism.},
  doi = {10.1038/ng1320},
  institution = {Department of Human Genetics, David Geffen School of Medicine at
	UCLA, University of California, Los Angeles, California 90095-7088,
	USA. ppajukanta@mednet.ucla.edu},
  owner = {pl4},
  pii = {ng1320},
  pmid = {14991056},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1038/ng1320}
}

@InProceedings{Palmgren1991,
  author    = {Palmgren, Juni},
  booktitle = {A Spectrum of Statistical Thought},
  title     = {Approaches to modelling bivariate binary responses: {A}n empirical adventure},
  pages     = {201--212},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1991},
}

@ARTICLE{Panickar2009,
  author = {Jayachandran Panickar and Monica Lakhanpaul and Paul C Lambert and
	Priti Kenia and Terence Stephenson and Alan Smyth and Jonathan Grigg},
  title = {Oral prednisolone for preschool children with acute virus-induced
	wheezing.},
  journal = {New England Journal of Medicine},
  year = {2009},
  volume = {360},
  pages = {329--338},
  number = {4},
  month = {Jan},
  abstract = {BACKGROUND: Attacks of wheezing induced by upper respiratory viral
	infections are common in preschool children between the ages of 10
	months and 6 years. A short course of oral prednisolone is widely
	used to treat preschool children with wheezing who present to a hospital,
	but there is conflicting evidence regarding its efficacy in this
	age group. METHODS: We conducted a randomized, double-blind, placebo-controlled
	trial comparing a 5-day course of oral prednisolone (10 mg once a
	day for children 10 to 24 months of age and 20 mg once a day for
	older children) with placebo in 700 children between the ages of
	10 months and 60 months. The children presented to three hospitals
	in England with an attack of wheezing associated with a viral infection;
	687 children were included in the intention-to-treat analysis (343
	in the prednisolone group and 344 in the placebo group). The primary
	outcome was the duration of hospitalization. Secondary outcomes were
	the score on the Preschool Respiratory Assessment Measure, albuterol
	use, and a 7-day symptom score. RESULTS: There was no significant
	difference in the duration of hospitalization between the placebo
	group and the prednisolone group (13.9 hours vs. 11.0 hours; ratio
	of geometric means, 0.90; 95\% confidence interval, 0.77 to 1.05)
	or in the interval between hospital admission and signoff for discharge
	by a physician. In addition, there was no significant difference
	between the two study groups for any of the secondary outcomes or
	for the number of adverse events. CONCLUSIONS: In preschool children
	presenting to a hospital with mild-to-moderate wheezing associated
	with a viral infection, oral prednisolone was not superior to placebo.
	(Current Controlled Trials number, ISRCTN58363576.)},
  doi = {10.1056/NEJMoa0804897},
  file = {Panickar2009.pdf:Panickar2009.pdf:PDF;Panickar2009.pdf:pdf\\Panickar2009.pdf:PDF},
  institution = {Division of Child Health, University of Leicester, Leicester, United
	Kingdom.},
  owner = {pl4},
  pii = {360/4/329},
  pmid = {19164186},
  timestamp = {2009.03.19},
  url = {http://dx.doi.org/10.1056/NEJMoa0804897}
}

@ARTICLE{Pappas1993,
  author = {Pappas, G. and Queen, S. and Hadden, W. and Fisher, G.},
  title = {The Increasing Disparity in Mortality Between Socioeconomic Groups
	in the {U}nited {S}tates, 1960 and 1986},
  journal = {New England Journal of Medicine},
  year = {1993},
  volume = {329},
  pages = {103-109},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@Article{Parkin2008,
  author      = {Parkin, Donald Maxwell},
  title       = {The role of cancer registries in cancer control.},
  doi         = {10.1007/s10147-008-0762-6},
  language    = {eng},
  number      = {2},
  pages       = {102--111},
  url         = {http://dx.doi.org/10.1007/s10147-008-0762-6},
  volume      = {13},
  abstract    = {Cancer control aims to reduce the incidence, morbidity, and mortality
	of cancer and to improve the quality of life of cancer patients through
	the systematic implementation of evidence-based interventions in
	prevention, early diagnosis, treatment, and palliative care. In the
	context of a national cancer control program (NCCP), a cancer surveillance
	program (CSP), built around a population-based cancer registry, is
	an essential element. Data on the size and evolution of the cancer
	burden in the population are essential to evaluation of the current
	situation, to setting objectives for cancer control, and defining
	priorities. Cancer data are essential in monitoring the progress
	of the implementation of an NCCP, as well as providing an evaluation
	of the many individual cancer control activities. In the context
	of an NCCP, the CSP should provide a focus of epidemiological expertise,
	not only for providing statistical data on incidence, mortality,
	stage distribution, treatment patterns, and survival but also for
	conducting studies into the important causes of cancer in the local
	situation, and for providing information about the prevalence of
	exposure to these factors in the population. Cancer surveillance
	via the population-based registry therefore plays a crucial role
	in formulating cancer control plans, as well as in monitoring their
	success.},
  institution = {Clinical Trials Service Unit and Epidemiological Studies Unit, University of Oxford, Richard Doll Building, Old Road Campus, Oxford, OX3 7LF, UK. max.parkin@ctsu.ox.ac.uk},
  journal     = {Int J Clin Oncol},
  keywords    = {Delivery of Health Care; Evaluation Studies as Topic; Government Programs; Health Policy; Humans; Neoplasms, epidemiology/prevention /&/ control; Population Surveillance; Registries},
  medline-pst = {ppublish},
  owner       = {sanelo},
  pmid        = {18463952},
  timestamp   = {2013.08.01},
  year        = {2008},
}

@Article{Parkin2006a,
  author      = {Parkin, Donald M.},
  title       = {The evolution of the population-based cancer registry.},
  doi         = {10.1038/nrc1948},
  language    = {eng},
  number      = {8},
  pages       = {603--612},
  url         = {http://dx.doi.org/10.1038/nrc1948},
  volume      = {6},
  abstract    = {The idea of recording information on all cancer cases in defined communities
	dates from the first half of the twentieth century, and there has
	been a steady growth in the number of such cancer registries since.
	Originally, they were concerned primarily with describing cancer
	patterns and trends. Later, many were able to follow up the registered
	patients and calculate survival. In the last 20 years the role of
	registries has expanded further to embrace the planning and evaluation
	of cancer control activities, and the care of individual cancer patients.
	This Review looks at the current status of cancer registration practice
	and use from an international perspective, mindful that the registration
	of cancer has expanded into a global activity.},
  institution = {Epidemiological Studies Unit, University of Oxford, Richard Doll Building, Old Road Campus, Oxford, OX3 7LF, UK. max.parkin@ctsu.ox.ac.uk},
  journal     = {Nat Rev Cancer},
  keywords    = {Humans; Neoplasms, diagnosis/epidemiology/therapy; Population Surveillance; Registries; Survival Analysis},
  medline-pst = {ppublish},
  month       = {Aug},
  owner       = {PaulD},
  pii         = {nrc1948},
  pmid        = {16862191},
  timestamp   = {2013.07.29},
  year        = {2006},
}

@Article{Parkin2009,
  author      = {Parkin, D Max and Bray, Freddie},
  title       = {Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness.},
  journal     = {Eur J Cancer},
  year        = {2009},
  language    = {eng},
  volume      = {45},
  number      = {5},
  month       = {Mar},
  pages       = {756--764},
  doi         = {10.1016/j.ejca.2008.11.033},
  url         = {http://dx.doi.org/10.1016/j.ejca.2008.11.033},
  abstract    = {The completeness of cancer registry data -- the extent to which all
	of the incident cancers occurring in the population are included
	in the registry database -- is an extremely important attribute of
	a cancer registry. Only a high degree of completeness in case-finding
	procedures will ensure cancer incidence rates and survival proportions
	are close to their true value. This second instalment of a two-part
	review of data quality methods at the cancer registry, focuses on
	the principles and techniques available for estimating completeness,
	separating methods into those that are semi-quantitative -- in that
	they give an indication of the degree of completeness relative to
	other registries or over time, and more quantitative techniques --
	those that provide a numerical evaluation of the extent to which
	all eligible cases have been registered.},
  file        = {:Parkin2009.pdf:PDF},
  institution = {Clinical Trials Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, UK. max.parkin@ctsu.ox.ac.uk},
  keywords    = {Adolescent; Child; Child, Preschool; Death Certificates; Female; Humans; Incidence; Infant; Infant, Newborn; Male; Neoplasms, diagnosis/epidemiology/mortality; Quality Control; Registries, standards/statistics /&/ numerical data; Reproducibility of Results; Research Design, standards},
  medline-pst = {ppublish},
  owner       = {pl4},
  pii         = {S0959-8049(08)00919-2},
  pmid        = {19128954},
  timestamp   = {2015.12.06},
}

@ARTICLE{Parmar1998,
  author = {M. K. Parmar and V. Torri and L. Stewart},
  title = {Extracting summary statistics to perform meta-analyses of the published
	literature for survival endpoints.},
  journal = {Statistics in Medicine},
  year = {1998},
  volume = {17},
  pages = {2815--2834},
  number = {24},
  month = {Dec},
  abstract = {Meta-analyses aim to provide a full and comprehensive summary of related
	studies which have addressed a similar question. When the studies
	involve time to event (survival-type) data the most appropriate statistics
	to use are the log hazard ratio and its variance. However, these
	are not always explicitly presented for each study. In this paper
	a number of methods of extracting estimates of these statistics in
	a variety of situations are presented. Use of these methods should
	improve the efficiency and reliability of meta-analyses of the published
	literature with survival-type endpoints.},
  file = {parmar1998.pdf:parmar1998.pdf:PDF},
  institution = {MRC Cancer Trials Office, Cambridge, U.K.},
  owner = {pl4},
  pii = {3.0.CO;2-8},
  pmid = {9921604},
  timestamp = {2008.11.18}
}

@Book{Parmar1995,
  author    = {Parmar, M. K. B. and Machin, D.},
  title     = {Survival Analysis: A Practical Approach},
  publisher = {John Wiley \& Sons},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@ARTICLE{Parner2010,
  author = {E. T. Parner and P. K. Andersen},
  title = {Regression analysis of censored data using pseudo-observations},
  journal = {The Stata Journal},
  year = {2010},
  volume = {10},
  pages = {408-422},
  file = {Parner2010.pdf:Parner2010.pdf:PDF;Parner2010.pdf:pdf\\Parner2010.pdf:PDF},
  owner = {pl4},
  timestamp = {2013.08.28}
}

@ARTICLE{Patel2006,
  author = {Katie Patel and Richard Kay and Lucy Rowell},
  title = {Comparing proportional hazards and accelerated failure time models:
	an application in influenza.},
  journal = {Pharmaceutical Statistics},
  year = {2006},
  volume = {5},
  pages = {213--224},
  number = {3},
  abstract = {The proportional hazards (PH) model is routinely employed for the
	analysis of time-to-event data in medical research when it is required
	to assess the effect of an intervention in the presence of covariates.
	The assumption of PH required for the PH approach may not hold, especially
	in circumstances where the effect of the intervention is to delay
	or accelerate the onset of an event rather than to reduce or increase
	the overall proportion of subjects who observe the event through
	time. If the assumption of PH is violated, the results from a PH
	model will be difficult to generalize to situations where the length
	of follow-up is different to that used in the analysis. It is also
	difficult to translate the results into the effect upon the expected
	median duration of illness for a patient in a clinical setting. The
	accelerated failure time (AFT) approach is an alternative strategy
	for the analysis of time-to-event data and can be suitable even when
	hazards are not proportional and this family of models contains a
	certain form of PH as a special case. The framework can allow for
	different forms of the hazard function and may provide a closer description
	of the data in certain circumstances. In addition, the results of
	the AFT model may be easier to interpret and more relevant to clinicians,
	as they can be directly translated into expected reduction or prolongation
	of the median time to event, unlike the hazard ratio. We recommend
	that consideration is given to an AFT modelling approach in the analysis
	of time-to-event data in medical research.},
  file = {Patel2006.pdf:pdf\\Patel2006.pdf:PDF;Patel2006.pdf:Patel2006.pdf:PDF},
  institution = {Roche Global Development, Welwyn Garden City, UK. katie_m.patel@roche.com},
  owner = {pl4},
  pmid = {17080754},
  timestamp = {2009.08.07}
}

@Book{Pawit2001,
  author    = {Yudi Pawitan},
  title     = {In all likelihood -- Statistical modelling and inference using likelihood},
  publisher = {Oxford University Press},
  owner     = {theand},
  timestamp = {2013.10.01},
  year      = {2001},
}

@Book{Pawitan2001,
  author    = {Pawitan, Yudi},
  title     = {{In all likelihood : statistical modelling and inference using likelihood}},
  isbn      = {9780198507659},
  publisher = {Clarendon Press ; Oxford University Press},
  owner     = {PaulD},
  timestamp = {2015.03.09},
  year      = {2001},
}

@ARTICLE{Pearce1987,
  author = {Pearce, N. and Checkoway, H.},
  title = {A simple computer program for generating person-time data in cohort
	studies involving time-related factors},
  journal = {American Journal of Epidemiology},
  year = {1987},
  volume = {125},
  pages = {1085-91},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Peek1996,
  author = {M. Peek and A. Shennan and A. Halligan and P. C. Lambert and D. J.
	Taylor and M. De Swiet},
  title = {Hypertension in pregnancy: which method of blood pressure measurement
	is most predictive of outcome?},
  journal = {Obstet Gynecol},
  year = {1996},
  volume = {88},
  pages = {1030--1033},
  number = {6},
  month = {Dec},
  abstract = {OBJECTIVE: To determine the clinical effectiveness of blood pressure
	(BP) measurement using conventional sphygmomanometry in the antenatal
	clinic and obstetric day unit compared with automated BP monitoring
	at home. METHODS: The study population consisted of 109 nulliparous
	white women with BPs of at least 140 or 90 mmHg at the antenatal
	clinic after 20 weeks' gestation, who underwent obstetric day unit
	and 24-hour automated BP monitoring on the same day. Automated measurement
	was obtained every half hour for 24 hours using a commercially available
	device that had been previously validated in pregnancy. RESULTS:
	At the traditional BP cutoff point (140/90 mmHg), the relative risk
	for subsequent development of adverse obstetric outcome was greatest
	for automated BP measurement: The relationships between outcome and
	automated diastolic BP were all statistically significant: proteinuria
	(P = .034), preterm delivery (P < .001), birth weight below the tenth
	percentile (P = .001), admission to the special care neonatal unit
	(P = .001), and cesarean delivery (P = .007). CONCLUSION: Automated
	BP measurement appears to improve the identification of patients
	who are at high risk of poor obstetric outcome. Automated BP measurement
	is worthy of further evaluation as an antenatal screening and diagnostic
	test.},
  doi = {10.1016/S0029-7844(96)00350-X},
  file = {peek1996.pdf:peek1996.pdf:PDF},
  institution = {Queen Charlotte's and Chelsea Hospital, London, United Kingdom.},
  owner = {pl4},
  pii = {S0029-7844(96)00350-X},
  pmid = {8942848},
  timestamp = {2008.10.15},
  url = {http://dx.doi.org/10.1016/S0029-7844(96)00350-X}
}

@ARTICLE{Peng1998,
  author = {Y. Peng and K. B. Dear and J. W. Denham},
  title = {A generalized F mixture model for cure rate estimation.},
  journal = {Statistics in Medicine},
  year = {1998},
  volume = {17},
  pages = {813--830},
  number = {8},
  month = {Apr},
  abstract = {Cure rate estimation is an important issue in clinical trials for
	diseases such as lymphoma and breast cancer and mixture models are
	the main statistical methods. In the last decade, mixture models
	under different distributions, such as exponential, Weibull, log-normal
	and Gompertz, have been discussed and used. However, these models
	involve stronger distributional assumptions than is desirable and
	inferences may not be robust to departures from these assumptions.
	In this paper, a mixture model is proposed using the generalized
	F distribution family. Although this family is seldom used because
	of computational difficulties, it has the advantage of being very
	flexible and including many commonly used distributions as special
	cases. The generalised F mixture model can relax the usual stronger
	distributional assumptions and allow the analyst to uncover structure
	in the data that might otherwise have been missed. This is illustrated
	by fitting the model to data from large-scale clinical trials with
	long follow-up of lymphoma patients. Computational problems with
	the model and model selection methods are discussed. Comparison of
	maximum likelihood estimates with those obtained from mixture models
	under other distributions are included.},
  file = {Peng1998.pdf:Peng1998.pdf:PDF;Peng1998.pdf:pdf\\Peng1998.pdf:PDF},
  institution = {Department of Statistics, University of Newcastle, NSW, Australia.
	peng@frey.newcastle.edu.au},
  keywords = {Cure models; theory},
  owner = {pl4},
  timestamp = {2009.01.07}
}

@ARTICLE{Peng2000,
  author = {Yingwei Peng and Keith B. G. Dear},
  title = {A Nonparametric Mixture Model for Cure Rate Estimation},
  journal = {Biometrics},
  year = {2000},
  volume = {56},
  pages = {237-243},
  owner = {theand},
  timestamp = {2010.09.29}
}

@ARTICLE{Penny1998,
  author = {J. A. Penny and A. W. Halligan and A. H. Shennan and P. C. Lambert
	and D. R. Jones and M. de Swiet and D. J. Taylor},
  title = {Automated, ambulatory, or conventional blood pressure measurement
	in pregnancy: which is the better predictor of severe hypertension?},
  journal = {Am J Obstet Gynecol},
  year = {1998},
  volume = {178},
  pages = {521--526},
  number = {3},
  month = {Mar},
  abstract = {OBJECTIVES: Our purpose was to investigate the benefit, if any, of
	automated blood pressure monitoring over obstetric day unit conventional
	blood pressure measurement in the assessment of hypertensive pregnancies.
	STUDY DESIGN: A prospective, observational study was carried out
	in two large teaching hospitals. Three hundred and forty-eight women
	with a confirmed clinic blood pressure of at least 140/90 mm Hg were
	recruited. Conventional blood pressure measurements (< or =5) were
	obtained on the day unit and simultaneously an ambulatory blood pressure
	monitor was applied for 24 hours. The predictive ability of day unit
	assessment (blood pressure > 140/90 mm Hg) and automated blood pressure
	monitoring (blood pressure > 130/85 mm Hg) was compared. Principal
	outcome measures included the occurrence of severe hypertension (>
	160/110 mm Hg) and proteinuria (> 500 mg or 2+) within (a) 2 weeks
	and (b) the remainder of the pregnancy. Thompson's method was used
	to compare sensitivity and specificity of the day unit blood pressure
	and automated blood pressure monitoring. RESULTS: Three hundred and
	forty-eight women were recruited to the study. The comparison between
	automated blood pressure monitoring and conventional blood pressure
	measurement for both sensitivity and specificity for systolic and
	diastolic blood pressure revealed increased sensitivity and decreased
	specificity with automated blood pressure monitoring for all principal
	outcomes except development of proteinuria for systolic blood pressure.
	Sensitivity for the outcomes was increased with automated blood pressure
	monitoring by between 14\% and 27\% for systolic blood pressure and
	between 7\% and 39\% for diastolic blood pressure, with the greatest
	improvement seen for the development of severe hypertension within
	2 weeks of assessment. CONCLUSIONS: In the assessment of hypertensive
	pregnancies, automated blood pressure measurement was a significantly
	better predictor (compared with conventional day unit assessment)
	for the development of severe hypertension within 2 weeks of assessment
	for both systolic and diastolic blood pressure.},
  institution = {Department of Obstetrics and Gynaecology, University of Leicester,
	United Kingdom.},
  owner = {pl4},
  pii = {S000293789800115X},
  pmid = {9539520},
  timestamp = {2008.10.15}
}

@ARTICLE{Pepe1993a,
  author = {Pepe, M. S. and Longton, G. and Pettinger, M. and Mori, M. and Fisher,
	L. D. and Storb, R.},
  title = {Summarizing data on survival, relapse, and chronic graft-versus-host
	disease after bone marrow transplantation: motivation for and description
	of new methods.},
  journal = {Br J Haematol},
  year = {1993},
  volume = {83},
  pages = {602--607},
  number = {4},
  month = {Apr},
  abstract = {Kaplan-Meier curves are frequently used to summarize survival, relapse,
	and chronic graft-versus-host disease (GVHD) data in the bone marrow
	transplant setting. Some fundamental problems with the use of Kaplan-Meier
	curves for the summary of relapse and GVHD are described. Alternatively,
	the use of simple probability and conditional probability curves
	for summarizing relapse incidence and transplant-related mortality
	is illustrated with previously published data from a randomized clinical
	trial. Prevalence curves provide an appropriate alternative for the
	summary of a transient condition such as chronic GVHD. When combined
	with Kaplan-Meier curves for survival and/or relapse-free survival,
	these methods provide a more accurate and comprehensive summary of
	the various marrow transplant outcomes. These methods of display
	are also applicable to other settings where more than one type of
	treatment failure can occur and where follow-up time may be variable.},
  file = {Pepe1993a.pdf:Pepe1993a.pdf:PDF;Pepe1993a.pdf:pdf\\Pepe1993a.pdf:PDF},
  institution = {Fred Hutchinson Cancer Research Center, Seattle, Washington 98104.},
  keywords = {Bone Marrow Transplantation, mortality; Chronic Disease; Graft vs
	Host Disease, epidemiology/prevention /&/ control; Humans; Methylprednisolone,
	therapeutic use; Postoperative Period; Prevalence; Statistics as
	Topic, methods},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pmid = {8518176},
  timestamp = {2015.03.24}
}

@ARTICLE{Pepe1993,
  author = {Pepe, M. S. and Mori, M.},
  title = {Kaplan-Meier, marginal or conditional probability curves in summarizing
	competing risks failure time data?},
  journal = {Stat Med},
  year = {1993},
  volume = {12},
  pages = {737--751},
  number = {8},
  month = {Apr},
  abstract = {In the context of competing risks the Kaplan-Meier estimator is often
	unsuitable for summarizing failure time data. We discuss some alternative
	descriptive methods including marginal probability and conditional
	probability estimators. Two-sample test statistics are also presented.},
  file = {Pepe1993.pdf:Pepe1993.pdf:PDF;Pepe1993.pdf:pdf\\Pepe1993.pdf:PDF},
  institution = {Fred Hutchinson Cancer Research Center, Seattle, Washington 98104.},
  keywords = {Bone Marrow Transplantation, mortality/statistics /&/ numerical data;
	Cause of Death; Data Display; Data Interpretation, Statistical; Graft
	vs Host Disease, mortality; Humans; Incidence; Leukemia, mortality/surgery;
	Neoplasm Recurrence, Local, mortality; Probability; Proportional
	Hazards Models; Risk Factors; Survival Rate; Treatment Failure},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pmid = {8516591},
  timestamp = {2015.03.24}
}

@ARTICLE{Percy1990a,
  author = {Percy, C. and Ries, L. G. and Van Holten, V. D.},
  title = {The accuracy of liver cancer as the underlying cause of death on
	death certificates},
  journal = {Public Health Reports},
  year = {1990},
  volume = {105},
  pages = {361-367},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Percy1990b,
  author = {Percy, C. L. and Miller, B. A. and Gloeckler Ries, L. A.},
  title = {Effect of changes in cancer classification and the accuracy of cancer
	death certificates on trends in cancer mortality (with discussion)},
  journal = {Annals of the New York Academy of Sciences},
  year = {1990},
  volume = {609},
  pages = {87-99},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Percy1981,
  author = {Percy, C. L. and Stanek, E. and Gloeckler, L.},
  title = {Accuracy of Cancer Death Certificates and its Effect on Cancer Mortality
	Statistics},
  journal = {American Journal of Public Health},
  year = {1981},
  volume = {71},
  pages = {242-250},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@InCollection{Peto1984,
  author    = {Peto, J.},
  booktitle = {Cancer Clinical Trial: Methods and Practice},
  title     = {The Calculation and Interpretation of Survival Curves},
  editor    = {Buyse, M. E. and Staquet, M. J. and Sylvester, R. J.},
  pages     = {361-380},
  publisher = {Oxford: Oxford University Press},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1984},
}

@ARTICLE{Peto1977,
  author = {Peto, R. and Pike, M. C. and Armitage, P. and Breslow, N. E. and
	Cox, D. R. and Howard, S. V. and Mantel, N. and McPherson, K. and
	Peto, J. and Smith, P. G.},
  title = {Design and analysis of randomized clinical trials requiring prolonged
	observation of each patient. {II. Analysis and examples.}},
  journal = {British Journal of Cancer},
  year = {1977},
  volume = {35},
  pages = {1-39},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Peto1976,
  author = {Peto, R. and Pike, M. C. and Armitage, P. and Breslow, N. E. and
	Cox, D. R. and Howard, S. V. and Mantel, N. and McPherson, K. and
	Peto, J. and Smith, P. G.},
  title = {Design and analysis of randomized clinical trials requiring prolonged
	observation of each patient. {I. Introduction and design.}},
  journal = {British Journal of Cancer},
  year = {1976},
  volume = {34},
  pages = {585-612},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@Book{Petrov1975,
  author    = {Petrov, V. V.},
  title     = {Sums of Independent Random Variables},
  publisher = {Berlin: Springer--Verlag},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1975},
}

@ARTICLE{Pettersson2013,
  author = {Andreas Pettersson and Max Gordon and Gustaf Edgren and Paul W Dickman},
  title = {Biostatistik har en central roll i epidemiologi - Introduktion till
	begrepp och metoder utifr{\"a}ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¬ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â kliniska observationella studier},
  journal = {L{\AA}Â£ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚ÂªÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¡rtidningen},
  year = {2013},
  volume = {110},
  pages = {470-474},
  note = {(In Swedish)},
  file = {Pettersson2013.pdf:pdf\\Pettersson2013.pdf:PDF;Pettersson2013.pdf:Pettersson2013.pdf:PDF},
  owner = {PaulD},
  timestamp = {2013.03.04}
}

@ARTICLE{Pheby1995,
  author = {Pheby, D. F. H. and Martinez, C. and Roumagnac, M. and Schouten,
	L.},
  title = {Recommendations for coding incidence date},
  journal = {ENCR},
  year = {1995},
  owner = {pl4},
  timestamp = {2015.12.06}
}

@ARTICLE{Pierga2001a,
  author = {Pierga, J. Y. and Asselain, B. and Jouve, M. and Di{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â±ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¡s, V. and Carton,
	M. and Laurence, V. and Girre, V. and Beuzeboc, P. and Palangi{\AA}Â§ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Âª?
	T. and Dorval, T. and Pouillart, P.},
  title = {Effect of adjuvant chemotherapy on outcome in patients with metastatic
	breast carcinoma treated with first-line doxorubicin-containing chemotherapy.},
  journal = {Cancer},
  year = {2001},
  volume = {91},
  pages = {1079--1089},
  number = {6},
  month = {Mar},
  abstract = {The objective of the current study was to analyze the impact of adjuvant
	chemotherapy in comparison with other prognostic parameters on the
	outcome of a series of patients with breast carcinoma at time of
	metastatic recurrence.Data from 1430 patients accrued in 8 prospective
	trials of anthracycline-based first-line chemotherapy conducted at
	the Institut Curie between 1977 and 1992 were reviewed.Patients who
	had not received adjuvant chemotherapy had better response rates
	(66\%) than pretreated patients (56\%; P < 0.0001). Median overall
	survival rates after metastatic recurrence were 26 months compared
	with 19 months, respectively (P < 0.0001). Local and regional recurrences
	as well as the number of organ sites involved with metastatic disease
	were reduced in patients who had received adjuvant chemotherapy.
	In a multivariate analysis, the following parameters if present at
	the initiation of treatment were associated with poor outcome: elevated
	lactico dehydrogenase (LDH), low Karnofsky index, short disease free
	interval, more than two involved sites, liver involvement, and prior
	adjuvant chemotherapy. This adverse prognostic effect of prior adjuvant
	chemotherapy was independent of the type of drugs and of the duration
	of the treatment and was present even in the subgroup patients with
	prolonged disease free intervals longer than 48 months.Adjuvant chemotherapy
	adversely affects overall response rates and overall survival rates
	in patients with metastatic breast carcinoma treated with first-line
	anthracycline based chemotherapy.},
  institution = {Medical Oncology Department, Institut Curie, Paris Cedex 05, France.
	Jean-Yves.Pierga@curie.net},
  keywords = {Adult; Aged; Antineoplastic Combined Chemotherapy Protocols, therapeutic
	use; Breast Neoplasms, drug therapy/pathology/surgery; Carcinoma,
	drug therapy/pathology/surgery; Chemotherapy, Adjuvant; Disease-Free
	Survival; Female; Health Status; Humans; Middle Aged; Neoplasm Metastasis;
	Prognosis; Randomized Controlled Trials as Topic; Treatment Outcome},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {3.0.CO;2-S},
  pmid = {11267952},
  timestamp = {2013.05.29}
}

@ARTICLE{Pierga2001,
  author = {Pierga, J. Y. and Robain, M. and Jouve, M. and Asselain, B. and Di{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â±ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¡s,
	V. and Beuzeboc, P. and Palangi{\AA}Â§ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚ÂªÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â T. and Dorval, T. and Extra, J.
	M. and Scholl, S. and Pouillart, P.},
  title = {Response to chemotherapy is a major parameter-influencing long-term
	survival of metastatic breast cancer patients.},
  journal = {Ann Oncol},
  year = {2001},
  volume = {12},
  pages = {231--237},
  number = {2},
  month = {Feb},
  abstract = {In cancer patients, correlation between response to chemotherapy and
	gain in survival remains debated. We addressed this question in a
	multivariate analysis evaluating response to chemotherapy as a factor
	influencing survival of patients with metastatic breast cancer.From
	1977 to 1992, 1430 patients included in eight consecutive prospective
	trials of anthracycline-based first-line chemotherapy in metastatic
	breast cancer, were available for assessment. Median follow-up was
	155 months.Median survival from the date of randomisation was 24
	months. Objective response rate was 63.6\%. A complete response (CR)
	was achieved in 17\% (249 patients). In a stepwise forward progression
	analysis objective response was the first independent prognostic
	factor for survival. Median survival time was 43 months for complete
	responders (CR), 29 months for partial responders (PR), 18 months
	for stable disease (SD), 5 months for progressive disease (PD). The
	probability of survival at 5 and 10 years was 35\% and 15\% for CR's
	and decreased to 18\% and 6\% for PR's. The timing of best response
	(at 4 or 8 months) was not related to outcome.Response to an anthracycline-based
	chemotherapy is a major independent prognostic factor in metastatic
	breast cancer. The use of this factor to investigate new drugs seems
	to be pertinent. The good prognosis of complete responders justifies
	further evaluation of new treatment strategies for this patient population.},
  institution = {Medical Oncology Department, Institut Curie, Paris, France. Jean-Yves.Pierga@curie.net},
  keywords = {Adult; Antibiotics, Antineoplastic, therapeutic use; Breast Neoplasms,
	drug therapy/mortality/secondary; Disease-Free Survival; Female;
	Humans; Middle Aged; Multivariate Analysis; Prognosis; Prospective
	Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Tumor
	Markers, Biological, analysis},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {11300330},
  timestamp = {2013.05.29}
}

@ARTICLE{Pike1980,
  author = {Pike, M. C. and Hill, A. P. and Smith, P. G.},
  title = {Bias and Efficiency in Logistic Analyses of Stratified Case-Control
	Studies},
  journal = {International Journal of Epidemiology},
  year = {1980},
  volume = {9},
  pages = {89-95},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Pinheiro1995,
  author = {Pinheiro, J. C. and Bates, D. M.},
  title = {Approximations to the log-likelihood function in the nonlinear mixed-effects
	model.},
  journal = {Journal of Computational and Graphical Statistics},
  year = {1995},
  volume = {4},
  pages = {12{\AA}Â‚ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Â“35},
  owner = {pl4},
  timestamp = {2013.03.25}
}

@ARTICLE{Pintilie2011,
  author = {Pintilie, M.},
  title = {An introduction to competing risks analysis.},
  journal = {Rev Esp Cardiol},
  year = {2011},
  volume = {64},
  pages = {599--605},
  number = {7},
  month = {Jul},
  abstract = {The need to develop treatments and/or programs specific to a disease
	requires the analysis of outcomes to be specific to that disease.
	Such endpoints as heart failure, death due to a specific disease,
	or control of local disease in cancer may become impossible to observe
	due to a prior occurrence of a different type of event (such as death
	from another cause). The event which hinders or changes the possibility
	of observing the event of interest is called a competing risk. The
	usual techniques for time-to-event analysis applied in the presence
	of competing risks give biased or uninterpretable results. The estimation
	of the probability of the event therefore needs to be calculated
	using specific techniques such as the cumulative incidence function
	introduced by Kalbfleisch and Prentice. The model introduced by Fine
	and Gray can be applied to test a covariate when competing risks
	are present. Using specific techniques for the analysis of competing
	risks will ensure that the results are unbiased and can be correctly
	interpreted. Full English text available from: www.revespcardiol.org.},
  doi = {10.1016/j.recesp.2011.03.017},
  file = {Pintilie2011.pdf:Pintilie2011.pdf:PDF},
  institution = {Department of Biostatistics, Ontario Cancer Institute/Princess Margaret
	Hospital, University Health Network, Dalla Lana School of Public
	Health, University of Toronto, Ontario, Canada. Pintilie@uhnres.utoronto.ca},
  language = {spa},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {S0300-8932(11)00402-7},
  pmid = {21621892},
  timestamp = {2012.02.28},
  url = {http://dx.doi.org/10.1016/j.recesp.2011.03.017}
}

@ARTICLE{Pintilie2010,
  author = {Melania Pintilie and Yan Bai and Lingsong Yun and David C Hodgson},
  title = {The analysis of case cohort design in the presence of competing risks
	with application to estimate the risk of delayed cardiac toxicity
	among Hodgkin lymphoma survivors.},
  journal = {Statistics in Medicine},
  year = {2010},
  volume = {29},
  pages = {2802--2810},
  number = {27},
  month = {Nov},
  abstract = {The case-cohort design is an economical solution to studying the association
	between an exposure and a rare disease. When the disease of interest
	has a delayed occurrence, then other types of event may preclude
	observation of the disease of interest giving rise to a competing
	risk situation. In this paper, we introduce a modification of the
	pseudolikelihood proposed by Prentice (Biometrika 1986; 73:1-11)
	for the analysis of case-cohort design, to accommodate the existence
	of competing risks. The modification is based on the Fine and Gray
	(J. Amer. Statist. Assoc. 1999; 94:496-509) approach to enable the
	modeling of the hazard of subdistribution. We show through simulations
	that the estimate that maximizes this modified pseudolikelihood is
	almost unbiased. The predictive probabilities based on the model
	are close to the theoretical probabilities. The variance for the
	estimates can be calculated using the jackknife approach. An application
	of this method on the analysis of late cardiac morbidity among Hodgkin
	Lymphoma survivors is presented.},
  doi = {10.1002/sim.4056},
  file = {Pintilie2010.pdf:Pintilie2010.pdf:PDF;Pintilie2010.pdf:pdf\\Pintilie2010.pdf:PDF},
  institution = {Biostatistics Department, Ontario Cancer Institute/University Health
	Network, Toronto, Ont., Canada. pintilie@uhnres.utoronto.ca},
  owner = {pl4},
  pmid = {20827727},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1002/sim.4056}
}

@ARTICLE{Pocock1982,
  author = {SJ Pocock and SM Gore and GR Kerr},
  title = {Long term survival analysis: the curability of breast cancer.},
  journal = {Stat Med},
  year = {1982},
  volume = {1},
  pages = {93-104},
  number = {2},
  abstract = {Methods of survival analysis for long-term follow-up studies are illustrated
	by a study of mortality in 3878 breast cancer patients in Edinburgh
	followed for up to 20 years. The problems of life tables, advantages
	of hazard plots and difficulties in statistical modelling are demonstrated
	by studying the relationship between survival and both clinical stage
	and initial menopausal status at diagnosis. To assess the 'curability'
	of breast cancer, mortality by year of follow-up is compared with
	expected mortality using Scottish age-specific death rates. Techniques
	for analysing such relative survival data include age-corrected life
	tables, ratio of observed to expected deaths and excess death rates.
	Finally, an additive hazard model is developed to incorporate covariates
	in the analysis of relative survival and curability.},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Pohar2006,
  author = {Maja Pohar and Janez Stare},
  title = {Relative survival analysis in R.},
  journal = {Comput Methods Programs Biomed},
  year = {2006},
  volume = {81},
  pages = {272--278},
  number = {3},
  month = {Mar},
  abstract = {Relative survival techniques are used to compare the survival experience
	in a study cohort with the one expected should they follow the background
	population mortality rates. The techniques are especially useful
	when the cause-specific death information is not accurate or not
	available since they provide a measure of excess mortality in a group
	of patients with a certain disease. There are several approaches
	to modeling relative survival, but there is no widely used statistical
	package that would incorporate the relevant techniques. The existing
	software was mostly written by the authors of different methods,
	in different computer languages and with different requirements for
	the data input, which makes it almost impossible for a user to choose
	between available models. We describe our R package relsurv that
	provides functions for easy and flexible fitting of several relative
	survival regression models.},
  doi = {10.1016/j.cmpb.2006.01.004},
  file = {Pohar2006.pdf:Pohar2006.pdf:PDF;Pohar2006.pdf:pdf\\Pohar2006.pdf:PDF},
  institution = {Department of Medical Informatics, University of Ljubljana, Vrazov
	trg 2, SI-1000 Ljubljana, Slovenia. maja.pohar@mf.uni-lj.si},
  owner = {pl4},
  pii = {S0169-2607(06)00022-8},
  pmid = {16510208},
  timestamp = {2008.12.16},
  url = {http://dx.doi.org/10.1016/j.cmpb.2006.01.004}
}

@Article{PoharPerme2016,
  author       = {Pohar Perme, Maja and Est{\AA}Â¨ve, Jacques and Rachet, Bernard},
  title        = {Analysing population-based cancer survival - settling the controversies.},
  journal      = {BMC cancer},
  year         = {2016},
  volume       = {16},
  issue        = {1},
  month        = {Dec},
  pages        = {933},
  issn         = {1471-2407},
  doi          = {10.1186/s12885-016-2967-9},
  abstract     = {The relative survival field has seen a lot of development in the last
	decade, resulting in many different and even opposing suggestions
	on how to approach the analysis. We carefully define and explain
	the differences between the various measures of survival (overall
	survival, crude mortality, net survival and relative survival ratio)
	and study their differences using colon and prostate cancer data
	extracted from the national population-based cancer registry of Slovenia
	as well as simulated data. The colon and prostate cancer data demonstrate
	clearly that when analysing population-based data, it is useful to
	split the overall mortality in crude probabilities of dying from
	cancer and from other causes. Complemented by net survival, it provides
	a complete picture of cancer survival in a given population. But
	when comparisons of different populations as defined for example
	by place or time are of interest, our simulated data demonstrate
	that net survival is the only measure to be used. The choice of the
	method should be done in two steps: first, one should determine the
	measure of interest and second, one should choose among the methods
	that estimate that measure consistently.},
  country      = {England},
  created      = {2016-12-03},
  file         = {:PoharPerme2016.pdf:PDF},
  issn-linking = {1471-2407},
  keywords     = {Cancer registries; Population-based studies; Relative survival; net survival},
  nlm-id       = {100967800},
  owner        = {NLM},
  pii          = {10.1186/s12885-016-2967-9},
  pmid         = {27912732},
  pubmodel     = {Electronic},
  pubstatus    = {epublish},
  revised      = {2016-12-04},
  timestamp    = {2016.12.13},
}

@ARTICLE{Perme2009,
  author = {M. {Pohar Perme} and R. Henderson and J. Stare},
  title = {An approach to estimation in relative survival regression},
  journal = {Biostatistics},
  year = {2009},
  volume = {10},
  pages = {136-146},
  month = {Jul},
  abstract = {The goal of relative survival methodology is to compare the survival
	experience of a cohort with that of the background population. Most
	often an additive excess hazard model is employed, which assumes
	that each person's hazard is a sum of 2 components-the population
	hazard obtained from life tables and an excess hazard attributable
	to the specific condition. Usually covariate effects on the excess
	hazard are assumed to have a proportional hazards structure with
	parametrically modelled baseline. In this paper, we introduce a new
	fitting procedure using the expectation-maximization algorithm, treating
	the cause of death as missing data. The method requires no assumptions
	about the baseline excess hazard thus reducing the risk of bias through
	misspecification. It accommodates the possibility of knowledge of
	cause of death for some patients, and as a side effect, the method
	yields an estimate of the ratio between the excess and the population
	hazard for each subject. More importantly, it estimates the baseline
	excess hazard flexibly with no additional degrees of freedom spent.
	Finally, it is a generalization of the Cox model, meaning that all
	the wealth of options in existing software for the Cox model can
	be used in relative survival. The method is applied to a data set
	on survival after myocardial infarction, where it shows how a particular
	form of the hazard function could be missed using the existing methods.},
  doi = {10.1093/biostatistics/kxn021},
  file = {Perme2009.pdf:Perme2009.pdf:PDF;Perme2009.pdf:pdf\\Perme2009.pdf:PDF},
  groups = {Excess mortality model},
  institution = {Department of Biomedical Informatics, University of Ljubljana, Vrazov
	trg 2, SI-1000 Ljubljana, Slovenia,. maja.pohar@mf.uni-lj.si.},
  owner = {pl4},
  pii = {kxn021},
  pmid = {18599516},
  timestamp = {2008.12.16},
  url = {http://dx.doi.org/10.1093/biostatistics/kxn021}
}

@Article{PoharPerme2011,
  author    = {Pohar Perme, M. and Stare, J. and Est\`{e}ve, J.},
  title     = {On Estimation in Relative Survival},
  doi       = {10.1111/j.1541-0420.2011.01640.x},
  issn      = {1541-0420},
  pages     = {113--120},
  url       = {http://dx.doi.org/10.1111/j.1541-0420.2011.01640.x},
  volume    = {68},
  abstract  = {Summary Estimation of relative survival has become the first and the
	most basic step when reporting cancer survival statistics. Standard
	estimators are in routine use by all cancer registries. However,
	it has been recently noted that these estimators do not provide information
	on cancer mortality that is independent of the national general population
	mortality. Thus they are not suitable for comparison between countries.
	Furthermore, the commonly used interpretation of the relative survival
	curve is vague and misleading. The present article attempts to remedy
	these basic problems. The population quantities of the traditional
	estimators are carefully described and their interpretation discussed.
	We then propose a new estimator of net survival probability that
	enables the desired comparability between countries. The new estimator
	requires no modeling and is accompanied with a straightforward variance
	estimate. The methods are described on real as well as simulated
	data.},
  file      = {PoharPerme2011.pdf:pdf\\PoharPerme2011.pdf:PDF},
  journal   = {Biometrics},
  owner     = {PaulD},
  publisher = {Blackwell Publishing Inc},
  timestamp = {2011.06.27},
  year      = {2012},
}

@ARTICLE{Pokhrel2008,
  author = {Arun Pokhrel and Tadeusz Dyba and Timo Hakulinen},
  title = {A Greenwood formula for standard error of the age-standardised relative
	survival ratio.},
  journal = {Eur J Cancer},
  year = {2008},
  volume = {44},
  pages = {441--447},
  number = {3},
  month = {Feb},
  abstract = {The age-standardised relative survival ratio is used to compare population-based
	cancer survival patterns when the population age structures differ.
	Traditionally, the direct standardisation method based on age-specific
	relative survival ratios has been used. In a new method [Brenner
	H, Arndt V, Gefeller O, Hakulinen T. An alternative approach to age
	adjustment of cancer survival rates. Eur J Cancer 2004;40:2317-22],
	weighted observations depending on the age structures of the study
	and standard populations are used to substitute the patients leading
	to a use of weighted counts. The relative survival ratio is then
	calculated in the conventional way. However, no standard error of
	the age-standardised relative survival estimate has been reported.
	In this paper, we introduce a generalisation of the well-known Greenwood
	formula for that purpose. This method is also applicable for the
	observed survival and particularly when the observed survival probabilities
	of the patient population differ by age stratum. The traditional
	Greenwood formula is a special case of the method when no specific
	weights are used and the observed survival probability is the same
	in each stratum. Data from the Finnish Cancer Registry are used for
	illustration.},
  doi = {10.1016/j.ejca.2007.10.026},
  file = {Pokhrel2008.pdf:pdf\\Pokhrel2008.pdf:PDF;Pokhrel2008.pdf:Pokhrel2008.pdf:PDF},
  institution = {Finnish Cancer Registry, Institute for Statistical and Epidemiological
	Cancer Research, Liisankatu 21B, FIN-00170 Helsinki, Finland. arun.pokhrel@cancer.fi},
  owner = {PaulD},
  pii = {S0959-8049(07)00857-X},
  pmid = {18053707},
  timestamp = {2008.08.22},
  url = {http://dx.doi.org/10.1016/j.ejca.2007.10.026}
}

@ARTICLE{Pokhrel2009,
  author = {Arun Pokhrel and Timo Hakulinen},
  title = {Age-standardisation of relative survival ratios of cancer patients
	in a comparison between countries, genders and time periods.},
  journal = {Eur J Cancer},
  year = {2009},
  volume = {45},
  pages = {642--647},
  number = {4},
  month = {Mar},
  abstract = {A recent method of age-standardisation of relative survival ratios
	for cancer patients does not require calculation of age-specific
	relative survival ratios, as ratios of age-specific proportions between
	the standard population and study group at the beginning of the follow-up
	are used to substitute the original individual observations. This
	method, however, leads to direct age-standardisation with weights
	that are different for each patient group if the general population
	mortality patterns for the groups are different. This is the case
	in international comparisons, and in comparisons between genders
	and time periods. The magnitude of the bias caused by the differences
	in general population mortality is investigated for comparisons involving
	European countries and the USA. Patients in each country are assumed
	to have exactly the same age-specific relative survival ratios as
	those diagnosed in Finland in 1985-2004. An application of a properly
	functioning age-standardisation method should then give exactly equal
	age-standardised relative survival ratios for each country. However,
	the recent method shows substantial differences between countries,
	with highest relative survival for populations, where the general
	population mortality in the oldest ages is the highest. This source
	of error can thus be a serious limitation for the use of the method,
	and other methods that are available should then be employed.},
  doi = {10.1016/j.ejca.2008.10.034},
  file = {Pokhrel2009.pdf:pdf\\Pokhrel2009.pdf:PDF;Pokhrel2009.pdf:Pokhrel2009.pdf:PDF},
  institution = {Finnish Cancer Registry, Institute for Statistical and Epidemiological
	Cancer Research, Pieni Roobertinkatu 9, FI-00130 Helsinki, Finland.
	arun.pokhrel@cancer.fi},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pii = {S0959-8049(08)00836-8},
  pmid = {19081246},
  timestamp = {2009.08.31},
  url = {http://dx.doi.org/10.1016/j.ejca.2008.10.034}
}

@ARTICLE{Pokhrel2008a,
  author = {A. Pokhrel and T. Hakulinen},
  title = {How to interpret the relative survival ratios of cancer patients.},
  journal = {European Journal of Cancer},
  year = {2008},
  volume = {44},
  pages = {2661--2667},
  number = {17},
  month = {Nov},
  abstract = {It is common in population-based cancer registries to use the relative
	survival ratio to estimate patients' probabilities of surviving if
	their cancer were the only cause of death. Results from the recently
	proposed new methods of age-standardisation can be interpreted as
	ratios between the observed and expected survival proportions. Like
	the non-standardised ratios, these age-standardised relative survival
	ratios have, however, the desired probability interpretation only
	under a specific condition. The condition involved is the survival
	with respect to other causes up to the given point of follow-up.
	With different lengths of follow-up, this condition is also different.
	As a consequence, the non-standardised relative survival ratios and
	those standardised with the two newest methods produce, for different
	lengths of follow-up, mutually incomparable estimates with respect
	to age. Not accounting for this may, for example, lead to erroneous
	conclusions about the cure of the patients. The traditional method
	of age-standardisation does not have this problem of incomparability.
	Results of relative survival analyses of data from the Finnish Cancer
	Registry are used to illustrate this issue. To avoid overinterpretation
	and confusion, the different interpretations of the relative survival
	ratios, both non-standardised and age-standardised, must be known.
	For example, the very popular cumulative relative survival curves,
	consisting of consecutive cumulative relative survival ratios, should
	not be produced for the non-standardised ratios or for ratios age-standardised
	with the two newest methods. In practical applications, it is crucial
	to know which method of standardisation, and not only which standard
	population, has been in use.},
  doi = {10.1016/j.ejca.2008.08.016},
  file = {Pokhrel2008a.pdf:Pokhrel2008a.pdf:PDF;Pokhrel2008a.pdf:pdf\\Pokhrel2008a.pdf:PDF},
  institution = {Finnish Cancer Registry, Institute for Statistical and Epidemiological
	Cancer Research, Helsinki, Finland. arun.pokhrel@cancer.fi},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {S0959-8049(08)00642-4},
  pmid = {18819791},
  timestamp = {2010.06.01},
  url = {http://dx.doi.org/10.1016/j.ejca.2008.08.016}
}

@ARTICLE{Pokhrel2010,
  author = {A. Pokhrel and P. Martikainen and E. Pukkala and M. Rautalahti and
	K. Sepp\"{a} and T. Hakulinen},
  title = {Education, survival and avoidable deaths in cancer patients in {F}inland.},
  journal = {British Journal of Cancer},
  year = {2010},
  volume = {103},
  pages = {1109-1114},
  abstract = {Background:Relative survival after cancer in Finland is at the highest
	level observed in Europe and has, in general, been on a steady increase.
	The aim of this study is to assess whether the high survival is equally
	shared by different population subgroups and to estimate the possible
	gains that might be achieved if equity prevailed.Materials and method:The
	educational level and occupation before the cancer diagnosis of patients
	diagnosed in Finland in 1971-2005 was derived from an antecedent
	population census. The cancers were divided into 27 site categories.
	Cancer (cause)-specific 5-year survival proportions were calculated
	for three patient categories based on the educational level and for
	an occupational group of potentially health-conscious patients (physicians,
	nurses, teachers etc.). Proportions of avoidable deaths were derived
	by assuming that the patients from the two lower education categories
	would have the same mortality owing to cancer, as those from the
	highest educational category. Estimates were also made by additionally
	assuming that even the mortalities owing to other causes of death
	were all equal to those in the highest category.Results:For almost
	all the sites considered, survival was consistently highest for patients
	with the highest education and lowest for those with only basic education.
	The potentially health-conscious patients had an even higher survival.
	The differences were, in part, attributable to less favourable distributions
	of tumour stages in the lower education categories. In 1996-2005,
	4-7\% of the deaths in Finnish cancer patients could have potentially
	been avoided during the first 5-year period after diagnosis, if all
	the patients had the same cancer mortality as the patients with the
	highest educational background. The proportion would have also been
	much higher, 8-11\%, if, in addition, the mortality from other causes
	had been the same as that in the highest educational category.Interpretation:Even
	in a potentially equitable society with high health care standards,
	marked inequalities persist in cancer survival. Earlier cancer diagnosis
	and the ability to cope within the health care system may be a partly
	relevant explanation, but personal habits and lifestyles also have
	a role, particularly for the cancer patients' mortality from other
	causes of death than cancer.British Journal of Cancer advance online
	publication, 17 August 2010; doi:10.1038/sj.bjc.6605861 www.bjcancer.com.},
  doi = {10.1038/sj.bjc.6605861},
  file = {Pokhrel2010.pdf:Pokhrel2010.pdf:PDF;Pokhrel2010.pdf:pdf\\Pokhrel2010.pdf:PDF},
  institution = {Finnish Cancer Registry, Institute for Statistical and Epidemiological
	Cancer Research, Pieni Roobertinkatu 9, FI-00130, Helsinki, Finland.},
  language = {eng},
  medline-pst = {aheadofprint},
  owner = {pl4},
  pii = {6605861},
  pmid = {20717112},
  timestamp = {2010.09.13},
  url = {http://dx.doi.org/10.1038/sj.bjc.6605861}
}

@ARTICLE{Pol2007,
  author = {Jaroslav Pol and Tiina J Kauppila and Markus Haapala and Ville Saarela
	and Sami Franssila and Raimo A Ketola and Tapio Kotiaho and Risto
	Kostiainen},
  title = {Microchip sonic spray ionization.},
  journal = {Anal Chem},
  year = {2007},
  volume = {79},
  pages = {3519--3523},
  number = {9},
  month = {May},
  abstract = {The first microchip version of sonic spray ionization (SSI) as an
	atmospheric pressure ionization source for mass spectrometry (MS)
	is presented. The microchip used for SSI has recently been developed
	in our laboratory, and it has been used before as an atmospheric
	pressure chemical ionization (APCI) and atmospheric pressure photoionization
	(APPI) source. Now the ionization is achieved simply by applying
	high (sonic) speed nebulizer gas, without heat, corona discharge,
	or high voltage. The microchip SSI was applied to the analysis of
	tetra-N-butylammonium, verapamil, testosterone, angiotensin I, and
	ibuprofen. The limits of detection were in the range of 15 nM to
	4 microM. The technique was found to be highly dependent on the position
	of the chip toward the mass spectrometer inlet, and on the gas and
	the sample solution flow rates. The microchip SSI provided dynamic
	linearity following a pattern similar to that used with electrospray,
	good quantitative repeatability (RSD=16\%), and long-term signal
	stability.},
  doi = {10.1021/ac070003v},
  institution = {Division of Pharmaceutical Chemistry, Faculty of Pharmacy, University
	of Helsinki, P.O. Box 56, FI-00014 University of Helsinki, Finland.
	jaroslav.pol@helsinki.fi},
  owner = {pl4},
  pmid = {17381071},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1021/ac070003v}
}

@ARTICLE{Pollock1994,
  author = {Pollock, A. M. and Vickers, N.},
  title = {The Impact on Colorectal Cancer Survival of Cases Registered by `Death
	Certificate Only': Implications for National Survival Rates},
  journal = {British Journal of Cancer},
  year = {1994},
  volume = {70},
  pages = {1229-1231},
  owner = {PaulD},
  timestamp = {2011.06.19}
}



@ARTICLE{Prattala1994,
  author = {Prattala, R. and Karisto, A. and Berg, M. A.},
  title = {Consistency and Variation in Unhealthy Behaviour among {F}innish
	Men, 1982-1990},
  journal = {Social Science \& Medicine},
  year = {1994},
  volume = {39},
  pages = {115-122},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Prentice1974,
  author = {R.L. Prentice},
  title = {A log gamma model and its maximum likelihood estimation},
  journal = {Biometrika},
  year = {1974},
  volume = {61},
  pages = {539-544},
  owner = {pl4},
  timestamp = {2009.04.28}
}

@ARTICLE{Prentice1981,
  author = {R.L. Prentice and B.J. Williams and A.V. Peterson},
  title = {On the regression analysis of multivariate failure time data},
  journal = {Biometrika},
  year = {1981},
  volume = {68},
  pages = {373-379},
  file = {Prentice1981.pdf:Prentice1981.pdf:PDF;Prentice1981.pdf:pdf\\Prentice1981.pdf:PDF},
  owner = {pl4},
  timestamp = {2010.01.07}
}

@ARTICLE{Prentice1996,
  author = {R. L. Prentice},
  title = {A case-cohort design for epidemiologic cohort studies and disease
	prevention trials},
  journal = {Biometrika},
  year = {1996},
  volume = {73},
  pages = {1-11},
  file = {Prentice1996.pdf:Prentice1996.pdf:PDF;Prentice1996.pdf:pdf\\Prentice1996.pdf:PDF},
  owner = {pl4},
  timestamp = {2011.05.24}
}

@ARTICLE{Prentice1978,
  author = {Prentice, R. L. and Kalbfleisch, J. D. and Peterson, A. V., Jr. and
	Flournoy, N. and Farewell, V. T. and Breslow, N. E.},
  title = {The Analysis of Failure Times in the Presence of Competing Risks},
  journal = {Biometrics},
  year = {1978},
  volume = {34},
  pages = {pp. 541-554},
  number = {4},
  abstract = {Distinct problems in the analysis of failure times with competing
	causes of failure include the estimation of treatment or exposure
	effects on specific failure types, the study of interrelations among
	failure types, and the estimation of failure rates for some causes
	given the removal of certain other failure types. The usual formulation
	of these problems is in terms of conceptual or latent failure times
	for each failure type. This approach is criticized on the basis of
	unwarranted assumptions, lack of physical interpretation and identifiability
	problems. An alternative approach utilizing cause-specific hazard
	functions for observable quantities, including time-dependent covariates,
	is proposed. Cause-specific hazard functions are shown to be the
	basic estimable quantities in the competing risks framework. A method,
	involving the estimation of parameters that relate time-dependent
	risk indicators for some causes to cause-specific hazard functions
	for other causes, is proposed for the study of interrelations among
	failure types. Further, it is argued that the problem of estimation
	of failure rates under the removal of certain causes is not well
	posed until a mechanism for cause removal is specified. Following
	such a specification, one will sometimes be in a position to make
	sensible extrapolations from available data to situations involving
	cause removal. A clinical program in bone marrow transplantation
	for leukemia provides a setting for discussion and illustration of
	each of these ideas. Failure due to censoring in a survivorship study
	leads to further discussion.},
  issn = {0006341X},
  jstor_formatteddate = {Dec., 1978},
  language = {English},
  owner = {PaulD},
  timestamp = {2015.03.25},
  url = {http://www.jstor.org/stable/2530374}
}

@ARTICLE{Price2004,
  author = {Dionne L Price and Amita K Manatunga},
  title = {Modelling relative survival using transformation methods.},
  journal = {Stat Med},
  year = {2004},
  volume = {23},
  pages = {2463-77},
  number = {15},
  month = {Aug},
  abstract = {Patient survival is often assessed as a measure of effectiveness of
	treatment in cancer clinical trials. The relative survival rate is
	a measure of patient survival corrected for the effect of other causes
	of death. We incorporate an additive hazards model for the overall
	force of mortality focusing attention on the form of the underlying
	disease process. Transformation models for the cause-specific hazard
	rate describing the disease process are considered. We demonstrate
	a method for estimating the transformation parameter providing insight
	into the appropriate choice of model structure. The models include
	the additive and multiplicative structures as special cases. We write
	the models in the generalized linear model framework and demonstrate
	ease of fitting via existing statistical software. The methodology
	is applied to a Hodgkin's disease data set to assess the effect of
	clinical trial results on population survival. Our analysis concludes
	that the multiplicative structure provides a more appropriate description
	of the data as compared to the additive structure.},
  doi = {10.1002/sim.1832},
  file = {Price2004.pdf:pdf\\Price2004.pdf:PDF;Price2004.pdf:Price2004.pdf:PDF},
  owner = {PaulD},
  timestamp = {2011.06.19},
  url = {http://dx.doi.org/10.1002/sim.1832}
}

@ARTICLE{Proust-Lima2009,
  author = {C. Proust-Lima and J.M.G. Taylor},
  title = {Development and validation of a dynamic prognostic tool for prostate
	cancer recurrence using repeated measures of post treatment {PSA}:
	a joint modeling approach.},
  journal = {Biostatistics},
  year = {2009},
  volume = {10},
  pages = {535-549},
  file = {Proust-Lima2009.pdf:Proust-Lima2009.pdf:PDF},
  owner = {pl4},
  timestamp = {2012.04.10}
}

@ARTICLE{Puchalski1996,
  author = {W. Puchalski and S. Saarela and G. R. Lynch},
  title = {Reentrainment of motor activity and spontaneous neuronal activity
	in the suprachiasmatic nucleus of Djungarian hamsters.},
  journal = {J Biol Rhythms},
  year = {1996},
  volume = {11},
  pages = {302--310},
  number = {4},
  month = {Dec},
  abstract = {Neurons in the suprachiasmatic nucleus (SCN) of the hypothalamus exhibit
	a daily rhythm in spontaneous electrical activity. Essentially two
	methods have been employed to record this circadian rhythm: (1) an
	in vitro brain slice technique and (2) in vivo multiunit recordings.
	Reentrainment of a circadian output to a shifted light:dark cycle
	commonly takes several cycles (depending on the amount of shift)
	until completed. Such a resetting kinetic has also been shown to
	be valid for SCN electrical activity if recorded in vivo. In an in
	vitro slice preparation, however, pharmacologically induced resetting
	is much faster and lacks transients; that is, a shift is completed
	within one cycle. This study was designed to probe for the presence
	of transients in the neuronal activity of the SCN in a brain slice
	preparation. The authors exposed Djungarian hamsters to an 8-h advanced
	or delayed light:dark cycle and monitored wheel-running activity
	during reentrainment. Additional groups of identically treated hamsters
	were used to record the pattern of spontaneous neuronal activity
	within the SCN using the brain slice preparation. Neuronal activity
	exhibited the usual rhythm with high firing rates during the projected
	day and low firing rates during the projected night. However, following
	1 day of exposure to the 8-h advanced light:dark cycle, this rhythm
	disappeared in 6 of 7 slices. Rhythmicity was still absent following
	3 days of exposure to the advanced light:dark cycle (n = 4). By contrast,
	3 of 7 slices prepared from hamsters exposed to a delayed light:dark
	cycle for 3 days exhibited a daily rhythm in electrical activity.
	Although pharmacological agents reset the in vitro SCN neuronal activity
	almost instantaneously and in in vivo studies a stable phase relationship
	to a shifted light:dark cycle occurs gradually over several cycles,
	the authors did not detect either of these patterns. Such differences
	in resetting kinetics (e.g., rapid resetting, gradual reentrainment,
	temporary lack of measurable rhythmicity) may be due to (a) application
	of a resetting stimulus in vivo versus in vitro, (b) duration of
	the resetting stimulus, (c) the nature of the resetting stimulus,
	or (d) the recording technique employed.},
  institution = {EPO Biology, University of Colorado, Boulden 80309-0334, USA.},
  owner = {pl4},
  pmid = {8946257},
  timestamp = {2011.05.26}
}

@Book{Pukkala1995,
  author    = {Pukkala, E.},
  title     = {Cancer Risk by Social Class and Occupation: A Survey of 109,000 Finns of Working Age},
  publisher = {Basel: Karger},
  series    = {Contributions to Epidemiology and Biostatistics},
  volume    = {7},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@Book{Finland1987,
  author    = {Pukkala, E. and Gustavsson, N. and Teppo, L.},
  title     = {Atlas of Cancer Incidence in {F}inland},
  publisher = {Helsinki: Cancer Society of Finland},
  series    = {Cancer Society of Finland Publication No. 37},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1987},
}

@ARTICLE{Putter2007,
  author = {H. Putter and M. Fiocco and R. B. Geskus},
  title = {Tutorial in biostatistics: competing risks and multi-state models.},
  journal = {Stat Med},
  year = {2007},
  volume = {26},
  pages = {2389--2430},
  number = {11},
  month = {May},
  abstract = {Standard survival data measure the time span from some time origin
	until the occurrence of one type of event. If several types of events
	occur, a model describing progression to each of these competing
	risks is needed. Multi-state models generalize competing risks models
	by also describing transitions to intermediate events. Methods to
	analyze such models have been developed over the last two decades.
	Fortunately, most of the analyzes can be performed within the standard
	statistical packages, but may require some extra effort with respect
	to data preparation and programming. This tutorial aims to review
	statistical methods for the analysis of competing risks and multi-state
	models. Although some conceptual issues are covered, the emphasis
	is on practical issues like data preparation, estimation of the effect
	of covariates, and estimation of cumulative incidence functions and
	state and transition probabilities. Examples of analysis with standard
	software are shown.},
  doi = {10.1002/sim.2712},
  file = {Putter2007.pdf:Putter2007.pdf:PDF;Putter2007.pdf:pdf\\Putter2007.pdf:PDF},
  institution = {Department of Medical Statistics and Bioinformatics, Leiden University
	Medical Center, Leiden, The Netherlands. h.putter@lumc.nl},
  owner = {pl4},
  pmid = {17031868},
  timestamp = {2009.10.15},
  url = {http://dx.doi.org/10.1002/sim.2712}
}

@ARTICLE{Putter2005,
  author = {Putter, H. and Sasako, M. and Hartgrink, H. H. and {van de Velde},
	C J H. and {van Houwelingen}, J. C.},
  title = {Long-term survival with non-proportional hazards: results from the
	{D}utch Gastric Cancer Trial.},
  journal = {Stat Med},
  year = {2005},
  volume = {24},
  pages = {2807--2821},
  number = {18},
  month = {Sep},
  abstract = {Randomized clinical trials with long-term survival data comparing
	two treatments often show Kaplan-Meier plots with crossing survival
	curves. Such behaviour implies a violation of the proportional hazards
	assumption for treatment. The Cox proportional hazards regression
	model with treatment as a fixed effect can therefore not be used
	to assess the influence of treatment of survival. In this paper we
	analyse long-term follow-up data from the Dutch Gastric Cancer Trial,
	a randomized study comparing limited (D1) lymph node dissection with
	extended (D2) lymph node dissection. We illustrate a number of ways
	of dealing with survival data that do not obey the proportional hazards
	assumption, each of which can be easily implemented in standard statistical
	packages.},
  doi = {10.1002/sim.2143},
  institution = {Department of Medical Statistics and Bioinformatics, Leiden University
	Medical Centre, University of Leiden, The Netherlands. h.putter@lumc.nl},
  keywords = {Aged; Biometry; Female; Humans; Lymph Node Excision, methods; Male;
	Middle Aged; Netherlands, epidemiology; Proportional Hazards Models;
	Prospective Studies; Randomized Controlled Trials as Topic, statistics
	/&/ numerical data; Stomach Neoplasms, mortality/surgery; Survival
	Rate},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pmid = {16134134},
  timestamp = {2016.05.30},
  url = {http://dx.doi.org/10.1002/sim.2143}
}

@ARTICLE{Quaglia2009,
  author = {A. Quaglia and A. Tavilla and L. Shack and H. Brenner and M. Janssen-Heijnen
	and C. Allemani and M. Colonna and E. Grande and P. Grosclaude and
	M. Vercelli and {EUROCARE Working Group}},
  title = {The cancer survival gap between elderly and middle-aged patients
	in {E}urope is widening},
  journal = {European Journal of Cancer},
  year = {2009},
  volume = {45},
  pages = {1006--1016},
  number = {6},
  month = {Apr},
  abstract = {The present study is aimed to compare survival and prognostic changes
	over time between elderly (70-84 years) and middle-aged cancer patients
	(55-69 years). We considered seven cancer sites (stomach, colon,
	breast, cervix and corpus uteri, ovary and prostate) and all cancers
	combined (but excluding prostate and non-melanoma skin cancers).
	Five-year relative survival was estimated for cohorts of patients
	diagnosed in 1988-1999 in a pool of 51 European populations covered
	by cancer registries. Furthermore, we applied the period-analysis
	method to more recent incidence data from 32 cancer registries to
	provide 1- and 5-year relative survival estimates for the period
	of follow-up 2000-2002. A significant survival improvement was observed
	from 1988 to 1999 for all cancers combined and for every cancer site,
	except cervical cancer. However, survival increased at a slower rate
	in the elderly, so that the gap between younger and older patients
	widened, particularly for prostate cancer in men and for all considered
	cancers except cervical cancer in women. For breast and prostate
	cancers, the increasing gap was likely attributable to a larger use
	of, respectively, mammographic screening and PSA test in middle-aged
	with respect to the elderly. In the period analysis of the most recent
	data, relative survival was much higher in middle-aged patients than
	in the elderly. The differences were higher for breast and gynaecological
	cancers, and for prostate cancer. Most of this age gap was due to
	a very large difference in survival after the 1st year following
	the diagnosis. Differences were much smaller for conditional 5-year
	relative survival among patients who had already survived the first
	year. The increase of survival in elderly men is encouraging but
	the lesser improvement in women and, in particular, the widening
	gap for breast cancer suggest that many barriers still delay access
	to care and that enhanced prevention and clinical management remain
	major issues.},
  doi = {10.1016/j.ejca.2008.11.028},
  file = {Quaglia2009.pdf:Quaglia2009.pdf:PDF;Quaglia2009.pdf:pdf\\Quaglia2009.pdf:PDF},
  institution = {Liguria Cancer Registry, National Cancer Research Institute, Genoa
	16132, Italy. alberto.quaglia@istge.it},
  owner = {pl4},
  pii = {S0959-8049(08)00905-2},
  pmid = {19121578},
  timestamp = {2010.03.21},
  url = {http://dx.doi.org/10.1016/j.ejca.2008.11.028}
}

@ARTICLE{Quantin1999,
  author = {C. Quantin and M. Abrahamowicz and T. Moreau and G. Bartlett and
	T. MacKenzie and M. A. Tazi and L. Lalonde and J. Faivre},
  title = {Variation over time of the effects of prognostic factors in a population-based
	study of colon cancer: comparison of statistical models.},
  journal = {American Journal of Epidemiology},
  year = {1999},
  volume = {150},
  pages = {1188--1200},
  number = {11},
  month = {Dec},
  abstract = {The authors compare the performance of different regression models
	for censored survival data in modeling the impact of prognostic factors
	on all-cause mortality in colon cancer. The data were for 1,951 patients,
	who were diagnosed in 1977-1991, recorded by the Registry of Digestive
	Tumors of C{\AA}ÂƒÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â´te d'Or, France, and followed for up to 15 years. Models
	include the Cox proportional hazards model and its three generalizations
	that allow for hazard ratio to change over time: 1) the piecewise
	model where hazard ratio is a step function; 2) the model with interaction
	between a predictor and a parametric function of time; and 3) the
	non-parametric regression spline model. Results illustrate the importance
	of accounting for non-proportionality of hazards, and some advantages
	of flexible non-parametric modeling of time-dependent effects. The
	authors provide empirical evidence for the dependence of the results
	of piecewise and parametric models on arbitrary a priori choices,
	regarding the number of time intervals and specific parametric function,
	which may lead to biased estimates and low statistical power. The
	authors demonstrate that a single, a priori selected spline model
	recovers a variety of patterns of changes in hazard ratio and fits
	better than other models, especially when the changes are non-monotonic,
	as in the case of cancer stages.},
  file = {Quantin1999.pdf:pdf\\Quantin1999.pdf:PDF;Quantin1999.pdf:Quantin1999.pdf:PDF},
  institution = {Department of Biostatistics and Medical Informatics, Teaching Hospital
	of Dijon, France.},
  owner = {pl4},
  pmid = {10588079},
  timestamp = {2009.02.12}
}

@Article{Quaresma2014,
  author      = {Quaresma, M. and Coleman, M. P. and Rachet, B.},
  title       = {40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in {E}ngland and {W}ales, 1971-2011: a population-based study.},
  journal     = {Lancet},
  year        = {2014},
  language    = {eng},
  volume      = {385},
  pages       = {1206-1218},
  doi         = {10.1016/S0140-6736(14)61396-9},
  url         = {http://dx.doi.org/10.1016/S0140-6736(14)61396-9},
  abstract    = {Assessment of progress in cancer control at the population level is
	increasingly important. Population-based survival trends provide
	a key insight into the overall effectiveness of the health system,
	alongside trends in incidence and mortality. For this purpose, we
	aimed to provide a unique measure of cancer survival.In this observational
	study, we analysed trends in survival with population-based data
	for 7ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·2 million adults diagnosed with a first, primary, invasive
	malignancy in England and Wales during 1971-2011 and followed up
	to the end of 2012. We constructed a survival index for all cancers
	combined using data from the National Cancer Registry and the Welsh
	Cancer Intelligence and Surveillance Unit. The index is designed
	to be independent of changes in the age distribution of patients
	with cancer and of changes in the proportion of lethal cancers in
	each sex. We analysed trends in the cancer survival index at 1, 5,
	and 10 years after diagnosis for the selected periods 1971-72, 1980-81,
	1990-91, 2000-01, 2005-06, and 2010-11. We also estimated trends
	in age-sex-adjusted survival for each cancer. We define the difference
	in net survival between the oldest (75-99 years) and youngest (15-44
	years) patients as the age gap in survival. We evaluated the absolute
	change (\%) in the age gap since 1971.The overall index of net survival
	increased substantially during the 40-year period 1971-2011, both
	in England and in Wales. For patients diagnosed in 1971-72, the index
	of net survival was 50\% at 1 year after diagnosis. 40 years later,
	the same value of 50\% was predicted at 10 years after diagnosis.
	The average 10\% survival advantage for women persisted throughout
	this period. Predicted 10-year net survival adjusted for age and
	sex for patients diagnosed between 2010 and 2011 ranged from 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·1\%
	for pancreatic cancer to 98ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·2\% for testicular cancer. Net survival
	for the oldest patients (75-99 years) was persistently lower than
	for the youngest (15-44 years), even after adjustment for the much
	higher mortality from causes other than cancer in elderly people.These
	findings support substantial increases in both short-term and long-term
	net survival from all cancers combined in both England and Wales.
	The net survival index provides a convenient, single number that
	summarises the overall patterns of cancer survival in any one population,
	in each calendar period, for young and old men and women and for
	a wide range of cancers with very disparate survival. The persistent
	sex difference is partly due to a more favourable cancer distribution
	in women than men. The very wide differences in survival for different
	cancers, and the persistent age gap in survival, suggest the need
	for renewed efforts to improve cancer outcomes. Future monitoring
	of the cancer survival index will not be possible unless the current
	crisis of public concern about sharing of individual data for public
	health research can be resolved.Cancer Research UK.},
  file        = {Quaresma2014.pdf:Quaresma2014.pdf:PDF},
  institution = {Tropical Medicine, London, UK.},
  medline-pst = {aheadofprint},
  owner       = {pl4},
  pii         = {S0140-6736(14)61396-9},
  pmid        = {25479696},
  timestamp   = {2015.03.14},
}

@ARTICLE{Quaresma2013,
  author = {Quaresma, M. and Coleman, M. P. and Rachet, B.},
  title = {Funnel plots for population-based cancer survival: principles, methods
	and applications},
  journal = {Statistics in Medicine},
  year = {2013},
  doi = {10.1002/sim.5953},
  file = {Quaresma2013.pdf:pdf\\Quaresma2013.pdf:PDF},
  issn = {1097-0258},
  keywords = {population base, cancer survival, funnel plot, surveillance, geographical
	variation},
  owner = {PaulD},
  timestamp = {2013.09.10},
  url = {http://dx.doi.org/10.1002/sim.5953}
}

@ARTICLE{Quinn2002,
  author = {M. Quinn and P. Babb},
  title = {Patterns and trends in prostate cancer incidence, survival, prevalence
	and mortality. {P}art {II}: individual countries.},
  journal = {BJU Int},
  year = {2002},
  volume = {90},
  pages = {174-84},
  number = {2},
  month = {Jul},
  owner = {PaulD},
  pii = {2823},
  timestamp = {2011.06.19}
}

@ARTICLE{Rabin2013,
  author = {Rabin, Borsika A. and Gaglio, Bridget and Sanders, Tristan and Nekhlyudov,
	Larissa and Dearing, James W. and Bull, Sheana and Glasgow, Russell
	E. and Marcus, Alfred},
  title = {Predicting cancer prognosis using interactive online tools: a systematic
	review and implications for cancer care providers.},
  journal = {Cancer Epidemiol Biomarkers Prev},
  year = {2013},
  volume = {22},
  pages = {1645--1656},
  number = {10},
  month = {Oct},
  abstract = {Cancer prognosis is of keen interest for patients with cancer, their
	caregivers, and providers. Prognostic tools have been developed to
	guide patient-physician communication and decision-making. Given
	the proliferation of prognostic tools, it is timely to review existing
	online cancer prognostic tools and discuss implications for their
	use in clinical settings. Using a systematic approach, we searched
	the Internet, Medline, and consulted with experts to identify existing
	online prognostic tools. Each was reviewed for content and format.
	Twenty-two prognostic tools addressing 89 different cancers were
	identified. Tools primarily focused on prostate (n = 11), colorectal
	(n = 10), breast (n = 8), and melanoma (n = 6), although at least
	one tool was identified for most malignancies. The input variables
	for the tools included cancer characteristics (n = 22), patient characteristics
	(n = 18), and comorbidities (n = 9). Effect of therapy on prognosis
	was included in 15 tools. The most common predicted outcome was cancer-specific
	survival/mortality (n = 17). Only a few tools (n = 4) suggested patients
	as potential target users. A comprehensive repository of online prognostic
	tools was created to understand the state-of-the-art in prognostic
	tool availability and characteristics. Use of these tools may support
	communication and understanding about cancer prognosis. Dissemination,
	testing, refinement of existing, and development of new tools under
	different conditions are needed.},
  doi = {10.1158/1055-9965.EPI-13-0513},
  file = {Rabin2013.pdf:pdf\\Rabin2013.pdf:PDF;Rabin2013.pdf:Rabin2013.pdf:PDF},
  institution = {Authors' Affiliations: Cancer Research Network Cancer Communication
	Research Center, Institute for Health Research; Kaiser Permanente
	Colorado; and University of Colorado, Denver, Colorado; Mid-Atlantic
	Permanente Research Institute, Kaiser Permanente; National Cancer
	Institute, Rockville, Maryland; and Department of Population Medicine,
	Harvard Medical School and Department of Medicine, Harvard Vanguard
	Medical Associates, Boston, Massachusetts.},
  keywords = {Caregivers; Humans; Internet; MEDLINE; Patient Education as Topic,
	methods; Prognosis},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pii = {1055-9965.EPI-13-0513},
  pmc = {PMC3832108},
  pmid = {23956026},
  timestamp = {2015.09.23},
  url = {http://dx.doi.org/10.1158/1055-9965.EPI-13-0513}
}

@ARTICLE{Rachet2003,
  author = {B Rachet and M Abrahamowicz and AJ Sasco and J Siemiatycki},
  title = {Estimating the distribution of lag in the effect of short-term exposures
	and interventions: adaptation of a non-parametric regression spline
	model.},
  journal = {Stat Med},
  year = {2003},
  volume = {22},
  pages = {2335-63},
  abstract = {Information on the distribution of lag duration between exposure or
	intervention and the subsequent changes in risk can help in assessing
	the impact of exposure, predicting cost-effectiveness of intervention,
	and understanding the underlying biological mechanisms. Previous
	approaches focused more on optimizing the strength of the exposure-disease
	association than on directly estimating lag duration. We propose
	an alternative approach applicable to the analysis of the lagged
	effects of binary exposure variables. The density function of the
	distribution of lags is estimated based on flexible modelling of
	changes in hazard ratio of exposed versus unexposed subjects. The
	methodology is evaluated in a simulation study and is applied to
	the Framingham data to investigate the lagged effect of smoking cessation
	on coronary heart disease risk.},
  doi = {10.1002/sim.1432},
  owner = {PaulD},
  timestamp = {2011.06.19},
  url = {http://dx.doi.org/10.1002/sim.1432}
}

@ARTICLE{Rachet2015,
  author = {Rachet, B. and Maringe, C. and Woods, L.M. and Ellis, L. and Spika,
	D. and Allemani, C.},
  title = {Multivariable flexible modelling for estimating complete, smoothed
	life tables for sub-national populations},
  journal = {BMC Public Health},
  year = {2015},
  volume = {15},
  pages = {1240},
  file = {Rachet2015.pdf:pdf\\Rachet2015.pdf:PDF;Rachet2015.pdf:Rachet2015.pdf:PDF},
  owner = {hanbow},
  timestamp = {2016.09.05}
}

@ARTICLE{Raftery1995,
  author = {Raftery, A. E.},
  title = {Bayesian model selection in social research},
  journal = {Sociological methodology},
  year = {1995},
  volume = {25},
  pages = {111-164},
  file = {Raftery1995.pdf:Raftery1995.pdf:PDF;Raftery1995.pdf:pdf\\Raftery1995.pdf:PDF},
  owner = {hanbow},
  timestamp = {2015.05.11}
}

@ARTICLE{Rahkonen1995a,
  author = {Rahkonen, O. and Arber, S. and Lahelma E.},
  title = {Health Inequalities in Early Adulthood: A Comparison of Young Men
	and Women in {B}ritain and {F}inland},
  journal = {Social Science \& Medicine},
  year = {1995},
  volume = {41},
  pages = {163-171},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Rahkonen1995,
  author = {Rahkonen, O. and Berg, M. A. and Puska, P.},
  title = {Relationship Between Educational Status, Gender and Smoking in {F}inland,
	1978-1992},
  journal = {Health Promotion International},
  year = {1995},
  volume = {10},
  pages = {115-120},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Rakba1999,
  author = {Rakba, N. and Nguyen-Van-Duong, M. K. and Nicolas, L. and Guillot,
	V. and Morel, I. and Pasdeloup, N. and Brissot, P. and Lescoat, G.},
  title = {Cytoprotection and iron mobilization in rat hepatocyte cultures by
	a new synthetic dihydroxamate chelator.},
  journal = {Toxicol Lett},
  year = {1999},
  volume = {110},
  pages = {19--27},
  number = {1-2},
  month = {Oct},
  abstract = {The cytoprotection and iron mobilization effect of a new dihydroxamate
	chelator 1,1 bis [(11-N-hydroxy)-2,5,11-triaza-1,6,10-trioxo dodecanyl]
	ethane or KD was studied in primary rat hepatocyte cultures exposed
	to iron-citrate. Lactate dehydrogenase (LDH) release and malondialdehyde
	(MDA) production were measured as indexes of cytotoxicity. Cell viability
	was evaluated using the [3-(4,5-dimethyl-thiazol-2-yl) 2,5-diphenyl
	tetrazolium bromide] (MTT) reduction test. To demonstrate that this
	chelator was able to decrease iron uptake or increase iron release
	from the hepatocytes, labelled cells were obtained by maintaining
	the cultures in the presence of 0.02 microM 55Fe-citrate. The efficacy
	of KD was compared to desferrioxamine B (DFO) at stoechiometry concentrations.
	After 24 h of exposure to 50 microM of iron-citrate, a significant
	release of LDH and MDA was observed. Cell viability was also significantly
	decreased. When 100 microM of KD were added at the same time as iron,
	LDH and MDA release was decreased and cell viability was improved.
	In the presence of the same chelator concentration, a net decrease
	of iron uptake by the cells was observed as attested by the low intracellular
	55Fe level. Moreover, in the 55Fe loaded hepatocytes, the chelator
	increased the iron extracellular level indicating its iron release
	effect from the cells. In all tested experimental conditions, the
	efficacy of 100 microM of the dihydroxamate chelator KD was close
	to that of 50 microM of the trihydroxamate chelator DFO. In conclusion,
	KD is effective at a level comparable to DFO in protecting rat hepatocytes
	against the toxic effect of iron-citrate by decreasing the uptake
	of the metal and increasing its release from the cells. This synthetic
	compound appears to have some potential therapeutical interest and
	the results obtained encourage the synthesis of new hydroxamate ligands.},
  institution = {INSERM U522, R{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¦ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Âµlations des Equilibres Fonctionnels du Foie Normal
	et Pathologique, H{\AA}Â³ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¯ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â´al de Pontchaillou, Rennes, France.},
  keywords = {Animals; Cell Survival, drug effects; Cells, Cultured; Chromatography,
	High Pressure Liquid; Coloring Agents; Hydroxamic Acids, pharmacology;
	Iron Chelating Agents, metabolism; Iron Radioisotopes; Iron, metabolism;
	L-Lactate Dehydrogenase, metabolism; Lipid Peroxidation, drug effects;
	Liver, cytology/drug effects/metabolism; Male; Rats; Rats, Sprague-Dawley;
	Tetrazolium Salts; Thiazoles},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {S0378-4274(99)00135-6},
  pmid = {10593591},
  timestamp = {2013.05.29}
}

@ARTICLE{Rama2010,
  author = {Rama, Ranganathan and Swaminathan, Rajaraman and Venkatesan, Perumal},
  title = {Cure models for estimating hospital-based breast cancer survival.},
  journal = {Asian Pac J Cancer Prev},
  year = {2010},
  volume = {11},
  pages = {387--391},
  number = {2},
  abstract = {Research on cancer survival is enriched by development and application
	of innovative analytical approaches in relation to standard methods.
	The aim of the present paper is to document the utility of a mixture
	model to estimate the cure fraction and compare it with other approaches.The
	data were for 1,107 patients with locally advanced breast cancer,
	who completed the neo-adjuvant treatment protocol during 1990-99
	at the Cancer Institute (WIA), Chennai, India. Tumour stage, post-operative
	pathological node (PN) and tumour residue (TR) status were studied.
	Event free survival probability was estimated using the Kaplan-Meier
	method. Cure models under proportional and non-proportional hazard
	assumptions following log normal distribution for survival time were
	used to estimate both the cure fraction and the survival function
	for the uncured.Event free survival at 5 and 10 years were 64.2\%
	and 52.6\% respectively and cure fraction was 47.5\% for all cases
	together. Follow up ranged between 0-15 years and survival probabilities
	showed minimal changes after 7 years of follow up. TR and PN emerged
	as independent prognostic factors using Cox and proportional hazard
	(PH) cure models. Proportionality condition was violated when tumour
	stage was considered and it was statistically significant only under
	PH and not under non PH cure models. However, TR and PN continued
	to be independent prognostic factors after adjusting for tumour stage
	using the non PH cure model. A consistent ordering of cure fractions
	with respect to factors of PN and TR was forthcoming across tumour
	stages using PH and non PH cure models, but perceptible differences
	in survival were observed between the two.If PH conditions are violated,
	analysis using a non PH model is advocated and mixture cure models
	are useful in estimating the cure fraction and constructing survival
	curves for non-cures.},
  institution = {Department of Epidemiology, Biostatistics and Cancer Registry, Cancer
	Institute (WIA), India.},
  keywords = {Cure models},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {20843121},
  timestamp = {2012.03.31}
}

@ARTICLE{Ramirez1999,
  author = {A. J. Ramirez and A. M. Westcombe and C. C. Burgess and S. Sutton
	and P. Littlejohns and M. A. Richards},
  title = {Factors predicting delayed presentation of symptomatic breast cancer:
	a systematic review.},
  journal = {Lancet},
  year = {1999},
  volume = {353},
  pages = {1127--1131},
  number = {9159},
  month = {Apr},
  abstract = {BACKGROUND: Delayed presentation of symptomatic breast cancer is associated
	with lower survival. Understanding of the factors that influence
	delay is important for the development of strategies to shorten delays.
	We did a systematic review to assess the quality and strength of
	evidence on risk factors for delays by patients and providers. METHODS:
	We generated hypotheses about the relation between each putative
	risk factor and delay, against which we tested studies. We did searches
	to identify papers containing original data related to risk factors
	for delays by patients (n=86) and providers (n=28). We critically
	appraised the papers for inclusion in the review according to predefined
	criteria. The small number of studies of adequate quality did not
	allow formal meta-analysis. We therefore assigned strength of evidence
	according to a combination of the number and size of studies supporting,
	not supporting, or refuting the hypotheses. FINDINGS: Most studies
	were deemed to be of poor quality and were excluded. Among 23 studies
	of adequate quality, however, there was strong evidence for an association
	between older age and delay by patients, and strong evidence that
	marital status was unrelated to delays by patients. Younger age and
	presentation with a breast symptom other than a lump were strong
	risk factors for delays by providers. Moderate evidence was shown
	for several other factors. INTERPRETATION: The strength of the current
	evidence is inadequate to inform the development of specific strategies
	to shorten delays by patients or providers. Clarification of the
	findings of this review through a major programme of primary research
	is urgently required.},
  file = {Ramirez1999.pdf:pdf\\Ramirez1999.pdf:PDF;Ramirez1999.pdf:Ramirez1999.pdf:PDF},
  institution = {ICRF Psychosocial Oncology Group, Guy's, King's and St Thomas's School
	of Medicine, Riddell House, St Thomas' Hospital, London, UK.},
  owner = {pl4},
  pii = {S014067369902142X},
  pmid = {10209975},
  timestamp = {2010.03.23}
}

@Book{Rauhala1966,
  author    = {Rauhala, U.},
  title     = {The Social Stratification of {F}innish Society},
  note      = {(in Finnish)},
  publisher = {Porvoo: Society for Social Policy},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1966},
}

@ARTICLE{Raymond1996,
  author = {Raymond, L. and Fischer, B. and Fioretta, G. and Bouchardy, C.},
  title = {Migration Bias in Cancer Survival Rates},
  journal = {Journal of Epidemiology and Biostatistics},
  year = {1996},
  volume = {1},
  pages = {167-173},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{ReboljKodre2013,
  author = {{Rebolj Kodre}, Anamarija and {Pohar Perme}, Maja},
  title = {Informative censoring in relative survival.},
  journal = {Stat Med},
  year = {2013},
  month = {Jun},
  abstract = {With changing the age distribution at the time of cancer diagnosis,
	the administrative censoring due to study end may be informative.
	This problem has been mentioned frequently in the relative survival
	field, and an estimator aiming to correct this problem has been developed.
	In this paper, we review the existing methods for estimation in relative
	survival, demonstrate their deficiencies, and propose weighting to
	correct both the recently introduced net survival estimator and the
	Ederer I estimator. Using simulations and real cancer registry data,
	we evaluate the magnitude of the informative censoring problem. We
	clarify the assumptions behind the reviewed methods and provide guidance
	to their usage in practice. Copyright {\AA}Â‚ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â© 2013 John Wiley & Sons,
	Ltd.},
  doi = {10.1002/sim.5877},
  file = {ReboljKodre2013.pdf:pdf\\ReboljKodre2013.pdf:PDF},
  institution = {Department of Biostatistics and Medical Informatics, University of
	Ljubljana, Vrazov trg 2, SI-1000 Ljubljana, Slovenia.},
  language = {eng},
  medline-pst = {aheadofprint},
  owner = {PaulD},
  pmid = {23761182},
  timestamp = {2013.06.20},
  url = {http://dx.doi.org/10.1002/sim.5877}
}

@ARTICLE{Reed2009,
  author = {M. W R Reed and R. A. Audisio and L. Wyld},
  title = {The role of surgery in the treatment of older women with breast cancer.},
  journal = {Clinical Oncology},
  year = {2009},
  volume = {21},
  pages = {103--110},
  number = {2},
  month = {Mar},
  abstract = {A significant proportion of women diagnosed with breast cancer are
	over the age of 70 years and there is evidence that these patients
	frequently do not receive standard treatments, including surgical
	procedures and adjuvant therapies, which would be routine practice
	in younger age groups. The factors underlying this may include the
	physiological effects of ageing, differences in the biology and stage
	of the tumour at presentation, patient co-morbidities and patient
	and clinician preferences. The interaction of all these factors needs
	to be considered when individualising treatment plans for patients.
	For some patients this will need to be undertaken in the context
	of an extended multidisciplinary team setting with additional input
	from geriatricians, in addition to surgeons and oncologists, in defining
	a treatment plan. Little is known about the preferences of older
	patients in their choice of surgical treatment for breast cancer
	and further research is required to increase the evidence base for
	the rational management of older women with breast cancer.},
  doi = {10.1016/j.clon.2008.11.010},
  file = {Reed2009.pdf:Reed2009.pdf:PDF;Reed2009.pdf:pdf\\Reed2009.pdf:PDF},
  institution = {Academic Surgical Oncology Unit, School of Medicine, University of
	Sheffield, Beech Hill Road, Sheffield, UK. m.w.reed@shef.ac.uk},
  owner = {pl4},
  pii = {S0936-6555(08)00455-X},
  pmid = {19073360},
  timestamp = {2010.03.21},
  url = {http://dx.doi.org/10.1016/j.clon.2008.11.010}
}

@ARTICLE{Reeves1999,
  author = {G. K. Reeves and V. Beral and D. Bull and M. Quinn},
  title = {Estimating relative survival among people registered with cancer
	in England and Wales.},
  journal = {British Journal of Cancer},
  year = {1999},
  volume = {79},
  pages = {18--22},
  number = {1},
  month = {Jan},
  abstract = {Because routinely collected survival data for cancer patients in England
	and Wales do not typically specify cause of death, conventional estimates
	of survival in cancer patients based on such data are a measure of
	their mortality from all causes rather than their mortality due to
	cancer. As a result, trends in survival over time are difficult to
	interpret because changes in overall survival may well reflect changes
	in the risk of death from other causes, rather than from the cancer
	of interest. One way of overcoming this problem is to use some form
	of 'relative survival' defined as a measure of survival corrected
	for the effect of other independent causes of death. Since this concept
	was first introduced, various methods for calculating relative survival
	have been proposed and this had led to some confusion as to the most
	appropriate choice of estimate. This paper aims to provide an introduction
	to the concept of relative survival and reviews some of the suggested
	methods of estimation. In addition, a particularly simple, but robust
	approach, is highlighted based on expected and observed mortality.
	This method is illustrated using preliminary data from the Office
	for National Statistics on cancer survival in patients born after
	1939 and diagnosed with cancer during 1972-84. The examples presented,
	although limited to analyses on a small number of selected sites,
	highlight some encouraging trends in survival in people aged under
	35 diagnosed with leukaemia, Hodgkin's disease and testicular cancer
	during this period.},
  doi = {10.1038/sj.bjc.6690005},
  file = {Reeves1999.pdf:Reeves1999.pdf:PDF;Reeves1999.pdf:pdf\\Reeves1999.pdf:PDF},
  institution = {Imperial Cancer Research Fund Cancer Epidemiology Unit, University
	of Oxford, UK.},
  owner = {pl4},
  pmid = {10408687},
  timestamp = {2008.12.16},
  url = {http://dx.doi.org/10.1038/sj.bjc.6690005}
}

@TechReport{APCR1990,
  author      = {Australian Paediatric Cancer Registry},
  institution = {Australian Paediatric Cancer Registry},
  title       = {Childhood Cancer in {Australia} 1977 to 1982: Incidence and Survival},
  owner       = {PaulD},
  timestamp   = {2011.06.19},
  year        = {1990},
}

@Book{Finland1997,
  author    = {Finnish Cancer Registry},
  title     = {Cancer Incidence in {F}inland 1995},
  publisher = {Helsinki: Cancer Society of Finland},
  series    = {Cancer Society of Finland Publication No. 58},
  groups    = {Cancer registry reports},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1997},
}

@Book{Sweden1996,
  author    = {Swedish Cancer Registry},
  title     = {Cancer Incidence in {S}weden 1993},
  publisher = {Stockholm: Socialstyrelsen},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1996},
}

@ARTICLE{Reibnegger2012,
  author = {G. Reibnegger},
  title = {Modeling Time in Medical Education Research: The Potential of New
	Flexible Parametric Methods of Survival Analysis},
  journal = {Creative Education},
  year = {2012},
  volume = {3},
  pages = {916-922},
  file = {Reibnegger2012.pdf:pdf\\Reibnegger2012.pdf:PDF;Reibnegger2012.pdf:Reibnegger2012.pdf:PDF},
  owner = {pl4},
  timestamp = {2014.03.03}
}

@ARTICLE{Reid1994,
  author = {N. Reid},
  title = {A conversation with {S}ir {D}avid {C}ox},
  journal = {Statistical Science},
  year = {1994},
  volume = {9},
  pages = {439-455},
  file = {Reid1994.pdf:Reid1994.pdf:PDF;Reid1994.pdf:pdf\\Reid1994.pdf:PDF},
  owner = {pl4},
  timestamp = {2009.03.26}
}

@ARTICLE{Reilly1996,
  author = {M Reilly},
  title = {Optimal sampling strategies for two-stage studies.},
  journal = {Am J Epidemiol},
  year = {1996},
  volume = {143},
  pages = {92-100},
  number = {1},
  month = {Jan},
  abstract = {The optimal allocation of available resources is the concern of every
	investigator in choosing a study design. The recent development of
	statistical methods for the analysis of two-stage data makes these
	study designs attractive for their economy and efficiency. However,
	little work has been done on deriving two-stage designs that are
	optimal under the kinds of constraints encountered in practice. The
	methods presented in this paper provide a means of deriving designs
	that will maximize precision for a fixed total budget or minimize
	the study cost necessary to achieve a desired precision. These optimal
	designs depend on the relative information content and the relative
	cost of gathering the first- and second-stage data. In place of the
	usual sample size calculations, the investigator can use pilot data
	to estimate the study size and second-stage sampling fractions. The
	gains in efficiency that can result from such carefully designed
	studies are illustrated here by deriving and implementing optimal
	designs using data from the Coronary Artery Surgery Study.},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Reiter1994,
  author = {R. J. Reiter and D. X. Tan and B. Poeggeler and A. Menendez-Pelaez
	and L. D. Chen and S. Saarela},
  title = {Melatonin as a free radical scavenger: implications for aging and
	age-related diseases.},
  journal = {Ann N Y Acad Sci},
  year = {1994},
  volume = {719},
  pages = {1--12},
  month = {May},
  institution = {Department of Cellular and Structural Biology, University of Texas
	Health Science Center, San Antonio 78284-7762.},
  owner = {pl4},
  pmid = {8010585},
  timestamp = {2011.05.26}
}

@ARTICLE{Remontet2007,
  author = {L. Remontet and N. Bossard and A. Belot and J. Est\`{e}ve and {French
	network of cancer registries FRANCIM}},
  title = {An overall strategy based on regression models to estimate relative
	survival and model the effects of prognostic factors in cancer survival
	studies.},
  journal = {Stat Med},
  year = {2007},
  volume = {26},
  pages = {2214--2228},
  number = {10},
  month = {May},
  abstract = {Relative survival provides a measure of the proportion of patients
	dying from the disease under study without requiring the knowledge
	of the cause of death. We propose an overall strategy based on regression
	models to estimate the relative survival and model the effects of
	potential prognostic factors. The baseline hazard was modelled until
	10 years follow-up using parametric continuous functions. Six models
	including cubic regression splines were considered and the Akaike
	Information Criterion was used to select the final model. This approach
	yielded smooth and reliable estimates of mortality hazard and allowed
	us to deal with sparse data taking into account all the available
	information. Splines were also used to model simultaneously non-linear
	effects of continuous covariates and time-dependent hazard ratios.
	This led to a graphical representation of the hazard ratio that can
	be useful for clinical interpretation. Estimates of these models
	were obtained by likelihood maximization. We showed that these estimates
	could be also obtained using standard algorithms for Poisson regression.},
  file = {Remontet2007.pdf:Remontet2007.pdf:PDF},
  institution = {Service de Biostatistique, Hospices Civils de Lyon, Lyon, France.
	laurent.remontet@chu-lyon.fr},
  owner = {PaulD},
  pmid = {16900570},
  timestamp = {2007.10.23}
}

@ARTICLE{Renshaw1988,
  author = {Renshaw, A. E.},
  title = {Modelling Excess Mortality Using {GLIM}},
  journal = {J. Inst. Actuaries},
  year = {1988},
  volume = {115},
  pages = {299-315},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Retsky2004,
  author = {Michael Retsky and Gianni Bonadonna and Romano Demicheli and Judah
	Folkman and William Hrushesky and Pinuccia Valagussa},
  title = {Hypothesis: {I}nduced angiogenesis after surgery in premenopausal
	node-positive breast cancer patients is a major underlying reason
	why adjuvant chemotherapy works particularly well for those patients.},
  journal = {Breast Cancer Res},
  year = {2004},
  volume = {6},
  pages = {R372-4},
  abstract = {BACKGROUND: We suggest that surgical extirpation of primary breast
	cancer among other effects accelerates relapse for some premenopausal
	node-positive patients. These accelerated relapses occur within 10
	months of surgery for untreated patients. The mechanism proposed
	is a stimulation of angiogenesis for distant dormant micrometastases.
	This has been suggested as one of the mechanisms to explain the mammography
	paradox for women aged 40-49 years. We could imagine that it also
	plays a role in adjuvant chemotherapy effectiveness since, perhaps
	not coincidentally, this is most beneficial for premenopausal node-positive
	patients. HYPOTHESIS: We speculate that there is a burst of angiogenesis
	of distant dormant micrometastases after surgery in approximately
	20\% of premenopausal node-positive patients. We also speculate that
	this synchronizes them into a temporal highly chemosensitive state
	and is the underlying reason why adjuvant chemotherapy works particularly
	well for that patient category. Furthermore, this may explain why
	cancer in younger patients is more often 'aggressive'. TESTING THE
	HYPOTHESIS: Stimulation of dormant micrometastases by primary tumor
	removal is known to occur in animal models. However, we need to determine
	whether it happens in breast cancer. Transient circulating levels
	of angioactive molecules and serial high-resolution imaging studies
	of focal angiogenesis might help. IMPLICATIONS: Short-course cytotoxic
	chemotherapy after surgery has probably reached its zenith, and other
	strategies, perhaps antiangiogenic methods, are needed to successfully
	treat more patients. In addition, the hypothesis predicts that early
	detection, which is designed to find more patients without involved
	lymph nodes, may not be a synergistic strategy with adjuvant chemotherapy,
	which works best with positive lymph node patients.},
  doi = {10.1186/bcr804},
  owner = {PaulD},
  pii = {bcr804},
  timestamp = {2011.06.19},
  url = {http://dx.doi.org/10.1186/bcr804}
}

@ARTICLE{Retsky2003,
  author = {Michael Retsky and Romano Demicheli and William Hrushesky},
  title = {Breast cancer screening: controversies and future directions.},
  journal = {Curr Opin Obstet Gynecol},
  year = {2003},
  volume = {15},
  pages = {1-8},
  abstract = {PURPOSE OF REVIEW: Recent criticisms of the mature breast cancer screening
	trials claimed that there is no evidence that screening saves lives.
	This has developed into a major public controversy, causing physicians,
	women, and policy analysts to rethink and debate mammography-screening
	guidelines. We have studied this subject from a different perspective
	-- using computer simulation to fit a simple growth model to clinical
	data. We can thus provide another viewpoint of the screening controversy
	that may help elucidate the underlying biology and aid policy makers
	in devising sound screening guidelines. RECENT FINDINGS: We agree
	with some reviewers that there is partial validity to the criticism.
	Based on our studies, we have arrived at a new explanation of why
	screening has not lived up to expectations. SUMMARY: Our fundamental
	hypothesis is that breast cancers often undergo periods during which
	they are temporarily dormant. In addition, surgical intervention
	to remove primary tumors can interrupt this dormancy. Therefore screening
	finds smaller tumors with fewer positive lymph nodes, which is beneficial.
	But then the resulting extirpation accelerates the growth of dormant
	distant micrometastases, and results in earlier relapses than in
	women who have not been screened. This partly offsets the early detection
	advantage. One hypothetical mechanism proposed to explain this biology
	is that surgical wounding, particularly for premenopausal node-positive
	patients, can trigger the angiogenesis of dormant avascular micrometastases.},
  doi = {10.1097/01.gco.0000051562.77832.a9},
  owner = {PaulD},
  timestamp = {2011.06.19},
  url = {http://dx.doi.org/10.1097/01.gco.0000051562.77832.a9}
}

@ARTICLE{Retsky2001,
  author = {M Retsky and R Demicheli and W Hrushesky},
  title = {Premenopausal status accelerates relapse in node positive breast
	cancer: hypothesis links angiogenesis, screening controversy.},
  journal = {Breast Cancer Res Treat},
  year = {2001},
  volume = {65},
  pages = {217-24},
  abstract = {Much attention has been given to determining the benefit of mammographic
	screening to reduce breast cancer mortality. Eight randomized clinical
	trials have been conducted in four countries: the US, Canada, Scotland
	and {S}weden. Trials report an early and stable 30\% reduction in
	breast cancer mortality for women aged 50-59. For women under 50,
	unexpectedly, the early years of screening produce a disadvantage
	to the screened population. Only in later years does an advantage
	appear. To help understand this, we studied relapse patterns using
	a breast cancer database of 1,173 pre- and postmenopausal, node negative
	and positive patients treated with surgery only and having 16-20
	years of follow-up. This approach is relevant since at least five
	of the eight screening trials began before the widespread use of
	adjuvant chemotherapy in the 1980s. Surgical cure rates were independent
	of menopausal status. However, a major difference in early relapse
	rate was found. In premenopausal and node positive patients, 27\%
	of all distant relapses occurred within the first 10 months following
	resection. This is twice the early relapse frequency of any other
	clinical group. Using computer simulation, we interpret that these
	early relapses probably result from a disadvantage induced at surgery.
	A disinhibition or surgery/wounding induced angiogenic surge might
	be responsible. Disinhibition is known to occur in animal models
	such as Lewis lung where lung metastases are avascular and dormant
	until the primary is removed. Sudden outgrowth of tumor after wounding
	has been observed for a century. According to the simulation, in
	breast cancer this induction apparently accelerates inevitable relapses
	by a median of two years. This is offset in later years with a balancing
	reduction in relapses. These data suggest that the angiogenic switch
	may be upregulated more frequently among premenopausal women, perhaps
	depending upon the sex hormones. The acceleration would cause 0.11
	deaths per 1,000 screened aged 40-49 subjects in years 2-3, a value
	comparable to the early year excess mortality in trials of a significant
	0.15 deaths per 1,000 subjects. Equal screening advantage is predicted
	for node negative (but not node positive) pre- and postmenopausal
	patients. The acceleration of relapse after surgery may explain the
	paradoxical effect of mammographic screening for women under 50.},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Reulen2010,
  author = {Reulen, Raoul C. and Winter, David L. and Frobisher, Clare and Lancashire,
	Emma R. and Stiller, Charles A. and Jenney, Meriel E. and Skinner,
	Roderick and Stevens, Michael C. and Hawkins, Michael M. and , British
	Childhood Cancer Survivor Study Steering Group},
  title = {Long-term cause-specific mortality among survivors of childhood cancer.},
  journal = {JAMA},
  year = {2010},
  volume = {304},
  pages = {172--179},
  number = {2},
  month = {Jul},
  abstract = {Survivors of childhood cancer are at increased risk of premature mortality
	compared with the general population, but little is known about the
	long-term risks of specific causes of death, particularly beyond
	25 years from diagnosis at ages when background mortality in the
	general population starts to increase substantially.To investigate
	long-term cause-specific mortality among 5-year survivors of childhood
	cancer in a large-scale population-based cohort.British Childhood
	Cancer Survivor Study, a population-based cohort of 17,981 5-year
	survivors of childhood cancer diagnosed with cancer before age 15
	years between 1940 and 1991 in Britain and followed up until the
	end of 2006.Cause-specific standardized mortality ratios (SMRs) and
	absolute excess risks (AERs).Overall, 3049 deaths were observed,
	which was 11 times the number expected (SMR, 10.7; 95\% confidence
	interval [CI], 10.3-11.1). The SMR declined with follow-up but was
	still 3-fold higher than expected (95\% CI, 2.5-3.9) 45 years from
	diagnosis. The AER for deaths from recurrence declined from 97 extra
	deaths (95\% CI, 92-101) per 10,000 person-years at 5 to 14 years
	from diagnosis, to 8 extra deaths (95\% CI, 3-22) beyond 45 years
	from diagnosis. In contrast, during the same periods of follow-up,
	the AER for deaths from second primary cancers and circulatory causes
	increased from 8 extra deaths (95\% CI, 7-10) and 2 extra deaths
	(95\% CI, 2-3) to 58 extra deaths (95\% CI, 38-90) and 29 extra deaths
	(95\% CI, 16-56), respectively. Beyond 45 years from diagnosis, recurrence
	accounted for 7\% of the excess number of deaths observed while second
	primary cancers and circulatory deaths together accounted for 77\%.Among
	a cohort of British survivors of childhood cancer, excess mortality
	from second primary cancers and circulatory diseases continued to
	occur beyond 25 years from diagnosis.},
  doi = {10.1001/jama.2010.923},
  institution = {Centre for Childhood Cancer Survivor Studies, School of Health and
	Population Sciences, Public Health Building, University of Birmingham,
	Edgbaston, Birmingham B15 2TT, England. r.c.reulen@bham.ac.uk},
  keywords = {Adolescent; Adult; Cause of Death; Child; Child, Preschool; Cohort
	Studies; Female; Great Britain, epidemiology; Humans; Infant; Male;
	Middle Aged; Neoplasms, Second Primary, mortality; Neoplasms, mortality;
	Survivors; Vascular Diseases, mortality},
  language = {eng},
  medline-pst = {ppublish},
  owner = {theand},
  pii = {304/2/172},
  pmid = {20628130},
  timestamp = {2013.10.02},
  url = {http://dx.doi.org/10.1001/jama.2010.923}
}

@Article{Reynolds2008,
  author      = {Rosy Reynolds and Paul C Lambert and Paul R Burton and {B. S. A. C. Extended Working Parties on Resistance Surveillance}},
  title       = {Analysis, power and design of antimicrobial resistance surveillance studies, taking account of inter-centre variation and turnover.},
  journal     = {J Antimicrob Chemother},
  year        = {2008},
  volume      = {62 Suppl 2},
  month       = {Nov},
  pages       = {ii29--ii39},
  doi         = {10.1093/jac/dkn350},
  abstract    = {OBJECTIVES: Logistic regression is commonly used to analyse resistance
	surveillance studies, but variation between collecting centres undermines
	its assumption that isolates are independent. We studied the impact
	of this problem and the ability of alternative methods to overcome
	it. We also investigated different study designs and estimated the
	statistical power of the BSAC Resistance Surveillance Programmes.
	METHODS: We simulated datasets with various combinations of study
	design, inter-centre variation, annual centre turnover, initial resistance
	level and odds ratio, and analysed 1000 repetitions of each for trends
	in resistance by five variants of logistic regression. RESULTS: Traditional
	analysis by unadjusted logistic regression was invalid because it
	gave very high type 1 (false-positive) error rates, up to 49\%, in
	the presence of high levels of inter-centre variation and turnover.
	Of the other methods investigated, logistic regression with random
	effects for centre performed best: it had appropriate error rates
	for all study designs assessed and generally had higher power than
	fixed-effects or cluster-robust approaches. A 'Diffuse' study with
	more centres contributing fewer isolates was less susceptible to
	the ill-effects of inter-centre variation than a study of equal overall
	size with fewer centres contributing more, and had slightly higher
	power. CONCLUSIONS: Unadjusted logistic regression, ignoring inter-centre
	variation, is unsuitable for the analysis of trends in typical resistance
	surveillance studies, often leads to erroneous conclusions and should
	be avoided. Random effects logistic regression is an appropriate,
	widely applicable alternative, available in most standard statistical
	software. Collecting isolates from a larger number of centres has
	both statistical and scientific advantages.},
  file        = {Reynolds2008.pdf:Reynolds2008.pdf:PDF;Reynolds2008.pdf:pdf\\Reynolds2008.pdf:PDF},
  institution = {Department of Medical Microbiology, Southmead Hospital, Southmead Road, Bristol BS10 5NB, UK. rreynolds@bsac.org.uk},
  owner       = {pl4},
  pmid        = {18819977},
  timestamp   = {2008.10.15},
}

@ARTICLE{Reynolds2002,
  author = {Tom Reynolds},
  title = {Acrylamide and Cancer: Tunnel Leak in {S}weden Prompted Studies},
  journal = {JNCI Cancer Spectrum},
  year = {2002},
  volume = {94},
  pages = {876--878},
  number = {12},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Rezaiguia1997,
  author = {Rezaiguia, S. and Garat, C. and Delclaux, C. and Meignan, M. and
	Fleury, J. and Legrand, P. and Matthay, M. A. and Jayr, C.},
  title = {Acute bacterial pneumonia in rats increases alveolar epithelial fluid
	clearance by a tumor necrosis factor-alpha-dependent mechanism.},
  journal = {J Clin Invest},
  year = {1997},
  volume = {99},
  pages = {325--335},
  number = {2},
  month = {Jan},
  abstract = {To study the rate and regulation of alveolar fluid clearance in acute
	pneumonia, we created a model of Pseudomonas aeruginosa pneumonia
	in rats. To measure alveolar liquid and protein clearance, we instilled
	into the airspaces a 5\% bovine albumin solution with 1.5 microCi
	of 125I-human albumin, 24 h after intratracheal instillation of bacteria.
	The concentration of unlabeled and labeled protein in the distal
	airspaces over 1 h was used as an index of net alveolar fluid clearance.
	Since there was histologic evidence of alveolar epithelial injury,
	several methods were used to measure alveolar fluid clearance, including
	the use of experiments in rats with blood flow and the use of experiments
	in rats without blood flow, so that movement across the epithelial
	barrier would be minimized in the latter group. The results with
	each method were identical. We found that P. aeruginosa pneumonia
	increased alveolar liquid clearance over 1 h by 48\% in studies with
	blood flow, and by 43\% in rats without blood flow, compared with
	respective controls (P < 0.05). In both studies, this increase was
	inhibited with amiloride. However, propranolol had no inhibitory
	effect, thus ruling out a catecholamine-dependent mechanism to explain
	the increase in alveolar fluid clearance. An antitumor necrosis factor-alpha
	neutralizing antibody, instilled into the lung 5 min before bacteria,
	prevented the increase in alveolar liquid clearance in rats with
	pneumonia (P < 0.05). Also, TNFalpha (5 microg) instilled in normal
	rats increased alveolar liquid clearance by 43\% over 1 h compared
	with control rats (P < 0.05). In normal rats instilled with TNFalpha,
	propranolol had no inhibitory effect. In conclusion, gram-negative
	pneumonia markedly upregulates net alveolar epithelial fluid clearance,
	in part by a TNFalpha-dependent mechanism. This finding provides
	a novel mechanism for the upregulation of alveolar epithelial sodium
	and fluid transport from the distal airspaces of the lung.},
  doi = {10.1172/JCI119161},
  institution = {Department of Anesthesia, Institut National de la Sant{\AA}Â§ÃƒÂƒÃ‚Â…ÃƒÂ‚Ã‚Â¸ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¥t de la
	Recherche M{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â£ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â©cale U 296, H{\AA}Â³ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¯ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â´al Henri Mondor, Cr{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â³ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¥il, France.},
  keywords = {Adrenergic beta-Antagonists, pharmacology; Amiloride, pharmacology;
	Animals; Antibodies, pharmacology; Bronchoalveolar Lavage Fluid,
	cytology; Epithelium, metabolism; Extravascular Lung Water, drug
	effects/metabolism; Male; Metabolic Clearance Rate; Permeability;
	Pneumonia, Bacterial, metabolism/mortality/pathology; Propranolol,
	pharmacology; Proteins, metabolism; Pseudomonas Infections, metabolism/mortality/pathology;
	Pulmonary Alveoli, metabolism; Rats; Rats, Sprague-Dawley; Sodium-Potassium-Exchanging
	ATPase, antagonists /&/ inhibitors; Tumor Necrosis Factor-alpha,
	immunology/metabolism},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {9006001},
  timestamp = {2013.05.29},
  url = {http://dx.doi.org/10.1172/JCI119161}
}

@TechReport{Ries1991,
  author      = {Ries, L. and Hankey, B. and Miller, B. and Hartman, A. and Edwards, B.},
  institution = {National Cancer Institute},
  title       = {Cancer Statistics Review},
  owner       = {PaulD},
  timestamp   = {2011.06.19},
  year        = {1991},
}

@ARTICLE{Riley2007a,
  author = {R. D. Riley and K. R. Abrams and P. C. Lambert and A. J. Sutton and
	J. R. Thompson},
  title = {An evaluation of bivariate random-effects meta-analysis for the joint
	synthesis of two correlated outcomes.},
  journal = {Statistics in Medicine},
  year = {2007},
  volume = {26},
  pages = {78--97},
  number = {1},
  month = {Jan},
  abstract = {Often multiple outcomes are of interest in each study identified by
	a systematic review, and in this situation a separate univariate
	meta-analysis is usually applied to synthesize the evidence for each
	outcome independently; an alternative approach is a single multivariate
	meta-analysis model that utilizes any correlation between outcomes
	and obtains all the pooled estimates jointly. Surprisingly, multivariate
	meta-analysis is rarely considered in practice, so in this paper
	we illustrate the benefits and limitations of the approach to provide
	helpful insight for practitioners.We compare a bivariate random-effects
	meta-analysis (BRMA) to two independent univariate random-effects
	meta-analyses (URMA), and show how and why a BRMA is able to 'borrow
	strength' across outcomes. Then, on application to two examples in
	healthcare, we show: (i) given complete data for both outcomes in
	each study, BRMA is likely to produce individual pooled estimates
	with very similar standard errors to those from URMA; (ii) given
	some studies where one of the outcomes is missing at random, the
	'borrowing of strength' is likely to allow BRMA to produce individual
	pooled estimates with noticeably smaller standard errors than those
	from URMA; (iii) for either complete data or missing data, BRMA will
	produce a more appropriate standard error of the pooled difference
	between outcomes as it incorporates their correlation, which is not
	possible using URMA; and (iv) despite its advantages, BRMA may often
	not be possible due to the difficulty in obtaining the within-study
	correlations required to fit the model. Bivariate meta-regression
	and further research priorities are also discussed.},
  doi = {10.1002/sim.2524},
  file = {riley2007a.pdf:riley2007a.pdf:PDF},
  institution = {Centre for Biostatistics and Genetic Epidemiology, Department of
	Health Sciences, University of Leicester, UK. rdr3@leicester.ac.uk},
  owner = {pl4},
  pmid = {16526010},
  timestamp = {2008.10.15},
  url = {http://dx.doi.org/10.1002/sim.2524}
}

@ARTICLE{Riley2003,
  author = {R. D. Riley and K. R. Abrams and A. J. Sutton and P. C. Lambert and
	D. R. Jones and D. Heney and S. A. Burchill},
  title = {Reporting of prognostic markers: current problems and development
	of guidelines for evidence-based practice in the future.},
  journal = {British Journal of Cancer},
  year = {2003},
  volume = {88},
  pages = {1191--1198},
  number = {8},
  month = {Apr},
  abstract = {Prognostic markers help to stratify patients for treatment by identifying
	patients with different risks of outcome (e.g. recurrence of disease),
	and are important tools in the management of cancer and many other
	diseases. Systematic review and meta-analytical approaches to identifying
	the most valuable prognostic markers are needed because (sometimes
	conflicting) evidence relating to markers is often published across
	a number of studies. To investigate the practicality of this approach,
	an empirical investigation of a systematic review of tumour markers
	for neuroblastoma was performed; 260 studies of prognostic markers
	were identified, which considered 130 different markers. The reporting
	of these studies was often inadequate, in terms of both statistical
	analysis and presentation, and there was considerable heterogeneity
	for many important clinical/statistical factors. These problems restricted
	both the extraction of data and the meta-analysis of results from
	the primary studies, limiting feasibility of the evidence-based approach.Guidelines
	for reporting the results of primary prognostic marker studies in
	cancer, and other diseases, are given in order to facilitate both
	the interpretation of individual studies and the undertaking of systematic
	reviews, meta-analysis and, ultimately, evidence-based practice.
	General availability of full individual patient data is a necessary
	step forward and would overcome the majority of problems encountered,
	including poorly reported summary statistics and variability in cutoff
	level, outcome assessed and adjustment factors used. It would also
	limit the problem of reporting bias, although publication bias will
	remain a concern until studies are prospectively registered. Such
	changes in practice would help important evidence-based reviews to
	be conducted in order to establish the most appropriate prognostic
	markers for clinical use, which should ultimately improve patient
	care.},
  doi = {10.1038/sj.bjc.6600886},
  file = {Riley2003.pdf:Riley2003.pdf:PDF;Riley2003.pdf:pdf\\Riley2003.pdf:PDF},
  institution = {Department of Epidemiology and Public Health, University of Leicester,
	Leicester, UK. rdr3@leicester.ac.uk},
  owner = {pl4},
  pii = {6600886},
  pmid = {12698183},
  timestamp = {2008.10.15},
  url = {http://dx.doi.org/10.1038/sj.bjc.6600886}
}

@Article{Riley2007,
  author      = {Richard D Riley and Keith R Abrams and Alexander J Sutton and Paul C Lambert and John R Thompson},
  title       = {Bivariate random-effects meta-analysis and the estimation of between-study correlation.},
  doi         = {10.1186/1471-2288-7-3},
  pages       = {3},
  url         = {http://dx.doi.org/10.1186/1471-2288-7-3},
  volume      = {7},
  abstract    = {BACKGROUND: When multiple endpoints are of interest in evidence synthesis,
	a multivariate meta-analysis can jointly synthesise those endpoints
	and utilise their correlation. A multivariate random-effects meta-analysis
	must incorporate and estimate the between-study correlation (rhoB).
	METHODS: In this paper we assess maximum likelihood estimation of
	a general normal model and a generalised model for bivariate random-effects
	meta-analysis (BRMA). We consider two applied examples, one involving
	a diagnostic marker and the other a surrogate outcome. These motivate
	a simulation study where estimation properties from BRMA are compared
	with those from two separate univariate random-effects meta-analyses
	(URMAs), the traditional approach. RESULTS: The normal BRMA model
	estimates rhoB as -1 in both applied examples. Analytically we show
	this is due to the maximum likelihood estimator sensibly truncating
	the between-study covariance matrix on the boundary of its parameter
	space. Our simulations reveal this commonly occurs when the number
	of studies is small or the within-study variation is relatively large;
	it also causes upwardly biased between-study variance estimates,
	which are inflated to compensate for the restriction on rhoB. Importantly,
	this does not induce any systematic bias in the pooled estimates
	and produces conservative standard errors and mean-square errors.
	Furthermore, the normal BRMA is preferable to two normal URMAs; the
	mean-square error and standard error of pooled estimates is generally
	smaller in the BRMA, especially given data missing at random. For
	meta-analysis of proportions we then show that a generalised BRMA
	model is better still. This correctly uses a binomial rather than
	normal distribution, and produces better estimates than the normal
	BRMA and also two generalised URMAs; however the model may sometimes
	not converge due to difficulties estimating rhoB. CONCLUSION: A BRMA
	model offers numerous advantages over separate univariate synthesises;
	this paper highlights some of these benefits in both a normal and
	generalised modelling framework, and examines the estimation of between-study
	correlation to aid practitioners.},
  file        = {riley2007a.pdf:riley2007a.pdf:PDF;riley2007.pdf:riley2007.pdf:PDF},
  institution = {Centre for Medical Statistics and Health Evaluation, School of Health Sciences, University of Liverpool, Shelley's Cottage, Brownlow Street, Liverpool, L69 3GS, UK. richard.riley@liv.ac.uk},
  journal     = {BMC Medical Research Methodology},
  owner       = {pl4},
  pii         = {1471-2288-7-3},
  pmid        = {17222330},
  timestamp   = {2008.10.15},
  year        = {2007},
}

@ARTICLE{Riley2003a,
  author = {R. D. Riley and S. A. Burchill and K. R. Abrams and D. Heney and
	P. C. Lambert and D. R. Jones and A. J. Sutton and B. Young and A.
	J. Wailoo and I. J. Lewis},
  title = {A systematic review and evaluation of the use of tumour markers in
	paediatric oncology: Ewing's sarcoma and neuroblastoma.},
  journal = {Health Technol Assess},
  year = {2003},
  volume = {7},
  pages = {1--162},
  number = {5},
  file = {Riley2003a.pdf:Riley2003a.pdf:PDF;Riley2003a.pdf:pdf\\Riley2003a.pdf:PDF},
  institution = {Department of Epidemiology and Public Health, University of Leicester,
	UK.},
  owner = {pl4},
  pmid = {12633526},
  timestamp = {2008.10.15}
}

@Article{Riley2003b,
  author      = {R. D. Riley and S. A. Burchill and K. R. Abrams and D. Heney and A. J. Sutton and D. R. Jones and P. C. Lambert and B. Young and A. J. Wailoo and I. J. Lewis},
  title       = {A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family.},
  number      = {1},
  pages       = {19--30},
  volume      = {39},
  abstract    = {The aims of this study were to perform the first systematic review
	of molecular and biological tumour markers in tumours of the Ewing's
	sarcoma family (ESFT), and evaluate the current evidence for their
	clinical use. A well-defined, reproducible search strategy was used
	to identify the relevant literature from 1966 to February 2000. Papers
	were independently assessed for tumour markers used in the screening,
	diagnosis, prognosis or monitoring of patients with ESFT. Eighty-four
	papers studying the use of 70 different tumour markers in ESFT's
	were identified. Low-quality, inconsistent reporting limited meta-analysis
	to that of prognostic data for 28 markers. Patients with tumours
	lacking S-100 protein expression have a better overall survival (OS)
	(hazard ratio (HR)=0.41, 95\% confidence interval (CI) 0.19, 0.89)
	than those with expression; patients with high levels of serum LDH
	had a worse OS and disease-free survival (DFS) (OS: HR=2.92, CI 2.16,
	3.94, DFS: HR=3.38, 95\% CI 2.28, 4.99); patients with localised
	disease and tumours expressing type 1 EWS-FLI1 fusion transcripts
	had an improved DFS compared with those with other fusion transcript
	types (HR=0.17, 95\% CI 0.079, 0.37). The knowledge base formed should
	facilitate more informative future research. Improved statistical
	reporting and large, multicentre prospective studies are advocated.},
  file        = {Riley2003b.pdf:Riley2003b.pdf:PDF;Riley2003b.pdf:pdf\\Riley2003b.pdf:PDF},
  institution = {Department of Epidemiology and Public Health, University of Leicester, 22-28 Princess Road West, Leicester LE1 6TP, UK. rdr3@leicester.ac.uk},
  journal     = {European Journal of Cancer},
  month       = {Jan},
  owner       = {pl4},
  pii         = {S0959804902005002},
  pmid        = {12504654},
  timestamp   = {2008.10.15},
  year        = {2003},
}

@Article{Riley2004a,
  author      = {Richard D Riley and David Heney and David R Jones and Alex J Sutton and Paul C Lambert and Keith R Abrams and Bridget Young and Alan J Wailoo and Susan A Burchill},
  title       = {A systematic review of molecular and biological tumor markers in neuroblastoma.},
  number      = {1 Pt 1},
  pages       = {4--12},
  volume      = {10},
  abstract    = {PURPOSE: The aim of this study was to conduct a systematic review,
	and where possible meta-analyses, of molecular and biological tumor
	markers described in neuroblastoma, and to establish an evidence-based
	perspective on their clinical value for the screening, diagnosis,
	prognosis, and monitoring of patients. Experimental Design: A well-defined,
	reproducible search strategy was used to identify the relevant literature
	from 1966 to February 2000. RESULTS: A total of 428 papers studying
	the use of 195 different tumor markers in neuroblastoma were identified.
	Small sample sizes, poor statistical reporting, large heterogeneity
	across studies (e.g., in cutoff levels), and publication bias limited
	meta-analysis to the area of prognosis only; MYCN, chromosome 1p,
	DNA index, vanillylmandelic acid:homovanillic acid ratio, CD44, Trk-A,
	neuron-specific enolase, lactate dehydrogenase, ferritin, and multidrug
	resistance were all identified as potentially important prognostic
	tools. CONCLUSIONS: This systematic review forms a knowledge base
	of the tumor markers studied thus far in neuroblastoma, and has identified
	some of the most important prognostic markers, which should be considered
	in future research and treatment strategies. Importantly, the review
	has also highlighted some general problems across primary tumor marker
	studies, in particular poor and heterogeneous reporting. These need
	to be addressed to allow better clinical interpretation and enable
	more appropriate evidence-based reviews in the future. In particular,
	collaboration of cancer research groups is needed to enable bigger
	sample sizes, standardize methods of analysis and reporting, and
	facilitate the pooling of individual patient data.},
  file        = {Riley2004a.pdf:Riley2004a.pdf:PDF;Riley2004a.pdf:pdf\\Riley2004a.pdf:PDF},
  institution = {Departments of Health Sciences, Medical Education, University of Leicester, Leicester. rdr3@leicester.ac.uk},
  journal     = {Clinical Cancer Research},
  month       = {Jan},
  owner       = {pl4},
  pmid        = {14734444},
  timestamp   = {2008.10.15},
  year        = {2004},
}

@Article{Riley2010,
  author      = {Richard D Riley and Paul C Lambert and Ghada Abo-Zaid},
  title       = {Meta-analysis of individual participant data: rationale, conduct, and reporting.},
  journal     = {BMJ},
  year        = {2010},
  volume      = {340},
  pages       = {c221},
  doi         = {10.1136/bmj.c221},
  file        = {Riley2010.pdf:Riley2010.pdf:PDF;Riley2010.pdf:pdf\\Riley2010.pdf:PDF},
  institution = {Department of Public Health, Epidemiology and Biostatistics, University of Birmingham, Birmingham B15 2TT. r.d.riley@bham.ac.uk},
  owner       = {pl4},
  pmid        = {20139215},
  timestamp   = {2010.09.26},
}

@ARTICLE{Riley2008,
  author = {Richard D Riley and Paul C Lambert and Jan A Staessen and Jiguang
	Wang and Francois Gueyffier and Lutgarde Thijs and Florent Boutitie},
  title = {Meta-analysis of continuous outcomes combining individual patient
	data and aggregate data.},
  journal = {Statistics in Medicine},
  year = {2008},
  volume = {27},
  pages = {1870--1893},
  number = {11},
  month = {May},
  abstract = {Meta-analysis of individual patient data (IPD) is the gold-standard
	for synthesizing evidence across clinical studies. However, for some
	studies IPD may not be available and only aggregate data (AD), such
	as a treatment effect estimate and its standard error, may be obtained.
	In this situation, methods for combining IPD and AD are important
	to utilize all the available evidence. In this paper, we develop
	and assess a range of statistical methods for combining IPD and AD
	in meta-analysis of continuous outcomes from randomized controlled
	trials.The methods take either a one-step or a two-step approach.
	The latter is simple, with IPD reduced to AD so that standard AD
	meta-analysis techniques can be employed. The one-step approach is
	more complex but offers a flexible framework to include both patient-level
	and trial-level parameters. It uses a dummy variable to distinguish
	IPD trials from AD trials and to constrain which parameters the AD
	trials estimate. We show that this is important when assessing how
	patient-level covariates modify treatment effect, as aggregate-level
	relationships across trials are subject to ecological bias and confounding.
	We thus develop models to separate within-trial and across-trials
	treatment-covariate interactions; this ensures that only IPD trials
	estimate the former, whilst both IPD and AD trials estimate the latter
	in addition to the pooled treatment effect and any between-study
	heterogeneity. Extension to multiple correlated outcomes is also
	considered. Ten IPD trials in hypertension, with blood pressure the
	continuous outcome of interest, are used to assess the models and
	identify the benefits of utilizing AD alongside IPD.},
  doi = {10.1002/sim.3165},
  file = {riley2008.pdf:riley2008.pdf:PDF},
  institution = {Centre for Medical Statistics and Health Evaluation, Faculty of Medicine,
	University of Liverpool, Shelley's Cottage, Brownlow Street, Liverpool,
	U.K. richard.riley@liv.ac.uk},
  owner = {pl4},
  pmid = {18069721},
  timestamp = {2008.10.15},
  url = {http://dx.doi.org/10.1002/sim.3165}
}

@ARTICLE{Riley2007b,
  author = {Richard D Riley and Mark C Simmonds and Maxime P Look},
  title = {Evidence synthesis combining individual patient data and aggregate
	data: a systematic review identified current practice and possible
	methods.},
  journal = {Journal of Clinical Epidemiology},
  year = {2007},
  volume = {60},
  pages = {431--439},
  number = {5},
  month = {May},
  abstract = {OBJECTIVE: Meta-analysis of individual patient data (IPD) is the "gold-standard"
	for synthesizing evidence across several studies. Some studies, however,
	may only provide aggregate data (AD). In this situation researchers
	might need to combine IPD with AD to utilize all the evidence available.
	Here, we review applied IPD meta-analysis articles to assess if and
	how AD is combined with IPD in practice. STUDY DESIGN AND SETTING:
	A systematic review of articles identified from bibliographic databases
	and searches. RESULTS: We identified 33 applied IPD articles that
	combined IPD and AD and 166 that did not. For each article, we recorded
	the proportion of total studies providing IPD, and found that articles
	combining IPD and AD had, on average, IPD available in only 64\%
	of studies (compared to 90\% in articles not combining IPD and AD).
	Two different methods were used to combine IPD and AD, the two-stage
	method and analysis of partially reconstructed IPD, but a review
	of methodological articles identified two further methods, multilevel
	modeling and Bayesian hierarchical related regression. We summarize
	each method to aid practitioners. CONCLUSION: Combining IPD and AD
	is a relevant issue for evidence synthesis, and the further development
	and validation of suitable meta-analysis methods is needed.},
  doi = {10.1016/j.jclinepi.2006.09.009},
  file = {riley2007b.pdf:riley2007b.pdf:PDF},
  institution = {Centre for Medical Statistics and Health Evaluation, School of Health
	Sciences, University of Liverpool, UK. richard.riley@liv.ac.uk},
  owner = {pl4},
  pii = {S0895-4356(06)00403-3},
  pmid = {17419953},
  timestamp = {2008.11.18},
  url = {http://dx.doi.org/10.1016/j.jclinepi.2006.09.009}
}

@ARTICLE{Riley2004,
  author = {Richard D Riley and Alex J Sutton and Keith R Abrams and Paul C Lambert},
  title = {Sensitivity analyses allowed more appropriate and reliable meta-analysis
	conclusions for multiple outcomes when missing data was present.},
  journal = {Journal of Clinical Epidemiology},
  year = {2004},
  volume = {57},
  pages = {911--924},
  number = {9},
  month = {Sep},
  abstract = {OBJECTIVE: A major problem for meta-analysis of multiple outcomes
	is the unavailability of some estimates from published and unpublished
	studies. Dissemination bias, in how and what outcomes are reported
	or published, may be causing this incompleteness. This article illustrates
	these problems and presents possible sensitivity analyses to allow
	the most reliable conclusions. STUDY DESIGN AND SETTING: In a systematic
	review of prognostic marker MYC-N in neuroblastoma, meta-analysis
	for overall survival (OS) and disease-free survival (DFS) was of
	interest. Only 17 published studies enabled extraction of both outcome
	estimates, 25 enabled only DFS, 39 enabled only OS, and 70 enabled
	neither outcome. Unidentified unpublished studies may also exist.
	We assessed the robustness of the pooled estimates to the problem
	of missing information. Because OS and DFS estimates seemed to be
	related, we used the known outcome estimates to predict estimates
	known to be missing, and combined this approach with existing methods
	for assessing dissemination bias. RESULTS: The results of the sensitivity
	analyses suggested that the original meta-analysis results were likely
	to be an overestimate of the true OS and DFS effect-sizes but strengthened
	the belief that MYC-N is a potentially important prognostic marker
	in neuroblastoma. CONCLUSION: Sensitivity analyses in meta-analysis
	allow more appropriate and reliable conclusions when problems such
	as unavailable estimates and dissemination bias are present.},
  doi = {10.1016/j.jclinepi.2004.01.018},
  file = {riley2004.pdf:riley2004.pdf:PDF;Riley2004a.pdf:Riley2004a.pdf:PDF},
  institution = {Centre for Biostatistics and Genetic Epidemiology, Department of
	Health Sciences, University of Leicester, Princess Road West, Leicester
	LE1 6TP, United Kingdom. rdr3@leicester.ac.uk},
  owner = {pl4},
  pii = {S0895-4356(04)00114-3},
  pmid = {15504634},
  timestamp = {2008.10.15},
  url = {http://dx.doi.org/10.1016/j.jclinepi.2004.01.018}
}

@ARTICLE{Riman2001,
  author = {T Riman and PW Dickman and S Nilsson and N Correia and H Nordlinder
	and CM Magnusson and IR Persson},
  title = {Risk factors for epithelial borderline ovarian tumors: results of
	a {S}wedish case-control study.},
  journal = {Gynecol Oncol},
  year = {2001},
  volume = {83},
  pages = {575-85},
  number = {3},
  month = {Dec},
  abstract = {OBJECTIVE: Borderline ovarian tumors have a favorable prognosis. Previous
	epidemiological studies indicate common risk factors for invasive
	epithelial ovarian cancers and borderline tumors, but it remains
	unresolved whether these tumors are precursors of invasive cancers
	or a separate disease entity. The objective of this population-based
	case-control study conducted in 1993-1995 was to examine reproductive
	and other factors in relation to the risk of borderline ovarian tumors.
	METHODS: Subjects were 193 histologically verified incident epithelial
	borderline tumor cases and 3899 randomly selected controls aged 50-74
	years, whose data were collected through mailed questionnaires. Risk
	estimates were calculated by unconditional logistic regression. RESULTS:
	Ever parous women were at reduced risk, with odds ratios of 0.44
	(95\% confidence interval (CI) 0.26-0.75) for serous and 0.63 (95\%
	CI 0.34-1.19) for mucinous tumors. No clear trends emerged for age
	at first birth, at menarche, and at menopause. Lactation reduced
	tumor risk. Oral contraceptive ever use conferred no protection,
	with odds ratios of 1.40 (95\% CI 0.87-2.26) for serous and 1.04
	(95\% CI 0.61-1.79) for mucinous tumors. The odds ratio for serous
	tumors following unopposed estrogen ever use was 2.07 (95\% CI 1.08-3.95),
	whereas no risk increase appeared with estrogens supplemented by
	cyclic or continuous progestins. Mucinous tumors were not associated
	with hormone replacement therapy. The odds ratio for serous tumors
	in the highest category of body mass index was 6.47 (95\% CI 3.09-13.5).
	CONCLUSIONS: Increasing parity and lactation reduce the risk of borderline
	ovarian tumors in women aged 50-74, while no protection follows oral
	contraceptive use. Hormonal situations such as unopposed estrogen
	use and obesity, where estrogens are not counteracted by progestins,
	may increase the risk of serous tumors.},
  doi = {10.1006/gyno.2001.6451},
  owner = {PaulD},
  pii = {S0090825801964510},
  timestamp = {2011.06.19},
  url = {http://dx.doi.org/10.1006/gyno.2001.6451}
}

@ARTICLE{Riman2002,
  author = {Tomas Riman and Paul W Dickman and Staffan Nilsson and Nestor Correia
	and Hans Nordlinder and Cecilia M Magnusson and Ingemar R Persson},
  title = {Risk factors for invasive epithelial ovarian cancer: results from
	a {S}wedish case-control study.},
  journal = {Am J Epidemiol},
  year = {2002},
  volume = {156},
  pages = {363-73},
  number = {4},
  month = {Aug},
  abstract = {This case-control study evaluated reproductive and other factors in
	relation to epithelial ovarian cancer (EOC) risk. Between 1993 and
	1995, the authors recruited 655 EOC cases and 3,899 population controls
	aged 50-74 years who were born in and residents of {S}weden. Data
	were collected through mailed questionnaires. Odds ratios were estimated
	by unconditional logistic regression. Parity reduced EOC risk (odds
	ratio = 0.61, 95\% confidence interval (CI): 0.46, 0.81) for uniparous
	compared with nulliparous women. The risk of EOC decreased with incomplete
	pregnancies, early menopausal age, late age at first birth, and unilateral
	oophorectomy; increased with family history of ovarian cancer; and
	was not associated with menarcheal age, lactation, irregular menses,
	and menopausal symptoms. Histology-specific odds ratios of EOC for
	ever compared with never users of oral contraceptives were: serous,
	0.56 (95\% CI: 0.42, 0.74); mucinous, 1.96 (95\% CI: 1.04, 3.68);
	endometrioid, 0.71 (95\% CI: 0.49, 1.03); clear cell, 0.66 (95\%
	CI: 0.31, 1.43); and all EOCs, 0.73 (95\% CI: 0.59, 0.90). Prolonged
	oral contraceptive use reduced EOC risk, with persistent protection
	up to 25 years after the last use. Ever use of hormone replacement
	therapy increased EOC risk (odds ratio = 1.41, 95\% CI: 1.15, 1.72).
	Among etiologic hypotheses, the retrograde transportation hypothesis
	accommodates most epidemiologic findings concerning EOC risk.},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Riman2002a,
  author = {Tomas Riman and Paul W Dickman and Staffan Nilsson and Nestor Correia
	and Hans Nordlinder and Cecilia M Magnusson and Elisabete Weiderpass
	and Ingemar R Persson},
  title = {Hormone replacement therapy and the risk of invasive epithelial ovarian
	cancer in {S}wedish women.},
  journal = {J Natl Cancer Inst},
  year = {2002},
  volume = {94},
  pages = {497-504},
  number = {7},
  month = {Apr},
  abstract = {BACKGROUND: Estrogen replacement therapy (ERT), which is mainly used
	to relieve climacteric symptoms, increases a woman's risk for uterine
	endometrial cancer and epithelial ovarian cancer (EOC). Estrogens
	are often combined with progestins in hormone replacement therapy
	(HRT) to reduce the risk of uterine endometrial cancer. Data on the
	association between HRT including progestins and EOC risk are limited.
	This nationwide case-control study examined EOC risk in relation
	to HRT regimens with sequentially added progestins (HRTsp) and continuously
	added progestins (HRTcp). METHODS: Between 1993 and 1995, we enrolled
	655 histologically verified incident case patients with EOC and 3899
	randomly selected population controls, all 50-74 years of age. Data
	on HRT use were collected through mailed questionnaires. Multivariate-adjusted
	odds ratios (ORs) and 95\% confidence intervals (CIs) were estimated
	by the use of unconditional logistic regression. RESULTS: Risks of
	EOC were elevated among ever users as compared with never users of
	both ERT (OR = 1.43, 95\% CI = 1.02 to 2.00) and HRTsp (OR = 1.54,
	95\% CI = 1.15 to 2.05); risks were elevated for serous, mucinous,
	and endometrioid subtypes. For all EOC types combined, the greatest
	risk increases were seen with hormone use exceeding 10 years. Ever
	use of HRTcp was not associated with increased EOC risk relative
	to HRTcp never use (OR = 1.02, 95\% CI = 0.73 to 1.43). The risk
	of EOC was elevated among HRTsp ever users as compared with HRTcp
	ever users (OR = 1.78, 95\% CI = 1.05 to 3.01). ORs for EOC after
	ever use of low-potency estrogens were 1.18 (95\% CI = 0.89 to 1.55)
	for oral and 1.33 (95\% CI = 1.03 to 1.72) for vaginal applications,
	but no relationship was seen between EOC risk and duration of use.
	CONCLUSION: Ever users of ERT and HRTsp but not HRTcp may be at increased
	risk of EOC.},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Rimpela1987,
  author = {Rimpel{\"a}, A. H. and Pukkala, E. I.},
  title = {Cancers of Affluence: Positive Social Class Gradient and Rising Incidence
	Trend in Some Cancer Forms},
  journal = {Social Science \& Medicine},
  year = {1987},
  volume = {24},
  pages = {601-606},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Robinson2007,
  author = {D. Robinson and R. Sankila and T. Hakulinen and H. M{\o}ller},
  title = {Interpreting international comparisons of cancer survival: the effects
	of incomplete registration and the presence of death certificate
	only cases on survival estimates.},
  journal = {European Journal of Cancer},
  year = {2007},
  volume = {43},
  pages = {909--913},
  number = {5},
  month = {Mar},
  abstract = {We have assessed the impact on survival estimates based on cancer
	registry data of incomplete ascertainment of cancer cases and the
	presence of cases registered purely from death certificate information
	(DCO cases). Using data from the Thames and Finnish Cancer Registries
	we obtained five-year relative survival estimates for 12 cancer sites,
	excluding DCOs as usual. We then made adjustments to allow for the
	effects of both the known proportion of DCOs and the estimated proportion
	of missing cases for each site. In general, adjusting for DCOs led
	to lower survival estimates, whilst adjusting for incompleteness
	had the opposite effect. The Finnish data were largely complete and
	had small proportions of DCOs, and hence the adjustments had little
	effect on estimated survival. The changes in the Thames estimates
	were more marked. When performing cohort survival analysis (based
	on diagnoses between 1990 and 1994), the increases in the survival
	estimates gained from adjusting for incompleteness were for the most
	part offset by the decrease produced when adjusting for DCOs. However,
	when performing period survival analysis based on the period 1997-2001
	(when the DCO rate at Thames had fallen by around a half relative
	to the earlier period), the final estimates (adjusted for both effects)
	were generally higher than the unadjusted values--thus reducing the
	apparent difference between the two countries. It is important to
	take variations in DCO proportion and/or completeness into consideration
	when comparing survival estimates between different populations.},
  doi = {10.1016/j.ejca.2007.01.007},
  file = {Robinson2007.pdf:Robinson2007.pdf:PDF;Robinson2007.pdf:pdf\\Robinson2007.pdf:PDF},
  institution = {King's College London, Thames Cancer Registry, 1st Floor, Capital
	House, 42 Weston Street, London SE1 3QD, UK. dave.robinson@kcl.ac.uk},
  owner = {pl4},
  pii = {S0959-8049(07)00011-1},
  pmid = {17300929},
  timestamp = {2010.03.23},
  url = {http://dx.doi.org/10.1016/j.ejca.2007.01.007}
}

@ARTICLE{Roche2012,
  author = {Roche, Laurent and Danieli, Coraline and Belot, Aur{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â«ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â©en and Grosclaude,
	Pascale and Bouvier, Anne-Marie and Velten, Michel and Iwaz, Jean
	and Remontet, Laurent and Bossard, Nadine},
  title = {Cancer net survival on registry data: Use of the new unbiased {P}ohar-{P}erme
	estimator and magnitude of the bias with the classical methods.},
  journal = {Int J Cancer},
  year = {2012},
  volume = {132},
  pages = {2359-69},
  number = {10},
  abstract = {Net survival, the survival which might occur if cancer was the only
	cause of death, is a major epidemiological indicator required for
	international or temporal comparisons. Recent findings have shown
	that all classical methods used for routine estimation of net survival
	from cancer-registry data, sometimes called "relative-survival methods,"
	provide biased estimates. Meanwhile, an unbiased estimator, the Pohar-Perme
	estimator (PPE), was recently proposed. Using real data, we investigated
	the magnitude of the errors made by four "relative-survival" methods
	(Ederer I, Hakulinen, Ederer II and a univariable regression model)
	vs. PPE as reference and examined the influence of time of follow-up,
	cancer prognosis, and age on the errors made. The data concerned
	seven cancer sites (2,51,316 cases) collected by FRANCIM cancer registries.
	Net survivals were estimated at 5, 10 and 15 years postdiagnosis.
	At 5 years, the errors were generally small. At 10 years, in good-prognosis
	cancers, the errors made in nonstandardized estimates with all classical
	methods were generally great (+2.7 to +9\% points in prostate cancer)
	and increased in age-class estimations (vs. 5-year ones). At 15 years,
	in bad- or average-prognosis cancers, the errors were often substantial
	whatever the nature of the estimation. In good-prognosis cancers,
	the errors in nonstandardized estimates of all classical methods
	were great and sometimes very important. With all classical methods,
	great errors occurred in age-class estimates resulting in errors
	in age-standardized estimates (+0.4 to +3.2\% points in breast cancer).
	In estimating net survival, cancer registries should abandon all
	classical methods and adopt the new Pohar-Perme estimator.},
  doi = {10.1002/ijc.27830},
  file = {Roche2012.pdf:pdf\\Roche2012.pdf:PDF},
  institution = {Hospices Civils de Lyon, Service de Biostatistique, F-69003, Lyon,
	France; Universit{\AA}Â§ÃƒÂƒÃ‚Â…ÃƒÂ‚Ã‚Â¸ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¤e Lyon, F-69000, Lyon, France; Universit{\AA}Â§ÃƒÂƒÃ‚Â…ÃƒÂ‚Ã‚Â¸ÃƒÂƒÃ‚Â…ÃƒÂ‚Ã‚Â’yon
	1, F-69100, Villeurbanne, France; CNRS, UMR5558, Laboratoire de Biom{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â³ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â²ie
	et Biologie Evolutive, Equipe Biotatistique-Sant{\AA}Â§ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚ÂªÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â F-69100, Villeurbanne,
	France. laurent.roche01@chu-lyon.fr.},
  language = {eng},
  medline-pst = {aheadofprint},
  owner = {pl4},
  pmid = {22961565},
  timestamp = {2012.10.09},
  url = {http://dx.doi.org/10.1002/ijc.27830}
}

@ARTICLE{Roche2013,
  author = {Roche, Laurent and Danieli, Coraline and Belot, Aur{\AA}Â©lien and Iwaz,
	Jean and Remontet, Laurent and Bossard, Nadine},
  title = {Author's reply to: Estimating net survival in population-based cancer
	studies.},
  journal = {Int J Cancer},
  year = {2013},
  volume = {133},
  pages = {522--523},
  number = {2},
  month = {Jul},
  doi = {10.1002/ijc.28039},
  file = {Roche2013.pdf:pdf\\Roche2013.pdf:PDF},
  keywords = {Female; Humans; Male; Models, Statistical; Neoplasms, mortality},
  language = {eng},
  medline-pst = {ppublish},
  owner = {sanelo},
  pmid = {23338765},
  timestamp = {2013.10.08},
  url = {http://dx.doi.org/10.1002/ijc.28039}
}

@ARTICLE{Rodrigues2012,
  author = {Rodrigues, Josemar and Cancho, Vicente G. and {de Castro}, M{\AA}Â¡rio
	and Balakrishnan, N.},
  title = {A Bayesian destructive weighted Poisson cure rate model and an application
	to a cutaneous melanoma data.},
  journal = {Stat Methods Med Res},
  year = {2012},
  volume = {21},
  pages = {585--597},
  number = {6},
  month = {Dec},
  abstract = {In this article, we propose a new Bayesian flexible cure rate survival
	model, which generalises the stochastic model of Klebanov et al.
	[Klebanov LB, Rachev ST and Yakovlev AY. A stochastic-model of radiation
	carcinogenesis--latent time distributions and their properties. Math
	Biosci 1993; 113: 51-75], and has much in common with the destructive
	model formulated by Rodrigues et al. [Rodrigues J, de Castro M, Balakrishnan
	N and Cancho VG. Destructive weighted Poisson cure rate models. Technical
	Report, Universidade Federal de S{\AA}Â£o Carlos, S{\AA}Â£o Carlos-SP. Brazil,
	2009 (accepted in Lifetime Data Analysis)]. In our approach, the
	accumulated number of lesions or altered cells follows a compound
	weighted Poisson distribution. This model is more flexible than the
	promotion time cure model in terms of dispersion. Moreover, it possesses
	an interesting and realistic interpretation of the biological mechanism
	of the occurrence of the event of interest as it includes a destructive
	process of tumour cells after an initial treatment or the capacity
	of an individual exposed to irradiation to repair altered cells that
	results in cancer induction. In other words, what is recorded is
	only the damaged portion of the original number of altered cells
	not eliminated by the treatment or repaired by the repair system
	of an individual. Markov Chain Monte Carlo (MCMC) methods are then
	used to develop Bayesian inference for the proposed model. Also,
	some discussions on the model selection and an illustration with
	a cutaneous melanoma data set analysed by Rodrigues et al. [Rodrigues
	J, de Castro M, Balakrishnan N and Cancho VG. Destructive weighted
	Poisson cure rate models. Technical Report, Universidade Federal
	de S{\AA}Â£o Carlos, S{\AA}Â£o Carlos-SP. Brazil, 2009 (accepted in Lifetime
	Data Analysis)] are presented.},
  doi = {10.1177/0962280210391443},
  institution = {Departamento de Estat{\AA}Â­stica, Universidade Federal de S{\AA}Â£o Carlos,
	S{\AA}Â£o Carlos, SP, Brazil. vjosemar@ufscar.br},
  keywords = {Bayes Theorem; Humans; Melanoma; Models, Statistical; Poisson Distribution;
	Skin Neoplasms},
  language = {eng},
  medline-pst = {ppublish},
  owner = {theand},
  pii = {0962280210391443},
  pmid = {21131689},
  timestamp = {2013.10.01},
  url = {http://dx.doi.org/10.1177/0962280210391443}
}

@ARTICLE{Rondeau2008,
  author = {V. Rondeau and S. Michiels and B. Liquet and J. P. Pignon},
  title = {Investigating trial and treatment heterogeneity in an individual
	patient data meta-analysis of survival data by means of the penalized
	maximum likelihood approach.},
  journal = {Statistics in Medicine},
  year = {2008},
  volume = {27},
  pages = {1894--1910},
  number = {11},
  month = {May},
  abstract = {In a meta-analysis combining survival data from different clinical
	trials, an important issue is the possible heterogeneity between
	trials. Such intertrial variation can not only be explained by heterogeneity
	of treatment effects across trials but also by heterogeneity of their
	baseline risk. In addition, one might examine the relationship between
	magnitude of the treatment effect and the underlying risk of the
	patients in the different trials. Such a scenario can be accounted
	for by using additive random effects in the Cox model, with a random
	trial effect and a random treatment-by-trial interaction. We propose
	to use this kind of model with a general correlation structure for
	the random effects and to estimate parameters and hazard function
	using a semi-parametric penalized marginal likelihood method (maximum
	penalized likelihood estimators). This approach gives smoothed estimates
	of the hazard function, which represents incidence in epidemiology.
	The idea for the approach in this paper comes from the study of heterogeneity
	in a large meta-analysis of randomized trials in patients with head
	and neck cancers (meta-analysis of chemotherapy in head and neck
	cancers) and the effect of adding chemotherapy to locoregional treatment.
	The simulation study and the application demonstrate that the proposed
	approach yields satisfactory results and they illustrate the need
	to use a flexible variance-covariance structure for the random effects.},
  doi = {10.1002/sim.3161},
  file = {Rondeau2008.pdf:Rondeau2008.pdf:PDF;Rondeau2008.pdf:pdf\\Rondeau2008.pdf:PDF},
  institution = {INSERM U875 (Biostatistics), Universit\'{e} Victor Segalen Bordeaux
	2, 146 rue L\'{e}o Saignat, Bordeaux, France. Virginie.Rondeau@isped.u-bordeaux2.fr},
  owner = {pl4},
  pmid = {18069745},
  timestamp = {2008.11.18},
  url = {http://dx.doi.org/10.1002/sim.3161}
}

@ARTICLE{Rooney2013,
  author = {Rooney, James and Byrne, Susan and Heverin, Mark and Corr, Bernie
	and Elamin, Marwa and Staines, Anthony and Goldacre, Ben and Hardiman,
	Orla},
  title = {Survival analysis of irish amyotrophic lateral sclerosis patients
	diagnosed from 1995-2010.},
  journal = {PLoS One},
  year = {2013},
  volume = {8},
  pages = {e74733},
  number = {9},
  abstract = {The Irish ALS register is a valuable resource for examining survival
	factors in Irish ALS patients. Cox regression has become the default
	tool for survival analysis, but recently new classes of flexible
	parametric survival analysis tools known as Royston-Parmar models
	have become available.We employed Cox proportional hazards and Royston-Parmar
	flexible parametric modeling to examine factors affecting survival
	in Irish ALS patients. We further examined the effect of choice of
	timescale on Cox models and the proportional hazards assumption,
	and extended both Cox and Royston-Parmar models with time varying
	components.On comparison of models we chose a Royston-Parmar proportional
	hazards model without time varying covariates as the best fit. Using
	this model we confirmed the association of known survival markers
	in ALS including age at diagnosis (Hazard Ratio (HR) 1.34 per 10
	year increase; 95\% CI 1.26-1.42), diagnostic delay (HR 0.96 per
	12 weeks delay; 95\% CI 0.94-0.97), Definite ALS (HR 1.47 95\% CI
	1.17-1.84), bulbar onset disease (HR 1.58 95\% CI 1.33-1.87), riluzole
	use (HR 0.72 95\% CI 0.61-0.85) and attendance at an ALS clinic (HR
	0.74 95\% CI 0.64-0.86).Our analysis explored the strengths and weaknesses
	of Cox proportional hazard and Royston-Parmar flexible parametric
	methods. By including time varying components we were able to gain
	deeper understanding of the dataset. Variation in survival between
	time periods appears to be due to missing data in the first time
	period. The use of age as timescale to account for confounding by
	age resolved breaches of the proportional hazards assumption, but
	in doing so may have obscured deficiencies in the data. Our study
	demonstrates the need to test for, and fully explore, breaches of
	the Cox proportional hazards assumption. Royston-Parmar flexible
	parametric modeling proved a powerful method for achieving this.},
  doi = {10.1371/journal.pone.0074733},
  file = {Rooney2013.pdf:pdf\\Rooney2013.pdf:PDF;Rooney2013.pdf:Rooney2013.pdf:PDF},
  institution = {Academic Unit of Neurology, Trinity Biomedical Sciences Institute,
	Dublin, Ireland.},
  language = {eng},
  medline-pst = {epublish},
  owner = {pl4},
  pii = {PONE-D-13-25962},
  pmid = {24098664},
  timestamp = {2014.03.03},
  url = {http://dx.doi.org/10.1371/journal.pone.0074733}
}

@PhdThesis{Rosen1987,
  author    = {Ros{\'e}n, M.},
  title     = {Epidemiology in Planning for Health: {W}ith Special Reference to Regional Epidemiology and the Use of Health Registers},
  owner     = {PaulD},
  school    = {University of Ume{\aa}, Ume{\aa}, {S}weden},
  timestamp = {2011.06.19},
  year      = {1987},
}

@ARTICLE{Rosenberg2006,
  author = {Lena U Rosenberg and Cecilia Magnusson and Emma Lindstr\"{o}m and
	Sara Wedr\'{e}n and Per Hall and Paul W Dickman},
  title = {Menopausal hormone therapy and other breast cancer risk factors in
	relation to the risk of different histological subtypes of breast
	cancer: a case-control study.},
  journal = {Breast Cancer Res},
  year = {2006},
  volume = {8},
  pages = {R11},
  abstract = {INTRODUCTION: Breast cancers of different histology have different
	clinical and prognostic features. There are also indications of differences
	in aetiology. We therefore evaluated the risk of the three most common
	histological subtypes in relation to menopausal hormone therapy and
	other breast cancer risk factors. METHODS: We used a population-based
	case-control study of breast cancer to evaluate menopausal hormone
	therapy and other breast cancer risk factors for risk by histological
	subtype. Women aged 50 to 74 years, diagnosed with invasive ductal
	(n = 1,888), lobular (n = 308) or tubular (n = 93) breast cancer
	in {S}weden in 1993 to 1995 were compared with 3,065 age-frequency
	matched controls randomly selected from the population. Unconditional
	logistic regression was used to calculate odds ratios (ORs) and 95\%
	confidence intervals (CIs) for ductal, lobular, and tubular cancer.
	RESULTS: Women who had used medium potency estrogen alone were at
	increased risks of both ductal and lobular cancer. Medium potency
	estrogen-progestin was associated with increased risks for all subtypes,
	but the estimates for lobular and tubular cancer were higher compared
	with ductal cancer. We found OR 5.6 (95\% CI 3.2-9.7) for lobular
	cancer, OR 6.5 (95\% CI 2.8-14.9) for tubular cancer and OR 2.3 (95\%
	CI 1.6-3.3) for ductal cancer with > or =5 years use of medium potency
	estrogen-progestin therapy. Low potency oral estrogen (mainly estriol)
	appeared to be associated with an increased risk for lobular cancer,
	but the association was strongest for short-term use. Reproductive
	and anthropometric factors, smoking, and past use of oral contraceptives
	were mostly similarly related to the risks of the three breast cancer
	subtypes. Recent alcohol consumption of > 10 g alcohol/day was associated
	with increased risk only for tubular cancer (OR 3.1, 95\% CI 1.4-6.8).
	CONCLUSION: Menopausal hormone therapy was associated with increased
	risks for breast cancer of both ductal and lobular subtype, and medium
	potency estrogen-progestin therapy was more strongly associated with
	lobular compared with ductal cancer. We also found medium potency
	estrogen-progestin therapy and alcohol to be strongly associated
	with tubular cancer. With some exceptions, most other risk factors
	seemed to be similarly associated with the three subtypes of breast
	cancer.},
  doi = {10.1186/bcr1378},
  owner = {PaulD},
  pii = {bcr1378},
  pmid = {16507159},
  timestamp = {2006.10.04},
  url = {http://dx.doi.org/10.1186/bcr1378}
}

@ARTICLE{Rosgaard2008,
  author = {K. Rosgaard},
  title = {Methods for stratification of person-time and events - a prerequisite
	for Poisson regression and {SIR} estimation},
  journal = {Epidemiologic Perspectives \& Innovations},
  year = {2008},
  volume = {5},
  file = {Rosgaard2008.pdf:Rosgaard2008.pdf:PDF;Rosgaard2008.pdf:pdf\\Rosgaard2008.pdf:PDF},
  owner = {pl4},
  timestamp = {2009.08.27}
}

@Book{Rosner2000,
  author    = {Rosner, B. A.},
  title     = {Fundamentals of Biostatistics},
  edition   = {5th},
  publisher = {Duxbury},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2000},
}

@Book{Rosner2000a,
  author    = {Rosner, B. A.},
  title     = {Study Guide for Fundamentals of Biostatistics},
  edition   = {5th},
  publisher = {Duxbury},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2000},
}

@ARTICLE{Ross2001,
  author = {Ross, P. L. and Scardino, P. T. and Kattan, M. W.},
  title = {A catalog of prostate cancer nomograms.},
  journal = {J Urol},
  year = {2001},
  volume = {165},
  pages = {1562--1568},
  number = {5},
  month = {May},
  abstract = {Prediction is central to the management of prostate cancer. Nomograms
	are devices that make predictions. We organized many nomograms for
	prostate cancer.Using MEDLINE a literature search was performed on
	prostate cancer nomograms from January 1966 to February 2000. We
	recorded input variables, prediction form, the number of patients
	used to develop the nomogram and the outcome being predicted. We
	also recorded the accuracy measures reported by the original authors
	and whether the nomograms have withstood validation. In addition,
	we noted whether the nomograms were proprietary or in the public
	domain. Each nomogram was classified into patient clinical disease
	state and the outcome being predicted.The literature search generated
	42 published nomograms that may be applied to patients in various
	clinical stages of disease. Of the 42 nomograms only 18 had undergone
	validation, of which 2 partially failed. Few nomograms have been
	compared for predictive superiority and none appears to have been
	compared with clinical judgment alone.Patients with prostate cancer
	need accurate predictions. Prognostic nomograms are available for
	many clinical states and outcomes, and may provide the most accurate
	predictions currently available. Selection among them and progress
	in this field are hampered by the lack of comparisons for predictive
	accuracy.},
  institution = {Department of Urology, Memorial Sloan-Kettering Cancer Center, New
	York, New York 10021, USA.},
  keywords = {Biopsy; Decision Support Techniques; Humans; Male; Probability; Prognosis;
	Prostate, pathology; Prostate-Specific Antigen, analysis; Prostatic
	Neoplasms, diagnosis/therapy; Sensitivity and Specificity},
  language = {eng},
  medline-pst = {ppublish},
  owner = {sanelo},
  pii = {S0022-5347(05)66349-5},
  pmid = {11342918},
  timestamp = {2013.09.16}
}

@ARTICLE{Rossi1990,
  author = {Rossi, C.},
  title = {Survival Analysis and Prognosis: A Comparison of Three Approaches
	(for the Analysis of Nasopharinx Data)},
  journal = {Computational Statistics {\&} Data analysis},
  year = {1990},
  volume = {9},
  pages = {93-111},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Roy1998,
  author = {Roy, P. and Piard, F. and Dusserre-Guion, L. and Martin, L. and Michiels-Marzais,
	D. and Faivre, J.},
  title = {Prognostic comparison of the pathological classifications of gastric
	cancer: a population-based study.},
  journal = {Histopathology},
  year = {1998},
  volume = {33},
  pages = {304--310},
  number = {4},
  month = {Oct},
  abstract = {There is controversy over the value of the pathological classifications
	of gastric carcinomas in the prediction of patient survival. This
	study was designed to assess the prognostic value of four widely
	used pathological classifications, in addition to classical prognostic
	factors.Records from the population-based registry of digestive tract
	tumours in the department of C{\AA}Â³ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â³ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â£ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â d'Or (France) have been analysed.
	All available histopathological slides of gastric cancer resected
	between 1976 and 1985 were reviewed and classified according to World
	Health Organization (WHO), Laur{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¬ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¬ Ming and Goseki pathological coding
	systems. A relative survival analysis was performed using a relative
	survival model with proportional hazard applied to net mortality
	by interval. WHO, Laur{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¬ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â or Goseki classifications were not found
	to be independent prognostic factors. In addition to advanced age
	group, depth of parietal involvement, nodal involvement, presence
	of metastases, tumour site and gross appearance of the tumour, the
	Ming's infiltrative type was associated with a lower survival.This
	study suggests an independent prognostic value of the Ming subtypes
	with respect to survival in patients resected for gastric carcinoma.},
  institution = {Registre des Tumeurs Digestives de la C{\AA}Â³ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â³ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â£ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â d'Or, INSERM CRI 95-05,
	Universit{\AA}Â§ÃƒÂƒÃ‚Â…ÃƒÂ‚Ã‚Â¸ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¤e Bourgogne, France.},
  keywords = {Adult; Aged; Aged, 80 and over; Carcinoma, mortality/pathology; Female;
	Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Risk;
	Stomach Neoplasms, mortality/pathology; Survival Rate},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {9822918},
  timestamp = {2013.05.29}
}

@ARTICLE{Roychoudhuri2007,
  author = {Roychoudhuri, Rahul and Robinson, David and Putcha, Venkata and Cuzick,
	Jack and Darby, Sarah and M{\AA}Â¸ller, Henrik},
  title = {Increased cardiovascular mortality more than fifteen years after
	radiotherapy for breast cancer: a population-based study.},
  journal = {BMC Cancer},
  year = {2007},
  volume = {7},
  pages = {9},
  abstract = {Breast radiotherapy as practised in the 1970s and 1980s resulted in
	significant myocardial exposure, and this was higher when the left
	breast was treated. It has been proposed that this difference might
	result in greater cardiovascular mortality following irradiation
	of the left breast when compared with the right.All cases of female
	breast cancer diagnosed between 1971 and 1988 and recorded on the
	Thames Cancer Registry database were followed up to the end of 2003
	to identify cases who had died from ischaemic heart disease (IHD)
	or any cardiovascular disease (CVD). A proportional hazards regression
	analysis was performed, stratified by time since diagnosis, using
	as the baseline group those women with right-sided disease who did
	not receive radiotherapy, and adjusting for age at diagnosis.A total
	of 20,871 women with breast cancer were included in the analysis,
	of which 51\% had left-sided disease. Mortality at 15+ years after
	diagnosis was increased in recipients of left-breast radiotherapy
	compared to non-irradiated women with right-sided breast cancer,
	both for IHD (hazard ratio 1.59; 95\% confidence interval 1.21-2.08;
	p = 0.001) and all CVD (hazard ratio 1.27; 95\% confidence interval
	1.07-1.51; p = 0.006). When irradiated women with left-sided breast
	cancer were compared with irradiated women with right-sided breast
	cancer, cardiovascular mortality at 15+ years after diagnosis was
	raised by around 25\% (IHD: hazard ratio 1.23; 95\% confidence interval
	0.95-1.60; p = 0.114; CVD: hazard ratio 1.25; 95\% confidence interval
	1.05-1.49; p = 0.014).We have found an elevation in cardiovascular
	mortality more than 15 years after breast radiotherapy in women diagnosed
	with breast cancer between 1971 and 1988. The risk was greater following
	irradiation of the left breast compared with the right. This confirms
	that radiotherapy as practised in the 1970s and 1980s has resulted
	in significant long-term cardiac toxicity. In absolute terms, the
	increase in cardiovascular mortality induced by radiotherapy may
	be substantial, as these mortality events are relatively common.},
  doi = {10.1186/1471-2407-7-9},
  file = {Roychoudhuri2007.pdf:pdf\\Roychoudhuri2007.pdf:PDF;Roychoudhuri2007.pdf:Roychoudhuri2007.pdf:PDF},
  institution = {>},
  keywords = {Aged; Breast Neoplasms, radiotherapy; Cardiovascular Diseases, etiology/mortality;
	Female; Follow-Up Studies; Heart, radiation effects; Humans; Middle
	Aged; Radiation Injuries, mortality; Time Factors},
  language = {eng},
  medline-pst = {epublish},
  owner = {sanelo},
  pii = {1471-2407-7-9},
  pmid = {17224064},
  timestamp = {2013.08.01},
  url = {http://dx.doi.org/10.1186/1471-2407-7-9}
}

@ARTICLE{Royston2006a,
  author = {P. Royston},
  title = {Explained variation for survival models},
  journal = {The Stata Journal},
  year = {2006},
  volume = {6},
  pages = {83-96},
  file = {Royston2006a.pdf:pdf\\Royston2006a.pdf:PDF;Royston2006a.pdf:Royston2006a.pdf:PDF},
  owner = {pl4},
  timestamp = {2009.11.04}
}

@ARTICLE{Royston2001,
  author = {Royston, P.},
  title = {Flexible parametric alternatives to the {C}ox model, and more},
  journal = {The Stata Journal},
  year = {2001},
  volume = {1},
  pages = {1--28},
  file = {Royston2001.pdf:Royston2001.pdf:PDF;Royston2001.pdf:pdf\\Royston2001.pdf:PDF},
  owner = {pl4},
  timestamp = {2008.10.15}
}

@ARTICLE{Royston2000,
  author = {P. Royston},
  title = {Choice of scale for cubic smoothing spline models in medical applications.},
  journal = {Statistics in Medicine},
  year = {2000},
  volume = {19},
  pages = {1191--1205},
  number = {9},
  month = {May},
  abstract = {The determination of the functional form of the relationship between
	an outcome variable and one or more continuous covariates is an important
	aspect of the modelling of medical data. For correct interpretation
	of the data it is essential that the functional form be specified
	at least approximately correctly. I show that for given model complexity,
	logarithmic transformation of a covariate can greatly improve the
	fit of one of the most useful and convenient non-parametric regression
	models, the cubic smoothing spline. A mathematical rationale for
	the idea is given. I propose a diagnostic for deciding initially
	whether a log transformation is needed. The method is illustrated
	using several medical data sets. No special software other than that
	used for fitting the spline models is needed.},
  file = {royston2000.pdf:royston2000.pdf:PDF},
  institution = {Department of Medical Statistics and Evaluation, Imperial College
	School of Medicine (Hammersmith campus), Ducane Road, London W12
	0NN, U.K.},
  owner = {pl4},
  pii = {3.0.CO;2-1},
  pmid = {10797516},
  timestamp = {2008.11.14}
}

@ARTICLE{Royston1994,
  author = {Royston, P. and Altman, D.G.},
  title = {Regression using fractional polynomials of continuous covariates:
	parsimonious parametric modelling},
  journal = {Applied Statistics},
  year = {1994},
  volume = {43},
  pages = {429--467},
  number = {3},
  file = {Royston1994.pdf:Royston1994.pdf:PDF;Royston1994.pdf:pdf\\Royston1994.pdf:PDF},
  owner = {pl4},
  timestamp = {2008.12.03}
}

@ARTICLE{RoyAltPar2010,
  author = {P. Royston and D. G. Altman and M. K. B. Parmar},
  title = {External validation and updating of a prognostic survival model},
  year = {2010},
  number = {000},
  institution = {Department of Statistical Science, University College London},
  owner = {pl4},
  timestamp = {2010.03.08}
}

@ARTICLE{Royston2006,
  author = {Patrick Royston and Douglas G Altman and Willi Sauerbrei},
  title = {Dichotomizing continuous predictors in multiple regression: a bad
	idea.},
  journal = {Statistics in Medicine},
  year = {2006},
  volume = {25},
  pages = {127--141},
  number = {1},
  month = {Jan},
  abstract = {In medical research, continuous variables are often converted into
	categorical variables by grouping values into two or more categories.
	We consider in detail issues pertaining to creating just two groups,
	a common approach in clinical research. We argue that the simplicity
	achieved is gained at a cost; dichotomization may create rather than
	avoid problems, notably a considerable loss of power and residual
	confounding. In addition, the use of a data-derived 'optimal' cutpoint
	leads to serious bias. We illustrate the impact of dichotomization
	of continuous predictor variables using as a detailed case study
	a randomized trial in primary biliary cirrhosis. Dichotomization
	of continuous data is unnecessary for statistical analysis and in
	particular should not be applied to explanatory variables in regression
	models.},
  doi = {10.1002/sim.2331},
  file = {royston2006.pdf:royston2006.pdf:PDF},
  institution = {MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK. patrick.royston@ctu.mrc.ac.uk},
  owner = {pl4},
  pmid = {16217841},
  timestamp = {2008.11.04},
  url = {http://dx.doi.org/10.1002/sim.2331}
}

@Article{Royston1999,
  author      = {P. Royston and G. Ambler and W. Sauerbrei},
  title       = {The use of fractional polynomials to model continuous risk variables in epidemiology.},
  number      = {5},
  pages       = {964--974},
  volume      = {28},
  abstract    = {BACKGROUND: The traditional method of analysing continuous or ordinal
	risk factors by categorization or linear models may be improved.
	METHODS: We propose an approach based on transformation and fractional
	polynomials which yields simple regression models with interpretable
	curves. We suggest a way of presenting the results from such models
	which involves tabulating the risks estimated from the model at convenient
	values of the risk factor. We discuss how to incorporate several
	continuous risk and confounding variables within a single model.
	The approach is exemplified with data from the Whitehall I study
	of British Civil Servants. We discuss the approach in relation to
	categorization and non-parametric regression models. RESULTS: We
	show that non-linear risk models fit the data better than linear
	models. We discuss the difficulties introduced by categorization
	and the advantages of the new approach. CONCLUSIONS: Our approach
	based on fractional polynomials should be considered as an important
	alternative to the traditional approaches for the analysis of continuous
	variables in epidemiological studies.},
  file        = {Royston1999.pdf:Royston1999.pdf:PDF;Royston1999.pdf:pdf\\Royston1999.pdf:PDF},
  institution = {Evaluation, Imperial College School of Medicine, London, UK. proyston@ic.ac.uk},
  journal     = {International Journal of Epidemiology},
  month       = {Oct},
  owner       = {pl4},
  pmid        = {10597998},
  timestamp   = {2008.12.03},
  year        = {1999},
}

@Book{Royston2011,
  author    = {P. Royston and P. C. Lambert},
  title     = {Flexible parametric survival analysis in Stata: Beyond the {C}ox model},
  publisher = {Stata Press},
  owner     = {pl4},
  timestamp = {2012.04.13},
  year      = {2011},
}

@ARTICLE{Royston2016,
  author = {Royston, Patrick and Parmar, Mahesh K B},
  title = {Augmenting the logrank test in the design of clinical trials in which
	non-proportional hazards of the treatment effect may be anticipated.},
  journal = {BMC medical research methodology},
  year = {2016},
  volume = {16},
  pages = {16},
  abstract = {Most randomized controlled trials with a time-to-event outcome are
	designed assuming proportional hazards (PH) of the treatment effect.
	The sample size calculation is based on a logrank test. However,
	non-proportional hazards are increasingly common. At analysis, the
	estimated hazards ratio with a confidence interval is usually presented.
	The estimate is often obtained from a Cox PH model with treatment
	as a covariate. If non-proportional hazards are present, the logrank
	and equivalent Cox tests may lose power. To safeguard power, we previously
	suggested a 'joint test' combining the Cox test with a test of non-proportional
	hazards. Unfortunately, a larger sample size is needed to preserve
	power under PH. Here, we describe a novel test that unites the Cox
	test with a permutation test based on restricted mean survival time.
	We propose a combined hypothesis test based on a permutation test
	of the difference in restricted mean survival time across time. The
	test involves the minimum of the Cox and permutation test P-values.
	We approximate its null distribution and correct it for correlation
	between the two P-values. Using extensive simulations, we assess
	the type 1 error and power of the combined test under several scenarios
	and compare with other tests. We investigate powering a trial using
	the combined test. The type 1 error of the combined test is close
	to nominal. Power under proportional hazards is slightly lower than
	for the Cox test. Enhanced power is available when the treatment
	difference shows an 'early effect', an initial separation of survival
	curves which diminishes over time. The power is reduced under a 'late
	effect', when little or no difference in survival curves is seen
	for an initial period and then a late separation occurs. We propose
	a method of powering a trial using the combined test. The 'insurance
	premium' offered by the combined test to safeguard power under non-PH
	represents about a single-digit percentage increase in sample size.
	The combined test increases trial power under an early treatment
	effect and protects power under other scenarios. Use of restricted
	mean survival time facilitates testing and displaying a generalized
	treatment effect.},
  citation-subset = {IM},
  country = {England},
  created = {2016-02-12},
  doi = {10.1186/s12874-016-0110-x},
  issn = {1471-2288},
  issn-linking = {1471-2288},
  journal-abbreviation = {BMC Med Res Methodol},
  nlm = {PMC4751641},
  nlm-id = {100968545},
  owner = {NLM},
  pmid = {26869168},
  pubmodel = {Electronic},
  pubstatus = {epublish},
  revised = {2016-02-14},
  status = {In-Process}
}

@ARTICLE{Royston2013,
  author = {Royston, Patrick and Parmar, Mahesh K B},
  title = {Restricted mean survival time: an alternative to the hazard ratio
	for the design and analysis of randomized trials with a time-to-event
	outcome.},
  journal = {BMC medical research methodology},
  year = {2013},
  volume = {13},
  pages = {152},
  abstract = {Designs and analyses of clinical trials with a time-to-event outcome
	almost invariably rely on the hazard ratio to estimate the treatment
	effect and implicitly, therefore, on the proportional hazards assumption.
	However, the results of some recent trials indicate that there is
	no guarantee that the assumption will hold. Here, we describe the
	use of the restricted mean survival time as a possible alternative
	tool in the design and analysis of these trials. The restricted mean
	is a measure of average survival from time 0 to a specified time
	point, and may be estimated as the area under the survival curve
	up to that point. We consider the design of such trials according
	to a wide range of possible survival distributions in the control
	and research arm(s). The distributions are conveniently defined as
	piecewise exponential distributions and can be specified through
	piecewise constant hazards and time-fixed or time-dependent hazard
	ratios. Such designs can embody proportional or non-proportional
	hazards of the treatment effect. We demonstrate the use of restricted
	mean survival time and a test of the difference in restricted means
	as an alternative measure of treatment effect. We support the approach
	through the results of simulation studies and in real examples from
	several cancer trials. We illustrate the required sample size under
	proportional and non-proportional hazards, also the significance
	level and power of the proposed test. Values are compared with those
	from the standard approach which utilizes the logrank test. We conclude
	that the hazard ratio cannot be recommended as a general measure
	of the treatment effect in a randomized controlled trial, nor is
	it always appropriate when designing a trial. Restricted mean survival
	time may provide a practical way forward and deserves greater attention.},
  citation-subset = {IM},
  completed = {2014-09-29},
  country = {England},
  created = {2014-02-11},
  doi = {10.1186/1471-2288-13-152},
  issn = {1471-2288},
  issn-linking = {1471-2288},
  journal-abbreviation = {BMC Med Res Methodol},
  keywords = {Algorithms; Humans; Models, Statistical; Outcome Assessment (Health
	Care), methods, statistics & numerical data; Randomized Controlled
	Trials as Topic; Research Design, statistics & numerical data; Survival
	Analysis; Time Factors},
  nlm = {PMC3922847},
  nlm-id = {100968545},
  owner = {NLM},
  pmid = {24314264},
  pubmodel = {Electronic},
  pubstatus = {epublish},
  revised = {2015-04-22},
  status = {MEDLINE}
}

@ARTICLE{Royston2011a,
  author = {Royston, Patrick and Parmar, Mahesh K B.},
  title = {The use of restricted mean survival time to estimate the treatment
	effect in randomized clinical trials when the proportional hazards
	assumption is in doubt.},
  journal = {Stat Med},
  year = {2011},
  volume = {30},
  pages = {2409--2421},
  number = {19},
  month = {Aug},
  abstract = {In most randomized clinical trials (RCTs) with a right-censored time-to-event
	outcome, the hazard ratio is taken as an appropriate measure of the
	effectiveness of a new treatment compared with a standard-of-care
	or control treatment. However, it has long been known that the hazard
	ratio is valid only under the proportional hazards (PH) assumption.
	This assumption is formally checked only rarely. Some recent trials,
	particularly the IPASS trial in lung cancer and the ICON7 trial in
	ovarian cancer, have alerted researchers to the possibility of gross
	non-PH, raising the critical question of how such data should be
	analyzed. Here, we propose the use of the restricted mean survival
	time at a prespecified, fixed time point as a useful general measure
	to report the difference between two survival curves. We describe
	different methods of estimating it and we illustrate its application
	to three RCTs in cancer. The examples are graded from a trial in
	kidney cancer in which there is no evidence of non-PH, to IPASS,
	where the opposite is clearly the case. We propose a simple, general
	scheme for the analysis of data from such RCTs. Key elements of our
	approach are Andersen's method of 'pseudo-observations,' which is
	based on the Kaplan-Meier estimate of the survival function, and
	Royston and Parmar's class of flexible parametric survival models,
	which may be used for analyzing data in the presence or in the absence
	of PH of the treatment effect.},
  doi = {10.1002/sim.4274},
  file = {Royston2011a.pdf:pdf\\Royston2011a.pdf:PDF},
  institution = {Hub for Trials Methodology Research, MRC Clinical Trials Unit and
	University College London, 222 Euston Road, London NW12DA, UK. pr@ctu.mrc.ac.uk},
  keywords = {Adenocarcinoma, drug therapy/mortality; Antineoplastic Agents, therapeutic
	use; Antineoplastic Combined Chemotherapy Protocols, therapeutic
	use; Female; Humans; Kidney Neoplasms, drug therapy/mortality; Lung
	Neoplasms, drug therapy/mortality; Ovarian Neoplasms, drug therapy/mortality;
	Randomized Controlled Trials as Topic, statistics /&/ numerical data;
	Survival Analysis},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {21611958},
  timestamp = {2013.03.24},
  url = {http://dx.doi.org/10.1002/sim.4274}
}

@ARTICLE{Royston2002,
  author = {P. Royston and M. K. B. Parmar},
  title = {Flexible parametric proportional-hazards and proportional-odds models
	for censored survival data, with application to prognostic modelling
	and estimation of treatment effects.},
  journal = {Statistics in Medicine},
  year = {2002},
  volume = {21},
  pages = {2175--2197},
  number = {15},
  month = {Aug},
  abstract = {Modelling of censored survival data is almost always done by Cox proportional-hazards
	regression. However, use of parametric models for such data may have
	some advantages. For example, non-proportional hazards, a potential
	difficulty with Cox models, may sometimes be handled in a simple
	way, and visualization of the hazard function is much easier. Extensions
	of the Weibull and log-logistic models are proposed in which natural
	cubic splines are used to smooth the baseline log cumulative hazard
	and log cumulative odds of failure functions. Further extensions
	to allow non-proportional effects of some or all of the covariates
	are introduced. A hypothesis test of the appropriateness of the scale
	chosen for covariate effects (such as of treatment) is proposed.
	The new models are applied to two data sets in cancer. The results
	throw interesting light on the behaviour of both the hazard function
	and the hazard ratio over time. The tools described here may be a
	step towards providing greater insight into the natural history of
	the disease and into possible underlying causes of clinical events.
	We illustrate these aspects by using the two examples in cancer.},
  doi = {10.1002/sim.1203},
  file = {Royston2002.pdf:pdf\\Royston2002.pdf:PDF;Royston2002.pdf:Royston2002.pdf:PDF},
  institution = {Cancer Division, MRC Clinical Trials Unit, 222 Euston Road, London
	NW1 2DA, UK. patrick.royston@ctu.mrc.ac.uk},
  owner = {PaulD},
  pmid = {12210632},
  timestamp = {2009.06.11},
  url = {http://dx.doi.org/10.1002/sim.1203}
}

@Article{Royston2008a,
  author    = {P. Royston and M. K. B. Parmar and D. G. Altman},
  title     = {Visualizing length of survival in time-to-event studies: A complement to {K}aplan-{M}eier plots},
  pages     = {92-97},
  volume    = {100},
  file      = {Royston2008a.pdf:Royston2008a.pdf:PDF;Royston2008a.pdf:pdf\\Royston2008a.pdf:PDF},
  journal   = {Journal of the National Cancer Institute},
  owner     = {pl4},
  timestamp = {2009.11.04},
  year      = {2008},
}

@Book{Royston2008,
  author    = {P. Royston and W. Sauerbrei},
  title     = {Multivariable model-building: A pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables.},
  publisher = {Wiley},
  owner     = {pl4},
  timestamp = {2009.08.07},
  year      = {2008},
}

@ARTICLE{Royston2004,
  author = {P. Royston and W. Sauerbrei},
  title = {A new measure of prognostic separation in survival data},
  journal = {Staistics in Medicine},
  year = {2004},
  volume = {237},
  pages = {723-748},
  file = {Royston2004.pdf:Royston2004.pdf:PDF;Royston2004.pdf:pdf\\Royston2004.pdf:PDF},
  owner = {pl4},
  timestamp = {2009.11.04}
}

@Book{Rubin2004,
  author    = {Rubin, D. B.},
  title     = {Multiple Imputation for Nonresponse in Surveys},
  publisher = {John Wiley and Sons},
  owner     = {hanbow},
  timestamp = {2016.08.18},
  year      = {2004},
}

@ARTICLE{Rundle2005,
  author = {Rundle, A. G.},
  title = {Design Options for Molecular Epidemiology Research within Cohort
	Studies},
  journal = {Cancer Epidemiology Biomarkers \& Prevention},
  year = {2005},
  volume = {14},
  pages = {1899-1907},
  number = {8},
  month = {Aug},
  doi = {10.1158/1055-9965.EPI-04-0860},
  file = {:Rundle2005.pdf:PDF},
  publisher = {American Association for Cancer Research},
  timestamp = {2005.11.01}
}

@ARTICLE{Rutherford2014,
  author = {Mark J Rutherford},
  title = {Care needed in interpretation of cancer survival measures},
  journal = {The Lancet},
  year = {2014},
  file = {Rutherford2014.pdf:pdf\\Rutherford2014.pdf:PDF;Rutherford2014.pdf:Rutherford2014.pdf:PDF},
  owner = {PaulD},
  timestamp = {2014.12.05}
}

@PhdThesis{Rutherford:phdthesis:2012,
  author    = {Mark J. Rutherford},
  title     = {Development and Application of Statistical Methods for Population-Based Cancer Patient Survival},
  type      = {PhD Thesis},
  url       = {http://hdl.handle.net/2381/10201},
  file      = {:pdf\\Thesis_Mark_Rutherford.pdf:PDF},
  groups    = {PhD Thesis},
  owner     = {PaulD},
  school    = {University of Leicester},
  timestamp = {2013.10.23},
  year      = {2012},
}

@Article{Rutherford2015b,
  author      = {Rutherford, M. J. and Andersson, T M-L. and M{\o}ller, H. and Lambert, P. C.},
  title       = {Understanding the impact of socioeconomic differences in breast cancer survival in {E}ngland and {W}ales: avoidable deaths and potential gain in expectation of life.},
  doi         = {10.1016/j.canep.2014.11.002},
  language    = {eng},
  number      = {1},
  pages       = {118--125},
  url         = {http://dx.doi.org/10.1016/j.canep.2014.11.002},
  volume      = {39},
  abstract    = {Socioeconomic differences in cancer patient survival are known to
	exist for women diagnosed with breast cancer. Standard metrics tend
	not to place great emphasis on evaluating the actual impact of these
	differences.We used two alternative, but related, methods of reporting
	the impact of socioeconomic differences for breast cancer patients
	in England and Wales. We calculated the average gain in life years
	for each patient should socioeconomic differences in relative survival
	be removed and show how this is related to the number of all-cause
	deaths that could be postponed by removing socioeconomic differences
	in cancer patient survival.Our results indicate that deprivation
	differences for women with breast cancer exist and result in women
	from more deprived areas losing a larger proportion of their life
	due to a diagnosis of cancer. We also estimate that on average 1.1
	years could be gained for a 60 year old breast cancer patient in
	the most deprived group by improving their relative survival to match
	the least deprived group. However, our results also show that deprivation
	differences in general survival have a large impact on life expectancy;
	showing that over two-thirds of the gap in differential life expectancy
	is explained by differences in other-cause survival.Socioeconomic
	differences in relative survival have an impact on life expectancy
	for patients and result in higher early mortality for more deprived
	patients. However, differences in general survival across socioeconomic
	groups explain a larger proportion of the deprivation gap in life
	expectancy for breast cancer patients.},
  file        = {Rutherford2015b.pdf:Rutherford2015b.pdf:PDF;Rutherford2015b.pdf:pdf\\Rutherford2015b.pdf:PDF},
  institution = {Department of Health Sciences, University of Leicester, LE1 7RH, UK; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm SE-171 77, Sweden.},
  journal     = {Cancer Epidemiology},
  medline-pst = {ppublish},
  owner       = {pl4},
  pii         = {S1877-7821(14)00192-1},
  pmid        = {25435402},
  timestamp   = {2015.04.19},
  year        = {2015},
}

@Article{Rutherford2013c,
  author    = {Rutherford, M. J. and Crowther, M. J. and Lambert, P. C.},
  title     = {The use of restricted cubic splines to approximate complex hazard functions in the analysis of time-to-event data: a simulation study.},
  journal   = {Journal of Statistical Computation and Simulation},
  year      = {2015},
  volume    = {85},
  pages     = {777-793},
  doi       = {10.1080/00949655.2013.845890},
  file      = {Rutherford2013c.pdf:pdf\\Rutherford2013c.pdf:PDF},
  owner     = {theand},
  timestamp = {2013.09.20},
}

@ARTICLE{Rutherford2012,
  author = {Rutherford, Mark J. and Dickman, Paul W. and Lambert, Paul C.},
  title = {Comparison of methods for calculating relative survival in population-based
	studies.},
  journal = {Cancer Epidemiology},
  year = {2012},
  volume = {36},
  pages = {16--21},
  number = {1},
  month = {Feb},
  abstract = {It is vital that unbiased estimates of relative survival are estimated
	and reported by cancer registries. A single figure of relative survival
	is often required to make reporting simpler. This can be obtained
	by pooling all ages or, more commonly, by using age-standardisation.
	The various methods for providing a single figure estimate of relative
	survival can give very different estimates.The problem is illustrated
	through an example using Finnish thyroid cancer data. The differences
	are further explored through a simulation study that investigates
	the effect of age on the estimates of relative survival.The example
	highlights that in practice the all-age estimates from the various
	methods can be substantially different (up to 6 percentage units
	at 15 years of follow-up). The simulation study confirms the finding
	that differing estimates for the all-age estimates of relative survival
	are obtained. Performing age-standardisation makes the methods more
	comparable and results in better estimation of the true net survival.The
	all-age estimates of relative survival rarely give an appropriate
	estimate of net survival. We feel that modelling or stratifying by
	age when calculating relative survival is vitally important as the
	lack of homogeneity in the cohort of patients leads to potentially
	biased estimates. We feel that the methods using modelling provide
	a greater flexibility than life-table based approaches. The flexible
	parametric approach does not require an arbitrary splitting of the
	time-scale, which makes it more computationally efficient. It also
	has the advantage of easily being extended to incorporate time-dependent
	effects.},
  doi = {10.1016/j.canep.2011.05.010},
  file = {Rutherford2012.pdf:pdf\\Rutherford2012.pdf:PDF},
  institution = {Department of Health Sciences, 2nd Floor, Adrian Building, University
	of Leicester, LE1 7RH, UK. mjr40@le.ac.uk},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {S1877-7821(11)00092-0},
  pmid = {21840284},
  timestamp = {2012.04.08},
  url = {http://dx.doi.org/10.1016/j.canep.2011.05.010}
}

@Article{Rutherford2013b,
  author      = {Rutherford, M. J. and Hinchliffe, S. R. and Abel, G. A. and Lyratzopoulos, G. and Lambert, P. C. and Greenberg, D. C.},
  title       = {How much of the deprivation gap in cancer survival can be explained by variation in stage at diagnosis: An example from breast cancer in the {E}ast of {E}ngland.},
  journal     = {International Journal of Cancer},
  year        = {2013},
  language    = {eng},
  volume      = {133},
  pages       = {2192-2200},
  doi         = {10.1002/ijc.28221},
  url         = {http://dx.doi.org/10.1002/ijc.28221},
  abstract    = {Socioeconomic differences in cancer patient survival exist in many
	countries and across cancer sites. In our article, we estimated the
	number of deaths in women with breast cancer that could be avoided
	within 5 years from diagnosis if it were possible to eliminate socioeconomic
	differences in stage at diagnosis. We analysed data on East of England
	women with breast cancer (2006-2010). We estimated survival for different
	stage-age-deprivation strata using both the observed and a hypothetical
	stage distribution (assuming all women acquired the stage distribution
	of the most affluent women). Data were analysed on 20,738 women with
	complete stage information (92\%). Affluent women were less likely
	to be diagnosed in advanced stage. Relative survival decreased with
	increasing level of deprivation. Eliminating differences in stage
	at diagnosis could be expected to nearly eliminate differences in
	relative survival for women in deprivation groups 3 and 4, but would
	only approximately halve the difference in relative survival for
	women in the most deprived group (5). This means, for a typical cohort
	of women diagnosed in a calendar year with breast cancer, eliminating
	deprivation differences in stage at diagnosis would prevent ?40 deaths
	in the East of England from occurring within 5 years from diagnosis.
	Using appropriate weighting we estimated the respective number of
	avoidable deaths for the whole of England to be ?450. The findings
	suggest that policies aimed at reducing inequalities in stage at
	diagnosis between women with breast cancer are important to reduce
	inequalities in breast cancer survival.},
  file        = {Rutherford2013b.pdf:pdf\\Rutherford2013b.pdf:PDF;Rutherford2013b.pdf:Rutherford2013b.pdf:PDF},
  institution = {Department of Health Sciences, University of Leicester, Leicester, United Kingdom.},
  medline-pst = {aheadofprint},
  owner       = {pl4},
  pmid        = {23595777},
  timestamp   = {2013.06.03},
}

@Article{Rutherford2015c,
  author      = {Rutherford, M. J. and Ironmonger, L. and Ormiston-Smith, N. and Abel, G. A. and Greenberg, D. C. and Lyratzopoulos, G. and Lambert, P. C.},
  title       = {Estimating the potential survival gains by eliminating socioeconomic and sex inequalities in stage at diagnosis of melanoma.},
  doi         = {10.1038/bjc.2015.50},
  language    = {eng},
  pages       = {S116--S123},
  url         = {http://dx.doi.org/10.1038/bjc.2015.50},
  volume      = {112 Suppl},
  abstract    = {Although inequalities in cancer survival are thought to reflect inequalities
	in stage at diagnosis, little evidence exists about the size of potential
	survival gains from eliminating inequalities in stage at diagnosis.We
	used data on patients diagnosed with malignant melanoma in the East
	of England (2006-2010) to estimate the number of deaths that could
	be postponed by completely eliminating socioeconomic and sex differences
	in stage at diagnosis after fitting a flexible parametric excess
	mortality model.Stage was a strong predictor of survival. There were
	pronounced socioeconomic and sex inequalities in the proportion of
	patients diagnosed at stages III-IV (12 and 8\% for least deprived
	men and women and 25 and 18\% for most deprived men and women, respectively).
	For an annual cohort of 1025 incident cases in the East of England,
	eliminating sex and deprivation differences in stage at diagnosis
	would postpone approximately 24 deaths to beyond 5 years from diagnosis.
	Using appropriate weighting, the equivalent estimate for England
	would be around 215 deaths, representing 11\% of all deaths observed
	within 5 years from diagnosis in this population.Reducing socioeconomic
	and sex inequalities in stage at diagnosis would result in substantial
	reductions in deaths within 5 years of a melanoma diagnosis.},
  file        = {Rutherford2015a.pdf:pdf\\Rutherford2015a.pdf:PDF;Rutherford2015a.pdf:Rutherford2015a.pdf:PDF},
  institution = {Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm SE-171 77, Sweden.},
  journal     = {British Journal of Cancer},
  medline-pst = {epublish},
  owner       = {pl4},
  pii         = {bjc201550},
  pmid        = {25734390},
  timestamp   = {2015.04.19},
  year        = {2015},
}

@Article{Rutherford2010,
  author      = {M. J. Rutherford and P. C. Lambert and J. R. Thompson},
  title       = {Age-period-cohort modelling},
  doi         = {10.1038/bjc.2015.51},
  language    = {eng},
  pages       = {606-627},
  volume      = {10},
  file        = {Rutherford2015.pdf:pdf/Rutherford2015.pdf:PDF;Rutherford2015.pdf:Rutherford2015.pdf:PDF},
  institution = {Health Behaviour Research Centre, Department of Epidemiology and Public Health, University College London, UCL, 1-19 Torrington Place, London WC1E 6BT, UK.},
  journal     = {The Stata Journal},
  medline-pst = {epublish},
  owner       = {pl4},
  timestamp   = {2009.03.25},
  year        = {2010},
}

@Article{Rutherford2013a,
  author      = {Rutherford, M. J. and M{\o}ller, H. and Lambert, P. C.},
  title       = {A comprehensive assessment of the impact of errors in the cancer registration process on 1- and 5-year relative survival estimates.},
  doi         = {10.1038/bjc.2013.12},
  language    = {eng},
  number      = {3},
  pages       = {691--698},
  url         = {http://dx.doi.org/10.1038/bjc.2013.12},
  volume      = {108},
  abstract    = {Background:When making international comparisons of cancer survival,
	it is essential reported differences are real effects and not an
	artefact of potential errors in cancer registration.Methods:We use
	simulation methods to assess the impact of various cancer registration
	errors on commonly reported outcomes of cancer survival (1-, and
	5-year relative survival estimates). We draw two samples of patients
	diagnosed with cancer from one population and introduce potential
	registration errors in one of the sample populations under various
	assumptions. We investigate the effect of errors individually as
	well as the composite effect when combined with other registration
	errors.Results:The results indicate that high levels of cancer registration
	errors are necessary to make a noticeable effect on commonly reported
	metrics of cancer survival. Differences of up to 3 percentage units
	in the 5-year relative survival proportion are seen under plausible
	scenarios.Conclusion:This study is a comprehensive assessment of
	cancer registration errors and the consequent impact on commonly
	reported survival statistics. We show that under plausible scenarios,
	it is very unlikely that these biases are large enough to explain
	the variation in international comparisons of cancer survival. Registration
	errors will also impact on other metrics reported from registry data,
	such as incidence.},
  file        = {Rutherford2013a.pdf:Rutherford2013a.pdf:PDF},
  institution = {University of Leicester, Department of Health Sciences, Leicester LE1 7RH, UK.},
  journal     = {British Journal of Cancer},
  medline-pst = {ppublish},
  month       = {Feb},
  owner       = {pl4},
  pii         = {bjc201312},
  pmid        = {23361055},
  timestamp   = {2013.03.05},
  year        = {2013},
}

@Article{Rutherford2012a,
  author      = {Rutherford, M. J. and Thompson, J. R. and Lambert, P. C.},
  title       = {Projecting cancer incidence using age-period-cohort models incorporating restricted cubic splines.},
  doi         = {10.1515/1557-4679.1411},
  language    = {eng},
  number      = {1},
  pages       = {33},
  url         = {http://dx.doi.org/10.1515/1557-4679.1411},
  volume      = {8},
  abstract    = {Age-period-cohort models provide a useful method for modeling incidence
	and mortality rates. There is great interest in estimating the rates
	of disease at given future time-points in order that plans can be
	made for the provision of the required future services. In the setting
	of using age-period-cohort models incorporating restricted cubic
	splines, a new technique for projecting incidence is proposed. The
	new technique projects the period and cohort terms linearly from
	10 years within the range of the available data in order to give
	projections that are based on recent trends. The method is validated
	via a comparison with existing methods in the setting of Finnish
	cancer registry data. The reasons for the improvements seen for the
	newly proposed method are twofold. Firstly, improvements are seen
	due to the finer splitting of the timescale to give a more continuous
	estimate of the incidence rate. Secondly, the new method uses more
	recent trends to dictate the future projections than previously proposed
	methods.},
  file        = {Rutherford2012a.pdf:Rutherford2012a.pdf:PDF},
  institution = {University of Leicester, UK.},
  journal     = {International Journal of Biostatistics},
  medline-pst = {epublish},
  owner       = {PaulD},
  pii         = {/j/ijb.2012.8.issue-1/1557-4679.1411/1557-4679.1411.xml},
  pmid        = {23152433},
  timestamp   = {2013.01.21},
  year        = {2012},
}

@ARTICLE{Rutqvist1990,
  author = {Rutqvist, L. E. and Johansson, H.},
  title = {Mortality by laterality of the primary tumour among 55,000 breast
	cancer patients from the {S}wedish {C}ancer {R}egistry.},
  journal = {Br J Cancer},
  year = {1990},
  volume = {61},
  pages = {866--868},
  number = {6},
  month = {Jun},
  abstract = {To examine the hypothesis that radiotherapy for breast cancer can
	cause myocardial infarction, cause-specific mortality by laterality
	of the primary tumour was analysed among 54,617 breast cancer patients
	reported to the Swedish Cancer Registry during 1970-1985. The rationale
	was that radiotherapy for a left-sided breast cancer invariably results
	in higher doses of radiation to the myocardium than a similar treatment
	given for a right-sided tumour whereas other possible risk factors
	for cardiovascular disease probably are unrelated to the laterality
	of the tumour. The median follow-up was 9 years (range 1-17 years).
	Patients with left-sided tumours were found to have a higher mortality
	due to myocardial infarction than patients with right-sided tumours
	(P less than 0.01) but there was no difference in regard to total
	intercurrent mortality. Further analyses of individual radiotherapy
	studies are warranted to quantify the excess risk associated with
	radiation and to study the significance of the type of radiation,
	portal arrangements, total dose and fractionation. It seems reasonable
	to assume that adverse effects of radiation are dose-related and
	may thus be minimised or prevented by the use of appropriate treatment
	techniques.},
  institution = {Oncologic Centre, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden.},
  keywords = {Breast Neoplasms, mortality/pathology/radiotherapy; Cause of Death;
	Female; Humans; Myocardial Infarction, mortality; Radiation Injuries,
	mortality; Registries; Sweden},
  language = {eng},
  medline-pst = {ppublish},
  owner = {sanelo},
  pmid = {2372488},
  timestamp = {2013.08.02}
}

@ARTICLE{Ryhaenen1977,
  author = {P. Ryh\"{a}nen and E. Saarela and J. Saukkonen and A. Hollm\'{e}n},
  title = {Circulatory responses to laryngoscopy and endotracheal intubation
	in patients with and without cardiovascular disease. Effect of prophylactic
	practolol.},
  journal = {Ann Chir Gynaecol},
  year = {1977},
  volume = {66},
  pages = {294--298},
  number = {6},
  abstract = {The effect of small intravenous doses of practolol (0.2 mg/kg body
	weight) on the circulatory response to laryngoscopy and endotracheal
	intubation, when administered with atropine (0.01 mg/kg b.w.) prior
	to anaesthesia was studied in 39 patients with and without cardiovascular
	disease. Practolol diminished significantly the rise of mean arterial
	pressure and pulse rate affected by laryngoscopy and endotracheal
	intubation when performed under thiopentone-succinylcholine anaesthesia.
	Arrhythmias were also less frequent through the statistical significance
	could not be ascertained in this small series. The small practolol
	dose used had no adverse circulatory effects. It is suggested that
	the administration of a small prophylactic dose of practolol is useful
	in preventing the excessive cardiovascular response due to laryngoscopy
	and endotracheal intubation.},
  owner = {pl4},
  pmid = {603221},
  timestamp = {2011.05.26}
}

@ARTICLE{Saarela2007a,
  author = {Jeffery M Saarela and Hardeep S Rai and James A Doyle and Peter K
	Endress and Sarah Mathews and Adam D Marchant and Barbara G Briggs
	and Sean W Graham},
  title = {Hydatellaceae identified as a new branch near the base of the angiosperm
	phylogenetic tree.},
  journal = {Nature},
  year = {2007},
  volume = {446},
  pages = {312--315},
  number = {7133},
  month = {Mar},
  abstract = {Although the relationship of angiosperms to other seed plants remains
	controversial, great progress has been made in identifying the earliest
	extant splits in flowering-plant phylogeny, with the discovery that
	the New Caledonian shrub Amborella trichopoda, the water lilies (Nymphaeales),
	and the woody Austrobaileyales constitute a basal grade of lines
	that diverged before the main radiation in the clade. By focusing
	attention on these ancient lines, this finding has re-written our
	understanding of angiosperm structural and reproductive biology,
	physiology, ecology and taxonomy. The discovery of a new basal lineage
	would lead to further re-evaluation of the initial angiosperm radiation,
	but would also be unexpected, as nearly all of the approximately
	460 flowering-plant families have been surveyed in molecular studies.
	Here we show that Hydatellaceae, a small family of dwarf aquatics
	that were formerly interpreted as monocots, are instead a highly
	modified and previously unrecognized ancient lineage of angiosperms.
	Molecular phylogenetic analyses of multiple plastid genes and associated
	noncoding regions from the two genera of Hydatellaceae identify this
	overlooked family as the sister group of Nymphaeales. This surprising
	result is further corroborated by evidence from the nuclear gene
	phytochrome C (PHYC), and by numerous morphological characters. This
	indicates that water lilies are part of a larger lineage that evolved
	more extreme and diverse modifications for life in an aquatic habitat
	than previously recognized.},
  doi = {10.1038/nature05612},
  institution = {UBC Botanical Garden and Centre for Plant Research (Faculty of Land
	and Food Systems), Centre for Biodiversity Research, and Department
	of Botany, 2357 Main Mall, The University of British Columbia, Vancouver,
	British Columbia V6T 1Z4, Canada.},
  owner = {pl4},
  pii = {nature05612},
  pmid = {17361182},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1038/nature05612}
}

@ARTICLE{Saarela2007b,
  author = {Lauri Saarela and Harri Sax\'{e}n},
  title = {[Not Available].},
  journal = {Duodecim},
  year = {2007},
  volume = {123},
  pages = {15--17},
  number = {1},
  owner = {pl4},
  pmid = {17328291},
  timestamp = {2011.05.26}
}

@ARTICLE{Saarela1998,
  author = {M. Saarela and S. Asikainen and S. Alaluusua and P. Fives-Taylor},
  title = {apaH polymorphism in Clinical Actinobacillus actinomycetemcomitans
	isolates.},
  journal = {Anaerobe},
  year = {1998},
  volume = {4},
  pages = {139--144},
  number = {3},
  month = {Jun},
  abstract = {In the present study the apaH polymorphism in clinical A. actinomycetemcomitans
	isolates were investigated in relation to their serotype and periodontal
	status of the donor subjects. The material included 122A. actinomycetemcomitans
	isolates representing serotypes a-e from 103 periodontally healthy
	and diseased subjects. The apaH polymorphism was investigated by
	both restriction analysis of the specific PCR amplification product
	and also by sequencing of PCR amplification products from selected
	clinical isolates. An apaH specific PCR amplification product was
	obtained from all isolates but the restriction patterns of the amplification
	products varied. Serotype c and genogroup 2 within serotype e formed
	genetically distinct groups, whereas isolates of serotype a, b, d
	and genogroup 1 within serotype e could not be separated from each
	other based on the apaH restriction analysis. No relation between
	the restriction pattern of apaH and the periodontal status of the
	individuals was detected. These results indicate that serotype c
	isolates form a uniformly distinct group within A. actinomycetemcomitans
	and that a subpopulation of serotype e isolates clearly diverge from
	all other A. actinomycetemcomitans isolates.},
  doi = {10.1006/anae.1998.0158},
  institution = {Institute of Dentistry, University of Helsinki, University of Helsinki,
	Finland. Maria.Saarela@VTT.fi},
  owner = {pl4},
  pii = {S1075-9964(98)90158-5},
  pmid = {16887634},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1006/anae.1998.0158}
}

@ARTICLE{Saarela1995,
  author = {M. Saarela and S. Asikainen and C. Chen and S. Alaluusua and J. Slots},
  title = {Comparison of arbitrarily primed polymerase chain reaction and ribotyping
	for subtyping Actinobacillus actinomycetemcomitans.},
  journal = {Anaerobe},
  year = {1995},
  volume = {1},
  pages = {97--102},
  number = {2},
  month = {Apr},
  abstract = {This study investigated the compatibility of arbitrarily primed polymerase
	chain reaction (AP-PCR) and ribotyping in the characterization of
	Actinobacillus actinomycetemcomitans , a major pathogen in the mixed
	anaerobic microflora of human periodontitis. AP-PCR was performed
	directly on lysed bacterial colonies using a random-sequence 10-base
	oligonucleotide primer. Ribotyping was carried out by using purified
	bacterial chromosomal DNA digested with BglI. DNA fragments were
	separated electrophoretically, blotted onto a nylon membrane and
	hybridized with the plasmid pKK3535 containing the rRNA operon of
	Escherichia coli. The two genetic methods were evaluated on isolates
	from single individuals and from family members. Twelve AP-PCR types
	and 47 ribotypes were distinguished among 76 A. actinomycetemcomitans
	isolates of different serotypes. AP-PCR typing and ribotyping gave
	compatible results in 18 of 20 comparisons. Although AP-PCR detected
	less genetic heterogeneity in A. actinomycetemcomitans than ribotyping,
	the rapid and relatively simple AP-PCR technique seems to be sufficiently
	discriminative to be used in large scale epidemiological studies
	which preclude the application of the more laborious ribotyping technique.},
  doi = {10.1006/anae.1995.1004},
  institution = {Institute of Dentistry, University of Helsinki, Helsinki, Finland.},
  owner = {pl4},
  pii = {S1075-9964(85)71004-9},
  pmid = {16887513},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1006/anae.1995.1004}
}

@ARTICLE{Saarela2007c,
  author = {Maria Saarela and Johanna Maukonen and Atte von Wright and Terttu
	Vilpponen-Salmela and Andrea J Patterson and Karen P Scott and Heikki
	H\"{a}mynen and Jaana M\"{a}tt\"{o}},
  title = {Tetracycline susceptibility of the ingested Lactobacillus acidophilus
	LaCH-5 and Bifidobacterium animalis subsp. lactis Bb-12 strains during
	antibiotic/probiotic intervention.},
  journal = {Int J Antimicrob Agents},
  year = {2007},
  volume = {29},
  pages = {271--280},
  number = {3},
  month = {Mar},
  abstract = {We investigated the effects of oral therapy with doxycycline, a tetracycline
	group antibiotic, on the gastrointestinal (GI) survival and tetracycline
	susceptibility of probiotic strains Lactobacillus acidophilus LaCH-5
	and Bifidobacterium animalis subsp. lactis Bb-12. In addition, the
	influence of doxycycline therapy on the diversity of the predominant
	faecal microbiota was evaluated by polymerase chain reaction-denaturing
	gradient gel electrophoresis (PCR-DGGE). Faecal samples from the
	antibiotic group (receiving antibiotics and probiotics) and the control
	group (receiving probiotics only) were analysed for anaerobically
	and aerobically growing bacteria, bifidobacteria and lactic acid
	bacteria as well as for the dominant microbiota. Although doxycycline
	consumption did not have a large impact on GI survival of the probiotics,
	it had a detrimental effect on the bifidobacteria and on the diversity
	of the dominant faecal microbiota. A higher proportion of tetracycline-resistant
	anaerobically growing bacteria and bifidobacteria was detected in
	the antibiotic group than in the control group. Several antibiotic
	group subjects had faecal B. animalis subsp. lactis Bb-12-like isolates
	with reduced tetracycline susceptibility. This was unlikely to be
	due to the acquisition of novel tetracycline resistance determinants,
	since only tet(W), which is also present in the ingested B. animalis
	subsp. lactis Bb-12, was found in the resistant isolates. Thus, concomitant
	ingestion of probiotic L. acidophilus LaCH-5 and B. animalis subsp.
	lactis Bb-12 with the antibiotic did not generate a safety risk regarding
	the possible GI transfer of tetracycline resistance genes to the
	ingested strains.},
  doi = {10.1016/j.ijantimicag.2006.09.020},
  institution = {VTT, Biotechnology, P.O. Box 1000, FI-02044 VTT, Finland. maria.saarela@vtt.fi},
  owner = {pl4},
  pii = {S0924-8579(06)00436-5},
  pmid = {17207972},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1016/j.ijantimicag.2006.09.020}
}

@ARTICLE{Saarela1999,
  author = {M. Saarela and J. Valvanne},
  title = {[Efficacy of geriatric rehabilitation].},
  journal = {Duodecim},
  year = {1999},
  volume = {115},
  pages = {1611--1618},
  number = {15},
  institution = {Kustaankartanon vanhustenkeskus Kivalterintie 16 K, 00620 Helsinki.
	mika.saarela@pp.fimnet.fi},
  owner = {pl4},
  pmid = {11912751},
  timestamp = {2011.05.26}
}

@ARTICLE{Saarela2007d,
  author = {Miiamaaria V Saarela and Yevhen Hlushchuk and Amanda C de C Williams
	and Martin Sch\"{u}rmann and Eija Kalso and Riitta Hari},
  title = {The compassionate brain: humans detect intensity of pain from another's
	face.},
  journal = {Cereb Cortex},
  year = {2007},
  volume = {17},
  pages = {230--237},
  number = {1},
  month = {Jan},
  abstract = {Understanding another person's experience draws on "mirroring systems,"
	brain circuitries shared by the subject's own actions/feelings and
	by similar states observed in others. Lately, also the experience
	of pain has been shown to activate partly the same brain areas in
	the subjects' own and in the observer's brain. Recent studies show
	remarkable overlap between brain areas activated when a subject undergoes
	painful sensory stimulation and when he/she observes others suffering
	from pain. Using functional magnetic resonance imaging, we show that
	not only the presence of pain but also the intensity of the observed
	pain is encoded in the observer's brain-as occurs during the observer's
	own pain experience. When subjects observed pain from the faces of
	chronic pain patients, activations in bilateral anterior insula (AI),
	left anterior cingulate cortex, and left inferior parietal lobe in
	the observer's brain correlated with their estimates of the intensity
	of observed pain. Furthermore, the strengths of activation in the
	left AI and left inferior frontal gyrus during observation of intensified
	pain correlated with subjects' self-rated empathy. These findings
	imply that the intersubjective representation of pain in the human
	brain is more detailed than has been previously thought.},
  doi = {10.1093/cercor/bhj141},
  institution = {Brain Research Unit, Low Temperature Laboratory, Helsinki University
	of Technology, Espoo, Finland. miiu@neuro.hut.fi},
  owner = {pl4},
  pii = {bhj141},
  pmid = {16495434},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1093/cercor/bhj141}
}

@ARTICLE{Saarela2006,
  author = {Riika Saarela and Kalevi Laitinen},
  title = {[Not Available].},
  journal = {Duodecim},
  year = {2006},
  volume = {122},
  pages = {2759, 2761},
  number = {22},
  institution = {Hyvink\"{a}\"{a}n sairaala.},
  owner = {pl4},
  pmid = {17240902},
  timestamp = {2011.05.26}
}

@ARTICLE{Saarela2006a,
  author = {Tanja Saarela and Mikko Hiltunen and Seppo Helisalmi and Seppo Heinonen
	and Markku Laakso},
  title = {Polymorphisms of interleukin-6, hepatic lipase and calpain-10 genes,
	and preeclampsia.},
  journal = {Eur J Obstet Gynecol Reprod Biol},
  year = {2006},
  volume = {128},
  pages = {175--179},
  number = {1-2},
  abstract = {We determined whether single nucleotide polymorphisms (SNPs) in interleukin-6
	(IL-6), hepatic lipase (HL) and calpain-10 (CAPN-10) genes contribute
	to susceptibility to develop preeclampsia.The study involved 133
	preeclamptic and 115 healthy pregnant women who were genotyped for
	the C-174G polymorphism in the IL-6 gene, the G-250A polymorphism
	in the HL gene and SNP 43 (G/A) in the CAPN-10 gene. The chi2-test
	was used to assess genotype and allele frequency differences between
	the preeclamptic and control groups.No significant differences were
	detected in genotype and allele distributions of the C-174G polymorphism
	in the IL-6 gene, between the preeclampsia and control groups (p=0.98
	and 0.85, respectively). With respect to the G-250A polymorphism
	in the HL gene, the genotype and allele distributions were similar
	in both groups (p=0.64 and 0.48, respectively). The genotype and
	allele distributions of SNP 43 in the CAPN-10 gene also showed no
	statistical differences in the preeclampsia and control groups (p=0.73
	and 0.45, respectively).The C-174G polymorphism in the IL-6 gene,
	the G-250A polymorphism in the HL gene and SNP 43 (G/A) in the CAPN-10
	gene are unlikely to be major genetic factors predisposing Finnish
	women to preeclampsia.},
  doi = {10.1016/j.ejogrb.2005.12.015},
  institution = {Department of Obstetrics and Gynecology, University of Kuopio, Finland.},
  owner = {pl4},
  pii = {S0301-2115(06)00019-4},
  pmid = {16427731},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1016/j.ejogrb.2005.12.015}
}

@ARTICLE{Saarela1999a,
  author = {T. Saarela and P. Lanning and M. Koivisto and T. Paavilainen},
  title = {Nephrocalcinosis in full-term infants receiving furosemide treatment
	for congestive heart failure: a study of the incidence and 2-year
	follow up.},
  journal = {Eur J Pediatr},
  year = {1999},
  volume = {158},
  pages = {668--672},
  number = {8},
  month = {Aug},
  abstract = {In order to study the incidence and course of nephrocalcinosis in
	full-term infants with congestive heart failure receiving long-term
	furosemide treatment, 36 such infants (median age 2.9 months, range
	1.2-8.0) and 36 full-term control infants not receiving any diuretics
	(median age 3.4 months, range 1.1-8.4) were studied by renal ultrasonography
	and random urine calcium variables. The infants with nephrocalcinosis
	were followed at 3-6 month intervals up to 2 years of age, or until
	ultrasonic resolution. Nephrocalcinosis was found in 5 out of the
	36 (14\%) treated infants, but in none of the controls (P = 0.03).
	The dose of furosemide was higher in the infants with nephrocalcinosis
	than in those without (1.9+/-0.6 vs. 1.3+/-0.4 mg/kg per day; P =
	0.01). The urinary calcium concentration was higher in the infants
	receiving furosemide than in controls and a similar trend was observed
	in the urinary calcium/creatinine ratio, but these variables did
	not differ between the study infants with and without nephrocalcinosis.
	Ultrasonic resolution of nephrocalcinosis was observed in 3 of the
	5 infants at 12 months, but in the other 2 the condition still persisted
	at 24 months. CONCLUSIONS: Long-term furosemide treatment in full-term
	infants with congestive heart failure entails a considerable risk
	of developing nephrocalcinosis. Renal ultrasonography is warranted
	in these patients within a few months after initiation of the treatment
	and in the case of nephrocalcinosis alteration of the diuretic regimen
	is to be considered.},
  institution = {Department of Paediatrics, University of Oulu, Finland.},
  owner = {pl4},
  pmid = {10445348},
  timestamp = {2011.05.26}
}

@ARTICLE{Salim2009,
  author = {Salim, Agus and Hultman, Christina and Spar{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¬ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¬ P{\AA}Â£ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â°ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â and Reilly, Marie},
  title = {Combining data from 2 nested case-control studies of overlapping
	cohorts to improve efficiency.},
  journal = {Biostatistics},
  year = {2009},
  volume = {10},
  pages = {70--79},
  number = {1},
  month = {Jan},
  abstract = {Researchers subject to time and budget constraints may conduct small
	nested case-control studies with individually matched controls to
	help optimize statistical power. In this paper, we show how precision
	can be improved considerably by combining data from a small nested
	case-control study with data from a larger nested case-control study
	of a different outcome in the same or overlapping cohort. Our approach
	is based on the inverse probability weighting concept, in which the
	log-likelihood contribution of each individual observation is weighted
	by the inverse of its probability of inclusion in either study. We
	illustrate our approach using simulated data and an application where
	we combine data sets from 2 nested case-control studies to investigate
	risk factors for anorexia nervosa in a cohort of young women in Sweden.},
  doi = {10.1093/biostatistics/kxn016},
  institution = {Department of Community, Occupational and Family Medicine, Yong Loo
	Lin School of Medicine, National University of Singapore.},
  keywords = {Anorexia Nervosa, epidemiology/etiology; Biometry, methods; Case-Control
	Studies; Cohort Studies; Data Collection, methods; Female; Humans;
	Likelihood Functions; Meta-Analysis as Topic; Proportional Hazards
	Models; Psychotic Disorders, epidemiology/etiology; Risk Factors;
	Sample Size; Schizophrenia, epidemiology/etiology; Sweden},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {kxn016},
  pmid = {18550564},
  timestamp = {2013.03.25},
  url = {http://dx.doi.org/10.1093/biostatistics/kxn016}
}

@ARTICLE{Sallinen2007a,
  author = {Pirkko Sallinen and Satu M\"{a}ntt\"{a}ri and Hanna Leskinen and
	Mika Ilves and Olli Vakkuri and Heikki Ruskoaho and Seppo Saarela},
  title = {The effect of myocardial infarction on the synthesis, concentration
	and receptor expression of endogenous melatonin.},
  journal = {J Pineal Res},
  year = {2007},
  volume = {42},
  pages = {254--260},
  number = {3},
  month = {Apr},
  abstract = {We examined the time course of changes in the synthesis and levels
	of endogenous melatonin and in the expression of MT(1) and MT(2)
	melatonin receptors 1 day, 2 and 4 wk after myocardial infarction
	(MI) in rats. MI was produced by ligation of the left anterior descending
	coronary artery. Transthoracic echocardiography was performed to
	characterize structural and functional changes after MI. mRNA levels
	were measured by real-time quantitative reverse transcription-polymerase
	chain reaction and proteins by Western blotting. One day after infarction,
	MI rats had 4.3 times (P < 0.001) higher pineal melatonin synthesis,
	than sham-operated animals, which was associated with the increased
	concentration of melatonin in plasma (P < 0.001) and left ventricle
	(LV) (P = 0.01). The amount of MT(1) receptor protein decreased significantly
	in MI LVs compared with control LVs 1 day after infarction (P < 0.01),
	followed by recovery during the next 2 wk. Furthermore, the expression
	of MT(1) receptor mRNA of the MI LVs was elevated 2 wk after infarction
	(P < 0.01) compared with control LVs. The amount of MT(2) receptor
	proteins in MI LVs was higher than in sham-operated LVs 1 day (P
	< 0.05) and 4 wk (P < 0.01) after MI. In conclusion, melatonin synthesis
	in the pineal gland increased rapidly in response to the MI, supporting
	an important role for endogenous melatonin in protecting the heart
	after MI. The observed changes in the expression of MT(1) and MT(2)
	receptors suggest that melatonin receptors may be involved in mediating,
	at least, in part, the protective effects of melatonin in the heart
	after infarction.},
  doi = {10.1111/j.1600-079X.2006.00413.x},
  institution = {Department of Biology, University of Oulu, Oulu, Finland. pirkko.sallinen@oulu.fi},
  owner = {pl4},
  pii = {JPI413},
  pmid = {17349023},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1111/j.1600-079X.2006.00413.x}
}

@ARTICLE{Samphier1988,
  author = {Samphier, M. L. and Robertson, C. and Bloor, M. J.},
  title = {A Possible Artefactual Component in Specific Cause Mortality Gradients:
	Social Class Variations in the Clinical Accuracy of Death Certificates},
  journal = {Journal of Epidemiology and Community Health},
  year = {1988},
  volume = {42},
  pages = {138-143},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Samuelsen1997,
  author = {Samuelsen, S. O.},
  title = {A pseudolikelhood approach to analysis of nested case-control studies},
  journal = {Biometrika},
  year = {1997},
  volume = {84},
  pages = {379-394},
  file = {Samuelsen1997.pdf:Samuelsen1997.pdf:PDF},
  owner = {pl4},
  timestamp = {2013.03.21}
}

@ARTICLE{Samuelsen2007,
  author = {Samuelsen, S. O. and {\AA}Â…nstead, H. and Skrondal A.},
  title = {Stratified case-cohort analysis of general cohort sampling designs},
  journal = {Scandinavian Journal of Statistics},
  year = {2007},
  volume = {34},
  pages = {103-119},
  file = {Samuelsen2007.pdf:Samuelsen2007.pdf:PDF;Samuelsen2007.pdf:pdf\\Samuelsen2007.pdf:PDF},
  owner = {pl4},
  timestamp = {2013.07.05}
}

@ARTICLE{Samuelsen2008,
  author = {Samuelsen, Sven Ove and Eide, Geir Egil},
  title = {Attributable fractions with survival data.},
  journal = {Stat Med},
  year = {2008},
  volume = {27},
  pages = {1447--1467},
  number = {9},
  month = {Apr},
  abstract = {Attributable fraction (AF) is an important concept in clinical and
	epidemiological studies. The concept has mainly been discussed in
	relation to case-control studies, cross-sectional studies, and follow-up
	studies of fixed length. Here, we propose and discuss several ways
	of defining and estimating AFs with right-censored survival data,
	and thus with varying lengths of follow-up. In particular, we define
	the attributable hazard fraction, the AF before time t, and the AF
	within study. These measures have different interpretations and may
	give different numerical values, as illustrated in an application
	to real data on time to the first receiving of cash benefits for
	hearing impairment in children. The results underline the need for
	careful selection of the type of measure and interpretation when
	reporting AFs for survival data.},
  doi = {10.1002/sim.3022},
  file = {Samuelsen2008.pdf:pdf\\Samuelsen2008.pdf:PDF;Samuelsen2008.pdf:Samuelsen2008.pdf:PDF},
  institution = {Department of Mathematics, University of Oslo, Oslo, Norway. osamuels@math.uio.no},
  keywords = {Bias (Epidemiology); Biometry; Confidence Intervals; Hearing Loss,
	epidemiology/etiology; Humans; Infant, Low Birth Weight; Infant,
	Newborn; Models, Statistical; Proportional Hazards Models; Survival
	Analysis},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pmid = {17694507},
  timestamp = {2015.03.25},
  url = {http://dx.doi.org/10.1002/sim.3022}
}

@ARTICLE{Sandiford2015,
  author = {Sandiford, Peter and Abdel-Rahman, Manar E. and Allemani, Claudia
	and Coleman, Michel P. and Gala, Geeta},
  title = {How many cancer deaths could New Zealand avoid if five-year relative
	survival ratios were the same as in Australia?},
  journal = {Aust N Z J Public Health},
  year = {2015},
  month = {Feb},
  abstract = {Aim: To determine how many M?ori and non-M?ori deaths might have been
	avoidable if cancer survival in New Zealand were as high as in Australia.
	Methods: Age-sex-tumour specific five-year relative survival ratios
	were calculated for cancer patients diagnosed with 27 tumour sites
	(representing about 92\% of all cancers) in 2006-10. These were used
	to estimate the number of M?ori, non-M?ori and total deaths (and
	proportion of excess deaths) that would have been avoidable within
	five years of diagnosis had New Zealand's relative survival been
	equivalent to Australia's. Results: A total of 3,631 cancer deaths
	(726/year; 13.4\% of excess deaths) could have been avoidable. Among
	25 tumours where ethnic-specific results were estimated, there were
	851 potentially avoidable deaths in M?ori (24.9\%) and 2,758 in non-M?ori
	(11.8\%). Breast, bowel, lung and prostate tumours made up 64\% of
	avoidable deaths. Those with the highest proportions of avoidable
	deaths were thyroid (44.7\%), prostate (35.5\%), breast (30.0\%)
	and uterus (23.5\%). More than 50\% of M?ori melanoma, prostate,
	testis and thyroid cancer deaths were avoidable. Conclusion: A significant
	number of cancer deaths could be avoidable if New Zealand achieved
	Australia's relative survival ratios. The proportion is much higher
	for M?ori than for non-M?ori. Implications: There is considerable
	scope to improve cancer outcomes in New Zealand.},
  doi = {10.1111/1753-6405.12344},
  institution = {Planning, Funding and Outcomes Division, Waitemata District Health
	Board, New Zealand.},
  language = {eng},
  medline-pst = {aheadofprint},
  owner = {PaulD},
  pmid = {25716332},
  timestamp = {2015.03.24},
  url = {http://dx.doi.org/10.1111/1753-6405.12344}
}

@ARTICLE{Sankila1998,
  author = {Sankila, R. and Hakulinen, T.},
  title = {Survival of Patients with Colorectal Carcinoma: {E}ffect of Prior
	Breast Cancer},
  journal = {Journal of the National Cancer Institute},
  year = {1998},
  volume = {90},
  pages = {63-65},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Sankila1995,
  author = {Sankila, R. and Pukkala, E. and Teppo, L.},
  title = {Risk of Subsequent Malignant Neoplasms among 470,000 Cancer Patients
	in {F}inland, 1953--1991},
  journal = {International Journal of Cancer},
  year = {1995},
  volume = {60},
  pages = {464-470},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Sant2004,
  author = {Milena Sant and Claudia Allemani and Franco Berrino and Michel P
	Coleman and Tiiu Aareleid and Gilles Chaplain and Jan Willem Coebergh
	and Marc Colonna and Paolo Crosignani and Arlette Danzon and Massimo
	Federico and Lorenzo Gaf{\AA}ÂƒÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â  and Pascale Grosclaude and Guy H\'{e}delin
	and Josette Mac\`{e}-Lesech and Carmen Martinez Garcia and Henrik
	M{\o}ller and Eugenio Paci and Nicole Raverdy and Brigitte Tretarre
	and Evelyn M I Williams and European Concerted Action on Survival
	and Care of Cancer Patients (EUROCARE) Working Group},
  title = {{B}reast carcinoma survival in {E}urope and the {U}nited {S}tates.},
  journal = {Cancer},
  year = {2004},
  volume = {100},
  pages = {715--722},
  number = {4},
  month = {Feb},
  abstract = {BACKGROUND: Breast carcinoma survival rates were found to be higher
	in the U.S. than in Europe. METHODS: Multiple regression analysis
	of breast carcinoma survival rates among women diagnosed between
	1990 and 1992 was performed using clinical data from population-based
	case series from the Surveillance, Epidemiogy, and End Results (SEER)
	program (13,172 women) and the European Concerted Action on survival
	and Care of Cancer Patients (EUROCARE) project (4478 women). RESULTS:
	Early-stage tumors (T1N0M0) were more frequent in the SEER data (41\%
	of cases) than in the EUROCARE data (29\%). In the SEER data, early
	tumors were more frequent in women age > or = 65 years (43\%) than
	in younger women (38\%), whereas the reverse was true in the European
	data (25\% vs. 31\%). In both case series, > 90\% of women underwent
	surgery and 81-82\% underwent lymphadenectomy, but the number of
	axillary lymph nodes evaluated was higher in the SEER data than in
	the EUROCARE data. The 5-year survival rate was higher in the U.S.
	case series (89\%) than in the European series (79\%). This differential
	was observed for each stage category evaluated: early (T1N0M0), large
	lymph node-negative (T2-3N0M0), lymph node-positive (T1-3N+M0), locally
	advanced (T4M0), and metastatic (M1) tumors. The overall relative
	excess risk (RER) of death was significantly higher (RER, 1.37; 95\%
	confidence interval [95\% CI], 1.25-1.50) among European women compared
	with U.S. women (referent group). Adjustment for stage, age, surgery,
	and the number of lymph nodes evaluated explained most of the excess
	risk (RER, 1.07; 95\% CI, 0.98-1.17). CONCLUSIONS: Transatlantic
	differences in the 5-year survival rates for women diagnosed with
	breast carcinoma between 1990 and 1992 were attributable mainly to
	differences in stage of disease. Resources should be invested to
	achieve earlier diagnosis of breast carcinoma in Europe, especially
	for elderly women.},
  owner = {PaulD},
  pmid = {14770426},
  timestamp = {2006.04.26}
}

@ARTICLE{Sant2003,
  author = {Milena Sant and Claudia Allemani and Riccardo Capocaccia and Timo
	Hakulinen and Tiiu Aareleid and Jan Willem Coebergh and Michel P
	Coleman and Pascale Grosclaude and Carmen Martinez and Janine Bell
	and Judith Youngson and Franco Berrino and E. U. R. O. C. A. R. E.
	Working Group},
  title = {Stage at diagnosis is a key explanation of differences in breast
	cancer survival across Europe},
  journal = {International Journal of Cancer},
  year = {2003},
  volume = {106},
  pages = {416--422},
  number = {3},
  month = {Sep},
  abstract = {We used multiple regression models to assess the influence of disease
	stage at diagnosis on the 5-year relative survival of 4,478 patients
	diagnosed with breast cancer in 1990-1992. The cases were representative
	samples from 17 population-based cancer registries in 6 European
	countries (Estonia, France, Italy, Netherlands, Spain and UK) that
	were combined into 9 regional groups based on similar survival. Five-year
	relative survival was 79\% overall, varying from 98\% for early,
	node-negative (T1N0M0) tumours; 87\% for large, node-negative (T2-3N0M0)
	tumours; 76\% for node-positive (T1-3N+M0) tumours and 55\% for locally
	advanced (T4NxM0) tumours to 18\% for metastatic (M1) tumours and
	69\% for tumours of unspecified stage. There was considerable variation
	across Europe in relative survival within each disease stage, but
	this was least marked for early node-negative tumours. Overall 5-year
	relative survival was highest in the French group of Bas-Rhin, C{\AA}ÂƒÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â´te
	d'Or, H\'{e}rault and Is\`{e}re (86\%), and lowest in Estonia (66\%).
	These geographic groups were characterised by the highest and lowest
	percentages of women with early stage disease (T1N0M0: 39\% and 9\%,
	respectively). The French, Dutch and Italian groups had the highest
	percentage of operated cases. The number of axillary nodes examined,
	a factor influencing nodal status, was highest in Italy and Spain.
	After adjusting for TNM stage and the number of nodes examined, survival
	differences were greatly reduced, indicating that for these women,
	diagnosed with breast cancer in Europe during 1990-1992, the survival
	differences were mainly due to differences in stage at diagnosis.
	However, in 3 regional groups, the relative risks of death remained
	high even after these adjustments, suggesting less than optimal treatment.
	Screening for breast cancer did not seem to affect the survival patterns
	once stage had been taken into account.},
  file = {Sant2003.pdf:Sant2003.pdf:PDF;Sant2003.pdf:pdf\\Sant2003.pdf:PDF},
  institution = {Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei
	Tumori, Via Venezian 1, I-20133 Milan, Italy. milena.sant@istitutotumori.mi.it},
  owner = {pl4},
  pmid = {12845683},
  timestamp = {2010.03.19}
}

@ARTICLE{Sant2009,
  author = {M. Sant and C. Allemani and M. Santaquilani and A. Knijn and F. Marchesi
	and R. Capocaccia and {EUROCARE} Working Group},
  title = {{EUROCARE}-4. Survival of cancer patients diagnosed in 1995-1999:
	Results and commentary},
  journal = {European Journal of Cancer},
  year = {2009},
  volume = {45},
  pages = {931--991},
  number = {6},
  month = {Apr},
  abstract = {EUROCARE-4 analysed about three million adult cancer cases from 82
	cancer registries in 23 European countries, diagnosed in 1995-1999
	and followed to December 2003. For each cancer site, the mean European
	area-weighted observed and relative survival at 1-, 3-, and 5-years
	by age and sex are presented. Country-specific 1- and 5-year relative
	survival is also shown, together with 5-year relative survival conditional
	to surviving 1-year. Within-country variation in survival is analysed
	for selected cancers. Survival for most solid cancers, whose prognosis
	depends largely on stage at diagnosis (breast, colorectum, stomach,
	skin melanoma), was highest in Finland, Sweden, Norway and Iceland,
	lower in the UK and Denmark, and lowest in the Czech Republic, Poland
	and Slovenia. France, Switzerland and Italy generally had high survival,
	slightly below that in the northern countries. There were between-region
	differences in the survival for haematologic malignancies, possibly
	due to differences in the availability of effective treatments. Survival
	of elderly patients was low probably due to advanced stage at diagnosis,
	comorbidities, difficult access or lack of availability of appropriate
	care. For all cancers, 5-year survival conditional to surviving 1-year
	was higher and varied less with region, than the overall relative
	survival.},
  doi = {10.1016/j.ejca.2008.11.018},
  file = {Sant2009.pdf:Sant2009.pdf:PDF;Sant2009.pdf:pdf\\Sant2009.pdf:PDF},
  institution = {Department of Preventive and Predictive Medicine, Fondazione IRCCS
	Istituto Nazionale dei Tumori, Milan, Italy. milena.sant@istitutotumori.mi.it},
  owner = {pl4},
  pii = {S0959-8049(08)00926-X},
  pmid = {19171476},
  timestamp = {2010.03.19},
  url = {http://dx.doi.org/10.1016/j.ejca.2008.11.018}
}

@ARTICLE{Sarfati2012,
  author = {Sarfati, Diana},
  title = {Review of methods used to measure comorbidity in cancer populations:
	no gold standard exists.},
  journal = {J Clin Epidemiol},
  year = {2012},
  volume = {65},
  pages = {924--933},
  number = {9},
  month = {Sep},
  abstract = {This article reviews methods used to measure comorbidity in the context
	of cancer; summarizing methods, identifying contexts in which they
	have been used, and assessing the validity, reliability, and feasibility
	of each approach.Studies describing methods to measure comorbidity
	in epidemiological studies related to cancer were identified. Data
	relating to content, face, and criterion validity, reliability, and
	feasibility were collected.Two thousand nine hundred seventy-five
	abstracts were reviewed and 21 separate approaches identified. Content
	and face validity varied but tended to be higher for measures developed
	for cancer populations. Some evidence supporting criterion validity
	of all approaches was found. Where reported, reliability tended to
	be moderate to high. Some approaches tended to score well on all
	aspects but were resource intensive in terms of data collection.
	Eight indices scored at least moderately well on all criteria, three
	of which demonstrated usefulness in relation to non-site specific
	cancer (Charlson Comorbidity Index, Elixhauser approach, and National
	Cancer Institute [Combined] Index).No gold standard approach to measuring
	comorbidity in the context of cancer exists. Approaches vary in their
	strengths and weaknesses, with the choice of measure depending on
	the study question, population studied, and data available.},
  doi = {10.1016/j.jclinepi.2012.02.017},
  file = {Sarfati2012.pdf:pdf\\Sarfati2012.pdf:PDF;Sarfati2012.pdf:Sarfati2012.pdf:PDF},
  institution = {Cancer Control and Screening Research Group, Department of Public
	Health, University of Otago, PO Box 7343, Wellington South 6242,
	New Zealand. diana.sarfati@otago.ac.nz},
  keywords = {Comorbidity; Epidemiologic Methods; Health Status Indicators; Humans;
	Neoplasms, epidemiology; Reproducibility of Results; Severity of
	Illness Index},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pii = {S0895-4356(12)00078-9},
  pmid = {22739245},
  timestamp = {2014.03.07},
  url = {http://dx.doi.org/10.1016/j.jclinepi.2012.02.017}
}

@ARTICLE{Sarfati2010,
  author = {D. Sarfati and T. Blakely and N. Pearce},
  title = {Measuring cancer survival in populations: relative survival vs cancer-specific
	survival.},
  journal = {International Journal of Epidemiology},
  year = {2010},
  volume = {39},
  pages = {598-610},
  month = {Feb},
  abstract = {BACKGROUND: Two main methods of quantifying cancer patient survival
	are generally used: cancer-specific survival and relative survival.
	Both techniques are used to estimate survival in a single population,
	or to estimate differences in survival between populations. Arguments
	have been made that the relative survival approach is the only valid
	choice for population-based cancer survival studies because cancer-specific
	survival estimates may be invalid if there is misclassification of
	the cause of death. However, there has been little discussion, or
	evidence, as to how strong such biases may be, or of the potential
	biases that may result using relative survival techniques, particularly
	bias arising from the requirement for an external comparison group.
	METHODS: In this article we investigate the assumptions underlying
	both methods of survival analysis. We provide simulations relating
	to the impact of misclassification of death and non-comparability
	of expected survival for cause-specific and relative survival approaches,
	respectively. RESULTS: For cause-specific analyses, bias through
	misclassification of cause of death resulted in error in descriptive
	analyses particularly of cancers with moderate or poor survival,
	but had smaller impact in analyses involving group comparisons. Relative
	survival ratio (RSR) estimations were robust in relation to non-comparability
	of comparison populations for single RSR but were less so in group
	comparisons where there was large variation in survival. CONCLUSIONS:
	Both cause-specific survival and relative survival are potentially
	valid epidemiological methods in population-based cancer survival
	studies, and the choice of method is dependent on the likely magnitude
	and direction of the biases in the specific analyses to be conducted.},
  doi = {10.1093/ije/dyp392},
  file = {Sarfati2010.pdf:Sarfati2010.pdf:PDF;Sarfati2010.pdf:pdf\\Sarfati2010.pdf:PDF},
  institution = {Department of Public Health, University of Otago Wellington, Wellington,
	New Zealand and Centre for Public Health Research, Massey University,
	Wellington, New Zealand.},
  owner = {pl4},
  pii = {dyp392},
  pmid = {20142331},
  timestamp = {2010.03.23},
  url = {http://dx.doi.org/10.1093/ije/dyp392}
}

@ARTICLE{Sarfati2013,
  author = {Sarfati, Diana and Gurney, Jason and Lim, Bee Teng and Bagheri, Nasser
	and Simpson, Andrew and Koea, Jonathan and Dennett, Elizabeth},
  title = {Identifying important comorbidity among cancer populations using
	administrative data: Prevalence and impact on survival.},
  journal = {Asia Pac J Clin Oncol},
  year = {2013},
  month = {Dec},
  abstract = {Our study sought to optimize the identification and investigate the
	impact of comorbidity in cancer patients using routinely collected
	hospitalization data.We undertook an iterative process of classification
	of important clinical conditions involving evaluation of relevant
	literature and consultation with clinicians. Patients diagnosed with
	colon, rectal, breast, ovarian, uterine, stomach, liver, renal or
	bladder cancers (n?=?14?096) between 2006 and 2008 were identified
	from the New Zealand Cancer Registry. Conditions were identified
	using data on diagnoses from hospital admissions for 5?years prior
	to cancer diagnosis. Patients were followed up until end of 2009
	using routine mortality data. Prevalence estimates for each condition
	by site were calculated. All-cause mortality impact of common conditions
	was investigated using Cox regression models adjusted for age and
	stage at diagnosis.Patients with liver and stomach cancers tended
	to have higher comorbidity and those with breast cancer, lower comorbidity
	than other cancer patients. Of the 50 conditions, the most common
	were hypertension (prevalence 8.0-20.9\%), cardiac conditions (2.1-13.5\%)
	and diabetes with (2.3-13.3\%) and without (2.9-12.9\%) complications.
	Comorbidity was associated with higher all-cause mortality but the
	impact varied by condition and across cancer site, with impact less
	for cancers with poor prognoses. Conditions most consistently associated
	with adverse outcomes across all cancer sites were renal disease,
	coagulopathies and congestive heart failure.Comorbidity is highly
	prevalent in cancer populations, but prevalence and impact of conditions
	differ markedly by cancer type.},
  doi = {10.1111/ajco.12130},
  file = {Sarfati2013.pdf:pdf\\Sarfati2013.pdf:PDF;Sarfati2013.pdf:Sarfati2013.pdf:PDF},
  institution = {Department of Public Health, University of Otago, Wellington, New
	Zealand.},
  language = {eng},
  medline-pst = {aheadofprint},
  owner = {PaulD},
  pmid = {24354451},
  timestamp = {2014.03.07},
  url = {http://dx.doi.org/10.1111/ajco.12130}
}

@ARTICLE{Sarfati2014,
  author = {Sarfati, Diana and Gurney, Jason and Stanley, James and Salmond,
	Clare and Crampton, Peter and Dennett, Elizabeth and Koea, Jonathan
	and Pearce, Neil},
  title = {Cancer-specific administrative data-based comorbidity indices provided
	valid alternative to Charlson and National Cancer Institute Indices.},
  journal = {J Clin Epidemiol},
  year = {2014},
  month = {Feb},
  abstract = {We aimed to develop and validate administrative data-based comorbidity
	indices for a range of cancer types that included all relevant concomitant
	conditions.Patients diagnosed with colorectal, breast, gynecological,
	upper gastrointestinal, or urological cancers identified from the
	National Cancer Registry between July 1, 2006 and June 30, 2008 for
	the development cohort (n=14,096) and July 1, 2008 to December 31,
	2009 for the validation cohort (n=11,014) were identified. A total
	of 50 conditions were identified using hospital discharge data before
	cancer diagnosis. Five site-specific indices and a combined site
	index were developed, with conditions weighted according to their
	log hazard ratios from age- and stage-adjusted Cox regression models
	with noncancer death as the outcome. We compared the performance
	of these indices (the C3 indices) with the Charlson and National
	Cancer Institute (NCI) comorbidity indices.The correlation between
	the Charlson and C3 index scores ranged between 0.61 and 0.78. The
	C3 index outperformed the Charlson and NCI indices for all sites
	combined, colorectal, and upper gastrointestinal cancer, performing
	similarly for urological, breast, and gynecological cancers.The C3
	indices provide a valid alternative to measuring comorbidity in cancer
	populations, in some cases providing a modest improvement over other
	indices.},
  doi = {10.1016/j.jclinepi.2013.11.012},
  file = {Sarfati2014.pdf:pdf\\Sarfati2014.pdf:PDF;Sarfati2014.pdf:Sarfati2014.pdf:PDF},
  institution = {Centre for Public Health Research, Massey University, PO Box 756,
	Wellington 6022, New Zealand; Department of Medical Statistics, London
	School of Hygiene and Tropical Medicine, Keppell Street, Bloomsbury,
	London WC1E7HT, UK.},
  language = {eng},
  medline-pst = {aheadofprint},
  owner = {PaulD},
  pii = {S0895-4356(13)00487-3},
  pmid = {24582212},
  timestamp = {2014.03.07},
  url = {http://dx.doi.org/10.1016/j.jclinepi.2013.11.012}
}

@ARTICLE{Sarfati2009,
  author = {Sarfati, Diana and Hill, Sarah and Blakely, Tony and Robson, Bridget
	and Purdie, Gordon and Dennett, Elizabeth and Cormack, Donna and
	Dew, Kevin},
  title = {The effect of comorbidity on the use of adjuvant chemotherapy and
	survival from colon cancer: a retrospective cohort study.},
  journal = {BMC Cancer},
  year = {2009},
  volume = {9},
  pages = {116},
  abstract = {Comorbidity has a well documented detrimental effect on cancer survival.
	However it is difficult to disentangle the direct effects of comorbidity
	on survival from indirect effects via the influence of comorbidity
	on treatment choice. This study aimed to assess the impact of comorbidity
	on colon cancer patient survival, the effect of comorbidity on treatment
	choices for these patients, and the impact of this on survival among
	those with comorbidity.This retrospective cohort study reviewed 589
	New Zealanders diagnosed with colon cancer in 1996-2003, followed
	until the end of 2005. Clinical and outcome data were obtained from
	clinical records and the national mortality database. Cox proportional
	hazards and logistic regression models were used to assess the impact
	of comorbidity on cancer specific and all-cause survival, the effect
	of comorbidity on chemotherapy recommendations for stage III patients,
	and the impact of this on survival among those with comorbidity.After
	adjusting for age, sex, ethnicity, area deprivation, smoking, stage,
	grade and site of disease, higher Charlson comorbidity score was
	associated with poorer all-cause survival (HR = 2.63 95\%CI:1.82-3.81
	for Charlson score > or = 3 compared with 0). Comorbidity count and
	several individual conditions were significantly related to poorer
	all-cause survival. A similar, but less marked effect was seen for
	cancer specific survival. Among patients with stage III colon cancer,
	those with a Charlson score > or = 3 compared with 0 were less likely
	to be offered chemotherapy (19\% compared with 84\%) despite such
	therapy being associated with around a 60\% reduction in excess mortality
	for both all-cause and cancer specific survival in these patients.Comorbidity
	impacts on colon cancer survival thorough both physiological burden
	of disease and its impact on treatment choices. Some patients with
	comorbidity may forego chemotherapy unnecessarily, increasing avoidable
	cancer mortality.},
  doi = {10.1186/1471-2407-9-116},
  file = {Sarfati2009.pdf:pdf\\Sarfati2009.pdf:PDF;Sarfati2009.pdf:Sarfati2009.pdf:PDF},
  institution = {Department of Public Health, University of Otago Wellington, PO Box
	7343, Wellington 6242, New Zealand. diana.sarfati@otago.ac.nz},
  keywords = {Adult; Aged; Cause of Death; Chemotherapy, Adjuvant; Cohort Studies;
	Colonic Neoplasms, drug therapy/epidemiology/mortality; Comorbidity;
	Female; Heart Diseases, epidemiology; Humans; Kidney Diseases, epidemiology;
	Logistic Models; Male; Middle Aged; Neoplasm Staging; Neoplasms,
	epidemiology; New Zealand, epidemiology; Proportional Hazards Models;
	Registries, statistics /&/ numerical data; Retrospective Studies;
	Survival Analysis; Survival Rate},
  language = {eng},
  medline-pst = {epublish},
  owner = {PaulD},
  pii = {1471-2407-9-116},
  pmid = {19379520},
  timestamp = {2014.03.07},
  url = {http://dx.doi.org/10.1186/1471-2407-9-116}
}

@ARTICLE{Sarfati2010b,
  author = {Sarfati, Diana and Hill, Sarah and Purdie, Gordon and Dennett, Elizabeth
	and Blakely, Tony},
  title = {How well does routine hospitalisation data capture information on
	comorbidity in New Zealand?},
  journal = {N Z Med J},
  year = {2010},
  volume = {123},
  pages = {50--61},
  number = {1310},
  month = {Mar},
  abstract = {This study aims to assess the quality of routinely collected comorbidity
	data in New Zealand which are increasingly used in health service
	planning and research.Detailed medical notes-based comorbidity data
	from a cohort study of New Zealanders diagnosed with colon cancer
	in 1996-2003, were compared with routine hospital discharge data
	collected from the same patients using 1-year and 8-year lookback
	periods. We compared agreement between data sources for individual
	conditions, Charlson comorbidity index scores and total comorbidity
	counts using McNemar's p-test and the kappa statistic. We also assessed
	the association of comorbidity with all-cause survival using Cox
	proportional hazard models using data ascertained from the two sources.Among
	these 569 patients, we found generally higher comorbidity was measured
	from notes than administrative data, with better comparability with
	an 8-year lookback period. Regardless of source of data, all measures
	of comorbidity significantly improved the ability of multivariable
	models to explain all-cause survival, but using both data sources
	combined resulted in better risk adjustment than either source separately.While
	differences in medical notes and administrative comorbidity data
	exist, the latter provides a reasonably useful source of accessible
	information on comorbidity for risk adjustment particularly in multivariable
	models.},
  file = {Sarfati2010b.pdf:pdf\\Sarfati2010b.pdf:PDF;Sarfati2010b.pdf:Sarfati2010b.pdf:PDF},
  institution = {Department of Public Health, University of Otago, Wellington, PO
	Box 7343, Wellington South, New Zealand. diana.sarfati@otago.ac.nz},
  keywords = {Cohort Studies; Comorbidity; Data Collection, methods; Hospital Records,
	statistics /&/ numerical data; Hospitalization, statistics /&/ numerical
	data; Humans; Longitudinal Studies; Medical Records, statistics /&/
	numerical data; New Zealand; Quality Control; Vocabulary, Controlled},
  language = {eng},
  medline-pst = {epublish},
  owner = {PaulD},
  pmid = {20360779},
  timestamp = {2014.03.07}
}

@ARTICLE{Sarfati2011,
  author = {Sarfati, Diana and Tan, Lavinia and Blakely, Tony and Pearce, Neil},
  title = {Comorbidity among patients with colon cancer in New Zealand.},
  journal = {N Z Med J},
  year = {2011},
  volume = {124},
  pages = {76--88},
  number = {1338},
  month = {Jul},
  abstract = {To identify patient factors that are associated with a higher risk
	of comorbidity, and to assess the impact of comorbidity on risk of
	in-hospital death, length of stay and 5-year all-cause survival among
	a large cohort of patients with colon cancer in New Zealand.Comorbidity
	data were collected from patients who were diagnosed with colon cancer
	and admitted to public hospitals during 1996-2003. The comorbidity
	measures included all conditions listed in the Charlson Comorbidity
	Index, as well as a predetermined list of additional conditions.
	We examined predictors of higher comorbidity scores. We also measured
	the impact of comorbidity on in-hospital death, length of stay and
	5-year all-cause survival using logistic, linear and Cox proportional
	hazard regression models to adjust for confounding by sex, age, ethnicity,
	extent of disease and area level deprivation.There were 11,524 patients
	included in the study. 7.5\% of females and 10.3\% of men had Charlson
	scores of three or more. Higher comorbidity scores were associated
	with increasing age, and were more common among males, M?ori and
	Pacific people, those with unknown extent of disease and those living
	in the most deprived quintile of New Zealand. Those with Charlson
	scores ? 3 had a higher risk of in-hospital death (OR=4.8; 95\% CI
	3.5-6.6), longer lengths of hospital stay (0.14 days 95\% CI 0.08-0.2)
	and lower 5-year survival HR=2.0; 95\%CI=1.8-2.3) compared with those
	with a score of 0.This study confirms that comorbidity is common
	among colon cancer patients in New Zealand, and has an adverse and
	independent effect on outcomes related to mortality and length of
	hospital stay.},
  file = {Sarfati2011.pdf:pdf\\Sarfati2011.pdf:PDF;Sarfati2011.pdf:Sarfati2011.pdf:PDF},
  institution = {Department of Public Health, University of Otago, Wellington, PO
	Box 7343, Wellington South, New Zealand. diana.sarfati@otago.ac.nz},
  keywords = {Adult; Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases,
	ethnology/mortality; Chronic Disease; Colonic Neoplasms, mortality/pathology;
	Comorbidity; Diabetes Mellitus, ethnology/mortality; European Continental
	Ancestry Group, ethnology; Female; Hospital Mortality; Humans; Length
	of Stay; Male; Middle Aged; New Zealand, epidemiology; Oceanic Ancestry
	Group, ethnology; Prevalence; Respiratory Tract Diseases, ethnology/mortality;
	Severity of Illness Index; Sex Factors; Socioeconomic Factors; Survival
	Rate},
  language = {eng},
  medline-pst = {epublish},
  owner = {PaulD},
  pmid = {21946965},
  timestamp = {2014.03.07}
}

@Article{Sasieni2016,
  author    = {Sasieni, P.and Brentnall, A.R.},
  title     = {On standardized relative survival},
  journal   = {Biometrics},
  year      = {2016},
  volume    = {73},
  pages     = {473-482},
  issn      = {1541-0420},
  doi       = {10.1111/biom.12578},
  url       = {http://dx.doi.org/10.1111/biom.12578},
  file      = {Sasieni2016.pdf:Sasieni2016.pdf:PDF;Sasieni2016.pdf:pdf\\Sasieni2016.pdf:PDF},
  keywords  = {Cancer, Ederer-II, Epidemiology, Excess Hazards, Heterogeneity, Net Survival, Relative Survival, Robust Estimation, Standardization, Weighted Excess Hazards, Weighted Net Survival, Weighted Relative Survival},
  owner     = {PaulD},
  timestamp = {2016.08.24},
}

@ARTICLE{Sasieni1996,
  author = {Sasieni, P. D.},
  title = {Proportional excess hazards},
  journal = {Biometrika},
  year = {1996},
  volume = {83},
  pages = {127-141},
  file = {Sasieni1996.pdf:pdf\\Sasieni1996.pdf:PDF;Sasieni1996.pdf:Sasieni1996.pdf:PDF},
  groups = {Excess mortality model},
  owner = {PaulD},
  timestamp = {2006.09.05}
}

@ARTICLE{Satagopan2004,
  author = {Satagopan, J. M. and Ben-Porat, L. and Berwick, M. and Robson, M.
	and Kutler, D. and Auerbach, A. D.},
  title = {A note on competing risks in survival data analysis.},
  journal = {Br J Cancer},
  year = {2004},
  volume = {91},
  pages = {1229--1235},
  number = {7},
  month = {Oct},
  abstract = {Survival analysis encompasses investigation of time to event data.
	In most clinical studies, estimating the cumulative incidence function
	(or the probability of experiencing an event by a given time) is
	of primary interest. When the data consist of patients who experience
	an event and censored individuals, a nonparametric estimate of the
	cumulative incidence can be obtained using the Kaplan-Meier method.
	Under this approach, the censoring mechanism is assumed to be noninformative.
	In other words, the survival time of an individual (or the time at
	which a subject experiences an event) is assumed to be independent
	of a mechanism that would cause the patient to be censored. Often
	times, a patient may experience an event other than the one of interest
	which alters the probability of experiencing the event of interest.
	Such events are known as competing risk events. In this setting,
	it would often be of interest to calculate the cumulative incidence
	of a specific event of interest. Any subject who does not experience
	the event of interest can be treated as censored. However, a patient
	experiencing a competing risk event is censored in an informative
	manner. Hence, the Kaplan-Meier estimation procedure may not be directly
	applicable. The cumulative incidence function for an event of interest
	must be calculated by appropriately accounting for the presence of
	competing risk events. In this paper, we illustrate nonparametric
	estimation of the cumulative incidence function for an event of interest
	in the presence of competing risk events using two published data
	sets. We compare the resulting estimates with those obtained using
	the Kaplan-Meier approach to demonstrate the importance of appropriately
	estimating the cumulative incidence of an event of interest in the
	presence of competing risk events.},
  doi = {10.1038/sj.bjc.6602102},
  institution = {Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering
	Cancer Center, New York 10021, USA. satagopj@mskcc.org},
  keywords = {Humans; Incidence; Neoplasms, pathology; Risk Assessment; Survival
	Analysis},
  language = {eng},
  medline-pst = {ppublish},
  owner = {sanelo},
  pii = {6602102},
  pmid = {15305188},
  timestamp = {2013.07.30},
  url = {http://dx.doi.org/10.1038/sj.bjc.6602102}
}

@ARTICLE{Sauerbrei1999a,
  author = {Sauerbrei, W. and Royston, P.},
  title = {Building multivariable prognostic and diagnostic models: transformation
	of the predictors by using fractional polynomials},
  journal = {Journal of the Royal Statistical Society: Series A (Statistics in
	Society)},
  year = {1999},
  volume = {162},
  pages = {71--94},
  number = {1},
  file = {Sauerbrei1999a.pdf:Sauerbrei1999a.pdf:PDF;Sauerbrei1999a.pdf:pdf\\Sauerbrei1999a.pdf:PDF},
  owner = {pl4},
  timestamp = {2008.12.03}
}

@ARTICLE{Sauerbrei2007,
  author = {W. Sauerbrei and P. Royston and H. Binder},
  title = {Selection of important variables and determination of functional
	form for continuous predictors in multivariable model building},
  journal = {Statistics in Medicine},
  year = {2007},
  volume = {26},
  pages = {5512-5528},
  file = {Sauerbrei2007.pdf:Sauerbrei2007.pdf:PDF;Sauerbrei2007.pdf:pdf\\Sauerbrei2007.pdf:PDF},
  owner = {pl4},
  timestamp = {2009.11.04}
}

@ARTICLE{Sauerbrei1999,
  author = {W. Sauerbrei and P. Royston and H. Bojar and C. Schmoor and M. Schumacher},
  title = {Modelling the effects of standard prognostic factors in node-positive
	breast cancer. German Breast Cancer Study Group (GBSG).},
  journal = {British Journal of Cancer},
  year = {1999},
  volume = {79},
  pages = {1752--1760},
  number = {11-12},
  month = {Apr},
  abstract = {Prognostic models that predict the clinical course of a breast cancer
	patient are important in oncology. We propose an approach to constructing
	such models based on fractional polynomials in which useful transformations
	of the continuous factors are determined. The idea may be applied
	with all types of regression model, including Cox regression, the
	method of choice for survival-time data. We analyse a prospective
	study of node-positive breast cancer. Seven standard prognostic factors--age,
	menopausal status, tumour size, tumour grade, number of positive
	lymph nodes, progesterone and oestrogen receptor concentrations--were
	investigated in 686 patients, of whom 299 had an event for recurrence-free
	survival and 171 died. We determine a final model with transformations
	of prognostic factors and compare it with the more traditional approaches
	using categorized variables or assuming a straight line relationship.
	We conclude that analysis using fractional polynomials can extract
	important prognostic information which the traditional approaches
	may miss.},
  doi = {10.1038/sj.bjc.6690279},
  file = {Sauerbrei1999.pdf:Sauerbrei1999.pdf:PDF;Sauerbrei1999.pdf:pdf\\Sauerbrei1999.pdf:PDF},
  institution = {Institute of Medical Biometry and Medical Informatics, University
	of Freiburg, Germany.},
  owner = {pl4},
  pmid = {10206288},
  timestamp = {2008.12.03},
  url = {http://dx.doi.org/10.1038/sj.bjc.6690279}
}

@ARTICLE{SauRoyLook07,
  author = {W. Sauerbrei and P. Royston and M. Look},
  title = {A new proposal for multivariable modelling of time-varying effects
	in survival data based on fractional polynomial time-transformation},
  journal = {Biometrical Journal},
  year = {2007},
  volume = {49},
  pages = {453--473},
  file = {SauRoyLook07.pdf:SauRoyLook07.pdf:PDF;SauRoyLook07.pdf:pdf\\SauRoyLook07.pdf:PDF},
  timestamp = {2005.11.01}
}

@ARTICLE{Sauerbrei2007a,
  author = {W. Sauerbrei and P. Royston and K. Zapien},
  title = {Detecting an interaction between treatment and a continuous covariate:
	A comparison of two approaches},
  journal = {Computational Statistics \& Data Analysis},
  year = {2007},
  volume = {51},
  pages = {4054-4063},
  file = {Sauerbrei2007a.pdf:Sauerbrei2007a.pdf:PDF;Sauerbrei2007a.pdf:pdf\\Sauerbrei2007a.pdf:PDF},
  owner = {pl4},
  timestamp = {2009.12.03}
}

@ARTICLE{Saxen1964,
  author = {Sax{\'e}n, E. and Hakama, M.},
  title = {Cancer Illnesss in {F}inland, With a Note on the Effect of Age Adjustment
	and Early Diagnosis},
  journal = {Annales Medicinae Experimentalis et Biologiae Fenniae},
  year = {1964},
  volume = {42 (Suppl. 2)},
  pages = {1-28},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Schaffar2015,
  author = {Schaffar, Robin and Rachet, Bernard and Belot, Aur{\'{e}}lien and
	Woods, Laura},
  title = {Cause-specific or relative survival setting to estimate population-based
	net survival from cancer? An empirical evaluation using women diagnosed
	with breast cancer in Geneva between 1981 and 1991 and followed for
	20 years after diagnosis.},
  journal = {Cancer Epidemiol},
  year = {2015},
  volume = {39},
  pages = {465--472},
  number = {3},
  month = {Jun},
  abstract = {Both cause-specific and relative survival settings can be used to
	estimate net survival, the survival that would be observed if the
	only possible underlying cause of death was the disease under study.
	Both resulting net survival estimators are biased by informative
	censoring and prone to biases related to the data settings within
	which each is derived. We took into account informative censoring
	to derive theoretically unbiased estimators and examine which of
	the two data settings was the most robust against incorrect assumptions
	in the data.We identified 2489 women in the Geneva Cancer Registry,
	diagnosed with breast cancer between 1981 and 1991, and estimated
	net survival up to 20-years using both cause-specific and relative
	survival settings, by tackling the informative censoring with weights.
	To understand the possible origins of differences between the survival
	estimates, we performed sensitivity analyses within each setting.
	We evaluated the impact of misclassification of cause of death and
	of using inappropriate life tables on survival estimates.Net survival
	was highest using the cause-specific setting, by 1\% at one year
	and by up to around 11\% twenty years after diagnosis. Differences
	between both sets of net survival estimates were eliminated after
	recoding between 15\% and 20\% of the non-specific deaths as breast
	cancer deaths. By contrast, a dramatic increase in the general population
	mortality rates was needed to see the survival estimates based on
	relative survival setting become closer to those derived from cause-specific
	setting.Net survival estimates derived using the cause-specific setting
	are very sensitive to misclassification of cause of death. Net survival
	estimates derived using the relative-survival setting were robust
	to large changes in expected mortality. The relative survival setting
	is recommended for estimation of long-term net survival among patients
	with breast cancer.},
  doi = {10.1016/j.canep.2015.04.001},
  file = {Schaffar2015.pdf:pdf\\Schaffar2015.pdf:PDF;Schaffar2015.pdf:Schaffar2015.pdf:PDF},
  institution = {Cancer Research UK Cancer Survival Group, Department of Non-Communicable
	Disease Epidemiology, Faculty of Epidemiology and Population Health,
	London School of Hygiene and Tropical Medicine, London, United Kingdom.},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pii = {S1877-7821(15)00082-X},
  pmid = {25907643},
  timestamp = {2015.06.22},
  url = {http://dx.doi.org/10.1016/j.canep.2015.04.001}
}

@ARTICLE{Schaffar2013,
  author = {Schaffar, Robin and Rapiti, Elisabetta and Rachet, Bernard and Woods,
	Laura},
  title = {Accuracy of cause of death data routinely recorded in a population-based
	cancer registry: impact on cause-specific survival and validation
	using the Geneva Cancer Registry.},
  journal = {BMC Cancer},
  year = {2013},
  volume = {13},
  pages = {609},
  abstract = {Information on the underlying cause of death of cancer patients is
	of interest because it can be used to estimate net survival. The
	population-based Geneva Cancer Registry is unique because registrars
	are able to review the official cause of death. This study aims to
	describe the difference between the official and revised cause-of-death
	variables and the impact on cancer survival estimates.The recording
	process for each cause of death variable is summarised. We describe
	the differences between the two cause-of-death variables for the
	5,065 deceased patients out of the 10,534 women diagnosed with breast
	cancer between 1970 and 2009. The Kappa statistic and logistic regression
	are applied to evaluate the degree of concordance. The impact of
	discordance on cause-specific survival is examined using the Kaplan
	Meier method.The overall agreement between the two variables was
	high. However, several subgroups presented a lower concordance, suggesting
	differences in calendar time and less attention given to older patients
	and more advanced diseases. Similarly, the impact of discordance
	on cause-specific survival was small on overall survival but larger
	for several subgroups.Estimation of cancer-specific survival could
	therefore be prone to bias when using the official cause of death.
	Breast cancer is not the more lethal cancer and our results can certainly
	not be generalised to more lethal tumours.},
  doi = {10.1186/1471-2407-13-609},
  file = {Schaffar2013.pdf:Schaffar2013.pdf:PDF;Schaffar2013.pdf:pdf\\Schaffar2013.pdf:PDF},
  institution = {Geneva Cancer Registry, Institute for Social and Preventive Medicine,
	University of Geneva, 55 Boulevard de la Cluse, Geneva, 1205, Switzerland.
	robin.schaffar@lshtm.ac.uk.},
  keywords = {Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms, epidemiology/mortality/pathology/therapy;
	Cause of Death; Child; Child, Preschool; Female; Humans; Infant;
	Infant, Newborn; Middle Aged; Neoplasm Staging; Population Surveillance;
	Registries; Risk Factors; Young Adult},
  language = {eng},
  medline-pst = {epublish},
  owner = {PaulD},
  pii = {1471-2407-13-609},
  pmid = {24373194},
  timestamp = {2015.06.22},
  url = {http://dx.doi.org/10.1186/1471-2407-13-609}
}

@ARTICLE{Scheike2008a,
  author = {Scheike, T. H. and Zhang, M-J.},
  title = {Flexible competing risks regression modeling and goodness-of-fit},
  journal = {Lifetime Data Analysis},
  year = {2008},
  volume = {14},
  pages = {464ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Â“483},
  file = {Scheike2008a.pdf:Scheike2008a.pdf:PDF;Scheike2008a.pdf:pdf\\Scheike2008a.pdf:PDF},
  owner = {pl4},
  timestamp = {2015.11.05}
}

@ARTICLE{Scheike2008,
  author = {Scheike, T. H. and Zhang, M-J. and Gerds, T. A.},
  title = {Predicting cmulative incidence probability by direct binomial regression},
  journal = {Biometrika},
  year = {2008},
  volume = {95},
  pages = {205-220},
  file = {Scheike2008.pdf:Scheike2008.pdf:PDF;Scheike2008.pdf:pdf\\Scheike2008.pdf:PDF},
  owner = {pl4},
  timestamp = {2015.11.05}
}

@ARTICLE{Schemper2009,
  author = {Michael Schemper and Samo Wakounig and Georg Heinze},
  title = {The estimation of average hazard ratios by weighted Cox regression.},
  journal = {Stat Med},
  year = {2009},
  volume = {28},
  pages = {2473--2489},
  number = {19},
  month = {Aug},
  abstract = {Often the effect of at least one of the prognostic factors in a Cox
	regression model changes over time, which violates the proportional
	hazards assumption of this model. As a consequence, the average hazard
	ratio for such a prognostic factor is under- or overestimated. While
	there are several methods to appropriately cope with non-proportional
	hazards, in particular by including parameters for time-dependent
	effects, weighted estimation in Cox regression is a parsimonious
	alternative without additional parameters. The methodology, which
	extends the weighted k-sample logrank tests of the Tarone-Ware scheme
	to models with multiple, binary and continuous covariates, has been
	introduced in the nineties of the last century and is further developed
	and re-evaluated in this contribution. The notion of an average hazard
	ratio is defined and its connection to the effect size measure P(X<Y)
	is emphasized. The suggested approach accomplishes estimation of
	intuitively interpretable average hazard ratios and provides tools
	for inference. A Monte Carlo study confirms the satisfactory performance.
	Advantages of the approach are exemplified by comparing standard
	and weighted analyses of an international lung cancer study. SAS
	and R programs facilitate application.},
  doi = {10.1002/sim.3623},
  file = {Schemper2009.pdf:Schemper2009.pdf:PDF;Schemper2009.pdf:pdf\\Schemper2009.pdf:PDF},
  institution = {Section of Clinical Biometrics, Department for Medical Statistics
	and Informatics, Medical University of Vienna, Spitalgasse 23, A-1090
	Vienna, Austria. michael.schemper@meduniwien.ac.at},
  owner = {pl4},
  pmid = {19472308},
  timestamp = {2010.12.13},
  url = {http://dx.doi.org/10.1002/sim.3623}
}

@ARTICLE{Schlattmann1993,
  author = {Schlattmann, P. and B{\"o}hning, D.},
  title = {Mixture Models and Disease Mapping},
  journal = {Statistics in Medicine},
  year = {1993},
  volume = {12},
  pages = {1943-1950},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Schloeffel1989,
  author = {Schloeffel, P. and Hains, D. and Roder, D. and Bonett, A. and Esterman,
	A.},
  title = {The Use of State and Hospital-Based Cancer-Registry Data to Describe
	the Epidemiological and Clinical Characteristics of Laryngeal Cancer
	in {S}outh {A}ustralia},
  journal = {Medical Journal of Australia},
  year = {1989},
  volume = {150},
  pages = {252-255},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Schmoor2013,
  author = {Schmoor, Claudia and Schumacher, Martin and Finke, J{\AA}Â¼rgen and Beyersmann,
	Jan},
  title = {Competing risks and multistate models.},
  journal = {Clin Cancer Res},
  year = {2013},
  volume = {19},
  pages = {12--21},
  number = {1},
  month = {Jan},
  abstract = {Complex clinical endpoints are present in studies in cancer. Especially
	in studies on hematopoietic stem-cell transplantation (HSCT), various
	risks exist after HSCT. Patients can experience acute and chronic
	graft versus host disease (GVHD) or need to undergo immunosuppressive
	therapy (IST), a relapse can occur, or patients can die after relapse
	or without former relapse (nonrelapse mortality, NRM). Sometimes,
	endpoints can be reasonably combined in a composite endpoint, as,
	for example, relapse and NRM are combined into disease-free survival
	(DFS). In this case, standard survival techniques, as Kaplan-Meier
	estimation of the DFS probability, can be applied. Often, interest
	focuses on endpoints for which competing risks are present, as, for
	example, GVHD, with death without prior GVHD as competing risk. This
	results in a competing risks model, a special case of a multistate
	model. A more complex multistate model is required when the effects
	of events occurring in the course of the study on further disease
	process shall be investigated, as, for example, the effect of GVHD
	on relapse and NRM. Another endpoint of interest is time under IST.
	As patients usually experience multiple episodes of IST, thus switching
	back and forth between "IST" and "no IST" during follow-up, the multistate
	model used for analysis must be adapted for this event structure.
	The aim of this nontechnical report is to explain use and interpretation
	of Cox-type regression models suitable for the different situations
	in a randomized trial on the effects of anti-T-cell globulin as GVHD
	prophylaxis.},
  doi = {10.1158/1078-0432.CCR-12-1619},
  file = {Schmoor2013.pdf:pdf\\Schmoor2013.pdf:PDF},
  institution = {Clinical Trials Unit, University Medical Center Freiburg, Freiburg,
	Germany. claudia.schmoor@uniklinik-freiburg.de},
  keywords = {Algorithms; Antilymphocyte Serum, therapeutic use; Graft vs Host Disease,
	drug therapy/mortality/prevention /&/ control; Hematopoietic Stem
	Cell Transplantation; Humans; Immunosuppressive Agents, therapeutic
	use; Models, Statistical; Recurrence},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {1078-0432.CCR-12-1619},
  pmid = {23172882},
  timestamp = {2014.06.02},
  url = {http://dx.doi.org/10.1158/1078-0432.CCR-12-1619}
}

@Article{Scholl2001,
  author      = {Scholl, S. and Beuzeboc, P. and Pouillart, P.},
  title       = {Targeting HER2 in other tumor types.},
  language    = {eng},
  pages       = {S81--S87},
  volume      = {12 Suppl 1},
  abstract    = {The human epidermal growth factor receptor-2 (HER2) is overexpressed/amplified
	in a range of tumor types including breast, ovarian, bladder, salivary
	gland, endometrial, pancreatic and non-small-cell lung cancer (NSCLC).
	HER2 is implicated in disease initiation and progression, associated
	with poor prognosis, and may also predict the response to chemotherapy
	and hormonal therapy. Anti-HER2 monoclonal antibodies (MAbs) have
	been designed to specifically antagonize the function of the HER2
	receptor in HER2-positive tumors. Clinical phase II and III trials
	have demonstrated the efficacy of the humanized anti-HER2 MAb, trastuzumab
	(Herceptin), both as a single agent and in combination with chemotherapy
	in HER2-positive, metastatic breast cancer patients. However, the
	prevalence of HER2 overexpression/amplification in various tumor
	types raises the possibility of using anti-HER2 MAbs to antagonize
	the abnormal function of overexpressed HER2 receptors in HER2-positive
	tumors other than breast. Preliminary in vitro studies indicate that
	anti-HER2 MAbs suppress the proliferation of ovarian, gastric and
	NSCLC cell lines that overexpress the HER2 receptor. These results
	indicate that anti-HER2 MAbs may have important therapeutic significance
	in patients presenting with these or other human carcinomas. Clinical
	trials are either planned or underway to assess the therapeutic role
	of trastuzumab in NSCLC, bladder and ovarian cancer.},
  institution = {Institut Curie, Paris, France. sscholl@curie.net},
  journal     = {Ann Oncol},
  keywords    = {Antibodies, Monoclonal, Humanized; Antibodies, therapeutic use; Antineoplastic Agents, therapeutic use; Clinical Trials as Topic; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, drug therapy/metabolism/pathology; Predictive Value of Tests; Prognosis; Receptor, erbB-2, drug effects/metabolism; Survival Analysis; Treatment Outcome; Up-Regulation},
  medline-pst = {ppublish},
  owner       = {pl4},
  pmid        = {11521727},
  timestamp   = {2013.05.29},
  year        = {2001},
}

@PhdThesis{Schrijvers1996,
  author    = {Schrijvers, Carola},
  title     = {Socioeconomic Inequalities in Cancer Survival in the {N}etherlands and {G}reat {B}ritain: Small-Area Based Studies Using Cancer Registry Data},
  groups    = {PhD Thesis},
  owner     = {PaulD},
  school    = {Erasmus University Rotterdam, The Netherlands},
  timestamp = {2011.06.19},
  year      = {1996},
}

@ARTICLE{Schrijvers1995c,
  author = {Schrijvers, C. T. and Coebergh, J. W. and van der Heijden, L. H.
	and Mackenbach, J. P.},
  title = {Socioeconomic status and breast cancer survival in the southeastern
	{N}etherlands, 1980-1989},
  journal = {European Journal of Cancer},
  year = {1995},
  volume = {31A},
  pages = {1660-1664},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Schrijvers1995d,
  author = {Schrijvers, C. T. and Coebergh, J. W. and van der Heijden, L. H.
	and Mackenbach, J. P.},
  title = {Socioeconomic variation in cancer survival in the southeastern {N}etherlands,
	1980-1989},
  journal = {Cancer},
  year = {1995},
  volume = {75},
  pages = {2946-2953},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Schrijvers1994,
  author = {Schrijvers, C. T. and Mackenbach, J. P.},
  title = {Cancer patient survival by socioeconomic status in seven countries:
	a review for six common cancer sites},
  journal = {Journal of Epidemiology and Community Health},
  year = {1994},
  volume = {48},
  pages = {441-446},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Schrijvers1995a,
  author = {Schrijvers, C. T. and Mackenbach, J. P. and Lutz, J. M. and Quinn,
	M. J. and Coleman, M. P.},
  title = {Deprivation, Stage at Diagnosis and Cancer Survival},
  journal = {International Journal of Cancer},
  year = {1995},
  volume = {63},
  pages = {324-329},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Schrijvers1995b,
  author = {Schrijvers, C. T. and Mackenbach, J. P. and Lutz, J. M. and Quinn,
	M. J. and Coleman, M. P.},
  title = {Deprivation and Survival from Breast Cancer},
  journal = {British Journal of Cancer},
  year = {1995},
  volume = {72},
  pages = {738-743},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Schumacher1987,
  author = {Schumacher, M. and Olschewski, M. and Schmoor, C.},
  title = {The Impact of Heterogeneity on the Comparison of Survival Times},
  journal = {Statistics in Medicine},
  year = {1987},
  volume = {6},
  pages = {773-784},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Schwarz1978,
  author = {G. Schwarz},
  title = {Estimating the dimension of a model},
  journal = {Annals of Statistics},
  year = {1978},
  volume = {6},
  pages = {461-464},
  file = {Schwarz1978.pdf:Schwarz1978.pdf:PDF;Schwarz1978.pdf:pdf\\Schwarz1978.pdf:PDF},
  owner = {pl4},
  timestamp = {2008.12.09}
}

@ARTICLE{Seaman2012,
  author = {Shaun R Seaman and Jonathan W Bartlett and Ian R White},
  title = {Multiple imputation of missing covariates with non-linear effects
	and interactions: an evaluation of statistical methods},
  journal = {BMC medical research methodology},
  year = {2012},
  volume = {12},
  file = {Seaman2012.pdf:Seaman2012.pdf:PDF},
  owner = {BettyS},
  timestamp = {2016.11.28}
}

@ARTICLE{Seaton2011,
  author = {Sarah Seaton},
  title = {Cure Models.},
  journal = {MSc in Medical Statistics Thesis},
  year = {MSc in Medical Statistics Thesis, 2011},
  volume = {Department of Health Sciences},
  pages = {University of Leicester},
  owner = {theand},
  school = {Department of Health Sciences, University of Leicester},
  timestamp = {2013.09.14}
}

@ARTICLE{Seddon1997,
  author = {Seddon, D. J. and Williams, E. M.},
  title = {Data quality in population-based cancer registration: {A}n assessment
	of the {M}erseyside and {C}heshire Cancer Registry},
  journal = {British Journal of Cancer},
  year = {1997},
  volume = {76},
  pages = {667-674},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Selvin1987,
  author = {S. Selvin},
  title = {Two issues concerning the analysis of grouped data.},
  journal = {European Journal of Epidemiology},
  year = {1987},
  volume = {3},
  pages = {284-7},
  number = {3},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Senn2006,
  author = {Stephen Senn},
  title = {Change from baseline and analysis of covariance revisited.},
  journal = {Statistics in Medicine},
  year = {2006},
  volume = {25},
  pages = {4334--4344},
  number = {24},
  month = {Dec},
  abstract = {The case for preferring analysis of covariance (ANCOVA) to the simple
	analysis of change scores (SACS) has often been made. Nevertheless,
	claims continue to be made that analysis of covariance is biased
	if the groups are not equal at baseline. If the required equality
	were in expectation only, this would permit the use of ANCOVA in
	randomized clinical trials but not in observational studies. The
	discussion is related to Lord's paradox. In this note, it is shown,
	however that it is not a necessary condition for groups to be equal
	at baseline, not even in expectation, for ANCOVA to provide unbiased
	estimates of treatment effects. It is also shown that although many
	situations can be envisaged where ANCOVA is biased it is very difficult
	to imagine circumstances under which SACS would then be unbiased
	and a causal interpretation could be made.},
  doi = {10.1002/sim.2682},
  file = {Senn2006.pdf:Senn2006.pdf:PDF;Senn2006.pdf:pdf\\Senn2006.pdf:PDF},
  institution = {Department of Statistics, 15 University Gardens, University of Glasgow,
	Glasgow G12 8QQ, UK. stephen@stats.gla.ac.uk},
  owner = {pl4},
  pmid = {16921578},
  timestamp = {2009.12.03},
  url = {http://dx.doi.org/10.1002/sim.2682}
}

@Article{Seppae2016,
  author      = {Sepp{\"{a}}, Karri and Hakulinen, Timo and L{\"{a}}{\"{a}}r{\"{a}}, Esa and Pitk{\"{a}}niemi, Janne},
  title       = {Comparing net survival estimators of cancer patients.},
  journal     = {Stat Med},
  year        = {2016},
  language    = {eng},
  volume      = {35},
  number      = {11},
  month       = {May},
  pages       = {1866--1879},
  doi         = {10.1002/sim.6833},
  url         = {http://dx.doi.org/10.1002/sim.6833},
  abstract    = {The net survival of a patient diagnosed with a given disease is a
	quantity often interpreted as the hypothetical survival probability
	in the absence of causes of death other than the disease. In a relative
	survival framework, net survival summarises the excess mortality
	that patients experience compared with their relevant reference population.
	Based on follow-up data from the Finnish Cancer Registry, we derived
	simulation scenarios that describe survival of patients in eight
	cancer sites reflecting different excess mortality patterns in order
	to compare the performance of the classical Ederer II estimator and
	the new estimator proposed by Pohar Perme et al. At 5ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years, the
	age-standardised Ederer II estimator performed equally well as the
	Pohar Perme estimator with the exception of melanoma in which the
	Pohar Perme estimator had a smaller mean squared error (MSE). At
	10 and 15ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years, the age-standardised Ederer II performed most often
	better than the Pohar Perme estimator. The unstandardised Ederer
	II estimator had the largest MSE at 5ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years. However, its MSE was
	often superior to those of the other estimators at 10 and 15ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years,
	especially in sparse data. Both the Pohar Perme and the age-standardised
	Ederer II estimator are valid for 5-year net survival of cancer patients.
	For longer-term net survival, our simulation results support the
	use of the age-standardised Ederer II estimator. Copyright ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â© 2015
	John Wiley & Sons, Ltd.},
  file        = {:Seppae2016 - Comparing net survival estimators of cancer patients..pdf:PDF},
  institution = {Department of Public Health, University of Helsinki, Finland.},
  medline-pst = {ppublish},
  owner       = {pl4},
  pmid        = {26707551},
  timestamp   = {2016.05.28},
}

@ARTICLE{Seppa2013,
  author = {Sepp\"{a}, K. and Hakulinen, T. and L\"{a}\"{a}r\"{a}, E.},
  title = {Regional variation in relative survivalÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Â”quantifying the effects of
	the competing risks of death by using a cure fraction model with
	random effects},
  journal = {J R Stat Soc Ser C Appl Stat},
  year = {2013},
  note = {(In press)},
  owner = {sanelo},
  timestamp = {2013.10.17}
}

@Article{Seppae2012,
  author      = {Sepp\"{a}, K. and Hakulinen, T. and L\"{a}\"{a}r\"{a}, E.},
  title       = {Avoidable deaths and random variation in patients' survival.},
  journal     = {Br J Cancer},
  year        = {2012},
  language    = {eng},
  volume      = {106},
  pages       = {1846--1849},
  doi         = {10.1038/bjc.2012.169},
  url         = {http://dx.doi.org/10.1038/bjc.2012.169},
  abstract    = {Background:Random error in the numbers of avoidable deaths among cancer
	patients has not been considered in earlier studies.Methods:Methods
	to obtain valid confidence intervals (CIs) for numbers of avoidable
	deaths were developed. The excess mortality rates were estimated
	for patients diagnosed with colon cancer in five cancer control regions
	in Finland during 2000-2007 using a relative survival regression
	model. Numbers of avoidable deaths due to colon cancer and other
	causes, respectively, were estimated in different scenarios.Results:Altogether,
	4139 and 1335 out of 10{\AA}Â¢ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â‚ÃƒÂ‚Ã‚Â¬ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Â°772 patients under 90 years at diagnosis
	were estimated to have died due to colon cancer and other causes,
	respectively, during the first 5 years after diagnosis. If all the
	patients had shared the relative survival of the largest cancer control
	region to which the country capital belongs, the estimated number
	of avoidable deaths would have been 146 (95\% CI 3-290).Conclusion:Random
	error in numbers of avoidable deaths, often substantial, can be quantified
	by realistic error margins, based on appropriate statistical methods.British
	Journal of Cancer advance online publication, 24 April 2012; doi:10.1038/bjc.2012.169
	www.bjcancer.com.},
  institution = {Department of Mathematical Sciences, FI-90014 University of Oulu, Oulu, Finland.},
  medline-pst = {aheadofprint},
  owner       = {pl4},
  pii         = {bjc2012169},
  pmid        = {22531640},
  timestamp   = {2012.05.13},
}

@Article{Seppae2013,
  author      = {Sepp\"{a}, K.i and Hakulinen, T. and Pokhrel, A.},
  title       = {Choosing the net survival method for cancer survival estimation.},
  journal     = {Eur J Cancer},
  year        = {2013},
  language    = {eng},
  doi         = {10.1016/j.ejca.2013.09.019},
  url         = {http://dx.doi.org/10.1016/j.ejca.2013.09.019},
  abstract    = {A new net survival method has been introduced by Pohar Perme et al.
	(2012 [4]) and recommended to substitute the relative survival methods
	in current use for evaluating population-based cancer survival.The
	new method is based on the use of continuous follow-up time, and
	is unbiased only under non-informative censoring of the observed
	survival. However, the population-based cancer survival is often
	evaluated based on annually or monthly tabulated follow-up intervals.
	An empirical investigation based on data from the Finnish Cancer
	Registry was made into the practical importance of the censoring
	and the level of data tabulation. A systematic comparison was made
	against the earlier recommended Ederer II method of relative survival
	using the two currently available computer programs (Pohar Perme
	(2013) [10] and Dickman et al. (2013) [11]).With exact or monthly
	tabulated data, the Pohar-Perme and the Ederer II methods give, on
	average, results that are at five years of follow-up less than 0.5\%
	units and at 10 and 14years 1-2\% units apart from each other. The
	Pohar-Perme net survival estimator is prone to random variation and
	may result in biased estimates when exact follow-up times are not
	available or follow-up is incomplete. With annually tabulated follow-up
	times, estimates can deviate substantially from those based on more
	accurate observations, if the actuarial approach is not used.At 5years,
	both the methods perform well. In longer follow-up, the Pohar-Perme
	estimates should be interpreted with caution using error margins.
	The actuarial approach should be preferred, if data are annually
	tabulated.},
  file        = {Seppae2013.pdf:pdf\\Seppae2013.pdf:PDF},
  institution = {Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Pieni Roobertinkatu 9, FI-00130 Helsinki, Finland; Department of Mathematical Sciences, University of Oulu, Oulu, Finland.},
  medline-pst = {aheadofprint},
  owner       = {PaulD},
  pii         = {S0959-8049(13)00894-0},
  pmid        = {24183462},
  timestamp   = {2013.11.25},
}

@PhdThesis{Seppae:phdthesis:2012,
  author    = {Karri Sepp{\"a}},
  title     = {Quantifying regional variation in the survival of cancer patients},
  type      = {PhD Thesis},
  url       = {http://urn.fi/urn:isbn:9789526200118},
  file      = {:pdf\\Thesis_Karri_Seppae.pdf:PDF},
  groups    = {PhD Thesis},
  owner     = {PaulD},
  school    = {University of Oulu},
  timestamp = {2013.10.23},
  year      = {2012},
}

@ARTICLE{Seppae2009,
  author = {Sepp{\"a}, Karri and Hakulinen, Timo},
  title = {Mean and median survival times of cancer patients should be corrected
	for informative censoring.},
  journal = {J Clin Epidemiol},
  year = {2009},
  volume = {62},
  pages = {1095--1102},
  number = {10},
  month = {Oct},
  abstract = {To estimate unbiasedly the mean and median survival time of cancer
	patients with incomplete follow-up. To assess the effects of informative
	censoring on estimates by using the crude and a bias-reducing method,
	based on weighted averages of the age-specific results.Colon cancer
	patients diagnosed in 1970-1979 and thyroid cancer patients diagnosed
	in 1978-1987 were followed up until the end of each diagnosis period.Because
	of informative censoring, the crude estimates of the mean lifetime
	grossly overestimate the survival of the colon cancer patients and
	underestimate the survival of the thyroid cancer patients. Together
	with the most recent population life tables, the bias-reducing method
	succeeds in estimating the mean and the median lifetime accurately.Stratifying
	by age is essential when the mean or median lifetime of the patients
	with a wide age range is to be estimated. The bias-reducing method
	should be used if a single summary estimate for the whole patient
	group is needed. The median is preferable if more than half of the
	patients die soon after diagnosis. Predicted population life tables
	should be used in extrapolation.},
  doi = {10.1016/j.jclinepi.2008.11.010},
  file = {Seppae2009.pdf:pdf\\Seppae2009.pdf:PDF;Seppae2009.pdf:Seppae2009.pdf:PDF},
  institution = {Finnish Cancer Registry, Institute for Statistical and Epidemiological
	Cancer Research, Helsinki, Finland. karri.seppa@cancer.fi},
  keywords = {Adolescent; Adult; Age Distribution; Age Factors; Aged; Aged, 80 and
	over; Child; Child, Preschool; Colonic Neoplasms, mortality; Epidemiologic
	Methods; Female; Finland, epidemiology; Humans; Infant; Infant, Newborn;
	Middle Aged; Thyroid Neoplasms, mortality; Young Adult},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pii = {S0895-4356(08)00327-2},
  pmid = {19251392},
  timestamp = {2013.11.25},
  url = {http://dx.doi.org/10.1016/j.jclinepi.2008.11.010}
}

@ARTICLE{Seppae2010,
  author = {Sepp{\"a}, Karri and Hakulinen, Timo and Kim, Hyon-Jung and L{\"a}{\"a}r{\"a}, Esa},
  title = {Cure fraction model with random effects for regional variation in
	cancer survival.},
  journal = {Stat Med},
  year = {2010},
  volume = {29},
  pages = {2781--2793},
  number = {27},
  month = {Nov},
  abstract = {Assessing regional differences in the survival of cancer patients
	is important but difficult when separate regions are small or sparsely
	populated. In this paper, we apply a mixture cure fraction model
	with random effects to cause-specific survival data of female breast
	cancer patients collected by the population-based Finnish Cancer
	Registry. Two sets of random effects were used to capture the regional
	variation in the cure fraction and in the survival of the non-cured
	patients, respectively. This hierarchical model was implemented in
	a Bayesian framework using a Metropolis-within-Gibbs algorithm. To
	avoid poor mixing of the Markov chain, when the variance of either
	set of random effects was close to zero, posterior simulations were
	based on a parameter-expanded model with tailor-made proposal distributions
	in Metropolis steps. The random effects allowed the fitting of the
	cure fraction model to the sparse regional data and the estimation
	of the regional variation in 10-year cause-specific breast cancer
	survival with a parsimonious number of parameters. Before 1986, the
	capital of Finland clearly stood out from the rest, but since then
	all the 21 hospital districts have achieved approximately the same
	level of survival.},
  doi = {10.1002/sim.4046},
  institution = {Finnish Cancer Registry, Pieni Roobertinkatu 9, 00130 Helsinki, Finland.
	karri.seppa@cancer.fi},
  keywords = {Adult; Age Factors; Aged; Algorithms; Bayes Theorem; Breast Neoplasms,
	mortality/therapy; Computer Simulation; Demography, statistics /&/
	numerical data; Disease-Free Survival; Female; Finland; Humans; Likelihood
	Functions; Markov Chains; Middle Aged; Models, Statistical; Monte
	Carlo Method; Neoplasms, mortality/therapy; Registries; Time Factors},
  language = {eng},
  medline-pst = {ppublish},
  owner = {theand},
  pmid = {20862662},
  timestamp = {2013.09.15},
  url = {http://dx.doi.org/10.1002/sim.4046}
}

@Article{Shack2012,
  author      = {Shack, L. G. and Shah, A. and Lambert, P. C. and Rachet, B.},
  title       = {Cure by age and stage at diagnosis for colorectal cancer patients in {N}orth {W}est {E}ngland, 1997-2004: a population-based study.},
  doi         = {10.1016/j.canep.2012.06.011},
  language    = {eng},
  number      = {6},
  pages       = {548--553},
  url         = {http://dx.doi.org/10.1016/j.canep.2012.06.011},
  volume      = {36},
  abstract    = {Stage and age at diagnosis are important prognostic factors for patients
	with colorectal cancer. However, the proportion cured by stage and
	age is unknown in England.This population-based study includes 29,563
	adult patients who were diagnosed and registered with colorectal
	cancer during 1997-2004 and followed till 2007 in North West England.
	Multiple imputation was used to provide more reliable estimates of
	stage at diagnosis, when these data were missing. Cure mixture models
	were used to estimate the proportion 'cured' and the median survival
	of the uncured by age and stage.For both colon and rectal cancer
	the proportion of patients cured and median survival time of the
	uncured decreased with advancing stage and increasing age. Patients
	aged under 65 years had the highest proportion cured and longest
	median survival of the uncured.Cure of colorectal cancer patients
	is dependent on stage and age at diagnosis with younger patients
	or those with less advanced disease having a better prognosis. Further
	efforts are required, in order to reduce the proportion of patients
	presenting with stage III and IV disease and ultimately increase
	the chance of cure.},
  file        = {Shack2012.pdf:Shack2012.pdf:PDF},
  institution = {Preventative Oncology and Community Health Sciences, University of Calgary, Calgary, Canada. lorraine.shack@albertahealthservice.ca},
  journal     = {Cancer Epidemiology},
  keywords    = {Adolescent; Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Colorectal Neoplasms, epidemiology/pathology/therapy; England, epidemiology; Female; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Registries; Survival Analysis; Young Adult},
  medline-pst = {ppublish},
  month       = {Dec},
  owner       = {pl4},
  pii         = {S1877-7821(12)00097-5},
  pmid        = {22819236},
  timestamp   = {2014.02.27},
  year        = {2012},
}

@Article{Shah2013,
  author      = {Shah, A. and Andersson, T. M-L. and Rachet, B. and Bj{\"o}rkholm, M. and Lambert, P. C.},
  title       = {Survival and cure of acute myeloid leukaemia in {E}ngland, 1971-2006: a population-based study.},
  doi         = {10.1111/bjh.12425},
  language    = {eng},
  number      = {4},
  pages       = {509--516},
  url         = {http://dx.doi.org/10.1111/bjh.12425},
  volume      = {162},
  abstract    = {The 5-year relative survival of adults diagnosed with acute myeloid
	leukaemia (AML) was less than 10\% during the 1970s and 1980s in
	England. This population-based study estimated the 5-year relative
	survival and 'cure' for 48ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â 380 adult patients diagnosed with AML
	in England during 1971-2006. Relative survival and cure mixture models
	were used to produce estimates of 5-year relative survival and the
	percentage 'cured'. 'Cure' was defined as the proportion of a group
	of survivors for whom there is no excess mortality compared with
	the general population. The 5-year relative survival and the percentage
	'cured' increased for patients aged under 70ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years at diagnosis during
	1971-2006, but advancing age was associated with poorer outcome.
	During the study period a dramatic increase in 5-year relative survival
	occurred in those aged 15-24ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years, from 7\% to 53\%. The percentage
	'cured' was less than 10\% for all ages in 1975, but increased to
	45\% for those aged 15-24ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years in 2000. Cure could not be estimated
	for patients over 70ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years, because survival was consistently low
	(<5\%). The long-term outcome of patients with AML has improved substantially,
	particularly in younger patients. The potential exists for further
	increasing levels of 'cure'.},
  file        = {Shah2013.pdf:pdf\\Shah2013.pdf:PDF},
  institution = {Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK. anjali.shah@npeu.ox.ac.uk},
  journal     = {British Journal of Haematology},
  keywords    = {Adolescent; Adult; Aged; Aged, 80 and over; England, epidemiology; Female; Humans; Leukemia, Myeloid, Acute, mortality/therapy; Male; Middle Aged; Mortality, trends; Registries, statistics /&/ numerical data; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult},
  medline-pst = {ppublish},
  month       = {Aug},
  owner       = {pl4},
  pmid        = {23786647},
  timestamp   = {2014.02.27},
  year        = {2013},
}

@ARTICLE{Shaikh1996,
  author = {Shaikh, S. and Collier, D. A. and Sham, P. C. and Ball, D. and Aitchison,
	K. and Vallada, H. and Smith, I. and Gill, M. and Kerwin, R. W.},
  title = {Allelic association between a {Ser-9-Gly} polymorphism in the dopamine
	{D3} receptor gene and schizophrenia},
  journal = {Hum Genet},
  year = {1996},
  volume = {97},
  pages = {714-9},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Shao2009,
  author = {Shao, Yu-Hsuan and Demissie, Kitaw and Shih, Weichung and Mehta,
	Amit R. and Stein, Mark N. and Roberts, Calpurnyia B. and Dipaola,
	Robert S. and Lu-Yao, Grace L.},
  title = {Contemporary risk profile of prostate cancer in the {U}nited {S}tates.},
  journal = {J Natl Cancer Inst},
  year = {2009},
  volume = {101},
  pages = {1280--1283},
  number = {18},
  month = {Sep},
  abstract = {National-level data that characterize contemporary prostate cancer
	patients are limited. We used 2004-2005 data from the Surveillance,
	Epidemiology, and End Results Program to generate a contemporary
	profile of prostate cancer patients (N = 82 541) and compared patient
	characteristics of this 2004-2005 population with those of patients
	diagnosed in 1998-1989 and 1996-1997. Among newly diagnosed patients
	in 2004-2005, the majority (94\%) had localized (ie, stage T1 or
	T2) prostate cancer and a median serum prostate-specific antigen
	(PSA) level of 6.7 ng/mL. Between 1988-1989 and 2004-2005, the average
	age at prostate cancer diagnosis decreased from 72.2 to 67.2 years,
	and the incidence rate of T3 or T4 cancer decreased from 52.7 per
	100 000 to 7.9 per 100 000 among whites and from 90.9 per 100 000
	to 13.3 per 100 000 among blacks. In 2004-2005, compared with whites,
	blacks were more likely to be diagnosed at a younger age (mean age:
	64.7 vs 67.5 years, difference = 2.7 years, 95\% confidence interval
	[CI] = 2.5 to 2.9 years, P < .001) and to have a higher PSA level
	at diagnosis (median PSA level: 7.4 vs 6.6 ng/mL, difference = 0.8
	ng/mL, 95\% CI = 0.6 to 1.0 ng/mL, P < .001). In conclusion, more
	men were diagnosed with prostate cancer at a younger age and earlier
	stage in 2004-2005 than in earlier years. The racial disparity in
	cancer stage at diagnosis has decreased statistically significantly
	over time.},
  doi = {10.1093/jnci/djp262},
  institution = {Department of Population Science, Cancer Institute of New Jersey,
	New Brunswick, NJ, USA.},
  keywords = {Adult; African Americans, statistics /&/ numerical data; Age Factors;
	Aged; European Continental Ancestry Group, statistics /&/ numerical
	data; Health Status Disparities; Humans; Incidence; Male; Middle
	Aged; Neoplasm Staging; Prostate-Specific Antigen, blood; Prostatectomy;
	Prostatic Neoplasms, diagnosis/epidemiology/ethnology/immunology/mortality/pathology/surgery;
	Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors;
	SEER Program; Severity of Illness Index; Survival Analysis; United
	States, epidemiology},
  language = {eng},
  medline-pst = {ppublish},
  owner = {sanelo},
  pii = {djp262},
  pmid = {19713548},
  timestamp = {2013.07.31},
  url = {http://dx.doi.org/10.1093/jnci/djp262}
}

@ARTICLE{Shavers2007,
  author = {Shavers, V. L.},
  title = {Measurement of socioeconomic status in health disparities research},
  journal = {Journal of the National Medical Association},
  year = {2007},
  volume = {99},
  pages = {1013-23},
  owner = {hanbow},
  timestamp = {2016.05.19}
}

@Article{Shi2013,
  author      = {Shi, Haiwen and Cheng, Yu and Jeong, Jong-Hyeon},
  title       = {Constrained parametric model for simultaneous inference of two cumulative incidence functions.},
  doi         = {10.1002/bimj.201200011},
  language    = {eng},
  number      = {1},
  pages       = {82--96},
  url         = {http://dx.doi.org/10.1002/bimj.201200011},
  volume      = {55},
  abstract    = {We propose a parametric regression model for the cumulative incidence
	functions (CIFs) commonly used for competing risks data. The model
	adopts a modified logistic model as the baseline CIF and a generalized
	odds-rate model for covariate effects, and it explicitly takes into
	account the constraint that a subject with any given prognostic factors
	should eventually fail from one of the causes such that the asymptotes
	of the CIFs should add up to one. This constraint intrinsically holds
	in a nonparametric analysis without covariates, but is easily overlooked
	in a semiparametric or parametric regression setting. We hence model
	the CIF from the primary cause assuming the generalized odds-rate
	transformation and the modified logistic function as the baseline
	CIF. Under the additivity constraint, the covariate effects on the
	competing cause are modeled by a function of the asymptote of the
	baseline distribution and the covariate effects on the primary cause.
	The inference procedure is straightforward by using the standard
	maximum likelihood theory. We demonstrate desirable finite-sample
	performance of our model by simulation studies in comparison with
	existing methods. Its practical utility is illustrated in an analysis
	of a breast cancer dataset to assess the treatment effect of tamoxifen,
	adjusting for age and initial pathological tumor size, on breast
	cancer recurrence that is subject to dependent censoring by second
	primary cancers and deaths.},
  file        = {Shi2013.pdf:pdf\\Shi2013.pdf:PDF;Shi2013.pdf:Shi2013.pdf:PDF},
  institution = {Proteomics Core Laboratories - Bioinformatics Analysis Core, University of Pittsburgh, Pittsburgh, PA 15260, USA.},
  journal     = {Biom J},
  keywords    = {Biometry, methods; Breast Neoplasms, epidemiology/pathology/therapy; Clinical Trials as Topic; Humans; Incidence; Likelihood Functions; Models, Statistical; Regression Analysis; Time Factors},
  medline-pst = {ppublish},
  month       = {Jan},
  owner       = {pl4},
  pmid        = {23090878},
  timestamp   = {2015.07.07},
  year        = {2013},
}

@ARTICLE{Silverman1985,
  author = {Silverman, BW},
  title = {Some aspects of the spline smoothing approach to nonparametric regression
	curve fitting},
  journal = {Journal of the Rotal Statistical Society, Series B},
  year = {1985},
  volume = {47},
  pages = {1--52},
  file = {Silverman1985.pdf:Silverman1985.pdf:PDF},
  owner = {pl4},
  timestamp = {2009.11.04}
}

@ARTICLE{Simmonds2007,
  author = {M. C. Simmonds and J. P T Higgins},
  title = {Covariate heterogeneity in meta-analysis: criteria for deciding between
	meta-regression and individual patient data.},
  journal = {Statistics in Medicine},
  year = {2007},
  volume = {26},
  pages = {2982--2999},
  number = {15},
  month = {Jul},
  abstract = {Meta-analyses of clinical trials are increasingly seeking to go beyond
	estimating the effect of a treatment and may also aim to investigate
	the effect of other covariates and how they alter treatment effectiveness.
	This requires the estimation of treatment-covariate interactions.
	Meta-regression can be used to estimate such interactions using published
	data, but it is known to lack statistical power, and is prone to
	bias.The use of individual patient data can improve estimation of
	such interactions, among other benefits, but it can be difficult
	and time-consuming to collect and analyse. This paper derives, under
	certain conditions, the power of meta-regression and IPD methods
	to detect treatment-covariate interactions. These power formulae
	are shown to depend on heterogeneity in the covariate distributions
	across studies. This allows the derivation of simple tests, based
	on heterogeneity statistics, for comparing the statistical power
	of the analysis methods.},
  doi = {10.1002/sim.2768},
  file = {Simmonds2007.pdf:Simmonds2007.pdf:PDF;Simmonds2007.pdf:pdf\\Simmonds2007.pdf:PDF},
  institution = {MPS Research Unit, University of Reading, P.O. Box 240, Earley Gate,
	Reading, RG6 6FN, UK. m.c.simmonds@reading.ac.uk},
  owner = {pl4},
  pmid = {17195960},
  timestamp = {2008.11.18},
  url = {http://dx.doi.org/10.1002/sim.2768}
}

@ARTICLE{Simmonds2005,
  author = {Mark C Simmonds and Julian P T Higgins and Lesley A Stewart and Jayne
	F Tierney and Mike J Clarke and Simon G Thompson},
  title = {Meta-analysis of individual patient data from randomized trials:
	a review of methods used in practice.},
  journal = {Clinical Trials},
  year = {2005},
  volume = {2},
  pages = {209--217},
  number = {3},
  abstract = {BACKGROUND: Meta-analyses based on individual patient data (IPD) are
	regarded as the gold standard for systematic reviews. However, the
	methods used for analysing and presenting results from IPD meta-analyses
	have received little discussion. METHODS: We review 44 IPD meta-analyses
	published during the years 1999-2001. We summarize whether they obtained
	all the data they sought, what types of approaches were used in the
	analysis, including assumptions of common or random effects, and
	how they examined the effects of covariates. RESULTS: Twenty-four
	out of 44 analyses focused on time-to-event outcomes, and most analyses
	(28) estimated treatment effects within each trial and then combined
	the results assuming a common treatment effect across trials. Three
	analyses failed to stratify by trial, analysing the data is if they
	came from a single mega-trial. Only nine analyses used random effects
	methods. Covariate-treatment interactions were generally investigated
	by subgrouping patients. Seven of the meta-analyses included data
	from less than 80\% of the randomized patients sought, but did not
	address the resulting potential biases. CONCLUSIONS: Although IPD
	meta-analyses have many advantages in assessing the effects of health
	care, there are several aspects that could be further developed to
	make fuller use of the potential of these time-consuming projects.
	In particular, IPD could be used to more fully investigate the influence
	of covariates on heterogeneity of treatment effects, both within
	and between trials. The impact of heterogeneity, or use of random
	effects, are seldom discussed. There is thus considerable scope for
	enhancing the methods of analysis and presentation of IPD meta-analysis.},
  file = {Simmonds2005.pdf:Simmonds2005.pdf:PDF;Simmonds2005.pdf:pdf\\Simmonds2005.pdf:PDF},
  institution = {MRC Biostatistics Unit, Robinson Way, Cambridge, UK.},
  owner = {pl4},
  pmid = {16279144},
  timestamp = {2008.11.18}
}

@ARTICLE{Sjoeberg2012,
  author = {Sj\"{o}berg, Jan and Halthur, Cat and Kristinsson, Sigurdur Y. and
	Landgren, Ola and Nygell, Ulla Axdorph and Bj\"{o}rkholm, Magnus
	and Dickman, Paul W.},
  title = {Progress in {H}odgkin lymphoma: a population-based study on patients
	diagnosed in {S}weden from 1973-2009.},
  journal = {Blood},
  year = {2012},
  volume = {119},
  pages = {990--996},
  number = {4},
  month = {Jan},
  abstract = {In recent decades, attention has focused on reducing long-term, treatment-related
	morbidity and mortality in Hodgkin lymphoma (HL). In the present
	study, we looked for trends in relative survival for all patients
	diagnosed with HL in Sweden from 1973-2009 (N = 6949; 3985 men and
	2964 women; median age, 45 years) and followed up for death until
	the end of 2010. Patients were categorized into 6 age groups and
	5 calendar periods (1973-1979, 1980-1986, 1987-1994, 1994-2000, and
	2001-2009). Relative survival improved in all age groups, with the
	greatest improvement in patients 51-65 years of age (P < .0005).
	A plateau in relative survival was observed in patients below 65
	years of age during the last calendar period, suggesting a reduced
	long-term, treatment-related mortality. The 10-year relative survival
	for patients diagnosed in 2000-2009 was 0.95, 0.96, 0.93, 0.80, and
	0.44 for the age groups 0-18, 19-35, 36-50, 51-65, and 66-80, respectively.
	Therefore, despite progress, age at diagnosis remains an important
	prognostic factor (P < .0005). Advances in therapy for patients with
	limited and advanced-stage HL have contributed to an increasing cure
	rate. In addition, our findings support that long-term mortality
	of HL therapy has decreased. Elderly HL patients still do poorly,
	and targeted treatment options associated with fewer side effects
	will advance the clinical HL field.},
  doi = {10.1182/blood-2010-08-302604},
  institution = {Department of Medicine, Division of Hematology, Karolinska University
	Hospital Solna and Karolinska Institutet, Stockholm, Sweden.},
  language = {eng},
  medline-pst = {ppublish},
  owner = {Paul},
  pii = {blood-2010-08-302604},
  pmid = {22147892},
  timestamp = {2012.06.07},
  url = {http://dx.doi.org/10.1182/blood-2010-08-302604}
}

@Article{sjolander2016,
  author    = {A. Sj{\"o}lander},
  title     = {Regression standardization with the {R} package std{R}eg},
  journal   = {European Journal of Epidemiology},
  year      = {2016},
  volume    = {31},
  number    = {6},
  pages     = {563-574},
  file      = {sjolander2016.pdf:sjolander2016.pdf:PDF},
  owner     = {BettyS},
  timestamp = {2016.11.28},
}

@ARTICLE{Skyrud2014,
  author = {Skyrud, Katrine Damgaard and Bray, Freddie and M{\o}ller, Bj{\o}rn},
  title = {A comparison of relative and cause-specific survival by cancer site,
	age and time since diagnosis.},
  journal = {Int J Cancer},
  year = {2014},
  volume = {135},
  pages = {196--203},
  number = {1},
  month = {Jul},
  abstract = {Relative survival (RS) estimates are widely used by cancer registries,
	mainly because they do not rely on the well-documented deficiencies
	of cause of death information. The aim of our study was to compare
	5-year cause-specific survival (CSS) estimates and 5-year RS estimates
	for different cancer sites by age and time since diagnosis, and discuss
	possible reasons for observed differences. Using data from the Cancer
	Registry of Norway, we identified 200,008 patients diagnosed with
	cancer at one of the 48 sites included in this analysis during the
	period 1996-2005, and followed them up until the end of 2010. CSS
	estimates were calculated (i) considering cause of death to be the
	cancer that was originally diagnosed and (ii) considering the cause
	of death to be a cancer within the same organ system. For most cancer
	sites the difference between CSS and RS estimates was small (<5\%).
	The greatest differences were seen for rarer cancers such as mediastinum
	and Kaposi sarcoma. Including deaths from the same organ system in
	the calculation of CSS further reduced the differences for many sites.
	For younger age groups and shorter time since diagnosis, RS and CSS
	estimates tended to be similar, whereas CSS estimates tended to be
	lower than RS estimates with longer time since diagnosis in the oldest
	age groups. When compared to RS estimates CSS estimates were reliable
	for most of the cancer sites included in our analysis. There are,
	however, some exceptions where CSS estimates may not be recommended,
	including for rarer cancers and for patients aged 85 and above.},
  doi = {10.1002/ijc.28645},
  file = {Skyrud2014.pdf:pdf\\Skyrud2014.pdf:PDF;Skyrud2014.pdf:Skyrud2014.pdf:PDF},
  institution = {Department of Registration Cancer Registry of Norway, Institute of
	Population-Based Cancer Research, Oslo, Norway.},
  keywords = {Adult; Age Factors; Aged; Aged, 80 and over; Cause of Death; Female;
	Humans; Male; Middle Aged; Neoplasms, diagnosis/mortality/pathology;
	Norway; Registries; Survival Analysis},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pmid = {24302538},
  timestamp = {2015.06.22},
  url = {http://dx.doi.org/10.1002/ijc.28645}
}

@Book{Smaastuen2008,
  author    = {M. Sm{\aa}stuen and B. Aagnes and T.B. Johannesen and B. M{\o}ller and F. Bray},
  title     = {Long-term cancer survival: patterns and trends in Norway 1965-2007},
  publisher = {Cancer Registry of Norway},
  address   = {Oslo},
  file      = {Smaastuen2008.pdf:pdf\\Smaastuen2008.pdf:PDF;Smaastuen2008.pdf:Smaastuen2008.pdf:PDF},
  owner     = {pl4},
  timestamp = {2010.04.06},
  year      = {2008},
}

@ARTICLE{Tudur-Smith2005,
  author = {Catrin Tudur Smith and Paula R Williamson and Anthony G Marson},
  title = {An overview of methods and empirical comparison of aggregate data
	and individual patient data results for investigating heterogeneity
	in meta-analysis of time-to-event outcomes.},
  journal = {J Eval Clin Pract},
  year = {2005},
  volume = {11},
  pages = {468--478},
  number = {5},
  month = {Oct},
  abstract = {Combining the results of individual studies using meta-analysis may
	be undertaken using either aggregate data (AD) or individual patient
	data (IPD). In any meta-analysis it is important to consider statistical
	heterogeneity between studies. Potential sources of heterogeneity
	can be explored using regression models with either AD or IPD. An
	overview of approaches and empirical assessment of how the results
	and conclusions differ from these analyses is undertaken using a
	meta-analysis of five randomized controlled trials comparing two
	antiepileptic drugs with time-to-event outcomes. Alternative meta-regression
	models using AD are compared to stratified Cox regression models
	using IPD. Age as a potential cause of heterogeneity is detected
	by both AD and IPD regression models. Time from first ever seizure
	to randomization is only identified by some AD models. A more thorough
	explanation of heterogeneity is obtained from the model using IPD
	but further empirical evidence comparing IPD and AD results are needed.},
  doi = {10.1111/j.1365-2753.2005.00559.x},
  file = {Tudor-Smith2005.pdf:Tudor-Smith2005.pdf:PDF},
  institution = {Centre for Medical Statistics and Health Evaluation, Shelley's Cottage,
	University of Liverpool, Liverpool, UK. cat1@liv.ac.uk},
  owner = {pl4},
  pii = {JEP559},
  pmid = {16164588},
  timestamp = {2008.11.18},
  url = {http://dx.doi.org/10.1111/j.1365-2753.2005.00559.x}
}

@ARTICLE{Tudur-Smith2005a,
  author = {Catrin Tudur Smith and Paula R Williamson and Anthony G Marson},
  title = {Investigating heterogeneity in an individual patient data meta-analysis
	of time to event outcomes.},
  journal = {Statistics in Medicine},
  year = {2005},
  volume = {24},
  pages = {1307--1319},
  number = {9},
  month = {May},
  abstract = {Differences across studies in terms of design features and methodology,
	clinical procedures, and patient characteristics, are factors that
	can contribute to variability in the treatment effect between studies
	in a meta-analysis (statistical heterogeneity). Regression modelling
	can be used to examine relationships between treatment effect and
	covariates with the aim of explaining the variability in terms of
	clinical, methodological, or other factors. Such an investigation
	can be undertaken using aggregate data or individual patient data.
	An aggregate data approach can be problematic as sufficient data
	are rarely available and translating aggregate effects to individual
	patients can often be misleading. An individual patient data approach,
	although usually more resource demanding, allows a more thorough
	investigation of potential sources of heterogeneity and enables a
	fuller analysis of time to event outcomes in meta-analysis. Hierarchical
	Cox regression models are used to identify and explore the evidence
	for heterogeneity in meta-analysis and examine the relationship between
	covariates and censored failure time data in this context. Alternative
	formulations of the model are possible and illustrated using individual
	patient data from a meta-analysis of five randomized controlled trials
	which compare two drugs for the treatment of epilepsy. The models
	are further applied to simulated data examples in which the degree
	of heterogeneity and magnitude of treatment effect are varied. The
	behaviour of each model in each situation is explored and compared.},
  doi = {10.1002/sim.2050},
  file = {Tudor-Smith2005a.pdf:Tudor-Smith2005a.pdf:PDF},
  institution = {Centre for Medical Statistics and Health Evaluation, University of
	Liverpool, Liverpool L69 3BX, UK. catl@liv.ac.uk},
  owner = {pl4},
  pmid = {15685717},
  timestamp = {2008.11.18},
  url = {http://dx.doi.org/10.1002/sim.2050}
}

@ARTICLE{Smith1996,
  author = {Smith, D. and Taylor, R. and Coates, M.},
  title = {Socioeconomic Differentials in Cancer Incidence and Mortality in
	Urban {New South Wales}, 1987--1991},
  journal = {Australian \& New Zealand Journal of Public Health},
  year = {1996},
  volume = {20},
  pages = {129-137},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Smith1991,
  author = {Smith, G. D. and Leon, D. and Shipley, M. J. and Rose, G.},
  title = {Socioeconomic Differentials in Cancer Among Men},
  journal = {International Journal of Epidemiology},
  year = {1991},
  volume = {20},
  pages = {339-345},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Smith1990,
  author = {Smith, G. D. and Shipley, M. J. and Rose, G.},
  title = {Magnitude and Causes of Socioeconomic Differentials in Mortality:
	Further Evidence from the {W}hitehall Study},
  journal = {Journal of Epidemiology and Community Health},
  year = {1990},
  volume = {44},
  pages = {265-270},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Smith2004,
  author = {L. K. Smith and P. C. Lambert and J. L. Botha and D. R. Jones},
  title = {Providing more up-to-date estimates of patient survival: a comparison
	of standard survival analysis with period analysis using life-table
	methods and proportional hazards models.},
  journal = {Journal of Clinical Epidemiology},
  year = {2004},
  volume = {57},
  pages = {14--20},
  number = {1},
  month = {Jan},
  abstract = {OBJECTIVE: Standard survival methods can yield out-of-date estimates
	of long-term survival. Period analysis, based on life-table methodology,
	provides more up-to-date survival estimates by exploring survival
	during a restricted recent period of interest. It excludes the short-term
	survival of patients recruited at the start of the study. We use
	statistical models to further develop the method of period analysis,
	providing more up-to-date estimates of survival and the ability to
	explore differences in survival by covariates and adjust for case
	mix. METHODS: We use cancer registry data for colorectal cancer in
	Leicestershire, UK, to illustrate the use of Cox proportional hazards
	(CPH) models to estimate period and standard survival. We compare
	these estimates with those obtained using life-table methodology.
	RESULTS: Period estimates were slightly higher than the standard
	estimates as they reflect recent improvements in short-term survival.
	The results for period analysis using the life-table approach and
	using CPH models were similar. However, CPH models allowed further
	investigation of other risk factors and the ability to control for
	potential confounding variables. CONCLUSION: Using period survival
	estimates, more up-to-date information is available to clinicians
	and others with an interest in monitoring survival. Period CHP models
	offer all the advantages of statistical modeling, and are straightforward
	to fit in standard statistical packages.},
  doi = {10.1016/S0895-4356(03)00253-1},
  file = {smith2004.pdf:smith2004.pdf:PDF},
  institution = {Department of Health Sciences, University of Leicester, 22-28 Princess
	Road West, Leicester, LE1 6TP, UK. lks1@le.ac.uk},
  owner = {pl4},
  pii = {S0895435603002531},
  pmid = {15019006},
  timestamp = {2008.10.15},
  url = {http://dx.doi.org/10.1016/S0895-4356(03)00253-1}
}

@Article{Smith2003,
  author      = {L. K. Smith and P. C. Lambert and D. R. Jones},
  title       = {Up-to-date estimates of long-term cancer survival in {E}ngland and {W}ales.},
  doi         = {10.1038/sj.bjc.6600976},
  number      = {1},
  pages       = {74--76},
  url         = {http://dx.doi.org/10.1038/sj.bjc.6600976},
  volume      = {89},
  abstract    = {Cancer survival in England and Wales has improved over the last 30
	years. However, cohort survival estimates delay recognition of these
	improvements. Here we show that period survival estimates, based
	on survival in a recent time period, suggest a more optimistic pattern
	for England and Wales than cohort-based measures for most cancers.British
	Journal of Cancer (2003) 89, 74-76. doi:10.1038/sj.bjc.6600976 www.bjcancer.com},
  file        = {smith2003.pdf:smith2003.pdf:PDF},
  institution = {Department of Epidemiology and Public Health, University of Leicester, 22-28 Princess Road West, Leicester LE1 6TP, UK. lksl@le.ac.uk},
  journal     = {British Journal of Cancer},
  month       = {Jul},
  owner       = {pl4},
  pii         = {6600976},
  pmid        = {12838303},
  timestamp   = {2008.10.15},
  year        = {2003},
}

@ARTICLE{Smith1979,
  author = {Patricia L. Smith},
  title = {Splines As a Useful and Convenient Statistical Tool},
  journal = {The American Statistician},
  year = {1979},
  volume = {33},
  pages = {57-62},
  owner = {theand},
  timestamp = {2012.09.04}
}

@ARTICLE{Solovieva2004,
  author = {Svetlana Solovieva and Sanna Kouhia and P\"{a}ivi Leino-Arjas and
	Leena Ala-Kokko and Katariina Luoma and Raili Raininko and Janna
	Saarela and Hilkka Riihim\"{a}ki},
  title = {Interleukin 1 polymorphisms and intervertebral disc degeneration.},
  journal = {Epidemiology},
  year = {2004},
  volume = {15},
  pages = {626--633},
  number = {5},
  month = {Sep},
  abstract = {Enzymatic breakdown of the extracellular matrix, and possibly local
	inflammation, contributes to intervertebral disc degeneration. We
	investigated whether polymorphisms within the IL-1 gene locus are
	associated with lumbar disc degeneration and whether the effect of
	occupational physical load on disc degeneration is modified by the
	polymorphisms.Genotypes were determined from 133 middle-aged men
	who underwent magnetic resonance imaging of the lumbar spine. The
	participants represented 3 occupations: 40 were machine drivers,
	42 carpenters, and 51 office workers. We evaluated decreased signal
	intensity of the nucleus pulposus, disc bulges, and decreased disc
	height as signs of degeneration in the L2/L3-L5/S1 discs.The odds
	ratio for disc bulges was 2.4 (95\% confidence interval = 1.2-4.8)
	and 1.9 (1.0-3.7), in carriers of the IL-1alphaT or IL-1betaT alleles,
	respectively. The TT genotype of the IL-1alpha gene carried more
	than 3-fold risk of disc bulges as compared with the CC genotype.IL-1
	gene cluster polymorphisms could affect the risk of disc degeneration.
	The effect of physical workload seems to be modified by the IL-1
	gene polymorphisms.},
  institution = {Department of Epidemiology and Biostatistics, Finnish Institute of
	Occupational Health, Helsinki, Finland. Svetlana.Solovieva@ttl.fi},
  owner = {pl4},
  pii = {00001648-200409000-00021},
  pmid = {15308963},
  timestamp = {2011.05.26}
}

@ARTICLE{Soneji2014,
  author = {Soneji, Samir and Beltr{\'{a}}n-S{\'{a}}nchez, Hiram and Sox, Harold
	C.},
  title = {Assessing progress in reducing the burden of cancer mortality, 1985-2005.},
  journal = {J Clin Oncol},
  year = {2014},
  volume = {32},
  pages = {444--448},
  number = {5},
  month = {Feb},
  abstract = {Measuring the effect of cancer interventions must take into account
	rising cancer incidence now that people live longer because of declines
	in mortality from cardiovascular disease (CVD). Cancer mortality
	rates in the population do not accomplish this objective. We sought
	a measure that would reveal the effects of changing mortality rates
	from other diseases.We obtained annual breast, colorectal, lung,
	and prostate cancer mortality rates from the Surveillance, Epidemiology,
	and End Results registries; we obtained noncancer mortality rates
	from national death certificates, 1975 to 2005. We used life-table
	methods to calculate the burden of cancer mortality as the average
	person-years of life lost (PYLL) as a result of cancer (cancer-specific
	PYLL) and quantify individual-and perhaps offsetting-contributions
	of the two factors that affect cancer-specific PYLL: mortality rates
	as a result of cancer and other-cause mortality.Falling cancer mortality
	rates reduced the burden of mortality from leading cancers, but increasing
	cancer incidence as a result of decreasing other-cause mortality
	rates partially offset this progress. Between 1985 and 1989 and between
	2000 and 2004, the burden of lung cancer in males declined by 0.1
	year of life lost. This decline reflects the sum of two effects:
	decreasing lung cancer mortality rates that reduced the average burden
	of lung cancer mortality by 0.33 years of life lost and declining
	other-cause mortality rates that raised it by 0.23 years. Other common
	cancers showed similar patterns.By using a measure that accounts
	for increased cancer incidence as a result of improvements in CVD
	mortality, we find that prior assessments have underestimated the
	impact of cancer interventions.},
  doi = {10.1200/JCO.2013.50.8952},
  file = {Soneji2014.pdf:Soneji2014.pdf:PDF;Soneji2014.pdf:pdf\\Soneji2014.pdf:PDF},
  institution = {t Dartmouth, Hanover; Samir Soneji, Norris Cotton Cancer Center,
	Lebanon, NH; and Hiram Beltr{\AA}Â¡n-S{\AA}Â¡nchez, Center for Population and
	Development Studies, Harvard University, Cambridge, MA.},
  keywords = {Age Factors; Cause of Death; Continental Population Groups; Death
	Certificates; Female; Humans; Incidence; Life Tables; Male; Neoplasms,
	ethnology/mortality; Prognosis; Risk Factors; SEER Program; Sex Factors;
	Time Factors; United States, epidemiology},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pii = {JCO.2013.50.8952},
  pmid = {24419122},
  timestamp = {2014.10.13},
  url = {http://dx.doi.org/10.1200/JCO.2013.50.8952}
}

@Book{Spiegelhalter2003a,
  author    = {D. Spiegelhalter and A. Thomas and N. Best and D. Lunn},
  title     = {WinBUGS User Manual Version 1.4},
  publisher = {MRC Biostatistics Unit,},
  address   = {Cambridge},
  owner     = {pl4},
  timestamp = {2010.07.15},
  year      = {2003},
}

@Book{Spiegelhalter2003b,
  author    = {D. J. Spiegelhalter and K. R. Abrams and J. P. Myles},
  title     = {Bayesian Approaches to Clinical Trials and Health-Care Evaluation},
  publisher = {Wiley},
  address   = {Chichester},
  owner     = {pl4},
  timestamp = {2010.07.15},
  year      = {2003},
}

@ARTICLE{Spiegelhalter2003,
  author = {David J Spiegelhalter and Nicola G Best},
  title = {Bayesian approaches to multiple sources of evidence and uncertainty
	in complex cost-effectiveness modelling.},
  journal = {Statistics in Medicine},
  year = {2003},
  volume = {22},
  pages = {3687--3709},
  number = {23},
  month = {Dec},
  abstract = {Increasingly complex models are being used to evaluate the cost-effectiveness
	of medical interventions. We describe the multiple sources of uncertainty
	that are relevant to such models, and their relation to either probabilistic
	or deterministic sensitivity analysis. A Bayesian approach appears
	natural in this context. We explore how sensitivity analysis to patient
	heterogeneity and parameter uncertainty can be simultaneously investigated,
	and illustrate the necessary computation when expected costs and
	benefits can be calculated in closed form, such as in discrete-time
	discrete-state Markov models. Information about parameters can either
	be expressed as a prior distribution, or derived as a posterior distribution
	given a generalized synthesis of available data in which multiple
	sources of evidence can be differentially weighted according to their
	assumed quality. The resulting joint posterior distributions on costs
	and benefits can then provide inferences on incremental cost-effectiveness,
	best presented as posterior distributions over net-benefit and cost-effectiveness
	acceptability curves. These ideas are illustrated with a detailed
	running example concerning the cost-effectiveness of hip prostheses
	in different age-sex subgroups. All computations are carried out
	using freely available software for conducting Markov chain Monte
	Carlo analysis.},
  doi = {10.1002/sim.1586},
  file = {Spiegelhalter2003.pdf:Spiegelhalter2003.pdf:PDF;Spiegelhalter2003.pdf:pdf\\Spiegelhalter2003.pdf:PDF},
  institution = {MRC Biostatistics Unit, Institute of Public Health, Robinson Way,
	Cambridge CB2 2SR, UK.},
  owner = {pl4},
  pmid = {14652869},
  timestamp = {2010.07.15},
  url = {http://dx.doi.org/10.1002/sim.1586}
}

@ARTICLE{Spiegelhalter2002,
  author = {Spiegelhalter, D. J. and Best, N. G. and Carlin, B. P. and van der
	Linde, A.},
  title = {Bayesian measures of model complexity and fit},
  journal = {Journal of the Royal Statistical Society (B)},
  year = {2002},
  volume = {64},
  pages = {583-639},
  file = {Spiegelhalter2002.pdf:pdf\\Spiegelhalter2002.pdf:PDF;Spiegelhalter2002.pdf:Spiegelhalter2002.pdf:PDF},
  owner = {hanbow},
  timestamp = {2015.05.26}
}

@ARTICLE{Sposto2002,
  author = {R. Sposto},
  title = {Cure model analysis in cancer: an application to data from the Children's
	Cancer Group.},
  journal = {Statistics in Medicine},
  year = {2002},
  volume = {21},
  pages = {293--312},
  number = {2},
  month = {Jan},
  file = {Sposto2002.pdf:Sposto2002.pdf:PDF;Sposto2002.pdf:pdf\\Sposto2002.pdf:PDF},
  keywords = {Cure models},
  owner = {pl4},
  pii = {10.1002/sim.987},
  pmid = {11782066},
  timestamp = {2009.01.07}
}

@ARTICLE{Squire2010,
  author = {Iain B Squire and Christopher P Nelson and Leong L Ng and David R
	Jones and Kent L Woods and Paul C Lambert},
  title = {Prognostic value of admission blood glucose concentration and diabetes
	diagnosis on survival after acute myocardial infarction; Results
	from 4702 index cases in routine practice.},
  journal = {Clinical Science},
  year = {2010},
  volume = {118},
  pages = {527-535},
  month = {Oct},
  abstract = {The diagnosis of diabetes and admission blood glucose concentration
	are associated with adverse outcome after acute coronary syndromes.
	We compared the relative association with survival after ST-elevation
	acute myocardial infarction of admission blood glucose concentration
	and of diabetes diagnosis. We carried out a retrospective cohort
	study in 4702 consecutive patients with ST elevation AMI (STEMI)
	occurring April 1st 1993 - December 31st 2005, assessed for mortality
	at 30 days and 1 year. Patients were classified according to antecedent
	diabetes, and by blood glucose concentration at admission (quartile
	1, <7mmol/L; quartile 2, 7 - 8.2 mmol/L; quartile 3, 8.3 - 10.9 mmol/L;
	quartile 4, >/=11 mmol/L). Multivariable models were constructed
	for determinants of mortality, including year of STEMI and demographic
	variables, entering blood glucose concentration and antecedent diabetes
	individually, and together. All-cause 30-day and 1-year mortality
	were 22.8\% and 31.3\% for patients with antecedent diabetes, compared
	to 16.3\% and 23.0\% respectively for those without. For glucose
	quartiles 1, 2, 3, and 4, crude 30-day mortality was 9.0\%, 10.6\%,
	17.9\% and 31.0\%. Adjusted 30-day mortality risk was similar in
	quartile 2, higher by >80\% in quartile 3 and by >150\% in quartile
	4, compared to glucose quartile 1. Antecedent diabetes was associated
	with an increase in mortality (unadjusted odds ratio (OR) 1.52 (95\%
	CI 1.24 , 1.86)). On multivariable analysis (excluding glucose quartile),
	this reduced to 1.24 (0.98 , 1.58) and changed to a small, statistically
	non-significant reduction in risk when glucose quartile was added
	to the analysis (adjusted OR 0.87 (0.67 , 1.13)). Inclusion of antecedent
	diabetes in multivariable models did not add to the predictive value
	for mortality of glucose quartile (p=0.368). Similar relationships
	were observed for 1 year mortality. In patients with STEMI, blood
	glucose concentration shows graded association with risk of 30-day
	and 1-year mortality and is of greater prognostic relevance than
	antecedent diabetes diagnosis. Moderate elevation of blood glucose,
	below levels previously considered to be clinically relevant, is
	associated with adverse impact on survival.},
  doi = {10.1042/CS20090322},
  file = {Squire2010.pdf:Squire2010.pdf:PDF;Squire2010.pdf:pdf\\Squire2010.pdf:PDF},
  owner = {pl4},
  pii = {CS20090322},
  pmid = {19824882},
  timestamp = {2010.04.05},
  url = {http://dx.doi.org/10.1042/CS20090322}
}

@InCollection{Stabin1996,
  author    = {Stabin, M. G.},
  booktitle = {Nuclear Medicine},
  title     = {Internal radiation dosimetry},
  editor    = {Henkin, R. E.},
  pages     = {316--333},
  publisher = {St Louis: Mosby},
  volume    = {I},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1996},
}

@ARTICLE{Staessen1997,
  author = {J. A. Staessen and R. Fagard and L. Thijs and H. Celis and G. G.
	Arabidze and W. H. Birkenh\"{a}ger and C. J. Bulpitt and P. W. de
	Leeuw and C. T. Dollery and A. E. Fletcher and F. Forette and G.
	Leonetti and C. Nachev and E. T. O'Brien and J. Rosenfeld and J.
	L. Rodicio and J. Tuomilehto and A. Zanchetti},
  title = {Randomised double-blind comparison of placebo and active treatment
	for older patients with isolated systolic hypertension. The Systolic
	Hypertension in Europe (Syst-Eur) Trial Investigators.},
  journal = {Lancet},
  year = {1997},
  volume = {350},
  pages = {757--764},
  number = {9080},
  month = {Sep},
  abstract = {BACKGROUND: Isolated systolic hypertension occurs in about 15\% of
	people aged 60 years or older. In 1989, the European Working Party
	on High Blood Pressure in the Elderly investigated whether active
	treatment could reduce cardiovascular complications of isolated systolic
	hypertension. Fatal and non-fatal stroke combined was the primary
	endpoint. METHODS: All patients (> 60 years) were initially started
	on masked placebo. At three run-in visits 1 month apart, their average
	sitting systolic blood pressure was 160-219 mm Hg with a diastolic
	blood pressure lower than 95 mm Hg. After stratification for centre,
	sex, and previous cardiovascular complications, 4695 patients were
	randomly assigned to nitrendipine 10-40 mg daily, with the possible
	addition of enalapril 5-20 mg daily and hydrochlorothiazide 12.5-25.0
	mg daily, or matching placebos. Patients withdrawing from double-blind
	treatment were still followed up. We compared occurrence of major
	endpoints by intention to treat. FINDINGS: At a median of 2 years'
	follow-up, sitting systolic and diastolic blood pressures had fallen
	by 13 mm Hg and 2 mm Hg in the placebo group (n = 2297) and by 23
	mm Hg and 7 mm Hg in the active treatment group (n = 2398). The between-group
	differences were systolic 10.1 mm Hg (95\% CI 8.8-11.4) and diastolic,
	4.5 mm Hg (3.9-5.1). Active treatment reduced the total rate of stroke
	from 13.7 to 7.9 endpoints per 1000 patient-years (42\% reduction;
	p = 0.003). Non-fatal stroke decreased by 44\% (p = 0.007). In the
	active treatment group, all fatal and non-fatal cardiac endpoints,
	including sudden death, declined by 26\% (p = 0.03). Non-fatal cardiac
	endpoints decreased by 33\% (p = 0.03) and all fatal and non-fatal
	cardiovascular endpoints by 31\% (p < 0.001). Cardiovascular mortality
	was slightly lower on active treatment (-27\%, p = 0.07), but all-cause
	mortality was not influenced (-14\%; p = 0.22). INTERPRETATION: Among
	elderly patients with isolated systolic hypertension, antihypertensive
	drug treatment starting with nitrendipine reduces the rate of cardiovascular
	complications. Treatment of 1000 patients for 5 years with this type
	of regimen may prevent 29 strokes or 53 major cardiovascular endpoints.},
  file = {Staessen1997.pdf:Staessen1997.pdf:PDF;Staessen1997.pdf:pdf\\Staessen1997.pdf:PDF},
  institution = {Department of Molecular and Cardiovascular Research, University of
	Leuvan, Belgium.},
  owner = {pl4},
  pii = {S0140673697053816},
  pmid = {9297994},
  timestamp = {2008.11.18}
}

@ARTICLE{Stamey89,
  author = {T. A. Stamey and J. N. Kabalin and J. E. McNeal and I. M. Johnstone
	and F. Freiha and E. A. Redwine and N. Yang},
  title = {Prostate specific antigen in the diagnosis and treatment of adenocarcinoma
	of the prostate. II. Radical prostatectomy treated patients},
  journal = {Journal of Urology},
  year = {1989},
  volume = {141},
  pages = {1076--1083},
  owner = {pl4},
  timestamp = {2011.01.21}
}

@ARTICLE{Stare2005a,
  author = {J. Stare and R. Henderson and M. Pohar},
  title = {An individual measure of relative survival},
  journal = {Applied Statistics},
  year = {2005},
  volume = {54},
  pages = {115-126},
  file = {Stare2005a.pdf:Stare2005a.pdf:PDF;Stare2005a.pdf:pdf\\Stare2005a.pdf:PDF},
  owner = {pl4},
  timestamp = {2008.12.16}
}

@ARTICLE{Stare2005,
  author = {Janez Stare and Maja Pohar and Robin Henderson},
  title = {Goodness of fit of relative survival models.},
  journal = {Statistics in Medicine},
  year = {2005},
  volume = {24},
  pages = {3911--3925},
  number = {24},
  month = {Dec},
  abstract = {Additive regression models are preferred over multiplicative models
	in the analysis of relative survival data. Such preferences are mainly
	grounded in practical experience with mostly cancer registries data,
	where the basic assumption of the additivity of hazards is more likely
	to be met. Also, the interpretation of coefficients is more meaningful
	in additive than in multiplicative models. Nonetheless, the question
	of goodness of fit of the assumed model must still be addressed,
	and while there is an abundance of methods to check the goodness
	of fit of multiplicative models, the respective arsenal for additive
	models is almost empty. We propose here a variety of procedures for
	testing the null hypothesis of a good fit. These are based on partial
	residuals defined similarly to Schoenfeld residuals familiar for
	Cox model diagnostics. The tests have appropriate sizes under the
	null hypothesis, and good power under different alternatives. We
	investigate their performance through simulations and apply the methods
	to data from a study into survival of colon cancer patients.},
  doi = {10.1002/sim.2414},
  file = {Stare2005.pdf:Stare2005.pdf:PDF;Stare2005.pdf:pdf\\Stare2005.pdf:PDF},
  institution = {Department of Biomedical Informatics, University of Ljubljana, Ljubljana,
	Slovenia. janez.stare@mf.uni-lj.si},
  owner = {pl4},
  pmid = {16320279},
  timestamp = {2008.12.16},
  url = {http://dx.doi.org/10.1002/sim.2414}
}

@Book{Stata2013,
  author    = {Stata},
  title     = {Stata base reference manual Release 13},
  publisher = {Stata Press: College Station},
  owner     = {sanelo},
  timestamp = {2013.07.30},
  year      = {2013},
}

@Manual{StataCorporation2007,
  author       = {{Stata Corporation}},
  title        = {Stata User's Guide Release 12.},
  organization = {{Stata Press, College Station}},
  owner        = {theand},
  timestamp    = {2012.09.03},
  year         = {2007},
}

@TechReport{SCB2009,
  author      = {{Statistics Sweden (Statistiska Centralbyr{\aa}n)}},
  institution = {Demographic reports 2009:1,},
  title       = {The future population of Sweden 2009-2060.},
  owner       = {sanelo},
  timestamp   = {2013.10.08},
  year        = {2009},
}

@ARTICLE{Stattin2010,
  author = {Stattin, P{\"a}r and Holmberg, Erik and Johansson, Jan-Erik and Holmberg,
	Lars and Adolfsson, Jan and Hugosson, Jonas and {on behalf of the
	National Prostate Cancer Register (NPCR) of Sweden}},
  title = {Outcomes in localized prostate cancer: {N}ational {P}rostate {C}ancer
	{R}egister of {S}weden follow-up study.},
  journal = {J Natl Cancer Inst},
  year = {2010},
  volume = {102},
  pages = {950--958},
  number = {13},
  month = {Jul},
  abstract = {Treatment for localized prostate cancer remains controversial. To
	our knowledge, there are no outcome studies from contemporary population-based
	cohorts that include data on stage, Gleason score, and serum levels
	of prostate-specific antigen (PSA).In the National Prostate Cancer
	Register of Sweden Follow-up Study, a nationwide cohort, we identified
	6849 patients aged 70 years or younger. Inclusion criteria were diagnosis
	with local clinical stage T1-2 prostate cancer from January 1, 1997,
	through December 31, 2002, a Gleason score of 7 or less, a serum
	PSA level of less than 20 ng/mL, and treatment with surveillance
	(including active surveillance and watchful waiting, n = 2021) or
	curative intent (including radical prostatectomy, n = 3399, and radiation
	therapy, n = 1429). Among the 6849 patients, 2686 had low-risk prostate
	cancer (ie, clinical stage T1, Gleason score 2-6, and serum PSA level
	of <10 ng/mL). The study cohort was linked to the Cause of Death
	Register, and cumulative incidence of death from prostate cancer
	and competing causes was calculated.For the combination of low- and
	intermediate-risk prostate cancers, calculated cumulative 10-year
	prostate cancer-specific mortality was 3.6\% (95\% confidence interval
	[CI] = 2.7\% to 4.8\%) in the surveillance group and 2.7\% (95\%
	CI = 2.1\% to 3.45) in the curative intent group. For those with
	low-risk disease, the corresponding values were 2.4\% (95\% CI =
	1.2\% to 4.1\%) among the 1085 patients in the surveillance group
	and 0.7\% (95\% CI = 0.3\% to 1.4\%) among the 1601 patients in the
	curative intent group. The 10-year risk of dying from competing causes
	was 19.2\% (95\% CI = 17.2\% to 21.3\%) in the surveillance group
	and 10.2\% (95\% CI = 9.0\% to 11.4\%) in the curative intent group.A
	10-year prostate cancer-specific mortality of 2.4\% among patients
	with low-risk prostate cancer in the surveillance group indicates
	that surveillance may be a suitable treatment option for many patients
	with low-risk disease.},
  doi = {10.1093/jnci/djq154},
  institution = {Urology and Andrology, Department of Surgical and Perioperative Science,
	Ume{\aa} University Hospital, Ume{\aa}, Sweden. par.stattin@urologi.umu.se},
  keywords = {Aged; Androgen Antagonists, administration /&/ dosage; Antineoplastic
	Agents, Hormonal, administration /&/ dosage; Comorbidity; Follow-Up
	Studies; Humans; Male; Middle Aged; Neoplasm Staging; Population
	Surveillance; Prostate-Specific Antigen, blood; Prostatectomy; Prostatic
	Neoplasms, epidemiology/immunology/mortality/pathology/therapy; Radiotherapy,
	Adjuvant; Registries; Research Design; Retrospective Studies; Selection
	Bias; Socioeconomic Factors; Sweden, epidemiology; Treatment Outcome;
	Tumor Markers, Biological, blood},
  language = {eng},
  medline-pst = {ppublish},
  owner = {sanelo},
  pii = {djq154},
  pmid = {20562373},
  timestamp = {2013.07.31},
  url = {http://dx.doi.org/10.1093/jnci/djq154}
}

@Article{destavola2014,
  author    = {Bianca L. {De Stavola} and Rhian M. Daniel and George B. Ploubidis and Nadia Micali},
  title     = {Mediation Analysis With Intermediate Confounding: Structural Equation Modeling Viewed Through the Causal Inference Lens.},
  journal   = {American Journal of Epidemiology},
  year      = {2014},
  volume    = {181},
  number    = {1},
  file      = {:pdf\\destavola2014.pdf:PDF},
  owner     = {BettyS},
  timestamp = {2016.12.09},
}

@ARTICLE{Stavraky1987,
  author = {Stavraky, K. M. and Kincade, J. E. and Stewart, M. A. and Donner,
	A. P.},
  title = {The Effect of Socioeconomic Factors on the Early Prognosis of Cancer},
  journal = {Journal of Chronic Diseases},
  year = {1987},
  volume = {40},
  pages = {237-244},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@Article{Stefanski2002,
  author  = {L.A. Stefanski and D.D. Boos},
  title   = {The Calculus of {M}-Estimation},
  journal = {The American Statistician},
  year    = {2002},
  volume  = {56},
  pages   = {29-38},
  file    = {Stefanski2002.pdf:Stefanski2002.pdf:PDF},
}

@ARTICLE{Steineck2002,
  author = {Gunnar Steineck and Karin Bergmark and Lars Henningsohn and Massoud
	al-Abany and Paul W Dickman and Asgeir Helgason},
  title = {Symptom documentation in cancer survivors as a basis for therapy
	modifications.},
  journal = {Acta Oncol},
  year = {2002},
  volume = {41},
  pages = {244-52},
  number = {3},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@Article{Steineck2002a,
  author    = {Gunnar Steineck and Fred Helgesen and Jan Adolfsson and Paul W Dickman and Jan-Erik Johansson and Bo Johan Norl\'{e}n and Lars Holmberg and Scandinavian Prostatic Cancer Group Study Number 4},
  title     = {Quality of life after radical prostatectomy or watchful waiting.},
  number    = {11},
  pages     = {790-6},
  volume    = {347},
  abstract  = {BACKGROUND: We evaluated symptoms and self-assessments of quality
	of life in men with localized prostate cancer who participated in
	a randomized comparison between radical prostatectomy and watchful
	waiting. METHODS: Between 1989 and 1999, a group of Swedish urologists
	randomly assigned men with localized prostate cancer to radical prostatectomy
	or watchful waiting. In this follow-up study, we obtained information
	from 326 of 376 eligible men (87 percent) concerning certain symptoms,
	symptom-induced distress, well-being, and the subjective assessment
	of quality of life by means of a mailed questionnaire. RESULTS: Erectile
	dysfunction (80 percent vs. 45 percent) and urinary leakage (49 percent
	vs. 21 percent) were more common after radical prostatectomy, whereas
	urinary obstruction (e.g., 28 percent vs. 44 percent for weak urinary
	stream) was less common. Bowel function, the prevalence of anxiety,
	the prevalence of depression, well-being, and the subjective quality
	of life were similar in the two groups. CONCLUSIONS: The assignment
	of patients to watchful waiting or radical prostatectomy entails
	different risks of erectile dysfunction, urinary leakage, and urinary
	obstruction, but on average, the choice has little if any influence
	on well-being or the subjective quality of life after a mean follow-up
	of four years.},
  journal   = {N Engl J Med},
  month     = {Sep},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2002},
}

@ARTICLE{Stensheim2009,
  author = {Stensheim, Hanne and M{\AA}Â¸ller, Bj{\AA}Â¸rn and {van Dijk}, Tini and Foss{\aa},
	Sophie D.},
  title = {Cause-specific survival for women diagnosed with cancer during pregnancy
	or lactation: a registry-based cohort study.},
  journal = {J Clin Oncol},
  year = {2009},
  volume = {27},
  pages = {45--51},
  number = {1},
  month = {Jan},
  abstract = {To assess if cancers diagnosed during pregnancy or lactation are associated
	with increased risk of cause-specific death.In this population-based
	cohort study using data from the Cancer Registry and the Medical
	Birth Registry of Norway, 42,511 women, age 16 to 49 years and diagnosed
	with cancer from 1967 to 2002, were eligible. They were grouped as
	not pregnant (reference), pregnant, or lactating at diagnosis. Cause-specific
	survival for all sites combined, and for the most frequent malignancies,
	was investigated using a Cox proportional hazards model. An additional
	analysis with time-dependent covariates was performed for comparison
	of women with and without a postcancer pregnancy. The multivariate
	analyses were adjusted for age at diagnosis, extent of disease, and
	diagnostic periods.For all sites combined, no intergroup differences
	in cause-specific death were seen, with hazard ratio (HR) of 1.03
	(95\% CI, 0.86 to 1.22) and HR 1.02 (95\% CI, 0.86 to 1.22) for the
	pregnant and lactating groups, respectively. Patients with breast
	(HR, 1.95; 95\% CI, 1.36 to 2.78) and ovarian cancer (HR, 2.23; 95\%
	CI, 1.05 to 4.73) diagnosed during lactation had an increased risk
	of cause-specific death. Diagnosis of malignant melanoma during pregnancy
	slightly increased this risk. For all sites combined, the risk of
	cause-specific death was significantly decreased for women who had
	postcancer pregnancies.In general, the diagnosis of most cancer types
	during pregnancy or lactation does not increase the risk of cause-specific
	death. Breast and ovarian cancer diagnosed during lactation represents
	an exception. We confirmed the "healthy mother effect" for women
	with a postcancer pregnancy.},
  doi = {10.1200/JCO.2008.17.4110},
  file = {Stensheim2009.pdf:Stensheim2009.pdf:PDF},
  institution = {Cancer Registry of Norway, Oslo, Norway. hanne.stensheim@kreftregisteret.no},
  keywords = {Adolescent; Adult; Breast Neoplasms, mortality; Cohort Studies; Female;
	Humans; Lactation; Middle Aged; Ovarian Neoplasms, mortality; Pregnancy;
	Pregnancy Complications, Neoplastic, mortality; Registries},
  language = {eng},
  medline-pst = {ppublish},
  owner = {CarolineW},
  pii = {JCO.2008.17.4110},
  pmid = {19029418},
  timestamp = {2014.04.28},
  url = {http://dx.doi.org/10.1200/JCO.2008.17.4110}
}

@ARTICLE{Stephansson2001,
  author = {O Stephansson and PW Dickman and A Johansson and S Cnattingius},
  title = {Maternal weight, pregnancy weight gain, and the risk of antepartum
	stillbirth.},
  journal = {Am J Obstet Gynecol},
  year = {2001},
  volume = {184},
  pages = {463-9},
  number = {3},
  month = {Feb},
  abstract = {OBJECTIVE: This study investigated whether the risk of antepartum
	stillbirth increases with body mass index during early pregnancy
	and also investigated the association between weight gain during
	pregnancy and the risk of antepartum stillbirth.Study Design: This
	population-based case-control study included 649 women with antepartum
	stillbirths and 690 control subjects among Swedish nulliparous women.
	RESULTS: Compared with lean mothers (body mass index < or = 19.9
	kg/m2), the odds ratios for risk of antepartum deaths were as follows:
	normal weight (body mass index, 20.0-24.9 kg/m2) odds ratio, 1.2
	(95\% confidence interval, 0.8-1.7); overweight (body mass index
	25.0-29.9 kg/m2), odds ratio, 1.9 (95\% confidence interval, 1.2-2.9);
	and obese (body mass index > or = 30.0 kg/m2) odds ratio, 2.1 (95\%
	confidence interval, 1.2-3.6). For term antepartum death corresponding
	risks were even higher, with odds ratios of 1.6 (95\% confidence
	interval, 0.9-2.6) for normal weight, 2.7 (95\% confidence interval,
	1.5-5.0) for overweight, and 2.8 (95\% confidence interval, 1.3-6.0)
	for obese women, respectively. Maternal weight gain during pregnancy
	was not associated with risk of antepartum stillbirth. CONCLUSION:
	Maternal overweight condition increased the risk of antepartum stillbirth,
	especially term antepartum stillbirth, whereas weight gain during
	pregnancy was not associated with risk.},
  owner = {PaulD},
  pii = {S0002937801685508},
  timestamp = {2011.06.19}
}

@ARTICLE{Stephansson2001a,
  author = {O Stephansson and PW Dickman and AL Johansson and S Cnattingius},
  title = {The influence of socioeconomic status on stillbirth risk in {S}weden.},
  journal = {Int J Epidemiol},
  year = {2001},
  volume = {30},
  pages = {1296-301},
  number = {6},
  month = {Dec},
  abstract = {BACKGROUND: Low socioeconomic status (SES) is generally associated
	with increased risk of stillbirth, but the mechanisms have rarely
	been investigated. Our aim was to study the association between SES
	and risk of stillbirth, and to assess whether any differences in
	risk are mediated by other maternal socio-demographic or anthropometrical
	characteristics, differences in lifestyle, or attendance at antenatal
	care. METHODS: Population-based individually-matched case-control
	study including 702 cases of stillbirth and 702 controls among Swedish
	primiparous women giving birth 1987-1996. We estimated the risk of
	stillbirth, and subgroups of stillbirth, for various categories of
	SES. Odds ratios (OR) with 95\% CI, estimated by conditional logistic
	regression, were used to approximate the relative risk. The estimates
	were adjusted for maternal age, height, body mass index, cigarette
	smoking, and when necessary mother's country of birth. RESULTS: Compared
	with women who were high level white-collar workers, the adjusted
	risks of stillbirth were as follows: unskilled blue-collar workers,
	2.2 (95\% CI : 1.3- 3.7), skilled blue-collar workers, 2.4 (95\%
	CI : 1.3-4.1), low level white-collar workers, 1.9 (95\% CI : 1.2-3.2),
	and intermediate level white-collar workers 1.4 (95\% CI : 0.9-2.4).
	These risks were not substantially changed when we further adjusted
	for attendance at antenatal care, previous reproductive history,
	or excluded pregnancies with maternal diseases, and pregnancy-related
	disorders. Low social class was most associated with risks of term
	antepartum and intrapartum stillbirths. CONCLUSIONS: Low SES increases
	the risk of stillbirth. The association could not be explained by
	any of the factors we studied, and the underlying reasons remain
	unclear.},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Stephansson2000,
  author = {O Stephansson and PW Dickman and A Johansson and S Cnattingius},
  title = {Maternal hemoglobin concentration during pregnancy and risk of stillbirth.},
  journal = {JAMA},
  year = {2000},
  volume = {284},
  pages = {2611-7},
  number = {20},
  abstract = {CONTEXT: High and low maternal hemoglobin concentrations during pregnancy
	have been reported to increase risk of small-for-gestational-age
	(SGA) birth, which is a predictor of stillbirth. The relationship
	between hemoglobin concentration during pregnancy and risk of stillbirth
	is unclear. OBJECTIVE: To study the associations among hemoglobin
	concentration at first measurement during antenatal care, change
	in hemoglobin concentration during pregnancy, and risk of stillbirth.
	DESIGN, SETTING, AND PARTICIPANTS: Population-based, matched case-control
	study of births from 1987 through 1996 in {S}weden including 702
	primiparous women with stillbirths occurring at 28 weeks' gestation
	or later and 702 primiparous women with live births. MAIN OUTCOME
	MEASURES: Risk of stillbirth, classified as malformed or nonmalformed,
	antepartum or intrapartum, preterm or term, and SGA or non-SGA, compared
	by maternal hemoglobin concentration at first antenatal measurement
	and weekly changes in hemoglobin concentration during pregnancy,
	adjusted for maternal age, body mass index, height, smoking, socioeconomic
	status, and week of first hemoglobin measurement. RESULTS: In multivariate
	analyses, compared with women with hemoglobin concentrations of 126
	to 135 g/L at first antenatal measurement, women with concentrations
	of 146 g/L or higher were at increased risk of stillbirth (odds ratio
	[OR], 1.8; 95\% confidence interval [CI], 1.0-3.3). This risk was
	slightly increased when the analysis was restricted to antepartum
	stillbirths without malformations (OR, 2.0; 95\% CI, 1.1-3.8). When
	we further restricted the analyses to preterm and SGA antepartum
	nonmalformed stillbirths, the ORs increased to 2.7 (95\% CI, 1.1-6.4)
	and 4.2 (95\% CI, 1.3-13. 9), respectively. Excluding women with
	preeclampsia and eclampsia further increased these risks. Average
	weekly change in hemoglobin concentration during early or late pregnancy
	was not significantly associated with risk of stillbirth, although
	a larger decrease in concentration tended to be protective. Anemia
	(hemoglobin concentration <110 g/L) was not significantly associated
	with risk of stillbirth in multivariate analyses (OR, 1.2; 95\% CI,
	0.5-2.7). CONCLUSIONS: High hemoglobin concentration at first measurement
	during antenatal care appears to be associated with increased risk
	of stillbirth, especially preterm and SGA antepartum stillbirths.
	JAMA. 2000;284:2611-2617.},
  owner = {PaulD},
  pii = {joc00741},
  timestamp = {2011.06.19}
}

@ARTICLE{Stephansson2003,
  author = {Olof Stephansson and Paul W Dickman and Sven Cnattingius},
  title = {The influence of interpregnancy interval on the subsequent risk of
	stillbirth and early neonatal death.},
  journal = {Obstet Gynecol},
  year = {2003},
  volume = {102},
  pages = {101-8},
  number = {1},
  month = {Jul},
  abstract = {OBJECTIVE: To study whether interpregnancy interval is associated
	with increased risks of stillbirth and early neonatal death and whether
	this possible association is confounded by maternal characteristics
	and previous reproductive history. METHODS: In a Swedish nationwide
	study of 410,021 women's first and second singleton deliveries between
	1983 and 1997, we investigated the influence of interpregnancy interval
	on the subsequent risks of stillbirth and early neonatal death. Odds
	ratios (ORs) with 95\% confidence intervals (CIs) estimated using
	unconditional logistic regression were adjusted for maternal characteristics
	and previous pregnancy outcome categorized into stillbirth, early
	neonatal death, preterm, or small for gestational age delivery. RESULTS:
	Compared with interpregnancy intervals between 12 and 35 months,
	very short interpregnancy intervals (0-3 months) were, in the univariate
	analyses, associated with increased risks of stillbirth and early
	neonatal death (crude OR 1.9; 95\% CI 1.3, 2.7; and 1.8; 1.2, 2.8,
	respectively). However, after adjusting for maternal characteristics
	and previous reproductive history, women with interpregnancy intervals
	of 0 to 3 months were not at increased risks of stillbirth (adjusted
	OR 1.3; 95\% CI 0.8, 2.1) or early neonatal death (adjusted OR 0.9;
	95\% CI 0.5, 1.6). Women with interpregnancy intervals of 72 months
	and longer were at increased risk of stillbirth (adjusted OR 1.5;
	95\% CI 1.1, 2.1) and possibly early neonatal death (adjusted OR
	1.3; 95\% CI 0.9, 2.1). CONCLUSION: Short interpregnancy intervals
	appear not to be causally associated with increased risk of stillbirth
	and early neonatal death, whereas long interpregnancy intervals were
	associated with increased risk of stillbirth and possibly early neonatal
	death.},
  owner = {PaulD},
  pii = {S0029784403003661},
  timestamp = {2011.06.19}
}

@ARTICLE{Stephansson2003a,
  author = {Olof Stephansson and Paul W Dickman and Anna L V Johansson and Helle
	Kieler and Sven Cnattingius},
  title = {Time of birth and risk of intrapartum and early neonatal death.},
  journal = {Epidemiology},
  year = {2003},
  volume = {14},
  pages = {218-22},
  number = {2},
  month = {Mar},
  abstract = {BACKGROUND: Previous studies have found that infants born at night
	and during weekends and holidays have an increased risk of perinatal
	mortality. However, these associations may be confounded by the distribution
	of high-risk deliveries according to time of birth. METHODS: We undertook
	a population-based cohort study of 694,888 singleton births without
	elective cesarean section in {S}weden between 1991 and 1997. We estimated
	relative risks of intrapartum and early neonatal death according
	to the hour, day and month of delivery. Estimated risk ratios were
	adjusted for gestational age, birth weight for gestational age, malformations,
	induction of labor, breech presentations and year of birth. RESULTS:
	Infants of high-risk deliveries were more often delivered during
	daytime (8:00 am to 7:59 pm). Compared with infants born during daytime,
	infants born at night were at increased risk of early neonatal death
	(adjusted risk ratio = 1.28; 95\% confidence interval = 1.13-1.46),
	but not intrapartum death (1.05; 0.71-1.54). If this association
	is causal, 12\% of early neonatal deaths can be attributed to the
	increased risk among nighttime births. There was no association of
	weekend or holiday births with risks of intrapartum or early neonatal
	death. CONCLUSIONS: Infants born at night may be at increased risk
	of early neonatal death.},
  doi = {10.1097/01.EDE.0000037975.55478.C7},
  owner = {PaulD},
  timestamp = {2011.06.19},
  url = {http://dx.doi.org/10.1097/01.EDE.0000037975.55478.C7}
}

@ARTICLE{Stevenson1993,
  author = {Stevenson, J. M. and Olson, D. R.},
  title = {Analysing County-Level Mortality Rates},
  journal = {Statistics in Medicine},
  year = {1993},
  volume = {12},
  pages = {393-401},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{steyerberg2003,
  author = {E. W. Steyerberg and S. E. Bleeker and H. A. Moll and D. E. Grobbee
	and K. G. M. Moons},
  title = {Internal and external validation of predictive models: a simulation
	study of bias and precision in small samples.},
  journal = {Journal of Clinical Epidemiology},
  year = {2003},
  volume = {56},
  pages = {441ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Â“447},
  file = {steyerberg2003.pdf:steyerberg2003.pdf:PDF},
  owner = {BettyS},
  timestamp = {2016.11.28}
}

@ARTICLE{Stijnen1993,
  author = {Stijnen, T. and Van Houwelingen, H. C.},
  title = {Relative Risk, Risk Difference and Rate Difference Models for Sparse
	Stratified Data: A Pseudo Likelihood Approach},
  journal = {Statistics in Medicine},
  year = {1993},
  volume = {12},
  pages = {2285-303},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@Book{Stoer2002,
  author    = {Stoer, Josef and Bulirsch, Roland},
  title     = {Introduction to Numerical Analysis (3rd ed.)},
  publisher = {Springer},
  owner     = {theand},
  timestamp = {2012.11.14},
  year      = {2002},
}

@ARTICLE{Stoppa-Lyonnet2000,
  author = {Stoppa-Lyonnet, D. and Ansquer, Y. and Dreyfus, H. and Gautier, C.
	and Gauthier-Villars, M. and Bourstyn, E. and Clough, K. B. and Magdel{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â­ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¡t,
	H. and Pouillart, P. and Vincent-Salomon, A. and Fourquet, A. and
	Asselain, B.},
  title = {Familial invasive breast cancers: worse outcome related to BRCA1
	mutations.},
  journal = {J Clin Oncol},
  year = {2000},
  volume = {18},
  pages = {4053--4059},
  number = {24},
  month = {Dec},
  abstract = {Although all studies confirm that BRCA1 tumors are highly proliferative
	and poorly differentiated, their outcomes remain controversial. We
	propose to examine, through a cohort study, the pathologic characteristics,
	overall survival, local recurrence, and metastasis-free intervals
	of 40 patients with BRCA1 breast cancer.A cohort of 183 patients
	with invasive breast cancer, treated at the Institut Curie and presenting
	with a familial history of breast and/or ovarian cancer, were tested
	for BRCA1 germ-line mutation. Tumor characteristics and clinical
	events were extracted from our prospectively registered database.Forty
	BRCA1 mutations were found among the 183 patients (22\%). Median
	follow-up was 58 months. BRCA1 tumors were larger in size (P =.03),
	had a higher rate of grade 3 histoprognostic factors (P =.002), and
	had a higher frequency of negative estrogen (P =.003) and progesterone
	receptors (P =.002) compared with non-BRCA1 tumors. Overall survival
	was poorer for carriers than for noncarriers (5-year rate, 80\% v
	91\%, P =.002). Because a long time interval between cancer diagnosis
	and genetic counseling artificially increases survival time due to
	unrecorded deaths, the analysis was limited to the 110 patients whose
	diagnosis-to-counseling interval was less than 36 months (19 BRCA1
	patients and 91 non-BRCA1 patients). The differences between the
	BRCA1 and non-BRCA1 groups regarding overall survival and metastasis-free
	interval were dramatically increased (49\% v 85\% and 18\% v 84\%,
	respectively). Multivariate analysis showed that BRCA1 mutation was
	an independent prognostic factor.Our results strongly support that
	among patients with familial breast cancer, those who have a BRCA1
	mutation have a worse outcome than those who do not.},
  institution = {Department of Oncology Genetics, Institut Curie, Paris, France. dominique.lyonnet@curie.net},
  keywords = {Adult; Breast Neoplasms, genetics/pathology/therapy; Cohort Studies;
	Disease-Free Survival; Family Health; Female; Follow-Up Studies;
	Genes, BRCA1, genetics; Germ-Line Mutation; Humans; Multivariate
	Analysis; Neoplasm Invasiveness; Neoplasm Recurrence, Local, genetics/pathology;
	Neoplasm Staging; Proportional Hazards Models; Survival Rate; Treatment
	Outcome},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {11118466},
  timestamp = {2013.05.29}
}

@ARTICLE{Storm1999,
  author = {HH Storm and PW Dickman and A Engeland and T Haldorsen and T Hakulinen},
  title = {Do morphology and stage explain the inferior lung cancer survival
	in {D}enmark?},
  journal = {Eur Respir J},
  year = {1999},
  volume = {13},
  pages = {430-5},
  number = {2},
  month = {Feb},
  abstract = {Danish lung cancer patients diagnosed during 1983-1987 experienced
	5-yr relative survival rates 2-7\% inferior to patients in the other
	Nordic countries, despite the similarity of cancer registration and
	healthcare systems in the Nordic countries. Is the inferior relative
	survival in Denmark due to differences in morphology or stage of
	lung cancers? The present study compared in detail the survival of
	92,719 patients diagnosed with lung cancer during 1978-1992 in Denmark,
	Finland, and Norway. In particular, differences in morphology and
	extent of disease were studied. A poor survival rate for small cell
	anaplastic lung carcinoma compared with all other morphologies was
	confirmed. However, this could not explain the relative survival
	differences observed between countries. Extent of disease was the
	most important predictor of survival. Part of the observed survival
	differences could be explained by a less favourable stage distribution
	in Denmark, combined with a slightly lower relative survival rate
	for those with metastatic disease. Differences in treatment are unlikely
	to explain the findings, although delays in diagnosing and treating
	patients in Denmark compared with neighbouring countries could partially
	explain the lower patient survival in Denmark. In conclusion, the
	main factor in the lower survival rate in Denmark is unfavourable
	stage distribution.},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Storm1998,
  author = {Storm, H. H. and Dickman, P. W. and Engeland, A. and Haldorsen, T.
	and Hakulinen, T.},
  title = {Do morphology and Stage Explain the Inferior Lung Cancer Survival
	in {D}enmark?},
  journal = {European Respiratory Journal},
  year = {1998},
  volume = {13},
  pages = {430-435},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Stotter2000,
  author = {A. Stotter and N. Bright and P. B. Silcocks and J. L. Botha},
  title = {Effect of improved data collection on breast cancer incidence and
	survival: reconciliation of a registry with a clinical database.},
  journal = {BMJ},
  year = {2000},
  volume = {321},
  pages = {214},
  number = {7255},
  institution = {Glenfield Hospital NHS Trust, Leicester LE3 9QP.},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pmid = {10903654},
  timestamp = {2011.06.13}
}

@ARTICLE{Straatman2004,
  author = {Straatman, Huub and Verbeek, Andr{\AA}Â© L M. and Peer, Petronella G M.
	and Borm, George},
  title = {Estimating life expectancy and related probabilities in screen-detected
	breast cancer patients with restricted follow-up information.},
  journal = {Stat Med},
  year = {2004},
  volume = {23},
  pages = {431--448},
  number = {3},
  month = {Feb},
  abstract = {Issues such as life expectancy after diagnosis, the number of life
	years gained by early diagnosis through screening, the probability
	of dying from breast cancer or of dying from other causes during
	the lead time period or thereafter can be derived from information
	on complete survival after diagnosis. A method is presented to estimate
	complete survival and relevant outcomes after diagnosis of screen-detected
	cancer when the follow-up period is substantially shorter than the
	maximum follow-up possible. Survival after diagnosis until death
	from breast cancer is modelled as the sum of the lead time (LT) and
	the post-lead time (PLT), where both time periods follow exponential
	distributions and are assumed to be independent. The survival period
	after diagnosis until death from causes other than breast cancer
	(X) is assumed to follow a Gompertz distribution. The survival period
	after diagnosis until death from any cause (Z) is modelled as the
	minimum of LT+PLT and X. Maximum likelihood methods were then used
	to estimate all parameters of Z. This procedure for obtaining maximum
	likelihood estimates of Z does not need the cause of death (breast
	cancer or other), which is an advantage over most other methods.
	Especially in older patients, it may be difficult or even impossible
	to ascertain the true cause of death. The model was applied to data
	from the long-term breast cancer screening programme in Nijmegen,
	the Netherlands. Complete survival was estimated on the basis of
	survival data on 528 screen-detected breast cancer patients, diagnosed
	in 1975-1997 and with a mean follow-up of 8.9 years. Estimated life
	expectancy ranged between 22.3 and 9.0 years for patients diagnosed
	at the age of 50 and 79 years, respectively, that is, 6.1 and 0.7
	life years gained by screening. Through early diagnosis and treatment,
	screen-detected patients diagnosed at the age of 50 years may have
	reduced their lifetime risk of dying from breast cancer from 79 per
	cent to 56 per cent; at the age of 79 the reduction of risk is reduced
	from 23 per cent to 13 per cent.},
  doi = {10.1002/sim.1539},
  institution = {Department of Epidemiology and Biostatistics, University of Nijmegen,
	Nijmegen, The Netherlands. h.straatman@epib.umcn.nl},
  keywords = {Aged; Breast Neoplasms, diagnosis; Female; Follow-Up Studies; Humans;
	Life Expectancy; Middle Aged; Models, Statistical; Survival Analysis},
  language = {eng},
  medline-pst = {ppublish},
  owner = {theand},
  pmid = {14748037},
  timestamp = {2012.09.18},
  url = {http://dx.doi.org/10.1002/sim.1539}
}

@Book{NHS1992,
  author    = {National Health Strategy},
  title     = {Enough to Make You Sick: How Income and Environment Affect Health},
  publisher = {Melbourne: National Health Strategy},
  series    = {Research Paper No. 1},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1992},
}

@ARTICLE{Streinchenberger2000,
  author = {Streinchenberger, R. and Barjoud, H. and Adeleine, P. and Larese,
	A. and Nemoz, C. and Chatelard, P. and Nedey, C. and Sabben, F. and
	Ganichot, F. and Jurus, C.},
  title = {Venous allografts preserved at 4 degrees C for infrainguinal bypass:
	long-term results from 170 procedures.},
  journal = {Ann Vasc Surg},
  year = {2000},
  volume = {14},
  pages = {553--560},
  number = {6},
  month = {Nov},
  abstract = {From April 21, 1982 to December 31, 1997, we performed 170 infrainguinal
	bypass procedures using isolated (n = 35) or composite (n = 135)
	venous allografts preserved at 4 degrees C as a substitute for saphenous
	autografts in 146 patients. The mean age of the patient population
	was 74 years. The indication was critical lower limb ischemia in
	71\% of cases. Seventy-five percent of procedures were below the
	knee and 26\% were infrapopliteal. Mean length and diameter were
	19.5 +/- 0.5 cm and 4.8 +/- 0.5 mm, respectively. After December
	8, 1993, a reinforcement net was placed over the graft to prevent
	expansion in 71\% of cases. Primary and secondary 5-year patency,
	calculated according to the Kaplan-Meier method, were 33 +/- 6\%
	and 43 +/- 6\%, respectively. Factors correlated with secondary patency
	were studied using the log-rank test. Previous ipsilateral infrainguinal
	revascularization was associated with a 40\% decrease in secondary
	patency at 2 years (71\% vs. 31\%). Patency at 5 years was correlated
	with the level of anastomosis (47\% for low popliteal anastomosis
	vs. 30\% for infrapopliteal anastomosis). The likelihood of stenosis
	or dilatation of the allograft was 8\% and 29.5\%, respectively,
	at 5 years. The 5-year limb salvage and survival rates were 84\%
	and 57\%, respectively. The encouraging results of this series suggest
	that venous allografts provide a useful alternative for infrainguinal
	bypass when autologous grafts or other more reliable conduits are
	unavailable.},
  institution = {Service de Chirurgie Vasculaire, Clinique du Tonkin, Lyon, France.},
  keywords = {Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Cryopreservation;
	Female; Follow-Up Studies; Graft Occlusion, Vascular, etiology; Humans;
	Ischemia, surgery; Leg, blood supply; Male; Middle Aged; Transplantation,
	Homologous; Veins, transplantation},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {11128448},
  timestamp = {2013.05.29}
}

@ARTICLE{Stroup2014,
  author = {Stroup, Antoinette M. and Cho, Hyunsoon and Scoppa, Steve M. and
	Weir, Hannah K. and Mariotto, Angela B.},
  title = {The impact of state-specific life tables on relative survival.},
  journal = {J Natl Cancer Inst Monogr},
  year = {2014},
  volume = {2014},
  pages = {218--227},
  number = {49},
  month = {Nov},
  abstract = {Relative survival is based on estimating excess cancer mortality in
	a study population compared to expected mortality of a comparable
	population without cancer. In the United States, expected mortality
	is estimated from national life tables matched by age, sex, race,
	and calendar year to each individual in the study population. We
	compared five-year relative survival using state life tables to five-year
	relative survival using US decennial life tables. We assessed variations
	by age, race, and cancer site for all cancers combined, lung, colorectal,
	prostate, and female breast cancers.We used data from 17 National
	Cancer Institute Surveillance, Epidemiology, and End Results Program
	registries, including diagnoses from January 1, 2000 to December
	31, 2009 with follow-up through December 31, 2010. Five-year relative
	survival was calculated using US-based life tables (USLT) and state-specific
	life tables (SLT).Differences in SLT- and USLT-based survival were
	generally small (SLT < 4 survival percentage points lower than USLT).
	Differences were higher for states with high SES and low mortality
	and for prostate cancer. Differences were largest for all cancers
	combined, colon and rectum, and prostate cancer among males aged
	85+ ranging from -10 to -17 survival points for whites and +9 to
	+17 for blacks.Differences between relative survival based on USLT
	and SLT were small and state-based estimates were less reliable than
	US-based estimates for older populations aged 85+. Our findings underscore
	the need to develop more appropriate life tables that better represent
	the varying mortality patterns in different populations in order
	to obtain accurate estimates of relative survival.},
  doi = {10.1093/jncimonographs/lgu017},
  file = {Stroup2014.pdf:pdf\\Stroup2014.pdf:PDF;Stroup2014.pdf:Stroup2014.pdf:PDF},
  institution = {Division of Cancer Registration and Surveillance, National Cancer
	Center, Goyang-si Gyeonggi-do, Korea (HC); Information Management
	Services, Inc., Calverton, MD (SS); Division of Cancer Prevention
	and Control, National Center for Chronic Disease Prevention and Health
	Promotion, Centers for Disease Control and Prevention, Atlanta, GA
	(HKW).},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pii = {lgu017},
  pmid = {25417235},
  timestamp = {2014.12.01},
  url = {http://dx.doi.org/10.1093/jncimonographs/lgu017}
}

@Book{Stuart1987,
  author    = {Stuart, A. and Ord, J. K.},
  title     = {Kendall's Advanced Theory of Statistics},
  publisher = {Oxford: Oxford University Press},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1987},
}

@ARTICLE{Eurocollab1991,
  author = {European Collaborative Study},
  title = {Children born to women with {HIV-}1 infection : natural history and
	risk of transmission},
  journal = {Lancet},
  year = {1991},
  volume = {337},
  pages = {253--260},
  owner = {pl4},
  timestamp = {2011.01.13}
}

@ARTICLE{Suissa1999,
  author = {Suissa, S.},
  title = {Relative excess risk: {A}n alternative measure of comparitive risk},
  journal = {American Journal of Epidemiology},
  year = {1999},
  volume = {150},
  pages = {279-282},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Sukhatme1938,
  author = {Sukhatme, P. V.},
  title = {On the Distribution of ${\chi}^2$ in Samples of the {P}oisson Series},
  journal = {Supplement to the Journal of the Royal Statistical Society},
  year = {1938},
  volume = {5},
  pages = {75-79},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Sun1997,
  author = {Sun, J. and Shibata, E. and Kamijima, M. and Toida, M. and Takeuchi,
	Y.},
  title = {An efficient {SAS} program for exact stratification of person-years},
  journal = {Comput Biol Med},
  year = {1997},
  volume = {27},
  pages = {49-53},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Sundelof02,
  author = {Martin Sundel\"{o}f and Weimin Ye and Paul W Dickman and Jesper Lagergren},
  title = {Improved survival in both histologic types of oesophageal cancer
	in {S}weden.},
  journal = {Int J Cancer},
  year = {2002},
  volume = {99},
  pages = {751-4},
  number = {5},
  month = {Jun},
  abstract = {The prognosis among patients diagnosed with oesophageal cancer is
	poor with an overall 5-year survival close to 5\% in most countries.
	Improved diagnostic and surgical strategies might influence the survival,
	however. We investigated the observed and relative survival among
	all patients in {S}weden diagnosed with oesophageal adenocarcinoma
	(n = 1,441) or squamous cell carcinoma (n = 6395) from 1961-1996
	with follow-up to December 1997. Observed survival rates were calculated
	by the life-table method. Relative survival rates were computed as
	the ratio of the observed to the expected survival. The expected
	survival was inferred from the survival among the entire Swedish
	population in the same age, sex and calendar year strata. The 5-year
	observed survival rate for adenocarcinoma increased from a stable
	figure close to 4\% during the entire period 1961-1989 to 10.5\%
	during 1990-1996. Similarly, the 5-year relative survival rate was
	stable around 5\% during 1961-1989, but during 1990-1996 the survival
	was increased to 13.7\%. For squamous cell carcinoma, the survival
	improved slightly by each decade, starting with 3.8\% 5-year observed
	survival in 1961-1969 to 7.0\% during 1990-1996. Similarly, the 5-year
	relative survival improved from 5.0\% to 8.9\% during the study period.
	In conclusion, the survival rates for both oesophageal adenocarcinoma
	and squamous cell carcinoma have increased significantly during the
	1990s compared to those in the previous 3 decades (p < 0.001).},
  doi = {10.1002/ijc.10420},
  owner = {PaulD},
  timestamp = {2011.06.19},
  url = {http://dx.doi.org/10.1002/ijc.10420}
}

@ARTICLE{Surkan2006,
  author = {Pamela J Surkan and Paul W Dickman and Gunnar Steineck and Erik Onel\"{o}v
	and Ulrika Kreicbergs},
  title = {Home care of a child dying of a malignancy and parental awareness
	of a child's impending death.},
  journal = {Palliat Med},
  year = {2006},
  volume = {20},
  pages = {161--169},
  abstract = {In this population-based study, we found that parents who are aware
	that their child will die from a malignancy are more likely to care
	for their child at home during the child's last month of life compared
	to parents who are not aware. End-of-life home care was comparable
	to hospital care for satisfactory pain relief, access to pain relief
	and access to medications for other physical symptoms. Using an anonymous
	postal questionnaire, we obtained information from 449 parents in
	{S}weden who had lost a child due to a malignancy between 1992 and
	1997, 4 to 9 years before participating in our study. The prevalence
	of dying at home and being cared for at home during the last month
	of life was 23.7\% when parents realized intellectually more than
	1 month in advance that the child would die (versus 12\% who did
	not), 28.7\% for parents who sensed that the child was aware of his
	or her imminent death (versus 7.8\% who did not sense this) and 21.9\%
	for those who received information that the child's illness was incurable
	(versus 9.4\% who did not receive the information). Prevalence of
	children's unrelieved pain was 11.6\% for those receiving home care
	and 15.3\% for those receiving care outside the home.},
  owner = {PaulD},
  pmid = {16764220},
  timestamp = {2006.10.04}
}

@ARTICLE{Surkan2004,
  author = {Pamela J Surkan and Chung-Cheng Hsieh and Anna L V Johansson and
	Paul W Dickman and Sven Cnattingius},
  title = {Reasons for increasing trends in large for gestational age births.},
  journal = {Obstet Gynecol},
  year = {2004},
  volume = {104},
  pages = {720-6},
  number = {4},
  month = {Oct},
  abstract = {OBJECTIVE: To describe the magnitude of change in the proportion of
	term and postterm (37 completed weeks or more) large for gestational
	age (LGA) infants between 1992-2001 in {S}weden and to examine whether
	time trends in prevalence of LGA births can be explained by changes
	in maternal risk factors. METHODS: Using the population-based Swedish
	Birth Register, we analyzed data from 1992 through 2001 on births
	of women who delivered live, singleton, term infants without malformations
	(N = 874,163). Unconditional logistic regression was used to model
	the odds of LGA birth. RESULTS: Mean birth weight and proportions
	of LGA births and births 4,500 g or more rose during the period 1992
	to 2001. An unadjusted analysis estimated that the risk of LGA birth
	increased by 23\% over 10 years. However, the prevalence of overweight
	and obesity (body mass index of 25 or greater) increased from 25\%
	to 36\%, and the prevalence of smoking decreased from 23\% to 11\%
	during the same period. After adjusting trends in all covariates
	simultaneously, the association between risk of LGA birth and calendar
	year disappeared. CONCLUSION: The increasing proportions of LGA births
	over time is explained by concurrent increases in maternal body mass
	index and decreases in maternal smoking. With the increasing prevalence
	of overweight among adolescents and young women, the prevalence of
	LGA infants and associated risks may increase over time. LEVEL OF
	EVIDENCE: II-2},
  doi = {10.1097/01.AOG.0000141442.59573.cd},
  owner = {PaulD},
  pii = {104/4/720},
  timestamp = {2011.06.19},
  url = {http://dx.doi.org/10.1097/01.AOG.0000141442.59573.cd}
}

@ARTICLE{Surkan2006a,
  author = {Pamela J Surkan and Ulrika Kreicbergs and Unnur Valdimarsd{\AA}ÂƒÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â³ttir
	and Ullakarin Nyberg and Erik Onel\"{o}v and Paul W Dickman and Gunnar
	Steineck},
  title = {Perceptions of inadequate health care and feelings of guilt in parents
	after the death of a child to a malignancy: a population-based long-term
	follow-up.},
  journal = {J Palliat Med},
  year = {2006},
  volume = {9},
  pages = {317--331},
  abstract = {BACKGROUND: Parental feelings of guilt can be a serious problem after
	the death of a child to a malignancy. This study identified predictors
	of feelings of guilt in parents during the year after a child's death.
	METHODS: The Swedish Cause of Death Register and Swedish Cancer Register
	were used to identify all parents in {S}weden who had a child who
	died of a malignancy between 1992-1997. RESULTS: Among parents not
	reporting recent depression, those who were not confident that their
	child would immediately receive help from the staff in the hospital
	while he or she was sick with a malignancy (compared to those who
	felt partly or entirely sure, relative risk [RR] 4.0; 95\% confidence
	interval [CI] 2.1-7.6), were at increased risk for reporting daily
	or weekly feelings of guilt in the year after the child's death.
	Parents who perceived that the staff in the pediatric cancer ward
	were incompetent were at increased risk (compared to parents reporting
	partial or total competence, RR 3.7; 95\% CI 1.6-8.6). Compared to
	parents reporting that their children had moderate or much access,
	those who felt their children had little or no access to pain relief,
	dietary advice, anxiety relief, and relief of other psychological
	symptoms beside anxiety were at more than two times greater risk
	for reporting feelings of guilt. CONCLUSIONS: Bereaved parents' perceptions
	of inadequate health care were associated with subsequent feelings
	of guilt during the year following their child's death due to a malignancy.},
  doi = {10.1089/jpm.2006.9.317},
  owner = {PaulD},
  pmid = {16629562},
  timestamp = {2006.10.04},
  url = {http://dx.doi.org/10.1089/jpm.2006.9.317}
}

@ARTICLE{Surkan2004a,
  author = {Pamela J Surkan and Olof Stephansson and Paul W Dickman and Sven
	Cnattingius},
  title = {Previous preterm and small-for-gestational-age births and the subsequent
	risk of stillbirth.},
  journal = {N Engl J Med},
  year = {2004},
  volume = {350},
  pages = {777-85},
  number = {8},
  month = {Feb},
  abstract = {BACKGROUND: Some causes of stillbirth may also lead to fetuses that
	are small for gestational age (have a low birth weight with respect
	to their gestational age) or are delivered preterm (before 37 weeks
	of gestation). It is not known whether the birth of a previous small-for-gestational-age
	or preterm infant increases the subsequent risk of stillbirth. METHODS:
	We assessed the associations between previous adverse outcomes of
	pregnancy and the risk of stillbirth in a nationwide Swedish study
	of 410,021 women who delivered first and second consecutive singleton
	infants between 1983 and 1997. There were 1842 and 1062 stillbirths
	during the first and second pregnancies, respectively. RESULTS: As
	compared with women whose first infant was born at term (37 weeks
	of gestation or more) and was not small for gestational age, women
	whose first infant was born at term or preterm and was small for
	gestational age had an increased risk of stillbirth during their
	second pregnancy. The odds ratios for subsequent stillbirth, after
	adjustment for covariates known to be associated with an increased
	risk of stillbirth, were 2.1 (95 percent confidence interval, 1.6
	to 2.8) among women with a first infant who was born at term and
	was small for gestational age, 3.4 (95 percent confidence interval,
	2.1 to 5.6) among women with a first infant who was moderately (32
	to 36 weeks of gestation) preterm and small for gestational age,
	and 5.0 (95 percent confidence interval, 2.5 to 9.8) among women
	with a first infant who was very (before 32 weeks of gestation) preterm
	and was small for gestational age. The odds ratio for subsequent
	stillbirth among women with a first stillborn infant was 2.5 (95
	percent confidence interval, 1.4 to 4.7), as compared with women
	whose first infant was not stillborn. The rates of stillbirth in
	second pregnancies ranged from 2.4 per 1000 births among women whose
	first infant was born at term and was not small for gestational age
	to 19.0 per 1000 births among women whose first child was very preterm
	and was small for gestational age. CONCLUSIONS: Delivery of a previous
	small-for-gestational-age infant is an important predictor of the
	subsequent risk of stillbirth, particularly if the infant was delivered
	preterm.},
  doi = {10.1056/NEJMoa031587},
  owner = {PaulD},
  pii = {350/8/777},
  timestamp = {2011.06.19},
  url = {http://dx.doi.org/10.1056/NEJMoa031587}
}

@Article{Sutton2005,
  author      = {Alexander J Sutton and Nicola J Cooper and Keith R Abrams and Paul C Lambert and David R Jones},
  title       = {A {B}ayesian approach to evaluating net clinical benefit allowed for parameter uncertainty.},
  doi         = {10.1016/j.jclinepi.2004.03.015},
  number      = {1},
  pages       = {26--40},
  url         = {http://dx.doi.org/10.1016/j.jclinepi.2004.03.015},
  volume      = {58},
  abstract    = {BACKGROUND AND OBJECTIVE: Although randomized controlled trials (RCTs)
	are conducted to establish whether novel interventions work on average
	in the patient population, there is a growing desire to move to a
	more individualized approach to evaluation. The potential benefits
	and harms of a treatment policy may differ between individuals. If
	these benefits and harms are not evaluated distinctly, and in a quantitative
	framework, transparency can be lost in the decision-making process.
	METHODS: Glasziou and Irwig have outlined the concept of net clinical
	treatment benefit for identifying the patients for whom the potential
	benefits of treatment outweigh the possible side effects. This study
	revisits the decision whether to use warfarin to treat atrial fibrillation.
	In this analysis, RCT and various sorts of observational data are
	synthesized. RESULTS: This reanalysis brings into question the conclusions
	of the original analysis on who would benefit from warfarin; however,
	caution is advised, due to limitations in the quality of life data
	available. CONCLUSION: A fully realized Bayesian implementation of
	the model is presented. This provides a framework for including uncertainty
	related to the estimation of all model parameters, and permits both
	direct probability statements and credible intervals for specific
	patient groups to be expressed.},
  file        = {sutton2005.pdf:sutton2005.pdf:PDF},
  institution = {Department of Health Sciences, University of Leicester, 22-28 Princess Road West, Leicester LE1 6TP, United Kingdom. ajs22@le.ac.uk},
  journal     = {Journal of Clinical Epidemiology},
  month       = {Jan},
  owner       = {pl4},
  pii         = {S0895-4356(04)00170-2},
  pmid        = {15649668},
  timestamp   = {2008.10.15},
  year        = {2005},
}

@ARTICLE{Sutton2007,
  author = {Alexander J Sutton and Nicola J Cooper and David R Jones and Paul
	C Lambert and John R Thompson and Keith R Abrams},
  title = {Evidence-based sample size calculations based upon updated meta-analysis.},
  journal = {Statistics in Medicine},
  year = {2007},
  volume = {26},
  pages = {2479--2500},
  number = {12},
  month = {May},
  abstract = {Meta-analyses of randomized controlled trials (RCTs) provide the highest
	level of evidence regarding the effectiveness of interventions and
	as such underpin much of evidence-based medicine. Despite this, meta-analyses
	are usually produced as observational by-products of the existing
	literature, with no formal consideration of future meta-analyses
	when individual trials are being designed. Basing the sample size
	of a new trial on the results of an updated meta-analysis which will
	include it, may sometimes make more sense than powering the trial
	in isolation. A framework for sample size calculation for a future
	RCT based on the results of a meta-analysis of the existing evidence
	is presented. Both fixed and random effect approaches are explored
	through an example. Bayesian Markov Chain Monte Carlo simulation
	modelling is used for the random effects model since it has computational
	advantages over the classical approach. Several criteria on which
	to base inference and hence power are considered. The prior expectation
	of the power is averaged over the prior distribution for the unknown
	true treatment effect. An extension to the framework allowing for
	consideration of the design for a series of new trials is also presented.
	Results suggest that power can be highly dependent on the statistical
	model used to meta-analyse the data and even very large studies may
	have little impact on a meta-analysis when there is considerable
	between study heterogeneity. This raises issues regarding the appropriateness
	of the use of random effect models when designing and drawing inferences
	across a series of studies.},
  doi = {10.1002/sim.2704},
  file = {sutton2007.pdf:sutton2007.pdf:PDF},
  institution = {Department of Health Sciences, University of Leicester, Leicester,
	UK. ajs22@le.ac.uk},
  owner = {pl4},
  pmid = {16981184},
  timestamp = {2008.10.15},
  url = {http://dx.doi.org/10.1002/sim.2704}
}

@ARTICLE{Sutton2008,
  author = {Alexander J Sutton and Julian P T Higgins},
  title = {Recent developments in meta-analysis.},
  journal = {Statistics in Medicine},
  year = {2008},
  volume = {27},
  pages = {625--650},
  number = {5},
  month = {Feb},
  abstract = {The art and science of meta-analysis, the combination of results from
	multiple independent studies, is now more than a century old. In
	the last 30 years, however, as the need for medical research and
	clinical practice to be based on the totality of relevant and sound
	evidence has been increasingly recognized, the impact of meta-analysis
	has grown enormously. In this paper, we review highlights of recent
	developments in meta-analysis in medical research. We outline in
	particular how emphasis has been placed on (i) heterogeneity and
	random-effects analyses; (ii) special consideration in different
	areas of application; (iii) assessing bias within and across studies;
	and (iv) extension of ideas to complex evidence synthesis. We conclude
	the paper with some remarks on ongoing challenges and possible directions
	for the future.},
  doi = {10.1002/sim.2934},
  file = {sutton2008.pdf:sutton2008.pdf:PDF},
  institution = {Department of Health Sciences, University of Leicester, Leicester
	LE1 7RH, UK. ajs22@le.ac.uk},
  owner = {pl4},
  pmid = {17590884},
  timestamp = {2008.11.18},
  url = {http://dx.doi.org/10.1002/sim.2934}
}

@ARTICLE{Sweeting2004,
  author = {Michael J Sweeting and Alexander J Sutton and Paul C Lambert},
  title = {What to add to nothing? Use and avoidance of continuity corrections
	in meta-analysis of sparse data.},
  journal = {Statistics in Medicine},
  year = {2004},
  volume = {23},
  pages = {1351--1375},
  number = {9},
  month = {May},
  abstract = {OBJECTIVES: To compare the performance of different meta-analysis
	methods for pooling odds ratios when applied to sparse event data
	with emphasis on the use of continuity corrections. BACKGROUND: Meta-analysis
	of side effects from RCTs or risk factors for rare diseases in epidemiological
	studies frequently requires the synthesis of data with sparse event
	rates. Combining such data can be problematic when zero events exist
	in one or both arms of a study as continuity corrections are often
	needed, but, these can influence results and conclusions. METHODS:
	A simulation study was undertaken comparing several meta-analysis
	methods for combining odds ratios (using various classical and Bayesian
	methods of estimation) on sparse event data. Where required, the
	routine use of a constant and two alternative continuity corrections;
	one based on a function of the reciprocal of the opposite group arm
	size; and the other an empirical estimate of the pooled effect size
	from the remaining studies in the meta-analysis, were also compared.
	A number of meta-analysis scenarios were simulated and replicated
	1000 times, varying the ratio of the study arm sizes. RESULTS: Mantel-Haenszel
	summary estimates using the alternative continuity correction factors
	gave the least biased results for all group size imbalances. Logistic
	regression was virtually unbiased for all scenarios and gave good
	coverage properties. The Peto method provided unbiased results for
	balanced treatment groups but bias increased with the ratio of the
	study arm sizes. The Bayesian fixed effect model provided good coverage
	for all group size imbalances. The two alternative continuity corrections
	outperformed the constant correction factor in nearly all situations.
	The inverse variance method performed consistently badly, irrespective
	of the continuity correction used. CONCLUSIONS: Many routinely used
	summary methods provide widely ranging estimates when applied to
	sparse data with high imbalance between the size of the studies'
	arms. A sensitivity analysis using several methods and continuity
	correction factors is advocated for routine practice.},
  doi = {10.1002/sim.1761},
  file = {sweeting2004.pdf:sweeting2004.pdf:PDF},
  institution = {MRC Biostatistics Unit, Institute of Public Health, Robinson Way,
	Cambridge CB2 2SR, UK.},
  owner = {pl4},
  pmid = {15116347},
  timestamp = {2008.10.15},
  url = {http://dx.doi.org/10.1002/sim.1761}
}

@ARTICLE{Sy2000,
  author = {Judy P Sy and Jeremy M. G. Taylor},
  title = {Estimation in a Cox Proportional Hazards Cure Model},
  journal = {Biometrics},
  year = {2000},
  volume = {56},
  pages = {227-236},
  owner = {theand},
  timestamp = {2010.09.29}
}

@ARTICLE{Tornblom2004,
  author = {Magnus T\"{o}rnblom and Henry Eriksson and Stefan Franz\'{e}n and
	Ove Gustafsson and Hans Lilja and Ulf Norming and Jonas Hugosson},
  title = {Lead time associated with screening for prostate cancer.},
  journal = {Int J Cancer},
  year = {2004},
  volume = {108},
  pages = {122-9},
  number = {1},
  month = {Jan},
  abstract = {Screening serum levels of prostate-specific antigen (PSA) is now a
	major strategy for early detection of prostate cancer (PC). Quantification
	of the lead time thus obtained is important both for understanding
	the development of PC and for evaluating the advantages and disadvantages
	of widespread screening. In our study, 1,233 randomly selected men
	living in Stockholm in 1988 were invited to participate in an early
	detection (ED) program, in which suspicious findings provided by
	digital rectal examination (DRE), transrectal ultrasonography (TRUS)
	and/or a PSA value >/=10.0 ng/mL were followed up by biopsy. The
	cumulative incidence (Kaplan-Meier) of PC in the 946 participants
	(ED) during 12 years of follow-up was compared to that of an age-matched,
	randomly selected reference population (RP) of 657 men for whom PSA
	values (from frozen serum samples) could also be obtained. The PC
	incidence in men in the RP with PSA values >/=3.0 ng/mL reached the
	corresponding level for the ED group after 10.6 years (the "catch-up"
	point). After 12 years of follow-up, the estimated median lead time
	for men with PSA values in this interval was 4.5 years in the ED
	population, compared to 7.8 years in the RP. With 20 years of follow-up,
	the estimated median lead time of the RP was enhanced to 10.7 years.
	The lead time in connection with PC was influenced by the initial
	PSA level (although with large variations), length of follow-up and
	sensitivity of the ED procedure employed. The ED program described
	here was not associated with major overdetection.},
  doi = {10.1002/ijc.11554},
  owner = {PaulD},
  timestamp = {2011.06.19},
  url = {http://dx.doi.org/10.1002/ijc.11554}
}

@ARTICLE{Torner2011,
  author = {T\"{o}rner, Anna and Dickman, Paul and Duberg, Ann-Sofi and Kristinsson,
	Sigurdur and Landgren, Ola and Bj{\AA}Â¯ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¿ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â½olm, Magnus and Svensson, {\AA}Â„ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â«e},
  title = {A method to visualize and adjust for selection bias in prevalent
	cohort studies.},
  journal = {Am J Epidemiol},
  year = {2011},
  volume = {174},
  pages = {969--976},
  number = {8},
  month = {Oct},
  abstract = {Selection bias and confounding are concerns in cohort studies where
	the reason for inclusion of subjects in the cohort may be related
	to the outcome of interest. Selection bias in prevalent cohorts is
	often corrected by excluding observation time and events during the
	first time period after inclusion in the cohort. This time period
	must be chosen carefully-long enough to minimize selection bias but
	not too long so as to unnecessarily discard observation time and
	events. A novel method visualizing and estimating selection bias
	is described and exemplified by using 2 real cohort study examples:
	a study of hepatitis C virus infection and a study of monoclonal
	gammopathy of undetermined significance. The method is based on modeling
	the hazard for the outcome of interest as a function of time since
	inclusion in the cohort. The events studied were "hospitalizations
	for kidney-related disease" in the hepatitis C virus cohort and "death"
	in the monoclonal gammopathy of undetermined significance cohort.
	Both cohorts show signs of considerable selection bias as evidenced
	by increased hazard in the time period after inclusion in the cohort.
	The method was very useful in visualizing selection bias and in determining
	the initial time period to be excluded from the analyses.},
  doi = {10.1093/aje/kwr211},
  institution = {Department of Epidemiology, Swedish Institute for Infectious Disease
	Control, Solna, Sweden. anna.torner@smi.se},
  language = {eng},
  medline-pst = {ppublish},
  owner = {Paul},
  pii = {kwr211},
  pmid = {21920949},
  timestamp = {2012.06.07},
  url = {http://dx.doi.org/10.1093/aje/kwr211}
}

@ARTICLE{Toerner2010,
  author = {Anna T\"{o}rner and Ann-Sofi Duberg and Paul Dickman and Ake Svensson},
  title = {A proposed method to adjust for selection bias in cohort studies.},
  journal = {Am J Epidemiol},
  year = {2010},
  volume = {171},
  pages = {602--608},
  number = {5},
  month = {Mar},
  abstract = {Selection bias is a concern in cohort studies in which selection into
	the cohort is related to the studied outcome. An example is chronic
	infection with hepatitis C virus, where the initial infection may
	be asymptomatic for decades. This problem leads to selection of more
	severely ill individuals into registers of such infections. Cohort
	studies often adjust for this bias by introducing a time window between
	entry into the cohort and entry into the study. This paper describes
	and assesses a novel method to improve adjustment for this type of
	selection bias. The size of the time window is decided by calculating
	a standardized incidence ratio as a continuous function of the size
	of the time window. The resulting graph is used to decide on an appropriate
	window size. The method is evaluated by using the Swedish register
	of hepatitis C virus infections for 1990-2006. The complications
	studied were non-Hodgkin lymphoma and liver cancer. Selection bias
	differed for the studied outcomes, and a time window of a minimum
	of 2 months and 12 months, respectively, was judged to be appropriate.
	The novel method may have advantages compared with an interval-based
	method, especially in cohort studies with small numbers of events.},
  doi = {10.1093/aje/kwp432},
  institution = {Department of Epidemiology, Swedish Institute for Infectious Disease
	Control, Tomtebodav\"{a}gen 19A, 171 82 Solna, Sweden.},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pii = {kwp432},
  pmid = {20106936},
  timestamp = {2010.11.30},
  url = {http://dx.doi.org/10.1093/aje/kwp432}
}

@PhdThesis{Talbaeck:phdthesis:2011,
  author    = {Mats Talb\"{a}ck},
  title     = {Cancer patient survival in {S}weden ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Â“ theory and application},
  type      = {PhD Thesis},
  url       = {http://publications.ki.se/xmlui/handle/10616/40791},
  file      = {:pdf\\Thesis_Mats_Talbaeck.pdf:PDF},
  groups    = {PhD Thesis},
  owner     = {PaulD},
  school    = {Karolinska Institutet},
  timestamp = {2013.10.23},
  year      = {2011},
}

@ARTICLE{Talback2012,
  author = {Talb\"{a}ck, Mats and Dickman, Paul W.},
  title = {Predicting the survival of cancer patients recently diagnosed in
	{S}weden and an evaluation of predictions published in 2004.},
  journal = {Acta Oncol},
  year = {2012},
  volume = {51},
  pages = {17--27},
  number = {1},
  month = {Jan},
  abstract = {Abstract Background. Estimates of cancer patient survival from traditional
	cohort-based methods may be heavily influenced by the survival experience
	of patients diagnosed many years ago and may not therefore be relevant
	to recently diagnosed patients. Period-based analysis provides better
	predictions of survival for recently diagnosed patients than cohort
	analysis. The first aim of this study is to provide predictions of
	the long-term survival of patients diagnosed in 2005-2009 using period
	analysis and to compare these estimates to the latest available cohort
	estimates. The second aim is to evaluate predictions published in
	2004 regarding the future survival of patients diagnosed 2000-2002.
	Material and methods. We studied survival among patients diagnosed
	1985-2009 reported to the nationwide, population-based Swedish Cancer
	Registry. Predictions of the future relative survival for recently
	diagnosed patients were made using period analysis with a window
	of 2005-2009. Results. The predictions made using period analysis
	and published in 2004 agreed well with the subsequently observed
	survival, with common sites showing a better agreement than less
	common sites. Updated predictions suggest that patients diagnosed
	today can expect improved survival for many forms of cancer. Conclusions.
	Period, rather than cohort, survival analysis should be used if the
	primary aim is to predict the future survival of recently diagnosed
	patients. Recently diagnosed cancer patients can, for many forms
	of cancer, expect an improved survival compared to patients diagnosed
	only a few years earlier.},
  doi = {10.3109/0284186X.2011.626444},
  file = {:C\:\\survbib\\pdf\\Talback2012.pdf:PDF;Talback2012.pdf:Talback2012.pdf:PDF},
  institution = {Unit for Epidemiology, Department of Statistics, Monitoring and Evaluation,
	National Board of Health and Welfare , Stockholm , Sweden.},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pmid = {22023089},
  timestamp = {2012.01.17},
  url = {http://dx.doi.org/10.3109/0284186X.2011.626444}
}

@ARTICLE{Talback2004a,
  author = {Mats Talb\"{a}ck and M{\aa}ns Ros\'{e}n and Magnus Stenbeck and Paul
	W Dickman},
  title = {Cancer patient survival in {S}weden at the beginning of the third
	millennium--predictions using period analysis.},
  journal = {Cancer Causes Control},
  year = {2004},
  volume = {15},
  pages = {967--976},
  number = {9},
  month = {Nov},
  abstract = {Estimates of cancer patient survival made using traditional, cohort-based,
	methods can be heavily influenced by the survival experience of patients
	diagnosed many years in the past and may not be particularly relevant
	to recently diagnosed patients. Period-based survival analysis has
	been shown to provide better predictions of survival for recently
	diagnosed patients and earlier detection of temporal trends in patient
	survival than cohort analysis. We aim to provide predictions of the
	long-term survival of recently diagnosed cancer patients using period
	analysis. The period estimates are compared with the latest available
	cohort-based estimates. Our results, based on period analysis for
	the years 2000-2002, suggest an improvement in survival for many
	forms of cancer during recent years. For all sites combined the 5-,
	10-, 15-, and 20-year relative survival ratios were 62\%, 53\%, 48\%,
	and 47\% for males and 67\%, 62\%, 60\%, and 59\%, for females. These
	estimates were 3-14\% units higher than those obtained using the
	latest available cohorts with the respective lengths of follow-up.
	The interval-specific relative survival stabilised for males at 97\%
	after 8 years of follow-up and for females at 98\% after 7 years
	for both period and cohort analyses.},
  doi = {10.1007/s10522-004-2475-1},
  institution = {Centre for Epidemiology, The National Board of Health and Welfare,
	Stockholm, Sweden. mats.talback@sos.se},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pii = {5382475},
  pmid = {15577299},
  timestamp = {2011.06.23},
  url = {http://dx.doi.org/10.1007/s10522-004-2475-1}
}

@ARTICLE{Talback2004,
  author = {Mats Talb\"{a}ck and Magnus Stenbeck and M{\aa}ns Ros\'{e}n},
  title = {{U}p-to-date long-term survival of cancer patients: an evaluation
	of period analysis on {S}wedish {C}ancer {R}egistry data.},
  journal = {Eur J Cancer},
  year = {2004},
  volume = {40},
  pages = {1361--1372},
  number = {9},
  abstract = {The natural development of cancers as well as the measures to fight
	the disease are often long processes that require decades of follow
	up. Available information on long-term survival will thus often appear
	outdated and irrelevant. A few years ago, period-survival analysis
	was proposed as a means to obtain more up-to-date information on
	long-term cancer survival. This article assesses period and conventional
	cohort-based survival analyses on their ability to predict future
	survival. Based on historical data from the nationwide Swedish Cancer
	Registry 5-, 10- and 15-year relative survival actually observed
	for patients diagnosed at one particular point in time are compared
	to the most recent period and cohort-based survival estimates available
	at that point in time. The study shows that period analysis can,
	in most cases, be used to provide more up-to-date long-term estimates
	of cancer survival. Period analysis reduces the time lag of the survival
	estimates by some 5-10 years for all cancers combined and especially
	affects the survival estimates for small intestine carcinoids, meningioma
	and intracranial neurinoma of the brain, non-seminoma testicular
	cancer, chronic lymphocytic leukaemia and Hodgkin's lymphoma.},
  doi = {10.1016/j.ejca.2004.02.004},
  owner = {PaulD},
  pii = {S0959804904001753},
  pmid = {15177496},
  timestamp = {2006.05.04},
  url = {http://dx.doi.org/10.1016/j.ejca.2004.02.004}
}

@ARTICLE{Talback2003,
  author = {Mats Talb\"{a}ck and Magnus Stenbeck and M{\aa}ns Ros\'{e}n and Lotti
	Barlow and Bengt Glimelius},
  title = {Cancer survival in {S}weden 1960-1998--developments across four decades.},
  journal = {Acta Oncol},
  year = {2003},
  volume = {42},
  pages = {637-59},
  number = {7},
  abstract = {This paper summarizes a comprehensive study of cancer survival in
	{S}weden from 1960 to 1998. A total of 1021421 persons and 40 different
	cancer sites were included in the analyses. The main outcome measure
	is the relative survival rate (RSR) for different sites and follow-up
	times after diagnosis. The 10-year RSR for all sites combined has
	increased steadily-from 26.6\% among men and 41.8\% among women in
	the 1960s, to 44.6\% (men) and 57.6\% (women) in the 1990s. The expectation
	of life for a person diagnosed with cancer today is about 7 years
	longer than that of one diagnosed during the mid-1960s. About 3 years
	are gained due to changes in the relative distribution of various
	cancer types and about 4 years due to improved relative survival.
	During the 1990s substantial survival improvements were observed
	not only for uncommon types, such as testicular cancer, Hodgkin's
	lymphoma and some other haematologic malignancies, but also for cancer
	of the rectum, kidney and malignant melanoma. Survival for breast
	and cervical cancer also improved during the 1990s, but not that
	for pancreatic, liver or lung cancer.},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Talback2011,
  author = {Talb{\"a}ck, Mats and Dickman, Paul W.},
  title = {Estimating expected survival probabilities for relative survival
	analysis--exploring the impact of including cancer patient mortality
	in the calculations.},
  journal = {Eur J Cancer},
  year = {2011},
  volume = {47},
  pages = {2626--2632},
  number = {17},
  month = {Nov},
  abstract = {Relative survival is a widely used measure of cancer patient survival,
	defined as the observed survival of the cancer patients divided by
	the expected survival of a comparable group from the general population,
	free from the cancer under study. In practise, expected survival
	is usually calculated from general population life tables. Such estimates
	are known to be biased since they also include mortality from the
	cancer patients, but the bias is ignored since mortality among individuals
	with a specific cancer is thought to constitute only a small proportion
	of total mortality. Using the computerised population registers that
	exist in Sweden we had the unique opportunity to calculate expected
	survival both including and excluding individuals with cancer, and
	thereby estimate the size of the bias arising from using general
	population estimates. We also evaluated a simple method to adjust
	expected survival probabilities estimated from general population
	statistics as an aid to researchers who do not have access to computerised
	registers of the entire national population. Our results show that
	the bias is sufficiently small to be ignorable for most applications,
	notably for cancers with high or low mortality and for younger age
	groups (<60 years). However, the bias in relative survival estimates
	can be greater than 1 percent unit for older age groups for common
	cancers and even larger for all sites combined. For example, the
	bias in 10-year relative survival for men aged 75+ diagnosed with
	prostate cancer was 2.6 percent units, which we think is of sufficient
	magnitude to warrant adjustment.},
  doi = {10.1016/j.ejca.2011.08.010},
  institution = {Unit for Epidemiology, Department of Statistics, Monitoring and Evaluation,
	National Board of Health and Welfare, Stockholm, Sweden. mats.talback@socialstyrelsen.se},
  keywords = {Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool;
	Female; Humans; Infant; Infant, Newborn; Life Expectancy; Male; Middle
	Aged; Neoplasms, mortality; Probability; Registries; Survival Rate;
	Sweden, epidemiology; Young Adult},
  language = {eng},
  medline-pst = {ppublish},
  owner = {theand},
  pii = {S0959-8049(11)00610-1},
  pmid = {21924892},
  timestamp = {2013.03.14},
  url = {http://dx.doi.org/10.1016/j.ejca.2011.08.010}
}

@ARTICLE{Tallis1988,
  author = {Tallis, G. M. and Leppard, P. and O'Neill, T. J.},
  title = {The Analysis of Survival Data from a Central Cancer Registry with
	Passive Follow-Up},
  journal = {Statistics in Medicine},
  year = {1988},
  volume = {7},
  pages = {483-490},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Tappenden2006,
  author = {Tappenden, Paul and Chilcott, Jim and Ward, Sue and Eggington, Simon
	and Hind, Daniel and Hummel, Silvia},
  title = {Methodological issues in the economic analysis of cancer treatments.},
  journal = {Eur J Cancer},
  year = {2006},
  volume = {42},
  pages = {2867--2875},
  number = {17},
  month = {Nov},
  doi = {10.1016/j.ejca.2006.08.010},
  keywords = {Clinical Trials as Topic; Cost-Benefit Analysis, methods; Decision
	Making; Disease-Free Survival; Health Resources, economics/utilization;
	Humans; Models, Economic; Neoplasms, economics/therapy; Prognosis;
	Quality of Life; Quality-Adjusted Life Years; Survival Analysis},
  language = {eng},
  medline-pst = {ppublish},
  owner = {theand},
  pii = {S0959-8049(06)00716-7},
  pmid = {17023160},
  timestamp = {2012.09.18},
  url = {http://dx.doi.org/10.1016/j.ejca.2006.08.010}
}

@Article{Tareke2000,
  author    = {E. Tareke and P. Rydberg and P. Karlsson and S. Eriksson and M. T\"{o}rnqvist},
  title     = {Acrylamide: A Cooking Carcinogen?},
  pages     = {517-522},
  volume    = {13},
  journal   = {Chemical Research in Toxicology},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2000},
}

@ARTICLE{Taub2005,
  author = {N. A. Taub and Z. Morgan and T. S. Brugha and P. C. Lambert and P.
	E. Bebbington and R. Jenkins and R. C. Kessler and A. M. Zaslavsky
	and T. Hotz},
  title = {Recalibration methods to enhance information on prevalence rates
	from large mental health surveys.},
  journal = {Int J Methods Psychiatr Res},
  year = {2005},
  volume = {14},
  pages = {3--13},
  number = {1},
  abstract = {Comparisons between self-report and clinical psychiatric measures
	have revealed considerable disagreement. It is unsafe to consider
	these measures as directly equivalent, so it would be valuable to
	have a reliable recalibration of one measure in terms of the other.
	We evaluated multiple imputation incorporating a Bayesian approach,
	and a fully Bayesian method, to recalibrate diagnoses from a self-report
	survey interview in terms of those from a clinical interview with
	data from a two-phase national household survey for a practical application,
	and artificial data for simulation studies. The most important factors
	in obtaining a precise and accurate 'clinical' prevalence estimate
	from self-report data were (a) good agreement between the two diagnostic
	measures and (b) a sufficiently large set of calibration data with
	diagnoses based on both kinds of interview from the same group of
	subjects. From the case study, calibration data on 612 subjects were
	sufficient to yield estimates of the total prevalence of anxiety,
	depression or neurosis with a precision in the region of +/-2\%.
	The limitations of the calibration method demonstrate the need to
	increase agreement between survey and reference measures by improving
	lay interviews and their diagnostic algorithms.},
  file = {Taub2005.pdf:Taub2005.pdf:PDF;Taub2005.pdf:pdf\\Taub2005.pdf:PDF},
  institution = {Department of Health Sciences, University of Leicester, UK.},
  owner = {pl4},
  pmid = {16097396},
  timestamp = {2008.10.15}
}

@ARTICLE{Taylor1995,
  author = {Jeremy M. G. Taylor},
  title = {Semi-parametric estimation in failure time mixture models},
  journal = {Biometrics},
  year = {1995},
  volume = {51},
  pages = {899-907},
  owner = {theand},
  timestamp = {2013.10.01}
}

@ARTICLE{Taylor1996,
  author = {Taylor, R. and Bell, J. and Coates, M. and Churches, T. and Wain,
	G.},
  title = {Cervical Cancer in {New South Wales} Women: five-year survival, 1972
	to 1991},
  journal = {Australian \& New Zealand Journal of Public Health},
  year = {1996},
  volume = {20},
  pages = {413-420},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Tenkanen1987,
  author = {Tenkanen, L. and Teppo, L. and Hakulinen, T.},
  title = {Smoking and Cardiac Symptoms as Predictors of Lung Cancer},
  journal = {Journal of Chronic Diseases},
  year = {1987},
  volume = {12},
  pages = {1121-1128},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Teppo1999,
  author = {L. Teppo and P. W. Dickman and T. Hakulinen and T. Luostarinen and
	E. Pukkala and R. Sankila and B. S\"{o}derman},
  title = {Cancer patient survival--patterns, comparisons, trends--a population-based
	Cancer Registry study in Finland.},
  journal = {Acta Oncol},
  year = {1999},
  volume = {38},
  pages = {283--294},
  number = {3},
  abstract = {The effects of primary site, sex, age, stage and histological type
	on cancer patient survival were analysed on the basis of the population-based
	material of the Finnish Cancer Registry from 1985 to 1994. In addition,
	trends in survival were constructed for the period 1955-1994. Detailed
	site-specific data are published as Supplement 12 to Vol. 38 of Acta
	Oncologica. Within a given site, the survival differences by gender
	were not large. However, because of different site distributions,
	the average prognosis for female patients, all sites taken together,
	was superior to that of males: the 5-year relative survival rates
	(RSR) were 58\% and 43\%, respectively. In general, older patients
	had a poorer outcome compared with younger patients (partly because
	of different stage and histology distributions). Stage was a strong
	determinant of patient survival. In some cancers with a poor average
	prognosis the 5-year RSR for localized tumours was reasonable, e.g.
	61\% for stomach cancer, males, 34\% for gallbladder cancer, females,
	and 29\% for lung cancer, males. Most of the survival rates clearly
	increased over time. In addition to improvements in cancer treatment,
	changes over time in several other factors affect the trends, such
	as changes in the stage distribution (early diagnosis as a result
	of health education, improved diagnostic methods, screening, etc.)
	and in the composition of the patient material because of changing
	definitions of cancer (e.g. papilloma versus papillary carcinoma
	of the bladder, occult carcinoma of the thyroid, and early prostate
	cancer). The large Cancer Registry material (466,000 patients) enabled
	accurate estimates of the survival rates of cancer patients in Finland.
	These rates reflect the effectiveness of the healthcare system as
	a whole and are useful for planning and evaluation purposes. However,
	the estimated survival rates are based on grouped data, and cannot
	be directly applied for predicting the prognoses of individual patients,
	although they can be used as guidelines.},
  file = {Teppo1999.pdf:Teppo1999.pdf:PDF;Teppo1999.pdf:pdf\\Teppo1999.pdf:PDF},
  institution = {Finnish Cancer Registry, Helsinki. lyly.teppo@cancer.fi},
  owner = {pl4},
  pmid = {10380818},
  timestamp = {2008.12.16}
}

@ARTICLE{Teppo1994,
  author = {L. Teppo and E. Pukkala and M. Lehtonen},
  title = {Data quality and quality control of a population-based cancer registry.
	Experience in Finland.},
  journal = {Acta Oncol},
  year = {1994},
  volume = {33},
  pages = {365--369},
  number = {4},
  abstract = {Cancer registries should pay great attention to the quality of their
	data, both in terms of completeness (all cancer patients in the population
	are registered) and accuracy (data on individual cancer patients
	must be correct). In addition to technical measures in the data processing,
	different types of checks and comparisons should be routine practice.
	Active research policy and ambitious, research-oriented staff with
	competence in medicine, biostatistics and computer science are essential
	in terms of maintaining good data quality.},
  file = {Teppo1994.pdf:Teppo1994.pdf:PDF;Teppo1994.pdf:pdf\\Teppo1994.pdf:PDF},
  institution = {Finnish Cancer Registry, Helsinki.},
  owner = {pl4},
  pmid = {8018367},
  timestamp = {2009.07.27}
}

@ARTICLE{Teppo1985,
  author = {Teppo, L. and Pukkala, E. and Sax{\'e}n, E.},
  title = {Multiple Cancer -- An Epidemiologic Exercise in {F}inland},
  journal = {Journal of the National Cancer Institute},
  year = {1985},
  volume = {75},
  pages = {207-217},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Teuff2005,
  author = {Gwena{\AA}ÂƒÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â«l Le Teuff and Michal Abrahamowicz and Philippe Bolard and
	Catherine Quantin},
  title = {Comparison of Cox's and relative survival models when estimating
	the effects of prognostic factors on disease-specific mortality:
	a simulation study under proportional excess hazards.},
  journal = {Statistics in Medicine},
  year = {2005},
  volume = {24},
  pages = {3887--3909},
  number = {24},
  month = {Dec},
  abstract = {In many prognostic studies focusing on mortality of persons affected
	by a particular disease, the cause of death of individual patients
	is not recorded. In such situations, the conventional survival analytical
	methods, such as the Cox's proportional hazards regression model,
	do not allow to discriminate the effects of prognostic factors on
	disease-specific mortality from their effects on all-causes mortality.
	In the last decade, the relative survival approach has been proposed
	to deal with the analyses involving population-based cancer registries,
	where the problem of missing information on the cause of death is
	very common. However, some questions regarding the ability of the
	relative survival methods to accurately discriminate between the
	two sources of mortality remain open. In order to systematically
	assess the performance of the relative survival model proposed by
	Esteve et al., and to quantify its potential advantages over the
	Cox's model analyses, we carried out a series of simulation experiments,
	based on the population-based colon cancer registry in the French
	region of Burgundy. Simulations showed a systematic bias induced
	by the 'crude' conventional Cox's model analyses when individual
	causes of death are unknown. In simulations where only about 10 per
	cent of patients died of causes other than colon cancer, the Cox's
	model over-estimated the effects of male gender and oldest age category
	by about 17 and 13 per cent, respectively, with the coverage rate
	of the 95 per cent CI for the latter estimate as low as 65 per cent.
	In contrast, the effect of higher cancer stages was under-estimated
	by 8-28 per cent. In contrast to crude survival, relative survival
	model largely reduced such problems and handled well even such challenging
	tasks as separating the opposite effects of the same variable on
	cancer-related versus other-causes mortality. Specifically, in all
	the cases discussed above, the relative bias in the estimates from
	the Esteve et al.'s model was always below 10 per cent, with the
	coverage rates above 81 per cent.},
  doi = {10.1002/sim.2392},
  file = {Teuff2005.pdf:Teuff2005.pdf:PDF;Teuff2005.pdf:pdf\\Teuff2005.pdf:PDF},
  institution = {Department of Biostatistics and Medical Informatics, Centre Hospitalier
	Universitaire de Dijon, BP 77908, 21079 Dijon Cedex, France.},
  owner = {pl4},
  pmid = {16320267},
  timestamp = {2008.12.16},
  url = {http://dx.doi.org/10.1002/sim.2392}
}

@ARTICLE{Thabane2015,
  author = {Thabane, Lehana and Kaczorowski, Janusz and Dolovich, Lisa and Chambers,
	Larry W and Mbuagbaw, Lawrence and , CHAP Investigators},
  title = {Reducing the confusion and controversies around pragmatic trials:
	using the Cardiovascular Health Awareness Program ({CHAP}) trial
	as an illustrative example.},
  journal = {Trials},
  year = {2015},
  volume = {16},
  pages = {387},
  month = {Sep},
  abstract = {Knowledge translation (KT) involves implementation of evidence-based
	strategies and guidelines into practice to improve the process of
	care and health outcomes for patients. Findings from pragmatic trials
	may be used in KT to provide patients, healthcare providers and policymakers
	with information to optimize healthcare decisions based on how a
	given strategy or intervention performs under the real world conditions.
	However, pragmatic trials have been criticized for having the following
	problems: i) high rates of loss to follow-up; ii) nonadherence to
	study intervention; iii) unblinded treatment and patient self-assessment,
	which can potentially create bias; iv) being less perfect experiments
	than efficacy trials; v) sacrificing internal validity to achieve
	generalizability; and vi) often requiring large sample sizes to detect
	small treatment effects in heterogeneous populations. In this paper,
	we discuss whether these criticisms hold merit, or if they are simply
	driven by confusion about the purpose of pragmatic trials. We use
	the Cardiovascular Health Awareness Program (CHAP) trial--a community
	randomized pragmatic trial designed to assess whether offering a
	highly organized, community-based CHAP intervention compared to usual
	care can reduce cardiovascular disease-related outcomes--to address
	these specific criticisms and illustrate how to reduce this confusion.Current
	controlled trials ISRCTN50550004 (9 May 2007).},
  doi = {10.1186/s13063-015-0919-3},
  file = {Thabane2015.pdf:Thabane2015.pdf:PDF;Thabane2015.pdf:pdf\\Thabane2015.pdf:PDF},
  institution = {Centre for the Development of Best Practices in Health, Yaound{\AA}ÂƒÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â©
	Central Hospital, Yaound{\AA}ÂƒÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â©, Cameroon. mbuagblc@mcmaster.ca.},
  keywords = {Age Factors; Awareness; Cardiovascular Diseases, diagnosis/epidemiology/therapy;
	Community Health Services; Evidence-Based Medicine; Health Knowledge,
	Attitudes, Practice; Health Services Research, methods; Health Status;
	Humans; Ontario; Patient Education as Topic; Practice Guidelines
	as Topic; Research Design; Risk Factors; Treatment Outcome},
  language = {eng},
  medline-pst = {epublish},
  owner = {PaulD},
  pii = {10.1186/s13063-015-0919-3},
  pmc = {PMC4557925},
  pmid = {26329614},
  timestamp = {2016.11.02},
  url = {http://dx.doi.org/10.1186/s13063-015-0919-3}
}

@TechReport{TheNationalBoardofHealthandWelfare2013,
  author      = {{The National Board of Health and Welfare}},
  institution = {The National Board of Health and Welfare},
  title       = {Causes of death 2012},
  owner       = {theand},
  timestamp   = {2013.09.30},
  year        = {2013},
}

@TechReport{TheNationalCancerInstitute2010,
  author      = {{The National Cancer Institute}},
  institution = {Division of Cnacer Control and Population Sciences, U.S. Department of Health and Human Sciences, National Institutes of Health},
  title       = {Surveillance Research Program Strategic Plan},
  owner       = {sanelo},
  timestamp   = {2013.10.08},
  year        = {2010},
}

@Book{Therneau2000,
  author    = {Therneau, T. M. and Grambsch, P. M.},
  title     = {Modelling Survival Data: {E}xtending the {C}ox Model},
  publisher = {Springer: New York},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2000},
}

@Electronic{TheSwedishCancerSociety2013,
  author       = {{The Swedish Cancer Society (Cancerfonden)}},
  title        = {Vad orsakar cancer?},
  note         = {http://www.cancerfonden.se (Accessed 10 Oct 2013)},
  organization = {Cancerfonden},
  owner        = {sanelo},
  timestamp    = {2013.10.08},
  year         = {2013},
}

@TechReport{WHO2002,
  author      = {{The World Health Organisation (WHO)}},
  institution = {Geneva},
  title       = {National cancer control programmes. {P}olicies and {M}anagerial {G}uidelines, 2nd edition},
  owner       = {sanelo},
  timestamp   = {2013.08.01},
  year        = {2002},
}

@Electronic{Wip2012,
  author    = {{The World Internet Project}},
  title     = {The fourth report of the {W}orld {I}nternet {P}roject},
  note      = {http://www.worldinternetproject.net (Accessed 15 July 2013)},
  owner     = {sanelo},
  timestamp = {2013.08.01},
  year      = {2012},
}

@ARTICLE{Thiebaut2004,
  author = {Anne C M Thi\'ebaut and Jacques B\'enichou},
  title = {Choice of time-scale in Cox's model analysis of epidemiologic cohort
	data: a simulation study.},
  journal = {Statistics in Medicine},
  year = {2004},
  volume = {23},
  pages = {3803--3820},
  number = {24},
  month = {Dec},
  abstract = {Cox's regression model is widely used for assessing associations between
	potential risk factors and disease occurrence in epidemiologic cohort
	studies. Although age is often a strong determinant of disease risk,
	authors have frequently used time-on-study instead of age as the
	time-scale, as for clinical trials. Unless the baseline hazard is
	an exponential function of age, this approach can yield different
	estimates of relative hazards than using age as the time-scale, even
	when age is adjusted for. We performed a simulation study in order
	to investigate the existence and magnitude of bias for different
	degrees of association between age and the covariate of interest.
	Age to disease onset was generated from exponential, Weibull or piecewise
	Weibull distributions, and both fixed and time-dependent dichotomous
	covariates were considered. We observed no bias upon using age as
	the time-scale. Upon using time-on-study, we verified the absence
	of bias for exponentially distributed age to disease onset. For non-exponential
	distributions, we found that bias could occur even when the covariate
	of interest was independent from age. It could be severe in case
	of substantial association with age, especially with time-dependent
	covariates. These findings were illustrated on data from a cohort
	of 84,329 French women followed prospectively for breast cancer occurrence.
	In view of our results, we strongly recommend not using time-on-study
	as the time-scale for analysing epidemiologic cohort data.},
  doi = {10.1002/sim.2098},
  file = {Thiebaut2004.pdf:Thiebaut2004.pdf:PDF;Thiebaut2004.pdf:pdf\\Thiebaut2004.pdf:PDF},
  institution = {INSERM, E3N-EPIC, Institut Gustave Roussy, Villejuif, France. biostatistique@chu-rouen.fr},
  owner = {pl4},
  pmid = {15580597},
  timestamp = {2009.04.16},
  url = {http://dx.doi.org/10.1002/sim.2098}
}

@ARTICLE{Thompson2006,
  author = {J. Thompson and T. Palmer and S. Moreno},
  title = {Bayesian analysis in Stata with WinBUGS},
  journal = {The Stata Journal},
  year = {2006},
  volume = {6},
  pages = {5300-549},
  file = {Thompson2006.pdf:Thompson2006.pdf:PDF;Thompson2006.pdf:pdf\\Thompson2006.pdf:PDF},
  owner = {pl4},
  timestamp = {2008.11.20}
}

@ARTICLE{Thompson2005,
  author = {Simon G Thompson and Julian P T Higgins},
  title = {Treating individuals 4: can meta-analysis help target interventions
	at individuals most likely to benefit?},
  journal = {Lancet},
  year = {2005},
  volume = {365},
  pages = {341--346},
  number = {9456},
  abstract = {Meta-analyses of randomised trials aim to summarise the effects of
	interventions across many patients, and can seem remote from the
	clinical issue of how individual patients should be treated and which
	patient groups will benefit the most from treatment. One method that
	attempts to address this point entails relating the overall effect
	in every trial to summaries of patient characteristics. This is called
	meta-regression. The interpretation of such analyses is not straightforward,
	however, because of a combination of confounding and other biases.
	Much more useful is to compare the outcomes for patient subgroups
	within trials and combine these results across trials. Unfortunately
	this method is rarely possible using published information, so analyses
	of individual patient data from trials are necessary. Also, although
	meta-analyses generally summarise an intervention's effect as a relative
	risk reduction, the groups of patients with the greatest absolute
	risk reduction have the most to gain.},
  doi = {10.1016/S0140-6736(05)17790-3},
  file = {Thompson2005.pdf:Thompson2005.pdf:PDF;Thompson2005.pdf:pdf\\Thompson2005.pdf:PDF},
  institution = {titute of Public Health, Cambridge CB2 2 sR, UK. simon.thompson@mrc-bsu.cam.ac.uk},
  owner = {pl4},
  pii = {S0140673605177903},
  pmid = {15664231},
  timestamp = {2008.11.18},
  url = {http://dx.doi.org/10.1016/S0140-6736(05)17790-3}
}

@ARTICLE{Titman2011,
  author = {Titman, Andrew C.},
  title = {Flexible nonhomogeneous markov models for panel observed data.},
  journal = {Biometrics},
  year = {2011},
  volume = {67},
  pages = {780--787},
  number = {3},
  month = {Sep},
  abstract = {Methods for fitting nonhomogeneous Markov models to panel-observed
	data using direct numerical solution to the Kolmogorov Forward equations
	are developed. Nonhomogeneous Markov models occur most commonly when
	baseline transition intensities depend on calendar time, but may
	also occur with deterministic time-dependent covariates such as age.
	We propose transition intensities based on B-splines as a smooth
	alternative to piecewise constant intensities and also as a generalization
	of time transformation models. An expansion of the system of differential
	equations allows first derivatives of the likelihood to be obtained,
	which can be used in a Fisher scoring algorithm for maximum likelihood
	estimation. The method is evaluated through a small simulation study
	and demonstrated on data relating to the development of cardiac allograft
	vasculopathy in posttransplantation patients.},
  doi = {10.1111/j.1541-0420.2010.01550.x},
  institution = {Department of Mathematics and Statistics, Lancaster University, Lancaster
	LA1 4YF, UK. a.titman@lancaster.ac.uk},
  keywords = {Computer Simulation; Data Interpretation, Statistical; Heart Transplantation,
	adverse effects; Humans; Likelihood Functions; Markov Chains; Observation;
	Time Factors; Transplantation, Homologous},
  language = {eng},
  medline-pst = {ppublish},
  owner = {miccro},
  pmid = {21306356},
  timestamp = {2015.10.21},
  url = {http://dx.doi.org/10.1111/j.1541-0420.2010.01550.x}
}

@ARTICLE{Tommiska2007,
  author = {Viena Tommiska and Kirsti Heinonen and Liisa Lehtonen and Martin
	Renlund and Timo Saarela and Outi Tammela and Martti Virtanen and
	Vineta Fellman},
  title = {No improvement in outcome of nationwide extremely low birth weight
	infant populations between 1996-1997 and 1999-2000.},
  journal = {Pediatrics},
  year = {2007},
  volume = {119},
  pages = {29--36},
  number = {1},
  month = {Jan},
  abstract = {Our goal was to investigate whether outcome in extremely low birth
	weight infants changes over time in Finland.All infants with a birth
	weight <1000 g born in Finland in 1996-1997 and 1999-2000 were included
	in the study. Perinatal and follow-up data were collected in a national
	extremely low birth weight infant research register. Data concerning
	cerebral palsy and visual impairment were obtained from hospitals,
	the national discharge, and visual impairment registers.A total of
	529 and 511 extremely low birth weight infants were born during 1996-1997
	and 1999-2000. No changes were detected in prenatal, perinatal, neonatal,
	and postneonatal mortality rates between the periods. The survival
	rates including stillborn infants were 40\% and 44\%. The incidence
	of respiratory distress syndrome and septicemia increased from 1996-1997
	to 1999-2000 (75\% vs 83\% and 23\% vs 31\%). The overall incidence
	of intraventricular hemorrhage increased (29\% vs 37\%), but the
	incidence of intraventricular hemorrhage grades 3 through 4 did not
	(16\% vs 17\%). The rates of oxygen dependency at the age corresponding
	with 36 gestational weeks, retinopathy of prematurity stages 3 to
	5, cerebral palsy, and severe visual impairment did not change. Mortality
	remained higher in 1 university hospital area during both periods
	compared with the other 4 areas, but no regional differences in morbidity
	were detected during the later period.No significant changes were
	detected in birth or mortality rate in extremely low birth weight
	infants born in Finland during the late 1990s, but some neonatal
	morbidities seemed to increase. Regional differences in mortality
	were detected in both cohorts. Repeated long-term follow-up studies
	on geographically defined very preterm infant cohorts are needed
	for establishing reliable outcome data of current perinatal care.
	Regional differences warrant thorough audits to assess causalities.},
  doi = {10.1542/peds.2006-1472},
  institution = {National Research and Development Centre for Welfare and Health,
	Helsinki, Finland. viena.tommiska@hus.fi},
  owner = {pl4},
  pii = {119/1/29},
  pmid = {17200268},
  timestamp = {2011.05.26},
  url = {http://dx.doi.org/10.1542/peds.2006-1472}
}

@ARTICLE{Touraine2013,
  author = {Touraine, C{\'e}lia and Helmer, Catherine and Joly, Pierre},
  title = {Predictions in an illness-death model},
  journal = {Statistical methods in medical research},
  year = {2013},
  owner = {miccro},
  publisher = {SAGE Publications},
  timestamp = {2015.12.02}
}

@ARTICLE{Travis1999,
  author = {Travis, L. B. and Holowaty, E. J. and Bergfeldt, K. and Lynch, C.
	F. and Kohler, B. A. and Wiklund, T. and Curtis, R. E. and Hall,
	P. and Andersson, M. and Pukkala, E. and Sturgeon, J and Stovall,
	M.},
  title = {Risk of leukemia after platinum-based chemotherapy for ovarian cancer},
  journal = {New England Journal of Medicine},
  year = {1999},
  volume = {340},
  pages = {351-357},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Tretli1996,
  author = {Tretli, S. and Engeland, A. and Haldorsen, T. and Hakulinen, T. and
	H{\"o}rte, L. G. and Luostarinen, T. and Schou, G. and Sigvaldason,
	H. and Storm, H. H. and Tulinius, H. and Vaittinen, P.},
  title = {Prostate Cancer - {L}ook to {D}enmark?},
  journal = {Journal of the National Cancer Institute},
  year = {1996},
  volume = {88},
  pages = {128},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@InCollection{Tsiatis2005,
  author    = {A.A. Tsiatis},
  booktitle = {Encyclopedia of Biostatistics},
  title     = {Competing Risks},
  edition   = {2},
  editor    = {P. Armitage and T. Colton},
  pages     = {1025-1035},
  publisher = {Wiley},
  file      = {Tsiatis2005.pdf:pdf\\Tsiatis2005.pdf:PDF;Tsiatis2005.pdf:Tsiatis2005.pdf:PDF},
  owner     = {pl4},
  timestamp = {2011.01.25},
  year      = {2005},
}

@ARTICLE{Tsiatis1975,
  author = {Tsiatis, A.},
  title = {A nonidentifiability aspect of the problem of competing risks (crude
	survival probabilities/net survival probabilities)},
  journal = {Proc Natl Acad Sci U S A},
  year = {1975},
  volume = {72},
  pages = {20--22},
  number = {1},
  month = {Jan},
  abstract = {For an experimental animal exposed to k greater than 1 possible risks
	of death R1, R2, ..., Rk, the term i-th potential survival time designates
	a random variable Yi supposed to represent the age at death of the
	animal in hypothetical conditions in which Ri is the only possible
	risk. The probability that Yi will exceed a preassigned t is called
	the i-th net survival probability. The results of a survival experiment
	are represented by k "crude" survival functions, empirical counterparts
	of the probabilities Qi(t) that an animal will survive at least up
	to the age t and eventually die from Ri. The analysis of a survival
	experiment aims at estimating the k net survival probabilities using
	the empirical data on those termed crude. Therorems 1 and 2 establish
	the relationship between the net and the crude probabilities of survival.
	In particular, Theorem 2 shows that, without the not directly verifiable
	assumption that in their joint distribution the variables Y1, Y2,
	..., Yk are mutually independent, a given set of crude survival probabilities
	Qi(t) does not identify the corresponding net probabilities. An example
	shows that the results of a customary method of analysis, based on
	the assumption that Y1, Y2, ..., Yk are independent, may have no
	resemblance to reality.},
  file = {Tsiatis1975.pdf:pdf\\Tsiatis1975.pdf:PDF;Tsiatis1975.pdf:Tsiatis1975.pdf:PDF},
  keywords = {Animals; Animals, Laboratory; Mathematics; Models, Biological; Mortality;
	Probability; Risk},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pmid = {1054494},
  timestamp = {2015.03.24}
}

@ARTICLE{Tsodikov1998,
  author = {Alexander Tsodikov},
  title = {A Proportional Hazards Model Taking Account of Long-Term Survivors},
  journal = {Biometrics},
  year = {1998},
  volume = {54},
  pages = {1508-1516},
  owner = {theand},
  timestamp = {2010.09.29}
}

@ARTICLE{Tsodikov2003,
  author = {Tsodikov, A. D. and Ibrahim, J. G. and Yakovlev, A. Y.},
  title = {Estimating Cure Rates From Survival Data: An Alternative to Two-Component
	Mixture Models.},
  journal = {J Am Stat Assoc},
  year = {2003},
  volume = {98},
  pages = {1063--1078},
  number = {464},
  month = {Dec},
  abstract = {This article considers the utility of the bounded cumulative hazard
	model in cure rate estimation, which is an appealing alternative
	to the widely used two-component mixture model. This approach has
	the following distinct advantages: (1) It allows for a natural way
	to extend the proportional hazards regression model, leading to a
	wide class of extended hazard regression models. (2) In some settings
	the model can be interpreted in terms of biologically meaningful
	parameters. (3) The model structure is particularly suitable for
	semiparametric and Bayesian methods of statistical inference. Notwithstanding
	the fact that the model has been around for less than a decade, a
	large body of theoretical results and applications has been reported
	to date. This review article is intended to give a big picture of
	these modeling techniques and associated statistical problems. These
	issues are discussed in the context of survival data in cancer.},
  doi = {10.1198/01622145030000001007},
  institution = {University of California, Davis, CA 95616.},
  language = {eng},
  medline-pst = {ppublish},
  owner = {theand},
  pmid = {21151838},
  timestamp = {2013.09.14},
  url = {http://dx.doi.org/10.1198/01622145030000001007}
}

@ARTICLE{Tukey1957,
  author = {J. W. Tukey},
  title = {On the comparative anatomy of transformations},
  journal = {Annals of Mathematical Statistics},
  year = {1957},
  volume = {28},
  pages = {602-603},
  file = {Tukey1957.pdf:Tukey1957.pdf:PDF;Tukey1957.pdf:pdf\\Tukey1957.pdf:PDF},
  owner = {pl4},
  timestamp = {2010.03.11}
}

@ARTICLE{Tulinius1992,
  author = {Tulinius, H. and Storm, H. H. and Pukkala, E. and Andersen, A. and
	Ericsson, J.},
  title = {Cancer in the {N}ordic Countries 1981-86},
  journal = {APMIS},
  year = {1992},
  volume = {100 (Suppl. 31)},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@PhdThesis{Turnbull1992,
  author    = {Turnbull, D. A.},
  title     = {Psychosocial Issues in Implementing Mammography Screening in {A}ustralia},
  owner     = {PaulD},
  school    = {University of Sydney},
  timestamp = {2011.06.19},
  year      = {1992},
}

@ARTICLE{Tutz1995,
  author = {G. Tutz},
  title = {Competing risks models in discrete time with nominal or ordinal categories
	of response},
  journal = {Quality and Quantity},
  year = {1995},
  volume = {29},
  pages = {405-420}
}

@ARTICLE{Ulfberg1996a,
  author = {Ulfberg, J. and Carter, N. and Talb{\"a}ck, M. and Edling, C.},
  title = {Excessive daytime sleepiness at work and subjective work performance
	in the general population and among heavy snorers and patients with
	obstructive sleep apnea.},
  journal = {Chest},
  year = {1996},
  volume = {110},
  pages = {659--663},
  number = {3},
  month = {Sep},
  abstract = {To evaluate excessive daytime sleepiness (EDS) at work and effects
	on reported work performance among men in the general population
	and male patients suffering from snoring and obstructive sleep apnea
	syndrome (OSAS).A cross-sectional study of Swedish men between the
	ages of 30 and 64 years in the county of Kopparberg, in mid-Sweden.
	A random sample of the general population (n = 285) and consecutive
	patients referred to a sleep laboratory who fulfilled objective diagnostic
	criteria (snorers = 289, OSAS = 62) responded to a questionnaire.
	Responders from the general population were divided into 2 groups,
	nonsnorers (n = 223) and snorers (n = 62). To validate a question
	on snoring in the questionnaire, 50 men, randomly selected from the
	sample of the general population, underwent sleep apnea screening
	in their homes.The specificity of the questions about snoring was
	83\% and the sensitivity was 42\%. The risk ratios for reporting
	EDS at work were 4-fold for snorers in the general population, 20-fold
	for snoring patients, and 40-fold for patients with OSAS as compared
	with nonsnoring men in the general population. Patients with OSAS
	and snoring patients both showed increased ratios on measures of
	difficulties with concentration, learning new tasks, and performing
	monotonous tasks when compared with nonsnorers.Snoring and sleep
	apnea were highly associated with excessive EDS at work and subjective
	work performance problems. The results provide additional evidence
	that snoring is not merely a nuisance.},
  institution = {Department of Internal Medicine, Avesta Hospital, Sweden.},
  keywords = {Adult; Cross-Sectional Studies; Fatigue, etiology; Humans; Male; Middle
	Aged; Occupational Health; Sensitivity and Specificity; Sleep Apnea
	Syndromes, complications; Snoring, complications; Workplace},
  language = {eng},
  medline-pst = {ppublish},
  owner = {theand},
  pmid = {8797408},
  timestamp = {2013.03.14}
}

@ARTICLE{Ulm1990,
  author = {Ulm, K.},
  title = {A simple method to calculate the confidence interval of a standardized
	mortality ratio ({SMR})},
  journal = {American Journal of Epidemiology},
  year = {1990},
  volume = {131},
  pages = {373-5},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@Booklet{indices2004,
  author    = {Neighbourhood Renewal Unit},
  date      = {2004},
  title     = {The English indices of deprivation 2004 (revised). London: Office of the Deputy Prime Minister},
  file      = {indices2004.pdf:indices2004.pdf:PDF},
  owner     = {BettyS},
  timestamp = {2016.12.08},
}

@ARTICLE{Uno2014,
  author = {Uno, Hajime and Claggett, Brian and Tian, Lu and Inoue, Eisuke and
	Gallo, Paul and Miyata, Toshio and Schrag, Deborah and Takeuchi,
	Masahiro and Uyama, Yoshiaki and Zhao, Lihui and Skali, Hicham and
	Solomon, Scott and Jacobus, Susanna and Hughes, Michael and Packer,
	Milton and Wei, Lee-Jen},
  title = {Moving beyond the hazard ratio in quantifying the between-group difference
	in survival analysis.},
  journal = {J Clin Oncol},
  year = {2014},
  volume = {32},
  pages = {2380--2385},
  number = {22},
  month = {Aug},
  abstract = {In a longitudinal clinical study to compare two groups, the primary
	end point is often the time to a specific event (eg, disease progression,
	death). The hazard ratio estimate is routinely used to empirically
	quantify the between-group difference under the assumption that the
	ratio of the two hazard functions is approximately constant over
	time. When this assumption is plausible, such a ratio estimate may
	capture the relative difference between two survival curves. However,
	the clinical meaning of such a ratio estimate is difficult, if not
	impossible, to interpret when the underlying proportional hazards
	assumption is violated (ie, the hazard ratio is not constant over
	time). Although this issue has been studied extensively and various
	alternatives to the hazard ratio estimator have been discussed in
	the statistical literature, such crucial information does not seem
	to have reached the broader community of health science researchers.
	In this article, we summarize several critical concerns regarding
	this conventional practice and discuss various well-known alternatives
	for quantifying the underlying differences between groups with respect
	to a time-to-event end point. The data from three recent cancer clinical
	trials, which reflect a variety of scenarios, are used throughout
	to illustrate our discussions. When there is not sufficient information
	about the profile of the between-group difference at the design stage
	of the study, we encourage practitioners to consider a prespecified,
	clinically meaningful, model-free measure for quantifying the difference
	and to use robust estimation procedures to draw primary inferences.},
  doi = {10.1200/JCO.2014.55.2208},
  file = {Uno2014.pdf:Uno2014.pdf:PDF},
  institution = {Hajime Uno, Deborah Schrag, and Susanna Jacobus, Dana-Farber Cancer
	Institute; Brian Claggett, Hicham Skali, and Scott Solomon, Harvard
	Medical School, Brigham and Women's Hospital; Michael Hughes and
	Lee-Jen Wei, Harvard School of Public Health, Boston, MA; Lu Tian,
	Stanford University School of Medicine, Palo Alto, CA; Eisuke Inoue
	and Masahiro Takeuchi, Kitasato University; Toshio Miyata, Health
	and Global Policy Institute; Yoshiaki Uyama, Pharmaceuticals and
	Medical Devices Agency, Tokyo, Japan; Paul Gallo, Novartis Pharmaceuticals,
	East Hanover, NJ; Lihui Zhao, Northwestern University Feinberg School
	of Medicine, Chicago, IL; and Milton Packer, University of Texas
	Southwestern Medical Center, Dallas, TX. wei@hsph.harvard.edu.},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {JCO.2014.55.2208},
  pmid = {24982461},
  timestamp = {2014.11.06},
  url = {http://dx.doi.org/10.1200/JCO.2014.55.2208}
}

@ARTICLE{Vagero1987,
  author = {V{\aa}ger{\"o}, D. and Persson, G.},
  title = {Cancer Survival and Social Class in {S}weden},
  journal = {Journal of Epidemiology and Community Health},
  year = {1987},
  volume = {41},
  pages = {204-209},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Vaeisaenen1999,
  author = {S. V\"{a}is\"{a}nen and S. Ryh\"{a}nen and J. T. Saarela and P. H.
	M\"{a}enp\"{a}\"{a}},
  title = {Structure-function studies of new C-20 epimer pairs of vitamin D3
	analogs.},
  journal = {Eur J Biochem},
  year = {1999},
  volume = {261},
  pages = {706--713},
  number = {3},
  month = {May},
  abstract = {A growing number of calcitriol (1alpha,25-dihydroxyvitamin D3) analogs
	have become available in recent years. Many of these analogs exhibit
	lower calcemic effects than calcitriol and inhibit cell proliferation
	and enhance cell differentation more efficiently than calcitriol.
	We have compared structure-function relationships of a series of
	new C-20 epimer (20-epi) vitamin D3 analogs with their natural C-20
	counterparts. In human MG-63 osteosarcoma cells, quantification of
	cellular osteocalcin mRNA levels by Northern blot analysis and osteocalcin
	biosynthesis by radioimmunoassay indicated that most studied analogs
	at a concentration of 10 nm induced osteocalcin gene expression more
	efficiently than the parent compound, calcitriol. Interestingly,
	when the biological responses were compared with the binding affinities
	of the analogs to in-vitro translated human vitamin D receptor and
	with their ability to protect the receptor against partial proteolytic
	digestion, significant correlations were not observed. Further, molecular
	modelling of the compounds by energy minimization did not reveal
	marked differences in the three-dimensional structures of the analogs.
	These results suggest that higher than normal ligand binding affinity
	or 'natural' conformation of the ligand-receptor complex are not
	necessarily required for the 'superagonist' transactivation activity.
	The mechanism of action of the efficient analogs may involve stabilization
	and/or differential binding of transcriptional coactivators or transcription
	intermediary factors to the hVDR during transactivation.},
  institution = {Department of Biochemistry, University of Kuopio, Finland.},
  owner = {pl4},
  pmid = {10215887},
  timestamp = {2011.05.26}
}

@ARTICLE{Vach1991,
  author = {W Vach and M Blettner},
  title = {Biased estimation of the odds ratio in case-control studies due to
	the use of ad hoc methods of correcting for missing values for confounding
	variables.},
  journal = {Am J Epidemiol},
  year = {1991},
  volume = {134},
  pages = {895-907},
  number = {8},
  month = {Oct},
  abstract = {The effects of missing values for a confounding variable are investigated
	in the setting of case-control studies in which, for simplicity,
	the effect of one binary risk factor and one categoric confounding
	variable on disease risk is under investigation. Some ad hoc techniques
	with which to deal with missing values are examined under different
	assumptions about the missing-data mechanism. Examples are given
	to illustrate that the magnitude of the bias that is introduced by
	applying an inadequate procedure can be large under circumstances
	that occur frequently in empiric research. This is true even for
	so-called complete case analysis, i.e., when only data on subjects
	with complete information are used. Appropriate bias corrections
	are derived. Making use of data on those subjects who are neglected
	in complete case analysis by creating an additional category always
	results in biased estimation. An alternative is to allocate these
	subjects to the cells of the contingency table in an appropriate
	manner. This approach yields consistent estimates if the data are
	missing at random. Choosing an appropriate method for dealing with
	missing values always requires some knowledge of why the data are
	missing. This suggests that investigators should carry out validation
	studies to understand whether the missing values occur randomly across
	the study population or occur more frequently in specific subgroups.},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@Book{Valkonen1975,
  author    = {Valkonen, T.},
  title     = {Socio-Economic Mortality Differences in {F}inland 1981-90},
  publisher = {Helsinki: Statistics Finland},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1975},
}

@TechReport{Valkonen1975a,
  author      = {Valkonen, T.},
  institution = {Institute of Sociology, University of Helsinki},
  title       = {Standard of Living, Urbanisation, and Regional Mortality Differences in {F}inland, {S}weden, and {N}orway},
  note        = {(in Finnish)},
  number      = {204},
  type        = {Research report no.},
  owner       = {PaulD},
  timestamp   = {2011.06.19},
  year        = {1975},
}

@ARTICLE{Buuren1999,
  author = {S. {van Buuren} and H. C. Boshuizen and D. L. Knook},
  title = {Multiple imputation of missing blood pressure covariates in survival
	analysis.},
  journal = {Statistics in Medicine},
  year = {1999},
  volume = {18},
  pages = {681--694},
  number = {6},
  month = {Mar},
  abstract = {This paper studies a non-response problem in survival analysis where
	the occurrence of missing data in the risk factor is related to mortality.
	In a study to determine the influence of blood pressure on survival
	in the very old (85+ years), blood pressure measurements are missing
	in about 12.5 per cent of the sample. The available data suggest
	that the process that created the missing data depends jointly on
	survival and the unknown blood pressure, thereby distorting the relation
	of interest. Multiple imputation is used to impute missing blood
	pressure and then analyse the data under a variety of non-response
	models. One special modelling problem is treated in detail; the construction
	of a predictive model for drawing imputations if the number of variables
	is large. Risk estimates for these data appear robust to even large
	departures from the simplest non-response model, and are similar
	to those derived under deletion of the incomplete records.},
  file = {Buuren1999.pdf:Buuren1999.pdf:PDF;Buuren1999.pdf:pdf\\Buuren1999.pdf:PDF},
  institution = {TNO Prevention and Health, Department of Statistics, Leiden, The
	Netherlands. S.vanBuuren@pg.tno.nl},
  owner = {pl4},
  pii = {3.0.CO;2-R},
  pmid = {10204197},
  timestamp = {2009.12.08}
}

@ARTICLE{VanderWeele2016a,
  author = {VanderWeele, Tyler J},
  title = {Explanation in causal inference: developments in mediation and interaction.},
  journal = {International journal of epidemiology},
  year = {2016},
  month = {Nov},
  country = {England},
  created = {2016-11-19},
  doi = {10.1093/ije/dyw277},
  issn = {1464-3685},
  issn-linking = {0300-5771},
  nlm-id = {7802871},
  owner = {NLM},
  pii = {dyw277},
  pmid = {27864406},
  pubmodel = {Print-Electronic},
  pubstatus = {aheadofprint},
  revised = {2016-11-20},
  timestamp = {2016.12.09}
}

@ARTICLE{VanderWeele2016b,
  author = {VanderWeele, Tyler J},
  title = {Mediation Analysis: A Practitioner's Guide.},
  journal = {Annual review of public health},
  year = {2016},
  volume = {37},
  pages = {17--32},
  abstract = {This article provides an overview of recent developments in mediation
	analysis, that is, analyses used to assess the relative magnitude
	of different pathways and mechanisms by which an exposure may affect
	an outcome. Traditional approaches to mediation in the biomedical
	and social sciences are described. Attention is given to the confounding
	assumptions required for a causal interpretation of direct and indirect
	effect estimates. Methods from the causal inference literature to
	conduct mediation in the presence of exposure-mediator interactions,
	binary outcomes, binary mediators, and case-control study designs
	are presented. Sensitivity analysis techniques for unmeasured confounding
	and measurement error are introduced. Discussion is given to extensions
	to time-to-event outcomes and multiple mediators. Further flexible
	modeling strategies arising from the precise counterfactual definitions
	of direct and indirect effects are also described. The focus throughout
	is on methodology that is easily implementable in practice across
	a broad range of potential applications.},
  citation-subset = {IM},
  country = {United States},
  created = {2016-03-19},
  doi = {10.1146/annurev-publhealth-032315-021402},
  issn = {1545-2093},
  issn-linking = {0163-7525},
  keywords = {direct effects; indirect effects; mechanism; pathway analysis},
  nlm-id = {8006431},
  owner = {NLM},
  pmid = {26653405},
  pubmodel = {Print-Electronic},
  pubstatus = {ppublish},
  revised = {2016-04-15},
  timestamp = {2016.12.09}
}

@ARTICLE{VanderWeele2013b,
  author = {VanderWeele, Tyler J},
  title = {Unmeasured confounding and hazard scales: sensitivity analysis for
	total, direct, and indirect effects.},
  journal = {European journal of epidemiology},
  year = {2013},
  volume = {28},
  pages = {113--117},
  month = {Feb},
  citation-subset = {IM},
  completed = {2013-07-10},
  country = {Netherlands},
  created = {2013-03-21},
  doi = {10.1007/s10654-013-9770-6},
  issn = {1573-7284},
  issn-linking = {0393-2990},
  issue = {2},
  keywords = {Educational Status; Health Behavior; Humans; Male},
  mid = {NIHMS441215},
  nlm = {PMC3606287},
  nlm-id = {8508062},
  owner = {NLM},
  pmc = {PMC3606287},
  pmid = {23371044},
  pubmodel = {Print-Electronic},
  pubstatus = {ppublish},
  revised = {2016-10-25},
  timestamp = {2016.12.09}
}

@Article{vanderweele2011,
  author    = {VanderWeele, T.J.},
  title     = {Causal Mediation Analysis with Survival Data.},
  journal   = {Epidemiology},
  year      = {2011},
  volume    = {22},
  number    = {4},
  pages     = {582--585},
  file      = {vanderweele2011.pdf:vanderweele2011.pdf:PDF},
  owner     = {BettyS},
  timestamp = {2016.11.28},
}

@ARTICLE{VanHemelrijck2012,
  author = {{Van Hemelrijck}, Mieke and Wigertz, Annette and Sandin, Fredrik
	and Garmo, Hans and Hellstr{\"o}m, Karin and Fransson, Per and Widmark,
	Anders and Lambe, Mats and Adolfsson, Jan and Varenhorst, Eberhard
	and Johansson, Jan-Erik and Stattin, P{\"a}r and , for N. P. C. R. and
	P. C. BaSe Sweden},
  title = {Cohort Profile: The {N}ational {P}rostate {C}ancer {R}egister of
	{S}weden and {P}rostate {C}ancer data {B}ase {S}weden 2.0.},
  journal = {Int J Epidemiol},
  year = {2012},
  month = {May},
  abstract = {In 1987, the first Regional Prostate Cancer Register was set up in
	the South-East health-care region of Sweden. Other health-care regions
	joined and since 1998 virtually all prostate cancer (PCa) cases are
	registered in the National Prostate Cancer Register (NPCR) of Sweden
	to provide data for quality assurance, bench marking and clinical
	research. NPCR includes data on tumour stage, Gleason score, serum
	level of prostate-specific antigen (PSA) and primary treatment. In
	2008, the NPCR was linked to a number of other population-based registers
	by use of the personal identity number. This database named Prostate
	Cancer data Base Sweden (PCBaSe) has now been extended with more
	cases, longer follow-up and a selection of two control series of
	men free of PCa at the time of sampling, as well as information on
	brothers of men diagnosed with PCa, resulting in PCBaSe 2.0. This
	extension allows for studies with case-control, cohort or longitudinal
	case-only design on aetiological factors, pharmaceutical prescriptions
	and assessment of long-term outcomes. The NPCR covers >96\% of all
	incident PCa cases registered by the Swedish Cancer Register, which
	has an underreporting of <3.7\%. The NPCR is used to assess trends
	in incidence, treatment and outcome of men with PCa. Since the national
	registers linked to PCBaSe are complete, studies from PCBaSe 2.0
	are truly population based.},
  doi = {10.1093/ije/dys068},
  institution = {King's College London, School of Medicine, Division of Cancer Studies,
	Cancer Epidemiology Group, London, UK, Regional Cancer Centre, Uppsala
	University Hospital, Uppsala, Sweden, Department of Nursing, Ume{\aa}
	University, Ume{\aa}, Sweden, Department of Radiation Sciences, Oncology,
	Ume{\aa} University, Ume{\aa}, Sweden, Department of Medical Epidemiology
	and Biostatistics, Karolinska Institutet, Stockholm, Sweden, Oncological
	Centre, CLINTEC Department, Karolinska Institutet, Stockholm, Sweden,
	Deparment of Urology, Link{\"o}ping University Hospital, Link{\"o}ping, Sweden,
	Department of Urology, {\AA}Â–rebro University Hospital and {\AA}Â–rebro University,
	Department of Surgical and Perioperative Sciences, Urology and Andrology,
	Ume{\aa} University, Ume{\aa}, Sweden and Department of Surgery, Urology
	Service, Memorial Sloan-Kettering Cancer Center, New York, New York,
	USA.},
  language = {eng},
  medline-pst = {aheadofprint},
  owner = {sanelo},
  pii = {dys068},
  pmid = {22561842},
  timestamp = {2013.08.01},
  url = {http://dx.doi.org/10.1093/ije/dys068}
}

@Article{Vansteelandt2011,
  author      = {Vansteelandt, S. and Keiding, N.},
  title       = {Invited commentary: G-computation--lost in translation?},
  journal     = {Am J Epidemiol},
  year        = {2011},
  language    = {eng},
  volume      = {173},
  number      = {7},
  pages       = {739--742},
  doi         = {10.1093/aje/kwq474},
  url         = {http://dx.doi.org/10.1093/aje/kwq474},
  abstract    = {In this issue of the Journal, Snowden et al. (Am J Epidemiol. 2011;173(7):731-738)
	give a didactic explanation of G-computation as an approach for estimating
	the causal effect of a point exposure. The authors of the present
	commentary reinforce the idea that their use of G-computation is
	equivalent to a particular form of model-based standardization, whereby
	reference is made to the observed study population, a technique that
	epidemiologists have been applying for several decades. They comment
	on the use of standardized versus conditional effect measures and
	on the relative predominance of the inverse probability-of-treatment
	weighting approach as opposed to G-computation. They further propose
	a compromise approach, doubly robust standardization, that combines
	the benefits of both of these causal inference techniques and is
	not more difficult to implement.},
  file        = {:Vansteelandt2011.pdf:PDF},
  institution = {Department of Applied Mathematics and Computer Science, Ghent University, Krijgslaan 281, Ghent, Belgium. stijn.vansteelandt@ugent.be},
  keywords    = {Causality; Computer Simulation; Confounding Factors (Epidemiology); Epidemiologic Research Design; Humans; Models, Statistical; Probability; Regression Analysis},
  medline-pst = {ppublish},
  owner       = {pl4},
  pii         = {kwq474},
  pmid        = {21415028},
  timestamp   = {2016.08.26},
}

@ARTICLE{Varadhan2010,
  author = {Varadhan, Ravi and Weiss, Carlos O. and Segal, Jodi B. and Wu, Albert
	W. and Scharfstein, Daniel and Boyd, Cynthia},
  title = {Evaluating health outcomes in the presence of competing risks: a
	review of statistical methods and clinical applications.},
  journal = {Med Care},
  year = {2010},
  volume = {48},
  pages = {S96--105},
  number = {6 Suppl},
  month = {Jun},
  abstract = {An evaluation of the effect of a healthcare intervention (or an exposure)
	must consider multiple possible outcomes, including the primary outcome
	of interest and other outcomes such as adverse events or mortality.
	The determination of the likelihood of benefit from an intervention,
	in the presence of other competing outcomes, is a competing risks
	problem. Although statistical methods exist for quantifying the probability
	of benefit from an intervention while accounting for competing events,
	these methods have not been widely adopted by clinical researchers.(1)
	To demonstrate the importance of considering competing risks in the
	evaluation of treatment effectiveness, and (2) to review appropriate
	statistical methods, and recommend how they might be applied.We reviewed
	3 statistical approaches for analyzing the competing risks problem:
	(a) cause-specific hazard (CSH), (b) cumulative incidence function
	(CIF), and (c) event-free survival (EFS). We compare these methods
	using a simulation study and a reanalysis of a randomized clinical
	trial.Simulation studies evaluating the statistical power to detect
	the effect of intervention under different scenarios showed that:
	(1) CSH approach is best for detecting the effect of an intervention
	if the intervention only affects either the primary outcome or the
	competing event; (2) EFS approach is best only when the intervention
	affects both primary and competing events in the same manner; and
	(3) CIF approach is best when the intervention affects both primary
	and competing events, but in opposite directions. Using data from
	a randomized controlled trial, we demonstrated that a comprehensive
	approach using all 3 approaches provided useful insights on the effect
	of an intervention on the relative and absolute risks of multiple
	competing outcomes.CSH is the fundamental measure of outcome in competing
	risks problems. It is appropriate for evaluating treatment effects
	in the presence of competing events. Results of CSH analysis for
	primary and competing outcomes should always be reported even when
	EFS or CIF approaches are called for. EFS is appropriate for evaluating
	the composite effect of an intervention, only when combining different
	endpoints is clinically and biologically meaningful, and the treatment
	has similar effects on all event types. CIF is useful for evaluating
	the likelihood of benefit from an intervention over a meaningful
	period. CIF should be used for absolute risk calculations instead
	of the widely used complement of the Kaplan-Meier (1 - KM) estimator.},
  doi = {10.1097/MLR.0b013e3181d99107},
  institution = {Department of Medicine, Johns Hopkins University School of Medicine,
	Baltimore, MD, USA. rvaradhan@jhmi.edu},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {20473207},
  timestamp = {2012.02.06},
  url = {http://dx.doi.org/10.1097/MLR.0b013e3181d99107}
}

@ARTICLE{Verdecchia2002,
  author = {Arduino Verdecchia and Giovanni De Angelis and Riccardo Capocaccia},
  title = {Estimation and projections of cancer prevalence from cancer registry
	data.},
  journal = {Stat Med},
  year = {2002},
  volume = {21},
  pages = {3511--3526},
  number = {22},
  month = {Nov},
  abstract = {A method, PIAMOD (Prevalence, Incidence, Analysis MODel), which allows
	the estimation and projection of cancer prevalence patterns by using
	cancer registry incidence and survival data is presented. As a first
	step the method involves the fit of incidence data by an age, period
	and cohort model to derive incidence projections. Prevalence is then
	estimated from modelled incidence and survival estimates. Cancer
	mortality is derived as a third step from modelled incidence, prevalence
	and survival. An application to female breast cancer is given for
	the Connecticut State by using data from the Connecticut Tumor Registry
	(CTR), 1973-1993. The age, period and cohort model fitted incidence
	quite well and allowed us to derive long-term projections up to 2030.
	Patients' survival was also projected to future years according to
	a scenario approach based on two extreme hypotheses: steady, that
	is, no more improvements after 1993 (conservative), and continuously
	improving at the same rate as during the observation period. Age-standardized
	estimated incidence shows a changing trend around the year 2005,
	when it starts decreasing. Age-standardized prevalence is expected
	to increase and change trend at a later date. Breast cancer mortality
	is projected as decreasing, as the combined result of no further
	increase in incidence and improving cancer patients' survival. An
	easy-to-use PIAMOD software package, on which work is in progress,
	will be made available to individual cancer registries and/or health
	planning institutions or authorities once it is developed. The use
	of the PIAMOD method for cancer registries will allow them to provide
	results of paramount importance for the whole community involved
	in the assessment of future disease burden scenarios in an evolving
	society.},
  doi = {10.1002/sim.1304},
  file = {Verdecchia2002.pdf:Verdecchia2002.pdf:PDF;Verdecchia2002.pdf:pdf\\Verdecchia2002.pdf:PDF},
  institution = {Laboratorio di Epidemiologia e Biostatistica, Istituto Superiore
	di Sanita', Rome, Italy. verdeck@iss.it},
  owner = {pl4},
  pmid = {12407687},
  timestamp = {2009.10.13},
  url = {http://dx.doi.org/10.1002/sim.1304}
}

@ARTICLE{Verdecchia1998,
  author = {A. Verdecchia and R. De Angelis and R. Capocaccia and M. Sant and
	A. Micheli and G. Gatta and F. Berrino},
  title = {The cure for colon cancer: results from the {EUROCARE} study.},
  journal = {Int J Cancer},
  year = {1998},
  volume = {77},
  pages = {322--329},
  number = {3},
  month = {Jul},
  abstract = {The interpretation of time trends and geographical differences of
	population-based survival rates is generally not easy, due to the
	difficulty in disentangling the effects of observational biases,
	diagnostic and therapeutic procedures and their interactions. Whereas
	descriptive analysis of relative survival is generally based on survival
	levels estimated at fixed time since diagnosis, interpretation issues
	can take advantage from the analysis of the shape of the considered
	relative survival. Parametric survival models allowing the estimation
	of the fraction of cured patients are applied here to analyze and
	discuss the differences in colon cancer relative survival between
	European countries, according to age and period of diagnosis. The
	survival curves of colon cancer patients are described according
	to 2 parameters: the proportion of cured patients and the mean survival
	time of fatal cases. These parameters are estimated by least square
	nonlinear regression of relative survival values derived from the
	EUROCARE Project publication. Exponential and Weibull survival functions
	are used to model the relative survival curve for the fraction of
	fatal cases. The Weibull model gives generally a better fit with
	respect to the exponential model, thus indicating that the mortality
	rate for fatal cases is decreasing with time since diagnosis. For
	the youngest patients, however, the 2 survival functions give practically
	overlapping estimates. The overall proportion of colon cancer patients
	in Europe that are estimated to be cured was 38.6\%. This proportion
	increased from 36\% to 40\% for patients diagnosed in 1978-1980 and
	in 1983-1985, respectively. Accordingly, mean survival time of fatal
	cases increased from 1.18 to 1.52 years. According to age, the proportion
	of cured patients present a marked decrease from young (48.4\% at
	age 15-44 years) to middle-aged patients (38.6\% at age 5564 years)
	and only a mild decrease from these to the oldest patients (34.4\%
	at age 75 or more). The opposite effect was shown by survival time
	of fatal cases, i.e., 1.71, 1.75 and 0.77 years for the same age
	classes, respectively. Proportion of cured cases and mean survival
	time of fatal cases tended to be positively correlated with each
	other across countries. Our results are consistent with the hypothesis
	that a real improvement in colon cancer survival took place in Europe
	during the years 1978-1985 and also suggest that the well-known decrease
	of relative survival with age at diagnosis could be mostly due to
	a decreasing efficacy of early diagnosis for patients under 60 years
	old and to less effective therapies for older patients.},
  file = {Verdecchia1998.pdf:Verdecchia1998.pdf:PDF;Verdecchia1998.pdf:pdf\\Verdecchia1998.pdf:PDF},
  institution = {ical@vm.iss.it},
  keywords = {Cure models},
  owner = {pl4},
  pii = {3.0.CO;2-Q},
  pmid = {9663589},
  timestamp = {2008.12.05}
}

@ARTICLE{Verdecchia2007,
  author = {Arduino Verdecchia and Silvia Francisci and Hermann Brenner and Gemma
	Gatta and Andrea Micheli and Lucia Mangone and Ian Kunkler and {EUROCARE-4
	working group}},
  title = {Recent cancer survival in {E}urope: a 2000-02 period analysis of
	{EUROCARE-4} data.},
  journal = {Lancet Oncol},
  year = {2007},
  volume = {8},
  pages = {784--796},
  number = {9},
  month = {Sep},
  abstract = {BACKGROUND: Traditional cancer-survival analyses provide data on cancer
	management at the beginning of a study period, and are often not
	relevant to current practice because they refer to survival of patients
	treated with older regimens that might no longer be used. Therefore,
	shortening the delay in providing survival estimates is desirable.
	Period analysis can estimate cancer survival by the use of recent
	data. We aimed to apply the period-analysis method to data that were
	collected by European cancer registries to estimate recent survival
	by country and cancer site, and to assess survival changes in Europe.
	We also compared our findings with data on cancer survival in the
	USA from the US SEER (Surveillance, Epidemiology, and End Results)
	programme. METHODS: We analysed survival data for patients diagnosed
	with cancer in 2000-02, collected from 47 of the European cancer
	registries participating in the EUROCARE-4 study. 5-year period relative
	survival for patients diagnosed in 2000-02 was estimated as the product
	of interval-specific relative survival values of cohorts with different
	lengths of follow-up. 5-year survival profiles for patients diagnosed
	in 2000-02 were estimated for the European mean and for five European
	regions, and findings were compared with US SEER registry data for
	patients diagnosed in 2000-02. A 5-year survival profile for patients
	diagnosed in 1991-2002 and a 10-year survival profile for patients
	diagnosed in 1997-2002 were also estimated by the period method for
	all malignancies, by geographical area, and by cancer site. FINDINGS:
	For all cancers, age-adjusted 5-year period survival improved for
	patients diagnosed in 2000-02, especially for patients with colorectal,
	breast, prostate, and thyroid cancer, Hodgkin's disease, and non-Hodgkin
	lymphoma. The European mean age-adjusted 5-year survival calculated
	by the period method for 2000-02 was high for testicular cancer (97.3\%
	[95\% CI 96.4-98.2]), melanoma (86.1\% [84.3-88.0]), thyroid cancer
	(83.2\% [80.9-85.6]), Hodgkin's disease (81.4\% [78.9-84.1]), female
	breast cancer (79.0\% [78.1-80.0]), corpus uteri (78.0\% [76.2-79.9]),
	and prostate cancer (77.5\% [76.5-78.6]); and low for stomach cancer
	(24.9\% [23.7-26.2]), chronic myeloid leukaemia (32.2\% [29.0-35.7]),
	acute myeloid leukaemia (14.8\% [13.4-16.4]), and lung cancer (10.9\%
	[10.5-11.4]). Survival for patients diagnosed in 2000-02 was generally
	highest for those in northern European countries and lowest for those
	in eastern European countries, although, patients in eastern European
	had the highest improvement in survival for major cancer sites during
	1991-2002 (colorectal cancer from 30.3\% [28.3-32.5] to 44.7\% [42.8-46.7];
	breast cancer from 60\% [57.2-63.0] to 73.9\% [71.7-76.2]; for prostate
	cancer from 39.5\% [35.0-44.6] to 68.0\% [64.2-72.1]). For all solid
	tumours, with the exception of stomach, testicular, and soft-tissue
	cancers, survival for patients diagnosed in 2000-02 was higher in
	the US SEER registries than for the European mean. For haematological
	malignancies, data from US SEER registries and the European mean
	were comparable in 2000-02, except for non-Hodgkin lymphoma. INTERPRETATION:
	Cancer-service infrastructure, prevention and screening programmes,
	access to diagnostic and treatment facilities, tumour-site-specific
	protocols, multidisciplinary management, application of evidence-based
	clinical guidelines, and recruitment to clinical trials probably
	account for most of the differences that we noted in outcomes.},
  file = {Verdecchia2007.pdf:Verdecchia2007.pdf:PDF;Verdecchia2007.pdf:pdf\\Verdecchia2007.pdf:PDF},
  institution = {National Centre for Epidemiology, Health Surveillance and Promotion,
	Istituto Superiore di Sanit{\AA}ÂƒÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â , Rome, Italy. arduino.verdecchia@iss.it},
  owner = {pl4},
  pmid = {17714993},
  timestamp = {2008.12.02}
}

@ARTICLE{Viget2000,
  author = {Viget, N. B. and Guery, B. P. and Ader, F. and Nevi{\AA}Â§ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â±ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¥, R. and Alfandari,
	S. and Creuzy, C. and Roussel-Delvallez, M. and Foucher, C. and Mason,
	C. M. and Beaucaire, G. and Pittet, J. F.},
  title = {Keratinocyte growth factor protects against Pseudomonas aeruginosa-induced
	lung injury.},
  journal = {Am J Physiol Lung Cell Mol Physiol},
  year = {2000},
  volume = {279},
  pages = {L1199--L1209},
  number = {6},
  month = {Dec},
  abstract = {We have previously reported that keratinocyte growth factor (KGF)
	attenuates alpha-naphthylthiourea-induced lung injury by upregulating
	alveolar fluid transport. The objective of this study was to determine
	the effect of KGF pretreatment in Pseudomonas aeruginosa pneumonia.
	A 5\% bovine albumin solution with 1 microCi of (125)I-labeled human
	albumin was instilled into the air spaces 4 or 24 h after intratracheal
	instillation of P. aeruginosa, and the concentration of unlabeled
	and labeled proteins in the distal air spaces over 1 h was used as
	an index of net alveolar fluid clearance. Alveolocapillary barrier
	permeability was evaluated with an intravascular injection of 1 microCi
	of (131)I-albumin. In early pneumonia, KGF increased lung liquid
	clearance (LLC) compared with that in nonpretreated animals. In late
	pneumonia, LLC was significantly reduced in the absence of KGF but
	increased above the control value with KGF. KGF pretreatment increased
	the number of polymorphonuclear cells recovered in the bronchoalveolar
	lavage fluid and decreased bacterial pulmonary translocation. In
	conclusion, KGF restores normal alveolar epithelial fluid transport
	during the acute phase of P. aeruginosa pneumonia and LLC in early
	and late pneumonia. Host response is also improved as shown by the
	increase in the alveolar cellular response and the decrease in pulmonary
	translocation of bacteria.},
  institution = {Laboratoire de Recherche en Pathologie Infectieuse, EA 2689, 59045
	Lille, France.},
  keywords = {Albumins, pharmacokinetics; Animals; Body Fluids, metabolism; Bronchoalveolar
	Lavage Fluid, cytology/immunology/microbiology; Disease Models, Animal;
	Fibroblast Growth Factor 10; Fibroblast Growth Factor 7; Fibroblast
	Growth Factors; Growth Substances, pharmacology; Iodine Radioisotopes,
	diagnostic use; Macrophages, Alveolar, immunology/microbiology; Pneumonia,
	Bacterial, drug therapy/mortality/pathology; Pseudomonas Infections,
	drug therapy/mortality/pathology; Pseudomonas aeruginosa; Pulmonary
	Alveoli, metabolism/microbiology/pathology; Rats; Rats, Sprague-Dawley;
	Specific Pathogen-Free Organisms; Survival Rate},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {11076810},
  timestamp = {2013.05.29}
}

@ARTICLE{ViscomiS2006,
  author = {S Viscomi and G Pastore and E Dama and L Zuccolo and N Pearce and
	F Merletti and C Magnani},
  title = {Life expectancy as an indicator of outcome in follow-up of population-based
	cancer registries: the example of childhood leukemia.},
  journal = {Annals of Oncology},
  year = {2006},
  volume = {17(1)},
  pages = {167-171},
  owner = {theand},
  timestamp = {2012.09.14}
}

@ARTICLE{Volinsky2000,
  author = {Volinsky, C. T. and Raftery, A. E.},
  title = {Bayesian information criterion for censored survival models.},
  journal = {Biometrics},
  year = {2000},
  volume = {56},
  pages = {256--262},
  number = {1},
  month = {Mar},
  abstract = {We investigate the Bayesian Information Criterion (BIC) for variable
	selection in models for censored survival data. Kass and Wasserman
	(1995, Journal of the American Statistical Association 90, 928-934)
	showed that BIC provides a close approximation to the Bayes factor
	when a unit-information prior on the parameter space is used. We
	propose a revision of the penalty term in BIC so that it is defined
	in terms of the number of uncensored events instead of the number
	of observations. For a simple censored data model, this revision
	results in a better approximation to the exact Bayes factor based
	on a conjugate unit-information prior. In the Cox proportional hazards
	regression model, we propose defining BIC in terms of the maximized
	partial likelihood. Using the number of deaths rather than the number
	of individuals in the BIC penalty term corresponds to a more realistic
	prior on the parameter space and is shown to improve predictive performance
	for assessing stroke risk in the Cardiovascular Health Study.},
  file = {Volinsky2000.pdf:pdf\\Volinsky2000.pdf:PDF;Volinsky2000.pdf:Volinsky2000.pdf:PDF},
  institution = {T Labs, Florham Park, New Jersey 07932, USA. volinsky@research.att.com},
  language = {eng},
  medline-pst = {ppublish},
  owner = {Paul},
  pmid = {10783804},
  timestamp = {2012.06.26}
}

@ARTICLE{Voskuil1999,
  author = {DW Voskuil and K Augustsson and PW Dickman and P van't Veer and G
	Steineck},
  title = {Assessing the human intake of heterocyclic amines: limited loss of
	information using reduced sets of questions.},
  journal = {Cancer Epidemiol Biomarkers Prev},
  year = {1999},
  volume = {8},
  pages = {809-14},
  number = {9},
  month = {Sep},
  abstract = {The aim of this study was to evaluate loss of information from a reduced
	food frequency questionnaire as compared with an extensive reference
	method developed to assess the intake of heterocyclic amines (HCAs).
	Food frequency data were linked to concentrations of HCAs in cooked
	foods to estimate the individual daily exposure to a combination
	of five HCAs. The number of food items in the questionnaire was reduced
	and selected in three ways: (a) according to the contribution to
	the estimated total intake; (b) the between-person variance; or (c)
	dishes included in other studies. The effect on sensitivity, specificity,
	concordance, the correlation coefficient, kappa, and simulated relative
	risks was determined using information from a population-based study
	conducted in Stockholm. Only a limited amount of misclassification
	was introduced when the number of dishes was reduced from 39 to 15
	or 20, and no major difference was seen when dishes were selected
	according to the total intake or the between-person variance. Our
	data indicate that for a specific exposure, such as HCAs, the loss
	of accuracy in an analytical epidemiological study is small and may
	not be relevant when the number of dishes in a food frequency questionnaire
	is decreased, if the initially chosen dishes are carefully selected
	and cover a reasonable part of the total intake or between-person
	variance.},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@Manual{Voutilainen2000,
  author       = {Voutilainen, E. T. and Dickman, P. W. and Hakulinen, T.},
  title        = {{SURV2}: {R}elative Survival Analysis Program},
  note         = {\url{http://www.cancerregistry.fi/surv2/}},
  organization = {Helsinki: Finnish Cancer Registry},
  owner        = {PaulD},
  timestamp    = {2011.06.19},
  year         = {2000},
}

@ARTICLE{Wacholder1986,
  author = {Wacholder, S.},
  title = {Binomial Regression in {GLIM}: {E}stimating Risk Ratios and Risk
	Differences},
  journal = {American Journal of Epidemiology},
  year = {1986},
  volume = {123},
  pages = {1},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Walter1992a,
  author = {Walter, S. D.},
  title = {The Analysis of Regional Patterns in Health Data. {I. D}istributional
	Considerations},
  journal = {American Journal of Epidemiology},
  year = {1992},
  volume = {136},
  pages = {730-741},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Walter1992b,
  author = {Walter, S. D.},
  title = {The Analysis of Regional Patterns in Health Data. {II. T}he Power
	to Detect Environmental Effects},
  journal = {American Journal of Epidemiology},
  year = {1992},
  volume = {136},
  pages = {742-759},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Walter1991,
  author = {Walter, S. D. and Birnie, S. E.},
  title = {Mapping Mortality and Morbidity Patterns: An International Comparison},
  journal = {International Journal of Epidemiology},
  year = {1991},
  volume = {20},
  pages = {678-689},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Walters2013,
  author = {Walters, Sarah and Maringe, Camille and Coleman, Michel P. and Peake,
	Michael D. and Butler, John and Young, Nicholas and Bergstr{\"o}m, Stefan
	and Hanna, Louise and Jakobsen, Erik and K{\"o}lbeck, Karl and Sundstr{\AA}Â¸m,
	Stein and Engholm, Gerda and Gavin, Anna and Gjerstorff, Marianne
	L. and Hatcher, Juanita and Johannesen, Tom B{\AA}Â¸rge and Linklater,
	Karen M. and McGahan, Colleen E. and Steward, John and Tracey, Elizabeth
	and Turner, Donna and Richards, Michael A. and Rachet, Bernard and
	, {ICBP Module 1 Working Group}},
  title = {Lung cancer survival and stage at diagnosis in {A}ustralia, {C}anada,
	{D}enmark, {N}orway, {S}weden and the {UK}: a population-based study,
	2004-2007.},
  journal = {Thorax},
  year = {2013},
  volume = {68},
  pages = {551--564},
  number = {6},
  month = {Jun},
  abstract = {The authors consider whether differences in stage at diagnosis could
	explain the variation in lung cancer survival between six developed
	countries in 2004-2007.Routinely collected population-based data
	were obtained on all adults (15-99 years) diagnosed with lung cancer
	in 2004-2007 and registered in regional and national cancer registries
	in Australia, Canada, Denmark, Norway, Sweden and the UK. Stage data
	for 57 352 patients were consolidated from various classification
	systems. Flexible parametric hazard models on the log cumulative
	scale were used to estimate net survival at 1 year and the excess
	hazard up to 18 months after diagnosis.Age-standardised 1-year net
	survival from non-small cell lung cancer ranged from 30\% (UK) to
	46\% (Sweden). Patients in the UK and Denmark had lower survival
	than elsewhere, partly because of a more adverse stage distribution.
	However, there were also wide international differences in stage-specific
	survival. Net survival from TNM stage I non-small cell lung cancer
	was 16\% lower in the UK than in Sweden, and for TNM stage IV disease
	survival was 10\% lower. Similar patterns were found for small cell
	lung cancer.There are comparability issues when using population-based
	data but, even given these constraints, this study shows that, while
	differences in stage at diagnosis explain some of the international
	variation in overall lung cancer survival, wide disparities in stage-specific
	survival exist, suggesting that other factors are also important
	such as differences in treatment. Stage should be included in international
	cancer survival studies and the comparability of population-based
	data should be improved.},
  doi = {10.1136/thoraxjnl-2012-202297},
  file = {Walters2013.pdf:pdf\\Walters2013.pdf:PDF},
  institution = {Department of Non Communicable Disease Epidemiology , London School
	of Hygiene and Tropical Medicine, London, UK. sarah.walters@lshtm.ac.uk},
  keywords = {Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Australia,
	epidemiology; Canada, epidemiology; Denmark, epidemiology; Female;
	Humans; Lung Neoplasms, mortality/pathology; Male; Middle Aged; Neoplasm
	Staging; Norway, epidemiology; Population Surveillance; Retrospective
	Studies; Survival Rate, trends; Sweden, epidemiology; Young Adult},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {thoraxjnl-2012-202297},
  pmid = {23399908},
  timestamp = {2013.11.01},
  url = {http://dx.doi.org/10.1136/thoraxjnl-2012-202297}
}

@ARTICLE{Wang2005,
  author = {Ji-Guang Wang and Jan A Staessen and Stanley S Franklin and Robert
	Fagard and Fran{\AA}ÂƒÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â§ois Gueyffier},
  title = {Systolic and diastolic blood pressure lowering as determinants of
	cardiovascular outcome.},
  journal = {Hypertension},
  year = {2005},
  volume = {45},
  pages = {907--913},
  number = {5},
  month = {May},
  abstract = {Based on individual patient data, we performed a quantitative overview
	of trials in hypertension to investigate to what extent lowering
	of systolic blood pressure (SBP) and diastolic blood pressure (DBP)
	contributed to cardiovascular prevention. We selected trials that
	tested active antihypertensive drugs against placebo or no treatment.
	Our analyses included 12,903 young (30 to 49 years of age) patients
	randomized in 3 trials and 14,324 old (60 to 79 years of age) and
	1209 very old (> or =80 years of age) patients enrolled in 8 trials.
	Antihypertensive treatment reduced SBP/DBP by 8.3/4.6 mm Hg in young
	patients, by 10.7/4.2 mm Hg in old patients, and by 9.4/3.2 mm Hg
	in very old patients, respectively, resulting in ratios of DBP to
	SBP lowering of 0.55, 0.39, and 0.32, respectively (P=0.004 for trend
	with age). In spite of the differential lowering of SBP and DBP,
	antihypertensive treatment reduced the risk of all cardiovascular
	events, stroke and myocardial infarction in the 3 age strata to a
	similar extent. Absolute benefit increased with age and with lower
	ratio of DBP to SBP lowering. Furthermore, in patients with a larger-than-median
	reduction in SBP, active treatment consistently reduced the risk
	of all outcomes irrespective of the decrease in DBP or the achieved
	DBP. These findings remained consistent if the achieved DBP averaged
	<70 mm Hg. In conclusion, our overview suggests that antihypertensive
	drug treatment improves outcome mainly through lowering of SBP.},
  doi = {10.1161/01.HYP.0000165020.14745.79},
  file = {Wang2005.pdf:Wang2005.pdf:PDF;Wang2005.pdf:pdf\\Wang2005.pdf:PDF},
  institution = {Study Coordinating Centre, Hypertension and Cardiovascular Rehabilitation
	Unit, Department of Molecular and Cardiovascular Research, University
	of Leuven, Belgium.},
  owner = {pl4},
  pii = {01.HYP.0000165020.14745.79},
  pmid = {15837826},
  timestamp = {2008.11.18},
  url = {http://dx.doi.org/10.1161/01.HYP.0000165020.14745.79}
}

@ARTICLE{Wang2012,
  author = {Wang, Lu and Du, Pang and Liang, Hua},
  title = {Two-component mixture cure rate model with spline estimated nonparametric
	components.},
  journal = {Biometrics},
  year = {2012},
  volume = {68},
  pages = {726--735},
  number = {3},
  month = {Sep},
  abstract = {In some survival analysis of medical studies, there are often long-term
	survivors who can be considered as permanently cured. The goals in
	these studies are to estimate the noncured probability of the whole
	population and the hazard rate of the susceptible subpopulation.
	When covariates are present as often happens in practice, to understand
	covariate effects on the noncured probability and hazard rate is
	of equal importance. The existing methods are limited to parametric
	and semiparametric models. We propose a two-component mixture cure
	rate model with nonparametric forms for both the cure probability
	and the hazard rate function. Identifiability of the model is guaranteed
	by an additive assumption that allows no time-covariate interactions
	in the logarithm of hazard rate. Estimation is carried out by an
	expectation-maximization algorithm on maximizing a penalized likelihood.
	For inferential purpose, we apply the Louis formula to obtain point-wise
	confidence intervals for noncured probability and hazard rate. Asymptotic
	convergence rates of our function estimates are established. We then
	evaluate the proposed method by extensive simulations. We analyze
	the survival data from a melanoma study and find interesting patterns
	for this study.},
  doi = {10.1111/j.1541-0420.2011.01715.x},
  institution = {Novartis Oncology, One Health Plaza, East Hanover, New Jersey 07936,
	USA.},
  keywords = {Adult; Aged; Aged, 80 and over; Algorithms; Analysis of Variance;
	Biometry; Clinical Trials as Topic, statistics /&/ numerical data;
	Confidence Intervals; Female; Humans; Kaplan-Meier Estimate; Logistic
	Models; Male; Melanoma, mortality/therapy; Middle Aged; Models, Statistical;
	Proportional Hazards Models; Statistics, Nonparametric; Survival
	Analysis; Young Adult},
  language = {eng},
  medline-pst = {ppublish},
  owner = {theand},
  pmid = {22169032},
  timestamp = {2013.10.01},
  url = {http://dx.doi.org/10.1111/j.1541-0420.2011.01715.x}
}

@Article{Waugh2003,
  author      = {Jason Waugh and Stephen C Bell and Mark D Kilby and Paul C Lambert and Claire N Blackwell and Andrew Shennan and Aidan Halligan},
  title       = {Urinary microalbumin/creatinine ratios: reference range in uncomplicated pregnancy.},
  doi         = {10.1042/CS20020170},
  number      = {2},
  pages       = {103--107},
  url         = {http://dx.doi.org/10.1042/CS20020170},
  volume      = {104},
  abstract    = {During uncomplicated pregnancy, the development of proteinuria is
	accepted as a poor prognostic sign and is associated with increasing
	maternal and perinatal mortality and morbidity. Physiological proteinuria
	increases with increasing gestation and one of its largest constituents
	is albumin. The reference range for the (micro)albumin/creatinine
	ratio (ACR) has not been described for normal pregnancy. This prospective
	cross-sectional study describes the gestation-specific 95\% reference
	ranges for urinary microalbumin concentration, creatinine concentration
	and ACR in uncomplicated pregnancy. There is a significant increase
	( P =0.016) in the ACR in the third trimester. The mean difference
	is 0.091 mg of albumin/mmol of creatinine (95\% confidence interval,
	0.014-0.168). Our results describe the first well-defined gestation-specific
	95\% reference range for a point-of-care measurement of the ACR.
	These data are essential if such testing is to be employed in antenatal
	care.},
  file        = {Waugh2003.pdf:Waugh2003.pdf:PDF;Waugh2003.pdf:pdf\\Waugh2003.pdf:PDF},
  institution = {Department of Obstetrics and Gynaecology, University of Leicester, Robert Kilpatrick Building, Leicester Royal Infirmary, Leicester LE2 7LX, UK. jason.waugh@uhl-tr.nhs.uk},
  journal     = {Clinical Science},
  month       = {Feb},
  owner       = {pl4},
  pii         = {CS20020170},
  pmid        = {12546632},
  timestamp   = {2008.10.15},
  year        = {2003},
}

@ARTICLE{Waugh2000,
  author = {J. Waugh and I. J. Perry and A. W. Halligan and M. De Swiet and P.
	C. Lambert and J. A. Penny and D. J. Taylor and D. R. Jones and A.
	Shennan},
  title = {Birth weight and 24-hour ambulatory blood pressure in nonproteinuric
	hypertensive pregnancy.},
  journal = {Am J Obstet Gynecol},
  year = {2000},
  volume = {183},
  pages = {633--637},
  number = {3},
  month = {Sep},
  abstract = {OBJECTIVE: The aim of this study was to examine the relationship between
	maternal ambulatory blood pressure monitor measurements during pregnancy
	and birth weight in a population of women considered to have hypertension
	according to conventional antenatal clinic measurement. STUDY DESIGN:
	A prospective observational study was carried out within the obstetric
	departments of Leicester Royal Infirmary and Queen Charlotte's Hospital.
	A total of 237 women were found to have hypertension (blood pressure
	>/=140/90 mm Hg) without significant proteinuria during examination
	in the antenatal assessment area. Sequential-day unit blood pressure
	recordings and a 24-hour automated ambulatory blood pressure recording
	were performed, and the results were compared with the principal
	outcome measure of birth weight. RESULTS: A significant inverse association
	(gradient, -13.5; 95\% confidence interval -23.4 to -3.6) was found
	between daytime ambulatory diastolic blood pressure measurement and
	birth weight. An increase of 5 mm Hg in daytime mean diastolic blood
	pressure was associated with a fall in birth weight of 68.5 g. This
	association remained after adjustment for potential confounders that
	included maternal age, maternal weight, smoking status, ethnicity,
	and gestational age at delivery. No such association was found between
	obstetric day unit assessment of blood pressure and birth weight.
	CONCLUSION: There is a significant association between blood pressure
	and birth weight in nonproteinuric hypertensive pregnancies. The
	best predictor of this association is the daytime mean ambulatory
	diastolic blood pressure measurement. This is further evidence that
	maternal blood pressure may be an important confounding and potentially
	genetic variable in the association between birth weight and subsequent
	adult hypertension.},
  doi = {10.1067/mob.2000.106448},
  file = {Waugh2000.pdf:Waugh2000.pdf:PDF;Waugh2000.pdf:pdf\\Waugh2000.pdf:PDF},
  institution = {Department of Obstetrics and Gynaecology, University of Leicester,
	Leicester, United Kingdom.},
  owner = {pl4},
  pii = {S0002-9378(00)38561-1},
  pmid = {10992185},
  timestamp = {2008.10.15},
  url = {http://dx.doi.org/10.1067/mob.2000.106448}
}

@ARTICLE{Weber2014,
  author = {Weber, Griffin M. and Mandl, Kenneth D. and Kohane, Isaac S.},
  title = {Finding the missing link for big biomedical data.},
  journal = {JAMA},
  year = {2014},
  volume = {311},
  pages = {2479--2480},
  number = {24},
  month = {Jun},
  doi = {10.1001/jama.2014.4228},
  file = {Weber2014.pdf:pdf\\Weber2014.pdf:PDF;Weber2014.pdf:Weber2014.pdf:PDF},
  keywords = {Algorithms; Biomedical Research, trends; Confidentiality; Data Collection;
	Delivery of Health Care, statistics /&/ numerical data/trends; Electronic
	Health Records, statistics /&/ numerical data; Humans},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pii = {1875648},
  pmid = {24854141},
  timestamp = {2014.10.10},
  url = {http://dx.doi.org/10.1001/jama.2014.4228}
}

@Other{CRUK2016,
  author    = {CRUK Website},
  owner     = {BettyS},
  timestamp = {2016.11.28},
  title     = {http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer},
  url       = {http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer},
  year      = {Accessed November 2016},
}

@ARTICLE{Wedren2004,
  author = {Wedren, S. and Lovmar, L. and Humphreys, K. and Magnusson, C. and
	Melhus, H. and Syvanen, A. C. and Kindmark, A. and Landegren, U.
	and Fermer, M. L. and Stiger, F. and Persson, I. and Baron, J. and
	Weiderpass, E.},
  title = {Oestrogen receptor alpha gene haplotype and postmenopausal breast
	cancer risk: a case control study.},
  journal = {Breast Cancer Res},
  year = {2004},
  volume = {6},
  pages = {R437-49},
  number = {4},
  abstract = {INTRODUCTION: Oestrogen receptor alpha, which mediates the effect
	of oestrogen in target tissues, is genetically polymorphic. Because
	breast cancer development is dependent on oestrogenic influence,
	we have investigated whether polymorphisms in the oestrogen receptor
	alpha gene (ESR1) are associated with breast cancer risk. METHODS:
	We genotyped breast cancer cases and age-matched population controls
	for one microsatellite marker and four single-nucleotide polymorphisms
	(SNPs) in ESR1. The numbers of genotyped cases and controls for each
	marker were as follows: TAn, 1514 cases and 1514 controls; c.454-397C
	--> T, 1557 cases and 1512 controls; c.454-351A --> G, 1556 cases
	and 1512 controls; c.729C --> T, 1562 cases and 1513 controls; c.975C
	--> G, 1562 cases and 1513 controls. Using logistic regression models,
	we calculated odds ratios (ORs) and 95\% confidence intervals (CIs).
	Haplotype effects were estimated in an exploratory analysis, using
	expectation-maximisation algorithms for case-control study data.
	RESULTS: There were no compelling associations between single polymorphic
	loci and breast cancer risk. In haplotype analyses, a common haplotype
	of the c.454-351A --> G or c.454-397C --> T and c.975C --> G SNPs
	appeared to be associated with an increased risk for ductal breast
	cancer: one copy of the c.454-351A --> G and c.975C --> G haplotype
	entailed an OR of 1.19 (95\% CI 1.06-1.33) and two copies with an
	OR of 1.42 (95\% CI 1.15-1.77), compared with no copies, under a
	model of multiplicative penetrance. The association with the c.454-397C
	--> T and c.975C --> G haplotypes was similar. Our data indicated
	that these haplotypes were more influential in women with a high
	body mass index. Adjustment for multiple comparisons rendered the
	associations statistically non-significant. CONCLUSION: We found
	suggestions of an association between common haplotypes in ESR1 and
	the risk for ductal breast cancer that is stronger in heavy women.},
  doi = {10.1186/bcr811},
  owner = {PaulD},
  pii = {bcr811},
  timestamp = {2011.06.19},
  url = {http://dx.doi.org/10.1186/bcr811}
}

@ARTICLE{Wei1992b,
  author = {Wei, C. Z.},
  title = {On predictive least squares principles},
  journal = {The Annals of Statistics},
  year = {1992},
  volume = {20},
  pages = {1-42},
  file = {Wei1992.pdf:pdf\\Wei1992.pdf:PDF;Wei1992.pdf:Wei1992.pdf:PDF},
  owner = {hanbow},
  timestamp = {2015.05.26}
}

@ARTICLE{Wei1989,
  author = {L.J. Wei and D.Y. Lin and L. Weissfeld},
  title = {Regression Analysis of multivariate incomplete failure time data
	by modeling marginal distributions},
  journal = {Journal of the American Statistical Association},
  year = {1989},
  volume = {84},
  pages = {1065-1073},
  file = {Wei1989.pdf:Wei1989.pdf:PDF;Wei1989.pdf:pdf\\Wei1989.pdf:PDF},
  owner = {pl4},
  timestamp = {2010.01.07}
}

@ARTICLE{Wei1992,
  author = {Wei, L. J.},
  title = {The accelerated failure time model: {A} useful alternative to the
	{C}ox regression model in survival analysis ({D}isc: p1881-1885)},
  journal = {Statistics in Medicine},
  year = {1992},
  volume = {11},
  pages = {1871--1879},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Weibull2016a,
  author = {Weibull, Caroline E. and Eloranta, Sandra and Smedby, Karin E. and
	Bj{\"{o}}rkholm, Magnus and Kristinsson, Sigurdur Y. and Johansson,
	Anna L V. and Dickman, Paul W. and Glimelius, Ingrid},
  title = {Pregnancy and the Risk of Relapse in Patients Diagnosed With Hodgkin
	Lymphoma.},
  journal = {J Clin Oncol},
  year = {2016},
  volume = {34},
  pages = {337--344},
  number = {4},
  month = {Feb},
  abstract = {Many patients and clinicians are worried that pregnancy after the
	diagnosis of Hodgkin lymphoma (HL) may increase the risk of relapse
	despite a lack of empirical evidence to support such concerns. We
	investigated if an association exists between pregnancy and relapse
	in women with a diagnosis of HL.Using Swedish healthcare registers
	combined with medical records, we included 449 women who received
	a diagnosis of HL between 1992 and 2009 and who were age 18 to 40
	years at diagnosis. Follow-up started 6 months after diagnosis, when
	the patients' condition was assumed to be in remission. Pregnancy-associated
	relapse was defined as a relapse during pregnancy or within 5 years
	after delivery. Hazard ratios (HRs) with 95\% CIs were estimated
	by using the Cox proportional hazards model.Among the 449 women,
	144 (32\%) became pregnant during follow-up. Overall, 47 relapses
	were recorded, of which one was a pregnancy-associated relapse. The
	adjusted HR for the comparison of the pregnancy-associated relapse
	rate to the non-pregnancy-associated relapse rate was 0.29 (95\%
	CI, 0.04 to 2.18). The expected number of relapses in women with
	a recent pregnancy, given that they would experience the same relapse
	rate as that of women without a recent pregnancy, was 3.76; the observed-to-expected
	ratio was 0.27 (95\% exact CI, 0.01 to 1.51).We found no evidence
	that a pregnancy after diagnosis increases the relapse rate among
	women whose HL is in remission. Survivors of HL need to consider
	a range of factors when deciding about future reproduction. However,
	given the results of this study, the risk of pregnancy-associated
	relapse does not need to be considered.},
  doi = {10.1200/JCO.2015.63.3446},
  institution = {Caroline E. Weibull, Sandra Eloranta, Karin E. Smedby, Anna L.V.
	Johansson, Paul W. Dickman, and Ingrid Glimelius, Karolinska Institutet;
	Karin E. Smedby, Magnus Bj{\"o}rkholm, Sigurdur Y. Kristinsson, and Ingrid
	Glimelius, Karolinska University Hospital Solna, Stockholm; Ingrid
	Glimelius, Uppsala University, Uppsala, Sweden; and Sigurdur Y. Kristinsson,
	University of Iceland, Reykjavik, Iceland.},
  keywords = {Adolescent; Adult; Female; Hodgkin Disease, epidemiology; Humans;
	Pregnancy; Pregnancy Complications, Neoplastic, epidemiology; Recurrence;
	Sweden, epidemiology; Young Adult},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pii = {JCO.2015.63.3446},
  pmid = {26668344},
  timestamp = {2016.06.14},
  url = {http://dx.doi.org/10.1200/JCO.2015.63.3446}
}

@ARTICLE{Weir2013,
  author = {Weir, Hannah K. and Johnson, Christopher J. and Thompson, Trevor
	D.},
  title = {The effect of multiple primary rules on population-based cancer survival},
  journal = {Cancer Causes Control},
  year = {2013},
  volume = {24},
  pages = {1231--1242},
  number = {6},
  month = {Jun},
  abstract = {Different rules for registering multiple primary (MP) cancers are
	used by cancer registries throughout the world, making international
	data comparisons difficult. This study evaluates the effect of Surveillance,
	Epidemiology, and End Results (SEER) and International Association
	of Cancer Registries (IACR) MP rules on population-based cancer survival
	estimates.Data from five US states and six metropolitan area cancer
	registries participating in the SEER Program were used to estimate
	age-standardized relative survival (RS\%) for first cancers-only
	and all first cancers matching the selection criteria according to
	SEER and IACR MP rules for all cancer sites combined and for the
	top 25 cancer site groups among men and women.During 1995-2008, the
	percentage of MP cancers (all sites, both sexes) increased 25.4 \%
	by using SEER rules (from 14.6 to 18.4 \%) and 20.1 \% by using IACR
	rules (from 13.2 to 15.8 \%). More MP cancers were registered among
	females than among males, and SEER rules registered more MP cancers
	than IACR rules (15.8 vs. 14.4 \% among males; 17.2 vs. 14.5 \% among
	females). The top 3 cancer sites with the largest differences were
	melanoma (5.8 \%), urinary bladder (3.5 \%), and kidney and renal
	pelvis (2.9 \%) among males, and breast (5.9 \%), melanoma (3.9 \%),
	and urinary bladder (3.4 \%) among females. Five-year survival estimates
	(all sites combined) restricted to first primary cancers-only were
	higher than estimates by using first site-specific primaries (SEER
	or IACR rules), and for 11 of 21 sites among males and 11 of 23 sites
	among females. SEER estimates are comparable to IACR estimates for
	all site-specific cancers and marginally higher for all sites combined
	among females (RS 62.28 vs. 61.96 \%).Survival after diagnosis has
	improved for many leading cancers. However, cancer patients remain
	at risk of subsequent cancers. Survival estimates based on first
	cancers-only exclude a large and increasing number of MP cancers.
	To produce clinically and epidemiologically relevant and less biased
	cancer survival estimates, data on all cancers should be included
	in the analysis. The multiple primary rules (SEER or IACR) used to
	identify primary cancers do not affect survival estimates if all
	first cancers matching the selection criteria are used to produce
	site-specific survival estimates.},
  doi = {10.1007/s10552-013-0203-3},
  file = {Weir2013.pdf:pdf\\Weir2013.pdf:PDF;Weir2013.pdf:Weir2013.pdf:PDF},
  institution = {Division of Cancer Prevention and Control, National Center for Chronic
	Disease Prevention and Health Promotion, Centers for Disease Control
	and Prevention, 4770 Buford Hwy. MS-K55, Atlanta, GA 30341, USA.
	hbw4@cdc.gov},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pmid = {23558444},
  timestamp = {2013.09.18},
  url = {http://dx.doi.org/10.1007/s10552-013-0203-3}
}

@ARTICLE{Welch2002,
  author = {Welch, H Gilbert and Black, William C.},
  title = {Are deaths within 1 month of cancer-directed surgery attributed to
	cancer?},
  journal = {J Natl Cancer Inst},
  year = {2002},
  volume = {94},
  pages = {1066--1070},
  number = {14},
  month = {Jul},
  abstract = {Cancer mortality should include not only deaths from cancer but also
	deaths from cancer treatment. By convention, deaths within 30 days
	of a surgical procedure are considered treatment-related deaths in
	the calculation of operative mortality-that is, the chance of dying
	from surgery. How cause of death is attributed in patients who die
	within 1 month of cancer-directed surgery is unknown.The National
	Cancer Institute's Surveillance, Epidemiology, and End Results (SEER)
	program data from 1994 through 1998 were used to examine the cause
	of death in patients diagnosed with one of 19 common solid tumors
	who had died within 1 month of diagnosis and had also received cancer-directed
	surgery. We determined the proportion of deaths not attributed to
	the cancer and the magnitude of the undercount in cancer-specific
	mortality.Among 4135 patients with only one cancer who died within
	1 month of diagnosis and cancer-directed surgery, the proportion
	of deaths not attributed to the coded cancer was 41\% (1714/4135),
	ranging from 13\% (1/8) for cervical cancer to 81\% (13/16) for laryngeal
	cancer. Selected intermediate values include 25\% (14/56) for esophageal
	cancer, 34\% (177/525) for lung cancer, 42\% (719/1695) for colorectal
	cancer, 59\% (110/186) for breast cancer, and 75\% (80/106) for prostate
	cancer. Restricting the analysis to deaths following specific major
	procedures (e.g., esophagectomy, pneumonectomy, colectomy) had little
	effect on the findings. If all deaths within 1 month of cancer-directed
	surgery were attributed to cancer, cancer mortality would rise about
	1\%.Some deaths that are conventionally attributed to surgery are
	not being attributed to the cancer for which the surgery was performed.
	Although the estimated effect of this misclassification on overall
	cancer mortality is modest, it may be indicative of more widespread
	confusion about how to code treatment-related deaths of patients
	with cancer.},
  file = {Welch2002.pdf:pdf\\Welch2002.pdf:PDF;Welch2002.pdf:Welch2002.pdf:PDF},
  institution = {International Agency for Research on Cancer, Lyon, France. h.gilbert.welch@dartmouth.edu},
  keywords = {Databases as Topic; General Surgery; Humans; Neoplasms, epidemiology/mortality/surgery;
	Time Factors},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pmid = {12122097},
  timestamp = {2015.09.16}
}

@ARTICLE{Welch2000,
  author = {H. G. Welch and L. M. Schwartz and S. Woloshin},
  title = {{A}re increasing 5-year survival rates evidence of success against
	cancer?},
  journal = {JAMA},
  year = {2000},
  volume = {283},
  pages = {2975--2978},
  number = {22},
  month = {Jun},
  abstract = {CONTEXT: Increased 5-year survival for cancer patients is generally
	inferred to mean that cancer treatment has improved and that fewer
	patients die of cancer. Increased 5-year survival, however, may also
	reflect changes in diagnosis: finding more people with early-stage
	cancer, including some who would never have become symptomatic from
	their cancer. OBJECTIVE: To determine the relationship over time
	between 5-year cancer survival and 2 other measures of cancer burden,
	mortality and incidence. DESIGN AND SETTING: Using population-based
	statistics reported by the National Cancer Institute Surveillance,
	Epidemiology, and End Results Program, we calculated the change in
	5-year survival from 1950 to 1995 for the 20 most common solid tumor
	types. Using the tumor as the unit of analysis, we correlated changes
	in 5-year survival with changes in mortality and incidence. MAIN
	OUTCOME MEASURE: The association between changes in 5-year survival
	and changes in mortality and incidence measured using simple correlation
	coefficients (Pearson and Spearman). RESULTS: From 1950 to 1995,
	there was an increase in 5-year survival for each of the 20 tumor
	types. The absolute increase in 5-year survival ranged from 3\% (pancreatic
	cancer) to 50\% (prostate cancer). During the same period, mortality
	rates declined for 12 types of cancer and increased for the remaining
	8 types. There was little correlation between the change in 5-year
	survival for a specific tumor and the change in tumor-related mortality
	(Pearson r=.00; Spearman r=-.07). On the other hand, the change in
	5-year survival was positively correlated with the change in the
	tumor incidence rate (Pearson r=+. 49; Spearman r=+.37). CONCLUSION:
	Although 5-year survival is a valid measure for comparing cancer
	therapies in a randomized trial, our analysis shows that changes
	in 5-year survival over time bear little relationship to changes
	in cancer mortality. Instead, they appear primarily related to changing
	patterns of diagnosis. JAMA. 2000.},
  owner = {PaulD},
  pii = {jsc00019},
  pmid = {11042744},
  timestamp = {2006.03.31}
}

@ARTICLE{Weller1999,
  author = {Weller, E. A. and Feuer, E. J. and Frey, C. M. and Wesley, M. N.},
  title = {Parametric relative survival regression using generalized linear
	models with application to {H}odgkin's lymphoma},
  journal = {Journal of the Royal Statistical Society Series C -- Applied Statistics},
  year = {1999},
  volume = {48},
  pages = {79-89},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@InCollection{Wennberg1990,
  author    = {Wennberg, J. E.},
  booktitle = {Small Area Analysis and the Medical Care Outcome Problem},
  title     = {Research Methodology: Strengthening Causal Interpretation of Nonexperimental Data},
  editor    = {Sechrest, L. and Perrin, E. and Bunker, J.},
  publisher = {Department of Health and Human Services, Public Health Service Agency for Health Care Policy and Research},
  series    = {DHHS Publication number (PHS) 90--3454},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1990},
}

@ARTICLE{Westerling1995,
  author = {Westerling, R.},
  title = {Components of Small Area Variation in Death Rates: A Method Applied
	to Data from {S}weden},
  journal = {Journal of Epidemiology and Community Health},
  year = {1995},
  volume = {49},
  pages = {214-221},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Westlake2009,
  author = {Susan Westlake},
  title = {Cancer incidence and mortality in the United Kingdom and constituent
	countries, 2004-06.},
  journal = {Health Statiistics Quarterly},
  year = {2009},
  pages = {56--62},
  number = {43},
  file = {Westlake2009.pdf:Westlake2009.pdf:PDF;Westlake2009.pdf:pdf\\Westlake2009.pdf:PDF},
  institution = {Office for National Statistics.},
  owner = {pl4},
  pmid = {19774835},
  timestamp = {2010.03.19}
}

@ARTICLE{White2009,
  author = {Ian R White and Patrick Royston},
  title = {Imputing missing covariate values for the {C}ox model.},
  journal = {Statistics in Medicine},
  year = {2009},
  volume = {28},
  pages = {1982--1998},
  number = {15},
  month = {Jul},
  abstract = {Multiple imputation is commonly used to impute missing data, and is
	typically more efficient than complete cases analysis in regression
	analysis when covariates have missing values. Imputation may be performed
	using a regression model for the incomplete covariates on other covariates
	and, importantly, on the outcome. With a survival outcome, it is
	a common practice to use the event indicator D and the log of the
	observed event or censoring time T in the imputation model, but the
	rationale is not clear.We assume that the survival outcome follows
	a proportional hazards model given covariates X and Z. We show that
	a suitable model for imputing binary or Normal X is a logistic or
	linear regression on the event indicator D, the cumulative baseline
	hazard H(0)(T), and the other covariates Z. This result is exact
	in the case of a single binary covariate; in other cases, it is approximately
	valid for small covariate effects and/or small cumulative incidence.
	If we do not know H(0)(T), we approximate it by the Nelson-Aalen
	estimator of H(T) or estimate it by Cox regression.We compare the
	methods using simulation studies. We find that using logT biases
	covariate-outcome associations towards the null, while the new methods
	have lower bias. Overall, we recommend including the event indicator
	and the Nelson-Aalen estimator of H(T) in the imputation model.},
  doi = {10.1002/sim.3618},
  file = {White2009.pdf:White2009.pdf:PDF;White2009.pdf:pdf\\White2009.pdf:PDF},
  institution = {MRC Biostatistics Unit, Institute of Public Health, Robinson Way,
	Cambridge CB2 0SR, UK. ian.white@mrc-bsu.cam.ac.uk},
  owner = {pl4},
  pmid = {19452569},
  timestamp = {2011.06.25},
  url = {http://dx.doi.org/10.1002/sim.3618}
}

@ARTICLE{White2011,
  author = {Ian R White and Patrick Royston and Angela M Wood},
  title = {Multiple imputation using chained equations: Issues and guidance
	for practice.},
  journal = {Statistics in Medicine},
  year = {2011},
  volume = {30},
  pages = {377--399},
  number = {4},
  month = {Feb},
  abstract = {Multiple imputation by chained equations is a flexible and practical
	approach to handling missing data. We describe the principles of
	the method and show how to impute categorical and quantitative variables,
	including skewed variables. We give guidance on how to specify the
	imputation model and how many imputations are needed. We describe
	the practical analysis of multiply imputed data, including model
	building and model checking. We stress the limitations of the method
	and discuss the possible pitfalls. We illustrate the ideas using
	a data set in mental health, giving Stata code fragments.},
  doi = {10.1002/sim.4067},
  file = {White2011.pdf:White2011.pdf:PDF},
  institution = {MRC Biostatistics Unit, Institute of Public Health, Robinson Way,
	Cambridge CB2 0SR, U.K.. ian.white@mrc-bsu.cam.ac.uk.},
  owner = {pl4},
  pmid = {21225900},
  timestamp = {2011.06.25},
  url = {http://dx.doi.org/10.1002/sim.4067}
}

@Book{Whitehead2002,
  author    = {A. Whitehead},
  title     = {Meta-analysis of controlled clinical trials},
  publisher = {Wiley},
  owner     = {pl4},
  timestamp = {2008.11.18},
  year      = {2002},
}

@Article{Whitehead1980,
  author    = {J. Whitehead},
  title     = {Fitting {C}ox's regression model to survival data using {GLIM}},
  journal   = {Applied Statistics},
  year      = {1980},
  volume    = {29},
  pages     = {268-275},
  file      = {Whitehead1980.pdf:Whitehead1980.pdf:PDF;Whitehead1980.pdf:pdf\\Whitehead1980.pdf:PDF},
  owner     = {pl4},
  timestamp = {2008.11.18},
}

@ARTICLE{Whitehead1992,
  author = {Whitehead, Margaret},
  title = {The Concepts and Principles of Equity and Health},
  journal = {International Journal of Health Services},
  year = {1992},
  volume = {22},
  pages = {429-445},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Wiebelt1991,
  author = {Wiebelt, H. and Hakulinen, T. and Ziegler, H. and Stegmaier, C.},
  title = {Leben die Krebspatienten heute l{\"a}nger als fr{\"u}her? Eine {\"U}berlebenszeitanalyse
	der Krebspatienten im Saarland der Jahre 1972 bis 1986},
  journal = {Soz. Pr{\"a}ventivmed},
  year = {1991},
  volume = {36},
  pages = {86-95},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Wildiers2007,
  author = {H. Wildiers and I. Kunkler and L. Biganzoli and J. Fracheboud and
	G. Vlastos and C. Bernard-Marty and A. Hurria and M. Extermann and
	V. Girre and E. Brain and R. A. Audisio and H. Bartelink and M. Barton
	and S. H. Giordano and H. Muss and M. Aapro and International Society
	of Geriatric Oncology},
  title = {Management of breast cancer in elderly individuals: recommendations
	of the International Society of Geriatric Oncology.},
  journal = {Lancet Oncology},
  year = {2007},
  volume = {8},
  pages = {1101--1115},
  number = {12},
  month = {Dec},
  abstract = {Breast cancer is the most commonly diagnosed cancer and the leading
	cause of cancer mortality in women worldwide. Elderly individuals
	make up a large part of the breast cancer population, and there are
	important specific considerations for this population. The International
	Society of Geriatric Oncology created a task force to assess the
	available evidence on breast cancer in elderly individuals, and to
	provide evidence-based recommendations for the diagnosis and treatment
	of breast cancer in such individuals. A review of the published work
	was done with the results of a search on Medline for English-language
	articles published between 1990 and 2007 and of abstracts from key
	international conferences. Recommendations are given on the topics
	of screening, surgery, radiotherapy, (neo)adjuvant hormone treatment
	and chemotherapy, and metastatic disease. Since large randomised
	trials in elderly patients with breast cancer are scarce, there is
	little level I evidence for the treatment of such patients. The available
	evidence was reviewed and synthesised to provide consensus recommendations
	regarding the care of breast cancer in older adults.},
  file = {Wildiers2007.pdf:Wildiers2007.pdf:PDF;Wildiers2007.pdf:pdf\\Wildiers2007.pdf:PDF},
  institution = {Department of General Medical Oncology, University Hospital Gasthuisberg,
	Leuven, Belgium. hans.wildiers@uzleuven.be},
  owner = {pl4},
  pmid = {18054880},
  timestamp = {2010.03.24}
}

@ARTICLE{Wilkinson2009,
  author = {E. Wilkinson},
  title = {Questions remain over validity of {EUROCARE} data},
  journal = {Lancet},
  year = {2009},
  volume = {374},
  pages = {964--965},
  number = {9694},
  month = {Sep},
  file = {Wilkinson2009.pdf:Wilkinson2009.pdf:PDF;Wilkinson2009.pdf:pdf\\Wilkinson2009.pdf:PDF},
  owner = {pl4},
  pmid = {19774705},
  timestamp = {2010.03.18}
}

@ARTICLE{Wilkinson1992,
  author = {Wilkinson, R. G.},
  title = {Income Distribution and Life Expectancy},
  journal = {BMJ},
  year = {1992},
  volume = {304},
  pages = {165-168},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@Book{Willett1998,
  author    = {Willett, Walter},
  title     = {Nutritional Epidemiology},
  edition   = {2nd},
  publisher = {New York. Oxford University Press},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1998},
}

@ARTICLE{Williams1999,
  author = {N. Williams and D. Jackson and P. C. Lambert and J. M. Johnstone},
  title = {Incidence of non-specific abdominal pain in children during school
	term: population survey based on discharge diagnoses.},
  journal = {BMJ},
  year = {1999},
  volume = {318},
  pages = {1455},
  number = {7196},
  month = {May},
  file = {Williams1999.pdf:Williams1999.pdf:PDF;Williams1999.pdf:pdf\\Williams1999.pdf:PDF},
  institution = {Department of Surgery, Leicester Royal Infirmary, Leicester LE1 5WW.
	willnma@dircon.co.uk},
  owner = {pl4},
  pmid = {10346771},
  timestamp = {2008.10.15}
}

@TechReport{Wilmoth2007,
  author    = {Wilmoth, J. R. and Andreev, K and Jdanov, D and Glei, D. A.},
  title     = {{M}ethods Protocol for the {H}uman {M}ortality {D}atabase},
  note      = {Accessible from: http://www.mortality.org},
  number    = {Version 5},
  type      = {Technical report},
  month     = {May},
  owner     = {sanelo},
  timestamp = {2013.08.01},
  year      = {2007},
}

@ARTICLE{Wishart2010,
  author = {Wishart, Gordon C. and Azzato, Elizabeth M. and Greenberg, David
	C. and Rashbass, Jem and Kearins, Olive and Lawrence, Gill and Caldas,
	Carlos and Pharoah, Paul D.},
  title = {{PREDICT}: {A} new {UK} prognostic model that predicts survival following
	surgery for invasive breast cancer.},
  journal = {Breast Cancer Res},
  year = {2010},
  volume = {12},
  pages = {R1},
  number = {1},
  abstract = {The aim of this study was to develop and validate a prognostication
	model to predict overall and breast cancer specific survival for
	women treated for early breast cancer in the UK.Using the Eastern
	Cancer Registration and Information Centre (ECRIC) dataset, information
	was collated for 5,694 women who had surgery for invasive breast
	cancer in East Anglia from 1999 to 2003. Breast cancer mortality
	models for oestrogen receptor (ER) positive and ER negative tumours
	were derived from these data using Cox proportional hazards, adjusting
	for prognostic factors and mode of cancer detection (symptomatic
	versus screen-detected). An external dataset of 5,468 patients from
	the West Midlands Cancer Intelligence Unit (WMCIU) was used for validation.Differences
	in overall actual and predicted mortality were <1\% at eight years
	for ECRIC (18.9\% vs. 19.0\%) and WMCIU (17.5\% vs. 18.3\%) with
	area under receiver-operator-characteristic curves (AUC) of 0.81
	and 0.79 respectively. Differences in breast cancer specific actual
	and predicted mortality were <1\% at eight years for ECRIC (12.9\%
	vs. 13.5\%) and <1.5\% at eight years for WMCIU (12.2\% vs. 13.6\%)
	with AUC of 0.84 and 0.82 respectively. Model calibration was good
	for both ER positive and negative models although the ER positive
	model provided better discrimination (AUC 0.82) than ER negative
	(AUC 0.75).We have developed a prognostication model for early breast
	cancer based on UK cancer registry data that predicts breast cancer
	survival following surgery for invasive breast cancer and includes
	mode of detection for the first time. The model is well calibrated,
	provides a high degree of discrimination and has been validated in
	a second UK patient cohort.},
  doi = {10.1186/bcr2464},
  institution = {Cambridge Breast Unit, Addenbrooke's Hospital, Hills Road, Cambridge,
	CB2 2QQ, UK. gordon.wishart@addenbrookes.nhs.uk},
  keywords = {Adult; Aged; Aged, 80 and over; Breast Neoplasms, epidemiology/mortality/surgery;
	Female; Great Britain; Humans; Middle Aged; Models, Statistical;
	Neoplasm Invasiveness; Prognosis; Receptors, Estrogen, analysis;
	Registries; SEER Program},
  language = {eng},
  medline-pst = {ppublish},
  owner = {sanelo},
  pii = {bcr2464},
  pmid = {20053270},
  timestamp = {2013.09.17},
  url = {http://dx.doi.org/10.1186/bcr2464}
}

@ARTICLE{Wolbers2014,
  author = {Wolbers, Marcel and Koller, Michael T. and Stel, Vianda S. and Schaer,
	Beat and Jager, Kitty J. and Leffondr{\AA}Â©, Karen and Heinze, Georg},
  title = {Competing risks analyses: objectives and approaches.},
  journal = {Eur Heart J},
  year = {2014},
  volume = {35},
  pages = {2936-41},
  month = {Apr},
  abstract = {Studies in cardiology often record the time to multiple disease events
	such as death, myocardial infarction, or hospitalization. Competing
	risks methods allow for the analysis of the time to the first observed
	event and the type of the first event. They are also relevant if
	the time to a specific event is of primary interest but competing
	events may preclude its occurrence or greatly alter the chances to
	observe it. We give a non-technical overview of competing risks concepts
	for descriptive and regression analyses. For descriptive statistics,
	the cumulative incidence function is the most important tool. For
	regression modelling, we introduce regression models for the cumulative
	incidence function and the cause-specific hazard function, respectively.
	We stress the importance of choosing statistical methods that are
	appropriate if competing risks are present. We also clarify the role
	of competing risks for the analysis of composite endpoints.},
  doi = {10.1093/eurheartj/ehu131},
  file = {Wolbers2014.pdf:Wolbers2014.pdf:PDF},
  institution = {Oxford University Clinical Research Unit, Hospital for Tropical Diseases,
	Wellcome Trust Major Overseas Programme, Ho Chi Minh City, Vietnam.},
  language = {eng},
  medline-pst = {aheadofprint},
  owner = {pl4},
  pii = {ehu131},
  pmid = {24711436},
  timestamp = {2014.06.02},
  url = {http://dx.doi.org/10.1093/eurheartj/ehu131}
}

@ARTICLE{Wolfe1996,
  author = {Wolfe, R. A. and Strawderman, R. L.},
  title = {Logical and statistical fallacies in the use of Cox regression models},
  journal = {Am J Kidney Dis},
  year = {1996},
  volume = {27},
  pages = {124-9},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@Book{Wolfson1993,
  author    = {Wolfson, R. and Zardetto-Aker, S.},
  title     = {Powerbook Companion},
  publisher = {Addison-Wesley},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1993},
}

@ARTICLE{Wood1997,
  author = {Wood, J. and Richardson, D. and Wing, S.},
  title = {A simple program to create exact person-time data in cohort analyses},
  journal = {Int J Epidemiol},
  year = {1997},
  volume = {26},
  pages = {395-9},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Woods2011,
  author = {Laura M Woods and Michel P Coleman and Gill Lawrence and Jem Rashbass
	and Franco Berrino and Bernard Rachet},
  title = {Evidence against the proposition that ``{UK} cancer survival statistics
	are misleading'': simulation study with {National Cancer Registry}
	data.},
  journal = {BMJ},
  year = {2011},
  volume = {342},
  pages = {d3399},
  abstract = {To simulate each of two hypothesised errors in the National Cancer
	Registry (recording of the date of recurrence of cancer, instead
	of the date of diagnosis, for registrations initiated from a death
	certificate; long term survivors who are never notified to the registry),
	to estimate their possible effect on relative survival, and to establish
	whether lower survival in the UK might be due to one or both of these
	errors.Simulation study.National Cancer Registry of England and Wales.
	Population Patients diagnosed as having breast (women), lung, or
	colorectal cancer during 1995-2007 in England and Wales, with follow-up
	to 31 December 2007.Mean absolute percentage change in one year and
	five year relative survival associated with each simulated error.To
	explain the differences in one year survival after breast cancer
	between England and Sweden, under the first hypothesis, date of diagnosis
	would have to have been incorrectly recorded by an average of more
	than a year for more than 70\% of women known to be dead. Alternatively,
	under the second hypothesis, failure to register even 40\% of long
	term survivors would explain less than half the difference in one
	year survival. Results were similar for lung and colorectal cancers.Even
	implausibly extreme levels of the hypothesised errors in the cancer
	registry data could not explain the international differences in
	survival observed between the UK and other European countries.},
  file = {Woods2011.pdf:pdf\\Woods2011.pdf:PDF;Woods2011.pdf:Woods2011.pdf:PDF},
  institution = {Cancer Research UK Cancer Survival Group, Department of Non-Communicable
	Disease Epidemiology, London School of Hygiene and Tropical Medicine,
	London WC1E 7HT, UK.},
  language = {eng},
  medline-pst = {epublish},
  owner = {PaulD},
  pmid = {21659366},
  timestamp = {2011.06.13}
}

@Article{Woods2009,
  author    = {L. M. Woods and B. Rachet and P. C. Lambert and M. P. Coleman},
  title     = {`{C}ure' from breast cancer among two populations of women followed for 23 years after diagnosis},
  doi       = {10.1093/annonc/mdn791},
  pages     = {1331-1336},
  volume    = {20},
  file      = {Woods2009.pdf:Woods2009.pdf:PDF;Woods2009.pdf:pdf\\Woods2009.pdf:PDF},
  journal   = {Annals of Oncology},
  owner     = {pl4},
  pmid      = {19465419},
  timestamp = {2009.03.25},
  year      = {2009},
}

@ARTICLE{Woods2005,
  author = {Woods, Laura M. and Rachet, Bernard and Riga, Michael and Stone,
	Noell and Shah, Anjali and Coleman, Michel P.},
  title = {Geographical variation in life expectancy at birth in {E}ngland and
	{W}ales is largely explained by deprivation.},
  journal = {J Epidemiol Community Health},
  year = {2005},
  volume = {59},
  pages = {115--120},
  number = {2},
  month = {Feb},
  abstract = {To describe the population mortality profile of England and Wales
	by deprivation and in each government office region (GOR) during
	1998, and to quantify the influence of geography and deprivation
	in determining life expectancy.Construction of life tables describing
	age specific mortality rates and life expectancy at birth from death
	registrations and estimated population counts. Life tables were created
	for (a) quintiles of income deprivation based on the income domain
	score of the index of multiple deprivation 2000, (b) each GOR and
	Wales, and (c) every combination of deprivation and geography.England
	and Wales.PATIENTS/ PARTICIPANTS: Residents of England and Wales,
	1998.Life expectancy at birth varies with deprivation quintile and
	is highest in the most affluent groups. The differences are mainly
	attributable to differences in mortality rates under 75 years of
	age. Regional life expectancies display a clear north-south gradient.
	Linear regression analysis shows that deprivation explains most of
	the geographical variation in life expectancy.Geographical patterns
	of life expectancy identified within these data for England and Wales
	in 1998 are mainly attributable to variations in deprivation status
	as defined by the IMD 2000 income domain score.},
  doi = {10.1136/jech.2003.013003},
  institution = {Non-communicable Disease Epidemiology Unit, London School of Hygiene
	and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. laura.woods@lshtm.ac.uk},
  keywords = {Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool;
	England, epidemiology; Female; Humans; Infant; Infant, Newborn; Life
	Expectancy; Life Tables; Linear Models; Male; Middle Aged; Mortality;
	Poverty Areas; Poverty, statistics /&/ numerical data; Sex Factors;
	Wales, epidemiology},
  language = {eng},
  medline-pst = {ppublish},
  owner = {sanelo},
  pii = {59/2/115},
  pmid = {15650142},
  timestamp = {2013.10.04},
  url = {http://dx.doi.org/10.1136/jech.2003.013003}
}

@ARTICLE{Wrigley1985,
  author = {Wrigley, E. A.},
  title = {The fall of marital fertility in nineteenth-century France: exemplar
	or exception? (Part I).},
  journal = {Eur J Popul},
  year = {1985},
  volume = {1},
  pages = {31--60},
  number = {1},
  month = {Jan},
  abstract = {In France, the decline in marital fertility began in 1800 and preceded
	the marital decline in other European countries by about 70 years.
	The French decline is generally regarded as differing from the decline
	in other European countries only in timing, and the decline in all
	these countries is attributed to the innovative use of modern fertility
	control methods, which once introduced, were widely and rapidly accepted.
	An alternative explanation for the early decline in French fertility
	is presented. It is argued that the fertility decline in France between
	1800 and 1980 reflects an adjustment process. It was suggested that
	in a peasant society, in contrast to an industrial society, there
	are only a limited number of available economic niches, and economic
	pressures will be intense if the population growth rate increases
	rapidly. In order to keep the population growth rate in balance with
	the economic resources, the net reproductive rate (NRR) must be kept
	near unity. In France, unity was maintained by keeping the marital
	fertility rate in balance with the nuptiality and mortality rates.
	Data on the population growth rates, mortality rates, marital fertility
	rates, NRRs, and on life expectancy is presented to support this
	argument. In France, between 1700-1800, the population increased
	by 35\% and between 1800-1900 by 38\%. This increase was exremely
	small compared to that which occurred in other European countries.
	For example, in England the corresponding increases were 71\% and
	252\%. These differences in growth were the result of differences
	in the marital fertility patterns of the 2 countries. Before 1800,
	marital fertility in France was similar to that of other European
	countries, but after 1800 the French rate declined rapidly. By 1840
	it was 2/3 of the 1800 level, and by 1900 it was 1/2 of the 1800
	level. In other European countries marital fertility did not begin
	to decline until the 1870s. The decline in France differed not only
	in timing, but in form. When these declines were plotted on a line
	graph, the differences in form were immediately apparent. The French
	decline was choppy, and there is even an increase in marital fertility
	between 1850-1870. In contrast, the decline in other European countries
	was sharp, consistent, and smooth. During the 1700s in France there
	was a marked increase in the age at marriage and in the proportion
	of never married individuals. By the late 1700s a strain in the nuptiality
	pattern was evidenced by a marked increase in the illegitimacy rate
	and in the number of premarital pregnancies among brides. Subsequently,
	there was an increase in the nuptiality rate. In addition, life expectancy
	leaped from 28-39 years between 1790-1820. To compensate for both
	the increase in nuptiality and the decline in mortality, couples
	apparently limited births. These efforts to keep the marital fertility
	rate, the mortality rate, and the nuptiality rate in balance are
	evidenced in the NRR which varied from only 0.97-1.08 throughout
	the 1740-1880 period. The adjustment explanation is supported by
	the fact that while the marital fertility rate varied between 1740-1880,
	the NRR rate; remained stable. A subsequent paper will analyze regional
	differences. In using a equilbrium model, it is necessary to determine
	if the unity observed in the national NRR is a statistical artifact,
	resulting from large regional differences canceling each other out
	at the national level.},
  keywords = {Birth Rate; Demography; Developed Countries; Europe; Family Planning
	Services; Fertility; France; Life Expectancy; Longevity; Marriage;
	Mortality; Population; Population Dynamics; Population Growth; Research;
	Statistics as Topic},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {12159012},
  timestamp = {2013.05.29}
}

@ARTICLE{Yaari1989,
  author = {Yaari, S. and Goldbourt, U.},
  title = {A {SAS} program for evaluating person-years of risk in cohort studies},
  journal = {Comput Biol Med},
  year = {1989},
  volume = {19},
  pages = {353-9},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@Book{Yakovlev1996,
  author    = {Yakovlev, A. Y. and Tsodikov, A.},
  title     = {Stochastic Models of Tumor Latency and Their Biostatistical Applications},
  publisher = {World Scientific},
  owner     = {theand},
  timestamp = {2013.09.14},
  year      = {1996},
}

@ARTICLE{Yakovlev1999,
  author = {A. Y. Yakovlev and A. D. Tsodikov and K. Boucher and R. Kerber},
  title = {The shape of the hazard function in breast carcinoma: curability
	of the disease revisited.},
  journal = {Cancer},
  year = {1999},
  volume = {85},
  pages = {1789--1798},
  number = {8},
  month = {Apr},
  abstract = {BACKGROUND: The question of curability of breast carcinoma remains
	controversial. Because the probability of cure essentially is an
	asymptotic notion, the corresponding estimation problems call for
	special statistical methods. Such methods should account for an intimate
	connection between the probability of cure and the shape of the hazard
	function. METHODS: The study was performed on survival data for 13,166
	women with breast carcinoma identified through the Utah Cancer Registry
	and stratified by clinical stage and age at diagnosis. For these
	patients, the follow-up period was 30 years. Three estimation procedures
	were used for estimating the hazard function from the data: the life
	table estimator, a kernel counterpart of the Nelson-Aalen estimator,
	and a parametric estimator specifically designed for two-component
	hazards. The parametric estimate of the hazard function was used
	to provide estimates of cure rates for each category of patients.
	RESULTS: For all categories of patients under study, the estimated
	hazard functions passed through a clear-cut maximum, showing a tendency
	to decrease as time approached the end of a follow-up period. The
	hazards appeared to be nonproportional across the strata. The estimated
	values of the cure rate and the corresponding confidence intervals
	were determined for each stratum of patients with breast carcinoma.
	CONCLUSIONS: The results of the current study strongly suggest that
	cure is a possible outcome of breast carcinoma treatment. The condition
	of proportionality of risks is not met in breast carcinoma survival
	data.},
  file = {yakovlev1999.pdf:yakovlev1999.pdf:PDF},
  institution = {Huntsman Cancer Institute, Department of Oncological Sciences, University
	of Utah, Salt Lake City 84108, USA.},
  owner = {pl4},
  pii = {3.0.CO;2-Q},
  pmid = {10223574},
  timestamp = {2008.10.15}
}

@ARTICLE{Yamaguchi1999,
  author = {T. Yamaguchi and Y. Ohashi},
  title = {Investigating centre effects in a multi-centre clinical trial of
	superficial bladder cancer.},
  journal = {Statistics in Medicine},
  year = {1999},
  volume = {18},
  pages = {1961--1971},
  number = {15},
  month = {Aug},
  abstract = {This paper examines the amount of variation among centres and estimates
	the overall effect of therapy in a multi-centre cancer clinical trial
	with censored failure time data. To investigate the centre effects,
	the variation in the treatment effect must be taken into consideration
	in addition to the variation in the baseline risk. We treat centre
	effects as random ones and extend the penalized partial likelihood
	approach proposed by McGilchrist to estimate the treatment-by-centre
	interaction as well as the baseline risk. This method is applied
	to data from a superficial bladder cancer clinical trial investigating
	the efficacy of intravesical chemotherapy after transurethral resection.
	In this trial, although there exists some degree of centre variation,
	especially in the baseline risk, the treatment is effective in preventing
	recurrence among the participating centres. This result indicates
	that the treatment effect is generalizable to the target population.},
  file = {Yamaguchi1999.pdf:Yamaguchi1999.pdf:PDF;Yamaguchi1999.pdf:pdf\\Yamaguchi1999.pdf:PDF},
  institution = {ces, School of Health Sciences and Nursing, University of Tokyo,
	Japan. tyamagu@nihs.go.jp},
  owner = {pl4},
  pii = {3.0.CO;2-3},
  pmid = {10440879},
  timestamp = {2008.11.18}
}

@ARTICLE{Yamaguchi2002,
  author = {T. Yamaguchi and Y. Ohashi and Y. Matsuyama},
  title = {Proportional hazards models with random effects to examine centre
	effects in multicentre cancer clinical trials.},
  journal = {Statistical Methods in Medical Research},
  year = {2002},
  volume = {11},
  pages = {221--236},
  number = {3},
  month = {Jun},
  abstract = {In randomized clinical trials comparing treatment effects on diseases
	such as cancer, a multicentre trial is usually conducted to accrue
	the required number of patients within a reasonable period of time.
	The fundamental point of conducting a multicentre trial is that all
	participating investigators must agree to follow the common study
	protocol. However, even with every attempt having been made to standardize
	the methods for diagnosing severity of disease and evaluating response
	to treatment, for example, they might be applied differently at different
	centres, and these may vary from comprehensive cancer centres to
	university hospitals to community hospitals. Therefore, in multicentre
	trials there is likely to be some degree of variation (heterogeneity)
	among centres in both the baseline risks and the treatment effects.
	While we estimate the overall treatment effect using a summary measure
	such as hazard ratio and usually interpret it as an average treatment
	effect over the centre, it is necessary to examine the homogeneity
	of the observed treatment effects across centres, that is, treatment-by-centre
	interaction. If the data are reasonably consistent with homogeneity
	of the observed treatment effects across centres, a single summary
	measure is adequate to describe the trial results and those results
	will contribute to the scientific generalization, the process of
	synthesizing knowledge from observations. On the other hand, if heterogeneity
	of treatment effects is found, we should carefully interpret the
	trial results and investigate the reason why the variation is seen.
	In the analyses of multicentre trials, a random effects approach
	is often used to model the centre effects. In this article, we focus
	on the proportional hazards models with random effects to examine
	centre variation in the treatment effects as well as the baseline
	risks, and review the parameter estimation procedures, frequentist
	approach-penalized maximum likelihood method--and Bayesian approach--Gibbs
	sampling method. We also briefly review the models for bivariate
	responses. We present a few real data examples from the biometrical
	literature to highlight the issues.},
  file = {Yamaguchi2002.pdf:Yamaguchi2002.pdf:PDF;Yamaguchi2002.pdf:pdf\\Yamaguchi2002.pdf:PDF},
  institution = {Department of Biostatistics/Epidemiology and Preventive Health Sciences,
	School of Health Sciences and Nursing, University of Tokyo, Hongo
	7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan. yamaguti@epistat.m.u-tokyo.ac.jp},
  owner = {pl4},
  pmid = {12094756},
  timestamp = {2008.11.18}
}

@Article{Yilmaz2013,
  author      = {Yilmaz, Yildiz E. and Lawless, Jerald F. and Andrulis, Irene L. and Bull, Shelley B.},
  title       = {Insights from mixture cure modeling of molecular markers for prognosis in breast cancer.},
  doi         = {10.1200/JCO.2012.46.6615},
  language    = {eng},
  number      = {16},
  pages       = {2047--2054},
  url         = {http://dx.doi.org/10.1200/JCO.2012.46.6615},
  volume      = {31},
  abstract    = {With the ultimate aim of improving clinical management of breast cancer,
	investigators have sought to identify molecular genetic markers that
	stratify newly diagnosed patients into subtypes differing in short-
	or long-term prognosis. Conventional survival models can fail to
	describe adequately the relationship between subtype and disease
	recurrence, particularly when there is a substantial proportion of
	long-term disease-free survivors. The observed patterns of disease-free
	survival in an undifferentiated patient cohort may be explained by
	an underlying mixture of two subgroups: patients who will remain
	free of disease in the long term (ie, cured), and those who will
	experience disease recurrence within their lifetime (ie, susceptible.)
	In this article, we review the concepts and methods of the mixture
	cure models and apply them in the analysis of molecular genetic prognostic
	factors for disease-free survival and time to disease recurrence
	in a cohort of patients with axillary lymph node-negative breast
	cancer.},
  file        = {Yilmaz2013.pdf:pdf\\Yilmaz2013.pdf:PDF;Yilmaz2013.pdf:Yilmaz2013.pdf:PDF},
  institution = {Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada.},
  journal     = {J Clin Oncol},
  keywords    = {Adult; Aged; Axilla; Breast Neoplasms, genetics/pathology; Cohort Studies; Disease Progression; Disease-Free Survival; Female; Genetic Markers, genetics; Humans; Kaplan-Meier Estimate; Keratin-5, analysis; Lymph Nodes, pathology; Lymphatic Metastasis, diagnosis; Middle Aged; Models, Statistical; Neoplasm Recurrence, Local, diagnosis; Predictive Value of Tests; Prognosis; Receptor, erbB-2, analysis; Receptors, Estrogen, Progesterone, analysis; Recurrence; Time Factors; Tumor Markers, Biological, analysis},
  medline-pst = {ppublish},
  month       = {Jun},
  owner       = {PaulD},
  pii         = {JCO.2012.46.6615},
  pmid        = {23630217},
  timestamp   = {2014.10.13},
  year        = {2013},
}

@ARTICLE{Yin2011,
  author = {Yin, Daixin and Morris, Cyllene R. and Bates, Janet H. and German,
	Robert R.},
  title = {Effect of misclassified underlying cause of death on survival estimates
	of colon and rectal cancer.},
  journal = {J Natl Cancer Inst},
  year = {2011},
  volume = {103},
  pages = {1130--1133},
  number = {14},
  month = {Jul},
  abstract = {Inaccurate coding of patients' Underlying Cause of Death (UCOD) has
	constrained cause-specific survival estimates for colon and rectal
	cancers. Using California data from the Accuracy of Cancer Mortality
	study, we compared the cancer site data from the California Cancer
	Registry (CCR) with UCODs reported on death certificates and reclassified
	the UCODs based on cancer registry data when they disagreed. We then
	calculated 1-, 3-, 5-, and 10-year cause-specific survival for colon
	and rectal cancers separately, before and after the reclassification.
	Records from 26 312 colon and 10 687 rectal cancer patients were
	examined. UCOD records disagreed with CCR records for 700 (6\%) of
	11 404 colon cancer deaths and with 1958 (39\%) of 5011 rectal cancer
	deaths, and 82\% of the misclassified rectal cancer deaths were coded
	as colon cancer deaths in the UCOD. Reclassification decreased cause-specific
	survival for both colon and rectal cancers, but the impact was more
	pronounced for rectal cancer (eg, 5-year cause-specific survival
	of colon cancer decreased by 2.8\% and of rectal cancer decreased
	by 20.0\% relative to previous estimates; absolute rates changed
	from 65.4\% to 63.6\%, and 81.2\% to 64.9\%, respectively, after
	reclassification). Interchangeable use of the terms colon cancer
	and colorectal cancer is likely to be one of the reasons for UCOD
	misclassification. Educational measures could improve the accuracy
	of UCOD for colon and rectal cancer deaths.},
  doi = {10.1093/jnci/djr207},
  file = {Yin2011.pdf:Yin2011.pdf:PDF;Yin2011.pdf:pdf\\Yin2011.pdf:PDF},
  institution = {California Cancer Registry, Public Health Institute, Sacramento,
	CA 95825, USA.},
  keywords = {California, epidemiology; Cause of Death; Colonic Neoplasms, mortality;
	Colorectal Neoplasms, mortality; Death Certificates; Humans; Life
	Tables; Rectal Neoplasms, mortality; Registries; Survival Analysis},
  language = {eng},
  medline-pst = {ppublish},
  owner = {PaulD},
  pii = {djr207},
  pmid = {21697545},
  timestamp = {2013.09.18},
  url = {http://dx.doi.org/10.1093/jnci/djr207}
}

@ARTICLE{Ylitalo2000,
  author = {N. Ylitalo and P. S{\o}rensen and A. M. Josefsson and P. K. Magnusson
	and P. K. Andersen and J. Pont\'{e}n and H. O. Adami and U. B. Gyllensten
	and M. Melbye},
  title = {Consistent high viral load of human papillomavirus 16 and risk of
	cervical carcinoma in situ: a nested case-control study.},
  journal = {Lancet},
  year = {2000},
  volume = {355},
  pages = {2194--2198},
  number = {9222},
  month = {Jun},
  abstract = {BACKGROUND: Persistent infection with certain types of human papillomavirus
	(HPV) is believed to be a prerequisite for the development of cervical
	neoplasia. Persistence may depend on certain characteristics, such
	as viral load, which has so far been given little attention. We investigated
	the association between HPV 16 viral load and cervical carcinoma
	in situ. METHODS: We did a nested case-control study of women participating
	in cytological screening in {S}weden. We used a sensitive quantitative
	PCR assay to estimate HPV 16 load in multiple smears for each woman,
	taken during a period of up to 26 years before diagnosis. We calculated
	C, values, which decrease as the number of viral DNA copies increases.
	FINDINGS: 2081 smears from 478 cases and 1754 smears from 608 controls
	were tested. Among cases, we found a consistently increased load
	of HPV 16 already 13 years or more before diagnosis, and when many
	smears were still cytologically normal. Women with high HPV 16 viral
	loads were at least 30 times the relative risk of HPV-16-negative
	women more than a decade before diagnosis. The increase in relative
	risk was constant over time. About 25\% of women (95\% CI 0.12-0.32)
	infected with a high viral load before age 25 years developed cervical
	carcinoma in situ within 15 years. INTERPRETATION: Cervical carcinoma
	in situ associated with HPV 16 occurs mainly in HPV-16-positive women
	who have consistently high viral loads long term. Women at high risk
	could be identified by use of a quantitative HPV test in addition
	to cytological screening.},
  doi = {10.1016/S0140-6736(00)02402-8},
  institution = {Department of Medical Epidemiology, Karolinska Institute, Stockholm,
	{S}weden. nathalie.ylitalo@mep.ki.se},
  owner = {PaulD},
  pii = {S0140-6736(00)02402-8},
  pmid = {10881892},
  timestamp = {2008.11.07},
  url = {http://dx.doi.org/10.1016/S0140-6736(00)02402-8}
}

@ARTICLE{Younes1997,
  author = {N. Younes and J. Lachin},
  title = {Link-based models for survival data with interval and continuous
	time censoring},
  journal = {Biometrics},
  year = {1997},
  volume = {53},
  pages = {1199-1211},
  owner = {pl4},
  timestamp = {2014.06.03}
}

@ARTICLE{Young2002,
  author = {B. Young and G. E. Fitch and M. Dixon-Woods and P. C. Lambert and
	A. M. Brooke},
  title = {Parents' accounts of wheeze and asthma related symptoms: a qualitative
	study.},
  journal = {Arch Dis Child},
  year = {2002},
  volume = {87},
  pages = {131--134},
  number = {2},
  month = {Aug},
  abstract = {AIMS: To examine parents' accounts of how they recognise and judge
	respiratory symptoms in children, and to investigate their interpretations
	of respiratory survey questions about wheeze, shortness of breath,
	and cough. METHODS: Qualitative study using semistructured interviews.
	Data were analysed using the constant comparative method. Nineteen
	parents of children aged under 6 years were recruited from a cohort
	of parents who had responded to an earlier respiratory symptom survey
	and from one general practice. RESULTS: Parents judged respiratory
	symptoms using a range of cues, including changes in the sound of
	breathing and changes in appearance and behaviour. Experiential resources
	and contextual factors played an important role in parents' judgements.
	Interpretations of questions about respiratory symptoms were varied,
	particularly in relation to the terms "attacks of wheeze" and "shortness
	of breath". Parents' descriptions of wheeze differed from descriptions
	of the sound of wheeze used in some survey questionnaires. Parents
	drew fine distinctions between different "types" of cough and identified
	a distinct "asthma" cough. CONCLUSIONS: Attention needs to be given
	to the complexity of reporting respiratory symptoms in children and
	to the importance of contextual factors in parents' judgements. We
	suggest that questions which require parents to report on children's
	internal feelings or states be avoided. Consideration should be given
	to providing parents with explicit direction on what cues to attend
	to or ignore in reporting symptoms, and to clarifying some questions
	that are currently used in clinical practice and in surveys.},
  file = {Young2002.pdf:Young2002.pdf:PDF;Young2002.pdf:pdf\\Young2002.pdf:PDF},
  institution = {Department of Psychology, University of Hull, UK.},
  owner = {pl4},
  pmid = {12138062},
  timestamp = {2008.10.15}
}

@ARTICLE{Yu2012,
  author = {Yu, Binbing},
  title = {A minimum version of log-rank test for testing the existence of cancer
	cure using relative survival data.},
  journal = {Biom J},
  year = {2012},
  volume = {54},
  pages = {45--60},
  number = {1},
  month = {Jan},
  abstract = {Cancer survival is one of the most important measures to evaluate
	the effectiveness of treatment and early diagnosis. The ultimate
	goal of cancer research and patient care is the cure of cancer. As
	cancer treatments progress, cure becomes a reality for many cancers
	if patients are diagnosed early and get effective treatment. If a
	cure does exist for a certain type of cancer, it is useful to estimate
	the time of cure. For cancers that impose excess risk of mortality,
	it is informative to understand the difference in survival between
	cancer patients and the general cancer-free population. In population-based
	cancer survival studies, relative survival is the standard measure
	of excess mortality due to cancer. Cure is achieved when the survival
	of cancer patients is equivalent to that of the general population.
	This definition of cure is usually called the statistical cure, which
	is an important measure of burden due to cancer. In this paper, a
	minimum version of the log-rank test is proposed to test the equivalence
	of cancer patients' survival using the relative survival data. Performance
	of the proposed test is evaluated by simulation. Relative survival
	data from population-based cancer registries in SEER Program are
	used to examine patients' survival after diagnosis for various major
	cancer sites.},
  doi = {10.1002/bimj.201100069},
  institution = {Laboratory of Epidemiology, Demography and Biometry, National Institute
	on Aging, Bethesda, MD 20892, USA. yubi@mail.nih.gov},
  keywords = {Humans; Likelihood Functions; Medical Informatics, methods; Monte
	Carlo Method; Neoplasms, diagnosis/epidemiology/mortality/therapy;
	Reproducibility of Results; Statistics, Nonparametric; Survival Rate;
	Treatment Outcome},
  language = {eng},
  medline-pst = {ppublish},
  owner = {theand},
  pmid = {22213092},
  timestamp = {2013.09.15},
  url = {http://dx.doi.org/10.1002/bimj.201100069}
}

@ARTICLE{Yu2009,
  author = {B. Yu and L. Huang and R. C. Tiwari and E. J. Feuer and K. A. Johnson},
  title = {Modelling population-based cancer survival trends by using join point
	models for grouped survival data},
  journal = {Journal of the Royal Statistical Society (Series A)},
  year = {2009},
  volume = {172},
  pages = {405-425},
  doi = {10.1111/j.1467-985X.2009.00580.x},
  file = {Yu2009.pdf:Yu2009.pdf:PDF;Yu2009.pdf:pdf\\Yu2009.pdf:PDF},
  owner = {pl4},
  timestamp = {2010.06.01}
}

@ARTICLE{Yu2006,
  author = {Binbing Yu and Ram C Tiwari},
  title = {Multiple imputation methods for modelling relative survival data.},
  journal = {Stat Med},
  year = {2006},
  volume = {25},
  pages = {2946--2955},
  number = {17},
  month = {Sep},
  abstract = {In population-based cancer survival studies, the cause-specific survival
	measures the net survival (excess mortality) due to cancer when the
	cause of death information is available and reliable. In contrast,
	when the cause of death is uncertain or unavailable, relative survival,
	the ratio of the survival rate due to all causes to the expected
	survival rate, is more appropriate. There is a large body of work
	on the modelling and hypothesis testing of cause-specific survival,
	but many of these methods are not directly applicable to relative
	survival. In this paper, we extend the multiple imputation (MI) methods
	(Stat. Methods Med. Res. 1999; 8:3-15) to the case of relative survival
	data. The MI methodology is combined with relative survival to estimate
	the net survival by changing relative survival data to cause-specific
	data. This facilitates the direct application to statistical methods
	developed for the cause-specific survival to the special situation
	of relative survival. The parameter estimates and the log-rank statistics
	are obtained by combining the results from multiple imputed cause-specific
	data. The likelihood-based methods for modelling relative survival
	data have been implemented by a Windows application called CANSURV
	(Comput. Meth. Prog. Biomed 2005). Although these methods produce
	accurate parameter estimates, the choice for models and diagnostic
	tools is limited. The MI method is presented as a simpler alternative.
	The relative survival data for the colorectal cancer patients from
	Surveillance, Epidemiology, and End Results (SEER) program (SEER
	Cancer Statistics Review, 1973-1999. National Cancer Institute: Bethesda,
	2002) is used as an illustration. The results are compared with those
	obtained from the likelihood-based relative survival analysis methods.
	A sample SAS macro for the MI method is provided.},
  doi = {10.1002/sim.2289},
  file = {Yu2006.pdf:Yu2006.pdf:PDF},
  institution = {Information Management Services, Inc., 12501 Prosperity Dr Suite
	200, Silver Spring, MD 20904, USA. yub@imsweb.com},
  owner = {pl4},
  pmid = {16013033},
  timestamp = {2011.06.25},
  url = {http://dx.doi.org/10.1002/sim.2289}
}

@ARTICLE{Yu2004,
  author = {Binbing Yu and Ram C Tiwari and Kathleen A Cronin and Eric J Feuer},
  title = {Cure fraction estimation from the mixture cure models for grouped
	survival data.},
  journal = {Stat Med},
  year = {2004},
  volume = {23},
  pages = {1733--1747},
  number = {11},
  month = {Jun},
  abstract = {Mixture cure models are usually used to model failure time data with
	long-term survivors. These models have been applied to grouped survival
	data. The models provide simultaneous estimates of the proportion
	of the patients cured from disease and the distribution of the survival
	times for uncured patients (latency distribution). However, a crucial
	issue with mixture cure models is the identifiability of the cure
	fraction and parameters of kernel distribution. Cure fraction estimates
	can be quite sensitive to the choice of latency distributions and
	length of follow-up time. In this paper, sensitivity of parameter
	estimates under semi-parametric model and several most commonly used
	parametric models, namely lognormal, loglogistic, Weibull and generalized
	Gamma distributions, is explored. The cure fraction estimates from
	the model with generalized Gamma distribution is found to be quite
	robust. A simulation study was carried out to examine the effect
	of follow-up time and latency distribution specification on cure
	fraction estimation. The cure models with generalized Gamma latency
	distribution are applied to the population-based survival data for
	several cancer sites from the Surveillance, Epidemiology and End
	Results (SEER) Program. Several cautions on the general use of cure
	model are advised.},
  doi = {10.1002/sim.1774},
  file = {Yu2004.pdf:Yu2004.pdf:PDF;Yu2004.pdf:pdf\\Yu2004.pdf:PDF},
  institution = {Information Management Services, Inc., 12501 Prosperity Dr. Suite
	200, Silver Spring, MD 20910, U.S.A. yub@imsweb.com},
  keywords = {Cure models; theory},
  owner = {pl4},
  pmid = {15160405},
  timestamp = {2009.01.07},
  url = {http://dx.doi.org/10.1002/sim.1774}
}

@ARTICLE{Yu2005,
  author = {Binbing Yu and Ram C Tiwari and Kathleen A Cronin and Chris McDonald
	and Eric J Feuer},
  title = {CANSURV: A Windows program for population-based cancer survival analysis.},
  journal = {Comput Methods Programs Biomed},
  year = {2005},
  volume = {80},
  pages = {195--203},
  number = {3},
  month = {Dec},
  abstract = {Patient survival is one of the most important measures of cancer patient
	care (the diagnosis and treatment of cancer). The optimal method
	for monitoring the progress of patient care across the full spectrum
	of provider settings is through the population-based study of cancer
	patient survival, which is only possible using data collected by
	population-based cancer registries. The probability of cure, "statistical
	cure", is defined for a cohort of cancer patients as the percent
	of patients whose annual death rate equals the death rate of general
	cancer-free population. Mixture cure models have been widely used
	to model failure time data. The models provide simultaneous estimates
	of the proportion of the patients cured from cancer and the distribution
	of the failure times for the uncured patients (latency distribution).
	CANSURV (CAN-cer SURVival) is a Windows software fitting both the
	standard survival models and the cure models to population-based
	cancer survival data. CANSURV can analyze both cause-specific survival
	data and, especially, relative survival data, which is the standard
	measure of net survival in population-based cancer studies. It can
	also fit parametric (cure) survival models to the individual data.
	The program is available at . The colorectal cancer survival data
	from the Surveillance, Epidemiology and End Results (SEER) program
	[Surveillance, Epidemiology and End Results Program, The Portable
	Survival System/Mainframe Survival System, National Cancer Institute,
	Bethesda, 1999.] of the National Cancer Institute, NIH is used to
	demonstrate the use of CANSURV program.},
  doi = {10.1016/j.cmpb.2005.08.002},
  file = {Yu2005.pdf:Yu2005.pdf:PDF;Yu2005.pdf:pdf\\Yu2005.pdf:PDF},
  institution = {Information Management Services, Inc., 12501 Prosperity Dr. Suite
	200, Silver Spring, MD 20904, USA.},
  keywords = {Cure models},
  owner = {pl4},
  pii = {S0169-2607(05)00167-7},
  pmid = {16257080},
  timestamp = {2008.12.16},
  url = {http://dx.doi.org/10.1016/j.cmpb.2005.08.002}
}

@ARTICLE{Yu2010,
  author = {Binbing Yu and Ram C Tiwari and Eric J Feuer},
  title = {Estimating the personal cure rate of cancer patients using population-based
	grouped cancer survival data.},
  journal = {Stat Methods Med Res},
  year = {2010},
  month = {Feb},
  abstract = {Cancer patients are subject to multiple competing risks of death and
	may die from causes other than the cancer diagnosed. The probability
	of not dying from the cancer diagnosed, which is one of the patients'
	main concerns, is sometimes called the 'personal cure' rate. Two
	approaches of modelling competing-risk survival data, namely the
	cause-specific hazards approach and the mixture model approach, have
	been used to model competing-risk survival data. In this article,
	we first show the connection and differences between crude cause-specific
	survival in the presence of other causes and net survival in the
	absence of other causes. The mixture survival model is extended to
	population-based grouped survival data to estimate the personal cure
	rate. Using the colorectal cancer survival data from the Surveillance,
	Epidemiology and End Results Programme, we estimate the probabilities
	of dying from colorectal cancer, heart disease, and other causes
	by age at diagnosis, race and American Joint Committee on Cancer
	stage.},
  doi = {10.1177/0962280209347046},
  file = {Yu2010.pdf:Yu2010.pdf:PDF;Yu2010.pdf:pdf\\Yu2010.pdf:PDF},
  institution = {Laboratory of Epidemiology, Demography and Biometry, National Institute
	on Aging, Bethesda, MD 20892, USA.},
  keywords = {Cure models; theory},
  language = {eng},
  medline-pst = {aheadofprint},
  owner = {pl4},
  pii = {0962280209347046},
  pmid = {20181780},
  timestamp = {2010.06.01},
  url = {http://dx.doi.org/10.1177/0962280209347046}
}

@Article{Yu2013,
  author      = {Yu, X. Q. and {De Angelis}, R. and Andersson, T M L. and Lambert, P. C. and O'Connell, D. L. and Dickman, P. W.},
  title       = {Estimating the proportion cured of cancer: Some practical advice for users.},
  doi         = {10.1016/j.canep.2013.08.014},
  language    = {eng},
  pages       = {836-842},
  url         = {http://dx.doi.org/10.1016/j.canep.2013.08.014},
  volume      = {37},
  abstract    = {Cure models can provide improved possibilities for inference if used
	appropriately, but there is potential for misleading results if care
	is not taken. In this study, we compared five commonly used approaches
	for modelling cure in a relative survival framework and provide some
	practical advice on the use of these approaches.Data for colon, female
	breast, and ovarian cancers were used to illustrate these approaches.
	The proportion cured was estimated for each of these three cancers
	within each of three age groups. We then graphically assessed the
	assumption of cure and the model fit, by comparing the predicted
	relative survival from the cure models to empirical life table estimates.Where
	both cure and distributional assumptions are appropriate (e.g., for
	colon or ovarian cancer patients aged <75 years), all five approaches
	led to similar estimates of the proportion cured. The estimates varied
	slightly when cure was a reasonable assumption but the distributional
	assumption was not (e.g., for colon cancer patients older than 75
	years). Greater variability in the estimates was observed when the
	cure assumption was not supported by the data (breast cancer).If
	the data suggest cure is not a reasonable assumption then we advise
	against fitting cure models. In the scenarios where cure was reasonable,
	we found that flexible parametric cure models performed at least
	as well, or better, than the other modelling approaches. We recommend
	that, regardless of the model used, the underlying assumptions for
	cure and model fit should always be graphically assessed.},
  file        = {Yu2013.pdf:pdf\\Yu2013.pdf:PDF},
  institution = {Cancer Council New South Wales, Sydney, Australia; Sydney School of Public Health, Sydney, Australia. Electronic address: xueqiny@nswcc.org.au.},
  journal     = {Cancer Epidemiology},
  medline-pst = {aheadofprint},
  month       = {Sep},
  owner       = {PaulD},
  pii         = {S1877-7821(13)00137-9},
  pmid        = {24042025},
  timestamp   = {2016.06.20},
  year        = {2013},
}

@ARTICLE{yu,
  author = {Xue Q Yu and Dianne L O'Connell and Robert W Gibberd and David P
	Smith and Paul W Dickman and Bruce K Armstrong},
  title = {Estimating regional variation in cancer survival: a tool for improving
	cancer care.},
  journal = {Cancer Causes Control},
  year = {2004},
  volume = {15},
  pages = {611-8},
  number = {6},
  month = {Aug},
  abstract = {OBJECTIVE: To improve estimation of regional variation in cancer survival
	and identify cancers to which priority might be given to increase
	survival. METHODS: Survival measures were calculated for 25 major
	cancer types diagnosed in each of 17 health service regions in New
	South Wales, Australia, from 1991 to 1998. Region-specific risks
	of excess death due to cancer were estimated adjusting for age, sex,
	and extent of disease at, and years since, diagnosis. Empirical Bayes
	(EB) methods were used to shrink the estimates. The additional numbers
	of patients who would survive beyond five years were estimated by
	shifting the State average risk to the 20th centile. RESULTS: Statistically
	significant regional variation in the shrunken estimates of risk
	of excess death was found for nine of the 25 cancer types. The lives
	of 2903 people (6.4\%) out of the 45,047 whose deaths within 5 years
	were attributable to cancer could be extended with the highest number
	being for lung cancer (791). CONCLUSIONS: The EB approach gives more
	precise estimates of region-specific risk of excess death and is
	preferable to standard methods for identifying cancer sites where
	gains in survival might be made. The estimated number of lives that
	could be extended can assist health authorities in prioritising investigation
	of and attention to causes of regional variation in survival.},
  doi = {10.1023/B:CACO.0000036165.13089.e8},
  owner = {PaulD},
  pii = {5272609},
  timestamp = {2011.06.19},
  url = {http://dx.doi.org/10.1023/B:CACO.0000036165.13089.e8}
}

@ARTICLE{Zagar2013,
  author = {Zagar, Timothy M. and Marks, Lawrence B.},
  title = {Breast cancer: risk of heart disease after radiotherapy-cause for
	concern.},
  journal = {Nat Rev Clin Oncol},
  year = {2013},
  volume = {10},
  pages = {310--312},
  number = {6},
  month = {Jun},
  doi = {10.1038/nrclinonc.2013.59},
  institution = {The University of North Carolina, Department of Radiation Oncology,
	101 Manning Drive, Campus Box 7512, Chapel Hill, NC 27599, USA. zagar@med.unc.edu},
  language = {eng},
  medline-pst = {ppublish},
  owner = {sanelo},
  pii = {nrclinonc.2013.59},
  pmid = {23609314},
  timestamp = {2013.08.01},
  url = {http://dx.doi.org/10.1038/nrclinonc.2013.59}
}

@ARTICLE{Zahl1997,
  author = {P. H. Zahl},
  title = {Frailty modelling for the excess hazard.},
  journal = {Statistics in Medicine},
  year = {1997},
  volume = {16},
  pages = {1573--1585},
  number = {14},
  month = {Jul},
  abstract = {Long-term excess hazards for cancer survival sometimes tend to zero
	or become negative even though we expect them to be positive. This
	may be explained by selection at diagnosis; individuals with certain
	cancers may have an increased risk of dying of other diseases in
	general. Then comparing with population mortality rates is not correct.
	Alternatively, we may have a continuous selection of the most robust
	individuals after diagnosis. When there are unobserved heterogeneity,
	and those with highest risk of dying of cancer also have the highest
	risk of dying of other diseases, this will cause selection after
	diagnosis. This may be modelled by multivariate frailty variables,
	and a corrected excess hazard may be estimated. In two examples,
	these corrected excess hazards give a better estimate when comparing
	to the cause-specific cancer mortality. Actually, this study questions
	the usefulness of long-term excess hazard rates.},
  file = {Zahl1997.pdf:Zahl1997.pdf:PDF;Zahl1997.pdf:pdf\\Zahl1997.pdf:PDF},
  institution = {Section of Medical Statistics, University of Oslo, Blindern, Norway.},
  owner = {pl4},
  pii = {3.0.CO;2-Q},
  pmid = {9257413},
  timestamp = {2008.12.16}
}

@ARTICLE{Zahl1995,
  author = {Zahl, P. H.},
  title = {A Proportional Regression Model for 20 Year Survival of Colon Cancer
	in {N}orway},
  journal = {Statistics in Medicine},
  year = {1995},
  volume = {14},
  pages = {1249-1261},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Zahl1998,
  author = {Zahl, P. H. and Aalen, O. O.},
  title = {Adjusting and comparing survival curves by means of an additive risk
	model.},
  journal = {Lifetime Data Anal},
  year = {1998},
  volume = {4},
  pages = {149--168},
  number = {2},
  abstract = {Survival curves may be adjusted for covariates using Aalen's additive
	risk model. Survival curves may be compared by taking the ratio of
	two adjusted survival curves; the ratio is denoted the generalized
	relative survival rate. Adjusting both survival curves for all but
	one of a common set of covariates gives the partial relative survival
	rate, which measures the covariate-specific contribution to the generalized
	relative survival rate. The generalized and partial relative survival
	rates have interpretations similar to the traditional relative survival
	rates frequently used in cancer epidemiology. In fact, the traditional
	relative survival rate can be generalized to a regression context
	using the additive risk model. This population-adjusted relative
	survival rate is an alternative and useful method for removing confounding
	effects of age, cohorts, and sex. The authors use a data set of malignant
	melanoma patients diagnosed from 1965 to 1974 in Norway. The 25-year
	survival of 1967 individuals is studied.},
  file = {Zahl1998.pdf:Zahl1998.pdf:PDF;Zahl1998.pdf:pdf\\Zahl1998.pdf:PDF},
  groups = {Excess mortality model},
  institution = {Section of Medical Statistics, University of Oslo. perhz@biostat.washington.edu},
  keywords = {Adolescent; Adult; Age Distribution; Aged; Child; Child, Preschool;
	Female; Humans; Incidence; Infant; Infant, Newborn; Male; Melanoma,
	epidemiology/mortality; Middle Aged; Models, Statistical; Norway,
	epidemiology; Risk Assessment; Sex Distribution; Skin Neoplasms,
	epidemiology/mortality; Survival Analysis},
  language = {eng},
  medline-pst = {ppublish},
  owner = {sanelo},
  pmid = {9658773},
  timestamp = {2013.09.16}
}

@ARTICLE{Zahl1997a,
  author = {Zahl, P. H. and Tretli, S.},
  title = {Long-term survival of breast cancer in {N}orway by age and clinical
	stage},
  journal = {Statistics in Medicine},
  year = {1997},
  volume = {16},
  pages = {1435-1449},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Zhang2016a,
  author = {Zhang, Chun-Dong and Wang, Ji-Nan and Sui, Bai-Qiang and Zeng, Yong-Ji
	and Chen, Jun-Qing and Dai, Dong-Qiu},
  title = {Prognostic and Predictive Model for Stage II Colon Cancer Patients
	With Nonemergent Surgery: Who Should Receive Adjuvant Chemotherapy?},
  journal = {Medicine},
  year = {2016},
  volume = {95},
  pages = {e2190},
  month = {Jan},
  abstract = {No ideal prognostic model has been applied to clearly identify which
	suitable high-risk stage II colon cancer patients with negative margins
	undergoing nonemergent surgery should receive adjuvant chemotherapy
	routinely. Clinicopathologic and prognostic data of 333 stage II
	colon cancer patients who underwent D2 or D3 lymphadenectomy during
	nonemergent surgery were retrospectively analyzed. Four pathologically
	determined factors, including adjacent organ involvement (RR 2.831,
	P = 0.001), histologic differentiation (RR 2.151, P = 0.009), lymphovascular
	invasion (RR 4.043, P < 0.001), and number of lymph nodes retrieved
	(RR 2.161, P = 0.011), were identified as independent prognostic
	factors on multivariate analysis. Importantly, a simple cumulative
	scoring system clearly categorizing prognostic risk groups was generated:
	risk score = ? coefficient' {\AA}Â— status (AOI + histological differentiated
	+ lymphovascular invasion + LNs retrieved). Our new prognostic model
	may provide valuable information on the impact of lymphovascular
	invasion, as well as powerfully and reliably predicting prognosis
	and recurrence for this particular cohort of patients. This model
	may identify suitable patients with an R0 resection who should receive
	routine postoperative adjuvant therapy and may help clinicians to
	facilitate individualized treatment. In this study, we aim to provide
	an ideal and quantifiable method for clinical decision making in
	the nonemergent surgical treatment of stage II colon cancer. Our
	prognostic and predictive model should be applied in multicenter,
	prospective studies with large sample sizes, in order to obtain a
	more reliable clinical recommendation.},
  citation-subset = {AIM, IM},
  completed = {2016-05-12},
  country = {United States},
  created = {2016-01-07},
  doi = {10.1097/MD.0000000000002190},
  issn = {1536-5964},
  issn-linking = {0025-7974},
  issue = {1},
  keywords = {Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Chemotherapy,
	Adjuvant; Colonic Neoplasms, drug therapy, mortality, pathology,
	surgery; Female; Humans; Kaplan-Meier Estimate; Lymph Node Excision,
	statistics & numerical data; Male; Middle Aged; Neoplasm Metastasis;
	Neoplasm Staging; Prognosis; Prospective Studies; Retrospective Studies;
	Sex Factors; Time Factors; Young Adult},
  nlm = {PMC4706247},
  nlm-id = {2985248R},
  owner = {NLM},
  pii = {00005792-201601050-00010},
  pmc = {PMC4706247},
  pmid = {26735527},
  pubmodel = {Print},
  pubstatus = {ppublish},
  revised = {2016-01-20},
  timestamp = {2016.12.09}
}

@ARTICLE{Zhang2008,
  author = {Mei-Jie Zhang and Xu Zhang and Thomas H Scheike},
  title = {Modeling cumulative incidence function for competing risks data.},
  journal = {Expert Rev Clin Pharmacol},
  year = {2008},
  volume = {1},
  pages = {391--400},
  number = {3},
  month = {May},
  abstract = {A frequent occurrence in medical research is that a patient is subject
	to different causes of failure, where each cause is known as a competing
	risk. The cumulative incidence curve is a proper summary curve, showing
	the cumulative failure rates over time due to a particular cause.
	A common question in medical research is to assess the covariate
	effects on a cumulative incidence function. The standard approach
	is to construct regression models for all cause-specific hazard rate
	functions and then model a covariate-adjusted cumulative incidence
	curve as a function of all cause-specific hazards for a given set
	of covariates. New methods have been proposed in recent years, emphasizing
	direct assessment of covariate effects on cumulative incidence function.
	Fine and Gray proposed modeling the effects of covariates on a subdistribution
	hazard function. A different approach is to directly model a covariate-adjusted
	cumulative incidence function, including a pseudovalue approach by
	Andersen and Klein and a direct binomial regression by Scheike, Zhang
	and Gerds. In this paper, we review the standard and new regression
	methods for modeling a cumulative incidence function, and give the
	sources of computer packages/programs that implement these regression
	models. A real bone marrow transplant data set is analyzed to illustrate
	various regression methods.},
  doi = {10.1586/17512433.1.3.391},
  file = {Zhang2008.pdf:Zhang2008.pdf:PDF;Zhang2008.pdf:pdf\\Zhang2008.pdf:PDF},
  institution = {Division of Biostatistics, Medical College of Wisconsin, 8701 Watertown
	Plank Road, Milwaukee, WI 53226, U.S.A. Tel: +1 414-456-8375;},
  owner = {pl4},
  pmid = {19829754},
  timestamp = {2010.07.09},
  url = {http://dx.doi.org/10.1586/17512433.1.3.391}
}

@ARTICLE{Zhang2007,
  author = {Zhang, Xu and Loberiza, Fausto R. and Klein, John P. and Zhang, Mei-Jie},
  title = {A SAS macro for estimation of direct adjusted survival curves based
	on a stratified Cox regression model.},
  journal = {Comput Methods Programs Biomed},
  year = {2007},
  volume = {88},
  pages = {95--101},
  number = {2},
  month = {Nov},
  abstract = {Often in biomedical research the aim of a study is to compare the
	outcomes of several treatment arms while adjusting for multiple clinical
	prognostic factors. In this paper we focus on computation of the
	direct adjusted survival curves for different treatment groups based
	on an unstratified or a stratified Cox model. The estimators are
	constructed by taking the average of the individual predicted survival
	curves. The method of direct adjustment controls for possible confounders
	due to an imbalance of patient characteristics between treatment
	groups. This adjustment is especially useful for non-randomized studies.
	We have written a SAS macro to estimate and compare the direct adjusted
	survival curves. We illustrate the SAS macro through the examples
	analyzing stem cell transplant data and Ewing's sarcoma data.},
  doi = {10.1016/j.cmpb.2007.07.010},
  file = {Zhang2007.pdf:Zhang2007.pdf:PDF},
  institution = {Department of Mathematics and Statistics, Georgia State University,
	Atlanta, GA 30303, USA. matxxz@langate.gsu.edu},
  keywords = {Biomedical Research, statistics /&/ numerical data; Confounding Factors
	(Epidemiology); Humans; Proportional Hazards Models; Sarcoma, Ewing;
	Survival Analysis; United States},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pii = {S0169-2607(07)00186-1},
  pmid = {17850917},
  timestamp = {2014.08.21},
  url = {http://dx.doi.org/10.1016/j.cmpb.2007.07.010}
}

@ARTICLE{Zhao1992,
  author = {L. P. Zhao and L. N. Kolonel},
  title = {Efficiency loss from categorizing quantitative exposures into qualitative
	exposures in case-control studies},
  journal = {American Journal of Epidemiology},
  year = {1992},
  volume = {136},
  pages = {464-74},
  number = {4},
  owner = {PaulD},
  timestamp = {2011.06.19}
}

@ARTICLE{Zhou2013,
  author = {Zhou, Bingqing and Fine, Jason and Laird, Glen},
  title = {Goodness-of-fit test for proportional subdistribution hazards model.},
  journal = {Stat Med},
  year = {2013},
  month = {Apr},
  abstract = {This paper concerns using modified weighted Schoenfeld residuals to
	test the proportionality of subdistribution hazards for the Fine-Gray
	model, similar to the tests proposed by Grambsch and Therneau for
	independently censored data. We develop a score test for the time-varying
	coefficients based on the modified Schoenfeld residuals derived assuming
	a certain form of non-proportionality. The methods perform well in
	simulations and a real data analysis of breast cancer data, where
	the treatment effect exhibits non-proportional hazards. Copyright
	ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â© 2013 John Wiley & Sons, Ltd.},
  doi = {10.1002/sim.5815},
  file = {Zhou2013.pdf:Zhou2013.pdf:PDF;Zhou2013.pdf:pdf\\Zhou2013.pdf:PDF},
  institution = {Division of Biostatistics, School of Public Health, Yale University,
	New Haven, CT?06520, U.S.A.; VA Cooperative Studies Program Coordinating
	Center, West Haven, CT?06516, U.S.A.},
  language = {eng},
  medline-pst = {aheadofprint},
  owner = {pl4},
  pmid = {23625840},
  timestamp = {2013.09.04},
  url = {http://dx.doi.org/10.1002/sim.5815}
}

@Article{Zhou2011,
  author      = {Zhou, Bingqing and Latouche, Aurelien and Rocha, Vanderson and Fine, Jason},
  title       = {Competing risks regression for stratified data.},
  doi         = {10.1111/j.1541-0420.2010.01493.x},
  language    = {eng},
  number      = {2},
  pages       = {661--670},
  url         = {http://dx.doi.org/10.1111/j.1541-0420.2010.01493.x},
  volume      = {67},
  abstract    = {For competing risks data, the Fine-Gray proportional hazards model
	for subdistribution has gained popularity for its convenience in
	directly assessing the effect of covariates on the cumulative incidence
	function. However, in many important applications, proportional hazards
	may not be satisfied, including multicenter clinical trials, where
	the baseline subdistribution hazards may not be common due to varying
	patient populations. In this article, we consider a stratified competing
	risks regression, to allow the baseline hazard to vary across levels
	of the stratification covariate. According to the relative size of
	the number of strata and strata sizes, two stratification regimes
	are considered. Using partial likelihood and weighting techniques,
	we obtain consistent estimators of regression parameters. The corresponding
	asymptotic properties and resulting inferences are provided for the
	two regimes separately. Data from a breast cancer clinical trial
	and from a bone marrow transplantation registry illustrate the potential
	utility of the stratified Fine-Gray model.},
  file        = {Zhou2011.pdf:Zhou2011.pdf:PDF;Zhou2011.pdf:pdf\\Zhou2011.pdf:PDF},
  institution = {Division of Biostatistics, School of Public Health, Yale University, New Haven, Connecticut 06520, USA. bingqing.zhou@yale.edu},
  journal     = {Biometrics},
  keywords    = {Biometry, methods; Bone Marrow Transplantation; Breast Neoplasms; Clinical Trials as Topic; Humans; Proportional Hazards Models; Risk; Risk Factors; Statistical Distributions},
  medline-pst = {ppublish},
  month       = {Jun},
  owner       = {pl4},
  pmid        = {21155744},
  timestamp   = {2013.09.04},
  year        = {2011},
}

@ARTICLE{Zou2004,
  author = {G. Zou},
  title = {A modified poisson regression approach to prospective studies with
	binary data.},
  journal = {Am J Epidemiol},
  year = {2004},
  volume = {159},
  pages = {702--706},
  number = {7},
  month = {Apr},
  abstract = {Relative risk is usually the parameter of interest in epidemiologic
	and medical studies. In this paper, the author proposes a modified
	Poisson regression approach (i.e., Poisson regression with a robust
	error variance) to estimate this effect measure directly. A simple
	2-by-2 table is used to justify the validity of this approach. Results
	from a limited simulation study indicate that this approach is very
	reliable even with total sample sizes as small as 100. The method
	is illustrated with two data sets.},
  file = {Zou2004.pdf:Zou2004.pdf:PDF;Zou2004.pdf:pdf\\Zou2004.pdf:PDF},
  institution = {Robarts Clinical Trials, Robarts Research Institute, London, Ontario,
	Canada. gzou@robarts.ca},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {15033648},
  timestamp = {2010.06.01}
}

@ARTICLE{Zucker2002,
  author = {Zucker, J. M.},
  title = {[Reaching a team consensus in pediatric oncology when treatment proves
	ineffective].},
  journal = {Arch Pediatr},
  year = {2002},
  volume = {9 Suppl 1},
  pages = {55s--59s},
  month = {Apr},
  abstract = {Modern treatments are able to cure 3/4 of paediatric cancers, but
	on another hand there is still a too high number of patients which
	will enter a resistant phase and test the ability of the medical
	and nursing team to face together the new modalities of care. At
	diagnosis, the reasonable hope to cure the child and the exciting
	feeling to be endued with a repairing mission strengthen among the
	team both the self-esteem and a rational and emotional consensus.
	Conversely, at the time of relapse or resistant disease, the feeling
	of a failure, added to anxiety and reciprocal aggressiveness, will
	contradictorily affect the group. In this atmosphere of loss of control
	of reality and emotions, elaborating new priorities of care is mandatory:
	medical positions have of course to be in keeping, but this is not
	enough since the nursing team has, through sharing information and
	feeling, to give their cure project of the child's cancer as lost
	while retaining and expanding their ability to care the child with
	cancer. Thanks to an over-investment of the symptomatic, psychological,
	and affective help support to the child, the nursing team will succeed
	in regaining this self-esteem absolutely necessary to their own professional
	survival. Consensus in the team is ultimately linked to its empathic
	ability of exchanging with the families which in turn results in
	giving them guidelines for the last weeks and months of life and
	helping them to be less emotionally unprovided when bereavement time
	has come: a pedagogy of the continuity of care is thus taking place
	which, equally distant from forsaking and therapeutic relentlessness,
	chooses to give up the idea of curing in order to go on caring.},
  institution = {D{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¯ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â¡rtement d'oncologie p{\AA}Â¨ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â£ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â©atrique, Institut Curie, 26, rue d'Ulm,
	75005 Paris, France. Jean-Michel.Zucker@curie.net},
  keywords = {Adult; Bereavement; Child; Child Welfare; Decision Making; Ethics,
	Medical; Family Health; Humans; Interprofessional Relations; Medical
	Oncology, trends; Nurse-Patient Relations; Palliative Care; Patient
	Care Team; Patient-Centered Care; Pediatrics, trends; Physician-Patient
	Relations; Prognosis},
  language = {fre},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {11998414},
  timestamp = {2013.05.29}
}

@Book{ZZ:Adami02,
  title     = {Textbook of Cancer Epidemiology},
  editor    = {Adami, H-O. and Hunter, D. J. and Trichopoulos, D.},
  publisher = {Oxford University Press},
  series    = {Monographs in Epidemiology and Biostatistics},
  booktitle = {Textbook of Cancer Epidemiology},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2002},
}

@Book{ZZ:EOB,
  title     = {Encyclopedia of Biostatistics},
  edition   = {2nd},
  editor    = {Armitage, P. and Colton, T.},
  publisher = {John Wiley \& Sons: Chichester},
  booktitle = {Encyclopedia of Biostatistics},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2005},
}

@Book{Boyle1989,
  title     = {Cancer Mapping},
  editor    = {Boyle, P. and Muir, C. S. and Grundmann, E.},
  publisher = {Berlin: Springer-Verlag},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1989},
}

@Book{Carstensen1993,
  title     = {Survival of {D}anish Cancer Patients 1943-1987},
  editor    = {Carstensen, B. and Storm, H. H. and Schou, G.},
  publisher = {Copenhagen: Danish Cancer Society},
  series    = {APMIS},
  volume    = {101 (Suppl. 33)},
  groups    = {Cancer registry reports},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1993},
}

@Book{Coleman2008,
  title     = {Responding to the challenge of cancer in {E}urope},
  editor    = {Michel P. Coleman and Delia-Marina Alexe and Tit Albreht and Martin McKee},
  publisher = {Ljubljana: Institute of Public Health of the Republic of Slovenia},
  file      = {Coleman2008.pdf:pdf\\Coleman2008.pdf:PDF;Coleman2008.pdf:Coleman2008.pdf:PDF},
  owner     = {PaulD},
  timestamp = {2008.08.12},
  year      = {2008},
}

@Book{CI195IX,
  title     = {Cancer Incidence in Five Continents, Volume {IX}},
  editor    = {Curado, M. P. and Edwards, B. and Shin, H. R. and Storm, H. and Ferlay, J. and Heanue, M. and Boyle, P.},
  publisher = {Lyon: IARC},
  series    = {IARC Scientific Publications No.\ 160},
  url       = {http://www-dep.iarc.fr/ci5_ix.htm},
  groups    = {Cancer registry reports},
  owner     = {PaulD},
  timestamp = {2008.08.11},
  year      = {2007},
}

@Book{ZZ:Elliott92,
  title     = {Geographical \& Environmental Epidemiology: {M}ethods for Small-Area Studies},
  editor    = {Elliott, P. and Cuzick, J. and English, D. and Stern, R.},
  publisher = {Oxford: Oxford University Press},
  booktitle = {Geographical \& Environmental Epidemiology: {M}ethods for Small-Area Studies},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1992},
}

@Book{GLIM194,
  title     = {The {GLIM} System: Generalized Linear Interactive Modelling},
  editor    = {Francis, Brian and Green, Mick and Payne, Clive},
  note      = {Release 4},
  publisher = {Oxford: Oxford University Press},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1993},
}

@Book{ZZ:Kogevinas97,
  title     = {Social Inequalities and Cancer},
  editor    = {Kogevinas, M. and Pearce, N. and Susser, M. and Boffetta, P.},
  publisher = {Lyon: International Agency for Research on Cancer},
  series    = {IARC Scientific Publications No. 138},
  booktitle = {Social Inequalities and Cancer},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1997},
}

@Book{ZZ:Magnus82,
  title     = {Trends in Cancer Incidence. Causes and Practical Implications},
  editor    = {Magnus, K.},
  publisher = {Hemisphere: Washington},
  booktitle = {Trends in Cancer Incidence. Causes and Practical Implications},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1982},
}

@Book{Parkin1994,
  title     = {Comparability and Quality Control in Cancer Registration},
  editor    = {Parkin, D. M. and Chen, V. W. and Ferlay, J. and Galceran, J. and Storm, H. H. and Whelan, S. L.},
  publisher = {Lyon: International Agency for Research on Cancer},
  series    = {IARC Technical Report No.\ 19},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1994},
}

@Book{SEER2002,
  title     = {{SEER} Cancer Statistics Review, 1973--1999},
  editor    = {Ries, L. A. G. and Eisner, M. P. and Kosary, C. L. and Hankey, B. F. and Miller, B. A. and Clegg, L. and Edwards, B. K.},
  note      = {\tt \verb+http://seer.cancer.gov/csr/1973_1999/+},
  publisher = {Bethesda: National Cancer Institute},
  groups    = {Cancer registry reports},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {2002},
}

@Book{Ringborg2008a,
  title     = {Onkologi},
  edition   = {Second},
  editor    = {U Ringborg and T Dalianis and R Henriksson},
  pages     = {608-620},
  publisher = {Liber},
  owner     = {sanelo},
  timestamp = {2013.09.16},
  year      = {2008},
}

@Book{Stenbeck1995,
  title     = {Cancer Survival in {S}weden in 1961-1991},
  editor    = {Stenbeck, M. and Ros{\'e}n, M.},
  publisher = {Scandinavian University Press},
  series    = {{Acta} Oncologica},
  volume    = {34 (Suppl. 4)},
  groups    = {Cancer registry reports},
  owner     = {PaulD},
  timestamp = {2011.06.19},
  year      = {1995},
}

@Misc{ACT1998,
  title        = {Lag (1998:543) om h{\"a}lsodataregister (The {H}ealth {D}ata {R}egisters {A}ct).},
  howpublished = {Government Offices of Sweden, Ministry of Health and Social Affairs, Stockholm, Sweden 1998},
  owner        = {sanelo},
  timestamp    = {2013.09.17},
}

@WWW{CaliforniaBerkeley,
  author       = {{University of California Berkeley and Max Planck Institute for Demographic Research}},
  title        = {The Human Mortality Database},
  howpublished = {http://www.mortality.org/},
  owner        = {pl4},
  timestamp    = {2010.03.19},
}

@Periodical{Saltus2008,
  title     = {What is cure? {P}aths and {P}rogress {F}all/{W}inter 2008},
  note      = {Dana-Farber Cancer Institute. Vol 17, 2:8-10, 2008},
  owner     = {sanelo},
  timestamp = {2013.08.01},
}

@Booklet{Soc2008,
  title     = {Ett halvt sekel med det svenska cancerregistret [artikelnr: 2008-126-48]},
  note      = {The National Board of Health and Welfare (Socialstyrelsen), Stockholm, Sweden, 2008},
  owner     = {sanelo},
  timestamp = {2013.08.01},
}

@TechReport{StatisticsSweden2012,
  institution = {Demographic reports 2012:2},
  title       = {The future population of {S}weden 2012-2060},
  note        = {Statistics Sweden (Statistiska Centralbyr{\aa}n), 2012},
  owner       = {sanelo},
  timestamp   = {2013.08.07},
}

@Electronic{cancer_registration_statistics,
  title        = {Registrations of cancer diagnosed in 2007, England},
  url          = {http://www.statistics.gov.uk/downloads/theme_health/MB1-38/MB1_No38_2007.pdf},
  organization = {{O}ffice for {N}ational {S}tatistics},
  owner        = {pl4},
  timestamp    = {2010.03.19},
  year         = {2007},
}

@ARTICLE{1993,
  title = {Expert Group Meeting on Population Growth and Demographic Structure.},
  journal = {Popul Bull UN},
  year = {1993},
  pages = {102--119},
  number = {34-35},
  abstract = {As part of the preparation for the forth-coming UN International Conference
	on Population and Development, an expert group met in Paris, France,
	in November 1992 to discuss population growth and demographic structure.
	As part of the demographic background for the meeting provided by
	the UN Population Division, participants were informed that although
	the world population growth rate began to decline in the late 1970s,
	this decline has not yet resulted in declining absolute numbers,
	and the annual increment to the world population was not expected
	to decline to the level that existed in 1985 until the period 2020-25.
	World population increased from 2.5 billion in 1950 to 5.3 billion
	in 1990. The medium variant population projection of the UN shows
	world population at 6.3 billion in 2000 and 8.5 billion in 2025 (the
	high variant shows 9.4 billion in 2025 and the low variant shows
	7.6 billion). Population aging is expected to reach unparalleled
	levels in 2010-20. The meeting then considered the topics of population
	growth and socioeconomic development, confronting poverty in developing
	countries, demographic impacts of development patterns, demographic
	and health transitions, population growth and employment, social
	change and the elderly in developing countries, and social development
	and ageing in developed countries, The expert group meeting then
	prepared 19 recommendations aimed at governments, social institutions,
	and the international community. The recommendations call for political
	commitment to human resources development and population and development
	programs, especially in least developed countries, alleviation of
	poverty and social inequality, and equality of access to social and
	health resources that will lead to reduced mortality and fertility.
	Governments are urged to place a high priority on education and on
	increasing women's access to education and to remove barriers to
	economic independence for women. Health-sector priorities should
	be reassessed to provide the most cost-effective and efficient means
	of providing health care, reproductive health-care programs should
	receive high priority, and efforts should be made to minimize the
	effects of HIV infection and reduce the spread of AIDS. The needs
	of the elderly should be met with a "safety net," which should be
	developed in countries with no social security programs. The elderly
	should be recognized as an important human resource for development,
	and intergenerational equity should exist to accommodate their needs,
	with special efforts made to help them remain in their own homes
	and communities. Governments should collect accurate, comprehensive,
	and regular data on population characteristics and trends, and the
	international community should facilitate the comparative analysis
	of such data. Training should be provided to professionals in demography
	and related fields in developing countries.},
  keywords = {Adult; Age Factors; Aged; Communication; Demography; Developed Countries;
	Developing Countries; Economics; Employment; Forecasting; Group Processes;
	Health; International Agencies; Organizations; Population; Population
	Characteristics; Population Dynamics; Population Growth; Poverty;
	Research; Social Change; Social Sciences; Socioeconomic Factors;
	Statistics as Topic; United Nations},
  language = {eng},
  medline-pst = {ppublish},
  owner = {pl4},
  pmid = {12287711},
  timestamp = {2013.05.29}
}

@ARTICLE{Extramural1990,
  title = {{M}easurement of progress against cancer. {E}xtramural {C}ommittee
	to {A}ssess {M}easures of {P}rogress {A}gainst {C}ancer.},
  journal = {J Natl Cancer Inst},
  year = {1990},
  volume = {82},
  pages = {825--835},
  number = {10},
  month = {May},
  abstract = {The questions of the extent of progress against cancer and how to
	measure it have stimulated attention among scientists and in Congress.
	In this presentation, we summarize a report requested by the Senate
	Appropriations Committee to address the adequacy of the existing
	measures of progress against cancer. The report was prepared by an
	extramural committee convened by the National Cancer Institute at
	the request of Congress. It includes extensive findings and recommendations
	on the existing measures of progress against cancer, the systems
	used to develop the data reported through the measures, the frequency
	and content of reports addressing progress, and the need for analytic
	research on this topic. Although the Extramural Committee To Assess
	Measures of Progress Against Cancer found the measures and systems
	to be generally adequate, they also found that modification or expansion
	of the information base is needed in many areas.},
  owner = {PaulD},
  pmid = {2332901},
  timestamp = {2006.03.31}
}

@Article{Rachet2008,
  author          = {Rachet, B and Woods, L M and Mitry, E and Riga, M and Cooper, N and Quinn, M J and Steward, J and Brenner, H and Est{\AA}Â¨ve, J and Sullivan, R and Coleman, M P},
  title           = {Cancer survival in {E}ngland and {Wales} at the end of the 20th century.},
  year            = {2008},
  volume          = {99 Suppl 1},
  month           = {Sep},
  pages           = {S2--10},
  issn            = {1532-1827},
  doi             = {10.1038/sj.bjc.6604571},
  abstract        = {Survival has risen steadily since the 1970s for most cancers in adults in England and Wales, but persistent inequalities exist between those living in affluent and deprived areas. These differences are not seen for children. For many of the common adult cancers, these inequalities in survival (the 'deprivation gap') became more marked in the 1990s. This volume presents extended analyses of survival for adults diagnosed during the 14 years 1986-1999 and followed up to 2001, including trends in overall survival in England and Wales and trends in the deprivation gap in survival. The analyses include individual tumour data for 2.2 million cancer patients. This article outlines the structure of the supplement - an article for each of the 20 most common cancers in adults, followed by an expert commentary from one of the leading UK clinicians specialising in malignancies of that organ or system. The available data, quality control and methods of analysis are described here, rather than repeated in each of the 20 articles. We open the discussion between clinicians and epidemiologists on how to interpret the observed trends and inequalities in cancer survival, and we highlight some of the most important contrasts in these very different points of view. Survival improved substantially for adult cancer patients in England and Wales up to the end of the 20th century. Although socioeconomic inequalities in survival are remarkably persistent, the overall patterns suggest that these inequalities are largely avoidable.},
  citation-subset = {IM},
  completed       = {2008-10-15},
  country         = {England},
  created         = {2008-09-24},
  issn-linking    = {0007-0920},
  journal         = {British journal of cancer},
  keywords        = {Adolescent; Adult; Aged; Aged, 80 and over; England, epidemiology; Female; Forecasting; History, 20th Century; Humans; Male; Middle Aged; Neoplasms, history, mortality; Registries; Social Class; Survival Analysis; Wales, epidemiology},
  nlm             = {PMC2557545},
  nlm-id          = {0370635},
  owner           = {NLM},
  pii             = {6604571},
  pmc             = {PMC2557545},
  pmid            = {18813248},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2016-10-19},
  timestamp       = {2017.01.20},
}

@Article{Rachet2009,
  author          = {Rachet, Bernard and Maringe, Camille and Nur, Ula and Quaresma, Manuela and Shah, Anjali and Woods, Laura M and Ellis, Libby and Walters, Sarah and Forman, David and Steward, John and Coleman, Michel P},
  title           = {Population-based cancer survival trends in {E}ngland and {W}ales up to 2007: an assessment of the {NHS} cancer plan for {E}ngland.},
  year            = {2009},
  volume          = {10},
  issue           = {4},
  month           = {Apr},
  pages           = {351--369},
  issn            = {1474-5488},
  doi             = {10.1016/S1470-2045(09)70028-2},
  abstract        = {The National Health Service (NHS) cancer plan for England was published in 2000, with the aim of improving the survival of patients with cancer. By contrast, a formal cancer strategy was not implemented in Wales until late 2006. National data on cancer patient survival in England and Wales up to 2007 thus offer the opportunity for a first formal assessment of the cancer plan in England, by comparing survival trends in England with those in Wales before, during, and after the implementation of the plan. We analysed population-based survival in 2.2 million adults diagnosed with one of 21 common cancers in England and Wales during 1996-2006 and followed up to Dec 31, 2007. We defined three calendar periods: 1996-2000 (before the cancer plan), 2001-03 (initialisation), and 2004-06 (implementation). We estimated year-on-year trends in 1-year relative survival for patients diagnosed during each period, and changes in those trends between successive periods in England and separately in Wales. Changes between successive periods in mean survival up to 5 years after diagnosis were analysed by country and by government office region of England. Life tables for single year of age, sex, calendar year, deprivation category, and government office region were used to control for background mortality in all analyses. 1-year survival in England and Wales improved for most cancers in men and women diagnosed during 1996-2006 and followed until 2007, although not all trends were significant. Annual trends were generally higher in Wales than in England during 1996-2000 and 2001-03, but higher in England than in Wales during 2004-06. 1-year survival for patients diagnosed in 2006 was over 60% for 12 of 17 cancers in men and 13 of 18 cancers in women. Differences in 3-year survival trends between England and Wales were less marked than the differences in 1-year survival. North-South differences in survival trends for the four most common cancers were not striking, but the North West region and Wales showed the smallest improvements during 2001-03 and 2004-06. The findings indicate slightly faster improvement in 1-year survival in England than in Wales during 2004-06, whereas the opposite was true during 2001-03. This reversal of survival trends in 2001-03 and 2004-06 between England and Wales is much less obvious for 3-year survival. These different patterns of survival suggest some beneficial effect of the NHS cancer plan for England, although the data do not so far provide a definitive assessment of the effectiveness of the plan.},
  citation-subset = {IM},
  completed       = {2009-04-21},
  country         = {England},
  created         = {2009-04-03},
  issn-linking    = {1470-2045},
  journal         = {The Lancet. Oncology},
  keywords        = {Delivery of Health Care; England, epidemiology; Female; Humans; Male; National Health Programs, statistics & numerical data; Neoplasms, mortality; Survival Rate; Time Factors; Wales, epidemiology},
  nlm-id          = {100957246},
  owner           = {NLM},
  pii             = {S1470-2045(09)70028-2},
  pmid            = {19303813},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2015-07-08},
  timestamp       = {2017.01.20},
}

@Article{Rachet2010,
  author          = {Rachet, B and Ellis, L and Maringe, C and Chu, T and Nur, U and Quaresma, M and Shah, A and Walters, S and Woods, L and Forman, D and Coleman, M P},
  title           = {Socioeconomic inequalities in cancer survival in {E}ngland after the {NHS} cancer plan.},
  year            = {2010},
  volume          = {103},
  issue           = {4},
  month           = {Aug},
  pages           = {446--453},
  issn            = {1532-1827},
  doi             = {10.1038/sj.bjc.6605752},
  abstract        = {Socioeconomic inequalities in survival were observed for many cancers in England during 1981-1999. The NHS Cancer Plan (2000) aimed to improve survival and reduce these inequalities. This study examines trends in the deprivation gap in cancer survival after implementation of the Plan. We examined relative survival among adults diagnosed with 1 of 21 common cancers in England during 1996-2006, followed up to 31 December 2007. Three periods were defined: 1996-2000 (before the Cancer Plan), 2001-2003 (initialisation) and 2004-2006 (implementation). We estimated the difference in survival between the most deprived and most affluent groups (deprivation gap) at 1 and 3 years after diagnosis, and the change in the deprivation gap both within and between these periods. Survival improved for most cancers, but inequalities in survival were still wide for many cancers in 2006. Only the deprivation gap in 1-year survival narrowed slightly over time. A majority of the socioeconomic disparities in survival occurred soon after a cancer diagnosis, regardless of the cancer prognosis. The recently observed reduction in the deprivation gap was minor and limited to 1-year survival, suggesting that, so far, the Cancer Plan has little effect on those inequalities. Our findings highlight that earlier diagnosis and rapid access to optimal treatment should be ensured for all socioeconomic groups.},
  citation-subset = {IM},
  completed       = {2010-09-01},
  country         = {England},
  created         = {2010-08-10},
  issn-linking    = {0007-0920},
  journal         = {British journal of cancer},
  keywords        = {Adolescent; Adult; Aged; Aged, 80 and over; England, epidemiology; Health Planning; Health Policy; Health Status Disparities; Healthcare Disparities, statistics & numerical data; Humans; Middle Aged; Neoplasms, diagnosis, mortality, therapy; Socioeconomic Factors; State Medicine; Survival Analysis; Young Adult},
  nlm             = {PMC2939774},
  nlm-id          = {0370635},
  owner           = {NLM},
  pii             = {6605752},
  pmc             = {PMC2939774},
  pmid            = {20588275},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2016-11-22},
  timestamp       = {2017.01.20},
}

@Report{nhsplan2000,
  author    = {{Department of Health}},
  title     = {The {NHS} cancer plan. {L}ondon: Department of health},
  file      = {:pdf\\nhsPlan2000.pdf:PDF},
  owner     = {BettyS},
  timestamp = {2017.01.20},
  year      = {2000},
}

@Report{strategy2011,
  author    = {{Department of Health}},
  date      = {2011},
  title     = {Improving outcomes: A strategy for cancer. {L}ondon: Department of health, 2011},
  file      = {:pdf\\Strategy2011.pdf:PDF},
  owner     = {BettyS},
  timestamp = {2017.01.20},
}

@Article{Lyratzopoulos2010,
  author          = {Lyratzopoulos, Georgios and Barbiere, Josephine M and Greenberg, David C and Wright, Karen A and Neal, David E},
  title           = {Population based time trends and socioeconomic variation in use of radiotherapy and radical surgery for prostate cancer in a UK region: continuous survey.},
  year            = {2010},
  volume          = {340},
  month           = {Apr},
  pages           = {c1928},
  issn            = {1756-1833},
  doi             = {10.1136/bmj.c1928},
  abstract        = {To examine variation in the management of prostate cancer in patients with different socioeconomic status. Survey using UK regional cancer registry data. Regional population based cancer registry. 35 171 patients aged >or=51 with a diagnosis of prostate cancer, 1995-2006. Use of radiotherapy and radical surgery. Socioeconomic status according to fifths of small area deprivation index. Over the nine years of the study, information on stage at diagnosis was available for 15 916 of 27 970 patients (57%). During the study period, the proportion of patients treated with radiotherapy remained at about 25%, while use of radical surgery increased significantly (from 2.9% (212/7201) during 1995-7 to 8.4% (854/10 211) during 2004-6, P<0.001). Both treatments were more commonly used in least deprived compared with most deprived patients (28.5% v 21.0% for radiotherapy and 8.4% v 4.0% for surgery). In multivariable analysis, increasing deprivation remained strongly associated with lower odds of radiotherapy or surgery (odds ratio 0.92 (95% confidence interval 0.90 to 0.94), P<0.001, and 0.91 (0.87 to 0.94), P<0.001, respectively, per incremental deprivation group). There were consistently concordant findings with multilevel models for clustering of observations by hospital of diagnosis, with restriction of the analysis to patients with information on stage, and with sequential restriction of the analysis to different age, stage, diagnosis period, and morphology groups. After a diagnosis of prostate cancer, men from lower socioeconomic groups were substantially less likely to be treated with radical surgery or radiotherapy. The causes and impact on survival of such differences remain uncertain.},
  citation-subset = {AIM, IM},
  completed       = {2010-05-11},
  country         = {England},
  created         = {2010-04-23},
  file            = {Lyratzopoulos2010.pdf:Lyratzopoulos2010.pdf:PDF},
  issn-linking    = {0959-535X},
  journal         = {BMJ (Clinical research ed.)},
  keywords        = {Age Distribution; Aged; Aged, 80 and over; Delivery of Health Care, trends; England; Humans; Male; Middle Aged; Prostatic Neoplasms, economics, radiotherapy, surgery; Residence Characteristics; Socioeconomic Factors},
  nlm             = {PMC2858795},
  nlm-id          = {8900488},
  owner           = {NLM},
  pii             = {bmj.c1928},
  pmc             = {PMC2858795},
  pmid            = {20413566},
  pubmodel        = {Electronic},
  pubstatus       = {epublish},
  revised         = {2016-11-22},
  timestamp       = {2017.01.20},
}

@Article{Riaz2011,
  author          = {Riaz, Sharma P and Horton, Marie and Kang, Jagdip and Mak, Vivian and L{\"u}chtenborg, Margreet and M\oller, Henrik},
  title           = {Lung cancer incidence and survival in {E}ngland: an analysis by socioeconomic deprivation and urbanization.},
  journal         = {Journal of Thoracic Oncology},
  year            = {2011},
  volume          = {6},
  issue           = {12},
  pages           = {2005--2010},
  issn            = {1556-1380},
  doi             = {10.1097/JTO.0b013e31822b02db},
  abstract        = {Most previous studies have investigated either socioeconomic deprivation or urbanization in relationship to lung cancer incidence or survival. We investigated the association between socioeconomic deprivation, urbanization, and lung cancer incidence and survival in England. We extracted data on patients diagnosed with lung cancer (ICD-10 C33-C34) between 2003 and 2007 and who were resident in England. We assigned each patient to an urbanization score and to a socioeconomic quintile based on their postcode of residence. We calculated age-specific and age-standardized incidence rates (per 100,000 European standard population) by urbanization, sex, and socioeconomic deprivation group. We used Kaplan-Meier survival analysis to compare the survival of patients from urban and rural areas by socioeconomic deprivation. A high proportion of urban areas in England were classified as deprived and rural areas were mostly affluent. The incidence of lung cancer was higher in urban areas than in rural areas. In the more affluent areas, the incidence of lung cancer in urban and rural areas was very similar. Survival from lung cancer was slightly higher in affluent areas than in deprived areas. Survival from lung cancer in urban and rural areas was similar across all socioeconomic deprivation quintiles. The difference in incidence between urban and rural areas can be explained by the differences in the distribution of socioeconomic deprivation quintiles in the two urbanization categories. When socioeconomic deprivation is taken into account, little difference is seen between both the incidence and survival of lung cancer in urban and rural areas.},
  citation-subset = {IM},
  completed       = {2012-04-11},
  country         = {United States},
  created         = {2011-11-17},
  file            = {Riaz2011.pdf:Riaz2011.pdf:PDF},
  issn-linking    = {1556-0864},
  keywords        = {Female; Humans; Incidence; Kaplan-Meier Estimate; Lung Neoplasms, epidemiology, mortality; Male; Poverty, statistics & numerical data; Rural Population, statistics & numerical data; Socioeconomic Factors; United Kingdom; Urban Population, statistics & numerical data},
  nlm-id          = {101274235},
  owner           = {NLM},
  pii             = {S1556-0864(15)31724-X},
  pmid            = {21892107},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2016-11-25},
  timestamp       = {2017.01.20},
}

@Article{Davies2013,
  author          = {Davies, Elizabeth A and Renshaw, Christine and Dixon, Steve and M{\AA}Â¸ller, Henrik and Coupland, Victoria H},
  title           = {Socioeconomic and ethnic inequalities in screen-detected breast cancer in London.},
  year            = {2013},
  volume          = {35},
  issue           = {4},
  month           = {Dec},
  pages           = {607--615},
  issn            = {1741-3850},
  doi             = {10.1093/pubmed/fdt002},
  abstract        = {We investigated socioeconomic and ethnic inequalities in screen-detected breast cancer in London-a city with relatively low breast cancer screening uptake and a diverse population. Data on 11 957 breast cancers in London women aged 50-64 between 1998 and 2005 were extracted from the Thames Cancer Registry. We investigated the relationship between socioeconomic deprivation and the incidence and 5-year relative survival of screen-detected and non screen-detected cancers. Using logistic regression analysis we explored whether differences in screen-detected cancers between White, Asian and Black women were influenced by age and socioeconomic deprivation. The incidence of screen-detected breast cancer was lower in deprived women and their 5-year relative survival was worse than affluent women. However, survival differences were smaller for screen-detected disease. Among women with breast cancer the odds ratios (OR) for screen-detected disease differed between ethnic groups and these differences were not influenced by adjustment for age and deprivation. Compared with White women, Indian women had higher odds (OR 1.50, 95% confidence interval (1.23-1.84)], and Black Caribbean [0.68 (0.54-0.87)] and Black African women [0.53 (0.38-0.76)] significantly lower odds. A sustained focus on increasing screening uptake among deprived women and in Black communities could decrease inequalities in early diagnosis.},
  citation-subset = {IM},
  completed       = {2014-08-13},
  country         = {England},
  created         = {2013-12-02},
  file            = {Davies2013.pdf:Davies2013.pdf:PDF},
  issn-linking    = {1741-3842},
  journal         = {Journal of public health (Oxford, England)},
  keywords        = {African Continental Ancestry Group, statistics & numerical data; Breast Neoplasms, diagnosis, epidemiology, mortality; Early Detection of Cancer, statistics & numerical data; Ethnic Groups, statistics & numerical data; European Continental Ancestry Group, statistics & numerical data; Female; Healthcare Disparities, ethnology, statistics & numerical data; Humans; Incidence; India, ethnology; Logistic Models; London, epidemiology; Middle Aged; Poverty, statistics & numerical data; Socioeconomic Factors; Survival Analysis; cancer; ethnicity; socioeconomics factors},
  nlm-id          = {101188638},
  owner           = {NLM},
  pii             = {fdt002},
  pmid            = {23440707},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2013-12-02},
  timestamp       = {2017.01.20},
}

@Article{Fairley2009,
  author          = {Fairley, L and Baker, M and Whiteway, J and Cross, W and Forman, D},
  title           = {Trends in non-metastatic prostate cancer management in the {N}orthern and {Y}orkshire region of {E}ngland, 2000-2006.},
  year            = {2009},
  volume          = {101},
  issue           = {11},
  month           = {Dec},
  pages           = {1839--1845},
  issn            = {1532-1827},
  doi             = {10.1038/sj.bjc.6605424},
  abstract        = {Our objective was to analyse variation in non-metastatic prostate cancer management in the Northern and Yorkshire region of England. We included 21,334 men aged > or = 55, diagnosed between 2000 and 2006. Principal treatment received was categorised into radical prostatectomy (11%), brachytherapy (2%), external beam radiotherapy (16%), hormone therapy (42%) and no treatment (29%). The odds ratio (OR) for receiving a radical prostatectomy was 1.53 in 2006 compared with 2000 (95% CI 1.26-1.86), whereas the OR for receiving hormone therapy was 0.57 (0.51-0.64). Age was strongly associated with treatment received; radical treatments were significantly less likely in men aged > or = 75 compared with men aged 55-64 years, whereas the odds of receiving hormone therapy or no treatment were significantly higher in the older age group. The OR for receiving radical prostatectomy, brachytherapy or external beam radiotherapy were all significantly lower in the most deprived areas when compared with the most affluent (0.64 (0.55-0.75), 0.32 (0.22-0.47) and 0.83 (0.74-0.94), respectively) whereas the OR for receiving hormone therapy was 1.56 (1.42-1.71). This study highlights the variation and inequalities that exist in the management of non-metastatic prostate cancer in the Northern and Yorkshire region of England.},
  citation-subset = {IM},
  completed       = {2009-12-23},
  country         = {England},
  created         = {2009-11-25},
  file            = {Fairley2009.pdf:Fairley2009.pdf:PDF},
  issn-linking    = {0007-0920},
  journal         = {British journal of cancer},
  keywords        = {Aged; Brachytherapy, trends; England; Humans; Male; Middle Aged; Neoplasm Staging; Prostatectomy, trends; Prostatic Neoplasms, drug therapy, radiotherapy, surgery, therapy; Radiotherapy, Adjuvant, trends; Registries; Treatment Outcome},
  nlm             = {PMC2788251},
  nlm-id          = {0370635},
  owner           = {NLM},
  pii             = {6605424},
  pmc             = {PMC2788251},
  pmid            = {19904264},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2014-12-04},
  timestamp       = {2017.01.20},
}

@Article{Downing2007,
  author          = {Downing, A and Prakash, K and Gilthorpe, M S and Mikeljevic, J S and Forman, D},
  title           = {Socioeconomic background in relation to stage at diagnosis, treatment and survival in women with breast cancer.},
  year            = {2007},
  volume          = {96},
  issue           = {5},
  month           = {Mar},
  pages           = {836--840},
  issn            = {0007-0920},
  doi             = {10.1038/sj.bjc.6603622},
  abstract        = {In a large population-based series of invasive breast cancer patients, we investigated socioeconomic background (SEB) in relation to (a) stage at diagnosis; (b) treatment pattern; and (c) 5-year survival. Women diagnosed during 1998-2000 and resident in the Northern and Yorkshire regions of England were identified from the cancer registry database (N=12,768). Logistic regression and Cox proportional hazards analyses were used to estimate associations between SEB (defined using the Townsend Index for area of residence) and tumour stage, treatment pattern, and survival. Living in a more deprived area was associated with increased likelihood of being diagnosed with stage III or IV disease (age-adjusted odds ratio (OR) 1.13; 95% confidence interval (CI) 1.08-1.18 per quartile increase in Townsend score), and, after adjustment for age and stage, reduced odds of having surgery (OR 0.85; 95% CI 0.80-0.91), and receiving radiotherapy (OR 0.91; 95% CI 0.88-0.94). Amongst patients receiving surgery, those living in more deprived areas had decreased odds of having breast conserving surgery (age plus stage-adjusted OR 0.92; 95% CI 0.89-0.95). Living in a more deprived area was also associated with increased mortality (age- plus stage-adjusted hazard ratio 1.08; 95% CI 1.05-1.11). These effects may operate through several pathways, such as later presentation leading to advanced disease.},
  citation-subset = {IM},
  completed       = {2007-05-04},
  country         = {England},
  created         = {2007-03-06},
  file            = {Downing2007.pdf:pdf\\Downing2007.pdf:PDF},
  issn-linking    = {0007-0920},
  journal         = {British journal of cancer},
  keywords        = {Aged; Breast Neoplasms, mortality, pathology, therapy; Female; Health Services Accessibility; Humans; Medically Underserved Area; Middle Aged; Neoplasm Staging; Socioeconomic Factors; Survival Analysis; United Kingdom},
  nlm             = {PMC2360059},
  nlm-id          = {0370635},
  owner           = {NLM},
  pii             = {6603622},
  pmc             = {PMC2360059},
  pmid            = {17311024},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2016-11-24},
  timestamp       = {2017.01.20},
}

@Article{Shack2008,
  author          = {Shack, Lorraine and Jordan, Catrina and Thomson, Catherine S and Mak, Vivian and M{\AA}Â¸ller, Henrik and UK Association of Cancer Registries},
  title           = {Variation in incidence of breast, lung and cervical cancer and malignant melanoma of skin by socioeconomic group in {E}ngland.},
  doi             = {10.1186/1471-2407-8-271},
  issn            = {1471-2407},
  pages           = {271},
  volume          = {8},
  abstract        = {Cancer incidence varies by socioeconomic group and these variations have been linked with environmental and lifestyle factors, differences in access to health care and health seeking behaviour. Socioeconomic variations in cancer incidence by region and age are less clearly understood but they are crucial for targeting prevention measures and health care commissioning. Data were obtained from all eight English cancer registries for patients diagnosed between 1998 and 2003, for all invasive cases of female breast cancer (ICD-10 code C50), lung cancer (ICD-10 codes C33-C34), cervical cancer (ICD-10 code C53), and malignant melanoma of the skin (ICD-10 code C43). Socioeconomic status was assigned to each patient based on their postcode of residence at diagnosis, using the income domain of the Index of Multiple Deprivation 2004. We analysed the socioeconomic variations in the incidence of breast, lung and cervical cancer and malignant melanoma of the skin for England, and regionally and by age. Incidence was highest for the most deprived patients for lung cancer and cervical cancer, whilst the opposite was observed for malignant melanoma and breast cancer. The difference in incidence between the most and the least deprived groups was higher for lung cancer patients aged under 65 at diagnosis than those over 65 at diagnosis, which may indicate a cohort effect. There were regional differences in the socioeconomic gradients with the gap being widest for lung and cervical cancer in the North (North East, North West and Yorkshire and Humberside) and for malignant melanoma in the East and South West. There were only modest variations in breast cancer incidence by region. If the incidence of lung and cervical cancer were decreased to that of the least deprived group it would prevent 36% of lung cancer cases in men, 38% of lung cancer cases in women and 28% of cervical cancer cases. Incidence of breast cancer and melanoma was highest in the least deprived group, therefore if all socioeconomic groups had incidence rates similar to the least deprived group it is estimated that the number of cases would increase by 7% for breast cancer, 27% for melanoma in men and 29% for melanoma in women. National comparison of socioeconomic variations in cancer incidence by region and age can provide an unbiased basis for public health prevention and health commissioning. Decreasing inequalities in incidence requires the integration of information on risk factors, incidence and projected incidence but targeted public health interventions could help to reduce regional inequalities in incidence and reduce the future cancer burden.},
  citation-subset = {IM},
  completed       = {2008-11-18},
  country         = {England},
  created         = {2008-11-03},
  file            = {Shack2008.pdf:pdf\\Shack2008.pdf:PDF},
  issn-linking    = {1471-2407},
  journal         = {BMC cancer},
  keywords        = {Adult; Age Factors; Aged; Aged, 80 and over; Breast Neoplasms, epidemiology, mortality, pathology; England; Female; Humans; Incidence; Income; Lung Neoplasms, pathology; Male; Melanoma, pathology; Middle Aged; Neoplasm Staging; Papillomavirus Infections, mortality; Risk Factors; Skin Neoplasms, pathology; Smoking; Social Class; Sunlight; Uterine Cervical Neoplasms, pathology},
  month           = {Sep},
  nlm             = {PMC2577116},
  nlm-id          = {100967800},
  owner           = {NLM},
  pii             = {1471-2407-8-271},
  pmc             = {PMC2577116},
  pmid            = {18822122},
  pubmodel        = {Electronic},
  pubstatus       = {epublish},
  revised         = {2014-09-03},
  timestamp       = {2017.01.20},
  year            = {2008},
}

@Report{DeprivationIndices2004,
  author    = {{ Neighbourhood Renewal Unit}},
  date      = {2004},
  title     = {The {E}nglish Indices of {D}eprivation 2004 (revised). {L}ondon: {O}ffice of the {D}eputy {P}rime {M}inister, 2004},
  file      = {:pdf\\DeprivationIndices2004.pdf:PDF},
  owner     = {BettyS},
  timestamp = {2017.01.20},
}

@Report{Ict2015,
  author    = {{Independent Cancer Taskforce}},
  title     = {Achieving word-class cancer outcomes: A strategy for {E}ngland 2015-2020, 2015},
  file      = {:pdf\\Ict2015.pdf:PDF},
  owner     = {BettyS},
  timestamp = {2017.01.20},
}

@Article{Morris2016,
  author       = {Morris, Melanie and Woods, Laura M and Rachet, Bernard},
  title        = {What might explain deprivation-specific differences in the excess hazard of breast cancer death amongst screen-detected women? Analysis of patients diagnosed in the West Midlands region of England from 1989 to 2011.},
  year         = {2016},
  volume       = {7},
  issue        = {31},
  month        = {Aug},
  pages        = {49939--49947},
  issn         = {1949-2553},
  doi          = {10.18632/oncotarget.10255},
  abstract     = {Breast cancer survival is higher in less deprived women, even amongst women whose tumor was screen-detected, but reasons behind this have not been comprehensively investigated. The excess hazard of breast cancer death in 20,265 women diagnosed with breast cancer, followed up to 2012, was estimated for screen-detected and non-screen-detected women, comparing more deprived to less deprived women using flexible parametric models. Models were adjusted for individual and tumor factors, treatment received and comorbidity. For screen-detected women, estimates were also corrected for lead-time and overdiagnosis. The excess hazard ratio (EHR) of breast cancer death in the most deprived group, adjusted only for age and year of diagnosis, was twice that of the least deprived among screen-detected women (EHR=2.12, 95%CI 1.48-2.76) and 64% higher among non-screen-detected women (EHR=1.64, 95%CI 1.41-1.87). Adjustment for stage at diagnosis lowered these estimates by 25%. Further adjustment had little extra impact. In the final models, the excess hazard for the most deprived women was 54% higher (EHR=1.54, 95%CI 1.10-1.98) among screen-detected women and 39% higher (EHR=1.39, 95%CI 1.20-1.59) among non-screen-detected women. A persistent socio-economic gradient in breast cancer-related death exists in this cohort, even for screen-detected women. The impact of differential lifestyles, management and treatment warrant further investigation.},
  country      = {United States},
  created      = {2016-06-30},
  issn-linking = {1949-2553},
  journal      = {Oncotarget},
  keywords     = {breast cancer; early diagnosis; population-based; socioeconomic inequalities; survival analysis},
  nlm-id       = {101532965},
  owner        = {NLM},
  pii          = {10255},
  pmc          = {PMC5226559},
  pmid         = {27363022},
  pubmodel     = {Print},
  pubstatus    = {ppublish},
  revised      = {2017-01-19},
  timestamp    = {2017.01.27},
}

@WWW{CRUKtables,
  author    = {Spika, D, and Rachet, B, and Bannon, F and Woods, LM, and Maringe, C and Bonaventure, A and Coleman, MP and Allemani, C.},
  title     = {Life tables for the CONCORD-2 study. {A}vailable from: http://csg.lshtm.ac.uk/life-tables.},
  url       = {http://csg.lshtm.ac.uk/life-tables},
  owner     = {BettyS},
  timestamp = {2017.02.06},
}

@Article{Sprague2011,
  author          = {Sprague, Brian L and Trentham-Dietz, Amy and Gangnon, Ronald E and Ramchandani, Ritesh and Hampton, John M and Robert, Stephanie A and Remington, Patrick L and Newcomb, Polly A},
  title           = {Socioeconomic status and survival after an invasive breast cancer diagnosis.},
  year            = {2011},
  volume          = {117},
  issue           = {7},
  month           = {Apr},
  pages           = {1542--1551},
  issn            = {0008-543X},
  doi             = {10.1002/cncr.25589},
  abstract        = {Women who live in geographic areas with high poverty rates and low levels of education experience poorer survival after a breast cancer diagnosis than women who live in communities with indicators of high socioeconomic status (SES). However, very few studies have examined individual-level SES in relation to breast cancer survival or have assessed the contextual role of community-level SES independent of individual-level SES. The authors of this report examined both individual-level and community-level SES in relation to breast cancer survival in a population-based cohort of women ages 20 to 69 years who were diagnosed with breast cancer in Wisconsin between 1995 and 2003 (N = 5820). Compared with college graduates, women who had no education beyond high school were 1.39 times more likely (95% confidence interval [CI], 1.10-1.76) to die from breast cancer. Women who had household incomes <2.5 times the poverty level were 1.46 times more likely (95% CI, 1.10-1.92) to die from breast cancer than women who had household incomes ?5 times the poverty level. Adjusting the analysis for use of screening mammography, disease stage at diagnosis, and lifestyle factors eliminated the disparity by income, but the disparity by education persisted (hazard ratio [HR], 1.27; 95% CI, 0.99-1.61). In multilevel analyses, low community-level education was associated with increased breast cancer mortality even after adjusting for individual-level SES (HR, 1.57; 95% CI, 1.09-2.27 for ?20% vs <10% of adults without a high school degree). The current results indicated that screening and early detection explain some of the disparity according to SES, but further research will be needed to understand the additional ways in which individual-level and community-level education are associated with survival.},
  citation-subset = {AIM, IM},
  completed       = {2011-05-03},
  country         = {United States},
  created         = {2011-03-22},
  issn-linking    = {0008-543X},
  journal         = {Cancer},
  keywords        = {Adult; Aged; Breast Neoplasms, diagnosis, mortality; Early Detection of Cancer; Educational Status; Female; Health Care Surveys; Healthcare Disparities; Humans; Middle Aged; Poverty; Residence Characteristics; Social Class},
  mid             = {NIHMS225856},
  nlm             = {PMC3116955},
  nlm-id          = {0374236},
  owner           = {NLM},
  pmc             = {PMC3116955},
  pmid            = {21425155},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2016-11-22},
  timestamp       = {2017.02.06},
}

@Article{VanderHeyden2009,
  author          = {Van der Heyden, J H A and Schaap, M M and Kunst, A E and Esnaola, S and Borrell, C and Cox, B and Leinsalu, M and Stirbu, I and Kalediene, R and Deboosere, P and Mackenbach, J P and Van Oyen, H},
  title           = {Socioeconomic inequalities in lung cancer mortality in 16 European populations.},
  year            = {2009},
  volume          = {63},
  issue           = {3},
  month           = {Mar},
  pages           = {322--330},
  issn            = {0169-5002},
  doi             = {10.1016/j.lungcan.2008.06.006},
  abstract        = {This paper aims to describe socioeconomic inequalities in lung cancer mortality in Europe and to get further insight into socioeconomic inequalities in lung cancer mortality in different European populations by relating these to socioeconomic inequalities in overall mortality and smoking within the same or reference populations. Particular attention is paid to inequalities in Eastern European and Baltic countries. Data were obtained from mortality registers, population censuses and health interview surveys in 16 European populations. Educational inequalities in lung cancer and total mortality were assessed by direct standardization and calculation of two indices of inequality: the Relative Index of Inequality (RII) and the Slope Index of Inequality (SII). SIIs were used to calculate the contribution of inequalities in lung cancer mortality to inequalities in total mortality. Indices of inequality in lung cancer mortality in the age group 40-59 years were compared with indices of inequalities in smoking taking into account a time lag of 20 years. The pattern of inequalities in Eastern European and Baltic countries is more or less similar as the one observed in the Northern countries. Among men educational inequalities are largest in the Eastern European and Baltic countries. Among women they are largest in Northern European countries. Whereas among Southern European women lung cancer mortality rates are still higher among the high educated, we observe a negative association between smoking and education among young female adults. The contribution of lung cancer mortality inequalities to total mortality inequalities is in most male populations more than 10%. Important smoking inequalities are observed among young adults in all populations. In Sweden, Hungary and the Czech Republic smoking inequalities among young adult women are larger than lung cancer mortality inequalities among women aged 20 years older. Important socioeconomic inequalities exist in lung cancer mortality in Europe. They are consistent with the geographical spread of the smoking epidemic. In the next decades socioeconomic inequalities in lung cancer mortality are likely to persist and even increase among women. In Southern European countries we may expect a reversal from a positive to a negative association between socioeconomic status and lung cancer mortality. Continuous efforts are necessary to tackle socioeconomic inequalities in lung cancer mortality in all European countries.},
  citation-subset = {IM},
  completed       = {2009-04-08},
  country         = {Ireland},
  created         = {2009-02-09},
  issn-linking    = {0169-5002},
  journal         = {Lung cancer (Amsterdam, Netherlands)},
  keywords        = {Adult; Aged; Europe, epidemiology; Female; Humans; Lung Neoplasms, mortality; Male; Middle Aged; Population Surveillance; Risk Factors; Socioeconomic Factors; Survival Rate, trends},
  nlm-id          = {8800805},
  owner           = {NLM},
  pii             = {S0169-5002(08)00317-6},
  pmid            = {18656277},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2009-02-09},
  timestamp       = {2017.02.06},
}

@Article{Ito2014,
  author          = {Ito, Yuri and Nakaya, Tomoki and Nakayama, Tomio and Miyashiro, Isao and Ioka, Akiko and Tsukuma, Hideaki and Rachet, Bernard},
  title           = {Socioeconomic inequalities in cancer survival: a population-based study of adult patients diagnosed in {O}saka, {J}apan, during the period 1993-2004.},
  year            = {2014},
  volume          = {53},
  issue           = {10},
  month           = {Oct},
  pages           = {1423--1433},
  issn            = {1651-226X},
  doi             = {10.3109/0284186X.2014.912350},
  abstract        = {Long-term recession of the Japanese economy during the 1990s led to growing social inequalities whilst health inequalities also appeared. The 2007 National Cancer Control Program of Japan targeted "equalisation of cancer medical services", but the system to monitor health inequalities was still inadequate. We aimed to measure socioeconomic inequalities in cancer survival in Japan. We analysed 13 common invasive, primary, malignant tumours diagnosed from 1993 to 2004 and registered by the population-based Cancer Registry of Osaka Prefecture. An ecological socioeconomic deprivation index based on small area statistics, divided into quintile groups, was linked to patients according to their area of residence at the time of diagnosis. We estimated one-, five-year and conditional five-year net survival by sex, period of diagnosis (1993-1996/1997-2000/2001-2004) and deprivation group. Changes in survival over time, deprivation gap in survival, and change in deprivation gap were estimated at one and five years after diagnosis using variance-weighted least square regression. The deprivation gap in one-year net survival was narrower than in five-year net survival and conditional five-year survival. During the study period, there was no change in deprivation gap, except for reductions for pancreas (men) and stomach (women), and an increase for lung (men) in one-year survival. We observed a linear association between level of survival and deprivation gap at five years and conditional five years, but no association at one-year survival. A wide deprivation gap in survival was observed in most of the adult, solid, malignant tumours, within the universal healthcare system in Japan. Overall, cancer survival improved in Osaka without any widening of inequalities in cancer survival in 1993-2004, shortly after the long-term economic recession and deep modifications in the social and work environments in Japan. The longer term impact of the recession on inequalities in cancer survival needs to be monitored using population-based cancer registry data.},
  citation-subset = {IM},
  completed       = {2015-04-23},
  country         = {England},
  created         = {2014-10-20},
  issn-linking    = {0284-186X},
  journal         = {Acta oncologica (Stockholm, Sweden)},
  keywords        = {Economic Recession; Female; Humans; Japan, epidemiology; Male; Neoplasms, economics, mortality; Sex Distribution; Small-Area Analysis; Socioeconomic Factors; Survival Analysis},
  nlm-id          = {8709065},
  owner           = {NLM},
  pmid            = {24865119},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2014-10-20},
  timestamp       = {2017.02.06},
}

@Article{Dalton2008,
  author    = {Dalton, Susanne Oksbjerg and Schu{{\AA}Â¼} z, Joachim and Engholm, Gerda and Johansen, Christoffer and Kj{{\AA}Â¦}r, Susanne Kru{{\AA}Â¼}ger and Steding-Jessen, Marianne and Storm, Hans H. and Olsen, J{{\AA}Â¸}rgen H.},
  title     = {Social inequality in incidence of and survival from cancer in a population-based study in Denmark, 1994ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Â“2003: Summary of findings.},
  year      = {2008},
  volume    = {44},
  issue     = {14},
  pages     = {2074 - 2085},
  journal   = {European Journal of Cancer , Volume 44 , Issue 14 , 2074 - 2085},
  owner     = {BettyS},
  timestamp = {2017.02.06},
}

@Article{Verheul1993,
  author          = {Verheul, H A and Dekker, E and Bossuyt, P and Moulijn, A C and Dunning, A J},
  title           = {Background mortality in clinical survival studies.},
  journal         = {Lancet (London, England)},
  year            = {1993},
  volume          = {341},
  number          = {8849},
  issue           = {8849},
  month           = apr,
  pages           = {872--875},
  issn            = {0140-6736},
  doi             = {10.1016/0140-6736(93)93073-a},
  abstract        = {In long-term follow-up studies of survival after an initial event (eg, an operation) mortality from causes other than the one under study obscures the results, especially in elderly patients. In the traditional approach to the calculation of expected mortality a fictitious cohort is drawn from the general population, being matched for age, sex, and calendar time at the time of the initial event. The membership of this cohort is then kept constant from the initial event until the closing date of the study. The survival and mortality of this static cohort is then compared with that of the dynamic patient cohort to throw light on mortality from extraneous causes. This method can lead to severe bias if there is a strong correlation between the duration of observation of the patients and their age. The analysis can be improved by applying rate adjustment when calculating the background component of mortality. In this approach mortality rates from the general population are adjusted (weighted) so that the age, sex, and calendar year are at all times identical with those of each of the patients still alive and under observation. This is illustrated by means of a simplified example and a real-life one from a study at survival after aortic valve replacement. Estimation of rate-adjusted background mortality provides a framework that may put long-term survival, especially of elderly patients, in proper perspective.},
  citation-subset = {AIM, IM},
  completed       = {1993-05-03},
  country         = {England},
  created         = {1993-05-03},
  file            = {:pdf\\Verheul1993.pdf:PDF},
  issn-linking    = {0140-6736},
  keywords        = {Adult; Aged; Aortic Valve; Bias (Epidemiology); Cause of Death; Cohort Studies; Coronary Artery Bypass, mortality; Female; Follow-Up Studies; Health Services Research, methods; Heart Valve Prosthesis, mortality; Humans; Male; Middle Aged; Mortality; Netherlands; Survival Analysis},
  nlm-id          = {2985213R},
  owner           = {NLM},
  pii             = {0140-6736(93)93073-A},
  pmid            = {8096574},
  publisher       = {Elsevier {BV}},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2015-06-16},
  timestamp       = {2017.02.07},
}

@Book{Ibrahim2001,
  author    = {J.G. Ibrahim and M.H. Chen and D. Sinha},
  title     = {Bayesian Survival Analysis},
  publisher = {Springer},
  pubstate  = {New York},
  year      = {2001},
}

@Article{Woods2016,
  author       = {Woods, L M and Morris, M and Rachet, B},
  title        = {No 'cure' within 12 years of diagnosis among breast cancer patients who are diagnosed via mammographic screening: women diagnosed in the {W}est {M}idlands region of {E}ngland 1989-2011.},
  journal      = {Annals of Oncology},
  year         = {2016},
  volume       = {27},
  issue        = {11},
  month        = nov,
  pages        = {2025--2031},
  issn         = {1569-8041},
  doi          = {10.1093/annonc/mdw408},
  abstract     = {We have previously reported that there is little evidence of population 'cure' among two populations of women diagnosed with invasive breast cancer. 'Cure' has not yet been examined in the context of screen-detection. We examined cancer registry data on 19 800 women aged 50-70, diagnosed with a primary, invasive, non-metastatic breast cancer between 1 April 1989 and 31 March 2011 in the West Midlands region of England, linked to Hospital Episode Statistics (HES) and the National Breast Screening Service (NBSS). Follow-up was complete on all women up to 31 July 2012. Analyses were stratified by screening status, age, tumour stage, deprivation and ethnicity. We estimated net survival for the whole cohort and each subgroup. Population 'cure' was evaluated by fitting flexible parametric log-cumulative excess hazard regression models in which the excess hazard of breast cancer death was assumed to be equal to zero after a given follow-up time. There was an overall lack of evidence for 'cure'. Across all subgroups examined, the general pattern was that of a continuous decrease in net survival over time, with no obvious asymptotic tendency within 12 years of follow-up. Model-based analyses confirmed this observation. Despite dramatic improvements in survival over past decades, diagnosis with breast cancer remains associated with a small but persistent increased risk of death for all groups of women, including those whose cancer is detected asymptomatically. These findings are unlikely to be due to methodological inadequacies. Communication of these long-term consequences of breast cancer among women recently diagnosed and to those considering undergoing screening should take due consideration of these patterns.},
  country      = {England},
  created      = {2016-08-30},
  issn-linking = {0923-7534},
  keywords     = {breast cancer; deprivation; early diagnosis; population-based; screen-detection; ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Â˜cureÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Â™},
  nlm-id       = {9007735},
  owner        = {NLM},
  pii          = {mdw408},
  pmc          = {PMC5091325},
  pmid         = {27573567},
  pubmodel     = {Print-Electronic},
  pubstatus    = {ppublish},
  revised      = {2017-02-20},
}

@Article{Studdert2016,
  author          = {Studdert, David M and Bismark, Marie M and Mello, Michelle M and Singh, Harnam and Spittal, Matthew J},
  title           = {Prevalence and Characteristics of Physicians Prone to Malpractice Claims.},
  journal         = {The New England Journal of Medicine},
  year            = {2016},
  volume          = {374},
  issue           = {4},
  pages           = {354--362},
  issn            = {1533-4406},
  doi             = {10.1056/NEJMsa1506137},
  abstract        = {The distribution of malpractice claims among physicians is not well understood. If claim-prone physicians account for a substantial share of all claims, the ability to reliably identify them at an early stage could guide efforts to improve care. Using data from the National Practitioner Data Bank, we analyzed 66,426 claims paid against 54,099 physicians from 2005 through 2014. We calculated concentrations of claims among physicians. We used multivariable recurrent-event survival analysis to identify characteristics of physicians at high risk for recurrent claims and to quantify risk levels over time. Approximately 1% of all physicians accounted for 32% of paid claims. Among physicians with paid claims, 84% incurred only one during the study period (accounting for 68% of all paid claims), 16% had at least two paid claims (accounting for 32% of the claims), and 4% had at least three paid claims (accounting for 12% of the claims). In adjusted analyses, the risk of recurrence increased with the number of previous paid claims. For example, as compared with physicians who had one previous paid claim, the 2160 physicians who had three paid claims had three times the risk of incurring another (hazard ratio, 3.11; 95% confidence interval [CI], 2.84 to 3.41); this corresponded in absolute terms to a 24% chance (95% CI, 22 to 26) of another paid claim within 2 years. Risks of recurrence also varied widely according to specialty--for example, the risk among neurosurgeons was four times as great as the risk among psychiatrists. Over a recent 10-year period, a small number of physicians with distinctive characteristics accounted for a disproportionately large number of paid malpractice claims.},
  citation-subset = {AIM, IM},
  completed       = {2016-02-16},
  country         = {United States},
  created         = {2016-01-28},
  file            = {Studdert2016.pdf:Studdert2016.pdf:PDF},
  issn-linking    = {0028-4793},
  keywords        = {Adult; Female; Humans; Male; Malpractice, statistics & numerical data; Medicine; Middle Aged; Multivariate Analysis; Physicians, statistics & numerical data; Risk; Sex Factors; United States},
  nlm-id          = {0255562},
  owner           = {NLM},
  pmid            = {26816012},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2016-01-28},
}

@Article{Grand2016,
  author          = {Grand, Mia Klinten and Putter, Hein},
  title           = {Regression models for expected length of stay.},
  journal         = {Statistics in Medicine},
  year            = {2016},
  volume          = {35},
  issue           = {7},
  month           = mar,
  pages           = {1178--1192},
  issn            = {1097-0258},
  doi             = {10.1002/sim.6771},
  abstract        = {In multi-state models, the expected length of stay (ELOS) in a state is not a straightforward object to relate to covariates, and the traditional approach has instead been to construct regression models for the transition intensities and calculate ELOS from these. The disadvantage of this approach is that the effect of covariates on the intensities is not easily translated into the effect on ELOS, and it typically relies on the Markov assumption. We propose to use pseudo-observations to construct regression models for ELOS, thereby allowing a direct interpretation of covariate effects while at the same time avoiding the Markov assumption. For this approach, all we need is a non-parametric consistent estimator for ELOS. For every subject (and for every state of interest), a pseudo-observation is constructed, and they are then used as outcome variables in the regression model. We furthermore show how to construct longitudinal (pseudo-) data when combining the concept of pseudo-observations with landmarking. In doing so, covariates are allowed to be time-varying, and we can investigate potential time-varying effects of the covariates. The models can be fitted using generalized estimating equations, and dependence between observations on the same subject is handled by applying the sandwich estimator. The method is illustrated using data from the US Health and Retirement Study where the impact of socio-economic factors on ELOS in health and disability is explored. Finally, we investigate the performance of our approach under different degrees of left-truncation, non-Markovianity, and right-censoring by means of simulation.},
  citation-subset = {IM},
  completed       = {2016-12-27},
  country         = {England},
  created         = {2016-03-02},
  issn-linking    = {0277-6715},
  keywords        = {Aged; Aged, 80 and over; Biostatistics; Computer Simulation; Female; Health Status; Humans; Length of Stay, statistics & numerical data; Male; Models, Statistical; Regression Analysis; Socioeconomic Factors; landmarking; length of stay; multi-state models; pseudo-observations; restricted mean residual life},
  nlm-id          = {8215016},
  owner           = {NLM},
  pmid            = {26497637},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2016-12-30},
}

@Article{Ieva2015,
  author       = {Ieva, Francesca and Jackson, Christopher H and Sharples, Linda D},
  title        = {Multi-state modelling of repeated hospitalisation and death in patients with heart failure: The use of large administrative databases in clinical epidemiology.},
  journal      = {Statistical Methods in Medical Research},
  year         = {2015},
  month        = mar,
  issn         = {1477-0334},
  doi          = {10.1177/0962280215578777},
  abstract     = {In chronic diseases like heart failure (HF), the disease course and associated clinical event histories for the patient population vary widely. To improve understanding of the prognosis of patients and enable health care providers to assess and manage resources, we wish to jointly model disease progression, mortality and their relation with patient characteristics. We show how episodes of hospitalisation for disease-related events, obtained from administrative data, can be used as a surrogate for disease status. We propose flexible multi-state models for serial hospital admissions and death in HF patients, that are able to accommodate important features of disease progression, such as multiple ordered events and competing risks. Fully parametric and semi-parametric semi-Markov models are implemented using freely available software in R. The models were applied to a dataset from the administrative data bank of the Lombardia region in Northern Italy, which included 15,298 patients who had a first hospitalisation ending in 2006 and 4 years of follow-up thereafter. This provided estimates of the associations of age and gender with rates of hospital admission and length of stay in hospital, and estimates of the expected total time spent in hospital over five years. For example, older patients and men were readmitted more frequently, though the total time in hospital was roughly constant with age. We also discuss the relative merits of parametric and semi-parametric multi-state models, and model assessment and comparison.},
  country      = {England},
  created      = {2015-03-30},
  issn-linking = {0962-2802},
  keywords     = {administrative data; competing risks; heart failure; hospital admissions; multi-state models},
  mid          = {EMS67649},
  nlm-id       = {9212457},
  owner        = {NLM},
  pii          = {0962280215578777},
  pmc          = {PMC4964935},
  pmid         = {25817136},
  pubmodel     = {Print-Electronic},
  pubstatus    = {aheadofprint},
  revised      = {2017-02-20},
}

@Article{Meier-Hirmer2013,
  author          = {Meier-Hirmer, Carolina and Schumacher, Martin},
  title           = {Multi-state model for studying an intermediate event using time-dependent covariates: application to breast cancer.},
  journal         = {BMC Medical Research Methodology},
  year            = {2013},
  volume          = {13},
  month           = jun,
  pages           = {80},
  issn            = {1471-2288},
  doi             = {10.1186/1471-2288-13-80},
  abstract        = {The aim of this article is to propose several methods that allow to investigate how and whether the shape of the hazard ratio after an intermediate event depends on the waiting time to occurrence of this event and/or the sojourn time in this state. A simple multi-state model, the illness-death model, is used as a framework to investigate the occurrence of this intermediate event. Several approaches are shown and their advantages and disadvantages are discussed. All these approaches are based on Cox regression. As different time-scales are used, these models go beyond Markov models. Different estimation methods for the transition hazards are presented. Additionally, time-varying covariates are included into the model using an approach based on fractional polynomials. The different methods of this article are then applied to a dataset consisting of four studies conducted by the German Breast Cancer Study Group (GBSG). The occurrence of the first isolated locoregional recurrence (ILRR) is studied. The results contribute to the debate on the role of the ILRR with respect to the course of the breast cancer disease and the resulting prognosis. We have investigated different modelling strategies for the transition hazard after ILRR or in general after an intermediate event. Including time-dependent structures altered the resulting hazard functions considerably and it was shown that this time-dependent structure has to be taken into account in the case of our breast cancer dataset. The results indicate that an early recurrence increases the risk of death. A late ILRR increases the hazard function much less and after the successful removal of the second tumour the risk of death is almost the same as before the recurrence. With respect to distant disease, the appearance of the ILRR only slightly increases the risk of death if the recurrence was treated successfully. It is important to realize that there are several modelling strategies for the intermediate event and that each of these strategies has restrictions and may lead to different results. Especially in the medical literature considering breast cancer development, the time-dependency is often neglected in the statistical analyses. We show that the time-varying variables cannot be neglected in the case of ILRR and that fractional polynomials are a useful tool for finding the functional form of these time-varying variables.},
  citation-subset = {IM},
  completed       = {2013-09-11},
  country         = {England},
  created         = {2013-07-04},
  issn-linking    = {1471-2288},
  keywords        = {Breast Neoplasms, mortality; Female; Humans; Neoplasm Recurrence, Local, mortality; Prognosis; Proportional Hazards Models; Risk Assessment; Survival Analysis; Time Factors},
  nlm             = {PMC3700854},
  nlm-id          = {100968545},
  owner           = {NLM},
  pii             = {1471-2288-13-80},
  pmc             = {PMC3700854},
  pmid            = {23786493},
  pubmodel        = {Electronic},
  pubstatus       = {epublish},
  revised         = {2015-04-24},
}

@Article{McMinn2012,
  author          = {McMinn, D J W and Snell, K I E and Daniel, J and Treacy, R B C and Pynsent, P B and Riley, R D},
  title           = {Mortality and implant revision rates of hip arthroplasty in patients with osteoarthritis: registry based cohort study.},
  doi             = {10.1136/bmj.e3319},
  issn            = {1756-1833},
  pages           = {e3319},
  volume          = {344},
  abstract        = {To examine mortality and revision rates among patients with osteoarthritis undergoing hip arthroplasty and to compare these rates between patients undergoing cemented or uncemented procedures and to compare outcomes between men undergoing stemmed total hip replacements and Birmingham hip resurfacing. Cohort study. National Joint Registry. About 275,000 patient records. Hip arthroplasty procedures were linked to the time to any subsequent mortality or revision (implant failure). Flexible parametric survival analysis methods were used to analyse time to mortality and also time to revision. Comparisons between procedure groups were adjusted for age, sex, American Society of Anesthesiologists (ASA) grade, and complexity. As there were large baseline differences in the characteristics of patients receiving cemented, uncemented, or resurfacing procedures, unadjusted comparisons are inappropriate. Multivariable survival analyses identified a higher mortality rate for patients undergoing cemented compared with uncemented total hip replacement (adjusted hazard ratio 1.11, 95% confidence interval 1.07 to 1.16); conversely, there was a lower revision rate with cemented procedures (0.53, 0.50 to 0.57). These translate to small predicted differences in population averaged absolute survival probability at all time points. For example, compared with the uncemented group, at eight years after surgery the predicted probability of death in the cemented group was 0.013 higher (0.007 to 0.019) and the predicted probability of revision was 0.015 lower (0.012 to 0.017). In multivariable analyses restricted to men, there was a higher mortality rate in the cemented group and the uncemented group compared with the Birmingham hip resurfacing group. In terms of revision, the Birmingham hip resurfacings had a similar revision rate to uncemented total hip replacements. Both uncemented total hip replacements and Birmingham hip resurfacings had a higher revision rate than cemented total hip replacements. There is a small but significant increased risk of revision with uncemented rather than cemented total hip replacement, and a small but significant increased risk of death with cemented procedures. It is not known whether these are causal relations or caused by residual confounding. Compared with uncemented and cemented total hip replacements, Birmingham hip resurfacing has a significantly lower risk of death in men of all ages. Previously, only adjusted analyses of hip implant revision rates have been used to recommend and justify use of cheaper cemented total hip implants. Our investigations additionally consider mortality rates and suggest a potentially higher mortality rate with cemented total hip replacements, which merits further investigation.},
  citation-subset = {AIM, IM},
  completed       = {2012-08-17},
  country         = {England},
  created         = {2012-06-15},
  file            = {McMinn2012.pdf:McMinn2012.pdf:PDF},
  issn-linking    = {0959-535X},
  journal         = {BMJ (Clinical research ed.)},
  keywords        = {Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip, methods; Cementation, mortality; Cohort Studies; Female; Humans; Male; Middle Aged; Multivariate Analysis; Osteoarthritis, mortality, surgery; Prosthesis Failure; Registries; Reoperation, statistics & numerical data; Survival Analysis; Young Adult},
  month           = jun,
  nlm             = {PMC3375206},
  nlm-id          = {8900488},
  owner           = {NLM},
  pii             = {bmj.e3319},
  pmc             = {PMC3375206},
  pmid            = {22700782},
  pubmodel        = {Electronic},
  pubstatus       = {epublish},
  revised         = {2017-02-20},
  year            = {2012},
}

@Article{Olszewski2015a,
  author          = {Olszewski, A.J. and Shrestha, R. and Castillo, Jorge J.},
  title           = {Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base.},
  journal         = {Journal of Clinical Oncology},
  year            = {2015},
  volume          = {33},
  issue           = {6},
  pages           = {625--633},
  issn            = {1527-7755},
  doi             = {10.1200/JCO.2014.58.7543},
  abstract        = {The choice between combined-modality therapy (CMT) and chemotherapy alone for early-stage Hodgkin lymphoma (HL) remains controversial. Our objective was to define factors affecting treatment selection and resulting survival outcomes in the United States. We identified 20,600 patients treated with CMT or chemotherapy between 2003 and 2011 from the National Cancer Data Base. Factors affecting treatment selection were studied in a mixed-effects logistic model. Survival outcomes were compared using a propensity score analysis to account for indication bias. Only 49.5% of patients received CMT, and this proportion steadily declined between 2003 (59.4%) and 2011 (45.2%), particularly in younger patients. Apart from classical prognostic factors (age, stage, tumor location, histology, comorbidities), treatment selection was significantly influenced by sex, black race, distance to facility, and type of insurance. Uninsured patients had the lowest odds of receiving CMT. A significant random effect related to facility-specific treatment preference was also evident. Estimated 5-year overall survival (OS) was 89.6%, and relative survival (RS) was 94.3%. After adjustment for guarantee-time and indication biases, CMT was associated with better OS (hazard ratio [HR], 0.61; 95% CI, 0.53 to 0.70) and RS (excess HR, 0.42; 95% CI, 0.33 to 0.54) than chemotherapy alone. This effect was without significant heterogeneity in subset analysis and was not sensitive to unobserved confounding. Socioeconomic factors affect selection of curative treatments in HL. Widespread abandonment of CMT beyond circumstances sanctioned by guidelines may affect survival. Further research should focus on developing strategies that minimize toxicity and access disparities without compromising survival.},
  citation-subset = {IM},
  completed       = {2015-04-14},
  country         = {United States},
  created         = {2015-02-20},
  issn-linking    = {0732-183X},
  keywords        = {Adolescent; Adult; Age Factors; Aged; Hodgkin Disease, epidemiology, pathology, therapy; Humans; Logistic Models; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome; United States, epidemiology; Young Adult},
  nlm-id          = {8309333},
  owner           = {NLM},
  pii             = {JCO.2014.58.7543},
  pmid            = {25584010},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2015-09-14},
}

@Article{Putter2006,
  author          = {Putter, Hein and van der Hage, Jos and de Bock, Geertruida H and Elgalta, Rachid and van de Velde, Cornelis J H},
  title           = {Estimation and prediction in a multi-state model for breast cancer.},
  issn            = {0323-3847},
  issue           = {3},
  pages           = {366--380},
  volume          = {48},
  abstract        = {An important aim in clinical studies in oncology is to study how treatment and prognostic factors influence the course of disease of a patient. Typically in these trials, besides overall survival, also other endpoints such as locoregional recurrence or distant metastasis are of interest. Most commonly in these situations, Cox regression models are applied for each of these endpoints separately or to composite endpoints such as disease-free survival. These approaches however fail to give insight into what happens to a patient after a first event. We re-analyzed data of 2795 patients from a breast cancer trial (EORTC 10854) by applying a multi-state model, with local recurrence, distant metastasis, and both local recurrence and distant metastasis as transient states and death as absorbing state. We used an approach where the clock is reset on entry of a new state. The influence of prognostic factors on each of the transition rates is studied, as well as the influence of the time at which intermediate events occur. The estimated transition rates between the states in the model are used to obtain predictions for patients with a given history. Formulas are developed and illustrated for these prediction probabilities for the clock reset approach.},
  citation-subset = {IM},
  completed       = {2006-10-12},
  country         = {Germany},
  created         = {2006-07-18},
  issn-linking    = {0323-3847},
  journal         = {Biometrical journal. Biometrische Zeitschrift},
  keywords        = {Biometry, methods; Breast Neoplasms, diagnosis, mortality; Computer Simulation; Data Interpretation, Statistical; Humans; Models, Biological; Models, Statistical; Neoplasm Recurrence, Local, mortality; Prevalence; Prognosis; Proportional Hazards Models; Reproducibility of Results; Retrospective Studies; Risk Assessment, methods; Risk Factors; Sensitivity and Specificity; Survival Analysis},
  month           = jun,
  nlm-id          = {7708048},
  owner           = {NLM},
  pmid            = {16845902},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2006-07-18},
  year            = {2006},
}

@Article{Edgren2016,
  author          = {Edgren, G. and Hjalgrim, H. and Rostgaard, K. and Lambert, P. C. and Wikman, A. and Norda, R. and Titlestad, K-E. and Erikstrup, C. and Ullum, H. and Melbye, M. and Busch, M. P. and Nyr\'{o}n, O.},
  title           = {Transmission of Neurodegenerative Disorders Through Blood Transfusion: A Cohort Study.},
  journal         = {Annals of Internal Medicine},
  year            = {2016},
  volume          = {165},
  issue           = {5},
  pages           = {316--324},
  issn            = {1539-3704},
  doi             = {10.7326/M15-2421},
  abstract        = {The aggregation of misfolded proteins in the brain occurs in several neurodegenerative disorders. Aberrant protein aggregation is inducible in rodents and primates by intracerebral inoculation. Possible transfusion transmission of neurodegenerative diseases has important public health implications. To investigate possible transfusion transmission of neurodegenerative disorders. Retrospective cohort study. Nationwide registers of transfusions in Sweden and Denmark. 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â 465ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â 845 patients who received transfusions between 1968 and 2012. Multivariable Cox regression models were used to estimate hazard ratios for dementia of any type, Alzheimer disease, and Parkinson disease in patients receiving blood transfusions from donors who were later diagnosed with any of these diseases versus patients who received blood from healthy donors. Whether excess occurrence of neurodegenerative disease occurred among recipients of blood from a subset of donors was also investigated. As a positive control, transmission of chronic hepatitis before and after implementation of hepatitis C virus screening was assessed. Among included patients, 2.9% received a transfusion from a donor diagnosed with one of the studied neurodegenerative diseases. No evidence of transmission of any of these diseases was found, regardless of approach. The hazard ratio for dementia in recipients of blood from donors with dementia versus recipients of blood from healthy donors was 1.04 (95% CI, 0.99 to 1.09). Corresponding estimates for Alzheimer disease and Parkinson disease were 0.99 (CI, 0.85 to 1.15) and 0.94 (CI, 0.78 to 1.14), respectively. Hepatitis transmission was detected before but not after implementation of hepatitis C virus screening. Observational study design, underascertainment of the outcome, and possible insufficient statistical power. The data provide no evidence for the transmission of neurodegenerative diseases and suggest that if transmission does occur, it is rare. Swedish Research Council, Swedish Heart-Lung Foundation, Swedish Society for Medical Research, and Danish Council for Independent Research.},
  citation-subset = {AIM, IM},
  country         = {United States},
  created         = {2016-09-06},
  issn-linking    = {0003-4819},
  nlm-id          = {0372351},
  owner           = {NLM},
  pii             = {2530857},
  pmid            = {27368068},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2016-09-06},
}

@Article{Goldoni2009,
  author          = {Goldoni, Carlo Alberto and Bonora, Karin and Ciatto, Stefano and Giovannetti, Lucia and Patriarca, Silvia and Sapino, Anna and Sarti, Samanta and Puliti, Donella and Paci, Eugenio and IMPACT Working Group},
  title           = {Misclassification of breast cancer as cause of death in a service screening area.},
  journal         = {Cancer causes \& control : CCC},
  year            = {2009},
  volume          = {20},
  issue           = {5},
  month           = jul,
  pages           = {533--538},
  issn            = {1573-7225},
  doi             = {10.1007/s10552-008-9261-3},
  abstract        = {The aim of this study was to assess the misclassification of cause of death for breast cancer cases, and to evaluate the differential misclassification between cases detected in an organized screening program and cases found in current clinical practice. All deaths occurring between 1999 and 2002 within breast cancer cases were linked to hospital discharge records. Death certificates and latest available hospital discharge notes were classified into various categories. We created a classification algorithm defining which combinations of categories (of death certificates and hospital discharge notes) suggested the probability of misclassification and the need for an in-depth diagnostic review. Questionable cases were reviewed by a team of experts in order to reach a consensus on cause of death. Based on our algorithmic classification and diagnostic review results, the agreement between original cause of death and that resulting from the assessment process was analyzed stratifying for every variable of interest. According to death certificates, breast cancer was the cause of death in 66.9% of subjects, and after assessment this figure changed to 65.7%. The misclassification rate was 4.3% and did not differ significantly between screen-detected (4.7%) and non-screen-detected (4.3%) cases. Higher misclassification rates in favor of false positivity (cause of death wrongly attributed to breast cancer in death certificates) was observed for subjects with multiple cancers (6.5% vs. 1.9%), with no admission in the year before death (4.6% vs. 2.4%) and with an unknown cancer stage (4.9% vs 2.4% or 2.3%). The cause of death misclassification rate is modest, causing a slight overestimate of deaths attributed to breast cancer, and is not affected by modality of diagnosis. The study confirmed the validity of using cause-specific mortality for service screening evaluation.},
  citation-subset = {IM},
  completed       = {2009-09-15},
  country         = {Netherlands},
  created         = {2009-05-25},
  investigator    = {Paci, E and Falini, P and Puliti, D and Esposito, I and Zappa, M and Crocetti, E and Naldoni, C and Finarelli, A C and Sassoli de' Bianchi, P and Ferretti, S and Baraldi, G P and Federico, M and Cirilli, C and Negri, R and De Lisi, V and Sgargi, P and Traina, A and Zarcone, M and Cattani, A and Borciani, N and Mangone, L and Falcini, F and Ravaioli, A and Vattiato, R and Colamartini, A and Serafini, M and Vitali, B and Bravetti, P and Desiderio, F and Canuti, D and Fabbri, C and Imolesi, C and Palazzi, M and Collina, N and Baldazzi, P and Manfredi, M and Perlangeli, V and Petrucci, C and Saguatti, G and Segnan, N and Ponti, A and Del Mastro, G and Senore, C and Frigerio, A and Pitarella, S and Patriarca, S and Zanetti, R and Vettorazzi, M and Zorzi, M and Molino, A and Mercanti, A and Mariotto, R and Tumino, R and Sigona, A and La Perna, G and Iacono, C and Stracci, F and La Rosa, F and Petrella, M and Fusco Moffa, I},
  issn-linking    = {0957-5243},
  keywords        = {Algorithms; Breast Neoplasms, mortality; Case-Control Studies; Cause of Death; Death Certificates; Female; Hospital Records; Humans; Patient Discharge; Survival Analysis},
  nlm-id          = {9100846},
  owner           = {NLM},
  pmid            = {19015942},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2009-05-25},
}

@Article{Chasse2016a,
  author          = {Chass{\AA}Â©, Micha{\AA}Â«l and Tinmouth, Alan and English, Shane W and Acker, Jason P and Wilson, Kumanan and Knoll, Greg and Shehata, Nadine and van Walraven, Carl and Forster, Alan J and Ramsay, Timothy and McIntyre, Lauralyn A and Fergusson, Dean A},
  title           = {Association of Blood Donor Age and Sex With Recipient Survival After Red Blood Cell Transfusion.},
  journal         = {JAMA internal medicine},
  year            = {2016},
  volume          = {176},
  issue           = {9},
  month           = sep,
  pages           = {1307--1314},
  issn            = {2168-6114},
  doi             = {10.1001/jamainternmed.2016.3324},
  abstract        = {While red blood cells (RBCs) are administered to improve oxygen delivery and patient outcomes, they also have been associated with potential harm. Unlike solid organ transplantation, the clinical consequences of donor characteristics on recipients have not been evaluated in transfusion medicine. To analyze the association of RBC donor age and sex with the survival of transfusion recipients. We established a longitudinal cohort by linking data from a blood collection agency with clinical and administrative data at 4 academic hospitals. Cox proportional hazards regression models were fitted to evaluate the risk of donor age and sex on transfusion recipient survival. Between October 25, 2006, and December 31, 2013, a total of 30?503 RBC transfusion recipients received 187?960 RBC transfusions from 80?755 unique blood donors. For recipients receiving an RBC unit from younger donors, the risk of death was increased compared with recipients receiving an RBC unit from a donor 40 to 49.9 years old (adjusted hazard ratio, 1.08; 95% CI, 1.06-1.10; P?<?.001 for donor age range 17-19.9 years and 1.06; 95% CI, 1.04-1.09; P?<?.001 for donor age range 20-29.9 years). Receiving an RBC transfusion from a female donor was associated with an 8% statistically significant increased risk of death compared with receiving an RBC transfusion from a male donor (adjusted hazard ratio, 1.08; 95% CI, 1.06-1.09; P?<?.001). Red blood cell transfusions from younger donors and from female donors were statistically significantly associated with increased mortality. These findings suggest that donor characteristics may affect RBC transfusion outcomes.},
  citation-subset = {AIM, IM},
  country         = {United States},
  created         = {2016-09-07},
  issn-linking    = {2168-6106},
  nlm-id          = {101589534},
  owner           = {NLM},
  pii             = {2532790},
  pmid            = {27398639},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2016-09-07},
}

@Article{Edgren2007,
  author          = {Edgren, Gustaf and Hjalgrim, Henrik and Reilly, Marie and Tran, Trung Nam and Rostgaard, Klaus and Shanwell, Agneta and Titlestad, Kjell and Adami, Johanna and Wikman, Agneta and Jersild, Casper and Gridley, Gloria and Wideroff, Louise and Nyr{\AA}Â©n, Olof and Melbye, Mads},
  title           = {Risk of cancer after blood transfusion from donors with subclinical cancer: a retrospective cohort study.},
  journal         = {Lancet (London, England)},
  year            = {2007},
  volume          = {369},
  issue           = {9574},
  month           = may,
  pages           = {1724--1730},
  issn            = {1474-547X},
  doi             = {10.1016/S0140-6736(07)60779-X},
  abstract        = {Although mechanisms for detection of short-term complications after blood transfusions are well developed, complications with delayed onset, notably transmission of chronic diseases such as cancer, have been difficult to assess. Our aim was to investigate the possible risk of cancer transmission from blood donors to recipients through blood transfusion. We did a register-based retrospective cohort study of cancer incidence among patients who received blood from donors deemed to have a subclinical cancer at the time of donation. These precancerous donors were diagnosed with a cancer within 5 years of the donation. Data from all computerised blood bank registers in Sweden and Denmark gathered between 1968 and 2002 were merged into a common database. Demographic and medical data, including mortality and cancer incidence, were ascertained through linkages with nationwide, and essentially complete, population and health-care registers. The risk of cancer in exposed recipients relative to that in recipients who received blood from non-cancerous donors was estimated with multivariate Poisson regression, adjusting for potential confounding factors. Of the 354 094 transfusion recipients eligible for this analysis, 12,012 (3%) were exposed to blood products from precancerous donors. There was no excess risk of cancer overall (adjusted relative risk 1.00, 95% CI 0.94-1.07) or in crude anatomical subsites among recipients of blood from precancerous donors compared with recipients of blood from non-cancerous donors. Our data provide no evidence that blood transfusions from precancerous blood donors are associated with increased risk of cancer among recipients compared with transfusions from non-cancerous donors.},
  citation-subset = {AIM, IM},
  completed       = {2007-05-31},
  country         = {England},
  created         = {2007-05-21},
  issn-linking    = {0140-6736},
  keywords        = {Blood Transfusion, adverse effects; Cohort Studies; Denmark; Female; Humans; Male; Neoplasms, etiology; Registries; Retrospective Studies; Risk Factors; Sweden},
  nlm-id          = {2985213R},
  owner           = {NLM},
  pii             = {S0140-6736(07)60779-X},
  pmid            = {17512857},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2015-06-16},
}

@Article{Hjalgrim2015,
  author          = {Hjalgrim, Henrik and Rostgaard, Klaus and Vasan, Senthil K and Ullum, Henrik and Erikstrup, Christian and Pedersen, Ole B V and Nielsen, Kaspar R and Titlestad, Kjell-Einar and Melbye, Mads and Nyr{\AA}Â©n, Olof and Edgren, Gustaf},
  title           = {No evidence of transmission of chronic lymphocytic leukemia through blood transfusion.},
  journal         = {Blood},
  year            = {2015},
  volume          = {126},
  issue           = {17},
  month           = oct,
  pages           = {2059--2061},
  issn            = {1528-0020},
  doi             = {10.1182/blood-2015-03-632844},
  abstract        = {Monoclonal B-cell lymphocytosis (MBL) is a precursor of chronic lymphocytic leukemia (CLL). Observations of MBL in blood donors raise concern that transmitted MBL may cause recipient CLL. Using a database with health information on 1.5 million donors and 2.1 million recipients, we compared CLL occurrence among 7413 recipients of blood from 796 donors diagnosed with CLL after donation cessation, and among 80,?431 recipients of blood from 7477 matched CLL-free donors. During follow-up, 12 and 107 cases of CLL occurred among the exposed and unexposed recipients, respectively, yielding a relative risk of 0.94 (95% confidence interval, 0.52-1.71). Analyses using the entire database showed no evidence of CLL clustering among recipients of blood from individual donors. In conclusion, when donor MBL was approximated by subsequent donor CLL diagnosis, data from 2 countries' entire computerized transfusion experience over more than 30 years indicate that MBL/CLL transmission does not contribute importantly to recipient CLL risk.},
  citation-subset = {AIM, IM},
  completed       = {2016-02-11},
  country         = {United States},
  created         = {2015-10-23},
  issn-linking    = {0006-4971},
  keywords        = {B-Lymphocytes, pathology; Blood Donors; Blood Transfusion, adverse effects; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell, diagnosis, etiology; Lymphocyte Count; Lymphocytosis, complications; Prognosis; Scandinavian and Nordic Countries},
  nlm-id          = {7603509},
  owner           = {NLM},
  pii             = {blood-2015-03-632844},
  pmid            = {26302757},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2015-10-23},
}

@Article{Halmin2017,
  author       = {Halmin, M{\"a}rit and Rostgaard, Klaus and Lee, Brian K and Wikman, Agneta and Norda, Rut and Nielsen, Kaspar Ren{\AA}Â© and Pedersen, Ole B and Holmqvist, Jacob and Hjalgrim, Henrik and Edgren, Gustaf},
  title        = {Length of Storage of Red Blood Cells and Patient Survival After Blood Transfusion: A Binational Cohort Study.},
  journal      = {Annals of Internal Medicine},
  year         = {2017},
  volume       = {166},
  issue        = {4},
  month        = feb,
  pages        = {248--256},
  issn         = {1539-3704},
  doi          = {10.7326/M16-1415},
  abstract     = {Possible negative effects, including increased mortality, among persons who receive stored red blood cells (RBCs) have recently garnered considerable attention. Despite many studies, including 4 randomized trials, no consensus exists. To study the association between the length of RBC storage and mortality in a large population-based cohort of patients who received transfusions, allowing detection of small yet clinically significant effects. Binational cohort study. All transfusion recipients in Sweden and Denmark. 854ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â 862 adult patients who received transfusions from 2003 to 2012. Patients were followed from first blood transfusion. Relative and absolute risks for death in 30 days or 1 year in relation to length of RBC storage were assessed by using 3 independent analytic approaches. All analyses were conducted by using Cox proportional hazards regression. Regardless of the analytic approach, no association was found between the length of RBC storage and mortality. The difference in 30-day cumulative mortality between patients receiving blood stored for 30 to 42 days and those receiving blood stored for 10 to 19 days was -0.2% (95% CI, -0.5% to 0.1%). Even among patients who received more than 6 units of RBCs stored for 30 days or longer, the hazard ratio of death was 1.00 (CI, 0.96 to 1.05) compared with those who received no such units. Observational study; risk of confounding by indication. Consistent with previous randomized trials, this study found no association between the length of storage of transfused RBCs and patient mortality. Results were homogeneous, with differences in absolute mortality consistently less than 1% among the most extreme exposure categories. These findings suggest that the current practice of storing RBCs for up to 42 days does not need to be changed. The Swedish Research Council, Swedish Heart-Lung Foundation, Swedish Society for Medical Research, Strategic Research Program in Epidemiology at Karolinska Institutet, and Danish Council for Independent Research.},
  country      = {United States},
  created      = {2016-12-19},
  issn-linking = {0003-4819},
  nlm-id       = {0372351},
  owner        = {NLM},
  pii          = {2593600},
  pmid         = {27992899},
  pubmodel     = {Print-Electronic},
  pubstatus    = {ppublish},
  revised      = {2017-02-20},
}

@Article{Tomic2015,
  author          = {Tomic, Katarina and Sandin, Fredrik and Wigertz, Annette and Robinson, David and Lambe, Mats and Stattin, P{\"a}r},
  title           = {Evaluation of data quality in the National Prostate Cancer Register of Sweden.},
  journal         = {European journal of cancer (Oxford, England : 1990)},
  year            = {2015},
  volume          = {51},
  issue           = {1},
  month           = jan,
  pages           = {101--111},
  issn            = {1879-0852},
  doi             = {10.1016/j.ejca.2014.10.025},
  abstract        = {Data in cancer quality registers are increasingly used for quality assurance, benchmarking, and research. Data in the National Prostate Cancer Register (NPCR) of Sweden were evaluated for completeness, timeliness, comparability and validity. Completeness and timeliness were assessed by cross-linkage to the Swedish Cancer Register, comparability was examined by comparing registration routines in NPCR with national and international guidelines, and validity was assessed by re-abstraction of data from medical charts for 731 men diagnosed with prostate cancer (Pca) in 2009. Furthermore, data on treatment were validated by record linkage to the Swedish Patient Register and The Prescribed Drug Register. NPCR captured 98% of Pca cases in the Cancer Register and the mean value for completeness of the 48 evaluated variables was 90% (range 64-100%). Timeliness increased substantially from 2008 to 2012 with 95% of cases reported within 12 months after diagnosis in 2012. NPCR complied with national and international coding routines. Overall, the agreement between original data and re-abstracted data from 731 charts was high. For example, the correlation between original and re-abstracted data was 1.00 for date of surgery, and 0.97 for serum levels of prostate specific antigen and exact agreement was 97% for Gleason score at biopsy, 83% for clinical local T stage and more than 95% of the androgen deprivation therapies registered in NPCR had a corresponding filled prescription. Record linkages with other data sources and re-abstraction of data showed that data quality in NPCR is high.},
  citation-subset = {IM},
  completed       = {2015-04-17},
  country         = {England},
  created         = {2014-12-26},
  issn-linking    = {0959-8049},
  keywords        = {Data Collection; Humans; Male; Prostatic Neoplasms, diagnosis, epidemiology, pathology; Registries; Sweden; Cancer quality register; Evaluation; Prostate cancer; Validity},
  nlm-id          = {9005373},
  owner           = {NLM},
  pii             = {S0959-8049(14)01061-2},
  pmid            = {25465187},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2014-12-26},
}

@Article{Liu2004,
  author          = {Liu, Lei and Wolfe, Robert A and Huang, Xuelin},
  title           = {Shared frailty models for recurrent events and a terminal event.},
  journal         = {Biometrics},
  year            = {2004},
  volume          = {60},
  issue           = {3},
  month           = sep,
  pages           = {747--756},
  issn            = {0006-341X},
  doi             = {10.1111/j.0006-341X.2004.00225.x},
  abstract        = {There has been an increasing interest in the analysis of recurrent event data (Cook and Lawless, 2002, Statistical Methods in Medical Research 11, 141-166). In many situations, a terminating event such as death can happen during the follow-up period to preclude further occurrence of the recurrent events. Furthermore, the death time may be dependent on the recurrent event history. In this article we consider frailty proportional hazards models for the recurrent and terminal event processes. The dependence is modeled by conditioning on a shared frailty that is included in both hazard functions. Covariate effects can be taken into account in the model as well. Maximum likelihood estimation and inference are carried out through a Monte Carlo EM algorithm with Metropolis-Hastings sampler in the E-step. An analysis of hospitalization and death data for waitlisted dialysis patients is presented to illustrate the proposed methods. Methods to check the validity of the proposed model are also demonstrated. This model avoids the difficulties encountered in alternative approaches which attempt to specify a dependent joint distribution with marginal proportional hazards and yields an estimate of the degree of dependence.},
  citation-subset = {IM},
  completed       = {2005-03-01},
  country         = {United States},
  created         = {2004-09-01},
  issn-linking    = {0006-341X},
  keywords        = {Algorithms; Biometry; Female; Hospitalization; Humans; Kidney Diseases, mortality, therapy; Kidney Transplantation; Likelihood Functions; Male; Middle Aged; Monte Carlo Method; Proportional Hazards Models; Survival Analysis},
  nlm-id          = {0370625},
  owner           = {NLM},
  pii             = {BIOM225},
  pmid            = {15339298},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2004-09-01},
}

@Article{Crowther2016,
  author          = {Crowther, Michael J and Andersson, Therese M-L and Lambert, Paul C and Abrams, Keith R and Humphreys, Keith},
  title           = {Joint modelling of longitudinal and survival data: incorporating delayed entry and an assessment of model misspecification.},
  doi             = {10.1002/sim.6779},
  issn            = {1097-0258},
  issue           = {7},
  pages           = {1193--1209},
  volume          = {35},
  abstract        = {A now common goal in medical research is to investigate the inter-relationships between a repeatedly measured biomarker, measured with error, and the time to an event of interest. This form of question can be tackled with a joint longitudinal-survival model, with the most common approach combining a longitudinal mixed effects model with a proportional hazards survival model, where the models are linked through shared random effects. In this article, we look at incorporating delayed entry (left truncation), which has received relatively little attention. The extension to delayed entry requires a second set of numerical integration, beyond that required in a standard joint model. We therefore implement two sets of fully adaptive Gauss-Hermite quadrature with nested Gauss-Kronrod quadrature (to allow time-dependent association structures), conducted simultaneously, to evaluate the likelihood. We evaluate fully adaptive quadrature compared with previously proposed non-adaptive quadrature through a simulation study, showing substantial improvements, both in terms of minimising bias and reducing computation time. We further investigate, through simulation, the consequences of misspecifying the longitudinal trajectory and its impact on estimates of association. Our scenarios showed the current value association structure to be very robust, compared with the rate of change that we found to be highly sensitive showing that assuming a simpler trend when the truth is more complex can lead to substantial bias. With emphasis on flexible parametric approaches, we generalise previous models by proposing the use of polynomials or splines to capture the longitudinal trend and restricted cubic splines to model the baseline log hazard function. The methods are illustrated on a dataset of breast cancer patients, modelling mammographic density jointly with survival, where we show how to incorporate density measurements prior to the at-risk period, to make use of all the available information. User-friendly Stata software is provided.},
  citation-subset = {IM},
  completed       = {2016-12-27},
  country         = {England},
  created         = {2016-03-02},
  issn-linking    = {0277-6715},
  journal         = {Statistics in Medicine},
  keywords        = {Biostatistics; Breast Density; Breast Neoplasms, mortality; Computer Simulation; Female; Humans; Likelihood Functions; Longitudinal Studies; Models, Statistical; Proportional Hazards Models; Survival Analysis; adaptive Gauss-Hermite quadrature; delayed entry; joint modelling; left truncation; mixed effects; survival analysis},
  month           = mar,
  nlm             = {PMC5019272},
  nlm-id          = {8215016},
  owner           = {NLM},
  pmc             = {PMC5019272},
  pmid            = {26514596},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2017-02-20},
  year            = {2016},
}

@Article{Fiocco2008,
  author          = {Fiocco, Marta and Putter, Hein and van Houwelingen, Hans C},
  title           = {Reduced-rank proportional hazards regression and simulation-based prediction for multi-state models.},
  journal         = {Statistics in medicine},
  year            = {2008},
  volume          = {27},
  issue           = {21},
  month           = sep,
  pages           = {4340--4358},
  issn            = {0277-6715},
  doi             = {10.1002/sim.3305},
  abstract        = {In this paper we address two issues arising in multi-state models with covariates. The first issue deals with how to obtain parsimony in the modeling of the effect of covariates. The standard way of incorporating covariates in multi-state models is by considering the transitions as separate building blocks, and modeling the effect of covariates for each transition separately, usually through a proportional hazards model for the transition hazard. This typically leads to a large number of regression coefficients to be estimated, and there is a real danger of over-fitting, especially when transitions with few events are present. We extend the reduced-rank ideas, proposed earlier in the context of competing risks, to multi-state models, in order to deal with this issue. The second issue addressed in this paper was motivated by the wish to obtain standard errors of the regression coefficients of the reduced-rank model. We propose a model-based resampling technique, based on repeatedly sampling trajectories through the multi-state model. The same ideas are also used for the estimation of prediction probabilities in general multi-state models and associated standard errors. We use data from the European Group for Blood and Marrow Transplantation to illustrate our techniques.},
  citation-subset = {IM},
  completed       = {2008-10-14},
  country         = {England},
  created         = {2008-08-12},
  issn-linking    = {0277-6715},
  keywords        = {Algorithms; Bone Marrow Transplantation, adverse effects; Computer Simulation; Graft vs Host Disease, etiology; Humans; Leukemia, therapy; Models, Biological; Proportional Hazards Models; Regression Analysis},
  nlm-id          = {8215016},
  owner           = {NLM},
  pmid            = {18425994},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2009-11-03},
}

@Article{Lee2017,
  author       = {Lee, Minjung and Gouskova, Natalia A and Feuer, Eric J and Fine, Jason P},
  title        = {On the choice of time scales in competing risks predictions.},
  journal      = {Biostatistics (Oxford, England)},
  year         = {2017},
  volume       = {18},
  issue        = {1},
  month        = jan,
  pages        = {15--31},
  issn         = {1468-4357},
  doi          = {10.1093/biostatistics/kxw024},
  abstract     = {In the standard analysis of competing risks data, proportional hazards models are fit to the cause-specific hazard functions for all causes on the same time scale. These regression analyses are the foundation for predictions of cause-specific cumulative incidence functions based on combining the estimated cause-specific hazard functions. However, in predictions arising from disease registries, where only subjects with disease enter the database, disease-related mortality may be more naturally modeled on the time since diagnosis time scale while death from other causes may be more naturally modeled on the age time scale. The single time scale methodology may be biased if an incorrect time scale is employed for one of the causes and an alternative methodology is not available. We propose inferences for the cumulative incidence function in which regression models for the cause-specific hazard functions may be specified on different time scales. Using the disease registry data, the analysis of other cause mortality on the age scale requires left truncating the event time at the age of disease diagnosis, complicating the analysis. In addition, standard Martingale theory is not applicable when combining regression models on different time scales. We establish that the covariate conditional predictions are consistent and asymptotically normal using empirical process techniques and propose consistent variance estimators for constructing confidence intervals. Simulation studies show that the proposed two time scales method performs well, outperforming the single time-scale predictions when the time scale is misspecified. The methods are illustrated with stage III colon cancer data obtained from the Surveillance, Epidemiology, and End Results program of National Cancer Institute.},
  country      = {England},
  created      = {2016-06-23},
  file         = {:Lee2017.pdf:PDF},
  issn-linking = {1465-4644},
  keywords     = {Cumulative incidence function; Disease registry data; Left truncation; Multiple time scales; Population risk; Proportional hazards model},
  nlm-id       = {100897327},
  owner        = {NLM},
  pii          = {kxw024},
  pmid         = {27335117},
  pubmodel     = {Print-Electronic},
  pubstatus    = {ppublish},
  revised      = {2017-01-20},
}

@Article{Schaffar2017,
  author       = {Schaffar, Robin and Rachet, Bernard and Belot, Aur{\AA}Â©lien and Woods, Laura M},
  title        = {Estimation of net survival for cancer patients: Relative survival setting more robust to some assumption violations than cause-specific setting, a sensitivity analysis on empirical data.},
  journal      = {European journal of cancer (Oxford, England : 1990)},
  year         = {2017},
  volume       = {72},
  month        = {Feb},
  pages        = {78--83},
  issn         = {1879-0852},
  doi          = {10.1016/j.ejca.2016.11.019},
  abstract     = {Net survival is the survival that would be observed if the only possible underlying cause of death was the disease under study. It can be estimated with either cause-specific or relative survival data settings, if the informative censoring is properly considered. However, net survival estimators are prone to specific biases related to the data setting itself. We examined which data setting was the most robust against violation of key assumptions (erroneous cause of death and inappropriate life tables). We identified 4285 women in the Geneva Cancer Registry, diagnosed with breast, colorectal, lung cancer and melanoma between 1981 and 1991ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â and estimated net survival up to 20 years using cause-specific and relative survival settings. We used weights to tackle informative censoring in both settingsÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â and performed sensitivity analyses to evaluate the impact of misclassification of cause of death in the cause-specific setting or of using inappropriate life tables on net survival estimates in the relative survival setting. For all the four cancers, net survival was highest when using the cause-specific setting and the absolute difference between the two estimators increased with time since diagnosis. The sensitivity analysis showed that (i) the use of different life tables did not compromise net survival estimation in the relative survival setting, whereas (ii) a small level of misclassification for the cause of death led to a large change in the net survival estimate in the cause-specific setting. The relative survival setting was more robust to the above assumptions violations and is therefore recommended for estimation of net survival.},
  country      = {England},
  created      = {2016-12-27},
  file         = {Schaffar2017.pdf:Schaffar2017.pdf:PDF;Schaffar2017.pdf:pdf\\Schaffar2017.pdf:PDF},
  issn-linking = {0959-8049},
  keywords     = {Cause-specific; Informative censoring; Net survival; Relative survival},
  nlm-id       = {9005373},
  owner        = {NLM},
  pii          = {S0959-8049(16)32597-7},
  pmid         = {28027519},
  pubmodel     = {Print-Electronic},
  pubstatus    = {ppublish},
  revised      = {2017-04-03},
  timestamp    = {2017.06.08},
}

@Article{Woods2012,
  author          = {Woods, Laura M and Rachet, Bernard and Ellis, Libby and Coleman, Michel P},
  title           = {Full dates (day, month, year) should be used in population-based cancer survival studies.},
  year            = {2012},
  volume          = {131},
  issue           = {7},
  month           = {Oct},
  pages           = {E1120--E1124},
  issn            = {1097-0215},
  doi             = {10.1002/ijc.27545},
  abstract        = {Accurate survival estimates are essential for monitoring cancer survival trends, for health care planning and for resource allocation. To obtain precise estimates of survival, full dates (day, month and year) rather than partial dates (month and year) are required. In some jurisdictions, however, cancer registries are constrained from providing full dates on the grounds of confidentiality. The bias resulting from the use of partial dates in the estimation and comparison of survival makes it impossible to determine precisely the differences in the risk of death from cancer between population groups or in successive calendar periods. Important operational arguments also exist against the use of incomplete dates for survival analysis, including increased workload for cancer registry staff and the introduction of avoidable complexity for quality control of survival data. Cancer survival is one of the most widely known outputs produced by population-based cancer registries, and it is a crucial metric for the comparative effectiveness of health services. The bodies that set data access guidelines must take a more balanced view of the risks and benefits of using full dates for the estimation of cancer survival.},
  citation-subset = {IM},
  completed       = {2012-10-17},
  country         = {United States},
  created         = {2012-07-31},
  file            = {Woods2012.pdf:Woods2012.pdf:PDF;Woods2012.pdf:pdf\\Woods2012.pdf:PDF},
  issn-linking    = {0020-7136},
  journal         = {International journal of cancer},
  keywords        = {Chronology as Topic; Humans; Neoplasms, mortality; Registries; Survival Analysis},
  nlm-id          = {0042124},
  owner           = {NLM},
  pmid            = {22438030},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2016-11-22},
  timestamp       = {2017.06.08},
}

@Book{SS2016,
  author    = {Statistics Sweden (Statistiska Centralbyr{\aa}n)},
  title     = {Trends in life expectancy by education and marital status in Sweden 2000ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Â“2014},
  file      = {SS2016.pdf:SS2016.pdf:PDF;SS2016.pdf:pdf\\SS2016.pdf:PDF},
  owner     = {hanbow},
  timestamp = {2017.06.29},
  year      = {2016},
}

@Article{Lundqvist2016,
  author    = {Adam Lundqvist and Emelie Andersson and Ida Ahlberg adn Mef Nilbert and Ulf Gerdtham},
  title     = {Socioeconomic inequalities in breast cancer incidence and mortality in EuropeÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Â”a systematic review and meta-analysis},
  journal   = {The European Journal of Public Health},
  year      = {2016},
  volume    = {26},
  number    = {5},
  pages     = {804-813},
  file      = {Lundqvist2016.pdf:Lundqvist2016.pdf:PDF;Lundqvist2016.pdf:pdf\\Lundqvist2016.pdf:PDF},
  owner     = {hanbow},
  timestamp = {2017.06.29},
}

@Article{Lehto2006,
  author    = {U-S Lehto and M Ojanen and T Dyba and A Aromaa and P Kellokumpu-Lehtinen},
  title     = {Baseline psychosocial predictors of survival in localised breast cancer},
  journal   = {British Journal of Cancer},
  year      = {2006},
  volume    = {94},
  pages     = {1245-1252},
  file      = {Lehto2006.pdf:Lehto2006.pdf:PDF;Lehto2006.pdf:pdf\\Lehto2006.pdf:PDF},
  owner     = {hanbow},
  timestamp = {2017.06.29},
}

@Book{Hernan2020,
  author    = {Hern\'{a}n and JM Robins},
  title     = {Causal Inference: What If},
  chapter   = {forthcoming},
  publisher = {Boca Raton: Chapman \& Hall/CRC},
  url       = {https://www.hsph.harvard.edu/miguel-hernan/causal-inference-book/},
  owner     = {hanbow},
  timestamp = {2017.06.29},
  year      = {2020},
}

@Book{UICC2002,
  author    = {UICC International Union Against Cancer},
  title     = {TNM Classification of Malignant Tumours},
  edition   = {6th},
  editor    = {LH Sobin and Ch Wittekind},
  publisher = {Wiley-Liss},
  file      = {UICC2002.pdf:UICC2002.pdf:PDF;UICC2002.pdf:pdf\\UICC2002.pdf:PDF},
  owner     = {hanbow},
  timestamp = {2017.06.29},
  year      = {2002},
}

@Article{Aalen2015,
  author          = {Aalen, Odd O and Cook, Richard J and R{\AA}Â¸ysland, Kjetil},
  title           = {Does Cox analysis of a randomized survival study yield a causal treatment effect?},
  journal         = {Lifetime data analysis},
  year            = {2015},
  volume          = {21},
  issue           = {4},
  month           = oct,
  pages           = {579--593},
  issn            = {1572-9249},
  doi             = {10.1007/s10985-015-9335-y},
  abstract        = {Statistical methods for survival analysis play a central role in the assessment of treatment effects in randomized clinical trials in cardiovascular disease, cancer, and many other fields. The most common approach to analysis involves fitting a Cox regression model including a treatment indicator, and basing inference on the large sample properties of the regression coefficient estimator. Despite the fact that treatment assignment is randomized, the hazard ratio is not a quantity which admits a causal interpretation in the case of unmodelled heterogeneity. This problem arises because the risk sets beyond the first event time are comprised of the subset of individuals who have not previously failed. The balance in the distribution of potential confounders between treatment arms is lost by this implicit conditioning, whether or not censoring is present. Thus while the Cox model may be used as a basis for valid tests of the null hypotheses of no treatment effect if robust variance estimates are used, modeling frameworks more compatible with causal reasoning may be preferrable in general for estimation.},
  citation-subset = {IM},
  completed       = {2016-12-13},
  country         = {United States},
  created         = {2015-09-17},
  issn-linking    = {1380-7870},
  keywords        = {Biostatistics; Causality; Humans; Likelihood Functions; Proportional Hazards Models; Randomized Controlled Trials as Topic, statistics & numerical data; Survival Analysis; Treatment Outcome; Causation; Collapsible model; Confounding; Hazard function; Survival data},
  nlm-id          = {9516348},
  owner           = {NLM},
  pii             = {10.1007/s10985-015-9335-y},
  pmid            = {26100005},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2016-12-30},
}

@Book{cin2016,
  author    = {{Cancer Registry of Norway}},
  title     = {Cancer in {N}orway 2016 - Cancer incidence, mortality, survival and prevalence in {N}orway},
  publisher = {Oslo: Cancer Registry of Norway},
  url       = {https://www.kreftregisteret.no/Generelt/Publikasjoner/Cancer-in-Norway/cancer-in-norway-2016/},
  file      = {:pdf\\cin2106.pdf:PDF},
  owner     = {PaulD},
  timestamp = {2017-11-23},
  year      = {2017},
}

@Article{Andersen2016,
  author  = {Andersen, P. K.},
  title   = {Life years lost among patients with a given disease},
  journal = {Statistics in Medicine},
  year    = {2016},
  issue   = {36},
  pages   = {3573-3582},
}

@Article{Andreassen2017,
  author          = {Andreassen, Bettina K and Myklebust, Tor {\AA}Â… and Haug, Erik S},
  title           = {Crude mortality and loss of life expectancy of patients diagnosed with urothelial carcinoma of the urinary bladder in Norway.},
  doi             = {10.1080/21681805.2016.1271354},
  issn            = {2168-1813},
  issue           = {1},
  pages           = {38--43},
  volume          = {51},
  abstract        = {Reports from cancer registries often lack clinically relevant information, which would be useful in estimating the prognosis of individual patients with urothelial carcinoma of the urinary bladder (UCB). This article presents estimates of crude probabilities of death due to UCB and the expected loss of lifetime stratified for patient characteristics. In Norway, 10,332 patients were diagnosed with UCB between 2001 and 2010. The crude probabilities of death due to UCB were estimated, stratified by gender, age and TÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â stage, using flexible parametric survival models. Based on these models, the loss in expectation of lifetime due to UCB was also estimated for the different strata. There is large variation in the estimated crude probabilities of death due to UCB (from 0.03 to 0.76 within 10 years since diagnosis) depending on age, gender and T stage. Furthermore, the expected loss of life expectancy is more than a decade for younger patients with muscle-invasive UCB and between a few months and 5 years for nonmuscle-invasive UCB. The suggested framework leads to clinically relevant prognostic risk estimates for individual patients diagnosed with UCB and the consequence in terms of loss of lifetime expectation. The published probability tables can be used in clinical praxis for risk communication.},
  citation-subset = {IM},
  completed       = {2017-07-18},
  country         = {England},
  created         = {2017-01-13},
  file            = {:Andreassen2017 - Crude mortality and loss of life expectancy of patients diagnosed with urothelial carcinoma of the urinary bladder in Norway:},
  issn-linking    = {2168-1805},
  journal         = {Scandinavian journal of urology},
  keywords        = {Age Factors; Aged; Aged, 80 and over; Carcinoma, Transitional Cell, mortality, pathology; Cause of Death; Female; Humans; Life Expectancy; Male; Middle Aged; Muscle, Smooth, pathology; Neoplasm Invasiveness; Neoplasm Staging; Norway, epidemiology; Prognosis; Registries; Sex Factors; Urinary Bladder, pathology; Urinary Bladder Neoplasms, pathology; Bladder cancer; crude survival; epidemiology; loss of lifetime expectancy; survival; urothelial carcinoma of the urinary bladder},
  month           = feb,
  nlm-id          = {101587186},
  owner           = {NLM},
  pmid            = {28084860},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2017-07-18},
  year            = {2017},
}

@Article{Radkiewicz2017,
  author    = {Radkiewicz, Cecilia and Johansson, Anna LV and Dickman, Paul W and Lambe, Mats and Edgren, Gustaf},
  title     = {Sex differences in cancer risk and survival: A {S}wedish cohort study},
  journal   = {European Journal of Cancer},
  year      = {2017},
  volume    = {84},
  pages     = {130--140},
  file      = {:Radkiewicz2017.pdf:PDF},
  publisher = {Elsevier},
}

@Article{Austin2016,
  author    = {Austin, Peter C and Lee, Douglas S and Fine, Jason P},
  title     = {Introduction to the analysis of survival data in the presence of competing risks},
  journal   = {Circulation},
  year      = {2016},
  volume    = {133},
  number    = {6},
  pages     = {601--609},
  owner     = {PaulD},
  publisher = {Am Heart Assoc},
  timestamp = {2017-12-20},
}

@Article{Engel1980,
  author    = {Engel, Linda W and Strauchen, James A and Chiazze Jr, Leonard and Heid, Marian},
  title     = {Accuracy of death certification in an autopsied population with specific attention to malignant neoplasms and vascular diseases},
  journal   = {American Journal of Epidemiology},
  year      = {1980},
  volume    = {111},
  number    = {1},
  pages     = {99--112},
  owner     = {PaulD},
  publisher = {Oxford University Press},
  timestamp = {2017-12-20},
}

@Article{Wolkewitz2017,
  author       = {Wolkewitz, Martin and von Cube, Maja and Schumacher, Martin},
  title        = {Multistate Modeling to Analyze Nosocomial Infection Data: An Introduction and Demonstration.},
  journal      = {Infection control and hospital epidemiology},
  year         = {2017},
  volume       = {38},
  issue        = {8},
  month        = aug,
  pages        = {953--959},
  issn         = {1559-6834},
  doi          = {10.1017/ice.2017.107},
  abstract     = {OBJECTIVE Multistate and competing risks models have become an established and adequate tool with which to quantify determinants and consequences of nosocomial infections. In this tutorial article, we explain and demonstrate the basics of these models to a broader audience of professionals in health care, infection control, and hospital epidemiology. METHODS Using a publicly available data set from a cohort study of intensive care unit patients, we show how hospital infection data can be displayed and explored graphically and how simple formulas are derived under some simplified assumptions for illustrating the basic ideas behind multistate models. Only a few simply accessible values (event counts and patient days) and a pocket calculator are needed to reveal basic insights into cumulative risk and clinical outcomes of nosocomial infection in terms of mortality and length of stay. RESULTS We show how to use these values to perform basic multistate analyses in own data or to correct biased estimates in published data, as these values are often reported. We also show relationships between multistate-based hazard ratios and odds ratios, which are derived from the popular logistic regression model. CONCLUSIONS No sophisticated statistical software is required to apply a basic multistate model and to avoid typical pitfalls such as time-dependent or competing-risks bias. Infect Control Hosp Epidemiol 2017;38:953-959.},
  country      = {United States},
  issn-linking = {0899-823X},
  nlm-id       = {8804099},
  owner        = {NLM},
  pii          = {S0899823X17001076},
  pmid         = {28633679},
  pubmodel     = {Print-Electronic},
  pubstatus    = {ppublish},
  revised      = {2017-07-31},
}

@Article{Cube2017,
  author       = {von Cube, Maja and Schumacher, Martin and Palomar-Martinez, Mercedes and Olaechea-Astigarraga, Pedro and Alvarez-Lerma, Francisco and Wolkewitz, Martin},
  title        = {A case-cohort approach for multi-state models in hospital epidemiology.},
  journal      = {Statistics in medicine},
  year         = {2017},
  volume       = {36},
  issue        = {3},
  month        = feb,
  pages        = {481--495},
  issn         = {1097-0258},
  doi          = {10.1002/sim.7146},
  abstract     = {Analysing the determinants and consequences of hospital-acquired infections involves the evaluation of large cohorts. Infected patients in the cohort are often rare for specific pathogens, because most of the patients admitted to the hospital are discharged or die without such an infection. Death and discharge are competing events to acquiring an infection, because these individuals are no longer at risk of getting a hospital-acquired infection. Therefore, the data is best analysed with an extended survival model - the extended illness-death model. A common problem in cohort studies is the costly collection of covariate values. In order to provide efficient use of data from infected as well as uninfected patients, we propose a tailored case-cohort approach for the extended illness-death model. The basic idea of the case-cohort design is to only use a random sample of the full cohort, referred to as subcohort, and all cases, namely the infected patients. Thus, covariate values are only obtained for a small part of the full cohort. The method is based on existing and established methods and is used to perform regression analysis in adapted Cox proportional hazards models. We propose estimation of all cause-specific cumulative hazards and transition probabilities in an extended illness-death model based on case-cohort sampling. As an example, we apply the methodology to infection with a specific pathogen using a large cohort from Spanish hospital data. The obtained results of the case-cohort design are compared with the results in the full cohort to investigate the performance of the proposed method. Copyright ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â© 2016 John Wiley & Sons, Ltd.},
  country      = {England},
  issn-linking = {0277-6715},
  keywords     = {Cox proportional hazards model; case-cohort design; cumulative hazard function; multi-state models; transition probability},
  nlm-id       = {8215016},
  owner        = {NLM},
  pmid         = {27774627},
  pubmodel     = {Print-Electronic},
  pubstatus    = {ppublish},
  revised      = {2017-01-03},
}

@Article{Cube2017a,
  author       = {von Cube, Maja and Schumacher, Martin and Wolkewitz, Martin},
  title        = {Basic parametric analysis for a multi-state model in hospital epidemiology.},
  journal      = {BMC medical research methodology},
  year         = {2017},
  volume       = {17},
  issue        = {1},
  month        = jul,
  pages        = {111},
  issn         = {1471-2288},
  doi          = {10.1186/s12874-017-0379-4},
  abstract     = {The extended illness-death model is a useful tool to study the risks and consequences of hospital-acquired infections (HAIs). The statistical quantities of interest are the transition-specific hazard rates and the transition probabilities as well as attributable mortality (AM) and the population-attributable fraction (PAF). In the most general case calculation of these expressions is mathematically complex. When assuming time-constant hazards calculation of the quantities of interest is facilitated. In this situation the transition probabilities can be expressed in closed mathematical forms. The estimators for AM and PAF can be easily derived from these forms. In this paper, we show how to explicitly calculate all the transition probabilities of an extended-illness model with constant hazards. Using a parametric model to estimate the time-constant transition specific hazard rates of a data example, the transition probabilities, AM and PAF can be directly calculated. With a publicly available data example, we show how the approach provides first insights into principle time-dynamics and data structure. Assuming constant hazards facilitates the understanding of multi-state processes. Even in a non-constant hazards setting, the approach is a helpful first step for a comprehensive investigation of complex data.},
  country      = {England},
  file         = {:Cube2017a - Basic Parametric Analysis for a Multi State Model in Hospital Epidemiology..pdf:PDF},
  issn-linking = {1471-2288},
  keywords     = {Attributable mortality; Homogeneous Markov process; Nosocomial infection; Population-attributable fraction; Transition probabilitiy},
  nlm-id       = {100968545},
  owner        = {NLM},
  pii          = {10.1186/s12874-017-0379-4},
  pmc          = {PMC5520301},
  pmid         = {28728582},
  pubmodel     = {Electronic},
  pubstatus    = {epublish},
  revised      = {2017-07-23},
}

@Article{Posch2017,
  author          = {Posch, Florian and Leitner, Lukas and Bergovec, Marko and Bezan, Angelika and Stotz, Michael and Gerger, Armin and Pichler, Martin and St{\"o}ger, Herbert and Liegl-Atzwanger, Bernadette and Leithner, Andreas and Szkandera, Joanna},
  title           = {Can Multistate Modeling of Local Recurrence, Distant Metastasis, and Death Improve the Prediction of Outcome in Patients With Soft Tissue Sarcomas?},
  doi             = {10.1007/s11999-017-5232-x},
  issn            = {1528-1132},
  issue           = {5},
  pages           = {1427--1435},
  volume          = {475},
  abstract        = {Exploration of the complex relationship between prognostic indicators such as tumor grade and size and clinical outcomes such as local recurrence and distant metastasis in patients with cancer is crucial to guide treatment decisions. However, in patients with soft tissue sarcoma, there are many gaps in our understanding of this relationship. Multistate analysis may help us in gaining a comprehensive understanding of risk factor-outcome relationships in soft tissue sarcoma, because this methodology can integrate multiple risk factors and clinical endpoints into a single statistical model. To our knowledge, no study of this kind has been performed before in patients with soft tissue sarcoma. We implemented a multistate model of localized soft tissue sarcoma to statistically evaluate the relationship among baseline risk factors, recurrence, and death in patients with localized soft tissue sarcoma undergoing curative surgery. Between 1998 and 2015, our center treated 539 patients for localized soft tissue sarcoma with surgery as curative intent. Of those, 96 patients (18%) were not included in this single-center retrospective study owing to missing baseline histopathology data (n = 3), not yet observed followup (n = 80), or because a neoadjuvant treatment approach in the presence of synchronous distant metastasis was used (n = 13), leaving 443 patients (82%) for the current analysis, of which 40 were lost to followup during the first year after surgery. All patients had tumors of the stages I to III according to the American Joint Committee on Cancer Stages. The median age of the patients was 62 years (range, 16-96 years), and 217 patients (49%) were female. Three hundred-forty-six patients (78%) had tumors of high grade (Grades 2 and 3), and 310 (70%) tumors were greater than 5 cm in maximum diameter. Patients who had died during the first year of followup were included in this analysis. Median followup for the 443 study patients was 6 years, with 84%, 52%, and 23% of patients being followed for more than 1, 5, and 10 years, respectively. The 15-year cumulative incidences of local recurrence, distant metastasis, and death from any cause, using a competing risk analysis, were 16% (95% CI, 11%-22%), 21% (95% CI, 17%-26%), and 55% (95% CI, 44%-67%), respectively. Wide resection with a margin of 1 mm was the preferred treatment for all patients, except for those with Grade 1 liposarcoma where a marginal resection was considered adequate. Multistate models were implemented with the mstate library in R. In multistate analysis, patients who experienced a local recurrence were more likely to have distant metastasis develop (hazard ratio [HR] = 8.4; 95% CI, 4.3-16.5; p < 0.001), and to die (HR = 3.4; 95% CI, 2.1-5.6; p < 0.001). The occurrence of distant metastasis was associated with a strong increase in the risk of death (HR = 12.6; 95% CI, 8.7-18.3; p < 0.001). Distant metastasis occurring after a long tumor-free interval was not associated with a more-favorable prognosis with respect to mortality than distant metastasis occurring early after surgery (estimated relative decrease in the adverse effect of distant metastasis on mortality for 1-year delay in the occurrence of distant metastasis = 0.9; 95% CI, 0.7-1.1; p = 0.28). High-grade histology (Grades 2 and 3) was associated with a higher risk of overall recurrence (defined as a composite of local recurrence and distant metastasis, HR = 3.8; 95% CI, 1.8-7.8; p = 0.0003) and a higher risk of death after recurrence developed (HR = 4.4; 95% CI, 1.1-18.2; p = 0.04). Finally, the multistate model predicted distinct outcome patterns depending on baseline covariates and how long a patient has remained free from recurrence after surgery. In patients with localized soft tissue sarcoma undergoing resection, the occurrence of local recurrence and distant metastasis contributes to a dramatically impaired long-term survival outcome. Local recurrences are a substantial risk factor for distant metastasis. Multistate modeling is a very powerful approach for analysis of sarcoma cohorts, and may be used in the future to obtain highly personalized, dynamic predictions of outcomes in patients with localized soft tissue sarcoma. Level III, therapeutic study.},
  citation-subset = {AIM, IM},
  completed       = {2017-04-17},
  country         = {United States},
  file            = {:Posch2017.pdf:PDF},
  issn-linking    = {0009-921X},
  journal         = {Clinical orthopaedics and related research},
  keywords        = {Adolescent; Adult; Aged; Aged, 80 and over; Austria; Decision Support Techniques; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Models, Statistical; Neoplasm Recurrence, Local; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Sarcoma, mortality, secondary, surgery; Soft Tissue Neoplasms, pathology, surgery; Time Factors; Treatment Outcome; Young Adult},
  month           = may,
  nlm-id          = {0075674},
  owner           = {NLM},
  pii             = {10.1007/s11999-017-5232-x},
  pmc             = {PMC5384928},
  pmid            = {28083752},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2017-08-24},
  year            = {2017},
}

@Online{SEERStat,
  author       = {{Surveillance Research Program}},
  title        = {{SEER*Stat} software},
  url          = {seer.cancer.gov/seerstat},
  note         = {Version 8.3.4},
  organization = {National Cancer Institute},
  owner        = {PaulD},
  timestamp    = {2018-01-10},
}

@Article{Shack2013,
  author          = {Shack, Lorraine and Bryant, Heather and Lockwood, Gina and Ellison, Larry F},
  title           = {Conditional relative survival: a different perspective to measuring cancer outcomes.},
  journal         = {Cancer epidemiology},
  year            = {2013},
  volume          = {37},
  issue           = {4},
  month           = aug,
  pages           = {446--448},
  issn            = {1877-783X},
  doi             = {10.1016/j.canep.2013.03.019},
  citation-subset = {IM},
  completed       = {2014-02-03},
  country         = {Netherlands},
  issn-linking    = {1877-7821},
  keywords        = {Humans; Neoplasms, pathology; Outcome Assessment (Health Care), methods; Survival Analysis; Survival Rate; Time Factors},
  nlm-id          = {101508793},
  owner           = {NLM},
  pii             = {S1877-7821(13)00060-X},
  pmid            = {23632048},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2013-06-10},
  timestamp       = {2018.01.19},
}

@Article{Pukkala2017,
  author       = {Pukkala, Eero and Engholm, Gerda and H{\AA}Â¸jsgaard Schmidt, Lise Kristine and Storm, Hans and Khan, Staffan and Lambe, Mats and Pettersson, David and {\AA}Â“lafsd{\AA}Â³ttir, El{\AA}Â­nborg and Tryggvad{\AA}Â³ttir, Laufey and Hakanen, Tiina and Malila, Nea and Virtanen, Anni and Johannesen, Tom B{\AA}Â¸rge and Lar{\AA}Â¸nningen, Siri and Ursin, Giske},
  title        = {Nordic Cancer Registries - an overview of their procedures and data comparability.},
  journal      = {Acta oncologica (Stockholm, Sweden)},
  year         = {2017},
  month        = dec,
  pages        = {1--16},
  issn         = {1651-226X},
  doi          = {10.1080/0284186X.2017.1407039},
  abstract     = {The Nordic Cancer Registries are among the oldest population-based registries in the world, with more than 60 years of complete coverage of what is now a combined population of 26 million. However, despite being the source of a substantial number of studies, there is no published paper comparing the different registries. Therefore, we did a systematic review to identify similarities and dissimilarities of the Nordic Cancer Registries, which could possibly explain some of the differences in cancer incidence rates across these countries. We describe and compare here the core characteristics of each of the Nordic Cancer Registries: (i) data sources; (ii) registered disease entities and deviations from IARC multiple cancer coding rules; (iii) variables and related coding systems. Major changes over time are described and discussed. All Nordic Cancer Registries represent a high quality standard in terms of completeness and accuracy of the registered data. Even though the information in the Nordic Cancer Registries in general can be considered more similar than any other collection of data from five different countries, there are numerous differences in registration routines, classification systems and inclusion of some tumors. These differences are important to be aware of when comparing time trends in the Nordic countries.},
  country      = {England},
  file         = {:Pukkala2017.pdf:PDF},
  issn-linking = {0284-186X},
  nlm-id       = {8709065},
  owner        = {NLM},
  pmid         = {29226751},
  pubmodel     = {Print-Electronic},
  pubstatus    = {aheadofprint},
  revised      = {2018-01-10},
  timestamp    = {2018.01.19},
}

@Article{Allemani2018,
  author       = {Allemani, Claudia and Matsuda, Tomohiro and Di Carlo, Veronica and Harewood, Rhea and Matz, Melissa and Niksic, Maja and Bonaventure, Audrey and Valkov, Mikhail and Johnson, Christopher J and Esteve, Jacques and Ogunbiyi, Olufemi J and Azevedo E Silva, Gulnar and Chen, Wan-Qing and Eser, Sultan and Engholm, Gerda and Stiller, Charles A and Monnereau, Alain and Woods, Ryan R and Visser, Otto and Lim, Gek Hsiang and Aitken, Joanne and Weir, Hannah K and Coleman, Michel P and CONCORD Working Group},
  title        = {Global surveillance of trends in cancer survival 2000-14 ({CONCORD-3}): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.},
  journal      = {Lancet},
  year         = {2018},
  month        = jan,
  issn         = {1474-547X},
  doi          = {10.1016/S0140-6736(17)33326-3},
  country      = {England},
  issn-linking = {0140-6736},
  nlm-id       = {2985213R},
  owner        = {PaulD},
  pii          = {S0140-6736(17)33326-3},
  pmid         = {29395269},
  pubmodel     = {Print-Electronic},
  pubstatus    = {aheadofprint},
  revised      = {2018-02-03},
  timestamp    = {2018-02-09},
}

@Article{Dehbi2017,
  author          = {Dehbi, Hakim-Moulay and Royston, Patrick and Hackshaw, Allan},
  title           = {Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards.},
  journal         = {BMJ (Clinical research ed.)},
  year            = {2017},
  volume          = {357},
  month           = may,
  pages           = {j2250},
  issn            = {1756-1833},
  doi             = {10.1136/bmj.j2250},
  citation-subset = {AIM, IM},
  completed       = {2017-11-21},
  country         = {England},
  issn-linking    = {0959-535X},
  keywords        = {Data Interpretation, Statistical; Humans; Kaplan-Meier Estimate; Life Expectancy; Randomized Controlled Trials as Topic, methods},
  nlm-id          = {8900488},
  owner           = {NLM},
  pmc             = {PMC5444092},
  pmid            = {28546261},
  pubmodel        = {Electronic},
  pubstatus       = {epublish},
  revised         = {2017-11-28},
}

@Article{Bower2017,
  author       = {Bower, H. and Andersson, T.M-L. and Crowther, M.J. and Dickman, P.W. and Lambe, M. and Lambert, P.C.},
  title        = {Adjusting expected mortality rates using information from a control population: An example using socioeconomic status.},
  journal      = {American Journal of Epidemiology},
  year         = {2018},
  volume       = {187},
  pages        = {828-836},
  issn         = {1476-6256},
  doi          = {10.1093/aje/kwx303},
  abstract     = {Expected or reference mortality rates are commonly used in the calculation of measures such as relative survival in population-based cancer survival studies and standardized mortality ratios. These expected rates are usually presented by age, sex and calendar year. In certain situations, stratification of expected rates by other factors is required to avoid potential bias if interest lies in quantifying measures by such factors, for example, socioeconomic status. If data on a population level are not available, information from a control population could be used to adjust expected rates. We present two approaches for adjusting expected mortality rates using information from a control population; a Poisson generalised linear model, and a flexible parametric survival model. We used a control group from BCBaSe, a Swedish register-based matched breast cancer cohort with diagnoses between 1992 and 2012, to illustrate the two methods using socioeconomic status as a risk factor of interest. Results showed that Poisson and flexible parametric survival approaches estimate similar adjusted mortality rates by socioeconomic status. Additional uncertainty involved in the methods to estimate stratified expected mortality rates described in this study can be accounted for using a parametric bootstrap, but may make little difference if using a large control population.},
  country      = {United States},
  file         = {:Bower2017.pdf:PDF},
  issn-linking = {0002-9262},
  keywords     = {Poisson model; control group; expected mortality rate; flexible parametric model; life tables; socioeconomic factors; standard population; standardized mortality ratio},
  nlm-id       = {7910653},
  owner        = {NLM},
  pii          = {4093017},
  pmid         = {29020167},
  pubmodel     = {Print-Electronic},
  pubstatus    = {aheadofprint},
  revised      = {2017-10-11},
  timestamp    = {2018.02.21},
}

@Article{Hernan2018,
  author       = {Hern\'{a}n, M. A.},
  title        = {How to estimate the effect of treatment duration on survival outcomes using observational data.},
  journal      = {BMJ (Clinical research ed.)},
  year         = {2018},
  volume       = {360},
  month        = feb,
  pages        = {k182},
  issn         = {1756-1833},
  doi          = {10.1136/bmj.k182},
  country      = {England},
  file         = {:Hernan2018.pdf:PDF},
  issn-linking = {0959-535X},
  nlm-id       = {8900488},
  owner        = {NLM},
  pmid         = {29419381},
  pubmodel     = {Electronic},
  pubstatus    = {epublish},
  revised      = {2018-02-11},
  timestamp    = {2018.03.02},
}

@Article{Emilsson2015c,
  author          = {Emilsson, L and Lindahl, B and K{\"o}ster, M and Lambe, M and Ludvigsson, J F},
  title           = {Review of 103 {Swedish} Healthcare Quality Registries.},
  journal         = {Journal of Internal Medicine},
  year            = {2015},
  volume          = {277},
  issue           = {1},
  month           = jan,
  pages           = {94--136},
  issn            = {1365-2796},
  doi             = {10.1111/joim.12303},
  abstract        = {In the past two decades, an increasing number of nationwide, Swedish Healthcare Quality Registries (QRs) focusing on specific disorders have been initiated, mostly by physicians. Here, we describe the purpose, organization, variables, coverage and completeness of 103 Swedish QRs. From March to September 2013, we examined the 2012 applications of 103 QRs to the Swedish Association of Local Authorities and Regions (SALAR) and also studied the annual reports from the same QRs. After initial data abstraction, the coordinator of each QR was contacted at least twice between June and October 2013 and asked to confirm the accuracy of the data retrieved from the applications and reports. About 60% of the QRs covered ?80% of their target population (completeness). Data recorded in Swedish QRs include aspects of disease management (diagnosis, clinical characteristics, treatment and lead times). In addition, some QRs retrieve data on self-reported quality of life (EQ5D, SF-36 and disease-specific measures), lifestyle (smoking) and general health status (World Health Organization performance status, body mass index and blood pressure). Detailed clinical data available in Swedish QRs complement information from government-administered registries and provide an important source not only for assessment and development of quality of care but also for research.},
  citation-subset = {IM},
  completed       = {2015-02-10},
  country         = {England},
  file            = {:Emilsson2015c.pdf:PDF},
  issn-linking    = {0954-6820},
  keywords        = {Delivery of Health Care, organization & administration; Female; Humans; Male; Quality Assurance, Health Care; Registries; Sweden; adult; child; life quality; morbidity; register; registry},
  nlm-id          = {8904841},
  owner           = {NLM},
  pmid            = {25174800},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2014-12-16},
}

@Article{Stringhini2017,
  author          = {Stringhini, Silvia and Carmeli, Cristian and Jokela, Markus and Avenda{\AA}Â±o, Mauricio and Muennig, Peter and Guida, Florence and Ricceri, Fulvio and d'Errico, Angelo and Barros, Henrique and Bochud, Murielle and Chadeau-Hyam, Marc and Clavel-Chapelon, Fran{\AA}Â§oise and Costa, Giuseppe and Delpierre, Cyrille and Fraga, Silvia and Goldberg, Marcel and Giles, Graham G and Krogh, Vittorio and Kelly-Irving, Michelle and Layte, Richard and Lasserre, Aur{\AA}Â©lie M and Marmot, Michael G and Preisig, Martin and Shipley, Martin J and Vollenweider, Peter and Zins, Marie and Kawachi, Ichiro and Steptoe, Andrew and Mackenbach, Johan P and Vineis, Paolo and Kivim{\"a}ki, Mika and LIFEPATH consortium},
  title           = {Socioeconomic status and the 25?{\AA}Â—?25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·7 million men and women.},
  journal         = {Lancet},
  year            = {2017},
  volume          = {389},
  issue           = {10075},
  pages           = {1229--1237},
  issn            = {1474-547X},
  doi             = {10.1016/S0140-6736(16)32380-7},
  abstract        = {In 2011, WHO member states signed up to the 25?{\AA}Â—?25 initiative, a plan to cut mortality due to non-communicable diseases by 25% by 2025. However, socioeconomic factors influencing non-communicable diseases have not been included in the plan. In this study, we aimed to compare the contribution of socioeconomic status to mortality and years-of-life-lost with that of the 25?{\AA}Â—?25 conventional risk factors. We did a multicohort study and meta-analysis with individual-level data from 48 independent prospective cohort studies with information about socioeconomic status, indexed by occupational position, 25?{\AA}Â—?25 risk factors (high alcohol intake, physical inactivity, current smoking, hypertension, diabetes, and obesity), and mortality, for a total population of 1?751?479 (54% women) from seven high-income WHO member countries. We estimated the association of socioeconomic status and the 25?{\AA}Â—?25 risk factors with all-cause mortality and cause-specific mortality by calculating minimally adjusted and mutually adjusted hazard ratios [HR] and 95% CIs. We also estimated the population attributable fraction and the years of life lost due to suboptimal risk factors. During 26ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·6 million person-years at risk (mean follow-up 13ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·3 years [SD 6ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·4 years]), 310?277 participants died. HR for the 25?{\AA}Â—?25 risk factors and mortality varied between 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·04 (95% CI 0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·98-1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·11) for obesity in men and 2?ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·17 (2ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·06-2ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·29) for current smoking in men. Participants with low socioeconomic status had greater mortality compared with those with high socioeconomic status (HR 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·42, 95% CI 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·38-1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·45 for men; 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·34, 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·28-1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·39 for women); this association remained significant in mutually adjusted models that included the 25?{\AA}Â—?25 factors (HR 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·26, 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·21-1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·32, men and women combined). The population attributable fraction was highest for smoking, followed by physical inactivity then socioeconomic status. Low socioeconomic status was associated with a 2ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·1-year reduction in life expectancy between ages 40 and 85 years, the corresponding years-of-life-lost were 0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·5 years for high alcohol intake, 0ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·7 years for obesity, 3ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·9 years for diabetes, 1ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·6 years for hypertension, 2ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·4 years for physical inactivity, and 4ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â·8 years for current smoking. Socioeconomic circumstances, in addition to the 25?{\AA}Â—?25 factors, should be targeted by local and global health strategies and health risk surveillance to reduce mortality. European Commission, Swiss State Secretariat for Education, Swiss National Science Foundation, the Medical Research Council, NordForsk, Portuguese Foundation for Science and Technology.},
  citation-subset = {AIM, IM},
  completed       = {2018-04-16},
  country         = {England},
  investigator    = {Alenius, Harri and Avendano, Mauricio and Barros, Henrique and Bochud, Murielle and Carmeli, Cristian and Carra, Luca and Castagn{\AA}Â©, Raphaele and Chadeau-Hyam, Marc and Clavel-Chapelon, Fran{\AA}Â§oise and Costa, Giuseppe and Courtin, Emilie and Delpierre, Cyrille and D'Errico, Angelo and Dugu{\AA}Â©, Pierre-Antoine and Elliott, Paul and Fraga, Silvia and Gares, Val{\AA}Â©rie and Giles, Graham and Goldberg, Marcel and Greco, Dario and Hodge, Allison and Irving, Michelle Kelly and Karisola, Piia and Kivim{\"a}ki, Mika and Krogh, Vittorio and Lang, Thierry and Layte, Richard and Lepage, Benoit and Mackenbach, Johan and Marmot, Michael and McCrory, Cathal and Milne, Roger and Muennig, Peter and Nusselder, Wilma and Panico, Salvatore and Petrovic, Dusan and Polidoro, Silvia and Preisig, Martin and Raitakari, Olli and Ribeiro, Ana Isabel and Ribeiro, Ana Isabel and Ricceri, Fulvio and Robinson, Oliver and Valverde, Jose Rubio and Sacerdote, Carlotta and Satolli, Roberto and Severi, Gianluca and Shipley, Martin J and Stringhini, Silvia and Tumino, Rosario and Vineis, Paolo and Vollenweider, Peter and Zins, Marie},
  issn-linking    = {0140-6736},
  keywords        = {Adult; Alcohol Drinking, mortality; Cohort Studies; Exercise, physiology; Female; Humans; Male; Middle Aged; Mortality, Premature; Obesity, mortality; Risk Factors; Smoking, mortality; Social Class},
  nlm-id          = {2985213R},
  owner           = {NLM},
  pii             = {S0140-6736(16)32380-7},
  pmc             = {PMC5368415},
  pmid            = {28159391},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2018-04-16},
}

@Article{Zhao2018,
  author       = {Zhao, J. and Ryd{\AA}Â©n, J. and Wikman, A. and Norda, R. and Stanworth, S. J. and Hjalgrim, H. and Edgren, G.},
  title        = {Blood use in hematologic malignancies: a nationwide overview in Sweden between 2000 and 2010.},
  journal      = {Transfusion},
  year         = {2018},
  volume       = {58},
  issue        = {2},
  pages        = {390--401},
  issn         = {1537-2995},
  doi          = {10.1111/trf.14440},
  abstract     = {Patients with hematologic malignancies receive large numbers of blood transfusions, and transfusion practices for this patient group are increasingly being scrutinized by randomized controlled trials. However, no studies so far have presented current transfusion statistics on a population level for this patient group. A retrospective descriptive study was conducted that was based on the Scandinavian Donations and Transfusions Database (SCANDAT2), which includes data on all blood donations and transfusions in Sweden and Denmark since the 1960s. Incident cases of hematologic malignancies were identified in the Swedish Cancer Register between 2000 and 2010. Cases were divided into nine patient groups based on diagnosis. A total of 28,693 patients were included in the cohort. Overall, the transfusion pattern varied depending on diagnosis and age. Patients with aggressive and acute diagnoses generally received more transfusions with immediate decline in transfusion incidence after diagnosis, whereas chronic diagnoses generally maintained more stable, but lower, transfusion incidence. In general, patients with leukemia received more transfusions than patients with lymphoma, and patients with acute leukemia as well as patients that had undergone allogeneic stem cell transplantations received the most transfusions. Within 2 years after diagnosis, patients with acute myeloid leukemia diagnosed at ages 0 to 65 years received on average between 30 to 40 red blood cell transfusions and platelet transfusions, respectively, corresponding to direct material costs close to 200,000 SEK (23,809 USD). Results from this population-based overview of blood use in hematologic malignancies showed high variability depending on diagnosis and age.},
  country      = {United States},
  issn-linking = {0041-1132},
  nlm-id       = {0417360},
  owner        = {NLM},
  pmid         = {29250794},
  pubmodel     = {Print-Electronic},
  pubstatus    = {ppublish},
  revised      = {2018-02-07},
}

@Article{Moerner2017,
  author          = {M{\"o}rner, Malin E M and Edgren, Gustaf and Martling, Anna and Gunnarsson, Ulf and Egenvall, Monika},
  title           = {Preoperative anaemia and perioperative red blood cell transfusion as prognostic factors for recurrence and mortality in colorectal cancer-a Swedish cohort study.},
  journal         = {International journal of colorectal disease},
  year            = {2017},
  volume          = {32},
  issue           = {2},
  pages           = {223--232},
  issn            = {1432-1262},
  doi             = {10.1007/s00384-016-2678-3},
  abstract        = {The hypothesis in this study was that anaemia prior to surgery and perioperative red blood cell transfusion increases the risk for recurrence and overall mortality in patients with stages I-III colorectal cancer after abdominal resection with curative intent. This is a Swedish single centre retrospective cohort study. Data on 496 consecutive radical abdominal resections stages I-III colorectal cancer performed at the Karolinska University Hospital 2007-2010 were extracted from the Swedish Colorectal Cancer Registry. Data were linked to local laboratory and transfusion databases to identify preoperative anaemia and perioperative transfusion. Disease recurrence was validated by scrutiny of patient records. A total of 496 stages I-III colorectal cancer patients were included in the analysis. Multivariate Cox regression analysis adjusted for tumour and patient characteristics were performed to assess risk for recurrence and overall mortality. Anaemia prior to surgery was associated with increased risk for overall mortality (HR 2.1, 95% CI 1.4-3.2). There was no association between anaemia and risk for recurrence (HR 1.6, 95% CI 0.97-2.6). Transfusion was not associated with increased risk of recurrence (HR 0.7, 95% CI 0.4-1.3) or overall mortality (HR 1.04, 95% CI 0.7-1.6). Anaemia prior to colorectal cancer surgery was associated with increased risk for overall mortality while a no increased risk was seen for recurrence. Previous findings indicating an association between blood transfusion and increased risk for recurrence could not be confirmed.},
  citation-subset = {IM},
  completed       = {2017-04-24},
  country         = {Germany},
  issn-linking    = {0179-1958},
  keywords        = {Aged; Anemia, complications; Cohort Studies; Colorectal Neoplasms, mortality, surgery; Erythrocyte Transfusion; Female; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local, pathology; Neoplasm Staging; Perioperative Care; Preoperative Care; Prognosis; Proportional Hazards Models; Regression Analysis; Sweden, epidemiology; Anaemia; Colorectal cancer; Mortality; Recurrence; Survival; Transfusion},
  nlm-id          = {8607899},
  owner           = {NLM},
  pii             = {10.1007/s00384-016-2678-3},
  pmc             = {PMC5285411},
  pmid            = {27770250},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2017-04-24},
}

@Article{Pavlic2018,
  author       = {Pavlic, K. and Pohar Perme, M.},
  title        = {Using pseudo-observations for estimation in relative survival.},
  journal      = {Biostatistics},
  year         = {2018},
  volume       = {20},
  number       = {3},
  pages        = {384-399},
  issn         = {1468-4357},
  doi          = {10.1093/biostatistics/kxy008},
  abstract     = {A common goal in the analysis of the long-term survival related to a specific disease is to estimate a measure that is comparable between populations with different general population mortality. When cause of death is unavailable or unreliable, as for example in cancer registry studies, relative survival methodology is used-in addition to the mortality data of the patients, we use the data on the mortality of the general population. In this article, we focus on the marginal relative survival measure that summarizes the information about the disease-specific hazard. Under additional assumptions about latent times to death of each cause, this measure equals net survival. We propose a new approach to estimation based on pseudo-observations and derive two estimators of its variance. The properties of the new approach are assessed both theoretically and with simulations, showing practically no bias and a close to nominal coverage of the confidence intervals with the precise formula for the variance. The approximate formula for the variance has sufficiently good performance in large samples where the precise formula calculation becomes computationally intensive. Using bladder cancer data and simulations, we show that the behavior of the new approach is very close to that of the Pohar Perme estimator but has the important advantage of a simpler formula that does not require numerical integration and therefore lends itself more naturally to further extensions.},
  country      = {England},
  file         = {:Pavlic2018.pdf:PDF},
  issn-linking = {1465-4644},
  nlm-id       = {100897327},
  owner        = {NLM},
  pii          = {4933919},
  pmid         = {29547896},
  pubmodel     = {Print-Electronic},
  pubstatus    = {aheadofprint},
  revised      = {2018-03-16},
}

@Article{Andersson2018,
  author       = {Andersson, Therese M-L and Engholm, Gerda and Pukkala, Eero and Stenbeck, Magnus and Tryggvadottir, Laufey and Storm, Hans and Weiderpass, Elisabete},
  title        = {Avoidable cancers in the Nordic countries-The impact of alcohol consumption.},
  journal      = {European journal of cancer (Oxford, England : 1990)},
  year         = {2018},
  month        = may,
  issn         = {1879-0852},
  doi          = {10.1016/j.ejca.2018.03.027},
  country      = {England},
  issn-linking = {0959-8049},
  keywords     = {Alcohol; Cancer; Nordic countries; Population-attributable fraction; Potential impact fraction; Prevent macro-simulation model; Prevention},
  nlm-id       = {9005373},
  owner        = {NLM},
  pii          = {S0959-8049(18)30776-7},
  pmid         = {29739641},
  pubmodel     = {Print-Electronic},
  pubstatus    = {aheadofprint},
  revised      = {2018-05-09},
}

@Article{Syriopoulou2017,
  author          = {Syriopoulou, E. and Bower, H. and Andersson, T.M-L and Lambert, P.C. and Rutherford, M.J.},
  title           = {Estimating the impact of a cancer diagnosis on life expectancy by socio-economic group for a range of cancer types in {E}ngland.},
  journal         = {British Journal of Cancer},
  year            = {2017},
  volume          = {117},
  issue           = {9},
  pages           = {1419--1426},
  issn            = {1532-1827},
  doi             = {10.1038/bjc.2017.300},
  citation-subset = {IM},
  completed       = {2017-11-09},
  country         = {England},
  file            = {:Syriopoulou2017.pdf:PDF},
  issn-linking    = {0007-0920},
  keywords        = {Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Life Expectancy; Male; Middle Aged; Neoplasm Staging; Neoplasms, diagnosis, mortality; Prognosis; Registries, statistics & numerical data; Socioeconomic Factors; Survival Rate},
  nlm-id          = {0370635},
  owner           = {NLM},
  pii             = {bjc2017300},
  pmc             = {PMC5672926},
  pmid            = {28898233},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2017-11-10},
}

@Article{Johansson2018,
  author       = {Johansson, Anna L V and Andersson, Therese M-L and Hsieh, Chung-Cheng and Jirstr{\"o}m, Karin and Cnattingius, Sven and Fredriksson, Irma and Dickman, Paul W and Lambe, Mats},
  title        = {Tumor characteristics and prognosis in women with pregnancy-associated breast cancer.},
  journal      = {International journal of cancer},
  year         = {2018},
  volume       = {142},
  issue        = {7},
  month        = apr,
  pages        = {1343--1354},
  issn         = {1097-0215},
  doi          = {10.1002/ijc.31174},
  country      = {United States},
  issn-linking = {0020-7136},
  keywords     = {TNM stage; breast cancer; hormone receptors; pregnancy; survival},
  nlm-id       = {0042124},
  owner        = {NLM},
  pmid         = {29168177},
  pubmodel     = {Print-Electronic},
  pubstatus    = {ppublish},
  revised      = {2018-02-08},
}

@Article{Baade2016a,
  author          = {Baade, Peter D and Youlden, Danny R and Andersson, Therese M and Youl, Philippa H and Walpole, Euan T and Kimlin, Michael G and Aitken, Joanne F and Biggar, Robert J},
  title           = {Temporal changes in loss of life expectancy due to cancer in Australia: a flexible parametric approach.},
  journal         = {Cancer causes \& control : CCC},
  year            = {2016},
  volume          = {27},
  issue           = {8},
  month           = aug,
  pages           = {955--964},
  issn            = {1573-7225},
  doi             = {10.1007/s10552-016-0762-1},
  abstract        = {To evaluate changes in cancer mortality burden over time by assessing temporal trends in life expectation for Australian residents diagnosed with cancer. The study cohort consisted of all people diagnosed with cancer in the period 1990-2000 and aged 15-89ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years (nÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â =ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â 1,275,978), with mortality follow-up to 31 December 2010. Flexible parametric survival models incorporating background age-sex-year-specific population mortality rates were applied to generate the observed survival curves for all cancers combined and selected major cancer types. Predicted values of loss of life expectancy (LOLE) in years were generated and then averaged across calendar year and age group (15-49, 50-69 and 70-89ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years) or spread of disease (localized, regional, distant, unknown). The greatest LOLE burden was for lung cancer (14.3ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years per diagnosis) and lowest for melanoma (2.5ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years). There was a significant decrease in LOLE over time (-0.13ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â LOLE per year) for all cancers combined. Decreases were also observed for female breast cancer (-0.21), prostate cancer (-0.17), colorectal cancer (-0.08), melanoma (-0.07) and stomach cancer (-0.02), with slight increases for lung cancer (+0.04). When restricted to the sub-cohort from New South Wales with spread of disease information, these decreases in LOLE were primarily among cancers categorized as localized or regional spread at diagnosis. In Australia, persons diagnosed with cancer have a steadily improving outlook that exceeds that expected by general improvement in population life expectancy. The overall improvement is observed in persons with localized or regional cancers but not in those with advanced cancers, findings which encourage earlier diagnosis.},
  citation-subset = {IM},
  completed       = {2017-06-15},
  country         = {Netherlands},
  issn-linking    = {0957-5243},
  keywords        = {Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Australia, epidemiology; Cohort Studies; Female; Humans; Life Expectancy; Male; Middle Aged; Models, Theoretical; Neoplasms, epidemiology, mortality; Young Adult; Australia; Cancer; Life expectancy; Prognosis; Spread of disease},
  nlm-id          = {9100846},
  owner           = {NLM},
  pii             = {10.1007/s10552-016-0762-1},
  pmid            = {27306518},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2017-12-11},
}

@Article{Andersson2017,
  author          = {Andersson, Therese M-L and Rutherford, Mark J and Humphreys, Keith},
  title           = {Assessment of lead-time bias in estimates of relative survival for breast cancer.},
  journal         = {Cancer epidemiology},
  year            = {2017},
  volume          = {46},
  month           = feb,
  pages           = {50--56},
  issn            = {1877-783X},
  doi             = {10.1016/j.canep.2016.12.004},
  citation-subset = {IM},
  completed       = {2017-09-05},
  country         = {Netherlands},
  issn-linking    = {1877-7821},
  keywords        = {Adult; Aged; Breast Neoplasms, diagnosis, mortality, pathology; Early Detection of Cancer, methods; Female; Humans; Mammography, methods; Mass Screening; Middle Aged; Prognosis; Survival Analysis; Breast cancer; Lead time; Mammography screening; Relative survival; Simulation study},
  nlm-id          = {101508793},
  owner           = {NLM},
  pii             = {S1877-7821(16)30247-8},
  pmid            = {28027488},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2017-09-06},
}

@Article{Duffy2008,
  author          = {Duffy, Stephen W and Nagtegaal, Iris D and Wallis, Matthew and Cafferty, Fay H and Houssami, Nehmat and Warwick, Jane and Allgood, Prue C and Kearins, Olive and Tappenden, Nancy and O'Sullivan, Emma and Lawrence, Gill},
  title           = {Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival.},
  doi             = {10.1093/aje/kwn120},
  issn            = {1476-6256},
  issue           = {1},
  pages           = {98--104},
  volume          = {168},
  abstract        = {Determination of survival time among persons with screen-detected cancer is subject to lead time and length biases. The authors propose a simple correction for lead time, assuming an exponential distribution of the preclinical screen-detectable period. Assuming two latent categories of tumors, one of which is more prone to screen detection and correspondingly less prone to death from the cancer in question, the authors have developed a strategy of sensitivity analysis for various magnitudes of length bias. Here they demonstrate these methods using a series of 25,962 breast cancer cases (1988-2004) from the West Midlands, United Kingdom.},
  citation-subset = {IM},
  completed       = {2008-07-03},
  country         = {United States},
  issn-linking    = {0002-9262},
  journal         = {American Journal of Epidemiology},
  keywords        = {Aged; Bias; Breast Neoplasms, diagnosis, epidemiology, mortality; Confidence Intervals; Female; Humans; Mass Screening; Middle Aged; Models, Statistical; Sensitivity and Specificity; Time Factors; United Kingdom},
  nlm-id          = {7910653},
  owner           = {NLM},
  pii             = {kwn120},
  pmid            = {18504245},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2017-11-16},
  year            = {2008},
}

@Misc{teaching_veneto2018_cansurv,
  author    = {Paul W Dickman and Paul C Lambert},
  title     = {Veneto 2018 -- Statistical methods for population-based cancer survival analysis},
  file      = {:veneto_handout_2018.pdf:PDF},
  keywords  = {Teaching},
  owner     = {PaulD},
  quality   = {1},
  timestamp = {2016.01.08},
}

@Article{Spika2017,
  author          = {Spika, Devon and Bannon, Finian and Bonaventure, Audrey and Woods, Laura M and Harewood, Rhea and Carreira, Helena and Coleman, Michel P and Allemani, Claudia},
  title           = {Life tables for global surveillance of cancer survival (the CONCORD programme): data sources and methods.},
  journal         = {BMC cancer},
  year            = {2017},
  volume          = {17},
  issue           = {1},
  month           = feb,
  pages           = {159},
  issn            = {1471-2407},
  doi             = {10.1186/s12885-017-3117-8},
  abstract        = {We set out to estimate net survival trends for 10 common cancers in 279 cancer registry populations in 67 countries around the world, as part of the CONCORD-2 study. Net survival can be interpreted as the proportion of cancer patients who survive up to a given time, after eliminating the impact of mortality from other causes (background mortality). Background mortality varies widely between populations and over time. It was therefore necessary to construct robust life tables that accurately reflected the background mortality in each of the registry populations. Life tables of all-cause mortality rates by single year of age and sex were constructed by calendar year for each population and, when possible, by racial or ethnic sub-groups. We used three different approaches, based on the type of mortality data available from each registry. With death and population counts, we adopted a flexible multivariable modelling approach. With unsmoothed mortality rates, we used the Ewbank relational method. Where no data were available from the registry or a national statistical office, we used the abridged UN Population Division life tables and interpolated these using the Elandt-Johnson method. We also investigated the impact of using state- and race-specific life tables versus national race-specific life tables on estimates of net survival from four adult cancers in the United StatesÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â (US). We constructed 6,514 life tables covering 327 populations. Wide variations in life expectancy at birth and mortality by age were observed, even within countries. During 1995-99, life expectancy was lowest in Nigeria and highest in Japan, ranging from 47 to 84ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years among females and 46 to 78ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years among males. During 2005-09, life expectancy was lowest in Lesotho and again highest in Japan, ranging from 45 to 86ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years among females and 45 to 80ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years among males. For the US, estimates of net survival differed by up to 4% if background mortality was fully controlled with state- and race-specific life tables, rather than with national race-specific life tables. Background mortality varies worldwide. This emphasises the importance of using population-specific life tables for geographic and international comparisons of net survival.},
  citation-subset = {IM},
  completed       = {2018-01-16},
  country         = {England},
  issn-linking    = {1471-2407},
  keywords        = {Aged; Aged, 80 and over; Female; Global Health; Humans; Japan, epidemiology; Lesotho, epidemiology; Life Expectancy; Life Tables; Male; Middle Aged; Mortality, trends; Neoplasms, mortality; Nigeria, epidemiology; Population Surveillance; Registries; Cubic splines; Generalised linear model; Global health; Life expectancy; Life tables; Mortality; Net survival},
  nlm-id          = {100967800},
  owner           = {NLM},
  pii             = {10.1186/s12885-017-3117-8},
  pmc             = {PMC5327577},
  pmid            = {28241815},
  pubmodel        = {Electronic},
  pubstatus       = {epublish},
  revised         = {2018-02-02},
}

@Article{Maringe2018,
  author       = {Maringe, Camille and Pohar Perme, Maja and Stare, Janez and Rachet, Bernard},
  title        = {Explained variation of excess hazard models.},
  journal      = {Statistics in medicine},
  year         = {2018},
  volume       = {37},
  issue        = {14},
  month        = jun,
  pages        = {2284--2300},
  issn         = {1097-0258},
  doi          = {10.1002/sim.7645},
  abstract     = {The availability of longstanding collection of detailed cancer patient information makes multivariable modelling of cancer-specific hazard of death appealing. We propose to report variation in survival explained by each variable that constitutes these models. We adapted the ranks explained (RE) measure to the relative survival data setting, ie, when competing risks of death are accounted for through life tables from the general population. RE is calculated at each event time. We introduce weights for each death reflecting its probability to be a cancer death. RE varies between -1 and +1 and can be reported at given times in the follow-up and as a time-varying measure from diagnosis onward. We present an application for patients diagnosed with colon or lung cancer in England. The RE measure shows reasonable properties and is comparable in both relative and cause-specific settings. One year after diagnosis, RE for the most complex excess hazard models reaches 0.56, 95% CI: 0.54 to 0.58 (0.58 95% CI: 0.56-0.60) and 0.69, 95% CI: 0.68 to 0.70 (0.67, 95% CI: 0.66-0.69) for lung and colon cancer men (women), respectively. Stage at diagnosis accounts for 12.4% (10.8%) of the overall variation in survival among lung cancer patients whereas it carries 61.8% (53.5%) of the survival variation in colon cancer patients. Variables other than performance status for lung cancer (10%) contribute very little to the overall explained variation. The proportion of the variation in survival explained by key prognostic factors is a crucial information toward understanding the mechanisms underpinning cancer survival. The time-varying RE provides insights into patterns of influence for strong predictors.},
  country      = {England},
  file         = {:Maringe2018.pdf:PDF},
  issn-linking = {0277-6715},
  keywords     = {excess hazard models; explained variation},
  nlm-id       = {8215016},
  owner        = {NLM},
  pmc          = {PMC6001643},
  pmid         = {29633343},
  pubmodel     = {Print-Electronic},
  pubstatus    = {ppublish},
  revised      = {2018-06-22},
}

@Article{Berglund2012,
  author          = {Berglund, Anders and Wigertz, Annette and Adolfsson, Jan and Ahlgren, Johan and Fornander, Tommy and W{\"a}rnberg, Fredrik and Lambe, Mats},
  title           = {Impact of comorbidity on management and mortality in women diagnosed with breast cancer.},
  journal         = {Breast cancer research and treatment},
  year            = {2012},
  volume          = {135},
  issue           = {1},
  month           = aug,
  pages           = {281--289},
  issn            = {1573-7217},
  doi             = {10.1007/s10549-012-2176-4},
  abstract        = {To investigate associations between comorbidity burden, management, and mortality in women with breast cancer. A total of 42,646 women diagnosed with breast cancer between 1992 and 2008 were identified in two Clinical Quality Registers in Central Sweden. Breast cancer-specific, conditional breast cancer, competing-cause and all-cause mortality were estimated in relation to comorbidity burden assessed by the Charlson comorbidity index. All analyses were stratified by stage at diagnosis using competing risk analyses, and all-cause mortality was estimated as a function of follow-up time. Following adjustment for age and calendar period, breast conserving surgery was significantly less likely to be offered to women with severe comorbidity (OR 0.63; 95 % CI 0.58-0.69). Similarly, the proportion treated with radiotherapy, tamoxifen, or chemotherapy was lower in women with severe compared to those with no comorbidity. In women with early stage disease, breast cancer-specific mortality was higher among patients with severe comorbidity (sHR 1.47; 95 % CI 1.11-1.94). In all stages of breast cancer, conditional breast cancer and competing-cause mortality were elevated in women with severe comorbidity. For all stages, the relative risk of all-cause mortality between women with severe versus no comorbidity varied by time since diagnosis, and was most pronounced at early follow-up. Comorbidity affects treatment decisions and mortality. In women with early stage breast cancer, severe comorbidity was associated not only with conditional breast cancer, competing-cause and all-cause mortality, but also breast cancer-specific mortality. The observed differences in breast cancer-specific mortality may be due to less extensive treatment, impaired tumor defense and differences in general health status and lifestyle factors.},
  chemicals       = {Antineoplastic Agents, Tamoxifen},
  citation-subset = {IM},
  completed       = {2013-01-24},
  country         = {Netherlands},
  issn-linking    = {0167-6806},
  keywords        = {Antineoplastic Agents, therapeutic use; Breast Neoplasms, epidemiology, mortality, therapy; Cause of Death; Comorbidity; Disease Management; Female; Health Status; Humans; Mastectomy, Segmental; Risk; Sweden, epidemiology; Tamoxifen, therapeutic use; Treatment Outcome},
  nlm-id          = {8111104},
  owner           = {NLM},
  pmid            = {22829398},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2013-11-21},
}

@Article{Land2012,
  author          = {Land, L H and Dalton, S O and Jensen, M-B and Ewertz, M},
  title           = {Influence of comorbidity on the effect of adjuvant treatment and age in patients with early-stage breast cancer.},
  journal         = {British journal of cancer},
  year            = {2012},
  volume          = {107},
  issue           = {11},
  month           = nov,
  pages           = {1901--1907},
  issn            = {1532-1827},
  doi             = {10.1038/bjc.2012.472},
  abstract        = {Prevalence of comorbidity at breast cancer diagnosis increases with age and is likely to influence the likelihood of receiving treatment according to guidelines. The aim of this study was to examine the effect of breast cancer treatment on mortality, taking age at diagnosis and comorbidity into account. Four nationwide population registries in Denmark: the Danish Civil Registration System, the Danish Breast Cancer Cooperative Group, the Danish National Patient Register, and the Danish Register of Causes of Death provided information on 62 591 women diagnosed with early-stage breast cancer, 1990-2008, of whom data on treatment were available for 39 943. Comorbidity was measured using the Charlson Comorbidity Index. Adjuvant treatment were categorised as none, chemotherapy, endocrine therapy, and unknown. Multivariable Cox modelling assessed the effect of comorbidity on breast cancer-specific mortality and other cause mortality according to treatment, adjusting for age at diagnosis and other clinical prognostic factors. The impact of comorbidity on mortality was most pronounced in patients aged 50-79 years. Patients receiving chemotherapy with mild to moderate comorbidity had HR 0.99 (95% confidence interval (CI); 0.82-1.19) and 1.06 (95% CI; 0.77-1.46) for breast cancer-specific mortality, respectively, compared with patients without comorbidity. Comorbidity at breast cancer diagnosis is an independent adverse prognostic factor for death after breast cancer. We identified a subgroup of patients with mild to moderate comorbidity receiving chemotherapy who had similar breast cancer mortality as patients with no comorbidity.},
  citation-subset = {IM},
  completed       = {2013-03-07},
  country         = {England},
  file            = {:Land2012.pdf:PDF},
  issn-linking    = {0007-0920},
  keywords        = {Adult; Age Factors; Aged; Aged, 80 and over; Breast Neoplasms, drug therapy, mortality, pathology; Chemotherapy, Adjuvant; Comorbidity; Female; Humans; Middle Aged; Neoplasm Staging; Proportional Hazards Models},
  nlm-id          = {0370635},
  owner           = {NLM},
  pii             = {bjc2012472},
  pmc             = {PMC3504938},
  pmid            = {23079577},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2015-02-22},
}

@Article{Mozumder2018,
  author       = {Mozumder, S.I. and Dickman, P.W. and Rutherford, M.J. and Lambert, P.C.},
  title        = {{InterPreT} cancer survival: A dynamic web interactive prediction cancer survival tool for health-care professionals and cancer epidemiologists.},
  journal      = {Cancer Epidemiology},
  year         = {2018},
  volume       = {56},
  pages        = {46--52},
  issn         = {1877-783X},
  doi          = {10.1016/j.canep.2018.07.009},
  abstract     = {There are a variety of ways for quantifying cancer survival with each measure having advantages and disadvantages. Distinguishing these measures and how they should be interpreted has led to confusion among scientists, the media, health care professionals and patients. This motivates the development of tools to facilitate communication and interpretation of these statistics. "InterPreT Cancer Survival" is a newly developed, publicly available, online interactive cancer survival tool targeted towards health-care professionals and epidemiologists (http://interpret.le.ac.uk). It focuses on the correct interpretation of commonly reported cancer survival measures facilitated through the use of dynamic interactive graphics. Statistics presented are based on parameter estimates obtained from flexible parametric relative survival models using large population-based English registry data containing information on survival across 6 cancer sites; Breast, Colon, Rectum, Stomach, Melanoma and Lung. Through interactivity, the tool improves understanding of various measures and how survival or mortality may vary by age and sex. Routine measures of cancer survival are reported, however, individualised estimates using crude probabilities are advocated, which is more appropriate for patients or health care professionals. The results are presented in various interactive formats facilitating understanding of individual risk and differences between various measures. "InterPreT Cancer Survival" is presented as an educational tool which engages the user through interactive features to improve the understanding of commonly reported cancer survival statistics. The tool has received positive feedback from a Cancer Research UK patient sounding board and there are further plans to incorporate more disease characteristics, e.g. stage.},
  country      = {Netherlands},
  file         = {:Mozumder2018.pdf:PDF},
  issn-linking = {1877-7821},
  keywords     = {Cancer survival; Crude probability of death; Flexible parametric survival model; Interactive web-tool; Net survival},
  nlm-id       = {101508793},
  owner        = {NLM},
  pii          = {S1877-7821(18)30198-X},
  pmid         = {30032027},
  pubmodel     = {Print-Electronic},
  pubstatus    = {aheadofprint},
  revised      = {2018-08-17},
}

@Article{Weibull2018,
  author       = {Weibull, C.E. and Johansson, A.L.V. and Eloranta, S. and Smedby, Ka.E. and Bj\"{o}rkholm, M. and Lambert, P.C. and Dickman, P.W. and Glimelius, I.},
  title        = {Contemporarily Treated Patients With {H}odgkin Lymphoma Have Childbearing Potential in Line With Matched Comparators.},
  journal      = {Journal of Clinical Oncology},
  year         = {2018},
  volume       = {36},
  pages        = {2718-2725},
  issn         = {1527-7755},
  doi          = {10.1200/JCO.2018.78.3514},
  abstract     = {Purpose With excellent cure rates for young patients with Hodgkin lymphoma (HL), there is an increasing number of female survivors of HL interested in becoming pregnant. Here, we report childbearing among contemporarily treated HL survivors in comparison with the general population. Material and Methods Using Swedish registers, 449 women (ages 18 to 40 years) diagnosed with HL between 1992 and 2009 and in remission 9 months after diagnosis were identified. Patients were age- and calendar-year-matched to 2,210 population comparators. Rates of first postdiagnosis childbirth were calculated. Hazard ratios (HRs) with 95% CIs were estimated for different follow-up periods using Cox regression. Cumulative probabilities of first childbirth were calculated in the presence of the competing risk of death or relapse. Results Twenty-two percent of relapse-free patients with HL had a child during follow-up, and first childbirth rates increased over time, from 40.2 per 1,000 person-years (1992 to 1997) to 69.7 per 1,000 person-years (2004 to 2009). For comparators, childbirth rates remained stable (70.1 per 1,000 person-years). Patients diagnosed between 2004 and 2009 had a cumulative probability of childbirth similar to comparators. Three years or more after diagnosis, no differences in childbirth rates were observed between patients and comparators, regardless of stage or treatment. Patients who received six to eight courses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone had a lower childbirth rate than comparators during the first 3 years (HR, 0.23; 95% CI, 0.06 to 0.94), as did patients who received six to eight courses of chemotherapy and radiotherapy (HR, 0.21; 95% CI, 0.07 to 0.65). Conclusion Childbearing potential among female survivors of HL has improved over time, and childbirth rates 3 years after diagnosis in contemporarily treated patients are, in the absence of relapse, similar to those in the general population, regardless of stage and treatment.},
  country      = {United States},
  issn-linking = {0732-183X},
  nlm-id       = {8309333},
  owner        = {NLM},
  pmid         = {30044694},
  pubmodel     = {Print-Electronic},
  pubstatus    = {aheadofprint},
  revised      = {2018-07-25},
}

@Article{Sjoelander2018,
  author       = {Sj{\"o}lander, Arvid},
  title        = {Estimation of causal effect measures with the {R}-package std{R}eg.},
  journal      = {European journal of epidemiology},
  year         = {2018},
  month        = mar,
  issn         = {1573-7284},
  doi          = {10.1007/s10654-018-0375-y},
  abstract     = {Measures of causal effects play a central role in epidemiology. A wide range of measures exist, which are designed to give relevant answers to substantive epidemiological research questions. However, due to mathematical convenience and software limitations most studies only report odds ratios for binary outcomes and hazard ratios for time-to-event outcomes. In this paper we show how logistic regression models and Cox proportional hazards regression models can be used to estimate a wide range of causal effect measures, with the R-package stdReg. For illustration we focus on the attributable fraction, the number needed to treat and the relative excess risk due to interaction. We use two publicly available data sets, so that the reader can easily replicate and elaborate on the analyses. The first dataset includes information on 487 births among 188 women, and the second dataset includes information on 2982 women diagnosed with primary breast cancer.},
  country      = {Netherlands},
  file         = {:Sjoelander2018.pdf:PDF},
  issn-linking = {0393-2990},
  keywords     = {Attributable fraction; Causal effect; Cox proportional hazards regression; Logistic regression; Number needed to treat; Relative excess risk due to interaction},
  nlm-id       = {8508062},
  owner        = {NLM},
  pii          = {10.1007/s10654-018-0375-y},
  pmid         = {29536223},
  pubmodel     = {Print-Electronic},
  pubstatus    = {aheadofprint},
  revised      = {2018-03-14},
}

@Article{Cook2014,
  author  = {R. Cook and J. Lawless},
  title   = {Statistical Issues in Modeling Chronic Disease in Cohort Studies},
  journal = {Statistics in Biosciences},
  year    = {2014},
  volume  = {6},
  pages   = {127--161},
  doi     = {doi:10.1007/s12561-013-9087-8.},
}

@Article{Syriopoulou2018,
  author       = {Syriopoulou, Elisavet and Mozumder, Sarwar I and Rutherford, Mark J and Lambert, Paul C},
  title        = {Robustness of individual and marginal model-based estimates: A sensitivity analysis of flexible parametric models.},
  journal      = {Cancer Epidemiology},
  year         = {2018},
  volume       = {58},
  pages        = {17--24},
  issn         = {1877-783X},
  doi          = {10.1016/j.canep.2018.10.017},
  abstract     = {Flexible parametric survival models (FPMs) are commonly used in epidemiology. These are preferred as a wide range of hazard shapes can be captured using splines to model the log-cumulative hazard function and can include time-dependent effects for more flexibility. An important issue is the number of knots used for splines. The reliability of estimates are assessed using English data for 10 cancer types and the use of online interactive graphs to enable a more comprehensive sensitivity analysis at the control of the user is demonstrated. Sixty FPMs were fitted to each cancer type with varying degrees of freedom to model the baseline excess hazard and the main and time-dependent effect of age. For each model, we obtained age-specific, age-group and internally age-standardised relative survival estimates. The Akaike Information Criterion and Bayesian Information Criterion were also calculated and comparative estimates were obtained using the Ederer II and Pohar Perme methods. Web-based interactive graphs were developed to present results. Age-standardised estimates were very insensitive to the exact number of knots for the splines. Age-group survival is also stable with negligible differences between models. Age-specific estimates are less stable especially for the youngest and oldest patients, of whom there are very few, but for most scenarios perform well. Although estimates do not depend heavily on the number of knots, too few knots should be avoided, as they can result in a poor fit. Interactive graphs engage researchers in assessing model sensitivity to a wide range of scenarios and their use is highly encouraged.},
  country      = {Netherlands},
  issn-linking = {1877-7821},
  keywords     = {Cancer; Flexible parametric survival model; Interactive graphs; Relative survival; Restricted cubic splines},
  nlm-id       = {101508793},
  owner        = {NLM},
  pii          = {S1877-7821(18)30328-X},
  pmid         = {30439603},
  pubmodel     = {Print-Electronic},
  pubstatus    = {aheadofprint},
  revised      = {2019-01-02},
}

@Article{Plym2018,
  author       = {Plym, A. and Bower, H. and Fredriksson, I. and Holmberg, L. and Lambert, P.C. and Lambe, M.},
  title        = {Loss in working years after a breast cancer diagnosis.},
  journal      = {British Journal of Cancer},
  year         = {2018},
  volume       = {118},
  issue        = {5},
  pages        = {738--743},
  issn         = {1532-1827},
  doi          = {10.1038/bjc.2017.456},
  abstract     = {Breast cancer can negatively influence working life, but it is unclear how many working years women with breast cancer can expect to lose. Women diagnosed with breast cancer between 1997 and 2012 were identified in the Breast Cancer Data Base Sweden (N=19,661), together with breast cancer-free comparison women (N=81ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Â‰303). Using flexible parametric survival modelling, the loss in working years was calculated as the difference in the remaining years in the work force between women with and without breast cancer. Women aged 50 years at diagnosis with stage I disease lost on average 0.5 years (95% CI, 0.2-0.7) of their remaining working time; the corresponding estimates were 0.9 years (0.5-1.2) in stage II, 2.5 years (1.9-3.1) in stage III and 8.1 years (6.5-9.7) in stage IV. Women with in situ breast cancer did not lose any working years. The strongest treatment determinant was axillary lymph node dissection. We found a loss in working years not only in late but also in early-stage breast cancer. Although it is reassuring that some groups had no or only a modest work loss, the economic consequences for society are considerable given the large number of women annually diagnosed with breast cancer.},
  country      = {England},
  issn-linking = {0007-0920},
  nlm-id       = {0370635},
  owner        = {NLM},
  pii          = {bjc2017456},
  pmc          = {PMC5846067},
  pmid         = {29360816},
  pubmodel     = {Print-Electronic},
  pubstatus    = {ppublish},
  revised      = {2018-11-13},
}

@Article{Weibull2019,
  author  = {C. E. Weibull and M. Bj{\"o}rkholm and I. Glimelius and P. C. Lambert and T. M-L. Andersson and K. E. Smedby and P. W. Dickman and S. Eloranta},
  title   = {Temporal trends in treatment-related incidence of diseases of the circulatory system among {H}odgkin lymphoma patients},
  doi     = {10.1002/ijc.32142},
  pages   = {1200-1208},
  volume  = {145},
  file    = {:Weibull2019.pdf:PDF},
  journal = {International Journal of Cancer},
  pmid    = {30666628},
  year    = {2019},
}

@Article{Young2018,
  author  = {J. G. Young and E. J. {Tchetgen Tchetgen} and M. A. Hernan},
  title   = {The choice to define competing risk events as censoring events and implications for causal inference},
  journal = {arXiv preprint},
  year    = {2018},
  doi     = {arXiv:1806.06136},
}

@Article{Stensrud2018,
  author       = {Stensrud, Mats J and Aalen, John M and Aalen, Odd O and Valberg, Morten},
  title        = {Limitations of hazard ratios in clinical trials.},
  journal      = {European heart journal},
  year         = {2018},
  month        = nov,
  issn         = {1522-9645},
  doi          = {10.1093/eurheartj/ehy770},
  country      = {England},
  issn-linking = {0195-668X},
  nlm-id       = {8006263},
  owner        = {NLM},
  pii          = {5219649},
  pmid         = {30500891},
  pubmodel     = {Print-Electronic},
  pubstatus    = {aheadofprint},
  revised      = {2018-11-30},
}

@Article{Bower2019,
  author  = {H. Bower and T. M-L. Andersson and E. Syriopoulou and M. J. Rutherford and M. Lambe and J. Ahlgren and P. W. Dickman and P. C. Lambert},
  title   = {Potential gain in life years for {S}wedish women with breast cancer if stage and survival differences between education groups could be eliminated - three what-if scenarios},
  doi     = {10.1016/j.breast.2019.03.005},
  pages   = {75-81},
  volume  = {45},
  file    = {:Bower2019.pdf:PDF},
  journal = {Breast},
  pmid    = {30904700},
  year    = {2019},
}

@Article{Latimer2018,
  author       = {Latimer, Nicholas R and Abrams, Keith R and Lambert, Paul C and Morden, James P and Crowther, Michael J},
  title        = {Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study.},
  doi          = {10.1177/0962280216642264},
  issn         = {1477-0334},
  issue        = {3},
  pages        = {765--784},
  volume       = {27},
  abstract     = {When patients randomised to the control group of a randomised controlled trial are allowed to switch onto the experimental treatment, intention-to-treat analyses of the treatment effect are confounded because the separation of randomised groups is lost. Previous research has investigated statistical methods that aim to estimate the treatment effect that would have been observed had this treatment switching not occurred and has demonstrated their performance in a limited set of scenarios. Here, we investigate these methods in a new range of realistic scenarios, allowing conclusions to be made based upon a broader evidence base. We simulated randomised controlled trials incorporating prognosis-related treatment switching and investigated the impact of sample size, reduced switching proportions, disease severity, and alternative data-generating models on the performance of adjustment methods, assessed through a comparison of bias, mean squared error, and coverage, related to the estimation of true restricted mean survival in the absence of switching in the control group. Rank preserving structural failure time models, inverse probability of censoring weights, and two-stage methods consistently produced less bias than the intention-to-treat analysis. The switching proportion was confirmed to be a key determinant of bias: sample size and censoring proportion were relatively less important. It is critical to determine the size of the treatment effect in terms of an acceleration factor (rather than a hazard ratio) to provide information on the likely bias associated with rank-preserving structural failure time model adjustments. In general, inverse probability of censoring weight methods are more volatile than other adjustment methods.},
  country      = {England},
  issn-linking = {0962-2802},
  journal      = {Statistical Methods in Medical Research},
  keywords     = {Treatment switching; health technology assessment; oncology; overall survival; prediction; survival analysis; time-to-event outcomes; treatment crossover},
  month        = mar,
  nlm-id       = {9212457},
  owner        = {NLM},
  pii          = {0962280216642264},
  pmid         = {27114326},
  pubmodel     = {Print-Electronic},
  pubstatus    = {ppublish},
  revised      = {2018-02-22},
  year         = {2018},
}

@Article{Morden2011,
  author          = {Morden, James P and Lambert, Paul C and Latimer, Nicholas and Abrams, Keith R and Wailoo, Allan J},
  title           = {Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study.},
  journal         = {BMC medical research methodology},
  year            = {2011},
  volume          = {11},
  issue           = {3},
  month           = jul,
  pages           = {572--582},
  issn            = {1468-4357},
  doi             = {10.1093/biostatistics/kxq007},
  abstract        = {When estimating the association between an exposure and outcome, a simple approach to quantifying the amount of confounding by a factor, Z, is to compare estimates of the exposure-outcome association with and without adjustment for Z. This approach is widely believed to be problematic due to the nonlinearity of some exposure-effect measures. When the expected value of the outcome is modeled as a nonlinear function of the exposure, the adjusted and unadjusted exposure effects can differ even in the absence of confounding (Greenland , Robins, and Pearl, 1999); we call this the nonlinearity effect. In this paper, we propose a corrected measure of confounding that does not include the nonlinearity effect. The performances of the simple and corrected estimates of confounding are assessed in simulations and illustrated using a study of risk factors for low birth-weight infants. We conclude that the simple estimate of confounding is adequate or even preferred in settings where the nonlinearity effect is very small. In settings with a sizable nonlinearity effect, the corrected estimate of confounding has improved performance.}}

@Report{IndCanTaskForce2015,
  author = {{Report of the Independent Cancer Taskforce}},
  title  = {Achieving world-class cancer outcomes: A strategy for England 2015-2020},
  year   = {2015},
}

@Article{Maringe2013,
  author          = {Maringe, Camille and Walters, Sarah and Rachet, Bernard and Butler, John and Fields, Tony and Finan, Paul and Maxwell, Roy and Nedreb{\AA}Â¸, Bj{\AA}Â¸rn and P{\aa}hlman, Lars and Sj{\"o}vall, Annika and Spigelman, Allan and Engholm, Gerda and Gavin, Anna and Gjerstorff, Marianne L and Hatcher, Juanita and Johannesen, Tom B and Morris, Eva and McGahan, Colleen E and Tracey, Elizabeth and Turner, Donna and Richards, Michael A and Coleman, Michel P and ICBP Module 1 Working Group},
  title           = {Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000-2007.},
  journal         = {Acta Oncologica},
  year            = {2013},
  volume          = {52},
  issue           = {5},
  month           = jun,
  pages           = {919--932},
  issn            = {1651-226X},
  doi             = {10.3109/0284186X.2013.764008},
  abstract        = {Large international differences in colorectal cancer survival exist, even between countries with similar healthcare. We investigate the extent to which stage at diagnosis explains these differences. Data from population-based cancer registries in Australia, Canada, Denmark, Norway, Sweden and the UK were analysed for 313 852 patients diagnosed with colon or rectal cancer during 2000-2007. We compared the distributions of stage at diagnosis. We estimated both stage-specific net survival and the excess hazard of death up to three years after diagnosis, using flexible parametric models on the log-cumulative excess hazard scale. International differences in colon and rectal cancer stage distributions were wide: Denmark showed a distribution skewed towards later-stage disease, while Australia, Norway and the UK showed high proportions of 'regional' disease. One-year colon cancer survival was 67% in the UK and ranged between 71% (Denmark) and 80% (Australia and Sweden) elsewhere. For rectal cancer, one-year survival was also low in the UK (75%), compared to 79% in Denmark and 82-84% elsewhere. International survival differences were also evident for each stage of disease, with the UK showing consistently lowest survival at one and three years. Differences in stage at diagnosis partly explain international differences in colorectal cancer survival, with a more adverse stage distribution contributing to comparatively low survival in Denmark. Differences in stage distribution could arise because of differences in diagnostic delay and awareness of symptoms, or in the thoroughness of staging procedures. Nevertheless, survival differences also exist for each stage of disease, suggesting unequal access to optimal treatment, particularly in the UK.},
  citation-subset = {IM},
  completed       = {2013-10-17},
  country         = {England},
  issn-linking    = {0284-186X},
  keywords        = {Adolescent; Adult; Aged; Aged, 80 and over; Australia, epidemiology; Canada, epidemiology; Colorectal Neoplasms, mortality, pathology; Delayed Diagnosis, statistics & numerical data; Denmark, epidemiology; Developed Countries; Female; Health Status Disparities; Humans; Male; Middle Aged; Neoplasm Staging; Norway, epidemiology; Prognosis; Registries; Sweden, epidemiology; United Kingdom, epidemiology; Young Adult},
  nlm-id          = {8709065},
  owner           = {NLM},
  pmid            = {23581611},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2017-11-10},
}

@Article{Li2016a,
  author          = {Li, Ruoran and Daniel, Rhian and Rachet, Bernard},
  title           = {How much do tumor stage and treatment explain socioeconomic inequalities in breast cancer survival? Applying causal mediation analysis to population-based data.},
  journal         = {European journal of epidemiology},
  year            = {2016},
  volume          = {31},
  issue           = {6},
  month           = jun,
  pages           = {603--611},
  issn            = {1573-7284},
  doi             = {10.1007/s10654-016-0155-5},
  abstract        = {Substantial socioeconomic inequalities in breast cancer survival persist in England, possibly due to more advanced cancer at diagnosis and differential access to treatment. We aim to disentangle the contributions of differential stage at diagnosis and differential treatment to the socioeconomic inequalities in cancer survival. Information on 36,793 women diagnosed with breast cancer during 2000-2007 was routinely collected by an English population-based cancer registry. Deprivation was determined for each patient according to her area of residence at the time of diagnosis. A parametric implementation of the mediation formula using Monte Carlo simulation was used to estimate the proportion of the effect of deprivation on survival mediated by stage and by treatment. One-third (35ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â % [23-48ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â %]) of the higher mortality experienced by most deprived patients at 6ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â months after diagnosis, and one tenth (14ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â % [-3 to 31ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â %]) at 5ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years, was mediated by adverse stage distribution. We initially found no evidence of mediation via differential surgical treatment. However, sensitivity analyses testing some of our study limitations showed in particular that up to thirty per cent of the higher mortality in most deprived patients could be mediated by differential surgical treatment. This study illustrates the importance of using causal inference methods with routine medical data and the need for testing key assumptions through sensitivity analyses. Our results suggest that, although effort for earlier diagnosis is important, this would reduce the cancer survival inequalities only by a third. Because of data limitations, role of differential surgical treatment may have been under-estimated.},
  citation-subset = {IM},
  completed       = {2017-09-08},
  country         = {Netherlands},
  issn-linking    = {0393-2990},
  keywords        = {Aged; Breast Neoplasms, diagnosis, mortality, surgery; Databases, Factual; England, epidemiology; Female; Health Status Disparities; Healthcare Disparities; Humans; Middle Aged; Neoplasm Staging; Population Surveillance; Socioeconomic Factors; Survival Analysis; Survival Rate; Breast cancer; Causal mediation; Population-based data; Socioeconomic inequalities; Surgical treatment; Survival; Tumour stage},
  nlm-id          = {8508062},
  owner           = {NLM},
  pii             = {10.1007/s10654-016-0155-5},
  pmc             = {PMC4956701},
  pmid            = {27165500},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2018-11-13},
}

@Article{Isheden2019,
  author       = {Isheden, Gabriel and Humphreys, Keith},
  title        = {Modelling breast cancer tumour growth for a stable disease population.},
  journal      = {Statistical Methods in Medical Research},
  year         = {2019},
  volume       = {28},
  issue        = {3},
  pages        = {681--702},
  issn         = {1477-0334},
  doi          = {10.1177/0962280217734583},
  abstract     = {Statistical models of breast cancer tumour progression have been used to further our knowledge of the natural history of breast cancer, to evaluate mammography screening in terms of mortality, to estimate overdiagnosis, and to estimate the impact of lead-time bias when comparing survival times between screen detected cancers and cancers found outside of screening programs. Multi-state Markov models have been widely used, but several research groups have proposed other modelling frameworks based on specifying an underlying biological continuous tumour growth process. These continuous models offer some advantages over multi-state models and have been used, for example, to quantify screening sensitivity in terms of mammographic density, and to quantify the effect of body size covariates on tumour growth and time to symptomatic detection. As of yet, however, the continuous tumour growth models are not sufficiently developed and require extensive computing to obtain parameter estimates. In this article, we provide a detailed description of the underlying assumptions of the continuous tumour growth model, derive new theoretical results for the model, and show how these results may help the development of this modelling framework. In illustrating the approach, we develop a model for mammography screening sensitivity, using a sample of 1901 post-menopausal women diagnosed with invasive breast cancer.},
  country      = {England},
  issn-linking = {0962-2802},
  keywords     = {Tumour growth model; breast cancer; screening},
  nlm-id       = {9212457},
  owner        = {NLM},
  pmid         = {29103360},
  pubmodel     = {Print-Electronic},
  pubstatus    = {ppublish},
  revised      = {2019-03-13},
}

@Article{Glymour2017,
  author          = {Glymour, M Maria and Spiegelman, Donna},
  title           = {Evaluating Public Health Interventions: 5. Causal Inference in Public Health Research-Do Sex, Race, and Biological Factors Cause Health Outcomes?},
  journal         = {American Journal of Public Health},
  year            = {2017},
  volume          = {107},
  issue           = {1},
  pages           = {81--85},
  issn            = {1541-0048},
  doi             = {10.2105/AJPH.2016.303539},
  abstract        = {Counterfactual frameworks and statistical methods for supporting causal inference are powerful tools to clarify scientific questions and guide analyses in public health research. Counterfactual accounts of causation contrast what would happen to a population's health under alternative exposure scenarios. A long-standing debate in counterfactual theory relates to whether sex, race, and biological characteristics, including obesity, should be evaluated as causes, given that these variables do not directly correspond to clearly defined interventions. We argue that sex, race, and biological characteristics are important health determinants. Quantifying the overall health effects of these variables is often a natural starting point for disparities research. Subsequent assessments of biological or social pathways mediating those effects can facilitate the development of interventions designed to reduce disparities.},
  chemicals       = {Biological Factors},
  citation-subset = {AIM, IM},
  completed       = {2017-06-12},
  country         = {United States},
  issn-linking    = {0090-0036},
  keywords        = {Biological Factors; Causality; Confounding Factors (Epidemiology); Ethnic Groups; Female; Health Services Research; Humans; Male; Models, Statistical; Prejudice; Public Health; Research Design; Sex Factors},
  nlm-id          = {1254074},
  owner           = {NLM},
  pmc             = {PMC5308179},
  pmid            = {27854526},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2019-03-20},
}

@Article{Andreassen2018,
  author          = {Andreassen, Bettina Kulle and Grimsrud, Tom Kristian and Haug, Erik Skaaheim},
  title           = {Bladder cancer survival: Women better off in the long run.},
  doi             = {10.1016/j.ejca.2018.03.001},
  issn            = {1879-0852},
  pages           = {52--58},
  volume          = {95},
  abstract        = {Mortality among patients with bladder cancer is usually reported to be higher for women than men, but how the risk differs and why remainÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â largely unexplained. We also described gender-specific differences in survival for patients with bladder cancer and estimated to what extent they can be explained by differences in T-stage distribution at the first diagnosis. The present study comprised all 15,129 new cases of histologically verified invasive and non-invasive urothelial carcinoma of the urinary bladder diagnosed between 1997 and 2011 as registered in the Cancer Registry of Norway. Gender-specific excess mortality risk rates and risk ratios were calculated based on a flexible parametric relative survival model adjusting for T-stage and age, allowing the effect of gender to vary over time. We also present gender-specific relative survival curves for different T-stage patterns adjusted for age. Risk rates were significantly higher for women than men up to 2 years after bladder cancer diagnosis, particularly for muscle-invasive cancers. Thereafter, risk rates appeared to be higher in men. Adverse T-Stage distribution in women explained half of the unfavourable survival difference in female patients 2 years after diagnosis. The common view of worse bladder cancer prognosis in women than in men needs to be revised. Norwegian women have a less favourable prognosis solely within the first 2 years after diagnosis, particularly when diagnosed with a muscle-invasive tumour; parts of this discrepancy can be attributed to more severe initial diagnoses in women.},
  citation-subset = {IM},
  completed       = {2019-01-11},
  country         = {England},
  issn-linking    = {0959-8049},
  journal         = {European Journal of Cancer},
  keywords        = {Adolescent; Adult; Aged; Aged, 80 and over; Cancer Survivors, statistics & numerical data; Carcinoma, Transitional Cell, mortality, pathology; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Male; Middle Aged; Neoplasm Staging; Norway, epidemiology; Registries; Retrospective Studies; Risk Factors; Sex Factors; Survival Rate; Time Factors; Urinary Bladder Neoplasms, pathology; Young Adult; Bladder cancer; Gender; Gender difference; Prognosis; Survival; Urothelial cancer},
  nlm-id          = {9005373},
  owner           = {NLM},
  pii             = {S0959-8049(18)30708-1},
  pmid            = {29635144},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2019-01-11},
  year            = {2018},
}

@Article{Rutherford2019,
  author  = {M. J. Rutherford and T. M-L. Andersson and M. Bj{\"o}rkholm and P. C. Lambert},
  title   = {Loss in life expectancy and gain in life years as measures of cancer impact},
  doi     = {10.1016/j.canep.2019.04.005},
  pages   = {168-173},
  volume  = {60},
  file    = {:Rutherford2019.pdf:PDF},
  journal = {Cancer Epidemiology},
  pmid    = {31054465},
  year    = {2019},
}

@Article{Syriopoulou2019,
  author  = {Syriopoulou, E. and Morris, E. and Finan P. and Lambert, P. C. and Rutherford, M.J.},
  title   = {Understanding the impact of socioeconomic differences in colorectal cancer survival: potential gain in life-years},
  doi     = {10.1038/s41416-019-0455-0},
  pages   = {1052-1058},
  volume  = {120},
  journal = {British Journal of Cancer},
  pmid    = {31040385},
  year    = {2019},
}

@Article{Delille2005,
  author      = {Delille, Jean-Paul and Slanetz, Priscilla J. and Yeh, Eren D. and Kopans, Daniel B. and Garrido, Leoncio},
  title       = {Physiologic changes in breast magnetic resonance imaging during the menstrual cycle: perfusion imaging, signal enhancement, and influence of the {T1} relaxation time of breast tissue.},
  journal     = {Breast J},
  year        = {2005},
  language    = {eng},
  volume      = {11},
  number      = {4},
  pages       = {236--241},
  doi         = {10.1111/j.1075-122X.2005.21499.x},
  url         = {http://dx.doi.org/10.1111/j.1075-122X.2005.21499.x},
  abstract    = {This study was undertaken to determine the best time during the menstrual cycle to perform dynamic breast magnetic resonance imaging (MRI). The contralateral "normal" breast of 50 premenopausal women (mean age 40.4 +/- 6.4 years, range 30--52 years) were enrolled in a protocol designed to correlate an ipsilateral suspicious breast lesion with pathology. The contralateral breast in each patient was examined with palpation and mammography prior to MRI on a 1.5 T scanner using gradient echo and dynamic contrast-enhanced echo-planar without and following gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) injection. Pre-contrast T1 relaxation times were measured before calculating extraction flow product (EFP) maps using a multicompartmental model. T1, EFP, and enhancement were measured in the control breast on four slices centered around the nipple and recorded as a function of the phases of the menstrual cycle. Lesions or areas with focal enhancement were excluded. Analysis of variance and Fisher's tests were performed. The cyclic changes in T1 relaxation time were not significant (p>0.2). EFP and enhancement varied significantly during the cycle (p<0.003 and p<0.004, respectively), with low values during the first half of the cycle and high values during the second half. The lowest values of EFP and enhancement (5.5+/-2.9 ml/100 g/min and 26+/-17\%) were observed during the proliferative phase (days 3--7), and the highest values (17+/-10.2 ml/100 g/min and 104+/-28\%) were observed during the secretory phase (days 21-27) (p<0.0006 and p<0.0008, respectively). Dynamic breast MRI should be performed during first half of the menstrual cycle (days 3--14) in order to minimize interpretative difficulties related to the uptake of gadolinium in normal breast tissue due to hormonal fluctuations during the menstrual cycle.},
  institution = {Division of Breast Imaging, Department of Radiology, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts 02135, USA.},
  keywords    = {Adult; Analysis of Variance; Breast Diseases, pathology; Breast, metabolism; Case-Control Studies; Contrast Media, pharmacokinetics; Echo-Planar Imaging, methods; Female; Gadolinium DTPA, pharmacokinetics; Humans; Image Enhancement; Linear Models; Menstrual Cycle, physiology; Middle Aged},
  medline-pst = {ppublish},
  owner       = {PaulD},
  pii         = {TBJ21499},
  pmid        = {15982388},
  timestamp   = {2016.04.18},
}

@Article{Feldman1986,
  author          = {Feldman, A R and Kessler, L and Myers, M H and Naughton, M D},
  title           = {The prevalence of cancer. Estimates based on the Connecticut Tumor Registry.},
  journal         = {The New England journal of medicine},
  year            = {1986},
  volume          = {315},
  issue           = {22},
  month           = nov,
  pages           = {1394--1397},
  issn            = {0028-4793},
  doi             = {10.1056/NEJM198611273152206},
  abstract        = {Cancer incidence and mortality do not fully reflect the effect of cancer. To estimate the number of persons alive who have a history of cancer, we derived prevalence rates based on data from the Connecticut Tumor Registry. We did not attempt to distinguish between people who had been cured of cancer and those who still had the disease. In 1982 the age-adjusted prevalence rates of cancer among males and females were 1,789 and 2,222, respectively, per 100,000. Age-specific prevalence rates were highest among the elderly; 12 percent of men and 11 percent of women over 70 had previously been given a diagnosis of cancer. Breast cancer in females and prostate cancer in males were the two most prevalent malignant diseases. We estimate that about 5 million persons alive in the United States today have at one time received a diagnosis of cancer.},
  citation-subset = {AIM, IM},
  completed       = {1986-12-15},
  country         = {United States},
  issn-linking    = {0028-4793},
  keywords        = {Adult; Age Factors; Aged; Breast Neoplasms, epidemiology; Connecticut; Female; Humans; Male; Middle Aged; Neoplasms, epidemiology; Prostatic Neoplasms, epidemiology; Registries; Sex Factors},
  nlm-id          = {0255562},
  owner           = {NLM},
  pmid            = {3773965},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2004-11-17},
}

@Article{Genovese2014,
  author      = {Genovese, Giulio and K{\"{a}}hler, Anna K. and Handsaker, Robert E. and Lindberg, Johan and Rose, Samuel A. and Bakhoum, Samuel F. and Chambert, Kimberly and Mick, Eran and Neale, Benjamin M. and Fromer, Menachem and Purcell, Shaun M. and Svantesson, Oscar and Land{\'{e}}n, Mikael and H{\"{o}}glund, Martin and Lehmann, S{\"{o}}ren and Gabriel, Stacey B. and Moran, Jennifer L. and Lander, Eric S. and Sullivan, Patrick F. and Sklar, Pamela and Gr{\"{o}}nberg, Henrik and Hultman, Christina M. and McCarroll, Steven A.},
  title       = {Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.},
  journal     = {N Engl J Med},
  year        = {2014},
  language    = {eng},
  volume      = {371},
  number      = {26},
  month       = {Dec},
  pages       = {2477--2487},
  doi         = {10.1056/NEJMoa1409405},
  url         = {http://dx.doi.org/10.1056/NEJMoa1409405},
  abstract    = {Cancers arise from multiple acquired mutations, which presumably occur over many years. Early stages in cancer development might be present years before cancers become clinically apparent.We analyzed data from whole-exome sequencing of DNA in peripheral-blood cells from 12,380 persons, unselected for cancer or hematologic phenotypes. We identified somatic mutations on the basis of unusual allelic fractions. We used data from Swedish national patient registers to follow health outcomes for 2 to 7 years after DNA sampling.Clonal hematopoiesis with somatic mutations was observed in 10\% of persons older than 65 years of age but in only 1\% of those younger than 50 years of age. Detectable clonal expansions most frequently involved somatic mutations in three genes (DNMT3A, ASXL1, and TET2) that have previously been implicated in hematologic cancers. Clonal hematopoiesis was a strong risk factor for subsequent hematologic cancer (hazard ratio, 12.9; 95\% confidence interval, 5.8 to 28.7). Approximately 42\% of hematologic cancers in this cohort arose in persons who had clonality at the time of DNA sampling, more than 6 months before a first diagnosis of cancer. Analysis of bone marrow-biopsy specimens obtained from two patients at the time of diagnosis of acute myeloid leukemia revealed that their cancers arose from the earlier clones.Clonal hematopoiesis with somatic mutations is readily detected by means of DNA sequencing, is increasingly common as people age, and is associated with increased risks of hematologic cancer and death. A subset of the genes that are mutated in patients with myeloid cancers is frequently mutated in apparently healthy persons; these mutations may represent characteristic early events in the development of hematologic cancers. (Funded by the National Human Genome Research Institute and others.).},
  institution = {The authors' affiliations are listed in the Appendix.},
  keywords    = {Adult; Age Factors; Aged; Aged, 80 and over; Blood; Cell Transformation, Neoplastic, genetics; Clone Cells; DNA Mutational Analysis; Exome; Hematologic Neoplasms, genetics/physiopathology; Hematopoiesis, physiology; Hematopoietic Stem Cells, physiology; Humans; Middle Aged; Mutation; Risk Factors; Young Adult},
  medline-pst = {ppublish},
  owner       = {PaulD},
  pmc         = {PMC4290021},
  pmid        = {25426838},
  timestamp   = {2016.04.19},
}

@Article{Hansen2014,
  author      = {Hansen, Nienke L. and Kuhl, Christiane K. and Barabasch, Alexandra and Strobel, Kevin and Schrading, Simone},
  title       = {Does {MRI} breast ``density'' (degree of background enhancement) correlate with mammographic breast density?},
  journal     = {J Magn Reson Imaging},
  year        = {2014},
  language    = {eng},
  volume      = {40},
  number      = {2},
  month       = {Aug},
  pages       = {483--489},
  doi         = {10.1002/jmri.24495},
  url         = {http://dx.doi.org/10.1002/jmri.24495},
  abstract    = {To investigate whether mammographic breast densities and the respective degree of MRI background enhancement would correlate. Mammographic breast density is coded to communicate how likely a cancer is obscured by parenchyma. Similarly, background enhancement in breast MRI could obscure enhancing cancer tissue.A total of 468 women underwent standard full-field digital mammography and dynamic contrast-enhanced breast MRI in our institution. Mammographic breast density was scored according to the American College of Radiology-classification; background enhancement in MRI was scored on a 4-point scale from absent to severe. Breast "density classes" were retrospectively compared by analyzing the differences between scores for mammography and MRI. Statistical correlation was calculated using the Spearman coefficient.Scores matched in 19\% of women (90/468) but differed in 81\% (378/468). A deviation by 1 point was observed in 33\% (157/468), by 2 points in 38\% (179/468), by 3 in 9\% (42/468). Scores for background enhancement were lower than mammographic scores in 371/468 (79.3\%), equivalent in 90/468 (19.2\%), and higher in 7/468 (1.5\%).Mammographic breast density does not correlate with the degree of background enhancement in MRI. In the majority of women, scores for background enhancement in MRI will be lower than the respective mammographic density scores.},
  institution = {Department of Diagnostic and Interventional Radiology, RWTH Aachen University Hospital, Aachen, Germany.},
  keywords    = {Absorptiometry, Photon, methods; Adult; Aged; Aged, 80 and over; Breast Neoplasms, diagnosis/physiopathology; Densitometry, methods; Female; Humans; Image Interpretation, Computer-Assisted, methods; Magnetic Resonance Imaging, methods; Male; Mammography, methods; Middle Aged; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic},
  medline-pst = {ppublish},
  owner       = {PaulD},
  pmid        = {24446230},
  timestamp   = {2016.04.18},
}

@Article{Johansson2013,
  author      = {Johansson, Anna L V. and Andersson, Therese M-L. and Hsieh, Chung-Cheng and Jirstr{\"{o}}m, Karin and Dickman, Paul and Cnattingius, Sven and Lambe, Mats},
  title       = {Stage at diagnosis and mortality in women with pregnancy-associated breast cancer ({PABC}).},
  journal     = {Breast Cancer Research and Treatment},
  year        = {2013},
  language    = {eng},
  volume      = {139},
  number      = {1},
  month       = {May},
  pages       = {183--192},
  doi         = {10.1007/s10549-013-2522-1},
  url         = {http://dx.doi.org/10.1007/s10549-013-2522-1},
  abstract    = {Converging evidence indicates that women with pregnancy-associated breast cancer (PABC) have increased mortality compared to women with breast cancer not diagnosed near pregnancy (non-PABC). Our aim was to investigate if the stage distribution differs between PABC and non-PABC and if stage at diagnosis can explain the poorer prognosis observed among women with PABC. We identified 3,282 breast cancers in women aged 15-44 years at diagnosis for whom staging data (tumor size, nodal involvement, metastasis) were available in the Swedish Cancer Register between 2002 and 2009. Information on reproductive history and vital status was obtained from the Multi-Generation Register and the Cause of Death Register. PABC was defined as breast cancers diagnosed during pregnancy and up to 2 years after delivery (n = 317). Non-PABC was defined as cases diagnosed before pregnancy or more than 2 years postpartum. Stage distributions were compared between PABC and non-PABC, and mortality rates were modeled using Cox regression. Compared to women with non-PABC, the mortality was almost 50 \% higher in women with PABC [unadjusted hazard ratio (HR) 1.47 (95 \% CI 1.04-2.08)], a difference which was reduced after adjustment for age and calendar year of diagnosis [HR 1.27 (95 \% CI 0.88-1.83)]. Although advanced stage of breast cancer at diagnosis was more common among PABC than among non-PABC, further adjustment for stage only slightly reduced the HR [1.22 (95 \% CI 0.84-1.78)]. The difference in mortality between PABC and non-PABC was more pronounced among women above 35 years and among women with PABC diagnosed within 1 year postpartum. Age, rather than stage at diagnosis, appears to act as the principal driver of the increased mortality observed in women with PABC. However, these findings do not preclude an untoward influence on mortality by pregnancy-associated factors affecting tumor aggressiveness and progression.},
  institution = {Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, P.O. Box 281, 17177, Stockholm, Sweden. anna.johansson@ki.se},
  keywords    = {Adolescent; Adult; Breast Neoplasms, mortality/pathology; Female; Humans; Neoplasm Staging; Pregnancy; Pregnancy Complications, Neoplastic, mortality/pathology; Young Adult},
  medline-pst = {ppublish},
  owner       = {PaulD},
  pmid        = {23576078},
  timestamp   = {2016.04.19},
}

@Article{Kuhl1997,
  author      = {Kuhl, C. K. and Bieling, H. B. and Gieseke, J. and Kreft, B. P. and Sommer, T. and Lutterbey, G. and Schild, H. H.},
  title       = {Healthy premenopausal breast parenchyma in dynamic contrast-enhanced {MR} imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency.},
  journal     = {Radiology},
  year        = {1997},
  language    = {eng},
  volume      = {203},
  number      = {1},
  month       = {Apr},
  pages       = {137--144},
  doi         = {10.1148/radiology.203.1.9122382},
  url         = {http://dx.doi.org/10.1148/radiology.203.1.9122382},
  abstract    = {To define the range of normal contrast medium enhancement, the variability in contrast medium enhancement patterns in healthy premenopausal breast parenchyma, and the implications for management strategies in cases with incidental contrast medium-enhancing foci on breast magnetic resonance (MR) images.Twenty healthy volunteers (aged 21-41 years) were examined on a 1.5-T system (dynamic two-dimensional gradient-echo protocol with subtraction postprocessing) during each week of a menstrual cycle (group 1) or over 4 months (group 2). The authors evaluated changes in the number of enhancing foci and the respective enhancement patterns within a cycle and between cycles.Both diffuse and nodular enhancement of breast parenchyma occurred during all phases of the menstrual cycle, especially in weeks 1 and 4. Enhancement was lowest in week 2. A total of 60 enhancing foci (73\% of which resolved completely during follow-up) were found in 16 of 20 volunteers. Twenty-six foci demonstrated enhancement velocities beyond the malignancy threshold (>80\% increase in the 1st minute).Contrast-enhancing foci are normal in healthy premenopausal breasts, even when formal malignancy criteria of enhancement velocity are met. This has to be kept in mind to avoid false-positive results, especially in younger patients.},
  institution = {Department of Radiology, University of Bonn, Germany.},
  keywords    = {Adult; Breast, anatomy /&/ histology; Contrast Media; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Premenopause; Prospective Studies; Reference Values; Subtraction Technique},
  medline-pst = {ppublish},
  owner       = {PaulD},
  pmid        = {9122382},
  timestamp   = {2016.04.18},
}

@Article{Kuhl2014,
  author      = {Kuhl, Christiane K. and Schrading, Simone and Strobel, Kevin and Schild, Hans H. and Hilgers, Ralf-Dieter and Bieling, Heribert B.},
  title       = {Abbreviated breast magnetic resonance imaging ({MRI}): first postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with {MRI}.},
  journal     = {J Clin Oncol},
  year        = {2014},
  language    = {eng},
  volume      = {32},
  number      = {22},
  month       = {Aug},
  pages       = {2304--2310},
  doi         = {10.1200/JCO.2013.52.5386},
  url         = {http://dx.doi.org/10.1200/JCO.2013.52.5386},
  abstract    = {We investigated whether an abbreviated protocol (AP), consisting of only one pre- and one postcontrast acquisition and their derived images (first postcontrast subtracted [FAST] and maximum-intensity projection [MIP] images), was suitable for breast magnetic resonance imaging (MRI) screening.We conducted a prospective observational reader study in 443 women at mildly to moderately increased risk who underwent 606 screening MRIs. Eligible women had normal or benign digital mammograms and, for those with heterogeneously dense or extremely dense breasts (n = 427), normal or benign ultrasounds. Expert radiologists reviewed the MIP image first to search for significant enhancement and then reviewed the complete AP (consisting of MIP and FAST images and optionally their nonsubtracted source images) to characterize enhancement and establish a diagnosis. Only thereafter was the regular full diagnostic protocol (FDP) analyzed.MRI acquisition time for FDP was 17 minutes, versus 3 minutes for the AP. Average time to read the single MIP and complete AP was 2.8 and 28 seconds, respectively. Eleven breast cancers (four ductal carcinomas in situ and seven invasive cancers; all T1N0 intermediate or high grade) were diagnosed, for an additional cancer yield of 18.2 per 1,000. MIP readings were positive in 10 (90.9\%) of 11 cancers and allowed establishment of the absence of breast cancer, with a negative predictive value (NPV) of 99.8\% (418 of 419). Interpretation of the complete AP, as with the FDP, allowed diagnosis of all cancers (11 [100\%] of 11). Specificity and positive predictive value (PPV) of AP versus FDP were equivalent (94.3\% v 93.9\% and 24.4\% v 23.4\%, respectively).An MRI acquisition time of 3 minutes and an expert radiologist MIP image reading time of 3 seconds are sufficient to establish the absence of breast cancer, with an NPV of 99.8\%. With a reading time < 30 seconds for the complete AP, diagnostic accuracy was equivalent to that of the FDP and resulted in an additional cancer yield of 18.2 per 1,000.},
  institution = {Christiane K. Kuhl, Simone Schrading, Kevin Strobel, Ralf-Dieter Hilgers, and Heribert B. Bieling, University Hospital of Aachen, Rheinisch-Westf{\"a}lische Technische Hochschule, Aachen; and Hans H. Schild, University of Bonn, Bonn, Germany.},
  keywords    = {Adult; Aged; Breast Neoplasms, diagnosis/pathology; Cohort Studies; Early Detection of Cancer, methods; Female; Humans; Magnetic Resonance Imaging, methods; Middle Aged; Prospective Studies},
  medline-pst = {ppublish},
  owner       = {PaulD},
  pii         = {JCO.2013.52.5386},
  pmid        = {24958821},
  timestamp   = {2016.04.18},
}

@Article{Morris2014,
  author      = {Morris, Elizabeth A.},
  title       = {Rethinking breast cancer screening: ultra {FAST} breast magnetic resonance imaging.},
  journal     = {J Clin Oncol},
  year        = {2014},
  language    = {eng},
  volume      = {32},
  number      = {22},
  month       = {Aug},
  pages       = {2281--2283},
  doi         = {10.1200/JCO.2014.56.1514},
  url         = {http://dx.doi.org/10.1200/JCO.2014.56.1514},
  institution = {Memorial Sloan Kettering Cancer Center, New York, NY morrise@mskcc.org.},
  keywords    = {Breast Neoplasms, diagnosis; Female; Humans; Magnetic Resonance Imaging, methods},
  medline-pst = {ppublish},
  owner       = {PaulD},
  pii         = {JCO.2014.56.1514},
  pmid        = {24958827},
  timestamp   = {2016.04.18},
}

@Article{Mueller-Schimpfle1997,
  author      = {M{\"{u}}ller-Schimpfle, M. and Ohmenha{\"{u}}ser, K. and Stoll, P. and Dietz, K. and Claussen, C. D.},
  title       = {Menstrual cycle and age: influence on parenchymal contrast medium enhancement in {MR} imaging of the breast.},
  journal     = {Radiology},
  year        = {1997},
  language    = {eng},
  volume      = {203},
  number      = {1},
  month       = {Apr},
  pages       = {145--149},
  doi         = {10.1148/radiology.203.1.9122383},
  url         = {http://dx.doi.org/10.1148/radiology.203.1.9122383},
  abstract    = {To evaluate the influence of menstrual cycle and age on parenchymal contrast medium enhancement in magnetic resonance (MR) imaging of the breast.Dynamic gadolinium-enhanced fast low-angle shot, three-dimensional breast MR imaging was performed with high temporal and spatial resolution (eight measurements in 10 minutes). Menstrual cycle evaluations and age-influence studies were performed in 44 patients aged 27-55 years with a regular cycle (mean age, 41.5 years) and in 103 patients aged 15-79 years (mean age, 49.3 years), respectively. A region of interest was placed in each quadrant of the breast for evaluation of parenchymal enhancement. Quadrants with complete involution or lesions and patients who received hormonal therapy were excluded [corrected]. Analysis of variance was performed.Parenchymal contrast medium enhancement in cycle days 7-20 (geometric mean enhancement at minutes 1-10 = 0.12-0.47) was significantly lower than that in cycle days 21-6 (geometric mean, 0.17-0.98; P < or = .001). Contrast medium enhancement in patients aged 35-50 years (mean enhancement, 0.17-0.75) was significantly higher than that in patients aged younger than 35 years or older than 50 years (mean enhancement, 0.12-0.40; P < .01).Patients showed statistically significantly lower parenchymal enhancement in menstrual cycle days 7-20 than in days 21-6. Patients aged 35-50 years yielded higher parenchymal enhancement than did younger patients and older patients.},
  institution = {Department of Diagnostic Radiology, University of T{\AA}Â¼bingen, Germany.},
  keywords    = {Adolescent; Adult; Aged; Aging; Breast, anatomy /&/ histology; Contrast Media; Drug Combinations; Female; Gadolinium; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Meglumine; Menstrual Cycle; Middle Aged; Organometallic Compounds; Pentetic Acid, analogs /&/ derivatives},
  medline-pst = {ppublish},
  owner       = {PaulD},
  pmid        = {9122383},
  timestamp   = {2016.04.18},
}

@Article{Pettersson2014,
  author      = {Pettersson, Andreas and Graff, Rebecca E. and Ursin, Giske and {Santos Silva}, Isabel Dos and McCormack, Valerie and Baglietto, Laura and Vachon, Celine and Bakker, Marije F. and Giles, Graham G. and Chia, Kee Seng and Czene, Kamila and Eriksson, Louise and Hall, Per and Hartman, Mikael and Warren, Ruth M L. and Hislop, Greg and Chiarelli, Anna M. and Hopper, John L. and Krishnan, Kavitha and Li, Jingmei and Li, Qing and Pagano, Ian and Rosner, Bernard A. and Wong, Chia Siong and Scott, Christopher and Stone, Jennifer and Maskarinec, Gertraud and Boyd, Norman F. and {van Gils}, Carla H. and Tamimi, Rulla M.},
  title       = {Mammographic density phenotypes and risk of breast cancer: a meta-analysis.},
  journal     = {J Natl Cancer Inst},
  year        = {2014},
  language    = {eng},
  volume      = {106},
  number      = {5},
  month       = {May},
  doi         = {10.1093/jnci/dju078},
  url         = {http://dx.doi.org/10.1093/jnci/dju078},
  abstract    = {Fibroglandular breast tissue appears dense on mammogram, whereas fat appears nondense. It is unclear whether absolute or percentage dense area more strongly predicts breast cancer risk and whether absolute nondense area is independently associated with risk.We conducted a meta-analysis of 13 case-control studies providing results from logistic regressions for associations between one standard deviation (SD) increments in mammographic density phenotypes and breast cancer risk. We used random-effects models to calculate pooled odds ratios and 95\% confidence intervals (CIs). All tests were two-sided with P less than .05 considered to be statistically significant.Among premenopausal women (n = 1776 case patients; n = 2834 control subjects), summary odds ratios were 1.37 (95\% CI = 1.29 to 1.47) for absolute dense area, 0.78 (95\% CI = 0.71 to 0.86) for absolute nondense area, and 1.52 (95\% CI = 1.39 to 1.66) for percentage dense area when pooling estimates adjusted for age, body mass index, and parity. Corresponding odds ratios among postmenopausal women (n = 6643 case patients; n = 11187 control subjects) were 1.38 (95\% CI = 1.31 to 1.44), 0.79 (95\% CI = 0.73 to 0.85), and 1.53 (95\% CI = 1.44 to 1.64). After additional adjustment for absolute dense area, associations between absolute nondense area and breast cancer became attenuated or null in several studies and summary odds ratios became 0.82 (95\% CI = 0.71 to 0.94; P heterogeneity = .02) for premenopausal and 0.85 (95\% CI = 0.75 to 0.96; P heterogeneity < .01) for postmenopausal women.The results suggest that percentage dense area is a stronger breast cancer risk factor than absolute dense area. Absolute nondense area was inversely associated with breast cancer risk, but it is unclear whether the association is independent of absolute dense area.},
  institution = {Cancer Care, Toronto, ON, Canada (AMC); Human Genetics, Genome Institute of Singapore, Singapore, Singapore (JL); Campbell Family Institute for Breast Cancer Research, Ontario Cancer Institute, Toronto, ON, Canada (QL, NFB); University of Hawaii Cancer Center, Honolu},
  keywords    = {Breast Neoplasms, pathology/radiography; Breast, pathology; Case-Control Studies; Female; Humans; Mammography; Middle Aged; Phenotype; Postmenopause},
  medline-pst = {epublish},
  owner       = {PaulD},
  pii         = {dju078},
  pmc         = {PMC4568991},
  pmid        = {24816206},
  timestamp   = {2016.04.21},
}

@Article{Colzani2014,
  author          = {Colzani, E. and Johansson, A L V. and Liljegren, A. and Foukakis, T. and Clements, M. and Adolfsson, J. and Hall, P. and Czene, K.},
  title           = {Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics.},
  journal         = {Br J Cancer},
  year            = {2014},
  language        = {eng},
  volume          = {110},
  number          = {5},
  issue           = {5},
  month           = {Mar},
  pages           = {1378--1384},
  issn            = {1532-1827},
  doi             = {10.1038/bjc.2014.5},
  url             = {http://dx.doi.org/10.1038/bjc.2014.5},
  abstract        = {Metastatic breast cancer is a severe condition without curative treatment.
	How relative and absolute risk of distant metastasis varies over
	time since diagnosis, as a function of treatment, age and tumour
	characteristics, has not been studied in detail.A total of 9514 women
	under the age of 75 when diagnosed with breast cancer in Stockholm
	and Gotland regions during 1990-2006 were followed up for metastasis
	(mean follow-up=5.7 years). Time-dependent development of distant
	metastasis was analysed using flexible parametric survival models
	and presented as hazard ratio (HR) and cumulative risk.A total of
	995 (10.4\%) patients developed distant metastasis; the most common
	sites were skeleton (32.5\%) and multiple sites (28.3\%). Women younger
	than 50 years at diagnosis, with lymph node-positive, oestrogen receptor
	(ER)-negative, >20 mm tumours and treated only locally, had the highest
	risk of distant metastasis (0-5 years' cumulative risk =0.55; 95\%
	confidence interval (CI): 0.47-0.64). Women older than 50 years at
	diagnosis, with ER-positive, lymph node-negative and ?20-mm tumours,
	had the same and lowest cumulative risk of developing metastasis
	0-5 and 5-10 years (cumulative risk=0.03; 95\% CI: 0.02-0.04). In
	the period of 5-10 years after diagnosis, women with ER-positive,
	lymph node-positive and >20-mm tumours were at highest risk of distant
	recurrence. Women with ER-negative tumours showed a decline in risk
	during this period.Our data show no support for discontinuation at
	5 years of clinical follow-up in breast cancer patients and suggest
	further investigation on differential clinical follow-up for different
	subgroups of patients.},
  chemicals       = {Antineoplastic Agents},
  citation-subset = {IM},
  completed       = {2014-06-23},
  country         = {England},
  created         = {2014-03-05},
  file            = {Colzani2014.pdf:Colzani2014.pdf:PDF},
  institution     = {Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.},
  issn-linking    = {0007-0920},
  keywords        = {Aged; Antineoplastic Agents, therapeutic use; Breast Neoplasms, drug therapy/pathology; Cohort Studies; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local, diagnosis/pathology; Risk; Sweden; Time Factors},
  medline-pst     = {ppublish},
  nlm             = {PMC3950882},
  nlm-id          = {0370635},
  owner           = {pl4},
  pii             = {bjc20145},
  pmc             = {PMC3950882},
  pmid            = {24434426},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2015-05-15},
  timestamp       = {2015.01.08},
}

@Article{Crowther2012a,
  author      = {Crowther, M.J. and Riley, R.D. and Staessen, J.A. and Wang, J. and Gueyffier, F. and Lambert, P.C.},
  title       = {Individual patient data meta-analysis of survival data using {P}oisson regression models.},
  doi         = {10.1186/1471-2288-12-34},
  language    = {eng},
  pages       = {34},
  url         = {http://dx.doi.org/10.1186/1471-2288-12-34},
  volume      = {12},
  abstract    = {An Individual Patient Data (IPD) meta-analysis is often considered
	the gold-standard for synthesising survival data from clinical trials.
	An IPD meta-analysis can be achieved by either a two-stage or a one-stage
	approach, depending on whether the trials are analysed separately
	or simultaneously. A range of one-stage hierarchical Cox models have
	been previously proposed, but these are known to be computationally
	intensive and are not currently available in all standard statistical
	software. We describe an alternative approach using Poisson based
	Generalised Linear Models (GLMs).We illustrate, through application
	and simulation, the Poisson approach both classically and in a Bayesian
	framework, in two-stage and one-stage approaches. We outline the
	benefits of our one-stage approach through extension to modelling
	treatment-covariate interactions and non-proportional hazards. Ten
	trials of hypertension treatment, with all-cause death the outcome
	of interest, are used to apply and assess the approach.We show that
	the Poisson approach obtains almost identical estimates to the Cox
	model, is additionally computationally efficient and directly estimates
	the baseline hazard. Some downward bias is observed in classical
	estimates of the heterogeneity in the treatment effect, with improved
	performance from the Bayesian approach.Our approach provides a highly
	flexible and computationally efficient framework, available in all
	standard statistical software, to the investigation of not only heterogeneity,
	but the presence of non-proportional hazards and treatment effect
	modifiers.},
  file        = {Crowther2012a.pdf:Crowther2012a.pdf:PDF},
  institution = {Centre for Biostatistics and Genetic Epidemiology, Department of Health Sciences, University of Leicester, Adrian Building, University Road, Leicester LE1 7RH, UK.},
  journal     = {BMC Medical Research Methodology},
  keywords    = {Analysis of Variance; Bayes Theorem; Cause of Death; Data Collection, statistics /&/ numerical data; Female; Health Status Indicators; Humans; Hypertension, mortality/therapy; Intention to Treat Analysis; Linear Models; Male; Meta-Analysis as Topic; Poisson Distribution; Proportional Hazards Models; Randomized Controlled Trials as Topic; Regression Analysis; Survival Analysis; Treatment Outcome},
  medline-pst = {epublish},
  owner       = {pl4},
  pii         = {1471-2288-12-34},
  pmid        = {22443286},
  timestamp   = {2013.03.05},
  year        = {2012},
}

@Article{GoenenHeller2005,
  author    = {M. G\"{o}nen and G. Heller},
  title     = {Concordance probability and discriminatory power in proportional hazards regression},
  journal   = {Biometrika},
  year      = {2005},
  volume    = {92},
  pages     = {965--970},
  file      = {GoenenHeller2005.pdf:GoenenHeller2005.pdf:PDF;GoenenHeller2005.pdf:pdf\\GoenenHeller2005.pdf:PDF},
  owner     = {pl4},
  timestamp = {2010.03.08},
}

@Article{Gigerenzer2003,
  author      = {G. Gigerenzer and A. Edwards},
  title       = {Simple tools for understanding risks: from innumeracy to insight.},
  journal     = {BMJ},
  year        = {2003},
  language    = {eng},
  volume      = {327},
  number      = {7417},
  month       = {Sep},
  pages       = {741--744},
  doi         = {10.1136/bmj.327.7417.741},
  url         = {http://dx.doi.org/10.1136/bmj.327.7417.741},
  file        = {Gigerenzer2003.pdf:Gigerenzer2003.pdf:PDF;Gigerenzer2003.pdf:pdf\\Gigerenzer2003.pdf:PDF},
  institution = {Centre for Adaptive Behaviour and Cognition, Max Planck Institute for Human Development, Lentzeallee 94, 14195 Berlin, Germany. gigerenzer@mpibberlin.mpg.de},
  keywords    = {Data Display; Humans; Patient Education as Topic; Patient Participation; Probability Theory; Risk Assessment; Sensitivity and Specificity},
  medline-pst = {ppublish},
  owner       = {pl4},
  pii         = {327/7417/741},
  pmid        = {14512488},
  timestamp   = {2009.03.25},
}

@Article{Giorgi2001,
  author      = {R. Giorgi and G. H\'{e}delin and P. Schaffer},
  title       = {Relative survival: comparison of regressive models and advice for the user.},
  journal     = {J Epidemiol Biostat},
  year        = {2001},
  language    = {eng},
  volume      = {6},
  number      = {6},
  pages       = {455--462},
  abstract    = {BACKGROUND: Relative survival is a method of analysis of failure-time
	data used to estimate the net survival. Cancer registries frequently
	use this method. The main regressive models are the Hakulinen and
	Tenkanen model, and the Esteve et al. model, which are easily used
	in practice thanks to their specific software (SURV and RELSURV,
	respectively). An assessment of the behaviour of the models is made,
	with the aim of giving advice for users of lifetime data in practice.
	METHODS: Simulations were done by respecting, then violating, the
	basic hypothesis supporting the theoretical foundation of these two
	proportional hazard models (independence of the death and censor
	process, proportionality of risks). For each simulation, 100 files
	of either 100, 1,000, or 10,000 individuals were generated to assess
	the behaviour of the model. RESULTS: Moderate censor rates, with
	or without proportionality assumption, lead to the use of the Hakulinen
	and Tenkanen model, especially for studies with little information.
	Non-proportionality of risks in the Hakulinen and Tenkanen model
	could be tested and analysed. If assumptions underlying the models
	are respected, the Esteve et al. model seems to be more precise.
	DISCUSSION: The choice of a model in practice depends on its performance,
	and on the user's knowledge of statistics and computer science. Non-proportionality
	of risks is common in cancer registries. In theory, non-proportionality
	of risks could be taken into account for both relative survival models
	but, for the moment, it is feasible in routine only for the Hakulinen
	and Tenkanen model. Characteristics of the software should also be
	taken into account for routine relative survival analyses.},
  file        = {Giorgi2001.pdf:Giorgi2001.pdf:PDF;Giorgi2001.pdf:pdf\\Giorgi2001.pdf:PDF},
  groups      = {Excess mortality model},
  institution = {Laboratoire d'Enseignement et de Recherche sur le Traitement de l'Information M\'{e}dicale, Facult\'{e} de M\'{e}decine, Universit\'{e} de la M\'{e}diterran\'{e}e, Marseille, France. rgiorgi@ap-fm.fr},
  keywords    = {Data Interpretation, Statistical; Humans; Linear Models; Proportional Hazards Models; Reproducibility of Results; Survival Analysis; Time Factors},
  medline-pst = {ppublish},
  owner       = {pl4},
  pmid        = {11831681},
  timestamp   = {2008.12.16},
}

@TechReport{EPC1999,
  author      = {The National Board of Health and Welfare, Centre for Epidemiology},
  institution = {The National Board of Health and Welfare},
  title       = {In-patient diseases in {S}weden 1987--1996},
  note        = {URL: \url{http://www.sos.se/epc/english/ParEng.htm } [accessed June 11, 2004]},
  pages       = {99-112},
  type        = {Article 1999-42-004},
  owner       = {PaulD},
  timestamp   = {2011.06.19},
  volume      = {5},
  year        = {1999},
}

@Article{Filipovic-Pierucci2017,
  author       = {Filipovic-Pierucci, Antoine and Zarca, Kevin and Durand-Zaleski, Isabelle},
  title        = {{Markov models for health economic evaluations: The R Package heemod}},
  note         = {arXiv: 1702.03252},
  url          = {http://arxiv.org/abs/1702.03252},
  abstractnote = {Health economic evaluation studies are widely used in public health to assess health strategies in terms of their cost-effectiveness and inform public policies. We developed an R package for Markov models implementing most of the modelling and reporting features described in reference textbooks and guidelines: deterministic and probabilistic sensitivity analysis, heterogeneity analysis, time dependency on state-time and model-time (semi-Markov and non-homogeneous Markov models), etc. In this paper we illustrate the features of heemod by building and analysing an example Markov model. We then explain the design and the underlying implementation of the package.},
  journal      = {arXiv:1702.03252 [stat]},
  month        = {Feb},
  year         = {2017},
}

@Article{Bjoerkholm2018,
  author          = {Bj{\"o}rkholm, Magnus and Weibull, Caroline E and Eloranta, Sandra and Smedby, Karin E and Glimelius, Ingrid and Dickman, Paul W},
  title           = {Greater attention should be paid to developing therapies for elderly patients with {H}odgkin lymphoma-A population-based study from {S}weden.},
  journal         = {European journal of haematology},
  year            = {2018},
  volume          = {101},
  issue           = {1},
  month           = jul,
  pages           = {106--114},
  issn            = {1600-0609},
  doi             = {10.1111/ejh.13090},
  abstract        = {Forty percent of Hodgkin lymphoma (HL) patients are older than 50ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years at diagnosis, a fact which is not commonly recognized. Older patients do significantly worse than younger patients and are rarely included in clinical trials. Using data from Swedish Cancer and Lymphoma Registries, we estimated relative survival ratios (RSRs) for 7997 HL patients (diagnosed 1973-2013; 45% ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â‰ÃƒÂ‚Ã‚Â¥50ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years). The 1-year RSRs (95% confidence interval; CI) for males aged 45-59, 60-69, 70-80, and 81ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years and over, diagnosed in 2013, were 0.95 (0.91-0.97), 0.88 (0.81-0.92), 0.74 (0.63-0.81), and 0.52 (0.35-0.67), respectively. The corresponding 1-year RSRs for females were 0.97 (0.94-0.98), 0.91 (0.85-0.95), 0.82 (0.73-0.88), and 0.66 (0.50-0.77). No improvements in 1-year of 5-year relative survival from 2000 to 2013 were observed for patients aged 45-59 or 60-69 but there were modest improvements for patients aged 70ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â years and older. Importantly, we saw no changes in the distribution of disease or patient characteristics between 2000 and 2013. Elderly patients constitute a large group with clearly unmet medical needs. Our findings motivate a more active approach to including elderly patients in clinical trials. Our study provides a baseline for outcome comparison after the broader introduction of targeted drugs.},
  citation-subset = {IM},
  completed       = {2018-10-11},
  country         = {England},
  issn-linking    = {0902-4441},
  keywords        = {Age Distribution; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols, therapeutic use; Female; Hodgkin Disease, diagnosis, drug therapy, mortality, pathology; Humans; Male; Middle Aged; Patient Selection, ethics; Registries; Survival Analysis; Sweden, epidemiology; Hodgkin lymphoma; elderly; relative survival; temporal trends},
  nlm-id          = {8703985},
  owner           = {NLM},
  pmid            = {29727497},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2018-10-11},
}

@Article{Barbui2014,
  author          = {Barbui, Tiziano and Bj{\"o}rkholm, Magnus and Gratwohl, Alois},
  title           = {Cancer survivorship programs: time for concerted action.},
  journal         = {Haematologica},
  year            = {2014},
  volume          = {99},
  issue           = {8},
  month           = aug,
  pages           = {1273--1276},
  issn            = {1592-8721},
  doi             = {10.3324/haematol.2014.104059},
  abstract        = {Hematologists, specialists in cancer survivorship and patient advocates met in Bergamo, Italy (Nov 14ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Â“16, 2013) to highlight the physical, mental, psychosocial and financial challenges faced by cancer survivors and their families. Gaps in research and resources were all too apparent. This planned meeting perspective, not a formal consensus statement, reflects the key points mentioned by the participants during the discussions and the personal view of the authors. It proposes urgent action in key areas to ensure that people surviving cancer will suffer fewer long-term health problems than their predecessors and to contain costs.},
  citation-subset = {IM},
  completed       = {2015-04-13},
  country         = {Italy},
  issn-linking    = {0390-6078},
  keywords        = {Humans; Italy; Neoplasms, diagnosis, epidemiology, therapy; Survival Rate, trends; Survivors, statistics & numerical data; Time Factors},
  nlm-id          = {0417435},
  owner           = {NLM},
  pii             = {haematol.2014.104059},
  pmc             = {PMC4116824},
  pmid            = {25082784},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2018-12-02},
}

@Article{Glimelius2015,
  author          = {Glimelius, Ingrid and Ekberg, Sara and Jerkeman, Mats and Chang, Ellen T and Bj{\"o}rkholm, Magnus and Andersson, Therese M L and Smedby, Karin E and Eloranta, Sandra},
  title           = {Long-term survival in young and middle-aged {H}odgkin lymphoma patients in {S}weden 1992-2009-trends in cure proportions by clinical characteristics.},
  journal         = {American journal of hematology},
  year            = {2015},
  volume          = {90},
  issue           = {12},
  month           = dec,
  pages           = {1128--1134},
  issn            = {1096-8652},
  doi             = {10.1002/ajh.24184},
  abstract        = {Trends in Hodgkin lymphoma (HL) survival among patients treated outside of clinical trials provide real-world benchmark estimates of prognosis and help identify patient subgroups for targeted trials. In a Swedish population-based cohort of 1947 HL patients diagnosed in 1992-2009 at ages 18-59 years, we estimated relative survival (RS), cure proportions (CP), and median survival times using flexible parametric cure models. Overall, the CP was 89% (95% CI: 0.87-0.91) and median survival of the uncured was 4.6 years (95% CI: 3.0-6.3). For patients aged 18-50 years diagnosed after the year 2000, CP was high and stable, whereas for patients of 50-59 years, cure was not reached. The survival of relapse-free patients was similar to that of the general population (RS5-year : 0.99; 95% CI: 0.98-0.99, RS15-year : 0.95; 95% CI: 0.92-0.97). The excess mortality of relapsing patients was 19 times (95% CI: 12-31) that of relapse-free patients. Despite modern treatments, patients with adverse prognostic factors (e.g., advanced stage) still had markedly worse outcomes [CP stage: IIIB 0.82 (95% CI: 0.73-0.89); CP stage: IVB 0.72, (95% CI: 0.60-0.81)] and patients with international prognostic score (IPS) ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â‰ÃƒÂ‚Ã‚Â¥3 had 2.7 times higher excess mortality (95% CI: 1.0-7.0, p = 0.04) than patients with IPS <3. High-risk patients selected for 6-8 courses of BEACOPP (bleomycin, etoposide, doxorubicin, cyclofosphamide, vincristine, procarbazine, prednisone)-chemotherapy had a 15-year relative survival of 87%, (95% CI: 0.80-0.92), whereas the corresponding estimate for patients selected for 6-8 courses of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) was 93% (95% CI: 0.88-0.97). These population-based results indicate limited fatal side-effects in the 15-year perspective with contemporary treatments, while the unmet need of effective relapse treatment remains of concern. BEACOPP-chemotherapy was still not sufficient in high-risk HL patients.},
  citation-subset = {IM},
  completed       = {2016-06-02},
  country         = {United States},
  issn-linking    = {0361-8609},
  keywords        = {Adolescent; Adult; Cohort Studies; Female; History, 20th Century; History, 21st Century; Hodgkin Disease, mortality, pathology; Humans; Male; Middle Aged; Survival Analysis; Sweden; Young Adult},
  nlm-id          = {7610369},
  owner           = {NLM},
  pmid            = {26349012},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2016-01-15},
}

@Article{Young2014,
  author       = {Young, Jessica G and HerÃƒÂƒÃ‚Â…ÃƒÂ‚Ã‚Â„an, Miguel A and Robins, James M},
  title        = {Identification, estimation and approximation of risk under interventions that depend on the natural value of treatment using observational data.},
  journal      = {Epidemiologic methods},
  year         = {2014},
  volume       = {3},
  issue        = {1},
  month        = dec,
  pages        = {1--19},
  issn         = {2194-9263},
  doi          = {10.1515/em-2012-0001},
  country      = {Germany},
  issn-linking = {2161-962X},
  mid          = {NIHMS674386},
  nlm-id       = {101593840},
  owner        = {NLM},
  pmc          = {PMC4387917},
  pmid         = {25866704},
  pubmodel     = {Print},
  pubstatus    = {ppublish},
  revised      = {2018-11-13},
}

@Article{Murray2017,
  author          = {Murray, Eleanor J and Robins, James M and Seage, George R and Freedberg, Kenneth A and Hern{\AA}Â¡n, Miguel A},
  title           = {A Comparison of Agent-Based Models and the Parametric G-Formula for Causal Inference.},
  journal         = {American journal of epidemiology},
  year            = {2017},
  volume          = {186},
  issue           = {2},
  month           = jul,
  pages           = {131--142},
  issn            = {1476-6256},
  doi             = {10.1093/aje/kwx091},
  abstract        = {Decision-making requires choosing from treatments on the basis of correctly estimated outcome distributions under each treatment. In the absence of randomized trials, 2 possible approaches are the parametric g-formula and agent-based models (ABMs). The g-formula has been used exclusively to estimate effects in the population from which data were collected, whereas ABMs are commonly used to estimate effects in multiple populations, necessitating stronger assumptions. Here, we describe potential biases that arise when ABM assumptions do not hold. To do so, we estimated 12-month mortality risk in simulated populations differing in prevalence of an unknown common cause of mortality and a time-varying confounder. The ABM and g-formula correctly estimated mortality and causal effects when all inputs were from the target population. However, whenever any inputs came from another population, the ABM gave biased estimates of mortality-and often of causal effects even when the true effect was null. In the absence of unmeasured confounding and model misspecification, both methods produce valid causal inferences for a given population when all inputs are from that population. However, ABMs may result in bias when extrapolated to populations that differ on the distribution of unmeasured outcome determinants, even when the causal network linking variables is identical.},
  citation-subset = {IM},
  completed       = {2017-09-13},
  country         = {United States},
  issn-linking    = {0002-9262},
  keywords        = {Bias; Causality; Cause of Death, trends; Computer Simulation, statistics & numerical data; Data Interpretation, Statistical; Decision Making; Epidemiologic Research Design; Humans; Models, Statistical; Monte Carlo Method; Outcome Assessment (Health Care), methods, statistics & numerical data; Risk Assessment, methods; Systems Analysis; Monte Carlo methods; agent-based models; causal inference; decision analysis; individual-level models; mathematical models; medical decision making; parametric g-formula},
  nlm-id          = {7910653},
  owner           = {NLM},
  pii             = {3904485},
  pmc             = {PMC5860229},
  pmid            = {28838064},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2018-11-13}
}

@Misc{Statswe2018,
  author = {{Statistics Sweden}},
  date   = {2018-04-26},
  title  = {The future population of Sweden 2019-2120},
  url    = {https://www.scb.se/contentassets/b3973c6465b446a690aec868d8b67473/be0401_2018i70_br_be51br1801.pdf},
  year   = {2018},
}

@Article{Alkner2011,
  author          = {Alkner, Sara and Bendahl, P{\"a}r-Ola and Fern{\"o}, M{\aa}rten and Manjer, Jonas and Ryd{\AA}Â©n, Lisa},
  title           = {Prediction of outcome after diagnosis of metachronous contralateral breast cancer.},
  doi             = {10.1186/1471-2407-11-114},
  issn            = {1471-2407},
  pages           = {114},
  volume          = {11},
  abstract        = {Although 2-20% of breast cancer patients develop a contralateral breast cancer (CBC), prognosis after CBC is still debated. Using a unique patient cohort, we have investigated whether time interval to second breast cancer (BC2) and mode of detection are associated to prognosis. Information on patient-, tumour-, treatment-characteristics, and outcome was abstracted from patients' individual charts for all patients diagnosed with metachronous CBC in the Southern Healthcare Region of Sweden from 1977-2007. Distant disease-free survival (DDFS) and risk of distant metastases were primary endpoints. The cohort included 723 patients with metachronous contralateral breast cancer as primary breast cancer event. Patients with less than three years to BC2 had a significantly impaired DDFS (p = 0.01), and in sub-group analysis, this effect was seen primarily in patients aged <50. By logistic regression analysis, patients diagnosed with BC2 within routine follow-up examinations had a significantly lower risk of developing metastases compared to those who were symptomatic at diagnosis (p < 0.0001). Chemotherapy given after breast BC1 was a negative prognostic factor for DDFS, whereas endocrine treatment and radiotherapy given after BC2 improved DDFS. In a large cohort of patients with CBC, we found the time interval to BC2 to be a strong prognostic factor for DDFS in young women and mode of detection to be related to risk of distant metastases. Future studies of tumour biology of BC2 in relation to prognostic factors found in the present study can hopefully provide biological explanations to these findings.},
  citation-subset = {IM},
  completed       = {2011-08-01},
  country         = {England},
  issn-linking    = {1471-2407},
  journal         = {BMC cancer},
  keywords        = {Adult; Age Factors; Aged; Aged, 80 and over; Breast Neoplasms, diagnosis, epidemiology, pathology, physiopathology; Carcinoma, physiopathology; Diagnosis; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms, Second Primary, physiopathology; Prognosis; Sweden},
  month           = mar,
  nlm-id          = {100967800},
  owner           = {NLM},
  pii             = {1471-2407-11-114},
  pmc             = {PMC3080341},
  pmid            = {21450091},
  pubmodel        = {Electronic},
  pubstatus       = {epublish},
  revised         = {2018-11-13},
  year            = {2011},
}

@Article{Vichapat2012,
  author          = {Vichapat, Voralak and Garmo, Hans and Holmqvist, Marit and Liljegren, G{\"o}ran and W{\"a}rnberg, Fredrik and Lambe, Mats and Fornander, Tommy and Adolfsson, Jan and L{\AA}Â¼chtenborg, Margreet and Holmberg, Lars},
  title           = {Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based study.},
  doi             = {10.1200/JCO.2011.39.3645},
  issn            = {1527-7755},
  issue           = {28},
  pages           = {3478--3485},
  volume          = {30},
  abstract        = {The number of breast cancer survivors at risk of developing contralateral breast cancer (CBC) is increasing. However, ambiguity remains regarding risk factors and prognosis for women with CBC. In a cohort of 42,670 women with breast cancer in the Uppsala/{\AA}Â–rebro and Stockholm regions in Sweden in 1992 to 2008, we assessed risk factors for and prognosis of metachronous CBC by using survival analysis. Breast cancer-specific survival for women with CBC was evaluated and compared with results for women with unilateral breast cancer (UBC) by using time-dependent Cox-regression modeling. An increased risk for CBC was observed among women who had primary breast cancer with ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â‰ÃƒÂ‚Ã‚Â¥ 10 involved lymph nodes compared with node-negative women (adjusted hazard ratio [HR], 1.8; 95% CI, 1.2 to 2.7). The prognosis was poorer in women with CBC than with UBC. The hazard of dying from breast cancer was especially high for women with a short interval time to CBC (adjusted HR, 2.3; 95% CI, 1.8 to 2.8 for CBC diagnosed ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â‰ÃƒÂ‚Ã‚Â¤ 5 years v UBC) and gradually decreased with longer follow-up time but remained higher than the hazard originating from the primary tumor for ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â‰ÃƒÂ‚Ã‚Â¥ 10 years. Women with advanced-stage primary breast cancer had an increased risk of developing CBC. CBC is associated with an increased risk of dying from breast cancer throughout a long period of follow-up after the primary tumor. Our findings suggest that the event of CBC marks a new clinical situation in terms of investigations for metastases, treatment considerations, and follow-up strategy.},
  citation-subset = {IM},
  completed       = {2012-12-10},
  country         = {United States},
  issn-linking    = {0732-183X},
  journal         = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  keywords        = {Aged; Breast Neoplasms, mortality, pathology; Female; Humans; Middle Aged; Neoplasms, Second Primary, pathology; Prognosis; Risk Factors; Survival Rate},
  month           = oct,
  nlm-id          = {8309333},
  owner           = {NLM},
  pii             = {JCO.2011.39.3645},
  pmid            = {22927521},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2012-10-01},
  year            = {2012},
}

@Article{Sandberg2012,
  author          = {Sandberg, Maria E C and Hartman, Mikael and Klevebring, Daniel and Eloranta, Sandra and Ploner, Alexander and Hall, Per and Czene, Kamila},
  title           = {Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer.},
  doi             = {10.1007/s10549-012-2096-3},
  issn            = {1573-7217},
  issue           = {2},
  pages           = {793--800},
  volume          = {134},
  abstract        = {Estrogen receptor (ER) status is important for breast cancer survival, it is however unclear how prognosis of contralateral breast cancer (CBC) is affected by ER-status of the two tumors. We conducted a large, population-based study of ER-status of both tumors in CBC patients and its influence on prognosis. The cohort consisted of all women diagnosed with CBC in Stockholm, Sweden during 1976-2005, with information on ER-status from medical records (N = 933). Prognosis was modeled as incidence rates of distant metastasis via Poisson regression. The proportion of CBCs with both cancers of the same ER-status was significantly larger than expected by chance. For synchronous (simultaneous) cancers the prognosis was significantly affected by the combined ER-status of both tumors (p = 0.01). Compared to unilateral breast cancer patients the incidence rate ratio (IRR) for patients with double ER-positive tumors was 1.25 (95 % CI: 0.88-1.76), for ER-discordant tumors 2.19 (95 % CI: 1.18-4.08) and for double ER-negative tumors 3.95 (95 % CI: 1.77-8.81). For metachronous (non-simultaneous) cancers, women with double ER-positive tumors had similarly bad prognosis (IRR = 2.95; 95 % CI: 2.39-3.64) as women with double ER-negative tumors (IRR = 2.88; 95 % CI: 1.83-4.52). Both shorter time span between first and second cancer and endocrine therapy for the first cancer further worsened prognosis of women with double ER-positive metachronous CBC. For synchronous CBC patients, ER-pattern of both tumors is an important prognosticator, while among metachronous CBC patients, double ER-positive tumors confer equally bad prognosis as double ER-negative cancers. Our results indicate that this might be due to endocrine therapy resistance.},
  chemicals       = {Receptors, Estrogen},
  citation-subset = {IM},
  completed       = {2012-11-23},
  country         = {Netherlands},
  issn-linking    = {0167-6806},
  journal         = {Breast cancer research and treatment},
  keywords        = {Aged; Breast Neoplasms, epidemiology, metabolism, pathology; Cohort Studies; Female; Humans; Incidence; Middle Aged; Neoplasm Metastasis; Neoplasms, Multiple Primary, pathology; Neoplasms, Second Primary, pathology; Poisson Distribution; Prognosis; Receptors, Estrogen, metabolism; Regression Analysis},
  month           = jul,
  nlm-id          = {8111104},
  owner           = {NLM},
  pmid            = {22622811},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2012-07-23},
  year            = {2012},
}

@Article{Sullivan2011,
  author          = {Sullivan, Richard and Peppercorn, Jeffrey and Sikora, Karol and Zalcberg, John and Meropol, Neal J and Amir, Eitan and Khayat, David and Boyle, Peter and Autier, Philippe and Tannock, Ian F and Fojo, Tito and Siderov, Jim and Williamson, Steve and Camporesi, Silvia and McVie, J Gordon and Purushotham, Arnie D and Naredi, Peter and Eggermont, Alexander and Brennan, Murray F and Steinberg, Michael L and De Ridder, Mark and McCloskey, Susan A and Verellen, Dirk and Roberts, Terence and Storme, Guy and Hicks, Rodney J and Ell, Peter J and Hirsch, Bradford R and Carbone, David P and Schulman, Kevin A and Catchpole, Paul and Taylor, David and Geissler, Jan and Brinker, Nancy G and Meltzer, David and Kerr, David and Aapro, Matti},
  title           = {Delivering affordable cancer care in high-income countries.},
  doi             = {10.1016/S1470-2045(11)70141-3},
  issn            = {1474-5488},
  issue           = {10},
  pages           = {933--980},
  volume          = {12},
  abstract        = {The burden of cancer is growing, and the disease is becoming a major economic expenditure for all developed countries. In 2008, the worldwide cost of cancer due to premature death and disability (not including direct medical costs) was estimated to be US$895 billion. This is not simply due to an increase in absolute numbers, but also the rate of increase of expenditure on cancer. What are the drivers and solutions to the so-called cancer-cost curve in developed countries? How are we going to afford to deliver high quality and equitable care? Here, expert opinion from health-care professionals, policy makers, and cancer survivors has been gathered to address the barriers and solutions to delivering affordable cancer care. Although many of the drivers and themes are specific to a particular field-eg, the huge development costs for cancer medicines-there is strong concordance running through each contribution. Several drivers of cost, such as over-use, rapid expansion, and shortening life cycles of cancer technologies (such as medicines and imaging modalities), and the lack of suitable clinical research and integrated health economic studies, have converged with more defensive medical practice, a less informed regulatory system, a lack of evidence-based sociopolitical debate, and a declining degree of fairness for all patients with cancer. Urgent solutions range from re-engineering of the macroeconomic basis of cancer costs (eg, value-based approaches to bend the cost curve and allow cost-saving technologies), greater education of policy makers, and an informed and transparent regulatory system. A radical shift in cancer policy is also required. Political toleration of unfairness in access to affordable cancer treatment is unacceptable. The cancer profession and industry should take responsibility and not accept a substandard evidence base and an ethos of very small benefit at whatever cost; rather, we need delivery of fair prices and real value from new technologies.},
  citation-subset = {IM},
  completed       = {2011-11-18},
  country         = {England},
  issn-linking    = {1470-2045},
  journal         = {The Lancet. Oncology},
  keywords        = {Australia; Cost Savings; Cost-Benefit Analysis; Delivery of Health Care, Integrated, economics, legislation & jurisprudence; Europe; Health Care Costs, legislation & jurisprudence; Health Care Reform, economics; Health Expenditures, legislation & jurisprudence; Health Policy, economics; Health Services Accessibility, legislation & jurisprudence; Health Services Misuse, economics; Health Services Research; Healthcare Disparities, economics; Humans; Insurance, Health, economics; Models, Economic; Neoplasms, diagnosis, therapy; Socioeconomic Factors; United States},
  month           = sep,
  nlm-id          = {100957246},
  owner           = {NLM},
  pii             = {S1470-2045(11)70141-3},
  pmid            = {21958503},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2014-08-18},
  year            = {2011},
}

@Article{Ohm2015,
  author          = {Ohm, Lotta and Lundqvist, Adam and Dickman, Paul and H{\"o}glund, Martin and Persson, Ulf and Stenke, Leif and Carlsson, Katarina Steen and Bj{\"o}rkholm, Magnus},
  title           = {Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib.},
  doi             = {10.3109/10428194.2014.953141},
  issn            = {1029-2403},
  issue           = {5},
  pages           = {1385--1391},
  volume          = {56},
  abstract        = {Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML). We evaluated clinical outcome and cost-effectiveness, using Swedish registry data based on patients with CML diagnosed 1973-2008. Outcome from three time periods (I: 1973-1979; II: 1991-1997; III: 2002-2008) associated with symptomatic treatment, interferon-ÃƒÂƒÃ‚ÂŽÃƒÂ‚Ã‚Â±/stem cell transplant and implementation of imatinib, respectively, were compared and a lifetime cost-effectiveness model developed. Survival data from population registries, estimated resource use from clinical practice and quality of life estimates were employed. Substantial health gains were noted over time, paralleled by increased treatment costs. Median survival was 1.9, 4.0 and 13 years during the respective time periods. The incremental cost-effectiveness ratio (ICER) between periods III and II was ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â‚ÃƒÂ‚Ã‚Â¬52,700 per quality-adjusted life year (QALY) gained. An estimated 80% price reduction of imatinib, related to patent expiry, would reduce this ICER to ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â‚ÃƒÂ‚Ã‚Â¬22,700. Our data from four decades reveal dramatically improved survival in CML, paralleled by ICER levels generally accepted by health authorities.},
  chemicals       = {Antineoplastic Agents, Protein Kinase Inhibitors, Imatinib Mesylate},
  citation-subset = {IM},
  completed       = {2016-03-25},
  country         = {United States},
  issn-linking    = {1026-8022},
  journal         = {Leukemia \& lymphoma},
  keywords        = {Adult; Aged; Antineoplastic Agents, economics, therapeutic use; Cost-Benefit Analysis; Drug Costs; Female; Humans; Imatinib Mesylate, therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, diagnosis, drug therapy, epidemiology; Male; Middle Aged; Prevalence; Protein Kinase Inhibitors, therapeutic use; Quality-Adjusted Life Years; Survival Analysis; Chronic myeloid leukemia; costs; imatinib; lifetime simulation; population-based; survival},
  month           = may,
  nlm-id          = {9007422},
  owner           = {NLM},
  pmid            = {25139694},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2019-01-16},
  year            = {2015},
}

@Article{Mozumder2017,
  author    = {Mozumder, Sarwar Islam and Rutherford, Mark J. and Lambert, Paul C.},
  title     = {A Flexible Parametric Competing-risks Model Using a Direct Likelihood Approach for the Cause-specific Cumulative Incidence Function},
  doi       = {10.1177/1536867x1701700212},
  issn      = {1536-8734},
  number    = {2},
  pages     = {462â€“489},
  url       = {http://dx.doi.org/10.1177/1536867X1701700212},
  volume    = {17},
  journal   = {The Stata Journal},
  month     = jun,
  publisher = {SAGE Publications},
  year      = {2017},
}

@Article{Kaufman2019,
  author       = {Kaufman, Jay S},
  title        = {Commentary: Causal Inference for Social Exposures.},
  journal      = {Annual review of public health},
  year         = {2019},
  volume       = {40},
  month        = apr,
  pages        = {7--21},
  issn         = {1545-2093},
  doi          = {10.1146/annurev-publhealth-040218-043735},
  abstract     = {Social epidemiology seeks to describe and quantify the causal effects of social institutions, interactions, and structures on human health. To accomplish this task, we define exposures as treatments and posit populations exposed or unexposed to these well-defined regimens. This inferential structure allows us to unambiguously estimate and interpret quantitative causal parameters and to investigate how these may be affected by biases such as confounding. This paradigm has been challenged recently by some critics who favor broadening the exposures that may be studied beyond treatments to also consider states. Defining the exposure protocol of an observational study is a continuum of specificity, and one may choose to loosen this definition, incurring the cost of causal parameters that become commensurately more vague. The advantages and disadvantages of broader versus narrower definitions of exposure are matters of continuing debate in social epidemiology as in other branches of epidemiology.},
  country      = {United States},
  file         = {:Kaufman2019.pdf:PDF},
  issn-linking = {0163-7525},
  keywords     = {causal inference; confounding; counterfactual; quasi-experimental; race/ethnicity; social determinants; well-defined exposure},
  nlm-id       = {8006431},
  owner        = {NLM},
  pmid         = {30601720},
  pubmodel     = {Print-Electronic},
  pubstatus    = {ppublish},
  revised      = {2019-04-02}
}

@Article{Song2019,
  author          = {Song, Huan and Fang, Fang and Arnberg, Filip K and Mataix-Cols, David and Fern{\'a}ndez de la Cruz, Lorena and Almqvist, Catarina and Fall, Katja and Lichtenstein, Paul and Thorgeirsson, Gudmundur and Valdimarsd{\'u}ttir, Unnur A},
  title           = {Stress related disorders and risk of cardiovascular disease: population based, sibling controlled cohort study.},
  doi             = {10.1136/bmj.l1255},
  issn            = {1756-1833},
  pages           = {l1255},
  volume          = {365},
  citation-subset = {AIM, IM},
  completed       = {2019-04-18},
  country         = {England},
  issn-linking    = {0959-8138},
  journal         = {BMJ},
  keywords        = {Adjustment Disorders, complications, diagnosis, epidemiology; Adult; Cardiovascular Diseases, epidemiology, etiology; Cohort Studies; Female; Humans; Incidence; Male; Middle Aged; Psychophysiologic Disorders, epidemiology; Risk Factors; Siblings; Stress Disorders, Post-Traumatic, epidemiology; Stress Disorders, Traumatic, Acute, epidemiology; Sweden},
  nlm-id          = {8900488},
  owner           = {NLM},
  pmid            = {30971390},
  pubmodel        = {Electronic},
  pubstatus       = {epublish},
  revised         = {2019-04-18},
  year            = {2019},
}

@Article{Adlam2017,
  author          = {Adlam, David and Peake, Michael D},
  title           = {Cancer and heart disease: new bedfellows in the cardiovascular landscape.},
  journal         = {European heart journal. Quality of care \& clinical outcomes},
  year            = {2017},
  volume          = {3},
  issue           = {3},
  month           = jul,
  pages           = {168--170},
  issn            = {2058-1742},
  doi             = {10.1093/ehjqcco/qcx002},
  citation-subset = {IM},
  completed       = {2018-09-06},
  country         = {England},
  file            = {:Adlam2017.pdf:PDF},
  issn-linking    = {2058-1742},
  keywords        = {Alzheimer Disease; Cardiovascular System; Heart Diseases; Heart Failure; Humans; Neoplasms; New Zealand; Politics; United States},
  nlm-id          = {101677796},
  owner           = {NLM},
  pii             = {3039237},
  pmc             = {PMC5805114},
  pmid            = {28838089},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2018-12-02}
}

@WWW{Simulacrum2019,
  title = {Simulacrum, https://simulacrum.healthdatainsight.org.uk/},
  url   = {https://simulacrum.healthdatainsight.org.uk/},
  year  = {2019},
}

@Article{Belot2019,
  author       = {Belot, Aur{\AA}Â©lien and Ndiaye, Aminata and Luque-Fernandez, Miguel-Angel and Kipourou, Dimitra-Kleio and Maringe, Camille and Rubio, Francisco Javier and Rachet, Bernard},
  title        = {Summarizing and communicating on survival data according to the audience: a tutorial on different measures illustrated with population-based cancer registry data.},
  journal      = {Clinical Epidemiology},
  year         = {2019},
  volume       = {11},
  pages        = {53--65},
  issn         = {1179-1349},
  doi          = {10.2147/CLEP.S173523},
  abstract     = {Survival data analysis results are usually communicated through the overall survival probability. Alternative measures provide additional insights and may help in communicating the results to a wider audience. We describe these alternative measures in two data settings, the overall survival setting and the relative survival setting, the latter corresponding to the particular competing risk setting in which the cause of death is unavailable or unreliable. In the overall survival setting, we describe the overall survival probability, the conditional survival probability and the restricted mean survival time (restricted to a prespecified time window). In the relative survival setting, we describe the net survival probability, the conditional net survival probability, the restricted mean net survival time, the crude probability of death due to each cause and the number of life years lost due to each cause over a prespecified time window. These measures describe survival data either on a probability scale or on a timescale. The clinical or population health purpose of each measure is detailed, and their advantages and drawbacks are discussed. We then illustrate their use analyzing England population-based registry data of men 15-80 years old diagnosed with colon cancer in 2001-2003, aiming to describe the deprivation disparities in survival. We believe that both the provision of a detailed example of the interpretation of each measure and the software implementation will help in generalizing their use.},
  country      = {New Zealand},
  file         = {:Belot2019.pdf:PDF;:Belot2019_supplementary.pdf:PDF},
  issn-linking = {1179-1349},
  keywords     = {competing risks; conditional survival; crude probability of death; net survival; number of life years lost; relative survival setting; restricted mean survival time; survival},
  nlm-id       = {101531700},
  owner        = {NLM},
  pii          = {clep-11-053},
  pmc          = {PMC6322561},
  pmid         = {30655705},
  pubmodel     = {Electronic-eCollection},
  pubstatus    = {epublish},
  revised      = {2019-01-20}
}

@Article{Belot2018,
  author       = {Belot, Aur{\AA}Â©lien and Remontet, Laurent and Rachet, Bernard and Dejardin, Olivier and Charvat, Hadrien and Bara, Simona and Guizard, Anne-Val{\AA}Â©rie and Roche, Laurent and Launoy, Guy and Bossard, Nadine},
  title        = {Describing the association between socioeconomic inequalities and cancer survival: methodological guidelines and illustration with population-based data.},
  journal      = {Clinical epidemiology},
  year         = {2018},
  volume       = {10},
  pages        = {561--573},
  issn         = {1179-1349},
  doi          = {10.2147/CLEP.S150848},
  abstract     = {Describing the relationship between socioeconomic inequalities and cancer survival is important but methodologically challenging. We propose guidelines for addressing these challenges and illustrate their implementation on French population-based data. We analyzed 17 cancers. Socioeconomic deprivation was measured by an ecological measure, the European Deprivation Index (EDI). The Excess Mortality Hazard (EMH), ie, the mortality hazard among cancer patients after accounting for other causes of death, was modeled using a flexible parametric model, allowing for nonlinear and/or time-dependent association between the EDI and the EMH. The model included a cluster-specific random effect to deal with the hierarchical structure of the data. We reported the conventional age-standardized net survival (ASNS) and described the changes of the EMH over the time since diagnosis at different levels of deprivation. We illustrated nonlinear and/or time-dependent associations between the EDI and the EMH by plotting the excess hazard ratio according to EDI values at different times after diagnosis. The median excess hazard ratio quantified the general contextual effect. Lip-oral cavity-pharynx cancer in men showed the widest deprivation gap, with 5-year ASNS at 41% and 29% for deprivation quintiles 1 and 5, respectively, and we found a nonlinear association between the EDI and the EMH. The EDI accounted for a substantial part of the general contextual effect on the EMH. The association between the EDI and the EMH was time dependent in stomach and pancreas cancers in men and in cervix cancer. The methodological guidelines proved efficient in describing the way socioeconomic inequalities influence cancer survival. Their use would allow comparisons between different health care systems.},
  country      = {New Zealand},
  issn-linking = {1179-1349},
  keywords     = {European Deprivation Index; cancer net survival; excess mortality hazard; flexible parametric model; socioeconomic inequalities},
  nlm-id       = {101531700},
  owner        = {NLM},
  pii          = {clep-10-561},
  pmc          = {PMC5961638},
  pmid         = {29844706},
  pubmodel     = {Electronic-eCollection},
  pubstatus    = {epublish},
  revised      = {2018-11-14}
}

@Article{Lesko2017,
  author          = {Lesko, Catherine R and Buchanan, Ashley L and Westreich, Daniel and Edwards, Jessie K and Hudgens, Michael G and Cole, Stephen R},
  title           = {Generalizing Study Results: A Potential Outcomes Perspective.},
  journal         = {Epidemiology},
  year            = {2017},
  volume          = {28},
  issue           = {4},
  month           = jul,
  pages           = {553--561},
  issn            = {1531-5487},
  doi             = {10.1097/EDE.0000000000000664},
  abstract        = {Great care is taken in epidemiologic studies to ensure the internal validity of causal effect estimates; however, external validity has received considerably less attention. When the study sample is not a random sample of the target population, the sample average treatment effect, even if internally valid, cannot usually be expected to equal the average treatment effect in the target population. The utility of an effect estimate for planning purposes and decision making will depend on the degree of departure from the true causal effect in the target population due to problems with both internal and external validity. Herein, we review concepts from recent literature on generalizability, one facet of external validity, using the potential outcomes framework. Identification conditions sufficient for external validity closely parallel identification conditions for internal validity, namely conditional exchangeability; positivity; the same distributions of the versions of treatment; no interference; and no measurement error. We also require correct model specification. Under these conditions, we discuss how a version of direct standardization (the g-formula, adjustment formula, or transport formula) or inverse probability weighting can be used to generalize a causal effect from a study sample to a well-defined target population, and demonstrate their application in an illustrative example.},
  citation-subset = {IM},
  completed       = {2018-04-04},
  country         = {United States},
  issn-linking    = {1044-3983},
  keywords        = {Bias; Causality; Epidemiologic Methods; Female; Humans; Male; Predictive Value of Tests; Reproducibility of Results; Statistics as Topic; United States},
  mid             = {NIHMS862564},
  nlm-id          = {9009644},
  owner           = {NLM},
  pmc             = {PMC5466356},
  pmid            = {28346267},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2018-11-13}
}

@Article{Pearl1995,
  author  = {Pearl, J.},
  title   = {Causal diagrams for empirical research},
  journal = {Biometrika},
  year    = {1995},
  volume  = {82},
  pages   = {669--688},
}

@InBook{Glymour2008,
  author    = {Glymour, M. \& Greenland, S},
  booktitle = {Modern Epidemiology},
  title     = {Causal Diagrams},
  pages     = {183-212},
  publisher = {Lippincott Williams \& Wilkins},
  year      = {2008},
}

@Article{Funk2011,
  author          = {Funk, M.J. and Westreich, D. and Wiesen, C. and St{\"u}rmer, T. and Brookhart, M.A. and Davidian, M.},
  title           = {Doubly robust estimation of causal effects.},
  journal         = {American Journal of Epidemiology},
  year            = {2011},
  volume          = {173},
  issue           = {7},
  pages           = {761--767},
  issn            = {1476-6256},
  doi             = {10.1093/aje/kwq439},
  abstract        = {Doubly robust estimation combines a form of outcome regression with a model for the exposure (i.e., the propensity score) to estimate the causal effect of an exposure on an outcome. When used individually to estimate a causal effect, both outcome regression and propensity score methods are unbiased only if the statistical model is correctly specified. The doubly robust estimator combines these 2 approaches such that only 1 of the 2 models need be correctly specified to obtain an unbiased effect estimator. In this introduction to doubly robust estimators, the authors present a conceptual overview of doubly robust estimation, a simple worked example, results from a simulation study examining performance of estimated and bootstrapped standard errors, and a discussion of the potential advantages and limitations of this method. The supplementary material for this paper, which is posted on the Journal's Web site (http://aje.oupjournals.org/), includes a demonstration of the doubly robust property (Web Appendix 1) and a description of a SAS macro (SAS Institute, Inc., Cary, North Carolina) for doubly robust estimation, available for download at http://www.unc.edu/~mfunk/dr/.},
  citation-subset = {IM},
  completed       = {2011-06-28},
  country         = {United States},
  issn-linking    = {0002-9262},
  keywords        = {Causality; Computer Simulation; Confidence Intervals; Confounding Factors (Epidemiology); Epidemiologic Methods; Humans; Likelihood Functions; Models, Statistical; Monte Carlo Method; Propensity Score; Regression Analysis},
  nlm-id          = {7910653},
  owner           = {NLM},
  pii             = {kwq439},
  pmc             = {PMC3070495},
  pmid            = {21385832},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2018-11-13},
}

@Article{Taubman2009,
  author          = {Taubman, S.L. and Robins, J.M. and Mittleman, M.A. and Hern{\'a}n, M.A.},
  title           = {Intervening on risk factors for coronary heart disease: an application of the parametric g-formula.},
  doi             = {10.1093/ije/dyp192},
  issn            = {1464-3685},
  issue           = {6},
  pages           = {1599--1611},
  volume          = {38},
  abstract        = {Estimating the population risk of disease under hypothetical interventions--such as the population risk of coronary heart disease (CHD) were everyone to quit smoking and start exercising or to start exercising if diagnosed with diabetes--may not be possible using standard analytic techniques. The parametric g-formula, which appropriately adjusts for time-varying confounders affected by prior exposures, is especially well suited to estimating effects when the intervention involves multiple factors (joint interventions) or when the intervention involves decisions that depend on the value of evolving time-dependent factors (dynamic interventions). We describe the parametric g-formula, and use it to estimate the effect of various hypothetical lifestyle interventions on the risk of CHD using data from the Nurses' Health Study. Over the period 1982-2002, the 20-year risk of CHD in this cohort was 3.50%. Under a joint intervention of no smoking, increased exercise, improved diet, moderate alcohol consumption and reduced body mass index, the estimated risk was 1.89% (95% confidence interval: 1.46-2.41). We discuss whether the assumptions required for the validity of the parametric g-formula hold in the Nurses' Health Study data. This work represents the first large-scale application of the parametric g-formula in an epidemiologic cohort study.},
  citation-subset = {IM},
  completed       = {2010-01-27},
  country         = {England},
  issn-linking    = {0300-5771},
  journal         = {International Journal of Epidemiology},
  keywords        = {Adult; Alcohol Drinking, adverse effects, epidemiology; Cause of Death; Cohort Studies; Coronary Disease, epidemiology, mortality, prevention & control; Exercise, physiology; Female; Health Behavior; Humans; Life Style; Mathematics; Middle Aged; Models, Statistical; Risk Assessment; Risk Factors; Smoking, epidemiology; Weight Loss},
  nlm-id          = {7802871},
  owner           = {NLM},
  pii             = {dyp192},
  pmc             = {PMC2786249},
  pmid            = {19389875},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2018-11-13},
  year            = {2009},
}

@InBook{Pearl2001,
  author     = {Pearl, J.},
  booktitle  = {In Proceedings of the Seventeenth Conference on Uncertainty in Artificial Intelligence, San Francisco, CA},
  title      = {Direct and indirect effects},
  bookauthor = {Morgan Kaufmann},
  pages      = {411ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Â“420},
  year       = {2001},
}

@Article{Imai2010,
  author          = {Imai, Kosuke and Keele, Luke and Tingley, Dustin},
  title           = {A general approach to causal mediation analysis.},
  journal         = {Psychological methods},
  year            = {2010},
  volume          = {15},
  issue           = {4},
  pages           = {309--334},
  issn            = {1939-1463},
  doi             = {10.1037/a0020761},
  abstract        = {Traditionally in the social sciences, causal mediation analysis has been formulated, understood, and implemented within the framework of linear structural equation models. We argue and demonstrate that this is problematic for 3 reasons: the lack of a general definition of causal mediation effects independent of a particular statistical model, the inability to specify the key identification assumption, and the difficulty of extending the framework to nonlinear models. In this article, we propose an alternative approach that overcomes these limitations. Our approach is general because it offers the definition, identification, estimation, and sensitivity analysis of causal mediation effects without reference to any specific statistical model. Further, our approach explicitly links these 4 elements closely together within a single framework. As a result, the proposed framework can accommodate linear and nonlinear relationships, parametric and nonparametric models, continuous and discrete mediators, and various types of outcome variables. The general definition and identification result also allow us to develop sensitivity analysis in the context of commonly used models, which enables applied researchers to formally assess the robustness of their empirical conclusions to violations of the key assumption. We illustrate our approach by applying it to the Job Search Intervention Study. We also offer easy-to-use software that implements all our proposed methods.},
  citation-subset = {IM},
  completed       = {2011-04-04},
  country         = {United States},
  issn-linking    = {1082-989X},
  keywords        = {Algorithms; Causality; Data Interpretation, Statistical; Linear Models; Models, Statistical; Sensitivity and Specificity; Social Sciences, methods},
  nlm-id          = {9606928},
  owner           = {NLM},
  pii             = {2010-21388-001},
  pmid            = {20954780},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2010-12-07},
}

@Article{PoharPerme2018,
  author  = {Pohar Perme, Maja and Pavlic, Klemen},
  title   = {Nonparametric Relative Survival Analysis with the {R} package relsurv},
  journal = {Journal of Statistical Software},
  year    = {2018},
  volume  = {87},
  issue   = {8},
  pages   = {1--27},
  issn    = {1548-7660},
  doi     = {10.18637/jss.v087.i08},
  url     = {https://www.jstatsoft.org/v087/i08},
  file    = {:PoharPerme2018.pdf:PDF},
}

@Article{Andersen2008,
  author    = {Andersen, Per Kragh and Perme, Maja Pohar},
  title     = {Inference for outcome probabilities in multi-state models},
  journal   = {Lifetime data analysis},
  year      = {2008},
  volume    = {14},
  number    = {4},
  pages     = {405},
  publisher = {Springer},
}

@Article{Kipourou2019,
  author       = {Kipourou, Dimitra-Kleio and Charvat, Hadrien and Rachet, Bernard and Belot, Aur{\AA}Â©lien},
  title        = {Estimation of the adjusted cause-specific cumulative probability using flexible regression models for the cause-specific hazards.},
  journal      = {Statistics in medicine},
  year         = {2019},
  month        = jun,
  issn         = {1097-0258},
  doi          = {10.1002/sim.8209},
  abstract     = {In competing risks setting, we account for death according to a specific cause and the quantities of interest are usually the cause-specific hazards (CSHs) and the cause-specific cumulative probabilities. A cause-specific cumulative probability can be obtained with a combination of the CSHs or via the subdistribution hazard. Here, we modeled the CSH with flexible hazard-based regression models using B-splines for the baseline hazard and time-dependent (TD) effects. We derived the variance of the cause-specific cumulative probabilities at the population level using the multivariate delta method and showed how we could easily quantify the impact of a covariate on the cumulative probability scale using covariate-adjusted cause-specific cumulative probabilities and their difference. We conducted a simulation study to evaluate the performance of this approach in its ability to estimate the cumulative probabilities using different functions for the cause-specific log baseline hazard and with or without a TD effect. In the scenario with TD effect, we tested both well-specified and misspecified models. We showed that the flexible regression models perform nearly as well as the nonparametric method, if we allow enough flexibility for the baseline hazards. Moreover, neglecting the TD effect hardly affects the cumulative probabilities estimates of the whole population but impacts them in the various subgroups. We illustrated our approach using data from people diagnosed with monoclonal gammopathy of undetermined significance and provided the R-code to derive those quantities, as an extension of the R-package mexhaz.},
  country      = {England},
  file         = {:Kipourou2019.pdf:PDF},
  issn-linking = {0277-6715},
  keywords     = {cause-specific hazards; competing risks; cumulative incidence function; cumulative probability of death; flexible parametric models},
  nlm-id       = {8215016},
  owner        = {NLM},
  pmid         = {31209905},
  pubmodel     = {Print-Electronic},
  pubstatus    = {aheadofprint},
  revised      = {2019-06-18},
}

@Article{Rosso2009,
  author   = {Stefano Rosso and Roberta De Angelis and Laura Ciccolallo and Eugenio Carrani and Isabelle Soerjomataram and Enrico Grande and Giulia Zigon and Hermann Brenner},
  title    = {Multiple tumours in survival estimates},
  journal  = {European Journal of Cancer},
  year     = {2009},
  volume   = {45},
  number   = {6},
  pages    = {1080 - 1094},
  note     = {Survival of cancer patients in Europe, 1995-2002: The EUROCARE 4 study},
  issn     = {0959-8049},
  doi      = {https://doi.org/10.1016/j.ejca.2008.11.030},
  url      = {http://www.sciencedirect.com/science/article/pii/S0959804908009027},
  file     = {:Rosso2009.pdf:PDF},
  keywords = {Neoplasm, Survival, Multiple tumours, Relative survival, Cancer registries},
}

@Article{Austin2017,
  author          = {Austin, Peter C and Fine, Jason P},
  title           = {Practical recommendations for reporting Fine-Gray model analyses for competing risk data.},
  journal         = {Statistics in medicine},
  year            = {2017},
  volume          = {36},
  issue           = {27},
  month           = nov,
  pages           = {4391--4400},
  issn            = {1097-0258},
  doi             = {10.1002/sim.7501},
  abstract        = {In survival analysis, a competing risk is an event whose occurrence precludes the occurrence of the primary event of interest. Outcomes in medical research are frequently subject to competing risks. In survival analysis, there are 2 key questions that can be addressed using competing risk regression models: first, which covariates affect the rate at which events occur, and second, which covariates affect the probability of an event occurring over time. The cause-specific hazard model estimates the effect of covariates on the rate at which events occur in subjects who are currently event-free. Subdistribution hazard ratios obtained from the Fine-Gray model describe the relative effect of covariates on the subdistribution hazard function. Hence, the covariates in this model can also be interpreted as having an effect on the cumulative incidence function or on the probability of events occurring over time. We conducted a review of the use and interpretation of the Fine-Gray subdistribution hazard model in articles published in the medical literature in 2015. We found that many authors provided an unclear or incorrect interpretation of the regression coefficients associated with this model. An incorrect and inconsistent interpretation of regression coefficients may lead to confusion when comparing results across different studies. Furthermore, an incorrect interpretation of estimated regression coefficients can result in an incorrect understanding about the magnitude of the association between exposure and the incidence of the outcome. The objective of this article is to clarify how these regression coefficients should be reported and to propose suggestions for interpreting these coefficients.},
  citation-subset = {IM},
  completed       = {2018-06-25},
  country         = {England},
  file            = {:Austin2017.pdf:PDF},
  issn-linking    = {0277-6715},
  keywords        = {Data Interpretation, Statistical; Humans; Models, Statistical; Probability; Proportional Hazards Models; Regression Analysis; Risk Assessment, methods; Survival Analysis; competing risks; cumulative incidence function; subdistribution hazard model; survival analysis},
  nlm-id          = {8215016},
  owner           = {NLM},
  pmc             = {PMC5698744},
  pmid            = {28913837},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2018-11-13},
}

@Article{Andersson2019,
  author  = {Andersson, T. M-L. and Rutherford, M. J. and Lambert, P. C.},
  title   = {Illustration of different modelling assumptions for estimation of loss in expectation of life due to cancer},
  doi     = {https://doi.org/10.1186/s12874-019-0785-x},
  number  = {145},
  pages   = {19},
  volume  = {19},
  journal = {BMC Medical Research Methodology},
  pmid    = {31288739},
  year    = {2019},
}

@Article{Muller2018,
  author          = {Muller, Patrick and Walters, Sarah and Coleman, Michel P and Woods, Laura},
  title           = {Which indicators of early cancer diagnosis from population-based data sources are associated with short-term mortality and survival?},
  journal         = {Cancer epidemiology},
  year            = {2018},
  volume          = {56},
  pages           = {161--170},
  issn            = {1877-783X},
  doi             = {10.1016/j.canep.2018.07.010},
  abstract        = {A key component of recent English cancer policy is the monitoring of trends in early diagnosis of cancer. Early diagnosis can be defined by the disease stage at diagnosis or by other indicators derived from electronic health records. We evaluate the association between different early diagnosis indicators and survival, and discuss the implementation of the indicators in surveillance of early diagnosis. We searched the PubMed database and grey literature to identify early diagnosis indicators and evaluate their association with survival. We analysed cancer registrations for 355,502 cancer patients diagnosed in England during the period 2009-2013, and quantified the association between each early diagnosis indicator and 30-day mortality and five-year net survival. Each incremental difference in stage (I-IV) predicts lower 5-year survival, so prognostic information is lost in comparisons which use binary stage indicators. Patients without a recorded stage have high risk of death shortly following diagnosis and lower 5-year survival. Emergency presentation is independently associated with lower five-year survival. Shorter intervals between first symptoms and diagnosis are not consistently associated with improved survival, potentially due to confounding from tumour characteristics. Contrary to current practice, we recommend that all the stage information should be used in surveillance. Patients missing stage should also be included to minimise bias. Combined data on stage and emergency presentation could be used to create summary prognostic measures. More work is needed to create statistics based on the diagnostic interval that will be useful for surveillance.},
  citation-subset = {IM},
  completed       = {2019-05-28},
  country         = {Netherlands},
  file            = {:Muller2018.pdf:PDF},
  issn-linking    = {1877-7821},
  keywords        = {Early Detection of Cancer, methods; Electronic Health Records; England, epidemiology; Humans; Meta-Analysis as Topic; Mortality, trends; Neoplasms, diagnosis, epidemiology, mortality; Population Surveillance; Prognosis; Cancer mortality; Cancer survival; Diagnostic interval; Early detection; Early diagnosis; Emergency presentation; Population-based; Routine data; Stage at diagnosis; Surveillance},
  nlm-id          = {101508793},
  owner           = {NLM},
  pii             = {S1877-7821(18)30368-0},
  pmc             = {PMC6189520},
  pmid            = {30056051},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2019-05-28},
}

@Article{Afshar2019,
  author       = {Afshar, Nina and English, Dallas R and Milne, Roger L},
  title        = {Rural-urban residence and cancer survival in high-income countries: A systematic review.},
  journal      = {Cancer},
  year         = {2019},
  issn         = {1097-0142},
  doi          = {10.1002/cncr.32073},
  abstract     = {There is some evidence that place of residence is associated with cancer survival, but the findings are inconsistent, and the underlying mechanisms by which residential location might affect survival are not well understood. We conducted a systematic review of observational studies investigating the association of rural versus urban residence with cancer survival in high-income countries. We searched the Ovid Medline, EMBASE, and CINAHL (Cumulative Index to Nursing and Allied Health Literature) databases up to May 31, 2016. Forty-five studies published between 1984 and 2016 were included. We extracted unadjusted and adjusted relative risk estimates with the corresponding 95% confidence intervals. Most studies reported worse survival for cancer patients living in rural areas than those in urban regions. The most consistent evidence, observed across several studies, was for colorectal, lung, and prostate cancer. Of the included studies, 18 did not account for socio-economic position. Lower survival for more disadvantaged patients is well documented; therefore, it could be beneficial for future research to take socio-economic factors into consideration when assessing rural/urban differences in cancer survival. Some studies cited differential stage at diagnosis and treatment modalities as major contributing factors to regional inequalities in cancer survival. Further research is needed to disentangle the mediating effects of these factors, which may help to establish effective interventions to improve survival for patients living outside major cities.},
  country      = {United States},
  issn-linking = {0008-543X},
  keywords     = {cancer survival; neoplasms; remoteness; rural; systematic review; urban},
  nlm-id       = {0374236},
  owner        = {NLM},
  pmid         = {30933318},
  pubmodel     = {Print-Electronic},
  pubstatus    = {aheadofprint},
  revised      = {2019-04-01},
}

@Article{McPhail2015,
  author          = {McPhail, S and Johnson, S and Greenberg, D and Peake, M and Rous, B},
  title           = {Stage at diagnosis and early mortality from cancer in England.},
  doi             = {10.1038/bjc.2015.49},
  issn            = {1532-1827},
  pages           = {S108--S115},
  volume          = {112 Suppl 1},
  abstract        = {Stage at diagnosis is a key predictor of overall cancer outcome. For the first time, stage completeness is high enough for robust analysis for the whole of England. We analysed data from the National Cancer Registration Service's (NCRS) Cancer Analysis System on persons diagnosed with breast, colorectal, lung, prostate or ovarian cancers in England in 2012. One-year relative survival (followed-up to the end of 2013) was calculated along with adjusted excess rate ratios, for mortality within 1 year. One-year relative survival decreased with increasing stage at diagnosis. For breast, prostate and colorectal cancers survival showed a major reduction for stage 4 cancers, whereas for lung and ovarian cancers there were substantial decreases in relative survival for each level of increase in stage. Excess rate ratios for mortality within 1 year of diagnosis showed that stage and age were the most important cofactors, but they also identified the statistically significant effects of sex, income deprivation and geographic area of residence. Further reductions in mortality may be most effectively achieved by diagnosing all cancers before they progress to stage 4, but for lung and ovarian cancers there is also a need for a stage shift to earlier stages together with efforts to improve stage-specific survival at all stages.},
  citation-subset = {IM},
  completed       = {2015-06-11},
  country         = {England},
  issn-linking    = {0007-0920},
  journal         = {British journal of cancer},
  keywords        = {Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms, diagnosis, mortality, pathology; Cohort Studies; Colorectal Neoplasms, pathology; Early Detection of Cancer; England; Female; Humans; Lung Neoplasms, pathology; Male; Middle Aged; Neoplasm Staging, mortality; Neoplasms, pathology; Ovarian Neoplasms, pathology; Prostatic Neoplasms, pathology; Registries; Survival Rate; Young Adult},
  nlm-id          = {0370635},
  owner           = {NLM},
  pii             = {bjc201549},
  pmc             = {PMC4385983},
  pmid            = {25734389},
  pubmodel        = {Electronic},
  pubstatus       = {epublish},
  revised         = {2018-11-13},
  year            = {2015},
}

@Article{Morrison1982,
  author          = {Morrison, A S},
  title           = {The effects of early treatment, lead time and length bias on the mortality experienced by cases detected by screening.},
  journal         = {International Journal of Epidemiology},
  year            = {1982},
  volume          = {11},
  issue           = {3},
  pages           = {261--267},
  issn            = {0300-5771},
  doi             = {10.1093/ije/11.3.261},
  abstract        = {This paper describes a means of analysing the effects that the benefit of early treatment, lead time and length-biased sampling (and other forms of prognostic selection bias) have on the mortality rate of cases detected in screening programmes. Both benefit and lead time reduce the mortality rate of screen-detected cases. A beneficial effect of early treatment will lead to a decrease in the number of deaths, the numerator of the rate. The amount of person-time among screen-detected cases, the denominator, is increased by early diagnosis as a result of screening (lead-time) as well as by prolongation of life due to early treatment. The numbers of cases experiencing benefit and lead time can be estimated by comparisons of the numbers of deaths and numbers of diagnosed cases between the entire screened population, from which the series of screen-detected cases is drawn, and an otherwise comparable unscreened population. Benefit and lead time, as reflected in these numbers, can be removed from the mortality rate of cases detected by screening. The effects of benefit or lead time on prognosis then can be assessed by comparing the observed mortality rate of screen-detected cases to the rates with benefit or lead time removed. Prognostic selection bias (a tendency of screen-detected cases to be relatively benign or relatively malignant) can be evaluated by comparing the case-mortality rate, with both benefit and lead time removed, to the mortality rate of cases in an unscreened population. The relationships described are illustrated with data from a breast cancer screening programme.},
  citation-subset = {IM},
  completed       = {1982-12-18},
  country         = {England},
  issn-linking    = {0300-5771},
  keywords        = {Breast Neoplasms, prevention & control; Humans; Mass Screening; Mortality; Preventive Medicine; Prognosis; Therapeutics; Time Factors},
  nlm-id          = {7802871},
  owner           = {NLM},
  pmid            = {7129740},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2019-05-12},
}

@WWW{PHE2019,
  author = {{Public Health England}},
  title  = {Stage at diagnosis, by Routes to Diagnosis 2015-2016 workbook},
  url    = {http://www.ncin.org.uk/publications/routes_to_diagnosis},
  year   = {2019},
}

@Article{Huang2017,
  author          = {Huang, Yen-Tsung and Yang, Hwai-I},
  title           = {Causal Mediation Analysis of Survival Outcome with Multiple Mediators.},
  doi             = {10.1097/EDE.0000000000000651},
  issn            = {1531-5487},
  issue           = {3},
  pages           = {370--378},
  volume          = {28},
  abstract        = {Mediation analyses have been a popular approach to investigate the effect of an exposure on an outcome through a mediator. Mediation models with multiple mediators have been proposed for continuous and dichotomous outcomes. However, development of multimediator models for survival outcomes is still limited. We present methods for multimediator analyses using three survival models: Aalen additive hazard models, Cox proportional hazard models, and semiparametric probit models. Effects through mediators can be characterized by path-specific effects, for which definitions and identifiability assumptions are provided. We derive closed-form expressions for path-specific effects for the three models, which are intuitively interpreted using a causal diagram. Mediation analyses using Cox models under the rare-outcome assumption and Aalen additive hazard models consider effects on log hazard ratio and hazard difference, respectively; analyses using semiparametric probit models consider effects on difference in transformed survival time and survival probability. The three models were applied to a hepatitis study where we investigated effects of hepatitis C on liver cancer incidence mediated through baseline and/or follow-up hepatitis B viral load. The three methods show consistent results on respective effect scales, which suggest an adverse estimated effect of hepatitis C on liver cancer not mediated through hepatitis B, and a protective estimated effect mediated through the baseline (and possibly follow-up) of hepatitis B viral load. Causal mediation analyses of survival outcome with multiple mediators are developed for additive hazard and proportional hazard and probit models with utility demonstrated in a hepatitis study.},
  citation-subset = {IM},
  completed       = {2018-02-21},
  country         = {United States},
  issn-linking    = {1044-3983},
  journal         = {Epidemiology},
  keywords        = {Carcinoma, Hepatocellular, epidemiology; Causality; Cohort Studies; Hepatitis B, Chronic, epidemiology, virology; Hepatitis C, virology; Humans; Liver Neoplasms, epidemiology; Models, Statistical; Proportional Hazards Models; Prospective Studies; Survival Analysis; Taiwan, epidemiology; Viral Load},
  mid             = {NIHMS859716},
  nlm-id          = {9009644},
  owner           = {NLM},
  pmc             = {PMC5408128},
  pmid            = {28296661},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2018-11-13},
  year            = {2017},
}

@Article{EllissBrookes2012,
  author          = {Elliss-Brookes, L and McPhail, S and Ives, A and Greenslade, M and Shelton, J and Hiom, S and Richards, M},
  title           = {Routes to diagnosis for cancer - determining the patient journey using multiple routine data sets.},
  journal         = {British Journal of Cancer},
  year            = {2012},
  volume          = {107},
  issue           = {8},
  pages           = {1220--1226},
  issn            = {1532-1827},
  doi             = {10.1038/bjc.2012.408},
  abstract        = {Cancer survival in England is lower than the European average, which has been at least partly attributed to later stage at diagnosis in English patients. There are substantial regional and demographic variations in cancer survival across England. The majority of patients are diagnosed following symptomatic or incidental presentation. This study defines a methodology by which the route the patient follows to the point of diagnosis can be categorised to examine demographic, organisational, service and personal reasons for delayed diagnosis. Administrative Hospital Episode Statistics data are linked with Cancer Waiting Times data, data from the cancer screening programmes and cancer registration data. Using these data sets, every case of cancer registered in England, which was diagnosed in 2006-2008, is categorised into one of eight 'Routes to Diagnosis'. Different cancer types show substantial differences between the proportion of cases that present by each route, in reasonable agreement with previous clinical studies. Patients presenting via Emergency routes have substantially lower 1-year relative survival. Linked cancer registration and administrative data can be used to robustly categorise the route to a cancer diagnosis for all patients. These categories can be used to enhance understanding of and explore possible reasons for delayed diagnosis.},
  citation-subset = {IM},
  completed       = {2012-12-11},
  country         = {England},
  issn-linking    = {0007-0920},
  keywords        = {Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Child; Child, Preschool; Delayed Diagnosis, statistics & numerical data; England, epidemiology; Feasibility Studies; Humans; Infant; Infant, Newborn; Middle Aged; Neoplasms, diagnosis; Patient Care; Quality of Health Care; Registries, statistics & numerical data; Survival Analysis; Young Adult},
  nlm-id          = {0370635},
  owner           = {NLM},
  pii             = {bjc2012408},
  pmc             = {PMC3494426},
  pmid            = {22996611},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2018-11-13},
}

@InBook{Tein2003,
  author    = {Tein, J. Y. and MacKinnon, D. P.},
  booktitle = {New Developments on Psychometrics},
  title     = {Estimating mediated effects with survival data},
  editor    = {Yanai H. and Rikkyo A.O. and Shigemasu K. and Kano Y. and Meulman J.J.},
  pages     = {405-412},
  publisher = {Springer-Verlag Tokyo Inc},
  year      = {2003},
}

@Article{Hong2015,
  author  = {Hong, G. and Deutsch, J. and Hill, H. D.},
  title   = {Ratio-of-mediator probability weighting for causal mediation analysis in the presence of treatment-by-mediator interaction},
  journal = {Journal of Educational and Behavioral Statistics},
  year    = {2015},
  volume  = {40},
  pages   = {307-340},
}

@WWW{DepIndices2011,
  author = {{Department for Communities and Local Government}},
  title  = {The {E}nglish Indices of Deprivation 2010},
  url    = {https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/6871/1871208.pdf},
  year   = {2011},
}

@WWW{ONS2019,
  author = {{The {O}ffice for {N}ational {S}tatistics}},
  title  = {Cancer survival smoothed life tables},
  url    = {https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/cancersurvivalsmoothedlifetables},
  year   = {2019},
}

@Article{VanderWeele2017,
  author          = {VanderWeele, Tyler J and Ding, Peng},
  title           = {Sensitivity Analysis in Observational Research: Introducing the E-Value.},
  journal         = {Annals of internal medicine},
  year            = {2017},
  volume          = {167},
  issue           = {4},
  month           = aug,
  pages           = {268--274},
  issn            = {1539-3704},
  doi             = {10.7326/M16-2607},
  abstract        = {Sensitivity analysis is useful in assessing how robust an association is to potential unmeasured or uncontrolled confounding. This article introduces a new measure called the "E-value," which is related to the evidence for causality in observational studies that are potentially subject to confounding. The E-value is defined as the minimum strength of association, on the risk ratio scale, that an unmeasured confounder would need to have with both the treatment and the outcome to fully explain away a specific treatment-outcome association, conditional on the measured covariates. A large E-value implies that considerable unmeasured confounding would be needed to explain away an effect estimate. A small E-value implies little unmeasured confounding would be needed to explain away an effect estimate. The authors propose that in all observational studies intended to produce evidence for causality, the E-value be reported or some other sensitivity analysis be used. They suggest calculating the E-value for both the observed association estimate (after adjustments for measured confounders) and the limit of the confidence interval closest to the null. If this were to become standard practice, the ability of the scientific community to assess evidence from observational studies would improve considerably, and ultimately, science would be strengthened.},
  citation-subset = {AIM, IM},
  completed       = {2017-08-22},
  country         = {United States},
  file            = {:VanderWeele2017.pdf:PDF},
  issn-linking    = {0003-4819},
  keywords        = {Confounding Factors (Epidemiology); Epidemiologic Research Design; Humans; Observational Studies as Topic, statistics & numerical data; Sensitivity and Specificity},
  nlm-id          = {0372351},
  owner           = {NLM},
  pii             = {2643434},
  pmid            = {28693043},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2017-08-22},
}

@Article{Ding2016,
  author          = {Ding, Peng and VanderWeele, Tyler J},
  title           = {Sensitivity Analysis Without Assumptions.},
  doi             = {10.1097/EDE.0000000000000457},
  issn            = {1531-5487},
  issue           = {3},
  pages           = {368--377},
  volume          = {27},
  abstract        = {Unmeasured confounding may undermine the validity of causal inference with observational studies. Sensitivity analysis provides an attractive way to partially circumvent this issue by assessing the potential influence of unmeasured confounding on causal conclusions. However, previous sensitivity analysis approaches often make strong and untestable assumptions such as having an unmeasured confounder that is binary, or having no interaction between the effects of the exposure and the confounder on the outcome, or having only one unmeasured confounder. Without imposing any assumptions on the unmeasured confounder or confounders, we derive a bounding factor and a sharp inequality such that the sensitivity analysis parameters must satisfy the inequality if an unmeasured confounder is to explain away the observed effect estimate or reduce it to a particular level. Our approach is easy to implement and involves only two sensitivity parameters. Surprisingly, our bounding factor, which makes no simplifying assumptions, is no more conservative than a number of previous sensitivity analysis techniques that do make assumptions. Our new bounding factor implies not only the traditional Cornfield conditions that both the relative risk of the exposure on the confounder and that of the confounder on the outcome must satisfy but also a high threshold that the maximum of these relative risks must satisfy. Furthermore, this new bounding factor can be viewed as a measure of the strength of confounding between the exposure and the outcome induced by a confounder.},
  citation-subset = {IM},
  completed       = {2017-01-05},
  country         = {United States},
  file            = {:Ding2016.pdf:PDF},
  issn-linking    = {1044-3983},
  journal         = {Epidemiology (Cambridge, Mass.)},
  keywords        = {Causality; Confounding Factors (Epidemiology); Epidemiologic Methods; Humans; Risk; Statistics as Topic},
  month           = may,
  nlm-id          = {9009644},
  owner           = {NLM},
  pmc             = {PMC4820664},
  pmid            = {26841057},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2018-11-13},
  year            = {2016},
}

@WWW{Lambert2019,
  author = {Lambert, P. C.},
  title  = {The standsurv for standardarised survival and related functions},
  url    = {https://pclambert.net/software/standsurv/},
  year   = {2019},
}

@Article{Turesson2007,
  author          = {Turesson, Ingemar and Linet, Martha S and Bj{\"o}rkholm, Magnus and Kristinsson, Sigurdur Y and Goldin, Lynn R and Caporaso, Neil E and Landgren, Ola},
  title           = {Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003.},
  journal         = {International journal of cancer},
  year            = {2007},
  volume          = {121},
  issue           = {10},
  month           = nov,
  pages           = {2260--2266},
  issn            = {1097-0215},
  doi             = {10.1002/ijc.22912},
  abstract        = {Population-based cancer registries are widely used to provide key information about cancer incidence, survival, determinants of progression and clues about pathogenesis. To substantially expand the limited data on diagnostic accuracy and completeness for lymphoproliferative (LP) tumors in such databases, we conducted a retrospective investigation of close to 1,000 cases diagnosed during 4 decades in Sweden. We identified and reviewed medical records for 494 LP tumor patients reported to the population-based Swedish Cancer registry and 503 LP tumor patients identified from hospitals in Sweden among patients with LP tumors diagnosed during 1964-2003. The stratified samples were randomly selected from patients according to LP subtype, over 4 equal calendar periods, and among 6 selected hospitals of diverse size and from different geographic regions. We found 97.9% of reported LP tumor cases to fulfill current diagnostic criteria for having an LP tumor and observed 89.7% to have accurate LP tumor subtype. The overall completeness of non-Hodgkin lymphoma, Hodgkin lymphoma and multiple myeloma cases in the Cancer registry was 95-99% but was lower for the more indolent tumors, chronic lymphocytic leukemia (87.9%) and Waldenstr{\"o}m's macroglobulinemia (68.1%). We observed increased overall under-ascertainment for patients diagnosed above age 80 (27%) and among individuals diagnosed before 1973 (12%). In conclusion the diagnostic accuracy and completeness for classically defined LP tumor entities in the Swedish Cancer registry is high. However, we found under-ascertainment of patients with indolent LP tumors, particularly among patients diagnosed at older ages, with early-stage disease and diagnosed in earlier years.},
  citation-subset = {IM},
  completed       = {2007-11-30},
  country         = {United States},
  issn-linking    = {0020-7136},
  keywords        = {Aged; Aged, 80 and over; Female; Humans; Lymphoma, diagnosis, epidemiology; Male; Middle Aged; Sweden, epidemiology; Time Factors},
  nlm-id          = {0042124},
  owner           = {NLM},
  pmid            = {17583571},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2016-03-03},
}

@Article{Richters2019,
  author          = {Richters, A and Dickman, P W and Witjes, J A and Boormans, J L and Kiemeney, L A L M and Aben, K K H},
  title           = {Bladder cancer survival: Women only fare worse in the first two years after diagnosis.},
  journal         = {Urologic oncology},
  year            = {2019},
  month           = aug,
  issn            = {1873-2496},
  doi             = {10.1016/j.urolonc.2019.08.001},
  abstract        = {It has consistently been shown that women who are diagnosed with bladder cancer have lower survival than men, but the exact mechanism remains unknown. Most studies assumed that the sex-specific mortality ratio is constant over time, possibly resulting in inaccurate estimates in various periods of follow-up. This study aimed to investigate the sex-specific excess mortality in bladder cancer patients and its variation over follow-up time. Observational cohort study. Using data from the population-based Netherlands Cancer Registry, we studied 24,169 patients diagnosed between 2003 and 2014 with histologically confirmed ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â‰ÃƒÂ‚Ã‚Â¥T1 bladder cancer with follow-up until January 2018. We used flexible parametric relative survival models to estimate excess mortality as a function of time for each sex and to explore the effect of covariates on these functions. Female patients (24%) had worse clinical tumor, node, and metastasis-stage at diagnosis and more often a nonurothelial tumor histology. The excess mortality ratio of sex was not constant over time; in the first two years after diagnosis excess mortality rates for women were higher than for men, but lower thereafter; this applied to both nonmuscle-invasive and muscle-invasive bladder cancer subgroups. Baseline differences in age, tumor, node, and metastasis-stage and histology accounted for only part of the excess mortality gap. The assumption of proportional hazards over time leads to underestimation of the excess mortality ratio for women in the first two years and overestimation thereafter, when excess mortality is comparable for women and men. Clinicians should incorporate the initial sex-specific poorer outcome in their considerations regarding prognosis and treatment options for female patients, e.g., more invasive treatment and neo-adjuvant treatment. These findings also point towards a mechanism of micrometastatic disease, warranting assessment of sex-specific efficacy in randomized controlled trials on treatments in this patient population.},
  citation-subset = {IM},
  country         = {United States},
  file            = {:Richters2019.pdf:PDF},
  issn-linking    = {1078-1439},
  keywords        = {Bladder cancer; Gender differences; Prognosis; Sex differences; Survival},
  nlm-id          = {9805460},
  owner           = {NLM},
  pii             = {S1078-1439(19)30319-9},
  pmid            = {31481299},
  pubmodel        = {Print-Electronic},
  pubstatus       = {aheadofprint},
  revised         = {2019-09-04},
}

@Article{Arnold2019,
  author  = {Arnold, M. and Rutherford, M. J. and Bardot, A. and Ferlay, J. and Andersson, T. M. and Myklebust, T. {\AA}. and Tervonen, H. and Thursfield, V. and Ransom, D. and Shack, L. and Woods, R. R. and Turner, D. and Leonfellner, S. and Ryan, S. and Saint-Jacques, N. and De, P. and McClure, C. and Ramanakumar, A. V. and Stuart-Panko, H. and Engholm, G. and Walsh, P. M. and Jackson, C. and Vernon, S. and Morgan, E. and Gavin, A. and Morrison, D. S. and Huws, D. W. and Porter, G. and Butler, J. and Bryant, H. and Currow, D. C. and Hiom, S. and Parkin, D. M. and Sasieni, P. and Lambert, P. C. and M{\"o}ller, B. and Soerjomataram, I. and Bray, F.},
  title   = {Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 ({I}{C}{B}{P} {S}{U}{R}{V}{M}{A}{R}{K}-2): a population-based study},
  number  = {11},
  pages   = {1493--1505},
  volume  = {20},
  file    = {:Arnold2019.pdf:PDF},
  journal = {Lancet Oncology},
  pmid    = {31521509},
  year    = {2019},
}

@Article{Wong2019,
  author          = {Wong, Kwok F and Lambert, Paul C and Mozumder, Sarwar I and Broggio, John and Rutherford, Mark J},
  title           = {Conditional crude probabilities of death for {E}nglish cancer patients.},
  doi             = {10.1038/s41416-019-0597-0},
  issn            = {1532-1827},
  pages           = {883-889},
  volume          = {121},
  abstract        = {Cancer survival statistics are typically reported by using measures discounting the impact of other-cause mortality, such as net survival. This is a hypothetical measure and is interpreted as excluding the possibility of cancer patients dying from other causes. Crude probability of death partitions the all-cause probability of death into deaths from cancer and other causes. The National Cancer Registration and Analysis Service is the single cancer registry for England. In 2006-2015, 1,590,477 malignant tumours were diagnosed for breast, colorectal, lung, melanoma and prostate cancer in adults. We used a relative survival framework, with a period approach, providing estimates for up to 10-year survival. Mortality was partitioned into deaths due to cancer or other causes. Unconditional and conditional (on surviving 1-years and 5-years) crude probability of death were estimated for the five cancers. Elderly patients who survived for a longer period before dying were more likely to die from other causes of death (except for lung cancer). For younger patients, deaths were almost entirely due to the cancer. There are different measures of survival, each with their own strengths and limitations. Careful choices of survival measures are needed for specific scenarios to maximise the understanding of the data.},
  citation-subset = {IM},
  country         = {England},
  issn-linking    = {0007-0920},
  journal         = {British Journal of Cancer},
  nlm-id          = {0370635},
  owner           = {NLM},
  pii             = {10.1038/s41416-019-0597-0},
  pmid            = {31601960},
  pubmodel        = {Print-Electronic},
  pubstatus       = {aheadofprint},
  revised         = {2019-10-11},
  year            = {2019},
}

@Article{Morris2019,
  author          = {Morris, Tim P and White, Ian R and Crowther, Michael J},
  title           = {Using simulation studies to evaluate statistical methods.},
  journal         = {Statistics in medicine},
  year            = {2019},
  volume          = {38},
  issue           = {11},
  month           = may,
  pages           = {2074--2102},
  issn            = {1097-0258},
  doi             = {10.1002/sim.8086},
  abstract        = {Simulation studies are computer experiments that involve creating data by pseudo-random sampling. A key strength of simulation studies is the ability to understand the behavior of statistical methods because some "truth" (usually some parameter/s of interest) is known from the process of generating the data. This allows us to consider properties of methods, such as bias. While widely used, simulation studies are often poorly designed, analyzed, and reported. This tutorial outlines the rationale for using simulation studies and offers guidance for design, execution, analysis, reporting, and presentation. In particular, this tutorial provides a structured approach for planning and reporting simulation studies, which involves defining aims, data-generating mechanisms, estimands, methods, and performance measures ("ADEMP"); coherent terminology for simulation studies; guidance on coding simulation studies; a critical discussion of key performance measures and their estimation; guidance on structuring tabular and graphical presentation of results; and new graphical presentations. With a view to describing recent practice, we review 100 articles taken from Volume 34 of Statistics in Medicine, which included at least one simulation study and identify areas for improvement.},
  citation-subset = {IM},
  country         = {England},
  issn-linking    = {0277-6715},
  keywords        = {Monte Carlo; graphics for simulation; simulation design; simulation reporting; simulation studies},
  nlm-id          = {8215016},
  owner           = {NLM},
  pmc             = {PMC6492164},
  pmid            = {30652356},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2019-05-08},
}



@Article{Shmueli2010,
  author  = {Galit Shmueli},
  title   = {To Explain or To Predict?},
  journal = {Statistical Science},
  year    = {2010},
  doi     = {https://dx.doi.org/10.2139/ssrn.1351252},
  file    = {:Shmueli2010.pdf:PDF},
}

@Book{Klein_handbook_of_survival_analysis,
  author    = {John P. Klein, Hans C. van Houwelingen, Joseph G. Ibrahim, Thomas H. Scheike},
  title     = {Handbook of Survival Analysis},
  edition   = {1},
  publisher = {CRC Press},
  file      = {:Klein_handbook_of_survival_analysis.pdf:PDF},
  year      = {2014},
}

@Article{Jackson2017,
  author    = {Christopher Jackson and John Stevens and Shijie Ren and Nick Latimer and Laura Bojke and Andrea Manca and Linda Sharples},
  title     = {Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods},
  doi       = {10.1177/0272989X16639900},
  eprint    = {https://doi.org/10.1177/0272989X16639900},
  number    = {4},
  pages     = {377-390},
  url       = {https://doi.org/10.1177/0272989X16639900},
  volume    = {37},
  abstract  = {This article describes methods used to estimate parameters governing long-term survival, or times to other events, for health economic models. Specifically, the focus is on methods that combine shorter-term individual-level survival data from randomized trials with longer-term external data, thus using the longer-term data to aid extrapolation of the short-term data. This requires assumptions about how trends in survival for each treatment arm will continue after the follow-up period of the trial. Furthermore, using external data requires assumptions about how survival differs between the populations represented by the trial and external data. Study reports from a national health technology assessment program in the United Kingdom were searched, and the findings were combined with ÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Âœpearl-growingÃƒÂƒÃ‚Â¢ÃƒÂ‚Ã‚Â€ÃƒÂ‚Ã‚Â searches of the academic literature. We categorized the methods that have been used according to the assumptions they made about how the hazards of death vary between the external and internal data and through time, and we discuss the appropriateness of the assumptions in different circumstances. Modeling choices, parameter estimation, and characterization of uncertainty are discussed, and some suggestions for future research priorities in this area are given.},
  journal   = {Medical Decision Making},
  owner     = {Enoch},
  timestamp = {2019-11-16},
  year      = {2017},
}


@Article{Hwang2017,
  author          = {Hwang, Jing-Shiang and Hu, Tsuey-Hwa and Lee, Lukas Jyuhn-Hsiarn and Wang, Jung-Der},
  title           = {Estimating lifetime medical costs from censored claims data.},
  journal         = {Health economics},
  year            = {2017},
  volume          = {26},
  issue           = {12},
  month           = dec,
  pages           = {e332--e344},
  issn            = {1099-1050},
  doi             = {10.1002/hec.3512},
  abstract        = {Claims databases consisting of routinely collected longitudinal records of medical expenditures are increasingly utilized for estimating expected medical costs of patients with a specific condition. Survival data of the patients of interest are usually highly censored, and observed expenditures are incomplete. In this study, we propose a survival-adjusted estimator for estimating mean lifetime costs, which integrates the product of the survival function and the mean cost function over the lifetime horizon. The survival function is estimated by a new algorithm of rolling extrapolation, aided by external information of age- and sex-matched referents simulated from national vital statistics. The mean cost function is estimated by a weighted average of mean expenditures of patients in a number of months prior to their death, of which the number could be determined by observed costs in their final months, and the weights depend on extrapolated hazards. We evaluate the performance of the proposed approach in comparison with that of a popular method using simulated data under various scenarios and 2 cohorts of intracerebral hemorrhage and ischemic stroke patients with a maximum follow-up of 13Ã‚Â years and conclude that our new method estimates the mean lifetime costs more accurately.},
  citation-subset = {IM},
  completed       = {2019-02-12},
  country         = {England},
  file            = {:pdf/Hwang2017.pdf:PDF},
  issn-linking    = {1057-9230},
  keywords        = {Adult; Aged; Algorithms; Databases, Factual; Female; Health Expenditures, trends; Humans; Life Expectancy; Male; Middle Aged; Reproducibility of Results; Stroke, economics; Survival Analysis; Taiwan; censored costs; life expectancy; survival extrapolation},
  nlm-id          = {9306780},
  owner           = {NLM},
  pmid            = {28497642},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2019-02-15},
  timestamp       = {2019-11-15}
}

@InProceedings{Adda2013,
  author       = {Adda, Mehdi and Hannech, Amel and Mcheick, Hamid},
  booktitle    = {2013 XXIV International Conference on Information, Communication and Automation Technologies (ICAT)},
  title        = {New web information retrieval paradigm based on a multi-space interpretation index and projection operations},
  organization = {IEEE},
  pages        = {1--7},
  owner        = {Enoch},
  timestamp    = {2019-11-19},
  year         = {2013},
}

@Online{NICE2013,
  author      = {{National Institute for Health Care and Excellence}},
  title       = {Guide to the methods of technology appraisal},
  url         = {https://www.nice.org.uk/process/pmg9},
  institution = {Narional Institute for Health and Care Excellence},
  owner       = {Enoch},
  timestamp   = {2020-01-07},
  year        = {2013},
}

{Negrin2017,
  author    = {Miguel A. NegrÃƒÂƒÃ‚Â­n and Julian Nam and Andrew H. Briggs},
  title     = {Bayesian Solutions for Handling Uncertainty in Survival Extrapolation},
  doi       = {10.1177/0272989X16650669},
  eprint    = {https://doi.org/10.1177/0272989X16650669},
  note      = {PMID: 27281336},
  number    = {4},
  pages     = {367-376},
  url       = {https://doi.org/10.1177/0272989X16650669},
  volume    = {37},
  abstract  = {Objective. Survival extrapolation using a single, best-fit model ignores 2 sources of model uncertainty: uncertainty in the true underlying distribution and uncertainty about the stability of the model parameters over time. Bayesian model averaging (BMA) has been used to account for the former, but it can also account for the latter. We investigated BMA using a published comparison of the Charnley and Spectron hip prostheses using the original 8-year follow-up registry data. Methods. A wide variety of alternative distributions were fitted. Two additional distributions were used to address uncertainty about parameter stability: optimistic and skeptical. The optimistic (skeptical) model represented the model distribution with the highest (lowest) estimated probabilities of survival but reestimated using, as prior information, the most optimistic (skeptical) parameter estimated for intermediate follow-up periods. Distributions were then averaged assuming the same posterior probabilities for the optimistic, skeptical, and noninformative models. Cost-effectiveness was compared using both the original 8-year and extended 16-year follow-up data. Results. We found that all models obtained similar revision-free years during the observed period. In contrast, there was variability over the decision time horizon. Over the observed period, we detected considerable uncertainty in the shape parameter for Spectron. After BMA, Spectron was cost-effective at a threshold of Â£20,000 with 93\% probability, whereas the best-fit model was 100\%; by contrast, with a 16-year follow-up, it was 0\%. Conclusions. This case study casts doubt on the ability of the single best-fit model selected by information criteria statistics to adequately capture model uncertainty. Under this scenario, BMA weighted by posterior probabilities better addressed model uncertainty. However, there is still value in regularly updating health economic models, even where decision uncertainty is low.},
  note      = {PMID: 27281336},
  doi       = {10.1177/0272989X16650669},
  eprint    = {https://doi.org/10.1177/0272989X16650669},
  url       = {
        https://doi.org/10.1177/0272989X16650669

},
  url       = {https://doi.org/10.1177/0272989X16650669},
  volume    = {37},
  file      = {:Negrin2017.pdf:PDF},
  journal   = {Medical Decision Making},
  owner     = {Enoch},
  timestamp = {2020-01-07},
  year      = {2017},
}

@Book{Carlshamre2019,
  author    = {Staffan Carlshamre},
  title     = {Philosophy of the Cultural Sciences Preliminary draft},
  owner     = {Enoch},
  timestamp = {2020-01-08},
  year      = {2019},
}

@Article{Bornkamp2015,
  author    = {BjÃƒÂƒÃ‚Â¶rn Bornkamp},
  title     = {Viewpoint: model selection uncertainty, pre-specification, and model averaging},
  journal   = {Pharmaceutical Statistics},
  year      = {2015},
  volume    = {14},
  number    = {2},
  month     = {jan},
  pages     = {79--81},
  doi       = {10.1002/pst.1671},
  owner     = {Enoch},
  publisher = {Wiley},
  timestamp = {2020-01-08},
}

@Article{FLECK2018,
  author    = {LEONARD M. Fleck},
  title     = {Controlling Healthcare Costs: Just Cost Effectiveness or {\textquotedblleft}Just{\textquotedblright} Cost Effectiveness?},
  journal   = {Cambridge Quarterly of Healthcare Ethics},
  year      = {2018},
  volume    = {27},
  number    = {2},
  month     = {mar},
  pages     = {271--283},
  doi       = {10.1017/s0963180117000603},
  file      = {:Fleck2018.pdf:PDF},
  owner     = {Enoch},
  publisher = {Cambridge University Press ({CUP})},
  timestamp = {2020-01-08},
}

@Article{Marseille2019,
  author    = {Elliot Marseille and James G. Kahn},
  title     = {Utilitarianism and the ethical foundations of cost-effectiveness analysis in resource allocation for global health},
  journal   = {Philosophy, Ethics, and Humanities in Medicine},
  year      = {2019},
  volume    = {14},
  number    = {1},
  month     = {apr},
  doi       = {10.1186/s13010-019-0074-7},
  file      = {:Marseille2019.pdf:PDF},
  owner     = {Enoch},
  publisher = {Springer Science and Business Media {LLC}},
  timestamp = {2020-01-08},
}

@Manual{NICE2015,
  author    = {{National Institute for Health and Care Excellence}},
  title     = {Developing NICE Guidelines: The Manual},
  url       = {https://www.ncbi.nlm.nih.gov/books/NBK310375/},
  owner     = {Enoch},
  timestamp = {2020-01-09},
  year      = {2015},
}

@Article{Bleichrodt2004,
  author          = {Bleichrodt, Han and Diecidue, Enrico and Quiggin, John},
  title           = {Equity weights in the allocation of health care: the rank-dependent QALY model.},
  doi             = {10.1016/j.jhealeco.2003.08.002},
  issn            = {0167-6296},
  issue           = {1},
  pages           = {157--171},
  volume          = {23},
  abstract        = {This paper introduces the rank-dependent quality-adjusted life-years (QALY) model, a new method to aggregate QALYs in economic evaluations of health care. The rank-dependent QALY model permits the formalization of influential concepts of equity in the allocation of health care, such as the fair innings approach, and it includes as special cases many of the social welfare functions that have been proposed in the literature. An important advantage of the rank-dependent QALY model is that it offers a straightforward procedure to estimate equity weights for QALYs. We characterize the rank-dependent QALY model and argue that its central condition has normative appeal.},
  citation-subset = {H},
  completed       = {2004-06-18},
  country         = {Netherlands},
  issn-linking    = {0167-6296},
  journal         = {Journal of health economics},
  keywords        = {Empirical Research; Ethical Theory; Health Care Rationing, economics, ethics; Humans; Models, Statistical; Policy Making; Principle-Based Ethics; Quality-Adjusted Life Years; Resource Allocation, ethics; Social Justice; Social Welfare; Uncertainty; Value of Life},
  month           = jan,
  nlm-id          = {8410622},
  owner           = {NLM},
  pii             = {S0167-6296(03)00083-3},
  pmid            = {15154692},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2006-11-15},
  timestamp       = {2020-01-09},
  year            = {2004},
}


@Article{Moore2015,
  author    = {Angela R. Moore and Natasha D. Buchanan and Temeika L. Fairley and Judith Lee Smith},
  title     = {Public Health Action Model for Cancer Survivorship},
  journal   = {American Journal of Preventive Medicine},
  year      = {2015},
  volume    = {49},
  number    = {6},
  month     = {dec},
  pages     = {S470--S476},
  doi       = {10.1016/j.amepre.2015.09.001},
  owner     = {Enoch},
  publisher = {Elsevier {BV}},
  timestamp = {2020-01-13},
}

@Article{Lai2020,
  author          = {Lai, Wu-Wei and Lin, Chia-Ni and Chang, Chao-Chun and Wang, Jung-Der},
  title           = {Lifetime risks, expected years of life lost, and cost-per-life year of esophageal cancer in Taiwan.},
  journal         = {Scientific reports},
  year            = {2020},
  volume          = {10},
  issue           = {1},
  month           = feb,
  pages           = {3722},
  issn            = {2045-2322},
  doi             = {10.1038/s41598-020-60701-3},
  abstract        = {Besides lifetime risks, we estimated life expectancy (LE), expected years of life lost (EYLL), lifetime costs, and cost-per-LY (life-year) stratified by different stages of esophageal cancer (EC). From the Taiwan Cancer Registry, we collected 14,420 EC to estimate the incidence rates during 2008-2014. They were followed to 2015 to obtain the survival function, which was extrapolated to lifetime by a semiparametric method. We abstracted the monthly healthcare expenditures from the reimbursement database of National Health Insurance, which were multiplied with the corresponding survival probabilities to quantify lifetime cost and cost-per-LY after adjustments. About 93.7% of patients were male; 90.8% had squamous cell carcinoma. Most patients were diagnosed at advanced stages, with 44.6% and 28.3% at stages III and IV. The lifetime risk of EC in males increased in Taiwan with a cumulative incidence rate (CIR ) of 0.0146% (2008~2010) to 0.0165% (2013-2014). The EYLL for stages I-IV were 15.8, 17.5, 20.5, and 22.5, while the average of cost-per-LY for stages I-IV were US$ 6,987, $8,776, $12,153, and $22,426. EC in Taiwan appears to have shifted into younger ages groups and incidence is still increasing. Strategies for prevention, early diagnosis and treatment are warranted to improve the cost-effectiveness and control of this cancer.},
  citation-subset = {IM},
  country         = {England},
  issn-linking    = {2045-2322},
  nlm-id          = {101563288},
  owner           = {NLM},
  pii             = {10.1038/s41598-020-60701-3},
  pmc             = {PMC7048720},
  pmid            = {32111930},
  pubmodel        = {Electronic},
  pubstatus       = {epublish},
  revised         = {2020-03-06},
  timestamp       = {2020-03-12},
}

@Article{Wu2018,
  author       = {Wu, Tzu-Yi and Chung, Chia-Hua and Lin, Chia-Ni and Hwang, Jing-Shiang and Wang, Jung-Der},
  title        = {Lifetime risks, loss of life expectancy, and health care expenditures for 19 types of cancer in Taiwan.},
  doi          = {10.2147/CLEP.S155601},
  issn         = {1179-1349},
  pages        = {581--591},
  volume       = {10},
  abstract     = {The mortality rates for different cancers are no longer an efficient tool for making national policy. The purpose of this study were to quantify the lifetime risks, life expectancies (LEs) after diagnosis, expected years of life lost (EYLL), and lifetime health care expenditures for 19 major cancers in Taiwan. A total of 831,314 patients with 19 pathologically proven cancers were abstracted from the Taiwan Cancer Registry from 1998 to 2012. They were linked to the National Mortality Registry (1998-2014) and National Health Insurance reimbursement database (1998-2013) for survival and health care costs. We estimated the cumulative incidence rate for ages 0-79 years and the lifetime survival function for patients with different cancer sites. The EYLL was calculated by subtracting the LE of each cancer cohort from that of the age- and sex-matched referents simulated from national life tables. The estimated lifetime cost was calculated by adding up the product of survival probability and mean cost at the corresponding duration-to-date after adjustment for the inflation to the year of 2013. There were 5 cancers with a lifetime risk exceeding 4%: colorectal, liver, lung, and prostate in males, and breast and colorectal in females. Cancers with EYLL of >10 years were: esophageal, intrahepatic bile ducts, liver, pancreas, oral, nasopharyngeal, leukemia, lung, and gallbladder, extrahepatic bile ducts and biliary tract in males, and intrahepatic bile ducts, pancreas, nasopharyngeal, lung, esophageal, leukemia, liver, gallbladder, extrahepatic bile ducts and biliary tract, ovary, and stomach in females. Cancers with lifetime health care expenditures exceeding US$50,000 to the National Health Insurance were as follows: leukemia, kidney, testis, renal pelvis and ureter in males, and renal pelvis and ureter, leukemia, breast, urinary bladder, kidney, ovary, and nasopharyngeal in females. All these impacts should be considered in health policy decisions. The impacts of cancer in Taiwan are very large. Future studies must consider both quality of life and the entire impact from societal perspectives.},
  country      = {New Zealand},
  issn-linking = {1179-1349},
  journal      = {Clinical Epidemiology},
  keywords     = {cancer prevention; expected years of life lost; health impacts; incidence rate},
  nlm-id       = {101531700},
  owner        = {NLM},
  pii          = {clep-10-581},
  pmc          = {PMC5973634},
  pmid         = {29872347},
  pubmodel     = {Electronic-eCollection},
  pubstatus    = {epublish},
  revised      = {2019-11-20},
  timestamp    = {2020-03-12},
  year         = {2018},
}

@Article{Bray2018,
  author    = {Freddie Bray and Jacques Ferlay and Isabelle Soerjomataram and Rebecca L. Siegel and Lindsey A. Torre and Ahmedin Jemal},
  title     = {Global cancer statistics 2018: {GLOBOCAN} estimates of incidence and mortality worldwide for 36 cancers in 185 countries},
  journal   = {{CA}: A Cancer Journal for Clinicians},
  year      = {2018},
  volume    = {68},
  number    = {6},
  month     = {sep},
  pages     = {394--424},
  doi       = {10.3322/caac.21492},
  owner     = {Enoch},
  publisher = {Wiley},
  timestamp = {2020-03-12},
}

@Article{Gaitatzis2004,
  author          = {Gaitatzis, Athanasios and Johnson, Anthony L and Chadwick, David W and Shorvon, Simon D and Sander, Josemir W},
  title           = {Life expectancy in people with newly diagnosed epilepsy.},
  doi             = {10.1093/brain/awh267},
  issn            = {1460-2156},
  issue           = {Pt 11},
  pages           = {2427--2432},
  volume          = {127},
  abstract        = {Epilepsy carries a risk of premature mortality, but little is known about life expectancy in people with the condition. The UK National General Practice Study of Epilepsy is a prospective, population-based study of people with newly diagnosed epilepsy. A cohort of 564 patients with definite epilepsy has been followed for nearly 15 years and there have been 177 deaths. These data have been used to estimate life expectancy of people in this cohort by employing a parametric survival model based on the Weibull distribution. Life expectancy in people with epilepsy was estimated as a function of age at, and time from, diagnosis according to two broad aetiological groups. These estimates were then compared with life expectancy in people of the same age and sex in the general population. Reduction in life expectancy can be up to 2 years for people with a diagnosis of idiopathic/cryptogenic epilepsy, and the reduction can be up to 10 years in people with symptomatic epilepsy. Reductions in life expectancy are highest at the time of diagnosis and diminish with time. Our model provides broad estimates, but it appears that the higher mortality rates in people with newly diagnosed epilepsy translate into decreased life expectancy.},
  citation-subset = {AIM, IM},
  completed       = {2005-01-18},
  country         = {England},
  issn-linking    = {0006-8950},
  journal         = {Brain : a Journal of Neurology},
  keywords        = {Adolescent; Adult; Age of Onset; Aged; Child; Child, Preschool; Epilepsy, mortality; Female; Follow-Up Studies; Humans; Infant; Life Expectancy; Male; Middle Aged; Prospective Studies; Survival Analysis; United Kingdom, epidemiology},
  month           = nov,
  nlm-id          = {0372537},
  owner           = {NLM},
  pii             = {awh267},
  pmid            = {15371287},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2016-11-24},
  timestamp       = {2020-03-15},
  year            = {2004},
}

@Article{Haybittle1998,
  author          = {Haybittle, J L},
  title           = {Life expectancy as a measurement of the benefit shown by clinical trials of treatment for early breast cancer.},
  journal         = {Clinical oncology (Royal College of Radiologists (Great Britain))},
  year            = {1998},
  volume          = {10},
  issue           = {2},
  pages           = {92--94},
  issn            = {0936-6555},
  doi             = {10.1016/s0936-6555(05)80485-6},
  abstract        = {Improvements in life expectancy could be a more readily appreciated measure of benefit from a clinical trial than relative risks, odds ratios or increases in survival rate at some arbitrary point in time. Parametric models of survival experience can be used to determine differences in life expectancy. Using the log-normal model, it is shown that the increases in 10-year survival rate found by the overviews of adjuvant systemic therapy trials in early breast cancer are consistent with only small overall increases in life expectancy of about 1 year for Stage I and about 2 years for Stage II. However, if adjuvant therapy transfers a patient from being not cured to being cured, then her life expectancy will have been improved by 16 years for Stage I disease and by 21 years for Stage II. Model analyses on large data sets, such as are available in overviews, could possibly provide some evidence on whether the effect of adjuvant systemic therapy is to increase the cure rate, with the consequent considerable increase in life expectancy for some patients, or whether the effect is only a small increase in life expectancy for those who are not cured.},
  citation-subset = {IM},
  completed       = {1998-07-23},
  country         = {England},
  issn-linking    = {0936-6555},
  keywords        = {Breast Neoplasms, mortality, pathology, therapy; Clinical Trials as Topic, methods; Female; Humans; Life Expectancy; Neoplasm Staging},
  nlm-id          = {9002902},
  owner           = {NLM},
  pii             = {S0936-6555(05)80485-6},
  pmid            = {9610897},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2019-09-14},
  timestamp       = {2020-03-15},
}

@InCollection{Zivot2003,
  author    = {Zivot, Eric and Wang, Jiahui},
  booktitle = {Modeling Financial Time Series with S-Plus{\textregistered}},
  title     = {Rolling analysis of time series},
  pages     = {299--346},
  publisher = {Springer},
  owner     = {Enoch},
  timestamp = {2020-03-15},
  year      = {2003},
}

@Article{Syriopoulou2020,
  author          = {Syriopoulou, E. and Rutherford, M.J. and Lambert, P.C.},
  title           = {Marginal measures and causal effects using the relative survival framework.},
  journal         = {International Journal of Epidemiology},
  year            = {2020},
  volume          = {49},
  pages           = {619-628},
  issn            = {1464-3685},
  doi             = {10.1093/ije/dyz268},
  abstract        = {In population-based cancer survival studies, the event of interest is usually death due to cancer. However, other competing events may be present. Relative survival is a commonly used measure in cancer studies that circumvents problems caused by the inaccuracy of the cause of death information. A summary of the prognosis of the cancer population and potential differences between subgroups can be obtained using marginal estimates of relative survival. We utilize regression standardization to obtain marginal estimates of interest in a relative survival framework. Such measures include the standardized relative survival, standardized all-cause survival and standardized crude probabilities of death. Contrasts of these can be formed to explore differences between exposure groups and under certain assumptions are interpreted as causal effects. The difference in standardized all-cause survival can also provide an estimate for the impact of eliminating cancer-related differences between exposure groups. The potential avoidable deaths after such hypothetical scenarios can also be estimated. To illustrate the methods we use the example of survival differences across socio-economic groups for colon cancer. Using relative survival, a range of marginal measures and contrasts were estimated. For these measures we either focused on cancer-related differences only or chose to incorporate both cancer and other cause differences. The impact of eliminating differences between groups was also estimated. Another useful way for quantifying that impact is the avoidable deaths under hypothetical scenarios. Marginal estimates within the relative survival framework provide useful summary measures and can be applied to better understand differences across exposure groups.},
  citation-subset = {IM},
  country         = {England},
  file            = {:Syriopoulou2020.pdf:PDF},
  issn-linking    = {0300-5771},
  keywords        = {Relative survival; avoidable deaths; causal effects; marginal measures},
  nlm-id          = {7802871},
  owner           = {NLM},
  pii             = {dyz268},
  pmid            = {31953948},
  pubmodel        = {Print-Electronic},
  pubstatus       = {aheadofprint},
  revised         = {2020-01-29},
}

@Article{Jagger1991,
  author          = {Jagger, C and Sutton, C J},
  title           = {Death after marital bereavement--is the risk increased?},
  journal         = {Statistics in medicine},
  year            = {1991},
  volume          = {10},
  issue           = {3},
  month           = mar,
  pages           = {395--404},
  issn            = {0277-6715},
  doi             = {10.1002/sim.4780100311},
  abstract        = {Previous studies on the effect of marital bereavement on mortality have suggested various time periods during which the risk of mortality is increased. As many of the studies compared the widowed group with national mortality statistics for the married, there has been no opportunity to adjust for confounders which might themselves be responsible for this increased risk after bereavement. In this paper the various hypotheses proposed are reviewed and then modelled on a dataset of 344 elderly persons who were living with a spouse and who were part of a survey of a population of people aged 75 years and over. The 344 index-cases and their spouses were followed up for seven years and the times of death (for those who died) of the index-case and spouse were noted. The data were analysed by fitting a proportional hazards model to the subject's survival time after adjustment for other factors such as mental and physical health which had already been shown to be associated with mortality. The bereavement effects were fitted as time-dependent covariates. The best fitting model for females and males indicated an increased relative risk of mortality which lasted for approximately six months after bereavement. In the case of widows this relative risk was significantly increased, being 3.8 with 95 per cent confidence interval (1.4, 10.3) while for widowers the risk was 0.03 with 95 per cent confidence interval (0.00, 37.3).},
  citation-subset = {IM},
  completed       = {1991-06-13},
  country         = {England},
  issn-linking    = {0277-6715},
  keywords        = {Aged; Aged, 80 and over; Bereavement; Cause of Death; Female; Humans; Male; Marriage; Models, Statistical; Regression Analysis; Risk; Single Person, psychology; Survival Analysis},
  nlm-id          = {8215016},
  owner           = {NLM},
  pmid            = {2028123},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2019-08-28},
}

@Article{Allemani2018a,
  author    = {Claudia Allemani and Tomohiro Matsuda and Veronica Di Carlo and Rhea Harewood and Melissa Matz and Maja Nik{\v{s}}i{\'{c}} and Audrey Bonaventure and Mikhail Valkov and Christopher J Johnson and Jacques Est{\`{e}}ve and Olufemi J Ogunbiyi and Gulnar Azevedo e Silva and Wan-Qing Chen and Sultan Eser and Gerda Engholm and Charles A Stiller and Alain Monnereau and Ryan R Woods and Otto Visser and Gek Hsiang Lim and Joanne Aitken and Hannah K Weir and Michel P Coleman and S Bouzbid and M Hamdi-Ch{\'{e}}rif and Z Zaidi and K Meguenni and D Regagba and S Bayo and T Cheick Bougadari and S S Manraj and K Bendahhou and A Fabowale and D Bradshaw and N I M Somdyala and I Kumcher and F Moreno and G H Calabrano and S B Espinola and B Carballo Quintero and R Fita and M C Diumenjo and W D Laspada and S G Iba{\~{n}}ez and C A Lima and P C F De Souza and K Del Pino and C Laporte and M P Curado and J C de Oliveira and C L A Veneziano and D B Veneziano and M R D O Latorre and L F Tanaka and M S Rebelo and M O Santos and J C Galaz and M Aparicio Aravena and J Sanhueza Monsalve and D A Herrmann and S Vargas and V M Herrera and C J Uribe and L E Bravo and L S Garcia and N E Arias-Ortiz and D Morantes and D M Jurado and M C Y{\'{e}}pez Chamorro and S Delgado and M Ramirez and Y H Gal{\'{a}}n Alvarez and P Torres and F Mart{\'{\i}}nez-Reyes and L Jaramillo and R Quinto and J Castillo and M Mendoza and P Cueva and J G Y{\'{e}}pez and B Bhakkan and J Deloumeaux and C Joachim and J Macni and R Carrillo and J Shalkow Klincovstein and R Rivera Gomez and E Poquioma and G Tortolero-Luna and D Zavala and R Alonso and E Barrios and A Eckstrand and C Nikiforuk and G Noonan and D Turner and E Kumar and B Zhang and F R McCrate and S Ryan and M MacIntyre and N Saint-Jacques and D E Nishri and C A McClure and K A Vriends and S Kozie and H Stuart-Panko and T Freeman and J T George and J T Brockhouse and D K O{\textquotesingle}Brien and A Holt and L Almon and S Kwong and C Morris and R Rycroft and L Mueller and C E Phillips and H Brown and B Cromartie and A G Schwartz and F Vigneau and G M Levin and B Wohler and R Bayakly and K C Ward and S L Gomez and M McKinley and R Cress and M D Green and K Miyagi and L P Ruppert and C F Lynch and B Huang and T C Tucker and D Deapen and L Liu and M C Hsieh and X C Wu and M Schwenn and S T Gershman and R C Knowlton and G Alverson and G E Copeland and S Bushhouse and D B Rogers and J Jackson-Thompson and D Lemons and H J Zimmerman and M Hood and J Roberts-Johnson and J R Rees and B Riddle and K S Pawlish and A Stroup and C Key and C Wiggins and A R Kahn and M J Schymura and S Radhakrishnan and C Rao and L K Giljahn and R M Slocumb and R E Espinoza and F Khan and K G Aird and T Beran and J J Rubertone and S J Slack and L Garcia and D L Rousseau and T A Janes and S M Schwartz and S W Bolick and D M Hurley and M A Whiteside and P Miller-Gianturco and M A Williams and K Herget and C Sweeney and A T Johnson and M B Keitheri Cheteri and P Migliore Santiago and S E Blankenship and S Farley and R Borchers and R Malicki and J R Espinoza and J Grandpre and R Wilson and B K Edwards and A Mariotto and Y Lei and N Wang and J S Chen and Y Zhou and Y T He and G H Song and X P Gu and D Mei and H J Mu and H M Ge and T H Wu and Y Y Li and D L Zhao and F Jin and J H Zhang and F D Zhu and Q Junhua and Y L Yang and C X Jiang and W Biao and J Wang and Q L Li and H Yi and X Zhou and J Dong and W Li and F X Fu and S Z Liu and J G Chen and J Zhu and Y H Li and Y Q Lu and M Fan and S Q Huang and G P Guo and H Zhaolai and K Wei and H Zeng and A V Demetriou and W K Mang and K C Ngan and A C Kataki and M Krishnatreya and P A Jayalekshmi and P Sebastian and A Nandakumar and R Malekzadeh and G Roshandel and L Keinan-Boker and B G Silverman and H Ito and H Nakagawa and M Sato and F Tobori and I Nakata and N Teramoto and M Hattori and Y Kaizaki and F Moki and H Sugiyama and M Utada and M Nishimura and K Yoshida and K Kurosawa and Y Nemoto and H Narimatsu and M Sakaguchi and S Kanemura and M Naito and R Narisawa and I Miyashiro and K Nakata and S Sato and M Yoshii and I Oki and N Fukushima and A Shibata and K Iwasa and C Ono and O Nimri and K W Jung and Y J Won and E Alawadhi and A Elbasmi and A Ab Manan and F Adam and E Sanjaajmats and U Tudev and C Ochir and A M Al Khater and M M El Mistiri and Y Y Teo and C J Chiang and W C Lee and R Buasom and S Sangrajrang and S Kamsa-ard and S Wiangnon and K Daoprasert and D Pongnikorn and A Leklob and S Sangkitipaiboon and S L Geater and H Sriplung and O Ceylan and I KÃƒÂ¶g and O Dirican and T KÃƒÂ¶se and T Gurbuz and F E Kara{\c{s}}ahin and D Turhan and U Akta{\c{s}} and Y Halat and C I Yakut and M Altinisik and Y Cavusoglu and A TÃƒÂ¼rkkÃƒÂ¶ylÃƒÂ¼ and N ÃƒÂœ{\c{c}}ÃƒÂ¼ncÃƒÂ¼ and M Hackl and A A Zborovskaya and O V Aleinikova and K Henau and L Van Eycken and Z Valerianova and M R Yordanova and M {\v{S}}ekerija and L Du{\v{s}}ek and M Zvolsk{\'{y}} and H Storm and K Innos and M MÃƒÂ¤gi and N Malila and K SeppÃƒÂ¤ and J J{\'{e}}gu and M Velten and E Cornet and X Troussard and A M Bouvier and A V Guizard and V Bouvier and G Launoy and P Arveux and M Maynadi{\'{e}} and M Mounier and A S Woronoff and M Daoulas and M Robaszkiewicz and J Clavel and S Goujon and B Lacour and I Baldi and C Pouchieu and B Amadeo and G Coureau and S Orazio and P M Preux and F Rharbaoui and E Marrer and B Tr{\'{e}}tarre and M Colonna and P Delafosse and K Ligier and S Plouvier and A Cowppli-Bony and F Molini{\'{e}} and S Bara and O Ganry and B Lap{\^{o}}tre-Ledoux and P Grosclaude and N Bossard and Z Uhry and F Bray and M Pi{\~{n}}eros and R Stabenow and H Wilsdorf-KÃƒÂ¶hler and A Eberle and S Luttmann and I LÃƒÂ¶hden and A L Nennecke and J Kieschke and E Sirri and K Emrich and S R Zeissig and B Holleczek and N Eisemann and A Katalinic and R A Asquez and V Kumar and E Petridou and E J {\'{O}}lafsd{\'{o}}ttir and L Tryggvad{\'{o}}ttir and K Clough-Gorr and P M Walsh and H Sundseth and G Mazzoleni and F Vittadello and E Coviello and F Cuccaro and R Galasso and G Sampietro and A Giacomin and M Magoni and A Ardizzone and A D{\textquotesingle}Argenzio and M Castaing and G Grosso and A M Lavecchia and A Sutera Sardo and G Gola and L Gatti and P Ricci and S Ferretti and D Serraino and A Zucchetto and M V Celesia and R A Filiberti and F Pannozzo and A Melcarne and F Quarta and A G Russo and G Carrozzi and C Cirilli and L Cavalieri d{\textquotesingle}Oro and M Rognoni and M Fusco and M F Vitale and M Usala and R Cusimano and W Mazzucco and M Michiara and P Sgargi and L Boschetti and E Borciani and P Seghini and M M Maule and F Merletti and R Tumino and P Mancuso and M Vicentini and T Cassetti and R Sassatelli and F Falcini and S Giorgetti and A L Caiazzo and R Cavallo and R Cesaraccio and D R Pirino and M L Contrino and F Tisano and A C Fanetti and S Maspero and S Carone and A Mincuzzi and G Candela and T Scuderi and M A Gentilini and S Piffer and S Rosso and A Barchielli and A Caldarella and F Bianconi and F Stracci and P Contiero and G Tagliabue and M Rugge and M Zorzi and S Beggiato and A Brustolin and F Berrino and G Gatta and M Sant and C Buzzoni and L Mangone and R Capocaccia and R De Angelis and R Zanetti and A Maurina and S Pildava and N Lipunova and I Vincer{\v{z}}evskien{\'{e}} and D Agius and N Calleja and S Siesling and S Lar{\o}nningen and B M{\o}ller and A Dyzmann-Sroka and M Trojanowski and S G{\'{o}}{\'{z}}d{\'{z}} and R M{\k{e}}{\.{z}}yk and T Mierzwa and L Molong and J Rachtan and S Szewczyk and J B{\l}aszczyk and K K{\k{e}}pska and B Ko{\'{s}}cia{\'{n}}ska and K Taroci{\'{n}}ska and M Zwierko and K Drosik and K M Maksimowicz and E Purwin-Porowska and E Reca and J W{\'{o}}jcik-Tomaszewska and A Tukiendorf and M Gr{\k{a}}dalska-Lampart and A U Radziszewska and A Gos and M Talerczyk and M Wyborska and J A Didkowska and U Wojciechowska and M Bielska-Lasota and G Forjaz de Lacerda and R A Rego and J Bastos and M A Silva and L Antunes and J Laranja Pontes and A Mayer-da-Silva and A Miranda and L M Blaga and D Coza and L Gusenkova and O Lazarevich and O Prudnikova and D M Vjushkov and A G Egorova and A E Orlov and L A Kudyakov and L V Pikalova and J Adamcik and C Safaei Diba and M Primic-{\v{Z}}akelj and V Zadnik and N Larra{\~{n}}aga and A Lopez de Munain and A A Herrera and R Redondas and R Marcos-Gragera and M L Vilardell Gil and E Molina and M J S{\'{a}}nchez Perez and P Franch Sureda and M Ramos Montserrat and M D Chirlaque and C Navarro and E E Ardanaz and M M Guevara and R Fern{\'{a}}ndez-Delgado and R Peris-Bonet and M Carulla and J Galceran and C Alberich and M Vicente-Raneda and S Khan and D Pettersson and P Dickman and I Avelina and K Staehelin and B Camey and C Bouchardy and R Schaffar and H Frick and C Herrmann and J L Bulliard and M Maspoli-Conconi and C E Kuehni and S M Redmond and A Bordoni and L Ortelli and A Chiolero and I Konzelmann and K L Matthes and S Rohrmann and J Broggio and J Rashbass and D Fitzpatrick and A Gavin and D I Clark and A J Deas and D W Huws and C White and L Montel and B Rachet and A D Turculet and R Stephens and E Chalker and H Phung and R Walton and H You and S Guthridge and F Johnson and P Gordon and K D{\textquotesingle}Onise and K Priest and B C Stokes and A Venn and H Farrugia and V Thursfield and J Dowling and D Currow and J Hendrix and C Lewis},
  title     = {Global surveillance of trends in cancer survival 2000{\textendash}14 ({CONCORD}-3): analysis of individual records for 37{\hphantom{,}}513{\hphantom{,}}025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries},
  journal   = {The Lancet},
  year      = {2018},
  volume    = {391},
  number    = {10125},
  month     = {mar},
  pages     = {1023--1075},
  doi       = {10.1016/s0140-6736(17)33326-3},
  owner     = {Enoch},
  publisher = {Elsevier {BV}},
  timestamp = {2020-03-24},
}

@Article{Latimer2013,
  author          = {Latimer, Nicholas R},
  title           = {Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide.},
  journal         = {Medical decision making : an international journal of the Society for Medical Decision Making},
  year            = {2013},
  volume          = {33},
  issue           = {6},
  month           = aug,
  pages           = {743--754},
  issn            = {1552-681X},
  doi             = {10.1177/0272989X12472398},
  abstract        = {In health technology assessments (HTAs) of interventions that affect survival, it is essential to accurately estimate the survival benefit associated with the new treatment. Generally, trial data must be extrapolated, and many models are available for this purpose. The choice of extrapolation model is critical because different models can lead to very different cost-effectiveness results. A failure to systematically justify the chosen model creates the possibility of bias and inconsistency between HTAs. To demonstrate the limitations and inconsistencies associated with the survival analysis component of HTAs and to propose a process guide that will help exclude these from future analyses. We reviewed the survival analysis component of 45 HTAs undertaken for the National Institute for Health and Clinical Excellence (NICE) in the cancer disease area. We drew upon our findings to identify common limitations and to develop a process guide. The chosen survival models were not systematically justified in any of the HTAs reviewed. The range of models considered was usually insufficient, and the rationale for the chosen model was universally limited: In particular, the plausibility of the extrapolated portion of fitted survival curves was very rarely explicitly considered. Limitations. We do not seek to describe and review all methods available for performing survival analysis-several approaches exist that are not mentioned in this article. Instead we seek to analyze methods commonly used in HTAs and limitations associated with their application. Survival analysis has not been conducted systematically in HTAs. A systematic approach such as the one proposed here is required to reduce the possibility of bias in cost-effectiveness results and inconsistency between technology assessments.},
  citation-subset = {IM},
  completed       = {2014-02-06},
  country         = {United States},
  issn-linking    = {0272-989X},
  keywords        = {Algorithms; Clinical Trials as Topic; Costs and Cost Analysis; Humans; Models, Economic; Survival Analysis; cost-utility analysis; modeling; oncology; overall survival; pharmacoeconomics; resource allocation; survival analysis; technology assessment},
  nlm-id          = {8109073},
  owner           = {NLM},
  pii             = {0272989X12472398},
  pmid            = {23341049},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2017-11-10},
  timestamp       = {2020-03-25},
}

@Article{Hung2018,
  author          = {Hung, Mei-Chuan and Ekwueme, Donatus U. and White, Arica and Rim, Sun Hee and King, Jessica B. and Wang, Jung-Der and Chang, Su-Hsin},
  title           = {Estimating health benefits and cost-savings for achieving the Healthy People 2020 objective of reducing invasive colorectal cancer.},
  doi             = {10.1016/j.ypmed.2017.09.022},
  issn            = {1096-0260},
  pages           = {38--44},
  pubstate        = {ppublish},
  volume          = {106},
  abstract        = {This study aims to quantify the aggregate potential life-years (LYs) saved and healthcare cost-savings if the Healthy People 2020 objective were met to reduce invasive colorectal cancer (CRC) incidence by 15%. We identified patients (n=886,380) diagnosed with invasive CRC between 2001 and 2011 from a nationally representative cancer dataset. We stratified these patients by sex, race/ethnicity, and age. Using these data and data from the 2001-2011 U.S. life tables, we estimated a survival function for each CRC group and the corresponding reference group and computed per-person LYs saved. We estimated per-person annual healthcare cost-savings using the 2008-2012 Medical Expenditure Panel Survey. We calculated aggregate LYs saved and cost-savings by multiplying the reduced number of CRC patients by the per-person LYs saved and lifetime healthcare cost-savings, respectively. We estimated an aggregate of 84,569 and 64,924 LYs saved for men and women, respectively, accounting for healthcare cost-savings of $329.3 and $294.2 million (in 2013$), respectively. Per person, we estimated 6.3 potential LYs saved related to those who developed CRC for both men and women, and healthcare cost-savings of $24,000 for men and $28,000 for women. Non-Hispanic whites and those aged 60-64 had the highest aggregate potential LYs saved and cost-savings. Achieving the HP2020 objective of reducing invasive CRC incidence by 15% by year 2020 would potentially save nearly 150,000 life-years and $624 million on healthcare costs.},
  citation-subset = {IM},
  completed       = {2018-12-17},
  country         = {United States},
  issn-linking    = {0091-7435},
  journal         = {Preventive Medicine},
  keywords        = {Age Factors; Aged; Colorectal Neoplasms, diagnosis, epidemiology; Cost Savings, economics, statistics & numerical data; Female; Health Expenditures, statistics & numerical data; Healthy People Programs, economics; Humans; Male; Middle Aged; Quality-Adjusted Life Years; Surveys and Questionnaires; United States; Healthy People 2020; Invasive colorectal cancer; Life years (LYs); Lifetime healthcare costs},
  mid             = {NIHMS951668},
  month           = jan,
  nlm-id          = {0322116},
  owner           = {NLM},
  pii             = {S0091-7435(17)30347-X},
  pmc             = {PMC5874792},
  pmid            = {28964854},
  pubmodel        = {Print-Electronic},
  revised         = {2019-10-08},
  timestamp       = {2020-03-25},
  year            = {2018},
}

@Article{Ekberg2018,
  author       = {Ekberg, Sara and Jerkeman, Mats and Andersson, Per-Ola and Enblad, Gunilla and Wahlin, BjÃ¶rn E. and Hasselblom, Sverker and Andersson, Therese M. and Eloranta, Sandra and Smedby, Karin E.},
  title        = {Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma.},
  doi          = {10.1002/ajh.25147},
  issn         = {1096-8652},
  pubstate     = {aheadofprint},
  abstract     = {Survival has improved among patients with diffuse large B-cell lymphoma (DLBCL) with the addition of anti-CD20 antibody therapy. We aimed to quantify trends and remaining loss in expectation of life (LEL) due to DLBCL at a national population-based level. Patients diagnosed with DLBCL 2000-2013 (Nâ€‰=â€‰7114) were identified through the Swedish Lymphoma Registry and classified according to the age-adjusted International Prognostic Index (aaIPI). The novel measure LEL is the difference between remaining life years among patients and the general population and was predicted using flexible parametric models from diagnosis and among 2-year survivors, by age and sex. Median age at DLBCL-diagnosis was 70 (18-105) years and 54.8% presented with stage III-IV disease. On average, LEL due to DLBCL decreased from 8.0 (95% CI: 7.7-8.3) to 4.6 (95% CI: 4.5-4.6) years over the study period. By risk group, LEL was most reduced among patients with aaIPI â‰¥2 aged 50-60 years. However, these patients were still estimated to lose >8 years in 2013 (eg, LEL  8.6 years (95% CI: 5.0-12.3)). Among 2-year survivors, LEL was reduced from 6.1 years (95% CI: 5.6-6.5) (aaIPIâ€‰â‰¥â€‰2) and 3.8 years (95% CI: 3.6-4.1) (aaIPIâ€‰<â€‰2) to 1.1 (95% CI: 1.1-1.2) and 1.0 year (95% CI: 0.8-1.1), respectively. The reduction was observed across all ages. Results for females were similar. By using LEL we illustrate the improvement of DLBCL survival over time. Despite adequate immunochemotherapy, substantial LEL among patients with IPIâ€‰â‰¥â€‰2 points to remaining unmet medical needs. We speculate that observed reduced losses among 2-year survivors indicate a reduction of late relapses.},
  country      = {United States},
  issn-linking = {0361-8609},
  journal      = {American Journal of Hematology},
  month        = may,
  nlm-id       = {7610369},
  owner        = {NLM},
  pmid         = {29770496},
  pubmodel     = {Print-Electronic},
  revised      = {2019-11-20},
  timestamp    = {2020-03-31},
  year         = {2018},
}

@Article{Kearns2020,
  author    = {Kearns, Ben and Stevens, John and Ren, Shijie and Brennan, Alan},
  title     = {How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness},
  number    = {2},
  pages     = {193--204},
  volume    = {38},
  journal   = {PharmacoEconomics},
  owner     = {Enoch},
  publisher = {Springer},
  timestamp = {2020-04-02},
  year      = {2020},
}

@Book{Adami2008a,
  author    = {Adami, Hans-Olov and Hunter, David John and Trichopoulos, Dimitrios},
  title     = {Textbook of cancer epidemiology},
  publisher = {Oxford University Press, USA},
  owner     = {Enoch},
  timestamp = {2020-04-02},
  year      = {2008},
}

@Book{Rothman2008,
  author    = {Rothman, Kenneth},
  title     = {Modern epidemiology},
  isbn      = {9780781755641},
  publisher = {Wolters Kluwer Health/Lippincott Williams \& Wilkins},
  address   = {Philadelphia},
  year      = {2008},
}

@Article{Booth2020,
  author          = {Booth, Sarah and Riley, Richard D and Ensor, Joie and Lambert, Paul C and Rutherford, Mark J},
  title           = {Temporal recalibration for improving prognostic model development and risk predictions in settings where survival is improving over time.},
  doi             = {10.1093/ije/dyaa030},
  issn            = {1464-3685},
  pages           = {1316--1325},
  volume          = {49},
  abstract        = {Prognostic models are typically developed in studies covering long time periods. However, if more recent years have seen improvements in survival, then using the full dataset may lead to out-of-date survival predictions. Period analysis addresses this by developing the model in a subset of the data from a recent time window, but results in a reduction of sample size. We propose a new approach, called temporal recalibration, to combine the advantages of period analysis and full cohort analysis. This approach develops a model in the entire dataset and then recalibrates the baseline survival using a period analysis sample.The approaches are demonstrated utilizing a prognostic model in colon cancer built using both Cox proportional hazards and flexible parametric survival models with data from 1996-2005 from the Surveillance, Epidemiology, and End Results (SEER) Program database. Comparison of model predictions with observed survival estimates were made for new patients subsequently diagnosed in 2006 and followed-up until 2015. Period analysis and temporal recalibration provided more up-to-date survival predictions that more closely matched observed survival in subsequent data than the standard full cohort models. In addition, temporal recalibration provided more precise estimates of predictor effects. Prognostic models are typically developed using a full cohort analysis that can result in out-of-date long-term survival estimates when survival has improved in recent years. Temporal recalibration is a simple method to address this, which can be used when developing and updating prognostic models to ensure survival predictions are more closely calibrated with the observed survival of individuals diagnosed subsequently.},
  citation-subset = {IM},
  country         = {England},
  file            = {:Booth2020.pdf:PDF},
  groups          = {pl4:6},
  issn-linking    = {0300-5771},
  journal         = {International Journal of Epidemiology},
  keywords        = {Cox proportional hazards models; Prognostic models; flexible parametric survival models; period analysis; temporal recalibration; up-to-date survival predictions},
  month           = apr,
  nlm-id          = {7802871},
  owner           = {NLM},
  pii             = {dyaa030},
  pmid            = {32243524},
  pubmodel        = {Print-Electronic},
  pubstatus       = {aheadofprint},
  revised         = {2020-04-03},
  year            = {2020},
}

@Article{Lin2000,
  author  = {D.Y. Lin},
  title   = {On fitting Coxâ€™s proportional hazards models to survey data},
  journal = {Biometrika},
  year    = {2000},
  volume  = {87},
  pages   = {37-47},
  doi     = {https://doi.org/10.1093/biomet/87.1.37},
}

@Article{Sweeting2017,
  author          = {Sweeting, Michael J and Barrett, Jessica K and Thompson, Simon G and Wood, Angela M},
  title           = {The use of repeated blood pressure measures for cardiovascular risk prediction: a comparison of statistical models in the ARIC study.},
  doi             = {10.1002/sim.7144},
  issn            = {1097-0258},
  issue           = {28},
  pages           = {4514--4528},
  volume          = {36},
  abstract        = {Many prediction models have been developed for the risk assessment and the prevention of cardiovascular disease in primary care. Recent efforts have focused on improving the accuracy of these prediction models by adding novel biomarkers to a common set of baseline risk predictors. Few have considered incorporating repeated measures of the common risk predictors. Through application to the Atherosclerosis Risk in Communities study and simulations, we compare models that use simple summary measures of the repeat information on systolic blood pressure, such as (i) baseline only; (ii) last observation carried forward; and (iii) cumulative mean, against more complex methods that model the repeat information using (iv) ordinary regression calibration; (v) risk-set regression calibration; and (vi) joint longitudinal and survival models. In comparison with the baseline-only model, we observed modest improvements in discrimination and calibration using the cumulative mean of systolic blood pressure, but little further improvement from any of the complex methods. Â© 2016 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd.},
  chemicals       = {Biomarkers},
  citation-subset = {IM},
  completed       = {2018-09-14},
  country         = {England},
  groups          = {pl4:6},
  issn-linking    = {0277-6715},
  journal         = {Statistics in medicine},
  keywords        = {Bias; Biomarkers; Blood Pressure; Blood Pressure Determination, statistics & numerical data; Cardiovascular Diseases, epidemiology; Computer Simulation; Female; Humans; Longitudinal Studies; Male; Middle Aged; Models, Statistical; Regression Analysis; Risk Assessment, methods; Risk Factors; Survival Analysis; C-index; cardiovascular risk prediction; joint models; regression calibration; repeat measures},
  month           = dec,
  nlm-id          = {8215016},
  owner           = {NLM},
  pmc             = {PMC5724484},
  pmid            = {27730661},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2020-04-20},
  year            = {2017},
}

@Article{Sanders2016,
  author          = {Sanders, Gillian D. and Neumann, Peter J. and Basu, Anirban and Brock, Dan W. and Feeny, David and Krahn, Murray and Kuntz, Karen M. and Meltzer, David O. and Owens, Douglas K. and Prosser, Lisa A. and Salomon, Joshua A. and Sculpher, Mark J. and Trikalinos, Thomas A. and Russell, Louise B. and Siegel, Joanna E. and Ganiats, Theodore G.},
  title           = {Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.},
  doi             = {10.1001/jama.2016.12195},
  issn            = {1538-3598},
  issue           = {10},
  pages           = {1093--1103},
  pubstate        = {ppublish},
  volume          = {316},
  abstract        = {Since publication of the report by the Panel on Cost-Effectiveness in Health and Medicine in 1996, researchers have advanced the methods of cost-effectiveness analysis, and policy makers have experimented with its application. The need to deliver health care efficiently and the importance of using analytic techniques to understand the clinical and economic consequences of strategies to improve health have increased in recent years. To review the state of the field and provide recommendations to improve the quality of cost-effectiveness analyses. The intended audiences include researchers, government policy makers, public health officials, health care administrators, payers, businesses, clinicians, patients, and consumers. In 2012, the Second Panel on Cost-Effectiveness in Health and Medicine was formed and included 2 co-chairs, 13 members, and 3 additional members of a leadership group. These members were selected on the basis of their experience in the field to provide broad expertise in the design, conduct, and use of cost-effectiveness analyses. Over the next 3.5 years, the panel developed recommendations by consensus. These recommendations were then reviewed by invited external reviewers and through a public posting process. The concept of a "reference case" and a set of standard methodological practices that all cost-effectiveness analyses should follow to improve quality and comparability are recommended. All cost-effectiveness analyses should report 2 reference case analyses: one based on a health care sector perspective and another based on a societal perspective. The use of an "impact inventory," which is a structured table that contains consequences (both inside and outside the formal health care sector), intended to clarify the scope and boundaries of the 2 reference case analyses is also recommended. This special communication reviews these recommendations and others concerning the estimation of the consequences of interventions, the valuation of health outcomes, and the reporting of cost-effectiveness analyses. The Second Panel reviewed the current status of the field of cost-effectiveness analysis and developed a new set of recommendations. Major changes include the recommendation to perform analyses from 2 reference case perspectives and to provide an impact inventory to clarify included consequences.},
  citation-subset = {AIM, IM},
  completed       = {2017-01-10},
  country         = {United States},
  file            = {:Sanders2016.pdf:PDF},
  groups          = {Health Economics},
  issn-linking    = {0098-7484},
  journal         = {JAMA},
  keywords        = {Consensus; Cost-Benefit Analysis, methods; Delivery of Health Care, economics, trends; Guidelines as Topic; Humans; Medicine, standards; Quality of Health Care},
  month           = sep,
  nlm-id          = {7501160},
  owner           = {NLM},
  pii             = {2552214},
  pmid            = {27623463},
  pubmodel        = {Print},
  revised         = {2017-09-22},
  timestamp       = {2020-05-01},
  year            = {2016},
}

@Article{Wright2020,
  author          = {Wright, Cameron M. and Moorin, Rachael E.},
  title           = {Does minimum follow-up time post-diagnosis matter? An assessment of changing loss of life expectancy for people with cancer in Western Australia from 1982 to 2016.},
  doi             = {10.1016/j.canep.2020.101705},
  issn            = {1877-783X},
  pages           = {101705},
  pubstate        = {aheadofprint},
  volume          = {66},
  abstract        = {Cancer survival has improved in Western Australia (WA) over recent decades. Loss of life expectancy (LOLE) is a useful measure for assessing cancer survival at a population-level. Some previous studies estimating LOLE have required a minimum follow-up beyond diagnosis to reduce the impact of modelled extrapolation, while others have not. The first aim of this study was to assess the impact of minimum length of follow-up on LOLE estimates for people diagnosed in 2006 with female breast, colorectal, prostate, lung, cervical, combined oesophageal and stomach cancers, and melanoma. Based on these results, the second aim was to assess temporal changes in LOLE for these cancer types for diagnoses between 1982 and 2016. Person-level linked cancer registry and mortality data were used for invasive primary cancer diagnoses for WA residents aged 15-89 years. The analysis for aim one included cases diagnosed from 1982 to the end of 2006, followed to the end of 2006 (i.e. no minimum follow-up), 2011 (i.e. five years minimum follow-up, assuming survival) or 2016 (i.e. 10 years minimum follow-up). To achieve the second study aim, the diagnostic period was extended to the end of 2016. Life expectancy estimates were obtained after fitting flexible parametric relative survival models. Single-year age and sex-specific death rates were used as a reference to estimate LOLE and proportionate loss of life expectancy. Temporal changes were not reported for prostate, cervical, oesophageal and stomach cancers or melanoma, due to differences in LOLE estimates by minimum follow-up time, or estimate imprecision. Marked reductions in LOLE were observed for female breast and colorectal cancer. There was minimal absolute reduction for lung cancer, where LOLE remained high. This study considered the appropriateness of including recent cancer diagnoses when assessing temporal changes in LOLE, finding variation in estimates with differing minimum follow-up or high parameter uncertainty for most included cancer types. Temporal changes in LOLE in-turn reflected changes in the life expectancy of the general population, cancer detection and management. These factors must be considered when estimating and interpreting LOLE estimates.},
  citation-subset = {IM},
  country         = {Netherlands},
  issn-linking    = {1877-7821},
  journal         = {Cancer epidemiology},
  keywords        = {Australia; Cancer; Life expectancy; Neoplasms; Prognosis},
  month           = mar,
  nlm-id          = {101508793},
  owner           = {NLM},
  pii             = {S1877-7821(20)30039-4},
  pmid            = {32224327},
  pubmodel        = {Print-Electronic},
  revised         = {2020-04-27},
  timestamp       = {2020-05-04},
  year            = {2020},
}

@Article{Fang2006,
  author    = {C.T. Fang and Y.Y. Chang and H.M. Hsu and S.J. Twu and K.T. Chen and C.C. Lin and L.Y.L. Huang and M.Y. Chen and J.S. Hwang and J.D. Wang and C.Y. Chuang},
  title     = {Life expectancy of patients with newly-diagnosed {HIV} infection in the era of highly active antiretroviral therapy},
  doi       = {10.1093/qjmed/hcl141},
  number    = {2},
  pages     = {97--105},
  volume    = {100},
  journal   = {{QJM}},
  month     = {dec},
  owner     = {Enoch},
  publisher = {Oxford University Press ({OUP})},
  timestamp = {2020-05-04},
  year      = {2006},
}


@Article{Stattin2017,
  author    = {PÃ¤r Stattin and Fredrik Sandin and Karin HellstrÃ¶m and David Robinson and Ingela Franck Lissbrant},
  title     = {The National Prostate Cancer Register of Sweden},
  doi       = {10.1007/s13629-017-0168-1},
  number    = {2-3},
  pages     = {50--59},
  volume    = {7},
  journal   = {Tijdschrift voor Urologie},
  month     = {feb},
  owner     = {Enoch},
  publisher = {Springer Science and Business Media {LLC}},
  timestamp = {2020-05-16},
  year      = {2017},
}

@Article{Lee2017a,
  author    = {J.H. Lee and J.S. Jeng and J.S. Hwang and Y.Y. Chang and J.D. Wang},
  title     = {Life years lost and lifetime healthcare expenditures of stroke: A 14-year population-based cohort study in Taiwan},
  doi       = {10.1016/j.jns.2017.08.2480},
  pages     = {880},
  volume    = {381},
  journal   = {Journal of the Neurological Sciences},
  month     = {oct},
  owner     = {Enoch},
  publisher = {Elsevier {BV}},
  timestamp = {2020-06-02},
  year      = {2017},
}

@Article{Yeh2020,
  author    = {Yeh, Tian-Shin and Wang, Jung-Der and Ku, Li-Jung Elizabeth},
  title     = {Estimating Life Expectancy and Lifetime Healthcare Costs for Alzheimerâ€™s Disease in Taiwan: Does the Age of Disease Onset Matter?},
  doi       = {10.3233/JAD-181060},
  editor    = {Tabira, TakeshiEditor},
  issn      = {1387-2877},
  number    = {1},
  pages     = {307--315},
  volume    = {73},
  journal   = {Journal of Alzheimerâ€™s Disease},
  month     = {Jan},
  owner     = {Enoch},
  publisher = {IOS Press},
  timestamp = {2020-06-02},
  year      = {2020},
}

@Article{Kearns2019,
  author    = {Benjamin Kearns and Matt D. Stevenson and Kostas Triantafyllopoulos and Andrea Manca},
  title     = {Generalized Linear Models for Flexible Parametric Modeling of the Hazard Function},
  doi       = {10.1177/0272989x19873661},
  number    = {7},
  pages     = {867--878},
  volume    = {39},
  journal   = {Medical Decision Making},
  month     = {sep},
  owner     = {Enoch},
  publisher = {{SAGE} Publications},
  timestamp = {2020-06-02},
  year      = {2019},
}

@Article{Rutherford2020,
  author          = {Rutherford, Mark J and Dickman, Paul W and Coviello, Enzo and Lambert, Paul C},
  title           = {Estimation of age-standardized net survival, even when age-specific data are sparse.},
  doi             = {10.1016/j.canep.2020.101745},
  issn            = {1877-783X},
  pages           = {101745},
  volume          = {67},
  abstract        = {Age-standardization is vital in international comparison studies of cancer patient survival, but standard approaches can fail to produce estimates in the case of sparsity. The purpose of this paper is to demonstrate that using a standardization pre-weighting approach is a viable alternative approach for external age-standardization in population-based cancer data and performs well in cases of sparsity. We further de;1;scribe how the pre-weighting approach to age-standardization can be coupled with the Pohar Perme estimator in both a cohort and period analysis setting. For period analysis, we compare approaches for defining the internal age distribution. We use SEER public use data to illustrate our approach and estimate survival for Connecticut and by race to create a scenario with sufficient sparsity. The pre-weighting approach gives comparable estimates to traditional age-standardization in cases with sufficient data and produces estimates throughout follow-up in cases of sparsity when a traditional approach would fail. International comparison studies and other national population-based survival studies that need to age-standardize estimates for comparability purposes should adopt the Pohar Perme estimator with pre-weighting. This approach avoids issues of non-estimation in the case of sparsity and will allow more consistent comparisons across the produced estimates.},
  citation-subset = {IM},
  country         = {Netherlands},
  file            = {:Rutherford2020.pdf:PDF},
  issn-linking    = {1877-7821},
  journal         = {Cancer Epidemiology},
  keywords        = {Age-standardization; Net survival; Period analysis; Population-based data},
  month           = jun,
  nlm-id          = {101508793},
  owner           = {NLM},
  pii             = {S1877-7821(20)30079-5},
  pmid            = {32554300},
  pubmodel        = {Print-Electronic},
  pubstatus       = {aheadofprint},
  revised         = {2020-07-13},
  year            = {2020},
}

@Article{Lambert2020,
  author          = {Lambert, P. C. and Andersson, T. M-L. and Rutherford, M. J. and Myklebust, T. {\AA}. and M{\o}ller, B.},
  title           = {Reference-adjusted and standardized all-cause and crude probabilities as an alternative to net survival in population-based cancer studies.},
  doi             = {10.1093/ije/dyaa112},
  issn            = {1464-3685},
  pages           = {1614-1623},
  volume          = {49},
  abstract        = {In population-based cancer survival studies, the most common measure to compare population groups is age-standardized marginal relative survival, which under assumptions can be interpreted as marginal net survival; the probability of surviving if it was not possible to die of causes other than the cancer under study (if the age distribution was that of a common reference population). The hypothetical nature of this definition has led to confusion and incorrect interpretation. For any measure to be fair in terms of comparing cancer survival, then differences between population groups should depend only on differences in excess mortality rates due to the cancer and not differences in other-cause mortality rates or differences in the age distribution. We propose using crude probabilities of death and all-cause survival which incorporate reference expected mortality rates. This makes it possible to obtain marginal crude probabilities and all-cause probability of death that only differ between population groups due to excess mortality rate differences. Choices have to be made regarding what reference mortality rates to use and what age distribution to standardize to. We illustrate the method and some potential choices using data from England for men diagnosed with melanoma. Various marginal measures are presented and compared. The new measures help enhance understanding of cancer survival and are a complement to the more commonly used measures.},
  citation-subset = {IM},
  country         = {England},
  file            = {:/media/paul/Storage/survbib/pdf/Lambert2020.pdf:PDF},
  groups          = {Paul:6},
  issn-linking    = {0300-5771},
  journal         = {International Journal of Epidemiology},
  keywords        = {Relative survival; age-standardization; excess mortality; model-based standardization; net survival},
  nlm-id          = {7802871},
  owner           = {NLM},
  pii             = {dyaa112},
  pmid            = {32829393},
  pubmodel        = {Print-Electronic},
  pubstatus       = {aheadofprint},
  revised         = {2020-08-23},
  year            = {2020},
}

@Article{Myklebust2020,
  author          = {Myklebust, T.{\AA}. and Andersson, T.M-L. and Bardot, A. and Vernon, S. and Gavin, A. and Fitzpatrick, D. and Jerm, M.B. and Rutherford, M.J. and Parkin, D.M. and Sasieni, P. and Arnold, M. and Soerjomataram, I. and Bray, F. and Lambert, P. C. and M{\o}ller, B.},
  title           = {Can different definitions of date of cancer incidence explain observed international variation in cancer survival? {A}n {ICBP} {SURVMARK-2} study.},
  doi             = {10.1016/j.canep.2020.101759},
  issn            = {1877-783X},
  pages           = {101759},
  pubstate        = {ppublish},
  volume          = {67},
  abstract        = {Differences in registration practices across population-based cancer registries may contribute to international variation in survival estimates. In particular, there are variations in recorded date of incidence (DOI) as cancer registries have access to different sources of information and use different rules to determine an official DOI. This study investigates the impact of different DOI rules on cancer survival estimates. Detailed data on dates of pathological confirmation and hospital admittance were collected from three registries participating in the ICBP SURVMARK-2 project (England, Northern Ireland and Norway). Multiple dates of incidence were determined for each cancer patient diagnosed during 2010-2014 by applying three sets of rules that prioritize either: a) histological date, b) hospital admittance date or c) the earliest date recorded. For each set of rules and registry, 1- and 5-year net survival were estimated for eight cancer sites (oesophagus, stomach, colon, rectum, liver, pancreas, lung and ovary). The mean difference between different DOIs within a country and cancer site ranged from 0.1-23 days. The variation in 1- and 5-year net survival using different DOIs were generally small for all registries and cancer sites. Only for liver and pancreatic cancer in Norway and ovarian cancer in England, were larger 1-year survival differences, of 2-3 % found. In the ongoing discussion of the comparability of survival estimates across registry populations, the use of different DOI definitions can be considered to have a very limited impact.},
  citation-subset = {IM},
  country         = {Netherlands},
  file            = {:Myklebust2020.pdf:PDF},
  issn-linking    = {1877-7821},
  journal         = {Cancer Epidemiology},
  keywords        = {Date of incidence; International variation; Registration practice; Survival},
  nlm-id          = {101508793},
  owner           = {NLM},
  pii             = {S1877-7821(20)30093-X},
  pmid            = {32544801},
  pubmodel        = {Print-Electronic},
  revised         = {2020-07-24},
  year            = {2020},
}

@Article{Welch2020,
  author          = {Welch, Catherine A. and Sweeting, Michael J. and Lambert, Paul C. and Rutherford, Mark J. and Jack, Ruth H. and West, Douglas and Adlam, David and Peake, Michael},
  title           = {Impact on survival of modelling increased surgical resection rates in patients with non-small-cell lung cancer and cardiovascular comorbidities: a {VICORI} study.},
  doi             = {10.1038/s41416-020-0869-8},
  issn            = {1532-1827},
  issue           = {3},
  pages           = {471--479},
  pubstate        = {ppublish},
  volume          = {123},
  abstract        = {The impact of cardiovascular disease (CVD) comorbidity on resection rates and survival for patients with early-stage non-small-cell lung cancer (NSCLC) is unclear. We explored if CVD comorbidity explained surgical resection rate variation and the impact on survival if resection rates increased. Cancer registry data consisted of English patients diagnosed with NSCLC from 2012 to 2016. Linked hospital records identified CVD comorbidities. We investigated resection rate variation by geographical region using funnel plots; resection and death rates using time-to-event analysis. We modelled an increased propensity for resection in regions with the lowest resection rates and estimated survival change. Among 57,373 patients with Stage 1-3A NSCLC, resection rates varied considerably between regions. Patients with CVD comorbidity had lower resection rates and higher mortality rates. CVD comorbidity explained only 1.9% of the variation in resection rates. For every 100 CVD comorbid patients, increasing resection in regions with the lowest rates from 24 to 44% would result in 16 more patients resected and alive after 1 year and two fewer deaths overall. Variation in regional resection rate is not explained by CVD comorbidities. Increasing resection in patients with CVD comorbidity to the levels of the highest resecting region would increase 1-year survival.},
  citation-subset = {IM},
  country         = {England},
  file            = {:Welch2020.pdf:PDF},
  issn-linking    = {0007-0920},
  journal         = {British Journal of Cancer},
  month           = aug,
  nlm-id          = {0370635},
  owner           = {NLM},
  pii             = {10.1038/s41416-020-0869-8},
  pmc             = {PMC7403296},
  pmid            = {32390010},
  pubmodel        = {Print-Electronic},
  revised         = {2020-08-14},
  year            = {2020},
}

@Article{Landtblom2020,
  author    = {Anna Ravn Landtblom and Therese M-L Andersson and Paul W Dickman and Karin E Smedby and Sandra Eloranta and Nurgul Batyrbekova and Jan Samuelsson and Magnus BjÃ¶rkholm and Malin Hultcrantz},
  title     = {Risk of infections in patients with myeloproliferative neoplasms{\textemdash}a population-based cohort study of 8363 patients},
  doi       = {10.1038/s41375-020-0909-7},
  file      = {:/Users/yitche/survbib/pdf/Landtblom2020.pdf:PDF},
  journal   = {Leukemia},
  month     = {jun},
  publisher = {Springer Science and Business Media {LLC}},
  year      = {2020},
}

@Article{Smith2020,
  author          = {Smith, Aiden J. and Lambert, Paul C. and Rutherford, Mark J.},
  title           = {Understanding the impact of sex and stage differences on melanoma cancer patient survival: a {SEER}-based study.},
  doi             = {10.1038/s41416-020-01144-5},
  issn            = {1532-1827},
  pages           = {671-677},
  pubstate        = {aheadofprint},
  volume          = {1124},
  abstract        = {This paper investigates the difference in survival of melanoma patients across stage and sex by utilising net survival measures. Metrics are presented at both the individual and population level. Flexible parametric models were fitted to estimate life-expectancy metrics to be applied to a group of 104,938 subjects with a melanoma skin cancer diagnosis from 2000 to 2017. Period analysis was used for better predictions for newly diagnosed patients, and missing-stage information was imputed for 9918 patients. Female relative survival was assigned to male subjects to demonstrate the survival discrepancies experienced between sexes. At the age of 60, males diagnosed at the regional stage lose an average of 4.99 years of life compared to the general population, and females lose 4.79 years, demonstrating the sex variation in expected mortality. In 2017, males contributed 3545 more life years lost than females, and a potential 1931 life years could be preserved if sex differences in survival were eliminated. This study demonstrates the survival differences across population subgroups as a result of a melanoma cancer diagnosis. Females experience better prognosis across age and stage at diagnosis; however, further investigation is necessary to better understand the mechanisms behind this difference.},
  citation-subset = {IM},
  country         = {England},
  file            = {:Smith2020.pdf:PDF},
  issn-linking    = {0007-0920},
  journal         = {British Journal of Cancer},
  month           = nov,
  nlm-id          = {0370635},
  owner           = {NLM},
  pii             = {10.1038/s41416-020-01144-5},
  pmid            = {33144697},
  pubmodel        = {Print-Electronic},
  revised         = {2020-11-04},
  year            = {2021},
}

@Article{Lundberg2020,
  author          = {Lundberg, F. E. and Andersson, T. M.-L. and Lambe, M. and Engholm, G. and M{\o}rch, L. S. and Johannesen, T. B. and Virtanen, A. and Pettersson, D. and Olafsdottir, E. J. and Birgisson, H. and Johansson, A.L.V. and Lambert, P. C.},
  title           = {Trends in cancer survival in the {N}ordic countries 1990-2016: the {NORDCAN} survival studies.},
  doi             = {10.1080/0284186X.2020.1822544},
  issn            = {1651-226X},
  issue           = {11},
  pages           = {1266--1274},
  pubstate        = {ppublish},
  volume          = {59},
  abstract        = {Differences in cancer survival between the Nordic countries have previously been reported. The aim of this study was to examine whether these differences in outcome remain, based on updated information from five national cancer registers. The data used for the analysis was from the NORDCAN database focusing on nine common cancers diagnosed 1990-2016 in Denmark, Finland, Iceland, Norway and Sweden with maximum follow-up through 2017. Relative survival (RS) was estimated at 1 and 5â€‰years using flexible parametric RS models, and percentage point differences between the earliest and latest years available were calculated. A consistent improvement in both 1- and 5-year RS was found for most studied sites across all countries. Previously observed differences between the countries have been attenuated. The improvements were particularly pronounced in Denmark that now has cancer survival similar to the other Nordic countries. The reasons for the observed improvements in cancer survival are likely multifactorial, including earlier diagnosis, improved treatment options, implementation of national cancer plans, uniform national cancer care guidelines and standardized patient pathways. The previous survival disadvantage in Denmark is no longer present for most sites. Continuous monitoring of cancer survival is of importance to assess the impact of changes in policies and the effectiveness of health care systems.},
  citation-subset = {IM},
  country         = {England},
  file            = {:Lundberg2020:},
  issn-linking    = {0284-186X},
  journal         = {Acta Oncologica},
  keywords        = {Cancer survival; NORDCAN; Nordic cancer registries; comparison},
  nlm-id          = {8709065},
  owner           = {NLM},
  pmid            = {33073632},
  pubmodel        = {Print-Electronic},
  revised         = {2020-11-04},
  year            = {2020},
}

@Article{Stensrud2020,
  author  = {M. J. Stensrud and J.G. Young and V. Didelez and J.M. Robins and M.A. HernÃ¡n},
  title   = {Separable Effects for Causal Inference in the Presence of Competing Events},
  doi     = {10.1080/01621459.2020.1765783},
  journal = {Journal of the American Statistical Association},
  year    = {2020},
}

@Article{Capocaccia2015,
  author          = {Capocaccia, R. and Gatta, G. and Dal Maso, L.},
  title           = {Life expectancy of colon, breast, and testicular cancer patients: an analysis of US-SEER population-based data.},
  doi             = {10.1093/annonc/mdv131},
  issn            = {1569-8041},
  issue           = {6},
  pages           = {1263--1268},
  pubstate        = {ppublish},
  volume          = {26},
  abstract        = {Cancer survivorship is an increasingly important issue in cancer control. Life expectancy of patients diagnosed with breast, colon, and testicular cancers, stratified by age at diagnosis and time since diagnosis, is provided as an indicator to evaluate future mortality risks and health care needs of cancer survivors. The standard period life table methodology was applied to estimate excess mortality risk for cancer patients diagnosed in 1985-2011 from SEER registries and mortality data of the general US population. The sensitivity of life expectancy estimates on different assumptions was evaluated. Younger patients with colon cancer showed wider differences in life expectancy compared with that of the general population (11.2 years in women and 10.7 in men at age 45-49 years) than older patients (6.3 and 5.8 at age 60-64 years, respectively). Life expectancy progressively increases in patients surviving the first years, up to 4 years from diagnosis, and then starts to decrease again, approaching that of the general population. For breast cancer, the initial drop in life expectancy is less marked, and again with wider differences in younger patients, varying from 8.7 at age 40-44 years to 2.4 at ages 70-74 years. After diagnosis, life expectancy still decreases with time, but less than that in the general population, slowly approaching that of cancer-free women. Life expectancy of men diagnosed with testicular cancer at age 30 years is estimated as 45.2 years, 2 years less than cancer-free men of the same age. The difference becomes 1.3 years for patients surviving the first year, and then slowly approaches zero with increasing survival time. Life expectancy provides meaningful information on cancer patients, and can help in assessing when a cancer survivor can be considered as cured.},
  citation-subset = {IM},
  completed       = {2016-05-13},
  country         = {England},
  issn-linking    = {0923-7534},
  journal         = {Annals of oncology : official journal of the European Society for Medical Oncology},
  keywords        = {Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Breast Neoplasms, diagnosis, epidemiology, mortality; Colonic Neoplasms, mortality; Female; Humans; Life Expectancy; Male; Middle Aged; Risk Factors; SEER Program; Sex Distribution; Sex Factors; Survival Analysis; Testicular Neoplasms, mortality; Time Factors; United States, epidemiology; SEER; cancer; cure; mortality; survival},
  month           = jun,
  nlm-id          = {9007735},
  owner           = {NLM},
  pii             = {S0923-7534(19)31806-X},
  pmid            = {25735314},
  pubmodel        = {Print-Electronic},
  revised         = {2020-06-27},
  year            = {2015},
}

@Article{Chung2020,
  author          = {Chung, Chia-Hua and Hu, Tsuey-Hwa and Wang, Jung-Der and Hwang, Jing-Shiang},
  title           = {Estimation of Quality-Adjusted Life Expectancy of Patients With Oral Cancer: Integration of Lifetime Survival With Repeated Quality-of-Life Measurements.},
  journal         = {Value in health regional issues},
  year            = {2020},
  volume          = {21},
  month           = may,
  pages           = {59--65},
  issn            = {2212-1102},
  pubstate        = {ppublish},
  doi             = {10.1016/j.vhri.2019.07.005},
  abstract        = {Quality-adjusted life year is widely applied nowadays, which consider both survival and quality of life (QoL). When most diseases are becoming chronic, it is imperative to quantify the overall health impact of a disease in lifetime perspective. The purpose of this study is to introduce methods for estimating quality-adjusted life expectancy (QALE) and loss of QALE in patients with a disease or specific conditions. The QALE of an index cohort can be represented as the integration of the product of lifetime survival function and mean QoL function. We introduce a robust extrapolation approach for estimating lifetime survival function and propose an approach for estimating lifetime mean QoL function for studies with limited follow-up. The best part of the proposed method is that the survival data and QoL data can be collected separately. A cohort of patients with a specific condition can be identified by databases that regularly collect data for the control of diseases, and their survival status is verified by linking to a mortality registry. Although nationwide QoL data are not available, researchers can implement a relative short-term follow-up interview on a random sample of patients to collect QoL data. For demonstration, we applied the proposed methods to estimate QALE and loss of QALE of oral cancer patients. The estimates (95% confidence interval) of QALE for oral cancer patients were 11.0 (10.5-11.6) and 14.2 (12.7-15.5) quality-adjusted life years (QALYs) for men and women, respectively. The estimates of loss of QALE for the male and female patients with oral cancer were 14.4 (13.8-14.9) and 7.5 (6.2-9.0) QALYs, respectively. The methods for estimating QALE and loss of QALE can be applied to economic evaluation of cancer control, including screening.},
  citation-subset = {IM},
  country         = {United States},
  issn-linking    = {2212-1099},
  keywords        = {cost-effectiveness analysis; quality of life; quality-adjusted life year; survival extrapolation},
  nlm-id          = {101592642},
  owner           = {NLM},
  pii             = {S2212-1099(19)30091-3},
  pmid            = {31655464},
  pubmodel        = {Print-Electronic},
  revised         = {2020-06-08},
  timestamp       = {2021-01-06},
}

@Article{Dzau2019,
  author          = {Dzau, Victor J. and Inouye, Sharon K. and Rowe, John W. and Finkelman, Elizabeth and Yamada, Tadataka},
  title           = {Enabling Healthful Aging for All - The National Academy of Medicine Grand Challenge in Healthy Longevity.},
  journal         = {The New England journal of medicine},
  year            = {2019},
  volume          = {381},
  issue           = {18},
  month           = oct,
  pages           = {1699--1701},
  issn            = {1533-4406},
  pubstate        = {ppublish},
  doi             = {10.1056/NEJMp1912298},
  citation-subset = {AIM, IM},
  completed       = {2019-11-13},
  country         = {United States},
  issn-linking    = {0028-4793},
  keywords        = {Aged; Aged, 80 and over; Aging; Awards and Prizes; Health Services Research; Humans; Longevity; Population Dynamics, trends; Quality of Life},
  nlm-id          = {0255562},
  owner           = {NLM},
  pmid            = {31633895},
  pubmodel        = {Print-Electronic},
  revised         = {2019-11-13},
}

@Article{Marchetti2017,
  author          = {Marchetti, Monia},
  title           = {Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review.},
  doi             = {10.1080/14737167.2017.1366858},
  issn            = {1744-8379},
  issue           = {5},
  pages           = {469--480},
  pubstate        = {ppublish},
  volume          = {17},
  abstract        = {Several genetic disruptions lead to constitutive activation of those kinases leukemic cells depend on for survival and proliferation. Kinase inhibitors (KI) are major therapeutic innovations for chronic myeloid leukemia (CML), chronic lymphoid leukemia (CLL) and myelofibrosis (MF) providing a relevant improvement of quality-adjusted survival in patients with high-risk or refractory disease. CML patients are being treated with first-generation KI imatinib since many years, achieving expected survivals longer than 10Â years. Second- and third generations KIs, such as nilotinib, dasatinib, ponatinib and bosutinib, recently expanded the therapeutic yield for CML and treatment discontinuation in patients with persistent deep molecular response is being pursued. Areas covered: This review summarizes available evidence on economic analyses of KI treatments for CML, CLL and MF aimed at identifying the key determinants of KI cost-effectiveness. Expert commentary: On converse, specific KIs for CLL and MF patients have been marketed only in the last few years. Ibrutinib and idelalisib allowed to improve the outcomes of relapsed/refractory CLL and of patients with poor genetic features, while the first-in-class JAK2 inhibitor ruxolitinib allowed to improve symptoms of advanced MF patients and to prolong survival in responders. In the current situation of healthcare budget restrictions worldwide, the value for cost of the above KIs has been questioned.},
  chemicals       = {Antineoplastic Agents, Protein Kinase Inhibitors},
  citation-subset = {IM},
  completed       = {2017-10-10},
  country         = {England},
  issn-linking    = {1473-7167},
  journal         = {Expert review of pharmacoeconomics \& outcomes research},
  keywords        = {Antineoplastic Agents, economics, therapeutic use; Cost-Benefit Analysis; Hematologic Neoplasms, drug therapy, genetics, pathology; Humans; Leukemia, Lymphocytic, Chronic, B-Cell, economics; Leukemia, Myelogenous, BCR-ABL Positive, economics; Primary Myelofibrosis, economics; Protein Kinase Inhibitors, therapeutic use; Recurrence; Survival Rate; Treatment Outcome; Cost-effectiveness; chronic lymphoid leukemia; chronic myeloid leukemia; dasatinib; ibrutinib; idelalisib; imatinib; myelofibrosis; nilotinib; ruxolitinib},
  month           = oct,
  nlm-id          = {101132257},
  owner           = {NLM},
  pmid            = {28796569},
  pubmodel        = {Print-Electronic},
  revised         = {2017-10-10},
  year            = {2017},
}

@Article{Mathes2013,
  author          = {Mathes, Tim and Jacobs, Esther and Morfeld, Jana-Carina and Pieper, Dawid},
  title           = {Methods of international health technology assessment agencies for economic evaluations--a comparative analysis.},
  doi             = {10.1186/1472-6963-13-371},
  issn            = {1472-6963},
  pages           = {371},
  pubstate        = {epublish},
  volume          = {13},
  abstract        = {The number of Health Technology Assessment (HTA) agencies increases. One component of HTAs are economic aspects. To incorporate economic aspects commonly economic evaluations are performed. A convergence of recommendations for methods of health economic evaluations between international HTA agencies would facilitate the adaption of results to different settings and avoid unnecessary expense. A first step in this direction is a detailed analysis of existing similarities and differences in recommendations to identify potential for harmonization. The objective is to provide an overview and comparison of the methodological recommendations of international HTA agencies for economic evaluations. The webpages of 127 international HTA agencies were searched for guidelines containing recommendations on methods for the preparation of economic evaluations. Additionally, the HTA agencies were requested information on methods for economic evaluations. Recommendations of the included guidelines were extracted in standardized tables according to 13 methodological aspects. All process steps were performed independently by two reviewers. Finally 25 publications of 14 HTA agencies were included in the analysis. Methods for economic evaluations vary widely. The greatest accordance could be found for the type of analysis and comparator. Cost-utility-analyses or cost-effectiveness-analyses are recommended. The comparator should continuously be usual care. Again the greatest differences were shown in the recommendations on the measurement/sources of effects, discounting and in the analysis of sensitivity. The main difference regarding effects is the focus either on efficacy or effectiveness. Recommended discounting rates range from 1.5%-5% for effects and 3%-5% for costs whereby it is mostly recommended to use the same rate for costs and effects. With respect to the analysis of sensitivity the main difference is that oftentimes the probabilistic or deterministic approach is recommended exclusively. Methods for modeling are only described vaguely and mainly with the rational that the "appropriate model" depends on the decision problem. Considering all other aspects a comparison is challenging as recommendations vary regarding detailedness and addressed issues. There is a considerable unexplainable variance in recommendations. Further effort is needed to harmonize methods for preparing economic evaluations.},
  citation-subset = {IM},
  completed       = {2014-07-28},
  country         = {England},
  issn-linking    = {1472-6963},
  journal         = {BMC health services research},
  keywords        = {Cost-Benefit Analysis, economics, methods; Government Agencies, organization & administration; Humans; Outcome Assessment, Health Care, methods; Technology Assessment, Biomedical, methods},
  month           = sep,
  nlm-id          = {101088677},
  owner           = {NLM},
  pii             = {1472-6963-13-371},
  pmc             = {PMC3849629},
  pmid            = {24079858},
  pubmodel        = {Electronic},
  revised         = {2019-12-10},
  year            = {2013},
}

@TechReport{SCB1654-1510,
  author      = {{Statistics Sweden (Statistiska Centralbyr{\aa}n)}},
  institution = {{Statistics Sweden (Statistiska Centralbyr{\aa}n)}},
  title       = {Forecast of deaths and life expectancy for 2020},
  url         = {https://www.scb.se/contentassets/93920ea973404af7804723ba589c2a53/be0701_2020a01_br_be51br2005eng.pdf},
  owner       = {sanelo},
  timestamp   = {2013.10.08},
  year        = {2020},
}

@Article{Martinussen2020,
  author          = {Martinussen, Torben and Vansteelandt, Stijn and Andersen, Per Kragh},
  title           = {Subtleties in the interpretation of hazard contrasts.},
  doi             = {10.1007/s10985-020-09501-5},
  issn            = {1572-9249},
  issue           = {4},
  pages           = {833--855},
  pubstate        = {ppublish},
  volume          = {26},
  abstract        = {The hazard ratio is one of the most commonly reported measures of treatment effect in randomised trials, yet the source of much misinterpretation. This point was made clear by HernÃ¡n (Epidemiology (Cambridge, Mass) 21(1):13-15, 2010) in a commentary, which emphasised that the hazard ratio contrasts populations of treated and untreated individuals who survived a given period of time, populations that will typically fail to be comparable-even in a randomised trial-as a result of different pressures or intensities acting on different populations. The commentary has been very influential, but also a source of surprise and confusion. In this note, we aim to provide more insight into the subtle interpretation of hazard ratios and differences, by investigating in particular what can be learned about a treatment effect from the hazard ratio becoming 1 (or the hazard difference 0) after a certain period of time. We further define a hazard ratio that has a causal interpretation and study its relationship to the Cox hazard ratio, and we also define a causal hazard difference. These quantities are of theoretical interest only, however, since they rely on assumptions that cannot be empirically evaluated. Throughout, we will focus on the analysis of randomised experiments.},
  citation-subset = {IM},
  country         = {United States},
  issn-linking    = {1380-7870},
  journal         = {Lifetime data analysis},
  keywords        = {Causality; Cox regression; Hazard difference; Hazard ratio; Randomised study; Survival analysis},
  month           = oct,
  nlm-id          = {9516348},
  owner           = {NLM},
  pii             = {10.1007/s10985-020-09501-5},
  pmid            = {32654089},
  pubmodel        = {Print-Electronic},
  revised         = {2020-11-13},
  year            = {2020},
}

@Article{Mozumder2021,
  author  = {S. I. Mozumder and M. J. Rutherford and P. C. Lambert},
  title   = {Estimating restricted mean survival time and expected life-years lost in the presence of competing risks within flexible parametric survival models},
  doi     = {10.1186/s12874-021-01213-0},
  pages   = {52},
  volume  = {21},
  file    = {:Mozumder2021.pdf:PDF},
  journal = {BMC Medical Research Methodology},
  pmid    = {33706711},
  year    = {2021},
}

@Article{Young2020,
  author          = {Young, Jessica G. and Stensrud, Mats J. and Tchetgen Tchetgen, Eric J. and HernÃ¡n, Miguel A.},
  title           = {A causal framework for classical statistical estimands in failure-time settings with competing events.},
  doi             = {10.1002/sim.8471},
  issn            = {1097-0258},
  issue           = {8},
  pages           = {1199--1236},
  pubstate        = {ppublish},
  volume          = {39},
  abstract        = {In failure-time settings, a competing event is any event that makes it impossible for the event of interest to occur. For example, cardiovascular disease death is a competing event for prostate cancer death because an individual cannot die of prostate cancer once he has died of cardiovascular disease. Various statistical estimands have been defined as possible targets of inference in the classical competing risks literature. Many reviews have described these statistical estimands and their estimating procedures with recommendations about their use. However, this previous work has not used a formal framework for characterizing causal effects and their identifying conditions, which makes it difficult to interpret effect estimates and assess recommendations regarding analytic choices. Here we use a counterfactual framework to explicitly define each of these classical estimands. We clarify that, depending on whether competing events are defined as censoring events, contrasts of risks can define a total effect of the treatment on the event of interest or a direct effect of the treatment on the event of interest not mediated by the competing event. In contrast, regardless of whether competing events are defined as censoring events, counterfactual hazard contrasts cannot generally be interpreted as causal effects. We illustrate how identifying assumptions for all of these counterfactual estimands can be represented in causal diagrams, in which competing events are depicted as time-varying covariates. We present an application of these ideas to data from a randomized trial designed to estimate the effect of estrogen therapy on prostate cancer mortality.},
  citation-subset = {IM},
  country         = {England},
  issn-linking    = {0277-6715},
  journal         = {Statistics in medicine},
  keywords        = {causal inference; competing risks; g-formula; inverse probability weighting; longitudinal data; survival analysis},
  mid             = {NIHMS1659396},
  month           = apr,
  nlm-id          = {8215016},
  owner           = {NLM},
  pmc             = {PMC7811594},
  pmid            = {31985089},
  pubmodel        = {Print-Electronic},
  revised         = {2021-01-19},
  year            = {2020},
}

@Article{Syriopoulou2021,
  author          = {Syriopoulou, E. and Rutherford, M. J. and Lambert, P. C.},
  title           = {Understanding disparities in cancer prognosis: An extension of mediation analysis to the relative survival framework.},
  doi             = {10.1002/bimj.201900355},
  issn            = {1521-4036},
  issue           = {2},
  pages           = {341--353},
  pubstate        = {ppublish},
  volume          = {63},
  abstract        = {Mediation analysis can be applied to investigate the effect of a third variable on the pathway between an exposure and the outcome. Such applications include investigating the determinants that drive differences in cancer survival across subgroups. However, cancer disparities may be the result of complex mechanisms that involve both cancer-related and other-cause mortality differences making it difficult to identify the causing factors. Relative survival, a commonly used measure in cancer epidemiology, can be used to focus on cancer-related differences. We extended mediation analysis to the relative survival framework for exploring cancer inequalities. The marginal effects were obtained using regression standardization, after fitting a relative survival model. Contrasts of interests included both marginal relative survival and marginal all-cause survival differences between exposure groups. Such contrasts include the indirect effect due to a mediator that is identifiable under certain assumptions. A separate model was fitted for the mediator and uncertainty was estimated using parametric bootstrapping. The avoidable deaths under interventions can also be estimated to quantify the impact of eliminating differences. The methods are illustrated using data for individuals diagnosed with colon cancer. Mediation analysis within relative survival allows focus on factors that account for cancer-related differences instead of all-cause differences and helps improve our understanding on cancer inequalities.},
  citation-subset = {IM},
  country         = {Germany},
  file            = {:Syriopoulou2020a.pdf:PDF},
  issn-linking    = {0323-3847},
  journal         = {Biometrical journal},
  keywords        = {cancer inequalities; mediation analysis; natural indirect effect; regression standardization; relative survival},
  nlm-id          = {7708048},
  owner           = {NLM},
  pmid            = {33314292},
  pubmodel        = {Print-Electronic},
  revised         = {2021-02-11},
  year            = {2021},
}

@Article{Rutherford2020a,
  author = {M.J. Rutherford and P.C. Lambert and M.J. Sweeting and B. Pennington and M.J. Crowther and K.R. Abrams and N.R. Latimer},
  title  = {NICE DSU TECHNICAL SUPPORT DOCUMENT 21:Flexible Methods for Survival Analysis},
  year   = {2020},
}


@Article{Zhu2012,
  author       = {Zhu, Ruoqing and Kosorok, Michael R.},
  title        = {Recursively Imputed Survival Trees.},
  doi          = {10.1080/01621459.2011.637468},
  issn         = {0162-1459},
  issue        = {497},
  pages        = {331--340},
  pubstate     = {ppublish},
  volume       = {107},
  abstract     = {We propose recursively imputed survival tree (RIST) regression for right-censored data. This new nonparametric regression procedure uses a novel recursive imputation approach combined with extremely randomized trees that allows significantly better use of censored data than previous tree based methods, yielding improved model fit and reduced prediction error. The proposed method can also be viewed as a type of Monte Carlo EM algorithm which generates extra diversity in the tree-based fitting process. Simulation studies and data analyses demonstrate the superior performance of RIST compared to previous methods.},
  country      = {United States},
  file         = {:/Users/yitche/survbib/pdf/Zhu2012.pdf:PDF},
  issn-linking = {0162-1459},
  journal      = {Journal of the American Statistical Association},
  mid          = {NIHMS334618},
  nlm-id       = {01510020R},
  owner        = {NLM},
  pmc          = {PMC3486435},
  pmid         = {23125470},
  pubmodel     = {Print-Electronic},
  revised      = {2019-11-20},
  year         = {2012},
}

@Article{Weibull2021,
  author          = {Weibull, C. E. and Lambert, P. C. and Eloranta, S. and Andersson, T. M-L. and Dickman, P. W. and Crowther, M. J.},
  title           = {A multistate model incorporating estimation of excess hazards and multiple time scales.},
  doi             = {10.1002/sim.8894},
  issn            = {1097-0258},
  pages           = {2139--2154},
  pubstate        = {aheadofprint},
  volume          = {40},
  abstract        = {As cancer patient survival improves, late effects from treatment are becoming the next clinical challenge. Chemotherapy and radiotherapy, for example, potentially increase the risk of both morbidity and mortality from second malignancies and cardiovascular disease. To provide clinically relevant population-level measures of late effects, it is of importance to (1) simultaneously estimate the risks of both morbidity and mortality, (2) partition these risks into the component expected in the absence of cancer and the component due to the cancer and its treatment, and (3) incorporate the multiple time scales of attained age, calendar time, and time since diagnosis. Multistate models provide a framework for simultaneously studying morbidity and mortality, but do not solve the problem of partitioning the risks. However, this partitioning can be achieved by applying a relative survival framework, allowing us to directly quantify the excess risk. This article proposes a combination of these two frameworks, providing one approach to address (1) to (3). Using recently developed methods in multistate modeling, we incorporate estimation of excess hazards into a multistate model. Both intermediate and absorbing state risks can be partitioned and different transitions are allowed to have different and/or multiple time scales. We illustrate our approach using data on Hodgkin lymphoma patients and excess risk of diseases of the circulatory system, and provide user-friendly Stata software with accompanying example code.},
  citation-subset = {IM},
  country         = {England},
  file            = {:Weibull2021.pdf:PDF},
  issn-linking    = {0277-6715},
  journal         = {Statistics in Medicine},
  keywords        = {competing risks; excess rate; multiple timescales; multistate models; relative survival; survival analysis},
  month           = {2},
  nlm-id          = {8215016},
  owner           = {NLM},
  pmid            = {33556998},
  pubmodel        = {Print-Electronic},
  revised         = {2021-02-08},
  year            = {2021},
}

@Article{Andersson2021,
  author          = {Andersson, T. M.-L. and Rutherford, M. J. and Myklebust, T. {\AA} and M{\o}ller, B. and Soerjomataram, I. and Arnold, M. and Bray, F. and Parkin, D. M. and Sasieni, P. and Bucher, O. and De, P. and Engholm, G. and Gavin, A. and Little, A. and Porter, G. and Ramanakumar, A. V. and Saint-Jacques, N. and Walsh, P. M. and Woods, R. R. and Lambert, P. C.},
  title           = {Exploring the impact of cancer registry completeness on international cancer survival differences: a simulation study.},
  doi             = {10.1038/s41416-020-01196-7},
  issn            = {1532-1827},
  issue           = {5},
  pages           = {1026--1032},
  pubstate        = {ppublish},
  volume          = {124},
  abstract        = {Data from population-based cancer registries are often used to compare cancer survival between countries or regions. The ICBP SURVMARK-2 study is an international partnership aiming to quantify and explore the reasons behind survival differences across high-income countries. However, the magnitude and relevance of differences in cancer survival between countries have been questioned, as it is argued that observed survival variations may be explained, at least in part, by differences in cancer registration practice, completeness and the availability and quality of the respective data sources. As part of the ICBP SURVMARK-2 study, we used a simulation approach to better understand how differences in completeness, the characteristics of those missed and inclusion of cases found from death certificates can impact on cancer survival estimates. Bias in 1- and 5-year net survival estimates for 216 simulated scenarios is presented. Out of the investigated factors, the proportion of cases not registered through sources other than death certificates, had the largest impact on survival estimates. Our results show that the differences in registration practice between participating countries could in our most extreme scenarios explain only a part of the largest observed differences in cancer survival.},
  citation-subset = {IM},
  country         = {England},
  issn-linking    = {0007-0920},
  journal         = {British Journal of Cancer},
  nlm-id          = {0370635},
  owner           = {NLM},
  pii             = {10.1038/s41416-020-01196-7},
  pmid            = {33293692},
  pubmodel        = {Print-Electronic},
  revised         = {2021-03-02},
  year            = {2021},
}

@Article{Hill2021,
  author          = {Hill, M. and Lambert, P. C. and Crowther, M. J.},
  title           = {Relaxing the assumption of constant transition rates in a multi-state model in hospital epidemiology.},
  doi             = {10.1186/s12874-020-01192-8},
  issn            = {1471-2288},
  issue           = {1},
  pages           = {16},
  pubstate        = {epublish},
  volume          = {21},
  abstract        = {Multi-state models are being increasingly used to capture complex disease pathways. The convenient formula of the exponential multi-state model can facilitate a quick and accessible understanding of the data. However, assuming time constant transition rates is not always plausible. On the other hand, obtaining predictions from a fitted model with time-dependent transitions can be challenging. One proposed solution is to utilise a general simulation algorithm to calculate predictions from a fitted multi-state model. Predictions obtained from an exponential multi-state model were compared to those obtained from two different parametric models and to non-parametric Aalen-Johansen estimates. The first comparative approach fitted a multi-state model with transition-specific distributions, chosen separately based on the Akaike Information Criterion. The second approach was a Royston-Parmar multi-state model with 4 degrees of freedom, which was chosen as a reference model flexible enough to capture complex hazard shapes. All quantities were obtained analytically for the exponential and Aalen-Johansen approaches. The transition rates for the two comparative approaches were also obtained analytically, while all other quantities were obtained from the fitted models via a general simulation algorithm. Metrics investigated were: transition probabilities, attributable mortality (AM), population attributable fraction (PAF) and expected length of stay. This work was performed on previously analysed hospital acquired infection (HAI) data. By definition, a HAI takes three days to develop and therefore selected metrics were also predicted from time 3 (delayed entry). Despite clear deviations from the constant transition rates assumption, the empirical estimates of the transition probabilities were approximated reasonably well by the exponential model. However, functions of the transition probabilities, e.g. AM and PAF, were not well approximated and the comparative models offered considerable improvements for these metrics. They also provided consistent predictions with the empirical estimates in the case of delayed entry time, unlike the exponential model. We conclude that methods and software are readily available for obtaining predictions from multi-state models that do not assume constant transition rates. The multistate package in Stata facilitates a range of predictions with confidence intervals, which can provide a more comprehensive understanding of the data. User-friendly code is provided.},
  citation-subset = {IM},
  country         = {England},
  issn-linking    = {1471-2288},
  journal         = {BMC Medical Research Methodology},
  keywords        = {Competing risks; Expected length of stay; Markov processes; Multi-state models; Software; Survival analysis; Transition probabilities},
  month           = jan,
  nlm-id          = {100968545},
  owner           = {NLM},
  pii             = {10.1186/s12874-020-01192-8},
  pmc             = {PMC7798316},
  pmid            = {33430778},
  pubmodel        = {Electronic},
  revised         = {2021-01-15},
  year            = {2021},
}

@Article{Andersson2021a,
  author          = {Andersson, Therese M.-L. and Myklebust, Tor {\AA}ge and Rutherford, Mark J. and MÃ¸ller, BjÃ¸rn and Soerjomataram, Isabelle and Arnold, Melina and Bray, Freddie and Parkin, D. Max and Sasieni, Peter and Bucher, Oliver and De, Prithwish and Engholm, Gerda and Gavin, Anna and Little, Alana and Porter, Geoff and Ramanakumar, Agnihotram V. and Saint-Jacques, Nathalie and Walsh, Paul M. and Woods, Ryan R. and Lambert, Paul C.},
  title           = {The impact of excluding or including {D}eath {C}ertificate {I}nitiated ({DCI}) cases on estimated cancer survival: {A} simulation study.},
  doi             = {10.1016/j.canep.2020.101881},
  issn            = {1877-783X},
  issue           = {Pt A},
  pages           = {101881},
  pubstate        = {aheadofprint},
  volume          = {71},
  abstract        = {Population-based cancer registries strive to cover all cancer cases diagnosed within the population, but some cases will always be missed and no register is 100 % complete. Many cancer registries use death certificates to identify additional cases not captured through other routine sources, to hopefully add a large proportion of the missed cases. Cases notified through this route, who would not have been captured without death certificate information, are referred to as Death Certificate Initiated (DCI) cases. Inclusion of DCI cases in cancer registries increases completeness and is important for estimating cancer incidence. However, inclusion of DCI cases will generally lead to biased estimates of cancer survival, but the same is often also true if excluding DCI cases. Missed cases are probably not a random sample of all cancer cases, but rather cases with poor prognosis. Further, DCI cases have poorer prognosis than missed cases in general, since they have all died with cancer mentioned on the death certificates. We performed a simulation study to estimate the impact of including or excluding DCI cases on cancer survival estimates, under different scenarios. We demonstrated that including DCI cases underestimates survival. The exclusion of DCI cases gives unbiased survival estimates if missed cases are a random sample of all cancer cases, while survival is overestimated if these have poorer prognosis. In our most extreme scenarios, with 25 % of cases initially missed, the usual practice of including DCI cases underestimated 5-year survival by at most 3 percentage points.},
  citation-subset = {IM},
  country         = {Netherlands},
  issn-linking    = {1877-7821},
  journal         = {Cancer Epidemiology},
  keywords        = {Cancer registry; Death certificate initiated cases; Simulation study; Survival},
  month           = jan,
  nlm-id          = {101508793},
  owner           = {NLM},
  pii             = {S1877-7821(20)30215-0},
  pmid            = {33440295},
  pubmodel        = {Print-Electronic},
  revised         = {2021-02-23},
  year            = {2021},
}

@Article{Shinozaki2015,
  author          = {Shinozaki, T. and Matsuyama, Y.},
  title           = {Brief Report: Doubly Robust Estimation of Standardized Risk Difference and Ratio in the Exposed Population.},
  doi             = {10.1097/EDE.0000000000000363},
  issn            = {1531-5487},
  issue           = {6},
  pages           = {873--877},
  volume          = {26},
  abstract        = {Standardization-a method used to adjust for confounding-estimates counterfactual risks in a target population. To adjust for confounding variables that contain too many combinations to be fully stratified, two model-based standardization methods exist: regression standardization and use of an inverse probability of exposure weighted-reweighted estimators. Whereas the former requires an outcome regression model conditional on exposure and confounders, the latter requires a propensity score model. In reconciling among their modeling assumptions, doubly robust estimators, which only require correct specification of either the outcome regression or the propensity score model but do not necessitate both, have been well studied for total populations. Here, we provide doubly robust estimators of standardized risk difference and ratio in the exposed population. Theoretical details, simple model extension for independently censored outcomes, and a SAS program are provided in the eAppendix (http://links.lww.com/EDE/A955).},
  chemicals       = {Antineoplastic Agents, Hormonal, Tamoxifen},
  citation-subset = {IM},
  completed       = {2016-07-11},
  country         = {United States},
  file            = {:Shinozaki2015.pdf:PDF},
  groups          = {[Paul:]},
  issn-linking    = {1044-3983},
  journal         = {Epidemiology},
  keywords        = {Antineoplastic Agents, Hormonal, therapeutic use; Breast Neoplasms, drug therapy; Chemotherapy, Adjuvant; Confounding Factors, Epidemiologic; Epidemiologic Methods; Female; Humans; Kaplan-Meier Estimate; Models, Statistical; Neoplasm Recurrence, Local, epidemiology; Odds Ratio; Propensity Score; Proportional Hazards Models; Reference Standards; Regression Analysis; Tamoxifen, therapeutic use},
  nlm-id          = {9009644},
  owner           = {NLM},
  pmid            = {26275176},
  pubmodel        = {Print},
  pubstatus       = {ppublish},
  revised         = {2019-12-10},
  year            = {2015},
}

@Article{Pilleron2021,
  author          = {Pilleron, S. and Charvat, H. and Araghi, M. and Arnold, M. and Fidler-Benaoudia, M.M. and Bardot, A. and Gr{\o}nlie G.M. and Tervonen, H. and Little, A. and O'Connell, D.L. and Gavin, A. and De, P. and Aagard Thomsen, L. and M{\o}ller, B. and Jackson, C. and Bucher, O. and Walsh, P.M. and Vernon, S. and Bray, F. and Soerjomataram, I.},
  title           = {Age disparities in stage-specific colon cancer survival across seven countries: An International Cancer Benchmarking Partnership {SURVMARK-2} population-based study.},
  doi             = {10.1002/ijc.33326},
  issn            = {1097-0215},
  issue           = {7},
  pages           = {1575--1585},
  volume          = {148},
  abstract        = {We sought to understand the role of stage at diagnosis in observed age disparities in colon cancer survival among people aged 50 to 99â€‰years using population-based cancer registry data from seven high-income countries: Australia, Canada, Denmark, Ireland, New Zealand, Norway and the United Kingdom. We used colon cancer incidence data for the period 2010 to 2014. We estimated the 3-year net survival, as well as the 3-year net survival conditional on surviving at least 6â€‰months and 1â€‰year after diagnosis, by country and stage at diagnosis (categorised as localised, regional or distant) using flexible parametric excess hazard regression models. In all countries, increasing age was associated with lower net survival. For example, 3-year net survival (95% confidence interval) was 81% (80-82) for 50 to 64â€‰year olds and 58% (56-60) for 85 to 99â€‰year olds in Australia, and 74% (73-74) and 39% (39-40) in the United Kingdom, respectively. Those with distant stage colon cancer had the largest difference in colon cancer survival between the youngest and the oldest patients. Excess mortality for the oldest patients with localised or regional cancers was observed during the first 6â€‰months after diagnosis. Older patients diagnosed with localised (and in some countries regional) stage colon cancer who survived 6â€‰months after diagnosis experienced the same survival as their younger counterparts. Further studies examining other prognostic clinical factors such as comorbidities and treatment, and socioeconomic factors are warranted to gain further understanding of the age disparities in colon cancer survival.},
  citation-subset = {IM},
  country         = {United States},
  groups          = {Paul:6},
  issn-linking    = {0020-7136},
  journal         = {International Journal of Cancer},
  keywords        = {cancer survival; epidemiology; older adults; population-based cancer registry},
  nlm-id          = {0042124},
  owner           = {NLM},
  pmid            = {33006395},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2021-02-15},
  year            = {2021},
}

@Article{Gray2020,
  author    = {Jodi Gray and Thomas Sullivan and Nicholas R. Latimer and Amy Salter and Michael J. Sorich and Robyn L. Ward and Jonathan Karnon},
  title     = {Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer},
  doi       = {10.1177/0272989x20978958},
  number    = {2},
  pages     = {179--193},
  volume    = {41},
  journal   = {Medical Decision Making},
  month     = {dec},
  publisher = {{SAGE} Publications},
  year      = {2020},
}

@PhdThesis{Zhu2013,
  author    = {{Zhu, Ruoqing}},
  title     = {Tree-based methods for survival analysis and high-dimensional data},
  doi       = {10.17615/TSM8-CJ31},
  language  = {en},
  copyright = {In Copyright},
  publisher = {University of North Carolina at Chapel Hill},
  year      = {2013},
}

@Article{Breiman1996,
  author    = {Leo Breiman},
  doi       = {10.1023/a:1018054314350},
  number    = {2},
  pages     = {123--140},
  volume    = {24},
  journal   = {Machine Learning},
  publisher = {Springer Science and Business Media {LLC}},
  year      = {1996},
}

@Article{Kosorok2019,
  author       = {Michael R. Kosorok, Nikki L. B. Freeman and Owen E. Leete},
  journal      = {University of North Carolina at Chapel Hill},
  title        = {Precision Medicine: Lecture 03 Machine Learning},
}

@Article{Geurts2006,
  author    = {Pierre Geurts and Damien Ernst and Louis Wehenkel},
  title     = {Extremely randomized trees},
  doi       = {10.1007/s10994-006-6226-1},
  number    = {1},
  pages     = {3--42},
  volume    = {63},
  journal   = {Machine Learning},
  month     = {mar},
  publisher = {Springer Science and Business Media {LLC}},
  year      = {2006},
}

@Article{Hochhaus2020,
  author          = {Hochhaus, A. and Baccarani, M. and Silver, R. T. and Schiffer, C. and Apperley, J. F. and Cervantes, F. and Clark, R. E. and Cortes, J. E. and Deininger, M. W. and Guilhot, F. and Hjorth-Hansen, H. and Hughes, T. P. and Janssen, J. J. W. M. and Kantarjian, H. M. and Kim, D. W. and Larson, R. A. and Lipton, J. H. and Mahon, F. X. and Mayer, J. and Nicolini, F. and Niederwieser, D. and Pane, F. and Radich, J. P. and Rea, D. and Richter, J. and Rosti, G. and Rousselot, P. and Saglio, G. and SauÃŸele, S. and Soverini, S. and Steegmann, J. L. and Turkina, A. and Zaritskey, A. and Hehlmann, R.},
  title           = {European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.},
  doi             = {10.1038/s41375-020-0776-2},
  issn            = {1476-5551},
  issue           = {4},
  pages           = {966--984},
  pubstate        = {ppublish},
  volume          = {34},
  abstract        = {The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal is achieving a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR). The European LeukemiaNet convened an expert panel to critically evaluate and update the evidence to achieve these goals since its previous recommendations. First-line treatment is a tyrosine kinase inhibitor (TKI; imatinib brand or generic, dasatinib, nilotinib, and bosutinib are available first-line). Generic imatinib is the cost-effective initial treatment in CP. Various contraindications and side-effects of all TKIs should be considered. Patient risk status at diagnosis should be assessed with the new EUTOS long-term survival (ELTS)-score. Monitoring of response should be done by quantitative polymerase chain reaction whenever possible. A change of treatment is recommended when intolerance cannot be ameliorated or when molecular milestones are not reached. Greater than 10% BCR-ABL1 at 3 months indicates treatment failure when confirmed. Allogeneic transplantation continues to be a therapeutic option particularly for advanced phase CML. TKI treatment should be withheld during pregnancy. Treatment discontinuation may be considered in patients with durable DMR with the goal of achieving TFR.},
  chemicals       = {4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide, Aniline Compounds, Antineoplastic Agents, BCR-ABL1 fusion protein, human, Nitriles, Protein Kinase Inhibitors, Pyrimidines, Quinolines, bosutinib, Imatinib Mesylate, Fusion Proteins, bcr-abl, Dasatinib},
  citation-subset = {IM},
  completed       = {2020-08-25},
  country         = {England},
  file            = {:/Users/yitche/survbib/pdf/Hochhaus2020.pdf:PDF;:Hochhaus2020.pdf:PDF},
  groups          = {ec_phd, CML},
  issn-linking    = {0887-6924},
  journal         = {Leukemia},
  keywords        = {Aniline Compounds, therapeutic use; Antineoplastic Agents, therapeutic use; Clinical Decision-Making; Consensus Development Conferences as Topic; Dasatinib, therapeutic use; Disease Management; Fusion Proteins, bcr-abl, antagonists & inhibitors, genetics, metabolism; Gene Expression; Humans; Imatinib Mesylate, therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, diagnosis, drug therapy, mortality; Life Expectancy, trends; Monitoring, Physiologic; Nitriles, therapeutic use; Protein Kinase Inhibitors, therapeutic use; Pyrimidines, therapeutic use; Quality of Life; Quinolines, therapeutic use; Survival Analysis},
  month           = apr,
  nlm-id          = {8704895},
  owner           = {NLM},
  pii             = {10.1038/s41375-020-0776-2},
  pmc             = {PMC7214240},
  pmid            = {32127639},
  pubmodel        = {Print-Electronic},
  readstatus      = {read},
  revised         = {2021-02-09},
  year            = {2020},
}

@Article{Rochau2014,
  author          = {Rochau, Ursula and Schwarzer, Ruth and Jahn, Beate and Sroczynski, Gaby and Kluibenschaedl, Martina and Wolf, Dominik and Radich, Jerald and Brixner, Diana and Gastl, Guenther and Siebert, Uwe},
  title           = {Systematic assessment of decision-analytic models for chronic myeloid leukemia.},
  doi             = {10.1007/s40258-013-0071-8},
  issn            = {1179-1896},
  issue           = {2},
  pages           = {103--115},
  pubstate        = {ppublish},
  volume          = {12},
  abstract        = {Several tyrosine kinase inhibitors (TKIs) are approved for the treatment of chronic myeloid leukemia (CML). Decision-analytic modeling can help to extrapolate data from short-term clinical trials and also consider quality of life when evaluating different treatment strategies. Our goal was to describe and analyze the structural and methodological approaches of published decision-analytic models for various treatment strategies in CML and to derive recommendations for the development of future CML models. We performed a systematic literature search in electronic databases (MEDLINE/PreMEDLINE, EconLit, EMBASE, NHS EED, and Tuft's CEA Registry) to identify published studies evaluating CML treatment strategies using mathematical models. The search was updated in August 2013. The models were required to compare different treatment strategies in relation to relevant clinical and patient-relevant health outcomes [e.g., life-years gained, quality-adjusted life-years] over a defined time horizon and population. We used standardized forms for data extraction, description of study design, methodological framework, and data sources for each model. We identified 18 different decision-analytic modeling studies. Of these, 17 included economic evaluations. Modeling approaches included decision trees, Markov cohort models, state-transition models with individual (Monte Carlo) simulations, and mathematical equations. Analytic time horizons ranged from 2 years to a lifetime. Treatment strategies compared included bone marrow or stem cell transplantation, conventional chemotherapy, interferon-Î±, and TKIs. Only one model evaluated a second-generation TKI. Most models did not report a model validation. All models conducted deterministic sensitivity analyses and four reported a probabilistic sensitivity analysis. Articles that were not published in English or German were not included in this review. Our literature search was restricted to published full-text articles in certain databases. Therefore, publications that met our inclusion criteria but were published in different databases, different languages, or as abstracts only may have been missed. While several well-designed models of CML treatment strategies exist, there remains a need for the assessment of the long-term efficacy and cost effectiveness of novel treatment options such as second-generation TKIs. Additionally, these models should be validated using independent data.},
  chemicals       = {Antineoplastic Agents, Interferon-alpha, Protein Kinase Inhibitors, Protein-Tyrosine Kinases},
  citation-subset = {IM},
  completed       = {2015-05-21},
  country         = {New Zealand},
  file            = {:/Users/yitche/survbib/pdf/Rochau2014.pdf:PDF},
  groups          = {Study 4. Cost-effectiveness, CML},
  issn-linking    = {1175-5652},
  journal         = {Applied health economics and health policy},
  keywords        = {Adult; Aged; Aged, 80 and over; Antineoplastic Agents, economics, therapeutic use; Bone Marrow Transplantation, economics; Decision Support Techniques; Female; Humans; Interferon-alpha, therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, therapy; Male; Markov Chains; Middle Aged; Models, Economic; Protein Kinase Inhibitors, therapeutic use; Protein-Tyrosine Kinases, antagonists & inhibitors; Quality of Life; Quality-Adjusted Life Years; Stem Cell Transplantation, economics; Treatment Outcome},
  month           = apr,
  nlm-id          = {101150314},
  owner           = {NLM},
  pmid            = {24385259},
  pubmodel        = {Print},
  revised         = {2014-03-21},
  year            = {2014},
}

@Article{Rogers2012,
  author          = {Rogers, G. and Hoyle, M. and Thompson Coon, J. and Moxham, T. and Liu, Z. and Pitt, M. and Stein, K.},
  title           = {Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.},
  doi             = {10.3310/hta16220},
  issn            = {2046-4924},
  issue           = {22},
  pages           = {1--410},
  pubstate        = {ppublish},
  volume          = {16},
  abstract        = {Chronic myeloid leukaemia (CML) is a form of cancer affecting the blood, characterised by excessive proliferation of white blood cells in the bone marrow and circulating blood. In the UK, an estimated 560 new cases of CML are diagnosed each year. The purpose of this study was to assess the clinical effectiveness and cost-effectiveness of dasatinib and nilotinib in the treatment of people with imatinib-resistant (ImR) and imatinib-intolerant (ImI) CML. A systematic review of the clinical effectiveness literature, a review of manufacturer submissions and a critique and exploration of manufacturer submissions for accelerated phase and blast crisis CML were carried out and a decision-analytic model was developed to estimate the cost-effectiveness of dasatinib and nilotinib in chronic phase CML. SYSTEMATIC REVIEW METHODS: Key databases were searched for relevant studies from their inception to June 2009 [MEDLINE (including MEDLINE In-Process & Other Non-Indexed Citations), EMBASE, (ISI Web of Science) Conference Proceedings Citation Index and four others]. One reviewer assessed titles and abstracts of studies identified by the search strategy, with a sample checked by a second reviewer. The full text of relevant papers was obtained and screened against the full inclusion criteria independently by two reviewers. Data from included studies were extracted by one reviewer and checked by a second. Clinical effectiveness studies were synthesised through narrative review. ECONOMIC EVALUATION METHODS: Cost-effectiveness analyses reported in manufacturer submissions to the National Institute of Health and Clinical Excellence were critically appraised and summarised narratively. In addition, the models for accelerated phase and blast crisis underwent a more detailed critique and exploration. Two separate decision-analytic models were developed for chronic phase CML, one simulating a cohort of individuals who have shown or developed resistance to normal dose imatinib and one representing individuals who have been unable to continue imatinib treatment owing to adverse events. One-way, multiway and probabilistic sensitivity analyses were performed to explore structural and parameter uncertainty. Fifteen studies were included in the systematic review. Chronic phase: effectiveness data were limited but dasatinib and nilotinib appeared efficacious in terms of obtaining cytogenetic response and haematological response in both ImR and ImI populations. In terms of cost-effectiveness, it was extremely difficult to reach any conclusions regarding either agent in the ImR population. All three models (Novartis, PenTAG and Bristol-Myers Squibb) were seriously flawed in one way or another, as a consequence of the paucity of data appropriate to construct robust decision-analytic models. Accelerated and blast crisis: all available data originated from observational single-arm studies and there were considerable and potentially important differences in baseline characteristics which seriously undermined any process for making meaningful comparisons between treatments. Owing to a lack of available clinical data, de novo models of accelerated phase and blast crisis have not been developed. The economic evaluations carried out by the manufacturers of nilotinib and dasatinib were seriously undermined by the absence of evidence on high-dose imatinib in these populations. The study has been necessarily constrained by the paucity of available clinical data, the differences in definitions used in the studies and the subsequent impossibility of undertaking a meaningful cost-effectiveness analyses to inform all policy questions. Dasatinib and nilotinib appeared efficacious in terms of obtaining cytogenetic and haematological responses in both ImR and ImI populations. It was difficult to reach any cost-effectiveness conclusions as a consequence of the paucity of the data. Future research should include a three-way, double-blind, randomised clinical trial of dasatinib, nilotinib and high-dose imatinib.},
  chemicals       = {4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide, Benzamides, Piperazines, Protein Kinase Inhibitors, Pyrimidines, Thiazoles, Imatinib Mesylate, Dasatinib},
  citation-subset = {IM},
  completed       = {2012-09-05},
  country         = {England},
  groups          = {Study 4. Cost-effectiveness, CML},
  issn-linking    = {1366-5278},
  journal         = {Health technology assessment (Winchester, England)},
  keywords        = {Benzamides; Blast Crisis, drug therapy; Clinical Trials as Topic; Cost-Benefit Analysis; Dasatinib; Decision Support Techniques; Disease Progression; Drug Resistance, Neoplasm; Health Care Costs, statistics & numerical data; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy; Leukemia, Myeloid, Accelerated Phase, Chronic-Phase, drug therapy; Models, Economic; Piperazines, pharmacology, therapeutic use; Prognosis; Protein Kinase Inhibitors, economics, therapeutic use; Pyrimidines, therapeutic use; Quality of Life; Thiazoles, therapeutic use},
  nlm-id          = {9706284},
  owner           = {NLM},
  pmc             = {PMC4781389},
  pmid            = {22551803},
  pubmodel        = {Print},
  revised         = {2018-12-01},
  year            = {2012},
}

@Article{Jabbour2020,
  author          = {Jabbour, Elias and Kantarjian, Hagop},
  title           = {Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.},
  doi             = {10.1002/ajh.25792},
  issn            = {1096-8652},
  issue           = {6},
  pages           = {691--709},
  pubstate        = {ppublish},
  volume          = {95},
  abstract        = {Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1-2 cases per 100â€‰000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults. CML is characterized by a balanced genetic translocation, t(9;22)(q34;q11.2), involving a fusion of the Abelson gene (ABL1) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. The molecular consequence of this translocation is the generation of a BCR-ABL1 fusion oncogene, which in turn translates into a BCR-ABL oncoprotein. Four tyrosine kinase inhibitors (TKIs), imatinib, nilotinib, dasatinib, and bosutinib are approved by the United States Food and Drug Administration for first-line treatment of newly diagnosed CML in chronic phase (CML-CP). Clinical trials with second generation TKIs reported significantly deeper and faster responses, but they had no impact on survival prolongation, likely because of the existence of highly effective salvage therapies for patients who have a cytogenetic relapse with frontline TKI. For CML post failure on frontline therapy, second-line options include second and third generation TKIs. Although potent and selective, these exhibit unique pharmacological profiles and response patterns relative to different patient and disease characteristics, such as patients' comorbidities, disease stage, and BCR-ABL1 mutational status. Patients who develop the T315I "gatekeeper" mutation display resistance to all currently available TKIs except ponatinib. Allogeneic stem cell transplantation remains an important therapeutic option for patients with CML-CP who have failed at least 2 TKIs, and for all patients in advanced phase disease. Even among older patients who have a cytogenetic relapse post failure on all TKIs, they can maintain long-term survival if they continue on a daily most effective/less toxic TKI, with or without the addition of non-TKI anti-CML agents (hydroxyurea, omacetaxine, azacitidine, decitabine, cytarabine, busulfan, others).},
  chemicals       = {BCR-ABL1 fusion protein, human, Protein Kinase Inhibitors, Fusion Proteins, bcr-abl},
  citation-subset = {IM},
  completed       = {2020-06-23},
  country         = {United States},
  file            = {:/Users/yitche/survbib/pdf/Jabbour2020.pdf:PDF;:Jabbour2020.pdf:PDF},
  groups          = {CML},
  issn-linking    = {0361-8609},
  journal         = {American journal of hematology},
  keywords        = {Chromosomes, Human, Pair 22, genetics; Chromosomes, Pair 9, genetics; Clinical Trials as Topic; Disease-Free Survival; Fusion Proteins, bcr-abl, genetics; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, diagnosis, drug therapy, genetics; Monitoring, Physiologic; Protein Kinase Inhibitors, adverse effects, therapeutic use; Survival Rate; Translocation, Genetic},
  month           = jun,
  nlm-id          = {7610369},
  owner           = {NLM},
  pmid            = {32239758},
  pubmodel        = {Print-Electronic},
  revised         = {2020-06-23},
  year            = {2020},
}

@Article{Hirt2019,
  author          = {Hirt, Carsten and Iannazzo, Sergio and Chiroli, Silvia and McGarry, Lisa J. and le Coutre, Philipp and Stenke, Leif and DahlÃ©n, Torsten and Lipton, Jeffrey H.},
  title           = {Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia.},
  doi             = {10.1007/s40258-019-00489-0},
  issn            = {1179-1896},
  issue           = {4},
  pages           = {555--567},
  pubstate        = {ppublish},
  volume          = {17},
  abstract        = {Third-line treatment options for patients with chronic-phase chronic myeloid leukemia include tyrosine kinase inhibitors and allogeneic hematopoietic stem cell transplantation (alloHSCT). The objective of this study was to develop a Markov model with a lifetime time horizon to assess the cost effectiveness of ponatinib for third-line chronic-phase chronic myeloid leukemia vs. second-generation tyrosine kinase inhibitors (dasatinib, nilotinib, bosutinib) or alloHSCT from the public healthcare system perspective in Germany, Sweden, and Canada. Clinical outcomes were derived from the literature, and from patient-level data (phase II PACE trial) for ponatinib. Resource use included drugs, alloHSCT, monitoring and follow-up, adverse events, and end-of-life care; costs were based on national tariffs. Quality-adjusted life-years (QALYs) were calculated using chronic myeloid leukemia health-state utilities from an international time-trade-off study. Costs and benefits were discounted at 3% per annum for Germany and Sweden, and 5% for Canada. Ponatinib yielded more discounted QALYs than any second-generation tyrosine kinase inhibitor/alloHSCT in all three countries, mainly owing to better response rates and longer durations of response. Incremental cost-effectiveness ratios for ponatinib vs. second-generation tyrosine kinase inhibitors were US$21,543-37,755/QALY in Germany, $24,018-38,227/QALY in Sweden, and $43,001-58,515/QALY in Canada. Ponatinib was dominant over alloHSCT in Germany, while incremental cost-effectiveness ratios for ponatinib vs. alloHSCT in Sweden and Canada were $715/QALY and $31,534/QALY, respectively. Ponatinib may improve outcomes (mainly because of higher response rates and longer response durations) at an acceptable cost level compared with other third-line treatment options for chronic-phase chronic myeloid leukemia in Germany, Sweden, and Canada; however, the lack of an indirect comparison is a limitation of our study.},
  chemicals       = {Imidazoles, Protein Kinase Inhibitors, Pyridazines, ponatinib},
  citation-subset = {IM},
  completed       = {2020-07-03},
  country         = {New Zealand},
  file            = {:/Users/yitche/survbib/pdf/Hirt2019.pdf:PDF;:Hirt2019.pdf:PDF},
  groups          = {CML, Study 4. Cost-effectiveness},
  issn-linking    = {1175-5652},
  journal         = {Applied health economics and health policy},
  keywords        = {Cost-Benefit Analysis, methods; Female; Humans; Imidazoles, economics; Internationality; Leukemia, Myeloid, Chronic-Phase, drug therapy, surgery; Male; Markov Chains; Middle Aged; Protein Kinase Inhibitors, economics; Pyridazines, economics; Quality-Adjusted Life Years; Stem Cell Transplantation, economics},
  month           = aug,
  nlm-id          = {101150314},
  owner           = {NLM},
  pii             = {10.1007/s40258-019-00489-0},
  pmid            = {31168745},
  pubmodel        = {Print},
  revised         = {2020-07-03},
  year            = {2019},
}

@Article{Lauseker2015,
  author          = {Lauseker, Michael and Hasford, Joerg and Hoffmann, Verena S. and MÃ¼ller, Martin C. and Hehlmann, RÃ¼diger and Pfirrmann, Markus and Group, German C.M.L. Study},
  title           = {A multi-state model approach for prediction in chronic myeloid leukaemia.},
  doi             = {10.1007/s00277-014-2246-2},
  issn            = {1432-0584},
  issue           = {6},
  pages           = {919--927},
  pubstate        = {ppublish},
  volume          = {94},
  abstract        = {Multi-state models support prediction in medicine. With different states of disease, chronic myeloid leukaemia (CML) is particularly suited for the application of multi-state models. In this article, we tried to find a model for CML that allows predicting the prevalence of three different states (initial state of disease, remission and progression) in dependence on treatment, adjusted for age, sex and risk score. Based on the German CML Study IV, one of the largest randomised studies in CML, the model was able to represent the known effects of age and risk score on the probabilities of remission and progression. Patients achieving a major molecular remission had a better chance of surviving without progression, but this effect was not significant. Comparing treatments, patient of the high-dose arm had the greatest chance to be in the state "remission" at 5 years but did not seem to have an advantage considering "progression". The proposed illness-death model can be useful for predicting the course of CML based on the patient's individual covariates (trial registration: this is an explorative analysis of ClinicalTrials.gov Identifier: NCT00055874).},
  citation-subset = {IM},
  completed       = {2015-07-24},
  country         = {Germany},
  file            = {:/Users/yitche/survbib/pdf/Lauseker2015.pdf:PDF;:Lauseker2015.pdf:PDF},
  groups          = {Study 2. Quality of Life, Study 3. Cost, Study 4. Cost-effectiveness, CML},
  issn-linking    = {0939-5555},
  journal         = {Annals of hematology},
  keywords        = {Adult; Disease Progression; Disease-Free Survival; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, diagnosis, epidemiology; Male; Markov Chains; Middle Aged; Models, Theoretical; Treatment Outcome},
  month           = jun,
  nlm-id          = {9107334},
  owner           = {NLM},
  pmid            = {25465231},
  pubmodel        = {Print-Electronic},
  readstatus      = {read},
  revised         = {2015-05-06},
  year            = {2015},
}

@Article{Shih2019,
  author          = {Shih, Ya-Chen Tina and Cortes, Jorge E. and Kantarjian, Hagop M.},
  title           = {Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.},
  doi             = {10.1016/S2352-3026(19)30087-0},
  issn            = {2352-3026},
  issue           = {8},
  pages           = {e398--e408},
  pubstate        = {ppublish},
  volume          = {6},
  abstract        = {Treatment-free remission in chronic myeloid leukaemia-ie, achievement of a sustained deep molecular response leading to discontinuation of BCR-ABL1 tyrosine kinase inhibitor (TKI) therapy-has become a potential aim of therapy. Highly priced second-generation TKIs might offer deep molecular response status more quickly and for more patients than imatinib; however, with the availability and lower cost of generic imatinib, the value of second-generation TKIs as frontline therapy for this particular treatment endpoint remains unknown. We aimed to assess the potential value of second-generation TKIs used as frontline therapy in patients with chronic myeloid leukaemia in chronic phase in relation to the probability of achieving sustained deep molecular responses compared with generic imatinib, and the associated cost of each modality. We used a decision analytic model to consider the value of different TKI approaches from the payer's perspective. The proportion of patients achieving sustained deep molecular response after 5 years of treatment in chronic phase was estimated at 26% with imatinib and 44% with second-generation TKIs. We also modelled more favourable scenarios of the proportion of patients achieving such response with second-generation TKIs at 66%, 88%, and a near-perfect response of 99%. For each scenario, we examined the impact of the combination of health utilities for chronic-phase chronic myeloid leukaemia (base case 0Â·89, range 0-1) and the annual cost of second-generation TKIs (base case US$152â€ˆ814 [ie, the price of nilotinib in the USA], range 0-240â€ˆ000) on the cost-effectiveness of second-generation TKIs compared with generic imatinib. We used different price scenarios for generic imatinib in the USA (average price $35â€ˆ000 per year; lowest price $4400 per year), Europe ($4000 per year), and developing countries ($2100 per year). We calculated incremental cost-effectiveness ratios (ICERs) and assessed cost-effectiveness by considering two societal willingness-to-pay thresholds: $50â€ˆ000 per quality-adjusted life-year (QALY) in all markets and $200â€ˆ000 per QALY in the USA. In the base case, we obtained an ICER of $22â€ˆ765â€ˆ208, meaning that second-generation TKIs as frontline therapy to achieve sustained deep molecular response was not cost-effective under either of the societal willingness-to-pay thresholds. In our sensitivity analyses, none of the explored scenarios showed potential treatment value for use of second-generation TKIs at the current prices in the USA or at the price of $30â€ˆ000-40â€ˆ000 per year elsewhere. For example, considering a scenario in the USA using second-generation TKIs versus imatinib (annual price $4400 per year) with the potential benefit in favour of second-generation TKI (willingness to pay $200â€ˆ000 per QALY, 66% of patients achieving sustained deep molecular response, and health utility of the chronic phase of 0Â·1), the cost of second-generation TKIs would need to be less than $25â€ˆ000 per year to be a cost-effective option. Under the same conditions in developing nations, with a price of generic imatinib of $2100 per year and a willingness to pay of $50â€ˆ000 per QALY, the annual price of second-generation TKIs should not exceed $10â€ˆ000 per year of therapy. Considering the current prices of second-generation TKIs and of generic imatinib under different pricing scenarios in the USA, Europe, and developing countries, second-generation TKIs at current prices do not offer good value as frontline therapy in chronic myeloid leukaemia in order to achieve sustained deep molecular response and treatment-free remission. National Cancer Institute.},
  chemicals       = {4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide, Antineoplastic Agents, Drugs, Generic, Protein Kinase Inhibitors, Pyrimidines, Imatinib Mesylate, Fusion Proteins, bcr-abl},
  citation-subset = {IM},
  completed       = {2019-10-30},
  country         = {England},
  file            = {:Shih2019.pdf:PDF},
  groups          = {Study 3. Cost, CML, Study 4. Cost-effectiveness},
  issn-linking    = {2352-3026},
  journal         = {The Lancet. Haematology},
  keywords        = {Antineoplastic Agents, therapeutic use; Cost-Benefit Analysis; Drugs, Generic, therapeutic use; Fusion Proteins, bcr-abl, antagonists & inhibitors, metabolism; Humans; Imatinib Mesylate, economics, therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, pathology; Protein Kinase Inhibitors, therapeutic use; Pyrimidines, therapeutic use; Quality-Adjusted Life Years; Remission Induction},
  mid             = {NIHMS1532787},
  month           = aug,
  nlm-id          = {101643584},
  owner           = {NLM},
  pii             = {S2352-3026(19)30087-0},
  pmc             = {PMC6658341},
  pmid            = {31208943},
  pubmodel        = {Print-Electronic},
  readstatus      = {read},
  revised         = {2020-08-01},
  year            = {2019},
}

@Article{Godman2019,
  author    = {Brian Godman and Andrew Hill and Steven Simoens and Amanj Kurdi and Jolanta Gulbinovi{\v{c}} and Antony P Martin and Angela Timoney and Dzintars Gotham and Janet Wale and Tomasz Bochenek and Celia C Rothe and Iris Hoxha and Admir Malaj and Christian HierlÃ¤nder and Robert Sauermann and Wouter Hamelinck and Zornitza Mitkova and Guenka Petrova and Ott Laius and Catherine Sermet and Irene Langer and Gisbert Selke and John Yfantopoulos and Roberta Joppi and Arianit Jakupi and Elita Poplavska and Ieva Greiciute-Kuprijanov and Patricia Vella Bonanno and JF (Hans) Piepenbrink and Vincent de Valk and Carolin Hagen and Anne Marthe Ringerud and Robert Plisko and Magdalene Wladysiuk and Vanda Markovi{\'{c}}-Pekovi{\'{c}} and Nata{\v{s}}a Grubi{\v{s}}a and Tatjana Ponorac and Ileana Mardare and Tanja Novakovic and Mark Parker and Jurij FÃ¼rst and Dominik Tomek and Merc{\`{e}} Obach Cortadellas and Corinne Zara and Maria Juhasz-Haverinen and Peter Skiold and Stuart McTaggart and Alan Haycox},
  title     = {Pricing of oral generic cancer medicines in 25 European countries; indings and implications},
  doi       = {10.5639/gabij.2019.0802.007},
  number    = {2},
  pages     = {49--70},
  volume    = {8},
  groups    = {Study 3. Cost},
  journal   = {Generics and Biosimilars Initiative Journal},
  month     = {jun},
  owner     = {Enoch},
  publisher = {Pro Pharma Communications International},
  timestamp = {2021-04-05},
  year      = {2019},
}

@Article{Marsh2014,
  author    = {Kevin Marsh and Peng Xu and Panagiotis Orfanos and Agnes Benedict and Kamal Desai and Ingolf Griebsch},
  title     = {Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Myeloid Leukaemia: A Review and Summary of Challenges},
  doi       = {10.1007/s40273-014-0177-3},
  number    = {9},
  pages     = {853--864},
  volume    = {32},
  journal   = {{PharmacoEconomics}},
  month     = {jun},
  publisher = {Springer Science and Business Media {LLC}},
  year      = {2014},
}

@Article{Rochau2015,
  author    = {Ursula Rochau and Martina Kluibenschaedl and David Stenehjem and Kuo Kuan-Ling and Jerald Radich and Gary Oderda and Diana Brixner and Uwe Siebert},
  title     = {Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis},
  doi       = {10.1155/2015/982395},
  pages     = {1--12},
  volume    = {2015},
  journal   = {Leukemia Research and Treatment},
  month     = {dec},
  publisher = {Hindawi Limited},
  year      = {2015},
}

@Article{Rochau2015a,
  author    = {Ursula Rochau and Gaby Sroczynski and Dominik Wolf and Stefan Schmidt and Beate Jahn and Martina Kluibenschaedl and Annette Conrads-Frank and David Stenehjem and Diana Brixner and Jerald Radich and GÃ¼nther Gastl and Uwe Siebert},
  title     = {Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia},
  doi       = {10.3109/10428194.2014.982635},
  number    = {8},
  pages     = {2315--2325},
  volume    = {56},
  journal   = {Leukemia {\&} Lymphoma},
  month     = {jan},
  publisher = {Informa {UK} Limited},
  year      = {2015},
}

@Article{Padula2016,
  author    = {William V. Padula and Richard A. Larson and Stacie B. Dusetzina and Jane F. Apperley and Rudiger Hehlmann and Michele Baccarani and Ekkehard Eigendorff and Joelle Guilhot and Francois Guilhot and Rudiger Hehlmann and Francois-Xavier Mahon and Giovanni Martinelli and Jiri Mayer and Martin C. MÃ¼ller and Dietger Niederwieser and Susanne Saussele and Charles A. Schiffer and Richard T. Silver and Bengt Simonsson and Rena M. Conti},
  title     = {Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States},
  doi       = {10.1093/jnci/djw003},
  number    = {7},
  pages     = {djw003},
  volume    = {108},
  journal   = {Journal of the National Cancer Institute},
  month     = {mar},
  publisher = {Oxford University Press ({OUP})},
  year      = {2016},
}

@Article{Yamamoto2019,
  author    = {Chihiro Yamamoto and Hirotomo Nakashima and Takashi Ikeda and Shin-ichiro Kawaguchi and Yumiko Toda and Shoko Ito and Kiyomi Mashima and Takashi Nagayama and Kento Umino and Daisuke Minakata and Hirofumi Nakano and Kaoru Morita and Ryoko Yamasaki and Miyuki Sugimoto and Yuko Ishihara and Masahiro Ashizawa and Kaoru Hatano and Kazuya Sato and Iekuni Oh and Shin-ichiro Fujiwara and Masuzu Ueda and Ken Ohmine and Kazuo Muroi and Yoshinobu Kanda},
  title     = {Analysis of the cost-effectiveness of treatment strategies for {CML} with incorporation of treatment discontinuation},
  doi       = {10.1182/bloodadvances.2019000745},
  number    = {21},
  pages     = {3266--3277},
  volume    = {3},
  journal   = {Blood Advances},
  month     = {oct},
  publisher = {American Society of Hematology},
  year      = {2019},
}

@Article{Kim2019,
  author    = {Kibum Kim and Gwendolyn A. McMillin and Philip S. Bernard and Srinivas Tantravahi and Brandon S. Walker and Robert L. Schmidt},
  title     = {Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia},
  doi       = {10.1371/journal.pone.0226552},
  editor    = {Chung Hoow Kok},
  number    = {12},
  pages     = {e0226552},
  volume    = {14},
  journal   = {{PLOS} {ONE}},
  month     = {dec},
  publisher = {Public Library of Science ({PLoS})},
  year      = {2019},
}

@Article{Nguyen2020,
  author    = {Joehl T. Nguyen and Ashley L. Cole and Ashley A. Leech and William A. Wood and Stacie B. Dusetzina},
  title     = {Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia},
  doi       = {10.1016/j.jval.2020.05.019},
  number    = {10},
  pages     = {1292--1299},
  volume    = {23},
  journal   = {Value in Health},
  month     = {oct},
  publisher = {Elsevier {BV}},
  year      = {2020},
}

@Article{Li2016b,
  author    = {Nanxin Li and Xi Yang and Liangyi Fan and Todor Totev and Annie Guerin and Lei Chen and Subrata Bhattacharyya and George Joseph},
  title     = {Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data},
  doi       = {10.1080/13696998.2016.1261032},
  number    = {4},
  pages     = {328--336},
  volume    = {20},
  journal   = {Journal of Medical Economics},
  month     = {dec},
  publisher = {Informa {UK} Limited},
  year      = {2016},
}

@Article{Nicolini2017,
  author          = {Nicolini, Franck E. and Basak, Grzegorz W. and Kim, Dong-Wook and Olavarria, Eduardo and Pinilla-Ibarz, Javier and Apperley, Jane F. and Hughes, Timothy and Niederwieser, Dietger and Mauro, Michael J. and Chuah, Charles and Hochhaus, Andreas and Martinelli, Giovanni and DerSarkissian, Maral and Duh, Mei Sheng and McGarry, Lisa J. and Kantarjian, Hagop M. and Cortes, Jorge E.},
  title           = {Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.},
  doi             = {10.1002/cncr.30558},
  issn            = {1097-0142},
  issue           = {15},
  pages           = {2875--2880},
  pubstate        = {ppublish},
  volume          = {123},
  abstract        = {Effective treatment options for patients with chronic myeloid leukemia (CML) or Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) who have the threonine to isoleucine mutation at codon 315 (T315I) are few. The objective of this study was to compare overall survival (OS) between patients with CML and those with Ph+ ALL who received treatment with ponatinib versus allogeneic stem cell transplantation (allo-SCT). A post hoc, retrospective, indirect comparison of OS among patients who received single-agent ponatinib in the Ponatinib Ph+ ALL and CML Evaluation (PACE) trial with those who underwent allo-SCT as reported to the European Bone Marrow Transplant registry, stratified by CML disease phase and Ph+ ALL, was conducted. Kaplan-Meier survival curves and multivariate Cox proportional-hazards models were used to compare OS between intervention groups, adjusting for time from diagnosis to intervention, age, sex, and geographic region; 24-month and 48-month OS rates and median OS were reported. After adjustment for potential confounders, 24-month and 48-month OS rates were significantly higher in patients with chronic-phase CML (CP-CML) who received ponatinib compared with those who underwent allo-SCT (24 months: 84% vs 60.5%, respectively; Pâ€‰=â€‰.004; 48 months: 72.7% vs 55.8%, respectively; Pâ€‰=â€‰.013), with a hazard ratio (HR) of 0.37 (95% confidence interval [CI], 0.16-0.84; Pâ€‰=â€‰.017). In patients who had accelerated-phase CML, OS rates were not significantly different between the groups (HR, 0.90; 95% CI, 0.20-4.10; Pâ€‰=â€‰.889). In patients who had blast-crisis CML and those with Ph+ ALL, ponatinib was associated with shorter OS compared with allo-SCT (blast-crisis CML: HR, 2.29 [95% CI, 1.08-4.82; Pâ€‰=â€‰.030]; Ph+ ALL: HR, 2.77 [95% CI, 0.73-10.56; Pâ€‰=â€‰.146]). Although allo-SCT remains an important treatment option for patients with T315I-positive advanced CML and Ph+ ALL, ponatinib represents a valuable alternative for patients with T315I-positive CP-CML. Cancer 2017;123:2875-80. Â© 2017 American Cancer Society.},
  chemicals       = {Antineoplastic Agents, Imidazoles, Pyridazines, ponatinib},
  citation-subset = {AIM, IM},
  completed       = {2017-09-11},
  country         = {United States},
  groups          = {CML},
  issn-linking    = {0008-543X},
  journal         = {Cancer},
  keywords        = {Adult; Aged; Antineoplastic Agents, therapeutic use; Blast Crisis, genetics, therapy; Female; Humans; Imidazoles, therapeutic use; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, therapy; Male; Middle Aged; Multivariate Analysis; Mutation; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma, therapy; Proportional Hazards Models; Pyridazines, therapeutic use; Retrospective Studies; Stem Cell Transplantation, methods; Survival Rate; Transplantation, Homologous; Treatment Outcome; Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL); allogeneic stem cell transplantation (allo-SCT); chronic myeloid leukemia (CML); ponatinib; threonine to isoleucine mutation at codon 315 (T315I)},
  month           = aug,
  nlm-id          = {0374236},
  owner           = {NLM},
  pmc             = {PMC5573914},
  pmid            = {28387926},
  pubmodel        = {Print-Electronic},
  revised         = {2018-11-13},
  timestamp       = {2021-04-07},
  year            = {2017},
}

@Article{Lee2008,
  author          = {Lee, Stephanie J. and Kukreja, Manisha and Wang, Tao and Giralt, Sergio A. and Szer, Jeffrey and Arora, Mukta and Woolfrey, Ann E. and Cervantes, Francisco and Champlin, Richard E. and Gale, Robert Peter and Halter, Joerg and Keating, Armand and Marks, David I. and McCarthy, Philip L. and Olavarria, Eduardo and Stadtmauer, Edward A. and Abecasis, Manuel and Gupta, Vikas and Khoury, H. Jean and George, Biju and Hale, Gregory A. and Liesveld, Jane L. and Rizzieri, David A. and Antin, Joseph H. and Bolwell, Brian J. and Carabasi, Matthew H. and Copelan, Edward and Ilhan, Osman and Litzow, Mark R. and Schouten, Harold C. and Zander, Axel R. and Horowitz, Mary M. and Maziarz, Richard T.},
  title           = {Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.},
  doi             = {10.1182/blood-2008-02-141689},
  issn            = {1528-0020},
  issue           = {8},
  pages           = {3500--3507},
  pubstate        = {ppublish},
  volume          = {112},
  abstract        = {Imatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data from the Center for International Blood and Marrow Transplant Research on 409 subjects treated with IM before HCT (IM(+)) and 900 subjects who did not receive IM before HCT (IM(-)) were analyzed. Among patients in first chronic phase, IM therapy before HCT was associated with better survival but no statistically significant differences in treatment-related mortality, relapse, and leukemia-free survival. Better HLA-matched donors, use of bone marrow, and transplantation within one year of diagnosis were also associated with better survival. A matched-pairs analysis was performed and confirmed a higher survival rate among first chronic phase patients receiving IM. Among patients transplanted with advanced CML, use of IM before HCT was not associated with treatment-related mortality, relapse, leukemia-free survival, or survival. Acute graft-versus-host disease rates were similar between IM(+) and IM(-) groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT.},
  chemicals       = {Antineoplastic Agents, Benzamides, HLA Antigens, Piperazines, Pyrimidines, Imatinib Mesylate},
  citation-subset = {AIM, IM},
  completed       = {2008-10-16},
  country         = {United States},
  groups          = {CML},
  issn-linking    = {0006-4971},
  journal         = {Blood},
  keywords        = {Adolescent; Adult; Aged; Antineoplastic Agents, therapeutic use; Benzamides; Child; Child, Preschool; Disease-Free Survival; Female; HLA Antigens, metabolism; Hematopoietic Stem Cell Transplantation, methods; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, therapy; Male; Middle Aged; Piperazines, therapeutic use; Pyrimidines, therapeutic use; Registries; Treatment Outcome},
  month           = oct,
  nlm-id          = {7603509},
  owner           = {NLM},
  pii             = {S0006-4971(20)59759-0},
  pmc             = {PMC2954751},
  pmid            = {18664621},
  pubmodel        = {Print-Electronic},
  revised         = {2021-02-06},
  timestamp       = {2021-04-07},
  year            = {2008},
}

@Article{Mahon2010,
  author    = {Fran{\c{c}}ois-Xavier Mahon and Delphine R{\'{e}}a and JoÃ«lle Guilhot and Fran{\c{c}}ois Guilhot and Fran{\c{c}}oise Huguet and Franck Nicolini and Laurence Legros and Aude Charbonnier and Agn{\`{e}}s Guerci and Bruno Varet and Gabriel Etienne and Josy Reiffers and Philippe Rousselot},
  title     = {Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib ({STIM}) trial},
  doi       = {10.1016/s1470-2045(10)70233-3},
  number    = {11},
  pages     = {1029--1035},
  volume    = {11},
  groups    = {CML},
  journal   = {The Lancet Oncology},
  month     = {nov},
  owner     = {Enoch},
  publisher = {Elsevier {BV}},
  timestamp = {2021-04-07},
  year      = {2010},
}

@Article{JaimePerez2015,
  author    = {Jos{\'{e}} Carlos Jaime-P{\'{e}}rez and Alberto Carlos Heredia-Salazar and Olga G. Cant{\'{u}}-Rodr{\'{\i}}guez and Homero Guti{\'{e}}rrez-Aguirre and C{\'{e}}sar Daniel Villarreal-Villarreal and Consuelo Manc{\'{\i}}as-Guerra and Jos{\'{e}} Lu{\'{\i}}s Herrera-Garza and David G{\'{o}}mez-Almaguer},
  title     = {Cost Structure and Clinical Outcome of a Stem Cell Transplantation Program in a Developing Country: The Experience in Northeast Mexico},
  doi       = {10.1634/theoncologist.2014-0218},
  number    = {4},
  pages     = {386--392},
  volume    = {20},
  groups    = {CML},
  journal   = {The Oncologist},
  month     = {mar},
  owner     = {Enoch},
  publisher = {Wiley},
  timestamp = {2021-04-07},
  year      = {2015},
}

@Article{TSD21,
  author       = {Mark J Rutherford and Paul C Lambert and Michael J Sweeting and Becky Pennington and Michael J Crowther and Keith R Abrams and Nicholas R Latime},
  journal      = {Decision Support Unit, University of Sheffield},
  title        = {{NICE DSU} TECHNICAL SUPPORT DOCUMENT 21: {F}lexible Methods for Survival Analysis},
  groups       = {Study 1. Extrapolation},
  owner        = {Enoch},
  timestamp    = {2021-04-09},
  year         = {2021},
}

@Article{IARCintro,
  author    = {IARC},
  title     = {Acturial life-table method vs. Kaplan-Meier's method},
  file      = {:/Users/yitche/Box/enochpdf/IARCintro.pdf:PDF;:/enochpdf/IARCintro.pdf:PDF},
  owner     = {Enoch},
  timestamp = {2021-04-09},
}

@Book{Baum2016,
  author    = {Christopher F. Baum},
  title     = {An Introduction to Stata Programming},
  file      = {:/Users/yitche/Box/enochpdf/Baum2016.pdf:PDF},
  owner     = {Enoch},
  timestamp = {2021-04-09},
}

@Article{Keiding1991a,
  author    = {Niels Keiding},
  title     = {Age-Specific Incidence and Prevalence: A Statistical Perspective},
  journal   = {Journal of the Royal Statistical Society. Series A (Statistics in Society)},
  year      = {1991},
  volume    = {154},
  number    = {3},
  pages     = {371},
  doi       = {10.2307/2983150},
  owner     = {Enoch},
  publisher = {{JSTOR}},
  timestamp = {2021-04-09},
}

@Book{Pagano2000,
  author    = {Marcello Pagano, Kimberlee Gauvreau},
  date      = {2000-03-09},
  title     = {Principles of Biostatistics},
  isbn      = {0534229026},
  pagetotal = {592},
  publisher = {Cengage Learning, Inc},
  url       = {https://www.ebook.de/de/product/3248824/marcello_pagano_kimberlee_gauvreau_principles_of_biostatistics_with_cd_rom.html},
  ean       = {9780534229023},
  owner     = {Enoch},
  timestamp = {2021-04-09},
  year      = {2000},
}

@Article{Robins2001,
  author          = {Robins, J. M.},
  title           = {Data, design, and background knowledge in etiologic inference.},
  doi             = {10.1097/00001648-200105000-00011},
  issn            = {1044-3983},
  issue           = {3},
  pages           = {313--320},
  pubstate        = {ppublish},
  volume          = {12},
  abstract        = {I use two examples to demonstrate that an appropriate etiologic analysis of an epidemiologic study depends as much on study design and background subject-matter knowledge as on the data. The demonstration is facilitated by the use of causal graphs.},
  citation-subset = {IM},
  completed       = {2001-09-06},
  country         = {United States},
  file            = {:/Users/yitche/Box/enochpdf/Robins2011.pdf:PDF;:enochpdf/Robins2011.pdf:PDF},
  issn-linking    = {1044-3983},
  journal         = {Epidemiology (Cambridge, Mass.)},
  keywords        = {Case-Control Studies; Cohort Studies; Data Collection; Endometrial Neoplasms, chemically induced; Epidemiologic Studies; Female; Hormone Replacement Therapy, adverse effects; Humans; Postmenopause; Randomized Controlled Trials as Topic; Research Design; Statistics as Topic},
  month           = may,
  nlm-id          = {9009644},
  owner           = {Enoch},
  pmid            = {11338312},
  pubmodel        = {Print},
  revised         = {2019-09-15},
  timestamp       = {2021-04-09},
  year            = {2001},
}

@Article{Melo2003,
  author          = {Melo, Junia V. and Hughes, Timothy P. and Apperley, Jane F.},
  title           = {Chronic myeloid leukemia.},
  doi             = {10.1182/asheducation-2003.1.132},
  issn            = {1520-4391},
  pages           = {132--152},
  pubstate        = {ppublish},
  abstract        = {Chronic myeloid leukemia (CML) was the first human malignancy to be associated with a specific genetic lesion, the Philadelphia chromosome, harboring the BCR-ABL oncogene. Since then, it has become a paradigm for the discovery of molecular mechanisms and targeted therapeutic approaches in the field of hematologic neoplasias. The past 5 years or so have been particularly fruitful in the dissection of the signal transduction pathways abnormally activated in CML and in the translation of this knowledge to clinical practice. In this report, we discuss the biological basis for such translation and highlight the current and potential tools for the effective treatment of CML patients. The first part presents a review of the basic concepts on the biology of CML and their application to the design of targeted therapy. The mechanisms of action of the molecular-specific drugs currently used in clinical trials are discussed, with emphasis on the description of the most promising new compounds that are enhancing the potential for effective alternative or combination chemotherapy in CML. In the following section, we explain how molecular monitoring of response to imatinib mesylate in patients with CML can be used as a guide to clinical management. In particular, we discuss the relative value of regular quantitative RT/PCR and cytogenetic analyses, how responding patients should be monitored and managed, and how to investigate patients who are refractory or become resistant to imatinib treatment. In the last part of this report, a discussion on the possibility of managing CML with patient-specific strategies is presented. We review the current treatment options, highlight the factors impacting on decision making, discuss the range of possibilities for future therapeutic strategies and propose a systematic approach for individualizing treatment for patients in different disease categories.},
  chemicals       = {Benzamides, Piperazines, Pyrimidines, Imatinib Mesylate, Protein-Tyrosine Kinases, Fusion Proteins, bcr-abl},
  citation-subset = {IM},
  completed       = {2004-09-23},
  country         = {United States},
  issn-linking    = {1520-4383},
  journal         = {Hematology. American Society of Hematology. Education Program},
  keywords        = {Benzamides; Drug Delivery Systems; Drug Monitoring; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy; Piperazines, pharmacology, therapeutic use; Protein-Tyrosine Kinases, antagonists & inhibitors; Pyrimidines, therapeutic use; Signal Transduction, drug effects},
  nlm-id          = {100890099},
  owner           = {Enoch},
  pmid            = {14633780},
  pubmodel        = {Print},
  references      = {141},
  revised         = {2019-11-08},
  timestamp       = {2021-04-09},
  year            = {2003},
}

@Article{GarciaManero2003,
  author    = {Guillermo Garcia-Manero and Moshe Talpaz and Francis J. Giles and Jorge Cortes and Stefan Faderl and Susan O{\textquotesingle}Brien and Deborah Thomas and Srdan Verstovsek and Mary Beth Rios and Jianquin Shan and Alessandra Ferrajoli and William Wierda and Hagop M. Kantarjian},
  title     = {Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside},
  doi       = {10.1002/cncr.11424},
  number    = {12},
  pages     = {3010--3016},
  volume    = {97},
  journal   = {Cancer},
  month     = {may},
  owner     = {Enoch},
  publisher = {Wiley},
  timestamp = {2021-04-09},
  year      = {2003},
}

@Book{Sundin2007,
  author    = {Sundin, Jan},
  title     = {Social change and health in Sweden},
  isbn      = {9789172575349},
  publisher = {Swedish National Institute of Public Health},
  address   = {Stockholm},
  file      = {:enochpdf/Sundin2007.pdf:PDF;:/Users/yitche/Box/enochpdf/Sundin2007.pdf:PDF},
  owner     = {Enoch},
  timestamp = {2021-04-09},
  year      = {2007},
}

@Article{Hung2011,
  author          = {Hung, Mei-Chuan and Lu, Hsin-Ming and Chen, Likwang and Hu, Fu-Chang and Chan, Soa-Yu and Yan, Yuan-Horng and Fan, Po-Sheng and Lin, Ming-Shian and Chen, Cheng-Ren and Kuo, Lu-Cheng and Yu, Chong-Jen and Wang, Jung-Der},
  title           = {Life expectancies and incidence rates of patients under prolonged mechanical ventilation: a population-based study during 1998 to 2007 in Taiwan.},
  doi             = {10.1186/cc10128},
  issn            = {1466-609X},
  issue           = {2},
  pages           = {R107},
  pubstate        = {ppublish},
  volume          = {15},
  abstract        = {The present study examined the median survival, life expectancies, and cumulative incidence rate (CIR) of patients undergoing prolonged mechanical ventilation (PMV) stratified by different underlying diseases. According to the National Health Insurance Research Database of Taiwan, there were 8,906,406 individuals who obtained respiratory care during the period from 1997 to 2007. A random sample of this population was performed, and subjects who had continuously undergone mechanical ventilation for longer than 21 days were enrolled in the current study. Annual incidence rates and the CIR were calculated. After stratifying the patients according to their specific diagnoses, latent class analysis was performed to categorise PMV patients with multiple co-morbidities into several groups. The life expectancies of different groups were estimated using a semiparametric method with a hazard function based on the vital statistics of Taiwan. The analysis of 50,481 PMV patients revealed that incidence rates increased as patients grew older and that the CIR (17 to 85 years old) increased from 0.103 in 1998 to 0.183 in 2004 before stabilising thereafter. The life expectancies of PMV patients suffering from degenerative neurological diseases, stroke, or injuries tended to be longer than those with chronic renal failure or cancer. Patients with chronic obstructive pulmonary disease survived longer than did those co-morbid with other underlying diseases, especially septicaemia/shock. PMV provides a direct means to treat respiratory tract diseases and to sustain respiration in individuals suffering from degenerative neurological diseases, and individuals with either of these types of conditions respond better to PMV than do those with other co-morbidities. Future research is required to determine the cost-effectiveness of this treatment paradigm.},
  citation-subset = {IM},
  completed       = {2011-12-07},
  country         = {England},
  issn-linking    = {1364-8535},
  journal         = {Critical care (London, England)},
  keywords        = {Aged; Aged, 80 and over; Databases, Factual; Female; Humans; Incidence; Life Expectancy, trends; Male; Middle Aged; Respiration, Artificial, mortality, statistics & numerical data; Survival Analysis; Taiwan, epidemiology; Time Factors; Treatment Outcome},
  nlm-id          = {9801902},
  owner           = {Enoch},
  pii             = {cc10128},
  pmc             = {PMC3219385},
  pmid            = {21457550},
  pubmodel        = {Print-Electronic},
  revised         = {2018-11-13},
  timestamp       = {2021-04-09},
  year            = {2011},
}

@Book{PRoyston2011,
  author    = {P Royston, PC Lambert},
  title     = {Flexible parametric survival analysis in Stata: Beyond the {C}ox model},
  year      = {2011},
  publisher = {Stata Press},
  owner     = {Enoch},
  timestamp = {2021-04-09},
}

@Article{Bjoerkholm2011,
  author          = {BjÃ¶rkholm, Magnus and Ohm, Lotta and Eloranta, Sandra and Derolf, Asa and Hultcrantz, Malin and SjÃ¶berg, Jan and Andersson, Therese and HÃ¶glund, Martin and Richter, Johan and Landgren, Ola and Kristinsson, Sigurdur Y. and Dickman, Paul W.},
  title           = {Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008.},
  doi             = {10.1200/JCO.2011.34.7146},
  issn            = {1527-7755},
  issue           = {18},
  pages           = {2514--2520},
  pubstate        = {ppublish},
  volume          = {29},
  abstract        = {Chronic myeloid leukemia (CML) management changed dramatically with the development of imatinib mesylate (IM), the first tyrosine kinase inhibitor targeting the BCR-ABL1 oncoprotein. In Sweden, the drug was approved in November 2001. We report relative survival (RS) of patients with CML diagnosed during a 36-year period. Using data from the population-based Swedish Cancer Registry and population life tables, we estimated RS for all patients diagnosed with CML from 1973 to 2008 (n = 3173; 1796 males and 1377 females; median age, 62 years). Patients were categorized into five age groups and five calendar periods, the last being 2001 to 2008. Information on use of upfront IM was collected from the Swedish CML registry. Relative survival improved with each calendar period, with the greatest improvement between 1994-2000 and 2001-2008. Five-year cumulative relative survival ratios (95% CIs) were 0.21 (0.17 to 0.24) for patients diagnosed 1973-1979, 0.54 (0.50 to 0.58) for 1994-2000, and 0.80 (0.75 to 0.83) for 2001-2008. This improvement was confined to patients younger than 79 years of age. Five-year RSRs for patients diagnosed from 2001 to 2008 were 0.91 (95% CI, 0.85 to 0.94) and 0.25 (95% CI, 0.10 to 0.47) for patients younger than 50 and older than 79 years, respectively. Men had inferior outcome. Upfront overall use of IM increased from 40% (2002) to 84% (2006). Only 18% of patients older than 80 years of age received IM as first-line therapy. This large population-based study shows a major improvement in outcome of patients with CML up to 79 years of age diagnosed from 2001 to 2008, mainly caused by an increasing use of IM. The elderly still have poorer outcome, partly because of a limited use of IM.},
  chemicals       = {Antineoplastic Agents, Benzamides, Neoplasm Proteins, Piperazines, Protein Kinase Inhibitors, Pyrimidines, Imatinib Mesylate, Protein-Tyrosine Kinases, Fusion Proteins, bcr-abl},
  citation-subset = {IM},
  completed       = {2011-08-23},
  country         = {United States},
  issn-linking    = {0732-183X},
  journal         = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  keywords        = {Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, therapeutic use; Antineoplastic Combined Chemotherapy Protocols, therapeutic use; Benzamides; Child; Child, Preschool; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl, antagonists & inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, mortality, surgery; Male; Middle Aged; Molecular Targeted Therapy; Mortality, trends; Neoplasm Proteins, antagonists & inhibitors; Piperazines, therapeutic use; Protein Kinase Inhibitors, therapeutic use; Protein-Tyrosine Kinases, antagonists & inhibitors; Pyrimidines, therapeutic use; Sex Factors; Sweden, epidemiology; Treatment Outcome; Young Adult},
  month           = jun,
  nlm-id          = {8309333},
  owner           = {Enoch},
  pii             = {JCO.2011.34.7146},
  pmc             = {PMC3138632},
  pmid            = {21576640},
  pubmodel        = {Print-Electronic},
  revised         = {2018-11-13},
  timestamp       = {2021-04-09},
  year            = {2011},
}

@Article{Hung2013,
  author    = {Mei-Chuan Hung and Ching-Lin Hsieh and Jing-Shiang Hwang and Jiann-Shing Jeng and Jung-Der Wang},
  title     = {Estimation of the Long-Term Care Needs of Stroke Patients by Integrating Functional Disability and Survival},
  doi       = {10.1371/journal.pone.0075605},
  editor    = {Alice Y. W. Chang},
  number    = {10},
  pages     = {e75605},
  volume    = {8},
  journal   = {{PLoS} {ONE}},
  month     = {oct},
  owner     = {Enoch},
  publisher = {Public Library of Science ({PLoS})},
  timestamp = {2021-04-09},
  year      = {2013},
}

@Article{Hoeglund2013,
  author          = {HÃ¶glund, Martin and Sandin, Fredrik and HellstrÃ¶m, Karin and BjÃ¶reman, Mats and BjÃ¶rkholm, Magnus and Brune, Mats and Dreimane, Arta and Ekblom, Marja and Lehmann, SÃ¶ren and Ljungman, Per and Malm, Claes and MarkevÃ¤rn, Berit and Myhr-Eriksson, Kristina and Ohm, Lotta and Olsson-StrÃ¶mberg, Ulla and SjÃ¤lander, Anders and Wadenvik, Hans and Simonsson, Bengt and Stenke, Leif and Richter, Johan},
  title           = {Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.},
  doi             = {10.1182/blood-2013-04-495598},
  issn            = {1528-0020},
  issue           = {7},
  pages           = {1284--1292},
  pubstate        = {ppublish},
  volume          = {122},
  abstract        = {Clinical management guidelines on malignant disorders are generally based on data from clinical trials with selected patient cohorts. In Sweden, more than 95% of all patients diagnosed with chronic myeloid leukemia (CML) are reported to the national CML registry, providing unique possibilities to compile population-based information. This report is based on registry data from 2002 to 2010, when a total of 779 patients (425 men, 354 women; median age, 60 years) were diagnosed with CML (93% chronic, 5% accelerated, and 2% blastic phase) corresponding to an annual incidence of 0.9/100,000. In 2002, approximately half of the patients received a tyrosine kinase inhibitor as initial therapy, a proportion that increased to 94% for younger (<70 years) and 79% for older (>80 years) patients during 2007-2009. With a median follow-up of 61 months, the relative survival at 5 years was close to 1.0 for patients younger than 60 years and 0.9 for those aged 60 to 80 years, but only 0.6 for those older than 80 years. At 12 months, 3% had progressed to accelerated or blastic phase. Sokal, but not European Treatment and Outcome Study, high-risk scores were significantly linked to inferior overall and relative survival. Patients living in university vs nonuniversity catchment areas more often received tyrosine kinase inhibitors up front but showed comparable survival.},
  chemicals       = {Protein Kinase Inhibitors, Protein-Tyrosine Kinases},
  citation-subset = {AIM, IM},
  completed       = {2013-11-07},
  country         = {United States},
  issn-linking    = {0006-4971},
  journal         = {Blood},
  keywords        = {Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, epidemiology, mortality; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors, therapeutic use; Protein-Tyrosine Kinases, antagonists & inhibitors; Registries, statistics & numerical data; Sex Factors; Survival Rate; Sweden, epidemiology; Young Adult},
  month           = aug,
  nlm-id          = {7603509},
  owner           = {Enoch},
  pii             = {blood-2013-04-495598},
  pmc             = {PMC3744993},
  pmid            = {23843494},
  pubmodel        = {Print-Electronic},
  revised         = {2018-11-13},
  timestamp       = {2021-04-09},
  year            = {2013},
}

@Book{Gordis2014,
  author    = {Gordis, Leon},
  title     = {Epidemiology},
  isbn      = {9781455737338},
  publisher = {Elsevier/Saunders},
  address   = {Philadelphia, PA},
  file      = {:enochpdf/Gordis2014.pdf:PDF;:/Users/yitche/Box/enochpdf/Gordis2014.pdf:PDF},
  owner     = {Enoch},
  timestamp = {2021-04-09},
  year      = {2014},
}

@Article{Leopold2014,
  author    = {Seth S. Leopold and Lee Beadling and Mark C. Gebhardt and Terence J. Gioe and Benjamin K. Potter and Clare M. Rimnac and Montri D. Wongworawat},
  title     = {Editorial: Words Hurt {\textendash} Avoiding Dehumanizing Language in Orthopaedic Research and Practice},
  doi       = {10.1007/s11999-014-3802-8},
  number    = {9},
  pages     = {2561--2563},
  volume    = {472},
  journal   = {Clinical Orthopaedics and Related Research{\textregistered}},
  month     = {jul},
  owner     = {Enoch},
  publisher = {Ovid Technologies (Wolters Kluwer Health)},
  timestamp = {2021-04-09},
  year      = {2014},
}

@Article{Hung2014,
  author    = {Mei-Chuan Hung and Junne-Ming Sung and Yu-Tzu Chang and Jing-Shiang Hwang and Jung-Der Wang},
  title     = {Estimation of Physical Functional Disabilities and Long-term Care Needs for Patients Under Maintenance Hemodialysis},
  doi       = {10.1097/mlr.0000000000000010},
  number    = {1},
  pages     = {63--70},
  volume    = {52},
  journal   = {Medical Care},
  month     = {jan},
  owner     = {Enoch},
  publisher = {Ovid Technologies (Wolters Kluwer Health)},
  timestamp = {2021-04-09},
  year      = {2014},
}

@Book{Bickel2015a,
  author    = {Peter J. Bickel, Kjell A. Doksum},
  date      = {2015-03-25},
  title     = {Mathematical Statistics Volume 1},
  isbn      = {9781498723817},
  pagetotal = {576},
  publisher = {Taylor & Francis Ltd.},
  url       = {https://www.ebook.de/de/product/24343535/peter_j_bickel_kjell_a_doksum_mathematical_statistics.html},
  ean       = {9781498723817},
  file      = {:enochpdf/Bickel2015a.pdf:PDF;:/Users/yitche/Box/enochpdf/Bickel2015a.pdf:PDF},
  owner     = {Enoch},
  timestamp = {2021-04-09},
  year      = {2015},
}

@Book{Bickel2015b,
  author    = {Peter J. Bickel, Kjell A. Doksum},
  date      = {2015-03-25},
  title     = {Mathematical Statistics Volume 2},
  isbn      = {9781498723817},
  pagetotal = {576},
  publisher = {Taylor & Francis Ltd.},
  url       = {https://www.ebook.de/de/product/24343535/peter_j_bickel_kjell_a_doksum_mathematical_statistics.html},
  ean       = {9781498723817},
  file      = {:enochpdf/Bickel2015b.pdf:PDF;:/Users/yitche/Box/enochpdf/Bickel2015b.pdf:PDF},
  owner     = {Enoch},
  timestamp = {2021-04-09},
  year      = {2015},
}

@Book{Drummond2015,
  author    = {Drummond, Michael},
  title     = {Methods for the economic evaluation of health care programmes},
  isbn      = {9780199665877},
  publisher = {Oxford University Press},
  address   = {Oxford},
  file      = {:/Users/yitche/Box/enochpdf/Drummond2015.pdf:PDF;:enochpdf/Drummond2015.pdf:PDF},
  owner     = {Enoch},
  timestamp = {2021-04-09},
  year      = {2015},
}

@Article{Hsu2015,
  author    = {Minchung Hsu and Pei-Ju Liao},
  title     = {Financing National Health Insurance: The Challenge of Fast Population Aging},
  pages     = {145-182},
  volume    = {43(2)},
  journal   = {Taiwan Economic Review},
  owner     = {Enoch},
  timestamp = {2021-04-09},
  year      = {2015},
}

@Book{Gruber2016,
  author    = {Gruber, Jonathan},
  title     = {Public finance and public policy},
  isbn      = {9781464143335},
  publisher = {Worth Publishers},
  address   = {New York},
  file      = {:/Users/yitche/Box/enochpdf/Gruber2016.pdf:PDF;:enochpdf/Gruber2016.pdf:PDF},
  owner     = {Enoch},
  timestamp = {2021-04-09},
  year      = {2016},
}

@Article{Hoffmann2016,
  author    = {V S Hoffmann and M Baccarani and J Hasford and F Castagnetti and F Di Raimondo and L F Casado and A Turkina and D Zackova and G Ossenkoppele and A Zaritskey and M HÃ¶glund and B Simonsson and K Indrak and Z Sninska and T Sacha and R Clark and A Bogdanovic and A Hellmann and L Griskevicius and G Schubert-Fritschle and D Sertic and J Guilhot and S Lejniece and I Zupan and S Burgstaller and P Koskenvesa and H Everaus and P Costeas and D Lindoerfer and G Rosti and S Saussele and A Hochhaus and R Hehlmann},
  title     = {Treatment and outcome of 2904 {CML} patients from the {EUTOS} population-based registry},
  doi       = {10.1038/leu.2016.246},
  number    = {3},
  pages     = {593--601},
  volume    = {31},
  file      = {:enochpdf/Hoffmann2016.pdf:PDF},
  journal   = {Leukemia},
  month     = {aug},
  owner     = {Enoch},
  publisher = {Springer Science and Business Media {LLC}},
  timestamp = {2021-04-09},
  year      = {2016},
}

@Article{Lin2016,
  author    = {Pei-Jung Lin and Aaron N. Winn and Susan K. Parsons and Peter J. Neumann and Elisa S. Weiss and Joshua T. Cohen},
  title     = {Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia},
  doi       = {10.1097/mlr.0000000000000496},
  number    = {4},
  pages     = {380--385},
  volume    = {54},
  file      = {:enochpdf/Lin2016.pdf:PDF},
  journal   = {Medical Care},
  month     = {apr},
  owner     = {Enoch},
  publisher = {Ovid Technologies (Wolters Kluwer Health)},
  timestamp = {2021-04-09},
  year      = {2016},
}

@Book{Neumann2016,
  author    = {Peter J. Neumann and Theodore G. Ganiats and Louise B. Russell and Gillian D. Sanders and and Joanna E. Siegel},
  date      = {2016-11-01},
  title     = {Cost-Effectiveness in Health and Medicine},
  isbn      = {0190492937},
  pagetotal = {536},
  publisher = {OXFORD UNIV PR},
  url       = {https://www.ebook.de/de/product/28780492/cost_effectiveness_in_health_and_medicine.html},
  ean       = {9780190492939},
  owner     = {Enoch},
  timestamp = {2021-04-09},
  year      = {2016},
}

@Article{Yang2017,
  author    = {Szu-Chun Yang and Wu-Wei Lai and Chien-Chung Lin and Wu-Chou Su and Li-Jung Ku and Jing-Shiang Hwang and Jung-Der Wang},
  title     = {Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan},
  doi       = {10.1016/j.lungcan.2017.04.001},
  pages     = {183--191},
  volume    = {108},
  journal   = {Lung Cancer},
  month     = {jun},
  owner     = {Enoch},
  publisher = {Elsevier {BV}},
  timestamp = {2021-04-09},
  year      = {2017},
}

@Article{Wang2018,
  author    = {Fuhmei Wang and Jung-Der Wang and Yu-Wen Hung},
  title     = {Universal health insurance, health inequality and oral cancer in Taiwan},
  doi       = {10.1371/journal.pone.0205731},
  editor    = {Sok Ching Cheong},
  number    = {10},
  pages     = {e0205731},
  volume    = {13},
  journal   = {{PLOS} {ONE}},
  month     = {oct},
  owner     = {Enoch},
  publisher = {Public Library of Science ({PLoS})},
  timestamp = {2021-04-09},
  year      = {2018},
}

@Book{Lantsoght2018,
  author    = {Lantsoght, Eva},
  title     = {The A-Z of the PhD Trajectory : a Practical Guide for a Successful Journey},
  isbn      = {9783319774244},
  publisher = {Springer International Publishing Imprint Springer},
  address   = {Cham},
  file      = {:enochpdf/Lantsoght2018.pdf:PDF;:/Users/yitche/Box/enochpdf/Lantsoght2018.pdf:PDF},
  owner     = {Enoch},
  timestamp = {2021-04-09},
  year      = {2018},
}

@Article{Aronsson2018,
  author    = {Linus Aronsson and Daniel Ansari and Bodil Andersson and Ulf Persson and Adam Fridhammar and Roland Andersson},
  title     = {Intraductal papillary mucinous neoplasms of the pancreas {\textendash} a cost-effectiveness analysis of management strategies for the branch-duct subtype},
  doi       = {10.1016/j.hpb.2018.06.1801},
  number    = {12},
  pages     = {1206--1214},
  volume    = {20},
  journal   = {{HPB}},
  month     = {dec},
  owner     = {Enoch},
  publisher = {Elsevier {BV}},
  timestamp = {2021-04-09},
  year      = {2018},
}

@Book{NDC2018,
  author    = {åœ‹å®¶ç™¼å±•å§”å“¡æœƒ},
  title     = {ä¸­è¯æ°‘åœ‹äººå£æŽ¨ä¼° (2018 è‡³ 2065)},
  isbn      = {9789860566451},
  publisher = {åœ‹å®¶ç™¼å±•å§”å“¡æœƒ},
  owner     = {Enoch},
  timestamp = {2021-04-09},
  year      = {2018},
}

@Article{Bullement2019,
  author    = {Ash Bullement and Nicholas R. Latimer and Helen Bell Gorrod},
  title     = {Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study},
  doi       = {10.1016/j.jval.2018.10.007},
  number    = {3},
  pages     = {276--283},
  volume    = {22},
  file      = {:/Users/yitche/survbib/pdf/Bullement2019.pdf:PDF},
  journal   = {Value in Health},
  month     = {mar},
  owner     = {Enoch},
  publisher = {Elsevier {BV}},
  timestamp = {2021-04-09},
  year      = {2019},
}

@Article{Huang2019,
  author    = {Cheng-Chih Huang ,Chia-Ni Lin, Chia-Hua Chung and Jing- Shiang Hwang, Sen-Tien Tsai, Jung-Der Wang},
  title     = {Cost-effectiveness analysis of the oral cancer screening program in Taiwan},
  doi       = {10.1016/j.oraloncology.2018.12.011},
  pages     = {59--65},
  volume    = {89},
  journal   = {Oral Oncology},
  month     = {feb},
  owner     = {Enoch},
  publisher = {Elsevier {BV}},
  timestamp = {2021-04-09},
  year      = {2019},
}

@Article{Karlsson2019,
  author    = {Andreas Karlsson and Alexandra Jauhiainen and Roman Gulati and Martin Eklund and Henrik GrÃ¶nberg and Ruth Etzioni and Mark Clements},
  title     = {A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data},
  doi       = {10.1371/journal.pone.0211918},
  editor    = {Neal Shore},
  number    = {2},
  pages     = {e0211918},
  volume    = {14},
  journal   = {{PLOS} {ONE}},
  month     = {feb},
  owner     = {Enoch},
  publisher = {Public Library of Science ({PLoS})},
  timestamp = {2021-04-09},
  year      = {2019},
}

@Book{IARC2020,
  author    = {IARC},
  title     = {WORLD CANCER REPORT : cancer research for cancer development},
  isbn      = {9789283204473},
  publisher = {IARC},
  address   = {Place of publication not identified},
  file      = {:enochpdf/IARC2020.pdf:PDF;:/Users/yitche/Box/enochpdf/IARC2020.pdf:PDF},
  owner     = {Enoch},
  timestamp = {2021-04-09},
  year      = {2020},
}

@Book{MiguelA.Hernan2020,
  author    = {Miguel A. Hern{\a}n, James M. Robins},
  title     = {Causal Inference: What If},
  year      = {2020},
  file      = {:enochpdf/Hernan2020.pdf:PDF;:/Users/yitche/Box/enochpdf/Hernan2020.pdf:PDF},
  owner     = {Enoch},
  timestamp = {2021-04-09},
}

@Book{Gabriel2020,
  author    = {Erin Gabriel, Paolo Frumento},
  publisher = {Epidemiology PhD program, Karolinska Institutet},
  owner     = {Enoch},
  timestamp = {2021-04-09},
  year      = {2020},
}

@Book{Goldsman2020,
  author    = {David Goldsman, Paul Goldsman},
  title     = {A First Course in Probability and Statistics},
  publisher = {Georgia Institute of Technology},
  owner     = {Enoch},
  timestamp = {2021-04-09},
  year      = {2020},
}

@Misc{Bower2020,
  author    = {Bower, Hannah and Andersson, Therese M-L and Crowther, Michael J. and Lambert, Paul},
  title     = {STMT: Stata module to model multiple timescales using flexible parametric survival models on the log-hazard scale},
  url       = {https://EconPapers.repec.org/RePEc:boc:bocode:s458849},
  abstract  = {stmt fits flexible parametric survival models (Royston-Parmar models) on the log hazard scale where multiple timescales are allowed},
  keywords  = {survival; parametric; flexible; log-hazard},
  owner     = {Enoch},
  timestamp = {2021-04-09},
  year      = {2020},
}

@Article{Fridhammar2020,
  author    = {Adam Fridhammar and Ulrika Axelsson and Ulf Persson and Anders Bjartell and Carl A. K. Borrebaeck},
  title     = {The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development},
  doi       = {10.1007/s41669-020-00226-7},
  journal   = {{PharmacoEconomics} - Open},
  month     = {aug},
  owner     = {Enoch},
  publisher = {Springer Science and Business Media {LLC}},
  timestamp = {2021-04-09},
  year      = {2020},
}

@Article{Etienne2017,
  author          = {Etienne, Gabriel and Guilhot, JoÃ«lle and Rea, Delphine and Rigal-Huguet, FranÃ§oise and Nicolini, Franck and Charbonnier, Aude and Guerci-Bresler, AgnÃ¨s and Legros, Laurence and Varet, Bruno and Gardembas, Martine and Dubruille, Viviane and Tulliez, Michel and Noel, Marie-Pierre and Ianotto, Jean-Christophe and Villemagne, Bruno and CarrÃ©, Martin and Guilhot, FranÃ§ois and Rousselot, Philippe and Mahon, FranÃ§ois-Xavier},
  title           = {{Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia}},
  doi             = {10.1200/JCO.2016.68.2914},
  issn            = {1527-7755},
  issue           = {3},
  pages           = {298--305},
  pubstate        = {ppublish},
  volume          = {35},
  abstract        = {Purpose Imatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia (CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years. We report the final results of the Stop Imatinib (STIM1) study with a long follow-up. Patients and Methods IM was prospectively discontinued in 100 patients with CML with UMRD sustained for at least 2 years. Molecular recurrence (MR) was defined as positivity of BCR-ABL transcript in a quantitative reverse transcriptase polymerase chain reaction assay confirmed by a second analysis point that indicated an increase of one log in relation to the first analysis point at two successive assessments or loss of major molecular response at one point. Results The median molecular follow-up after treatment discontinuation was 77 months (range, 9 to 95 months). Sixty-one patients lost UMRD after a median of 2.5 months (range, 1 to 22 months), and one patient died with UMRD at 10 months. Molecular recurrence-free survival was 43% (95% CI, 33% to 52%) at 6 months and 38% (95% CI, 29% to 47%) at 60 months. Treatment was restarted in 57 of 61 patients with MR, and 55 patients achieved a second UMRD with a median time of 4 months (range, 1 to 16 months). None of the patients experienced a CML progression. Analyses of the characteristics of the study population identified that the Sokal risk score and duration of IM treatment were significantly associated with the probability of MR. Conclusion With a median follow-up of more than 6 years after treatment discontinuation, the STIM1 study demonstrates that IM can safely be discontinued in patients with a sustained deep molecular response with no late MR.},
  chemicals       = {Antineoplastic Agents, BCR-ABL1 fusion protein, human, Biomarkers, Tumor, Protein Kinase Inhibitors, Imatinib Mesylate, Fusion Proteins, bcr-abl},
  citation-subset = {IM},
  completed       = {2017-08-08},
  country         = {United States},
  groups          = {CML},
  issn-linking    = {0732-183X},
  journal         = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  keywords        = {Adult; Aged; Aged, 80 and over; Antineoplastic Agents, administration & dosage, adverse effects; Biomarkers, Tumor, genetics; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; France; Fusion Proteins, bcr-abl, genetics; Humans; Imatinib Mesylate, adverse effects; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, enzymology, genetics, pathology; Male; Middle Aged; Molecular Diagnostic Techniques; Neoplasm, Residual; Patient Selection; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors, adverse effects; Recurrence; Risk Factors; Time Factors; Treatment Outcome},
  month           = jan,
  nlm-id          = {8309333},
  owner           = {NLM},
  pmid            = {28095277},
  pubmodel        = {Print-Electronic},
  revised         = {2017-08-08},
  year            = {2017},
}

@Article{Kim2020,
  author    = {David D. Kim and Madison C. Silver and Natalia Kunst and Joshua T. Cohen and Daniel A. Ollendorf and Peter J. Neumann},
  title     = {Perspective and Costing in Cost-Effectiveness Analysis, 1974{\textendash}2018},
  doi       = {10.1007/s40273-020-00942-2},
  number    = {10},
  pages     = {1135--1145},
  volume    = {38},
  file      = {:Kim2020.pdf:PDF},
  groups    = {Health Economics},
  journal   = {{PharmacoEconomics}},
  month     = {oct},
  owner     = {Enoch},
  publisher = {Springer Science and Business Media {LLC}},
  timestamp = {2021-04-19},
  year      = {2020},
}

@Article{Efficace2016,
  author    = {Fabio Efficace and Laura Cannella},
  title     = {The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors},
  doi       = {10.1182/asheducation-2016.1.170},
  number    = {1},
  pages     = {170--179},
  volume    = {2016},
  groups    = {Study 2. Quality of Life},
  journal   = {Hematology},
  month     = {dec},
  publisher = {American Society of Hematology},
  year      = {2016},
}

@Article{Efficace2018,
  author          = {Efficace, Fabio and Castagnetti, Fausto and Martino, Bruno and Breccia, Massimo and D'Adda, Mariella and Angelucci, Emanuele and Stagno, Fabio and Cottone, Francesco and Malato, Alessandra and Trabacchi, Elena and Capalbo, Silvana Franca and Gobbi, Marco and Visani, Giuseppe and Salvucci, Marzia and Capodanno, Isabella and Tosi, Patrizia and Tiribelli, Mario and Scortechini, Anna Rita and Levato, Luciano and Maino, Elena and Binotto, Gianni and Gugliotta, Gabriele and Vignetti, Marco and Baccarani, Michele and Rosti, Gianantonio},
  title           = {Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.},
  doi             = {10.1002/cncr.31323},
  issn            = {1097-0142},
  issue           = {10},
  pages           = {2228--2237},
  pubstate        = {ppublish},
  volume          = {124},
  abstract        = {Although a wealth of efficacy and safety data is available for many tyrosine kinase inhibitors used in chronic myeloid leukemia (CML), there is a dearth of information on their impact on patients' health-related quality of life (HRQOL). The primary objective of this study was to evaluate HRQOL and fatigue outcomes in patients with CML receiving first-line therapy with nilotinib. This was a multicenter, prospective study enrolling 130 patients with chronic-phase CML. HRQOL and fatigue were evaluated with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and its validated Fatigue module at the baseline and then at 3, 6, 12, 18, and 24 months. The primary prespecified HRQOL endpoints defined in the study protocol for longitudinal analysis were the Physical Functioning, Social Functioning, Role Functioning, and Fatigue scales. The remaining scales were investigated on an exploratory basis. The rate of baseline compliance with the HRQOL assessment was 95.4% (124 of 130), and the rate of overall compliance with HRQOL forms was 91%. Among the 4 prespecified primary HRQOL endpoints, statistically significant improvements over time were found for Physical Functioning (P = .013), Role Functioning (P = .004), and Fatigue (P < .001). Clinically meaningful improvements were found already 3 months after the treatment start. The baseline patient self-reported fatigue severity was an independent predictive factor for the achievement of a major molecular response with an odds ratio of 0.960 (95% confidence interval, 0.934-0.988; P = .005). For most patients, HRQOL improvements with nilotinib occur during the early phase of therapy and are maintained over time. Also, a more systematic HRQOL evaluation during the diagnostic workup of CML may help to predict clinical outcomes. Cancer 2018;124:2228-37. Â© 2018 American Cancer Society.},
  chemicals       = {4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide, Protein Kinase Inhibitors, Pyrimidines},
  citation-subset = {AIM, IM},
  completed       = {2019-09-11},
  country         = {United States},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0008-543X},
  journal         = {Cancer},
  keywords        = {Adult; Aged; Aged, 80 and over; Fatigue, diagnosis, etiology, psychology; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, complications, drug therapy, psychology; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors, administration & dosage, adverse effects; Pyrimidines, adverse effects; Quality of Life; Self Report, statistics & numerical data; Severity of Illness Index; Treatment Outcome; Young Adult; chronic myeloid leukemia; fatigue; nilotinib; quality of life; tyrosine kinase inhibitors},
  month           = may,
  nlm-id          = {0374236},
  owner           = {NLM},
  pmid            = {29499087},
  pubmodel        = {Print-Electronic},
  revised         = {2019-09-11},
  year            = {2018},
}

@Article{Huguet2019,
  author          = {Huguet, FranÃ§oise and Cayuela, Jean-Michel and Cambier, Nathalie and Carpentier, Nathalie and Tindel, Malka and Violet, Isabelle and Zunic, Patricia and Lascaux, Axelle and Etienne, Gabriel and Investigators, AdheRM. C.},
  title           = {Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice.},
  doi             = {10.1111/bjh.16145},
  issn            = {1365-2141},
  issue           = {5},
  pages           = {615--626},
  pubstate        = {ppublish},
  volume          = {187},
  abstract        = {This observational, prospective study assessed, in a daily clinical practice, the molecular response, safety, quality of life (QoL) and treatment adherence in 183 patients with chronic myeloid leukaemia in chronic phase (CML-CP), receiving nilotinib as first-line treatment. Premature study termination before 24Â months of follow-up occurred in 61 patients (33Â·3%), and was essentially due to nilotinib treatment discontinuation (nÂ =Â 53; 29%), motivated by treatment intolerance (nÂ =Â 29; 15Â·8%) and inefficacy (nÂ =Â 19; 10Â·4%). After 24Â months of treatment, 112/122 patients (91Â·8%) had a molecular assessment, 95Â·5% of whom achieved a major molecular response (MMR), 32Â·1% achieved uMR  , defined as an undetectable molecular disease with 4-log molecular response sensitivity (â‰¥10Â 000 ABL1 transcripts). The Morisky Green Levine Medication Adherence Scale was completed by 94/122 patients (77Â·0%), and 89Â·4% of these patients obtained a satisfactory level of treatment adherence, defined as a score â‰¥3. Patients' QoL was good at baseline and stable during the follow-up period. The two most common nilotinib-related adverse events (AEs) were pruritus (14Â·8%) and asthenia (13Â·7%). Seven patients (3Â·8%) experienced at least one cardiovascular ischaemic AE. This French nationwide cohort study provides relevant information in daily clinical practice indicating that nilotinib is a valuable first-line treatment option for CML-CP patients.},
  chemicals       = {4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide, Antineoplastic Agents, BCR-ABL1 fusion protein, human, Biomarkers, Tumor, Pyrimidines, Protein-Tyrosine Kinases, Fusion Proteins, bcr-abl},
  citation-subset = {IM},
  completed       = {2020-06-22},
  country         = {England},
  groups          = {Study 2. Quality of Life},
  investigator    = {Didier Innocent, Adiko and Shanti, Ame Natarajan and Carla, Araujo and Omar, Benbrahim and Martial, Boisseau and Dominique, Bordessoule and Azzedine, Bouderbala and Nathalie, Cambier and Valerie, Coiteux and Pascale, Cony Makhoul and Regis, Costello and Martine, Delain and Viviane, Dubruille and Abderrazak, El Yamani and Gabriel, Etienne and Jose, Fernandes and Reda, Garidi and Agnes, Guerci Bresler and Denis, Guyotat and Maya, Hacini and Eric, Hermet and Francoise, Huguet and Jean Christophe, Ianotto and Bertrand, Joly and Eric, Jourdan and Fabrice, Larosa and Axelle, Lascaux and Sophie, Lefort and Anne, Marfaing and Jean-Pierre, Marolleau and Jessica, Michel and Franck, Nicolini and Isabelle, Plantier and Philippe, Quittet and Philippe, Rodon and Laurence, Sanhes and Ioana, Vaida and Bruno, Villemagne and Sorin, Visanica and Laurent, Voillat and Patricia, Zunic},
  issn-linking    = {0007-1048},
  journal         = {British journal of haematology},
  keywords        = {Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, adverse effects, therapeutic use; Asthenia, chemically induced; Biomarkers, Tumor, genetics; Drug Eruptions, etiology; Female; Follow-Up Studies; Fusion Proteins, bcr-abl, genetics; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, genetics; Male; Medication Adherence, statistics & numerical data; Middle Aged; Prospective Studies; Protein-Tyrosine Kinases, antagonists & inhibitors; Pruritus, chemically induced; Psychometrics; Pyrimidines, therapeutic use; Quality of Life; Treatment Outcome; Young Adult; adherence; chronic myeloid leukaemia; daily clinical practice; nilotinib; tyrosine-kinase inhibitor},
  month           = dec,
  nlm-id          = {0372544},
  owner           = {NLM},
  pmid            = {31394591},
  pubmodel        = {Print-Electronic},
  revised         = {2020-08-07},
  year            = {2019},
}

@Article{Bruemmendorf2020,
  author          = {BrÃ¼mmendorf, Tim H. and Gambacorti-Passerini, Carlo and Bushmakin, Andrew G. and Cappelleri, Joseph C. and Viqueira, Andrea and Reisman, Arlene and Isfort, Susanne and Mamolo, Carla},
  title           = {Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia.},
  doi             = {10.1007/s00277-020-04018-1},
  issn            = {1432-0584},
  issue           = {6},
  pages           = {1241--1249},
  pubstate        = {ppublish},
  volume          = {99},
  abstract        = {Patients with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) can be effectively treated with tyrosine kinase inhibitors (TKIs) and achieve a lifespan similar to the general population. The success of TKIs, however, requires long-term and sometimes lifelong treatment; thus, patient-assessed health-related quality of life (HRQoL) has become an increasingly important parameter for treatment selection. Bosutinib is a TKI approved for CP CML in newly diagnosed adults and in those resistant or intolerant to prior therapy. In the Bosutinib Trial in First-Line Chronic Myelogenous Leukemia Treatment (BFORE), bosutinib demonstrated a significantly higher major molecular response rate compared with imatinib, with maintenance of HRQoL (measured by the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) questionnaire), after 12Â months of first-line treatment. We examined relationships between molecular response (MR) and HRQoL. MR values were represented by a log-reduction scale (MRLR; a continuous variable). A repeated-measures longitudinal model was used to estimate the relationships between MRLR as a predictor and each FACT-Leu domain as an outcome. Effect sizes were calculated to determine strength of effects and allow comparisons across domains. The majority of FACT-Leu domains (with the exception of social well-being and physical well-being) demonstrated a significant relationship with MRLR (pâ€‰<â€‰0.05). Our results showed variable impact of clinical improvement on different dimensions of HRQoL. For patients who achieved MR , emotional well-being and leukemia-specific domains showed the greatest improvement, with medium differences in effect sizes, whereas social well-being and physical well-being had the weakest relationship with MR.},
  chemicals       = {Aniline Compounds, Antineoplastic Agents, Nitriles, Quinolines, bosutinib, Imatinib Mesylate},
  citation-subset = {IM},
  completed       = {2020-06-01},
  country         = {Germany},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0939-5555},
  journal         = {Annals of hematology},
  keywords        = {Aniline Compounds, therapeutic use; Antineoplastic Agents, therapeutic use; Humans; Imatinib Mesylate, therapeutic use; Leukemia, Myeloid, Chronic-Phase, blood, drug therapy, psychology; Nitriles, therapeutic use; Quality of Life, psychology; Quinolines, therapeutic use; Treatment Outcome; Bosutinib; Chronic myeloid leukemia; Health-related quality of life; Imatinib; Molecular response},
  month           = jun,
  nlm-id          = {9107334},
  owner           = {NLM},
  pii             = {10.1007/s00277-020-04018-1},
  pmc             = {PMC7237399},
  pmid            = {32307568},
  pubmodel        = {Print-Electronic},
  revised         = {2020-06-01},
  year            = {2020},
}

@Article{Trask2013,
  author          = {Trask, Peter C. and Cella, David and Powell, Christine and Reisman, Arlene and Whiteley, Jennifer and Kelly, Virginia},
  title           = {Health-related quality of life in chronic myeloid leukemia.},
  doi             = {10.1016/j.leukres.2012.09.013},
  issn            = {1873-5835},
  issue           = {1},
  pages           = {9--13},
  pubstate        = {ppublish},
  volume          = {37},
  abstract        = {The increased survival associated with treatments for CML emphasize the importance of understanding the HRQOL of newly diagnosed and previously treated CML patients with all phases of disease. Functional Assessment of Cancer Therapy-Leukemia results from a phase 3 and a phase 2 trial are reported for over 900 1st, 2nd, 3rd line CP, AP, and BP patients. Physical Well-being and Leukemia symptoms were worse for patients in later lines of therapy. Individuals with AP and BP CML had poorer HRQOL than individuals with CP CML. HRQOL of CML patients was predominantly consistent with the longitudinal clinical trajectory of the disease.},
  citation-subset = {IM},
  completed       = {2013-03-20},
  country         = {England},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0145-2126},
  journal         = {Leukemia research},
  keywords        = {Adult; Aged; Female; Health Status; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, physiopathology, psychology; Male; Middle Aged; Quality of Life},
  month           = jan,
  nlm-id          = {7706787},
  owner           = {NLM},
  pii             = {S0145-2126(12)00386-4},
  pmid            = {23116602},
  pubmodel        = {Print-Electronic},
  revised         = {2012-12-18},
  year            = {2013},
}

@Article{Sacha2017,
  author    = {Tomasz Sacha and Joanna G{\'{o}}ra-Tybor and Ewa W{\k{a}}sak-Szulkowska and S{\l}awomira Kyrcz-Krzemie{\'{n}} and Ewa M{\k{e}}dra{\'{s}} and Rafa{\l} Becht and Gra{\.{z}}yna Bober and Aneta Kotowska and Joanna W{\k{a}}c{\l}aw and Andrzej Hellmann},
  title     = {Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second-Line Therapy: A~Multicenter Prospective Observational Study},
  doi       = {10.1016/j.clml.2017.01.001},
  number    = {5},
  pages     = {283--295},
  volume    = {17},
  groups    = {Study 2. Quality of Life},
  journal   = {Clinical Lymphoma Myeloma and Leukemia},
  month     = {may},
  publisher = {Elsevier {BV}},
  year      = {2017},
}

@Article{Flynn2016,
  author    = {Kathryn E. Flynn and Ehab Atallah},
  title     = {Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia},
  doi       = {10.1007/s11899-016-0306-5},
  number    = {2},
  pages     = {80--85},
  volume    = {11},
  groups    = {Study 2. Quality of Life},
  journal   = {Current Hematologic Malignancy Reports},
  month     = {feb},
  publisher = {Springer Science and Business Media {LLC}},
  year      = {2016},
}

@Article{Unnikrishnan2017,
  author       = {Unnikrishnan, Radhika and Veeraiah, Surendran and Ganesan, Prasanth},
  title        = {Symptom Burden and Quality of Life Issues among Patients of Chronic Myeloid Leukemia on Long-term Imatinib Therapy.},
  doi          = {10.4103/ijmpo.ijmpo_160_16},
  issn         = {0971-5851},
  issue        = {2},
  pages        = {165--168},
  pubstate     = {ppublish},
  volume       = {38},
  abstract     = {Tyrosine kinase inhibitors such as imatinib have improved survival in chronic myeloid leukemia (CML). Imatinib can cause chronic side effects which are not considered serious but can impact the quality of life (QoL) of the patient. The results of a detailed symptom burden analysis and its impact on QoL scores in a cohort of patients on long-term imatinib is presented in this study. Symptom burden was assessed using the M. D. Anderson Symptom Inventory specific for CML patients. An indigenously developed QoL questionnaire (Cancer Institute Quality of Life II) was administered simultaneously. Of 221 patients of CML (M:F = 133:88; median age: 39 years [18-65], median duration of imatinib: 4 years), QoL scores were high in 46%, average in 39%, and low in 14%. QoL scores were negatively correlated with general symptoms (  = -0.612,   < 0.001), CML-specific symptoms (  = -0.513,   < 0.001), and interference of symptoms (  = -0.596,   < 0.001). Significant impairment of QoL was noted among patients with CML primarily due to the burden of symptom related to side effects of imatinib. This issue must be addressed both in the clinic as well as in all studies of CML.},
  country      = {India},
  groups       = {Study 2. Quality of Life},
  issn-linking = {0971-5851},
  journal      = {Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology},
  keywords     = {Chronic myeloid leukemia; quality of life; symptom burden},
  nlm-id       = {9604571},
  owner        = {NLM},
  pii          = {IJMPO-38-165},
  pmc          = {PMC5582554},
  pmid         = {28900325},
  pubmodel     = {Print},
  revised      = {2020-10-01},
  year         = {2017},
}

@Article{Efficace2019,
  author    = {Fabio Efficace and Fabio Stagno and Alessandra Iurlo and Massimo Breccia and Francesco Cottone and Massimiliano Bonifacio and Elisabetta Abruzzese and Fausto Castagnetti and Giovanni Caocci and Monica Crugnola and Isabella Capodanno and Bruno Martino and Mario Tiribelli and Andrea Patriarca and Antonella Gozzini and Patrizia Pregno and Susanne Saussele and Nicola Cascavilla and Claudio Fozza and Micaela Bergamaschi and Gianni Binotto and Marco Vignetti and Gianantonio Rosti},
  title     = {Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy},
  doi       = {10.1038/s41375-019-0563-0},
  number    = {2},
  pages     = {488--498},
  volume    = {34},
  groups    = {Study 2. Quality of Life},
  journal   = {Leukemia},
  month     = {sep},
  publisher = {Springer Science and Business Media {LLC}},
  year      = {2019},
}

@Article{Foulon2021,
  author          = {Foulon, S. and Cony-Makhoul, P. and Guerci-Bresler, A. and Daban, M. and Kapso, R. and Tubert-Bitter, P. and Bonastre, J.},
  title           = {Health state utility and quality of life measures in patients with chronic myeloid leukemia in France.},
  doi             = {10.1007/s11136-021-02794-5},
  issn            = {1573-2649},
  pubstate        = {aheadofprint},
  abstract        = {Tyrosine kinase inhibitors (TKIs) have dramatically improved the prognosis of chronic myeloid leukemia (CML). We aimed to assess health state utility and quality of life (QoL) in French patients with CML in real-life setting, to study the determinants of utility score and to compare health-related QoL values to general population norms. We conducted a cross-sectional study in 412 patients with CML. Data were collected by electronic survey. Three patient-reported outcomes questionnaires were used: EORTC QLQ-C30, EORTC QLQ-CML24 and EuroQol EQ-5D-3L. Health state utility values were computed using the French value set. We computed deviations from reference norms from the general population. We studied the determinants of health utility score using multiple regression models. The mean utility score (SD) was 0.72 (0.25) in the chronic phase and 0.84 (0.21) in treatment-free remission, with marked variations by gender. Patients with CML had a deviation from the reference norm of -0.15 on average (SD: 0.25). In terms of QoL, social functioning, role functioning and cognitive functioning were notably impacted with a mean difference of -16.0, -13.1 and -11.7 respectively. Fatigue, dyspnea and pain were the symptoms with the highest deviation from general population norms (mean difference of 20.6, 14.0 and 8.3 respectively). In the multiple regression analysis, fatigue was the most important independent predictor of the utility score. Although TKIs prevent the disease from progressing and even allow remission without treatment, QoL in patients with CML is notably altered. The utility scores deteriorate with CML symptoms.},
  citation-subset = {IM},
  country         = {Netherlands},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0962-9343},
  journal         = {Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation},
  keywords        = {Chronic myeloid leukemia; Health utility score; Quality of life; Tyrosine kinase inhibitor},
  month           = mar,
  nlm-id          = {9210257},
  owner           = {NLM},
  pii             = {10.1007/s11136-021-02794-5},
  pmid            = {33651280},
  pubmodel        = {Print-Electronic},
  revised         = {2021-03-02},
  year            = {2021},
}

@Article{Malagola2021,
  author          = {Malagola, Michele and Iurlo, Alessandra and Abruzzese, Elisabetta and Bonifacio, Massimiliano and Stagno, Fabio and Binotto, Gianni and D'Adda, Mariella and Lunghi, Monia and Crugnola, Monica and Ferrari, Maria Luisa and Lunghi, Francesca and Castagnetti, Fausto and Rosti, Gianantonio and Lemoli, Roberto M. and Sancetta, Rosaria and Coppi, Maria Rosaria and Corsetti, Maria Teresa and Rege Cambrin, Giovanna and Romano, Atelda and Tiribelli, Mario and Russo Rossi, Antonella and Russo, Sabina and Aprile, Lara and Gandolfi, Lisa and Farina, Mirko and Bernardi, Simona and Polverelli, Nicola and Roccaro, Aldo M. and De Vivo, Antonio and Baccarani, Michele and Russo, Domenico},
  title           = {Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study.},
  doi             = {10.1002/cam4.3778},
  issn            = {2045-7634},
  issue           = {5},
  pages           = {1726--1737},
  pubstate        = {ppublish},
  volume          = {10},
  abstract        = {Intermittent treatment with TKIs is an option for the great majority (70%-80%) of CML patients who do not achieve a stable deep molecular response and are not eligible for treatment discontinuation. For these patients, the only alternative is to assume TKI continuously, lifelong. The Italian phase III multicentric randomized OPTkIMA study started in 2015, with the aim to evaluate if a progressive de-escalation of TKIs (imatinib, nilotinib, and dasatinib) is able to maintain the molecular response (MR  ) and to improve Health Related Quality of Life (HRQoL). Up to December 2018, 166/185 (90%) elderly CML patients in stable MR  /MR  completed the first year of any TKI intermittent schedule 1Â month ON and 1Â month OFF. The first year probability of maintaining the MR  was 81% and 23.5% of the patients who lost the molecular response regained the MR  after resuming TKI continuously. Patients' HRQoL at baseline was better than that of matched peers from healthy population. Women was the only factor independently associated with worse baseline HRQoL (pÂ >Â 0.0001). Overall, global HRQoL worsened at 6 (pÂ <Â 0.001) but returned to the baseline value at 12Â months and it was statistically significantly worse in women (pÂ =Â 0.001). De-escalation of any TKI by 1Â month ON/OFF schedule maintains the MR  /MR  in 81% of the patients during the first 12-24Â months. No patients progressed to accelerated/blastic phase, all the patients (23.5%) losing MR  regained the MR  and none suffered from TKI withdrawn syndrome. The study firstly report on HRQoL in elderly CML patients moving from a continuous daily therapy to a de-escalated intermittent treatment.},
  citation-subset = {IM},
  country         = {United States},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {2045-7634},
  journal         = {Cancer medicine},
  keywords        = {chronic myeloid leukaemia; intermittent; quality of life; tyrosine kinase inhibitor},
  month           = mar,
  nlm-id          = {101595310},
  owner           = {NLM},
  pmc             = {PMC7940223},
  pmid            = {33594821},
  pubmodel        = {Print-Electronic},
  revised         = {2021-03-17},
  year            = {2021},
}

@Article{Efficace2021,
  author          = {Efficace, Fabio and Vignetti, Marco and Sparano, Francesco and Scalzulli, Emilia and Breccia, Massimo},
  title           = {Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.},
  doi             = {10.1080/17474086.2021.1886918},
  issn            = {1747-4094},
  pages           = {1--10},
  pubstate        = {aheadofprint},
  abstract        = {: The current treatment landscape of chronic myeloid leukemia (CML) is challenging for several reasons, and health-related quality of life (HRQOL) data may be of critical importance to help physicians and patients make more informed decisions. : A systematic literature search was performed in PubMed to identify the most recent studies (between April 2016 and June 2020) assessing the impact of tyrosine kinase inhibitors (TKIs) on adult CML patients' HRQOL. Studies assessing treatment discontinuation were also considered. For each study, we evaluated characteristics of CML patients included, treatment information and basic HRQOL data, including questionnaires used, and summary findings. : Valuable information can be gleaned from recent CML studies including a HRQOL assessment; however, major gaps remain in our knowledge. These include, for example, a better understanding of the impact of second- and third-generation TKIs on patients' HRQOL compared to imatinib therapy. Also, the benefits of TKI treatment discontinuation, in terms of symptom burden and HRQOL, are yet to be fully elucidated. More research efforts are needed in this area to generate high-quality evidence that can facilitate decision-making.},
  citation-subset = {IM},
  country         = {England},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {1747-4094},
  journal         = {Expert review of hematology},
  keywords        = {Chronic myeloid leukemia; quality of life; symptoms; targeted therapy; tyrosine kinase inhibitors},
  month           = mar,
  nlm-id          = {101485942},
  owner           = {NLM},
  pmid            = {33554672},
  pubmodel        = {Print-Electronic},
  revised         = {2021-03-10},
  year            = {2021},
}

@Article{Efficace2021a,
  author          = {Efficace, Fabio and Iurlo, Alessandra and Patriarca, Andrea and Stagno, Fabio and Bee, Ping-Chong and Ector, GeneviÃ¨ve and Capodanno, Isabella and Elena, Chiara and Bonifacio, Massimiliano and Blijlevens, Nicole M. A. and Caocci, Giovanni and Wan, Chonghua and Abruzzese, Elisabetta and Breccia, Massimo and Cottone, Francesco and Okumura, Iris and Oerlemans, Simone and Cascavilla, Nicola and Albano, Francesco and Kota, Vamsi and Sztankay, Monika and Miggiano, Maria Cristina and Saussele, Susanne and Di Renzo, Nicola and SorÃ , Federica and Castagnetti, Fausto and Baccarani, Michele and Vignetti, Marco and Rosti, Gianantonio},
  title           = {Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia.},
  doi             = {10.1080/10428194.2020.1838509},
  issn            = {1029-2403},
  issue           = {3},
  pages           = {669--678},
  pubstate        = {ppublish},
  volume          = {62},
  abstract        = {Health-related quality of life (HRQOL) assessment is important to facilitate decisions in the current treatment landscape of chronic myeloid leukemia (CML). Therefore, the availability of a validated HRQOL questionnaire, specifically developed for CML patients treated with tyrosine kinase inhibitors (TKIs), may enhance quality of research in this area. We performed an international study including 782 CML patients to assess the validity of the EORTC QLQ-CML 24 questionnaire, and to generate HRQOL reference values to facilitate interpretation of results in future studies. Internal consistency, assessed with Cronbach's alpha coefficients, ranged from 0.66 to 0.83. In the confirmatory factor analysis, all standardized factor loadings exceeded the threshold of 0.40 (range 0.49-0.97), confirming the hypothesized scale structure. Reference values stratified by age and sex were also generated. Our findings support the use of the EORTC QLQ-CML 24, in conjunction with the EORTC QLQ-C30, as a valuable measure to assess HRQOL in CML patients.},
  citation-subset = {IM},
  country         = {United States},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {1026-8022},
  journal         = {Leukemia & lymphoma},
  keywords        = {Quality of life; chronic myeloid leukemia; patient-reported outcomes; symptoms; tyrosine kinase inhibitors},
  month           = mar,
  nlm-id          = {9007422},
  owner           = {NLM},
  pmid            = {33153355},
  pubmodel        = {Print-Electronic},
  revised         = {2021-04-01},
  year            = {2021},
}

@Article{Bostan2020,
  author          = {Bostan, Hayri and Toptas, Tayfur and Tanrikulu, Funda Pepedil and Kut, Kevser and Arikan, Fatma and Yilmaz, Fergun and Atagunduz, Isik and Firatli-Tuglular, Tulin},
  title           = {Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia.},
  doi             = {10.1016/j.clml.2020.08.009},
  issn            = {2152-2669},
  issue           = {12},
  pages           = {836--842},
  pubstate        = {ppublish},
  volume          = {20},
  abstract        = {With the advent of tyrosine kinase inhibitors (TKIs), patients with chronic myeloid leukemia (CML) have a life expectancy similar to those of age- and gender-matched healthy populations. Nevertheless, patients receiving TKIs report chronic adverse events such as fatigue, edema, and muscle cramps, which lead to a decrease in their quality of life (QoL). Therefore, the aim of this study was to assess the QoL and symptom burden in patients receiving original imatinib, generic imatinib, dasatinib, and nilotinib. A total of 121 patients with CML who received TKIs for at least 3 months were enrolled in the study. The QoL was assessed with the Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and Quality of Life Questionnaire-Chronic Myeloid Leukemia (QLQ-CML24) modules. The symptom burden was assessed with MD Anderson Symptom Inventory for Chronic Myeloid Leukemia (MDASI-CML) and EORTC QLQ-CML24. The median age of the study population was 53 years (range, 28-90 years), and 83 (81.4%) patients had a low-to-medium Sokal risk score. The Eastern Cooperative Oncology Group performance status of most patients were good (< 2; 96%), and comorbidity scores were low (HCT-CIÂ < 3; 90.8%). There was no significant difference between the general health status of patients in terms of EORTC QLQ-C30 and QLQ-CML24. According to the results of the MDASI-CML and QLQ-CML24 modules, the most common symptom was fatigue (58.7%) in all groups, and there were no significant differences between the groups in terms of the effects on the daily life activities of the patients. Patients with CML receiving first- and second-generation TKIs were seen to have a similar QoL and symptom burden.},
  citation-subset = {IM},
  country         = {United States},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {2152-2669},
  journal         = {Clinical lymphoma, myeloma & leukemia},
  keywords        = {CML; Dasatinib; Generic imatinib; Imatinib mesylate; Nilotinib},
  month           = dec,
  nlm-id          = {101525386},
  owner           = {NLM},
  pii             = {S2152-2650(20)30424-9},
  pmid            = {32958432},
  pubmodel        = {Print-Electronic},
  revised         = {2020-11-30},
  year            = {2020},
}

@Article{Shacham2020,
  author       = {Shacham Abulafia, Adi and Shemesh, Sivan and Rosenmann, Lena and Berger, Tamar and Leader, Avi and Sharf, Giora and Raanani, Pia and Rozovski, Uri},
  title        = {Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors.},
  doi          = {10.3390/jcm9113417},
  issn         = {2077-0383},
  issue        = {11},
  pubstate     = {epublish},
  volume       = {9},
  abstract     = {The life expectancy of patients with chronic myeloid leukemia (CML) approaches that of the age-matched population and quality of life (QOL) issues are becoming increasingly important. To describe patients' characteristics and assess QOL, we delivered a 30-item core questionnaire, a 24-item CML-specific questionnaire, both from the European Organization for Research and Treatment of Cancer (EORTC), and additional health-related items to 350 patients. Among 193 patients who completed the questionnaires, 139 received either imatinib (  = 70, 33%), dasatinib (  = 45, 23%) or nilotinib (  = 24, 12%). Patients' median age was 58 (range: 23 to 89) years and 86 (63%) were males. Stratifying patients by treatment, we recognized two distinct populations. In comparison to patients on dasatinib and nilotinib, patients on imatinib were two decades older, had a longer duration of disease and current treatment, experienced fewer limitations on daily activities (  = 0.02), less fatigue (  = 0.001), lower degree of impaired body image (  = 0.022) and less painful episodes (  = 0.014). Similarly, they had better emotional functioning, were less worried, stressed, depressed or nervous (  = 0.01) and were more satisfied with their treatment (  = 0.018). Not only does age associate with current treatments, but it also predicts how patients perceive QOL. Young patients express impaired QOL compared with elderly patients.},
  country      = {Switzerland},
  groups       = {Study 2. Quality of Life},
  issn-linking = {2077-0383},
  journal      = {Journal of clinical medicine},
  keywords     = {chronic myeloid leukemia; patient-reported outcome; quality of life; tyrosine kinase inhibitors},
  month        = oct,
  nlm-id       = {101606588},
  owner        = {NLM},
  pii          = {E3417},
  pmc          = {PMC7692789},
  pmid         = {33113857},
  pubmodel     = {Electronic},
  revised      = {2020-11-28},
  year         = {2020},
}

@Article{Yu2018,
  author          = {Yu, Lu and Wang, Haibo and Milijkovic, Darko and Huang, Xiaojun and Jiang, Qian},
  title           = {Achieving optimal response at 12Â months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study.},
  doi             = {10.1186/s12885-018-4699-5},
  issn            = {1471-2407},
  issue           = {1},
  pages           = {782},
  pubstate        = {epublish},
  volume          = {18},
  abstract        = {To assess the relationship between responses within 1Â year and health-related quality of life (HRQoL) outcomes by exploring profiles of patients with CML-CP who were treated with front-line imatinib or nilotinib. A prospective, longitudinal, single-center study was conducted to assess the response to treatment with imatinib or nilotinib and the HRQoL profile of patients who were newly diagnosed with CML in chronic phase enrolled in the ENESTchina study. Fifty-nine patients were randomized to receive imatinib (nâ€‰=â€‰31) or nilotinib (nâ€‰=â€‰28). With a median follow-up of 5Â years, there was no difference in HRQoL profile observed between patients receiving imatinib and nilotinib. Achieving optimal response at 12Â months was associated with better role limitations due to physical health problems (RP; Pâ€‰=â€‰0.0019) and emotional problems (RE; Pâ€‰=â€‰0.0110) and was the sole factor associated with significantly improving physical component summary over time (PCS; Pâ€‰=â€‰0.0160). Achieving optimal response at 6Â months had high probability of better physical functioning (PF; Pâ€‰=â€‰0.0674), better social functioning (SF; Pâ€‰=â€‰0.0571), and reduced role limitations due to emotional problems (RE; Pâ€‰=â€‰0.0916). In addition, factors including ageâ€‰<â€‰40 years, female gender, and higher level of education were also associated with better HRQoL subscale scores. However, optimal response at 3Â months had no impact on HRQoL profile. The proportions of patients with failure-free survival and PFS at 5Â years were significantly higher among patients who achieved optimal response at 3, 6, or 12Â months than among those who did not achieve optimal response (warning or failure), and the OS rate at 5Â years was significantly higher among those who achieved optimal response at 12Â months. In a multivariate analysis, treatment received (nilotinib vs imatinib) was identified as an independent factor for the achievement of optimal response at both 6Â months (OR, 3.9; 95% CI, 1.0-14.9) and 12Â months (OR, 5.6; 95% CI, 1.7-17.9). Achieving optimal response at 12Â months was not only associated with longer OS and reduced treatment failure rates and disease progression but also better HRQoL in newly diagnosed patients with CML-CP receiving front-line tyrosine kinase inhibitor treatment. Chinese Clinical Trial Registry ( http://www.chictr.org.cn ): ChiCTR-OCH-11001699 .},
  chemicals       = {4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide, Antineoplastic Agents, Pyrimidines, Imatinib Mesylate},
  citation-subset = {IM},
  completed       = {2019-01-15},
  country         = {England},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {1471-2407},
  journal         = {BMC cancer},
  keywords        = {Adult; Antineoplastic Agents, therapeutic use; Female; Humans; Imatinib Mesylate, therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, mortality; Longitudinal Studies; Male; Prospective Studies; Pyrimidines, therapeutic use; Quality of Life; Survival Analysis; Treatment Outcome; CML; Chronic myeloid leukemia; HRQoL; Imatinib; Nilotinib},
  month           = aug,
  nlm-id          = {100967800},
  owner           = {NLM},
  pii             = {10.1186/s12885-018-4699-5},
  pmc             = {PMC6091091},
  pmid            = {30075760},
  pubmodel        = {Electronic},
  revised         = {2019-01-15},
  year            = {2018},
}

@Article{Jiang2017,
  author          = {Jiang, Qian and Wang, Haibo and Yu, Lu and Gale, Robert Peter},
  title           = {Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.},
  doi             = {10.1007/s00432-017-2517-0},
  issn            = {1432-1335},
  issue           = {12},
  pages           = {2619--2630},
  pubstate        = {ppublish},
  volume          = {143},
  abstract        = {To explore health-related quality-of-life (HRQoL) profiles and identify socio-demographic and clinical variables associated with HRQoL in persons with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitors (TKIs). A cross-sectional questionnaire was distributed to adults with chronic-phase CML receiving tyrosine kinase-inhibitor (TKI) therapy >3Â months in complete cytogenetic response (CCyR). Respondents were anonymous. SF-36 Health Survey was used to measure HRQoL. Data from 828 respondents were analyzable. 524 (63%) were male. Median age was 42Â years (range 18-88Â years). 648 (78%) were receiving imatinib. Median TKI-therapy duration was 36Â months (range 3-178Â months). 638 (77%) paid some or all of their TKI costs. Annual out-of-pocket expenses >$4600 USD was associated with lower physical component summary (PCS; -2.8 to -3.8; PÂ =Â 0.0081 and 0.0009) and mental component summary (MCS; -2.1 to -4.3; PÂ =Â 0.0394 and 0.0080) in multivariate analyses. Other variables significantly associated with a lower PCS and/or MCS included: (1) female sex; (2) increasing age; (3) education levelÂ <Â bachelor degree; (4) co-morbidity(ies); and (5) generic drug use. TKI-therapy duration 3-5Â years was associated with higher PCS and MCS. Higher out-of-pocket expense for TKI therapy is significantly associated with worse HRQoL in persons with chronic-phase CML in CCyR receiving TKI therapy. These data indicate the importance of drug cost and health insurance policies on people's HRQoL.},
  chemicals       = {Protein Kinase Inhibitors},
  citation-subset = {IM},
  completed       = {2017-11-27},
  country         = {Germany},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0171-5216},
  journal         = {Journal of cancer research and clinical oncology},
  keywords        = {Adolescent; Adult; Aged; Aged, 80 and over; China; Cross-Sectional Studies; Female; Health Expenditures; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, economics; Male; Middle Aged; Protein Kinase Inhibitors, administration & dosage, economics; Quality of Life; Surveys and Questionnaires; Young Adult; Chronic; Health-related quality-of-life; Leukemia; Tyrosine kinase inhibitor},
  month           = dec,
  nlm-id          = {7902060},
  owner           = {NLM},
  pii             = {10.1007/s00432-017-2517-0},
  pmid            = {28894944},
  pubmodel        = {Print-Electronic},
  revised         = {2018-11-13},
  year            = {2017},
}

@Article{Ugur2017,
  author          = {UÄŸur, Mehmet Can and Kutbay, YaÅŸar Bekir and Ã–zer Kaya, Ã–zge and Ceylan, Cengiz},
  title           = {Assessment of Quality of Life of Chronic Myeloid Leukemia Patients by Using the EORTC QLQ-C30.},
  doi             = {10.4274/tjh.2016.0409},
  issn            = {1308-5263},
  issue           = {2},
  pages           = {197--199},
  pubstate        = {ppublish},
  volume          = {34},
  citation-subset = {IM},
  completed       = {2018-10-23},
  country         = {Turkey},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {1300-7777},
  journal         = {Turkish journal of haematology : official journal of Turkish Society of Haematology},
  keywords        = {Depression, complications, diagnosis, psychology; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, genetics, psychology; Male; Middle Aged; Quality of Life; Surveys and Questionnaires},
  month           = jun,
  nlm-id          = {9606065},
  owner           = {NLM},
  pmc             = {PMC5440881},
  pmid            = {28044992},
  pubmodel        = {Print-Electronic},
  revised         = {2018-11-13},
  year            = {2017},
}

@Article{Breccia2016,
  author          = {Breccia, Massimo and Graffigna, Guendalina and Galimberti, Sara and Iurlo, Alessandra and Pungolino, Ester and Pizzuti, Michele and Maggi, Alessandro and Falzetti, Franca and Capalbo, Silvana Franca and Intermesoli, Tamara and Maffioli, Margherita and Elena, Chiara and Melosi, Alessandro and Simonetti, Federico and Capochiani, Enrico and Seta, Roberta Della and Pacilli, Matteo and Luppi, Mario and Di Renzo, Nicola and Mastrullo, Lucia and Trabacchi, Elena and Vallisa, Daniele and Rapezzi, Davide and Orlandi, Ester Maria and Gambacorti-Passerini, Carlo and Efficace, Fabio and Alimena, Giuliana},
  title           = {Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis.},
  doi             = {10.1007/s00520-016-3286-z},
  issn            = {1433-7339},
  issue           = {11},
  pages           = {4487--4493},
  pubstate        = {ppublish},
  volume          = {24},
  abstract        = {Tyrosine kinase inhibitors (TKIs) drastically changed the outcome of patients diagnosed with chronic myeloid leukemia (CML). Several reports indicated the advantage of continue long-term adherence associated with positive outcome. Therefore, it is important to better understand from the patient's standpoint the experience of living with the disease and the related treatment. In this study, quantitative analysis and narrative medicine were combined to get insights on this issue in a population of 257 patients with CML in chronic phase treated with TKIs (43Â % men, with a median age of 58Â years, 27Â % aged 31-50Â years), followed for a median time of 5Â years. Sixty-one percent of patients enrolled were treated in first line, whereas 37Â % were treated in second line. The results showed more positive perceptions and acceptance in males compared to females, without impact of disease on relationships. Level of positive acceptance was more evident in elderly compared to younger patients, with a close connection with median time from diagnosis. Overall, female patients reported negative perceptions and an impact of disease on family daily living. The majority of patients understood the importance of continue adherence to treatment, with 27Â % resulting less adherent (60Â % for forgetfulness), even if well informed and supported by his/her physician. Narrative medicine, in association to quantitative analysis, can help physicians to understand needs of their patients in order to improve communication.},
  chemicals       = {Protein Kinase Inhibitors},
  citation-subset = {IM},
  completed       = {2017-09-27},
  country         = {Germany},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0941-4355},
  journal         = {Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer},
  keywords        = {Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Evaluation Studies as Topic; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, psychology, therapy; Male; Middle Aged; Narration; Protein Kinase Inhibitors, therapeutic use; Quality of Life, psychology; Chronic myeloid leukemia; Narrative medicine; Tyrosine kinase inhibitors},
  month           = nov,
  nlm-id          = {9302957},
  owner           = {NLM},
  pii             = {10.1007/s00520-016-3286-z},
  pmid            = {27260015},
  pubmodel        = {Print-Electronic},
  revised         = {2018-12-02},
  year            = {2016},
}

@Article{Breccia2016a,
  author          = {Breccia, Massimo and Efficace, Fabio},
  title           = {Health-related quality of life outcomes in chronic myeloid leukemia patients treated with second generation tyrosine kinase inhibitors: do we know enough?},
  doi             = {10.1080/03007995.2016.1185399},
  issn            = {1473-4877},
  issue           = {8},
  pages           = {1453--1454},
  pubstate        = {ppublish},
  volume          = {32},
  citation-subset = {IM},
  country         = {England},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0300-7995},
  journal         = {Current medical research and opinion},
  month           = aug,
  nlm-id          = {0351014},
  owner           = {NLM},
  pmid            = {27142666},
  pubmodel        = {Print-Electronic},
  revised         = {2019-11-20},
  year            = {2016},
}

@Article{Whiteley2016,
  author          = {Whiteley, Jennifer and Reisman, Arlene and Shapiro, Mark and Cortes, JorgeE and Cella, David},
  title           = {Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.},
  doi             = {10.1185/03007995.2016.1174108},
  issn            = {1473-4877},
  issue           = {8},
  pages           = {1325--1334},
  pubstate        = {ppublish},
  volume          = {32},
  abstract        = {The tyrosine kinase inhibitor (TKI) bosutinib has demonstrated activity in patients with advanced phase chronic myeloid leukemia (CML), but effects on health-related quality of life (HRQoL) remain unexplored. This study evaluated HRQoL in advanced CML patients receiving bosutinib in an ongoing phase 2 study following resistance or intolerance to prior imatinib therapy. This analysis included data from 76 accelerated-phase (AP) and 64 blast-phase (BP) patients resistant/intolerant to prior imatinib with or without prior exposure to other TKIs. Patient-reported HRQoL assessments completed at baseline; weeks 4, 8, and 12; every 12 weeks thereafter; and at treatment completion included the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu); general health status was assessed using the 5-item EuroQol (EQ-5D) instrument and a visual analog scale (VAS). HRQoL at baseline was somewhat worse in BP versus AP CML patients. There was a significant improvement in the mean FACT-Leu Total scale at weeks 24, 36, and 48 in AP CML patients and at weeks 4, 8, 12, 24, 36, 48, and 96 in BP CML patients compared with baseline. EQ-5D Utility scores were stable throughout treatment in AP CML patients but significantly improved versus baseline in BP CML patients at weeks 4, 8, 12, and 36. Mean VAS scores were significantly improved at weeks 8, 36, and 48 in AP CML patients and at weeks 4, 8, 12, 24, 36, and 96 in BP CML patients. The lack of a comparison group limits attribution of improvements in HRQoL specifically to bosutinib treatment; potential bias due to non-ignorable dropout may limit the ability to generalize these findings to situations where durations of therapy exceed the 96-week follow-up duration of the present study. These findings suggest that bosutinib therapy is associated with improved HRQoL in advanced phase CML patients. NCT00261846.},
  chemicals       = {Aniline Compounds, Antineoplastic Agents, Nitriles, Protein Kinase Inhibitors, Quinolines, bosutinib, Imatinib Mesylate},
  citation-subset = {IM},
  completed       = {2017-09-28},
  country         = {England},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0300-7995},
  journal         = {Current medical research and opinion},
  keywords        = {Adolescent; Adult; Aged; Aged, 80 and over; Aniline Compounds, therapeutic use; Antineoplastic Agents, therapeutic use; Blast Crisis; Female; Humans; Imatinib Mesylate, therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, pathology, psychology; Male; Middle Aged; Nitriles, therapeutic use; Protein Kinase Inhibitors, therapeutic use; Quality of Life; Quinolines, therapeutic use; Advanced phase chronic myeloid leukemia; Bosutinib; Health-related quality of life; Patient-reported outcomes},
  month           = aug,
  nlm-id          = {0351014},
  owner           = {NLM},
  pmid            = {27045164},
  pubmodel        = {Print-Electronic},
  revised         = {2020-05-02},
  year            = {2016},
}

@Article{Efficace2016a,
  author          = {Efficace, F. and Rosti, G. and Breccia, M. and Cottone, F. and Giesinger, J. M. and Stagno, F. and Iurlo, A. and Russo Rossi, A. and Luciano, L. and Martino, B. and Galimberti, S. and Turri, D. and Bergamaschi, M. and Tiribelli, M. and Fava, C. and Angelucci, E. and Mandelli, F. and Baccarani, M.},
  title           = {The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia.},
  doi             = {10.1007/s00277-015-2541-6},
  issn            = {1432-0584},
  issue           = {2},
  pages           = {211--219},
  pubstate        = {ppublish},
  volume          = {95},
  abstract        = {The primary objective of this study was to investigate whether the presence of comorbidities was associated with a lower health-related quality of life (HRQOL) in elderly patients with chronic myeloid leukemia (CML). A sample of 174 CML patients aged 60Â years or above was analyzed. HRQOL was assessed with the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). A number of pre-selected sociodemographic and disease-related factors were considered as potential confounding factors for the association between comorbidity and HRQOL. Mean age of the 174 patients analyzed was 70Â years (range 60-87Â years) and 55Â % were male. Overall, 111 patients (64Â %) reported at least one comorbidity. Analysis stratified by age group category showed a greater proportion of patients with comorbidities in the older sub-group population (â‰¥70Â years) compared to younger patients (60 to 69Â years). Differences in HRQOL outcomes between patients with no comorbidity at all and those with two or more comorbid conditions were at least twice the magnitude of a clinically meaningful difference in all the physical and mental health scales of the SF-36. In multivariate analysis, after adjusting for key confounding factors, the following scales were significantly lower in those with comorbidity: general health (pâ€‰<â€‰0.001), bodily pain (pâ€‰<â€‰0.001), physical functioning (pâ€‰=â€‰0.002), and vitality (pâ€‰=â€‰0.002). Assessing comorbidity in elderly patients with CML is important to facilitate identification of those most in need of HRQOL improvements.},
  citation-subset = {IM},
  completed       = {2016-05-20},
  country         = {Germany},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0939-5555},
  journal         = {Annals of hematology},
  keywords        = {Aged; Aged, 80 and over; Comorbidity; Cross-Sectional Studies; Female; Health Status; Health Surveys, methods; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, epidemiology, psychology; Male; Middle Aged; Musculoskeletal Diseases, psychology; Pain, psychology; Quality of Life, psychology; Chronic myeloid leukemia; Comorbidity; Quality of life},
  month           = jan,
  nlm-id          = {9107334},
  owner           = {NLM},
  pii             = {10.1007/s00277-015-2541-6},
  pmid            = {26546359},
  pubmodel        = {Print-Electronic},
  revised         = {2016-01-13},
  year            = {2016},
}

@Article{Kekaele2015,
  author       = {KekÃ¤le, Meri and Peltoniemi, Marikki and Airaksinen, Marja},
  title        = {Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment.},
  doi          = {10.2147/PPA.S92125},
  issn         = {1177-889X},
  pages        = {1733--1740},
  pubstate     = {epublish},
  volume       = {9},
  abstract     = {To evaluate adverse drug reactions (ADRs) experienced by chronic myeloid leukemia (CML) patients during per oral tyrosine kinase inhibitor (TKI) treatment and correlation of ADR symptoms with medication adherence and perceived quality of life (QoL). Eighty-six adult, chronic-phase CML patients who had been on TKI treatment (79% on imatinib, 10.5% dasatinib, and 10.5% nilotinib) for at least 6 months participated in the study (mean age: 57.8 years, 52% males). The mean time from diagnosis was 5.1 years. All patients were interviewed, and patient-reported ADRs were obtained using a structured list. Adherence was assessed using Morisky's 8-item Medication Adherence Scale (MMAS). The symptoms' interference with patient's daily QoL was measured by asking patients about the influence of symptom(s) on their mood, general condition, enjoyment of life, walking, relationships, and work. Ninety-seven percent of the patients were suffering from at least one ADR. The mean number of different symptoms was seven (range: 0-15, median 6). The most commonly perceived ADRs were muscle soreness or cramp (69/86, 80%); swelling of hands, legs, feet, or around the eyes (59/86, 69%); and fatigue (43/86, 50%). No correlation was found between adherence and ADRs, because symptoms were equally common in each MMAS adherence class. Half of the patients felt that the ADRs had a negative influence on their daily QoL. A quarter of the patients reported that ADRs affected either their mood, general condition, or enjoyment of life. The incidence of almost all ADRs was much higher among patients reporting negative influence of ADRs on their daily life compared to total study population (P=0.016). TKI-related ADRs were common among CML patients irrespective of patient's adherence level. Patients who reported that ADRs had a negative influence on their daily QoL perceived more ADRs than those who did not experience a negative influence.},
  completed    = {2015-12-17},
  country      = {New Zealand},
  groups       = {Study 2. Quality of Life},
  issn-linking = {1177-889X},
  journal      = {Patient preference and adherence},
  keywords     = {adherence; adverse drug reaction; chronic myeloid leukemia; patient-reported outcomes; quality of life; tyrosine kinase inhibitors},
  nlm-id       = {101475748},
  owner        = {NLM},
  pii          = {ppa-9-1733},
  pmc          = {PMC4677761},
  pmid         = {26677317},
  pubmodel     = {Electronic-eCollection},
  revised      = {2020-10-01},
  year         = {2015},
}

@Article{Hamerschlak2014,
  author          = {Hamerschlak, Nelson and de Souza, Carmino and Cornacchioni, Ana LÃºcia and Pasquini, Ricardo and Tabak, Daniel and Spector, Nelson and Steagall, Merula},
  title           = {Quality of life of chronic myeloid leukemia patients in Brazil: ability to work as a key factor.},
  doi             = {10.1007/s00520-014-2196-1},
  issn            = {1433-7339},
  issue           = {8},
  pages           = {2113--2118},
  pubstate        = {ppublish},
  volume          = {22},
  abstract        = {The purpose of this study was to evaluate the quality of life (QOL) of patients receiving treatment by the public health system in Brazil for chronic myeloid leukemia (CML), a disease requiring daily and strict compliance to oral medication and regular blood and bone marrow controls, which are invasive exams. Between 2008 and 2010, patients with CML were surveyed by telephone. Quality of life was evaluated by the functional assessment of chronic illness therapy (FACIT) tool. The mean QOL among CML patients was 92.53 (out of 124 total points) in the trial outcome index, 78.50 (out of 108) in the general total score, and 130.43 (out of 176) in the leukemia total score. Patients who had the prescriptions recently changed anyway had better QOL general score (p = 0.012) and leukemia-specific score (p = 0.043) than those who remained with the same treatment. Imatinib was not associated with this change in QOL (p > 0.797). The more the patient felt able to work, the higher the scores in all three FACIT scales (p < 0.001, Spearman's correlation). The use of imatinib (p = 0.012) was associated with a better ability to work, while chemotherapy (p = 0.017) and the use of hydroxyurea (p = 0.001) were inversely associated with work capability. A recent change in medication can improve quality of life. The ability to work is an important component of quality of life of patients with CML. Ability to work should be specifically considered in CML treatment.},
  chemicals       = {Antineoplastic Agents, Benzamides, Piperazines, Pyrimidines, Imatinib Mesylate},
  citation-subset = {IM},
  completed       = {2014-09-01},
  country         = {Germany},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0941-4355},
  journal         = {Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer},
  keywords        = {Adult; Aged; Antineoplastic Agents, therapeutic use; Benzamides, therapeutic use; Brazil, epidemiology; Cross-Sectional Studies; Data Collection; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, epidemiology, physiopathology, psychology; Male; Middle Aged; Piperazines, therapeutic use; Prospective Studies; Pyrimidines, therapeutic use; Quality of Life; Work, psychology, statistics & numerical data},
  month           = aug,
  nlm-id          = {9302957},
  owner           = {NLM},
  pmid            = {24647489},
  pubmodel        = {Print-Electronic},
  revised         = {2020-03-05},
  year            = {2014},
}

@Article{Mo2014,
  author          = {Mo, X.-D. and Jiang, Q. and Xu, L.-P. and Liu, D.-H. and Liu, K.-Y. and Jiang, B. and Jiang, H. and Chen, H. and Chen, Y.-H. and Zhang, X.-H. and Han, W. and Wang, Y. and Huang, X.-J.},
  title           = {Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib.},
  doi             = {10.1038/bmt.2013.232},
  issn            = {1476-5365},
  issue           = {4},
  pages           = {576--580},
  pubstate        = {ppublish},
  volume          = {49},
  abstract        = {To evaluate and compare the health-related quality of life (HRQOL) of patients with newly diagnosed CML in the first chronic phase (CML-CP1) receiving HLA-identical sibling donor (ISD) hematopoietic SCT (HSCT) or imatinib, a cross-sectional study that was part of a prospective cohort study at the Institute of Hematology, Peking University was performed. A total of 222 patients including 126 and 96 in the imatinib and ISD HSCT groups, respectively, were enrolled. HRQOL was measured using the Medical Outcomes Study 36-Item Short-Form Health Survey. The ISD HSCT group functioned significantly better on the role-physical functioning and mental health subscales, as well as the mental component summary (MCS) than the imatinib group. HRQOL was generally comparable to groups in the young population. Multivariate analysis showed that white blood cell count â‰¥ 30 Ã— 10(9)/L and plts count â‰¥ 450 Ã— 10(9)/L were the major adverse factors affecting HRQOL in long-term survivors. Imatinib therapy was also an adverse factor affecting the MCS (odds ratio=1.7, P=0.032). Thus, long-term CML-CP1 survivors receiving ISD HSCT can attain desirable HRQOL comparable to or better than that of patients receiving imatinib.},
  chemicals       = {Antineoplastic Agents, Benzamides, Piperazines, Pyrimidines, Imatinib Mesylate},
  citation-subset = {IM},
  completed       = {2015-01-14},
  country         = {England},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0268-3369},
  journal         = {Bone marrow transplantation},
  keywords        = {Adult; Antineoplastic Agents, therapeutic use; Benzamides, therapeutic use; Cohort Studies; Cross-Sectional Studies; Female; Hematopoietic Stem Cell Transplantation, methods; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, psychology, therapy; Male; Piperazines, therapeutic use; Prospective Studies; Pyrimidines, therapeutic use; Quality of Life; Risk Factors; Transplantation, Homologous},
  month           = apr,
  nlm-id          = {8702459},
  owner           = {NLM},
  pii             = {bmt2013232},
  pmid            = {24442252},
  pubmodel        = {Print-Electronic},
  revised         = {2018-11-13},
  year            = {2014},
}

@Article{Efficace2014,
  author          = {Efficace, Fabio and Baccarani, Michele and Breccia, Massimo and Saussele, Susanne and Abel, Gregory and Caocci, Giovanni and Guilhot, Francois and Cocks, Kim and Naeem, Adel and Sprangers, Mirjam and Oerlemans, Simone and Chie, Weichu and Castagnetti, Fausto and Bombaci, Felice and Sharf, Giora and Cardoni, Annarita and Noens, Lucien and Pallua, Stephan and Salvucci, Marzia and Nicolatou-Galitis, Ourania and Rosti, Gianantonio and Mandelli, Franco},
  title           = {International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.},
  doi             = {10.1007/s11136-013-0523-5},
  issn            = {1573-2649},
  issue           = {3},
  pages           = {825--836},
  pubstate        = {ppublish},
  volume          = {23},
  abstract        = {Health-related quality of life (HRQOL) is a key aspect for chronic myeloid leukemia (CML) patients. The aim of this study was to develop a disease-specific HRQOL questionnaire for patients with CML to supplement the European Organization for Research and Treatment of Cancer (EORTC)-QLQ C30. The process followed a predefined and systematic stepwise iterative process as defined by the EORTC guidelines for questionnaire development. The process was divided into 3 phases: (1) generation of relevant HRQOL issues, (2) operationalization of the HRQOL issues into a set of items, and (3) pretesting the questionnaire for relevance and acceptability. Descriptive statistics and psychometric analyses were also performed. Overall, 655 CML patients were enrolled in 10 countries including the USA and countries in Europe and Asia. Interviews with health-care professionals experienced in CML (nÂ =Â 59) were also conducted. Results from the interviews, clinical experiences, and statistical analyses were used to develop the EORTC QLQ-CML24. The final module consists of 24 items assessing the following aspects: symptom burden, impact on daily life and on worry/mood, body image problems, and satisfaction with care and with social life. Internal consistency, assessed with Cronbach's alpha coefficients, ranged from 0.73 to 0.83 for the proposed scales. The EORTC QLQ-CML24 is an internationally developed HRQOL questionnaire for CML patients, and its implementation in clinical research and practice can provide important information to facilitate clinical decision-making.},
  chemicals       = {Benzamides, Piperazines, Protein Kinase Inhibitors, Pyrimidines, Imatinib Mesylate},
  citation-subset = {IM},
  completed       = {2014-10-04},
  country         = {Netherlands},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0962-9343},
  journal         = {Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation},
  keywords        = {Adult; Aged; Aged, 80 and over; Benzamides, therapeutic use; Female; Health Status Indicators; Humans; Imatinib Mesylate; International Cooperation; Interviews as Topic; Karnofsky Performance Status; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, psychology; Male; Middle Aged; Piperazines, therapeutic use; Protein Kinase Inhibitors, therapeutic use; Psychometrics, instrumentation; Pyrimidines, therapeutic use; Quality of Life; Residence Characteristics; Social Class; Surveys and Questionnaires, standards; Young Adult},
  month           = apr,
  nlm-id          = {9210257},
  owner           = {NLM},
  pmid            = {24026634},
  pubmodel        = {Print-Electronic},
  revised         = {2018-12-02},
  year            = {2014},
}

@Article{Baccarani2014,
  author          = {Baccarani, Michele and Efficace, Fabio and Rosti, Gianantonio},
  title           = {Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden.},
  doi             = {10.3324/haematol.2013.094045},
  issn            = {1592-8721},
  issue           = {2},
  pages           = {205--208},
  pubstate        = {ppublish},
  volume          = {99},
  citation-subset = {IM},
  completed       = {2014-07-24},
  country         = {Italy},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0390-6078},
  journal         = {Haematologica},
  keywords        = {Decision Making; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, therapy; Quality of Health Care},
  month           = feb,
  nlm-id          = {0417435},
  owner           = {NLM},
  pii             = {haematol.2013.094045},
  pmc             = {PMC3912949},
  pmid            = {24497557},
  pubmodel        = {Print},
  revised         = {2018-11-13},
  year            = {2014},
}

@Article{Cella2014,
  author          = {Cella, David and Nowinski, Cindy J. and Frankfurt, Olga},
  title           = {The impact of symptom burden on patient quality of life in chronic myeloid leukemia.},
  doi             = {10.1159/000362816},
  issn            = {1423-0232},
  issue           = {3},
  pages           = {133--147},
  pubstate        = {ppublish},
  volume          = {87},
  abstract        = {Patients with chronic myeloid leukemia (CML) in chronic phase are living longer on BCR-ABL1 tyrosine kinase inhibitor (TKI) therapy, placing emphasis on issues related to symptom burden and quality of life (QoL). Furthermore, the potential for adverse events with longer-term therapy may result in dose adjustments, treatment discontinuation, or nonadherence, all of which may negatively affect treatment efficacy and QoL. However, instruments to specifically measure the impact of symptom burden and treatment on health-related QoL in patients with CML have not been widely available until recently. The FACT-Leu is a validated tool that measures leukemia-specific and more general QoL concerns. Other tools specific to CML, including the MDASI-CML and the EORTC QLQ-CML24, are undergoing validation. Here, we describe TKI therapy-related symptom burden and its effect on adherence and treatment response, outline instruments to measure symptom burden and QoL in CML, and summarize the available clinical data on QoL of patients on TKI therapy. QoL is an aspect of CML disease management that will continue to gain prominence in the coming years. We believe that the instruments developed now will have a role in informing treatment decisions in routine practice and allowing clinicians to proactively address issues related to symptom burden and QoL.},
  citation-subset = {IM},
  completed       = {2014-09-18},
  country         = {Switzerland},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0030-2414},
  journal         = {Oncology},
  keywords        = {Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, pathology, psychology; Quality of Life, psychology; Severity of Illness Index; Sickness Impact Profile; Tumor Burden},
  nlm-id          = {0135054},
  owner           = {NLM},
  pii             = {000362816},
  pmid            = {25012261},
  pubmodel        = {Print-Electronic},
  revised         = {2014-07-25},
  year            = {2014},
}

@Article{Jain2013,
  author       = {Jain, Parveen and Das, V. N. R. and Ranjan, Alok and Chaudhary, Rahul and Pandey, Krishna},
  title        = {Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea.},
  doi          = {10.4103/2279-042X.128145},
  issn         = {2319-9644},
  issue        = {4},
  pages        = {156--161},
  pubstate     = {ppublish},
  volume       = {2},
  abstract     = {Chronic myeloid leukemia (CML) is a clonal hematopoietic disorder caused by acquired genetic defect in pluripotent stem cells characterized by acquisition of the philadelphia chromosome. The aim of this study was to compare the efficacy, safety and quality of life (QoL) in CML patients treated with imatinib or hydroxyurea. A prospective observational study was conducted on 40 patients with pathologically confirmed CML in an in-patient department of Mahavir Cancer Sansthan and Research Centre (tertiary care cancer hospital) in India. Patients were divided into two groups (group A: Imatinib consuming patients and group B: Hydroxyurea consuming patients). Complete blood count was done every month to assess the efficacy and safety/toxicity profile of these drugs. The results were analyzed 12 months after completion of treatment. QoL was assessed by The European Organization for Research and Treatment of Cancer QoL Questionnaire core 30. Hematological response was analyzed using kaplan-meier survival analysis. Chi-square test was applied to assess the association of two regimens with complete hematological response, hematological and non-hematological toxicity. White blood cell (WBC) was noted each month in every patient of each group and analyzed by generalized linear mode (repeated measures) analysis of variance (ANOVA). Independent t-test was used to compare changes in QoL between treatment groups. At the end of treatment, significant improvement (P = 0.001) in hematological response was observed in the group A (95%) compared to group B (30%). WBC count analyzed at each month of treatment by ANOVA achieved better results for patients treated with imatinib (P = 0.0001). The hematological toxicity was higher in imatinib group while non-hematological toxicity was higher in the hydroxyurea group; however only little toxicities such as nausea and constipation were statistically significant. QoL assessment of patients related to functional scale showed significantly better results in group A (P = 0.046). The study showed that imatinib has better profile compared to hydroxyurea, with siginificant statistical differences in terms of efficacy, non-hematological toxicity and QoL in CML patients. Even with such better efficacy and safety profile, pharmacoeconomic evaluation needs to be done to justify and support the use of imatinib for CML patients in India.},
  completed    = {2014-07-03},
  country      = {India},
  groups       = {Study 2. Quality of Life},
  issn-linking = {2279-042X},
  journal      = {Journal of research in pharmacy practice},
  keywords     = {Chronic myeloid leukemia; Hydroxyurea; Imatinib; quality of life},
  month        = oct,
  nlm-id       = {101614023},
  owner        = {NLM},
  pii          = {JRPP-2-156},
  pmc          = {PMC4076923},
  pmid         = {24991625},
  pubmodel     = {Print},
  revised      = {2020-09-30},
  year         = {2013},
}

@Article{Efficace2013,
  author          = {Efficace, F. and Baccarani, M. and Breccia, M. and Cottone, F. and Alimena, G. and Deliliers, G. L. and BaratÃ¨, C. and Specchia, G. and Di Lorenzo, R. and Luciano, L. and Turri, D. and Martino, B. and Stagno, F. and Dabusti, M. and Bergamaschi, M. and Leoni, P. and Simula, M. P. and Levato, L. and Fava, C. and Veneri, D. and Sica, S. and Rambaldi, A. and Rosti, G. and Vignetti, M. and Mandelli, F.},
  title           = {Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.},
  doi             = {10.1038/leu.2013.51},
  issn            = {1476-5551},
  issue           = {7},
  pages           = {1511--1519},
  pubstate        = {ppublish},
  volume          = {27},
  abstract        = {Health-related quality of life (HRQOL) is an important goal of therapy for chronic myeloid leukemia (CML) patients treated with current molecular-targeted therapies. The main objective of this study was to investigate factors associated with long-term HRQOL outcomes of CML patients receiving imatinib. Analysis was performed on 422 CML patients recruited in an observational multicenter study. HRQOL was assessed with the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). Key socio-demographic and clinical data were investigated for their association with HRQOL outcomes. Chronic fatigue and social support were also investigated. Univariate and multivariate linear regression analyses were used to identify independent factors associated with HRQOL outcomes. Fatigue was the only variable showing an independent and consistent association across all physical and mental HRQOL outcomes (P<0.01). Differences between patients reporting low versus high fatigue levels were more than eight and seven times the magnitude of a clinically meaningful difference, respectively, for the role physical (Î”=70 points) and emotional scale (Î”=63 points) of the SF-36. Fatigue did not occur as an isolated symptom and was most highly correlated with musculoskeletal pain (r=0.511; Pâ‰¤0.001) and muscular cramps (r=0.448; Pâ‰¤0.001). Chronic fatigue is the major factor limiting HRQOL of CML patients receiving imatinib.},
  chemicals       = {Antineoplastic Agents, Benzamides, Piperazines, Pyrimidines, Imatinib Mesylate},
  citation-subset = {IM},
  completed       = {2013-09-16},
  country         = {England},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0887-6924},
  journal         = {Leukemia},
  keywords        = {Adult; Aged; Aged, 80 and over; Antineoplastic Agents, therapeutic use; Benzamides, therapeutic use; Cross-Sectional Studies; Fatigue Syndrome, Chronic, complications, psychology; Female; Health Surveys; Humans; Imatinib Mesylate; Leukemia, Myelogenous, BCR-ABL Positive, drug therapy, psychology; Male; Middle Aged; Multivariate Analysis; Muscle Cramp, psychology; Musculoskeletal Pain, psychology; Piperazines, therapeutic use; Pyrimidines, therapeutic use; Quality of Life; Social Behavior; Young Adult},
  month           = jul,
  nlm-id          = {8704895},
  owner           = {NLM},
  pii             = {leu201351},
  pmid            = {23417029},
  pubmodel        = {Print-Electronic},
  revised         = {2015-11-19},
  year            = {2013},
}

@Article{Phillips2013,
  author          = {Phillips, Kristin M. and Pinilla-Ibarz, Javier and Sotomayor, Eduardo and Lee, Morgan R. and Jim, Heather S. L. and Small, Brent J. and Sokol, Lubomir and Lancet, Jeffrey and Tinsley, Sara and Sweet, Kendra and Komrokji, Rami and Jacobsen, Paul B.},
  title           = {Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.},
  doi             = {10.1007/s00520-012-1630-5},
  issn            = {1433-7339},
  issue           = {4},
  pages           = {1097--1103},
  pubstate        = {ppublish},
  volume          = {21},
  abstract        = {Tyrosine kinase inhibitors (TKIs) are now standard treatment for chronic myeloid leukemia (CML). While TKIs have less toxicity than previous treatments, they have side effects that can impact quality of life (QOL). This study compared CML patients taking a TKI for an average of 4.01 years (range 0.50-9.79 years) to age- and gender-matched controls with no history of cancer on measures of symptom burden, depression, fatigue, sleep, and health-related QOL. Compared to controls (nâ€‰=â€‰62), CML patients (nâ€‰=â€‰62) taking a TKI (imatinib 55 %, nilotinib 31 %, and dasatinib 14 %) reported significantly worse fatigue severity (pâ€‰<â€‰.001), fatigue interference (pâ€‰<â€‰.001), depression (pâ€‰=â€‰.007), symptom burden (pâ€‰<â€‰.001), and physical QOL (pâ€‰<â€‰.001). TKI patients were also more likely meet established cutoffs for clinically meaningful fatigue (p valuesâ€‰<â€‰.001) and depression (pâ€‰=â€‰.004). There were no differences in mental QOL or sleep (p valuesâ€‰>â€‰.010). Regarding specific symptoms, TKI patients were more likely to report nausea, diarrhea, itching, skin changes, swelling of arms or legs, and not looking like themselves (p valuesâ€‰<â€‰.001). These data suggest the need for interventions to address QOL in CML patients taking TKIs.},
  chemicals       = {4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide, Antineoplastic Agents, Benzamides, Piperazines, Protein Kinase Inhibitors, Pyrimidines, Thiazoles, Imatinib Mesylate, Dasatinib},
  citation-subset = {IM},
  completed       = {2013-09-17},
  country         = {Germany},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0941-4355},
  journal         = {Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer},
  keywords        = {Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, adverse effects; Benzamides, adverse effects; Case-Control Studies; Dasatinib; Depression, chemically induced; Fatigue, chemically induced; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines, adverse effects; Protein Kinase Inhibitors, adverse effects; Pyrimidines, adverse effects; Quality of Life; Surveys and Questionnaires; Thiazoles, adverse effects; United States; Young Adult},
  month           = apr,
  nlm-id          = {9302957},
  owner           = {NLM},
  pmid            = {23179489},
  pubmodel        = {Print-Electronic},
  revised         = {2019-12-10},
  year            = {2013},
}

@Article{Efficace2012,
  author          = {Efficace, Fabio and Breccia, Massimo and Saussele, Susanne and Kossak-Roth, Ute and Cardoni, Annarita and Caocci, Giovanni and Chie, Weichu and Naeem, Adel and Nicolatou-Galitis, Ourania and Cocks, Kim and Vignetti, Marco and Baccarani, Michele and Mandelli, Franco and Sprangers, Mirjam},
  title           = {Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.},
  doi             = {10.1007/s00277-012-1458-6},
  issn            = {1432-0584},
  issue           = {9},
  pages           = {1371--1381},
  pubstate        = {ppublish},
  volume          = {91},
  abstract        = {The objective of this study was to investigate the health-related quality of life (HRQOL) aspects valued the most by patients with chronic myeloid leukemia (CML) receiving targeted therapies (TT), and to compare their perception with that of health-care professionals' (HCPs). Semi-structured interviews were conducted with 137 CML patients receiving TT from five different countries. An additional sample of 99 CML patients, completing an online interview, was considered for supportive analyses. A sample of 59 HCPs from 12 countries also participated in the study. Patients and HCPs were asked to rate and rank the importance of a predefined list of 74 HRQOL aspects of potential relevance for CML patients. Patients and HCPs agreed that the following five aspects are most important: fatigue, muscle cramps, swelling, worries, and uncertainty about health condition in the future, and importance of social support in coping with the disease. However, the difference in rankings between the two groups was substantial with respect to other HRQOL aspects investigated. Patients valued some issues related to symptoms much higher than HCPs, thus suggesting that a better symptom management could be the crucial aspects to improve HRQOL of CML patients.},
  chemicals       = {Antineoplastic Agents, Benzamides, Piperazines, Protein Kinase Inhibitors, Pyrimidines, Imatinib Mesylate},
  citation-subset = {IM},
  completed       = {2012-10-23},
  country         = {Germany},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0939-5555},
  journal         = {Annals of hematology},
  keywords        = {Adult; Aged; Aged, 80 and over; Antineoplastic Agents, therapeutic use; Anxiety; Benzamides; Edema, etiology, psychology; Europe; Fatigue, psychology; Female; Health Personnel, psychology; Humans; Imatinib Mesylate; Iraq; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, psychology; Male; Middle Aged; Molecular Targeted Therapy, psychology; Muscle Cramp, psychology; Patients, psychology; Piperazines, therapeutic use; Protein Kinase Inhibitors, therapeutic use; Pyrimidines, therapeutic use; Quality of Life; Social Support; Surveys and Questionnaires; Taiwan; Young Adult},
  month           = sep,
  nlm-id          = {9107334},
  owner           = {NLM},
  pmid            = {22543826},
  pubmodel        = {Print-Electronic},
  revised         = {2015-11-19},
  year            = {2012},
}

@Article{Trask2012,
  author          = {Trask, Peter C. and Cella, David and Besson, Nadine and Kelly, Virginia and Masszi, TamÃ¡s and Kim, Dong-Wook},
  title           = {Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia.},
  doi             = {10.1016/j.leukres.2011.10.011},
  issn            = {1873-5835},
  issue           = {4},
  pages           = {438--442},
  pubstate        = {ppublish},
  volume          = {36},
  abstract        = {Understanding the impact of second-line tyrosine kinase inhibitor therapy on the health-related quality of life (HRQOL) of imatinib (IM)-resistant and IM-intolerant chronic phase chronic myeloid leukemia (CP CML) patients is important given the increased survival that comes with therapy. As part of a bosutinib single-arm phase 2 trial, 200 IM-resistant and 88 IM-intolerant CP CML patients' HRQOL was assessed prior to and throughout treatment with the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu). Little HRQOL impairment was demonstrated at baseline. Over the course of 96 weeks on bosutinib therapy, patients noted statistically significant and/or clinically meaningful improvements on several FACT-Leu scales.},
  chemicals       = {Aniline Compounds, Antineoplastic Agents, Benzamides, Nitriles, Piperazines, Pyrimidines, Quinolines, bosutinib, Imatinib Mesylate},
  citation-subset = {IM},
  completed       = {2012-04-11},
  country         = {England},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0145-2126},
  journal         = {Leukemia research},
  keywords        = {Adult; Aged; Aged, 80 and over; Aniline Compounds, therapeutic use; Antineoplastic Agents, therapeutic use; Benzamides; Drug Resistance, Neoplasm, drug effects; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy; Male; Middle Aged; Nitriles, therapeutic use; Piperazines, therapeutic use; Pyrimidines, therapeutic use; Quality of Life; Quinolines, therapeutic use; Young Adult},
  month           = apr,
  nlm-id          = {7706787},
  owner           = {NLM},
  pii             = {S0145-2126(11)00508-X},
  pmid            = {22036634},
  pubmodel        = {Print-Electronic},
  revised         = {2015-11-19},
  year            = {2012},
}

@Article{Efficace2012a,
  author          = {Efficace, F. and Cocks, K. and Breccia, M. and Sprangers, M. and Meyers, C. A. and Vignetti, M. and Baccarani, M. and Mandelli, F. and GIMEMA and of Life Group, E.O.R.T.C. Quality},
  title           = {Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes.},
  doi             = {10.1016/j.critrevonc.2011.02.007},
  issn            = {1879-0461},
  issue           = {2},
  pages           = {123--135},
  pubstate        = {ppublish},
  volume          = {81},
  abstract        = {Health-related quality of life (HRQOL) and other patient-reported outcomes (PROs) might be crucial in comparing effectiveness of treatments as they could provide invaluable information to better inform clinical decision-making. This is particularly true in the era of targeted therapies (TT). A systematic review was undertaken on all studies with CML patients published from 1980 to 2010 and including a PRO evaluation. Out of 619 articles scrutinized, 15 met eligibility criteria and no study was published before 1995. Six dealt mainly with interferon-based therapies, 7 with bone marrow transplantation and only 2 evaluated PROs in the context of TT. No disease-specific, validated PRO instrument for these patients was found. The main evidence being that Imatinib provides clear advantage in terms of HRQOL over interferon-based treatments. There is lack of data concerning PROs in patients treated with current TT. Documenting HRQOL and side effects of CML treatments, from the patients' perspective is needed to evaluate overall treatment effectiveness and net clinical benefit of newer therapeutic strategies.},
  citation-subset = {IM},
  completed       = {2012-09-17},
  country         = {Netherlands},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {1040-8428},
  journal         = {Critical reviews in oncology/hematology},
  keywords        = {Bone Marrow Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, therapy; Molecular Targeted Therapy; Quality of Life; Time Factors; Treatment Outcome},
  month           = feb,
  nlm-id          = {8916049},
  owner           = {NLM},
  pii             = {S1040-8428(11)00053-9},
  pmid            = {21435899},
  pubmodel        = {Print-Electronic},
  revised         = {2018-12-01},
  year            = {2012},
}

@Article{Efficace2011,
  author          = {Efficace, Fabio and Baccarani, Michele and Breccia, Massimo and Alimena, Giuliana and Rosti, Gianantonio and Cottone, Francesco and Deliliers, Giorgio Lambertenghi and BaratÃ¨, Claudia and Rossi, Antonella Russo and Fioritoni, Giuseppe and Luciano, Luigia and Turri, Diamante and Martino, Bruno and Di Raimondo, Francesco and Dabusti, Melissa and Bergamaschi, Micaela and Leoni, Pietro and Simula, Maria Pina and Levato, Luciano and Ulisciani, Stefano and Veneri, Dino and Sica, Simona and Rambaldi, Alessandro and Vignetti, Marco and Mandelli, Franco and GIMEMA},
  title           = {Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.},
  doi             = {10.1182/blood-2011-04-347575},
  issn            = {1528-0020},
  issue           = {17},
  pages           = {4554--4560},
  pubstate        = {ppublish},
  volume          = {118},
  abstract        = {The main objective of this study was to investigate whether patients with chronic myeloid leukemia (CML) in treatment with long-term therapy imatinib have a different health-related quality-of-life (HRQOL) profile compared with the general population. In total, 448 CML patients were enrolled, and the SF-36 Health Survey was used to compare generic HRQOL profiles. Symptoms were also assessed. HRQOL comparisons were adjusted for key possible confounders. The median age of patients was 57 years and the median time of imatinib treatment was 5 years (range 3-9 years). The largest HRQOL differences were found in younger patients. In particular, patients aged between 18 and 39 years had marked impairments in role limitations because of physical and emotional problems, respectively: -22.6 (P < .001), -22.3 (P < .001). Patients with CML age 60 or older had a HRQOL profile very similar to that reported by the general population. Women had a worse profile than men when each were compared with their peers in the general population. Fatigue was the most frequently reported symptom. The HRQOL of CML patients is comparable with that of population norms in many areas, however, younger and female patients seem to report the major limitations.},
  chemicals       = {Antineoplastic Agents, Benzamides, Piperazines, Pyrimidines, Imatinib Mesylate},
  citation-subset = {AIM, IM},
  completed       = {2012-01-03},
  country         = {United States},
  groups          = {Study 2. Quality of Life},
  investigator    = {Baccarani, M and Rosti, G and Alimena, G and Breccia, M and Lambertenghi, Deliliers G and Petrini, M and BaratÃ¨, C and Specchia, G and Russo, Rossi A and Fioritoni, G and Di Lorenzo, R and Rotoli, B and Luciano, L and Mirto, S and Turri, D and Nobile, F and Martino, B and Di Raimondo, F and Stagno, F and Cuneo, A and Dabusti, M and Gobbi, M and Pierri, I and Leoni, P and Angelucci, E and Simula, M P and Peta, A and Levato, L and Saglio, G and Fava, C and Pizzolo, G and Veneri, D and Leone, G and Sica, S and Rambaldi, A and Ferrari, M and Longinotti, M and Pardini, S and Gherlinzoni, F and Zaccaria, A and Fanin, R and Tiribelli, M and D'odorico, C and Rossi, G and Ferrara, F and Lauria, F},
  issn-linking    = {0006-4971},
  journal         = {Blood},
  keywords        = {Adolescent; Adult; Antineoplastic Agents, adverse effects, therapeutic use; Benzamides; Cross-Sectional Studies; Female; Health Status; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, epidemiology, psychology; Maintenance Chemotherapy; Male; Middle Aged; Piperazines, therapeutic use; Population; Pyrimidines, therapeutic use; Quality of Life; Time Factors; Young Adult},
  month           = oct,
  nlm-id          = {7603509},
  owner           = {NLM},
  pii             = {S0006-4971(20)40966-8},
  pmid            = {21750313},
  pubmodel        = {Print-Electronic},
  revised         = {2021-02-06},
  year            = {2011},
}

@Article{Aziz2011,
  author          = {Aziz, Zeba and Iqbal, Javaid and Aaqib, Muhammad and Akram, Muhammad and Saeed, Asif},
  title           = {Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia.},
  doi             = {10.3109/10428194.2011.560310},
  issn            = {1029-2403},
  issue           = {6},
  pages           = {1017--1023},
  pubstate        = {ppublish},
  volume          = {52},
  abstract        = {Imatinib mesylate (IM) is a first-line treatment of chronic phase-chronic myeloid leukemia (CP-CML). The primary objective of this study was to assess the quality of life (QOL) in patients with CP-CML treated with IM. Ninety patients with newly diagnosed CP-CML were assessed for QOL with first-line IM. Patients completed the cancer-specific FACT-BRM questionnaire (functional assessment of cancer therapy-biologic response modifiers) at baseline and at 3 and 6 months. FACT-BRM consists of subscales including physical well-being (PWB), social and family well-being (SFWB), emotional well-being (EWB), functional well-being (FWB), BRM-physical, and BRM-mental. The primary endpoint was the Trial Outcome Index (TOI), created as a measure of physical function and well-being. An increase of â‰¥5 from baseline was considered to be a clinically significant improvement. The mean TOI score increased from 75.5 at baseline to 85.2 (p<0.0001) at 6 months, representing a healthy QOL. When comparing the individual TOI subscales, there was a mean increase of 16.4 in the daily functioning and well-being score, and a mean decrease of 6.2, 4.9, and 16.1 was noted in fatigue, emotional/cognitive dysfunction, and side-effects scores at 6 months, respectively. Improvement was not affected by age, sex, or Sokal score. With prolonged treatment, IM results in a higher physical well-being, less fatigue and emotional and cognitive dysfunction, and very few side-effects.},
  chemicals       = {Benzamides, Piperazines, Pyrimidines, Imatinib Mesylate},
  citation-subset = {IM},
  completed       = {2011-10-24},
  country         = {United States},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {1026-8022},
  journal         = {Leukemia & lymphoma},
  keywords        = {Adolescent; Adult; Analysis of Variance; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase, drug therapy, psychology; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines, adverse effects, therapeutic use; Prospective Studies; Pyrimidines, therapeutic use; Quality of Life; Surveys and Questionnaires; Time Factors; Young Adult},
  month           = jun,
  nlm-id          = {9007422},
  owner           = {NLM},
  pmid            = {21534871},
  pubmodel        = {Print-Electronic},
  revised         = {2019-12-10},
  year            = {2011},
}

@Article{Hahn2003,
  author          = {Hahn, Elizabeth A. and Glendenning, G. Alastair and Sorensen, Mark V. and Hudgens, Stacie A. and Druker, Brian J. and Guilhot, Francois and Larson, Richard A. and O'Brien, Stephen G. and Dobrez, Deborah G. and Hensley, Martee L. and Cella, David and Investigators, I. R. I. S.},
  title           = {Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.},
  doi             = {10.1200/JCO.2003.12.154},
  issn            = {0732-183X},
  issue           = {11},
  pages           = {2138--2146},
  pubstate        = {ppublish},
  volume          = {21},
  abstract        = {Quality of life (QOL) outcomes in patients with chronic myeloid leukemia (CML) were evaluated in an international phase III study. Newly diagnosed patients with chronic phase CML were randomly assigned to imatinib or interferon alfa plus subcutaneous low-dose cytarabine (IFN+LDAC). Cross-over to the other treatment was permitted because of intolerance or lack of efficacy. Patients completed cancer-specific QOL (Functional Assessment of Cancer Therapy-Biologic Response Modifiers) and utility (Euro QoL-5D) questionnaires at baseline and during treatment (n = 1,049). The primary QOL end point was the Trial Outcome Index (TOI; a measure of physical function and well-being). Secondary end points included social and family well-being (SFWB), emotional well-being (EWB), and the utility score. Primary analyses were intention to treat with secondary analyses accounting for cross-over. Patients receiving IFN+LDAC experienced a large decline in the TOI, whereas those receiving imatinib maintained their baseline level. Treatment differences at each visit were significant (P <.001) and clinically relevant in favor of imatinib. Mean SFWB, EWB, and utility scores were also significantly better for those patients taking imatinib. Patients who crossed over to imatinib experienced a large increase in TOI; significant (P <.001) differences were observed between patients who did and did not cross over in favor of imatinib. Imatinib offers clear QOL advantages compared with IFN+LDAC as first-line treatment of chronic phase CML. In addition, patients who cross over to imatinib from IFN+LDAC experience a significant improvement in QOL compared with patients who continue to take IFN+LDAC.},
  chemicals       = {Antineoplastic Agents, Benzamides, Interferon-alpha, Piperazines, Pyrimidines, Cytarabine, Imatinib Mesylate},
  citation-subset = {IM},
  completed       = {2003-06-19},
  country         = {United States},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0732-183X},
  journal         = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  keywords        = {Adolescent; Adult; Aged; Antineoplastic Agents, adverse effects, therapeutic use; Antineoplastic Combined Chemotherapy Protocols, therapeutic use; Benzamides; Cross-Over Studies; Cytarabine, administration & dosage; Female; Humans; Imatinib Mesylate; Interferon-alpha, administration & dosage; Leukemia, Myeloid, Chronic-Phase, drug therapy; Logistic Models; Male; Middle Aged; Multivariate Analysis; Piperazines, therapeutic use; Prospective Studies; Pyrimidines, therapeutic use; Quality of Life},
  month           = jun,
  nlm-id          = {8309333},
  owner           = {NLM},
  pii             = {JCO.2003.12.154},
  pmid            = {12775739},
  pubmodel        = {Print},
  revised         = {2015-11-19},
  year            = {2003},
}

@Article{Kiss2002,
  author          = {Kiss, T. L. and Abdolell, M. and Jamal, N. and Minden, M. D. and Lipton, J. H. and Messner, H. A.},
  title           = {Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation.},
  doi             = {10.1200/JCO.2002.06.077},
  issn            = {0732-183X},
  issue           = {9},
  pages           = {2334--2343},
  pubstate        = {ppublish},
  volume          = {20},
  abstract        = {Benchmark analysis of patients with chronic myeloid leukemia (CML) alive for more than 10 years after allogeneic bone marrow transplantation (BMT) including data on disease status, bone marrow reserve, long-term complications, and quality of life (QOL). Eighty-nine patients (46 in first chronic phase, 43 in advanced phase) received an allogeneic BMT for CML during the study period. Medical outcomes and QOL of patients were analyzed retrospectively. Twenty-eight (31.5%) of 89 patients were alive at 10 years and included in this analysis. Thirteen (46.4%) of 28 long-term survivors never relapsed. Fifteen patients relapsed between 0.5 and 16 years after transplantation. Ten patients showed a hematologic relapse and received salvage treatment. Five patients showed transient low levels of BCR-ABL-positive cells by Southern blot with no subsequent hematologic relapse. One of the 28 patients died in blast crisis at 12 years. The most frequent long-term complications were chronic graft-versus-host disease, osteoporosis, and cataracts. Frequency of clonogenic progenitors remained persistently decreased. QOL assessment yielded lower scores in physical performance as compared with an age-matched normative population, whereas social functioning was equivalent. A high degree of satisfaction was noted with interpersonal relationships. Patients with CML surviving their BMT long term do well in terms of medical outcomes. A constant rate of relapse was noted, with a high salvage rate of affected patients, suggesting the need for lifelong monitoring. QOL is perceived as good, particularly as related to social functioning; however, it is inferior to a normative population with regard to physical performance.},
  citation-subset = {IM},
  completed       = {2002-05-28},
  country         = {United States},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0732-183X},
  journal         = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  keywords        = {Adult; Blotting, Southern; Bone Marrow Transplantation; Chi-Square Distribution; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, psychology, therapy; Male; Middle Aged; Outcome Assessment, Health Care; Quality of Life; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Surveys and Questionnaires; Survival Analysis; Transplantation, Homologous},
  month           = may,
  nlm-id          = {8309333},
  owner           = {NLM},
  pmid            = {11981005},
  pubmodel        = {Print},
  revised         = {2019-12-10},
  year            = {2002},
}

@Article{Molassiotis1999,
  author          = {Molassiotis, A. and Morris, P. J.},
  title           = {Quality of life in patients with chronic myeloid leukemia after unrelated donor bone marrow transplantation.},
  doi             = {10.1097/00002820-199910000-00002},
  issn            = {0162-220X},
  issue           = {5},
  pages           = {340--349},
  pubstate        = {ppublish},
  volume          = {22},
  abstract        = {A descriptive study was designed to assess the quality of life and quantify potential long-term physical and psychosocial problems resulting from unrelated donor bone marrow transplantation. A sample of 28 survivors of an average 41.2 months post-bone marrow transplantation showed that quality of life was good to excellent in most subjects, with a small fraction having impaired physical or psychosocial functioning. Psychosocial adjustment was most impaired in domains of life related to sexual relationships, vocational adjustment, social adjustment, and psychological distress. Females and older adults reported significantly higher dysfunction compared with males and younger subjects. Passage of time since bone marrow transplantation was unrelated to psychosocial improvement. Fatigue was the main symptom interfering with daily life in most (78.6%). Regression analysis showed that development of fatigue in our sample was mainly the result of the combined effects of anxiety, presence of pain, and infections (R2 = 0.75, p < .001), with weight loss showing a trend in relation to fatigue. Results indicate that unrelated donor bone marrow transplantation long-term survivors have an acceptable degree of quality of life, but rehabilitative services still need to be used for those who exhibit difficulties with their daily life.},
  citation-subset = {IM, N},
  completed       = {1999-11-04},
  country         = {United States},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0162-220X},
  journal         = {Cancer nursing},
  keywords        = {Adaptation, Psychological; Adolescent; Adult; Bone Marrow Transplantation, psychology; Female; Follow-Up Studies; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, psychology; Male; Middle Aged; Quality of Life; Regression Analysis; Transplantation, Homologous, psychology},
  month           = oct,
  nlm-id          = {7805358},
  owner           = {NLM},
  pmid            = {10526427},
  pubmodel        = {Print},
  revised         = {2019-11-03},
  year            = {1999},
}

@Article{Molassiotis1998,
  author          = {Molassiotis, A. and Morris, P. J.},
  title           = {The meaning of quality of life and the effects of unrelated donor bone marrow transplants for chronic myeloid leukemia in adult long-term survivors.},
  doi             = {10.1097/00002820-199806000-00008},
  issn            = {0162-220X},
  issue           = {3},
  pages           = {205--211},
  pubstate        = {ppublish},
  volume          = {21},
  abstract        = {Qualitative data, as part of a larger study, were collected to assess perceptions about quality of life (QOL) after bone marrow transplant (BMT) and its impact on long-term survivors who had undergone an unrelated donor bone marrow transplant. A sample of 28 survivors participated in the study. Quality of life was described in terms of "normality," enjoyment, and fulfillment with life: being psychologically and physically healthy, being independent, having family and relationships, having work, experiencing happiness, and having material support. There were many factors with which survivors found it difficult to cope: symptoms, frustration brought from the inabilities to function in life, family life, returning to work, and infertility. However, about 25% of the survivors reported a positive impact of the BMT on their lives. Main concerns about the future were related to health status, the long-term effects of the transplant, financial concern, infertility, the normalization process, and the family. These data confirmed that unrelated donor BMT patients do not have a different perception about their QOL than other BMT patients receiving autologous or allogeneic marrow transplants. Some of the issues that differed from the previous BMT literature included higher inability to perform daily tasks and dependency on others, adverse memories of the transplant, and concerns about the future. These areas should be the target of pretransplant interventions and the long-term psychosocial services provided to patients. As mentioned by the respondents, health care professionals could further improve their patients' QOL by providing counseling and psychologic support, education about the effects of the various treatments, and improved research in BMT treatment and side effects.},
  citation-subset = {IM, N},
  completed       = {1998-07-31},
  country         = {United States},
  groups          = {Study 2. Quality of Life},
  issn-linking    = {0162-220X},
  journal         = {Cancer nursing},
  keywords        = {Adaptation, Psychological; Adolescent; Adult; Bone Marrow Transplantation, adverse effects, psychology; Clinical Nursing Research; Counseling; Female; Health Status; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, psychology, therapy; Male; Middle Aged; Patient Education as Topic; Quality of Life; Social Support; Survivors},
  month           = jun,
  nlm-id          = {7805358},
  owner           = {NLM},
  pmid            = {9615511},
  pubmodel        = {Print},
  revised         = {2019-11-02},
  year            = {1998},
}

@Article{KML2019,
  author = {Regionalt cancercentrum Stockholm-Gotland},
  date   = {2019-10-04},
  title  = {Kronisk myeloiskleukemi: Nationellt vÃ¥rdprogram},
  file   = {:/Users/yitche/survbib/pdf/KML2019.pdf:PDF},
  groups = {Swedish CML doc},
}

@Article{Lambert2021,
  author  = {Lambert, P. C. and Syriopoulou, E. and Rutherford, M. J.},
  title   = {Direct modelling of age standardized marginal relative survival through incorporation of time-dependent weights},
  doi     = {10.1186/s12874-021-01266-1},
  pages   = {84},
  volume  = {21},
  file    = {:Lambert2021.pdf:PDF},
  journal = {BMC Medical Research Methodology},
  pmid    = {33894741},
  year    = {2021},
}

@Article{Ensor2021,
  author          = {Ensor, Joie and Snell, Kym I E and Debray, Thomas P A and Lambert, Paul C and Look, Maxime P and Mamas, Mamas A and Moons, Karel G M and Riley, Richard D},
  title           = {Individual participant data meta-analysis for external validation, recalibration, and updating of a flexible parametric prognostic model.},
  doi             = {10.1002/sim.8959},
  issn            = {1097-0258},
  pages           = {3066--3084},
  volume          = {40},
  abstract        = {Individual participant data (IPD) from multiple sources allows external validation of a prognostic model across multiple populations. Often this reveals poor calibration, potentially causing poor predictive performance in some populations. However, rather than discarding the model outright, it may be possible to modify the model to improve performance using recalibration techniques. We use IPD meta-analysis to identify the simplest method to achieve good model performance. We examine four options for recalibrating an existing time-to-event model across multiple populations: (i) shifting the baseline hazard by a constant, (ii) re-estimating the shape of the baseline hazard, (iii) adjusting the prognostic index as a whole, and (iv) adjusting individual predictor effects. For each strategy, IPD meta-analysis examines (heterogeneity in) model performance across populations. Additionally, the probability of achieving good performance in a new population can be calculated allowing ranking of recalibration methods. In an applied example, IPD meta-analysis reveals that the existing model had poor calibration in some populations, and large heterogeneity across populations. However, re-estimation of the intercept substantially improved the expected calibration in new populations, and reduced between-population heterogeneity. Comparing recalibration strategies showed that re-estimating both the magnitude and shape of the baseline hazard gave the highest predicted probability of good performance in a new population. In conclusion, IPD meta-analysis allows a prognostic model to be externally validated in multiple settings, and enables recalibration strategies to be compared and ranked to decide on the least aggressive recalibration strategy to achieve acceptable external model performance without discarding existing model information.},
  citation-subset = {IM},
  country         = {England},
  file            = {:Ensor2021.pdf:PDF},
  groups          = {Paul:6},
  issn-linking    = {0277-6715},
  journal         = {Statistics in Medicine},
  keywords        = {IPD Meta-analysis; external validation; model recalibration; model updating; time-to-event models},
  month           = mar,
  nlm-id          = {8215016},
  owner           = {NLM},
  pmid            = {33768582},
  pubmodel        = {Print-Electronic},
  pubstatus       = {aheadofprint},
  revised         = {2021-03-26},
  year            = {2021},
}

@Article{CrowtherPhD,
  author       = {Crowther M.J.},
  journal      = {PHD Leicester},
  title        = {Development and application of methodology for the parametric analysis of complex survival and joint longitudinal-survival data in biomedical research},
  file         = {:Crowther_PhD:},
}

@Article{Sweeting2021,
  author          = {Sweeting, Michael J and Oliver-Williams, Clare and Teece, Lucy and Welch, Catherine A and de Belder, Mark A and Coles, Briana and Lambert, Paul C and Paley, Lizz and Rutherford, Mark J and Elliss-Brookes, Lucy and Deanfield, John and Peake, Mick D and Adlam, David},
  title           = {Data Resource Profile: {T}he {V}irtual {C}ardio-{O}ncology {R}esearch {I}nitiative ({VICORI}) linking national {E}nglish cancer registration and cardiovascular audits.},
  doi             = {10.1093/ije/dyab082},
  issn            = {1464-3685},
  pages           = {1768-1779},
  volume          = {50},
  citation-subset = {IM},
  country         = {England},
  groups          = {Paul:6},
  issn-linking    = {0300-5771},
  journal         = {International Journal of Epidemiology},
  keywords        = {Data resource; cardio-oncology; cardiovascular; oncology},
  month           = jun,
  nlm-id          = {7802871},
  owner           = {NLM},
  pii             = {dyab082},
  pmid            = {34089612},
  pubmodel        = {Print-Electronic},
  pubstatus       = {aheadofprint},
  revised         = {2021-06-05},
  year            = {2022},
}

@Article{Coles2021,
  author          = {Coles, Briana and Teece, Lucy and Weston, Clive and de Belder, Mark A and Oliver-Williams, Clare and Welch, Catherine A and Rutherford, Mark J and Lambert, Paul C and Bidulka, Patrick and Paley, Lizz and Nitsch, Dorothea and Deanfield, John and Peake, Mick D and Adlam, David and Sweeting, Michael J and VICORI collaborative},
  title           = {Case-ascertainment of acute myocardial infarction hospitalisations in cancer patients: a cohort study using {E}nglish linked electronic health data.},
  doi             = {10.1093/ehjqcco/qcab045},
  issn            = {2058-1742},
  pages           = {86-95},
  volume          = {8},
  abstract        = {To assess the recording and accuracy of acute myocardial infarction (AMI) hospital admissions between two electronic health record databases within an English cancer population over time and understand the factors that affect case-ascertainment. We identified 112,502 hospital admissions for AMI in England 2010-2017 from the Myocardial Ischaemia National Audit Project (MINAP) disease registry and Hospital Episode Statistics (HES) for 95,509 patients with a previous cancer diagnosis up to 15 years prior to admission. Cancer diagnoses were identified from the National Cancer Registration Dataset (NCRD). We calculated the percentage of AMI admissions captured by each source and examined patient characteristics associated with source of ascertainment. Survival analysis assessed whether differences in survival between case-ascertainment sources could be explained by patient characteristics.57,265 (50.9%) AMI admissions in patients with a prior diagnosis of cancer were captured in both MINAP and HES. Patients captured in both sources were younger, more likely to have ST-segment elevation MI and had better prognosis, with lower mortality rates up to 9 years after AMI admission compared with patients captured in only one source. The percentage of admissions captured in both data sources improved over time. Cancer characteristics (site, stage and grade) had little effect on how AMI was captured. MINAP and HES define different populations of patients with AMI. However, cancer characteristics do not substantially impact on case-ascertainment. These findings support a strategy of using multiple linked data sources for observational cardio-oncological research into AMI.},
  citation-subset = {IM},
  country         = {England},
  groups          = {Paul:6},
  issn-linking    = {2058-1742},
  journal         = {European Heart Journal. Quality of care \& Clinical outcomes},
  keywords        = {Cardio-oncology; HES; MINAP; cancer; case-ascertainment; myocardial infarction},
  month           = jun,
  nlm-id          = {101677796},
  owner           = {NLM},
  pii             = {qcab045},
  pmid            = {34156470},
  pubmodel        = {Print-Electronic},
  pubstatus       = {aheadofprint},
  revised         = {2021-06-22},
  year            = {2021},
}

@Article{Crowther2020,
  author       = {Crowther, M. J.},
  date         = {2020},
  journal      = {The Stata Journal},
  title        = {merlinâ€”A unified modeling framework for dataanalysis and methods development in {S}tata},
  doi          = {10.1177/1536867X20976311},
  pages        = {763â€“784},
  volume       = {20},
}

@Article{Peters2017,
  author          = {Peters, Tracy L. and Weibull, Caroline E. and Fang, Fang and Sandler, Dale P. and Lambert, Paul C. and Ye, Weimin and Kamel, Freya},
  date            = {2017-08},
  title           = {Association of fractures with the incidence of amyotrophic lateral sclerosis.},
  doi             = {10.1080/21678421.2017.1300287},
  issn            = {2167-9223},
  issue           = {5-6},
  pages           = {419--425},
  pubstate        = {ppublish},
  volume          = {18},
  abstract        = {Elevated bone turnover observed in ALS patients suggests poor bone health and increased fracture risk. We therefore evaluated the relationship of fracture to subsequent ALS risk. We followed 4,529,460 Swedes from 1987 to 2010 and identified ALS and fractures from the Swedish National Patient Register. We examined associations of ALS risk with all fractures, osteoporotic and non-osteoporotic fractures, and traumatic and non-traumatic fractures among individuals aged 30-80 years. We used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). We analysed the association of ALS with time since fracture using a Poisson regression model. All fractures (HR: 1.51, 95% CI 1.39-1.65) as well as osteoporotic (HR: 1.59, 95% CI 1.41-1.79), non-osteoporotic (HR: 1.46, 95% CI 1.31-1.63), traumatic (HR: 1.50, 95% CI 1.37-1.63), and non-traumatic (HR: 1.80, 95% CI 1.35-2.40) fractures were associated with a higher incidence of ALS. Increased ALS incidence was associated with fractures occurring from one (HR: 2.33, 95% CI 2.04-2.66) to 18 (HR: 1.19, 95% CI 1.01-1.43) years before ALS diagnosis. Poor bone health may be related to ALS. These findings may offer insight into ALS pathophysiology.},
  citation-subset = {IM},
  completed       = {2018-04-10},
  country         = {England},
  issn-linking    = {2167-8421},
  journal         = {Amyotrophic lateral sclerosis \& frontotemporal degeneration},
  keywords        = {Aged; Amyotrophic Lateral Sclerosis, diagnosis, epidemiology; Cohort Studies; Female; Fractures, Bone, epidemiology; Humans; Incidence; Male; Middle Aged; Prospective Studies; Registries; Risk Factors; Sweden, epidemiology; Amyotrophic lateral sclerosis; cohort study; fractures; risk factors},
  mid             = {NIHMS867506},
  nlm-id          = {101587185},
  owner           = {NLM},
  pmc             = {PMC5527744},
  pmid            = {28316249},
  pubmodel        = {Print-Electronic},
  revised         = {2019-12-20},
  year            = {2017},
}

@Article{Cramb2016,
  author          = {Cramb, Susanna M. and Mengersen, Kerrie L. and Lambert, Paul C. and Ryan, Louise M. and Baade, Peter D.},
  date            = {2016-12},
  title           = {A flexible parametric approach to examining spatial variation in relative survival.},
  doi             = {10.1002/sim.7071},
  issn            = {1097-0258},
  issue           = {29},
  pages           = {5448--5463},
  pubstate        = {ppublish},
  volume          = {35},
  abstract        = {Most of the few published models used to obtain small-area estimates of relative survival are based on a generalized linear model with piecewise constant hazards under a Bayesian formulation. Limitations of these models include the need to artificially split the time scale, restricted ability to include continuous covariates, and limited predictive capacity. Here, an alternative Bayesian approach is proposed: a spatial flexible parametric relative survival model. This overcomes previous limitations by combining the benefits of flexible parametric models: the smooth, well-fitting baseline hazard functions and predictive ability, with the Bayesian benefits of robust and reliable small-area estimates. Both spatially structured and unstructured frailty components are included. Spatial smoothing is conducted using the intrinsic conditional autoregressive prior. The model was applied to breast, colorectal, and lung cancer data from the Queensland Cancer Registry across 478 geographical areas. Advantages of this approach include the ease of including more realistic complexity, the feasibility of using individual-level input data, and the capacity to conduct overall, cause-specific, and relative survival analysis within the same framework. Spatial flexible parametric survival models have great potential for exploring small-area survival inequalities, and we hope to stimulate further use of these models within wider contexts. Copyright Â© 2016 John Wiley & Sons, Ltd.},
  citation-subset = {IM},
  completed       = {2018-02-23},
  country         = {England},
  issn-linking    = {0277-6715},
  journal         = {Statistics in Medicine},
  keywords        = {Bayes Theorem; Humans; Linear Models; Neoplasms, mortality; Queensland; Registries; Survival Analysis; Australia; Bayesian; cancer; flexible parametric; relative survival; small area},
  nlm-id          = {8215016},
  owner           = {NLM},
  pmid            = {27503837},
  pubmodel        = {Print-Electronic},
  revised         = {2018-12-02},
  year            = {2016},
}

@Article{Ahyow2013,
  author          = {Ahyow, Lauren C. and Lambert, Paul C. and Jenkins, David R. and Neal, Keith R. and Tobin, Martin},
  date            = {2013-10},
  title           = {Bed occupancy rates and hospital-acquired Clostridium difficile infection: a cohort study.},
  doi             = {10.1086/673156},
  issn            = {1559-6834},
  issue           = {10},
  pages           = {1062--1069},
  pubstate        = {ppublish},
  volume          = {34},
  abstract        = {An emergent strain (ribotype 027) of Clostridium difficile infection (CDI) has been implicated in epidemics worldwide. Organizational factors such as bed occupancy have been associated with an increased incidence of CDI; however, the data are sparse, and the association has not been widely demonstrated. We investigated the association of bed occupancy and CDI within a large hospital organization in the United Kingdom. To establish whether bed occupancy rates are a significant risk factor for CDI in the general ward setting. A retrospective cohort study was carried out on data from 2006 to 2008. Univariate and multivariate Cox regression modeling was used to examine the strength and significance of the associations. Variables included patient characteristics, antibiotic policy exposure, case mix, and bed occupancy rates. A total of 1,589 cases of hospital-acquired CDI were diagnosed (1.7% of admissions), with an overall infection rate of 2.16 per 1,000 patient-days. Median bed occupancy was 93.3% (interquartile range, 83.3%-100%) Univariate and multivariate analyses showed positive and statistically significant associations. In the adjusted model, patients on wards with occupancy rates of 80%-89.9% had rates of CDI that were 56% higher (hazard ratio, 1.56 [95% confidence interval, 1.18-2.04]; P < .001) compared with baseline (0%-69.9% occupancy). CDI rates were 55% higher for patients on wards with maximal bed occupancy (100%). There is strong evidence of an association between high bed occupancy and CDI. Without effective interventions at high levels of bed occupancy, the economic benefits sought from reducing bed numbers may be negated by the increased risk of CDI.},
  citation-subset = {IM, N},
  completed       = {2014-05-12},
  country         = {United States},
  issn-linking    = {0899-823X},
  journal         = {Infection control and hospital epidemiology},
  keywords        = {Adult; Aged; Aged, 80 and over; Bed Occupancy, statistics & numerical data; Clostridioides difficile; Cross Infection, epidemiology, microbiology; Enterocolitis, Pseudomembranous, microbiology; Female; Humans; Incidence; Male; Middle Aged; Retrospective Studies; United Kingdom, epidemiology; Young Adult},
  nlm-id          = {8804099},
  owner           = {NLM},
  pii             = {S0195941700033944},
  pmid            = {24018923},
  pubmodel        = {Print-Electronic},
  revised         = {2020-12-09},
  year            = {2013},
}

@Article{Radkiewicz2020,
  author          = {Radkiewicz, Cecilia and Edgren, Gustaf and Johansson, Anna Louise Viktoria and Jahnson, Staffan and H\"{a}ggstr\"{o}m, Christel and Akre, Olof and Lambe, Mats and Dickman, Paul William},
  title           = {Sex Differences in Urothelial Bladder Cancer Survival.},
  doi             = {10.1016/j.clgc.2019.10.020},
  issn            = {1938-0682},
  issue           = {1},
  pages           = {26--34.e6},
  pubstate        = {ppublish},
  volume          = {18},
  abstract        = {While urinary bladder cancer is consistently more common in men worldwide, women have poorer prognosis. The aim of this study was to outline sex differences in prognostic factors and clinical management and to explore whether these can explain the poorer urinary bladder cancer outcome in women. We performed a population-based cohort study including all patients diagnosed with urothelial bladder cancer between 1997 and 2014 at age 18 to 89 who had data recorded in the Swedish Urinary Bladder Cancer Register (nÂ = 36,344). Female-to-male odds ratios for clinical management parameters were estimated by logistic regression. To quantify sex differences in bladder cancer-specific survival, we estimated empirical survival proportions and mortality rates as well as applied flexible parametric models to estimate female-to-male hazard ratios and survival proportions over follow-up. Adjusted models included age, year, World Health Organization grade, stage, marital status, education, health care region, birth country, and comorbidity. Except for an adverse stage distribution in women, we found no evidence of unequal clinical management. Among those diagnosed with bladder cancer, women had a higher bladder cancer mortality (adjusted hazard ratio, 1.15; 95% confidence interval, 1.08-1.23) driven by muscle-invasive tumors (adjusted hazard ratio, 1.24; 95% confidence interval, 1.14-1.34). The female survival disadvantage was confined to the first 2 years after diagnosis. The excess bladder cancer mortality in women is limited to those diagnosed with muscle-invasive tumors and cannot be explained by the examined clinicopathologic factors. Further investigations of sex differences in therapeutic procedures and outcomes, including complications, of muscle-invasive bladder cancer, must be performed.},
  chemicals       = {Antineoplastic Agents},
  citation-subset = {IM},
  completed       = {2021-01-29},
  country         = {United States},
  issn-linking    = {1558-7673},
  journal         = {Clinical genitourinary cancer},
  keywords        = {Administration, Intravesical; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, administration & dosage; Carcinoma, Transitional Cell, mortality, pathology, therapy; Chemotherapy, Adjuvant, methods; Cystectomy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Registries, statistics & numerical data; Sex Factors; Sweden, epidemiology; Urinary Bladder, surgery; Urinary Bladder Neoplasms, therapy; Young Adult; Registries; Sex factors; Survival analysis; Sweden/epidemiology; Urinary bladder neoplasms/mortality},
  nlm-id          = {101260955},
  owner           = {NLM},
  pii             = {S1558-7673(19)30324-6},
  pmid            = {31787542},
  pubmodel        = {Print-Electronic},
  revised         = {2021-01-29},
  year            = {2020},
}

@Article{Radkiewicz2019,
  author          = {Radkiewicz, Cecilia and Dickman, Paul William and Johansson, Anna Louise Viktoria and Wagenius, Gunnar and Edgren, Gustaf and Lambe, Mats},
  date            = {2019},
  journal         = {PloS one},
  title           = {Sex and survival in non-small cell lung cancer: A nationwide cohort study.},
  doi             = {10.1371/journal.pone.0219206},
  issn            = {1932-6203},
  issue           = {6},
  pages           = {e0219206},
  pubstate        = {epublish},
  volume          = {14},
  abstract        = {To in detail delineate sex differences in non-small cell lung cancer outcome and investigate possible underlying drivers. We performed a nationwide, population-based cohort study using data on all incident cases of lung squamous cell carcinoma (n = 10,325) and adenocarcinoma (n = 23,465) recorded in the Swedish Lung Cancer Register in 2002-2016. Flexible parametric models were applied to compute adjusted female-to-male hazard ratios (aHRs) and standardized survival proportions over follow-up including age, calendar year, education, marital status, birth country, health care region, performance status, smoking history, comorbidities, and tumor location in the final model. Women presented with better performance status, were younger, and more often never-smokers. Women with adenocarcinoma also had lower comorbidity burden, less advanced stage, and were more often EGFR positive. Men with adenocarcinoma had a consistently poorer lung cancer-specific survival across stage; HR 0.69; 95% CI 0.63-0.76 (stage IA-IIB) to 0.94; 95% CI 0.88-0.99 (stage IIIB-IV), remaining largely unchanged after adjustments; aHR 0.74; 95% CI 0.66-0.82 to 0.84; 95% CI 0.81-0.87. The same pattern was observed in squamous cell carcinoma, except in stage IIIA disease, where we found no sex differences in survival. Men with non-small cell lung cancer have a consistently poorer prognosis, even after careful adjustments for a wide range of prognostic factors. While the pattern was similar in both squamous cell and adenocarcinoma, it was larger and more consistent in the latter.},
  citation-subset = {IM},
  completed       = {2020-02-24},
  country         = {United States},
  issn-linking    = {1932-6203},
  keywords        = {Adenocarcinoma, mortality, pathology; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung, pathology; Carcinoma, Squamous Cell, pathology; Cohort Studies; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms, pathology; Male; Middle Aged; Neoplasm Staging; Prognosis; Proportional Hazards Models; Sex Factors; Sweden, epidemiology; Young Adult},
  nlm-id          = {101285081},
  owner           = {NLM},
  pii             = {PONE-D-19-10489},
  pmc             = {PMC6597110},
  pmid            = {31247015},
  pubmodel        = {Electronic-eCollection},
  revised         = {2020-03-09},
}

@Article{Johansson2022,
  author          = {Johansson, Anna L. V. and Dickman, Paul W. and Eloranta, Sandra and BjÃ¶rkholm, Magnus},
  date            = {2022-04},
  journal         = {Acta oncologica (Stockholm, Sweden)},
  title           = {Reproductive history, as measured by parity, age at first birth and sex of offspring, and cancer-specific survival after a haematological malignancy.},
  doi             = {10.1080/0284186X.2022.2064726},
  issn            = {1651-226X},
  pages           = {1--9},
  pubstate        = {aheadofprint},
  abstract        = {Overall, women have better cancer-specific survival than men following haematological malignancies. The effect of reproductive factors on prognosis in women remains unknown and population-based studies are needed. A nationwide cohort of 21,237 Swedish women with a recorded haematological malignancy at ages 18-69â€‰years was identified in the Swedish Cancer Register 1970-2018. Pre-diagnosis childbirths for each woman were linked to the Swedish Multigeneration Register. Net survival and excess hazard ratios for parity, age at first birth, time since the latest birth, and sex of offspring were estimated using flexible parametric models adjusted for age, year, and educational level. In unadjusted analyses, parity ( â€‰=â€‰0.0012) and high age at first birth ( â€‰<â€‰0.0001) were associated with better survival. After co-adjustments for reproductive factors and confounders, the associations were attenuated. The adjusted association with parity was mainly observed among women aged above 40â€‰years at diagnosis ( â€‰=â€‰0.0033). The associations with reproductive factors were non-significant across subtypes of haematological malignancy. There was a tendency of higher excess mortality for an increasing number of boys compared to girls, although only significant for women with three or more children ( â€‰=â€‰0.0126). Reproductive factors were in part associated with survival following diagnosis of a haematological malignancy. However, the effect sizes were small with inconsistent association patterns, and thus reproductive factors may only partly contribute to the survival advantage of women over men.},
  citation-subset = {IM},
  country         = {England},
  issn-linking    = {0284-186X},
  keywords        = {Pregnancy; age at first birth; haematological malignancy; parity; relative survival},
  nlm-id          = {8709065},
  owner           = {NLM},
  pmid            = {35451928},
  pubmodel        = {Print-Electronic},
  revised         = {2022-04-22},
}

@Article{Kalager2021,
  author          = {Kalager, Mette and Adami, Hans-Olov and Dickman, Paul W. and Lagergren, Pernilla and Steindorf, Karen},
  date            = {2021-12},
  journal         = {Molecular oncology},
  title           = {Cancer outcome research - a European challenge Part II: Opportunities and priorities.},
  doi             = {10.1002/1878-0261.13169},
  issn            = {1878-0261},
  pubstate        = {aheadofprint},
  abstract        = {In Part I of our review of cancer outcome research, we analysed pros and cons of various measures relevant to quantifying the burden of cancer. Based on our recommendations in Part I, we now discuss in Part II opportunities and priorities in four areas of outcome research: primary prevention; early detection screening; treatment; and quality-of-life assessment. We recommend the establishment of an infrastructure that facilitates high-quality research in these areas: (a) progress in primary prevention can be assessed most directly by monitoring cancer incidence although the interpretation of temporal trends is notoriously confounded by numerous factors that complicate causal inference. (b) preventive screening, with the aim to prevent advanced disease, appears to work well in in some tumours but not in others. It will require randomized control trials (RCTs) to quantify benefits and harms although conclusive studies are increasingly difficult to undertake. We therefore propose learning screening programmes (randomization at the time of rolling out population-based programmes) as the most feasible approach. (c) New therapeutic interventions tailored to the individual patient often require assessment in RCTs with rather complex and dynamic structure, making their design and analyses increasingly challenging but also more suited to be executed as academic, PI-initiated trials. (d) We next discuss assessment of quality-of-life aspects. Quality of life is a neglected component in outcome research with an urgent need for development, validation and standardization. We finally recommend four initiatives that would pave the way for a valid and informative assessment of the goals for improved cancer control in Europe as defined by the European Academy of Cancer Sciences.},
  citation-subset = {IM},
  country         = {United States},
  issn-linking    = {1574-7891},
  keywords        = {cancer; prevention; quality of life; screening; treatment},
  nlm-id          = {101308230},
  owner           = {NLM},
  pmid            = {34939327},
  pubmodel        = {Print-Electronic},
  revised         = {2022-01-15},
}

@Article{Steingrimsson2022,
  author          = {SteingrÃ­msson, VilhjÃ¡lmur and Lund, SigrÃºn H. and Dickman, Paul W. and Weibull, Caroline E. and BjÃ¶rkholm, Magnus and Landgren, Ola and Kristinsson, SigurÃ°ur Y.},
  date            = {2022-02},
  journal         = {European journal of haematology},
  title           = {Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: A population-based study.},
  doi             = {10.1111/ejh.13720},
  issn            = {1600-0609},
  issue           = {2},
  pages           = {145--153},
  pubstate        = {ppublish},
  volume          = {108},
  abstract        = {To evaluate temporal trends in survival and causes of death in patients with chronic lymphocytic leukemia (CLL) in a nationwide study. The cohort consisted of 13,009 Swedish CLL patients diagnosed 1982-2013. Relative survival (RS) and excess mortality rate ratios (EMRR) with 95% confidence intervals (95% CIs) were estimated using flexible parametric survival models. Cause-specific hazard ratios (HRs) were estimated for the linear effect of 10-year increase in year of diagnosis. The excess mortality decreased comparing 2003-2013 to 1982-1992 (EMRRÂ =Â 0.53, 95% CI 0.48-0.58). The 5-year RS increased between 1982 and 2012 for patients >51Â years at diagnosis and improved for patients â‰¤51Â years after 2002. The rate of CLL-specific deaths decreased over time (HRÂ =Â 0.78, 95% CI 0.75-0.81). Compared to patients with no comorbidity, patients with 1 and 2+ Charlson Comorbidity Index points had HRÂ =Â 1.35 (95% CI 1.25-1.45) and HRÂ =Â 1.47 (95% CI 1.37-1.57) for CLL-related mortality, respectively. Survival in CLL patients improved in the era of chemoimmunotherapy, and this was largely explained by reduced CLL-related mortality. The increased rate of CLL-related mortality in patients with comorbidities emphasizes the importance of the newer and better tolerated targeted therapy.},
  chemicals       = {Piperidines, ibrutinib, Adenine},
  citation-subset = {IM},
  completed       = {2022-03-23},
  country         = {England},
  issn-linking    = {0902-4441},
  keywords        = {Adenine, administration & dosage, adverse effects, analogs & derivatives, therapeutic use; Adult; Aged; Aged, 80 and over; Cause of Death; Comorbidity; Disease Management; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell, epidemiology, mortality, therapy; Male; Middle Aged; Mortality; Piperidines, therapeutic use; Population Surveillance; Prognosis; Registries; Sweden, epidemiology; cause of death analysis; chronic lymphocytic leukemia; comorbidities; survival},
  nlm-id          = {8703985},
  owner           = {NLM},
  pmid            = {34714556},
  pubmodel        = {Print-Electronic},
  revised         = {2022-03-23},
}

@Article{Kalager2021a,
  author          = {Kalager, Mette and Adami, Hans-Olov and Lagergren, Pernilla and Steindorf, Karen and Dickman, Paul W.},
  title           = {Cancer outcomes research-a {E}uropean challenge: measures of the cancer burden.},
  doi             = {10.1002/1878-0261.13012},
  issn            = {1878-0261},
  issue           = {12},
  pages           = {3225--3241},
  pubstate        = {ppublish},
  volume          = {15},
  abstract        = {In a mission that aims to improve cancer control throughout Europe, the European Academy of Cancer Sciences has defined two key indicators of progress: within one to two decades, overall cancer-specific 10-year survival should reach 75%, and in each country, overall cancer mortality rates should be convincingly declining. To lay the ground for assessment of progress and to promote cancer outcomes research in general, we have reviewed the most common population-based measures of the cancer burden. We emphasize the complexities and complementary approaches to measure cancer survival and the novel opportunities for improved assessment of quality of life. We propose that: incidence and mortality rates are standardized to the European population; net survival is used as the measure of prognosis but with proper adjustments for confounding when temporal trends in overall cancer survival are assessed; and cancer-specific quality of life is measured by a combination of existing questionnaires and utilizes emerging communication technologies. We conclude that all measures are important and that a meaningful interpretation also requires a deep understanding of the larger clinical and public health context.},
  citation-subset = {IM},
  completed       = {2022-04-07},
  country         = {United States},
  issn-linking    = {1574-7891},
  journal         = {Molecular oncology},
  keywords        = {Europe, epidemiology; Humans; Incidence; Neoplasms, epidemiology, therapy; Outcome Assessment, Health Care; Quality of Life; cancer; health-related quality of life; incidence; mortality; outcomes; survival},
  nlm-id          = {101308230},
  owner           = {NLM},
  pmc             = {PMC8637567},
  pmid            = {34003576},
  pubmodel        = {Print-Electronic},
  revised         = {2022-04-07},
  year            = {2021},
}

@Article{Orrason2021,
  author          = {Orrason, Andri Wilberg and Garmo, Hans and Styrke, Johan and Dickman, Paul W. and Stattin, PÃ¤r},
  title           = {Comparison of Relative Survival and Cause-Specific Survival in Men With Prostate Cancer According to Age and Risk Category: A Nationwide, Population-Based Study.},
  doi             = {10.1093/aje/kwab146},
  issn            = {1476-6256},
  issue           = {10},
  pages           = {2053--2063},
  pubstate        = {ppublish},
  volume          = {190},
  abstract        = {Net survival, estimated in a relative survival (RS) or cause-specific survival (CSS) framework, is a key measure of the effectiveness of cancer management. We compared RS and CSS in men with prostate cancer (PCa) according to age and risk category, using Prostate Cancer data Base Sweden, including 168,793 men younger than age 90 years, diagnosed 1998-2016 with PCa. RS and CSS were compared according to age and risk category based on TNM (tumor, nodes, and metastases) stage, Gleason score, and prostate-specific antigen level. Each framework requires assumptions that are unlikely to be appropriate for PCa. Ten-year RS was substantially higher than CSS in men aged 80-89 with low-risk PCa: 125% (95% confidence interval: 113, 138) versus 85% (95% confidence interval: 82, 88). In contrast, RS and CSS were similar for men under age 70 and for all men with regional or distant metastases. Both RS and CSS produce biased estimates of net survival for men with low- and intermediate-risk PCa, in particular for men over 80. Due to biases, net survival is overestimated in analysis of RS but underestimated in analysis of CSS. These results highlight the importance of evaluating the underlying assumptions for each method, because the "true" net survival is expected to lie between the limits of RS and CSS.},
  chemicals       = {Prostate-Specific Antigen},
  citation-subset = {IM},
  completed       = {2021-10-18},
  country         = {United States},
  issn-linking    = {0002-9262},
  journal         = {American journal of epidemiology},
  keywords        = {Adult; Age Factors; Aged; Aged, 80 and over; Cause of Death; Databases, Factual; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prostate-Specific Antigen, blood; Prostatic Neoplasms, blood, mortality, pathology; Risk Factors; Survival Analysis; Sweden, epidemiology; cause-specific survival; net survival prostate cancer; prognosis; relative survival; survival},
  nlm-id          = {7910653},
  owner           = {NLM},
  pii             = {6277990},
  pmc             = {PMC8485148},
  pmid            = {34007984},
  pubmodel        = {Print},
  revised         = {2021-10-18},
  year            = {2021},
}

@Article{Zhao2021,
  author          = {Zhao, Jingcheng and Gabriel, Erin and Norda, Rut and HÃ¶glund, Petter and Baden, Lindsey and Diedrich, Beatrice A. and Marits, Per and Enoksson, Sara L. and Gansner, John M. and Kaufman, Richard and Dickman, Paul W. and Edgren, Gustaf},
  date            = {2021-02},
  journal         = {Transfusion},
  title           = {Frequent platelet donation is associated with lymphopenia and risk of infections: A nationwide cohort study.},
  doi             = {10.1111/trf.16175},
  issn            = {1537-2995},
  issue           = {2},
  pages           = {464--473},
  pubstate        = {ppublish},
  volume          = {61},
  abstract        = {Recently, plateletpheresis donations using a widely used leukoreduction system (LRS) chamber have been associated with T-cell lymphopenia. However, clinical health consequences of plateletpheresis-associated lymphopenia are still unknown. A nationwide cohort study using the SCANDAT3-S database was conducted with all platelet- and plasmapheresis donors in Sweden between 1996 and 2017. A Cox proportional hazards model, using donations as time-dependent exposures, was used to assess the risk of infections associated with plateletpheresis donations using an LRS chamber. A total of 74â€‰408 apheresis donors were included. Among donors with the same donation frequency, plateletpheresis donors using an LRS chamber were at an increased risk of immunosuppression-related infections and common bacterial infections in a dose-dependent manner. While very frequent donors and infections were rare in absolute terms resulting in wide confidence intervals (CIs), the increased risk was significant starting at one-third or less of the allowed donation frequency in a 10-year exposure window, with hazard ratios reaching 10 or more. No plateletpheresis donors that used an LRS chamber experienced a Pneumocystis jirovecii, aspergillus, disseminated mycobacterial, or cryptococcal infection. In a subcohort (n = 42), donations with LRS were associated with low CD4+ T-cell counts (Pearson's R = -0.41; 95% CI,â€‰-â€‰0.63 to -0.12). Frequent plateletpheresis donation using an LRS chamber was associated with CD4+ T-cell lymphopenia and an increased risk of infections. These findings suggest a need to monitor T-lymphocyte counts in frequent platelet donors and to conduct future investigations of long-term donor health and for regulators to consider steps to mitigate lymphodepletion in donors.},
  citation-subset = {IM},
  completed       = {2021-07-08},
  country         = {United States},
  issn-linking    = {0041-1132},
  keywords        = {Adult; Bacterial Infections, epidemiology, etiology; Blood Donors, statistics & numerical data; Databases, Factual; Disease Susceptibility; Female; Follow-Up Studies; Humans; Immunocompromised Host; Infections, etiology; Leukocyte Reduction Procedures, instrumentation; Lymphocyte Count; Lymphopenia, etiology; Male; Middle Aged; Mycoses, etiology; Plateletpheresis, adverse effects, instrumentation; Proportional Hazards Models; Retrospective Studies; Risk; Sweden, epidemiology; Young Adult; immunosuppression; infection; platelet donation; plateletpheresis; platelets},
  nlm-id          = {0417360},
  owner           = {NLM},
  pmc             = {PMC7894559},
  pmid            = {33186486},
  pubmodel        = {Print-Electronic},
  revised         = {2021-07-09},
}

@Article{Qaderi2021,
  author          = {Qaderi, Seyed M. and Andersson, Therese M. L. and Dickman, Paul W. and de Wilt, Johannes H. W. and Verhoeven, Rob H. A.},
  date            = {2021-09},
  journal         = {Journal of clinical epidemiology},
  title           = {Temporal improvements noted in life expectancy of patients with colorectal cancer; a Dutch population-based study.},
  doi             = {10.1016/j.jclinepi.2021.03.024},
  issn            = {1878-5921},
  pages           = {92--103},
  pubstate        = {ppublish},
  volume          = {137},
  abstract        = {Specific survival estimates are needed for the increasing number of colorectal cancer (CRC) survivors. The aim of this population-based study was to determine conditional loss in expectation of life (LEL) due to CRC. All surgically treated patients with CRC registered in the Netherlands Cancer Registry with stage I-III between 1990-2016, were included (NÂ =Â 203,216). Estimates of conditional LEL were predicted using flexible parametric models and the total life years lost due to cancer were estimated. LEL decreased with older age and patients with rectal cancer or higher disease stage had highest LEL. In 2010, LEL for sixty-year old male and female patients was 2 vs. 2, 4 vs. 4, and 7 vs. 8 years for colon cancer, and 2 vs. 2, 4 vs. 5 and 7 vs. 8 years for rectal cancer, respectively. Conditional LEL in patients with CRC decreased during follow-up. Patients with combined stage I-III colon and rectal cancer in 2010 lost an estimated 18,628 and 11,336 life years. This study quantified the impact of CRC on patient's life expectancy, both on individual and population level and demonstrated temporal improvements in CRC survival. These results provide meaningful information that can be used during follow-up.},
  citation-subset = {IM},
  completed       = {2021-11-10},
  country         = {United States},
  issn-linking    = {0895-4356},
  keywords        = {Aged; Aged, 80 and over; Colorectal Neoplasms, mortality; Female; Humans; Life Expectancy; Male; Middle Aged; Netherlands; Survival Rate; Colorectal cancer; Flexible parametric models; Life expectancy; Loss in expectation of life; Relative survival; Survival analysis},
  nlm-id          = {8801383},
  owner           = {NLM},
  pii             = {S0895-4356(21)00106-2},
  pmid            = {33836257},
  pubmodel        = {Print-Electronic},
  revised         = {2021-11-10},
}

@Article{Chen2021,
  author          = {Chen, Enoch Yi-Tung and Sachs, Michael C. and Dickman, Paul W.},
  date            = {2021-09},
  journal         = {Journal of the Formosan Medical Association = Taiwan yi zhi},
  title           = {No evidence of substantial underreporting of COVID-19 deaths in Taiwan during 2020.},
  doi             = {10.1016/j.jfma.2021.03.018},
  issn            = {0929-6646},
  issue           = {9},
  pages           = {1788--1789},
  pubstate        = {ppublish},
  volume          = {120},
  citation-subset = {IM},
  completed       = {2021-08-26},
  country         = {Singapore},
  issn-linking    = {0929-6646},
  keywords        = {COVID-19; Cause of Death; Humans; SARS-CoV-2; Taiwan, epidemiology},
  nlm-id          = {9214933},
  owner           = {NLM},
  pii             = {S0929-6646(21)00123-6},
  pmc             = {PMC7988443},
  pmid            = {33832837},
  pubmodel        = {Print-Electronic},
  revised         = {2021-09-20},
}

@Article{Qaderi2020,
  author          = {Qaderi, Seyed M. and Dickman, Paul W. and de Wilt, Johannes H. W. and Verhoeven, Rob H. A.},
  date            = {2020-09},
  journal         = {Journal of the National Comprehensive Cancer Network : JNCCN},
  title           = {Conditional Survival and Cure of Patients With Colon or Rectal Cancer: A Population-Based Study.},
  doi             = {10.6004/jnccn.2020.7568},
  issn            = {1540-1413},
  issue           = {9},
  pages           = {1230--1237},
  pubstate        = {ppublish},
  volume          = {18},
  abstract        = {The increasing number of colorectal cancer (CRC) survivors need survival estimates that account for the time already survived. The aim of this population-based study was to determine conditional survival, cure proportions, and time-to-cure (TTC) of patients with colon or rectal cancer. All patients with pathologic stage I-III CRC treated with endoscopy or surgery, diagnosed and registered in the Netherlands Cancer Registry between 1995 and 2016, and aged 18 to 99 years were included. Conditional survival was calculated for those diagnosed before and after 2007. Cure proportions were calculated using flexible parametric models. A total of 175,384 patients with pathologic stage I (25%), II (38%), or III disease (37%) were included. Conditional 5-year survival of patients with stage I, II, and III colon cancer having survived 5 years was 98%, 94%, and 92%, respectively. For patients with stage I-III rectal cancer, this was 96%, 89%, and 85%, respectively. Statistical cure in patients with colon cancer was reached directly after diagnosis (stage I) to 6 years (stage III) after diagnosis depending on age, sex, and disease stage. Patients with rectal cancer reached cure 0.5 years after diagnosis (stage I) to 9 years after diagnosis (stage III). In 1995, approximately 42% to 46% of patients with stage III colon or rectal cancer, respectively, were considered cured, whereas in 2016 this percentage increased to 73% to 78%, respectively. The number of patients with CRC reaching cure has increased substantially over the years. This study's results provide valuable insights into trends of CRC patient survival and are important for patients, clinicians, and policymakers.},
  citation-subset = {IM},
  completed       = {2021-11-04},
  country         = {United States},
  issn-linking    = {1540-1405},
  keywords        = {Colonic Neoplasms, diagnosis, epidemiology, therapy; Humans; Neoplasm Staging; Rectal Neoplasms, therapy; Registries; Survival Rate},
  nlm-id          = {101162515},
  owner           = {NLM},
  pii             = {jnccn20006},
  pmid            = {32886900},
  pubmodel        = {Print},
  revised         = {2021-11-04},
}

@Article{Leandersson2021,
  author          = {Leandersson, Pia and Hogberg, Thomas and Dickman, Paul W. and Malander, Susanne and Borgfeldt, Christer},
  date            = {2021-04},
  journal         = {BMC cancer},
  title           = {Incidence and survival of epithelial ovarian, fallopian tube, peritoneal, and undesignated abdominal/pelvic cancers in Sweden 1960-2014: A population-based cohort study.},
  doi             = {10.1186/s12885-021-08169-w},
  issn            = {1471-2407},
  issue           = {1},
  pages           = {465},
  pubstate        = {epublish},
  volume          = {21},
  abstract        = {Despite improved surgical and oncological treatment, ovarian cancer continues to be the most lethal of the gynecologic malignancies. We aimed to analyze survival trends in epithelial ovarian cancer with regard to age, tumor site, and morphology in Sweden 1960 to 2014. A nationwide population-based study was conducted using data from the Swedish Cancer Registry on 46,350 women aged 18 or older with a diagnosis of epithelial ovarian, fallopian tube, peritoneal, or undesignated abdominal/pelvic cancer 1960 to 2014. Analyses of age-standardized incidence and relative survival (RS) were performed and time trends modelled according to age, tumor site, and morphology. Overall incidence of ovarian, tubal, peritoneal, and undesignated abdominal/pelvic cancers declined since 1980. Median age at diagnosis increased. Serous carcinoma increased in incidence. RS at 1, 2 and 5â€‰years from diagnosis improved since 1960, although not for the youngest and the oldest patients. Ten-year RS did not improve. The best RS was found for fallopian tube cancer and the worst RS for undesignated abdominal/pelvic cancer. Among the morphologic subgroups, endometrioid carcinoma had the best RS. Survival in epithelial ovarian, tubal, peritoneal, and undesignated abdominal/pelvic cancers in Sweden has improved over the last six decades. Advances in epithelial ovarian cancer treatment have extended life for the first 5â€‰years from diagnosis but 10-year survival remains poor.},
  citation-subset = {IM},
  completed       = {2021-08-06},
  country         = {England},
  issn-linking    = {1471-2407},
  keywords        = {Abdominal Neoplasms, epidemiology, mortality, pathology; Adult; Age Distribution; Aged; Aged, 80 and over; Carcinoma, Endometrioid, pathology; Cystadenocarcinoma, Serous, pathology; Fallopian Tube Neoplasms, pathology; Female; Humans; Incidence; Middle Aged; Mortality, trends; Ovarian Neoplasms, pathology; Pelvic Neoplasms, pathology; Peritoneal Neoplasms, pathology; Prognosis; Sweden, epidemiology; Young Adult; cancer registry; histopathology; long-term follow-up; ovarian cancer; population-based; relative survival},
  nlm-id          = {100967800},
  owner           = {NLM},
  pii             = {10.1186/s12885-021-08169-w},
  pmc             = {PMC8077696},
  pmid            = {33902507},
  pubmodel        = {Electronic},
  revised         = {2021-08-06},
}

@Article{Eloranta2021,
  author          = {Eloranta, S. and Smedby, K. E. and Dickman, P. W. and Andersson, T. M.},
  title           = {Cancer survival statistics for patients and healthcare professionals - a tutorial of real-world data analysis.},
  doi             = {10.1111/joim.13139},
  issn            = {1365-2796},
  issue           = {1},
  pages           = {12--28},
  pubstate        = {ppublish},
  volume          = {289},
  abstract        = {Monitoring survival of cancer patients using data collected by population-based cancer registries is an important component of cancer control. In this setting, patient survival is often summarized using net survival, that is survival from cancer if there were no other possible causes of death. Although net survival is the gold standard for comparing survival between groups or over time, it is less relevant for understanding the anticipated real-world prognosis of patients. In this review, we explain statistical concepts targeted towards patients, clinicians and healthcare professionals that summarize cancer patient survival under the assumption that other causes of death exist. Specifically, we explain the appropriate use, interpretation and assumptions behind statistical methods for competing risks, loss in life expectancy due to cancer and conditional survival. These concepts are relevant when producing statistics for risk communication between physicians and patients, planning for use of healthcare resources, or other applications when consideration of both cancer outcomes and the competing risks of death is required. To reinforce the concepts, we use Swedish population-based data of patients diagnosed with cancer of the breast, prostate, colon and chronic myeloid leukaemia. We conclude that when choosing between summary measures of survival it is critical to characterize the purpose of the study and to determine the nature of the hypothesis under investigation. The choice of terminology and style of reporting should be carefully adapted to the target audience and may range from summaries for specialist readers of scientific publications to interactive online tools aimed towards lay persons.},
  citation-subset = {IM},
  completed       = {2021-06-28},
  country         = {England},
  issn-linking    = {0954-6820},
  journal         = {Journal of internal medicine},
  keywords        = {Breast Neoplasms, mortality; Cause of Death; Colonic Neoplasms, mortality; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, mortality; Life Expectancy; Male; Neoplasms, mortality; Prostatic Neoplasms, mortality; Registries; Survival Analysis; Sweden, epidemiology; biostatistics; cancer; death risk; epidemiology},
  nlm-id          = {8904841},
  owner           = {NLM},
  pmid            = {32656940},
  pubmodel        = {Print-Electronic},
  revised         = {2021-06-28},
  year            = {2021},
}

@Article{Hellgren2020,
  author          = {Hellgren, Roxanna and Saracco, Ariel and Strand, Fredrik and Eriksson, Mikael and Sundbom, Ann and Hall, Per and Dickman, Paul W.},
  date            = {2020-12},
  journal         = {Acta radiologica (Stockholm, Sweden : 1987)},
  title           = {The association between breast cancer risk factors and background parenchymal enhancement at dynamic contrast-enhanced breast MRI.},
  doi             = {10.1177/0284185120911583},
  issn            = {1600-0455},
  issue           = {12},
  pages           = {1600--1607},
  pubstate        = {ppublish},
  volume          = {61},
  abstract        = {Background parenchymal enhancement (BPE) of normal tissue at breast magnetic resonance imaging is suggested to be an independent risk factor for breast cancer. Its association with established risk factors for breast cancer is not fully investigated. To study the association between BPE and risk factors for breast cancer in a healthy, non-high-risk screening population. We measured BPE and mammographic density and used data from self-reported questionnaires in 214 healthy women aged 43-74 years. We estimated odds ratios for the univariable association between BPE and risk factors. We then fitted an adjusted model using logistic regression to evaluate associations between BPE (high vs. low) and risk factors, including mammographic breast density. The majority of women had low BPE (84%). In a multivariable model, we found statistically significant associations between BPE and age ( â€‰=â€‰0.002) and BMI ( â€‰=â€‰0.03). We did find a significant association between systemic progesterone medication and BPE, but due to small numbers, the results should be interpreted with caution. The adjusted odds ratio for high BPE was 3.1 among women with density D (compared to B) and 2.1 for density C (compared to B). However, the association between high BPE and density was not statistically significant. We did not find statistically significant associations with any other risk factors. Our study confirmed the known association of BPE with age and BMI. Although our results show a higher likelihood for high BPE with increasing levels of mammographic density, the association was not statistically significant.},
  citation-subset = {IM},
  completed       = {2020-12-15},
  country         = {England},
  issn-linking    = {0284-1851},
  keywords        = {Adult; Age Factors; Aged; Body Mass Index; Breast, diagnostic imaging; Breast Density; Breast Neoplasms, diagnostic imaging, pathology; Female; Humans; Magnetic Resonance Imaging, methods; Middle Aged; Risk Factors; Magnetic resonance imaging; breast; epidemiology; primary neoplasms},
  nlm-id          = {8706123},
  owner           = {NLM},
  pmc             = {PMC7720360},
  pmid            = {32216451},
  pubmodel        = {Print-Electronic},
  revised         = {2020-12-19},
}

@Article{Hellgren2019,
  author          = {Hellgren, Roxanna J. and Sundbom, Ann E. and Czene, Kamila and Izhaky, David and Hall, Per and Dickman, Paul W.},
  date            = {2019-11},
  journal         = {European radiology},
  title           = {Does three-dimensional functional infrared imaging improve breast cancer detection based on digital mammography in women with dense breasts?},
  doi             = {10.1007/s00330-019-06248-y},
  issn            = {1432-1084},
  issue           = {11},
  pages           = {6227--6235},
  pubstate        = {ppublish},
  volume          = {29},
  abstract        = {We aimed to estimate the incremental cancer detection rate achieved by adding three-dimensional functional infrared imaging (3DIRI) to digital mammography in women with dense breasts. In this prospective study conducted between December 2014 and April 2016, 1727 women (median age 56) with percentage volumetric breast density >â€‰6% were recruited at routine screening mammography to undergo additional 3DIRI. The 3DIRI findings were classified as negative or positive. Women with a negative mammography but positive 3DIRI were referred to dynamic contrast-enhanced MRI, whereas all other women underwent routine follow-up based on the mammography finding. Diagnosis of breast cancer was verified by histopathologic examination. The number of women diagnosed with a malignancy formed the basis of our statistical analysis. Mammography detected 7 cancers in 7 women. Of 1692 women with negative mammography, 222 women (13%) had a positive 3DIRI of which 219 underwent MRI. An additional 6 cancers were identified in 5 women, increasing the diagnostic yield from 7 of 1727 (0.41%) to 12 of 1727 (0.69%). The incremental cancer detection rate associated with using 3DIRI to select women for MRI was 5 of 222 (22.5 additional cancers per 1000). The use of 3DIRI to select women for an additional MRI can result in the detection of additional cancers in women with dense breasts, but at the expense of additional false positives and considerably lower positive predictive value of the combined examinations. Additional studies are necessary to evaluate the role of 3DIRI as an adjunct to mammography. â€¢ Use of three-dimensional functional infrared imaging to select women for an MRI in addition to screening mammography has the potential to improve breast cancer detection in women with dense breasts.},
  citation-subset = {IM},
  completed       = {2020-01-14},
  country         = {Germany},
  issn-linking    = {0938-7994},
  keywords        = {Adult; Aged; Breast Density; Breast Neoplasms, diagnostic imaging, pathology; Early Detection of Cancer, methods; Female; Humans; Imaging, Three-Dimensional, methods; Mammography, methods; Middle Aged; Predictive Value of Tests; Prospective Studies; Spectrophotometry, Infrared, methods; Breast density; Breast neoplasms; Magnetic resonance imaging; Mammography; Risk assessment},
  nlm-id          = {9114774},
  owner           = {NLM},
  pii             = {10.1007/s00330-019-06248-y},
  pmc             = {PMC6795638},
  pmid            = {31115623},
  pubmodel        = {Print-Electronic},
  revised         = {2020-03-30},
}

@Article{Hultcrantz2020,
  author          = {Hultcrantz, M. and Ravn Landtblom, A. and AndrÃ©asson, B. and Samuelsson, J. and Dickman, P. W. and Kristinsson, S. Y. and BjÃ¶rkholm, M. and Andersson, T. M.-L.},
  date            = {2020-04},
  journal         = {Journal of internal medicine},
  title           = {Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden.},
  doi             = {10.1111/joim.13019},
  issn            = {1365-2796},
  issue           = {4},
  pages           = {448--454},
  pubstate        = {ppublish},
  volume          = {287},
  abstract        = {The reported incidence of Philadelphia-negative myeloproliferative neoplasms (MPNs) differs substantially between previous reports, likely due to true regional differences in incidence and/or variations in the quality and coverage of the cancer registers. We therefore assessed MPN incidence in Sweden during recent years using prospectively collected information captured in Swedish health registers. Patients with MPNs were identified through the Swedish Cancer Register and Swedish Blood Cancer Register between 2000 and 2014. Information on the Swedish population was obtained from the Human Mortality Database. Crude and age-standardized incidence rates of MPNs with 95% confidence intervals (CIs) were calculated. A total of 6281 MPN cases were reported to the Swedish Cancer Register and Swedish Blood Cancer Register during 2000-2014. The age-standardized, to the Swedish population in 2000, incidence for all MPNs was 4.45 (95% confidence interval [CI] 4.34-4.56)/100Â 000 person-years. The age-standardized incidence for polycythemia vera was 1.48 (1.42-1.54), for essential thrombocythemia 1.60 (1.53-1.66) and for primary myelofibrosis 0.52 (0.48-0.56)/100Â 000 person-years, respectively. The incidence rate of MPNs was substantially higher in the older compared to the younger age groups. The incidence increased during the study period, likely to do better reporting and increasing age of the general population. The reported MPN incidences in our study, which were in the higher interval of previously published studies, are likely more accurate compared to previous reports due to the population-based setting and high level of coverage in the Swedish Cancer and Blood Cancer Registers.},
  citation-subset = {IM},
  completed       = {2020-12-14},
  country         = {England},
  issn-linking    = {0954-6820},
  keywords        = {Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bone Marrow Neoplasms, epidemiology; Female; Humans; Incidence; Male; Middle Aged; Polycythemia Vera, epidemiology; Primary Myelofibrosis, epidemiology; Prospective Studies; Registries; Sweden, epidemiology; Thrombocythemia, Essential, epidemiology; Young Adult; essential thrombocythemia; incidence; myeloproliferative neoplasms; polycythemia vera; primary myelofibrosis},
  mid             = {NIHMS1635648},
  nlm-id          = {8904841},
  owner           = {NLM},
  pmc             = {PMC7598815},
  pmid            = {31927786},
  pubmodel        = {Print-Electronic},
  revised         = {2021-04-02},
}

@Article{Bjoerkholm2019,
  author          = {BjÃ¶rkholm, Magnus and Edgren, Gustaf and Dickman, Paul W.},
  date            = {2019-07},
  journal         = {Blood},
  title           = {Trends in survival of young adult patients with acute lymphoblastic leukemia in Sweden and the United States.},
  doi             = {10.1182/blood.2019001168},
  issn            = {1528-0020},
  issue           = {4},
  pages           = {407--410},
  pubstate        = {ppublish},
  volume          = {134},
  citation-subset = {IM},
  completed       = {2020-01-01},
  country         = {United States},
  issn-linking    = {0006-4971},
  keywords        = {Acute Disease; Adolescent; Child; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sweden; United States; Young Adult},
  nlm-id          = {7603509},
  owner           = {NLM},
  pii             = {S0006-4971(20)42389-4},
  pmid            = {31023701},
  pubmodel        = {Print-Electronic},
  revised         = {2021-02-02},
}

@Article{Landtblom2018,
  author          = {Landtblom, Anna Ravn and Bower, Hannah and Andersson, Therese M.-L. and Dickman, Paul W. and Samuelsson, Jan and BjÃ¶rkholm, Magnus and Kristinsson, Sigurdur Yngvi and Hultcrantz, Malin},
  date            = {2018-10},
  journal         = {Leukemia},
  title           = {Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients.},
  doi             = {10.1038/s41375-018-0027-y},
  issn            = {1476-5551},
  issue           = {10},
  pages           = {2203--2210},
  pubstate        = {ppublish},
  volume          = {32},
  abstract        = {To determine the risk of a wide range of second malignancies in patients with myeloproliferative neoplasms (MPNs), we conducted a large population-based study and compared the results to matched controls. From national Swedish registers, 9379 patients with MPNs diagnosed between 1973 and 2009, and 35,682 matched controls were identified as well as information on second malignancies, with follow-up until 2010. Hazard ratios (HRs) with 95 % confidence intervals (CIs) were calculated using Cox regression and a flexible parametric model. There was a significantly increased risk of any non-hematologic cancer with HR of 1.6 (95% CI: 1.5-1.7). The HRs for non-melanoma skin cancer was 2.8 (2.4-3.3), kidney cancer 2.8 (2.0-4.0), brain cancer 2.8 (1.9-4.2), endocrine cancers 2.5 (1.6-3.8), malignant melanoma 1.9 (1.4-2.7), pancreas cancer 1.8 (1.2-2.6), lung cancer 1.7 (1.4-2.2), and head and neck cancer 1.7 (1.2-2.6). The HR of second malignancies was similar across all MPN subtypes, sex, and calendar periods of MPN diagnosis. The risk of developing a hematologic malignancy was also significantly increased; the HR for acute myeloid leukemia was 46.0 (32.6-64.9) and for lymphoma 2.6 (2.0-3.3). In conclusion, our study provides robust population-based support of an increased cancer risk in MPN patients.},
  citation-subset = {IM},
  completed       = {2019-06-13},
  country         = {England},
  issn-linking    = {0887-6924},
  keywords        = {Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Hematologic Neoplasms, complications, pathology; Humans; Lymphoma, etiology, pathology; Male; Melanoma, pathology; Middle Aged; Myeloproliferative Disorders, pathology; Neoplasms, Second Primary, pathology; Proportional Hazards Models; Risk Factors; Sweden; Young Adult},
  mid             = {NIHMS1632824},
  nlm-id          = {8704895},
  owner           = {NLM},
  pii             = {10.1038/s41375-018-0027-y},
  pmc             = {PMC7552081},
  pmid            = {29535425},
  pubmodel        = {Print-Electronic},
  revised         = {2020-10-16},
}

@Article{Thorsteinsdottir2018,
  author          = {Thorsteinsdottir, Sigrun and Dickman, Paul W. and Landgren, Ola and Blimark, Cecilie and Hultcrantz, Malin and Turesson, Ingemar and BjÃ¶rkholm, Magnus and Kristinsson, Sigurdur Y.},
  date            = {2018-09},
  journal         = {Haematologica},
  title           = {Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study.},
  doi             = {10.3324/haematol.2017.183475},
  issn            = {1592-8721},
  issue           = {9},
  pages           = {e412--e415},
  pubstate        = {ppublish},
  volume          = {103},
  citation-subset = {IM},
  completed       = {2019-09-11},
  country         = {Italy},
  issn-linking    = {0390-6078},
  keywords        = {History, 20th Century; History, 21st Century; Humans; Multiple Myeloma, epidemiology, history, mortality; Population Surveillance; Registries; Survival Rate; Sweden},
  nlm-id          = {0417435},
  owner           = {NLM},
  pii             = {haematol.2017.183475},
  pmc             = {PMC6119139},
  pmid            = {29567776},
  pubmodel        = {Print-Electronic},
  revised         = {2019-09-11},
}

@Article{Zeebari2017,
  author          = {Zeebari, Zangin and Lundin, Andreas and Dickman, Paul W. and Hallgren, Mats},
  date            = {2017-07},
  journal         = {Alcohol and alcoholism (Oxford, Oxfordshire)},
  title           = {Are Changes in Alcohol Consumption Among Swedish Youth Really Occurring 'in Concert'? A New Perspective Using Quantile Regression.},
  doi             = {10.1093/alcalc/agx020},
  issn            = {1464-3502},
  issue           = {4},
  pages           = {487--495},
  pubstate        = {ppublish},
  volume          = {52},
  abstract        = {Recent studies of youth alcohol consumption indicate a collective downward drinking trend at all levels of consumption, i.e. reductions occurring 'in concert'. We re-examine the collectivity of drinking theory by applying quantile regression methods to the analysis and interpretation of Swedish youth alcohol consumption. Changes in youth alcohol consumption between 2000 and 2014 were assessed using a school-based survey conducted in Stockholm (n = 86,402). Participants were Swedish youth aged 15-18 years. The rate of change in consumption was examined using quantile regression, and compared to Ordinary Least Squares modelling. The hypothesis of parallelism or 'in concert' changes in consumption was assessed using the test of the equality of linear regression slopes corresponding to different quantiles of log consumption. In both models, changes in consumption over time did not occur in parallel, contrary to the collectivity of drinking theory. Instead, a clear divergence in the rate of drinking was observed, with most adolescent quantiles reducing consumption, while heavy consuming remained stable. Contrary to previous studies, our findings do not support a collectivity of drinking behaviour among Swedish youth. Quantile regression is a robust and appropriate method for analysing temporal changes in alcohol consumption data.},
  citation-subset = {IM},
  completed       = {2018-02-08},
  country         = {England},
  issn-linking    = {0735-0414},
  keywords        = {Adolescent; Adolescent Behavior; Female; Humans; Least-Squares Analysis; Male; Psychological Theory; Regression Analysis; Sweden, epidemiology; Underage Drinking, trends},
  nlm-id          = {8310684},
  owner           = {NLM},
  pii             = {3100243},
  pmid            = {28379324},
  pubmodel        = {Print},
  revised         = {2022-03-21},
}

@Article{Toerner2017,
  author          = {TÃ¶rner, Anna and Stokkeland, Knut and Svensson, Ã…ke and Dickman, Paul W. and Hultcrantz, Rolf and Montgomery, Scott and Duberg, Ann-Sofi},
  date            = {2017-03},
  journal         = {Hepatology (Baltimore, Md.)},
  title           = {The underreporting of hepatocellular carcinoma to the cancer register and a log-linear model to estimate a more correct incidence.},
  doi             = {10.1002/hep.28775},
  issn            = {1527-3350},
  issue           = {3},
  pages           = {885--892},
  pubstate        = {ppublish},
  volume          = {65},
  abstract        = {The Cancer Register (CR) in Sweden has reported that the incidence of primary liver cancer (PLC) has slowly declined over the last decades. Even though all cancers, irrespective of diagnostic method, should be reported to the CR, the PLC incidence may not reflect the true rate. Improved diagnostic tools have enabled diagnosis of hepatocellular carcinoma based on noninvasive methods without histological verification, possibly associated with missed cancer reports or misclassification in the CR. Our objective was to study the completeness and assess the underreporting of PLC to the CR and to produce a more accurate estimate based on three registers. The CR, the Cause of Death Register, and the Patient Register were investigated. Differences and overlap were examined, the incidence was estimated by merging data from the registers, and the number reported to none of the registers was estimated using a log-linear capture-recapture model. The results show that 98% of the PLCs reported to the CR were histologically verified; 80% were hepatocellular carcinoma and 20% were intrahepatic cholangiocarcinoma. Unspecified liver cancer decreased over time and constituted <10% of all reported liver cancers. The CR may underestimate the liver cancer incidence by 37%-45%, primarily due to missed cancer reports. The estimated annual number of liver cancers increased over time, but the standardized incidence was stable around 11 per 100,000. Hepatitis C-associated liver cancer increased and constituted 20% in 2010. There was an underreporting of PLC diagnosed by noninvasive methods; the incidence was considerably higher than estimated by the CR, with a stable incidence over time; reporting needs to improve and combining registers is recommended when studying incidence. (Hepatology 2017;65:885-892).},
  citation-subset = {IM},
  completed       = {2017-08-07},
  country         = {United States},
  issn-linking    = {0270-9139},
  keywords        = {Carcinoma, Hepatocellular, diagnosis, epidemiology; Female; Humans; Liver Neoplasms, epidemiology; Male; Needs Assessment; Prevalence; Registries; Risk Assessment; Sensitivity and Specificity; Sweden, epidemiology},
  nlm-id          = {8302946},
  owner           = {NLM},
  pmid            = {27533761},
  pubmodel        = {Print-Electronic},
  revised         = {2022-03-31},
}

@Article{Bower2017a,
  author          = {Bower, Hannah and BjÃ¶rkholm, Magnus and Dickman, Paul W. and HÃ¶glund, Martin and Lambert, Paul C. and Andersson, Therese M.-L.},
  date            = {2017-02},
  journal         = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  title           = {Reply to D. Pulte et al.},
  doi             = {10.1200/JCO.2016.70.9279},
  issn            = {1527-7755},
  issue           = {6},
  pages           = {696--697},
  pubstate        = {ppublish},
  volume          = {35},
  citation-subset = {IM},
  completed       = {2019-05-08},
  country         = {United States},
  issn-linking    = {0732-183X},
  keywords        = {Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Sweden},
  nlm-id          = {8309333},
  owner           = {NLM},
  pii             = {10.1200/JCO.2016.70.9279},
  pmid            = {27893321},
  pubmodel        = {Print-Electronic},
  revised         = {2019-05-08},
}

@Article{Kristinsson2013,
  author          = {Kristinsson, Sigurdur Y. and Eloranta, Sandra and Dickman, Paul W. and Andersson, Therese M.-L. and Turesson, Ingemar and Landgren, Ola and BjÃ¶rkholm, Magnus},
  date            = {2013-01},
  journal         = {American journal of hematology},
  title           = {Patterns of survival in lymphoplasmacytic lymphoma/WaldenstrÃ¶m macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005.},
  doi             = {10.1002/ajh.23351},
  issn            = {1096-8652},
  issue           = {1},
  pages           = {60--65},
  pubstate        = {ppublish},
  volume          = {88},
  abstract        = {Clinical management of lymphoplasmacytic lymphoma (LPL)/WaldenstrÃ¶m macroglobulinemia (WM) has changed considerably over recent years, reflected in the use of new therapeutic agents (purine analogs, monoclonal antibodies, thalidomide- and bortezomib-based therapies). No population-based studies and few randomized trials have been performed to assess survival in newly diagnosed LPL/WM. We performed a large population-based study in Sweden including 1,555 LPL/WM patients diagnosed from 1980 to 2005. Relative survival ratios (RSRs) and excess mortality rate ratios (EMRR) were computed as measures of survival. Survival of LPL/WM patients has improved significantly (P = 0.007) over time with 5-year RSR = 0.57 (95% confidence interval [CI] 0.46-0.68), 0.65 (0.57-0.73), 0.74 (0.68-0.80), 0.72 (0.66-0.77), and 0.78 (0.71-0.85) for patients diagnosed during the calendar periods 1980-1985, 1986-1990, 1991-1995, 1996-2000, and 2001-2005, respectively. Improvement in 1- and 5-year relative survival was found in all age groups and for LPL and WM separately. Patients with WM had lower excess mortality compared to LPL (EMRR = 0.38; 95% CI 0.30-0.48). Older age at diagnosis was associated with a poorer survival (P < 0.001). Taken together, we found a significant improvement in survival in LPL/WM over time. Despite this progress, new effective agents with a more favourable toxicity profile are needed to further improve survival in LPL/WM, especially in the elderly.},
  chemicals       = {Antineoplastic Agents},
  citation-subset = {IM},
  completed       = {2013-02-12},
  country         = {United States},
  issn-linking    = {0361-8609},
  keywords        = {Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, administration & dosage; Disease-Free Survival; Female; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Sweden, epidemiology; Time Factors; Waldenstrom Macroglobulinemia, diagnosis, drug therapy, mortality},
  mid             = {NIHMS1022532},
  nlm-id          = {7610369},
  owner           = {NLM},
  pmc             = {PMC7020669},
  pmid            = {23165980},
  pubmodel        = {Print-Electronic},
  revised         = {2021-10-21},
}

@Article{Latimer2022,
  author  = {Nicholas R Latimer and Amanda I Adler},
  title   = {Extrapolation beyond the end of trials to estimate long term survival and cost effectiveness},
  doi     = {10.1136/bmjmed-2021-000094},
  journal = {BMJ Medicine},
  year    = {2022},
}

@Article{BellGorrod2019,
  author          = {Bell Gorrod, Helen and Kearns, Ben and Stevens, John and Thokala, Praveen and Labeit, Alexander and Latimer, Nicholas and Tyas, David and Sowdani, Ahmed},
  title           = {A Review of Survival Analysis Methods Used in {NICE} Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement.},
  doi             = {10.1177/0272989X19881967},
  issn            = {1552-681X},
  issue           = {8},
  pages           = {899--909},
  pubstate        = {ppublish},
  volume          = {39},
  abstract        = {In June 2011, the National Institute for Health and Care Excellence (NICE) Decision Support Unit published a Technical Support Document (TSD) providing recommendations on survival analysis for NICE technology appraisals (TAs). Survival analysis outputs are influential inputs into economic models estimating the cost-effectiveness of new cancer treatments. Hence, it is important that systematic and justifiable model selection approaches are used. This study investigates the extent to which the TSD recommendations have been followed since its publication.   We reviewed NICE cancer TAs completed between July 2011 and July 2017. Information on survival analyses undertaken and associated critiques for overall survival (OS) and progression-free survival were extracted from the company submissions, Evidence Review Group (ERG) reports, and final appraisal determination documents.   Information was extracted from 58 TAs. Only 4 (7%) followed all TSD recommendations for OS outcomes. The vast majority (91%) compared a range of common parametric models and assessed their fit to the data (86%). Only a minority of TAs included an assessment of the shape of the hazard function (38%) or proportional hazards assumption (40%). Validation of the extrapolated portion of the survival function using external data was attempted in a minority of TAs (40%). Extrapolated survival functions were frequently criticized by ERGs (71%).   Survival analysis within NICE TAs remains suboptimal, despite publication of the TSD. Model selection is not undertaken in a systematic way, resulting in inconsistencies between TAs. More attention needs to be given to assessing hazard functions and validation of extrapolated survival functions. Novel methods not described in the TSD have been used, particularly in the context of immuno-oncology, suggesting that an updated TSD may be of value.},
  citation-subset = {IM},
  completed       = {2020-07-10},
  country         = {United States},
  issn-linking    = {0272-989X},
  journal         = {Medical decision making : an international journal of the Society for Medical Decision Making},
  keywords        = {England, epidemiology; Guideline Adherence, statistics & numerical data; Humans; Neoplasms, mortality, therapy; Progression-Free Survival; Proportional Hazards Models; Survival Analysis; Technology Assessment, Biomedical; Treatment Outcome; cancer; extrapolation; health technology assessment; survival analysis; technology appraisal},
  nlm-id          = {8109073},
  owner           = {NLM},
  pmid            = {31707911},
  pubmodel        = {Print-Electronic},
  revised         = {2021-01-10},
  year            = {2019},
}

@Article{Syriopoulou2021a,
  author          = {Syriopoulou, Elisavet and Rutherford, Mark J. and Lambert, Paul C.},
  date            = {2021},
  title           = {Inverse probability weighting and doubly robust standardization in the relative survival framework.},
  doi             = {10.1002/sim.9171},
  issn            = {1097-0258},
  pages           = {6069-6092},
  pubstate        = {aheadofprint},
  volume          = {40},
  abstract        = {A commonly reported measure when interested in the survival of cancer patients is relative survival. Relative survival circumvents issues with inaccurate cause of death information by incorporating the expected mortality rates of cancer individuals from population lifetables of the general population. A summary of the cancer population prognosis can be obtained using the marginal relative survival. To explore differences between exposure groups, such as socioeconomic groups, the difference in marginal relative survival between exposed and unexposed can be obtained and under assumptions is interpreted as the average causal effect of exposure to survival. In a modeling context, this is usually estimated by applying regression standardization as the average of the individual-specific estimates after fitting a relative survival model. Regression standardization yields an estimator that consistently estimates the causal effect under standard causal inference assumptions and if the relative survival model is correctly specified. We extend inverse probability weighting (IPW) and doubly robust standardization methods in the relative survival framework as additional valuable tools for obtaining average causal effects when correct model specification might not hold for the relative survival model. IPW yields an unbiased estimate of the average causal effect if a correctly specified model has been fitted for the exposure (propensity score) whereas doubly robust standardization requires that at least one of the propensity score model or the relative survival model is correctly specified. An example using data on melanoma is provided and a simulation study is conducted to investigate how sensitive are the methods to model misspecification, including different ways for obtaining standard errors.},
  citation-subset = {IM},
  country         = {England},
  issn-linking    = {0277-6715},
  journal         = {Statistics in Medicine},
  keywords        = {Monte Carlo simulation study; doubly robust standardization; inverse probability weighting; regression standardization; relative survival},
  nlm-id          = {8215016},
  owner           = {NLM},
  pmid            = {34523751},
  pubmodel        = {Print-Electronic},
  revised         = {2021-09-15},
  year            = {2021},
}

@Article{Crowther2015,
  author          = {Crowther, Michael J. and Lambert, Paul C.},
  date            = {2015-11},
  title           = {Reply to Letter to the {E}ditor by {R}emontet et al.},
  doi             = {10.1002/sim.6606},
  issn            = {1097-0258},
  issue           = {25},
  pages           = {3378--3380},
  pubstate        = {ppublish},
  volume          = {34},
  citation-subset = {IM},
  completed       = {2015-12-29},
  country         = {England},
  issn-linking    = {0277-6715},
  journal         = {Statistics in Medicine},
  keywords        = {Biomedical Research, statistics & numerical data; Female; Humans; Likelihood Functions; Male; Neoplasms, mortality; Regression Analysis; Survival Analysis},
  nlm-id          = {8215016},
  owner           = {NLM},
  pmid            = {26434359},
  pubmodel        = {Print},
  revised         = {2018-12-02},
  year            = {2015},
}

@Article{Gao2014,
  author          = {Gao, H. and HÃ¤gg, S. and SjÃ¶gren, P. and Lambert, P. C. and Ingelsson, E. and van Dam, R. M.},
  date            = {2014-07},
  title           = {Serum selenium in relation to measures of glucose metabolism and incidence of TypeÂ 2 diabetes in an older Swedish population.},
  doi             = {10.1111/dme.12429},
  issn            = {1464-5491},
  issue           = {7},
  pages           = {787--793},
  pubstate        = {ppublish},
  volume          = {31},
  abstract        = {The relation between selenium status and risk of TypeÂ 2 diabetes is controversial. We aimed to evaluate associations of serum selenium, a marker of dietary selenium, with measures of glucose metabolism and risk of diabetes. We used data from a population-based, longitudinal cohort of 1925 Swedish men who were 50Â years old and did not have diabetes at baseline in the 1970s. At baseline, an intravenous glucose tolerance test was performed and, at a follow-up examination after 20Â years, an oral glucose tolerance test and a hyperinsulinaemic euglycaemic clamp for the assessment of insulin sensitivity were conducted. At baseline, the mean (standard deviation) selenium concentration was 75.6 (14.3) Î¼g/l. During 20Â years of follow-up, 88 incident cases of diabetes occurred in 1024 participants with follow-up data. Baseline serum selenium levels were not associated with risk of diabetes (odds ratioÂ 1.06; 95%Â CI 0.83-1.38). Higher selenium levels were associated with lower early insulin response (standardized Î² -0.08; 95%Â CI -0.14 to -0.03) at baseline after adjusting for potential confounders, but not with any other measures of Î²-cell function or insulin sensitivity at baseline or follow-up. The association with early insulin response was non-significant after taking multiple testing into account. Our results do not support a role of dietary selenium in the development of disturbances in glucose metabolism or diabetes in older individuals.},
  chemicals       = {Biomarkers, Blood Glucose, Selenium},
  citation-subset = {IM},
  completed       = {2015-03-30},
  country         = {England},
  issn-linking    = {0742-3071},
  journal         = {Diabetic medicine : a journal of the British Diabetic Association},
  keywords        = {Aged; Biomarkers, blood; Blood Glucose, metabolism; Diabetes Mellitus, Type 2, blood, epidemiology; Follow-Up Studies; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Incidence; Insulin Resistance; Longitudinal Studies; Male; Reference Values; Selenium, blood; Sweden, epidemiology},
  nlm-id          = {8500858},
  owner           = {NLM},
  pmid            = {24606531},
  pubmodel        = {Print-Electronic},
  revised         = {2015-11-19},
  year            = {2014},
}

@Article{Rutherford2022,
  author          = {Rutherford, Mark J. and Andersson, Therese M.-L. and Myklebust, Tor {\AA}ge and M{\o}ller, BjÃ¸rn and Lambert, Paul C.},
  date            = {2022-01},
  title           = {Non-parametric estimation of reference adjusted, standardised probabilities of all-cause death and death due to cancer for population group comparisons.},
  doi             = {10.1186/s12874-021-01465-w},
  issn            = {1471-2288},
  issue           = {1},
  pages           = {2},
  pubstate        = {epublish},
  volume          = {22},
  abstract        = {Ensuring fair comparisons of cancer survival statistics across population groups requires careful consideration of differential competing mortality due to other causes, and adjusting for imbalances over groups in other prognostic covariates (e.g. age). This has typically been achieved using comparisons of age-standardised net survival, with age standardisation addressing covariate imbalance, and the net estimates removing differences in competing mortality from other causes. However, these estimates lack ease of interpretability. In this paper, we motivate an alternative non-parametric approach that uses a common rate of other cause mortality across groups to give reference-adjusted estimates of the all-cause and cause-specific crude probability of death in contrast to solely reporting net survival estimates. We develop the methodology for a non-parametric equivalent of standardised and reference adjusted crude probabilities of death, building on the estimation of non-parametric crude probabilities of death. We illustrate the approach using regional comparisons of survival following a diagnosis of rectal cancer for men in England. We standardise to the covariate distribution and other cause mortality of England as a whole to offer comparability, but with close approximation to the observed all-cause region-specific mortality. The approach gives comparable estimates to observed crude probabilities of death, but allows direct comparison across population groups with different covariate profiles and competing mortality patterns. In our illustrative example, we show that regional variations in survival following a diagnosis of rectal cancer persist even after accounting for the variation in deprivation, age at diagnosis and other cause mortality. The methodological approach of using standardised and reference adjusted metrics offers an appealing approach for future cancer survival comparison studies and routinely published cancer statistics. Our non-parametric estimation approach through the use of weighting offers the ability to estimate comparable survival estimates without the need for statistical modelling.},
  citation-subset = {IM},
  country         = {England},
  issn-linking    = {1471-2288},
  journal         = {BMC Medical Research Methodology},
  keywords        = {Age-standardisation; Competing risks; Crude probability of death; Net survival},
  nlm-id          = {100968545},
  owner           = {NLM},
  pii             = {10.1186/s12874-021-01465-w},
  pmc             = {PMC8740504},
  pmid            = {34991487},
  pubmodel        = {Electronic},
  revised         = {2022-01-10},
  year            = {2022},
}

@Article{Andersson2022,
  author          = {Andersson, Therese M.-L. and Rutherford, Mark J. and Myklebust, Tor {\AA}ge and MÃ¸ller, BjÃ¸rn and Arnold, Melina and Soerjomataram, Isabelle and Bray, Freddie and Elkader, Hazem Abd and Engholm, Gerda and Huws, Dyfed and Little, Alana and Shack, Lorraine and Walsh, Paul M. and Woods, Ryan R. and Parkin, D. Maxwell and Lambert, Paul C.},
  date            = {2022-02},
  title           = {A way to explore the existence of "immortals" in cancer registry data - An illustration using data from {ICBP SURVMARK-2}.},
  doi             = {10.1016/j.canep.2021.102085},
  issn            = {1877-783X},
  pages           = {102085},
  pubstate        = {ppublish},
  volume          = {76},
  abstract        = {Accurately recorded vital status of individuals is essential when estimating cancer patient survival. When deaths are ascertained by linkage with vital statistics registers, some may be missed, and such individuals will wrongly appear to be long-term survivors, and survival will be overestimated. Interval-specific relative survival that levels off above one indicates that the survival among the cancer patients is better than expected, which could be due to the presence of immortals. We included colon cancer cases diagnosed in 1995-1999 within the 19 jurisdictions in seven countries participating in ICBP SURVMARK-2, with follow-up information available until end-2015. Interval-specific relative survival was estimated for each year following diagnosis, by country and age group at diagnosis. The interval-specific relative survival levels off at 1 for all countries and age groups, with two exceptions: for the age group diagnosed at age 75 years and above in Ireland, and, to a lesser extent, in New Zealand. Overall, a subset of immortals are not apparent in the early years within the ICBP SURVMARK-2 study, except for possibly in Ireland. We suggest this approach as one strategy of exploring the existence of immortals, and to be part of routine checks of cancer registry data.},
  citation-subset = {IM},
  country         = {Netherlands},
  issn-linking    = {1877-7821},
  journal         = {Cancer Epidemiology},
  keywords        = {Cancer Survival; Cancer registry; Immortals},
  nlm-id          = {101508793},
  owner           = {NLM},
  pii             = {S1877-7821(21)00202-2},
  pmid            = {34954495},
  pubmodel        = {Print-Electronic},
  revised         = {2022-01-21},
  year            = {2022},
}

@Article{Riley2021,
  author          = {Riley, Richard D. and Collins, Gary S. and Ensor, Joie and Archer, Lucinda and Booth, Sarah and Mozumder, Sarwar I. and Rutherford, Mark J. and van Smeden, Maarten and Lambert, Paul C. and Snell, Kym I. E.},
  date            = {2021-12},
  title           = {Minimum sample size calculations for external validation of a clinical prediction model with a time-to-event outcome.},
  doi             = {10.1002/sim.9275},
  issn            = {1097-0258},
  pages           = {1280-1295},
  pubstate        = {aheadofprint},
  volume          = {41},
  abstract        = {Previous articles in Statistics in Medicine describe how to calculate the sample size required for external validation of prediction models with continuous and binary outcomes. The minimum sample size criteria aim to ensure precise estimation of key measures of a model's predictive performance, including measures of calibration, discrimination, and net benefit. Here, we extend the sample size guidance to prediction models with a time-to-event (survival) outcome, to cover external validation in datasets containing censoring. A simulation-based framework is proposed, which calculates the sample size required to target a particular confidence interval width for the calibration slope measuring the agreement between predicted risks (from the model) and observed risks (derived using pseudo-observations to account for censoring) on the log cumulative hazard scale. Precise estimation of calibration curves, discrimination, and net-benefit can also be checked in this framework. The process requires assumptions about the validation population in terms of the (i) distribution of the model's linear predictor and (ii) event and censoring distributions. Existing information can inform this; in particular, the linear predictor distribution can be approximated using the C-index or Royston's D statistic from the model development article, together with the overall event risk. We demonstrate how the approach can be used to calculate the sample size required to validate a prediction model for recurrent venous thromboembolism. Ideally the sample size should ensure precise calibration across the entire range of predicted risks, but must at least ensure adequate precision in regions important for clinical decision-making. Stata and R code are provided.},
  citation-subset = {IM},
  country         = {England},
  issn-linking    = {0277-6715},
  journal         = {Statistics in Medicine},
  keywords        = {calibration; external validation; prediction model; sample size; time-to-event & survival data},
  nlm-id          = {8215016},
  owner           = {NLM},
  pmid            = {34915593},
  pubmodel        = {Print-Electronic},
  revised         = {2021-12-16},
  year            = {2021},
}

@Article{Skourlis2021,
  author          = {Skourlis, Nikolaos and Crowther, Michael J. and Andersson, Therese M.-L. and Lambert, Paul C.},
  date            = {2021},
  title           = {Development of a dynamic interactive web tool to enhance understanding of multi-state model analyses: {MSM}plus.},
  doi             = {10.1186/s12874-021-01420-9},
  issn            = {1471-2288},
  issue           = {1},
  pages           = {262},
  pubstate        = {epublish},
  volume          = {21},
  abstract        = {Multi-state models are used in complex disease pathways to describe a process where an individual moves from one state to the next, taking into account competing states during each transition. In a multi-state setting, there are various measures to be estimated that are of great epidemiological importance. However, increased complexity of the multi-state setting and predictions over time for individuals with different covariate patterns may lead to increased difficulty in communicating the estimated measures. The need for easy and meaningful communication of the analysis results motivated the development of a web tool to address these issues. MSMplus is a publicly available web tool, developed via the Shiny R package, with the aim of enhancing the understanding of multi-state model analyses results. The results from any multi-state model analysis are uploaded to the application in a pre-specified format. Through a variety of user-tailored interactive graphs, the application contributes to an improvement in communication, reporting and interpretation of multi-state analysis results as well as comparison between different approaches. The predicted measures that can be supported by MSMplus include, among others, the transition probabilities, the transition intensity rates, the length of stay in each state, the probability of ever visiting a state and user defined measures. Representation of differences, ratios and confidence intervals of the aforementioned measures are also supported. MSMplus is a useful tool that enhances communication and understanding of multi-state model analyses results. Further use and development of web tools should be encouraged in the future as a means to communicate scientific research.},
  citation-subset = {IM},
  country         = {England},
  issn-linking    = {1471-2288},
  journal         = {BMC {M}edical {R}esearch {M}ethodology},
  keywords        = {Interactive; Multi-state models; Shiny; Web tool},
  nlm-id          = {100968545},
  owner           = {NLM},
  pii             = {10.1186/s12874-021-01420-9},
  pmc             = {PMC8627614},
  pmid            = {34837946},
  pubmodel        = {Electronic},
  revised         = {2021-12-03},
  year            = {2021},
}

@Article{Lee2022,
  author          = {Lee, S. F. and Vellayappan, B. A. and Wong, L. C. and Chiang, C. L. and Chan, S. K. and Wan, E. Y.-F. and Wong, I. C.-K. and Lambert, P. C. and Rachet, B. and Ng, A. K. and Luque-Fernandez, M. A.},
  date            = {2022-01},
  title           = {Cardiovascular diseases among diffuse large B-cell lymphoma long-term survivors in Asia: a multistate model study.},
  doi             = {10.1016/j.esmoop.2021.100363},
  issn            = {2059-7029},
  issue           = {1},
  pages           = {100363},
  pubstate        = {aheadofprint},
  volume          = {7},
  abstract        = {We modeled the clinical course of a cohort of diffuse large B-cell lymphoma (DLBCL) patients with no prior cardiovascular diseases (CVDs) using a multistate modeling framework. Data on 2600 patients with DLBCL diagnosed between 2000 and 2018 and had received chemotherapy with or without radiotherapy were obtained from a population-wide electronic health database of Hong Kong. We used the Markov illness-death model to quantify the impact of doxorubicin and various risk factors (therapeutic exposure, demographic, comorbidities, cardiovascular risk factors, and lifestyle factors which included smoking) on the clinical course of DLBCL (transitions into incident CVD, lymphoma death, and other causes of death). A total of 613 (23.6%) and 230 (8.8%) of 2600 subjects died of lymphoma and developed incident CVD, respectively. Median follow-up was 7.0 years (interquartile range 3.8-10.8 years). Older ages [hazard ratio (HR) for >75 versus â‰¤60 years 1.88; 95% confidence interval (CI) 1.25-2.82 and HR for 61-75 versus â‰¤60 years 1.60; 95% CI 1.12-2.30], hypertension (HR 4.92; 95% CI 2.61-9.26), diabetes (HR 1.43; 95% CI 1.09-1.87), and baseline use of aspirin (HR 5.30; 95% CI 3.93-7.16) were associated with an increased risk of incident CVD. In a subgroup of anticipated higher-risk patients (aged 61-75 years, smoked, had diabetes, and received doxorubicin), we found that they remained on average 7.9 (95% CI 7.2-8.8) years in the DLBCL state and 0.1 (95% CI 0.0-0.4) years in the CVD state, if they could be followed up for 10 years. The brief time in the CVD state is consistent with the high chance of death in patients who developed CVD. Other causes of death have overtaken DLBCL-related death after about 5Â years. In this Asian population-based cohort, we found that incident CVDs can occur soon after DLBCL treatment and continued to occur throughout survivorship. Clinicians are advised to balance the risks and benefits of treatment choices to minimize the risk of CVD.},
  citation-subset = {IM},
  country         = {England},
  issn-linking    = {2059-7029},
  journal         = {ESMO {O}pen},
  keywords        = {chemotherapy; diffuse large B-cell lymphoma; non-Hodgkinâ€™s lymphoma; radiotherapy; survival},
  nlm-id          = {101690685},
  owner           = {NLM},
  pii             = {S2059-7029(21)00325-2},
  pmc             = {PMC8760397},
  pmid            = {35026723},
  pubmodel        = {Print-Electronic},
  revised         = {2022-01-21},
  year            = {2022},
}

@Article{Andersson2022a,
  author          = {Andersson, Therese M.-L. and Myklebust, Tor {\AA}ge and Rutherford, Mark J. and MÃ¸ller, BjÃ¸rn and Arnold, Melina and Soerjomataram, Isabelle and Bray, Freddie and Parkin, D. Maxwell and Lambert, Paul C.},
  date            = {2022-01},
  title           = {Five ways to improve international comparisons of cancer survival: lessons learned from ICBP SURVMARK-2.},
  doi             = {10.1038/s41416-022-01701-0},
  issn            = {1532-1827},
  pages           = {1224â€“1228},
  pubstate        = {aheadofprint},
  volume          = {126},
  abstract        = {Comparisons of population-based cancer survival between countries are important to benchmark the overall effectiveness of cancer management. The International Cancer Benchmarking Partnership (ICBP) Survmark-2 study aims to compare survival in seven high-income countries across eight cancer sites and explore reasons for the observed differences. A critical aspect in ensuring comparability in the reported survival estimates are similarities in practice across cancer registries. While ICBP Survmark-2 has shown these differences are unlikely to explain the observed differences in cancer-specific survival between countries, it is important to keep in mind potential biases linked to registry practice and understand their likely impact. Based on experiences gained within ICBP Survmark-2, we have developed a set of recommendations that seek to optimally harmonise cancer registry datasets to improve future benchmarking exercises. Our recommendations stem from considering the impact on cancer survival estimates in five key areas: (1) the completeness of the registry and the availability of registration sources; (2) the inclusion of death certification as a source of identifying cases; (3) the specification of the date of incidence; (4) the approach to handling multiple primary tumours and (5) the quality of linkage of cases to the deaths register. These recommendations seek to improve comparability whilst maintaining the opportunity to understand and act upon international variations in outcomes among cancer patients.},
  citation-subset = {IM},
  country         = {England},
  issn-linking    = {0007-0920},
  journal         = {British Journal of Cancer},
  nlm-id          = {0370635},
  owner           = {NLM},
  pii             = {10.1038/s41416-022-01701-0},
  pmid            = {35058590},
  pubmodel        = {Print-Electronic},
  revised         = {2022-01-21},
  year            = {2022},
}

@Article{ForjazdeLacerda2019,
  author          = {Forjaz de Lacerda, GonÃ§alo and Howlader, Nadia and Mariotto, Angela B.},
  date            = {2019-09},
  journal         = {Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology},
  title           = {Differences in Cancer Survival with Relative versus Cause-Specific Approaches: An Update Using More Accurate Life Tables.},
  doi             = {10.1158/1055-9965.EPI-19-0125},
  issn            = {1538-7755},
  issue           = {9},
  pages           = {1544--1551},
  pubstate        = {ppublish},
  volume          = {28},
  abstract        = {We investigated differences in net cancer survival (survival observed if the only possible cause of death was the cancer under study) estimated using new approaches for relative survival (RS) and cause-specific survival (CSS). We used SEER data for patients diagnosed in 2000 to 2013, followed-up through December 31, 2014. For RS, we used new life tables accounting for geography and socio-economic status. For CSS, we used the SEER cause of death algorithm for attributing cancer-specific death. Estimates were compared by site, age, stage, race, and time since diagnosis. Differences between 5-year RS and CSS were generally small. RS was always higher in screen-detectable cancers, for example, female breast (89.2% vs. 87.8%) and prostate (98.5% vs. 93.7%) cancers; differences increased with age or time since diagnosis. CSS was usually higher in the remaining cancer sites, particularly those related to specific risk factors, for example, cervix (70.9% vs. 68.3%) and liver (20.7% vs. 17.1%) cancers. For most cancer sites, the gap between estimates was smaller with more advanced stage.  RS is the preferred approach to report cancer survival from registry data because cause of death may be inaccurate, particularly for older patients and long-term survivors as comorbidities increase challenges in determining cause of death. However, CSS proved to be more reliable in patients diagnosed with localized disease or cancers related to specific risk factors as general population life tables may not capture other causes of mortality. Different approaches for net survival estimation should be considered depending on cancer under study.},
  citation-subset = {IM},
  completed       = {2020-09-18},
  country         = {United States},
  issn-linking    = {1055-9965},
  keywords        = {Female; Humans; Life Tables; Male; Neoplasms, mortality; Risk Factors; Survival Analysis},
  mid             = {NIHMS1532754},
  nlm-id          = {9200608},
  owner           = {NLM},
  pii             = {1055-9965.EPI-19-0125},
  pmc             = {PMC6726514},
  pmid            = {31221717},
  pubmodel        = {Print-Electronic},
  revised         = {2021-01-10},
}

@Article{Cole2015,
  author          = {Cole, Stephen R. and Hudgens, Michael G. and Brookhart, M. Alan and Westreich, Daniel},
  title           = {Risk.},
  doi             = {10.1093/aje/kwv001},
  issn            = {1476-6256},
  issue           = {4},
  pages           = {246--250},
  pubstate        = {ppublish},
  volume          = {181},
  abstract        = {The epidemiologist primarily studies transitions between states of health and disease. The purpose of the present article is to define a foundational parameter for such studies, namely risk. We begin simply and build to the setting in which there is more than 1 event type (i.e., competing risks or competing events), as well as more than 1 treatment or exposure level of interest. In the presence of competing events, the risks are a set of counterfactual cumulative incidence functions for each treatment. These risks can be depicted visually and summarized numerically. We use an example from the study of human immunodeficiency virus to illustrate concepts.},
  chemicals       = {Anti-HIV Agents},
  citation-subset = {IM},
  completed       = {2015-04-20},
  country         = {United States},
  issn-linking    = {0002-9262},
  journal         = {American journal of epidemiology},
  keywords        = {Anti-HIV Agents, therapeutic use; Cohort Studies; HIV Infections, drug therapy, mortality; Humans; Incidence; Mathematical Computing; Risk Assessment; Risk Factors; Time Factors; United States, epidemiology; causal inference; cohort study; semi-Bayes method; semiparametric inference; survival analysis},
  nlm-id          = {7910653},
  owner           = {NLM},
  pii             = {kwv001},
  pmc             = {PMC4325680},
  pmid            = {25660080},
  pubmodel        = {Print-Electronic},
  revised         = {2022-03-30},
  year            = {2015},
}

@InBook{Gail2005,
  author    = {Gail, Mitchell H.},
  booktitle = {Encyclopedia of Biostatistics},
  title     = {Crude Risk},
  doi       = {https://doi.org/10.1002/0470011815.b2a03043},
  eprint    = {https://onlinelibrary.wiley.com/doi/pdf/10.1002/0470011815.b2a03043},
  isbn      = {9780470011812},
  publisher = {John Wiley & Sons, Ltd},
  url       = {https://onlinelibrary.wiley.com/doi/abs/10.1002/0470011815.b2a03043},
  abstract  = {Abstract Crude risk (or absolute risk) is defined and contrasted with â€œnet riskâ€, which refers to the probability of developing a given disease if competing risks are eliminated. Crude risk may also refer to risk in a heterogeneous population.},
  keywords  = {crude risk, absolute risk, competing risks, net risk, Aalenâ€“Johansen estimator},
  year      = {2005},
}

@Article{Syriopoulou2022,
  author          = {Syriopoulou, Elisavet and Mozumder, Sarwar I. and Rutherford, Mark J. and Lambert, Paul C.},
  date            = {2022-08},
  title           = {Estimating causal effects in the presence of competing events using regression standardisation with the Stata command {s}tandsurv.},
  doi             = {10.1186/s12874-022-01666-x},
  issn            = {1471-2288},
  issue           = {1},
  pages           = {226},
  pubstate        = {epublish},
  volume          = {22},
  abstract        = {When interested in a time-to-event outcome, competing events that prevent the occurrence of the event of interest may be present. In the presence of competing events, various estimands have been suggested for defining the causal effect of treatment on the event of interest. Depending on the estimand, the competing events are either accommodated or eliminated, resulting in causal effects with different interpretations. The former approach captures the total effect of treatment on the event of interest while the latter approach captures the direct effect of treatment on the event of interest that is not mediated by the competing event. Separable effects have also been defined for settings where the treatment can be partitioned into two components that affect the event of interest and the competing event through different causal pathways. We outline various causal effects that may be of interest in the presence of competing events, including total, direct and separable effects, and describe how to obtain estimates using regression standardisation with the Stata command standsurv. Regression standardisation is applied by obtaining the average of individual estimates across all individuals in a study population after fitting a survival model. With standsurv several contrasts of interest can be calculated including differences, ratios and other user-defined functions. Confidence intervals can also be obtained using the delta method. Throughout we use an example analysing a publicly available dataset on prostate cancer to allow the reader to replicate the analysis and further explore the different effects of interest. Several causal effects can be defined in the presence of competing events and, under assumptions, estimates of those can be obtained using regression standardisation with the Stata command standsurv. The choice of which causal effect to define should be given careful consideration based on the research question and the audience to which the findings will be communicated.},
  citation-subset = {IM},
  completed       = {2022-08-16},
  country         = {England},
  issn-linking    = {1471-2288},
  journal         = {BMC Medical Research Methodology},
  keywords        = {Causality; Humans; Male; Prostatic Neoplasms; Causal effect; Competing events; Direct effect; Regression standardisation; Separable effects; Total effect},
  nlm-id          = {100968545},
  owner           = {NLM},
  pii             = {10.1186/s12874-022-01666-x},
  pmc             = {PMC9375409},
  pmid            = {35963987},
  pubmodel        = {Electronic},
  revised         = {2022-09-02},
  year            = {2022},
}

@Article{Wang2021,
  author  = {Wenjie Wang and Jun Yan},
  title   = {Shape-Restricted Regression Splines with {R} Package {splines2}},
  doi     = {10.6339/21-JDS1020},
  number  = {3},
  pages   = {498--517},
  volume  = {19},
  journal = {Journal of Data Science},
  year    = {2021},
}

@Book{cin2019,
  author    = {{Cancer Registry of Norway}},
  title     = {Cancer in {N}orway 2019 - Cancer incidence, mortality, survival and prevalence in {N}orway},
  publisher = {Oslo: Cancer Registry of Norway},
  url       = {https://www.kreftregisteret.no/globalassets/cancer-in-norway/2019/cin_report.pdf},
  owner     = {PaulD},
  timestamp = {2017-11-23},
  year      = {2020},
}

@Article{Bright2020,
  author          = {Bright, Chloe J. and Brentnall, Adam R. and Wooldrage, Kate and Myles, Jonathon and Sasieni, Peter and Duffy, Stephen W.},
  title           = {Errors in determination of net survival: cause-specific and relative survival settings.},
  doi             = {10.1038/s41416-020-0739-4},
  issn            = {1532-1827},
  issue           = {7},
  pages           = {1094--1101},
  pubstate        = {ppublish},
  volume          = {122},
  abstract        = {Cause-specific and relative survival estimates differ. We aimed to examine these differences in common cancers where by possible identifying the most plausible sources of error in each estimate. Ten-year cause-specific and relative survival were estimated for lung, breast, prostate, ovary, oesophagus and colorectal cancers. The cause-specific survival was corrected for misclassification of cause of death. The Pohar-Perme relative survival estimator was modified by (1) correcting for differences in deaths from ischaemic heart disease (IHD) between cancers and general population; or (2) correcting the population hazard for smoking (lung cancer only). For all cancers except breast and prostate, relative survival was lower than cause-specific. Correction for published error rates in cause of death gave implausible results. Correction for rates of IHD death gave slightly different relative survival estimates for lung, oesophagus and colorectal cancers. For lung cancer, when the population hazard was inflated for smoking, survival estimates were increased. Results agreed with the consensus that relative survival is usually preferable. However, for some cancers, relative survival might be inaccurate (e.g. lung and prostate). Likely solutions include enhancing life tables to include other demographic variables than age and sex, and to stratify relative survival calculation by cause of death.},
  citation-subset = {IM},
  completed       = {2021-01-15},
  country         = {England},
  issn-linking    = {0007-0920},
  journal         = {British journal of cancer},
  keywords        = {Adolescent; Adult; Aged; Aged, 80 and over; Cause of Death, trends; Female; Humans; Male; Middle Aged; Survival Analysis; Young Adult},
  nlm-id          = {0370635},
  owner           = {NLM},
  pii             = {10.1038/s41416-020-0739-4},
  pmc             = {PMC7109046},
  pmid            = {32037401},
  pubmodel        = {Print-Electronic},
  revised         = {2021-01-15},
  year            = {2020},
}

@Article{Bullement2020,
  author          = {Bullement, Ash and Willis, Anna and Amin, Amerah and Schlichting, Michael and Hatswell, Anthony James and Bharmal, Murtuza},
  title           = {Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection.},
  doi             = {10.1186/s12874-020-00997-x},
  issn            = {1471-2288},
  issue           = {1},
  pages           = {103},
  pubstate        = {epublish},
  volume          = {20},
  citation-subset = {IM},
  completed       = {2021-06-24},
  country         = {England},
  issn-linking    = {1471-2288},
  journal         = {BMC medical research methodology},
  keywords        = {Humans; Models, Statistical; Neoplasms, therapy; Retrospective Studies; Survival Analysis; Survival Rate; Cancer; Extrapolation; Immune-oncology; Immunotherapy; Survival},
  nlm-id          = {100968545},
  owner           = {NLM},
  pii             = {10.1186/s12874-020-00997-x},
  pmc             = {PMC7204248},
  pmid            = {32375680},
  pubmodel        = {Electronic},
  revised         = {2021-06-24},
  year            = {2020},
}

@Article{Buckland1997,
  author       = {Buckland, S and Burnham, K and Augustin, N},
  date         = {1997},
  journaltitle = {Biometrics},
  title        = {Model Selection: An Integral Part of Inference},
  doi          = {10.2307/2533961},
  number       = {2},
  pages        = {603},
  volume       = {53},
  journal      = {Biometrics},
  publisher    = {JSTOR},
  year         = {1997},
}

@Article{Stensrud2020a,
  author   = {Stensrud, Mats J. and Hern\'{a}n, Miguel A.},
  title    = {{Why Test for Proportional Hazards?}},
  doi      = {10.1001/jama.2020.1267},
  eprint   = {https://jamanetwork.com/journals/jama/articlepdf/2763185/jama\_stensrud\_2020\_gm\_200003.pdf},
  issn     = {0098-7484},
  number   = {14},
  pages    = {1401-1402},
  url      = {https://doi.org/10.1001/jama.2020.1267},
  volume   = {323},
  abstract = {{The Cox proportional hazards model, introduced in 1972, has become the default approach for survival analysis in randomized trials. The Cox model estimates the ratio of the hazard of the event or outcome of interest (eg, death) between 2 treatment groups. Informally, the hazard at any given time is the probability of experiencing the event of interest in the next interval among individuals who had not yet experienced the event by the start of the interval. Because the Cox model requires the hazards in both groups to be proportional, researchers are often asked to â€œtestâ€ whether hazards are proportional.}},
  journal  = {JAMA},
  month    = {04},
  year     = {2020},
}

@Article{DiRienzo2001,
  author   = {DiRienzo, A. G. and Lagakos, S. W.},
  title    = {Effects of model misspecification on tests of no randomized treatment effect arising from {C}ox's proportional hazards model},
  doi      = {https://doi.org/10.1111/1467-9868.00310},
  eprint   = {https://rss.onlinelibrary.wiley.com/doi/pdf/10.1111/1467-9868.00310},
  number   = {4},
  pages    = {745-757},
  url      = {https://rss.onlinelibrary.wiley.com/doi/abs/10.1111/1467-9868.00310},
  volume   = {63},
  journal  = {Journal of the Royal Statistical Society: Series B (Statistical Methodology)},
  keywords = {Censored data, Martingale, Misspecified model, Model-based variance estimator, Partial likelihood, Robust variance estimator},
  year     = {2001},
}

<<<<<<< .mine
@Article{Lundberg2022,
  author          = {Lundberg, Frida E. and Birgisson, Helgi and Johannesen, Tom B. and Engholm, Gerda and Virtanen, Anni and Pettersson, David and Ã“lafsdÃ³ttir, ElÃ­nborg J. and Lambe, Mats and Lambert, Paul C. and MÃ¸rch, Lina S. and Johansson, Anna L. V. and Andersson, Therese M.-L.},
  date            = {2022-09},
  journaltitle    = {European Journal of Cancer},
  title           = {Survival trends in patients diagnosed with colon and rectal cancer in the {N}ordic countries 1990-2016: The {NORDCAN} survival studies.},
  doi             = {10.1016/j.ejca.2022.05.032},
  issn            = {1879-0852},
  pages           = {76--84},
  pubstate        = {ppublish},
  volume          = {172},
  abstract        = {Survival of patients with colon and rectal cancer has improved in all Nordic countries during the past decades. The aim of this study was to further assess survival trends in patients with colon and rectal cancer in the Nordic countries by age at diagnosis and to present additional survival measures. Data on colon and rectal cancer cases diagnosed in the Nordic countries between 1990 and 2016 were obtained from the NORDCAN database. Relative survival was estimated using flexible parametric models. Both age-standardized and age-specific measures for women and men were estimated from the models, as well as reference-adjusted crude probabilities of death and life-years lost. The five-year age-standardized relative survival of colon and rectal cancer patients continued to improve for women and men in all Nordic countries, from around 50% in 1990 to about 70% at the end of the study period. In general, survival was similar across age and sex. The largest improvement was seen for Danish men and women with rectal cancer, from 41% to 69% and from 43% to 71%, respectively. The age-standardized and reference-adjusted five-year crude probability of death in colon cancer ranged from 30% to 36% across countries, and for rectal cancer from 20% to 33%. The average number of age-standardized and reference-adjusted life-years lost ranged between six and nine years. There were substantial improvements in colon and rectal cancer survival in all Nordic countries 1990-2016. Of special note is that the previously observed survival disadvantage in Denmark is no longer present.},
  citation-subset = {IM},
  completed       = {2022-08-16},
  country         = {England},
  issn-linking    = {0959-8049},
  journal         = {European Journal of Cancer},
  keywords        = {Age Distribution; Child; Colon; Denmark, epidemiology; Female; Humans; Incidence; Male; Rectal Neoplasms, therapy; Registries; Risk Factors; Scandinavian and Nordic Countries, epidemiology; Survival Analysis; Survival Rate; Colonic neoplasms; Comparison; NORDCAN; Nordic cancer registries; Rectal cancer; Rectal neoplasms; Survival; colon cancer},
  nlm-id          = {9005373},
  owner           = {NLM},
  pii             = {S0959-8049(22)00320-3},
  pmid            = {35759813},
  pubmodel        = {Print-Electronic},
  revised         = {2022-11-08},
  year            = {2022},
}

@Article{Syriopoulou2022a,
  author          = {Syriopoulou, Elisavet and WÃ¤sterlid, Tove and Lambert, Paul C. and Andersson, Therese M.-L.},
  date            = {2022-11},
  journaltitle    = {British Journal of Cancer},
  title           = {Standardised survival probabilities: a useful and informative tool for reporting regression models for survival data.},
  doi             = {10.1038/s41416-022-01949-6},
  issn            = {1532-1827},
  issue           = {10},
  pages           = {1808--1815},
  pubstate        = {ppublish},
  volume          = {127},
  abstract        = {When interested in studying the effect of a treatment (or other exposure) on a time-to-event outcome, the most popular approach is to estimate survival probabilities using the Kaplan-Meier estimator. In the presence of confounding, regression models are fitted, and results are often summarised as hazard ratios. However, despite their broad use, hazard ratios are frequently misinterpreted as relative risks instead of relative rates. We discuss measures for summarising the analysis from a regression model that overcome some of the limitations associated with hazard ratios. Such measures are the standardised survival probabilities for treated and untreated: survival probabilities if everyone in the population received treatment and if everyone did not. The difference between treatment arms can be calculated to provide a measure for the treatment effect. Using publicly available data on breast cancer, we demonstrated the usefulness of standardised survival probabilities for comparing the experience between treated and untreated after adjusting for confounding. We also showed that additional important research questions can be addressed by standardising among subgroups of the total population. Standardised survival probabilities are a useful way to report the treatment effect while adjusting for confounding and have an informative interpretation in terms of risk.},
  citation-subset = {IM},
  completed       = {2022-11-10},
  country         = {England},
  issn-linking    = {0007-0920},
  journal         = {British Journal of Cancer},
  keywords        = {Humans; Female; Survival Analysis; Proportional Hazards Models; Probability; Breast Neoplasms, therapy; Risk},
  nlm-id          = {0370635},
  owner           = {NLM},
  pii             = {10.1038/s41416-022-01949-6},
  pmc             = {PMC9643385},
  pmid            = {36050446},
  pubmodel        = {Print-Electronic},
  revised         = {2022-11-20},
  year            = {2022},
}

@Article{Schmidt2022,
  author          = {Schmidt, James C. F. and Lambert, Paul C. and Gillies, Clare L. and Sweeting, Michael J.},
  date            = {2022},
  journaltitle    = {PloS one},
  title           = {Patterns of rates of mortality in the {C}linical {P}ractice {R}esearch {D}atalink.},
  doi             = {10.1371/journal.pone.0265709},
  issn            = {1932-6203},
  issue           = {8},
  pages           = {e0265709},
  pubstate        = {epublish},
  volume          = {17},
  abstract        = {The Clinical Practice Research Datalink (CPRD) is a widely used data resource, representative in demographic profile, with accurate death recordings but it is unclear if mortality rates within CPRD GOLD are similar to rates in the general population. Rates may additionally be affected by selection bias caused by the requirement that a cohort have a minimum lookback window, i.e. observation time prior to start of at-risk follow-up. Standardised Mortality Ratios (SMRs) were calculated incorporating published population reference rates from the Office for National Statistics (ONS), using Poisson regression with rates in CPRD GOLD contrasted to ONS rates, stratified by age, calendar year and sex. An overall SMR was estimated along with SMRs presented for cohorts with different lookback windows (1, 2, 5, 10 years). SMRs were stratified by calendar year, length of follow-up and age group. Mortality rates in a random sample of 1 million CPRD GOLD patients were slightly lower than the national population [SMR = 0.980 95% confidence interval (CI) (0.973, 0.987)]. Cohorts with observational lookback had SMRs below one [1 year of lookback; SMR = 0.905 (0.898, 0.912), 2 years; SMR = 0.881 (0.874, 0.888), 5 years; SMR = 0.849 (0.841, 0.857), 10 years; SMR = 0.837 (0.827, 0.847)]. Mortality rates in the first two years after patient entry into CPRD were higher than the general population, while SMRs dropped below one thereafter. Mortality rates in CPRD, using simple entry requirements, are similar to rates seen in the English population. The requirement of at least a single year of lookback results in lower mortality rates compared to national estimates.},
  citation-subset = {IM},
  completed       = {2022-08-08},
  country         = {United States},
  issn-linking    = {1932-6203},
  journal         = {PloS One},
  keywords        = {Cause of Death; Cohort Studies; Humans; Mortality; Selection Bias},
  nlm-id          = {101285081},
  owner           = {NLM},
  pii             = {e0265709},
  pmc             = {PMC9352072},
  pmid            = {35925908},
  pubmodel        = {Electronic-eCollection},
  revised         = {2022-08-22},
  year            = {2022},
}

@Article{Smith2022,
  author          = {Smith, Aiden and Lambert, Paul C. and Rutherford, Mark J.},
  date            = {2022-06},
  journaltitle    = {BMC Medical Research Methodology},
  title           = {Generating high-fidelity synthetic time-to-event datasets to improve data transparency and accessibility.},
  doi             = {10.1186/s12874-022-01654-1},
  issn            = {1471-2288},
  issue           = {1},
  pages           = {176},
  pubstate        = {epublish},
  volume          = {22},
  abstract        = {A lack of available data and statistical code being published alongside journal articles provides a significant barrier to open scientific discourse, and reproducibility of research. Information governance restrictions inhibit the active dissemination of individual level data to accompany published manuscripts. Realistic, high-fidelity time-to-event synthetic data can aid in the acceleration of methodological developments in survival analysis and beyond by enabling researchers to access and test published methods using data similar to that which they were developed on. We present methods to accurately emulate the covariate patterns and survival times found in real-world datasets using synthetic data techniques, without compromising patient privacy. We model the joint covariate distribution of the original data using covariate specific sequential conditional regression models, then fit a complex flexible parametric survival model from which to generate survival times conditional on individual covariate patterns. We recreate the administrative censoring mechanism using the last observed follow-up date information from the initial dataset. Metrics for evaluating the accuracy of the synthetic data, and the non-identifiability of individuals from the original dataset, are presented. We successfully create a synthetic version of an example colon cancer dataset consisting of 9064 patients which aims to show good similarity to both covariate distributions and survival times from the original data, without containing any exact information from the original data, therefore allowing them to be published openly alongside research. We evaluate the effectiveness of the methods for constructing synthetic data, as well as providing evidence that there is minimal risk that a given patient from the original data could be identified from their individual unique patient information. Synthetic datasets using this methodology could be made available alongside published research without breaching data privacy protocols, and allow for data and code to be made available alongside methodological or applied manuscripts to greatly improve the transparency and accessibility of medical research.},
  citation-subset = {IM},
  completed       = {2022-06-27},
  country         = {England},
  issn-linking    = {1471-2288},
  journal         = {BMC Medical Research Methodology},
  keywords        = {Biomedical Research; Humans; Reproducibility of Results; Survival Analysis; Data accessibility; Flexible parametric survival models; Reproducible research; Simulation; Survival; Synthetic data; Time-to-event},
  nlm-id          = {100968545},
  owner           = {NLM},
  pii             = {176},
  pmc             = {PMC9229142},
  pmid            = {35739465},
  pubmodel        = {Electronic},
  revised         = {2022-07-16},
  year            = {2022},
}

@Article{Stannard2022,
  author          = {Stannard, Rachael and Lambert, Paul C. and Andersson, Therese M.-L. and Rutherford, Mark J.},
  date            = {2022-10},
  title           = {Obtaining long-term stage-specific relative survival estimates in the presence of incomplete historical stage information.},
  doi             = {10.1038/s41416-022-01866-8},
  issn            = {1532-1827},
  issue           = {6},
  pages           = {1061--1068},
  pubstate        = {ppublish},
  volume          = {127},
  abstract        = {Completeness of recording for cancer stage at diagnosis is often historically poor in cancer registries, making it challenging to provide long-term stage-specific survival estimates. Stage-specific survival differences are driven by differences in short-term prognosis, meaning estimated survival metrics using period analysis are unlikely to be sensitive to imputed historical stage data. We used data from the Surveillance, Epidemiology, and End Results (SEER) Program for lung, colon and breast cancer. To represent missing data patterns in less complete registry data, we artificially inflated the proportion of missing stage information conditional on stage at diagnosis and calendar year of diagnosis. Period analysis was applied and missing stage at diagnosis information was imputed under four different conditions to emulate extreme imputed stage distributions. We fit a flexible parametric model for each cancer stage on the excess hazard scale and the differences in stage-specific marginal relative survival were assessed. Estimates were also obtained from non-parametric approaches for validation. There was little difference between the 10-year stage-specific marginal relative survival estimates, regardless of the assumed historical stage distribution. When conducting a period analysis, multiple imputation can be used to obtain stage-specific long-term estimates of relative survival, even when the historical stage information is largely incomplete.},
  citation-subset = {IM},
  completed       = {2022-09-15},
  country         = {England},
  issn-linking    = {0007-0920},
  journal         = {British Journal of Cancer},
  keywords        = {Breast Neoplasms; Female; Humans; Neoplasm Staging; Prognosis; Registries; SEER Program; Survival Analysis},
  nlm-id          = {0370635},
  owner           = {NLM},
  pii             = {10.1038/s41416-022-01866-8},
  pmc             = {PMC9470741},
  pmid            = {35715629},
  pubmodel        = {Print-Electronic},
  revised         = {2022-11-13},
  year            = {2022},
}

@Article{Skourlis2022,
  author          = {Skourlis, Nikolaos and Crowther, Michael J. and Andersson, Therese M.-L. and Lambert, Paul C.},
  date            = {2022-10},
  title           = {On the choice of timescale for other cause mortality in a competing risk setting using flexible parametric survival models.},
  doi             = {10.1002/bimj.202100254},
  issn            = {1521-4036},
  issue           = {7},
  pages           = {1161--1177},
  pubstate        = {ppublish},
  volume          = {64},
  citation-subset = {IM},
  completed       = {2022-10-18},
  country         = {Germany},
  issn-linking    = {0323-3847},
  journal         = {Biometrical Journal},
  keywords        = {Bias; Computer Simulation; Incidence; Proportional Hazards Models; Regression Analysis; Risk Assessment; attained age; choice of timescale; competing risks; flexible parametric models; simulation study},
  nlm-id          = {7708048},
  owner           = {NLM},
  pmc             = {PMC9795972},
  pmid            = {35708221},
  pubmodel        = {Print-Electronic},
  revised         = {2022-12-29},
  year            = {2022},
}

@Article{Andersson2022b,
  author          = {Andersson, Therese M.-L. and Rutherford, Mark J. and MÃ¸ller, BjÃ¸rn and Lambert, Paul C. and Myklebust, Tor {\AA}ge},
  date            = {2022-09},
  title           = {Reference-Adjusted Loss in Life Expectancy for Population-Based Cancer Patient Survival Comparisons-with an Application to Colon Cancer in {S}weden.},
  doi             = {10.1158/1055-9965.EPI-22-0137},
  issn            = {1538-7755},
  issue           = {9},
  pages           = {1720--1726},
  pubstate        = {ppublish},
  volume          = {31},
  abstract        = {The loss in life expectancy, LLE, is defined as the difference in life expectancy between patients with cancer and that of the general population. It is a useful measure for summarizing the impact of a cancer diagnosis on an individual's life expectancy. However, it is less useful for making comparisons of cancer survival across groups or over time, because the LLE is influenced by both mortality due to cancer and other causes and the life expectancy in the general population. We present an approach for making LLE estimates comparable across groups and over time by using reference expected mortality rates with flexible parametric relative survival models. The approach is illustrated by estimating temporal trends in LLE of patients with colon cancer in Sweden. The life expectancy of Swedish patients with colon cancer has improved, but the LLE has not decreased to the same extent because the life expectancy in the general population has also increased. When using a fixed population and other-cause mortality, that is, a reference-adjusted approach, the LLE decreases over time. For example, using 2010 mortality rates as the reference, the LLE for females diagnosed at age 65 decreased from 11.3 if diagnosed in 1976 to 7.2 if diagnosed in 2010, and from 3.9 to 1.9 years for women 85 years old at diagnosis. The reference-adjusted LLE is useful for making comparisons across calendar time, or groups, because differences in other-cause mortality are removed. The reference-adjusted approach enhances the use of LLE as a comparative measure.},
  citation-subset = {IM},
  completed       = {2022-09-08},
  country         = {United States},
  issn-linking    = {1055-9965},
  journal         = {Cancer Epidemiology, Biomarkers \& Prevention},
  keywords        = {Aged; Colonic Neoplasms, epidemiology; Female; Humans; Life Expectancy; Research; Sweden, epidemiology},
  mid             = {EMS145911},
  nlm-id          = {9200608},
  owner           = {NLM},
  pii             = {704892},
  pmc             = {PMC9437567},
  pmid            = {35700010},
  pubmodel        = {Print},
  revised         = {2022-11-10},
  year            = {2022},
}

@Article{Leontyeva2022,
  author          = {Leontyeva, Yuliya and Bower, Hannah and Gauffin, Oskar and Lambert, Paul C. and Andersson, Therese M.-L.},
  date            = {2022-05},
  title           = {Assessing the impact of including variation in general population mortality on standard errors of relative survival and loss in life expectancy.},
  doi             = {10.1186/s12874-022-01597-7},
  issn            = {1471-2288},
  issue           = {1},
  pages           = {130},
  pubstate        = {epublish},
  volume          = {22},
  abstract        = {A relative survival approach is often used in population-based cancer studies, where other cause (or expected) mortality is assumed to be the same as the mortality in the general population, given a specific covariate pattern. The population mortality is assumed to be known (fixed), i.e. measured without uncertainty. This could have implications for the estimated standard errors (SE) of any measures obtained within a relative survival framework, such as relative survival (RS) ratios and the loss in life expectancy (LLE). We evaluated the existing approach to estimate SE of RS and the LLE in comparison to if uncertainty in the population mortality was taken into account. The uncertainty from the population mortality was incorporated using parametric bootstrap approach. The analysis was performed with different levels of stratification and sizes of the general population used for creating expected mortality rates. Using these expected mortality rates, SEs of 5-year RS and the LLE for colon cancer patients in Sweden were estimated. Ignoring uncertainty in the general population mortality rates had negligible (less than 1%) impact on the SEs of 5-year RS and LLE, when the expected mortality rates were based on the whole general population, i.e. all people living in a country or region. However, the smaller population used for creating the expected mortality rates, the larger impact. For a general population reduced to 0.05% of the original size and stratified by age, sex, year and region, the relative precision for 5-year RS was 41% for males diagnosed at age 85. For the LLE the impact was more substantial with a relative precision of 1286%. The relative precision for marginal estimates of 5-year RS was 3% and 30% and for the LLE 22% and 313% when the general population was reduced to 0.5% and 0.05% of the original size, respectively. When the general population mortality rates are based on the whole population, the uncertainty in the estimates of the expected measures can be ignored. However, when based on a smaller population, this uncertainty should be taken into account, otherwise SEs may be too small, particularly for marginal values, and, therefore, confidence intervals too narrow.},
  citation-subset = {IM},
  completed       = {2022-05-04},
  country         = {England},
  issn-linking    = {1471-2288},
  journal         = {BMC Medical Research Methodology},
  keywords        = {Aged, 80 and over; Colonic Neoplasms; Humans; Life Expectancy; Male; Survival Analysis; Sweden, epidemiology; Uncertainty; Flexible parametric survival models; Loss in life expectancy; Relative survival},
  nlm-id          = {100968545},
  owner           = {NLM},
  pii             = {130},
  pmc             = {PMC9059421},
  pmid            = {35501701},
  pubmodel        = {Electronic},
  revised         = {2022-05-11},
  year            = {2022},
}

@Article{Lundberg2022a,
  author          = {Lundberg, Frida E. and Kroman, Niels and Lambe, Mats and Andersson, Therese M.-L. and Engholm, Gerda and Johannesen, Tom BÃ¸rge and Virtanen, Anni and Pettersson, David and Ã“lafsdÃ³ttir, ElÃ­nborg J. and Birgisson, Helgi and Lambert, Paul C. and MÃ¸rch, Lina Steinrud and Johansson, Anna L. V.},
  date            = {2022-12},
  journaltitle    = {Acta Oncologica},
  title           = {Age-specific survival trends and life-years lost in women with breast cancer 1990-2016: the {NORDCAN} survival studies.},
  doi             = {10.1080/0284186X.2022.2156811},
  issn            = {1651-226X},
  issue           = {12},
  pages           = {1481--1489},
  pubstate        = {ppublish},
  volume          = {61},
  abstract        = {A recent overview of cancer survival trends 1990-2016 in the Nordic countries reported continued improvements in age-standardized breast cancer survival among women. The aim was to estimate age-specific survival trends over calendar time, including life-years lost, to evaluate if improvements have benefited patients across all ages in the Nordic countries. Data on breast cancers diagnosed 1990-2016 in Denmark, Finland, Iceland, Norway, and Sweden were obtained from the NORDCAN database. Age-standardized and age-specific relative survival (RS) was estimated using flexible parametric models, as was reference-adjusted crude probabilities of death and life-years lost. Age-standardized period estimates of 5-year RS in women diagnosed with breast cancer ranged from 87% to 90% and 10-year RS from 74% to 85%. Ten-year RS increased with 15-18 percentage points from 1990 to 2016, except in Sweden (+9 percentage points) which had the highest survival in 1990. The largest improvements were observed in Denmark, where a previous survival disadvantage diminished. Most recent 5-year crude probabilities of cancer death ranged from 9% (Finland, Sweden) to 12% (Denmark, Iceland), and life-years lost from 3.3â€‰years (Finland) to 4.6â€‰years (Denmark). Although survival improvements were consistent across different ages, women aged â‰¥70Â years had the lowest RS in all countries. Period estimates of 5-year RS were 94-95% in age 55Â years and 84-89% in age 75Â years, while 10-year RS were 88-91% in age 55Â years and 69-84% in age 75Â years. Women aged 40Â years lost on average 11.0-13.8â€‰years, while women lost 3.8-6.0â€‰years if aged 55 and 1.9-3.5â€‰years if aged 75Â years. Survival for Nordic women with breast cancer improved from 1990 to 2016 in all age groups, albeit with larger country variation among older women where survival was also lower. Women over 70â€‰years of age have not had the same survival improvement as women of younger age.},
  citation-subset = {IM},
  completed       = {2023-01-18},
  country         = {England},
  issn-linking    = {0284-186X},
  journal         = {Acta Oncologica},
  keywords        = {Humans; Female; Aged; Aged, 80 and over; Breast Neoplasms, therapy; Survival Rate; Risk Factors; Scandinavian and Nordic Countries, epidemiology; Finland, epidemiology; Sweden, epidemiology; Norway, epidemiology; Registries; Age Factors; Denmark, epidemiology; Breast cancer; NORDCAN; Nordic cancer registries; comparison; survival},
  nlm-id          = {8709065},
  owner           = {NLM},
  pmid            = {36542678},
  pubmodel        = {Print-Electronic},
  revised         = {2023-01-18},
  year            = {2022},
}

@Article{Batyrbekova2022,
  author          = {Batyrbekova, Nurgul and Bower, Hannah and Dickman, Paul W. and Ravn Landtblom, Anna and Hultcrantz, Malin and Szulkin, Robert and Lambert, Paul C. and Andersson, Therese M.-L.},
  date            = {2022-11},
  journaltitle    = {BMC Medical Research Methodology},
  title           = {Modelling multiple time-scales with flexible parametric survival models.},
  doi             = {10.1186/s12874-022-01773-9},
  issn            = {1471-2288},
  issue           = {1},
  pages           = {290},
  pubstate        = {epublish},
  volume          = {22},
  abstract        = {There are situations when we need to model multiple time-scales in survival analysis. A usual approach in this setting would involve fitting Cox or Poisson models to a time-split dataset. However, this leads to large datasets and can be computationally intensive when model fitting, especially if interest lies in displaying how the estimated hazard rate or survival change along multiple time-scales continuously. We propose to use flexible parametric survival models on the log hazard scale as an alternative method when modelling data with multiple time-scales. By choosing one of the time-scales as reference, and rewriting other time-scales as a function of this reference time-scale, users can avoid time-splitting of the data. Through case-studies we demonstrate the usefulness of this method and provide examples of graphical representations of estimated hazard rates and survival proportions. The model gives nearly identical results to using a Poisson model, without requiring time-splitting. Flexible parametric survival models are a powerful tool for modelling multiple time-scales. This method does not require splitting the data into small time-intervals, and therefore saves time, helps avoid technological limitations and reduces room for error.},
  citation-subset = {IM},
  completed       = {2022-11-11},
  country         = {England},
  issn-linking    = {1471-2288},
  journal         = {BMC Medical Research Methodology},
  keywords        = {Humans; Survival Analysis; Time Factors; Proportional Hazards Models; Models, Statistical; Cohort studies; Epidemiological methods; Flexible parametric survival models; Matched cohort; Multiple time-scales; Time-varying covariate},
  nlm-id          = {100968545},
  owner           = {NLM},
  pii             = {290},
  pmc             = {PMC9644623},
  pmid            = {36352351},
  pubmodel        = {Electronic},
  revised         = {2023-01-06},
  year            = {2022},
}

@Article{Teece2023,
  author          = {Teece, Lucy and Sweeting, Michael J. and Hall, Marlous and Coles, Briana and Oliver-Williams, Clare and Welch, Cathy A. and de Belder, Mark A. and Deanfield, John and Weston, Clive and Rutherford, Mark J. and Paley, Lizz and Kadam, Umesh T. and Lambert, Paul C. and Peake, Michael D. and Gale, Chris P. and Adlam, David and {VICORI Collaborative}},
  date            = {2023-06},
  journaltitle    = {Circulation. Cardiovascular Quality and Outcomes},
  title           = {Impact of a Prior Cancer Diagnosis on Quality of Care and Survival Following Acute Myocardial Infarction: Retrospective Population-Based Cohort Study in {E}ngland.},
  doi             = {10.1161/CIRCOUTCOMES.122.009236},
  issn            = {1941-7705},
  issue           = {6},
  pages           = {e009236},
  pubstate        = {ppublish},
  volume          = {16},
  abstract        = {An increasing proportion of patients with cancer experience acute myocardial infarction (AMI). We investigated differences in quality of AMI care and survival between patients with and without previous cancer diagnoses. A retrospective cohort study using Virtual Cardio-Oncology Research Initiative data. Patients aged 40+ years hospitalized in England with AMI between January 2010 and March 2018 were assessed, ascertaining previous cancers diagnosed within 15 years. Multivariable regression was used to assess effects of cancer diagnosis, time, stage, and site on international quality indicators and mortality. Of 512â€‰388 patients with AMI (mean age, 69.3 years; 33.5% women), 42â€‰187 (8.2%) had previous cancers. Patients with cancer had significantly lower use of ACE (angiotensin-converting enzyme) inhibitors/angiotensin receptor blockers (mean percentage point decrease [mppd], 2.6% [95% CI, 1.8-3.4]) and lower overall composite care (mppd, 1.2% [95% CI, 0.9-1.6]). Poorer quality indicator attainment was observed in patients with cancer diagnosed in the last year (mppd, 1.4% [95% CI, 1.8-1.0]), with later stage disease (mppd, 2.5% [95% CI, 3.3-1.4]), and with lung cancer (mppd, 2.2% [95% CI, 3.0-1.3]). Twelve-month all-cause survival was 90.5% in noncancer controls and 86.3% in adjusted counterfactual controls. Differences in post-AMI survival were driven by cancer-related deaths. Modeling improving quality indicator attainment to noncancer patient levels showed modest 12-month survival benefits (lung cancer, 0.6%; other cancers, 0.3%). Measures of quality of AMI care are poorer in patients with cancer, with lower use of secondary prevention medications. Findings are primarily driven by differences in age and comorbidities between cancer and noncancer populations and attenuated after adjustment. The largest impact was observed in recent cancer diagnoses (<1 year) and lung cancer. Further investigation will determine whether differences reflect appropriate management according to cancer prognosis or whether opportunities to improve AMI outcomes in patients with cancer exist.},
  citation-subset = {IM},
  country         = {United States},
  issn-linking    = {1941-7713},
  journal         = {Circulation. Cardiovascular Quality and Outcomes},
  keywords        = {humans; myocardial infarction; neoplasms; prognosis; retrospective studies},
  nlm-id          = {101489148},
  owner           = {NLM},
  pmc             = {PMC10281182},
  pmid            = {37339190},
  pubmodel        = {Print-Electronic},
  revised         = {2023-06-20},
  year            = {2023},
}

@Article{Skourlis2023,
  author          = {Skourlis, Nikolaos and Crowther, Michael J. and Andersson, Therese M.-L. and Lu, Donghao and Lambe, Mats and Lambert, Paul C.},
  date            = {2023-04},
  journaltitle    = {BMC Medical Research Methodology},
  title           = {Exploring different research questions via complex multi-state models when using registry-based repeated prescriptions of antidepressants in women with breast cancer and a matched population comparison group.},
  doi             = {10.1186/s12874-023-01905-9},
  issn            = {1471-2288},
  issue           = {1},
  pages           = {87},
  pubstate        = {epublish},
  volume          = {23},
  abstract        = {Multi-state models are used to study several clinically meaningful research questions. Depending on the research question of interest and the information contained in the data, different multi-state structures and modelling choices can be applied. We aim to explore different research questions using a series of multi-state models of increasing complexity when studying repeated prescriptions data, while also evaluating different modelling choices. We develop a series of research questions regarding the probability of being under antidepressant medication across time using multi-state models, among Swedish women diagnosed with breast cancer (nâ€‰=â€‰18,313) and an age-matched population comparison group of cancer-free women (nâ€‰=â€‰92,454) using a register-based database (Breast Cancer Data Base Sweden 2.0). Research questions were formulated ranging from simple to more composite ones. Depending on the research question, multi-state models were built with structures ranging from simpler ones, like single-event survival analysis and competing risks, up to complex bidirectional and recurrent multi-state structures that take into account the recurring start and stop of medication. We also investigate modelling choices, such as choosing a time-scale for the transition rates and borrowing information across transitions. Each structure has its own utility and answers a specific research question. However, the more complex structures (bidirectional, recurrent) enable accounting for the intermittent nature of prescribed medication data. These structures deliver estimates of the probability of being under medication and total time spent under medication over the follow-up period. Sensitivity analyses over different definitions of the medication cycle and different choices of timescale when modelling the transition intensity rates show that the estimates of total probabilities of being in a medication cycle over follow-up derived from the complex structures are quite stable. Each research question requires the definition of an appropriate multi-state structure, with more composite ones requiring such an increase in the complexity of the multi-state structure. When a research question is related with an outcome of interest that repeatedly changes over time, such as the medication status based on prescribed medication, the use of novel multi-state models of adequate complexity coupled with sensible modelling choices can successfully address composite, more realistic research questions.},
  chemicals       = {Antidepressive Agents},
  citation-subset = {IM},
  completed       = {2023-04-12},
  country         = {England},
  issn-linking    = {1471-2288},
  journal         = {BMC Medical Research Methodology},
  keywords        = {Humans; Female; Breast Neoplasms, drug therapy; Neoplasm Recurrence, Local; Antidepressive Agents, therapeutic use; Registries; Drug Prescriptions; Clock approaches; Flexible parametric models; Multi-state models; Prescribed drug register; Time until medication},
  nlm-id          = {100968545},
  owner           = {NLM},
  pii             = {87},
  pmc             = {PMC10084660},
  pmid            = {37038100},
  pubmodel        = {Electronic},
  revised         = {2023-04-15},
  year            = {2023},
}

@Article{Coles2023,
  author          = {Coles, Briana and Welch, Catherine A. and Motiwale, Rishabh S. and Teece, Lucy and Oliver-Williams, Clare and Weston, Clive and de Belder, Mark A. and Lambert, Paul C. and Rutherford, Mark J. and Paley, Lizz and Kadam, Umesh T. and Lawson, Clare A. and Deanfield, John and Peake, Michael D. and McDonagh, Theresa and Sweeting, Michael J. and Adlam, David and {VICORI Collaborative}},
  date            = {2023-05},
  journaltitle    = {European Heart Journal. Acute Cardiovascular Care},
  title           = {Acute heart failure presentation, management, and outcomes in cancer patients: a national longitudinal study.},
  doi             = {10.1093/ehjacc/zuad020},
  issn            = {2048-8734},
  issue           = {5},
  pages           = {315--327},
  pubstate        = {ppublish},
  volume          = {12},
  abstract        = {Currently, little evidence exists on survival and quality of care in cancer patients presenting with acute heart failure (HF). The aim of the study is to investigate the presentation and outcomes of hospital admission with acute HF in a national cohort of patients with prior cancer. This retrospective, population-based cohort study identified 221 953 patients admitted to a hospital in England for HF during 2012-2018 (12 867 with a breast, prostate, colorectal, or lung cancer diagnosis in the previous 10 years). We examined the impact of cancer on (i) HF presentation and in-hospital mortality, (ii) place of care, (iii) HF medication prescribing, and (iv) post-discharge survival, using propensity score weighting and model-based adjustment. Heart failure presentation was similar between cancer and non-cancer patients. A lower percentage of patients with prior cancer were cared for in a cardiology ward [-2.4% age point difference (ppd) (95% CI -3.3, -1.6)] or were prescribed angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists (ACEi/ARB) for heart failure with reduced ejection fraction [-2.1 ppd (-3.3, -0.9)] than non-cancer patients. Survival after HF discharge was poor with median survival of 1.6 years in prior cancer and 2.6 years in non-cancer patients. Mortality in prior cancer patients was driven primarily by non-cancer causes (68% of post-discharge deaths). Survival in prior cancer patients presenting with acute HF was poor, with a significant proportion due to non-cancer causes of death. Despite this, cardiologists were less likely to manage cancer patients with HF. Cancer patients who develop HF were less likely to be prescribed guideline-based HF medications compared with non-cancer patients. This was particularly driven by patients with a poorer cancer prognosis.},
  chemicals       = {Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Antagonists},
  citation-subset = {IM},
  completed       = {2023-05-05},
  country         = {England},
  investigator    = {Darby, Sarah and Gale, Chris and Hawkins, Mike and Lyon, Alexander and Rashbass, Jem and Reulen, Raoul and Timmis, Alistair Ring Adam and Lai, Sally Vernon Jennifer and Charlton, Paul and Donkor, Akosua and Fazal, Nadeem and Gunesh, Anil and Harrison, Andrew and Khushnood, Abbas and Goodwin, Andrew and Ludman, Peter and McDonagh, Theresa and Murgatroyd, Francis and Shand, Brian and Vernon, Sally and Forman, David},
  issn-linking    = {2048-8726},
  journal         = {European Heart Journal. Acute Cardiovascular Care},
  keywords        = {Male; Humans; Angiotensin-Converting Enzyme Inhibitors, therapeutic use, pharmacology; Angiotensin Receptor Antagonists, therapeutic use; Patient Discharge; Longitudinal Studies; Retrospective Studies; Aftercare; Cohort Studies; Heart Failure, complications, diagnosis, epidemiology; Stroke Volume; Neoplasms, complications, epidemiology},
  nlm-id          = {101591369},
  owner           = {NLM},
  pii             = {7072737},
  pmc             = {PMC10156472},
  pmid            = {36888552},
  pubmodel        = {Print},
  revised         = {2023-05-05},
  year            = {2023},
}

@Article{Myklebust2023,
  author          = {Myklebust, Tor {\AA}Age and Aagnes, Bjarte and Nilssen, Yngvar and Rutherford, Mark and Lambert, Paul C. and Andersson, Therese M. L. and Johansson, Anna L. V. and Dickman, Paul W. and MÃ¸ller, BjÃ¸rn},
  date            = {2023-09},
  journaltitle    = {British Journal of Cancer},
  title           = {Improving communication of cancer survival statistics-feasibility of implementing model-based algorithms in routine publications.},
  doi             = {10.1038/s41416-023-02360-5},
  issn            = {1532-1827},
  issue           = {5},
  pages           = {819--828},
  pubstate        = {ppublish},
  volume          = {129},
  abstract        = {Routine reporting of cancer patient survival is important, both to monitor the effectiveness of health care and to inform about prognosis following a cancer diagnosis. A range of different survival measures exist, each serving different purposes and targeting different audiences. It is important that routine publications expand on current practice and provide estimates on a wider range of survival measures. We examine the feasibility of automated production of such statistics. We used data on 23 cancer sites obtained from the Cancer Registry of Norway (CRN). We propose an automated way of estimating flexible parametric relative survival models and calculating estimates of net survival, crude probabilities, and loss in life expectancy across many cancer sites and subgroups of patients. For 21 of 23 cancer sites, we were able to estimate survival models without assuming proportional hazards. Reliable estimates of all desired measures were obtained for all cancer sites. It may be challenging to implement new survival measures in routine publications as it can require the application of modeling techniques. We propose a way of automating the production of such statistics and show that we can obtain reliable estimates across a range of measures and subgroups of patients.},
  citation-subset = {IM},
  completed       = {2023-08-28},
  country         = {England},
  issn-linking    = {0007-0920},
  journal         = {British Journal of Cancer},
  keywords        = {Humans; Survival Analysis; Feasibility Studies; Neoplasms, therapy; Probability; Algorithms},
  nlm-id          = {0370635},
  owner           = {NLM},
  pii             = {10.1038/s41416-023-02360-5},
  pmc             = {PMC10449893},
  pmid            = {37433898},
  pubmodel        = {Print-Electronic},
  revised         = {2023-08-28},
  year            = {2023},
}

@Article{Sweeting2023,
  author          = {Sweeting, Michael J. and Rutherford, Mark J. and Jackson, Dan and Lee, Sangyu and Latimer, Nicholas R. and Hettle, Robert and Lambert, Paul C.},
  date            = {2023-08},
  journaltitle    = {Medical Decision Making},
  title           = {Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial.},
  doi             = {10.1177/0272989X231184247},
  issn            = {1552-681X},
  issue           = {6},
  pages           = {737--748},
  pubstate        = {ppublish},
  volume          = {43},
  abstract        = {Different parametric survival models can lead to widely discordant extrapolations and decision uncertainty in cost-effectiveness analyses. The use of excess hazard (EH) methods, which incorporate general population mortality data, has the potential to reduce model uncertainty. This review highlights key practical considerations of EH methods for estimating long-term survival. Demonstration of methods used a case study of 686 patients from the German Breast Cancer Study Group, followed for a maximum of 7.3â€‰y and divided into low (1/2) and high (3) grade cancers. Seven standard parametric survival models were fit to each group separately. The same 7 distributions were then used in an EH framework, which incorporated general population mortality rates, and fitted both with and without a cure parameter. Survival extrapolations, restricted mean survival time (RMST), and difference in RMST between high and low grades were compared up to 30 years along with Akaike information criterion goodness-of-fit and cure fraction estimates. The sensitivity of the EH models to lifetable misspecification was investigated. In our case study, variability in survival extrapolations was extensive across the standard models, with 30-y RMST ranging from 7.5 to 14.3â€‰y. Incorporation of general population mortality rates using EH cure methods substantially reduced model uncertainty, whereas EH models without cure had less of an effect. Long-term treatment effects approached the null for most models but at varying rates. Lifetable misspecification had minimal effect on RMST differences. EH methods may be useful for survival extrapolation, and in cancer, EHs may decrease over time and be easier to extrapolate than all-cause hazards. EH cure models may be helpful when cure is plausible and likely to result in less extrapolation variability. In health economic modeling, to help anchor long-term survival extrapolation, it has been recommended that survival models incorporate background mortality rates using excess hazard (EH) methods.We present a thorough description of EH methods with and without the assumption of cure and demonstrate user-friendly software to aid researchers wishing to use these methods.EH models are applied to a case study, and we demonstrate that EHs are easier to extrapolate and that the use of the EH cure model, when cure is plausible, can reduce extrapolation variability.EH methods are relatively robust to lifetable misspecification.},
  citation-subset = {IM},
  completed       = {2023-08-14},
  country         = {United States},
  issn-linking    = {0272-989X},
  journal         = {Medical Decision Making},
  keywords        = {Humans; Female; Survival Analysis; Proportional Hazards Models; Breast Neoplasms, therapy; Survival Rate; excess hazard models; health technology assessment; modeling; overall survival; survival extrapolation},
  nlm-id          = {8109073},
  owner           = {NLM},
  pmc             = {PMC10422853},
  pmid            = {37448102},
  pubmodel        = {Print-Electronic},
  revised         = {2023-08-30},
  year            = {2023},
}

@Article{Waterhouse2023,
  author          = {Waterhouse, J. V. and Welch, C. A. and Battisti, N. M. L. and Sweeting, M. J. and Paley, L. and Lambert, P. C. and Deanfield, J. and de Belder, M. and Peake, M. D. and Adlam, D. and Ring, A.},
  date            = {2023-09},
  journaltitle    = {Clinical Oncology},
  title           = {Geographical Variation in Underlying Social Deprivation, Cardiovascular and Other Comorbidities in Patients with Potentially Curable Cancers in {E}ngland: Results from a National Registry Dataset Analysis.},
  doi             = {10.1016/j.clon.2023.08.009},
  issn            = {1433-2981},
  pages           = {e709--e719},
  volume          = {35},
  abstract        = {To describe the prevalence of cardiovascular disease (CVD), multiple comorbidities and social deprivation in patients with a potentially curable cancer in 20 English Cancer Alliances. This National Registry Dataset Analysis used national cancer registry data and CVD databases to describe rates of CVD, comorbidities and social deprivation in patients diagnosed with a potentially curable malignancy (stage I-III breast cancer, stage I-III colon cancer, stage I-III rectal cancer, stage I-III prostate cancer, stage I-IIIA non-small cell lung cancer, stage I-IV diffuse large B-cell lymphoma, stage I-IV Hodgkin lymphoma) between 2013 and 2018. Outcome measures included observation of CVD prevalence, other comorbidities (evaluated by the Charlson Comorbidity Index) and deprivation (using the Index of Multiple Deprivation) according to tumour site and allocation to Cancer Alliance. Patients were allocated to CVD prevalence tertiles (minimum: <33.3rd percentile; middle: 33.3rd to 66.6th percentile; maximum: >66.6th percentile). In total, 634Â 240 patients with a potentially curable malignancy were eligible. The total CVD prevalence for all cancer sites varied between 13.4% (CVD n = 2058; 95% confidence interval 12.8, 13.9) and 19.6% (CVD n = 7818; 95% confidence interval 19.2, 20.0) between Cancer Alliances. CVD prevalence showed regional variation both for male (16-26%) and female patients (8-16%) towards higher CVD prevalence in northern Cancer Alliances. Similar variation was observed for social deprivation, with the proportion of cancer patients being identified as most deprived varying between 3.3% and 32.2%, depending on Cancer Alliance. The variation between Cancer Alliance for total comorbidities was much smaller. Social deprivation, CVD and other comorbidities in patients with a potentially curable malignancy in England show significant regional variations, which may partly contribute to differences observed in treatments and outcomes.},
  citation-subset = {IM},
  country         = {England},
  issn-linking    = {0936-6555},
  journal         = {Clinical Oncology},
  keywords        = {Cancer alliance; cardiology; cardiovascular disease; epidemiology; health care disparities; medical oncology},
  nlm-id          = {9002902},
  owner           = {NLM},
  pii             = {S0936-6555(23)00300-X},
  pmid            = {37741712},
  pubmodel        = {Print-Electronic},
  revised         = {2023-09-23},
  year            = {2023},
}

@Article{Wells2023,
  author          = {Wells, Molly and Rutherford, Mark J. and Lambert, Paul C.},
  date            = {2023-08},
  journaltitle    = {Cancer Epidemiology},
  title           = {Fair comparisons of cause-specific and relative survival by accounting for the systematic removal of patients from risk-sets.},
  doi             = {10.1016/j.canep.2023.102408},
  issn            = {1877-783X},
  pages           = {102408},
  pubstate        = {aheadofprint},
  volume          = {86},
  abstract        = {In population-based cancer studies it is common to try to isolate the impact of cancer by estimating net survival. Net survival is defined as the probability of surviving cancer in the absence of any other-causes of death. Net survival can be estimated either in the cause-specific or relative survival framework. Cause-specific survival considers deaths from the cancer as the event of interest. Relative survival incorporates general population expected mortality rates to represent the other-cause mortality rate. Estimation approaches in both frameworks are impacted by the systematic removal of patients from the risk-set, commonly referred to as informative censoring in the cause-specific framework. In the relative survival framework, the Pohar Perme estimator combats the effect of this systematic removal of patients through weighting. When the two frameworks have been compared, informative censoring is rarely accounted for in the cause-specific framework. We investigate the use of weighted cause-specific Kaplan-Meier estimates to overcome the impact of informative censoring and compared approaches to defining weights. Individuals remaining in the risk-set are upweighted using their predicted other-cause survival obtained through various model-based approaches. We also compare weights derived from expected mortality rates. We applied the approaches to US cancer registry data and conducted a simulation study. Using weighted cause-specific estimates provides a better estimate of marginal net survival. The unweighted Kaplan-Meier estimates have a similar bias to the Ederer II method for relative survival. Weighted Kaplan-Meier estimates are unbiased and similar to the Pohar Perme estimator. There was little variation between the several weighting approaches. In comparisons of cause-specific and relative survival, it is important to compare "like-with-like", therefore, a weighted approach should be considered for both frameworks. If researchers are interested in obtaining net measures in a cause-specific framework, then weighting is needed to account for informative censoring.},
  citation-subset = {IM},
  country         = {Netherlands},
  issn-linking    = {1877-7821},
  journal         = {Cancer Epidemiology},
  keywords        = {Cause-specific; Informative censoring; Relative survival; Survival Analysis; Weights},
  nlm-id          = {101508793},
  owner           = {NLM},
  pii             = {S1877-7821(23)00088-7},
  pmid            = {37591148},
  pubmodel        = {Print-Electronic},
  revised         = {2023-08-17},
  year            = {2023},
}

@Article{Tyrer2023,
  author          = {Tyrer, Freya and Chudasama, Yogini V. and Lambert, Paul C. and Rutherford, Mark J.},
  date            = {2023-09},
  journaltitle    = {Population Health Metrics},
  title           = {Flexible parametric methods for calculating life expectancy in small populations.},
  doi             = {10.1186/s12963-023-00313-x},
  issn            = {1478-7954},
  issue           = {1},
  pages           = {13},
  pubstate        = {epublish},
  volume          = {21},
  abstract        = {Life expectancy is a simple measure of assessing health differences between two or more populations but current life expectancy calculations are not reliable for small populations. A potential solution to this is to borrow strength from larger populations from the same source, but this has not formally been investigated. Using data on 451,222 individuals from the Clinical Practice Research Datalink on the presence/absence of intellectual disability and type 2 diabetes mellitus, we compared stratified and combined flexible parametric models, and Chiang's methods, for calculating life expectancy. Confidence intervals were calculated using the Delta method, Chiang's adjusted life table approach and bootstrapping. The flexible parametric models allowed calculation of life expectancy by exact age and beyond traditional life expectancy age thresholds. The combined model that fit age interaction effects as a spline term provided less bias andÂ greater statistical precision for small covariate subgroups by borrowing strength from the larger subgroups. However, careful consideration of the distribution of events in the smallest group was needed. Life expectancy is a simple measure to compare health differences between populations. The use of combined flexible parametric methods to calculate life expectancy in small samples has shown promising results by allowing life expectancy to be modelled by exact age, greater statistical precision, less bias and prediction of different covariate patterns without stratification. We recommend further investigation of their application for both policymakers and researchers.},
  citation-subset = {IM},
  completed       = {2023-09-14},
  country         = {England},
  issn-linking    = {1478-7954},
  journal         = {Population Health Metrics},
  keywords        = {Humans; Diabetes Mellitus, Type 2; Life Expectancy; Life Tables; Chiang; Electronic health records; Epidemiology; Flexible parametric methods; Life expectancy; Observational studies},
  nlm-id          = {101178411},
  owner           = {NLM},
  pii             = {13},
  pmc             = {PMC10498577},
  pmid            = {37700289},
  pubmodel        = {Electronic},
  revised         = {2023-09-21},
  year            = {2023},
}

@Article{Booth2023,
  author          = {Booth, Sarah and Mozumder, Sarwar I. and Archer, Lucinda and Ensor, Joie and Riley, Richard D. and Lambert, Paul C. and Rutherford, Mark J.},
  date            = {2023-09},
  journaltitle    = {Statistics in Medicine},
  title           = {Using temporal recalibration to improve the calibration of risk prediction models in competing risk settings when there are trends in survival over time.},
  doi             = {10.1002/sim.9898},
  issn            = {1097-0258},
  pages           = {5007--5024},
  volume          = {30},
  abstract        = {We have previously proposed temporal recalibration to account for trends in survival over time to improve the calibration of predictions from prognostic models for new patients. This involves first estimating the predictor effects using data from all individuals (full dataset) and then re-estimating the baseline using a subset of the most recent data whilst constraining the predictor effects to remain the same. In this article, we demonstrate how temporal recalibration can be applied in competing risk settings by recalibrating each cause-specific (or subdistribution) hazard model separately. We illustrate this using an example of colon cancer survival with data from the Surveillance Epidemiology and End Results (SEER) program. Data from patients diagnosed in 1995-2004 were used to fit two models for deaths due to colon cancer and other causes respectively. We discuss considerations that need to be made in order to apply temporal recalibration such as the choice of data used in the recalibration step. We also demonstrate how to assess the calibration of these models in new data for patients diagnosed subsequently in 2005. Comparison was made to a standard analysis (when improvements over time are not taken into account) and a period analysis which is similar to temporal recalibration but differs in the data used to estimate the predictor effects. The 10-year calibration plots demonstrated that using the standard approach over-estimated the risk of death due to colon cancer and the total risk of death and that calibration was improved using temporal recalibration or period analysis.},
  citation-subset = {IM},
  country         = {England},
  issn-linking    = {0277-6715},
  journal         = {Statistics in Medicine},
  keywords        = {calibration; competing risks; prognostic models; risk prediction; temporal recalibration},
  nlm-id          = {8215016},
  owner           = {NLM},
  pmid            = {37705296},
  pubmodel        = {Print-Electronic},
  revised         = {2023-09-14},
  year            = {2023},
}

@Article{Bower2016c,
  author    = {Bower, H. and Crowther, M. J. and Lambert, P. C.},
  title     = {{s}trcs: A command for fitting flexible parametric survival models on the log-hazard scale},
  doi       = {10.1177/1536867X1601600410},
  eprint    = {https://doi.org/10.1177/1536867X1601600410},
  number    = {4},
  pages     = {989-1012},
  url       = {https://doi.org/10.1177/1536867X1601600410},
  volume    = {16},
  file      = {Bower2016c.pdf:pdf\\Bower2016c.pdf:PDF;Bower2016c.pdf:Bower2016c.pdf:PDF},
  journal   = {The Stata Journal},
  owner     = {hanbow},
  timestamp = {2017.01.10},
  year      = {2016},
}

@Article{Lee2024,
  author          = {Lee, Sangyu and Lambert, Paul C. and Sweeting, Michael J. and Latimer, Nicholas R. and Rutherford, Mark J.},
  date            = {2024-01},
  title           = {Evaluation of Flexible Parametric Relative Survival Approaches for Enforcing Long-Term Constraints When Extrapolating All-Cause Survival.},
  doi             = {10.1016/j.jval.2023.10.003},
  issn            = {1524-4733},
  issue           = {1},
  pages           = {51--60},
  pubstate        = {ppublish},
  volume          = {27},
  abstract        = {Parametric models are used to estimate the lifetime benefit of an intervention beyond the range of trial follow-up. Recent recommendations have suggested more flexible survival approaches and the use of external data when extrapolating. Both of these can be realized by using flexible parametric relative survival modeling. The overall aim of this article is to introduce and contrast various approaches for applying constraints on the long-term disease-related (excess) mortality including cure models and evaluate the consequent implications for extrapolation. We describe flexible parametric relative survival modeling approaches. We then introduce various options for constraining the long-term excess mortality and compare the performance of each method in simulated data. These methods include fitting a standard flexible parametric relative survival model, enforcing statistical cure, and forcing the long-term excess mortality to converge to a constant. We simulate various scenarios, including where statistical cure is reasonable and where the long-term excess mortality persists. The compared approaches showed similar survival fits within the follow-up period. However, when extrapolating the all-cause survival beyond trial follow-up, there is variation depending on the assumption made about the long-term excess mortality. Altering the time point from which the excess mortality is constrained enables further flexibility. The various constraints can lead to applying explicit assumptions when extrapolating, which could lead to more plausible survival extrapolations. The inclusion of general population mortality directly into the model-building process, which is possible for all considered approaches, should be adopted more widely in survival extrapolation in health technology assessment.},
  citation-subset = {IM},
  completed       = {2024-01-15},
  country         = {United States},
  issn-linking    = {1098-3015},
  journal         = {Value in Health},
  keywords        = {Humans; Survival Analysis; cure models; extrapolation; flexible parametric survival regression; relative survival modeling},
  nlm-id          = {100883818},
  owner           = {NLM},
  pii             = {S1098-3015(23)06147-8},
  pmid            = {37858887},
  pubmodel        = {Print-Electronic},
  revised         = {2024-01-15},
  year            = {2024},
}

@Article{Leontyeva2023,
  author          = {Leontyeva, Yuliya and Lambe, Mats and Bower, Hannah and Lambert, Paul C. and Andersson, Therese M.-L.},
  date            = {2023-12},
  title           = {Including uncertainty of the expected mortality rates in the prediction of loss in life expectancy.},
  doi             = {10.1186/s12874-023-02118-w},
  issn            = {1471-2288},
  issue           = {1},
  pages           = {291},
  pubstate        = {epublish},
  volume          = {23},
  abstract        = {This study introduces a novel method for estimating the variance of life expectancy since diagnosis (LE (C)) and loss in life expectancy (LLE) for cancer patients within a relative survival framework in situations where life tables based on the entire general population are not accessible. LE (C)and LLE are useful summary measures of survival in population-based cancer studies, but require information on the mortality in the general population. Our method addresses the challenge of incorporating the uncertainty of expected mortality rates when using a sample from the general population. To illustrate the approach, we estimated LE (C)and LLE for patients diagnosed with colon and breast cancer in Sweden. General population mortality rates were based on a random sample drawn from comparators of a matched cohort. Flexible parametric survival models were used to model the mortality among cancer patients and the mortality in the random sample from the general population. Based on the models, LE (C)and LLE together with their variances were estimated. The results were compared with those obtained using fixed expected mortality rates. By accounting for the uncertainty of expected mortality rates, the proposed method ensures more accurate estimates of variances and, therefore, confidence intervals of LE (C)and LLE for cancer patients. This is particularly valuable for older patients and some cancer types, where underestimation of the variance can be substantial when the entire general population data are not accessible. The method can be implemented using existing software, making it accessible for use in various cancer studies. The provided example of Stata code further facilitates its adoption.},
  citation-subset = {IM},
  completed       = {2023-12-16},
  country         = {England},
  issn-linking    = {1471-2288},
  journal         = {BMC Medical Research Methodology},
  keywords        = {Humans; Female; Uncertainty; Life Expectancy; Breast Neoplasms; Sweden, epidemiology; Mortality; Expected mortality rates; Flexible parametric survival models; Loss in life expectancy; Relative survival},
  nlm-id          = {100968545},
  owner           = {NLM},
  pii             = {291},
  pmc             = {PMC10714581},
  pmid            = {38087236},
  pubmodel        = {Electronic},
  revised         = {2024-01-11},
  year            = {2023},
}

@Article{Jennings2023,
  author          = {Jennings, Angus C. and Rutherford, Mark J. and Latimer, Nicholas R. and Sweeting, Michael J. and Lambert, Paul C.},
  date            = {2023-12},
  title           = {Perils of Randomized Controlled Trial Survival Extrapolation Assuming Treatment Effect Waning: Why the Distinction Between Marginal and Conditional Estimates Matters.},
  doi             = {10.1016/j.jval.2023.12.008},
  issn            = {1524-4733},
  pubstate        = {aheadofprint},
  abstract        = {A long-term, constant, protective treatment effect is a strong assumption when extrapolating survival beyond clinical trial follow-up; hence, sensitivity to treatment effect waning is commonly assessed for economic evaluations. Forcing a hazard ratio (HR) to 1 does not necessarily estimate loss of individual-level treatment effect accurately because of HR selection bias. A simulation study was designed to explore the behavior of marginal HRs under a waning conditional (individual-level) treatment effect and demonstrate bias in forcing a marginal HR to 1 when the estimand is "survival difference with individual-level waning". Data were simulated under 4 parameter combinations (varying prognostic strength of heterogeneity and treatment effect). Time-varying marginal HRs were estimated in scenarios where the true conditional HR attenuated to 1. Restricted mean survival time differences, estimated having constrained the marginal HR to 1, were compared with true values to assess bias induced by marginal constraints. Under loss of conditional treatment effect, the marginal HR took a value >1 because of covariate imbalances. Constraining this value to 1 lead to restricted mean survival time difference bias of up to 0.8 years (57% increase). Inflation of effect size estimates also increased with the magnitude of initial protective treatment effect. Important differences exist between survival extrapolations assuming marginal versus conditional treatment effect waning. When a marginal HR is constrained to 1 to assess efficacy under individual-level treatment effect waning, the survival benefits associated with the new treatment will be overestimated, and incremental cost-effectiveness ratios will be underestimated.},
  citation-subset = {IM},
  country         = {United States},
  issn-linking    = {1098-3015},
  journal         = {Value in Health},
  keywords        = {efficacy waning; hazard ratio noncollapsability; health technology assessment; survival extrapolation; treatment effect waning},
  nlm-id          = {100883818},
  owner           = {NLM},
  pii             = {S1098-3015(23)06241-1},
  pmid            = {38154594},
  pubmodel        = {Print-Electronic},
  revised         = {2024-01-20},
  year            = {2023},
}

@Article{Kalbfleisch1988a,
  author      = {Kalbfleisch, J. D. and Lawless, J. F.},
  title       = {Likelihood analysis of multi-state models for disease incidence and mortality.},
  language    = {eng},
  number      = {1-2},
  pages       = {149--160},
  volume      = {7},
  abstract    = {Data related to life histories of individuals can be obtained in many
	different ways, and the usefulness of multi-state models for statistical
	analysis is generally highly dependent on the type and nature of
	the data. In this paper, we focus on this, and present an approach
	to estimation for certain 'difficult' situations associated with
	retrospective or incomplete prospective observation. The paper begins
	with the identification of some problem areas in the analysis of
	data on life history processes. We discuss maximum likelihood estimation
	in some simple contexts and introduce a pseudo-likelihood which enables
	the simple analysis of some sampling procedures. This approach is
	illustrated on standard retrospective and case-cohort designs.},
  file        = {Kalbfleisch1988a.pdf:pdf\\Kalbfleisch1988a.pdf:PDF;Kalbfleisch1988a.pdf:Kalbfleisch1988a.pdf:PDF},
  journal     = {Statistics in Medicine},
  medline-pst = {ppublish},
  owner       = {pl4},
  pmid        = {3353602},
  timestamp   = {2012.11.07},
  year        = {1988},
}

@Article{Batyrbekova2022b,
  author    = {Batyrbekova, Nurgul and Bower, Hannah and Dickman, Paul W and Szulkin, Robert and Lambert, Paul C and Andersson, Therese M-L},
  title     = {Potential bias introduced by not including multiple time-scales in survival analysis: a simulation study},
  language  = {en},
  pages     = {1--14},
  copyright = {http://creativecommons.org/licenses/by/4.0/},
  journal   = {Commun. Stat. Simul. Comput.},
  month     = mar,
  publisher = {Informa UK Limited},
  year      = {2022},
}

@Article{Bower2022,
  author    = {Bower, Hannah and Andersson, Therese M.-L. and Crowther, Michael J. and Lambert, Paul C.},
  title     = {Flexible parametric survival analysis with multiple timescales: Estimation and implementation using stmt},
  doi       = {10.1177/1536867x221124552},
  issn      = {1536-8734},
  number    = {3},
  pages     = {679â€“701},
  url       = {http://dx.doi.org/10.1177/1536867X221124552},
  volume    = {22},
  journal   = {The Stata Journal},
  month     = sep,
  publisher = {SAGE Publications},
  year      = {2022},
}

@Article{Latimer2017,
  author          = {Latimer, Nicholas R. and Abrams, K. R. and Lambert, P. C. and Crowther, M. J. and Wailoo, A. J. and Morden, J. P. and Akehurst, R. L. and Campbell, M. J.},
  date            = {2017-04},
  title           = {Adjusting for treatment switching in randomised controlled trials - A simulation study and a simplified two-stage method.},
  doi             = {10.1177/0962280214557578},
  issn            = {1477-0334},
  issue           = {2},
  pages           = {724--751},
  pubstate        = {ppublish},
  volume          = {26},
  abstract        = {Estimates of the overall survival benefit of new cancer treatments are often confounded by treatment switching in randomised controlled trials (RCTs) - whereby patients randomised to the control group are permitted to switch onto the experimental treatment upon disease progression. In health technology assessment, estimates of the unconfounded overall survival benefit associated with the new treatment are needed. Several switching adjustment methods have been advocated in the literature, some of which have been used in health technology assessment. However, it is unclear which methods are likely to produce least bias in realistic RCT-based scenarios. We simulated RCTs in which switching, associated with patient prognosis, was permitted. Treatment effect size and time dependency, switching proportions and disease severity were varied across scenarios. We assessed the performance of alternative adjustment methods based upon bias, coverage and mean squared error, related to the estimation of true restricted mean survival in the absence of switching in the control group. We found that when the treatment effect was not time-dependent, rank preserving structural failure time models (RPSFTM) and iterative parameter estimation methods produced low levels of bias. However, in the presence of a time-dependent treatment effect, these methods produced higher levels of bias, similar to those produced by an inverse probability of censoring weights method. The inverse probability of censoring weights and structural nested models produced high levels of bias when switching proportions exceeded 85%. A simplified two-stage Weibull method produced low bias across all scenarios and provided the treatment switching mechanism is suitable, represents an appropriate adjustment method.},
  citation-subset = {IM},
  completed       = {2017-10-16},
  country         = {England},
  issn-linking    = {0962-2802},
  journal         = {Statistical Methods in Medical Research},
  keywords        = {Algorithms; Biostatistics, methods; Computer Simulation; Cross-Over Studies; Disease Progression; Humans; Models, Statistical; Randomized Controlled Trials as Topic, statistics & numerical data; Survival Analysis; Technology Assessment, Biomedical, statistics & numerical data; health technology assessment; inverse probability of censoring weights; prediction; survival analysis; time-to-event outcomes; treatment crossover; treatment switching},
  nlm-id          = {9212457},
  owner           = {NLM},
  pii             = {0962280214557578},
  pmid            = {25416688},
  pubmodel        = {Print-Electronic},
  revised         = {2022-01-29},
  year            = {2017},
}

@Article{Rutherford2015d,
  author    = {Rutherford, M J and Abel, G A and Greenberg, D C and Lambert, P C and Lyratzopoulos, G},
  title     = {The impact of eliminating age inequalities in stage at diagnosis on breast cancer survival for older women},
  doi       = {10.1038/bjc.2015.51},
  issn      = {1532-1827},
  number    = {S1},
  pages     = {S124â€“S128},
  url       = {http://dx.doi.org/10.1038/bjc.2015.51},
  volume    = {112},
  journal   = {British Journal of Cancer},
  month     = mar,
  publisher = {Springer Science and Business Media LLC},
  year      = {2015},
}

@Article{Baker2003a,
  author          = {Baker, Richard and Fraser, Robin C. and Stone, Margaret and Lambert, Paul and Stevenson, Keith and Shiels, Chris},
  date            = {2003-04},
  journaltitle    = {The British journal of general practice : the journal of the Royal College of General Practitioners},
  title           = {Randomised controlled trial of the impact of guidelines, prioritized review criteria and feedback on implementation of recommendations for angina and asthma.},
  issn            = {0960-1643},
  issue           = {489},
  pages           = {284--291},
  pubstate        = {ppublish},
  volume          = {53},
  abstract        = {Guidelines are frequently used in an attempt to influence the performance of health professionals, and a national agency has been established in England and Wales to develop and disseminate guidelines. Professionals prefer short guidelines that highlight key recommendations, but whether such guidelines are more likely to be implemented is unknown. To determine the relative impact of the dissemination of full guidelines, reduced guidelines in the form of prioritized review criteria, and review criteria supplemented by feedback. Cluster randomised controlled trial, with an incomplete block design. Eighty-one general practices in Leicestershire, Lincolnshire, Northamptonshire, North Derbyshire, and Nottinghamshire. The practices received one of the study interventions, either for care of adults with asthma or for care of people with angina. Data were collected before and after the interventions, the process measures being adherence to ten recommendations about asthma and 14 about angina, and outcome measures being scores in response to an asthma symptom questionnaire or the Seattle Angina Questionnaire, and levels of patient satisfaction. There were no consistent differences between the interventions in stimulating improvements in performance as indicated by adherence to the recommendations for asthma or angina. Patients with angina in practices that had received criteria or criteria plus feedback reported better symptom control. The dissemination of guidelines in the format of prioritized review criteria does not increase adherence to recommendations in comparison with the traditional guideline format, and the further provision of feedback has minimal additional effect.},
  citation-subset = {IM},
  completed       = {2003-10-03},
  country         = {England},
  issn-linking    = {0960-1643},
  keywords        = {Aged; Angina Pectoris, drug therapy; Asthma, drug therapy; Family Practice, standards; Feedback; Female; Guideline Adherence; Humans; Male; Middle Aged; Practice Guidelines as Topic},
  nlm-id          = {9005323},
  owner           = {NLM},
  pmc             = {PMC1314570},
  pmid            = {12879828},
  pubmodel        = {Print},
  revised         = {2008-11-20},
}

@Article{Cooper2003,
  author    = {Cooper, Nicola J. and Abrams, Keith R. and Sutton, Alex J. and Turner, David and Lambert, Paul C.},
  title     = {A Bayesian Approach to Markov Modelling in Cost-Effectiveness Analyses: Application to Taxane use in Advanced Breast Cancer},
  doi       = {10.1111/1467-985x.00283},
  issn      = {1467-985X},
  number    = {3},
  pages     = {389â€“405},
  url       = {http://dx.doi.org/10.1111/1467-985X.00283},
  volume    = {166},
  journal   = {Journal of the Royal Statistical Society Series A: Statistics in Society},
  month     = sep,
  publisher = {Oxford University Press (OUP)},
  year      = {2003},
}

@Article{Waugh2003b,
  author    = {Waugh, Jason and Kilby, Mark and Lambert, Paul and Bell, Stephen C. and Blackwell, Claire N. and Shennan, Andrew and Halligan, Aidan},
  title     = {Validation of the DCA{\textregistered} 2000 Microalbumin:Creatinine Ratio Urinanalyzer for Its Use in Pregnancy and Preeclampsia},
  doi       = {10.1081/prg-120017006},
  issn      = {1525-6065},
  number    = {1},
  pages     = {77â€“92},
  url       = {http://dx.doi.org/10.1081/PRG-120017006},
  volume    = {22},
  journal   = {Hypertension in Pregnancy},
  month     = jan,
  publisher = {Informa UK Limited},
  year      = {2003},
}

@Article{Sutton2002,
  author    = {Sutton, Alexander J and Cooper, Nicola J and Lambert, Paul C and Jones, David R and Abrams, Keith R and Sweeting, Michael J},
  title     = {Meta-analysis of rare and adverse event data},
  doi       = {10.1586/14737167.2.4.367},
  issn      = {1744-8379},
  number    = {4},
  pages     = {367â€“379},
  url       = {http://dx.doi.org/10.1586/14737167.2.4.367},
  volume    = {2},
  journal   = {Expert Review of Pharmacoeconomics and Outcomes Research},
  month     = aug,
  publisher = {Informa UK Limited},
  year      = {2002},
}

@Article{Luyt1995,
  author    = {Luyt, DK and Bourke, AM and Lambert, P and Burton, P and Simpson, H},
  title     = {Wheeze in preschool children: who is followed-up, who is treated and who is hospitalized?},
  doi       = {10.1183/09031936.95.08101736},
  issn      = {1399-3003},
  number    = {10},
  pages     = {1736â€“1741},
  url       = {http://dx.doi.org/10.1183/09031936.95.08101736},
  volume    = {8},
  journal   = {European Respiratory Journal},
  month     = oct,
  publisher = {European Respiratory Society (ERS)},
  year      = {1995},
}

@Article{Hultcrantz2015,
  author          = {M. Hultcrantz and S. R. Wilkes and S. Y. Kristensson and T. M-L. Andersson and A. Derolf and S. Eloranta and O. Landgren O. and P. C. Lambert and M. Bj\"{o}rkholm},
  title           = {Risk and cause of death in 9,285 patients diagnosed with myeloproliferative neoplasms in {S}weden between 1973 and 2005. A population-based study},
  doi             = {10.1200/JCO.2014.57.6652},
  issn            = {1539-3704},
  issue           = {5},
  pages           = {2288-95},
  volume          = {33},
  abstract        = {Patients with myeloproliferative neoplasms (MPNs) are reported to be at increased risk for thrombotic events. However, no population-based study has estimated this excess risk compared with matched control participants. To assess risk for arterial and venous thrombosis in patients with MPNs compared with matched control participants. Matched cohort study. Population-based setting in Sweden from 1987 to 2009, with follow-up to 2010. 9429 patients with MPNs and 35ÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â 820 matched control participants. The primary outcomes were rates of arterial and venous thrombosis. Flexible parametric models were used to calculate hazard ratios (HRs) and cumulative incidence with 95% CIs. The HRs for arterial thrombosis among patients with MPNs compared with control participants at 3 months, 1 year, and 5 years were 3.0 (95% CI, 2.7 to 3.4), 2.0 (CI, 1.8 to 2.2), and 1.5 (CI, 1.4 to 1.6), respectively. The corresponding HRs for venous thrombosis were 9.7 (CI, 7.8 to 12.0), 4.7 (CI, 4.0 to 5.4), and 3.2 (CI, 2.9 to 3.6). The rate was significantly elevated across all age groups and was similar among MPN subtypes. The 5-year cumulative incidence of thrombosis in patients with MPNs showed an initial rapid increase followed by gentler increases during follow-up. The HR for venous thrombosis decreased during more recent calendar periods. No information on individual laboratory results or treatment. Patients with MPNs across all age groups have a significantly increased rate of arterial and venous thrombosis compared with matched control participants, with the highest rates at and shortly after diagnosis. Decreases in the rate of venous thrombosis over time likely reflect advances in clinical management. The Cancer Research Foundations of Radiumhemmet, Blodcancerfonden, the Swedish Research Council, the regional agreement on medical training and clinical research between Stockholm County Council and Karolinska Institutet, the Adolf H. Lundin Charitable Foundation, and Memorial Sloan Kettering Cancer Center.},
  citation-subset = {AIM, IM},
  completed       = {2019-01-03},
  country         = {United States},
  issn-linking    = {0003-4819},
  journal         = {Journal of Clinical Oncology},
  keywords        = {Adolescent; Adult; Aged; Aged, 80 and over; Case-Control Studies; Female; Humans; Incidence; Male; Middle Aged; Myeloproliferative Disorders, complications; Registries; Risk; Risk Factors; Sweden, epidemiology; Thrombosis, epidemiology, etiology},
  month           = mar,
  nlm-id          = {0372351},
  owner           = {pl4},
  pii             = {2669847},
  pmid            = {29335713},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2019-01-03},
  timestamp       = {2015.04.14},
  year            = {2015},
}

@Article{Johansson2024,
  author          = {Johansson, Anna L. V. and KÃ¸nig, Simon M. and LarÃ¸nningen, Siri and Engholm, Gerda and Kroman, Niels and SeppÃ¤, Karri and Malila, Nea and Steig, Bjarni Ã. and GudmundsdÃ³ttir, Eva Maria and Ã“lafsdÃ³ttir, ElÃ­nborg J. and Lundberg, Frida E. and Andersson, Therese M.-L. and Lambert, Paul C. and Lambe, Mats and Pettersson, David and Aagnes, Bjarte and Friis, SÃ¸ren and Storm, Hans},
  date            = {2024-04},
  journaltitle    = {Acta Oncologica},
  title           = {Have the recent advancements in cancer therapy and survival benefitted patients of all age groups across the {N}ordic countries? {NORDCAN} survival analyses 2002-2021.},
  doi             = {10.2340/1651-226X.2024.35094},
  issn            = {1651-226X},
  pages           = {179--191},
  pubstate        = {epublish},
  volume          = {63},
  abstract        = {Since the early 2000s, overall and site-specific cancer survival have improved substantially in the Nordic countries. We evaluated whether the improvements have been similar across countries, major cancer types, and age groups. Using population-based data from the five Nordic cancer registries recorded in the NORDCAN database, we included a cohort of 1,525,854 men and 1,378,470 women diagnosed with cancer (except non-melanoma skin cancer) during 2002-2021, and followed for death until 2021. We estimated 5-year relative survival (RS) in 5-year calendar periods, and percentage points (pp) differences in 5-year RS from 2002-2006 until 2017-2021. Separate analyses were performed for eight cancer sites (i.e. colorectum, pancreas, lung, breast, cervix uteri, kidney, prostate, and melanoma of skin). Five-year RS improved across nearly all cancer sites in all countries (except Iceland), with absolute differences across age groups ranging from 1 to 21 pp (all cancer sites), 2 to 20 pp (colorectum), -1 to 36 pp (pancreas), 2 to 28 pp (lung), 0 to 9 pp (breast), -11 to 26 pp (cervix uteri), 2 to 44 pp (kidney), -2 to 23 pp (prostate) and -3 to 30 pp (skin melanoma). The oldest patients (80-89 years) exhibited lower survival across all countries and sites, although with varying improvements over time. Nordic cancer patients have generally experienced substantial improvements in cancer survival during the last two decades, including major cancer sites and age groups. Although survival has improved over time, older patients remain at a lower cancer survival compared to younger patients.},
  citation-subset = {IM},
  completed       = {2024-04-11},
  country         = {Sweden},
  issn-linking    = {0284-186X},
  keywords        = {Male; Humans; Female; Melanoma, epidemiology, therapy; Survival Rate; Risk Factors; Follow-Up Studies; Scandinavian and Nordic Countries, epidemiology; Neoplasms, epidemiology, therapy, diagnosis; Registries; Survival Analysis; Incidence},
  nlm-id          = {8709065},
  owner           = {NLM},
  pmid            = {38597666},
  pubmodel        = {Electronic},
  revised         = {2024-04-11},
}

@Article{Lundberg2024,
  author          = {Lundberg, Frida E. and Birgisson, Helgi and Engholm, Gerda and Ã“lafsdÃ³ttir, ElÃ­nborg J. and MÃ¸rch, Lina Steinrud and Johannesen, Tom BÃ¸rge and Pettersson, David and Lambe, Mats and SeppÃ¤, Karri and Lambert, Paul C. and Johansson, Anna L. V. and HÃ¶lmich, Lisbet Rosenkrantz and Andersson, Therese M.-L.},
  date            = {2024-05},
  journaltitle    = {European Journal of Cancer},
  title           = {Survival trends for patients diagnosed with cutaneous malignant melanoma in the {N}ordic countries 1990-2016: The {NORDCAN} survival studies.},
  doi             = {10.1016/j.ejca.2024.113980},
  issn            = {1879-0852},
  pages           = {113980},
  pubstate        = {ppublish},
  volume          = {202},
  abstract        = {The survival in patients diagnosed with cutaneous malignant melanoma (CMM) has improved in the Nordic countries in the last decades. It is of interest to know if these improvements are observed in all ages and for both women and men. Patients diagnosed with CMM in the Nordic countries in 1990-2016 were identified in the NORDCAN database. Flexible parametric relative survival models were fitted, except for Iceland where a non-parametric Pohar-Perme approach was used. A range of survival metrics were estimated by sex, both age-standardised and age-specific. The 5-year relative survival improved in all countries, in both women and men and across age. While the improvement was more pronounced in men, women still had a higher survival at the end of the study period. The survival was generally high, with age-standardised estimates of 5-year relative survival towards the end of the study period ranging from 85% in Icelandic men to 95% in Danish women. The age-standardised and reference-adjusted 5-year crude probability of death due to CMM ranged from 5% in Danish and Swedish women to 13% in Icelandic men. Although survival following CMM was relatively high in the Nordic countries in 1990, continued improvements in survival were observed throughout the study period in both women and men and across age.},
  citation-subset = {IM},
  completed       = {2024-04-22},
  country         = {England},
  issn-linking    = {0959-8049},
  keywords        = {Male; Humans; Female; Melanoma, Cutaneous Malignant; Survival Rate; Risk Factors; Survival Analysis; Melanoma; Scandinavian and Nordic Countries, epidemiology; Skin Neoplasms; Registries; Incidence; Denmark, epidemiology; Comparison; Melanoma; NORDCAN; Nordic cancer registries; Survival},
  nlm-id          = {9005373},
  owner           = {NLM},
  pii             = {S0959-8049(24)00136-9},
  pmid            = {38452724},
  pubmodel        = {Print-Electronic},
  revised         = {2024-04-22},
}

@Article{Hall2024,
  author          = {Hall, Marlous and Smith, Lesley and Wu, Jianhua and Hayward, Chris and Batty, Jonathan A. and Lambert, Paul C. and Hemingway, Harry and Gale, Chris P.},
  date            = {2024-02},
  journaltitle    = {PLoS Medicine},
  title           = {Health outcomes after myocardial infarction: A population study of 56 million people in {E}ngland.},
  doi             = {10.1371/journal.pmed.1004343},
  issn            = {1549-1676},
  issue           = {2},
  pages           = {e1004343},
  pubstate        = {epublish},
  volume          = {21},
  abstract        = {The occurrence of a range of health outcomes following myocardial infarction (MI) is unknown. Therefore, this study aimed to determine the long-term risk of major health outcomes following MI and generate sociodemographic stratified risk charts in order to inform care recommendations in the post-MI period and underpin shared decision making. This nationwide cohort study includes all individuals aged â‰¥18 years admitted to one of 229 National Health Service (NHS) Trusts in England between 1 January 2008 and 31 January 2017 (final follow-up 27 March 2017). We analysed 11 non-fatal health outcomes (subsequent MI and first hospitalisation for heart failure, atrial fibrillation, cerebrovascular disease, peripheral arterial disease, severe bleeding, renal failure, diabetes mellitus, dementia, depression, and cancer) and all-cause mortality. Of the 55,619,430 population of England, 34,116,257 individuals contributing to 145,912,852 hospitalisations were included (mean age 41.7 years (standard deviation [SD 26.1]); n = 14,747,198 (44.2%) male). There were 433,361 individuals with MI (mean age 67.4 years [SD 14.4)]; n = 283,742 (65.5%) male). Following MI, all-cause mortality was the most frequent event (adjusted cumulative incidence at 9 years 37.8% (95% confidence interval [CI] [37.6,37.9]), followed by heart failure (29.6%; 95% CI [29.4,29.7]), renal failure (27.2%; 95% CI [27.0,27.4]), atrial fibrillation (22.3%; 95% CI [22.2,22.5]), severe bleeding (19.0%; 95% CI [18.8,19.1]), diabetes (17.0%; 95% CI [16.9,17.1]), cancer (13.5%; 95% CI [13.3,13.6]), cerebrovascular disease (12.5%; 95% CI [12.4,12.7]), depression (8.9%; 95% CI [8.7,9.0]), dementia (7.8%; 95% CI [7.7,7.9]), subsequent MI (7.1%; 95% CI [7.0,7.2]), and peripheral arterial disease (6.5%; 95% CI [6.4,6.6]). Compared with a risk-set matched population of 2,001,310 individuals, first hospitalisation of all non-fatal health outcomes were increased after MI, except for dementia (adjusted hazard ratio [aHR] 1.01; 95% CI [0.99,1.02];p = 0.468) and cancer (aHR 0.56; 95% CI [0.56,0.57];p < 0.001). The study includes data from secondary care only-as such diagnoses made outside of secondary care may have been missed leading to the potential underestimation of the total burden of disease following MI. In this study, up to a third of patients with MI developed heart failure or renal failure, 7% had another MI, and 38% died within 9 years (compared with 35% deaths among matched individuals). The incidence of all health outcomes, except dementia and cancer, was higher than expected during the normal life course without MI following adjustment for age, sex, year, and socioeconomic deprivation. Efforts targeted to prevent or limit the accrual of chronic, multisystem disease states following MI are needed and should be guided by the demographic-specific risk charts derived in this study.},
  citation-subset = {IM},
  completed       = {2024-02-19},
  country         = {United States},
  issn-linking    = {1549-1277},
  keywords        = {Humans; Male; Adolescent; Adult; Aged; Female; Cohort Studies; Atrial Fibrillation, diagnosis; State Medicine; Myocardial Infarction, epidemiology; Heart Failure, complications; Diabetes Mellitus; Cerebrovascular Disorders; Dementia; Outcome Assessment, Health Care; Renal Insufficiency, complications; Neoplasms, complications},
  nlm-id          = {101231360},
  owner           = {NLM},
  pii             = {e1004343},
  pmc             = {PMC10868847},
  pmid            = {38358949},
  pubmodel        = {Electronic-eCollection},
  revised         = {2024-02-19},
}

@Comment{jabref-meta: databaseType:biblatex;}

@Comment{jabref-meta: fileDirectory:.\\pdf;}

@Comment{jabref-meta: fileDirectory-pl4-LT-2Y1018-001:.\\pdf;}

@Comment{jabref-meta: grouping:
0 AllEntriesGroup:;
1 StaticGroup:Markings\;2\;1\;\;\;\;;
2 StaticGroup:Paul:6\;2\;1\;\;\;\;;
1 StaticGroup:Markings\;2\;1\;\;\;\;;
2 StaticGroup:Paul:6\;2\;1\;\;\;\;;
1 StaticGroup:Markings\;2\;1\;\;\;\;;
1 StaticGroup:ec_phd\;0\;1\;0x8a8a8aff\;\;\;;
2 StaticGroup:By status\;0\;0\;0x8a8a8aff\;\;\;;
3 StaticGroup:To be read\;0\;1\;0xff0000ff\;\;\;;
3 StaticGroup:Last read\;0\;1\;0x8a8a8aff\;\;\;;
2 StaticGroup:Study 1. Extrapolation\;0\;1\;0x8a8a8aff\;\;\;;
2 StaticGroup:Study 2. Quality of Life\;0\;0\;0x8a8a8aff\;\;\;;
2 StaticGroup:Study 3. Cost\;0\;1\;0x8a8a8aff\;\;\;;
2 StaticGroup:Study 4. Cost-effectiveness\;0\;1\;0x8a8a8aff\;\;\;;
2 StaticGroup:CML\;0\;0\;0x8a8a8aff\;\;\;;
2 StaticGroup:Swedish CML doc\;0\;1\;0x8a8a8aff\;\;\;;
}
